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CONFIDENTIAL
MK9 REFILLABLE INERT TRAINING UNIT
The MK9 refillable unit was developed with training in mind The unit delivers a stream
pattern to 25 30 feet 910 meters This unit will provide 7 one second bursts before it needs
refilling It has the same firing mechanism as the non refillable MK9 unit and is a cost
effective training alternative
SABRE inert MK9 Refill kit contains Refill Instructions Plastic Funnel Refill Bottle and
Rubber 0Ring
READ THE INSTRUCTIONS CAREFULLY PRIOR TOFILLING ANDPRESSURIZING
THE UNIT It is essential that the user follows all safety procedures prescribed by Security
Equipment Corporation
EYE PROTECTION REQUIRED
PRESSURIZE WITH NITROGEN CO2 OR COMPRESSED AIRONLY
WARNING THE DISPENSER MAY RUPTURE IF OVERPRESSURIZED
DONOT ATTEMPT PRESSURIZATION WITHOUTA REGULATED
CHARGING SOURCE DO NOT USE LOCKING TYPE INFLATION
CHUCKS
1 Invert canister and depress valve lever to release all remaining pressure
2 Making sure the dispenser has no pressure remaining unscrew the valve head from the
bottle and empty any remaining liquid
3 Fill the empty plastic bottle in the refill kit with clean cool water
4 Place funnel into neck of bottle and pour contents of plastic bottle approximately 215
grams 75ozs 225 mL into the funnel ONLY FILL WITH CLEAN WATER
5 Observe O Ring on valve If it is warped or cracked replace withnew O Ring
6 Place firing handle including the valve back onto canister and hand tighten until the
handle is tightened firmly against the top of the canister
PLEASE NOTE THE FIRINGHANDLE MUST BE TIGHTENED FIRMLY j
ONTO THE BOTTLE OR LEAKAGE WILLOCCUR
7 Remove the protective cap from the Schrader Valve
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-9 I    I  
The -9 refillable unit as developed ith training in ind. The unit delivers a strea  
tt r  t  -30 f t / -10 t rs. is it ill r i e   s  rsts f re it s 
r filli . It  t  e firin  i   t  -r filla le -9 it,  i   t 
e ing l r ti e. 
 i rt -9 fill it t i : fill I tr ti , l ti  el, fill ttl ,  
er O-Ri . 
        I  
 I . It is essential that the user follo s all safety procedures prescribed by Security 
i t r r ti . 
•   I . 
• I  I  I , 0    I  . 
• I :       SURIZED. 
   SURI     
 .       
. 
. I ert ca ister a  e ress al e le er t  release all re ai i  ressure. 
2. aking sure the dispenser has no pressure re aining, unscre  the valve head fro  the 
bottle and e pty any re aining liquid. 
3. ill the e pty plastic bottle in the refill kit ith clean, cool ater. 
4. Place funnel into neck of bottle and pour contents of plastic bottle, approximately, 215 
gra s (7 .5 OZS., 225 L), into the funnel. ONLY FILL IT  CLEAN ATER. 
5. bserve 0 ing on valve. If it is arped or cracked, replace ith ne  0 ing. 
6. Place firing handle, including the valve, back onto canister and hand tighten until the 
handle is tightened fir ly against the top of the canister. 
S  :       I  
      CCUR!!! 
7. Remove the protective cap from the Schrader Valve. 
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CONFIDENTIAL
8 Before beginning pressurization verify that the inflation chuck does not lock down on
the stem
9 The system includes a pressure gauge DO NOT PRESSURIZE THE UNITPAST
250 PSI
NITROGEN PROPELLANT FILLING INSTRUCTIONS
1 Open Nitrogen valve on the cylinder and adjust the regulator to 250 PSI
2 Engage the air chuck and begin pressurizing for 10 seconds until the pressure has
equalized Internal pressure will reach approximately 220 PSI
WARNING NEVER EXCEED 275 PSI WHILE PRESSURIZING IF YOU HEARA
HISSING NOISE STOP PRESSURIZATION
3 If the canister is accidentally over pressurized turn the MK9 upsidedown and press
the yellow lever to relieve the excess pressure
4 Replace the protective cap on the Schrader Valve
CO2 PROPELLANT FILLING INSTRUCTIONS
1 Open CO2 valve on the cylinder and adjust the regulator to 500 PSI
2 Engage the air chuck and begin pressurizing for 25to 3 seconds Internal pressure
will reach approximately 250 PSI
3 By pressurizing the canister for25 to 3 seconds approximately 125grams of CO2
will be added to the canister The MK9 Total Filled Weight is approximately 600 g
4 DO NOT FILL THE MK9 greater than 600 g
WARNING WARNING NEVER EXCEED 275 PSI WHILE PRESSURIZING IF
YOU HEAR A HISSING NOISE STOP PRESSURIZATION
5 If the canister is accidentally over pressurized turn the MK9 upsidedown and press
the yellow lever to relieve the excess pressure
6 Replace the protective cap on the Schrader Valve
COMPRESSED AIR PROPELLANT FILLING INSTRUCTIONS
1 Open valve on the cylinder and adjust the regulator to 250 PSI
2 Engage the air chuck and begin pressurizing for 10 seconds until the pressure has
equalized Internal pressure will reach approximately 250 PSI
WARNING WARNING NEVER EXCEED 275 PSI WHILE PRESSURIZING IF
YOU HEAR A HISSING NOISE STOP PRESSURIZATION
3 If the canister is accidentally over pressurized turn the MK9 upside down and press
the yellow lever to relieve the excess pressure
4 Replace the protective cap on the Schrader Valve
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. f re i ing r ri ti , rif  t t t  i flati    t l    
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1. pen itrogen valve on the cylinder and adjust the regulator to 250 I. 
. e t  ir   i  r ssuri i  f r   s s til t  r ss r  s 
e alize . I ternal ress re ill reac  a r i atel   I. 
: E    I.  SURIZI ,     
IS I  I ,  SURIZA I . 
3. If the canister is accidentally over pressurized, turn the ·9 upside do n and press 
t  ll  l  t  lie e t   . 
. e lace t e r tective ca   t e c ra er al e. 
0    I : 
1. Open C02 valve on the cylinder and adjust the regulator to 500 PSI. 
2. Engage the air chuck and begin pressurizing for 2.5 to 3 seconds. Internal pressure 
ill reach approxi ately 250 I. 
3. By pressurizing the canister for 2.5 to 3 seconds, approxi ately 12.5 gra s of C02 
ill   t  t e ister.  -9 t l ille  i t is r i t l   . 
.     -9    . 
I : I :    I.  SURIZI ,  
    ,  SURIZATI . 
. If t  ister is i t ll  r r ssurized, t r  t  -9 si    r ss 
t  ll  l r t  r lie  t  ess r r . 
6. eplace the protective cap on the Schrader alve. 
  EL  I  I : 
1. Open valve on the cylinder and adjust the regulator to 250 PSI. 
2. Engage the air chuck and begin pressurizing for 10 seconds until the pressure has 
equalized. Internal pressure ill reach approxi ately 250 PSI. 
I : I : E    I. I  SURIZI , I  
 R  IS I  I ,  SSURIZATI . 
3. If the canister is accidentally over pressurized, turn the -9 upside do n and press 
t e ell  le er t  relie e t e e cess ress re. 
4. Replace the protective cap on the Schrader alve. 
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SABRE DECON STEP I STEP II
It is impossible to both clean and soothe the skin with a single decontamination formula
SABRE DECON uses two unique solutions to combat the effects of Oleoresin Capsicum
prevent reactivation and stop further spreading of OC to limit contaminated areas
CLEANSE STEP I
Cleanse effectively removes OC from the skin prevents additional penetration into the pores
and further spreading of OC
Immediately after contamination wash thoroughly with the Step I Cleanse solution in the
GREEN labeled bottle
Wash with large amounts of Step 1 Cleanse solution until a thick soapy lather
develops scrub vigorously about 30 seconds per application Very Important DO
NOTRUB OVER YOUR EYES
Rinse with Cold water until all soapy lather is removed including hands
Repeat Step I Cleanse process 34 times over the next few minutes
Rinse out eyes for about 5 10 minutes then go on to the Soothe application
SOOTIIE STEP II
Moistens cleansed skin treated by Step 1 and dramatically reduces the affects ofOC
Complete instructions of Step I Cleanse before applying Step II Soothe
Thoroughly shake Step II Soothe in the Blue Labeled bottle then apply copious amounts
of solution to exposed areas Pat the solution onto the skin
Repeat Step II Soothe solution as it becomes dry on the skin Some discomfort may return
as the solution dries
Reapply Step II Soothe solution multiple times if discomfort continues
Do not use these products if you are pregnant nursing or have a known sensitivity to
aspirin containing products Do not use on children Do not use beyond the expiration
date Ask female subjects if they are pregnant or nursing If they confirm they are
pregnant or nursing do not apply or let them apply these products
The 4 oz field treatment model is ideal for use on officers and subjects after deploying
chemical agents to control subjectsinmatesVehicl Intake areas Arsenal Room EMS
The 1 gallon size is ideal for decontaminating multiple recruits or inservice officers
after chemical agent contamination drills Training Academy
1 Gallon Cleanse and Soothe 4 Ounce Cleanse and Soothe
Decon Approximately 200 Decon Approximately 6
Both have a two year shelf life
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  -  I & ST  II 
It is i possible to both clean and soothe the skin ith a single decontamination fonnula. 
SA E E  uses t o unique solutions to co bat the effects of Oleoresin Capsicum, 
prevent reactivation, and stop further spreading of  to li it conta inated areas. 
CLEANSE - STEP I 
leanse effectively re oves  fro  the skin, prevents additional penetration into the pores 
a  r spreadi  f . 
• I di tel  aft r t i ti  h t r hl  it  t  t p I Cl  soluti n i  t  
EE  labeled bottle. 
• ash ith large a ounts of Step 1 leanse solution until a thick soapy lather 
develops (scrub vigorously) about 30 seconds per application ( ery I portant)!  
    S! 
• Rinse with Cold water until all soapy lather is re oved, including hands. 
 t  I   -4   t  t  i t s. 
 t ,    - 10 inutes, then go on to the Soothe application. 
SOOTHE -  II 
istens l s  s i  tr t   t  I  r ati ll  r s t  ff ts f C. 
• o plete instructions of tep I leanse before applying tep II oothe. 
• horoughly shake Step II Soothe in the lue abeled bottle then apply copious a ounts 
 l    .   l    i . 
• epeat Step II Soothe solution as it beco es dry on the skin. So e disco fort ay return 
as the solution dries. 
• -ap     l  e i es f  . 
o not use these products if you are pregnant, nursing or have a kno n sensitivity to 
aspirin containing products. Do not use on children. Do not use beyond the expiration 
date. sk fe ale subjects if they are pregnant or nursing. If they confir  they are 
pregnant or nursing, do not apply, or let the  apply these products. 
The 4 oz. field treatment model is ideal for use on officers and subjects after deploying 
chemical agents to control subjectsiinmates.(Vehicles, Intake areas, Arsenal Room, EMS) 
he  gallon size is ideal for dec ta inating ltiple recruits or i -ser ice fficers 
after che ical agent conta ination drills (Training cade y) 
I Ga lon Cleanse and Soothe 4 Ounce Cleanse and Soothe 
Decou A proximately 2 0 Decon Approximately 6 
Both have a two year shelf life. 
3 
( 
SEC 0364 
CONFIDENTIAL
Superior to 1 st and 2nd generation Aerosol Irritant Projectors Crossfire introduces
3rd generation technology which allows SABRE OC canisters to deploy continuously
from any position
Picture the face ofan analog clock which displays the time through the use of fixed
numbered dials and moving hands
o 1st generation OC sprays only deploy upright between the clocks10 and 2
dials
o 2nd generation OC sprays increase target acquisition with the addition of 2
second bursts deployments between the clocks4 and 8 dials
The 3rd generation Crossfire will deploy continuously from any position or dial on a
clock to maximize target acquisition when encountering aggressive subjects
Practice is required with Crossfire as target acquisition with an inverted canister may
be difficult at first Be sure to use caution in training
IM 03l Mal Generation OrdG
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SAB  C SSFI  
• Superior to 1st and 2nd generation erosollrritant Projectors, rossfire introduces 
3rd generation technology which allows SABRE OC canisters to deploy continuously 
  iti . 
• Picture the face of an analog clock which displays the ti e through the use of fixed 
r  i ls  ing ds. 
o 1st generation  sprays only deploy upright bet een the clock's 10 and 2 
dials. 
o 2nd generation C sprays increase target acquisition ith the addition of Y2 
 rsts l e ts t een t  l ck's    i l . 
• The 3rd generation Crossfire will deploy continuously from any position or dial on a 
clock to maximize target acquisition when encountering aggressive subjects. 
• Practice is required with Crossfire, as target acquisition with an inverted canister may 
be difficult at first. Be sure to use caution in training. 
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DEPLOYMENT VERSATILITY
IF NECESSARY SABRE MK2 MK3 MK35 MK4 CANISTERS WILL FIRE FROM
AN INVERTED POSITION
By firing upside down SABRE provides officers with a tactical safety advantage
allowing deployment with less effort during an altercation Officers are better able to
incapacitate subjects attempting to duck or block the spray Other products will not
fire upside down and if they are mistakenly fired from an inverted position it is very
likely that they will no longer fire right side up either
SABRE DPS SERIES
DELIVERY INVERTED PERFORMANCE
STREAM to 1 second bursts no shaking needed
CONE z second bursts only shaking required
SABRE H2O SERIES
DELIVERY INVERTED PERFORMANCE
STREAM z second bursts only no shaking needed
FOAM h second bursts only shake if necessary
SABRE VISUALIZATION PROCESS
The yelloworange liquid projected from SABRE canisters enables officers to see the areas
which have been contaminated This visualization process increases accuracy and allows
officers to use less spray to provide a quicker decontamination Furthermore the officer is
able to wipe the OC off the skin before water is used to decontaminate This will reduce the
amount of OC which contacts the subject eyes when decontamination takes place
000769
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 I  
IF , S BRE -2, -3, -3.5 & -4 ISTERS I  IRE  
N INVERTED I . 
y fIring upside do n, RE provides offIcers ith a tactical safety advantage 
allowing deployment with less effort during an altercation. OffIcers are better able to 
incapacitate subjects attempting to duck or block the spray. Other products will not 
fIre pside , and if the  are ista e l  fIre  fro  a  inverted siti , it is er  
likely that they ill no longer fire right side up either. 
   
I    
 
 
Y2 t    ursts -  ing . 
Y:z s  rsts l  - s i g r ir . 
 20  
 
 
AM . 
  
Y2  sts  -   . 
Y2 sec  rsts l  -   sary. 
  S  
he yello -orange liquid projected fro  S  canisters enables officers to see the areas 
i    t i t . is is li ti  r cess i reas s r   ll s 
officers to use less spray to provide a quicker deconta ination. Further ore, the officer is 
able to ipe the  off the skin before ater is used to deconta inate. his ill reduce the 
a ou,nt of  hich contacts the subject's eyes hen deconta ination takes place. 
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HYDRAULIC NEEDLE
At distances less than three 3 feet one 1 meter the possibility exists of injury to soft body
tissues such as the eyes Because of this Security Equipment recommends that officers do
not fire their SABRE products at distances of less than three 3 feet one 1 meter The
SABRE MK9 models should not be fired at distances less than six 6 feet two 2 meters
This will be worked on during the drills session
ULTRAVIOLET MARKING DYE
The UV marking dye allows officers to identify subjects which they sprayed for up to forty
eight 48 hours UV dye can be found on skin and clothing The UV Dye provides an
advantage during crowd control If a subject is later apprehended and denies being involved
in the previous altercation the UV dye can provide evidence linking the subject to the crime
NOMENCLATURE CHART
COVER
CAP
VALVE
iURE
ulb
1
s1 qi
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At distances less than three (3) feet / one (1) eter, the possibility exists of injury to soft body 
ti  s  as t  eyes.  f t is, ecurity i t  t t f i   
t fire t eir  r cts at ista ces of less t a  t ree ( ) feet / e (1) eter. e 
 -  ls s l  t e fir  at ist s l ss t  si  ( ) f t / t  (2) t rs. 
 ill    ri   ril  session. 
   
The UV marking dye allows officers to identify subjects which they sprayed for up to forty-
eight (48) hours.  dye can be found on skin and clothing. The  ye provides an 
advantage during cro d control. If a subject is later apprehended and denies being involved 
in the previous altercation, the UV dye can provide evidence linking the subject to the crime 
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STORAGE
Do not expose to temperatures exceeding 120 degrees F or488 degrees C
Aerosol projectors may lose pressure at temperatures below 32 degrees F or 0
Degrees C resulting in a decreased distance of spray pattern
H2O Series will fire effectively when exposed to zero 0 degrees Fahrenheit or
negative eighteen 18 degrees Celsius at twentyfour 24 hours
Store in a cool dry place at normal room temperatures
Shake if the canister has been in storage for a long period
Unlike other aerosol projectors SABRE does not require regular shaking When out
of storage it is recommended that canisters be test fired annually
FIRING MECHANISM
The FlipTop firing mechanism available in MK2 MK3 MK35MK4 and MK6 sizes
contains a safety cover designed to prevent accidental discharge which conveniently moves
out of the way for unobstructed access to the actuator when maneuvered by the users thumb
forefinger Providing access to the push button from one side only the flip top requires the
nozzle be pointed away from the user making it possible to fire the unit in little or no light
circumstances
The Trigger Top mechanism contains a break away safety This device must be removed
before the canister can be deployed for the first time It also allows agencies to visually
monitor whether or not canisters have been previously deployed After removing the safety
tab pull inward on the trigger mechanism with the index finger to deploy the spray The
trigger top is available on SABRE MK2 size canisters and all trigger top model numbers
begin with a 7
TRAINING CAUTION
In the article entitled Maintenance of Visual Acuity After Exposure to Oleoresin Capsicum
Spray Following LASIK from the Journal ofRefractive Surgery Volume 18 MayJune
2002 it is stated Since LASIK and OC exposure cause a decrease in corneal sensitivity and
the natural protection against an ocular foreign body is therefore compromised it would be
reasonable and prudent to advise against participation in such an OC training exercise for a
person who is less than three months after LASIK See appendix for full article
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~  t s  t  t r t r s i   re s  r 8. 8 r s . 
~ r l r j t r   l  r r  t t r t r  l   r   r  
egrees  resulting in a decreased distance f spray pattern. 
>- 0 eries ill fire effecti el  e  e se  t  zer  (0) e rees fahre eit r 
negative eighteen (18) degrees elsius at t enty-four (24) hours. 
~ t re i  a c ol, r  lace at r al r  te erat res. 
~ Shake if the canister has been in storage for a long period. 
(Unlike other aerosol projectors,  does not require regular shaking. hen out 
f st r , it is r  t t isters  t st fir  nnually.) 
  
e -Top  i ', i   -2, -3, -3.5, -4  -6 i s, 
c tai s a safet  c er esi e  t  re e t acci e tal isc ar e ic  c e ie tl  es 
t  t   f r tr t  ss t  t  t t r  r   t  r  t  / 
forefinger. Providing access to the push button fro  one side only, the flip-top requires the 
nozzle be pointed a ay fro  the user aking it possible to fire the unit in little or no light 
circ sta ces. 
he rigger op echanis  contains a break a ay safety. his device ust be re oved 
fore t  ister   l e  f r t  first ti . It l  ll  ies t  i ll  
." 
onitor hether or not canisters have been previously deployed. fter re oving the safety ( 
ta , ll i ar   t e tri er ec a is  it  t e i e  fm er t  e l  t e s ra . e 
trigger t  is il l    -2 si  ist rs  ll tri r t  l rs 
in it   "7". 
  
In the article entitled" aintenance of isual cuity fter xposure to leoresin apsicu  
pray ollo ing I ", fro  the Journal f efractive urgery (Volume 18 ay/June 
2), it is st t  "Since I    s re se  r s  i  r l s nsitivit ,  
the natural protection against an ocular foreign body is therefore co pro ised, it would be 
reasonable and prudent to advise against participation in such an  training exercise for a 
person ho is less than three onths after I ". (See appendix for full article). 
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WHEN TO USE AEROSOL PROJECTORS
USE OF FORCE CHART OCAT
Verbal NonVe
PR24 Draws
And Blocks
Passive Control
PR24 Restraint
OC Aerosol Sprays
Decentralization
PR24 Baton spins chops Jabs
Intermediate Force
PR24 Techniques
Neck Restraints
Chemical Agents
CN CS
Empty Hand Impact
Stunning Tactics
The situational force model requires selection of the least violent means available relative to
the situation The Officer relies upon reasoned discretion in making the selection
Officers at all times must be aware of the subjects actions and de escalate when the subject
stops resisting
38
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    (OeAT) 
Officer Presence 
r l I - erbal 
(P -2   
 ks) 
assive ontrol 
(P -24 tr i t) 
 e  s 
ecentralization 
(P -24 at  , s & Ja s) 
  
(PR-24 Techniques) 
 t  
e ical e ts 
/CS 
Empty Hand Impact 
(Stunning Tactics) 
he situational force odel re ires s le tion f the least violent ea s ila le relative to 
the situation. The Officer relies upon reasoned discretion in making the selection. 
Officer's, at all times, must be aware of the subjects actions, and de-escalate when the subject 
stops res . 
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SITUATIONAL FORCE MODEL OCAT
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Whenever an officer chooses to use force against an individual that officer is required to
prove that their actions were justified See Appendix item Graham v Connor The officer is
obligated to apply the least amount of force necessary to control an individual An officer
may immediately escalate to whatever use of force is necessary to take control of a situation
to protect his or her safety and the safety of others The higher the level of resistance the
higher will be the level of force necessary for an officer to control the subject However
when resistance stops and the subject is controlled the officer must deescalate immediately
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henever an officer chooses to use force against an individual, that officer is required to 
prove that their actions ere justified, See ppendix ite  raha  v. Connor The officer is. 
obligated to apply the least a ount of force necessary to control an individual. n officer 
a  i e iatel  escalate t  hate er se f f rce is ecessar  t  ta e c tr l f a sit ati  
to protect his or her safety and the safety of others, The higher the level of resistance, the 
higher ill be the level of force necessary for an officer to control the subject. o ever, 
e  resista ce st s, a  t e s ject is c tr lle , t e fficer st e-escalate i e iatel . 
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FACTORS WHICH EFFECT CHOOSEN LEVEL
OF FORCE
1 Number of Subjects The greater the number of subjects the greater the safety
risk to the officer which may cause the officer to escalate to a higher level of force
2Weapons If the subject has a weapon escalation is imperative
3 Size Strength The Size Strength of both the officer and the subject are
important factors in determining the appropriate level of force
4 SubjectsMental State Goal oriented subjects mentally ill subjects and subjects
under the influence of drugs or alcohol maybe more combative and difficult to control
which would require an escalation in force by the officer
5 Skill Level The subject may be trained in self defense martial arts or may have
significant fighting experience may have extensive military training All of which
may require the officer to escalate to a higher level of force
Much can be learned about a subject from neighbors and family There are several
people returning from the war what is their military specialty Were they marksman
infantry Special Forces demolition ect Getting information may aid in a peaceful
resolution It is also imperative that comprehensive reports of the entire incident are
completed as soon as possible Keep in mind these reports could become court
documents
6 Injury Fatigue Should either become an issue additional force may be
necessary
7 OfficersPosition If the officer falls or should end up on the ground while the
attacker is standing the officer is at a disadvantage and may need to opt for a higher
level of force
8 History with Subject Prior dealings with a subject may indicate to an officer that
the subject is carrying a firearm or has superior fighting skills Either case may cause
the officer to use additional force
9 Disability Officers with a disability may need to opt to an additional level of
force
10 DutyBelt Protection Officer should always protect hiser weapons from the
subject If the subject attempts or is able to obtain an officersweapon then escalation
to a higher level of force is imperative
It is imperative that officers consider all factors at hand when choosing the appropriate
level of force to take control of a subject The combination of all factors that affect
the level of response on the Use of Force chart would be the Totality of
Circumstances
40
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). r f ubj ct  - he greater the nu ber of subjects, the greater the safety 
risk to the officer, which ay cause the officer to escalate to a higher level of force. 
).  - If t  subj t s  apon, escalati  is i perative. 
). i  & t  - he Size & Strength of both the officer and the subject are 
i rta t fact rs in eter i i  t e appr riate le el f f rce. 
). ubject's   - Goal oriented subjects, mentally ill subjects, and subjects 
r t  i fl e  f r s r l l y  r  ti   iffi lt t  tr l 
i  l  r ir   c l ti  i  f r   t  ffi er. 
).  el- The subject may be trained in self-defense, martial arts, or may have 
significant fighting experience, may have extensive military training. All of which, 
ay require the officer to escalate to a higher level f force. 
uch can be learned about a subject fro  neighbors and fa ily. There are several 
people returning fro  the ar, hat is their ilitary specialty. ere they arks an, 
try, i  , oliti n, ct.. Getting information may aid in a peaceful 
resolution. It is also i perative that co prehensive reports of the entire incident are 
co pleted as soon as possible. eep in ind these reports could beco e court 
docu ents. 
).  & igue - Should either beco e an issue, additional force ay be 
sary. 
). f i er's ition - If the officer falls or should end up on the ground hile the 
attacker is standing, the officer is at a disadvantage and may need to opt for a higher 
le el f f r . 
). istory t  e t - Prior dealings with a subject may indicate to an officer that 
the subject is carrying a firear  or has superior fighting skills. Either case ay cause 
the officer t  use tional . 
9). isa lity - Officers with a disability may need to opt to an additional level of 
force. 
). uty-Belt r te tion - Officer should always protect hislher weapons from the 
subject If the subject attempts or is able to obtain an officer's weapon, then escalation 
to a higher level of force is i perati e. 
It is imperative that officers consider all factors at hand when choosing the appropriate 
level of force to take control of a subject. he co bination of all factors that affect 
the level of response on the Use of Force chart would be the "Totality of 
ircu t ces. " 
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PROPER USE OF AEROSOL PROJECTORS
Instruct
Verbal commands should be short and loud such as Do It Now Stop No
Get Down Verbal commands may cause submission confusion or disorientation
making it easier for the officer to take control of the situation
Draw
Straight Draw Officer draws the unit from the holster and removes the canister with
the hand on the side of the body that the unit is on
Tactical Draw Officer draws the unit from the holster and removes the canister with
the hand on the opposite side of the body from the holster
Officers should repeatedly practice removing their canister from their holster until
they can remove the canister in a controlled but rapid motion
Grip
Hold together and extend fingers firmly around the canister The thumb or actuation
finger should be positioned over the safety lid until the officers is ready to fire the
canister
Actuation
The officer should use either the index finger or thumb to fire the canister There are
more advantages in using the thumb to actuate the unit because it is easiest to
maneuver the thumb from the actuator to other parts of the canister and the thumb
allows the user to apply greater pressure on the actuator to ensure release of the OC
Short Bursts
Press actuator and fire at subject face in 2 second to 1second bursts It is not
recommended that an individual be sprayed more than three times If incapacitation
does not take place after 3 bursts of spray then the officer should escalate to a higher
level of force
Move
Upon spraying a subject the officer should shuffle step to the side Subjects will most
likely be unable to open their eyes and they will attack the area where the officer was
while spraying the canister Officers should never stay in one place after having
sprayed a subject
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Instruct 
 
 
r l s s l   s rt  l d, s  s  It w; top; o; 
t .     sub ission, onfusion,  i ri t ti  
     ic    tr l  t  i ti n. 
trai t ra  -    it       i  i  
t    t  i   t   t t t  it i  . 
actical ra  -    i          
t    t  it  i   t    t  l t r. 
fficers s l  r t l  r ti  r i  t ir ist r fr  t ir lst r til 
they can re ove the canister in a controlled but rapid otion. 
l  t t   t  ingers i l   t  i t r.  t   t ti  
finger should be positioned over the safety lid until the officers is ready to fire the 
ister. 
t ti  
e fficer s l  se eit er t e i e  fi er r t  t  fire t e ca ister. ere are 
re a ta es i  si  t e t  t  t t  t  it s  it is si st t  
aneuver the thu b fro  the actuator to other parts of the canister, and the thu b 
all s t e ser t  a l  reater ress re  t e act at r t  e s re release f t e oc. 
t s  
ove 
Press actuator and fire at subject's face in 12 second to 1-second bursts.    
r e e  that  i i i l  s r  r  t  t ree ti s. If i it ti  
does not take place after 3 bursts of spray, then the officer should escalate to a higher 
l l f f r . 
pon spraying a subject, the officer should shuffle step to the side. Subjects ill ost 
likely be unable to open their eyes and they ill attack the area here the officer as 
hile spraying the canister. Officers should never stay in one place after having 
s ra e  a s ject. 
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Prior to spraying the subject the officer should be moving to create distance which
will allow time to deploy the necessary weapon The officer may use lateral steps to
change direction
Secure
Once the subject has been sprayed and incapacitation begins the subject should be
commanded to cooperate Carefully approach the subject with your safety in mind
After the subject has been properly restrained decontamination should begin as soon
as possible Reassure the subject that they will be okay and the effects will diminish
Transport
While transporting monitor the subject for medical distress respiration or other
physical ailments Remind the subject that they will be okay and that the effects will
continue to diminish
Incarceration
After the subject has been detained heshe should be monitored for at least two hours
after the contamination takes place If their behavior suddenly changes this could be
the result of a medical emergency Contact EMS
i
000776
( 
FIDENTIAL 
ec re 
i  t  r i  t  ubject, t  f i  h l   i  t  t  i t nce, i  
ill all  ti e t  e l  t e ecessar  eapon. e fficer a  se lateral ste s t  
 ti . 
nce the subject has been sprayed and incapacitation begins, the subject should be 
co anded to cooperate. Carefully approach the subject with your safety in ind. 
fter the subject has been properly restrained, deconta ination should begin as soon 
as ssible. eass re t e s ject t at t e  ill e a  a  t e effects ill i i ish. 
 
ile tra sporti , it r t e s ject f r e ical istress, respirati  r t er 
physical ail ents. Re ind the subject that they ill be okay, and that the effects ill 
  . 
I r r ti  
fter t  j t   t i d, /s  l   it r  f r t l t t  r  
after t e c ta i ati  ta es lace. If t eir e a i r s e l  c a es t is c l  e 
t  r lt   i l r cy. t t . 
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SUBJECT DECONTAMINATION
After the subject has been properly restrained remove the subject from the contaminated area
and immediately examine to ensure that the subject is breathing properly Then ask the
subject if they have any pre existing medical conditions which include
Heart Problems
Respiratory Problems
Lung Problems
Diabetes
High Blood Pressure
If a serious medical condition exists call EMS immediately
In addition to the above call EMS immediately for any of the following reasons
Subject is under the influence ofAlcohol andor drugs
Subject is experiencing significantfi t breathing difficulty
In many cases normal breathing patterns can be restored by asking the subject
simple questions and insisting on answers This will distract and calm the
subject
Subject requests medical attention
Subject loses consciousness Apply CPR ifnecessary
Shallow breathing combined with sweating f
Afterth initial examination has taken place begin the decontamination process
If available remove the resin from the facial area with a wet or dry towel Paper
towels have been used successful to remove the resin from the skin to speed up the
decontamination period Press a wet paper towel onto the skin and then repeat using a
dry paper towel This task should be repeated numerous times to remove theresin
If available apply cool running water to the subject eyes and facial area Be sure to
thoroughly flush the eyes A garden hose held upright to the sky until 1 s inches of
water deploys will create the proper water pressure for decontamination The hose
should be held over the bridge of the nose aiming horizontally over one eye towards
the outside of the face so as not to recontaminate the other eye A drinking fountain or
decontaminate solution may also be used if a hose is not available Do not use
commercial eyewash or creams The creams will trap the resin in the skin causing
increased pain Another way to decontaminate is to cup the hand under water place
the eye into the cupped hand and let the water force theproduct out
Do not remove the subject contacts Only Medical personnel should remove them
Hard contacts should be cleaned thoroughly and soft contacts should be discarded
Ice can also be applied to burning areas Do not allow the subject to rub the burning
areas The subject should also be told not to rub the eves
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fter t  je t s  r rl  r tr i , r e t  j t fr  t  t i t  r , 
and i ediately exa ine to ensure that the subject is breathing properly. hen, ask the 
j t if t    re- i ti  i l iti , i  i l e: 
• rt r le s 
•   
•  le s 
• Diabetes 
• i  l  r r  
  rious i l ition i t , ll  i i t l . 
I  addition to the above, call  i ediately for any f the follo ing reasons: 
• ject i  r t  i fluence  lco l nd/or r . 
• ject  e ing can  t  i lty. 
(In any cases, nor al breathing patterns can be restored by asking the subject 
si le esti s a  i sisti   a s ers. is ill istract a  cal  t e 
subject.) 
• ubject requests edical attention. 
• ubject loses consciousness. pply  if necessary. 
• hallo  breathing co bined ith s eating. 
fterthe initial exa ination has taken place, begin the deconta ination process. 
 il l ,       ea   t   el.  
els      e          
deconta ination period. Press a et paper to el onto the skin and then repeat using a 
dry paper to el. his task should be repeated nu erous ti es to re ove the resin. 
If available, apply cool running water to the subject's eyes and facial area. Be sure to 
thoroughly flush the eyes.  garden hose held upright to the sky until 1 Y2 inches of 
ater deploys ill create the proper ater pressure for deconta ination. he hose 
should be held over the bridge of the nose ai ing horizontally over one eye to ards 
the outside f the face so as not to re-conta inate the other eye.  drinking fountain or 
deconta inate solution ay also be used if a hose is not available.    
co ercial eye ash or crea s.  r  ill tr  t  r i  i  t  i  i  
increased pain. nother ay to deconta inate is to cup the hand under ater, place 
the eye into the cupped hand and let the ater force the product out. 
o not re ove the subject's contacts. nly edical personnel should re ove the . 
ard contacts should be cleaned thoroughly and soft contacts should be discarded. 
Ice ca  als  e a lie  t  r i  areas.  t all  t e s ject t  r  t e r i  ( 
s.           y s. 
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If water is not available or after it has been applied expose the subject to fresh
moving air Turn them in the direction of the moving wind Placing them in front of a
fan or air conditioner will also work NOTE Placing a subject in front of a fan or air
conditioner may dry the eyes causing additional discomfort If you do this keep the
eyes closed and just cool the skin
Eye Strobbing will help to speed up the recovery period by creating natural tears
Close eyes tightly and then open widely Do not use hands to assist with opening and
closing of eyes Only the eye muscles should be engaged to complete this process
Repeat numerous times to create natural flow of tears to reduce dryness and irritation
Throughout the decontamination process the officer needs to continually reassure the
subject to remain calm and remind the subject that the effects are only temporary
Verbal reassurance is one of most important steps of the decontamination process
The Ioss of breath sensation coupled with the burning of the eyes and facial area may
cause the subject to panic If the subject panics they may begin to hyperventilate
which could cause the subject to lose consciousness Constant reassurance that they
will recover fully in a few minutes will prevent or end a panic attack If a panic attack
begins inform the subject that they are hyperventilating and they need to calm down
and slow down their breathing They should be informed to take slow deep breaths
The subject should begin to feel significant relief within in 20 to 30 minutes Most
effects will have completely subsided within one hour If the subject is not feeling
significant relief after 45 minutes contact EMS
Be sure the subject is dry from OC before transporting begins
The length of the decontamination period will likely vary with each subiect There are
many factors affecting the length of the decontamination which include
Target Acquisition Area
Humidity
Wind
Subject Cooperation
Keeping the Subject Calm and Focused
Available Decontamination Resources
It is essential during decontamination that the officer also remain calm focused and in
control Proper decontamination is very important and should be handled in a serious
business like and professionalmanner
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If water is not available, or after it has been applied, expose the subject to fresh 
movi  air. T m the  in the direction of th  ovi  wind. Placing the  in front of a 
fan or air conditi er ill also ork. NOTE: Placi  a subject in front of a fan or air 
conditioner ay dry the eyes causing additional discomfort. If you do this, keep the 
eyes cl d and j t cool the skin. 
ye Strobbing ill help to speed up the recovery period by creating natural tears. 
Close eyes tightly and then open widely. Do not use hands to assist with opening and 
closing of eyes. nly the eye uscles should be engaged to co plete this process. 
epeat nu erous ti es to create natural flo  oftears to reduce dryness and irritation. 
Throughout the decontamination process the officer needs to continually reassure the 
subject to re ain cal  and re ind the subject that the effects are only te porary. 
erbal reassurance is one of ost i portant steps of the deconta ination process. 
The loss of breath sensation coupled ith the burning of the eyes and facial area ay 
cause the subject to panic. If the subject panics, they may begin to hyperventilate 
which could cause the subject to lose consciousness. Constant reassurance that they 
ill recover fully in a fe  inutes ill prevent or end a panic attack. If a panic attack 
begins, infor  the subject that they are hyperventilating and they need to cal  do n 
and slow down their breathing. They should be informed to take slow deep breaths. 
   i   l i i  l f      s.  
effects will have completely subsided within one bour. If the subject is not feeling 
ica t  t r  ,  . 
 s r  t  s j t is r  fr   f re tr s rti  i s. 
be length oftbe deconta ination period ill likely vary ith each subject. here are 
 fa tors ff tin  t e l t  f t  t i ti  ic  i l : 
~ arget cq is tion rea 
~ t  
~ ind 
~ ject ooperation 
}> ee ing t  bject al   cuse  
}> vailable e t ation es urces 
It is ss tial ring e t i ation that the fficer lso re ain l , focuse  d in 
control. Proper decontamination is very important and should be bandIed in a serious, 
busine s like and profess  ma . 
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REPORTING FORCE
Most Law Enforcement Agencies have an existing report in place to be completed
after an officer uses force to control a subject Security Equipment Corporation
recommends that the following be documented in the report
Officers at the scene
Verbal correspondence between the officers and subject prior to the
physical encounter
Subjectsreaction to verbal commands
Subject response to physical control techniques
Why the encounter began
Why it could not be avoided
Control used
How long did the resistance last
Deescalation techniques used after subject submitted
Concerns you had causing you to escalate to the chosen level of force
Decontamination process if OC was used
Details of the transport
Second to decontamination properlreportingforceis one of the most important topics of
this program Producing a comprehensive report shortly after the incident takes places will
significantly justify your chosen level of force should it ever come into question By taking
the time to produce a thorough and welldocumented report you will likelysave yourself a
significant amount of time by avoiding an investigation ofyour actions Keep in mind that
video cameras are everywhere Be sure your reports are as accurate and complete as possible
You may not always know you are being recorded you should treat every situation as though
it were being recorded
NOTE DO NOT LEAVE FORCE HANGING
Whenever an Officer decides to escalate force it is
essential that the Officer also show the deescalation of
force in hisher report
000779
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TI   
ost La  Enforce ent gencies have an existing report in place to be completed 
after an officer uses force to control a subject. Security Equip ent Corporation 
reco ends that the follo ing be docu ented in the report: 
> f r  at the scene. 
~ erbal correspondence bet een the officers and subject prior to the 
i l encounter. 
> Subject's r cti  to r l ands. 
~ Subject's res se t  sical c tr l techni ues. 
~  t  t r gan. 
~  i  coul  t  voided. 
~ tr l sed. 
~  l  i   i  l st? 
~ e-escalation techniques used after subject sub itted. 
~ oncerns you had causing you to escalate to the chosen level offorce. 
~     ed. 
~ t il   t  t port. 
..... 
Second to decontamination, properly reporting force is one of the most important topics of 
this program. Producing a comprehensive report shortly after the incident takes places will 
significantly justify your chosen level of force should it ever come into question. By taking 
the ti e to produce a thorough and ell-docu ented report, you ill likely save yourself a ( 
significant amount of time by avoiding an investigation of your actions. Keep in mind that 
video ca eras are everywhere. Be sure your reports are as accurate and co plete as possible. 
You may not always know you are being recorded; you should treat every situation as though 
t ere  r . 
:     GING!!! 
henever an fficer decides to escalate force, it is 
ti l t t t  ffic  ls   t e - l ti  f 
fo ce i  is/he  rt. 
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PRACTICAL TRAINING
The following training issues will be covered in the range session of this class Inert products
will be used
Movement Patterns You should always be able to side step the attacker If the subject you
are spraying is moving towards you you must be able to side step the attackersmomentum
The fact heshe cannot see you does not mean that the attack is over Be in the athletic
position and be ready to defend yourself
Reactionary Gap The reactionary gap puts the officer at a safe distance to respond to the
subject movements after the subject has been exposed to SABRE SABRE is not the final
means to the end of the situation You must continue to react until the subject is under
control
Range of Product It is important for officers to be fully aware of the range of the various
products and when to begin to use the products
Verbalization Officers should continue to give orders to the subject after heshe has t
been sprayed Get down stop on the ground before you fall dontmove dontrub
your eyes Communicating with the subject also causes breathing As long as the subject is I
talking heshe is breathing This is also good when there are bystanders it shows a human
side of the officer Remember video cameras are everywhere
Drawing Officers should work on drawing their OC This will instill in the
officer the importance of carry location
Contamination Officers should work on moving their canister in different patterns
Moving the canister ensures a proper contamination Remember the target location Eyes
Nose and Mouth A stream must be moved around to affect all areas
Mandatory Contamination Thismay save your life someday OC is sold everywhere
which increases the officerschance of being sprayed with OC This contamination will show
you that you can survive in the event that you are sprayed on duty It also offers the following
advantages
1 Lends credibility while on the stand in a court of law
2 It helps ensure handgun retention
3 It provides experience in observing a recovery period
4 Permits the officer to understand what the subject is experiencing
The contamination should be dynamic rather than passive Officers will gain the realistic
view of the advantages and limitations of OC Officers should defend themselves after the
contamination which will build confidence in the event ofan on duty contamination
Decontaminating the subject is considered de escalation of force and should be
properly documented in all use of force reports
Contamination Should NEVER be done with a finger or a Cotton Swab This has been found
to be excessive force and should be avoided See the Humboldt County Case in the Appendix
000780
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RACTI  T AI I  
The follo ing training issues will be covered in the range session of this class. Inert products 
will be used. 
ove ent Patterns: You should always be able to side step the attacker. If the subject you 
are spraying is oving to ards you, you ust be able to side step the attacker's momentum. 
T e f ct h l  cannot se  u does not ean t t the at ack is over. Be in the athletic 
ositi  and  r ady t  def nd y urself. 
eacti r  ap: The reactionary gap puts the officer at a safe distance to respond to the 
subject's e e ts after t e subject has ee  ex se  t  ABRE. SA  is ot the fi al 
means to the end of the situation. You must continue to react until the subject is under 
control. 
a e f roduct: It is i portant for officers to be fully a are of the range of the various 
r cts, a   t  i    t  r cts. 
Verbalization: fficers should continue to give orders to the subject after helshe has 
 prayed. "Ge  ", "st ", "o  t  r  f r   f ll", "d n't v ", "d n't r  
 ". Communicating with the subject also causes breathing. As long as the subject is 
talking, helshe is breathing. his is also good hen there are bystanders; it sho s a hu an 
si  f t  ffi er. e ber, i  ras r  r r . 
rawing: fficers should ork on dra ing their ac. his ill instill in the 
  t   r  ti n. 
Conta ination: Officers should work on oving their canister in different patterns. 
Moving the canister ensures a proper contamination. Remember the target location: Eyes, . 
se  th.     e      . 
andatory Conta ination: This ay save your life so eday! ae is sold everywhere, 
hich increases the officer's chance f being sprayed ith ae. his conta ination ill sho  
you that you can survive in the event that you are sprayed on duty. It also offers the following 
: 
1. 
2. 
3. 
4. 
ends i i    e       
It el s e s re a  rete tio  
It provides experience in observing a recovery period 
Per its the officer to understand hat the subject is experiencing 
The conta ination should be dyna ic rather than passive. fficers ill gain the realistic 
ie  of the advantages and limitations of ac. fficers s ld fe  the selves after the 
contamination, which will build confidence in the event of an on duty contamination. 
econta inating the s ject is considered d - l tion off rce  s ld be 
properly docu ented in all use of force re rt . 
Conta ination Should NEVER be done ith a finger or a Cotton S ab. This has been found 
to be excessive force and should be avoided. See the Humboldt County Case in the Appendix 
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DECONTAMINATION GUIDE
The process of decontamination is one ofthe most important topics ofyour training
day
Properly decontaminating your students will aid in getting everyone home safely and
avoid costly litigation and medical issues
The process of decontamination should be well thought out and planned for in advance
of your training day
You should have members ofyour team available to assist you on this day so that you
are not alone to handle everything being done
o It is recommended to have at least four4male and two2 female staff
members who are familiar with the decontamination process more if you have
extremely large classes It is important that you have female staff present if
you have female trainees
Set your decontamination team up in stations to simplify the process and to help
everyone know their area of responsibility
Station One This is for the immediate rinsing of the face to remove excess
OC from the skin Conduct SABRE DECON Cleanse Step I
Station Two Thoroughly rinse each eye for at least five minutes per eye
Hold the hose over the bridge of the nose aiming away from the opposite eye
This prevents further contamination of the opposite eye
Station Three This station is to make sure the trainee is feeling relief and to
jhelp apply SABRE Soothe follow directions on SABRE Soothe label Once
the trainee is feeling better they will be led inside to change into dry clothing
at this station This will help to prevent hypothermia especially during the
winter months Be sure all dry clothing is in this area prior to contaminations
Station Four This station is to monitor the trainees as they walk around in
the fresh air ifpossible This Officer will make sure that all trainees remain
within the training area designated for them at this point No one is allowed to
leave this area until the lead instructor has determined that they are
decontaminated enough to drive If the female staff trainers are done they will
help at this station Every trainee will end up in this area and it will become a
very busy area to watch
If the trainees are bused to the training site they can be moved back to the starting
point of the day as long as the bus driver did not receive a contamination Again no
one is allowed to leave the area until the lead trainer is satisfied that they can drive a
vehicle SAFELY
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• The process of decontamination is one of the most i portant topics of your training 
day. 
• roperly decontami ati  r stude ts ill ai  in getti  every e ho e safely and 
avoid stl  liti ti n and edical issues. 
• he process of deconta ination should be ell thought out and planned for in advance 
of r t i i  ay. 
• You should have e bers of your tea  available to assist you on this day, so that you 
are t al e t  a le everythi  ei  one. 
o Itis reco ended to have at least four (4) ale and t o (2) fe ale staff 
e bers who are fa iliar with the deconta ination process ( ore if you have 
extre ely large classes). It is i portant that you have fe ale staff present if 
  l  t i s. 
• et r ec ta i ati  tea  up i  stati s to si plif  t e r cess a  t  el  
     sponsibil ty. 
o t ti   - This is for the i ediate rinsing of the face to re ove excess 
   kin.    -  - Step I 
o t ti   - Thoroughly rinse each eye for at least five minutes per eye. 
Hold the hose over the bridge of the nose aiming away from the opposite eye. 
his prevents further conta ination of the opposite eye. 
o Station Three - This station is to make sure the trainee is feeling relief and to 
help apply S  Soothe (follo  directions on S  Soothe label). nce 
the trainee is feeling better, they will be led inside to change into dry clothing 
at this station. This will help to prevent hypother ia, especially during the 
winter months. (Be sure all dry clothing is in this area prior to contaminations). 
o Station Four - his station is to onitor the trainees as they alk around in 
t e fres  ir (if ssible). is fficer ill  s r  t t ll trainees r i  
ithin the training area designated for the  at this point. o one is allo ed to 
leave this area until the lead instructor has deter ined that they are 
decontaminated enough to drive. If the female staff trainers are done they will 
help at this station. Every trainee ill end up in this area, and it ill beco e a 
r  us  rea to t . 
• If the trainees are bused to the training site, they can be oved back to the starting 
point of the day as long as the bus driver did not receive a contamination. Again, no 
one is allowed to leave the area until the lead trainer is satisfied that they can drive a 
ve le . 
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DRILLS
Proper Grip of Canister Finger Thumb on Actuator
Drawing from Strong and weak side
Range of product Use partners to work on best distance from the subject
Work on drills to avoid Hydraulic Needle Push out Back out
Work on weapon retention prior to contamination drill Officers should be
walked through what is expected of them
Work on procedure for calling for assistance Recognize safe areas actual
location by landmarks back to safety which will allow us to deal with only 180
degrees as opposed to 360 degrees
Contamination Drill Teach Safety First Stay safe
SECStatement We realize you must follow your agencysSOP in regards to an on duty
contamination However Security Equipment Corporation feels that it is in the best interest of
the Officer NOT to confront the subject after the officer has been contaminated You are at a
disadvantage once contaminated Therefore we recommend that you get to a safe location
call for assistance protect your weapon and be able to defend against an attack but not
initiate anything physical with the subject
Armed Officer
Spray Officer can be done as surprise as you are talking to the group
Attack the Officer half speed
Officer should be able to defend against attack
P Officer should be flashing an eye to see you Can use Tactical C
forefinger and thumb used to open eye
If the Officer draws hiser weapon back out Attack is over at this point
Officer needs to call for assistance and be able to give exact location
Once the Officer can give exact location or repeat a pre determined
statement heshe can be brought to decontamination area
Make sure to observe the decontaminating officers You must keep control
of the area and know what is going on at all times
Once you have a couple of officers decontaminated they can be used to
assist with the decontamination of others Make sure to rotate the officers
so that everyone gets a good idea ofthe process
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I  
• Proper Grip of anister ( i er / Thumb) on Act ator 
• rawi g fr  Str  an  ak si  
• Range of product. ( se partners to ork on best distance fro  the subject). 
• ork on drills to avoid ydraulic eedle. (Push out / ack out). 
• r    r tenti  pri r t  conta i ti  drill. f i rs should be 
l  t r  t is ex t  f t em. 
• ork on procedure for calling for assistance. (Recognize safe areas, actual 
location by landmarks, back to safety which will allow us to deal with only 180 
     egrees. 
t i ti  rill:  f t  irst. t  f  
S.E.C. Statement: e realize you must follow your agency's S.O.P. in regards to an on duty 
t i ation. ver, curit  i t r r ti  f ls t t it is i  t  st i t r st f 
t  ffi r  t  fr t t  subj t ft r t  ffi r   t i t d.  r  t  
disadvantage once contaminated. Therefore, we recommend that you get to a safe location, 
call for assistance, protect your eapon, and be able to defend against an attack, but not 
i itiat  t i  i l it  t  bj ct. 
 i r: 
• Spray Officer- (can be done as surprise as you are talking to the group). 
• ttac  t e fficer - (half s d) 
• fficer l   l  t  f  i t tt k. 
,. fficer s l   fl s i    t  s  .  s  'Ta tic l ' 
(forefinger and thu b used to open eye). 
• If the Officer draws hislher weapon, back out. Attack is over at this point. 
• fficer needs to call for assistance and be able to give exact location. 
• nce the fficer can give exact location, or repeat a pre-deter ined 
state e t, e/she can e rought t  ec ta i ati  area. 
• Make sure to observe the decontaminating officers. You must keep control 
of the area and kno  hat is going on at all ti es. 
• nce you have a couple of officers deconta inated, they can be used to 
as st ith t  ation  . ake s re t  tate the fficers 
so that everyone gets a good idea of the process. 
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CONFIDENTIAL
Unarmed Officer
Spray the Officer Same as Armed Officer
Officer should immediately attempt to get to a safe location such as a
Control Center or other area where another Officer can keep watch
over you until help arrives
Officer should be able to activate a body alarm or call over a radio for
help
If there is no control center in the area the Officer should get to a safe
area and maintain control
The Officer may need to defend against an attack and should be able to
do so
The Officer should flash an eye Tactical C to be able to identify the
subjects
If there is no immediate backup remember to call for assistance and
defend against any attacks that may take place Do not initiate any
physical contact with the subjects SeeSECStatement above
These drills have been designed to help you defend against an attack We have designed them
with your safety in mind You must decide what level of force would be acceptable in each
situation There are several alternatives that will be dictated by the level of resistance or
attack offered by the subject The higher the level of resistanceattack the higher the level
of force that will be acceptable
000783
I I  
e  r: 
• ray t  fficer (Same s r e  ffi r) 
• fficer s l  i e iat l  tt t t  t t   s f  loc ti , s  s  ( 
tr l t r, r t r area here t er fficer   atch 
over you until help arrives. 
• fficer l  e le t  ti ate   l r , r ll r  r i  for 
l . 
• If there is no control center in the area, the fficer should get to a safe 
ea  a ntain l. 
• he ficer a   t   i t  tt ck,  l   l  to 
 s . 
• he fficer s l  flas   , 'Tactical ', t  e le t  i tif  t  
s j ts. 
• f e is  e iate ,     ,  
defend against any attacks that ay take place. o not initiate any 
sical c tact it  t e s jects. (See .E.C. tate e t a ove). 
es  rills   i  t  l   f  i t  tt ck. e  i  t  
ith your safety in ind. ou ust decide hat level offorce ould be acceptable in each 
sit ti . here r  s r l lt r tives t t ill e i tat   t  l l f r sist  r 
attack offered by the subject(s). The higher the level of resist ancei attack, the higher the level 
of force that will be acceptable. 
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OC AEROSOL PROJECTOR TEST
NAME 1 a OY
DATE b
1 What active ingredient in OC is responsible for pungency
A Pepper
B Oils
C Solvents
DCapsaicin
2 What are the two types of OC formulations
A Water Alcohol
B Water Salt
C Water Oil
D Water Pepper
3 The personal decontamination time for water based OC will usually be quicker than the personal
decontamination for oil basedOC
QD TRUE
B FALSE
4 What propellant is used in Sabre Red OC
A Isobutane
B Compressed Air
134aPand Nitrogen
D Carbon Dioxide
5 When breathing for decontamination it is recommended that you inhale through your mouth and
exhale through your nose to allow a continuous exchange of air to cleanse your respiratory
system
A TRUE
B FALSE
6 When making OC an emulsifier is used as a bonding agent to ensure even dispersion of the
Capsaicin
TRUE
FALSE
7 OC is classified as an
A Irritant
B Vitamin
C Lacrymator
tInflammatory
DEPOSITION
EXHIBIT
1
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~ 4aIP  tr  
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) e  reat i  f r ec ntamination, it is rec e e  t at you i ale t r  r t  and 
exhale through your nose to allow a continuous exchange of air to cleanse your respiratory 
t . 
®  
.  
)  i  , ~ lsifier is s  s  i  t t  s r   is rsi  f t  
aicin. 
CA\ .. __  lr. ___  
)  s a ied  (n) 
 .... 
 .~ 
~ 
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---. ita  
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OC AEROSOL PROJECTOR TEST
NAME
DATE
8 What are capsaicinoids
ZAgroup of compounds naturally occurring in the fats and oils
B A group of atoms naturally occurring in the fats and oils
C A Group of neutrons naturally occurring in the fats and oils
D A group of spots naturally occurring in the fats and oils
9 Which delivery system has the greatest potential for hydraulic needle effect
A Fog
B Cone
C
Ballistic stream
D Foam
10 What are the four types ofdelivery systems
iStreamCone Foam Fogger
B
Blast Pyrotechnic Liquid Aerosol
Stream Fogger Gas Aerosol
D Stream Cone Foam Blast
11 What is the recommended minimum distance for deploying MK 9 high volume projectors
A 3 feet
6 feet
C 9 feet
D 12 feet
12 What is the color code ofOC
A Red
Blue
QOrange
36 inches
D Yellow
13 What is the recommended minimum distance for deploying theMK 3 or MK 4
A 24 inches
B 32 inches
D 48 inches
000823
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8) hat are capsaicinoids? 
~ A group of compounds naturally occurring in the fats and oils. 
.  r   t s t r ll  rring i  t  f t   il . 
.  r   tr s t r ll  rri  in t  fats  il . 
.  group of spots naturally occurring in the fats and oils. 
) i  li r  s st  s t  r t st t ti l f r r lic l  ff ct? 
. Fog 
.  © istic  
.  
10) hat are the four types f delivery systems? 
CD Stream, Cone, Foam, Fogger ~ last, r tec nic, i i , er s l 
. trea , ogger, as, erosol 
. trea , e, a , last 
11) hat is the reco ended ini u  distance for deploying  9 high volu e projectors? 
.   
<JP   
.   
.   
12)       ? 
. ___  
. lue 
~ Orange 
.  
) at is t e rec e e  i i  ista ce f r e l i  t e   r  ? 
.   
.   ©   
.   
OC AEROSOL PROJECTOR TEST
NAME
DATE
14 What are the 3 distinct physical effects when contaminated with OC
Facial burning Eye closure Respiratory
B Air Wind and Water
Face Chest and Nose
Anxiety Fear and Panic
15 What are the 3 distinctmental effects when contaminated with OC
A Facial Burning Eye closure Respiratory
B Air Wind Water
C Face Chest Nose
D Anxiety Fear Panic
16 What is the first step in decontamination
A Raise the heat in the room
Provide immediate ventilation
C Wet the room down with hot water
D Call 911
17 You should use an oil based soap when decontaminating a person
A TRUE
FALSE
18 A first aid cream or lotion can be used to stop the inflammation on the face immediately after
contamination
A TRUE
FALSE
19 Officers should remove a subject contact lens as soon as possible
A TRUE
FALSE
20 Which delivery system produces the most aerosolized delivery
A Stream
Fogger
C Cone
D Foam
000824
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14) hat are the 3 distinct physical effects hen conta inated ith C? 
~ ___ ---' acial burning, ye closure, espiratory 
. ir, i ,  t  ' 
~ , t,  se 
~ nxiety, ear,and anic t1\'~ chLY'-'~~ 
) t r  t   i ti t t l ff t   t inated it  ? 
. Facial urning, Eye closure, espiratory 
. ir, i , t r 
. , st,  ® i ty, ar,  
) t is t e first t  i  t ination? 
. se e  n   
® ide  o  
. et    t    
. ll  
17) ou should use an oil-based soap hen deconta inating a person. 
.  S!0 F S  
18)  first aid crea  or lotion can be used to stop the infla ation on the face i ediately after 
i ti . 
.  
~ S  
19) fficers should re ove a subject's contact lens as soon as possible. 
.  ®_-c S  
) hich delivery syste  produces the ost aerosolized delivery? 
.  
~ er 
.  
.  
te
OC AEROSOL PROJECTOR PEST
NAME
DATE
Using the spray pattern below match them with the recommended spray method
DIRECTION OF SPRAY
21 C Stream
Cone
A b Fogger
A In a circular motion
B Up and Down nose to mouth
C Side to side Ear to Ear
24 The Sabre Red MK4 ballistic stream can be deployed with the can upside down
TRUE
B FALSE
25 Which delivery system is the most target specific
A Cone
B Fogger
Stream
V All ofthe above
Number Missed
Percentage
Minimum required scored 80
Instructor Y
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sing the spray pattern belo , atch the  ith the reco ended spray ethod. 
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. i  t  i  (Ea  t  ar) 
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~ T E 
. S  
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. _____  
. r 
\©. Stream 1i'   e  
-----' 
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Oleoresin Capsicum Test
Aerosol Projector
NamelScore
Date b y Ot Instru ralL
thing1
Ma
j Capsaicinoids
2 Emulsifier
3Propelant
4
5Oleoresin Capsicum
6iPungency
7 D Solvent
Oil of capsicum
The heat or intensity of the pepper or OC
formulation
6The gas or liquid which pressurizes the
canister and propels the carrier and active
ingredient to thetarget
The liquid substance capable of
dissolving 1 or more other substances
EAsubstance that creates a mixture of
mutually insoluble liquids
Y A group of compounds naturally
occurring within the fats oils and waxes of
the pepper plant
Ct The ingredients other than the OC
which comprise the formulation
8What is the primary ingredient ofwaterbased formulations
A Solvent denatured Alcohol
B Emulsifier Propylene Glycol
QWater
D OC Active ingredient
9Which statement is typically NOT true of oilbased formulations
b4Usually quicker to decontaminate
B Contains the majority of the fats oils and waxes of the pepper
Require longer decontamination time
D Can be cleaned up with soap and water
10What term is used to classify OC
Vritantflammatoryalodorant
E Diuretic
DEPOSITION
EXHIBIT
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8.What is the pri ary ingredient f ater-based for ulations? 
. l t,  c  
. lsifi r, r le  l l 
©.  
. ~C, ctive i i t 
p.''I..3~Which t      -bas  l tions? 
~1~ Usually i r t  t i t . 
B. Contains the ajority of the fats, oils and axes ofthe pepper. 
~ equire longer deconta ination ti e. 
. a  e clea e   it  s a  a  ater. 
10. hat ter  is used to classify C? 
~Irritant B nfla atory ; M  
. i re ic 
I I  ~ 
EXHIBIT ~ 
~ So 
11 What are the psychological effects ofOC
Anxiety Fear Panic
B Redness of the eyes runny nose and shortness of breath
C Sneezing drowsiness and dopiness
D None of the above
12 What are the physiological effects of OC
C Redness of the eyes runny nose and shortness ofbreath
B Anxiety Fear Panic
C Fever asthma and heart attack
E None ofthe above
13 What is the minimum deployment distance for a MK4 projector
K 36 inches
B 42 inches
C 1 foot
D 4 feet
14 What is the minimum deployment distance for the MK 9 projector
A 3 feet
B 4 feet
C 24 inches
T 6 feet
15 What are the first steps to decontamination
A Remove from area provide fresh air and establish verbal report
B Wipe face with a clean rag
C Provide individual with soap
D None ofthe above
16 What is the recommended spray method for the ballistic stream pattern
A Circular motion aroundthe face
B Nose to Mouth
CEar to Ear
D In the mouth
What is the recommended spray method for fogc nespray patternNose toMouth
B Circular motion around the face
C In the eyes
D Ear to Ear
18 A Sabre Red ballistic stream can be deployed upside down
True
False
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16. hat is the reco ended spray ethod for the ballistic strea  pattern? 
. rcular ion  t e a  
. s   outh © Ear to Ear 
.   th 
~ What is the reco ended spray ethod for fog/cone spray pattern? 
~ s  t  t  
. ircular tion  t  a  
. I  t e e es 
.    
.  a re e  allistic strea  ca  e e l e  si e n? 
WTr  
):f." alse 
19 What spray pattern has the greatest risk of hydraulic needle effect
Ballistic Stream
B FogC ne
20 Which spray pattern has the greatest risk of cross contamination
A Ballistic Stream
C FogC ne
2100CSblend aerosol has the same deployment and decontamination considerations
as OC sprayb True
B False
2 OCCS blend aerosol isby effective than the individual ingredients
000829
• 
19. hat spray pattern has the greatest risk of hydraulic needle effect? 
,'4) Ba listic Streain 
~. Fog/Cone 
20. hich spray pattern has the greatest risk of cross conta ination? 
At.. A. Ba listic Strea  
~.~ C. Fog/Cone 
21. OC/CS blend r s l has the sa e e loy ent and e t i ation c nsiderations 
~_ ~ OC spray: 
D~ rue 
. alse 
~2. /CS lend aer s l s M 6YlL- fe tive   id  in . 
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Instructor Assoc ID
Certification Test SABRE Aerosol Projectors
Each question is worth 4 points
Match the following terms to the appropriate definition
Circle the best answer
7 An officer should always use when arresting or subduing a subject
A Maximum force
B A low level offorce
C A significant level of force
D The least amount of force necessary
8 Exposure to the SABRE Law Enforcement Sprays during training
A Will better permit an officer to protect himselfer l if contaminated
B Will better permit an officer to protect hiser firearm ifcontaminated
MWill
allow the officer to better decontaminate a contaminated subject
All ofthe above
9 Physiological effects of being sprayed with OC spray are
A Runny nose with mucous discharge
B Eyes tear and involuntarily close
C Respiration ofOC causes inflammation of the respiratory tract
0 All of the above
10 The psychological effect we do not want is
A Fear
AnxietyQI Panic
DEMME
IDOC Sabre Aerosol Products Certification Course Page 1 of 3
An invisible ingredient that is detectable with
1 Oleoresin Capsicum a blacklight on skin clothing for up to 48
hours
2 Scoville Heat Units Liquid or gas used to push the active
ingredients out of an OC canister towards a
3Ultraviolet Marking Dye target
A mixture ofoil resin found in red peppers
4 Sabre Marking Dye Inactive ingredients responsible for even
5 J Propellant
disbursement ofOC
Measurement used to determine OC pungency
1 A reddish orange liquid used to help determine
6 Carrier where the OC has been deployed what
needs to be washed or rinsed off
000831
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A' Will ll  t  fficer t  tt r t i t   t inate  j ct. 
\£)   e . 
. si l ical ff ts f i  s r  it   s r  re: 
.   it  s i r  
. Eyes tear and involuntarily close 
. espiration of  causes infla ation of the respiratory tract 
@ All of the above 
. he psychological effect e do not ant is: 
.  A iet  
~Pani  
moc re er s l t  ti ic ti   age 1 f  
Match the following Contamination Levels to the appropriate definition
A Situation where aperson receives direct
A
contact with OC in the facial area
11 A Level 1 Exposure Situation where a person is exposed to a
12 C11
contaminated area
VLevel 2Exposure Situation where a person is contaminated
indirectly by attempting to control a person
13 Level 3 Exposure who has received direct contamination
Circle the best answer
14 Which of the following spray patterns will have the longest range and best accuracy
Cone Fog
Stream
C Foam
15 For which of the following do you spray in a sideto side motion along the brow line
A Cone Fog
Stream
C Foam
16 For which ofthe following do you spray in an upand downmotion at the vertical center
of the facial area
ConeFog
B Stream
C Foam
17 Minimum Recommended distance for a MK4 is
2 feet
3 feet
C 4 feet
D 6 feet
18 Minimum Recommended distance for aMK9 is
A 2 feet
B 3 feet
C 4 feet
Q 6 feet
19 When OC has been deployed what Level of Force has been used
A Level
B Level
Leve14
Level 5
20 e officer should spray the subject in second bursts
z to 1
B 2
C 3
IDOC Sabre Aerosol Products Certification Course Page 2 of
000832
, -
atch the following Conta ination evels to the a ropriate fi iti : 
1 . 
. 
. 
~ evell Exposure 
~Level  Exposure 
~ Level 3 xposure 
ircle the est  
' .. Situation here  pers n receives direct 
contact ith  in the fa ial are . 
~ itua io  here  person is pose  t   
-........ conta inated r . 
~ t io  here a person s ta inated 
indirectly  atte ting t  c tr l a ers n 
ho as received irect c t . 
. hich of the follo ing spray patterns ill have the longest range and best accuracy? 
.A one/  
~Stre  
.  
. For hich of the follo ing do you spray in a side-to-side otion along the bro -line'? 
. one/Fog ® trea  
.  
. For hich ofthe follo ing do you spray in an up-and-do n otion at the vertical center 
   a? 
@ one/Fog 
.  
.  
.      -4 : 
A   
'J1)   
.  t 
.   
. i      -9 : 
.   
.   
.   ® 6 feet 
9. hen C has been deployed, hat Level of Force has been used? 
. l 2 
. l 3 
hLevel4 
<.I1~ vel  
0. Ae officer should spray the subject in __  rsts. 
'-...A).. Y2   
.  
.  
I oe Sabre erosol Products ertification ourse Page 2 01'3 
21 If the officer cannot control the subject after having deployed then the officer
should choose anothermethod to gain control
1 burst
B 3 bursts
C 5 bursts
22 The best decontaminate for aerosol projectors is
Cool Water
B Vaseline
C Saline Solution
D Moving Air
23 In which of the following situations should the officer call Medical
A Subject loses consciousness
B Subject requests Medical attention
Subject experiences breathing difficulty
All ofthe above
24 The subject should be Zonitored for up to hours after being decontaminated
A 1
2
C 3
25 After decontamination and medical attention has been provided is the
most important topic of this training class
A Visualization Process
Properly Reporting Force documentation
C Practical Training
D Deployment Versatility
IDOC Sabre Aerosol Products Certification Course Page 3 of 3
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',-
, v 
2 . If the officer cannot c trol the s ject after ha ing lo e  _' _, the  the officer 
s ld choose t r ethod to gain c tr l. 
4d 1 rst . 3 ursts G. 5 rsts 
2 . he est dec ta inate for aer s l r jectors is: o  ater 
. aseline 
. ine tion 
. oving ir 
2 .  ich f e follo in  t ations  the ficer  i al? 
. ubject loses consciousness 
. ject re ests edical atte ti  
J; Subject experiences breathing difficulty 
(P)   the e 
. The subject should be monitored for up to __  ter  inate . 
.I 
~2 
.  
. fter t i ti   i l tt ti  s  r i d, _______ is the 
ost i portant topic of this training class. 
. s   ® Properly Reporting Force (documentation) 
C. Practical Training 
. eploy ent ersatility 
I   l roducts ertifi ti n  Page 3 of3 
EXHIBIT 0
000834
  
IDCRecords 000046 03172010
Material Safety Data Sheet SABRE Red
May be used to Comply with O Hazard Communleation Standard Ou Iftntl4w
29CFR 1910 1200 Standard must be reviewed for spedflc requirarneats JanuaryW 2002
ISECTION 1 CHEMICAL PRODUCT COMPANY IDENTIFICATION
Men 4orf
QCI I IbTH1GnACrr mnwT EmPAC
rveme vv VVP w OVVJ677J00Number
330 SUN VALLEY CIRCLE
olrhva 1d
6363430200
My S1846 zip
FENTO MO63026
ie Jt rnbm
6363431318
hwrNvWNme
Oleoresin Capsicum Red Pepper
ns ftfne
SABRE Red
ECTION 2 HAZARDOUS INGREDIENTS 1 IDENTITY
Oleoresin Capsicum 10 NA No
Scoville Heat Units 2000 NIA No
Major Capsaicinoids 133 NA No
Capsaidn CAS 94048
Nordihydrocapsaicin CAS 1940885
Dlhydrocapsaicin CAS 92878935
Dymel 134aP is used with nitrogen creating a dual propellant system Other ingredients are trade secrets
as defined in Harard Communications Act 29 CFR 191020 Para 1 1 end Apendix D to CFR 191020
ISECTION 3 PHYSICAL CHEMICAL CHARACTERISTICS I
370 Degrees F 1
seablmyrnrverer Insoluble egwPreirwr 60 PSI
AAPearoWe 9
odor RedOrange in color Odor is pungent
SECTIO 4 F EXPLOSION DATA
rr rnmrrrrrnww
AtOIM
4uu degreesr
Tempe NIA Halon Carbon Dioxide Dry Chemical or Water
Fighft Wear respirator or self contained breathing apparatus
Praedures
JwwrFlre end
Proekn Smoke would be irritating to eyes and mucous membranes
SECTION 6 PHYSICAL HAZARDS REACTIVITY DATA
smMy unto
cm a h To jammgeUmNow ers 7o Vmf NA
8rnbk X
Hazmdws Mov Ocwr
Hrzed6vs uer NA
wa Not obese X
M
IDCRecords 000046 03172010
000835
I.D.C. ecords  3/17/2010 
t i l f t  t  t   
 b  us  t  comply it  SHA's  I'  Standard. LL QuIck tlenB'.,. 
29  1910. 120D. tandard Ullt  I"It  f  spe fl  requirements. January 1st. 2002 
SECTION 1 - I   &  I I I I  
SECURI'TY EOUIPMENT CORPORATION 800-325-9568 
   I  36~ -0  
CUr. SlIIIo, Zip ENTON,  30  -3 -  
l r i  i  (  epper) 
7~NI>me: SAB E Red 
S I   -   I I  
., om''''111 SHA PGL 
 i : 0% /A 
coyiIJe eat nits ,0 0,000 /   
 l  .33% /A  
lcl   tt D4-M-4 
r i r i :i   #1 408-84.5 
lIl cJrocapslli irl  # 8789.35 
l /P i   it  itr  r tl   l r ll t t . t r i r i t  r  tr  r t  
 i  i   i ti  t   910. 2 0   (1)  i   t   910. 2 0. 
  -  &  I I  
   
SoIubIbIylnWooI8r. I l l  
s , 
(H2O. 1) 
:alll_'-' /Orange i  l r. r i  t 
ISECTION 4 - IRE & I  T  
00  F, 
.2 
BO I 
JJ 
/  l . r  i i , r  i l r t r 
s;;:;;t;l?Ita l'is~6n9 r r spirator r lf- t i ed r t i g r t . 
PrwerA.lres: 
1JrnIJua/ FI,e fl  . 
/!Xp/os/on oke ould be irrit tI g to eyes and ucous e branes, 
I  5 - I   (REACTI I  ) 
COIlIfIiOII. r. Inca psNDIfIIY IMa_ TO AVOIISI /A 
IlnSlllble AIIIW 
SlAII'"  f.~~Pf&iUCI': 
Halmr1ou.< M"YO .... ' 
/A 
eqtyrpQ'l.ttpno 
co;;c;GII; 1'1 WIll Nol Ooeur X 
I.D.C. ec r  000046 3/17/2010 
IDCRecords 000047 03172010
I SECTION 6 HEALTH HAZARDS I
spasMpnmsoGupea Ingredients cause irritation through all routes of entry Repeated contact
may cause dermatitis ingestion may cause nausea vomiting andor diarrhea
nr dW1C AgMvekdBy May cause more severe temporary effects on those persons who are
btPmro
asthmatics or suffer from emphysema
FmeNency RW Aid Rmossdurss
Rmft OfEn
Remove victim from contaminated area and remove contaminated clothing
Provide fresh air irrigate with copious amounts of coot water Obtain medical
advice is symptoms persist
hm Provide fresh air
IEyes Qnly exposed subject or EMS should remove subject contact tenses
or until relieved
3 skin Flush with coot water Wash with mild soap and water
o mgesrlon Rinse mouth with water ingest milkor water Obtain medical
advice immediately
SECTION 7 SPECIAL PRECAUTIONS AND SPILL LEAK PROCEDURES I
store in a coot dry area Avoid direct lightand heat
V6e
bmroDetekenmtau
DO NOT expose to temperatures over 120 degrees F
DO NOT puncture or incinerate container
offimPrsaxons NIA
swtwowlimw@dwh pwor Wipe up smallspills with absorbent material With large spills use
fflfwa
respiratory equipment to avoid irritation and collect absorbent materi
Nnsdo Ventilate area and after absorbent process wash area with soap and cold
water
HoWWde Stay upwind
waste okwaa mono Consult Federal State and Local Regulations
Evacuate contents in a safe area dispose of container
SECTION 8 SPECIAL PROTECTION INFORMATION CONTROL MEASURES I
ROVWftPmMOW Not required under normal conditions of use
yw Yes
Pmmeeveaowe Suggested not required
EyePmrocl Yes Exposure without protection in training environment is acceptable
00WPmt04Owor Not re aired
cgrM q
Atfiy0Gpncfts Normal
SECTION 9 PROPELLANT
SABRE used Dvmel 134aPa pharmaceutical orade oronellant 134aPis non flammable
Inaddition 134aP is not a VOC VolatileOrganicCompound has an ozone depletion potential
of 0 and
TDCRecords000047 03172010
000836
LD.C. ecords 00004  3/17/2010 
 I   •   • 
I r i t   irrit ti  t r  ff r t  f ntry. t  co t t 
  r titis. I   c  s , iti , nd/or iar hea. 
   evere, t porary, ff t   t  r   r  
asthmatics or suffer from emphysema. 
 i ti  fr  t i t  r   r  t i t  l thing. 
r i  fr  ir, irri t  it  i  t  f l ater. t i  i l 
i  i   r ist. 
1. InMlttlon: i  fresh ir. 
2. yell: O l  eO  SU     r  ubject's  lenses. 
outes f Entry Irn ate with cool water at least 15 minutes, O  til r lieved. 
3. Skin: l  it  l ter.  i  il    ter. 
4. In(JtlSlfon:   Wi  ter. i  il   t r.   
i  i i t l . 
IS I   -~PECI     I  O  
_S~to~r~e~in~a~c ~ ~I,~d~ry~are~a.~ ~~o~i ~d~i ~c~t~lig~h~t~a~nd~he~a~t.~ ____________________ _ 
Pmcg,4Iomo 10 b9lak~ /JJ /lMI1eIIf/t1 _ 
&IMI.;         . 
  et r    t iner. 
ot/Iot~ /  
If out!id,: t   
lt r l. t t ,  l l ti  
 t t     , &   . 
se I  · I   I  I   
t i  r r l iti  f . 
-- t  (not r ir d) 
s. osure it t r t cti  i  tr i i  ir t is t l . 
Not re uirea 
or al 
I I   ~  
 used y eI 34a1P, a phar aceutic l grad  pr p ll t. 1 4a1P is on-fl l . 
In a ditio . 134a1P Is not a voe (Volatile rganic ompo ), s an ozone depleti  t ti l 
(ODP) of O. an  Its global warming potential is negligible. 
---- .. 1'. D.c:-Record~;-00 47·---03/17/201 0 
IDCRecords 000048 03172010
Material Safety Data Sheet FIRSTDEFENSE
QUICK IDENTIFIER
May be used to comply withOSHAsHazard Communication Standard Common Narne used on label and Est
29CFR 1910 1200 Standard must be consulted forspecific requirements
5049 MS4 F1rstDefense Stream
Manufacturers
NA NA ArA
Name
Defense Technology Laboratories
404864
Propylene Glycol USP
Address Emergency
13 57556
Telephone No
PostalBox 248
NA
800 4249300
City State and ZIP Other
NA A NA
Information
NA
Casper Wyoming 82642 Calls 877 243835
Signature of Person Date
There are no HCFCsorCFCs
Responsible for Preparation Optional Prepared
1104
SECTION HAZARDOUS 1 IDENTITY
Hazardous Component chemical common names OSHA ACGIH Other Exposure CAS
PEL TLV Limits optional NO
Capsoicinoids 18
NA NA NA
Specialty Denatured AlcoholSDA 40B 1000PPm 1000pprn 28 64175
Deionized H2O 58lo
Nitrogen is the exclusive propellant
US Patent5217708
SECTI L CHARACTER
BoilingP nt 220 SpecificGravityH20 1 0955
Vapor
Pressure mm Hg NA
Vapor
Density Air 1 r4A
Solubility
in Water Soluble
Reactivity in
Water None
Appearance
and odor CreamyPungent
Melting
Point NA
SECTI EXPLOSION
Flash Method
Point 220 Used SW8461010
DATA
FlammableLimits LE
In Air by Volume Lower NA
UEL
Upper NA
Auto Ignition Extinguisher
Temperature 220F Media Water foam dry chemical CO2
Special Fire
Fighting Procedures Wear respirator or settcontainedbreathing apparatus to avoid irritation
Unusual Fire and
Fxot a on Hazards None
IDCRecords 000048 03172010
000837
I.D.C. r   3/17/2010 
aterial afety ata eet IRST DEFENS ® 
May be  to comply it  A's u rd Co unication Stan r . 
29CFR 19 . 1 . Standard must be consulted f  speclic req ir . 
ICK I I I  
o on am : (used  l l and ti ) 
SECTION 1 -
cturer's 
Name f  l gy 1 Federal La r t i  
Addr  
 ar 248 
ity. late. and I  
s r, ing 82602 
Signature of Person 
R ¥ .lb~ f r r r ti  (Opti l) 
ergency 
l  NO. 
ther 
I f r ti  
lls 
O t  
r red 
I  2 -  INGREDIENTS I I  
9 - K4 i  efense ea  
(80 ) 4-9300 
(8 ) 8-3835 
]]101 04 
azardous o ponent(s) (chemical & co on name(s»  
l 
 
 
 sur. % CAS 
i its (opti l) NO. 
'Capsal i1l0ids /A IA 
'Propyl,ne Glycol USP IA IA 
'Spe lalty e tured l l (S )  . 0 pp  ,  ppm 
'Deioni:ed 20 /A N/A 
"Nitroge  is t e erc/ sive r ell t. 
 e  FC's  '  
"U.S. Patent 5,2 J 7, 708, 
ECTION 3 - PHYSICAL & CHEMICA  HARACTERISTICS 
Boiling 
i t > 1 · 
olubility 
I  t r l l  
Appearance 
 Odor 
apor 
ity (Air = ) N/A 
rea y 1 Pungent 
ECTION 4 - FIRE &   
ifi  
r it  (H20: ) .955 
cti i   
l r 
lli  
O  
  l l   EL 
 >22 · d -JOIO  ir %  l   IA 
t -I iti  Extinguioher 
r ture> 22 · . i  t r,f . r  i l 02. 
Special Fire 
Fighting Procedures 
l i   
E p!0si  r  
ear respirator or selfcontained breathing apparatus 10 avoid irritation. 
m. 
NIA .18% 404-86-4 
IA 3% -55-6 
IA 8% 64-17-5 
lA 8% IA 
 
r . re (m  ) /A 
 
IA 
 
r IA 
I.D.C. ecor s  3/17/2010 
IDCRecords 000049 03172010
FIRSTDEFENSE
QUICK IDENTIFIER
Common Name used on label and list
5049 MK4 FirstDefense Stream
Stability UnstableU ConditionsStable to Avoid
Incompatibility
Materials to Avoid NA
Hazardous
Decomposition Products XIA
Hazardous May Occur Conditions
Polymerization Will Not Occur W to Avoid
1 2 Chronic
See Signs and Symptoms See Signs andSymptoms
Signs and
Symptoms of Exposure Ingredients may cause irritation through all routes ofentry Repeated contact may cause dermatitis
Ingestion may cause nausea vomiting andlor diarrhea
Medical Conditions Generally
Aggravated by Exposure May cause more severe temporary elects on those persons who are asthmatics
or sufferfrom emphysema
Chemical Listed as Carcinogen National Toxicology Yes IARC YesLj OSHA Yes
or Potential Carcinogen Program No Monographs No Dg No
Emergency and
First AidProcedures Providefresh air Irrigate with copious amounts ofcool water Obtain medical advice tfsymptomspersist
Other
Precautions NA
Steps to be Taken inCase
Material is Released orSpillod Wipe up smallspills with absorbent With large spills use respiratory equipment
to avoid irritationand collect withan absorbent
Waste tsposa
Methods Consult Federal State and Local Regulations
Evacuate contents in a safe area anddisposeolcontainer
Respiratory Protection
Specify Type Not required under normal conditions of use
Ventilation Local Mechanical Special Other
Yes Exhaust Yes General
Protective Eye Protection
Gloves To be utileed ina manufacturingenvin
Other Protective
Clothing or Equipment Not required and aroundmachinery Minimal exposurewpr
WorkHygienic Practices
Normal evewear in an officer training environment IS acceptable
IMPORTANT
Do not leave any blank spaces If required information is unavailable unknown or does not apply so indicate
IDCRecords 000049 03172010
Precautions to be Taken
In Handling and Storage Store in a cool dry area Avoid direct light and heat Do not expose to temperatures over 120 F
000838
.D.C.   3/17/2010 
 NSE® 
I  I I I  
n : (u   l  t) 
 -  t efe  tr  
SECTION 5 - PHYSICAL HAZARDS (REACTIVITY DATA) 
t ilit  t l  0 iti s 
Stable IXI t  i  
I ti ilit  
(Materials t  i ) 
z r s 
Decomposition Products 
IA 
NI  
r  
i ti  
  0 
Ill t r IXI 
On iti  
 i  
SECTION 6 - HEALTH HAZARDS 
1. Acute  i  
.      i s  t s 
I   
t  01 r  Ingredienls may cause irrilation through all routes of entry. Repeated contact may cause dermatitis. 
ingestion y cause nausea. vo iting. QI2d)or diarrhea. 
i l iti s  
r t   re  s  Ore s r . t porary, ffiets  t s  rs s  r. sllr /ics 
 i t d 8!  
r ti l  .. rcln  
 SU 
   
  
IAR.C. s 
r   
r   
  r s i  f e  ir. Irrigate it  i  t  f l t r. t i  i l i  if t  Si t. 
1. Inhalation 
Provide fresh air. 
2. Eyes 
Irrigate with cool water at least 1 j minutes, or until relieved 
3. Skin 
Flush with cool water. Wash with mild soap and water. 
4. Ingestion 
Rinse mouth with water. Ingest milk, or water. Obtain medical advice immediately. 
I SECTION 7 ~ SPECIAL PRECAUTIONS AND SPILL I LEAK PROCEDURES 
ti  t   n 
   t rage 
t r 
r c U s /A 
ta  i  Q l,  . i  i t li t  t.  t  t  t t   ·  
      
t ri t i  l  r illed i   s ll s ills il  s r t. it  l r  s ills, s  r s ir t r  Ui t 
  ti n,  lect   t. 
te DI l 
t ods ( n eral, te.  l lations)  t ts    .  s  f contai r. 
SECTION 8 - SPECIAL PROTECTION INFORMATION I CONTROL MEASURES 
ir t r  r t tion 
( Cif  pe ) 
lt  
 
l 5 
s 
t r ll  
lothing r quip ent 
ork/Hygienic r ctice. 
 
t e ired  l ilions f . 
l ical i l  
t  ( General) 
 r t li  
  tili::e  i   joctul"i  nvironment i  
t re ire   lDl  i . ini l , ithout rou-clive 
 ,      ,,,,,i  s t l . 
 t l   l k . If r ir  i f r ti  I  vailable. , r  t ly,  i i t . 
.D.C.   3/17/2010 
IDCRecords 000050 03172010
Material Safety Data Sheet
NIA NA
F
May be used to comply with OSHAsHazard Communication Standard QUICK IDENTIFR
29CFR 1910 1200 Standard must be consulted for specific requirements Common Name used on label and list
NA
5099 MX9 First Defense HVStreain
13 57556
Specialty Denatured Alcohol SDA 40B 1 000 ppm
Manufacturers
NA
Name
Defense Technology Federal Laboratories
64175
Address
Emergency
PostalBox 248 Telephone No
58
800 4149300
City State and ZIP
Other
Casper Wyoming 82602
Information
cal 877 2483835
Signature of Person
Date
Responsible for Preparation Optional Prepared
1104
MOM a A 1 i
Hazardous Componentachemical6 common names OSHA ACGIH Other Exposure CAS
Limits Optional NO
Capsaicinoids NA 18 404864
Propylene Glycol USP AM NA
1 000 ppm 28
Deionised H2O NA NA NA NA
Nitro en is the exclusivepropellant
There are no HCFCs orCFCs
USPatent5217708
a A
Boiling Specific VaporPoint 220 Gravity H2O 1 0955 Pressure mm Hg NA
Vapor
Density Air 1 N14
Solubility
Reactivity inin Water Soluble Water None
Appearance Melting
and Odor CreamyPungent Point MA
Special Fire
Fighting Procedures Wear espirator or self contained breathing apparatus to avoid irritation
Unusual Fire and
CxposionHazards None
IDCRecords 000050 03172010
y txtmguisnerTemperature 220F Media Water foam dry chemical CO2
000839
I.D.C. Records 000050 03/17/2010 
t i l f t    FIRST DEFENSE® 
QUICK IDENTIFIER May be use  to co ply wit  OSHA's Hazard Communication Standard. 
29CF  1910. 1200 Sta r  must be consul1  for specific requirements. Common Name: (used on label and list) 
5099 - K9 First Defense  St,ea/n 
SECTION 1 -
Manufaclurer's 
Name f s  l  1 Fed l r tories 
Address 
Postal Box 248 
City, State, and ZIP 
Casper, i  2 
Signature of Person 
i l  f  i  ( i nal) 
E er  
Telephone o. 
oth  
Infor a1  
( 0) 424- 00 
Calls (877) 248-3835 
Dale 
Prepar  
11101 04 
SECTION 2 - HAZARDOUS INGREDIENTS / IDENTITY 
ot r  omponent(s) (ch i l &  name(on  
PEL 
I  
TLV 
t f Exp r  
i , " (o ti .l) 
' apsaicinoidr  /A IA .18% 
' ropyle  l l  NIA IA IA /3% 
*Spe t  l   (S )  /,OOOpp  I,OOO  IA 8% 
'Deionized H20 IA IA IA S8% 
"Nitr ge  is Ihe excl sive r el/ I. 
r  r   FC's  '  
"u.s. l l ,217, 708, 
SECTION 3 - PHYSICAL & CHEMICAL CHARACTERISTICS 
A  
NO. 
-8 -  
-5 -6 
64-/7-j 
IA 
Boiling 
Point >2200 
C C 
ravity (H20 z 1) Q.955 
Vapor 
Pressure (m  Hg) NIA 
SOlubility 
i  al r l l  
r  
and Odor 
r 
ity (Air = ) IA 
rea y I Pungent 
SECTION 4 - FIRE & EXPLOSION DATA 
ti it  i  
t  
lting 
oint 
Flash Method Flammable Limits LEL 
P()int >2200 Used SW846-1010 in Air % by Volume Lower NIA 
Aulo·lgnltion Extinguisher 
Temperatur. >220° F. edia t .[oa , ry i l 0 . 
Special Fire 
Fighting rocedures 
Unu.ual Fir .. and 
ExpJosign Hazards 
e  respiralor or s l ined re thing e f1ralus 10 avoid i ritali . 
Non . 
 
NI  
UEL 
Upper NIA 
I.D.C. Records 000050 03/17/2010 
IDCRecords 000051 03172010
FIRSTDEFENSE
QUICK IDENTIFIER
Common Name used on label and list
5099 MK9 First Defense H Stream
Stability Unstable Conditions
Stable to Avoid
nw ny
Materials to Avoid NA
Decomposition Products hA
Hazardous May Occur Conditions
WillPolymerization ll Not Occur to Avoid
SECTION HEALTH HAZARDS
1 Acute
2 Chronic
See Sig and Symptoms See Sigand S m toms
Signs and
Symptoms of Exposure Ingredients may cause irritation through all routes ofentry Repeated contact may cause dermatitis
htgesdonmay cause nausea vomiting andordiarrhea
Medical Conditions Generally
Aggravated by Exposure May cause more severe temporary efon those persons who are asthmatics
or
Chemical Listed as Carcinogen National Toxicology Yes IARC Yes OSHA Yes
or Potential Carcinogen Program tJo Monographs No No
Emergency and
First Aid Procedure Provide fresh air Irrigate with copious amounts ofcool water Obtain medical advice ifsymploms persist
1 Inhalation
Provide fresh air
2 Eyes
Irrigatewith coot water at least 15 minutes or until relieved
3 Skin
Flush with cool water Wash with mild soap andwater
4 Ingestion Rinse mouth with water breest milk or water Obtain medical advice immediately
Precautions to be Taken
in Handling and Storage Store in a cool dry area Avoid direct light andheat Do not expose to temperatures over 120 F
Other
Precautions NA
Steps to be Taken In Case
Material is Released or Spilled Wpeup small spills with absorbent With large spills use respiratory equipment
to avoid irritation and collect withan absorbent
Waste Disposa
Methods Consult Federal State and Local Regulations
Evacuate contents in asafe area and dispose ofcontainer
Respiratory Protection
Specify Type Vol required under normal conditions ofuse
Ventilation Local Mechanical Special Other
Yes Exhaust Yes General
Protective Eye Protection
Gloves To be utilised in a manufacturing environment in
Other Protective
Clothing or Equipment Not required andaround machinerydtrtimal exposure without protective
WorkirHygienic Practices
Normal eyewear inan officer trainimt environment is acceptable
IMPORTANT
Do not leave any blank spaces if required information is unavailable unknown or does not apply so indicate
IDCRecords 000051 03172010
000840
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FI T DEFENSE® 
I  IDENTIFI  
Go on Name: (used on label and list) 
509  - MK9 First Defense HV Stream 
SECTION 5 - PHYSICAL HAZARDS (REACTIVITY DATA) 
Stability Unstable 0 Conditi  
Stable 181 to Avoid 
IncompatibUit  
( aterials to Avoid) 
Hazardous 
Decomposition Products 
NIA 
,vIA 
Ha~ardou$ 
Poly enzalion 
ay ccur 0 
Will Not Occur lZI 
onditions 
to Avoid 
I  6 -   
1. Acute 2. ronic 
 igns  y  See Signs and Sy pto s 
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Tel 208 3192600
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CHRISTOPHER D RICH ClerkBy JAMIE RANDALL
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff Case No CVPI1003515
V
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
Defendant
STATE OF UTAH
ss
COUNTY OF SALT LAKE
AFFIDAVIT OF NICHOLAS J
ROBERTS IN SUPPORT OF
DEFENDANTSOPPOSITION TO
PLAINTIFF CROSS MOTION FOR
SUMMARY JUDGMENT
I Nicholas J Roberts being first duly sworn upon oath depose and say
I I make this Affidavit based on my own personal knowledge I am of legal age to
make this Affidavit and I am competent to testify to the matters stated herein if called upon to do
SO
2 I have been employed in active law enforcement for 32 years I am currently the
Rangemaster for the Unified Police Department of Greater Salt Lake During my tenure as a law
enforcement officer I have used trained with and provided training for various types of OC
AFFIDAVIT OF NICHOLAS J ROBERTS IN SUPPORT OF OPPOSITION TO PLAINTIFFSCROSS MOTION
FOR SUMMARY JUDGMENT Page 1 14542 011 398388doc
000841
Ot~\G\NA~ 
Christopher C. Burke, ISB #2098 
Thomas 1. Lloyd III, ISB #7772 
GREENER BURKE SHOE AKER PA 
950 . annock Street, Suite 900 
Boise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
NO~ A. GOp FILED 
-"'-'~--P.M. ___ _ 
JUN   20 1 
RIST PHER 0 RI 
By JAMIE RANO.~~H, Clark 
DEPUTY 
I  E IS ICT  F E F  J I I  IS I  F E 
E  I , I    E    
I IE J  J , a  in i i al, 
Plaintiff, 
v. 
SECURITY EQUIPMENT 
CORPORATION, a issouri corporation, 
ant. 
ST TE F T  ) 
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    ) 
ase o.: -PI- 5 
  S . 
    
FENDANT'S I   
LAINTIF 'S -   
  
I, Nicholas 1. Roberts, being first duly sworn upon oath, depose and say: 
1. I a e t is ffi a it ase     ers al ledge, I a  f le al a e t  
make this Affidavit and I am competent to testify to the matters stated herein if called upon to do 
so. 
2. I have been employed in active law enforcement for 32 years. I am currently the 
Rangemaster for the Unified Police Department of Greater Salt Lake. During my tenure as a law 
enforcement officer, I have used, trained with and provided training for various types of OC 
AFFIDA VIT OF NI H L  1. ROBE T  IN SUPPORT OF OPPOSITION TO PLAINTIF 'S CR S-MOTION 
FOR SUMMARY JUDGMENT-Page 1 14542-011 ( 983 8.doc) 
spray products including but not limited to Security Equipment Corporations SECs Sabre
products My experience with SECsSabre products includes its law enforcement branded OC
products as well as its civilian OC products
3 During my tenure of employment in law enforcement I have witnessed first hand
or have personal knowledge of law enforcement OC products being used in various locations
including prisons correctional facilities private homes apartment buildings office buildings
airports parks and other buildings and public locations
4 The purpose of law enforcement use of OC products is to control or subdue
individuals or groups of individuals without having to escalate to higher levels of force As a
result it is used whenever and wherever possible to avoid permanent injury to individuals
5 One of the standard issued articles of equipment to all officers and members of
the Unified Police Department of Greater Salt Lake and the Salt Lake County SheriffsOffice is
a Sabre 50 OC spray stream canister This is to be maintained on each officers utility belt at all
times the officer is in uniform By virtue of this requirement these OC spray containers are
inside private homes office buildings airports restaurants malls parking garages warehouses
apartment buildings and any other building or structure that any officer enters during any time
that the officer is on duty
6 Based on my knowledge and experience it is reasonably foreseeable and indeed
likely that law enforcement branded OC products will be brought into and used within homes
apartment buildings dormitories and other places where people regularly dwell This includes
various types of OC products including sprays streams fogs foams and aerosol grenades
Signature on next page
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spray products including, but not li ited to, Security quip ent orporation's ("S 's") a re 
products. y experience with SEC's Sabre products includes its law enforcement branded OC 
products as ell as its civilian  products. 
. uring y tenure of e ploy ent in la  enforce ent, I have itnessed first hand 
or have personal kno ledge of la  enforce ent  products being used in various locations, 
i l in  ris s, rr tio al fa iliti s, rivate s, rt t il i s, ffic  il i s, 
airports, parks and other buildings and public locations. 
. The purpose of la  enforce ent use of C products is to control or subdue 
individuals or groups of individuals ithout having to escalate to higher levels of force. s a 
r sult, it is s  r  r r ssi le t  i  r t i j r  t  i i i ls. 
.  f t e st r  iss  rti les f i t t  ll ffic rs  rs f 
the nified olice epart ent of reater alt ake and the alt ake ounty heriff s ffice is 
a Sabre 5.0  spray strea  canister. This is to be aintained on each officer's utility belt at all 
e      .  irt e f t is re ire ent, t ese  s ra  c tai ers are 
inside private homes, office buildings, airports, restaurants, malls, parking garages, warehouses, 
apart ent buildings and any other building or structure that any officer enters during any ti e 
that the officer is on duty. 
.    le   eri nce, it i  r abl  f r eable,  i  
likely, that law enforce ent branded OC products will be brought into and used within ho es, 
apartment buildings, dormitories, and other places where people regularly dwell. This includes 
ri s t s f  r ts, i l i  s rays, str s, f s, f ms,  r s l r des. 
[Signature on next page] 
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing document to be served on the
following named personson the date indicated below in the manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
P O Box 7808
Boise Ida 83707
ViaUSMail
x Via Hand Delivery
Via Facsimile 2084898988
ViaOvernight Delivery
DATED this 30 day of June 2011
Christopher C Burke
Thomas J Lloyd III
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C IFICATE F S CE 
I hereby certify that I caused to be served the foregoing document to be served on the 
following named person( s) on the date indicated below, in the manner indicated below: 
Darwin Overson, Esq. 
ric . S artz, Esq. 
J ES & S , C 
3 . reline ri , ite  
. . ox 7808 
Boise, Idaho 83707 
DATED this 30th day of June, 2011. 
[ ] ia .S. a l 
[  ] ia and elivery 
[ ] ia le (208/489-89 ) 
[ ] ia er ight ive  
;:;;Gc~1/71 ~ 
ho as J. loyd III 
AFFIDA VI  OF NICHOL  J. ROBERTS IN SUPPORT OF OPPOSITION TO PLAINTIF 'S CROSS-MOTI  
FOR SUMMARY JUDGMENT-Page 4 14542-011 ( 983 8.doc) 
1
ORIGINAL
Christopher C Burke ISB 2098
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Fax 208 3192601
Attorneys for Defendant
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CHRISTOPHER D RICH
BY JAMIE RANOALL Clerk
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
V
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
Case No CVPI1003515
SECOND AFFIDAVIT OF ROBERT
NANCE FILED IN SUPPORT OF
DEFENDANTOPPOSITION TO
PLAINTIFFSCROSS MOTION FOR
SUMMARY JUDGMENT
Defendant
STATE OF MISSOURI
ss
COUNTY OF ST LOUIS
I Robert Nance being first duly sworn upon oath depose and say
1 I make this Affidavit based on my own personal knowledge I am of legal age to
make this Affidavit and I am competent to testify to the matters stated herein if called upon to do
M2
2 I have been employed in some capacity with Defendant Security Equipment
Corporation SEC for approximately 14 years During that time I have held various positions
within SEC including but not limited to the position of Vice President of Operations which I
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Thomas J. Lloyd III, ISB #7772 
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950 . annock Street, Suite 900 
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Fax: (208) 319-2601 
Attorneys for Defendant 
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  I , I    E    
I IE J  J ,  i i i l, 
laintiff, 
v. 
SECURITY EQUIP ENT 
PORATI N, a issouri corporation, 
ant. 
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I, obert ance, being first duly s orn upon oath, depose and say: 
. I  t is ffi it s     rs l l e, I  f l l  t  
make this Affidavit and I am competent to testify to the matters stated herein if called upon to do 
so. 
. I have been employed in some capacity with Defendant Security Equipment 
Corporation ("SEC") for approxi ately 14 years. uring that ti e I have held various positions 
within SEC, including, but not limited to, the position of Vice President of Operations, which I 
SECON  FFIDA I  F ROBERT N  FI  I  S  OF OPPOSITI  TO PLAINTIF 'S 
C SS- TI  F  SUMMA Y JUDGMENT- Page 1 14542-  ( 8310) 
currently hold and have held since October 2001 As Vice President of Operations for SEC I
am familiar with SECsproducts including the law enforcement brand OC products
3 SEC markets it law enforcement branded OC products to all variations of law
enforcement personnel including correctional officers local police departments military
SWAT teams tactical teams and security companies As such SEC expects and in fact intends
that OC products can and will be used in prisons and other correctional facilities but also in
office buildings banks stores restaurants homes apartments parks vehicles public gatherings
and any other building or location where a criminal or suspect might be found
4 SEC expects that any of its law enforcement branded products including the
SABRE Red spray fogger Cell Buster and aerosol grenades will be used in any of the scenarios
detailed above By example SEC markets its law enforcement branded SABRE Red Cell Buster
product which contains the same formula as the MK9 Fogger with a puncture wand that is
designed specifically to enable law enforcement to penetrate walls doors windows and other
obstructions found in homes apartments office buildings restaurants banks etc The
obstructions which the puncture wand was designed for are less typically encountered in prisons
or correctional facilities which more commonly utilize more solid and secure construction
materials eg steel doors reinforced windows etc On SECswebsitewwwsabreredcom
SEC markets its law enforcement branded SABRE Red products as pecifically designed
to permit passive entries into cells rooms attics storage areas and buildings underneath
doors or through windows The product is neither designed nor intended to be limited to
use within correctional facilities
SECOND AFFIDAVIT OF ROBERT NANCE FILED IN SUPPORT OF OPPOSITION TO PLAINTIFFS
CROSS MOTION FOR SUMMARY JUDGMENT Page 2 14542011 398310
000846
currently hold and have held since October, 2001. As Vice-President of Operations for SEC, I 
a  fa iliar with SEC's products, including the law enforce ent brand OC products. 
3. S  arkets it la  rce e t branded  products to ll ariations f la  
enforcement personnel, including correctional officers, local police departments, military, 
S  tea s, tactical tea s a  sec rity c a ies. s s c ,  e pects a , in fact, intends 
that OC products can and will be used in prisons and other correctional facilities, but also in 
office buildings, banks, stores, restaurants, ho es, apart ents, parks, vehicles, public gatherings 
and any other building or location where a cri inal or suspect ight be found. 
. SE  expects that any of its la  enforce ent branded products, including the 
S BRE Red spray, fogger, Cell Buster and aerosol grenades, ill be used in any of the scenarios 
detailed above. By exa ple, SEC arkets its law enforce ent branded SABRE Red Cell Buster 
product (which contains the same formula as the K-9 Fogger) with a puncture wand that is 
designed specifically to enable law enforcement to penetrate walls, doors, windows and other 
str cti s f  i  es, a art ents, ffice il i s, resta ra ts, anks, etc. he 
obstructions which the puncture wand was designed for are less typically encountered in prisons 
r c rrecti al facilities, ic  re c l  tilize re s li  a  sec re c structi  
aterials (e.g. steel doors, reinforced windows, etc.). On SEC's website (www.sabrered.com). 
 r t  it  l  f r t r    r t   " ... [s]pe ifically desi d 
to permit passive entries into cells, rooms, attics, storage areas and buildings ... underneath 
doors or through windows .... " he product is neither designed nor intended to be li ited to 
use ithin correctional facilities. 
SECOND AFFIDAVI   ROBERT NA E FILED I  SUPPOR   PPOSITI  TO PLAINTIF 'S 
SS-M TI  FOR SUMMA Y JUDGMENT- Page 2 14542-  ( 8310) 
5 SEC does not sell its law enforcement branded OC products through its website
SEC sells its law enforcement branded products only to its various distributors or through direct
contract In the case of the Idaho Department of Corrections for example SEC has always
contracted with and sold its product to an independent distributor However many of the
civilian defense products sold on SECs website are the exact same as the law enforcement
branded OC products The civilian products are simply branded as civilian products SEC does
not restrict its distributors from selling SECslaw enforcement branded products to the general
public or on the internet I am aware of several in fact likely over 50 distributors and other
commercial enterprises that openly sell SEC law enforcement branded OC products to the
general public The only reason that SEC does not sell its law enforcement branded OC products
through its own website is to avoid competing with its distributors
6 Based on my knowledge of SECs products and market and my experience with
the law enforcement industry I believe it is reasonably foreseeable that law enforcement branded
OC products whether manufactured by SEC or otherwise will be brought into and used within
houses apartments dormitories and other places where people dwell As such SEC complies
with the labeling standards required by the Federal Hazardous Substances Act as I have testified
to in an earlier affidavit in these proceedings
Signature on following page
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5. SEC does not se l its la  e force ent branded  roducts through its e . 
SE  sells its la  enforce ent branded products only to its various distributors or through direct 
c t. In the case of the Idaho epart ent of orrections, for exa ple,  has al ays 
contracted ith and s ld its product to a  independent istri t r. r, a   the 
civilian defense products sold on SEC's website are the exact same as the law enforcement 
branded  products. The civilian products are si ply branded as civilian products. SE  does 
not restrict its distributors fro  selling SEC's law enforce ent branded products to the general 
public or on the internet.     r l,  a  i   ,    
co ercial enterprises that openly sell SEC law enforce ent branded OC products to the 
general public. The only reason that SEC does not sell its law enforcement branded OC products 
through its o n ebsite is to avoid co peting ith its distributors. 
. ase    le e f EC's r cts a  ar et, a   e erie ce it  
the law enforcement industry, I believe it is reasonably foreseeable that law enforcement branded 
 products, hether anufactured by SE  or other ise, ill be brought into and used ithin 
houses, apartments, dormitories and other places where people dwell. As such, SEC complies 
ith the labeling standards required by the Federal azardous Substances ct, as I have testified 
to in an earlier affidavit in these proceedings. 
[Signature on follo ing page] 
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DATED this day of June 2011
B Xo0
o Nance
SUBSCRIBED AND SWORN TO before me thisg ay ofJune 2011
A
Not ry Public for
JKlE WILUAMS Residing at
Notary Public Notary Seal Commission Expires
State of Missouri Jefferson County
Commission 09914168
My Commission Expires ec 28 2013
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing document to be served on the
following named personson the date indicated below in the manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
P O Box 7808
Boise Idaho 83707
ViaUSMail
x Via Hand Delivery
Via Facsimile 2084898988
ViaOvernight Delivery
DATED this 30 day of June 2011
Christopher C Burke
Thomas J Lloyd III
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I hereby certify that I caused to be served the foregoing document to be served on the 
following na ed person(s) on the date indicated below, in the anner indicated below: 
ar in r , . 
Eric B. Swartz, Esq. 
J S & S TZ, PLLC 
 . line i , ite  
. .   
Boise, Idaho 83707 
TE  this 30th day of June, 2011. 
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[ ] ia  e  
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[ ] i  r i t li r  
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Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
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Tel 208 3192600
Fax 208 3192601
Attorneys for Defendant
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CHRISTOPHER D RICH Clerk
BY ELYSHIA HOLMES
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
V
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
Defendant
STATE OF IDAHO
ss
County of Ada
Case No CVPI1003515
AFFIDAVIT OF THOMAS J LLOYD III
IN SUPPORT OF OPPOSITION TO
PLAINTIFF CROSS MOTION FOR
SUMMARY JUDGMENT
I Thomas J Lloyd III being first duly sworn upon oath state as follows
I I am one of the attorneys of record for Defendant Security Equipment Corporation
SEC or Defendant and make this Affidavit in support of DefendantsOpposition to
PlaintiffsCross Motion for Summary Judgment based upon personal knowledge
2 Attached hereto as Exhibit A is a true and correct copy of the draft transcript of
the deposition of J P Purswell PhDPECPE which was taken on June 30 2011
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I, ho as J. loyd III, being first duly s orn upon oath, state as follo s: 
1. I a  e f t e att rne s f rec r  f r efe a t ec rit  i e t r rati  
("S " r "Defend "), and ake this ffidavit in support of efendant's pposition to 
laintiffs r ss- tio  f r ar  J ent, ase   ers al le e. 
. ttached hereto as xhibit  is a true and correct copy of the draft transcript of 
the deposition of 1. P. Purs ell, Ph.D., P.E., PE, hich as taken on June 30, 2011. 
III 
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  J  - a e  -011 (3 9352.doc) 
DATED this 30 day of June 2011
B JLY
Thomas J Lloyd III
SUBSCRIBED AND SWORN TO before me this0 day of June 2011
AU I
o
0TARy S otary Public f r
E Residing at
pUBt O Commission Expires
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Affidavit of Thomas J Lloyd
III in Support of Opposition to Plaintiffs Cross Motion for Summary Judgment to be
served on the following named persons on the date indicated below in the manner indicated
below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq X ViaHand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O Box 7808
Boise Idaho 83707
DATED this 30 day ofJune 2011
Christopher C Burke
Thomas J Lloyd III
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I hereby certify that I caused to be served the foregoing ffidavit of ho as J. loyd 
III in Support of Opposition to Plaintifrs Cross- otion for Summary Judgment to be 
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 "A" 
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT
OF THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an
individual
Plaintiff
VS
SECURITY EQUIPMENT
CORPORATION a Missouri
corporation
Defendant
Case No CVPI1003515
DEPOSITION OF JP PURSWELL PhD
June 30 2011
Boise Idaho
Colleen P Zeimantz CSR No 345
000853
 E IS ICT      S  
 E TE  I ,        
LIE J  J ,  
l, 
l intif , 
vs. 
  
I , a iss ri 
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1 DEPOSITION OF JPPURSWELL PhD 1
2 BE IT REMEMBERED that the deposition ofJP
2 EXAMINATION
3 PURSWELL PhD was taken on behalf ofthe Defendant at
4 the law offices of Greener Burke Shoemaker PA located at 3 BY MR LLOYD
5 950 W Bannock Street Suite 900 Boise Idaho before 4 Q Good morning Dr Purswell
6 Colleen P Zeimantz a Court Reporter and Notary Public in
5 A M name is Jerry PurswellY7 and for the County of Ada State of Idaho on Thursday
8 the 30th dayof June 2011 commencing at the hour of900 6 Q Last name
9 amin the above entitled matter 7 A PURSWELL
10
11
APPEARANCES
For the Plaintiff
8 Q Oka Dr Purswell m name is TomY Y
JONES SWARTZ PLLC 9 employed I dont know if I actually identified
12 By Darwin Overson Esq 10 myself prior to minutes now I represent SEC
13
1673 W Shoreline Drive Suite
200
11 security equipment corporation in this litigation
Post Office Box 7808 12 and were also joined here by Mr Overson who
14 Boise Idaho 83707 13 also
15
Telephone 208 4898989
Facsimile 208 4898988 14 A Behavior management I understand from
darwin@jonesandswartzlawm 15 some of the the depositioningIve looked through
16
17 For the Defendant 16 youvehad your deposition taken before
GREENER BURKE SHOEMAKER PA 17 A That is correct
18 By Thomas J Lloyd Esq 18 Q Im going never the less go through
19
950 W Bannock Street suite 900
Boise Idaho 83702
19 some of the round rules just to make sure is ong
Telephone 208 3192600 20 the same page sort of standard protocol Number
20 Facsimile 208 3192601 21 one and I think is the most important rule this
21
tlloyd@GreenerLawcom 22 is not a marathon competition if you need a break
22 23 at any time let me know we can take breaks really
23 24 for any reason the only thing that I do ask if I
25 25 do have a question pending on the tableygo
Page 3 Page 5
1 INDEX 1 ahead and answer that question before we take a
2 EXAMINATION 2 break
3 3 A I will certainly try to do that
JPPURSWELL PhD PAGE
4 Q Obviously we have a court reporter here4
By Mr Burke 4
5 with us and we want to make sure we have we etg
5 6 an accurate record a full complete record and
7 7 that way its helpful for the court reporter that
8 8 we do our best not to speak over each other that
EXHIBITS 9 means let me finish my question before you begin
9 10 your answer andIm going to try to to extend the
NO PAGE 11 same courtesy to you Further on that point we
10
12 have again the court reporter here trying to get11
12
13 down every word which means gestures shakes of
13 14 the heads nods those dontconvey on the record
14 15 quite as well so we need to make sure that all of
15 16 our questions on my part and answers on your part
16 17 are fully audible
17 18 A I understand all that and I will try to
18
19 make do my best to NA it easy on the SGLOURT
19
20 thank you are you on any medications that would20
21 21 affect our ability to tell the truthY
22 22 A No
23 23 Q Dr Purswell Ive reviewed some of the
24 24 materials that have been provided in conjunction
25 25 with your report in this case And I would like
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3  . D: 
4 . ood orning r. Purswell? 
5 . y  i  r  urswell. 
6 . a t e? 
7 .  LL. 
8 . y. r. ll y  i   
9 e ployed I don't kno  if I actually identified 
10 yself prior to, minutes now. I represent SEC 
11 security equip ent corporation in this litigation 
12       r.   
13 lso? 
 . e a i r a a e e t I ersta  fr  
 s e f t e t e e siti i  I've l e  t r  
 ou've  r siti  t  f r . 
1 7 .   rr ct. 
18 . I'm i  e er t e less  t r  
19 so e f the ground rules just to ake sure is on 
       r tocol.  
21 one and I think is the ost i portant rule this 
22 is not a arathon co petition if you need a break 
23 at any ti e let e kno  e can take breaks really 
 for any reason the only thing that I do ask if I 
25 do have a question pending on the table you go 
a e 5 
 ahead and ans er that question before e take a 
2 ak? 
3 . I ill certainly try to do that. 
4 . bviously e have a court reporter here 
5 ith us and e ant to ake sure e have e get 
6  r t  r r   f ll lete r r   
7 that ay it's helpful for the court reporter that 
8 e do our best not to speak over each other that 
9 eans let e finish y question before you begin 
10 your ans er and I'm going to try to to extend the 
 sa e courtesy to you. Further on that point e 
  i  t  rt r rt r r  tr in  t  t 
 do n every ord hich eans gestures shakes of 
14 the heads nods those don't convey on the record 
 it  s ll s    t   s r  t t ll f 
 our questions on y part and answers on your part 
1 7 are fully audible? 
 A. I understand all that and I will try to 
19 make do my best to NA it easy on the SGLOURT 
20 thank you are you on any edications that ould 
21 affect your ability to tell the truth. 
 . . 
 . r. rs ell I've re ie e  s e f t e 
 aterials that have been provided in conjunction 
 ith your report in this case. nd I ould like 
 (Pages 2 to 5) 
1 A Okay URG ergonomics is generally the
2 study of trying to make products equipment and
3 tools STO they do not have requirements on the
4 worker that exceed what we know about the XAEKT
5 of the population wer trying to design that for
6 the good example thatsgiven in one ofmy old
7 professors text the design of the cockpit on
8 certain airplane long LELGS to reach the pedals
9 ifyou thought about the people that have long
10 legs long trunks physical space for somebody that
11 didntexist somebody short torso long TLEGS
12 thats an an example of physical ones and XAKTS
13 we have to consider as well as cognitive
14 limitations and XAKTS and I can give you examples
15 of those if you like
16 Q No I think thatssufficient for now
17 Lets go
18 Q Lets go ahead and take a look at Im
19 going to ask the court reporter to NASHG this as
20 our first Exhibit 97
21 Exhibit 97 marked
22 Q HALGTs M handing exhibit to the the
23 A Im not sure if my mine was second
24 amended
25 Q I can represent the second amended
Page 8
changes the date to today you can hold on TLO
that wer going to go through it
A
Q On the SKENLD shall you were asked to
bring Before we went on the record you did
indicate to me that you had brought some
documents I would like to go through this list
and figure out which ones these documents are
responsive to And so to the as to the first one
each and every written report including all
written drafts of each report prepared in
connection with the deponents work on in case did
you bring NRI documents in response to that
A I have the final document TRUL 26
report by federal the courts have ruled that
drafts of those arentdiscoverable in any case
but I dontrecall having any other drafts of any
reports I have whats on my computer and there
might be a way to go back and figure out when I
last changed something on the report back in
March and I havent I haventnot sent any
updates since then
Q That was my next question
Q Up just indicated that you are familiar
with the Federal Rules of Civil Procedure Do
Page 9
1 you understand that we are in Idaho state court
2 in this case
3 A I do
4 Q And are you familiar with the Idaho
5 rules civil procedure
6 A I am not familiar with the Idaho rules
7 As I said I donthave anything in response to
8 that in this case
9 Q All right Copies much all memorandum
10 correspondence and other documents relating to
11 the deponents work on this case have you PRUFSD
12 anything responsive to that request
13 A I dontgenerally generate a long paper
14 trial deposition I donttry and create a long
15 paper trial in the course of reviewing documents
16 any notes that I have made I have scribbled a few
17 things on front much depositions anything
18 thats not clear but that would be the only thing
19 that I have generated in terms ofnotes
20 Q Okay
21 A Copies of all the documents this is No
22 3 copies of all documents reviewed by the did DEE
23 upon NENGSinconnection with the deponents work
24 in this case ofas II mentioned I donthave the
25 hard copy ofNANS deposition but Ive showed you
3 Pages 6 to 9
Page 6
1 to go through some of that First of all lets 1
2 go through your personal background Where are 2
3 you 3
4 A I reside in Colorado Springs Colorado 4
5 Q And do you have any place of residence 5
6 other than Colorado Springs 6
7 A I do not 7
8 Q And where are you employed 8
9 A I am employed by two places my primary 9
10 where I spend most of my time my consulting firm 10
11 which is Purswell and Purswell and that is an 11
12 ergonomics safety consulting firm based out of 12
13 Colorado Springs Colorado which employers and 13
14 attorneys in Gray issues regarding ergonomics and 14
15 safety in general And the second place Im 15
16 employed Im not employed at the moment the 16
17 summertime add JUNGTS Colorado State Universit 17
18 in PUB belowwhere I have for more NANan a 18
19 decade survey course graduate level as well as 19
20 the safety course 20
21 Q I dontwant to personal background 21
22 and educational background but I think its going 22
23 to be helpful moving forward even in that regard 23
24 that I ask you first of all to give me a general 24
25 laymansdefinition of ergonomics 25
Page 7
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4
5
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7
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10
11
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13
14
15
16
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18
19
20
21
22
23
24
25
and whether or not the occupational salary and
the appeals up through the federal courts would
make that continue to be the requirement and
everything that Ive been able to find says that
the court have affirmed OSHG STHAUS
A Hazards as GIEND in the standard
includes target Oregon information
Q No 6 copies much all treatises
articles or publications reviewed by the did Don
upon NENT and relied upon by the did deponent
or connection with the deponents work in this
case
A I really did not reviewed any SKOL
LARIy these TISs in regard to this so there would
not be anything
Q Resume LOR KRUM LUM vitae
A That should be in this the stack
Q A list of all publications AU the TLORD
by the deponent in last ten years
A Have it TAU
Q Deposition and trial in the last the
four years
A That should also number the stack
Q All the documents to be used in summary
or in support of the did deponents review in this
Page 12
case
A That should be in the stack as well
Q Your complete file in this case that
should be everything on the THABL
A The stuffthats on the laptop and
Q Billing statements and invoices
submitted by yourself reflecting costs fees and
bills produced in this case wev only issued
one or two invoices and I FRUSD the first invoice
there was the second one apparently looking at
the log sheet was also issued and I dont have a
particular hard copy of that particular the
different activity and the different amount of
time
Q Okay All written electronic and email
communications between yourself and the plaintiff
or the plaintiffs attorneys any consultant or
RECH sent TIF of the NRFT in this case
A Let flee just SPOENG to bill plea major
myselfonly Oversonsoffice and actually I dont
think Ive gotten anything from anyone but
Mr Overson directly I have GOB BAN that was
from Mr Overson and I have attempted to produc
that in an and that should be in that stack
Q Okay Incidentally have you ever had
Page 13
1 any other work with Mr Overson or anyone else in
2 Mr Oversonsoffice
3 A To the best of my recall this is the
4 first time wev had interaction with anyone at
5 Jones Swartz
6 Q Okay And the last one on here jumping
7 back to the deposition notice copies of all
8 publications RGS or coauthored by yourself
9 A Those are certainly available on
10 request I didntbring everything Ive ever
11 published but if you want particular copies of
12 stuffon my vitae I can certainly produce it
13 about
14 Q Have you ever authored LOR coauthored
15 any article study treatise or other publication
16 relating to Oleo Capsicum
17 A Not specifically to that chemical no
18 Q When you say not specifically have you
19 authored anything generally TROELG pepper spray
20 A Not to the best ofmy recall not with
21 regard to pepper spray I think there are
22 certainly articles on there that would be having
23 a hard time in all these can I have my vitae
24 back
25 Q We can get to that in a minute
4 Pages 10 to 13
Page 10
1 whatson the lap the top and we can go through 1
2 that as well 2
3 Q Copies of all data and relied upon in 3
4 RENLDing any opinions in this case 4
5 A I believe I have produced that 5
6 Q Copies of all government and industries 6
7 statutes standards rules and regulations and 7
8 guidelines reviewed by the did deponent and or 8
9 relied on by DEE upon or deponents work on this 9
10 case 10
11 A I believe thats also in that same 11
12 stack 12
13 Q So every statute rule regular GAGS that 13
14 you have relied upon you have produced in this 14
15 stack 15
16 A As I mentioned before Imnot sure if I 16
17 got a copy of the 19102 but I dont know if I 17
18 got the copy of the standard itself but the 18
19 certainly to the extent the standard itself is 19
20 something if its not in the stack that would be 20
21 the only thing of course thats easily publicly 21
22 available 22
23 Q Have you reviewed any case law on the 23
24 standards that you have relied upon I have REE 24
25 A I have reviewed target Oregon issue 25
Page 11
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1Page 14
1
1 A There may be warnings articles 1
2 regarding chemical warning warnings on it but 2
3 nothing regarding specific to pepper spray 3
4 Q Have you yourself ever been exposed to 4
5 pepper spray 5
6 A I dontknow if I have a recall of that 6
7 or not It seems like I have but I dontrecall 7
8 the particular circumstances 8
9 Q Are you married 9
10 A I am 10
11 Q Valerie 11
12 Q LAS Valerie ever been exposed to pepper 12
13 SPA to your knowledge I have not discussed this 13
14 issue with her so I have no idea 14
15 Q Do you have kids 15
16 A My ELD DES is Luke and apply SKENLD i 16
17 rash she will 17
18 Q How old is Luke 18
19 A Luke is has just turned 18 hesan 19
20 adult now and hes no longer our responsibility 20
21 of course thats not exactly accurately we got 21
22 limb to 18 22
23 Q Some would say that 18 is a prime age 23
24 to be exposed to pepper spray if you get yourself 24
25 inwrong situation 25
Page 15
A To the best of my knowledge neither of
2 my kids have 2
3 Q Knowledge of being exposed to pepper 3
4 spray 4
5 A And no and of course anything that I 5
6 would anyone that I know of I dont have anyone 6
7 who is law enforcementIve got a friend whos a 7
8 LAUF guy casual acquaintance but I havent talked 8
9 about this case with him hes sexual but you 9
10 have I have not discussed it with him But no 10
11 one else around my extended family is law 11
12 enforcement prison guard or thinking like that 12
13 would have been exposed to 13
14 Q Other than plaintiffs Counsel and today 14
15 me have you had any discussions with anybody 15
16 regarding this case 16
17 A I dontbelieve so 17
18 Q Okay I would like to ask you some 18
19 questions about your prior testimony so I think 19
20 before I get to your KRUM LUM vitae letsgo 20
21 ahead and look at the list that you have provided 21
22 of prior testimony and I believe today you 22
23 produced 23
24 A There have been a couple of depositions 24
25 since the report I believe and I tried to update 25
Page 16
TWHAFS there so youvegot whatever was exis
before and additional few depositions only that
were added at the bottom of the list
Q Okay Letsgo ahead and put your most
recent into the record mark mark that is as
Exhibit 92
Exhibit 98 marked
Q BY 01 Okay Im going to hand you a
copy ofExhibit 98 I donthave a copy so as we
get toward the end of the list there I may ask to
look over your shoulder a bit But its my
understanding that everything prior to the last
few entries would be the same as the document
that you had previously produced which is dated
January 16th 200911
Q That should be correct So first of
all you produced that document today so that is
true and accurate
A Well I generated it back on June 15th
but yes
Q You produced it here
A Yes I produced it to you here
Q Under the first Roman numeral entitled
depositions on the copy that Im looking at the
January 16th copy of the case dial first case
Page 17
tile FRAN SES KO FRES KO north America Ray met
al is that the STAM
A No its dropped off list because more
than four years old
Q Whatsthe first on your
A Do I as versus applied warehouse
systems
Q I would like to ask you about FRAN SIS
KO FRES XO that first case nonetheless
A Okay
Q What was the nature of that case
A It concerned a fellow who lost both
arms andor part of both arms and a leg while he
was taking a SNOOZ out on a rail bridge across
the rock river he was apparently quite EE NEEB
BER rated got in that motion and pasted out the
operating the train across that those tracks its
several hundred feet And it was a difficult
place to get himself into and an unpredict TABL
place probably not hall that comfortable either
but he was passed OUNT the tracks and TA train
operated by the did defendant in that case came
by and ran over him and he lost strangely enough
both arms and one leg so he was in I dontknow
how he was laving
5 Pages 14 to 17
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Page 14 a e 6 
1 A. There ay be warnings articles 1 T HAFS there so u've got whatever as e istenc 
2 regarding che ical arning arnings on it but 2 before and a tional fe  de s tions only that 
3 nothing regarding specific to pepper spray. 3 ere added at the tto   the list. 
4 Q. Have you yourself ever been exposed to 4 . . L t's go a ead  t o r  
5 pepper spray? 5 recent into the record a  a  that is as 
6 . I d 't no  if I have a re l f that 6 ibit . 
7 or n . It see s like I have but I d 't re l 7 (Exhibit  rked.) 
8 the particular circumstances. 8 . (BY #01) kay I'm i  to hand o  a 
9 Q. Are you married?    bit  I n't have      
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 A. y ELD DES is Luke and apply SKENLD i 16 . hat  e t.  r   
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 Q. How old is Luke?  true  rate? 
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20 adult no  and he's no longer our responsibility  t . 
21 of course that's not exactly accurately e got  .  r  it r ? 
 i   .  . ,   t   . 
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 A. To the best of my knowledge neither of 
 my kids have. 
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 spray? 
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 regarding this case? 
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 both ar s and one leg so he as in I don't kno  
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Q Thank you for clarifying Go on the
next case Hays V fleet superior court for state
ofCalifornia what was the in nature THUR of SHA
case
A That was the case where I was REE taped
by plaintiff battle cleansing product and people
have to go in after they are 50 and get a
colonoscopy they wanted as clean and visible as
possible bowl cleaning products cleansing
products I guess is the treat term that are used
and if those cleansing products are not used or
consumed with an appropriate amount ofwater the
you can have a bad reaction I dontrecall what
HPD to the plaintiff in the case in fact died
from it but basically it LAS a very strong effect
on the body and if you donttake enough water
with the medicine then you can have very adverse
reactions
Q So what was the construction of your
testimony
A That the instructions that a company of
the product were inadequate to explain to people
how much water they needed to drink and that it
was not explained clearly on the product insert
I dontremember if I dealt with the product
Page 21
SNERD label of the case but one ofthe two was
not what it should have been
Q According to what standard
A I dontrecall any more what standard I
was applying But it was not clear to the
plaintiffhow much water was necessary to drink
with it and SLE didntdrink enough
Q Lets go ahead and go to the in next
case Murphy V blue monkey
A That concerned a fellow who went into a
bar will a few beers in the bar and fell on the
steps outside the bar the steps were quite
irregular in terms of the tread length tread
riser height and it was my testimony in that case
that if you are operating the bar it is unwise no
make an obstacle for somebody who exit the bar
who presumably come in a restaurant and buy the
stuffyou were sell
Q Do I understand that you were
testifying on behalf of the plaintiff
A Thats correct
Q STAG inner Craig lot ofFEN trailer
sales the next case
A That was amatter where the ULT tie tea
the who hadasmall kid The the parent the dad
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Page 18
1 Q Okay Did you testify on behalf of the 1
2 plaintiff THOR defendant on that case 2
3 A On that case I testified on behalf of 3
4 the defendant 4
5 Q North P America rail net 5
6 A That is correct 6
7 Q And what was the construction of your 7
8 testimony 8
9 A Well its been awhile but generally 9
10 perception reaction time issues and LUM nation 10
11 issues whether or not the train in question met 11
12 the F R A requirements for head lamp used and if 12
13 it did why didnt the folks see them The 13
14 curvature to the track and the head lamp will be 14
15 pointing straight to the curve eliminate right 15
16 where the track is curving 16
17 Q Letsgo ahead go to the next applied 17
18 warehouses systems Inc what was the nature of 18
19 that case 19
20 A That related to a contractor who had 20
21 gone to a warehouse to set up some storage racks 21
22 and the storage racks were being assembled on a 22
23 floor and STHOU tipped up with NA forklift or 23
24 something and in the course of tipping them up it 24
25 was a faster way generally but the usually ended 25
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1 up with a few bit pieces and if you are defend 1
2 DPECHBDing upon column or strength weakened s 2
3 they would have to climb up in the racks and 3
4 replace the bent pieces and the guys were doing 4
5 it without appropriate fall protection a guy fell 5
6 on the racks on the concrete floor and he died 6
7 Q Did you testify on behalf of the rather 7
8 maybe a better way to put this were you retained 8
9 by the plaintiff LOR defendant in that case 9
10 A No that case I was retained by the 10
11 defendant 11
12 Q And what was the crux of your testimony 12
13 an in that case 13
14 A Its really basically all I can recall 14
15 was the work methods that they were using to 15
16 assemble the racks were unsafe and not 16
17 appropriate and approved so certainly the fall 17
18 protection was anyone climbing into the racks to 18
19 fix broken pieces 19
20 Q So you were testifying on behalf ofthe 20
21 defendant that the defendants 21
22 A I was testifying on behalf of the 22
23 premises owner and the injured party worked for a 23
24 contractor who had come on site to assemble the 24
25 racks 25
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coffee was adequate franchise operator
Q The warnings on the actual cup
A Yes and that no additional warnings
were necessary to advise the guy in the car of
the HAZ card
Q Do you recall about in that case ifyou
right lie upon any state federal or local
warnings standards or labeling standards
A No
Q No you dont recall or no you did not
rely on them
A To the best ofmy recall I did not rely
upon the consensus label standard for products
but an ROO 0 arcs product and an see S z 121
industrial chemical labeling and has appropriate
precautionary statements for hazardous industrial
chemicals and that would one that I have relied
upon in some cases but not in that case or in
even in fact in this case is since wer
dealing with regulatory requirements not
voluntary consensus standards
Q The next case is MAR KWEZ versus BAN
did it
A That was a matter involving a fellow
that I recall the the facts much that one wood
Page 25
chipper where they were feeding wood he was
found feet NIRS the chipper and he was dead by
the time anybody found him but of course it was
no doubt an unpleasant death but the tissues
involved in that perception reaction time in
order to hit the safety control bar on the
outside of the chipper if you get snagged
certainly LAUL the warnings on the chipper
putting their hand into the in feed hopper and
certainly advising standing in the in feed hopper
kicking into the in feed hopper and my opinion in
that case generally the warnings were adequate
Q And you were testifying on behalfof
the defendant
A On behalf of band did it yes
Q Do you know in that class if you relied
on any state federal or local warning signs
A We generally in those BAN did it case
and Ive testified in more than one of those but
there is an applicable an see standards but the
in that case that TRELTS to the design I dont
know that it I dontthink it has any statements
about whatsrequired in terms of labeling on
there but its an see z 133 dot 1 is the design
standard but no labeling standards with regard to
7 Pages 22 to 25
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1 and the mom were the dad was trying to instruct 1
2 the mom on how to hook up the trailer to take it 2
3 some SPLAS and they were raising it back on hitcf 3
4 somehow the got unlatched the kid at the time was 4
5 four or five or six but he was able MD operate 5
6 the latch and apparently he operated the latch 6
7 and it came on down on top of him and caused liml 7
8 a brain injury and I was testifying on behalfof 8
9 the plaintiff in that case and generally the 9
10 means of securing the trailer gate to the utility 10
11 latch it up higher than the kid could reach 11
12 andor should have been a means to have a lock 12
13 that could lock the trailer gate to the back of 13
14 the trailer 14
15 Q Was there NRI allegation in that case 15
16 regarding inadequate warnings or labeling 16
17 A Yes 17
18 Q And did you have any testimony relative 18
19 to that 19
20 A Its been four years but generally that 20
21 the trailer needed a warning again starting from 21
22 first principles any time that you are dealing 22
23 with a hazard on a consumer product you want to 23
24 do what you can to design the hazard out you want 24
25 to the try to guard the user last resortrely on 25
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1 a warning but to the extent that a warning to the 1
2 extent that the trailer manufacturer and retailer 2
3 did not otherwise deal with the hazard falling 3
4 trailer gate with little kids and other 4
5 appropriate to make sure that the parents knew 5
6 that the gate could come down and have some means 6
7 of securing the gate to the back of the trailer 7
8 Q That case do you recall whether you 8
9 were relying upon state local federal labeling 9
10 standards 10
11 A It was a generally no I dontbelieve 11
12 so but no I dontbelieve 12
13 Q The next case that I see on the list is 13
14 LOR RENS L O R E N z versus valley food services 14
15 A That was another McDonald hot coffee 15
16 case not the most not able one another one like 16
17 that in that case I was retained by Counsel for 17
18 the defense and generally my testimony on that 18
19 one was the fact that if you are providing 19
20 somebody with selling coffee retail people are 20
21 going to be served hot not Luke warm that the 21
22 coffee cups contained printed warnings on them 22
23 and whether or not that the person the drive 23
24 through window needed to provide additional oral 24
25 warnings everything else hazard about the hot 25
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degraded over time or got but any point the
propane did not contain an adequate of odor rant
so I testified on behalf of the plaintiff in that
case
Q Were there any issues in that case
relative to written labeling or warning
A There was an an insert or I dontknow
what you call it but a little communication from
the propane supplier and the propane if I recall
correctly the insert did not warn ofwhat they
call odor rant fade which is the decreasing
concentration of order rant in the propane so I
was critical on that one as well
Q The next case is David English bay
limited in January 2010 yes that
A Yes that concerned refine REE David
English was a longer term sued DO employee I
would say of the refine REE but he was basically
directing the work of the con contractor refine
REE they were trying to operate with no employe
so he was an he directed that they set up some
heavy electrical cabinets like the dome knows and
they fell on him hesunfortunately a
quadriplegic and my testimony in that case
relat d to the the duties of bay limited with
Page 28
regard to whether or not they should have said
setting up those things like dome no sir I
thought their
Q I you testified on bay less
A Yes
Q And in that case I understand it was an
employeeemployer relationship or was it more
independent contractor or
A Both of them were classified BOst both
of them received the way I tell do you get a W 2
or 1099 They were both 1099 people from what I
understand
Q Was OSHA a factor in that case
A They were certainly OSHA did not
investigate the accident if I recall but there
were certain issues with regard to the insult
THEE employer work site policy for OSH saw citin
for people for types of injuries types of
violations in standards
Q That case OSHA did not issue any site
taste GS itself
A OSHA did not do any investigation of
the incident as you may know there are a lot of
workplace accidents including the Major one where
there is not an OSHA investigation In the case
Page 29
1 of the only ones where you get where OSHA
2 required to investigate if you have a fatality or
3 three more people to the hospital And anything
4 else they get to when they can but not a
5 requirement for OSHA to investigate
6 Q Does that STAM standard that you just
7 discussed about whether OSHA will investigate an
8 accident does that also apply to whether or not
9 the incident goes on the OSHA on line data place
10 workplace injuries do you know
11 A Itsmy understanding that the only
12 records that occur in the OSHA accident database
13 from the ones that get investigated by OSHA
14 Q Okay I have some more questions about
15 that but letsgo ahead and finish up the list
16 here so we dontget distracted the next case I
17 see on here is Nagel AUR REE REE student housir
18 at the REE general see
19 A You did very well on PROUN NOUNGS
20 Q Thank you
21 A That one SKERND a matter in which a
22 premises or row REEN housing complex which rents
23 apartments its not HAN official arrangement but
24 they rent to students in various downtown KAM
25 pose us PUS PUS in open area with the picn
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1 that 1
2 Q The next case DOD I want to say chew we 2
3 SHAOI 3
4 A Thatsa close young woman accepted a 4
5 ride on the back of the motorcycle who was her 5
6 boyfriend at the time and the 6
7 Q Spare helmet there was an accident the 7
8 helmet came off and she had a fat at all branch 8
9 injury and the to make sure you have an adequate 9
10 fit and my opinion in that case was basically 10
11 that the warning on there was appropriate 11
12 Q And there was no more warning for 12
13 warning that was there 13
14 Q Next case KET to versus LUD VIG propane 14
15 yes that concerned I think this was a propane 15
16 retailer and the propane retailer went out to TA 16
17 place prop main in a tank Its not clear at 17
18 what particular LAT background propane is a but 18
19 there is a natural gas smell thatsadded to it 19
20 and that smell the ET they are MAR captain was 20
21 not present in the concentration that it 21
22 specified needed to be present as a warning an 22
23 olfactory warning that the gas was around And 23
24 so generally my I dontknow if the if it was 24
25 inadequate amount when first put in or got 25
Page 27
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regard to what they are supposed to be inspecting
for and looking for in they are up in front with
regard to how customers from flowing what hazards
may be present on the in floor TLINGS like that
Q The next case you have after that the
A The next one after that would be or
stone versus Holly refine REE
Q Versus say that one more time please
A Holly REE finaling H O
Q HOLLI
A HHOLLY
Q And what was the nature of that case
A Well that involved a guy who got
scaleded very badly during a course of an
operation where he was attempting to operate a
valve and when he freighted the valve there was a
lotof large amount of hot water and scaling
steam which was in the same SKALTD by my opini
in that case was basically there the fact that it
was a well known hazard to the refine REE they
documented that existence of the hazard they they
just never implemented it And in that case they
got bad legal counsel on that particular one with
regard to what they were doing with their hazard
identification and fixes but in that case they
Page 33
that was the substance of what happened So I
didnt have to do much with regard to showing the
hazard existed because they had already done it
they should have fixed the problem to identify
Q You testified on behalf of the
plaintiff
A That is correct
Q Any OSHA standards involved in that
case
A The process safety standard 1910 dot
119 was significant in that case It didn tell
them to do anything with regard to identify and
if the you do need to go ahead and fix what
youveidentified as a hazard
Q Any other warnings or LABLing issues
that came up in that case
A Not that I recall
Q Okay Do you have NRI others after
Horton for the depositions
A There is one more and that would be one
that happened just recently that is WES Lynn
versus NAR RA THON
Q What was the in nature of that case
A It was depending on how you look at it
it was IERTD a machine guarding issue or lock out
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1 tables concrete pedal stool basis and as long 1
2 has my findings in the case as long has the pedal 2
3 is securityly doesnt fall recovery and nothing 3
4 bad happens In this case a table top became 4
5 unattached if it was at all attached to the 5
6 pedestal fell off the pedestal and bended up 6
7 crushing the tips of about three or four 7
8 plaintiffs fingers off the end of his hand he 8
9 lost those fingertips on in that case my 9
10 testimony was on behalfof the plaintiff as well 10
11 Q And your general the crux of your 11
12 testimony 12
13 A The crux ofmy testimony was that there 13
14 were inadequate inspections of the tables in 14
15 question and had the AERGS the AU row REE an 15
16 housing complex done RU NREEN and question th 16
17 table wouldnthave fallen over 17
18 Q NRI issues in that case with labeling 18
19 and warnings 19
20 A No 20
21 Q Thatswhere my list ends on the 21
22 depositions so Im going to ask you to go ahead 22
23 and read from the copy you have if the next case 23
24 after the Nagel that you have listed on your 24
25 ucase list is okay 25
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1 A Okay that would be Martinez versus 1
2 WalMart stores and Ill put that over in the 2
3 front much the court reporter so that concerned a 3
4 slip and fall hazard in a wall north matter store 4
5 in front of the question was number one following 5
6 its own poles he is and No 2 doing adequate 6
7 inspections of the in floor surface specifically 7
8 high FRAFK areas 8
9 Q You testified on behalf of the 9
10 plaintiff or for the defendant 10
11 A On that one I also testified for the on 11
12 behalf of the plaintiff f 12
13 Q Was NAR tin knees an employ of the 13
14 WalMart 14
15 A He was not 15
16 Q Independent contractor 16
17 A He was a store he was a 17
18 Q Customer 18
19 A Customer 19
20 Q Any issues with warnings or label 20
21 instance in that case 21
22 A Generally no The only communications 22
23 regarding hazards that would be of significance 23
24 in that case would be WAL matters instructions to 24
25 its managers and what the person up front with 25
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1
1 tag out issue There was LA regard that had been 1
2 removed to the create paper bales in envelope 2
3 manufacturers and if the guard that had been 3
4 supplied by the manufacturer and I thought the 4
5 evidence showed arrived with a machine or depart 5
6 TRD the manufacturers place with the guard in 6
7 place was still in place at the time of the 7
8 accident the accident could not have occurred 8
9 So there was NA guard removed and after that 9
10 guard was removed somebody stuck their hand in 10
11 and got their hand taken off in a baler 11
12 Q And so you testified on behalf of 12
13 A Of the defendant 13
14 Q Marathon 14
15 Q Marathon 15
16 Q Okay I take it there was a third 16
17 party in here WES Lynn being the plaintiff 17
18 marathon being the manufacturer of the product 18
19 A That is correct 19
20 Q And then there was the facility I STHUM 20
21 the owner of the premises 21
22 A Yes 22
23 Q I dontknow were they aparty to the 23
24 case 24
25 A N 25
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Q Any issues with warnings or labels in
2 that case 2
3 A The plaintiff in the case thought there 3
4 should have been a warning somewhere on the pape 4
5 baler indicating thatpointing to the spot where 5
6 the guard should be if the guard is not here take 6
7 some precaution dontoperate the machine put the 7
8 guard back on But that seemed to me to be a 8
9 matter of infinite regression the part that 9
10 should could if you take the warning off take 10
11 the part HOF whatsgoing to warn you about the 11
12 part being gone so 12
13 Q I didntquite catch that last part can 13
14 you maybe explain that to me a little further 14
15 WHAF your opinion was relative to the warning the 15
16 existence or nonexistent of the warning on the 16
17 baler itself 17
18 A My opinion about that was that if they 18
19 remove TH the guard and didntsay anything or 19
20 anything about removing the warning there should 20
21 be a guard over here there would be nothing no 21
22 reason why they would not ever remove the piece 22
23 that had the warning on it Its a machine 23
24 covered with metal and the only metal intend Todd 24
25 enclose the hazard EX POED on the machine 125
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supplied it had hall the appropriate guards in
place and the accident could not have occurred
In this particular instance that particular guard
was not on the machine at the time ofthe
accident The plaintiff wanted to argue that the
guard had not been supplied with the machine I
thought the the evidence and of course matter NO
jury to guard was on the machine when it arrived
at the plant there was an issue did the LFT take
it off somebody at the employers operation take
it off things like that If somebody else took
it off could should there be guy there that
there should have been a guard over that
particular warning if this machine doesnthave
TA guard here somebody at your place of business
has taken it off and you need to go put this
guard back on I thought it was a rather unusual
WAURNG to propose
Q Why
A Its covered by OSHA regulations and
its a lock out tack out issue if you remove
guards which enclose machine hazards there are
certain procedures to do NA and you need to
follow the those makes SHEENS
Q Do you have any opinion in that case
Page 37
has to whom you assign fault for the plaintiffs
injuries
A I assign fault to whoever removed the
guard
Q So if it was the plaintiff that removed
TH the guard you AU STIEN the fault there
A Thats correct if and if some other
employee I would assign fault with them There
were also issues about how hard should you make
it to remove this particular guard It was
bolted on you could weld it on but if you needed
to remove the guard for some reason you have to
have NA cutting touch so I thought bolts were an
adequate way to attach the guard
Q Okay If the plaintiff in that case
was aware that the guard was supposed to be on
there and somebody else removed the guard would
that change your opinion has to assigning fault
to whoever removed the guard
A Im sorry say that again
Q So if the plaintiff had operated this
same machine for years in advance And in that
particular case it in all of those cases leading
up to that point the guard had been there so the
plaintiffwas aware that the guard needed to be
10 Pages 34 to 37
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my testimony was it was the clean claim through
the plaintiff size had been on that particular
location and so that was a thats you know
something that I didnt testify about there was
no that was not a possibility that was considered
or admitted by the plaintiff that the plaintiff
knew that there was supposed to be that guard
there
Q Okay But in all events your
assumption is that whoever removed the guard wa
acting as an agent of the employer
A I dontknow that for certain but we
just know that the I believe the guard left the
marathon facility in Alabama with the guard on
and at some point before this particular
plaintiff stuck his hands in the point of
operation the day that it occurred the guard was
no longer there Where it was taken off Im not
able to say
Q Again Im if trying to understand your
testimony in that case previously you told me you
the assigned fault with whoever took the guard
off
A Thats still the case
Q Does that change if whoever the took
Page 41
the guard off was not acting as an agent of the
employer
MR OVERSON Object tune FRIEMT
The reporter read back the requested
testimony
THE WITNESS In that class and again
its an a manufacturing its something as LARNG
as this room but its it was shipped apparently
from the facility in Alabama out to wherever it
is in Washington that the machine was operating
the guard NA have been removed by the company i
shipment it may have been REE by the plaintiffs
employer at some point by somebody acting as the
plaintiffs facility in Washington before the
plaintiff ever got there and again my opinion is
that there is a lock out tag out regulation which
applies to removal ofmachine the guards from
REE guard will HAN obligation to put the
machine guard back on before the machine was RE
NRGD and
Q Based on what youvejust told me if
the guard was pre moved by the shipping company
would the employer carry any responsibility for
not EN NUSHing that that that guard was put back
on the machine before operated in their facility
11 Pages 38 to 41
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1 there and then another employee came along and 1
2 removed the guard one night as a practical joke 2
3 or otherwise would that change your opinion as to 3
4 whether you would you assign fault with the 4
5 plaintiffs injuries to the individual who removed 5
6 the guard 6
7 A Purely on that particular case I would 7
8 still assign fault to the person who REE 8
9 approximate moved the the guard 9
10 Q Would the plaintiff be at fault at all 10
11 for operating a machine that he or she knew was 11
12 supposed to have a guard in your opinion 12
13 A There might be some other reason to say 13
14 that but under applicable OSHA RES GS the 14
15 obligation to put the guard back on is placed on 15
16 the if person who removed T guard 16
17 Q Placed MRON the the person removed TH 17
18 if guard such as another employee or removed T if 18
19 guard upon the employer 19
20 A The person who removed TH the guard 20
21 working as an agent of the employer but it would 21
22 be unwise of the plaintiff in question to have 22
23 operate TID the machine absent the guard if he 23
24 had seen it there previously But I would not 24
25 say that he was the one who caused the the OSH 12 5
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1 saw violation in free moving to if guard on the 1
2 machine 2
3 Q So assuming NA whoever removed D the 3
4 guard was acting on the capacity of the employee 4
5 of the employer as an agent of the employer if NA 5
6 person pre moved it in that capacity then you 6
7 assign responsibility or fault to the employer 7
8 MR OVERSON Okay Im going to object 8
9 to this line of questioning I think one there has 9
10 been a number including this of inappropriate 10
11 hypotheticals Im not sure if you are asking him 11
12 questions about the specific case he testified in 12
13 which you have asked what happens to me several 13
14 questions about that And then youvealso asked 14
15 about kind of a vague hypothetical that youve 15
16 presented and gone back and forth Lloyd Lloyd 16
17 okay 17
18 MROVERSON So thatsthe nature of 18
19 my objection Lloyd Lloyd I would and then Darwin 19
20 in the future you state your objection I believe 20
21 that was that speaking objection 21
22 MR OVERSON But I want to clarify 22
23 PRECHS was perhaps you couldIm Lloyd LloydIm 23
24 just trying to WES tin versus marathon 24
25 THE WITNESS To the point that of what 25
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 THE ITNESS: To the point that of what  
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not E  S ing that that that guard as put back 
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somebody who had been hit in an eye by pool toy
or actually by a piece that came off after pool
toy and there was a question as to whether or not
the warnings on the case wer or the warnings on
the pool toy needed to address the eye injury
that the plaintiffs sustained in a case Its
been too long ago and I didntdo a deposition in
that case as youllnotice so the defendant in
the case provided me with some information I
showed up at trial and testified based on the
information I had in the case but thats all I
really remember on the case I believe I testified
on that one for the defendant but beyond that
some part of the piece of the tool
Q So in that case in forming your
opinions you relies exclusively on the
information thats provide to you by the
defendant
A I may have dug up something on the CPC
I dontrecall
Q Generally speaking whether you are
testifying in that deposition or in a trial is it
your practice to rely exclusively on information
provided to you by the counsel that retains you
or do you request specific information Im just
Page 44
trying to understand your standard practice
A My standard practice and usually again
when Imretained in cases like this Im retained
to to deal with liability issues not typically
damages so I will typically request the complaint
proceedings deposition testimony that relates to
the liability issues in the case If it is the
something strictly regarding damages then I say
you can send it to me for the incompleteness of
the file but I dont expect to tree lie upon it
much With regard to to other RISHS like on this
chase clearly there is a fair amount of stuff
thatIve generated thats either CPC or OSHA
stuff in that case I dontthink there was
anything regarding pool toy safety from the C P
SC it wasn a big thing that happened a lot
before
A I may have checked the nice N e i SS
database that XR P SC prior similar instances and
if to the best of my recall if I did there
weren any so
Q So generally speaking when you are
testifying in an a case do you request that any
specific deposition testimony I mean is there a
standard request that you put out that you get
Page 45
1 that that deposition testimony and plaintiff in
2 the defendant for example
3 A Offer offer asked and answered
4 A There is no standard form I request it
5 simply depends upon the facts of the case and the
6 information availableIveIm asked for new
7 materials
8 Q BY 01 Okay
9 Q When you form an opinion if a case do
10 you I take it you form that opinion based upon
11 that information that is available according to
12 what youvejust said
13 A Well if
14 MROVERSON Vague
15 THE WITNESS When you say form an
16 opinion you mean form an opinion thats somethin
17 to look into form further and paper its going to
18 be my opinion in this case
19 Q The TLAT they are so when you are
20 forming your opinion for purposes much a report
21 like youvedone in this case do you rely
22 exclusively on the information that is then
23 available or do you seek from counsel or
24 otherwise periodic updates as information comes
25 up from the course of the case
12 Pages 42 to 45
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1 A The the shipping company wasnt 1
2 identified in has a matter in the case so I 2
3 presume thats not an argument thats there 3
4 Your height is there a company accepts a modify 4
5 it before necessity deliver it and then the 5
6 employer or the the final customer doesn 6
7 realize something is missing and in that 7
8 particular circumstance that hypothetical I would 8
9 assign fault to again the entity that removed the 9
10 guard or agents to entity which removed D the 10
11 guard 11
12 Q Does that cover all of the deposition 12
13 testimony listed on Exhibit 98 13
14 A It does 14
15 Q Okay Moving the the trial testimony 15
16 again just to be clear On the trial testimony 16
17 document that I received dated January 16th 2011 17
18 I have three cases 18
19 A That is still the case There have 19
20 been no additional trial appearances since that 20
21 testimony list that you have 21
22 Q Okay First on the trial testimony 22
23 Low versus main key toys what was the nature of 23
24 that case 24
25 A That was an injury that involved 25
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. r  i   t r  f r  I r t it 
i l    t  t   t    t  
r  i  've 'm    
t ri l . 
. (B  #0 ) ay. 
. hen you for  an opinion if a case do 
you I take it you for  that opinion based upon 
t at i f r ati  t at is a aila le acc r i  t  
at ou've j st said? 
. ell, if. 
R. OVERSO : a e. 
 I SS: hen you say for  an 
opinion you ean for  an opinion that's somethin~ 
to look into for  further and paper it's going to 
be y opinion in this case. 
.    t  r  s    r  
f r i  r i i  f r r s s   r rt 
like ou've  i  t is s    r l  
e cl si el   t e i f r ati  t at is t e  
available or do you seek fro  counselor 
other ise periodic updates as infor ation co es 
up fro  the course of the case? 
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stuffIve brought responsive to your subpoena
wasntnecessarily NRISD the report But
everything that was the only thing that was sent
to me by Mr Overson that I have figured out
since the time of the writing of the report that
I had inadvertently omitted
A But it was certainly nothing and I did
look at it and I do have it and I have looked it
up
Q Okay Those questions just came to
mind when you were discussing your testimony in
low versus NAN key toys so letsget back to this
list Case style TRING loan versus loaf and jug
A And that was an issue that was a matter
in which I was REE FANLD in a workers
compensation case being litigated by a store
clerk who had a fall in an actually at the place
of her employment and there was an issue as to
whether or not her fall was caused by anything
related to her employment or whether it was just
something that happened due to a preexisting
medical condition she had with the knee
Q Okay And what was your testimony well
first of all did you testify on behalf of the
plaintiff for the defendant
Page 49
A In that case I was retained by Counsel
for the defendant My testimony in that case was
that the store video which documented her fall
showed that it was not something that was not the
typical fall pattern where somebody slips and the
leaning foot goes out from under them and their
upper torso goes backward the store lady showed
her stumbling fell forward and it seemed to be
her preexisting medical condition with regard to
a knee injury caused her to fall forward and
inner knee collapsed basically
Q Do you have NRI medical training
A No perfection chemistry but no
particular medical training
Q Okay
A I haveIm fair enough background in
gait analysis so to the extent that goes to that
issue in that case but nothing in regard to
medical training
Q What where does
A Graduate studies
Q Okay And wellget into that in a
minute has well Lets finish up this list and
once again wer back on DOD versus SHU we which
wev already discussed With regard to your
13 Pages 46 to 49
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1 MR OVERSON Vague and asked and 1
2 answered go ahead 2
3 THE WITNESS As I said before when I 3
4 reported line as I have in this case I draw up 4
5 the opinions as I believe I hold them at the time 5
6 I have I is am NSHG the report deadline was back 6
7 at the tend much March or and so I wrote up the 7
8 report at that time and sometimes when I report 8
9 write a report it will come out substantially 9
10 information which I need to change my report and 10
11 I you know notice I REE severe the radio to 11
12 it to amend it if new information becomes 12
13 available But I draft the report based upon 13
14 whats available at the time 14
15 Q And whats available at the time how 15
16 the do you determine whatsavailable at the 16
17 time 17
18 A Again I will have generally asked the 118
19 in plaintiff orIm sorry the Counsel thats 19
20 retained me to provide me with I like to see the 20
21 complaint because thats that good summary of 21
22 what the allegations are at least the answer of 22
23 the complaint if there is one 23
24 A Interrogatories that address issues 24
25 whichIm asked to Im thinking about there is 25
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1 damages interrogatories I may ask them for them 1
2 for the the completeness of the file but I dont 2
3 generally need those Requests for production I 3
4 ask for those if there has been substantial 4
5 requests for production relatively to to the in 5
6 liability issues in the case and LERN certain 6
7 therapy deposition testimony if as youllnotice 7
8 in the case thats fairly typical as well we have 8
9 a substantial library of safety TEFRLS in our 9
10 office and I have relied upon knows as well in 10
11 forming my opinions 11
12 Q BY 01 Im sorry to belabor the 12
13 point and the reason I ask is because when I 13
14 review your report I notice that you did not 14
15 reviewed the plaintiffs deposition in this case 15
16 in forming your opinions 16
17 A And that was an omission on the listing 17
18 on my party I should have corrected that when we 18
19 sat here first I do have her deposition and I 19
20 have read it Im sorry for that omission 20
21 Q Any other information that youve 21
22 omitted from that report that you did in fact 22
23 review And if you would like to wait to answer 23
24 that question until pull it out we can actually 24
25 A Yes why dontwe do that obviously the 2 5
000865
  
 . : a e    
 a s ered  . 
 E : s    hen  
4 reported line s I  in t is ase I r   
 the opinions as I believe I hold the  at the ti e 
 I a e I is ,  t  r rt line s  
 at t e te  c  arc  r a  s  I rote  t e 
 re rt at t at ti e a  s eti es e  I re rt 
 rite a re rt it ill c e t s sta tiall  
 infor ation hich I need to change y report and 
 I , you kno , notice, I REE severe the radio to 
 t   t f  for ation e  
 il l . t I r ft the re rt ase   
 at's  t e . 
 . n  at's il le t t  ti   
16 the do you deter ine hat's available at the 
 t ? 
 A. Again I will have generally asked the 
 in plaintiff or I'm sorry the ounsel that's 
 retained me to provide me with I like to see the 
21 complaint because that's that good summary of 
 what the allegations are at least the answer of 
23 the co plaint if there is one. 
 A. Interrogatories that address issues 
25 
1 
2 
 
 
I  
 
 
 
 
 
 
 
 
 
 
,  
17 
118 
 
 
 
 
 
 
 
  
t ff I've r t r i e t  r a 
sn't ril  IS  t e rt. t 
  as   t ing  a  s  
t    r. rs  t t I  figure  t 
si  t e ti e f t e ritin  f t e r rt t t 
I  i rt tl  itt . 
. t it as certai l  t i  a  I i  
l  t it  I   it  I  l  it 
. 
. y. s  sti s just  t  
i    r  is ssi  r t sti  i  . 
lo  versus  key toys so let's get back to this 
list. ase style I  loan versus loaf and jug? 
.   as       
i  i  I s    i   r rs' 
   tigate     
l r     f ll i   t ll  t t  l  
f r l t  t r  s  iss  s t  
    ll  se    
related to her e ploy ent or hether it as just 
s et i  t at a e e  e t  a ree isti  
i l itio  s   it  t  e. 
ic  I'm as e  t  I'm t i in  a t t ere is 
. y.  t s r t sti  B 
first f ll i   t stif   lf f t  
lai tiff f r t e efendant? 
I--------------~-------+-----:--------------~----,~---, 
    
 da ages interrogatories I ay ask the  for the   .         
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 lia ility iss es i  t e case a   certai            
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 a substantial library of safety TEFRLS in our  er ree isti  e ical c iti  it  re ar  t  
 office and I have relied upon kno s as eB in lOa knee injury caused her to fall for ard and 
 forming my opinions.  inner knee collapsed basically. 
 . (B  #01) I'm sorry to belabor the  .      ining? 
 point and the reason I ask is because hen I  . o perfection, che istry but no 
 revie  your report I notice that you did not  particular edical training. 
 reviewed the plaintiffs deposition in this case  . kay. 
 in for ing your opinions?  . I have I'm fair enough background in 
 . nd that as an o ission on the listing   it l i   t  t  t t t t  t  t t 
 on y party I should have corrected that hen e  i  i  t t  t t i  i   t  
 sat here first I do have her deposition and I  i l t i i g. 
 have read it I'm sorry for that o ission.  . t r  oes? 
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 o itted fro  that report that you did, in fact,  . y.  e'll t i t  t t i   
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total that up that would be my best guess
Q Okay For as I understand it in this
case you have been retained by plaintiff in your
capacity as an employee of Purswell or Purswell
or are you an owner
A Im S corp Im both an employee and
owner
Q As an agent of Purswell and Purswell
thatsthe capacity for which you have been
retained in this case
A Thats true
Q Is that the STAM for hall of the cases
that we have gone through in your deposition and
trial list
A Yes
Q And is that the STAM for all the cases
in which youve been a consultant
A Yes
Q Other than testifying or consulting for
purpose of litigation what other job duties do
you have within Purswell and Purswell
A Well as I say we assist manufacturers
and employers with OSHA compliance we assist
manufacturers and employers with MDS
development We consult with them regarding
Page 53
their own internal employers with their own
internal safety programs
Q What percentage of your income would
you attribute to consulting andor testifying in
litigation
A In terms of percentage of income thats
tough to guesstimate but I would say maybe 70
percent
Q Slightly different question but could
be a significantly different answer what
percentage of your time do you spend consulting
or testifying in litigation and everything that
accompanies that preparing reviewing documents
et cetera et cetera
A Something less than the 70 percent
because my teaching obligations at the university
do require substantial time specially during the
school year However the amount thatIm
compensated about by the the university for is
considerably less for what I charge for my
deposition or my trial testimony time Or my
litigation related consulting
Q So when you say something less than 70
percent can you again guesstimate
A Not really
14 Pages 50 to 53
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1 list of depositions so I take it you were deposed 1
2 in pretrial and then you were also called to 2
3 testify at trial 3
4 A Thats correct 4
5 Q Did your opinion change from pretrial 5
6 to trial 6
7 A Not as I recall 7
8 Q So everything youvealready told me 8
9 about your opinions on DOD versus SHU we would I e 9
10 the same 10
11 A Yes 11
12 Q Anything else you want to add to that 12
13 A No 13
14 Q Okay Have I covered everything then 14
15 on your prior testimony your list of prior 15
16 testimony 16
17 A Yes 17
18 Q Are there any other cases within the 18
19 relevant time period and by that I mean the four 19
20 years asked for in your deposition notice four 20
21 years preceding today are there any other cases 21
22 that youveeither been deposed in or 22
23 A Not no the best of any recall I dont 23
24 thinkIve omitted anything 24
25 Q Other than being deposed actually 25
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1 deposed or actually testifying at trial are 1
2 there any cases or Im going to make this a 2
3 little more broad Are there any instances in 3
4 which you have been retained by an attorney to 4
5 opine as to one issue or another 5
6 MR OVERSON Objection the question 6
7 calls for an answer that may be invading third 7
8 party work product and attorneyclient privilege 8
9 Under the rule you are entitled to know what 9
10 cause cases he has testified either by deposition 10
11 or trial You are not entitled to know what his 11
12 opinions were when he consults with an attorney 12
13 whether its for that purpose Lloyd Lloyd again 13
14 lets refrain from the speaking objections 14
15 Q BY 01 Have you been retained to 15
16 consult on any other cases 16
17 A Yes 17
18 Q Okay On how many KAEGS indications 18
19 A Several I donthave a particular 19
20 count 20
21 Q Can you estimate 21
22 A I can give you a what I would call a 22
23 guesstimate so for every case listed on there I 23
24 would say there R are five which Ive been asked 24
25 to consult with an attorney on So however many 25
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 consult on any other cases? 
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not plugged in probably does
Discussion held off the record
Q BY 01 Wellgo ahead and mark this
document Exhibit 99mark MRASH 99
Q BY 01 Okay Dr Purswell Im handing
youwhatsbeen marked as Exhibit 9
Q And it is a copy of your CV that was
originally produced to my office along
MR OVERSON Do you have a copy for
me
Q BY 01 Yes sorry
Q So this was produced along with your
original report I can represent to you Has your
CV changed since that time
A It has
A I believe the current version contains
two additional articles
Q And can you identify what those
articles are without pulling it out
A Generally they were conflict
proceedings presentations conference proceedings
but I believe one relating to OSHA citation of
ergonomic hazards in the employment environmet
and then the other one regarded an analysis of
truck crane accidents as contained in the OSHA
Page 57
accident database
Q Okay For now I think Illconduct the
deposition with the did document that Ive placed
in front of you marked as Exhibit 99
A Okay
Q Are there any other changes other than
those two articles that youvejust discussed to
this document as compared to your current CV
A I may have deleted the university email
address off the vitae and took one with the G
mail one I found the G mail one typically works
pretty well for me and I get with my an DROID
phone I get more rapid notices when Colorado
State one generally REL gateing for student yeast
use
Q Sure okay Looking at your education I
think I would like to ask you some questions but
in reverse order so we walk progressively through
your education rather than starting at the end of
it and working backwards to
A No
Q Im going to start with as you
proceeded with your education starting with
undergrad moving on to your graduate programs and
ultimately doctoral oroLrams
15 Pages 54 to 57
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1 Q Less than 50 percent 1
2 A Im sorry tell me the original question 2
3 again 3
4 Q It might be easier if I rephrase 4
5 A Please 5
6 Q What percentage of if you can 6
7 guesstimate what percentage of your time do you 7
8 spend in litigation related matters whether that 8
9 be consulting testifying reviewing documents for 9
10 litigation 10
11 A Out of a five day work week ask those 11
12 are not always as common as my wife would like 12
13 but assuming a five day work week if I work five 13
14 days in a week about three and a half of those 14
15 days are usually devoted to something related to 15
16 litigation or litigation related work three to 16
17 three and a half 17
18 Q So over 50 percent of your time 18
19 A I would say that 50 to 60 to whatever 19
20 that wouldbe 20
21 Q Okay 21
22 A Yes 22
23 Q 23
24 Q Is has that generally increased or 24
2 5 decreased or stayed the same over the past four 25
Page 55
1 years thatwev gone over these cases 1
2 A It really varies depending upon what 2
3 time period were talk looking at There was a 3
4 period last fall where I was retained by a LOP 4
5 chain do do some use ability analysis hospital 5
6 beds they were looking at Engaged in matters 6
7 currently involving litigation but it was 7
8 certainly one they were looking at both patient 8
9 safety as well as employee safety with regard to 9
10 patient handling issues and so that took a fair 10
11 amount of time from like I want to say August 11
12 through January and so my litigation related time 12
13 was generally less at that time In the past 13
14 several months the spring there have been a 14
15 number of cases SNAP finger somebody wanted 15
16 something yesterday there have been anumber of 16
17 times like that 17
18 Q We tend to do TA as lawyers I apologize 18
19 on behalf of my entire profession 19
20 A Thank you 20
21 Q Lets go ahead now I would like to 21
22 jump back into a bit of your background and I 22
23 think the easiest way to start walking through 23
24 that would be to take a look at your V C 24
25 MROVERSON Does that mean you are 25
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Page 60
1 A Okay I understand now what you are 1 Q When did you first read through it
2 talking about 2 A A decade ago perhaps
3 Q So I see on your CV that you have a 3 Q Have you ever had any formal education
4 double major in chemistry and biology 4 regarding the F H S A
5 A That is true 5 MR OVERSON Objection vague
6 Q From Oklahoma BAP TIS university 6 Q BY 01 Have you ever had any formal
7 A That is also correct 7 educating regarding the F H S A
8 Q Do you also recall what your GPA was 8 MR OVERSON Same objection
9 A High TLOOES 9 THE WITNESS I dontrecall at the
10 Q And your studies at the Oklahoma BAP 10 time H F H S A is part of the class I think it is
11 TIS university did you take any classes about 11 something I reference when I am teaching my
12 regulations regarding warnings labeling 12 students at C S U PUB below things they need to
13 A No 13 be aware of hazardous substances act with regard
14 Q Did you take any pre law classes 14 to to the stuff strictly consumer and anything
15 A No 15 that comes into the occupational environment that
16 Q Have you ever taken any pre law 16 may be used in the matter that is greater
17 classes 17 intensity greater recommendation hazard
18 A I do not know what you mean by pre law 18 communication standard would also apply
19 classes 19 Q Wellget more on that later Your M S
20 Q Have you ever taken any classes through 20 in industrial engineering 1989 from the
21 an institution of higher learning such as a law 21 University ofOklahoma Do you recall what first
22 school 22 of all how long did it take you to obtain that
23 A No 23 degree after graduation from your undergraduate
24 Q Okay Have you ever taken in any of 24 A It took me three years to do that I had
25 your other studies have you taken any classes 25 to take another a number of leveling courses
Page 59 Page 61
that were dedicated to legal analysis to legal leveling courses in various different areas of
2 writing 2 engineering to catch up what I would have seen if
3 A No 3 I was getting a BS in industrial engineering
4 Q Have you ever studied the law in any 4 Q Your M S from industrial engineering
5 manner 5 from University of Oklahoma did you ever take ar
6 A I am well acquainted with the OSHA 6 classes regarding OSHA standards
7 regulations in the C P SC regulations I am pretty 7 A Yes
8 well acquaint with the authorizing legislation 8 Q Can you identify what classes those
9 for OSHA the AU shack fairly well AU KWANLTed tho 9 were
10 authorizes although not has clear OSHA 10 A There was a course in safety research
11 authorizing legislation other than that I would 11 methods and that covered some issues in OSHA
12 say that would be the extent of it 12 regulations
13 Q And where did you obtain that 13 Q Other than OSHA regulations did your
14 education 14 safety research analysis was that the class
15 A Through the course ofmy graduate study 15 A Imnot sure what the title was it was
16 in doing work for the publications in which I 16 a safety class and generally safety analysis
17 prepared 17 methods like federal facility TERing OOCHLT
18 Q When you say your graduate study are 18 failure modes effects analysis OSHA regulations
19 you VEFRG to your M S in industrial engineer or 19 and what OSHA regulations exist how they are
20 PhD in industrial systems engineering 2 0 applied that kind of stuff
21 A Both 21 Q Okay Other than OSHA did that safety
22 Q Have you ever study TD the federal 22 class cover any other federal state or local
23 hazardous substance act F H S A 23 regulations such as the F H SA
24 A I have read through it I am fairly well 24 A I think we were made aware of the
25 acquainted with it 2 5 requirements of the F H S A as part of some
16 Pages 58 to 61
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1 . Okay. I understand now what you are 1 
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 nner?  
 . I a  ell acquainted ith the   
 regulations in the C P SC regulations I am pretty  
 well acquaint with the authorizing legislation  
 for OSHA the AU shack fairly well AU K ANLTed the 9 
10 authorizes although not has clear OSHA  
11 authorizing legislation other than that I would  
12 say that would be the extent of it.  
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if you had any specific classes relative to
labeling or warning standards
A I believe the answer to that would be
still be yes same class
Q The same question for Oklahoma BAP TIS
university any classes related to labeling and
warning standards
A Not for there may have been some stuff
in the chemistry department when I was both has
the student and as a lab assistant in the
chemistry department where I was working with
labels and got instruction from the professors
but I dont recall specifically to that at this
time
Q Since graduating with yourPhDfrom
Virginia tech have you taken any continuing
education courses any other method of formal
education where you are actually signing up for a
class ask its being instructed by somebody
A Yes
Q And talk tome about that What other
formal education have you had had since your
PhD
A There have been a number of seminars
that HOOIF taken There is also a couple of
Page 651
semester of welding classes that I took when I
was trying to get a little more familiarity with
that process where I spent sometime in the
welding objection see TUL welding and also stick
welding as its known
Q In the seminars that you just mentioned
anything relative to OSHA standards
A I would have to look again to see what
the seminars were but
Q Are they listed on your CV
A The ones Im thinking ofwould be yes
Q Go ahead and review through that then
and then
A And Im sorry give me the question
again
Q Any of the seminars that youvetaken
that relate to HOSH Shaw standards
A Yes
Q And can you identify those for me on
the CV
A The forklift truck operator instructor
development as presented by the Colorado safety
association was one specifically designed to get
knee in position where I would be a certified
OSHA certified training inner NOR forklift
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1 coverage on the C P SC again you are asking about 1
2 stuffwhich is distant in my recollection Im not 2
3 sure which time I picked up what information but 3
4 I believe it did cover something has the F S in 4
5 just generally saying these are out there about 5
6 be aware of them know if they are XIT if you are 6
7 selling a product for consumer use keep in mind 7
8 knees regulations do apply if its a hazardous 8
9 chemical under the DPECHGS of cfs C 9
10 Q Industrial and systems engineering 10
11 PhD1997 from Virginia Tech it indicates that 11
12 after you human factors optionwhatsthat 12
13 A At the time I was getting the degree 13
14 the there was basically four tracks at in the 14
15 KAEJ T program and the track TA I took was the 15
16 industrial the was the safety track Im sorry 16
17 not the safety track the human factors track 17
18 Q Was there a safety track 18
19 A Not separate safety was part of the 19
20 human track 20
21 Q Okay What sorts of classes did you 21
22 take in the human factor option how long did it 22
23 take to bet get that PhD 23
24 A Too long start to finish but generally 24
25 I spent about three or four years in residence at 25
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1 BLAX BURG actually I dontrecall exactly how 1
2 long I was doing the course work and when I was 2
3 doing disservice TAGS But I spent from 1989 3
4 until 1994 I think in residence and at BLAX BURG 4
5 and by 94 wrapped up I had gotten all my DES sir 5
6 TAGS all disservice TAGS writeup and come bact 6
7 and defend it which I did subsequently but in 7
8 terms ofclass work I believe there was about two 8
9 to two andahalfyears of solid class work 9
10 Q What was the subject matter of your 10
11 disservice TAGS 11
12 A Subject matter Antagonistic KO con 12
13 tracks ofmuscles and what the data showed the 13
14 validity of certain assumptions regarding lifting 14
15 techniques and biomechanical models of the low 15
16 back 16
17 Q Did you take any classes at Virginia 17
18 Tech relating to labeling requirements standards 18
19 warning requirements or standards 19
20 A I dontrecall that at this time 20
21 Q How about at I apologize Ive BUR 21
22 MR OVERSON University of Oklahoma 22
23 THE WITNESS You already asked about 23
24 that answer yes 24
25 O I believe I asked about OSHA Im asking 25
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labeling and warning requirements
A No
Q The same question but as it relates to
F H S A standards for labeling and warning
A Well apart from Im assuming you are
saying formal education Im assuming you are
excluding the research background to write the
articles and PR beyond that that would be true
yes
MR OVERSON Take that short break
A recess was had
Q BY MR LLOYD Back on the record
Dr Purswell when we took a break we were going
through your CV and I would like to pick up wher
we left off there and in particularly your
education and perhaps I can narrow my questionin
a little bit what have you done whether in your
formal education or your independent research for
publications that youve authored anything what
have you done to familiarize yourselfwith the
FARNDZ standards of the F H S A
A I have read the the regulations and run
the interpretations of the has documented on my
website I have an interpretation of the F H S A
up for probably a decade now and Im certainly
Page 69
extended familiarity with the F H S A and their
requirements
Q Okay Have you what do you do to
regularly keep up on developments in the F H S A
A Well Im a subscriber to safety lift
from University of San Diego and they have
periodic updates on all the types ofmatters and
safety regulation and includes stuff relating to
OSHA C P SC and if the FDA I dontget into FDi
stuffvery much but that same list has
information TLON that so they publish Cal OSH
what do they call it its the Cal OSHA summary
but they cover OSHA enforcement actions all
around the country and they produce a nice SUP
REE Ima subscriber
Q On the Cal OSHA does that cover if the
FHSAatall
A I dontrecall if I see saw stuff on
the F H S A
Q Go that he had
A OSH HAU in takes OSH saw puts out
every comments on other federal regulatory
agencies and what they do not all the time
periodically
Q Anything else
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1 operations And then the welding health 1
2 ventilation one was also one which dealt with 2
3 labeling issues and also personal protective 3
4 equipment for people who were exposed fumes 4
5 coming offwelding 5
6 Q Any of these seminars or courses that 6
7 youve taken relate to standards whether they be 7
8 HOSH Shaw or otherwise for labeling or warning oi 8
9 chemicals 9
10 A The welding health and ventilation one 10
11 I believe we went through the information that 11
12 would be there on the rolling rods in regard to 12
13 what kind of fumes could beROOVLD around that 13
14 burned down 14
15 Q Whats contained in the welding rods 15
16 A Various different health ventilation 16
17 burn hazards that are also associated with that 17
18 Its been five years at least since I worked at 18
19 WELing rod warnings but its pretty distant in 19
20 recollection big once making sure no come budget 20
21 TABLS around being aware of the proper personal 21
22 equipment and the welding fume issues with regard 22
23 TLO that 23
24 Q And I think my question I apologize my 24
25 question is more what sorts of chemicals elem 25
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1 compounds are contained within the welding rods 1
2 A That depends on the type of welding 2
3 rods high KROM me you mean 6 which is a 3
4 particular variety of KROM me you mean that can 4
5 be known from what that would causes right now 5
6 maybe a cancer risk There is also ones for 6
7 issues involving manganese there are allegations 7
8 at least that you can get a high enough 8
9 concentration ifyou are welding in tight space 9
10 without ventilation and ventilator you can get 10
11 nagging making GA NICHL which is similar to 11
12 Parkinson So that would be the two that I would 12
13 relate 13
14 Q Okay 14
15 A There is also you can get some sort of 15
16 over dose of iron or led in your system well I 16
17 guess it doesn have iron you can get iron 17
18 which causes another syndrome but its not of 18
19 course as dangerous or IR rear VERS able as the 19
20 other two 20
21 Q Other than what wev discussed do you 21
22 have any other formal education whether through 22
23 seminars courses your graduate work anything do 23
24 you have any other formal education regarding 24
25 compliance with OSHA standards as it relates to 25
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original
Q So long has OSHA applies to that
particular product
A To anything thatsused in an
occupational setting in a manner thatsaccording
to both the courts ask OSHA in a manner thats
greater intensity than would be considered in
TOUPGS approximate natural or greater frequenc
or both
Q Down on your V CV into your
professional experience I think wev discussed
in large part what you do with Purswell and
Purswell already
A Okay
Q Anything else you would like to add
about what you do what your job duties are what
your functions are within SXUR Purswell that we
haventalready discussed
A Well as I think I referred to before I
have both drafted warning labels on product
warning labels as well as N S D S for clients in
a non litigation context and of course Im
acquainted an see 400 dot I the standard which
relates to the requirements for material safety
data sheets also of course the great detail which
Page 73
are general therapy COMPLE men meant TAER but
the extent that detail is also present in the
191012 dot00 standard familiar Im familiar with
that
Q Lets go ahead and move down to your
position as an adjunct professor for C S U PUB
below
Q And I want FO focus in on the second
sentence of your job description there supervise
the student research on product safety ask use
ability issues Have you had had any students do
research on pepper spray and Oleoresin capsicum
A No
Q No
Q Have you ever done any pepper spray or
OL Leo resin cap SKUN
A Not apart from this case Oleoresin
capsicum
Q What textbook you currently using to
teach the graduate level course
A The course website the one I willly
hammer called occupational safety and health
something or other Ive also used oneIve just
aboutBRAU BRAURIthinkthatsitso
Ive just a number of different texts I dont
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1 A Those would be the major ones I recall 1
2 Q Whether safety net Cal OSHA the OSHA 2
3 out takes public GAGS and any other source that 3
4 you regularly review do you obtain updates 4
5 analysis notifications regarding case law 5
6 around the OSHA standards or the F H S A 6
7 standards 7
8 A There is a course a recent fall 8
9 recollection standard by OSHA and fall protection 9
10 directives I dontknow the extent to which 10
11 thats considered case law as OSHA amplification 11
12 compliance safety fall protection but that kind 12
13 of thing I do get I dont try and go read court 13
14 opinions if thatsthe gist of your question 14
15 Q Okay So everything that you have just 15
16 answered I dont want to ask a redundant question 16
17 but my next question what have you done to 17
18 familiarize yourselfwith what do you do to 18
19 regularly keep abreast of the standards and 19
20 changes to OSHA would all the same apply 20
21 A I believe that would be true 21
22 Q Anything else 22
23 A Well of course I have to pick 23
24 textbooks every time I teach the industrial 24
25 safety class and I will periodically who will get 25
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1 people would you teach out of my text than the 1
2 review most of what I teach in terms of that 2
3 class regarding OSHA is actually directly from 3
4 the OSHA website here are the regulations here 4
5 are interpretations of the regulations who here 5
6 are the compliance directives compliance health 6
7 officers on how to enforce those here are the 7
8 preambles of those standards for OSHA why it 8
9 required when it required something so all those 9
10 things TR things I try to keep my students aware 10
11 of and of course I have to know those myself 11
12 Q In the context of everything you just 12
13 described do you in that tree SFEKT review court 13
14 opinions or 14
15 A Sometimes I will have to go and look at 15
16 what the occupational health safety review 16
17 commission has said about something to the extent 17
18 that it goes into the federal courts out of the 18
19 occupational safety health people process I dont 19
20 generally as AU saw in my initial report I did 20
21 refer to a court case that did establish that the 21
22 standard enumerated on the warning label I dont 22
23 try to read those opinion in great depth butIm 23
24 generally aware that the courts upheld that the 24
125 OSHA requirement to include hazard to target 25
000871
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chemicals specific STLEE z 129 dot I so I do
mention those to both of them in that REE PEEKT
Q Both an see standards
A I make them aware both out there yes
Q NRI OSHA TARNDZ you cover in URG N
mix course
A Yes
Q And which standards TR those
A The primary one some of the had TIS
history on some of the first what Illcall the
URG nonmix standard the repetitive motion
standard was adopted back in 2000 which was
subsequently REE isnted shortly therefore
enforce OSH saw general duty clause to provide a
safe and health full workplace and the history of
that as you can see there are a number of
publication that is I published BLISHD in that
area so I make them aware of that That would be
the primary one there are also some citations I
make them aware of for hazards under the general
duty clause regard to heat stress thatsusually
more sun related or thermal ones rather than
chemical pepper spray the type ones but those
would be the main ones that I would talk about in
that respect
Page 77
Q Im going to head off for FA tangent
for just a moment because you mentioned this In
this case you have opined and correct me ifIm
wrong but you have opined that the labeling on
SECS pepper spray products is not OSHA complian
A That is true
Q Is your testimony in that regard with
reference to the general duty clause or the
specific duty clause
A There is no specific duty clause The
general duty clause refers to the section 5 A 1
ofthe OSHA act and that is the one that says you
have the general duty to the provide a safety
safe health full work employer to the employer
so they will also reference oh TA AB p
particular consensus standard as well employer
knew this was a HAZ start they should have done
something about it and there are four different
right TER general duty clause citation if its
contested and those are laid out some of the
papersIve authored but the one Im referencing
here is not from the general duty clause its the
one specific requirement from the hazard
communication standard 1910 dot 1200 hard SARD
warnings be given
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1 recall the one of the oneIm current 1
2 Q Do you recall the title of it 2
3 A Something like to 3
4 Q Okay 4
5 A I didnt look at that again before I 5
6 came here today 6
7 Q On in the graduate ergonomics course 7
8 when it says teaches the graduate level course 8
9 and senior level safety course those are two 9
10 separate courses 10
11 A Those are indeed and the course is 11
12 course in URG not DMIX 12
13 Q So are the only two courses that you 13
14 currently teach NOR C S U PUB below 14
15 A Those are the only two courses that I 15
16 have TAUD or currently teach yes 16
17 Q What books do you leafE earlier 17
18 A But 18
19 Q No before I asked about the graduate 19
20 URG nonin connection 20
21 A I need to the text that I have used for 21
22 a number of years in the ergonomics course is 22
23 STEF fan consequence and a student muches work 23
24 design and I have typically used the most current 24
25 version of that knows curren by text byCarl 25
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1 KROM MER benefit CR O EM E R and there is a 1
2 couple of different ones that hes authored or 2
3 coauthored thatIve used There is that text 3
4 by Charles wick KENS somewhere sham pain urban 4
5 NA I think who Ive used a couple of times and 5
6 Ive kind of a flipped around but the for used 6
7 the work design by STEF fan cans and you asked 7
8 the question with respect to the safety 8
9 Q Please do 9
10 A On the safety text Ive used three 10
11 different authors the oneIm currently using 11
12 Ive lot the name of at the moment but its 12
13 something you can find on this issue C S U PUB 13
14 below B R by BROUR B R A U R and by 14
15 Q Willly hammer 15
16 A Willly hammer and a colleague of his 16
17 Dennis price 17
18 Q And in the graduate URG NOM mix course 18
19 is there any part of that course that you teach 19
20 that relates to warnings or labeling 20
21 requirements 21
22 A That is something that is covered N the 22
23 cans text and I do spend time on here are the 23
24 requirements under the general product labeling 24
125 standard A N S 35 dot 4 the one relating to the 25
000872
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1 reca l the one of the one I'm curre . 
2 Q. Do you recall the title of it? 
3 A. So ething like to. 
4 Q. Okay. 
5 A. I didn't look at that again before I 
6 came here today. 
7 Q. On in the graduate ergonomics course 
8 when it says teaches the graduate level course 
9 and senior level safety course those are t o 
10 separate courses? 
1 . hose are indeed and the course is 
2 course in  not . 
13 Q. SO are the only two courses that you 
4 currently teach NOR C S U PUB below? 
5 . hose are the ly t o c urses t at I 
16 have T AUD or currently teach yes. 
1 7 Q. What books do you leaf E earlier? 
 . t. 
 Q. No before I asked about the graduate 
0  i  ection? 
 . I eed to the te t that I e s  for 
 a number of years in the ergonomics course is 
 STEF fan consequence and a student muches work 
 design and I have typically used the most current 
25 version of that knows current by text by Carl 
a e  
  E , benefit,  0 E  and there is a 
 couple of different ones that he's authored or 
co-authored that I've used. here is that text  
 by Charles wick KENS somewhere, sham pain urba 
 NA I think who I've used a couple of times and 
 I've kind of a flipped around but the for, used 
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1 che icals spe ific S LEE z 129 dot 1 so I do 
2 mention those to both f them in that EE P . 
3 Q. Both an see st ? 
4 . I ake them a are both out there yes. 
5 Q. I S  R DZ you cover in R  OlV 
6 mix c rs ? 
7 . es. 
8 . n  hich standards  th ? 
9 . he primary one s e of the a  IS 
0 history  so e f the first hat I'll call the 
1  x  the re tive tion 
12 sta dard as a ted a  in 000 hich as 
3 s s tly  i n'ted rtly t r f r , 
14 e ,   l t  lause t  r ide  
 s e  t   r place  the  f 
 that s  a   t ere re  ber  
 p lication that is I lished IS  i  t t 
 ea  I e    t. at   
 the ri ar  e t ere are als  s e citations I 
  t e  are       
 t  cla se re ar  t  eat stress t at's s all  
 r  s  r l t  r t r l es r t r t  
23 ical r s r  t e t  s t t s  
            
 t at res ect. 
  
 . I'm i  t    f r  t t 
  us       i .  
 t i     i e   t  l'm 
4 rong but you have opined that the labeling on 
 s  r      l t: 
 . t i  t e. 
 the work design by STEF fan cans and you asked  . I  r t ti  i  t t r r  it  
 the question with respect to the safety.  r f r  t  t  r l t  l  r t  
 Q. Please do?  specific duty clause? 
 A. On the safety text I've used three lOA.  i   ecifi  t  l use.  
11 different authors the one I'm currently using  general duty clause refers to the section 5  1 
 've l        t it's  f   act  t t i  t   t t   
 something you can find on this issue C S U PUB  have the general duty to the provide a safety 
14 below B R by BROUR BRA U R and by.  saf  lt  f ll r  e pl r t  t  ployer, 
15 
 
Q. Wilily hammer? 1  so they ill also reference oh, T  B [p] 
A. ilily hammer and a colleague of his  particular consensus standard as ell, e ployer 
1 7 Dennis price. 1   t i  s a  start t y shoul  have do  
 Q. And in the graduate URG NOM mix course 1  so ethi  about it and t ere are f ur iffere t 
 is there any part of that course that you teach 1  ri t ER, general duty cla se citati  if it's 
20 that relates to warnings or labeling 20 co t t   th  r  lai  o t so  of t  
21 requirements? 
22 A. That is something that is covered N the 
23 cans text and I do spend time on here are the 
24 requirements under the general product labeling 
25 standard N S, 35 dot 4 the one relating to the 
 papers I've authore  b t t e o e I'm refere ci  
22 here is not fro  the general duty clause it's the 
 one specific require ent fro  the hazard 
24 co unication standar  1910 dot 1,20 , har  SAR  
2  r i s be given. 
20 (  74 t  77) 
Page 80
something to occur yes you are obligated to
provide an M S D A and the identifying the
liability I dontrecall anything from the C P
SC federal LAZ SARD Oregon issue so I dont
think that thats in there as well but generally
I am encouraged clients who are using something
which maybe used in both context to put that
target Oregon information on there
Q So its your testimony that one is
obligated in certain circumstances to comply with
both the OSHA standards the and the F H SA
A Thats true
Q And what do you base your testimony
A Well if you are using a good example
is bleach you go bleach in store if and you are
only using it in a manner thats anticipated NOR
home use then you donthave to get MSDS label on
the product contempt intensity use then what you
would find in that home COMBRIERNT
A Bought like at SAMS club or Costco
where the folks are coming in for a restaurant
intending to use that in an employment context
then the supplier is obligated to provide that
and provide OSHA compliant hazard communicatic
information and the if employer is obligated to
Page 81
follow OSHA regulations regarding what it informs
employees about the chemicals to which they may
be EX noticed the work environment
Q So youve given me HAN example my
question was what do you base your opinion that
one can be obligated to comply with both OSHA an
the F S H A
A I believe the best pieces of evidence
contained in that stack there that you look at
the stuff I produced will relate to this opinion
Q And the stack to youveproduced Ill
ask this question so that I dontdig for it if
its not here but in the stack that you produce
you had did you include a copy of the OSHA
standard on which you base your opinion
A Again we talked about that off the
record I have included a copy of the compliance
directive for the is standard I dontknow if I
got a copy of the standard itself
Q I believe you may have
A IfI recall correctly section A 2
addresses the scope ofwhos supposed to be
providing which manufacturers are supposed to be
providing what information
Q Okay You have produced a copy of the
21 Pages 78 to 81
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1 Q Okay On your list of professional 1
2 experience as an URG go nonmix and Purswell and 2
3 associates why did you leave that position or 3
4 what happened 4
5 A That was a sole proprietorship that was 5
6 being operated by my father I was doing work for 6
7 him while I was doing work for PhD continued to 7
8 operate in that way NOR a little bit In 1999 we 8
9 went ahead and formed the S corporation which you 9
10 see there as identified as Purswell and Purswell 10
11 Q I assumed that was the case but 1 11
12 wanted to be sure Under your research and 12
13 interpretation paragraph what I reference the 13
14 last paragraph on the first page of your CV you 14
15 indicated OSHA C P SC and an see standards for 15
16 clients including the legislative record for OSHA 16
17 standards In that capacity did you do any 17
18 research or interpretation of S F H S A standard 18
19 A Yes 19
20 Q Why not listed on here 20
21 A I dontknow why 21
22 Q What research and interpretation did 22
23 you do with respect to F H S A standards 23
24 A Im not recalling what I did back in 24
25 the middle in 90s but I can tell you recent three 25
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1 last year or two yearsIve done work for both a 1
2 supplier of candle making equipment where its a 2
3 hobby type thing clearly which would not be one 3
4 that would out certainly not an occupational 4
5 exposure which would be greater intensity tore 5
6 duration such that would be subject to the that 6
7 is come standard but that would be one thats 7
8 recent there is also automotive products company 8
9 that came to me that needed both labels and M S D 9
10 A labels C P SC compliance for us for 10
11 occupational uses and also OSHA compliant for our 11
12 employment uses so I helped them with that 12
13 Q Okay 13
14 A To the best of my knowledge there are 14
15 not any conflicting requirements between the 15
16 federal hazard substances act and the you can do 16
17 both the same one if you need to 17
18 Q Are you obligated to 18
19 A If you do not sell things for a 19
20 purposes in which it would be used in an 20
21 employment context and intensity or duration 21
22 greater than a consumer use then no you are not 22
23 But if its something thats going to be 23
24 reasonably anticipated to used in an an 24
25 employment context where you know thats 25
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you had did you include a copy of the OSHA 
standard on hich you base your opinion? 
. gain e talked about that ff the 
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addresses the scope of who's supposed to be 
providing hich anufacturers are supposed to be 
providing hat infor ation. 
. kay. ou have produced a copy of the 
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22 Pages 82 to 85
Page 82 Page 84
1 standard but I also have one available and I have 1 over to paragraph 3 Im going to skip through
2 multiple copies so Im going to go ahead and use 2 subsection 1 2 3 and 4 subsection 5 Any
3 that And if you would like to review the two 3 consumer product or hazardous substance as those
4 together to ensure that what IveIm producing 4 terms TR defined in the C P S A 15 KWUS A 25501
5 the the STAM you are producing by all means 1 5 F H S TA 15US C 125 one etcetera
6 will have no problem the with that Exhibit 100 6 A Okay
7 mark mark 100 7 Q When subject to that consumer product
8 Q BY MR LLOYD Okay Dr Purswell Im 8 safety standard or labeling requirement much
9 handing you whats what HOOIF marked from Exhib t 9 those acts or regulations issued under those acts
10 100 mark a new has 10 by the consumer product safety commission
11 Q BY MR LLOYD Now Im handing you 11 A Okay
12 whats been marked as Exhibit 100 its a copy of 12 Q What do you understand this section to
13 CFR 1910 point 100 which I an object object TOIND 13 mean
14 depressed the commercial database Dr Purswell 14 A Well as youllnotice it doesn end
15 from WES law legal research 15 with a period it ends with an and it goes on to
16 A Okay 16 list some other conditions and among those
17 Q Do you believe this is a fair or 17 conditions you will note further down the page it
18 adequate copy of or representation ofCFR the 18 is the fact it has to be Im not finding it on
19 1910210 19 your particular copy here but the its used and
20 A Ifyou are going to ask that question I 20 thats clear from the OSHA regulations clarifying
21 would prefer to rely to my for the copy that I 21 this the OSHA interpretations clarifying this
22 printed from the OSHA one and we can cross 22 Ifits used in the matter not any more the
23 reference those two 23 intensity exposure used in the consumer
24 Q Before we do that 24 environment its not has KASHGS concentration
25 Q If the hazard communication standard is 25 or if its used for a longer durat then it is
Page 83 Page 85
1 located where Is it in 29 C F TR 191020 1 subject to those requirements Thats not on
2 A Yes 1910 dot 1200 its not in there it 2 this particular page but its in the HOSH Shaw
3 is that 3 clarifications and amplification GS thatIve
4 Q Thatswhat wer looking at here 4 provided
5 Exhibit 100 5 Q But does this standard not defer to the
6 A Okay 6 federal hazardous substances act
7 Q Is that correct 7 MR OVERSON Im sorry defer
8 A Ill accept your EP representation in 8 Q Defer does this hazard communication
9 what youve SPRINTD the right one 9 standard that youve relied upon does that not
10 Q Okay Go ahead and turn to the second 10 defer to the federal hazardous substance act when
11 page of the document that Ive provided you 11 the federal hazardous substance act applies
12 A Okay 12 MR OVERSON Hold on and the question
13 Q About two thirds of the way down the 13 is vague and I think at this point you are asking
14 page do you see the PARN THET TIK call 5 14 for legal conclusions go ahead
15 A Yes 15 MR LLOYD Just to to the respond to
16 Q 16 that Darwin Dr Purswell are legal conclusions so
17 MR OVERSON Which page are you on 17 I have to ask about his understanding of the law
18 Tom 18 TLO that effect
19 Q BY MR LLOYD 2 Im going to read 19 MR OVERSON So much for your
20 from this PARN THENT TIK call five It indicate 20 objections as speaking objections but go ahead
21 this section does not require labeling of the 21 THE WITNESS Im sorry the question
22 following chemicals 22 again
23 A Yes there are certain using which are 23 Q BY MR LLOYD Does the hazard
24 excluded 24 communications standard thatwer looking HAT as
25 Q And Im going to go from there actually 25 Exhibit 100 does that not defer to the federal
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is vague and I think at this point you are asking 
for legal conclusions go ahead. 
. : Just to to the respond to 
that ar in r. urs ell are legal conclusions so 
I have to ask about his understanding f the la  
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objections as speaking objections but go ahead. 
 I SS: I'm sorry the question 
agam. 
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23 Pages 86 to 89
Page 86 Page 88
1 hazard discuss substances act in subsection or 1 page here again and i would like to have my copy
2 section B sub 5 sub 35 2 ofthe OSHA version ofthis rather than the WES
3 MR OVERSON Same objections 3 law version of this to rely on
4 THE WITNESS I do not believe it 4 Q Let the record reflect that I have
5 refers DEFRS to that consumer instance then you 5 handed the copy of the hazard communication
6 dont have to have it labeled for employment use 6 standard that Dr Purswell brought with him today
7 and that again is based upon the considerable 7 to refer to in answering this question
8 amplification GS and considerations to the text 8 A And soIm sorry which reference you
9 itself thatIve provided 9 are saying the section does not apply to and this
10 Q So if the federal hazardous substances 10 is 1910120
11 act says that it applies TLO a particular product 11 Q Subparagraph 5
12 how do you read that in conjunction with this 12 A Subparagraph 5
13 section 13 Q Section 5 of subparagraph 5
14 A If the federal Im sorry give me the 14 A Okay And would you say TA TA
15 question SGEN 15 particular you are looking at subsection B 55 and
16 Q If the federal hazardous substances act 16 that is one where it says that if consumer
17 and the regulations concerning it determine that 17 product safety commission has jurisdiction over
18 an a product is subject to the federal hazardous 18 that particular use and I would refer you to the
19 substances act how do you start that again 19 letter from C P S specifically disclaiming
20 MR OVERSON Start that again Tom 20 jurisdiction over the uses of chemicals which are
21 youve lost me man 21 used in duration and intensity which are greater
22 Q BY MR LLOYD Lets back up Go 22 than what we use in the household XHUN applies
23 ahead and turn to the first page were Exhibit 100 23 to this particular one again mine has better blue
24 and again two thirds down the page do you see 24 headings where I can actually tell where things
2S that subsection B 25 are
Page 87 Page 89
1 A Yes 1 Q Okay I understand that
2 Q Scope and application 2 A So thats my basis for saying there can
3 A Yes 3 be joint jurisdiction and the stuffyou choose
4 Q What do you understand that section to 4 certainly home context can be be only employmen
5 be describing 5 context in any duration or intensity what would
6 A The scope and application to the 6 be used in home context there then the hazard
7 standard to which and the instances to which it 7 communication standard also applies
8 applies 8 Q Where do you see that in the the text
9 Q Would it be fair to say then that 9 of29 CFR 91910120
10 thatssort of the jurisdictional limits of the 10 A Well you asked me before and I pulled
11 hazardous substances act 11 it out Any consumer that does not apply to any
12 A Yes that my understanding of it 12 consumer product or hazardous substance as terms
13 Q And then turning to page 2 whichwev 13 applied in the C F consumer product standard
14 already discussed subsection 5 limits that scope 14 safety standard or labeling requirements of those
15 and application is that correct 15 acts and again in the OSHA both says as well as
16 A Thats true 16 the CPC intention NAMT used in intensity or
17 Q And then turning to page 3 subsection 5 17 intensity greater than what would be used in home
18 of that limits that to not include any hazardous 18 use then the C P SC requirements dontapply 1
19 substances as that term is defined in the federal 19 cantsay it the OSH saw says it applies in c
20 hazardous substances act I think you need to 20 if it employment context with the greater
21 try that one againIm totally confused by that 21 intensity tore duration what would be used in the
22 question thats a vague question 22 home context
23 Q I understand your question 23 Q Lets continue to pick this section
24 MR OVERSON Do you understand the 24 apart
25 question you are going from first page now to the 25 A Okay
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Page 92
of the C P SC regarding that particular language
I dont have NRI interpretation ofwhat is there
MR OVERSON Beyond what youve
already testified
THE WITNESS Beyond what Ive already
said
Q So reading through this sentence again
any KURM product tore hazardous substance as
those terms TR defined as in the safety hazardous
substance when subject to the SXURMT or
labeling requirement of those acts or regulations
issued under those acts by the consumer product
safety commission
Does the phrase those acts not refer to
the two acts that are actually referenced in that
particular sentence
A I dontknow
Q Okay So you dontknow what that
sentence means then
A I know that the interpretation you are
suggesting for that sentence is in clear
contradiction to the OSHA GROOCHLS of the has
come standard and the C C P SC interpretations of
the federal hazardous substance act that the
hc standa does not comply 1
Page 90
1 Q If we can And Im going to refer 1
2 again to 29 CFR section 191020 subsection B 2
3 section 5 ZSHGS 5 which is what wev both been 3
4 reading from 4
5 A Okay 5
6 Q And taking about halfway through that 6
7 sentence when subject to a consumer product 7
8 safety standard or labeling requirement of those 8
9 acts 9
10 A Okay 10
11 Q What do you understand those acts the 11
12 term the phrase those acts to refer to 12
13 A I donthave better more clarification 13
14 on that particular INS sentence than whatIve 14
15 already said Im relying upon the C P SC 15
16 disclaiming jurisdictional in occupational uses 16
17 and Im relying on both the numerous OSH HAU 17
18 documents that we do have jurisdiction for 18
19 intensity or duration more than what expected in 19
20 the consumer use but we know what OSHA says it 2 0
21 greater amplification GS in this public 21
22 particular one and the we know what the standards 22
23 dont apply if its used in if its an employment 23
24 context 24
25 Q I would like FO pick that ap 25
24 Pages 90 to 93
Page 91 Page 93
1 further 1 anything federal hazardous substances act I think
2 A I dont have any more to say on that 2 thatsCLEERTly HOSH Shaw compliance record
3 particular sentence Ive said everything I can 3 the OSHA preambles and the C P SC under
4 say about that sentence but Ill listen to the 4 providing
5 next question 5 Q What about the F H S A
6 Q My next question is the same question I 6 A The F H S A standard it says I dont
7 just had because I dont believe you answered it I 7 have the has the the has come standard by the F H
8 When the phrase those acts are written in this 8 S A standard letter from the F H S A applying
9 particular section to what does that phrase 9 to the the employment use of hazardous chemicals
10 refer 10 Q Thatsyour interpretation
11 A AndIll say I dontknow 11 A Thats what the C P SC says
12 Q From reading this particular from this 12 Q Okay
13 sentence in totality you cannot determine what 13 A Thats the EN next ofthe
14 the phrase those acts refers to 14 interpretation of it
15 A Beyond the OSHA interpretations Ive 15 Q And well get to that later So you
16 answered in regarding the C P SC interpretation 16 disagree that my interpretation of the phrase
17 Ive already provided I dont have NRI different 17 those acts refers to the consumer products safety
18 interpretation than those ones I have referenced 18 act and the federal hazardous substance act
19 so no those acts I canttell you what that 19 referenced in that that same sentence
20 means 20 A
21 Q So you donthave a complete 21 MR OVERSON Objection
22 understanding of this standard 22 mischaracterizes
23 A I have a complete understandingof the 23 THE WITNESS I haventdisagreed with
24 interpretations that OSHA says and has issued 24 it I said when subject to TA consumer product
25 regarding this and I have complete understanding 25 safety standard or labeling requirement much
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1 Q. If e can. nd I'm going to refer 1 
2 again to 29 CFR section 1910.1,200 subsection   
3 section 5 ZSHGS 5 hich is hat we've both been  
4 reading from?  
5 . kay. 5 
6 Q. And taking about halfway through that  
7 sentence hen subject to a consu er product 7 
8 safety standard or labeling requirement of those  
9 a ? I  
 A. Okay.  
 Q. hat do you understand those acts the  
12 term the phrase those acts to refer to?  
 . I 't e ter ore clarification  
 on that particular INS sentence than what I've  
 already said I'm relying upon the C P SC  
 disclai ing jurisdictional in occupational uses  
 and I'm relying on both the numerous OSH HAU  
 documents that we do have jurisdiction for  
19 intensity or duration more than what expected in ~ 19 
 the consu er use but e kno  hat  says i I 20 
 greater amplification GS in this public I  
22 particular one and the we know what the standards 22 
 don't apply if it's used in if it's an employment  
 xt.  
 Q. I would like FO pick that apart  
  
 er?  
 A. I don't have any more to say on that  
 particular sentence I've said everything I can  
 say about that sentence but I'll listen to the  
 next question.  
 Q. y next question is the same question I  
 just had because I don't believe you answered it.   
 hen the phrase those acts are written in this  
 particular section to what does that phrase  
 r fer?  
 . nd I'll say I don't kno .  
 Q. From reading this particular from this  
 sentence in totality you cannot determine what  
 the phrase those acts refers to?  
 A. Beyond the OSHA interpretations I've  
 ans ered in regarding the C P SC interpretation  
 I've already provided I don't have NRI different 1  
 interpretation than those ones I have referenced  
 so no those acts I can't tell you what that  
 ns. 
1
 
 Q. SO you don't have a complete  
 understanding of this standard?  
 . I have a co plete understanding of the  
 interpretations that S  says and has issued  
 regarding this and I have complete understanding 25 
'v~, 
Page 92 
f the  P S  re ar ing that particular language 
I 't have I interpretation  hat is t . 
. E : eyond hat ou've 
alrea  t ti i . 
THE IT : e ond hat I've already 
s . 
. SO re i  through this s tence i  
a   ro ct t re a ardous s bstance s 
those ter s  ne  s i  the s  us 
, hen e t t  t  ,  
la ling req ire ent  those ts r re lations 
ss  er se ts  the nsu er t 
 i . 
oes the rase those ts  re er  
the t o  t at   e ere ce  i   
c lar t ce? 
.  n't . 
. .   n't  at t  
e ea s t n? 
.     te re on   
suggesting for that sentence is in clear 
     t   
        te re o s  
  s ce    
azard ommunications tandard   l  b ~ 
  
   es    
at's Tly,   ia c  s 
the  prea bles and the    under 
providing. 
.      ? 
.          on't 
       t      
  t  l tt   t ,     ppl i  
to the the e ploy ent use of hazardous che icals. 
. hat's your interpretation? 
. hat's t t     ys. 
. ay. 
. hat's    f t  
i t r r t ti  f it. 
.  e'll t t  t t l ter.   
disagree that y interpretation of the phrase 
t    t  t  r r  safety 
t  t  f r l r  t  t 
r f r  i  t t t t sa  entence? 
. 
. SON: j ti  
i aracterizes. 
 I SS: I haven't di gr d it  
it. I sai   subj t t    consu er r t 
safet  sta ar  r labeli  require e t uch 
 (P   t  3) 
25 Pages 94 to 97
Page 94 Page 96
1 those acts Again the C P SC says our standards 1 with respect to the OSH saw standards what we
2 dont apply to the use in employment context so 2 discussed 29 C F T FR
3 its not subject to those consumer product safety 3 A
4 acts 4 Q That so you understand this document to
5 Q But if the F H S A did say that a 5 come from the CFR
6 product was subject to its labeling requirement 6 A I I dont really refer to it as coming
7 what impact would that have on this sentence 7 from the CFR I refer it to come the OSHA
8 MR OVERSON Objection 8 regulations and and GOFR
9 THE WITNESS I would like to see what 9 Q Do you have any understanding of what
10 your offer offer objection vague 10 CFR
11 THE WITNESS I would like to see what 11 A I understand KOD of federal
12 you are referring to to and from the C P SC 12 regulations
13 affirming what you are referring to 13 Q So what wer looking at the code of
14 Q So your understanding of the F H S A is 14 federal regulations as it RETS to the OSHA
15 that it only applies what is your interpretation 15 standards
16 of the F H S A as to when it applies 16 A Yes I understand that the code of
17 A It applies to hazardous chemicals that 17 federal regulations has different sections which
18 are used in and around the home and are used in 18 refer to different things that it regulates one
19 concentrations and in frequency in anticipated 19 of those is occupational safety and that would be
20 for THOEM use and not anticipated for 20 under 1910 BRALIy some of the 19 HUNS I
21 occupational use 21 understand that the consumers regulations for the
22 Q Have you reviewed the regulations 22 C P SC are arent16 C CFR1500 and it has what
23 object F H S A 23 Ive already seen is the text of F H S A and I
24 A I have seen them before I have not gone 24 have not observed on the places that I have gone
25 through with regard to the F H S A on this 25 and EEN other KPS
Page 95 Page 97
1 particular case 1 Q So you just referred to the 16 CFR
2 A I have referred and REE have relied 2 1500 being regulations regarding the KPS
3 upon that as being authoritative 3 A It has the the text of federal
4 Q But you have not recently reviewed the 4 hazardous substances act Im not aware OSHA has
5 regulations relative to the F H S A 5 for implementing the occupation facility natural
6 A That would be correct 6 safety and health act in 1970
7 Q And so you have formed your opinion the 7 Q And you did not refer to that 16 CFR
8 F H S A does not apply in this case without a 8 section 173 prior to forming your opinions in
9 recent review of the regulations of the F H S A 9 this case
10 MR OVERSON Objection vague 10 A
11 THE WITNESS I dontrecall the last 11 MR OVERSON Objection asked and
12 time I read the of the F H S A I have read 12 answered
13 through them I dont recall how recently thats 13 THE WITNESS I have general facility
14 been but it hasn been in the last week 14 tea I went back and looked at the the letter C
15 Q Has it been in the last year 15 P SC we SKI ET and what it referred to and what
16 A I have reviewed stuff F H S A in the 16 it
17 THAst year 17 Q So the letter you are referring to was
18 Q Have you reviewed regulation there is 18 published R published or issued more than a
19 for F H S A 19 decade ago
20 A Regulations RGS I dont knowwhat you 20 A I believe the date on it is mid 80s
21 are talking about I know the F H S A and 21 Q Okay FHSA
22 interpretations of the F H S A if there are other 22 Q Letsgo ahead and take an off the
23 regulations implementing of the requirements of 23 record
24 the F H S A Im not aware of them 24 Discussion held off the record
125 Q Okay Whatwer looking at right now 25 A recess was had OSHA
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1 those ts. gain the    s s r st r s 
2 don't apply to the use in e ploy ent context so 
3 it's not subject to those consu er product safety 
4 a . 
5 . ut if the F  S  did say that a 
6 product as subject to its labeling require ent 
7 what impact would that have on this sentence? 
 . S : bjection. 
 E IT E : I  like t    
10 your offer offer objection; vague. 
 E :   like    
12 you are referring to to and fro  the  P S  
 affirming hat you are referring to. 
 . SO your understanding of the F  S  is 
15 that it only applies what is your interpretation 
16 of the F H S A as to when it applies? 
 A. It applies to hazardous chemicals that 
 re  in   e e   s   
19 concentrations and in frequency in anticipated 
 for  use and not anticipated for 
21 occupational use. 
 . ave you revie ed the regulations 
 object F  S ? 
 . I have seen the  before I have not gone 
25 through ith regard to the F  S  on this 
a e 95 
 particular case. 
 . I have referred, and EE have relied 
 upon that as being authoritative. 
 . ut you have not recently revie ed the 
 regulations relative to the F H SA? 
 .    rr ct. 
 Q. And so you have formed your opinion the 
 F H S A does not apply in this case without a 
 recent revie  of the regulations of the F  S ? 
 . E S : bjection; vague. 
  :  on't    
 ti  I r  t   t      I  r  
 through them I don't recall how recently that's 
    sn't     k. 
 . as it been in the last year? 
 .   e  t f        
1 7 THAst year. 
 Q. Have you reviewed regulation there is 
     ? 
 A. Regulations RGS I don't know what you 
21 are talking about I know the F H S A and 
 interpretations of the F H S A if there are other 
 regulations implementing of the requirements of 
      'm   f t e . 
25 Q. Okay. hat we're looking at right now 
e  
1 ith es t t  t    t s hat e 
2 iscusse      ? 
3 . 
4 . t  ou erstand t is t t  
5 e fro  the ? 
6 . I I don't really refer to it as co ing 
7  t e    it t  e t   
,  r l tions   . 
9 .     t i   t 
 R? 
 .  sta     
 regulations. 
13 . O hat e're in   e   
 federal regulations as it S to the  
 ards? 
16 . ,  sta      
1 7 federal regulations has different sections hich 
18   fere t    ates  
1   s         
I           
 r t  t t t  r  r l ti  f r t  
    r  ren't    ,500  it  t 
2 3 I've lr   is t  t t       I 
  t r   t  la  t t I   
    . 
  
 . SO you just referred to the 16 F  
2 1,500 being regulations regarding the PS? 
3 .     t f l 
4 r  t  t I'm t re,  ~ 
5 for i ple enting the occupation facility natural 
 f t   lt  t i  70. 
 . nd you did not refer to that 16 F  
8 section 17.3 prior to for ing your opinions in 
  se? 
 . 
 . S N: bjection; asked and 
 nswered. 
 T E IT ESS: I have general facility 
  I     t   t r,  
      t i     t 
r 16 it. 
.1  .  t  l tt r  r  r f rri  t  s 
 lis e   lis e  r iss e  re t a  a 
 decade ago? 
 .  l  t    i  i  i  s. 
 . kay. FHSA? 
 . et's go ahead and take an off the 
 r cord. 
 (Discussion held off the record.) 
 (  recess as had.) SHA? 
 (Pa    7) 
Page 100
A And Ill read it into any consumer
product or hazardous substances as those terms
are kind defined in the and the FX where the
employer can show that it is used in the
workplace and for the purpose intended by the
chemical manufacturer and order the ofthe
property exposure which is not greater than the
range of exposures which could it could
reasonably SPEERNTSD by consumers when used
the purpose intended Ive
Q Youveidentified similar language I
believe in your prior the testimony does this
language here echo some of the testimony that
youvealready given
A I believe it does I had actually
referenced that from TOESH opinion letter and the
direct yes
Q And I figured rather than pouring
through those if its in the regulation we can
look directly at the regulation
A Okay
Q So this is another list ofEX SLUSs
correct and it excludes a hazard DUS substance as
that term is defined in the F H S A where the
employer can show that it is used in the
Page 101
workplace for the purpose intended by the
chemical manufacturer or important TER of the
product lets stop there Do you have any
understanding in this case WLAF the intent of the
manufacturer was with the pepper spray at issue
A The intent
MR OVERSON Objection the question is
vague go ahead
THE WITNESS Well again youvechoppe
the TLIS of conditions in half but Ill address
my understanding that the ofwhat SEC they dont
sell it to consumers but they intend it to YOOB
used for occupational use to deter or tree strain
people who are declining to comply with law
enforcement request SEC SECs
Q Are you aware of whether SECs law
enforcement branded KOORNLTS
A Its not COMBRESHGS bill plea majors
testimony that when STHE wanted to buy another
sample of it she had to take somebody from the or
not available I should say directly TLO consumers
that they have to get somebody who is a law
enforcement person to buy it for them and then
consumers can get it that way of course marijuana
NFS is not or crystal meth and of course its out
26 Pages 98 to 101
Page 98
1 MR LLOYD We can go ahead and go back 1
2 on the record 2
3 Q BY MR LLOYD All right Dr Purswell 3
4 when we took a break we were going through the 4
5 regulations relative to the hazard communication 5
6 standard under OSHA I would like to the continue 6
7 down that line of questioning for now You have 7
8 made reference repeatedly to an opinion letter 8
9 that was issued by was it by OSHA or by C P SC 9
10 there are ones by both OSHA saying if a hazardous 10
11 chemical in use of employment context consumer 11
12 context XHUN SKAGS standard there is also the C 12
13 P SC letter specifically addressing somebody who 13
14 wrote in to say is the federal had SARS DUS 14
15 substance act applicable if somebody brings a 15
16 workplace chemical home NOR whatever reason in 16
17 incidental use and the C P SC said no thats not 17
18 in the our jurisdiction the APS A does not apply 18
19 in that particular case 19
20 Q The first letter when you say 20
21 A The first letter that you just 21
22 referenced 22
23 A Well actually there are a number of 23
24 OSH OSHA interpretations that say that and 1 24
25 think Ive printed 25
Page 99
1 Q Maybe to better focus this lets go 1
2 ahead and look at whats been marked as Exhibit 1 2
3 100 Ill hand it over to you and you can cross 3
4 reference if you like to tell me 4
5 A Just tell me the section Whatwer 5
6 looking at section B scope and application 6
7 subsection 6 7
8 A Okay and then Roman numeral 9 8
9 A Okay 9
10 Q First of all go ahead and read what 10
11 subsection 6 says just that first line of it 11
12 MR OVERSON Go ahead and read as muc 12
13 as you need to read 13
14 Q BY MR LLOYD Well yes 14
15 A Subsection 6 this section does not 15
16 apply and it gives a long list 16
17 Q What SDU understand this subsection 6 17
18 TOK doing 18
19 A Excluding coverage from OSH OEB from 19
20 certain types of things not covered by it 20
21 Q And thenIve directed your attention 21
22 to subsection 9 there in but go ahead and review 22
23 the whole thing if you need to 23
24 A Okay I see 9 24
25 O Okay 25
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. : e can go ahead and go back 1 . n  ' l  t    
  r . 2        
. (B  . )   r. l   r  i  fi  i  t e  t e  r  t  
 hen e took a break e ere going through the  l    t t it i   i  t  
 regulations relative to the hazard co unication  la    t   i te   t  
      e   nue 6  e       
 do n that line f questioning for no . ou have 7 erty, e       
 ade reference repeatedly to an opinion letter 8   es    l  
 that as issued by as it by  or by  P S   bl       f( r 
 there are ones by both  saying if a hazardous  the purpose intended I've, ". 
 che ical in use f e ploy ent context consu er  . ou've ie  i    
 t xt,  S        l         
 P SC letter specifically addressing so ebody who 13 a e    t    
 rote i  t  sa  is t e fe eral a   D   ou've  i n? 
 s sta ce act a lica le if s e  ri s a  .       ll  
 orkplace che ical ho e  hatever reason in  referenced that fro   opinion letter and the 
  d          at's    irect, es. 
 in the our jurisdiction the PS  does not apply 18 .       
 in that particular case?  t r  t s  if it's i  t  r l ti    
 . The first letter hen you say?  l  ir tl  t t  r ulation? 
 . he first letter that you just  . y. 
 .  . O t i  i  t r list   Ss 
 . ell, actually there are a nu ber of           
   interpretations that say that and I 24             
 think I've printed.           
~---------------------------------------+------------------------------------------
    
 . aybe to better focus this let's go  r place f r t e r se i te e   t e 
     at's    t I  i l f t r r r i rt t  f t  
 100 I'll hand it over to you and you can cross  product let's stop there. o you have any 
 refere ce if  li e t  tell e?  ersta i  i  t is case  t e i te t f t e 
 
 
.   e  ti .  e're  a fact rer as it  t e e er s ra  at issue? 
lo in  at secti   sc e a  a licatio   .  nt. 
 on .  R. OVERSON: Objection the question is ; 
 . kay and then o an nu eral 9.  vague go ahead. 
 . ay.  T E IT ESS: ell again you've choppe 
 . irst f all  a ea  a  rea  at     ons  l   ' l  
 s secti   sa s j st t at first li e f it?   ersta i  t at t e f at  t e  n't 
 . :      et  sell it t  c s ers t t e  i te  it t   
 as ou ee  t  read.  se  f r cc ati al se t  eter r tree strai  
 
 
. (B  . D) ell yes?  people ho are declining to co ply ith la  
. t   s     enforce ent request S  SEC's. 
16 apply and it gives a long list.  . re you a are of hether S s la  
 . hat SO  understand this subsection 6   e  L S? 
18  doing?  A. It's not CO BRESHGS bill plea majors 
 . Excluding coverage fro  S  E  fro   testi ony that hen ST E anted to buy another 
20 certain types of things not covered by it.  sa ple of it she had to take so ebody fro  the or" 
 . nd then I've directed your attention  not available I should say directly TL  consu ers 
22 to subsection 9 there in but go ahead and review  that they have to get so ebody who is a law 
 the hole thing if you need to?  enforce ent person to buy it for the  and then 
 . kay. I see 9.  consu ers can get it that ay f course arijuana 
 Q. y. 25 FS is not or crystal eth and of course it's out 
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Page 104
specifics
Q Okay
A Again with regard to the SEC form
listings there are ones for both intensity ask
delivering methods and things like that so they
are specific products and I believe the sell
buster is a particular product that is not sold
to the public and from everything Ive reviewed
and I believe that there are you know certain
pepper spray that woman can buy to water warnir
off attack KERS late at night its a similar its
a same general type of product but differs in
intense fee and certainly differs in delivery
method
Q Okay So do you base your opinions in
part on the notion that the concentration of OC
product in the law enforcement brand is not
available in consumer brand
A I dont know that for a packet but the
sell buster formulation contains the highest
level of OC product that Im aware of regardless
of anything anywhere consumer use or law
enforcement use
Q Do you know if OC
Q Do you know if Billie Major was exposed
Page 105
to the sell buster eye dock employees
A Eye dock employees is that she was EX
POEXD to familiarize herself with the effects of
the product and itsmy understanding it was the
sell buster formulation OC
A
Q Okay
A Its my understanding as well there is
a similar formulation one of MK designations
which offers some difference in the delivery
method but is basically the same product
Q All right
Q Whats the purpose much pepper spray
whats your understanding of the your
understanding of the purpose for pepper spray
A To cause a burning sensation in the
eyes the skin and apparently from the MSDS
respiratory TRAKT of the person you are trying to
ward offor control
Q Is that only for watering off waiting
off or controlling people in a law enforcement or
correctional facility
A Its my understanding that there are
weaker formulations that are sold for consumer
use as well
27 Pages 102 to 105
Page 102
1 there according to to thats that different 1
2 matter people can get ahold of it but its not a 2
3 legal or not an improved method of securing it if 3
4 you are not a 4
5 Q According to whom 5
6 A Thats my understanding of the controls 6
7 that SEC has put on their own SDRPGS of the 7
8 product they dont sell it to consumers 8
9 Q Where do you gather that Billie Major 9
10 TAES testimony that STHED to go get somebody t 10
11 purchase the product 1 11
12 Q But you yourself didntdo any 112
13 independent investigation to see if you could 13
14 purchase this product without a law enforcement 14
15 chaperone 15
16 A That is true 16
17 Q So attorney Billie Majors deposition 17
18 testimony you have no knowledge as to whether 18
19 this item can be purchased by the general 19
20 consumer 20
21 A Its my understanding again that SEC 21
22 makes a variety of concentrations of the product 22
23 and the sell buster product consumer use from 23
24 the totality of the material I reviewed I dont 24
25 have a specific document that I can put my 25
Page 103
1 document finger on they dontsell sell buster to 1
2 Joe average citizen 2
3 Q Okay 3
4 Q BY MR LLOYD Moving on the next 4
5 condition as youvecalled it under that same 5
6 subsection if and the use results in a duration 6
7 and frequency of exposure which is not greater on 7
8 the range of exposures that can reasonably be 8
9 experienced from consumers when used for the 9
10 purpose intended Whats your understanding of 10
11 that phrase 11
12 A Well the key word there is consumers 12
13 Now when OSHA talks about consumers they are 13
14 talking about people not in an occupational 14
15 context they are not talking about employees they 15
16 say employees they will mean employees they if 16
17 its member much the public and sorts of the 17
18 grade stuff that SEC is not TA consumer product 18
19 Q Are you aware of whether the law 19
20 enforcement branded products of SEC are availablc 20
21 in a nonlaw enforcement brand 21
22 A No 22
23 Q You are not aware or no they do not 23
24 A There may have been SMFG in the NANs 24
25 deposition about that but I dont recall 25
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 . here ay have been S F  in the N's         
25 deposition about that but I don't recall    l . 
,,"" 
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Page 108
could happen Im not here to testify about
possibilities Imnot here to testify to the you
are gone knock
Q Unfortunately the laws that do apply in
this case carry with them a requirement for
reasonable foresee able so to a certain extent
Im asking you to testify Im asking you to
testify whether it would be reasonably foresee
able that that product the OC product be
discharged in some place other than a
correctional facility in that same concentration
A To the extent that it would be would it
would be I would say that it would not be for the
duration and for the interest T intensity that is
anticipated there I dontsee anybody creating
the same kinds of test conditions that they ran
the trainees outside of the employment context I
dont find that to be plausible
Q You dont see somebody creating the
same type of test conditions
A Why
Q What about actual use
A Well again my understanding the sell
buster product is its intented to create the
basically HAN atmosphere with stuff in it and
Page 109
thatswhat Ms Major alleges caused her problem
and I dont see that occurring anywhere and again
the sell buster form in PKT with the OC product
in it and apparently high concentration of that
and I dontsee that occurring in TA consumer
circumstance
Q Do you see that occurring however
outside a correctional facility
MR OVERSON Asked and answered
THE WITNESS Not outside of an
employment context I dont know where would yc
do it that would have the same concentrating
EEKTS if you do it in a same urban home and no
guess I would say
Q Whether inside or outside of an
employment context is it reasonably foresee able
in your mind that a police officer would use a
pepper spray product such as the sell buster to
extract a criminal from a hiding place
A I would have to have more information
about the particular type of hiding place whether
it was an open area Im not aware of the sell
buster product being used outside of the actually
outside the correctional facility in context for
that for that chemical is they may use pepper
28 Pages 106 to 109
Page 106
1 Q Okay 1
2 A I think I referenced that previously 2
3 Q But what about the law enforcement 3
4 branded are they intended is it your 4
5 understanding that the law enforcement branded 5
6 products are solely to be used in the 6
7 correctional facility 7
8 A No itsmy understanding police 8
9 officers also may carry it it may be used by law 9
10 enforcement personnel outside of correctional 10
11 facilities 11
12 Q In homes 12
13 A Its my understanding that Billie 13
14 Majorson one occasion an officer did come to 14
15 her home got an incidental exposure as C P SC 15
16 would define it and have did have a product with 16
17 him that contained the OC product but it was 17
18 would clearly fall within the category described 18
19 by both SXOESH C P SC would not render it subjec t 19
20 to the F A AB KOB 20
21 Q Why is that 21
22 A Incidental use not used for very long 22
23 and not used in the duration or intensity in if 23
24 product used in the THOUPGS natural context 24
25 Q Onwhat do ybase that 25
Page 107
1 A Well I base that testimony of upon 1
2 testimony of Billie Major which said the guy came 2
3 to her house he was there for halfanhour then 3
4 he left 4
5 Q So is it inconceivable in your mind 5
6 that the product would actually be discharged in 6
7 the home 7
8 A No but its inconceivable that it was 8
9 discharged the concentration than the 9
10 occupational context I dont believe there is any 10
11 testimony from any of the witnesses that 11
12 described anything In the home context similar 12
13 to the training that was done with the tie dock 13
14 employees where they were taken in the sell sell 14
15 buster products used in the high concentration in 15
16 the sell and made to stand in the STEL until they 16
17 had a reaction to it 17
18 Q Thatsnot going to conceivably happen 18
19 but anywhere in a correctional facility is that 19
20 your testimony 20
21 A Im not aware that anybody testified 21
22 that they were observing anywhere other than a 22
23 correctional facility 23
24 Q Do you think that could happen 24
25 A You know pigs go fly a lot of things 125
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1 Q. Okay. 
2 A. I think I referenced that pre io l . 
3 Q. But hat about the la  enforcement 
4 branded are they intended is it your 
5 understanding that the law enforcement branded 
6 products are solely to be used in the 
7 correctional facility? 
8 . o it's y understanding police 
 officers also ay carry it it ay be used by la  
10 enforce ent personnel outside of correctional 
 fa ilitie . 
 . In ho es? 
 . It's y understanding that illie 
 ajor's on one occasion an officer did come to 
15 her home got an incidental exposure as C P SC 
 o ld fine it  e id   ro t it  
17 hi  that contained the  product but it as 
18 ould clearly fall ithin the category described 
19 by both S ES  C P SC ould not render it subjec 
 t  the    . 
 Q. hy is that? 
 A. Incidental use not used for very long 
 and not used in the duration or intensity in if 
24 product used in the THOUPGS natural context. 
 . n hat do you base that testimony? 
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 testimony of Billie Major which said the guy came 
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 . SO is it inconceivable in your ind 
 that the product ould actually be discharged in 
 t e e? 
 .  t it's i c cei a le t at it as 
 discharged the concentration than the 
 occupational context I don't believe there is any 
11 testimony from any of the witnesses that 
 described anything? In the ho e context si ilar 
13 to the training that was done with the tie dock 
 e ployees where they were taken in the sell sell 
 buster products used in the high concentration in 
 the sell and ade to stand in the S  until they 
   cti   it. 
 Q. That's not going to conceivably happen 
19 but anywhere in a correctional facility is that 
 your testimony? 
 . I'm not a are that anybody testified 
22 that they were observing anywhere other than a 
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could ha . I'm not ere to te  a out 
p ssi ilities I'm not here to testify to the you 
are gone k . 
. nfortunately the la s that  a ly in 
this case carr  ith t e  a req ire ent for 
reas le foresee le  to  tain te t 
I'm as ing ou to te tif . I'm a ing you to 
testify hether it ld e reas l  foresee 
a le t t t at r t the  ro t e 
ischarged in s e lace ther t   
correctional fa it   that s e tr ti ? 
.  t e t t t d e   
ould e I ld  t t it l  t  f  t  
ion   the interest  inte t  that s 
ticipated t r . I n't e  r ti  
the e inds  test ions    
t e trainees t i   t  l e t t t I 
n't fin  t t t   l i l . 
. ou n't see s e  creating t e 
sa e t e f test c iti s? 
. . 
.    e? 
. l , i     l  
t r r t i  its i te te  t  r t  t  
i ll   t r  it  t ff i  it  
  
at's  s.  l     
  on't       
          
i  it  r tl  i  tr ti  f t t 
  on't   r      
. 
.   see t at cc rri  e er 
   f cil ty? 
. N:   red. 
 :  e   
e ploy ent context I don't kno  here ould yOl 
 i       t  
 if   it i  a sa e r a  e a  o, 
ess I l  say. 
. hether inside or outside f an 
e pl e t c te t is it reasonabl  f resee a le 
in your ind that a police officer ould use a 
pepper spray product such as the sell buster to 
  ri  f   i  lace? 
. I ul   t    i f ti  
t t  rti l r t   i i  pl  t r 
it as an open area. I'm not a are of the sell 
buster r t ei  sed tsi  f t  actually 
out i  t  corr cti l f cilit  in context for 
t t f  t t chemical i  t     
2  (P  1  t  09) 
29 Pages 110 to 113
Page 110 Page 112
1 spray the circumstances but itsmy understanding 1 asked me FO speculate about it and so Im
2 that would be different type ofproduct and may 2 speculating about it again I dontconsider this
3 be a different concentration and certainly a 3 to be engineering and URG MIK speculate to
4 different delivery SGLETD and what do you base 4 offer Bates Nos about what you are asking me
5 that understanding 5 speculate on
6 A Well to the sell buster one I 6 Q So you have just so that I had
7 understand goes into from reading the 7 understand you have no basis and it is not your
8 instructions and directions as to how its 8 yet your expert opinion that this product would
9 supposed to be used to the sale buster is one 9 not be used outside of a correctional facility
10 that you go in and fill a particular space with 10 A I have no awareness from reading the
11 it and thatswhat is used to control the 11 deposition testimony that anyone ever testified
12 prisoner With regard to the other products that 12 to anything like that and Im not aware of any
13 TR used as a safe deterrent effect itsa stream 13 particular circumstances where that would be used
14 a spray you are directing to a particular person 14 outside so in all the stuff that I have seen the
15 rather than to an environment 15 sell buster product is uniformly used in a
16 Q So in your mind itsinconceivable that 16 correctional context
17 a criminal could have locked himself into a room 17 Q Now you mentioned also that from what
18 in a home refuses to come out and law enforcement 18 you reviewed you understood that this sell buster
19 would never use pepper spray in that instance 19 product was available in a different discharging
20 MR OVERSON Objection I think you are 20 format for lack of a better discharging device
21 mischaracterizing his testimony 21 A Its my understanding that the STAM
22 THE WITNESS You are asking me to 22 formulation that is contained in the sell buster
23 comment on incomplete HOOIPTS HOOIPTS and I thinb 23 product is also contained in some of the fog GER
24 Ive said everything I can say about the foresee 24 products but the method of delivery is different
25 able I dontsee that no I dontreally see 25 something about the met FD of delivery is
Page 111 Page 113
1 that happening that they would use the sell 1 different Again I havent had my hands on the
2 buster product to try to smoke somebody out 2 physical products itself so Im not exactly oh
3 THE WITNESS You dont 3 how to describe those differences to you but its
4 Q No do you have any 4 my understanding the same product discharged
5 A No 5 number
6 Q Do you have any training in law 6 Q So do you have any understanding as to
7 enforcement 7 whether that method of discharge in the fog GER
8 A The I dont 8 products would be used outside of a correctional
9 Q Any of your family members law 9 facility in any way different than what youve
10 enforcement 10 testified or what youve speculated op the sell
11 A No I have a family friend who is a 11 buster
12 retired police officer and I think I mentioned 12 A No
13 that before But I dont have that would be my 13 Q Okay lets go ahead and turn to on
14 only connection 14 Exhibit 100 or I would say the equivalent that
15 Q Did you ever discuss tactical maneuvers 15 you are reviewing there Subsection C
16 with him 16 A Okay
17 A No 17 Q Which is definitions
18 Q Strategy 18 A Yes
19 A No 19 Q And what Im looking for it doesn
20 Q So you have no personal knowledge as to 20 appear as though they are all numbered its just
21 whether a law enforcement person would use that 21 in alphabetical order is that your understanding
22 method to extract 22 A That generally seems to be true yes
23 A You asked me to speculate about it 23 Q Okay So I would like you to go ahead
24 And I told you I didnt think that was something 24 and turn to the definition of health hazard
25 that I had an expert opinion about But you 125 A Okay
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1     it's  t i  
2     t  f   y 
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asked e F  speculate about it and so I'm 
speculating about it again I don't consider this 
to be, engineering and  I  speculate, to 
offer ates os. about hat you are asking e 
speculate on. 
. SO you have just so that I had 
understand you have no basis and it is not your 
t  t i i  t t t i  r t l  
t   t i  f  r ti l f cility? 
. I have no a areness fro  reading the 
deposition testi ony that anyone ever testified 
to anything like that and I'm not a are f any 
particular circu stances here that ould be used 
   ll  tuff      
sell buster product is unifor ly used in a 
 ntext. 
. o , you entioned also that fro  hat 
you revie ed you understood that this sell buster 
product as available in a different discharging 
for at for lack of a better discharging device? 
. It's y understanding that the S  
      l   
product is also contained in some of the fog GER 
products but the method of delivery is different 
something about the met FD of delivery is 
age 113 
different. gain I haven't had y hands on the 
physical products itself so I'm not exactly oh, 
how to describe those differences to you but it's 
y understanding the sa e product discharged 
er. 
Q. SO do you have any understanding as to 
whether that method of discharge in the fog GER 
products ould be used outside f a correctional 
facility in any way different than what you've 
testified or what you've speculated op the sell 
t r? 
. . 
. kay let's go ahead and turn to on 
Exhibit 100 or I would say the equivalent that 
you are reviewing there. Subsection C? 
. kay. 
. hich is definitions? 
. . 
.  at I'm l in  f r it esn't 
a ear as t  t e  are all ere  it's just 
in alphabetical order is that your understanding? 
A. That generally seems to be true yes. 
Q. Okay. So I would like you to go ahead 
 t r  t  t e de inition   rd? 
. a . 
 (Pages 0 t  ) 
Page 116
Q Im going to turn to well the
definition just above the definition for health
hazard
A Okay
Q For hazard warning
A Okay
Q Do you see that
A Yes
Q Okay Hazard warning means any words
pictures symbols or combination there of
appearing on a label or other appropriate form of
warning which convey the SFEF or gone effects
of the chemicals in the container
A You read that correctly
Q Okay Now applying the definition of
health hazard that we just went over is an
employer or a manufacturer under the OSHA
standards in your opinion required to warn
against a health hazard tore which there is not
staticly significant evidence based on one study
in accord with scientific
A With acute or chronic
Q In there is no statistically
significant evidence regarding that particular
adverse health effect does an employer or a
Page 117
manufacturer have an obligation under the OSHA
standards to warn against that effect
A If its a matter in dispute I would say
that would be true if it is a matter where the
appear on the MSDS from the manufacturer I wot
say that that would be target or gone effect
needs to be on the product label
Q Just to clarify your previous answer so
if there is no statistically scientific evidence
then that obligation for HAN employer or a
manufacturer to place a health hazard warning on
the product does not exist
A Well let me clarify youvegiven one
Q Im trying to own in on your first
answer
A My first answer is if there is no
statistically reliable scientific evidence of
that effect that would be true the only exception
I would make ofthat is that common sense if its
something that appeared on the MSDS from the
manufacturer or other sources then and they say
that this product also causes skin irritation eye
irritation and respiratory effects then all those
three target areas need to be listed on the
product label
30 Pages 114 to 117
Page 114
1 Q 1
2 MR OVERSON What one is that on 2
3 yours
3
4 MR LLOYD On mine its 6 4
5 Q Have you found that 5
6 A I have 6
7 Q Okay Have you read through that 7
8 definition ofhealth hazard 8
9 A Im familiar with it from before yes 9
10 Q Okay And just to read it into the 10
11 record the definition of health hazard means a 11
12 chemical for which there is a statistically 12
13 significant apologize a chemical for which there 13
14 is statistically significant evidence based on at 14
15 least one study conducted in accordance with 15
16 established scientific principles that acute or 16
17 chronic health effects may occur in exposed 17
18 employees did I read that correctly 18
19 A You did 19
20 Q Okay Are you aware of any 20
21 statistically significant evidence based on at 21
22 least one study conducted in accord DABSwith 22
23 established scientific principles that chronic 23
24 health effects may occur in an exposed VICHLD 24
25 A You are asking about only half of the 25
Page 115
1 definition and you are asking about only part of 1
2 whats there when you go on its going to talk 2
3 about IR STANTS it in Billie Majorscase chronic 3
4 effects as well but for and I didntunderstand 4
5 the SEC was still disputing if it was an irritant 5
6 if SEC does not dispute the fact that its an 6
7 irritant its covered 7
8 Q Again not my question I would like you 8
9 to answer my questions 9
10 A Okay 10
11 Q Are you aware of any statistically 11
12 significant evidence based upon at least one 12
13 study conducted in accordance with established 13
14 scientific principles that chronic health effects 14
15 may occur in health individuals 15
16 A I have research dontknow 16
17 Q You dontknow with respect to chronic 17
18 health effects the OSHA standard or the OSHA 18
19 definition of health hazard would even 19
20 membership 20
21 A For the chronic effects I have not 21
22 researched that particular one to document 22
23 whether or not thats the case Again health 23
24 hazard can be acute or chronic but if chronic I 24
25 have not resear that 25
000882
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1 XAKTS and limitations and trying to make sure th 1
2 workplace has tools and equipment and humans us 2
3 do not does them to do things that which we know 3
4 from not possible for them to do or a substantial 4
5
Page 118
5
1 Q In your experience or education do you 1
2 have have you ever had the opportunity to review 2
3 requirements for labeling warning on prescription 3
4 medications 4
5 A Ive had some interaction with the FDA 5
6 requirements for that but I didntreview them 6
7 particular to this case and I dontcarry those 7
8 around in my head 8
9 Q Mr Overson undoubtedly going to object 9
10 to this question So be ready 10
11 MR OVERSON All right 11
12 Q BY MR LLOYD But as an ergonomics 12
13 expert part of what you study correct me if Im 13
14 wrong would be the interaction of the human body 14
15 in a particular environment earlier you were 15
16 describing the cockpit individual in a cockpit 16
17 and how the cockpit is designed to fit the the 17
18 human body in a way that does no not produce 18
19 energy injury 19
20 MR OVERSON Is there an a question in 20
21 there 21
22 Q BY MR LLOYD In his capacity as an 22
23 ergonomics expert you study 23
24 A In the my capacity of ergonomics I in 24
25 respe tophysical pe and cogni 25
Page 119
portion of the population on a routine basis
6 Q Would it be fair to stay that not only 6
7 do you investigate things that are not possible 7
8 NOR humans to do but things that may actually 8
9 cause injury to humans if they do do that 9
10 A With an example yes Back injury 10
11 prevention is something that we I teach and we 11
12 talk about in frequent core cases and such where 12
13 people are lifting too much and with twisting 13
14 motion or from the floor or up above their 14
15 shoulders and say thats too much for if the 15
16 person to lift and employer should know that 16
17 General duty clause for people who have done that 17
18 so yes 18
19 Q Okay Has as it RELDZ P relates to 19
20 warnings ask labels is that also the case that 20
21 part of the your research and part of your 21
22 studies is to ensure that research that the 22
23 labels and the warnings adequately address and 23
24 warn against the possible adverse health effects 24
25 that arise out of particular products 25
Page 120
A To the extent that a product a
particular chemical product like this has hazards
that need to be warned about and precautionary
measures that need to be provided and also
something that has been shown to motivate people
and said if you can include statements of
severity in TERNLS of the consequences to in
failure to hedthe warning all those things
would be a prepare warnings for industrial
clients I try and do that
Q Would that include something such as a
warning to wear protective eye wear
A Im sorry its not thatsa precaution
thatsnot a warning because a warning would
identify the hazard and state the consequences
failing to avoid the hazard
Q Fair enough If a particular product
was known to cause no Im going to save that for
a little bit later Part of your testimony today
has been about MSDS sheets
A Thats true
Q And that was in fact a part of your
report youvemade reference to the MSDS sheets
A Yes
Q In your report which we may pull out in
Page 121
just an and admit it into evidence now In your
report you indicated that you did not have the
complete MSDS sheet for SECsproduct at the
you made that report do you recall that
A I dont recall what language I used I
recall something to that effect
Q Letsgo ahead and take a look at your
report
A
Exhibit 101 marked
Q BY MR LLOYD Okay Dr Purswell Ive
handled you Exhibit No 101 whatsmarked as
Exhibit 101 do you recognize that document
A DoI
Q What is that
A Thatsmy report ofMarch 28th of this
year
Q Okay Your report for this case
A Yes
Q And on the first page it indicates the
materials that you reviewed
A Yes and again I mentioned before that I
was in error of omission but I did have a review
and I did review of the plaintiff
Q And that goes on to the actually the
31 Pages 118 to 121
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Page 118 
1 Q. In your experience or education do you 1 
2 have have you ever had the opportunity to revie  2 
3 requirements for labeling warning on prescription 3 
4 e i ti ? 4 
5 A. I've had some interaction ith the  5 
6 requirements for that but I didn't review them 6 
7 particular to this case and I don't carry those 7 
8 around in y head. 8 
9 . r. verson undoubtedly going to object 9 
10 to this question. So be ready? 10 
1 R. OVERSON: All right. 11 
 Q. (BY R. LLOYD) But as an ergono ics 12 
 expert part of what you study correct me if I'm 13 
 wrong would be the interaction of the human body 14 
 in a particular environment earlier you were 1  
 describing the cockpit individual in a cockpit 116 
 7 and ho  the cockpit is designed to fit the the  7 
 hu an body in a way that does no, not produce  
19 energy injury?  
 R. OVERSON: Is there an a question in  
 t .  
 Q. (BY R. LLOYD) In his capacity as an 22 
 ergonomics expert you study? 23 
 A. In the my capacity of ergonomics I in  
25 respect to physical perceptual and cognitive  
a e  
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easures that need to e r ided and also 
s ing that as been n to otivate pe ple 
 id if  can include state e ts f 
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 ou've  ere ce  e S ets? 
. es. 
.   t i    ll t i  
  
 XAKTS and limitations and trying to make sure th(  s    it it i t  i e .   
 workplace has tools and equip ent and hu ans us(  re rt  i icate  t at  i  t a e t e 
 do not does them to do things that which we know  co plete  sheet for EC's product at the time 
 from not possible for them to do or a substantial  you ade that report do you recall that? 
 portion of the population on a routine basis.  .  n't l       
 Q. ould it be fair to stay that not only  recall so ething to that effect. 
 do you investigate things that are not possible  . et's    t   l  t r 
 NOR humans to do but things that may actually  report? 
 cause injury to humans if they do do that? 9 . 
 A. ith an example, yes. Back injury  (E i it  arked.) 
11 prevention is something that we I teach and we  . (B  . YD)  r. urswell I've 
12 talk about in frequent core cases and such where  l   i it .  hat's r   
 people are lifting too much and with twisting  Exhibit 101 do you recognize that document? 
 otion or fro  the floor or up above their  .  . 
 shoulders and say that's too much for if the  . t i  t at? 
16 person to lift and employer should know that.  . hat's  r rt f r  t  f t i  
  eneral duty clause for people ho have done that 
 so yes. 
 Q. Okay. Has as it RELDZ P relates to 
20 warnings ask labels is that also the case that 
21 part of the your research and part of your 
 t  i  t   t t r r  t t  
 labels and the warnings adequately address and 
 warn against the possible adverse health effects 
 that arise out of particular products? 
17 ear. 
18 . ay. r re rt f r t is case? 
1  . s. 
 . nd on the first page it indicates the 
 t ri l  t t  r viewed? 
2  .   again I ti  bef r  t t I 
23  i  er or of o i i   I i  hav  a revi  
2  and I di  review f t e laintiff. 
 .  t t g   t  t  actual y t  
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1
1 second page where you have the list of the 1
2 depositions that you have also reviewed 2
3 A Yes 3
4 Q Have you reviewed the deposition of 4
5 Dr YOES you know I was provided with a rough 5
6 copy of that I have not looked at that but I was 6
7 provided with a rough copy I only realized it was 7
8 in my file this morning when I did go through my 8
9 stuff I have I didntlook 9
10 Q How about the deposition of 10
11 Dr Pacheco 11
12 A I assume they are expert REE sports as 12
13 you know but I have not seen the reports as you 13
14 recall 14
15 Q On the second page of Exhibit 101 15
16 following your list of the depositions you 16
17 indicate that you make the following opinions 17
18 related to this matter to a reasonable degree of 18
19 engineering and ergonomics certainty 19
20 A That is true 20
21 Q And number one where we start to 21
22 discuss theMDS SD 22
23 A 23
24 Q Con STUX SEC products has only nine 24
25 sections and appears to be incomplete 125
Page 123
A That is true its not in compliance
2 with the N CD dot 1 so I was wanting to know if 2
3 SEC had anything to MSDS if that was hall they 3
4 had available in the con tin Wednesday suppliers 4
5 Q And you received this from plaintiffs 5
6 counsel the MSDS sheet you referred to 6
7 A No I found that on my own 7
8 Q Where did you find it 8
9 A I youllnotice in Google that if you 9
10 type in the word MSDS chemical name you can 10
11 typically pull up MSDS pretty quickly 11
12 Q Did you ask plaintiffs counsel to see 12
13 a copy of MSDS approved in this case 13
14 A I did ask MSDS from the con TIS went 14
15 AU PREEFTD section like it did and I said did 15
16 they provide with us or is that all SEC ever 16
17 received 17
18 Q And what was the response that you 18
19 received 19
20 A Well I believe he checked with 20
21 somebody here at your firm and what I have been 21
22 provided was all that SEC CLANLD to have in their 22
23 files 23
24 Q Well Im going to go ahead and mark 24
25 Exhibit 102 MSDS sheet D SH sheet complete PROM 25
Page 124
FRUSD if MSDS
Q Now comparing Exhibit 102 with what
youveWRIRN in your report you indicate that the
report you only appeared to have nine sections
now can you take a look at Exhibit 1021 st of all
identify what Exhibit 102 is
A Exhibit 102 MSDS sheet it does not I
guess it does have and that is one it indicates
that it is before the sell buster for the sell
buster product apparently produced by security
equipment corporation
Q Okay Now looking at the first two
pages of this document its a three page document
but the first two pages is where we have sections
1 through 9 is that accurate
A Thats true
Q Now is those two pages that all you
reviewed when you made your report
A For whatever reason I think that was
all I got yes
Q Okay So go ahead and turn to the
third page
A Okay
Q And review that for a moment and let me
know when you have
Page 125
A Witness complying Okay
Q Now having now reviewed the third page
of the MSDS do you believe that this MSDS sheet
is complete HOR incomplete
A It seems to have all 16 sections as I
noted and it does say its in compliance with C
SEC1400 dot 1
Q Now going back to your report Exhibit
101 the next sentence reading on however a
publicly available MSDS for Oleoresin capsicum
from and then you give a website shows that the
OC product has an MMI S has a health hazard
reading of three out of four
A Thats what the science lab for
Oleoresin capsicum MSDS
Q Was that a MSDS for sell buster
A No it was for the Oleoresin capsicum
Q Okay
A They obviously science lab will not
produce TA MSDS for the particular object that
Q Whats an H M I S health hazard read
rating
A Right acute AU effects chronic
effects climb NAT tea it a triangle and it is
something where they talk about different
32 Pages 122 to 125
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. , i  i it  it  at 
ou've      indicate  e 
report you only appeared to have nine sections 
no  can you take a look at Exhibit 1021 st of all 
identify hat Exhibit 102 is? 
. t    t    
 t        icates 
t t it is  t  ll t   t  ll 
ster r ct a are tl  r ce   sec rit  
equip ent corporation. 
. y.  n    rs   
a es  t is t it's  t  e t 
t t  irst t  es is e e  ti  
 t r   i  t t urate? 
. at's . 
.  i  t s  t  s t t ll  
r ie e    e r r ort? 
.        
ll  t . 
. kay. So go ahead and turn to the 
t ird e? 
. y. 
.  r i  t t f r  t  l t  
   ve? 
-------------------
  
. (Witness co plying.) kay. 
. , i   r ie e  t  t ir   
of the S S do you believe that this S S sheet 
is co plete  inco plete? 
.       t    
te   it   it's i  lia  it   
 ,4 0  . 
. o , going back to your report Exhibit 
 t  t s t  r i   r  
publicly available S S for leoresin capsicu  
fr   t   i   it   t t t  
 r t s  I  s  lt  r  
r i  f t r  t f f ur? 
. at's      
l r si  si  . 
. as t t   f r ll ster? 
. o, it  f r t  l r i  sicu . 
. y. 
. e  i sl  scie ce la  ill t 
r ce    f r t e artic lar ject t at. 
. hat's a   IS ealt  azar  rea  
rating? 
. ight, acute  effects, chronic 
ff t  li   t  it  tri l   it is 
s et i  ere t e  tal  a t iffere t 
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A The specific H M I S numbers are I
would say those specific phrasing are not general
public knowledge thatscertainly publicly
available and if you type in H M I is S the
ratings on Google you should find descriptors for
each one of those four categories
Q What about for four do you know what
the language would be associated with a rating of
four
A Not off the top of my head
Q But
A Something more intense than whats
given there
Q So the intensity ranges from one being
the LOESD to four being the greatest is that
correct
A Thatsmy understanding of the rating
system
Q And your reference in your report to
the H M I S health hazard rating refers to the
manner much rating thats on the triangle form as
opposed to the color form if you understand my
question
A I dont work with H M I S ratings all
the time so my recall of that is its a diamond
Page 129
and there is rating health hazards for different
categories of health hazards acute effects or
chronic effects longterm effects flame ability
KRO Ross ZIFness those are the things off the top
ofmy head being recovered
Q Okay among those particular among that
particular rating system are you aware of whether
there is any specific demarcation identifying or
indicating that there are chronic health effects
associated with a particular product
A Im sorry can you say that one more
time
Q Are you aware under the standard that
you have referred to here in your report are
there any indications of demarcations that give
rise to an in reference or a not indication that
there are chronic adverse health effects that are
associated with that particular product
A It is my recall that there are ones
which deal there is a category that deals with
acute EECHKTS and another one deals with chronic
effects that may or may not be accurate but the
point is it does constitute an irritant both by
by the science lab MSDS as well as the C E C MSDS
and other information and intended to be an
33 Pages 126 to 129
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1 possible hazards associated with the use of the 1
2 chemical ask on the health rating it did have a 2
3 three out of four on the one that I looked at 3
4 Q And that was not the SEC 4
5 A That was not the SEC version no 5
6 Q Okay Go ahead and look at Exhibit 102 6
7 and under section 3 hazard identification on the 7
8 first page 8
9 A Okay All right 9
10 Q A couple much lines down H M I S rating 10
11 health 2 is that health hazard rating 11
12 A Thats the same type of rating and they 12
13 have 2 as opposed to 3 from the Oleoresin 13
14 capsicum from the MSDS science lab I would gathe 14
15 that the my inference from that would be the 15
16 lower rating on the SEC product is actually 16
17 probably a DLU TED version from the what the con 17
18 SEN TRAITD Oleoresin capsicum is in pure form 18
19 Q The next sentence the consequences of 19
20 exposure to a health hazard with a rating of 20
21 three are described has major injury likely and 21
22 unless FROMT action is given and medical 22
23 treatment is given did I read that correctly 23
24 A You did 24
25 Q And when you say the consequences of 25
Page 127
1 described as according to whom 1
2 A I believe I got that from either one of 2
3 my safety teches or I believe that would have 3
4 come from whatever safety teches that I use 4
5 currently possibly that are or maybe from the 5
6 wilily hammer text wilily hammer FRIES text that 6
7 I previously referenced 7
8 Q Did you produce that today 8
9 A I have not produce you had that public 9
10 COMPLEE for purchase 10
11 Q Okay Have you produced anything that 11
12 refers to the rate DEENT rating system for the M 12
13 H H M I S health HAZ standards 13
14 A No I thought that was general public 14
15 knowledge 15
16 Q Okay Are you aware from the general 16
17 public knowledge then what what words would be 17
18 associated with a health hazard rating of two out 18
19 of four as opposed to the quoted language you 19
20 have on your report 20
21 A NoIm not aware of specific language 21
22 for two out of four it would be something less 22
23 intense as three out of four 23
24 Q Its not quite question public 24
25 knowledge then 25
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1 i   s i  i    f t  
2     l  t      
3 three out f four on the one that I looked at. 
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.  specifi   IS r  r  I 
ould say those specific phrasing are not general 
public kno ledge that's certainly publicly 
available and if you type in   I is S the 
ratings on oogle you should find descriptors for 
each one of those four categories. 
. hat about for four do you kno  hat 
the language ould be associated ith a rating of 
ur? 
. ot off the top of y head. 
. ut? 
. So ething ore intense than hat's 
 re. 
. SO the intensity ranges fro  one being 
the  to four being the greatest; is that 
rrect? 
A. That's my understanding of the rating 
t . 
. nd your reference in your report to 
the  IS health hazard rating refers to the 
anner uch rating that's on the triangle for  as 
opposed to the color form if you understand my 
question? 
A. I don't work with H IS ratings all 
the ti e so y recall of that is it's a dia ond 
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 t r  is r ti  lt  r s f r iffere t 
categories of health hazards acute effects or 
chronic effects long-ter  effects fla e ability 
 oss ZIFness those are the things off the top 
   i  red. 
Q. Okay among those particular among that 
particular rating syste  are you a are of hether 
there is any specific demarcation identifying or 
indicating that there are chronic health effects 
associated ith a particular product? 
. I'm sorry can you say that one ore 
. 
. re you a are under the standard that 
you have referred to here in your report, are 
there any indications of de arcations that give 
s  t    eference    ication  
t ere   erse  e ts   
ass ciate  it  t at articular r uct? 
. It is  recall t at t ere are es 
hich deal there is a category that deals ith 
t    ther ne ls ith i  
effects that ayor ay not be accurate but the 
point is it does constitute an irritant both by 
 the scie ce la  S S as ell as t e     
  infor ation  intended t  e  
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A That would be my understanding as well
Q And it indicates the severity of that
of skin TOJTS gee is slightly irritating
A Thats what it indicates
Q And the next one same tests its a
DRAZed test for TOJS R toxicology in eyes ask t
test subject was a rabbit
A Mildly irritating
A That is true
Q Do you have in I understanding of the
difference between slightly LOR mildly
irritating
A I do not have any particular
understanding of the difference
Q Okay And then the final one on there
acute inhalation L C 50 do you have any
understanding WLAF that means
A The L C 50 is not something that is I
guess that would be lethal concentration usually
thats referred to as an LD 50 meaning how much
of the stuffdo you have to get before you
experience death Im not sure if that leads the
L C concentration or refers to something short of
death or in terms of acute inhalation but it
generally refers to how much of it is required to
Page 133
generate a pretty big effect
Q Okay And then based on your testimony
there do you have any understanding of what
greater than 1005milligrams per LEET tier would
indicate
A It means that it must be more of that
particular amount then in a cubic litter of air
in order to generate the effect the L C 50
effect
Q Now looking at all these different
tests under section 11 do you have any
understanding of these test correspond to the H L
S rating we were discussing
A I would expect that we have a
connection but I donthave information on
tracking stuff from the section 11 information
too the H M I S rating I have not tried to do
that myself in terms of looking at the TOX KOLG
call results and going to ask saying thatsgoing
to give you an H M I S referring to the H M I S
rating from the TOJ Cole logical rating
Q Okay So you have no understanding as
to whether that greater than 1005milligrams per
leader designation correspondence to an MM rating
of2 3 or 4
34 Pages 130 to 133
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1 irritant the only point of the first one it is 1
2 certainly an irritant as the chemical as it would 2
3 be defined by the standards and by this hazards 3
4 rating system 4
5 Q Does it refresh your memory that 5
6 chronic effect may come with an asterisks or some 6
7 other marking after the marking of the health 7
8 hazard number 8
9 A No I donthave any recall about that 9
10 as I sit here 10
11 Q Okay Prior to opining about an H M I 11
12 S health hazard rating did you do anything to 12
13 refresh your memory on H M I S 13
14 A I didnt really offer an opinion here I 14
15 just referenced MRITly part of the phrase and 15
16 that is just thatsmy language but its also 16
17 echoing back the same language that SEC uses so I 17
18 dontthink this matter in contention Other 18
19 stuff in reference to the degree of the IR 19
20 instant that is the present in Oleoresin 20
21 capsicum So the point of that first opinion is 21
22 just to establish that it is an irritant in 22
23 accord to both commonly used DEFRNSs includin 23
24 OSHA definitions 24
25 Q Does the fact that the H M I S health 25
Page 131
1 hazard rating for the actual product you refer to 1
2 in your opinion sell buster two to four H M I S 2
3 rating does that change your opinion in any other 3
4 paragraphs an at all 4
5 A To the extent its SEC is not an 5
6 irritant its certainly an irritant its not as 6
7 much of a degree of an irritant it is an irritant 7
8 in hazard communication center and thatsthe 8
9 only meaning of that particular reference 9
10 Q Looking again at the MSDS Exhibit 10
11 No 102 and staying on or actually going on page 11
12 3 12
1313 A Okay
14 Q Do you have any familiarity with those 14
15 tests that are identified there 15
16 A I haventconducted those tests but Im 16
17 aware that those are tests to assess the impact 17
18 of exposure to certain chem KAMS everything from 18
19 nail polish to Oleoresin capsicum upon the skin 19
20 the rabbits or eyes of rabbits to see what 20
21 happens 21
22 Q So the first test we see there is the 22
23 testing the toxicology of skin and the test 23
24 subject was a rabbit is that how I read that is 24
25 that correct 25
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2 
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6 
Q. Does it refresh your memory that 5 . And the next one sa e tests i 's a 
chronic effect may come with an asterisks or some 6 R Zed test for O]S  toxicology in e es ask the 
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 hazard rating for the actual product you refer to 
 in your opinion selI buster two to four H MIS 
 rating does that change your opinion in any other 
 paragraphs an at alI? 
 .    t's     
 irritant it's certainly an irritant it's not as 
7 much of a degree of an irritant it is an irritant 
 i  r  i ti  t r  t at's t  
 only meaning of that particular reference. 
 Q. Looking again at the MSDS Exhibit 
11 No. 102 and staying on or actually going on page 
 3? 
 A. Okay. 
 Q. Do you have any familiarity with those 
 t t  t t r  i ti  t ere? 
 . I haven't conducted those tests but I'm 
1 7 aware that those are tests to assess the impact 
 of exposure to certain chern KA S everything froIT 
 nail polish to Oleoresin capsicum upon the skin 
 the rabbits or eyes of rabbits to see what 
 happens. 
 Q. SO the first test we see there is the 
 testing the toxicology of skin and the test 
 subject was a rabbit is that how I read that; is 
2 5 that correct? 
  
 e erate a rett  i  effect. 
 . y.      t  
      r t i    
 greater than 100.5 illigra s per  tier ould 
 i ate? 
6 .   t t it t    t t 
 rti l r t t  i   i  litt r  ir 
 i  r r t  r t  t  ff t t     
 ff ct. 
 . o , looking at all these different 
   ecti       
 t   t  t  t  t   L 
 S rating e ere discussing? 
 .   ex t t t    
 c necti  t I on't  i t  o  
 tr i  tuff fr  t  secti  11 i f r ti  
1 7 t  t   IS r ti  I hav  t tri  t  do 
18 t at yself i  ter s f l ki  at t e   
1  cal  r sult  a  goi  t  ask sayi  that's goi g 
2  t  i e  a   IS referri  t  t e  IS 
1 rating fro  t e T ] ole logical rating. 
2 . kay. So you have no understanding as 
23 t  t r that gr at r t  10 .5 illi r  per 
24 l d r designati  correspondence to an  rating 
25 of2,3,or4? 
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If there is statistically SN significant evidence
based on at least one study in accord with the
established scientific principles that acute
health effects may occur if exposed individuals
is it your opinion that the OSHA standards
require the product also to carry with it a
warning against chronic effects
A It is my opinion that the acute effects
renders the RIRPT to have TA target organ
identified be effective its not necessarily my
opinion that if there is dispute and there isnt
a scientifically valid study to suggest chronic
effects were frequent then I wouldn necessarily
hold a manufacturer to having to warn about
chronic effects if there is not a scientifically
valid study at least one scientifically valid
study saying chronic effects could occur yes to
target organ issue yes no to the chronic effects
if there is not one study that says there is
chronic effects from it
Q Are you aware of any STAPT TIS CLEEly
significant evidence at least one study conducted
with STEEBD if I can principles that chronic HEIR
effects could occur with exposure to Oleoresin
capsicum
Page 137
A I have not researched that issue and I
do not know
Q Is it your understanding that the
plaintiffs alleged injuries in this case are
acute or chronic adverse health effects from
exposure to Oleoresin capsicum
A Itsmy understanding that she EX PEX
she alleging that there is also chronic effects
ongoing and again to the extent there is not NA
particular study that demonstrates chronic I
wouldn hold the manufacturer to warning about
chronic effects Generally that benzene exposure
where you get an exposure over time and then
benzene you develop leukemia and something like
that
Q Okay Letsgo ahead and jump down to
paragraph 3 The Oleoresin capsicum is present
insufficient concentrations in the various Sabre
Red products sold by SEC and in the sell buster
form TLAGS in particular to render the sell
buster product the hazardous come bus ability and
in products quote 16910200 did I read that
correctly
A You did
at Exhibit 100 or the
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1 A That would be reasonable for one to 1
2 infer but I donthave I canttell you that a 2
3 certain amount of this refers to a certain rating 3
4 on MM 4
5 Q Okay H M I S 5
6 Q Okay Letsgo ahead and look back at 6
7 your report Exhibit 101 Page 2 now numbered 7
8 paragraph 2 You opine here that the OC compound 8
9 used by SEC well now actually I have a question 9
10 about that Do you base your opinions in 10
11 paragraphs 2 3 and 4 of the remainder of your 11
12 report on the MSDS that was for the product 12
13 different than SECs product 13
14 A It was the only one that was available 14
15 to me at the time that was complete so yes I did 15
16 base it on that However its contained in the 16
17 MSDS for the one there itself I believe the if 17
18 I recall correctly the sell buster product 18
19 identifies the sell buster productwhich is as 19
20 one causes irritation also identified it as an 20
21 irritant its also based upon the MSDS for the 21
22 sell buster product for the first page which I 22
23 did get had available to me at the time 23
24 Q And now that you have the third page of 24
25 the fir MSDS tha doesntchange your opini 25
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1 at all 1
2 A Its still an irritant 2
3 Q Just checking So whatsyour opinion 3
4 in paragraph 2 is it merely that the OC compound 4
5 is an irritant 5
6 A Its an irritant as defined by the OC 6
7 hazard communication standard and that renders it 7
8 a health hazard 8
9 Q Okay And you have REE quoted or 9
10 rather quoted the language from the OSHA standard 10
11 that wev already discussed here today 11
12 A Yes 12
13 Q And that includes the RIRPT that there 13
14 is a statistically significant evidentiary basis 14
15 from at least one study conducted in accord with 15
16 established and scientific principles that acute 16
17 and health EEFX may occur in specific VICHLDZ 17
18 A Yes and again on that once that study 18
19 has begun and once identified as an irritant I 19
20 didntoriginal study again once the 20
21 manufacturer says its an irritant I have to 21
22 reason to differ from with that SEC and say its 22
23 an irritant 23
24 Q Sure sure 24
2 5 Q Letshone in on this language again 125
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1 . hat ould be reasonable for one to 1 If ere is st s icaIly  significant evidence 
2 infer but I d 't have I c 't tell you that a 2 based on at least ne study in accord ith the 
3 certain a ount of this refers to a certain rating 3 esta lished s ie tific principles that acute 
4 on . 4 he th effects a  occur if e posed individuals 
5 . kay. H I ? 5 is it our o inion that the S  standards 
6 . kay. Let's go ahead and look back at 6 require the product lso to carry ith it a 
7 your report Exhibit 101. Page 2 no  nu bered 7 arning inst chronic ff ts? 
8 paragraph 2. You opine here that the OC compounc 8 . It is  i ion that the te effects 
9 used by SEC weIl now actuaIly I have a question 9 renders the IRPT to ha e   target a  
 about that. Do you base your opinions in  ide fied be e ive i 's  e y  
1 paragraphs 2,3, and 4 of the remainder of your  i ion that ift re is ispute and there i 't 
 report on the S S that as for the product   s i tifi Il  lid st  t  s gest r ic 
3 different than SEC's product?  ffects ere fre e t t en I l n't ss rily 
4 . It as the only one that as available    a turer   to arn t 
15 to e at the time that as co plete so yes, I did   fects    t  i ti  
 base it n t t. e er it's contained i  t e  li  t y t l t e i tifi ll  lid 
1 7 SDS  t e ne there its lf. I ieve t e if 1 7 t y i  r ic ffects ld r es t  
 I recall correctly the sell buster product  t r t rgan iss  es  t  the r ic ffects 
 identifies the sell buster product which is as    s  e   s t ere  
 e ca ses irritation als  i e tified it as a   r ic ffe t  fr  it. 
1 irritant it's also based upon the SDS for the  . re      IS  
 sell buster product for the first page which I  ica t de ce      
 did get had available to me at the time.  th  f   iples   M1~ 
 Q. And now that you have the third page of  e ts   th e  e  
 the first SDS that doesn't change your opinions  sicum? 
.~~~-~-4--------~-------------------~-----------~~ 
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 t ll?  
 . t's til   r t t.  
 Q. Just checking. So what's your opinion  
 in paragraph 2 is it erely that the OC co pound  
   nt?  
 . It's an irritant as defined by the C  
  i t        
  l  rd.  
 Q. Okay. And you have REE quoted or  
 rather quoted the language from the OSHA standard 10 
11 that we've already discussed here today?  
 . es.  
 Q. And that includes the RIRPT that there  
 is a statistically significant evidentiary basis  
 from at least one study conducted in accord with  
 established and scientific principles that acute  
 and health EEFX may occur in specific VICHLDZ? 1 7 
 A. Yes and again on that once that study  
 has begun and once identified as an irritant I  
 didn't, original study again, once the  
21 manufacturer says it's an irritant I have to  
 reason to differ from with that SEC and say it's  
 an irritant.  
 Q. Sure sure.  
5 Q. Let's hone in on this language again. 25 
  
.         
  . 
. Is it r r t i  t t t  
l i tiffs ll  i j ries i  t is s  r  
    l  f   
s r  t  l r si  psicum? 
. It's  ersta i  t at s e  EX, 
she's alleging t at there is also chronic effects 
ongoing and again to the extent there is not  
particular study that de onstrates chronic I 
uldn't   f     
 f ts. neral    x  
ere  et a  e s re er ti e a  t e  
benzene  develop leuke ia and so ething like 
t. 
. kay. et's go ahead and j  do n to 
paragraph 3. he leoresin capsicu  is present 
i ff  t t  i  t   abr  
 r t  l     i  t  sell b st r 
f r   i  arti l r t  r r t  sell 
t r r t t  z r   b  abilit  and 
in products, quote, 16910.1,200 did I read that 
correctly? 
.  id. 
Q. Looking bag at x i it 10  or t  
3  (Pa  1  t  137) 
1 for amoment 1
2 Q BY MR LLOYD Lets go ahead and to 2
3
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3
1 equivalent document that you have brought with 1
2 you today that is the 29 CFR 1012 0 regulations 2
3 Can you point me to where hazardous industrial 3
4 chemical is defined in this document 4
5 A I believe I can HAZ 5
6 Q I may have just missed it Im 6
7 wondering 7
8 A I guess the term of art that OSHA uses 8
9 hazardous not hazardous industrial check KAM or 9
10 health has hazard it is under the definition 10
11 section 11
12 Q Okay So as you sit here today there 12
13 is no definition of hazardous industrial 13
14 chemical 14
15 A I believe I typed that wrong it should 15
16 have just said hazardous chemical 16
17 MR OVERSON Are you pretty close to a 17
18 breaking point 18
19 MR LLOYD Never I did say 1230 it 19
20 shouldnttake me too long to get through it and 20
21 that will be a good breaking point 21
22 MR OVERSON Okay 22
23 Q BY MR LLOYD Im taking a long time 23
24 thinking and I need to think about what we need 24
25 to go through to speed thi up so bear with me 25
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to the back page
4 A Okay 4
5 Q Of your report Specifically paragraph 5
6 4 6
7 A Witness complying All right 7
8 Q The second sentence of paragraph had 4 8
9 you indicate the omission of this required 9
10 information on the product label was a proximate 10
11 cause of Ms Major injury A couple questions 11
12 about this what your definition of proximate 12
13 cause 13
14 A It means that it was one of the causes 14
15 that which caused Ms Major to be expose today 15
16 the chemical on the day in question and not the 16
17 sole cause but one cause which caused her it was 17
18 the next thing that was going to happen after the 18
19 omission of that particular information 19
20 Q And just so that the record is clear 20
21 the required information that were discussing am 21
22 I correct is that the information you would have 22
23 expected under the OSHA standards would be 23
24 identification of the target organs as previously 24
25 described in your report 125
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A That is true The target organ the SEC
documents do list scan DA nice he had but they do
not list the RES approximate PIER RA inventory
TRAKT
Q On the label
A On the label itself
Q So proximate cause is that a term of
art thatsused frequently in ergonomics
A No its a term I use from attorneys
next thing to happenIm not intending to have
that particular legal meeting except this
happened except that allowed this sort of thing
to happen as well
Q Do you have any understanding that the
term proximate cause requires any level of bad
question
Do you have any understanding as to
for example youve indicated that your
understanding of proximate cause does not require
that it be the single sole cause of the injury
A I believe I would say that would be
true
Q Okay So there can be multiple causes
A I think I would agree with that
Q Do you have NRI understanding as to the
Page 141
term proximate cause whether that requires a
certain level of percentage that could be
attributed to that cause as compared the others
MR OVERSON Objection he said he
already said he didntinclude the term as a
legal issue or legal term So I think you are
asking him to render a legal opinion about what
the meaning of that term is under the law And
he just said thats not what hes referring to
Q BY MR LLOYD Well thats fine Im
just trying to get gives
A I gave you my definition ofproximate
cause before I cantquote you the definition of
Idaho law as a difference I dontknow what
Q Eye ignoring Idaho law your definition
of proximate cause as you have placed here in
your report in order to be a proximate cause must
that particular item instance act omission
comprise more than one percent of the causation
chain towards that injury
A Im not able to put a quantification
number on it I would say as a for instance the
fact that Billie Major got up and went to work
that day was not a particular proximate cause of
the accident happening So far enough back
36 Pages 138 to 141
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is that they could have done differently in
particular circumstances and I OSHA acts and
database facility tree and figure out what
condition you could have changed to make the
accident not occur if they only come up with a
single one that they could change thatsnot the
best answer for me
Q Okay In this particular case you
played reference to in what youvejust told me
you made reference to an analyzing things that
someone could have done differently Does that
include in this particular case the plaintiff
A Certainly she could have not shown up
for work that day
Q Okay Does that include the I doc
employees
A There are other people who could have
done things differently yes
Q The trainers
A That is true
Q Having reviewed Ms Major deposition
testimony you are aware that she had undergone
several trainings with OC products prior to her
final exposure is that correct
A I believe I understand that to be the
Page 145
case
Q She had taken classes both classroom
classes and field classes regarding OC exposure
A I dontreally recall all the different
times that she was trained prior and LAUL the
different things received in the products OC
products over the course of an extended period
and she received multiple FRANGS my recall my
best recall is about two or three of happened
prior to the this particular exposure of the sell
buster product but that would be my best recall
Q Do you recall from her testimony that
at one point she indicated to one of the the I
doc trainers that she wasn sure if she should
go through with that training in light of her
recent illness
A I recall that was a question that got
tossed around and the I doc people said that if
she told us we would have EMT SEMD he had he
from this particular EMT R EX SEMed so I dont
know whether the where the actual facts on the
case are and if who would have done who is
telling the truth there or who has the best
recollection the most accurate who has the most
accurate recollection ofwhat actually happened
37 Pages 142 to 145
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1 proximate cause of the accident happening or her 1
2 exposure was a number of things but among them 2
3 the fact that the target organ information was 3
4 not HAN on the label LOR render visible to her or 4
5 the other trainers at the time 5
6 Q Under your definition then much 6
7 proximate cause do you have any opinions as to 7
8 other causes other proximate causes for 8
9 Ms Majors JIFRNtle I really haventtried to 9
10 analyze that and would not feel comfortable 10
11 trying to recall all the information I looked 11
12 into that regarding that particular opinion off 12
13 the cuff so I would need some time to review the 13
14 stacks again Everything I did read and 14
15 everything I did not read in the last 24 THOURS 15
16 again and other materials I want to go through 16
17 the definition or the depositions which I have 17
18 not yet seen final copies of and analyze that to 18
19 answer that question so I haventdone that 19
20 Q Would you also be interested in seeing 20
21 the depositions that you have not yet been 21
22 provided 22
23 A Certainly to the extent that there is 23
24 depositions out there which deal with CLIEBLT R 24
25 liabil issues ifcertainly something which 25
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1 just deals with damages in the case then I dont 1
2 know that I would necessarily need to rely upon 2
3 that but to the extent there is is final 3
4 depositions I would want to STLEE that as well 4
5 Q Do you have any opinions in this case 5
6 as to whether there are other proximate causes to 6
7 Ms Majors injury 7
8 MROVERSON Asked and answered 8
9 THE WITNESS I dontknow how that 9
10 differs 10
11 Q BY MR LLOYD Before I asked you 11
12 perhaps what others there are what others you are 12
13 aware of under your definition now Im asking 13
14 simply if you are if you have any opinion has to 14
15 whether their exist any other proximate cause his 15
16 or if this is the sole proximate cause 16
17 MR OVERSON Asked and answered 17
18 THE WITNESS I think that in any 18
19 accident that happens there is will there are 19
20 multiple places people could have taken certain 20
21 actions do do different things outcome sometimes 21
22 worse sometimes a lot less damage But in terms 22
23 of the safety analysis moldsesthat I teach in my 23
24 TRIL safety class in particular I always 24
125 encourage people to try to think through what it 125
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1 proximate cause of the accident happening or her 
2 exposure as a nu ber of things but a ong the  
3 the fact that the target organ information as 
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back
THE WITNESS If she had an orientation
to being very opposed to being exposed to
chemicals generally just from her own background
then that would have been something which could
have changed the outcome in this case as well as
I just repeated noted earlier her level of
decision inclination ofbeing exposed again as
well as the I dock trainers excusing her would
both be functions as well intertwined with the
fact that the label was incomplete according to
the OSHA requirements so but everybody brings tl
background assign a particular percentage Im
Q You made reference to quote her level
ofdisinclination what do you mean by that
A There are certain people who are just
disinclined to be exposed to any chemicals that
they are aware of in their environment if she had
come in being more opposed relatively careless
with regard to being EX FOEBSD those kinds of
chemicals if she had brought in her background
was one where she was more or I should say less
stringent in her opposition of being exposed to
chemicals then independent of what the label said
she might have done differently the receptive tea
Page 149
of the I dock employees their reactions to it
that could be different but we know in this case
she recalls objecting the I dock trainers dont
recall her making protest so apparently it didn
register strong flee BLEEly approximate enough
with her that to have a result
Q So when you are referring to her level
of disinclination you are referring to the
strength with which she perhaps verbally objected
to the exposure you are not talking about her FIS
see logical reaction her pre dispose fees logical
reaction
A Im talking about the strenuous NESZ
she objected the reaccept
Q Both which could be proximate causes
A I would say both of those could also be
proximate causes in the way Ive used the term
Q So as youvetestified you have at
least read in some of the deposition testimony
that Ms Major had taken classes on the use and
effects ofOC
A She had been through training programs
previously I dont know ifall of them were SEC
programs or just some of them but she had been
trained on OC prior to the sell buster incident
38 Pages 146 to 149
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1 Q BY MR LLOYD Assuming for a moment 1
2 that Ms Major recollection is the most 2
3 accurate its your understanding then that she 3
4 testified that she indicated to somebody one of 4
5 the trainers that perhaps she should not go 5
6 through that training that exposure ask she they 6
7 told her to go ahead and do any it anyway 7
8 A I would have to look back at her 8
9 deposition to say exactly what it was 9
10 Q And if I doc trainer told her to go 10
11 through the training regardless ofLER recent 11
12 illness would that be in your definition of 12
13 proximate cause included in those number of 13
14 proximate causes 14
15 A Im sorry let me have that question 15
16 again 16
17 Q Sure Again focusing only on your 17
18 definition of proximate cause in setting aside 18
19 any legal analysis on that based on the 19
20 terminology proximate cause that you have used in 20
21 your report would the fact that Ms Major was 21
22 instructed to go throughwith the training even 22
23 when she alerted her trainers that she had a 23
24 recent respiratory illness would that fact be 24
25 counted into your basket of proximate causes 25
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1 A I think that would be an additional 1
2 proximate cause of the accident Of course being 2
3 the strength new with usness ofwhich she AU 3
4 TLERTD the trainers and receptive tea of the 4
5 trainers doing something different with her 1 5
6 would both attribute back to whether the warning 6
7 label on the product is complete and I would say 7
8 both of those reactions are not independent of 8
9 having the appropriate hazard product on the 9
10 product but certainly if IDOC doc had taken a 10
11 much more TLEEN YENT shall we say standard for 11
12 excusing people then even with the labelled 12
13 differently than what it was a different outcome 13
14 might have occurred thats all speculation 14
15 Q Or for that matter based on what you 15
16 just said ifMs Major had more VEEP mentally HOP 16
17 add mentally protested to her exposure to OC that 17
18 could also be a proximate cause 18
19 MR OVERSON Objection I think you 19
20 misstated that try that again timeIm not 20
21 MR LLOYD Im not going you are 21
22 trying to ask a question Im trying to be helpful 22
23 here Im not trying to be a jerk try your 23
24 question again you are not asking the question 24
25 you think you are YCHBLT ROOCHLT re read read 25
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yes
Q And she had exposure to OC prior to the
CLL INS sell buster
A Itsmy understanding she had exposure
to
Q Do you recall in the testimony a
particular occasion where Ms Major went through
a training and sat down to watch the other I doc
employees go through their training and laughed
at them has they came out
A I dontrecall something about her
laughing at them if you could refer plea to the
particular deposition I would like to refresh my
recollection on that before I get any more
specific
Q But you are aware that she experienced
exposure to OC prior to the I guess what wer
referring to as the sell buster incident its my
understanding that she had been expose today the
HOEK containing products before sell buster
formulation
Q She knew the effects on the eyes one
would assume
A Again if she being exposed outdoors
then she wouldnthave and again concentrations
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1
2
3
4
5
6
7
8
9
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12
13
14
15
16
17
18
19
20
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23
24
25
and containment of the her holding of the
formulation within an enclosed place would be
something that I would expect to be novel to her
in terms ofthe sell buster formulation
Q But generally speaking with her
exposures and classroom training would you expe
or not expect that she would have some
understanding of the effects off the eyes
A I would expect that she be shot in the
face that she would have an understanding that
would mean something which would be the strong
irritant to the eyes
Q The STAM thing with the skin
A That would be true
Q The STAM thing with respiratory TRAKT
A The respiratory TRAKT would be
something to the extent it had an effect on her
simply because the previous training my
understanding is wer not in enclosed space
where they were trying to build up the
concentration of OC product in enclosed space the
other ones where she did get exposed were where
she was either shot or whatever else outside or
not in as enclosed space the particular day in
question she was asked to go into the sell and
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1 asked to be exposed to an atmosphere containing
2 significant levels of OC again I cant quantify
3 that but enough to cause reaction to her and to
4 the other SDPOLGS then she also my understandin
5 is waited in the same general area and place
6 without great ventilation and was exposed to more
7 of the product for an extended period of time not
8 intentionally but just because of a lack of
9 adequate ventilation in that particular general
10 area
11 Q We can pull out the testimony if we
12 need to but I think this question should be
13 answerable without doing that
14 If Ms Major had on prior occasions
15 witnessed other individuals coughing as a result
16 of exposure to OC and herself had the reaction of
17 coughing as a result of exposure to OC would you
18 expect or would you not expect that she would
19 have some knowledge or idea of the respiratory of
20 effects of OC or even TA OC has respiratory
21 effects
22 A I would expect she would have some
23 awareness that it could have an acute effect
24 Q And the enact that she never the less
25 went through theOexposure whether by her own
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1 volition or the instruction of the I doc
2 instructors at the incident with the sell buster
3 would TA potentially be under your DECHGS an
4 proximate cause
5 A Im sorry say that again or can I have
6 it read back
7 The reporter read back the requested
8 testimony
9 MROVERSON Vague
10 THE WITNESS Well again we talked
11 about I mean she didnthave to show up for work
12 that day she could have stayed home She could
13 have refused to go into the cell the trainers
14 could have done differently a number of things
15 could have also occurred You know thatsone
16 of the uses of the safety analysis techniques
17 that I referenced earlier to try to figure out
18 why is it the person got expose today the
19 long term problem and in this particular case
20 there is a number of factors and the her her not
21 standing firm and saying pounding the table and
22 saying Im not going in there because I have had
23 a RIS peer rare inventory issue with NIS in the
24 past yeah thats one possible way that she could
25 have avoid TD the exposure which caused her I
39 Pages 150 to 153
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1 yes.  
2 Q. And she had exposure to  prior to the 2 
3 C  INS se l b r? 3 
4 A. It's my understanding she had exposure 4 
5 to. 5 
6 . o you recall in the testi ony a  
7 particular occasion here s. ajor ent through  
8 a training and sat down to watch the other I doc  
9 e ployees go through their training and laughed  
 at the  has they ca e out?  
 . I n't re ll s ething t er  
 laughing at the  if you could refer plea to the  
 particular deposition I would like to refresh my  
 recollection on that before I get any ore  
 specific.  
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1 dock employers her trainers could have said look 1
2 majors had problems with this stuff we know she 2
3 KOFS a lot letsexcuse her from this that could 3
4 have also hand Bost both of those likelihoods are 4
5 also influenced by the information on the product 5
6 LAB influenced by a lot of things But one of 6
7 the proximate causes was the fact that the target 7
8 organ information not on label 8
9 Q Do you have NRI knowledge of whether 9
10 Ms Major even saw the label with respect to the 10
11 exposure to the sell buster product 11
12 A I dontknow if she was ever EX FOEXD 12
13 the label It is my understanding or its my 13
14 reading of the OSHA regulations that the 14
15 employers are required by applicable regulation 15
16 toss provide that information to the in employees 16
17 and to make sure that they understand the stuff 17
18 that is actually on the label but I dont have 18
19 information about whether SLE actually ever saw 19
20 it I dontthink she was asked that question in 20
21 her deposition 21
22 Q So according to your testimony just now 22
23 it would be the employers obligation to present 23
24 her with that information prior to exposing her 24
25 A It would be my testimony th the 25
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1 employer had the obligation to to run through the 1
2 that you have that was actually on the label with 2
3 the employee 3
4 Q BY MR LLOYD Would that obligation 4
5 only extend to whatson the label or would it 5
6 extend to the MSDS sheets what provided with 6
7 the training materials what provided with any 7
8 other materials offered by the manufacturer 8
9 A Well under the OSH OSHA regulation TS 9
10 the employer has the obligation to provide the 10
11 MSDS to make it available to the employees the 11
12 OSHA regulations and OSHA interpretations 12
13 regarding the target effect on the able recognize 13
14 the fact that its frequently the on the case 14
15 when the if employ needs to know the information 15
16 is not readily available and thatswhy it is 16
17 required to be on the product label and not just 17
18 MSDS and YES msds is another way she could haw 18
19 determined that 19
20 Q So that was hatch long answer GIEM 20
21 going to backup a bit into that answer 21
22 I thinkwev established that its 22
23 your opinion that her getting up in the morning 23
24 and going to work you do not consider that a 24
25 proximate cause of her injury is that correct 125
Page 156 f
A I that is true
Q But you do consider the omission of the
required information on the product label as you
have put it here in your report to be a proximate
cause
A That would be true both in the effects
on her as well upon the I dock training NERS
Q So please understand Im trying to
understand where that line is drawn in your mind
where something that constitutes a proximate
cause and something that does no constitute a
proximate cause Can you provide any other
explanation of your definition of proximate cause
that will help me figure that out
A No
Q Okay But have we established that the
potential proximate cause of her injury would be
whether she objected strongly enough to her
exposure to the OC product to her trainers
A Im sorry I need that one more time
Q Have we established that one potential
proximate cause under your definition would be
whether or not Ms Major effectively communica
her desire to avoid exposure the OC product
MR OVERSON Objection vague
Page 157
THE WITNESS Again she you know as
she stamps her foot and says Im not doing that
training today thatsone way she can avoid
exposure my understanding she already been run
into discipline problems with her employer so
she disinclined to be noncompliant with what
the employer is saying So she trying to do
what they ask her to do I hope And the her
level of or her willingness to refuse an
instruction on the part of her employer to do
that is going to be decreased by the fact that
she already got a couple strikes against her in
terms of her discipline issues
Q But never the less would that be
considered a proximate cause under your
definition
A And you are saying would that and I
need what that is
Q IfMs Major did not protest strongly
enough to the I doc instructors would that be
under your definition a proximate cause of
Ms MAIRNLGS injury
A You know I cantsay that I cant
identify that without knowing what the
interaction was between the trainers and
40 Pages 154 to 157
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1 dock e ployers her trainers could have said look 
2 majors had problems ith this stuff e know she 
3 OFS a lot let's excuse her from this that could 
1 . I that is tr . 
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4 have also hand Ost both of those likelih ods re 
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5 c e? 
6 . hat o ld e tr , oth i  the fects tl 
7 the proximate causes was the fact that the target 7 n her s  pon the I ck training . 
8 organ information not on label. 8 . SO lease derstand I'm tr ing to 
9 Q. Do you have NRI knowledge of whether 
10 s. ajor even saw the label with respect to the 
11 exposure to the sell buster product? 
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 other materials offered by the manufacturer?  
 A. ell, under the OSH OSHA regulation TS  
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13 regarding the target effect on the able recognize  
14 the fact that it's frequently the on the case  
15 when the if employ needs to know the information  
 is not readily available and that's why it is  
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brought today
Q If she never saw the label how would
that have helped her
A If she did not see the label it would
not have impacted her behavior Ill agree with
that It may have impacted the behavior of I doe
employees either responding to her request to be
excuse you had andor sharing that information by
the people whom they were about to expose but
again wer talking hypotheticals well beyond the
range of the facts of the case
Q Okay The same question about the I
doc instructors could they have not obtained that
same information from their trainings and from
the MSDS sheets such that they would be
knowledgeable enough to know that would be in
effect when MsMajor objected
A There were alternative method or
alternative method to learn that same information
in the approximate MSDS and the HOESH target
organ information because not everybody will go
back and look at the MSDS frequently enough so
yes there were other avenues to learn that no
they did not learn that and the answer of the
information on the product label itselfwas both
Page 161
an OSHA violation and my view proximate cause
her ultimately being exposed
Q Im sorry Darwin Im trying to finish
up I want FO get through the report here When
you say you just said in fact can I have you read
the last portion of the LAT
The reporter read back the requested
testimony
Q BY MR LLOYD So is it your opinion
that the lack of the allegedly required
information on the label was a proximate cause as
you just said of her ultimately being exposed or
a proximate cause of her injury as youve
indicated in your report
A Are you asking me difference between
exposure or injury
Q Im asking if is there TA distinction
between exposure and injury
A In my mind no
Q Okay
A I believe her exposure caused the
injury of which she complains That of course is
a TOJ CLOJ call determination and
Q Are you a toxicologist
A Im not rendering a TOBLGS JOLG gist
41 Pages 158 to 161
Page 158
1 Ms Major saying how much more protesting would 1
2 have taken if she just fill CLEE RUCHS to do it 2
3 what that would involve so I dontknow how much 3
4 resistance she would have had to do to actually 4
5 cause HEM them to excuse her that day so I cant 5
6 answer that 6
7 Q So you cannot identify with any 7
8 certainty or exclude with any certainty any other 8
9 potential circumstance that would be considered 9
10 or not considered a proximate cause 10
11 MROVERSON Objection 11
12 Q BY MR LLOYD According to your 12
13 opinion 13
14 MROVERSON Compound 14
15 THE WITNESS I think Ive testified 15
16 before that there are a whole lot of factors that 16
17 go into any particular accident and this is the 17
18 if fact that the target organ effects not listed 18
19 on the product label is one of the cause not the 19
20 only cause 20
21 Q You just don have enough information 21
22 is that what you are saying 22
23 A I would have needed to see her in 23
24 action I would have needed to see the trainers 24
25 in action I dontthink thats a noble thing 25
Page 159
1 Q You dontthink that whatsa noble 1
2 thingIm sorry I lost that last part 2
3 A I dontthink its a no I able I dont 3
4 think it no able how much more she pro tested and 4
5 how much more the trainers let her off retrospect 1 5
6 actively Target organ she would have recognized 6
7 yes its cause he me the problem yes sir major 7
8 has a RES PIER 8
9 Q If she never saw the label how would 9
10 she recognize that 10
11 A Ifshe didn see the label she may 11
12 have again she may not have seen the sell buster 12
13 if she knew the HOEK containing product and 13
14 familiar with the FA 14
15 Q Couldntshe have also gotten that same 15
16 basis from the MSDS sheets 16
17 A Thats that good question If those 17
18 MSDS sheets had been readily available to her and 18
19 easily obtained then yes and that is again an 19
20 OSHA requirement that be the case But again 20
21 OSHA also recognizes that in the real world 21
22 people also need hazard information about 22
23 chemicals has they are using the product and MSDS 23
24 may not be readily and target organ effects 24
25 thats what the hazard communications that I 25
000893
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1 s. ajor saying how much more protesting would 
2 have taken if she just fill CLEE RUCHS to do it 
3 what that ould involve so I d 't kno  how uch 
4 resistance she would have had to do to a t lly 
5 cause E  them to excuse her that day so I c 't 
6 ans er that. 
7 Q. SO you cannot identify with any 
8 certainty or exclude with any certainty any other 
9 potential circumstance that would be considered 
 or not considered a proximate cause? 
1 R. OVERSON: bjection. 
2 Q. (BY R. LLOYD) According to your 
13 opinion? 
4 R. OVERSON: o pound. 
 E ITNES : I t ink 've te fied 
 before at there re a hole lot  a tors t at 
 go into any particular accident and this is the 
 if fact that the target organ effects not listed 
 on the product label is one of the cause not the 
 only cause. 
 Q. You just don't have enough information 
 is that what you are saying? 
 . I l    t  s  r i  
 ti . I l  e  to  t  trainers 
 in action. I don't think that's a noble thing. 
e  
1 Q. You don't think that what's a noble 
 thing I'm sorry I lost that last part? 
 . I don't think it's a no, I able I don't 
5 
6 
 think it no able ho  uch ore she pro tested and 
  r  t  tr i r  l t r ff r tr t 
actively. Target organ she would have recognized 
7 yes it's cause he me the problem yes, sir major 
 as a  I . 
 Q. If she never saw the label how would 
 she recognize that? 
 A. If she didn't see the label she ay 
 have again she may not have seen the sell buster 
 if she knew the HOEK containing product and 
 fa iliar it  t e A. 
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 OSHA also recognizes that in the real world  
 people also need hazard information about 22 
 chemicals has they are using the product and MSDS 23 
 may not be readily and target organ effects 24 
25 that's hat the hazard co unications that I 25 
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caused her to be exposed
Q Well I appreciate you making that
clarification Im wondering if that
clarification has any impact on the final
sentence that you have there in paragraph 4 that
reads had this information been included on the
product label has the hazard communication
standard required the causal relationship between
Ms Majors exposure to the various OC containing
SAB BER read products and respiratory would haN
been apparent to her and more readily apparent to
the I doc personnel in charge of the training
Are you competent to testify that there is a
causal relationship between LER exposure and her
persistent respiratory difficulties
MR OVERSON Asked and answered
THE WITNESS I think I clarified that
before she complaining Im expect that other
people will come in and address that issue as to
whether or not the OC containing product is able
to cause and a persistent respiratory chronic
condition Im not making that claim myself Im
saying the answer of the information did cause
her to be exposed or was one of the causes of her
being exposed and if she had had that information
Page 165
if the IDOC doc people would have had that on th
label they would not have put her through the
training
Q But you have no opinion has to a quote
unquote causal relationship between exposure and
persistent REES PIER RA inventory defendants
MR OVERSON Asked and answered for
the third time
Q BY MR LLOYD Im trying to get
clarification hesmodifying his report while
hes sitting here I need
MR OVERSON Youveasked that
Q With respect to different sentences I
would say
A I will say here that the clarification
that you asked for 1 was intending to indicate
that the answer of the in information caused her
to be expose today the product and I will leave
that the that medical causation and TOJ KOLG
Q Would youmodify the last sentence in
paragraph 4 of your report and if so how
A I dontthink I would I think it
stands as it reads fairly well and I think in her
case she did get experience did get exposure to
the product she did have acute respiratory
42 Pages 162 to 165
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1 opinion in this case But I believe what SLE 1
2 testified to in terms of her issues after she was 2
3 exposed 3
4 Q And you previously testified that you 4
5 have no medical training 5
6 A That is true Im not making a 6
7 determination Im not doing TA dose response 7
8 opinion here that she that the exposure caused 8
9 the symptoms of which she complained but given 9
10 her own testimony Im basing the fact that the 10
11 injury in which she complains happened after in 11
12 close time after and after was caused both her 12
13 exposure as well as her injury 13
14 Q So you are opining that her exposure to 14
15 OC caused her injury 15
16 A No if you are asking for that 16
17 particular distinction Im just saying caused her 17
18 exposure I guess if thatswhat you are trying to 18
19 get at it caused her to be exposed the sell 19
20 buster EX and intensely exposed FO R a short 20
21 period of time and exposed sort of background 21
22 levels of it for more than an hour 22
23 Q Are you comfortable testifying based on 23
24 your knowledge and experience on ergonomics an 24
25 engineering that exposure to OC on any level will 25
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1 cause a chronic long term adverse health effect 1
2 A No I think thatsjust what I clarified 2
3 is that time not given that kind of dose response 3
4 TOJ CLOJ call opinion I expect that to be 4
5 addressed by the folks and Im not making that 5
6 opinion Im making a layman inference if you 6
7 will with respect to toxicology that she CHSZ 7
8 exposed and experienced projection after she was 8
9 EX SXOESD those have continued 9
10 Q So your statement in the report the 10
11 omission of this required information on the 11
12 product label was a proximate cause of Ms Majors 12
13 injury do you stand by that statement 13
14 A Well would you modify that as youve 14
15 tried to enumerate here and say its a proximate 15
16 cause of her exposure which she complains has 16
17 caused her injury 17
18 Q And you would make that modification 18
19 because you do not feel that you are medically or 19
20 scientifically qualified to associate her 20
21 exposure with her acute I mean chronic long term 21
22 adverse health effect or injury 22
23 A Iwas not careful enough in the wording 23
24 and I did not intend to convey TOJS KOLG logical 24
125 opinions andor medical opinions to the the 125
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4 Q. And you previously testified that you  la ification as  i pact  the inal 
 ha e o e ical trai i g?  sentence that you have there in paragraph 4 that 
 . hat is true. I'm not aking a  reads a  s for a io   lude   the 
 deter ination I'm not doing   dose response  roduct la l as t   i tion 
 opinion here that she that the exposure caused  st r  re ired t  s l r l tions ip t e  
 the symptoms of which she complained but given  . ajors osure t  t  rious  t i i  
 her o n testi ony I'm basing the fact that the    rea  r cts  r ir t r  l  v{ 
 injury in which she complains happened after in  been apparent to her and ore readily apparent to 
 close ti e after and after, as caused both her  the I doc personnel in charge of the training? 
 exposure as well as her injury.  re you co petent to testify that there is a 
 Q. SO you are opining that her exposure to   re a ions    s re   
15 C caused her injury?  ersiste t res irat r  iffic lties? 
 . o if you are asking for that  . : s e   r . 
17 particular distinction I'm just saying caused her   I : I t i  I l rifie  t t 
18 exposure I guess if that's hat you are trying to  re e's ing 'm    
 get at it caused her to be exposed the sell  people ill co e in and address that issue as to 
 buster EX, and intensely exposed FO R a short 1  t   t t   t i i  t i  l  
 period of time and exposed sort of background  t     r i t t r ir t r  r i  
 le els  it  re t a   r.  condition I'm not aking that clai  yself I'm 
 Q. Are you comfortable testifying based on  saying the ans er of the infor ation did cause 
24 your knowledge and experience on ergonomics and  her to be exposed or as one of the causes of her 
25 engineering that exposure to OC on any level will  being exposed and if she had had that infor ation 
    
 cause a chronic long ter  adverse health effect?  if t e I  c e le l  a e a  t at  t e \ 
 A. No I think that's just what I clarified           
 is that ti e not given that kind of dose response  trai i g. 
 J J call opinion I expect that to be  . ut you have no opinion has to a quote 
 addressed by the folks and I'm not aking that  unquote causal relationship bet een exposure and 
 opinion I'm making a layman's inference if you  persistent  I   inventory defendants? 
 will with respect to toxicology that she CHSZ  . N:   r   
 exposed and experienced projection after she was    e. 
     ti d.  Q. (BY R. LLOYD) I'm trying to get 
 Q. SO your statement in the report the  clarificati  e's if i  is re rt ile 
11 o ission f this required infor ation on the  e's sitti  ere I eed? 
12 product label was a proxi ate cause of s. ajors 12 . N: ou've  t at. 
 injury do you stand by that statement?  . ith respect to different sentences I 
 A. ell, would you modify that as you've  l  say? 
15 tried to enu erate here and say it's a proxi ate  . I ill say here that the clarification 
 cause of her exposure which she complains has  that you asked for I as intending to indicate 
 caused her injury. 1  t t t  s er f t  i  i ti   r 
 . nd you ould ake that odification  t   s  t  t  r t  I ill l ve 
19 because you do not feel that you are medically or   t  t t i l c usati    LG. 
 scientifically qualified to associate her  . ould you odify the last sentence in 
21 exposure with her acute I mean chronic long term  paragraph 4 of your report and if so how? 
 adverse health effect or injury?  .  on't t i  I uld. I t i k i  
 . I as not careful enough in the ording  stands as it reads fairly ell and I think in her 
 and I did not intend to convey TOJS KOLG logical  case she did get experience did get exposure to 
25 opinions and/or medical opinions to, the, the 25 t    i   c t  spir t r  
 (Pa   t  65) 
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Page 166 Page 168
1 infection ask SHUN and also had persistent 1 you recognize that document
2 chronic EEKTS effects in addition to that she 2 A I do
3 associates she didnthave those effects before 3 Q What is that document
4 land she has them after the fact she 4 A That was an affidavit I prepared in
5 associating that with her and I give KREED dense 5 regard to the issue ofwhether or not the chronic
6 to that particular belief and Ill let people 6 label on the case was subject to the OSHA
7 other people DWEEL with medical and TOX SKOJ YEE 7 requirement for target organ effects
8 issues ofthat issue 8 Q Okay Go ahead and turn to page 3 of
9 Q Okay What I would like to do at this 9 that document
10 point is break for five and Im going to 10 A Okay Witness complying
11 determine whether I have anything else and if I 11 Q Is this that your signature towards the
12 dontthen Illbe done and you can I dontknow 12 bottom
13 if you plan on deposing the witness at all we can 13 A Yes
14 do that at that time or take a lunch break if 1 14 Q And whose signature is there do you
15 determineImnot done 15 know the person who signed this as a notary
16 MR OVERSON Im1 need to be eatIm 16 public
17 in therapy If I determine Im not done take a 17 A No it was somebody at a hotel where I
18 lunch break 118 was staying and I was at a conference where I
19 A recess was had 19 needed presenting the paper and I needed a
20 MR LLOYD Back on the record 20 document not TAR rise I had and somebody did
21 Q BY MR LLOYD Dr Purswell before we 21 Q This is peculiar line of questioning I
22 went on a break we were going through your 22 donthave the TORG document in front ofme Did
23 report I think I may be have one wrap up 23 this individual affix material stamp or EM boss a
24 question on that report and then wellmove on to 24 not tear RAL not tear RALmark on to the documen
25 TA different item In order to do that I have to 25 that you sign
Page 167 Page 169
1 know where I put your report thats Exhibit 101 1 A I dontrecall any mark It was I was
2 So as youvetestified there maybe other what you 2 trying to get out the did door to leave after a
3 define as proximate causes for Ms Majors 3 conference and my recollection is that I had
4 exposure to OC products SEC OC products 4 gotten the language ironed out with Mr Overson
5 A I would say thats correct 5 and I was just going down there to get the
6 Q But as you sit here today you cannot 6 document notarized and I didntpay any attention
7 identify what those other proximate causes are if 7 to what the notary did to this document
8 any exist 8 Q Do you have the TORG of this document
9 A We had a long discussion about that 9 or did you produce that to Mr Overson
10 And I thought I had Im not saying I could do 10 A I dontrecall any more
11 it exhaustively and I am not sure I can allow a 11 MR LLOYD Darwin do you recall if you
12 certain percentage responsibility for each 12 received the original of that
13 proximate cause but I think we did that 13 MR OVERSON Sitting right here right
14 Q I think you just asked the question 14 now I dont
15 that I was going to ask so I wontask it again 15 Q BY MR LLOYD And the reason I ask
16 Following your report in this case you 16 Im looking at the copy Ive provided and I dont
17 were also asked to complete an affidavit do you 17 see a not TAR RAL stamp or mark indication on
18 recall that 18 that document
19 A Yes 19 A I dontsomebody staying in the star
20 Q And that was recently 20 wood four points and at the bath more in bath
21 A Within the last couple ofweeks 21 more by the airport and I had the office manager
22 Q Okay Im going to go ahead and mark 22 and if you need to call them up and say in fax
23 NIS as Exhibit 103 23 them back a copy of that signature does anybody
24 Exhibit 103 marked 24 not TAR rise documents that looks like that but
25 Q BY MR LLOYD Okay Dr Purswell do 2 5 bath more four points the B W airport
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2 chronic  effects in addition to that she 2 
3 associates she didn't have those effects before 3 
 l  s  s t  ft r t  f t s e's !  
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6 t  t t ti l  li   'll l t l  6 
7           
8 i  f t t i ue.  
 . .       t   
 i t i    i   'm i  t   
 t i  t    t i  l   i    
 n't  'll       n't   
       itness  l     
  
 i  t t ocument? 
.  o. 
.    cument? 
. That as an affidavit I prepared in 
regard to the issue of hether or not the chronic 
label on the case as subject to the  
re ire e t f r tar et r a  effects. 
. ay.  a ea  a  t m t  a e  f 
 u ent? 
. kay. ( itness co plying.) 
. Is this that your signature to ards the 
ttom? 
. es. 
  t t t t t ti  r t   l  r  ifI  .  se si at re is t ere   
  t  rs   si  t is s  t r  
 blic? 
 t r i  I'm t ne? 
 . : I'm I  t   t I'm 
   r py.    'm     
 l  r k. 
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 . o, it as s e  at a tel ere I 
 s st i   I s t  f re ce r  I 
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 c e t t  rise I a  a  s e  i . 
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 ort.  t i          t is i i id al affi  aterial sta  r  ss a 
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1  e  t  t t at's i it . 
2 So as you've testified there aybe other hat you 
3 ne  i ate ses  . rs 
4 s re   ts   cts? 
5 .  ld  at's r ct. 
6 . t   it r  t   t 
7 identify hat those other proximate causes are if 
  ist? 
9 . e had a long discussion about that. 
 nd I thought I had. I'm not saying I could do 
 it ti l   I  t re I  ll   
12 t i  ta e si ilit    
13 i at   t  t in  e i  t t. 
 . I t in   just  t e ti  
 that I as ing t  as  s  I n't as  it a ai . 
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. I don't recall any ark. It as I as 
trying to get out the did door to leave after a 
ere ce   ll ti  i  t t   
tt  t  l  i  t it  r.  
and I as just going do n there to get the 
t t rize   I idn't   tt ti  
t  t t  t r  i  t  t is nt. 
. o you have the T R  ofthis docu ent 
or did you produce that to r. verson? 
. I don't recall any ore. 
R. LL : ar in do you recall if you 
r i e  t  ri i l  t t. 
R. ERS : Sitting right here right 
  on't. 
. (B  . )  t e reas  I as  
I'm looking at the copy I've provided and I don't 
see a t   sta  r ar  i icati   
 ent? 
. I don't so ebody staying in the star 
ood four points and at the bath ore in bath 
ore by the airport and I had the office anager 
and if you need to call the  up and say in fax 
the  back a copy of that signature does anybody 
  s  e ts   e   
bath ore four points the   airport. 
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Page 172
were available to every day consumers via the
internet
A In our case its being used in an
occupational standards regardless of how SEC
intends that it be used it is being used in
occupational context and all the clarifications
and interpretations of from OSHA and from the S
P SC that I referenced communication labeling
requirements hazard labeling requirements
Q And those the letters the opinion
letters that you referenced earlier from the
1980s and early 1990s
A Yes and post 1990s Im not sure how
recently the last opinion letter is that I
produced But there is also in that same
interpretation is contained in the compliance
directive for the hazard communication standard
and the preamble lays out the rationale for
requiring that the TAR target organ effects be on
the label those are the ones that if its a
chemical and its a health hazard it needs to be
identified this way
Q And you would agree that that standard
applies that it must be labeled in this way as
you just said if and only if the OSHA statute
Page 173
regulation apply to the particular product
A To the extent that the product in
question would only be GOVNG by the government
federal sub has SAR DUSHGS TAR again organ
effects on that is that responsive to your
question
Q I think so
Q On the sentence in paragraph 5 that
extends from the very last of page 2 into page 3
you indicate while my review of the product
information and information from SECswebsite
suggest that it is highly unlikely that Sabre Red
law enforcement grade 10 percent spray products
would be found inhouse HOULDZ or used by
children the use of the product by employees
remember DERS labeling of the product subject to
the OSHAhazardous communication center
regardless of if it is always
A Hazard communication
Q Okay Other than that did I read that
correctly
A Yes
Q Isntthat a legal conclusion
MR OVERSON That calls for a legal
conclusion
44 Pages 170 to 173
Page 170 I
1 Q Do you know if that person in 1
2 Baltimore Maryland was a notary public for 2
3 Colorado as is indicated on this document 3
4 A I dontknow that 4
5 Q With those somewhat procedural 5
6 questions out of the way I would like for you 6
7 to turn back to page 2 of this document 7
8 A Okay 8
9 Q Paragraph 5 9
10 A Yes 10
11 Q Sort of a lengthy paragraph did you 11
12 draft that paragraph 12
13 A Im not sure how much was originally 13
14 proposed by Mr Overson office and what I 14
15 tweaked and adjusted but I had input into the 15
16 phrasing on that I would note in addition to 16
17 here Sabre Red fog GER and I have I believe my 17
18 understanding of is the fog GER product and the 18
19 sell buster product is larger similar 19
20 clarification Ive used those two terms 20
21 interchangeably 21
22 Q Okay Thank you for that 22
23 clarification On the last line of page 2 we see 23
24 again this reference that wev already gone 24
25 through beforeHazardous industri chemical 25
Page 171
1 Do you see that 1
2 A Yes 2
3 Q And do you have NRI further testimony 3
4 other than what youve previously provided on the 4
5 did definition of that term or again is that term 5
6 really intended to mean a hazardous chemical 6
7 A It should read hazardous chemical 7
8 Q The same has the change in your report 8
9 A Yes The original rig engine or 9
10 genesis of that testimony is an see standard 10
11 chemical labeling which refers to HAZ SURD DU 11
12 industrial chemicals z 129 dot 1 12
13 Q Okay Thank you and the second 13
14 sentence of paragraph 5 you indicate that may or 14
15 may not be true for other products sold by SEC 15
16 but the Sabre Red fog GER product is clearly 16
17 intended for occupational use On what basis do 17
18 you testify that the Sabre Red fog GER product is 18
19 clearly intended to for occupational use 19
20 A Its my understanding that the Sabre 20
21 Red fog GER product is not S EK and is one whict 21
22 requires a law enforcement or comparable person 22
23 to present credentials in order to order and 23
24 obtain 24
25 Q Would your opinion on that change if it 25
000896
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 , ar land       
 l ra  s is i icated  t is ent? 3 
 .  n't  t.  
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16 r si   t t. I l  t  i  iti  t   
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d.      t  
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   r    
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 really intended to ean a hazardous chemical?  
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 . es. he original rig engine or  
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 sentence of paragraph 5 you indicate that ayor  
15 ay not be true for other products sold by SE   
 but the Sabre Red fog GER product is clearly  
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question ould only be  by the govern ent R; 
federal sub has S  S S, T  again organ 
ff t   t t i  t t r i  t  r 
question. 
. I t i  so. 
Q. On the sentence in paragraph 5 that 
extends fro  the very last of page 2 into page 3 
you indicate while my review of the product 
i ti   i ti   EC's it  
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la  e f rce e t ra e  erce t s ra  r cts 
would be found in-house HOULDZ or used by 
children the use of the product by e ployees 
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THE WITNESS It is my interpretation
relying upon the OSHA provided documents whicl
discuss all this itsmy its my consensus after
reading all the OSHA opinions and compliance
directives and clients routinely ask me this what
kind of stuff do we have to have on the label and
what basis for that Come to me because I know
the C P SC REK he can regulations
Q Has you testified you dontknow the
details
A I dontknow them as well as the the
OSHA regulations but I do know they define
certain terms able MABL and defined but they do
provide those definitions of the terms and they
do allow labeling requirements I do work with a
client who makes portable gasoline containers and
the label they have read those in make sure our
labels did comply and again I dont hold that
particular regulation the text of the F H S A in
my head but I have read it
Q I want to zero in on one particular
part of that sentence that I just read
Q It is highly unlikely that Sabre Red 10
percent OC products would be found inhouse
holds on what do you base that opinion
Page 175
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
A The main basis for that opinion is that
the 10 percent OC products are not available for
consumer purchase off the website well as well
as
Q As well as the the testimony in the
various witnesses in the chase that established
that the only Sabre Red products ten percent OC
sprays was from the manufacturer you cant go
down and buy that at your WalMart
Q But you dont know when you sit here
today whether you can go on your computer and b
that
A Its my understanding and I believe
Ive done that whereIve gone to look at the SEC
website and said can you purchase that the this
and I dontbelieve that they offered that to
purchase
Q Okay
A To consumers
Q Would you also say I just want to
understand the extent of your testimony here to
make sure that Im clear on the boundaries of
what you are saying Would you agree or disagree
with the following statement It is highly
unlikely that SEC SAB BER read law enforcement
Page 176
1 red law enforcement grade 10 percent OC products
2 would be brought to a household in the context
3 after police investigation
4 A If there is a police investigation and
5 if the police are carrying that as something that
6 they had with them its certainly feasible that
7 there is certainly possibly that could be brought
8 into the household thatsnot in the meanings C
9 P SC what they means by inhouse holds or around
10 children thats meet completely contrary REE
11 instead fastly refuse to discuss
12 Q Im not refuse to discuss it
13 A Or ask me about it
14 Q Im going through the inventory
15 documents at this point Doctor I like to keep
16 things in order and organized
17 Would you
18 MR OVERSON Speaking of those
19 opinions I dontsee them on the
20 MR LLOYD Im having them copied
21 Im having them copied
22 MR OVERSON Thatsokay
23 Q BY MR LLOYD Would you agree or
24 disagree with the if following statement It is
25 highly unlikely that SEC SAB BER read NRAUF
Page 177
1 10 percent OC products would be used in an
2 apartment building where a hostage was being held
3 Saber Red
4 A I dont have an particular aspect of it
5 I have not heard of anybody testifying that they
6 used from the OC spray for that kind of
7 extraction its one of those hypothetical
8 possibilities of out there its not my happened
9 before andor anything that would you have an
10 understanding about
11 Q Have you ever had a law enforcement
12 officer come to your house
13 A In the impasse tea of a law enforcement
14 officer
15 Q In capacity law enforcement officer
16 A No HOOIF had friends police officers
17 come mow FO my house to respond to a call come
18 my house
19 Q Have you ever had your friends who are
20 law enforcement officers visit your house in full
21 uniform
22 A I dontrecall that
23 Q Do you have any personal knowledge of a
24 law enforcement officer visiting a residence it
25 doesntmatter whos residence in full uniform
45 Pages 174 to 177
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THE ITNESS: It is my interpretation I 1 red la  enforce ent grade 0 ercent C products 
relying upon the OSHA provided documents hid 2 ould be broug t to a house old in the context 
discuss all this it's y it's y consensus after 3 a ter police inve ti ? 
reading all the OSHA opinions and compliance 4 . If there is  police inves igation  
directives and clients routinely ask me this what 5 if the police are ca r ing that s s et ing that 
kind of st f do e have to have on the label and 6 t e  had ith the  it's t i l  fea i le that 
hat asis for tha . ome to e because I know 7 there is ce t  pos ly that c ld e ro t 
the  P S   he can regulations. 8 into the house ld t's   the e ,  
 Q. Has you testified you don't know the    hat t  eans  in-house holds   
0 d t ils? 0 c ildren t t's eet letely   
1 . I 't no  the  as e l as the the 1 instea  fas  s   s . 
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3 certain ter s a le  a  efine  t the   13 . r   t it. 
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 do allow labeling requirements I do work with a  ts  t is t, r,  i e t   
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 the I 0 percent OC products are not available for  
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 that the only, Sabre Red products ten percent OC  
 sprays was from the manufacturer you can't go  
 down and buy that at your al-Mart?  
 Q. But you don't know when you sit here  
 today whether you can go on your computer and bm  
 at?  
 A. It's my understanding and I believe  
 I've done that where I've gone to look at the SEC  
 website and said can you purchase that the this  
 and I don't believe that they offered that to  
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 Q. ould you also say I just want to 1  
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Page 180
Q Its where they DWEL
A Itswhere they dwell
Q In other words a correctional facility
isnt just a place where law enforcement officers
go to clean their guns
A I would agree with that
Q So again looking at this sentence the
purpose of the products is for use by law
enforcement officials in sub Doug suspected KRI1V
NALS do you have any limiting language that you
would like to tad to that as to where those KRIM
NALSmight be found
A No
Q So it could be anywhere
A It could in fact be in a private
location but that is not consistent with the
testimony interest W the interpretation letter
and the C P S Cs own language what they would
call subject to the F H S so the fact that it may
incidentally brought by the police officers and
used in NA residence does not render a subject to
FHSA
Q Whats your understanding of the word
incidental
A It means that the product is not held
Page 181
by the house or by person who either rents the
house or owns the house
Q Of course you can bring make SHET tease
you can brick knives whatever else in and sit
there but its not as if you are holding that
stuff in your house you could bring kerosene to
somebody house that would be requirements he
it there NOR five minutes or a halfanhour while
you were in their house would not necessarily
render by itselfsubject to the FHSA from an
occupational perspective
Q But from an occupational perspective
the carrying of OC spray for law enforcement
officers isntjust an incidental carrying isnt
it its intented its purpose for
A It is again its contrary Im agree to
contrary Im happy for the jury to decide the
question its contrary about the in FHSA provided
by the C P SC under a federal hazardousIm quite
willing to threat thejury to decide if thats a
household product according to the if FHSA
definition is FHSA interpretations
Q Did you bring any FHSA interpretations
and regulations to you
A I brought the C P SC letter that we
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1 A Im sure that occurs on occasion 1
2 Q Do you have any knowledge as to whether 2
3 OC spray is a standard item in a police uniform 3
4 A I donthave information about that one 4
5 way or the other 5
6 Q Okay Have you ever personally 6
7 witnessed discharge of OC spray canister or 7
8 container by a law enforcement officer 8
9 A I dontrecall that 9
10 Q And youvenever yourself been trained 10
11 in those methods or when what a law enforcement 11
12 officer would do in aparticular situation 12
13 A Other than the background material 13
14 thats been provided in this case I donthave 14
15 any particular understanding of how that occurs 15
16 Q Toot sentence on your affidavit the 16
17 purpose much SECs Saber Red 10 percent OC 17
18 products is for use of law enforcement officer 18
19 officials in sub Doug officials crowd control and 19
20 inmate compliance 20
21 Do you intend for that statement to 21
22 apply only to the walls half correctional 22
23 facility 23
24 A I dont I believe that language was 24
25 suggested by Mr Overson office and I believe 25
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1 thats an accurate representation of the product 1
2 to be used for that language was not original 2
3 with me 3
4 Q So by youretestifying to this 4
5 statement you do not personally intend that that 5
6 be limited within the walls of the correctional 6
7 facility 7
8 A I believe that the 10 percent OC spray 8
9 product may foresee BLEE be used outside the 9
10 correctional facility by a police officer 10
11 Q Whats your understanding of a 11
12 correctional facility 12
13 A I dontknow how to define that term 13
14 other than its evident from its a place where 14
15 somebody has been charged with an a crime and 15
16 tore convicted of a crime is sent for either 16
17 holding for trial or for being incarcerated after 17
18 being convicted 18
19 Q And in those situations where they are 19
20 incarcerated after they are convicted from that 20
21 point on until they are released that 21
22 correctional facility is their home isntit 22
23 A It is 23
24 Q Its where they live 24
25 A It is where they are held yes 25
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A It is further my understanding that
while the C P SC requirements Im not aware of
having been litigated back and forth the OSHA
requirements regarding the hazard communication
standard have in fact been litigated
extensively and the updated position of the
agencies included in the current version of the
standard as well as updated conversion of the
updated documents thatIve provided
MR LLOYD Darwin what I previously
said in this deposition I am actually going to
ask you to give me a speaking objection on your
last objection I would like to know the basis of
why you were objecting Read back the legal
MR LLOYD The question was whether h
had any understanding as to the legal effect of
an opinion letter
MR OVERSON I do understand that you
were asking for a yes or no answer I think if
you were to ask him what that legal effect is or
whatever how that should how that works legally
then you are asking for a legal opinion so
MR LLOYD Okay
Q BY MR LLOYD Do you have any
understanding as to whether an opinion letter is
Page 185
considered law
A The opinion letters of OSHA are
considered to be agency opinions until they are
litigated and adopted they are not exactly they
are not law themselves once theyv been
incorporated into the letter my understanding is
they are binding
Q Is it your opinion that an opinion
letter would be more legally binding than a
federal regulation
MR OVERSON Objection vague
THE WITNESS Its if the regulation
and the opinion letter conflict and I would
expect that the opinion letter had been issued
and clarification of the regulation and I would
certainly give weight to the clarifying opinion
letter in interpreting the regulation I dont
see that those two conflict on the face and if
they do then I think there is a mistake in
interpretation of the regulation and thatswhy
the agency issued a clarifying opinion
Q What if the opinion is issued first and
then a regulation comes along later and perhaps
says something different than whats in the
opinion letter
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1 talked about 1
2 Q AndIve got them off for copying right 2
3 now but off the top of your head do you remember 3
4 the most recent opinion letter that you are 4
5 referring to that you rely upon 5
6 A I believe the C P SC addressed this 6
7 once and they have not revisited the letters and 7
8 I believe the interpretation is 1980s 1986 if I 8
9 recall 9
10 Q Are you aware if congress has since 10
11 addressed this issue 11
12 A Im not aware of congress over turning 12
13 any of the language that I referred to I the 13
14 letter that I referenced remains up on the C P SC 14
15 listed documents as currently available letter 15
16 and I would assume that the policy no longer 16
17 represented C P SC policy that the letter would 17
18 have been removed by now thats certainly the 18
19 practice of on or about Shaw R OSHA updated 19
20 opinion note on the opinion that the policies 20
21 have changed the and the updated policies 21
22 available in certain web link 22
23 Q Thatsa presumption 23
24 A No thatsmy experience with what OSHA 24
25 does and mypresumption that C P SC doe not 25
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1 leave opinion letters that they no longer hold to 1
2 up on their we sight yes that is the PRULGS that 2
3 they dont keep outdated letters on their website 3
4 and if they will not update TID letter on their 4
5 website and updated compliance guidance that they 5
6 provide a link on that one to the older one as 6
7 OSHA does 7
8 Q Do you have any understanding or 8
9 knowledge as to what legal effect an opinion 9
10 letter has 10
11 MR OVERSON That one certainly calls 11
12 for a legal conclusion 12
13 Q BY MR LLOYD Im asking if he has an 13
14 understanding yes or no 14
15 A Read the question please 15
16 The reporter read back the requested 16
17 testimony 17
18 THE WITNESS I have a laymans 18
19 understanding that the C P SC has issued 19
20 clarifying language on their federal hazardous 20
21 substances act and OSHA has N guidance to be 21
22 taken as the eggses position on how the standard 22
23 in question or requirements inquestion are to be 23
24 interpreted and applied 24
125 Q BY MR LLOYD Okay 125
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mind carry more weight in the opinion letter
which you have based your opinion
A If there is a subsequent court TRULG in
the particular issue involved in the opinion
letter yes the opinion letter is the agencies
position of the time ofthe writing of the
opinion
Q Okay Do you have any understanding as
to whether OSHA PROVTSDZ a private KAUFS action
private right of action
A I dontreally have
MR OVERSON Calls for a legal
conclusion
THE WITNESS Donthave an opinion
about it
MR LLOYD Again Darwin is it your
position that this witness is not competent to
testify to legal conclusions
MR OVERSON It depends how you phrase
that and what question you are asking you are
getting outside of the purpose for which he was
retained And the in the opinion letter or the
opinion that he is opinion he has expressed
MR LLOYD How am I outside of it
MR OVERSON You are asking him
Page 189
questions such as and letsGOF oh the order to
record
MR LLOYD I am going to stay on the
record
MR OVERSON Im not obligated
MR LLOYD Offthe record
Discussion held off the record
Saber Red
MR LLOYD Okay back on the record
Q BY MR LLOYD Dr Purswell youve
just been witness to a conversation off the
record thatsgiven rise to another question in
my mind Again roading from your affidavit
testimony here the use of the product by
employees in the course of their work renders the
labeling of the product subject to the OSHA had
SARD communication standard regardless ofwh
it is also subject to the fast federal hazardous
substance act FHSA do you believe yourself
competent to testify as to whether one law
applies to another when in conflict
A Thats a different question than you
just asked these are both regulations and as I
said Im not going to testify regarding which law
GOVRNSZ but I dontbelieve the question is REL
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1 A In this case we have an FHSA from 1986 1
2 I dont recall when the original act was put in 2
3 place well before that In the OSHA regulations 3
4 its always the case they are clarifying the 4
5 existing regulation with opinion letter and 5
6 usually responding to particular questions of 6
7 people who are impacted or likely to be impacted 7
8 from those regulations so if they for instance in 8
9 the revisions and they do revise the FHSA I dont 9
10 believe has been revised in several decades but 10
11 the hazard communication standard has been 11
12 revised and LAUL the guidance and stuff regardin 12
13 TASHG effects are REE VEESD target organ 13
14 regulations so 14
15 Q If there is a conflict between an 15
16 opinion letter issued and Im going FO use random 16
17 dates here just to put some chronological order 17
18 on it If there is a conflict between an opinion 18
19 letter issued in 1990 and a court opinion on the 19
20 same subject matter issued in 2000 which in your 20
21 mind carries more legal effect 21
22 A If the my understanding again opinion 22
23 letters are the agencies position at the time the 23
24 opinion letter is written If the opinion if the 24
25 issue subsequently lit GLIETD the courts and the 25
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1 agency loses on the question and it is in fact 1
2 has to follow court guidance on that has happened 2
3 well it did not happen with regard to the has 3
4 come standard but its happened in other cases in 4
5 the binding aspect of that is whatever the court 5
6 rules is the correct interpretation of the 6
7 regulation 7
8 Q So you would defer it to the court 8
9 opinion 9
10 A I would defer to the federal court 10
11 which interprets the federal regulations yes and 11
12 usually thatspretty quickly incorporated in the 12
13 in compliance directive which is in effect at the 13
14 time the which is all subsequently in effect 14
15 And again we have a compliance directive which is 15
16 quite EECHBT target organ effects required 16
17 Q But you didnt reviewNRI federal cases 17
18 regarding the if FHSA and its applicability 18
19 prior to coming in THEER and testifying or prior 19
20 to writing your report for that matter 20
21 A Im not aware that those are publicly 21
22 available if you would like me to to provide P me 22
23 one to approximate review I am certainly happy to 23
24 provide whatever 24
25 O But in hall events that would in your 25
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apply the circumstance which forms the batches c
this incident discovered by the OSHA regulations
and not the FHSA
Q What do you base that opinion
A The text ofthe standard itself and all
the interpretations which you removed from the
room
Q Ill bring them back in Im the get
entitled to do that
A And indeed USH
Q Okay Further in subsection 6 where it
indicates this section does not apply to you are
making the opinion that none of the items under
that category are relevant to this case
A I am of the opinion that the OSHA
hazard communications applies to the proximate
cause ofMs products held by Saber Red yes
Q How is that not a legal opinion
A It is an application of OSHA standards
and thats what I do for my clients and thats it
involves a familiarity with OSHA and its
policies and procedures all of which I have
gained over the course of a considerable period
of time and my understanding of that Ive gained
through researching to do the publications ask as
Page 193
you look at my publication list you can see
several publications regarding OSHA compliance
issues and OSHA citation issues and OSHA accide
database issues and all ofthose are ones I have
been become acquainted with OSHA if those
policies
Q Were all of those articles or
publication that you just mentioned that
otherwise identified in your CV have any of them
been about the application of the FHSA
A There was an actually there was an
article in the C P SC as well which Ive also
published BLISHD on and there were ones that
talked about the ability to search the C P SC
records and find the information I believe thats
right find the text of that particular its been
thats one of the older articles on my via have
it TA the use RABLT analysis the C P SC website I
believe there are two articles on that and both
of those relate to finding useful information and
not finding useful information on the C P SC
website
Q Did that article include a discussion
of when theFHSA applies
A Not specifically
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1 formed 1
2 Q You just testified by this what I just 2
3 read here that one law applies did you not 3
4 A The OSHA standards clearly apply to the 4
5 design of this product Im not taking the 5
6 position in favor or against whether or not the 6
7 fast FHSA also applies 7
8 Q But if the regulations itself take the 8
9 position that one will not apply if the other 9
10 does you would defer to that not your own 10
11 opinion 11
12 MR OVERSON Objection you are calling 12
13 now for a legal conclusion 13
14 MR LLOYD Im asking what he deferred 14
15 to to form his opinion 15
16 MR OVERSON Hes already stated that 16
17 Q BY MR LLOYD Go ahead and answer 17
18 A I believe the OSHA regulations apply 18
19 and itsmy opinion that the Ost apply to the the 19
20 by the trainers of the prison guards for this 20
21 product I dont have an expert opinion as to 21
22 the whether or not the FHSA also applies to this 22
23 Q Let me ask you this Earlier we went 23
24 through the various sections in Exhibit 100 which 24
25 was the copy of 29 CFR section 191020 in 25
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1 forming the opinion that the TOESH standards 1
2 apply which that is your opinion correct 2
3 A That is my opinion 3
4 Q Are you not also there by necessarily 4
5 forming the opinion that the items discussed in 5
6 subsection B 5 and 6 do not apply 6
7 A I do not believe the language in the 7
8 standards self intended to exclude this 8
9 particular product from coverage by the hazard 9
10 communication standard and if you are 10
11 interpreting that time not interpreting 11
12 necessarily its one or the other but its 12
13 certainly my opinion that if there that were the 13
14 case the OSHA regulations would apply and not th 14
15 FHSA to this product to the Saber Red 2 10 15
16 percent 16
17 Q So in this section 5 when you read this 17
18 section does not require labeling of the 18
19 following chemicals and it lists the ones other 19
20 which we have discussed and others we have not 20
21 Its your opinion that that particular section is 21
22 not applicable to this case 22
23 A It is my opinion that the OSHA 23
24 regulations apply it is my opinion I donthave 24
25 an expert opinion whether the FHSA if one can 25
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2003 was published in 2004 it was rather dated
Do you know want to know if is there any warnings
articles I can find out but I did not
specifically look at that before I came here
Q So have you not updated your on line
database of warnings articles since 2004
A That would be true
Q Okay I also saw in your CV actually
no I saw on your website reference to OESHS
OSHAs accident database
A Thats true
Q Are you familiar with that
A Im very familiar with that yes
Q How often would you say you use that
A In industrial cases probably at least
half the time I have something happening with
that I go and see And particularly if there is
an unusual accident where something atypical
happens I would go and see if that accident ever
happened before The most recent articles an
accident analysis of the accident database truck
cranes and the TRUB type of accident patterns
that occur in those and categorize them according
to a number of scenarios
Q I think thats what I am look at here
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in so in this case with Ms Majors subsequent
A They would not have anything TAS
specific as this particular chem KAM in OSHA
database would not have a particular category
particular to OC spray you can go to the chemical
ones search for the list there is a brief list
its a rather long list of under chemical
categories that was just generally chemicals
thats as specific as OSHA would categorize
Q Did you review that
A I did not review that in anticipation
of this particular deposition
Q Are you aware of anything in the OSHA
accident database referring to or relating to
exposure to pepper spray
A I am not familiar with anything
relating to that particular issue I have not
looked
Q The same question but for Oleoresin
capsicum in case there is any confusion
A I have not looked on that particular
one either
Q How about in the chemical as a chemical
database is that what you were just referring to
A Its a category under which OSHA
50 Pages 194 to 197
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1 Q Where can I get a copy of that article 1
2 A You can get a copy of the article from 2
3 me if you want to request a copy from meIll 3
4 send it across to Mr Overson and Im sure hell 4
5 provide it to you 5
6 Q Okay 6
7 A There was fan initial article and then 7
8 an update article in 2003 The initial article 8
9 was in 2001 9
10 Q All right If 10
11 A If I recall correctly it involved both 11
12 investigations where we asked people FO to find 12
13 on the C P SC website where it was and we asked 13
14 them if we could locate it 14
15 Q It have anything to do with the 15
16 application of the FHSA 16
17 A I dontask I dontremember if at this 17
18 time if we asked what the search terms were We 18
19 were asking to identify they may ask can you find 19
20 definitions from the C P SC website 20
21 Q BY MR LLOYD Thats more about 21
22 finding them on the website its not about 22
23 whether that particular law applies LOR doesnt 23
24 apply to that set of circumstances is that 24
25 right 25
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1 A It did not deal with the application of 1
2 FHSA to particular circumstances 2
3 Q Okay While wer looking at back at 3
4 your CV just a couple other quick questions In 4
5 2004 and I think youveactually referenced it in 5
6 other places as well but you authored its either 6
7 an article or a presentation entitled development 7
8 of an online database and warnings articles does 8
9 that 9
10 A Yes that is true 10
11 Q Have you yourself developed an online 11
12 database of warning articles 12
13 A Yes 13
14 Q Is that what that article is about 14
15 A Yes 15
16 Q Now Ive gone through and Ive looked 16
17 at an online database ofwarnings articles that 17
18 I found on your website I couldntfind anything 18
19 so correct me ifIm wrong Is there any on line 19
20 warnings articles relative to Oleoresin capsicum 20
21 A Im not aware of anything that is that 21
22 specific 22
23 Q Pepper spray generally 23
24 A Pepper spray Individual to look back 24
25 at my warnings references and again that was in 25
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 specific. 
 . Pepper spray generally? 
 . Pepper spray. Individual to look back 
 t  r ings r fere ces  i  t t s i  
a e  
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 specific as this particular chern  in  
 database ould not have a particular category 
 particular to  spray you can go to the che ical 
6     s     f  
 it's a rather long list of under che ical 
 categories that was just generally chemicals 
 that's as specific as S  ould categorize. 
 . id you revie  that? 
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 of this particular deposition. 
 Q. Are you aware of anything in the OSHA 
 accident database referring to or relating to 
 exposure to pepper spray? 
 . I a  not fa iliar ith anything 
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was for speeding
Q Did you ever notice its been
A Its been a decade since that occurred
FO I donthave a recall of that
Q Okay Do you have any other personal
interaction with Oleoresin capsicum or pepper
spray that we have not discussed here today
A I have seen people and I have with a
key chain thing that are used for consumer
purposes that I have not seen discharge it but I
have seen them carry the stuffaround that would
be the only other interaction that Ive had with
the product
Q Prior to this case did you have any
understanding of the effects of Oleoresin
capsicum spray
A I understood it the effects of pepper
spray but I did not understand I mean I did not
identify Oleoresin capsicum as the active
ingredient of pepper spray
Q And what was your understanding of the
effects of pepper spray
A That it would cause burning on the skin
and the eyes
Q Anything else
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A I dont believe I had any understanding
about that to
Q And where did you get that
understanding
A I have no basis to say where I got it
from Just generally aware
Q Okay
MR LLOYD I dont think I have any
further questions
MR OVERSON Can we get those copies
before I offthe record
A recess was had
MR OVERSON
EXAMINATION
QUESTIONS BY MR OVERSON
Q First off Dr Purswell for the
industry of chemical products manufacturers
producing products for use in the occupational
setting are you familiar with the industry
standards for those manufacturers in terms of the
warning labels their products require
MR LLOYD Object to the form
THE WITNESS Yes there is is voluntary
consensus in S z 1129 dot 1 is the one published
in the terms of the regular once products to be
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1 categorizes accident types accident 1
2 investigations and there are so much abroad like 2
3 crane and if you want to look there truck cranes 3
4 and crawler cranes and entry cranes so those are 4
5 broken down Im not aware of any break down for 5
6 chem KAM sodium high the DROX side but in 6
7 general I didntnot go DPEEX particular 7
8 Q So in six INS you are in nitrogen on 8
9 that website 9
10 A I would say that would be unlikely 10
11 Q Can you nevertheless perform a search 11
12 for nitrogen to come up with any chemical 12
13 articles or mentions of the word nitrogen 13
14 A Any accidents that have been occurred 14
15 that have been investigated where they key worded 15
16 it with nitrogen you can find it yes 16
17 Q Did you do that for Oleoresin capsicum 17
18 prior to today 18
19 A I did not 19
20 Q So as you sit here today whether for 20
21 the OSHA accident database or otherwise are you 21
22 aware of any incident prior to Ms Major where 22
23 there was an OSHA investigation that referred 23
24 related to or otherwise mentioned Oleoresin 24
25 capsicum 25
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1 A Not among the OSHA accident database 1
2 articles that I have looked at before Again 2
3 they dont they would have a category for 3
4 chemicals and they do and they may have a 4
5 particular category for few chemicals like so 5
6 type of chemical that is Oleoresin capsicum 6
7 Q Okay Have you ever been arrested 7
8 A No 8
9 Q Anybody in your immediate family ever 9
10 been arrested 10
11 A Not that Imaware of 11
12 Q Do you have any general sentiment for 12
13 or against law enforcement officials officers 13
14 A We have a family friend who is a 14
15 retired law enforcement officer Generally like 15
16 them I find my interactions with them are 16
17 fairly pleasant as long as Im polite as long as 17
18 I say hey buddy yes officer what can I do for you 18
19 today 19
20 Q Have you ever been stopped by an 20
21 officer 21
22 A I have been stopped 22
23 Q Did you happen to was it I assume it 23
24 was for speeding 24
25 A I believe the last time I was stopped 125
000903
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 Q. Okay. Have you ever been arrested? 
 . . 
 Q. Anybody in your immediate family ever 
   r sted? 
 .   'm  f. 
 Q. Do you have any general sentiment for 
 or against law enforcement officials officers? 
 A. e have a family friend who is a 
 retired la  enforce ent officer. enerally like 
 them. I find my interactions with them are 
  fairly pleasant as long as I'm polite as long as 
 I say hey buddy yes officer what can I do for you 
 today. 
  Q. Have you ever been stopped by an 
 ffi er? 
 A. I have been stopped. 
 Q. Did you happen to was it I assume it 
 was for speeding? 
 . I believe the last ti e I as stopped 
 . t i  lse? 
  
 . I don't believe I had any understanding 
   . 
 .  ere i   et t at 
 erstanding? 
 . I   sis t  s  r  I t it 
 .  r l  re. 
 . y. 
 . : I don't think I have any 
 further questions. 
 . S : an e get those copies 
   ff  cord. 
 (A   ad.) 
 . : 
  
 I   . ON: 
 . First off r. Purswell, for the 
  industry of che ical products anufacturers 
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extended applicability of the FHSA to stuff that
is a hazardous chemical which is and when it is
concerned to be subject to the FHSA versus other
labeling standard
Q And did you rely oh on that opinion
letter
A I did
Q And my following question is did you
rely on that opinion letter in forming your
opinions in this case
A Yes I did
Q And what does that opinion letter
state
A The text the heart of it is in the
SKREND paragraph in order to be regulated quote
hazardous substance intended or packaged in that
more suitable in for use in this the household or
by children which it gives aUScode reference
while in or responding to the particular
hypothetical possessed by the person riding in
they said while the use by the employees HOR
landlords and janitorial services could STROVL
the use ofOVN cleaners in the homes of the
consumers the commission regulations hazardous
substance is intended orIm sorry the letter got
Page 205
kind of chopped up on the computer while the use
by employees on an or landlords for janitorial
services could involve the use of the TOVN
cleaner in the homes much consumers the
commissions regulations and it references the the
commission regulations hazardous STAUNS or
packaged in a normal suitable for use in the
household does not include industrial supplies
which might be taken into the home by serviceme
an article labeled and marketed for solely for
industrial use does not become subject to the
FHSA because of the industrial supply home for
his own use
Q Would you say that the opinion that
youve rendered in this kiss case is consistent
with that opinion letter LO I had Lloyd objection
calls for a legal conclusion
A It is consistent with that I would say
and I rely on the FHSA extent much FHSA to the
products in question
Q BY MR OVERSON And to your
understanding is that opinion letter consistent
with your understanding of the standards
applicable in the industry for whats required on
warning labels
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1 continued to be used in the OSHA standard 1910 1
2 dot1200 2
3 Q And that the testimony youvejust 3
4 provided what is the basis for that 4
5 understanding 5
6 MR LLOYD Objection form vague 6
7 THE WITNESS The basis for my 7
8 understanding about the an see standard is the 8
9 Im familiarity with the an see standards and 9
10 applying those both to matters in lit days as 10
11 well as both in preparing product labels and MSDS 11
12 or an see standard z 129 dot 1 industrial 12
13 chemicals being sold for industrial use THOR 13
14 occupational use 14
15 Q BY MR OVERSON So in terms of the 15
16 Saber Red law enforcement product where would w 16
17 go to find the standards for warning labels that 17
18 are applicable to TO in the industry when those 18
19 products are sold for occupational use 19
20 MR LLOYD Object to form it calls for 20
21 a legal conclusion 21
22 THE WITNESS The two standards one of 22
23 the those would be the an see standard ZZ 121 dot 23
24 1 and the ERMS the ofthe standard and the 24
25 emis SDPIT tby SEC the 10 percent cap say 25
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1 SUP IRTANLT and would be covered about TI th 1
2 standards requirements in NA respect thats a 2
3 voluntary con SEN SUPS STARNTD the the the 3
4 content than format would be provided in the 4
5 TOESH regulations and they are there are both 5
6 OSHA regulations that apply TLO labels and to 6
7 MSDSes 7
8 Q So combined is it your understanding 8
9 that those are the industry standards 9
10 A That is true and when I prepared labels 10
11 for clients who had products for sale to 11
12 commercial accounts and to other occupational 12
13 users the standards which I followed were the 13
14 ones specified by OSHA and by the an see see 129 14
15 dot 1 15
16 Q Mark that this 16
17 Exhibit 104 marked 17
18 MROVERSON 18
19 Q BY MR LLOYD Youve been handed 19
20 Exhibit 104 can you identify that for the record 20
21 A That is an October 241986 C P SC 21
22 website under their library and under F Y area it 22
23 is one where I down loaded another copy of in the 23
24 last week and so my interpretation is that this 24
25 contin to be C P SC policy regarding the 25
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1
1 MR LLOYD Objection calls for a legal 1
2 conclusion 2
3 THE WITNESS Yes offer offer mark that 3
4 HND 1505108 of to 4
5 Exhibit 105 marked 5
6 Q BY MR LLOYD Youvebeen handed 6
7 Exhibit 105 can you tell us what that it is 7
8 A It is a response to a person WROIG in 8
9 for a clarification much the hazard 9
10 communications standards requirements 10
11 Q And what does it say 11
12 A The second paragraph the text of the 12
13 letter says the labeling requirements addressed 13
14 in my June 3 memorandum to the regional add had 14
15 MIN straight TORS has changed target normal 15
16 target organ EECHtle are still and the for all 16
17 shipped containers therefore if you sell an 17
18 aerosol product which contains a hazardous organs 18
19 effected must an on the label 19
20 Q Okay And is that opinion letter 20
21 consistent with the opinion that youveoffered 21
22 in this case 22
23 A Yes and this guy has also been 23
24 integrate I had into the subsequent professions 24
25 andthe is tandar itself as well asc 25
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directives
2 Q And is there that compliance letter I 2
3 had standards adopted by in the industry yes it 3
4 is PRASHG 4
5 Exhibit marked Mark 106 5
6 Q BY MR OVERSON Im sorry before we 6
7 go on the next one as did you rely on the opinion 7
8 letter as IECHSD ace as exhibit 105 8
9 MR LLOYD Object to the form 9
10 Q When you developed your opinions in 10
11 this case 11
12 A I relied upon approximate the if 12
13 opinion letter in part but I mostly relied on the 13
14 guidance which contains in the in police 14
15 directive which applies to the standard 15
16 Q Okay And youvebeen handed Exhibit 16
17 106 17
18 A Thats true 18
19 Q And what is that 19
20 A That is a letter from 1987 addressed to 20
21 Mr Frank bell a green knee and the it is an 21
22 extended comment on the requirement for target 22
23 organ effects to be included on the product 23
24 label 24
25 Q And did you rely on that opinion letter 125
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from OSHA in developing your opinions in this
case
A Yes
Q And is that opinion letter consistent
with the industry standards as you understand
them
A Yes
MR OVERSON Sorry Tom Ive kind of
moved along
MR LLOYD Im keeping along
Q So that
Exhibit 107 marked
MR OVERSON
Q BY MR LLOYD Okay youvebeen handed
0107 tell us what that is
A Opinion from 1990 Im not sure this is
the one I wanted this regards the obligation of
material safety data sheets in the hazard
communication center
Q And did you rely on that opinion in
developing your opinions that you developed in
this case
A Yes and if if in your letter you
correctly summarize OESHS RISHT MSDS for
consumer products MSDS be provided to purchasers
Page 209
of household consumer products when products used
in workplace in the STAM manner consumers use
THELS e i and is not create GRAER they are then
TLASHGS consumer would experience this SEMGS i
the OSHA regulations based upon LOEFR not upon
the chemical but how it is actually used in the
workplace Employees who required to work with
hazardous chem KAMS in a manner that ruts
greater than what a normal consumer would
experience have a right FO know about the FROTS
Visa these chemicals
Q And is that opinion letter consistent
with your understanding of the standards in the
industry for warning labels
A Yes and if we
Exhibit 1 marked 08
MR OVERSON
Q BY MR LLOYD Youve been hand
A Hats letter regarding the compliance
directive in effect that the time and 1990 and it
relates to the occupational exposure to consumer
products And it further states occupation NAX
so covered the hand H C S when an employees use
e that are more frequent of or a than would
be expected for and it says see the AU pen
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Page 2101 Page 212
1 narrative discussion and on Appendix A of the 1 A Thats an 1996 May 9 1996 The heart
2 compliance directive on background Ill note that 2 of the opinion starts in the second paragraph it
3 the current version of the compliance directive 3 says please understand that the occupational
4 that D version has a similar language or similar 4 safety and health administration is committed to
5 discussion 5 common scenarios you describe in your letter of
6 Q Did you 6 consumer product use such as polishing tables
7 A In addition pages 3 to 4 of the 7 would the FRNLS In never not require that you
8 instruction contain information regarding Supreme 8 main TDZ paragraph 1910 dot 1200B29 of the
9 Court decision of February 21 st of this year the 9 A The
10 effect is full enforcement of the hazard 10 A The shall which are used in the MRA
11 communication standard with regard to the three 11 NARN SPREENS tea EE and duration of the expos
12 PREES MRIK act to the rule much consumer 12 that are not greater than the range of exposures
13 products when in use in the work lays 13 that could be reasonably experienced by
14 Q And did you rely upon that opinion in 14 consumers
15 forming your opinions in this case 15 Q And did you rely on that opinion in
16 A Yes 16 developing opinions youve rendered in this case
17 Q And is that opinion consistent with the 17 A Yes
18 industry standards for warning labels 18 Q And is that opinion consistent with the
19 A Yes 19 industry standards for warning labels
20 Q 20 A Yes make NASHG l 1 is
21 Exhibit 1 marked 09 21 Exhibit 111 marked
22 Q 109 opinion letter in August 15th 191 22 Q BY MR OVERSON Its rather lengthy
23 this is clarification much 29 CFR retail 23 document but can you just tell us generally what
24 establishments which use consumer products for 24 111 is
25 cleaning purposes And this is also a followup 25 A Check No 111 is a summary and
54 Pages 210 to 213
Page 211 Page 2134ii
1 in into several conversations between our staff 1 explanation of the issues and provisions of the
2 members on the specific case involved Safeway 2 final rule NA final rule being the hazard
3 incorporated store No 914 hearing date August 3 communication rule This one is dated this was
4 13th has been set The heart of it is really 4 published 1984 February 9th C P SC
5 again the fact that they are saying that if you 5 Q Where did you obtain that
6 are using a consumer product to when with the 6 A Off the OSHA website
7 frequency or duration what a reasonable person 7 A When did you obtain it
8 would be a normal consumer use in a normal 8 A As you can see from the printout I
9 household environment then the hazards 9 obtained it two days ago
10 communication standard police close or similar 10 Q That was the day you printed it
11 to or similar in the way to which similar or to 11 A That was the day I printed it I PRIBTD
12 the amount of times a consumer could be using a 12 it off and brought it numerous time
13 product should not be cited as violations of the 13 Q And did you rely on that document in
14 H C S 14 developing the opinions that youverendered in
15 Q And did you rely on that opinion in 15 this case
16 developing your opinions in this case 16 A I did
17 A Yes 17 Q And is that the information contained
18 Q And is it is that a written opinion 18 in that document is that consistent with the
19 consistent with the industry standards for 19 industry standards for warning labels
20 warning labels 20 A Yes and in fact they layout the
21 A Yes 21 reasons for the industry standards that OSHA
22 Q Lets see mark that one 1150 22 promulgates
23 Exhibit 1 marked 10 23 Q Do you know what those standards are
24 Q BY MR OVERSON Youvebeen handed 24 A Yes
25 Exhibit 110 can you tell us what that is 25 MR LLOYD Object as to speculation
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1 narrative discussion and on Appendix A f the 
2 co pliance directive on background I'll note that 
3 the current version of the co pliance directive 
4 that D version has a similar language or similar 
5 discus . 
6 . id you? 
7 A. In addition pages 3 to 4 of the 
8 instruction contain information regarding Supreme 
9 Court decision of February 21 st of this year the 
 e fect is fu  e forcement  the ha ard 
1 co unication standard ith regard to the three 
 P , I  act to the rule uch consu er 
 products when in use in the work lays. 
 . nd did you rely upon that opinion in 
15 forming your opinions in this case? 
 . . 
 Q. And is that opinion consistent with the 
 industry standards for warning labels? 
 . e . 
 Q. 
 (Exhibit 1 arked.) 09? 
 Q. 109 opinion letter in August 15th 191 
 t is  fication    r  
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 cleaning purposes. And this is also a follow-up 
e  
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 incorporated store No. 914 hearing date August 
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 again the fact that they are saying that if you 
 are using a consu er product to when with the 
 frequency or duration what a reasonable person 
    l      
 l  iron e t t  t e  
10 communication standard police, close or similar 
11 to or similar in the way to which similar or to 
12 the a ount of ti es a consu er could be using a 
13 product should not be cited as violations of the 
   ? 
 Q. And did you rely on that opinion in 
 developing your opinions in this case? 
 . . 
 . nd is it is that a ritten opinion 
19 consistent ith the industry standards for 
 warning labels? 
 . s. 
 Q. Let's see mark that one 1150. 
 (Exhibit 1 marked.) 10? 
 Q. (BY R. OVERSON) You've been handed 
 i it 1    t ll s t t t is? 
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1 . t's  1996 ay , 1 . he  
2 of the opinion starts in the second paragraph it 
3 says please understand that the occupational 
4 safety a d health a inistration is c itte  to 
5 co on scenarios you describe in your letter of 
6 consu er product use such as polishing tables 
7 ld the . In , n t re ire that ou 
8 ai , T Z paragraph 910 t ,2 0  '29 f t e. 
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3 i  l . s    s  
 published 1984 February 9th C P SC. 
5 . r  i   t i  t at? 
 . ff t e  e site. 
 .     . 
 . s  ca  see fr  t e ri t t I 
 obtained it t  days ago. 
 . hat as the day  printed it? 
 . hat as the day I printed it I I  
 it ff and brought it nu erous ti e. 
 .  i   rel   t at c e t i  
 e el i  t e i i s t at ou've re ere  i  
  ase? 
 .  id. 
117 . nd is that the infor ation contained 
I  i   t i  t t i  i   
 i tr  t r  f r r i  l bels? 
 .  and, i  f ct, t  l t t  
 r  f  t  i t  standar  t t SH  
 pro ulgates. 
 . o you kno  hat those standards are? 
24 . es. 
 R. YD: bject a  t  speculation. 
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Page 216
you rendered in this case
A It is
Q And Im wondering do you know what the
stated reason for the these OSHA opinions are
A The reasons
MR LLOYD Object to vagueness form
generally confusing
Q BY MR OVERSON HOK
A The opinions issued by OSHA
Q Let me rephrase it These opinions
issued by OSHA do you know the reason that OSl
issues those opinions
A OSHA receives particular letters
communications from people who are effected by
may be affected by the regulations or asking for
clarifications of what those regulations require
and the opinion letters constitute OESHS position
at until such time the court specifically rules
against OESHS specific issues The example of
where OSHA got overruled was at one point they
said they would be can inspecting home offenses
computer desk top and they got slapped down on
that pretty quickly and they have retracted that
guidance mark mark 113
Exhibit 11 marked 3
Page 217
Q BY MR OVERSON What is 113 Exhibi
113
A 113 is the current compliance directive
for the TOESH hazard communication again
compliance DPREKT TIFS compliance safety and
health officers for guidance on how to site and
whether to sight specific hazards under the OSHA
ton is standard referenced so in this case OSHA
is providing guidance to its SECHLT on to site
whether to site for violations of the the hazards
communication standard
Q Did you rely on that document in
formulating the opinions youverendered here
A Yes
Q And is it consistent for the industry
standards for warning labels
A It is and I would note nonExhibit 527
there is the scope and application and they
discussed further what is involved in paragraph B
and some ofthe issues which we discussed withou
the benefit of this particular MRINGS guidance
SFURT explained on page 5 of 27 Again the
standard thatOSHA uses in terms of trying to
figure out whether or not the product is TA
consumer product or one for occupational use is
55 Pages 214 to 217
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1 Q BY MR OVERSON Do you know what the 1
2 is stated reasons are 2
3 A The stated reasons in these standard 3
4 include not just target organ effects 4
5 requirements but lots of different MRANGSs why 5
6 they did what they did with the standard but the 6
7 target organ effects are specifically addressed 7
8 on page 24 of 41 about 4 paragraphs actually from 8
9 the middle of the page There is a lets see 9
10 its the fourth paragraph down a common sense 10
11 approach must be employed whenever a product is 11
12 used in a manner similar TLO what used by a 12
13 consumer thus REECHLT KURM the frequency and 13
14 duration of use should be considered for 14
15 example it may not be necessary to have TA data 15
16 sheet on a can much cleanser to clean a SOOING in 16
17 IS a clean or process equipment it should be 17
18 addressed in the HAZ KK program hazard 18
19 communication program the a couple more PRACHS 19
20 it any consumer product or hazardous substance as 20
21 those KURM products safety economics HOR KUR 1
22 SPRUKT HAZ study where the in employer can 22
23 demonstrate that it is used in the workplace in 23
24 the manner in the same manner has the in normal 24
25 consume useand which results in that duration 25
Page 215
1 much frequency much exposure which is not greatei 1
2 than the exposure experienced by consumers 2
3 Q Let me hand you one more 3
4 A Im sorry something on the preceding 4
5 page further reference 5
6 Q What was that 6
7 A More language wont REEP hazard hazard 7
8 communication applies under OSHA view 8
9 Q Okay 9
10 Exhibit marked 10
11 Exhibit 112 marked 11
12 A This one is the guidance TOESH hazard 12
13 communication standard this one is in the 13
14 reasonable form with definitions and questions 14
15 and responses to questions but does not contain 15
16 anything that I dontbelieve is contained in the 16
17 standard itself 17
18 Q And did you rely on that document 18
19 developing the opinions that youverendered in 19
20 this case 20
21 A To the EBS tent it doesn really add 21
22 anything to the standard to the compliance 22
23 directive but its a more user friendly NOR 23
24 consumer level explanation ofwhats required 24
125 Q Is it consistent with the opinions that 25
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
the duration is intensity of the chemical resin
Q
Exhibit marked
Exhibit 114 marked
Q BY MR OVERSON What is Exhibit 114
A Exhibit 114 are the had by OSHA for its
own standard again this is the exhaustive list of
everything OSHA said about its own hazard
communication standard and all the positions its
taken
Q And did you obtain that document
A I did obtain that document
Q And when did you obtain it and where
did you obtain it from
A I obtained it off the OSHA website and
printed it off two days ago
Q And is that that document that you used
in formulating the opinions youverendered in
this case
A It is
Q And how did you use that document
A Well I went and picked off the a few
of the ones that deal with consumer products
under this and I think I did a search because you
can see there is a lot of different
Page 219
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
interpretations of an issue This looks like
several hundred here have been issued and what I
did was pulled up this page and I did a search of
the word consumer on the list and found some of
the interpretations which I presented today I
dontknow if they are exhaustive of everyone
much to the list but whatNOOIF found consistent
with what I testified to today and compliance
director we discussed
Q Is so have you reviewed opinions OSHA
opinion letters that are more the current
A I have not actually printed those HOF I
started from the top I went to the bottom
Q Okay
A But those are certainly available and I
would have expected that if there were further
ones on consumer on this particular issue of
consumer product being covered or not covered by
the hazard communication standard that those
would be the opinion letters which were already
out there be up SGATD whats that based upon
A Again the situation I described earlier
where OSHA has changed its position on an issue
and is retracting or if they still make available
the opinion letter they note that the opinion
Page 220
1 letter no longer constitutes current policy
2 Q Thatsbased on your experience with
3 OSHA
4 A With researching issues off the OSHA
5 website yes
6 Q This MK 9 fog GER product Saber Red 1
7 enforcement 10 percent OC spray If it were to
8 be used by say a tact TIK call team or a SWAT
9 Team by going to a residence and deploying the
10 product in order to get the occupants of the home
11 to surrender or exit or render them incapacitated
12 would that change your opinions as to whether
13 this product is governed by the standards set by
14 OSHA for warning labels
15 A No it is to be consistent with an
16 occupational use of the product and would not
17 change my opinion about that
18 Q You had indicated you went to the Saber
19 Red or SECs website and it didn appear to you
20 that website was an available to the general
21 public for purpose of the Saber Red law
22 enforcement products is that right
23 A I believe I have a recollection of that
24 yes
25 Q Would you mind after this deposition
Page 221
1 making NA attempt and LTing us know ifyou are
2 successful
3 A I will
4 Q Okay
5 MR OVERSON I believe
6 Q Has there been anything today that that
7 been asked about and youveprovided an answer
8 that you would either like to correct or clarify
9 that you feel that maybe you didntget the
10 opportunity to do so earlier
11 A No I think we mentioned the fact that I
12 had been using the sell buster and terms
13 interchange plea the delivery OC involved in each
14 is the same
15 MR OVERSON Okay
16 MR OVERSON Let me hand you what
17 wellsoon bemark mash 115 and 116
18 Q BY MR OVERSON Do you review Exhi
19 115
20 A Yes
21 Q And did you review 116
22 A Yes
23 Q And the MK 9 fog GER identified on 116
24 is that the product that youvebeen referring to
25 here today interchangeably with the product
56 Pages 218 to 221
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Q In fact rooms attics storage areas
those would be things that you donttypically
thing of where a prisoner would be located in LA
correctional facility is that right
A Depending upon the correctional
facility ask and the prisoner they might be but
they could be ones outside a prison
Q All right Mr Overson asked you to we
can you can set that one aside Mr Overson
asked you to follow in this deposition and go
ahead and look around on the SEC website and let
us know ifyou are able to purchase an MK 9 fog
GER for example via the SEC website Im going
to ask also if you would dont limit yourself to
the SEC website look around the internet see if
you can purchase the product will you do that as
well
A I can try that
Q And can I trust that the response you
give to that question you will take as seriously
being as serious as it will still be under oath
A Yes
Q Okay And youllbe completely truthful
in that
A Ill ao Goode MK 9 foa GER and do a
Page 224
Google search Ill pick the shopping tag under
Google and Illsee what comes up
Q Thank you And Darwin I didnt keep
past with how you marked these as exhibits but I
would like to to look at a couple of these
opinion letters
A Okay If you are going to be more than
a half hour I would lying to take a rest room
break
Q I dontthink Illbe more than a half
hour looking at the first one we looked at
exhibit which was why dontyou go ahead and grab
the did exhibits Tom and maybe even hand him you
copy and switch back
Q So Im handing you Exhibit No 104
Dr Purswell
A Yes
Q And at the bottom of the first page of
that exhibit it indicates a copy of section
15003C 101 is enclosed FO R your information
now I dontsee that copy with this Exhibit 1504
that you produced do you know when you obtain
A There was no exhibit included C P SC
figures ifyou got TO there remember sight you
can
Page 225
1 Q And did you in fact down load a copy
2 ofthe FHSA
3 A Ive done that before
4 Q After you read this opinion letter and
5 saw that notation a copy of section15003 C 10 I
6 did you go back and reference section 1500
7 point 3 C 10 I
8 A Not in this particular instance
9 Q Have you ever gone back and looked at
10 this section in relation to this case
11 A Not in relation to this case I have
12 read the the entire
13 Q So you dontknow for sure that the
14 section 153C 10 I referenced in this opinion
15 letter of 1986 you dontNovember if the section
16 15003correctional facility 10 1 then enforce
17 in 1986 when this opinion letter is drafted is
18 the same regulation that is still in police
19 today
20 A The FHSA has not changed
21 Q And you are sure of that
22 A Im pretty darn sure
23 Q How about the regulations have they
2 4 changed
25 A Well again the C P SC doesnthave
57 Pages 222 to 225
Page 222
1 thats identified on 115 1
2 A Yes Sylvester and MK 9 offer 2
3 Q Antifog GER K 9 fog GER MK 9 fog GER
4 A Yes 4
5 MR OVERSON All right thats it 5
6 EXAMINATION 6
7 QUESTIONS BY MR LLOYD 7
8 Q Why dontyou go ahead and keep a hold 8
9 of that I dontknow what number wer looking at 9
10 that Exhibit No 115 go ahead and read that 10
11 paragraph thats above the picture of that room 11
12 where its illustrated that the product is being 12
13 deployed 13
14 A Superior ZIL delivers does not 14
15 require FAUSHL IESHGS specifically designed to 15
16 permit passive entry INTREENS to to SAEFL and 16
17 sell sell buster with an employ EE or through 17
18 windows food slots and vents 18
19 Q Once again in reading that language do 19
20 you interpret that marketing material there put 20
21 out by SEC to be limping limiting the use of its 21
22 products in correctional facilities 22
23 A Its my understanding its primarily 23
24 intended for that but not not necessarily CLEE 24
25 receively limino 25
Page 223
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 .   I tr st t t t  r s s    t ay? 
 give to that question you will take as seriously  . e  as t c a ed. 
 being as serious as it will still be under oath?  . nd you are sure f that? 
 
 
. .  . I'm pretty darn sure. 
. kay. nd you'll be co pletely truthful  . o  about the regulations have they 
  at?  nged? 
 . 'll g  gle   g      . ell, a ai  t e    esn't a e 
 (Pa   t  25) 
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Q Looking at the fourth paragraph there
which I believe is the same it may have not have
been the same paragraph that you referenced but
go ahead and read that paragraph
A Okay Witness complying All right
Q Looking at first of all whatsyour
understanding of that paragraph
A It appears again to be saying its in
its an either or proposition between the C P S
consumer products safety act or the hazard
communication standard so it would be one or the
other in KRA description what I had said earlier
on that it was I was mistaken HOON that one or
the other
Q Okay And thenIm going to focus on
the sentence that really occupies the middle
portion of this paragraph this is an especially
period of time NEN when has a condition of
employment the employee must utilize hazardous
consumer product greater duration of exposure
than what is typical of a normal consumer or
household use did I read that correctly
A Yes
Q And whatsyour understanding of that
sentence
Page 229
A That is saying that something which
would otherwise be like in bleach or known
ammonia or something if you were using that in
HAN employment context and used with greater
duration or intensity of exposure which you
expect in a normal household use it falls under
the provision of hazard communication standard
Q Now everything youvetestified to
today has indicated that you dont have any
knowledge as to use of force mechanisms as to
police procedure as to procedure of personnel in
correctional facilities is that true
MR OVERSON Object to the extent it
mischaracterizes his testimony
THE WITNESS Im certainly familiar
with the testimony of the I doc employees
regarding typical patterns of use of this but I
dont have experience with those procedures
beyond what was testified to in the depositions
but I do believe those are addressed in
Q BY MR LLOYD So other than those
depositions and what youvereviewed in
connection with this case being in those
depositions you dont have any independent
knowledge as to the frequency tore duration that
58 Pages 226 to 229
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1 implementing regulations to the same extent and 1
2 documented the same way OSHA does 2
3 Q When was the last time you looked at 3
4 that 4
5 A A few years ago 5
6 Q But again Ill ask my question You 6
7 are not sure as you sit here today that the SA 7
8 15003C 10 I referenced in this opinion letter 8
9 is the STHAM15003C 10 I is still in effect 9
10 today 10
11 A That would be true 11
12 Q And the same goes for whether itsthe 12
13 same that was in effect in March of 2008 13
14 A That would be true 14
15 Q All right The next document I would 15
16 like to look at is the opinion letter ofNovember 16
17 27th 1990 which was Exhibit 108 17
18 Q Do you want that back 18
19 Q Yes 19
20 A Okay 20
21 Q In the second to last paragraph of that 21
22 letter why dont you go ahead and read that 22
23 A Okay Witness complying Okay 23
24 Q All rightIm going to look at the 24
25 approximate the sentence that says OSHA and the 25
Page 227
1 department much labor are precluded under section 1
2 4 B 1 of the occupational safety and health act 2
3 much 1970 from exercising statutory authority to 3
4 prescribe andor enforce standards and 4
5 regulations over areas or issues that other 5
6 federal agencies already prescribe or enforce 6
7 A Okay 7
8 Q Did I read that correctly 8
9 A Yes 9
10 Q And what is your inning of that 10
11 sentence if any 11
12 A I guess that would be consistent with 12
13 your other interpretation that either one applies 13
14 or one or the other applies but not both 14
15 Q Okay And then the last thatsthe 15
16 last question I have on that the 16
17 A The 17
18 Q The last maybe one or two items that 18
19 wer looking at 19
20 Q Can I get that yes wellmake it 20
21 consistent later in chronological order I mean 21
22 Okay And now Im going to look at the opinion 22
23 letter dated August 15th 1991 which was marked 23
24 as Exhibit 109 24
25 A Okay 25
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 implementing regulations to the sa e extent and 
2 docu ented the sa e ay  d es. 
 Q. hen was the last time you looked at 
4 t t? 
 A. A few years ago. 
 Q. But again I'll ask y question. You 
 are not sure as you sit here today that the  
 1,500.3 C 10 I referenced in this opinion letter 
 is the  1,500.3  10 I is still in effect 
10 today? 
1 . hat   . 
 Q. And the same goes for whether it's the 
 e that as  fect in arch  8? 
 . hat   . 
 . ll ri t. he e t c e t I ld 
 like to look at is the opinion letter of Nove ber 
 7 t , , ic  as i it 8? 
 Q. Do you want that back? 
 . es. 
 . kay. 
 Q. In the second to last paragraph of that 
 letter why don't you go ahead and read that? 
 A. Okay. (Witness complying.) Okay. 
 Q. All right I'm going to look at the 
25 approximate the sentence that says OSHA and the 
  
a e  
1 . ooking at the fourth paragraph there 
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 . a  (Witness c plying.) ll ri t. 
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 understanding f that paragraph? 
8 . It appears again to be saying it's in 
9 it's a  either r r siti  et ee  the , 
 c s er roducts safet  act r t e azar  
      e e   
 t r i   s ri ti  t I a  s i  rlier 
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24 . nd hat's your understanding of that 
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 uch 1970 fro  exercising statutory authority to 
 prescribe and/or enforce standards and 
 regulations over areas or issues that other 
 
 
 
 
federal agencies already prescribe or enforce" ? 
. kay. 
Q. Did I read that correctly? 
. . 
 Q. And what is your inning of that 
 sentence if any? 
 . I guess that ould be consistent ith 
 your other interpretation that either one applies 
 or one or the other applies but not both. 
 Q. Okay. And then the last that's the 
 last question I have on that the? 
 . . 
 Q. The last maybe one or two items that 
 we're looking at? 
 . an I get that yes e'll ake it 
 consistent later in chronological order I mean. 
 Okay. And now I'm going to look at the opinion 
 letter dated August 15th, 1991 which was marked 
  i  09? 
 . kay. 
 a onia or so ething if you ere using that in 
  e ploy ent context and used ith greater 
5 ti   i t it    i   
 expect in a nor al household use it falls under 
7 the provision of hazard co unication standard. 
 . o , everything you've testified to 
 today has indicated that you don't have any 
 kno ledge as to use f force echanis s as to 
 police procedure as to procedure of personnel in 
 t  il   t t r e? 
 . : j t t  t  t t it 
i r t ri  i  t ti ony. 
1
 
 
'1  
 
 I : I'm rt i l  f ili r 
ith the testi ony of the I doc e ployees 
r r i  t i l tt r s f s  f t is t I 
 don't have experience with those procedures 
 e  at as testifie  t  i  t e epositi s 
 t I  li  t  r  r  i . 
 . (B  . )  t er t a  t se 
 e siti s a  at ou've re ie e  in 
 connection ith this case being in those 
 depositions you don't have any independent 
 l  as t  t  fr ncy t r  r ti  t t 
 (Pa   t  29) 
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A No I plan to run faster than the next
hike KER
Q Okay Thats a good philosophy
MR OVERSON The real reason they say
donthike alone
MR LLOYD Yes exactly
Q BY MR LLOYD Have you ever had an
interaction with somebody who did carry pepper
spray while doing any of those kind of
activities
A I dontrecall that
Q Earlier you testified as to having
knowledge of persons who carry pepper spray
canisters in one form or another on key chains
things of that nature
A I dont have a specific recall of the
specific context of that where I have seen
consumer grade pepper sprays are SCOMBRUSD
sometimes some women that I know or women th
HOOIF come across small single use sort of thing
and its likely not a 10 percent OC product but
Q When you say not likely a 10 percent OC
product do you have any independent knowledge
believe that those key chain lipstick container
containers have anything other than ten percent
Page 233
OC
A Its my impression from again from the
SEC website that those ten percent products are
not sold for public use not sold for consumer use
so thatsthe basis upon which I would surmise
that the key chain products would not be the full
ten percent
Q Would it change your opinion if the
lipstick product on the SEC website was the same
formulation
A Change my opinion in what way
Q Has to whether somebody could be
exposed to the same product in the regular
consumer use versus in the law enforcement
occupational use
A Well the containers as youllnotice
in the pictures of the device look like they
contain a whole lot more than what you can get
into a lipstick the lipstick seems to be a very
small amount of the product And that also in
this particular circumstance if its something
like ass best toss and benzene a little or a lot
Difference in impact between a lipstick size
versus what I would call a fire EX twin KWISH
SHER size
59 Pages 230 to 233
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1 a pepper spray is used in the law enforcement and 1
2 Ill put quotes around this word workplace 2
3 A Yes 3
4 Q You do have independent knowledge 4
5 A No I donthave independent knowledge 5
6 Q Okay Thank you So now as wev 6
7 established even to these opinion letters from 7
8 the occupational safety and health administration 8
9 identify what youvetermed the either or 9
10 standard is that correct 10
11 A Thats true 11
12 Q And so the OSHA standard will apply if 12
13 I understand this correctly when that product 13
14 will be used with a greater frequency and 14
15 duration of exposure than what is typical of a 15
16 normal consumer household use 16
17 A I think thatstrue 17
18 Q And based on that its your opinion 18
19 that the TOESH standard applies to this product 19
20 A That is the true that is true but Im 20
21 certainly willing to make the let the jury make 21
22 its own independent determination as to myself I 22
23 haventset off any OC containing products in the 23
24 last five years and I would expect that to be 24
25 true in the jury so any exposure would be in 25
Page 231
1 excess of the household use 1
2 Q But you dont know you dont have any 2
3 personal experience as you sit here today any 3
4 independent base of knowledge as to what the 4
5 frequency and duration of exposure in the law 5
6 enforcement occupation is 6
7 A Not beyond that to which was testified 7
8 in the depositions Again they did employee 8
9 training of that and I believe they said at least 9
10 annually and certainly I would expect people in a 10
11 household or around children not to be setting 11
12 off pepper spray in their own house at least 12
13 annually j13
14 Q Do you hunt 14
15 A I dont 15
16 Q Do you camp 16
17 A A little bit 17
18 Q Fish 18
19 A I if I drop a hook in the water its 19
20 not usually BATed because I dont want to be 20
21 bothered 21
22 Q Backpack 22
23 A Some 23
24 Q Do you carry pepper spray with you when 24
125 you do any of those activities 25
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1 a pepper spray is used in the law enforcement and 
2 I'll put quotes around this word workplace? 
3 A. Yes. 
4 Q. You do have independent knowledge? 
5 A. No, I don't have independent knowledge. 
6 Q. Okay. Thank you. So now as we've 
7 established even to these opinion letters from 
8 the occupational safety and health administration 
9 identify what you've termed the either or 
10 standard; is that correct? 
11 A. T t's tr . 
 Q. And so the OSHA standard will apply if 
 I understand this correctly when that product 
14 will be used ith a greater frequency and 
15 duration of exposure than hat is typical of a 
6 n r al consu er s ld u ? 
1 7 . I think that's true. 
 Q. And based on that, it's your opinion 
 that the TOESH standard applies to this product? 
 . hat is the true t at is true t I'm 
21 certainly willing to make the let the jury make 
 its own independent determination as to myself I 
 haven't set off any OC containing products in the 
 last five years and I would expect that to be 
25 true in the jury so any exposure would be in 
  
 excess of the household use. 
 Q. But you don't know you don't have any 
 personal experience as you sit here today any 
 independent base of knowledge as to what the 
 frequency and duration of exposure in the law 
 enforcement occupation is? 
 A. Not beyond that to which was testified 
 in the depositions. Again they did employee 
 training of that and I believe they said at least 
 annually and certainly I would expect people in a 
 household or around children not to be setting 
 off pepper spray in their own house at least 
 annually. 
 Q. Do you hunt? 
 . I don't. 
 Q. Do you camp? 
1 7 .  little bit. 
18 Q. Fish? 
 A. I if I drop a hook in the water it's 
 not usually BATed because I don't want to be 
 bothered. 
 Q. Backpack? 
 A. Some. 
24 Q. Do you carry pepper spray with you when 
25 you do any of those activities? 
Page 232 
1 A. No, I plan to run faster than the next 
2 hike KE . 
3 . Oka . Th t's a good philos ? 
4 . ERS : he real reason they sa  
5 d 't hike alo e. 
6 . LL : es e t . 
7 . (BY . ) ave you ever had a ) 
8 interaction ith s e dy ho did carry pe per' 
9 spray hile doing any of those kind of 
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11 A. I d 't re l tha . 
12 . a ier ou tes ified as to ing 
 no ledge f ersons ho carry pepper s ra  
 a isters in e for   a ther on ke  c ains 
I  t ings f that t r ? 
 . I d 't   c re l  the 
1 7 s ific t t  that here I e  
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 d t's ike  t      t. 
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. t's  e      
        
t l   li   t l     
 at's       r  
6 t t t   i  t  l  t  t  f ll 
7 ten percent. 
 .  i    i i  i  t  
9 li ti  r t  t   it   t  sa  
 ulation? 
 .  y pi i  i  t ay. 
 . s t  t r so ebod  l   
 ex  t  t  sa e pr duct i  t  r gul r 
 c  u  r  i  t  l  nf  
1  occupational use? 
 . ell, t  contai rs as you'll noti  
1  i  t  i t r s of t  devi  l  li  t y 
18 contai  a ol  l t or  t  t y  c  get 
19 into a li ti k t  li ti  see  t  b  a very 
2  smal  amount of the product.  that also in 
this particular circu stance if it's something 
li  ass best t s and benzen  a littl  or a lot. 
Diff r  in i pact bet en a li ti  size 
versus what I would call a fire EX twin K I H 
SHER size. 
21 
22 
23 
1
124 
25 
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IM employ the in next appropriate force option
did I read that correctly
A The portion on the label that you read
seems to comport with my recollection
Q Okay
A I would note that the the directions
for use specifically limited to directions to be
used by law enforcement correction military TLO
security personnel trained in the proper use of
aerosol project TORS
Q I understand
A So thats a lead
Q BY MR LLOYD The rest of the
discussion
Q Okay And I believe the applicable
case law does address that language soIm not
going to go through it today because we dont
need to those are legal conclusions But has to
the exposure that the SEC recommends for its
product aim incorrect and saying that the
instructions there specifically limit the amount
of the frequency and the duration in a particular
use of that product for the law enforcement
personnel
A No you are correct in saying they do
Page 237
have limits on it
Q Okay Well earlier you testified that
as compared to the key chain item that a key
chain canister of OC spray seemed smaller and
therefore the amount of exposure for a person
using the key chain dispensing item would be
different than the MK 9 fog GER wasn that your
testimony
A I believe thats true
Q Okay But SEC specifically labels not
to use the product in an extensive way in other
words it specifically says in so many words
dont walk around with the trigger held down is
that correct
A It does say language to that effect
limited to short bursts
Q Okay So any greater exposure that an
individual would have from using this canister
versus a smaller key chain canister wouldn that
just be a product much misuse by the person
handling the the product
MR OVERSON If you know dont
speculate
THE WITNESS I dontknow the answer
to that but I would also say it would have to be
60 Pages 234 to 237
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1 Q But in reviewing your materials did you 1
2 have an opportunity to review the suggested use 2
3 that SEC instructs with its that you have 3
4 product 4
5 MR OVERSON Im sorry thats vague 5
6 THE WITNESS I have seen the overheats 6
7 were used and I thought were supplied by SEC for 7
8 use by eye doc but beyond that I dont know 8
9 THE WITNESS Im going to have to stop 9
10 and pause there and take a rest room break 10
11 MR LLOYD Well finish beyond that 11
12 off the record 12
13 Discussion held off the record 13
14 A recess was had 14
15 Exhibit 117 marked 15
16 Q BY MR LLOYD BRP Im handle BRP 16
17 Dr Purswell Im handing you Exhibit 117 which I 17
18 can represent to you was produced by SEC in this 18
19 litigation and contains copies of the various 19
20 labels have you reviewed those labels before 20
21 A I have seen them yes 21
22 Q Okay Will you go ahead and TLIP to 22
23 the third page 23
24 A Okay 124
25 Q Can you identify that 125
Page 235
1 A That is a Saber Red MK 9 fog GER label 1
2 Q And on the portion of that label that 2
3 is to the right hand side whereyouvegot a lot 3
4 of probably very small writing in that 4
5 particular 5
6 A Witness reading 6
7 Q Are you read that 7
8 A Yes 8
9 Q On that label in fact can I see that 9
10 document so that we can make sure that I read the 10
11 accurate 11
12 MR OVERSON They are the same Tom 12
13 MR LLOYD Are they the same 13
14 MR OVERSON Apparently thats the one 14
15 your guy sent 15
16 Q BY MR LLOYD So DO I read this 16
17 correctly under the did directions category 17
18 remove pin and press act weight tore to fire at 18
19 subjects face in one half to one second bursts 19
20 aim for the eyes forehead if wearing glasses nose 2 0
21 and mouth To stop firing release pressure from 21
22 act weight tore caution avoid discharge into head 22
23 winds or blow back exposures do not EX soft 23
24 body tissue if you are unable to restrain the 24
25 subiect after three one half to one second bursts 25
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product?  s  t ith  . 
. : I'm s rr  t at's a e. 5 . . 
E : I   t e erheats 6 .  l  te t at t  t e irections 
 ere used and I thought ere supplied by SEC for 7  se i  i ite   re tions   
 use by eye doc but beyond that I don't kno .    a  c   ita  "R 
9  I : I'm ing t  a e t  st     trained    s   
 and pause there and take a rest roo  break.  r s l r je t . 
 . : e'll finish  t t  . I rstand? 
   . 12 .  t at's  l . 
 (Discussion held ff the record.) 13 . (B  . )     
 
 
(A recess as had.). 14 is i . 
(Exhibit 117 arked.)  . y.     ca e 
 Q. (BY R. LLOYD) BRP I'm handle BRP  s        'm  
1 7 r. Purs ell I'm handing you Exhibit 117 hich I  7 i  t   t r  it t  s  e n't 
 can represent to you as produced by SEC in this   t  t s  r  l l l si s. t s t  
 litigation and contains copies of the various  t e s r  t t t   r s f r its 
 labels have you revie ed those labels before?  product ai  incorrect and saying that the 
 A. I have seen them yes.  instructions there specifically li it the a ount 
 Q. Okay. ill you go ahead and TLIP to  f the frequency and the duration in a particular 
 the third page?  use of that product for the la  enforce ent 
 . kay. 24 personnel? 
 . an you identify that? 25 .    t i  yi  t   
a e    
 A. That is a Saber Red K 9 fog GER label.   i its  . 
 Q. And on the portion of that label that  . ay. ell, earlier  testifie  t at 
 is to the right-hand side where you've got a lot  as c are  t  t e e  c ai  ite  t at a e  
 of probably very s all writing in that  c ai  ca ister f  s ra  see e  s aller a  
 particular?  f r ,        
 . (Witness reading.)  using the key chain dispensing ite  ould be 
 . re you read that?  iffere t t  t    f   sn't t t r 
 . .  testi ony? 
 . n that label, in fact, can I see that  .   at's e. 
             . y. t  s cifi ll  l ls t 
 urate?  to use the product in an extensive ay in other 
 . E S : They are the sa e To .  r s, it ecifi ll   i  so  r  
 . LL : re they the sa e.  on't l  r  it  t  tri r l  own; i  
 . E S : pparently that's the one   rrect? 
15 your guy sent.  . It s s  l  t  t t ff t 
 Q. (BY R. LLOYD) So DO I read this  t    r ts. 
17 correctly under the did directions category  . ay.  a  reater e s re t at a  
 re ove pin and press act weight tore to fire at  i l    i   i  
 subjects face in one half to one second bursts    ll   i  i t  ouldn't t t 
i 
20 ai  for the eyes forehead if earing glasses nose :20 j t   t  i   t  r on 
 and mouth. To stop firing release pressure from  dli  t  t  roduct? 
 act weight tore caution avoid discharge into head  . SON: If   on't 
 inds or blo  back exposures do not, E  soft  speculate. 
 body tissue if you are unable to restrain the   I S: I on't  t  answer 
 j     l  t       t t   ul  al o ay i  uld    
 (Pa es 234 t  237) 
Page 238
1 the STAM formulation
2 Q And if it was the STAM formulation
3 A And I dont know with regard to the
4 conditions the use of the prison guards and what
5 they may have to encounter in that
6 MR LLOYD I dontthink I have any
7 NOR questions
8 MR OVERSON Followup go ahead and
9 mark this
10 Q Thats
11 MR LLOYD Thats marked already
12 MR OVERSON 117 okay all right
13 EXAMINATION
14 QUESTIONS BY MR OVERSON
15 Q
16 MR OVERSON Thatsokay I just wanted
17 to make sure its marked to her Lloyd LOI I
18 think wer done off the record so I can have you
19 email that to you
20
21
22
23
24
25
61 Page 238
000913
age  I 
 the   for . 
2 . n  if it as the   f r l ti n? 
3 . nd I don't kno  ith regard to the 
4 conditions the use of the prison guards and hat 
 they ay have to encounter in that. 
 . : I 't t ink I a e  
 NOR questions. 
 . : ll -up    
 a  t . 
0 . That's? 
 . : at's r e  lr dy. 
 . :  a  ll ri t. 
 IO  
 I   . : 
 Q. 
 R. ERS : That's okay I just anted 
17 to ake sure it's arked to her. Lloyd L I I 
 t in  e're  ff t e r r   I    
 e ail that to you. 
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Plaintiff respectfully opposes the efendant's otion to strike portions of the affidavit of 
Dr. Yost. The Defendant oved to strike clai ing the deposition testi ony of Dr. Yost was in 
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contradiction was actually a sham Kennedy v Allied Mutual Insurance Co 952F2d 262
26667 9 Cir 1991 cited in Frazier v JR Simplot 136 Idaho 100 103 2001
Furthermore in construing whether there is a conflict this Court must view the facts in a light
most favorable to the Plaintiff Frazier 136 Idaho at 104
II ARGUMENT
The Defendant claims that Dr Yost was very clear that he did not believe that there was
any literature or other publication available at any time prior to March 2008 that would have put
SEC on notice that the longterm chronic injuries alleged by Plaintiff could be caused by
exposure to OC products However the question posed to Dr Yost was whether there was
anything definitively published in the peer reviewed scientific and medical literature that would
have put a manufacturer of pepper spray products such as SEC on notice that the exposure to
their products by somebody with the chronic health conditions ofMrs Major would have caused
her an exacerbated response which would have included an ongoing chronic cough for the
subsequent period of time Aff of Pltfs Counsel 14 Ex 2 Yost Dep 153625 The
question asked whether there were any definitive articles at the time to which Dr Yost testified
that there were none he was aware o However he explains in his affidavit that statements
relating to the issues of causation and whether a manufacturer would have been on notice at the
time cannot be couched in absolute certainty Rather many of the conclusions Dr Reilly draws
should be based on the a sum of scientific evidence and judgments of the expert scientists Yost
Aff 18 He explained in his affidavit that it is misleading to make absolute statements from
data that does not warrant conclusions with absolute certainty Id The questions put to Dr Yost
relating to the state of the science in March 2008 were couched in terms of certainties and
absolutes Aff of Pltfs Counsel 4 Ex 2 Yost Dep 153625 There is nothing
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FurtheI ore, in construing hether there is a conflict, this ourt ust vie  the facts in a light 
   t  i tiff. i r,  a   . 
.  
 e da t ai s  . os  a  ''ver  e          
 literat r  r t er li ti  il l  t  ti e ri r t  r ,  t t l   t 
  tice t t t  l -term i  i j ie  lle   l i ti  l     
exposure to  products." o ever, the question posed to r. ost as hether there as 
anything "definitively published in the peer-revie ed scientific and edical literature that ould 
have put a anufacturer f pepper spray products such as  on notice that the exposure to 
t eir r cts  s e  it  t e c r ic ealt  c itions f rs. aj r l  a e ca se  
her an exacerbated response hich ould have included an ongoing chronic cough for the 
subsequent period of ti e?" ff. of ltfs ounsel, ~ 4 x. 2, (Yost ep. 153:16-25). he 
esti  as e  et er t ere ere a  "defi iti e" articles at t e ti e t  ic  r. st testifie  
that there ere none he as a are of. o ever, he explains in his affidavit that state ents 
r l ti  t  t  iss s f s ti   t r  f t r r l     ti  t t  
ti e cannot be couched in "absolute certainty. ather, any of the conclusions r. eilly dra s 
l     t     i nti i  i   j e ts  t  rt ientists." t 
ff., ~ . e e laine  i  is affi a it t at it is islea i  t  a e a s l te state e ts fr  
data that does not arrant conclusions ith absolute certainty. Id. he questions put to r. ost 
relating to the state of the science in arch 2008 ere couched in teI S of certainties and 
ol t s. fr.  ltrs sel, , 4 x. 2, (Yost ep. 153:16-25). r  i  t i  
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inconsistent between Dr Yostsdeposition and affidavit testimony and certainly the Defendant
has not identified a direct conflict which is what the law in Idaho requires before an affidavit
may be stricken as a sham
Furthermore Dr Yostsanswer made it clear that he his opinions were not based on any
single definitive study or article He explained that it was based on a preponderance of the
scientific evidence I dont think it exists except through the preponderance of evidence and it
may very well be that other people dontbelieve that thats the case but I do Id Yost Dep
154610
The Plaintiff is not required to point to any single definitive study that concludes that
exposure to OC Spray would have caused her an exacerbated response which would have
included an ongoing chronic cough for the subsequent period of time which is how the question
was put to Dr Yost in his deposition See Id Yost Dep 1532225 The Plaintiff is only
required to show that based on the scientific knowledge as it existed at the time the Defendant
should have known that there was a risk of injury to the respiratorypulmona system There is
no requirement that the Plaintiff present some definitive study showing a precise causal link
between the Defendantsproduct and the specific symptoms suffered by the Plaintiff It is
sufficient that the injury is to the target organ
Additionally Dr Yosts affidavit identifies specifically eleven articles that support his
opinions as expressed in his report Of those only three were published after March 2008 Yost
Aff 16 It is clear from reviewing Dr Yosts affidavit and deposition testimony that if defense
counsel had asked Dr Yost the relevant question Dr Yost would have answered just as he did in
his affidavit where he said
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may be stricken as a sham. 
rt er re, r. st's a s er a e it clear that e is i ions ere t ase   a  
single definitive study or article. e e lained that it as ase   a preponderance f the 
i tific i : ''1 n't t in  it ists ce t t rough the re era ce f i ,  it 
ay very ell be that other people don't believe that that's the case, but I do." Id (Yost ep. 
154:6-10). 
 l i tiff is t r ire  t  i t t   si le fmitive st  t t ludes t t 
exposure to C Spray "would have caused her an exacerbated response hich ould have 
included an ongoing chronic cough for the subsequent period of ti e" hich is ho  the question 
was put to Dr. Yost in his deposition.   (Yost . 53:22-2 ). e l i ti    
required to show that based on the scientific lmowledge as it existed at the time, the Defendant 
should have kno n that there as a risk f injury to the respiratory/pulmonary syste . here is 
no requirement that the Plaintiff present some definitive study showing a precise causal link 
t ee  t  f ndant's r t  t  s cifi  s t s s ff r   t  laintiff. It is 
s fficie t t at t e i j r  is t  t e tar et r an. 
dditionally, r. ost's affidavit identifies specifically eleven articles that support his 
opinions as expressed in his report. f those, only three were published after arch 2008. Yost 
ff., ~6. It is clear fro  revie ing r. ost's affidavit and deposition testi ony that if defense 
l   r. t t  r l t stion, r. t l  hav  r  j t   i  i  
i  ffi it r   i  
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The articles cited above are just a few of many that support my
opinions as expressed in my report in this case Based on my
review of the abovecited articles and my education training
research and knowledge of the scientific literature in the relevant
area it is my opinion that the risks to the respiratory tract posedby
exposure to SECsSabre Red law enforcement 10 OC Spray
MK9 Fogger were known and foreseeable risks at the time SEC
sold its product to the IDOC
200050 9
Id at 6 Similarly had the relevant question been posed to him during his deposition he would
have explained as he did in his affidavit the foreseeable risks associated with the Defendants
product
It is known now and it was known prior to 2008 that people with
asthma and chronic cough are more sensitive to pepper spray than
other people with normal respiratory function People with greater
sensitivity to capsaicin would be expected to have increased
TRPV1 receptor populations Other important TRP channels exist
and several of them particularly TRPA1 are activated by irritants
such as those that exist in cigarette smoke and other environmental
sources Thus it is reasonable to expect the multiple TRP
channels to act in concert with each other to result in higher acute
respiratory responses to a multitude of respiratory irritants
particularly in people with increased sensitivity to pepper sprays
Id at 17 Dr Yost went on to explain not only the specific mechanisms by which injury to the
respiratorypulmonary system was foreseeable he also explained why he disagreed with the
opinions expressed by Dr Reilly
In paragraph 8 Dr Reilly presents a series of claims relating to the
Plaintiffs discovery responses that are based upon 11 articles
Many of those articles were coauthored by Dr Reilly The
conclusions made in paragraph 8 prompted Dr Reilly to state that
none of these articles definitively state or otherwise establish
within a reasonable degree of scientific probability a conclusive or
causal association between exposure to OC spray and chronic or
longterm health conditions or chronic exacerbation ofpreexisting
health conditions Again Dr Reillysstatement is in the absolute
and is really not based upon the compilation of scientific evidence
alluded to in the articles To say that none of the articles state or
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~ 00510009 
l . t ~6. i il rl ,  t e r l t sti   s  t  i  ri  is siti ,  l  
 lained s  i  in is ffi it t e f res l  ris s ss i t  it  t e f ndant's 
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 s  ,     r  ,    
ast a a  c r ic c  are re se siti e t  e er s ra  t a  
other people ith nor al respiratory function. People ith greater 
sensitivity to capsaicin ould be expected to have increased 
T P l receptor populations. ther i portant T P channels exist, 
 r l f t , rti l rl   I, r  ti t   irrita t  
such as those that exist in cigarette s oke and other environ ental 
s. s, it is reas a le t  e ect t e lti le  
ls t  t i  rt it   t r t  r s lt i  i r t  
respiratory responses to a ultitude of respiratory irritants, 
particularly i  people ith increased sensitivity to pepper sprays. 
ld at ~ 7. r. ost ent on to explain not only the specific echanis s by hich injury to the 
respiratory/pulmonary syste  as foreseeable, he also explained hy he disagreed ith the 
opinions expressed by Dr. Reilly: 
I  ara ra  8, r. eill  rese ts a series f clai s relati  t  t e 
laintiff's i r  r  t t r     rti l s. 
any of those articles ere co-authored by r. eilly.  
l i   i    t  . ill  t  t t  t t 
none of these articles definitively state or other ise establish 
ithin a reasonable degree of scientific probability a conclusive or 
l i ti  t   t     i   
long-ter  health conditions or chronic exacerbation of pre-existing 
health conditions. gain, r. eilly's state ent is in the absolute 
and is really not based upon the co pilation of scientific evidence 
ll  t  i  t  rti l s.  s  t t  f t  rti l s st t  r 
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establish the association between acute and chronic effects
extrapolates to absolute and does not allow one to take a synthesis
of scientific weight of evidence presented in the sum of these
papers When one takes a synthesis of weight of evidence
presented in sum of these papers the opinions and conclusions I
have reached in my report are support to a reasonable degree of
scientific certainty
Id at 111 In his critique ofDr Reillysopinions Dr Yost explains that indeed the 2004 article
identified by Dr Reilly in his affidavit provides sound scientific evidence for the direct
relationship between chronic cough and expression of the receptors that respond to capsaicin
In paragraph 8 Dr Reilly presents a series of claims relating to the
Plaintiffs discovery responses that are based upon l 1 articles
Many of those articles were coauthored by Dr Reilly The
conclusions made in paragraph 8 prompted Dr Reilly to state that
none of these articles definitively state or otherwise establish
within a reasonable degree of scientific probability a conclusive or
causal association between exposure to OC spray and chronic or
longterm health conditions or chronic exacerbation ofpre existing
health conditions Again Dr Reillysstatement is in the absolute
and is really not based upon the compilation of scientific evidence
alluded to in the articles To say that none of the articles state or
establish the association between acute and chronic effects
extrapolates to absolute and does not allow one to take a synthesis
of scientific weight of evidence presented in the sum of these
papers When one takes a synthesis of weight of evidence
presented in sum of these papers the opinions and conclusions I
have reached in my report are support to a reasonable degree of
scientific certainty
Yost Aff 112
Dr Yost provided the same explanation in his deposition regarding the dangers ofmaking
absolute statements regarding scientific evidence as he has done in his affidavit For instance
Dr Yost testified as follows
Q Now you say here under your Acute Toxicities
paragraph that inhalation Im sorry that among the responses to
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141  
I  , . I  i  riti  f r. eilly's pinions, r. t l i  t t i  t   rti l  
i tifie   r. eill  i  is affi vit r i s "sou  scientifi  i  f r t  ir t 
relationship between chronic cough and expression of the receptors that respond to capsaicin" 
ost fT., , . 
In paragraph 8, Dr. Reilly presents a series of claims relating to the 
laintiff's discovery responses that are based upon II articles. 
any of those articles were co-authored by Dr. Reilly.  
conclusions ade in paragraph 8 pro pted r. Reilly to state that 
  t  rti l  fi iti l  t t  r t r ise t li  
ithin a reasonable degree of scientific probability a conclusive or 
causal association bet een exposure to  spray and chronic or 
long-tenn health conditions or chronic exacerbation of pre-existing 
l  i . i , . eilly's      
 s l     e   ti  e e 
llude  t  in t  rti l .   t t   t  rti l  t t  r 
t li  t e i ti  t e  t   i  ects 
extrapolates to absolute and does not allo  one to take a synthesis 
f scie tific eig t f e ide ce rese ted i  t e s  f t ese 
. hen one takes a synthesis of eight of evidence 
res te  i    t  r , t e i ions  lusions I 
have reached in y report are support to a reasonable degree of 
scie tific certai t . 
Dr. Yost provided the same explanation in his deposition regarding the dangers of making 
absolute statements regarding scientific evidence as he has done in his affidavit. For instance. 
r. ost testified as follo s: 
. o , you say here under your Acute Toxicities 
paragraph that inhalation -- I'm sorry, that a ong the responses to 
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OC exposure are leading to severe respiratory depression
cardiovascular dysfunction and death Do you see that there
AYes
Q What is the source of that statement
A I dontrecall what I have there are cases in the literature of
people dying from capsaicin exposure and we documented several
of those in some of our publications So I could go back and find
out where those cases occurred give you the specific references if
you would like but people have died
Q But isn it also true that studies have gone back and looked at
those death cases and determined that those cases of death actually
occurred with other issues going on specifically drug use alcohol
use and other underlying physical force issues that were not related
to capsaicin exposure
A rm aware that there was at least a study or two that had that
the office had the opinions that other factors could either contribute
to or be amajor cause ofmorbidity or mortality in those cases
Q Did you do any research that would indicate that there was
that that was not an accurate conclusion
AOh no Its possible
Q So wouldyou accept that conclusion as being accurate
A No I would accept it as being a possibility Theresa difference
between proving something and postulating something Its
possible
Q When you say theresa difference between proving something
and postulating something what do you mean that difference to
be What is the difference between proving and postulating
A Well there is no such thing as absolute proof in science If
youre a true scientist then nothing is ever absolute So proof to me
means a weight of evidence argument that the weight of the
evidence provided is convincing and well convincing
Q And asimple Im sorry
A Its convincing to me Im only going to talk about myself here
but its convincing to me that its true that until proven otherwise
thats a process that Ill accept as being proof where there is no
such thing as true proof
QA simple case report does not by itselfmake proof does it
A No
Aff ofPltfs Counsel 14 Ex 2 Yost Dep 1282 13024
IM 00079
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III CONCLUSION
For the above stated reasons the Defendantsmotion to strike portions of Dr Yosts
affidavit must be denied
DATED this 1 day of July 2011
JONES SWARTZ PLLC
By
ERSO
ERIC B SWARTZ
PLAINTIFFSOPPOSITION TO DEFENDANTSMOTION TO STRIKE PORTIONS OF THE AFFIDAVIT OF
GAROLD YOSTPHD 7
000920
07/01/2011 16:56 FAX 208 489 8988 Jones Swartz ~ 000810009 
.. 
In. I  
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affi vit t  nied. 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
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CaseNo CV PI 1003515
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
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Plaintiff Billie Jo Major by and through her counsel of record Jones Swartz PLLC
respectfully submits the following Reply to DefendantsOpposition to PlaintiffsCross Motion
for Partial Summary Judgment pursuant to Idaho Rule of Civil Procedure 56 on the issue of
Defendantsbreach of the standard of care on the duty to warn by affixing warning labels to the
SABRE Red Law Enforcement 10 OC Spray that comply with the Hazard Communication
Standard 29CFR 191020
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l i tiff illie J  j r,   t r  r s l f r cord, J s &  L , 
respectfully submits the following Reply to Defendant's Opposition to Plaintiffs Cross-Motion 
for Partial Su ary Judg ent pursuant to Idaho ule of ivil Procedure 56 on the issue of 
f ndant's r   t  t r  f r   t  t  t  r   ffi i  r i  l l  t  t  
S E ed La  Enforce ent 10%  Spray that co ply ith the azard o unication 
Standard, 29 C.F.R. § 910. 200. 
LAINTIF 'S EPL   EFENDANT'S PPOSITI  T  
LAINTIF 'S - I   PARTIA  SUMMARY JUDG T - 1 
A THE HAZARD COMMUNICATION STANDARD APPLIES TO WORKPLACE
PRODUCTS USED WITH A FREQUENCY AND DURATION GREATER THAN
WHAT WOULD BE EXPECTED OF A CONSUMER USING THE SAME
PRODUCT
The warning label standards for Defendant Security Equipment CorporationsSEC
SABRE Red Law Enforcement 10 OC Spray MK9 Fogger are those set forth by the Hazard
Communication Standard 29 CFR 191020 Amended Affidavit of JP Purswell in
Opposition to DefendantsMotion for Summary Judgment Amended Purswell Aff 16
Ex C This section applies to any chemical which is known to be present in the workplace in
such a manner that employees may be exposed under normal conditions of use or in a foreseeable
emergency 191020b Even a consumer product can fall under the Hazard
Communication Standard if it is used in the workplace with a greater frequency and duration that
what would reasonably be experienced by consumers when they use it for its intended purpose
191020b6ixThe label in this case clearly states that the product is to be used by
Law Enforcement Corrections Military or Security Personnel trained in the proper use of
aerosol projectors Aff ofPltfsCounsel 110 Ex 8 Nance Dep 904 942 and Exs D and
E It is undisputed that SECsSABRE Red Law Enforcement 10 OC Spray products were
used by the Plaintiff in the course of her employment with the IDOC It is also undisputed that
exposures by IDOC employees to OC Spray was for a duration frequency and purpose not
reasonably expected with a typical consumersuse Defs Statement of Undisputed Facts 111
57 10 16 Aff of Pltfs Counsel 19 Ex 7 Schaffer Dep 3120 110 Ex 8 Nance
Dep 443 483 506 5420 5924 635 755 762774 824 9123
9214 12225 1273 Exs E J K 11 Ex 9 Link Dep 571 5825 6014
6215 Aff DefsCounsel 13 Ex B Kimmel Dep 9814 9911
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he arning label standards for efendant Security quip ent orporation's (S ) 
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o  rd,  .F.R. § 910. 2 0. e  id   .P.   
pposition to efendant's otion for u ary Judg ent ("Amended urs ell ff."), -,r 6, 
x. . "This section applies to any che ical hich is kno n to be present in the orkplace in 
such a anner that e ployees ay be exposed under nor al conditions of use or in a foreseeable 
emergency." § 1910.1200(b)(2). Even a consu er product can fall under the azard 
icatio  ta ar  if it is se  i  t e r lace it  a reater fre e c  a  rati  t at 
hat ould reasonably be experienced by consu ers hen they use it for its intended purpose. 
§ 910.1200(b)(6)(ix).  l l i  t i   l rl  t t  t t t  r t i  "[t]o    
a  f r t, rr ti , ilitar  r rit  r l tr i  i  t  r r  f 
aerosol projectors." ff. ofPltf's ounsel, -,r 10, Ex. 8 (Nance ep., 90:4 - 4:24  .   
). It is undisputed that C's  ed a  nforce ent 10%  pray products ere 
used by the Plaintiff in the course of her e ploy ent ith the I . It is also undisputed that 
exposures by I C e ployees to C Spray as for a duration, frequency, and purpose not 
reasonably expected ith a typical consumer's use. ef's State ent of ndisputed Facts, " , 
-7, , ; ff. f Itf's sel, '  .  (Sc affer ep., 1:3-2 ), '10, x.  (Nance 
Dep., 44:3 - 48:3, 50:6 - 54:20, 59:24 - 3:5, 5:5 - 6:2, 7:4 - 2:4, 1:23 -
92:14, 122:25 - 27:13 & s. ,  & ), '1 , x.  (Lin  ep., 7:1 - 8:25, 0:14-
62: 15); ff. ef's Counsel, '3, Ex. B (Kim el ep., 98: 14 - 9: 1). 
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Finally it should be noted that SEC went to the trouble to prepare thorough and complete
material safety data sheets MSDS as required for chemicals covered by 191020 for its
SABRE Red products There is no requirement for consumer products subject to the FHSA to
provide an MSDS While the provision of MSDS by SEC to purchasers of the product is not
determinative it certainly suggests that even SEC considered the SABRE Red products subject
to the requirements of 191020
B THE FHSA STANDARDS APPLY ONLY TO HOUSEHOLD GOODS AND NOT
TO PRODUCTS USED IN THE WORKPLACE WITHA FEQUENCY AND
DURATION GREATERTHANWHAT WOULD REASONABLY BE EXPECTED
BY A CONSUMER USING THE SAME PRODUCT
The label warning requirements for household goods are found under the FHSA The
Consumer Product Safety Commission CPSC issues the governing regulation pursuant to and
for the implementation of the FHSA 15 USCA 12611278 16 CFR 1500
Authority under the Federal Hazardous Substances Act is vested in the Consumer Product
Safety Commission by section 30a of the Consumer Product Safety Act 15USC2079a
16CFR 15002 The CPSC has defined a misbranded hazardous substance as follows
Hazardous substances intended or packaged in a form suitable for
use in the household means any hazardous substance whether or
not packaged that under any customary or reasonably foreseeable
condition of purchase storage or use may be brought into or
around a house apartment or other place where people dwell or
in or around any related building or shed including but not
limited to a garage carport barn or storage shed The term
includes articles such as polishes or cleaners designed primarily
for professional use but which are available in retail stores such as
hobby shops for nonprofessional use Also included are items
such as antifreeze and radiator cleaners that although principally
for car use may be stored in or around dwelling places The term
does not include industrial supplies that might be taken into a
home by a serviceman An article labeled as and marketed solely
for industrial use does not become subject to this act because of
the possibility that an industrial worker may take a supply for his
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i lly, it l   te  t t  e t t  t  tr l  t  r r  t r gh  lete 
aterial safety data sheets (MS S) (as required for che icals covered by § 910. 2 0) f r its 
  r t . r  i   r ir t f r "consu er r cts" j t t  t   t  
r i e a  . ile t e r isio  f    t  rc asers f t e r ct is t 
deter inative, it certainly suggests that even S  considered the S  ed products subject 
to the require ents of § 910. 2 0. 
.   S        
          
        
       
he label arning require ents for household goods are found under the F SA. he 
r r t f t  i i  (CP ) i  t  r i  r l ti  r t t   
for the i ple entation of the F S .  .S.C.A. §§ -12 ;  .F.R. § 50 .1. 
"Authorit  r t  r l a r s t  t i  t  i  t  r r t 
f t  issi   s ti  0(a) f t  s r r t f t  t (1  .S.C. 079(a))." 
 .F.R. § 50 .2.      "misbrande  s tance"  s: 
azardous substances intended, or packaged in a for  suitable, for 
use in the household eans any hazardous substance, hether or 
not packaged, that under any custo ary or reasonably foreseeable 
condition of purchase, storage, or use ay be brought into or 
around a house, apart ent, or other place where people dwell, or 
i  r r  y rel te  il i  r s e  i cl i g, t t 
li ite  to,  r e, c r rt, r , r st r e s ed.   
includes articles, such as polishes or cleaners, designed pri arily 
for professional use but hich are available in retail stores, such as 
hobby shops, for nonprofessional use. ls    s, 
such as antifreeze and radiator cleaners, that although principally 
for car use ay be stored in or around d elling places. The ter  
s t i l  i stri l s li s t t i t  t  i t   
   .    s,   l l  
for, industrial use does not beco e subject to this act because f 
the possibility that an industrial orker ay take a supply for his 
I TIFF'S   FENDANT'S SITI   
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own use Size of unit or container is not the only index ofwhether
the article is suitable for use in or around the household the test
shall be whether under any reasonably foreseeable condition of
purchase storage or use the article may be found in or around a
dwelling
16CFR 15003ciemphasis added The FHSA defines a misbranded hazardous
substance as follows
The term misbranded hazardous substance means a hazardous
substance intended or packaged in a form suitable for use in
the household or by children if the packaging or labeling of such
substance is in violation of an applicable regulation issued pursuant
to section 1472 or 1473 of this title or if such substance except as
otherwise provided by or pursuant to section 1262 of this title fails
to bear a label1 which states conspicuously A the name and
place of business of the manufacturer packer distributor or seller
B the common or usual name or the chemical name if there be
no common or usual name of the hazardous substance or of each
component which contributes substantially to its hazard unless the
Commission by regulation permits or requires the use of a
recognized generic name Cthe signal word DANGER on
substances which are extremely flammable corrosive or highly
toxic Dthe signal word WARNING or CAUTION on all
other hazardous substances E an affirmative statement of the
Principal hazard or hazards such as Flammable
Combustible Vapor Harmful Causes Burns Absorbed
Throuzh Skin or similar wording descriptive of the hazard
F precautionary measures describing the action to be followed or
avoided except when modified by regulation of the Commission
pursuant to section 1262 of this title G instruction when
necessary or appropriate for firstaid treatment Hthe word
poison for any hazardous substance which is defined as highly
toxic by subsection h of this section Iinstructions for handling
and storage of packages which require special care in handling or
storage and J the statement iKeep out of the reach of
children or its practical equivalent or iiif the article is intended
for use by children and is not a banned hazardous substance
adequate directions for the protection of children from the hazard
and
15USCA 1261pemphasis added see also 15USCA 1471 definition of household
substance under the Special Packaging of Household Substances for Protection of Children
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 . ize  it  tainer is t t  l  i de   ether 
 le is ta le      t  l ;   
 e hether    orese e tion  
rc ase, st ra e, r se t e article a  e f  i  r ar  a 
elli . 
 .F.R. § 1500.3(c)(10)(i) (emphasis added).     "misbrande   
t nce"  : 
  "misbranded s t nce"    
e ... d,      l ,    
t e se l  r v c il re , if t e ac a i  r la eli  f s c  
 s  la    e    
to section 1472 or 1473 f this title or if such substance, except as 
other ise provided by or pursuant to section 1262 f this title, fails 
t  r  label-(l) ic  st t s s i sl  (A) t    
place of business of the anufacturer, packer, distributor or seller; 
(B) the co on or usual na e or the che ical na e (if there be 
  r s l e) f t  r s s st  r f  
c e t ic  c tri tes s stantiall  t  its azard, less t e 
Co ission by regulation per its or requires the use of a 
rec ize  e eric a e; (C) t e si al r  "DA "  
substances hich are extre ely fla able, corrosive, or highly 
toxic; (D) the signal ord "WA I " or "CA I " on all 
other hazardous substances; eEl an a(fir ative state ent f the 
p    r ,   "Flam  ", 
"Co bustible", "Vapor armful", "Causes urns", "Absorbed 
g   ", or si ilar ording descriptive f the hazard; 
(F) precautionary easures describing the action to be follo ed or 
avoided, except hen odified by regulation of the o ission 
pursuant to section 1262 of this title; (G) instruction, hen 
necessary or appropriate, for first-aid treat ent; (H) the ord 
"poison" for any hazardous substance hich is defined as "highly 
t xic"  s s cti  (h) f t is s cti n; (I) i str tions f r li  
and storage of packages hich require special care in handling or 
storage; and (J) the statement (i) "Keep out of the reach of 
children" or its practical equivalent, or, (ii) if the article is intended 
for use by children and is not a banned hazardous substance, 
adequate directions for the protection of children fro  the hazard, 
nd .... 
 .S.C.A. § 1261(p) (e phasis added); see also 15 .S.C.A. §  (definitio  f "house l  
substance" under the Special Packaging of ousehold Substances for Protection of hildren 
I TIFF'S   FENDANT'S I   
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standards The clear intent of the FHSA is to protect the consumer at home and not the
employee in the workplace
C EVEN IFTHE FHSA APPLIED SECHAS NOT PROVEN ITS PREEMPTION
DEFENSE BY SHOWING THAT THE PLAINTIFF SEEKS LABELWARNINGS
DIFFERENT FROM THOSE REQUIRED UNDER THE FHSA
Even if the FHSA was applicable to SECsSABRE Red Law Enforcement 10 OC
Spray MK9 Fogger SEC has not complied with the labeling requirements of the FHSA The
FHSA requires a label to include an affirmative statement of the principal hazard or hazards
such as Flammable Combustible Vapor Harmful Causes Burns Absorbed Through
Skin or similar wording descriptive of the hazard 15USCA 1261pE The MK9
Fogger has no such statement relating to any hazards to the respiratorypulmonary system even
though SEC knew the products primary action by design was to inflame the respiratory
pulmonary tract and that overexposure to OC Spray could cause long term damage or extremely
long recovery periods Aff of Pltfs Counsel 110 Ex 8 Nance Dep 398 407443 483
6322 643 654911 92149815 1012 and Ex E Bates Nos SEC 353 358
It is SEC burden to demonstrate preemption in this case Bruesewitz v Wyeth LLC 131
S Ct 1068 1087 n 2 2011 it is defendant burden to prove affirmative defense of
preemption quoting Brown v Earthboard Sports USA Inc 481 F3d 901 912 6th Cir 2007
and citing Silkwood v KerrMcGee Corp 464 US 238 255 1984 Fifth Third Bank v CSX
Corp 415 F3d 741 745 7th Cir 2005 Heath v HonkersMiniMart Inc 134 Idaho 711
712 Ct App 2000 party not carrying burden of proof at trial may establish right to summary
judgment by showing absence of proof on element required to be proven at trial While SEC
has argued that the FHSA is the appropriate standard for warning labels on its law enforcement
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t ndards).  l r i te t f t   i  t  r t t t  r t   t t  
e ployee in the orkplace. 
.  I    LI ,     I  I  
     IFF   S 
I    I     
ven if the  as applicable to EC's  ed a  nforce ent 10%  
Spray, -9 Fogger, S  has not co plied ith the labeling require ents of the F SA. he 
F S  requires a label to include "an affir ative state ent of the principal hazard or hazards, 
  "Flamma ", "Comb ti l ", "Vap  ", "Causes ", "Absorbed Through 
", r si ilar r i  escri ti e f t e azard."  .S.C.A. § 261(P)(E).  -9 
ogger has no such state ent relating to any hazards to the respiratory/pulmonary syste , even 
t    t  duct's i  ti   i   t  i la  t  piratory/ 
pul onary tract and that overexposure to  Spray could cause "long ter  da age or extre ely 
long recovery periods." ff. ofPltfs ounsel, ~ 10, Ex. 8 (Nance ep., 39:8 - 0:7, 4:3 - 8:3, 
3:6-22, 4:3 - 5:4, :1- 2:14, 8:15 -101:20,  x. , t  .   - 358). 
It is SEC's burden to de onstrate pree ption in this case. Bruesewitz v. yeth LLC, 131 
S. t. 1068, 1087 n. 2 (2011) (it is defendant's burden to prove affir ative defense of 
pree ption) (quoting Bro n v. Earthboard Sports SA, Inc., 481 F.3d 901, 912 (6th ir. 2007) 
and citing Silk ood v. err- cGee orp., 464 .S. 238, 255 (1984); Fifth Third Bank v. SX 
Corp., 415 F.3d 741, 745 (7th Cir. 2005)); eath v. onker's ini-Mart Inc., 134 Idaho 711, 
712 (Ct. pp. 2000) (party not carrying burden of proof at trial ay establish right to su ary 
judg ent by sho ing absence of proof on ele ent required to be proven at trial). hile S  
has argued that the F S  is the appropriate standard for arning labels on its la  enforce ent 
I TIFF'S   FENDANT'S I   
I TIFF'S -      -  
products it has not shown how the Plaintiffsstate law claims would be different from the FHSA
requirements
A state law claim is only preempted when the state law would require labels different
from those prescribed by the FHSA The preemption provision of the Federal Hazardous
Substances Act FHSA precludes plaintiffs from bringing common law tort claims which seek
to impose cautionary labeling requirements for hazardous substances which are different from
and are designed to protect against the same risk of illness or injury as those imposed by the
FHSA Busch v Graphic Color Corp 662NE2d397 40508 Ill 1996 Moss v Parks Corp
985 F2d 736 73841 4th Cir 1993 Canty v EverLast Supply 685A2d 1365 137174 NJ
Superior Ct 1996 Chem Specialties Manuf Assoc v Allenby 744FSuppNDCa 1990
Oakley v Air Products Chem 2008 WL 45250933ED Tex 72ACJSProduct Liability
44 69ALR5th 1377cAmerican Law ofProduct Liability 3d 20
We agree with the plaintiff that under the subject preemption
provision only those labeling requirements which are designed to
protect against the same risk of illness or injury as those targeted
by the Federal statute are preempted Emphasis added
15USC 1261 noteb1A1988 We also agree that the
Safety Commissionsprimary focus in issuing its 1987 Notice was
in fact to warn consumers of the carcinogenic risks posed by
methylene chloride found in products such as paint strippers We
disagree however that the risk of cancer was the Safety
Commission sole focus The Safety Commission has expressly
acknowledged its concern with the risk to individuals of acute
inhalation intoxication posed by methylene chloride vapors This
concern is evidenced by statements made by the Safety
Commission in 1992 when it responded to several individuals
comments regarding the preemptive scope of the FHSA In
responding to one individuals comment that the labeling
requirements of the FHSA were too weak and vague to preempt
State laws the Commission responded
The requirements of the FHSA are not vague The labeling
must communicate to the consumer an understanding of the
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r ts, it s t s   t  l intiff s st t  l  l i s l   iffere t fr  t   
require ents. 
 state la  clai  is only pree pted hen the state la  ould require labels different 
fro  those prescribed by the . he pree ption provision of the ederal azardous 
ubstances ct (F ) precludes plaintiffs fro  bringing co on la  tort clai s hich seek 
t  i pos  ti r  l li  re ire ents f r r s t  ic  r  iffere t fr  
 r  si  t  r t t i st t  s  ris  f illness r i j r  s t s  i pose   t  
. s  . r i  l r orp.,  .E.2d , -08 (Ill. 96); ss . r s orp., 
 .2d , -4  (4th ir. 93); t  . -Last pply,  .2d , -74 (N.J. 
Superior t. 1996); hern. Specialties anu! ssoc. v.  llen by, 744 F.Supp. (N.D. a. 1990); 
akley v. ir roducts & ern.,   *3 (E.D. ex);  c.J.S. t i ilit  
§ 44; 69 A.L.R. 5th 137(7)(c); A erican Law of Product Liability 3d § :2 . 
e agree ith the plaintiff that under the subject pree ption 
provision, only those labeling require ents hich are "designed to 
protect against the sa e risk of illness or injury" as those targeted 
by the  statute are pree pted. (Emphasis added.) 
(15 .S.C. § 1261 note (b)(I)(A) (1988).) e also agree that the 
Safety o ission's pri ary focus in issuing its 1987 otice as, 
in fact, to arn consu ers of the carcinogenic risks posed by 
ethylene chloride found in products such as paint strippers. e 
disagree, ho ever, that the risk of cancer as the Safety 
o ission's sole focus. he afety o ission has expressly 
ackno ledged its concern ith the risk to individuals f acute 
inhalation intoxication posed by ethylene chloride vapors. his 
  e  by     t  
o ission in 1992 hen it responded to several individuals' 
co ents regarding the pree ptive scope of the F S . I  
responding   i idual's t   labeling 
require ents of the F S  ere too eak and vague to pree pt 
State laws, the Co ission responded: 
"The require ents of the F S  are not vague. * * * [T]he labeling 
ust co unicate to the consu er an understanding of the 
I TIFF'S   FENDANT'S I   
L INTIF 'S -   I    -  
potential principal hazard or hazards presented by the product in
order to avoid beingmisbranded and subject to legal action
The cautionary label required under section 1261p of the FHSA
must present a balanced perspective of the potential hazards of the
product Many products which may cause chronic health effects
may also be acutely toxic and present physical hazards such as
flammability 57 FedR g 4662646664 1992
The Commission then went on to highlight the labeling
requirements under the FHSA for paint strippers containing
methylene chloride
The suggested labeling for methylene chloride paint strippers had
to take into consideration the productsacute inhalation toxicity in
addition to the carcinogenicity hazard Therefore the suggested
front panel label statement is VAPOR HARMFUL with the
instruction Read Other Cautions and HEALTH HAZARD
INFORMATION on back panel and the back panel statement is
Contains methylene chloride which has been shown to cause
cancer in certain laboratory animals For products where the only
hazard is carcinogenicity and the evidence of increased risk of
cancer to humans is clear the labeling would be more
straightforward 57 FedR g46626466641992
Busch 662NE2d at 408
Here SEC has provided no warnings on the SABRE Red Law Enforcement 10 OC
Spray MK9 Fogger warning of anyrespiratorypulmonary hazards As such even assuming for
the sake of argument that the FHSA applied Plaintiffsstate law claims are not preempted
insofar as they are limited to warnings identical to those required by the FHSA
D PLAINTIFF HAS MET THE SANCHEZ v GALEYSTANDARD FOR
NEGLIGENCE PER SE
Under Sanchez v Galey 112 Idaho 609 1986 a plaintiff must establish negligence
per se by demonstrating 1 the statute or regulation clearly defines the required standard of
conduct 2 the statute or regulation was intended to prevent the type of harm caused by the
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t ti l ri i l r  r r s r t   t  r t i  
 t  i  i  is ra   j t t  l l ti . 
****** 
e ca ti ar  la el re ire  er [secti  261(p) f] t e  
ust present a balanced perspective f the potential hazards f the 
product. any products hich ay cause chronic health effects 
ay also be acutely toxic and present physical hazards, such as 
fla ability." 57 ed.Reg. 46,626,46,664 (1992). 
 s   t   highlight  labeling 
r ire e ts r t   f r i t tri r  t i i  
t le  l ri : 
"The s st  l li  f r t l  l ri  i t stri rs  
to take into consideration the product's acute inhalation toxicity in 
addition to the carcinogenicity hazard. herefore, the suggested 
front panel label state ent is ' AP  F L' ith the 
 'Rea       
I I    el'  t   l t t t i  
' ontains ethylene chloride, hich has been sho n to cause 
cancer in certain laboratory ani als.' For products here the only 
azar  is carci e icit  a  t e e i e ce f i crease  ris  f 
    r,  la eli  l    
straightforward." 57 ed.Reg. 46,626,46,664 (1992). 
,  .E.2d  . 
ere,  has provided no arnings on the  ed a  nforce ent 10%  
Spray, -9 Fogger, arning of any respiratory/pulmonary hazards. s such, even assu ing for 
the sake of argu ent that the  applied, laintiffs state la  clai s are not pree pted 
insofar as they are limited to warnings identical to those required by the FHSA. 
. IFF     .    
   
nder Sanchez v. aley, 112 Idaho 609 (1986), a plaintiff ust establish negligence 
per se by de onstrating (1) the statute or regulation clearly defines the required standard of 
conduct; (2) the statute or regulation was intended to prevent the type of harm caused by the 
I TIFF'S   ENDANT'S I   
I TIFF'S SS-      -  
defendant 3 the plaintiff was a member of the class the statute or regulation was designed to
protect and 4 violation of the statute or regulation was the proximate cause of the injury As
noted in Sanchez the fourth element is necessary to hold the defendant liable Issues ofmaterial
fact exist in this case on the proximate cause element However the Plaintiff is entitled to
summary judgment on the other three elements
1 The Hazard Communication Standard required SEC to include on its label a
warning that theMK9Fogger contained a respiratorypulmonary irritant that
would cause inflammation of the target organ
There is no dispute that SEC knew its MK9 Fogger was designed to target the
respiratorypulmona tract that it was an irritant and would cause inflammation of the
respiratorypulmona system Aff of Pltfs Counsel 110 Ex 8 Nance Dep 398 407443
4836322 643 654911 9214 9815 1012 and Ex E Bates Nos SEC 353
358 SEC admitted that it knew exposure to high concentration could cause long term injury or
prolong an already existing illness and that its product was an irritant aimed specifically at the
respiratorypulmona system Id Because it at least knew its product was an irritant of the
respiratorypulmona system and it did not warn of such risk on its label it is undisputed that
SECsMK9 Fogger labeling was not compliant with the Hazard Communication Standard
Amended Purswell Aff 45 and Ex B
The Hazard Communication Standard requires the manufacturer to test to determine
whether chemicals in their products are hazardous 191020bd1andd2 It also
requires that the manufacturer include on the label warning ofthe effects ofhazardous chemicals
on target organs Martin v American Cyanamid Co 5 F3d 140 14142 6th Cir 1993 SEC
conducted some testing but chose not to test for chronic health effects from either chronic or
acute exposure Aff ofPltf s Counsel 110 Ex 8 Nance Dep 214 4311441217 567
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efe ant; (3) t e lai tiff as a e er f t e class t e stat te r re lati  as esi e  t  
protect; and (4) violation f the statute or regulation as the proxi ate cause f the injury. s 
t  i  z, t  f rt  l t i  r  t  l  t e f t li l . I  f t ri l 
f t ist i  t is s   t  r i t  s  l t. er,  l intif   t   
su ary judg ent on the other three ele ents. 
1. e azar  o icatio  ta ar  re ire   to i cl e o  its la el a 
r i  t t t e K-9 er c t i e   res ir t r /pulmo r  irrita t t t 
     g  n. 
here is no dispute that  kne  its -9 ogger as designed to target the 
respiratory/pulmonary tract, that it as an irritant and ould cause infla ation of the 
respiratory/pulmonary syste . Aff. ofPltfs Counsel, -,r 10, Ex. 8 (Nance Dep., 39:8 - 0:7, 4:3 
- 48:3, 63:6-22, 64:3 - 65:4, 91:1 - 2:14, 8:15 - 01 :20  . ,  .   -
358). S  ad itted that it kne  exposure to high concentration could cause long ter  injury or 
prolong an already existing illness, and that its product as an irritant ai ed specifically at the 
respiratory/pulmonary syste . !d. ecause it at least kne  its product as an irritant of the 
respiratory/pulmonary s ste  a  it i  t ar  f s c  ris   its la el, it is is te  t at 
S C's -9 Fogger labeling as not co pliant ith the azard o unication Standard. 
(Amended Purs ell ff., -,r-,r -5  . .) 
he azard o unication Standard requires the anufacturer to test to deter ine 
hether che icals in their products are hazardous. § 191O.l200(b)(1), (d)(1) and (d)(2). It also 
requires that the anufacturer include on the label arning of the effects of hazardous che icals 
on "target organs." artin v. American Cyanamid Co., 5 F.3d 140, 141-42 (6th Cir. 1993). SEC 
conducted so e testing but chose not to test for chronic health effects fro  either chronic or 
acute exposure. Aff. ofPltfs Counsel, -,r 10, Ex. 8 (Nance Dep., 21:24 - 3: 1, 4:12-17, :7-
I TIFF'S   FENDANT'S I   
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5917 1307 13725 1390 1402 and Exs LO A material issue of fact may exist as to
whether the science at the time should have put SEC on notice of the risk posed by its product
and even whether the Plaintiffsspecific injuries were caused by exposure to SECsproducts A
material issue of fact does not exist however as to whether SEC was required to include on its
label a warning that the product was a respiratorypulmonary irritant As such the Plaintiff has
met her burden on the first element of the Sanchez standard for proving negligence per se
2 The Hazard Communication Standard was intended to prevent the type of harm
involved in this case
The type of harm suffered in this case is respiratorypulmonary irritation and
inflammation The extent of the harm is different from the type of harm See Durez Div of
Occidental Chem Corp v OSHA 906 F2d 1 25 DCCir 1990 Hazard Communication
Standard required manufacturer to include in its MSDS that overexposure to phenol and
formaldehyde might cause damage to liver kidney or heart despite manufacturerscontention
that such damage was unlikely at foreseeable levels of exposure General Carbon Co v OSHA
860 F2d 479 48385 DCCir 1988 rejecting manufacturerscontention that there is no
labeling requirement under the Hazard Communication Standard to warn where there is no
evidence of significant risk to particular workers That a material issue of fact may or may not
exist as to whether the extent ofharm is what the Hazard Communication Standard was intended
to prevent does not preclude partial summary judgment where the injury is the type the
Regulation sought to prevent See id SEC was required under the Hazard Communication
Standard to provide an appropriate hazard warning for the protection of employees such as the
Plaintiff See id 29CFR 191020 Martin v American Cyanamid Co 5F3d 140 14142
6th Cir 1993 An appropriate hazard warning requires warning of the effects of hazardous
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9:17, 0:7 - 37:25, 39:10- 40:12  . -O).  t i l is   t  i t  t  
hether the science at the ti e should have put S  on notice of the risk posed by its product, 
  t r t  l intiffs s ifi  i j ries ere s   s r  t  C's r ts.  
aterial iss e f fact es t e ist, e er, as t  het er  as re ire  t  i cl e  its 
label a arning that the product as a respiratory/pulmonary irritant. s such, the laintiff has 
t  rde   t  irst l t  t   t   ing ligence  . 
.   ion  as te e     pe   
lve   is e. 
 t  f r  s ffer  m t is s  is r s ir t r /pulmon r  irritatio   
i la . he extent f the har  is different fro  the type f har . See urez iv. f 
cci e t l e . r . v. ,  .2d 1, -5 (D.C. ir. 0) (Hazar  icati  
tandard required anufacturer to include in its  that overexposure to phenol and 
for aldehyde ight cause da age to liver, kidney or heart despite anufacturer's contention 
that such da age as unlikely at foreseeable levels of exposure); eneral arbon o. v. S A, 
 .2d , -85 (D.C. ir. ) (rejecti  anufacturer's c te ti  t at t ere is  
l li  r ir t r t  r  i ti  t r  t  r  r  t r  is  
evidence f significant risk to particular orkers). hat a aterial issue f fact ayor ay not 
                
to prevent does not preclude partial su ary judg ent here the injury is the type the 
egulation sought to prevent.  .  as required under the azard o unication 
Standard to provide an appropriate hazard arning for the protection of e ployees such as the 
l intif .  .  .F.R. § 1910.1200; artin v. erican yana id o., 5 .3d 140, 141-42 
(6th ir. 1993). n "appropriate hazard arning" requires arning of the effects of hazardous 
I TIFF'S   FENDANT'S SITI   
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chemicals on target organs American Cyanamid Co 5 F3d at 14142 Durez 906F2d at 25
Manufacturers must include such warnings on their shipping and product labels Id
Manufacturers must also provide appropriate hazard warnings by including such information in
a Material Safety Data Sheet and supplying the MSDS to downstream employers Id While the
Defendant included warning information in its MSDS it failed to identify any effects of its
product on the target organ which was the respiratorypulmona tract As such there is no
genuine issue ofmaterial fact as to whether the Hazard Communication Standard was intended to
prevent the type of harm involved in this case Partial summary judgment is appropriate
3 There is also no dispute that Plaintiff was within the class of persons which the
Hazard Communication Standard was intended to protect
The Hazard Communication Standard was intended to protect employees from chemical
hazards in the workplace General Carbon Co v OSHA 860 F2d 479 480DCCir 1988
It is undisputed that the Plaintiff was working at the IDOC during each of her exposures to OC
Spray As such SEC cannot contend that the Plaintiff was not within the intended class of
persons the Regulation was intended to protect
4 Defendantsproximate cause argument is irrelevant at this stage since the
Plaintiff is not seeking summary judgment on causation
Plaintiff seeks partial summary judgment which includes only the first three elements of
the Sanchez standard Plaintiffconcedes an issue ofmaterial fact exists as to proximate cause
DATED this 7th day of July 2011
JONES SWARTZPLLC
DARWINL OVERSON
ERIC B SWARTZ
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BILLIE JO MAJOR and individual
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SECURITY EQUIPMENT CORPORATION
a Missouri corporation
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ss
County of El Paso
Case No CV PI 1003515
AMENDED AFFIDAVIT OF
JPPURSWELL PHDPECPE
IN OPPOSITION TO DEFENDANTS
MOTION FOR SUMMARY JUDGMENT
I JP PURSWELL PhDPECPE being first duly sworn upon oath depose and state
of my own personal knowledge that if called upon to testify I would competently testify to the
following
1 I am vice president of Purswell Purswell Ergonomic Safety Consulting I
consult with manufacturers and attorneys on ergonomic and safety issues I perform hazard
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I, J.P. PURS ELL, Ph.D., P.E., CPE, being first duly sworn upon oath, depose and state 
of y own personal knowledge that, if called upon to testify, I would co petently testify to the 
following: 
. I am vice president of Purswell & urswell, rgono ic & afety onsulting. I 
consult ith anufacturers and attorneys on ergono ic and safety issues. I perfor  hazard 
 I I   J.P. SWELL, H.D., .E., ePE, I  POSITI   
EFENDANT'S    J  - 1 
analysis of products for manufacturers and consult with manufacturers on the development of
warnings and instructions for new and redesigned products In addition I assist manufacturers in
product risk assessment development of material safety data sheets and analysis of OSHA
compliance issues
2 I hold a BS in Chemistry and Biology as a double degree an MS in Industrial
Engineering and a PhDin Industrial and Systems EngineeringHuman Factors I am an adjunct
professor in the Engineering Department of Colorado State University Pueblo I teach the
graduate ergonomics and senior level safety courses and supervise student research on product
safety and usability issues
3 Attached hereto as Exhibit A is a true and correct copy of my curriculum vitae
4 Attached hereto as Exhibit B is a true and correct copy of the report of my expert
opinions as to whether Defendant SECswarning labels provided with its SABRE Red law
enforcement 10 OC Spray products were OSHA compliant and in line with industry standards
In the attached report I explain why SECswarning labels were not compliant and how I came to
that conclusion
5 I understand from reviewing Defendantsmotion for summary judgment that the
position taken by SEC in this case is that the requirements for its warning labels on its SABRE
Red law enforcement 10 OC Spray products is governed by the Federal Hazardous Substance
Act That may or may not be true for other products sold by SEC but the SABRE Red Fogger
product is clearly intended for occupational use at a frequency and duration that would greatly
exceed any foreseeable use by a consumer in a non occupational circumstance Thus the
requirements for the label ofthese law enforcement grade products are found in the Occupational
Safety and Health AdministrationsHazard Communication Standard Regulation 191020 as
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In the attached report, I explain hy SEC's arning labels ere not co pliant and ho  I ca e to 
 l sion. 
. I understand fro  revie ing efendant's otion for su ary judg ent that the 
position taken by SEC in this case is that the requirements for its warning labels on its SABRE 
ed la  enforce ent 10%  pray products is governed by the ederal azardous ubstance 
Act. That mayor may not be true for other products sold by SEC, but the SABRE Red Fogger 
product is clearly intended for occupational use at a frequency and duration that would greatly 
exceed any foreseeable use by a consu er in a non-occupational circu stance. s, t  
require ents for the label of these la  enforce ent grade products are found in the ccupational 
Safety and Health Administration's Hazard Communication Standard, Regulation 1910.1200, as 
 I I   J.P. URSWEL , PH.D., P.E., E, I  PPOSITI   
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that is the express standard in the industry for labeling of hazardous industrial chemicals While
my review of the product information and information from SECswebsite suggests that it is
highly unlikely that SECs SABRE Red law enforcement grade 10 OC Spray products would
be found in households or used by children the use of the product by employees in the course of
their work with a frequency and duration much greater than would be expected by a consumer
renders the labeling of the product subject to the OSHA Hazard Communication Standard The
purpose of SECsSABRE Red law enforcement 10 OC Spray products is for use by law
enforcement officials in subduing suspected criminals crowd control and inmate compliance
Even more specifically the product at issue in this case which the Plaintiff was exposed to in
March 2008 was a product known as the SABRE Red Fogger which would have virtually no
use in the household and would not be a product used by children It is also my informed opinion
that due to the apparent nature of the product at issue in this case the Occupational Safety and
Health AdministrationsHazard Communication Standard Regulation 191020 applies to the
product label It is further my opinion that SEC under OSHA Hazard Communication Standard
Regulation 191020 has the affirmative obligation to evaluate the potential health hazards of
the chemicals in their 10 OC spray products and communicate that information and
appropriate protective measures on a warning label for the safety of the people using their
product
6 In formulating the opinions I have expressed relating to the applicability of OSHA
Hazard Communication Standard to SECs SABRE Red law enforcement 10 OC Spray MK9
Fogger I have relied on the guidance and opinion letters from OSHA and the US Consumer
Product Safety Commission CPSC I have attached hereto as Exhibit C true and correct copies
of the following guidance and opinion materials that I have reviewed in the process of informing
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my opinions expressed in this case CPSC Opinion 308 OSHA Instruction CPL 0202038
3201998 OSHA Guidance Letter to Ms Cohen April 14 2005 OSHA Guidance Letter to
Mr Schaizow January 9 1990 and OSHA Memorandum August 15 1991 While these are
just a select few of OSHA and CPSC guidance materials I have reviewed in formulating my
opinions in this case I believe they are most instructive on the points raised by SEC in their
motion for summary judgment relating to the applicability of OSHA and FHSA standards in this
case
7 I have applied the OSHA Hazard Communication Standard in formulating my
opinions in this case because that is the standard in the industry for warning label practices for
products intended for and packaged for occupational use
FURTHER YOUR AFFIANT SAYETH NOT
A
4PURSWELL
SUBSCRIBED AND SWORN TO before me this day of July 2011
BRYCE SCHUETTPELZ
NOTARY PUBLIC Notary Public for Colorado
STATE OF COLORADO
My Commission expiresT3p i
My Commission Expires1032011
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Curriculum Vitae
NAME JPPurswell
PHONE 7193300126
FAX 7192656905
ADDRESS 2035 Mulligan Drive Colorado Springs CO 80920
EMAIL jPpurswellogmailcom
EDUCATION
PhD Industrial and Systems Engineering Human Factors Option 1997 Virginia Tech
Blacksburg Virginia
MS Industrial Engineering 1989 The University of Oklahoma Norman OK
BS ChemistryBiology double degree 1986 Oklahoma Baptist University Shawnee OK
PROFESSIONAL EXPERIENCE
Vice President 1999 Present
Purswell Purswell Engineering Ergonomics Inc Colorado Springs CO 80920
Consults with manufacturers and attorneys on ergonomics and safety issues Performs hazard
analyses of products for manufacturers Consults with manufacturers on the development of
warnings and instructions for new and redesigned products Consults with employers on the
development and implementation of safe and ergonomically sound work practices
Adjunct Professor 1999 Present
Engineering Department Colorado State University Pueblo Pueblo CO 81001
Teaches the graduate ergonomics course and the senior level safety course for the Engineering
department Supervises student research on product safety and usability issues As part of his
involvement with CSUPueblo Dr Purswell has also initiated and supervised several graduate
student ergonomics projects for Pueblo area manufacturing warehousing and retail
establishments
Ergonomics and Safety Consultant 19941999
Purswell Associates Colorado Springs CO 80920
Designed and conducted research concerning user perceptions and comprehension of potential
product hazards Developed experimental protocols and questionnaires performed data
collection data reduction and analysis and wrote reports for clients
Performed hazard analyses of consumer and industrial products applied system safety
principles of hazard abatement including suggested redesign guarding and preparation of
cameraready copies of instructions and onproduct warnings for clients
Researched and interpreted OSHA CPSC and ANSI standards for clients including the
legislative record for OSHA standards Acquired familiarity with OSHA standards applicable to
chemical safety workplacemachine interface issues and constructionmaintenance operations
These include for example the Hazard Communication Standard LockoutTagout Standard
Hearing Conservation Standard Fall Protection Standards etc Performed forensic consulting
for attorneys involved in workplace and product safety litigation including preparation of reports
and research applicable to a given issue involved in the litigation
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Graduate TeachingResearch Assistant 19891992
Virginia Tech Blacksburg Virginia 24061
Assisted with Introduction to Industrial Engineering and Probability and Queuing Systems
classes Lectured in the absence of the professor Prepared and graded homework and exams
Documented and analyzed railroad work methods Prepared task descriptions and
ergonomicssafety analyses of work methods Recommended methods improvements and
changes in tool design Authored the project report
Researched finger strength capabilities Designed the data collection equipment Wrote the
software routines to collect and reduce the data Performed statistical analysis of the data
Authored the project report
Industrial Engineer Intern Summer 1989
General Motors Assembly Division Oklahoma City OK 73135
Performed analyses of assembly line ergonomics and safety issues Prepared a safety and
ergonomics training program for plant use
Graduate TeachingResearch Assistant 19871989
University of Oklahoma Norman OK 73072
Interfaced a computerized data collection system with analog electrical equipment Taught
ergonomics labs
CERTIFICATIONS LICENCES
Registered Professional Engineer by examination
Board Certified Professional Ergonomist by examination
PROFESSIONAL AFFILIATIONS AND SERVICE
Member Industrial Advisory Board Industrial Engineering Department CSU Pueblo
Program Chair 2004 1St Annual Spring Symposium of the Rocky Mountain Chapter of the Human
Factors and Ergonomics Society
Member Human Factors and Ergonomics Society Served as a newsletter editor and paper
reviewer for several technical groups Instructor for CPE prep course sponsored by the Rocky
Mountain Chapter of HFES
Secretary 20035 International Society for Occupational Ergonomics and Safety
Senior Member and Director of Professional Registration 20032009 for the Institute of Industrial
Engineers Responsible for preparing the Industrial Engineering PE licensure exam administered
by NCEES Served on the 20022003 PAK committee to review and reformulate the Industrial
Engineering PE content areas Dr Purswell continues to serve as a member on the committee
that develops the exam specifications for the IE PE exam as well as continuing to write questions
for the exam
Member American Industrial Hygiene Association
Associate Member American Council of Government Industrial Hygienists
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HONORS AND AWARDS
Inducted into Alpha Pi Mu the Industrial Engineering Honor Society 1990
Recipient of the Gordon Fellowship from the University of Oklahoma 1986
SHORT COURSESSEMINARS
Psychometric Training presented by the Chauncey Group February 2004
Forklift Truck Operator Instructor Development presented by the Colorado Safety Association
August 2004
Oxyfuel Welding Pikes Peak Community College Fall 2005
Welding Health and Ventilation for Hot Work in Confined Spaces PCIH 2005 102305
SMAW stick welding Pikes Peak Community College Spring 2006
PAPERS AND PRESENTATIONS
Purswell JP and Purswell Jerry L 2011 Citation of Ergonomic Hazards under the General
Duty Clause an Update in Proceedings of the 23rd Annual International Occupational
Ergonomics and Safety Conference
Purswell JP and Purswell Jerry L 2011 Truck Crane Accident Patterns in Proceedings of the 23rd
Annual International Occupational Ergonomics and Safety Conference
Purswell JP 2010 The distribution of pedestrianbacking vehicle accidents by backup alarm status
and vehicle type 3rd International Conference on Applied Human Factors and Ergonomics edited by
Gavriel Salvendy and Waldemar Karwowski
Purswell JP2009 Crawler Crane Accident Patterns in Proceedings of the 21st Annual International
Occupational Ergonomics and Safety Conference edited by Robert Marley et al
Brickman D Purswell JP 2009 Tree Chipper Human PerceptionReaction Testing in Proceedings
of the 21st Annual International Occupational Ergonomics and Safety Conference edited by Robert
Marley et al
Purswell JP and Purswell Jerry L 2005 OSHAsRecent Citation Practices of Ergonomic Hazards
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Gonzalez R and Purswell JP2003 Usability of the CPSCWebsite An Update 8th Annual
International Conference on Industrial Engineering Theory Applications Practice Las Vegas
Nevada
Purswell JP 2003 Development Of A Searchable Database Of Warnings Articles 8th Annual
International Conference on Industrial Engineering Theory Applications Practice Las Vegas
Nevada
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Purswell JP 1997 The Effects of Perturbation Frequency Magnitude and Uncertainty During
Static and Dynamic Tracking on the Estimated Level of Muscle CoContraction Unpublished
doctoral dissertation Virginia Polytechnic Institute State University Blacksburg Virginia
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March 28 2011
Mr Darwin Overson
Jones Swartz pllc
PO Box 7808
Boise ID 837077808
Re Major v SEC
Dear Mr Overson
In response to your request I have reviewed the following materials
related to this matter
1 Complaint
2 SEC Product Labels 1
3 SEC Product Labels 2
4 SEC Product Labels 3
5 SEC Product Line
6 SEC MSDS
7 SEC Suppliers MSDS
8 Product labels from manufacturers other than SEC
9 Expert Report of Dr Pacheco
10 Expert Report of Dr Yost
11 SEC Trainers Certification Manual
12 SEC Training PowerPoint Presentation
13 Defendantsresponses to Plaintiffs requests for admissions
14 DefendantsResponses to Plaintiffs Interrogatories
15 Depositions with exhibits of the following individuals
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a JOSHUAEOVERGAARD with exhibits 4244
b Nicholas Doan with exhibits 45 and 46
c Robert Nance
d Bret Kimmel with exhibit 2235
e Daniel J Schaffer with exhibit 3641
f SARA ANNE MARIE LINK
Based upon my review of the materials listed above my education research
and experience I have the following opinions related to the matter to a
reasonable of degree of engineering and ergonomics certainty
1 Oleoresin capsicum OC constitutes an irritant to the skin eyes and
respiratory tract of persons exposed to it The material safety data sheet
MSDS for the constituent of the SEC products has only nine sections
and appears to be incomplete However a publicly available MSDS for
oleoresin capsicum from
wwwsciencelabcommsdsphpmsdsld9926319 shows that the OC
product has a HMIS health hazard rating of 3 out of 4 The consequences
of exposure to a health hazard with a rating of 3 are described as major
injury likely unless prompt action is taken and medical treatment is given
2 Because the OC compound is an irritant it constitutes a health hazard
as the term is used in the OSHA Hazard Communication Standard The
standard defines a health hazard as follows
Health hazard means a chemical for which there is statistically
significant evidence based on at least one study conducted in
accordance with established scientific principles that acute or chronic
health effects may occur in exposed employees The term health
hazardincludes chemicals which are carcinogens toxic or highly toxic
agents reproductive toxins irritants corrosives sensitizers
hepatotoxins nephrotoxins agents which act on the hematopoietic
system and agents which damage the lungs skin eyes ormucous
membranes Appendix A provides further definitions and explanations
of the scope ofhealth hazards covered and Appendix B describes the
criteria to beused to determine whether or not a chemical is to be
considered hazardous for purposes of the standard
3 The oleoresin capsicum is present in sufficient concentrations 1in
the various Sabre Red products sold by SEC and in the Cell buster
formulation in particular to render the CellBuster product a hazardous
industrial chemical according to the definitions in 29 CFR 191020 As
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such SEC had a duty to develop MSDSs and product labels for the Cell
buster formulation that met the requirements of 191020 the OSHA
Hazard Communication Standard for these products Among the
requirements for a product label for a covered chemical or chemical
mixture is that the affected target organs be specified on the product
label The OSHA interpretation entitled The HCSs requirement for target
organ effects on labels for shipped containers of hazardous chemicals
issued on6291987 explains OSHA reasoning for this requirement The
interpretation includes the following statement The hazard warning must
convey the hazard of the chemical Appendix A of the standard makes it
clear that employees must be apprised of the change in body function and
the signs and symptoms that may occur to signal that changeFurther
clarification of OSHA position on the need to include complete target
organ information on the product label is provided in the 1994 preamble to
the Final Rule
Hazard warning The 1983 and 1987 final rules included a definition for
hazard warning which states that it means any words pictures
symbols or combination thereof which convey the hazardsof the
chemical in the containersAppropriate hazard warnings are to be
put on container labels Since the rule covers physical and health
hazards specific information regarding these would be required on a label
to comply and be considered appropriate OSHA provided clarification
regarding theAgencysinterpretations of these requirements in the
preamble to the revised final rule see 52 FR 31864 In the NPRM the
Agency proposed to incorporate these clarifications into the text of the
rule Thus the new definition proposed was that hazard warning means
any words pictures symbols or combination thereof appearing on a
label or otherappropriate forms ofwarning which convey the specific
physical and health hazards including target organ effects of the
chemical in the container See the definitions for physical hazard
and health hazard to determine the hazards which must be conveyed
This modification is being adopted in this final rule The Agency
interpretation of the rule in requiring health effects information including
information on target organ effects was challenged and upheld in Martin
v American Cyanamid on No 923321 6th Circuit September 15
1993 In the development of the 1983 final rule the Agency sought to
require on labels that information that it considered to be necessary to
employee protection and which did not appear on many of the labels in
use in industry at that time It appeared to OSHA based on the
information available at that time that labels frequently included
precautionary information but infrequently enumerated the actual hazards
of the chemical In addition the labels often lacked identity information
Thus OSHA chose to require that this limited information the identity and
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hazards be included on the label while not precluding the addition of
othertypes of information thought to be appropriate by the chemical
industry The rule also took a performance oriented approach to the
presentation of information allowing various formats to be used as long as
the information required by the HCS was included OSHA did not endorse
or support any particular existing labeling system as being in compliance
with the requirements as drawn In fact it was thought likely that many
existing labels regardless ofwhat system was used would have to be
revised to meet the new requirements
The Sabre Red product label for Cellbuster product does NOT include
any identification of the lungs or respiratory tract as a target organ and is
therefore not in compliance the OSHAs Hazard Communication
Standardslabeling requirements
4 The failure of SEC to include the lungs or respiratory tract as a target
organs of OC on the Cell Buster product label was a violation the Hazard
Communication Standard The omission of this required information on the
product label was a proximate cause of Ms Major injury Had this
information been included on the product label as the Hazard
Communication Standard required the causal relationship between Ms
Majors exposure to the various OC containing Sabre Red products and
her persistent respiratory difficulties would have been apparent to her and
more readily apparent to the IDOC personnel in charge of the training
My curriculum vita is attached which provides a record of my education
experience and research publications My schedule of fees is attached which
lists the charges for services I reserve the right to supplement my report should
new information be made available to me that would affect my opinions
Sincerely
JP Purswell PhDPE CPE
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Office of the General Counsel
U S Consumer Product Safety Commission
Washington DC 20207
Re Kathryn A Becker File
Dear SirMadam
I am writing to request an advisory opinion based
on the following hypothethical fact patterns
1 ABC Corporation manufactures a heavy duty ver
cleaner The oven cleaner contains 10 Socium
Hydroxide ABC Corp sells and distributes the
oven cleaner to restaurants landlords and jani
torial services The oven cleaner is marked
for institutional use only and sold in cases
of four one gallon bottles It is not sold to
individuals and the gallon jugs do not have a
childproof cap In fact its dispenser is
stopped only by an easily removed funnel
2 ABC sold its oven cleaner to XYZ Restaurant An
employee of XYZ took one gallon of the oven
cleaner to his residence A 20 month old child
whom the employee was babysitting ingested some
of the cleaner and received severe esophago
trachial burns Does any liability attach to
ABCCorporation under the Federal Hazardous Sub
stance Act andor the Poison Prevention Packaging
Act
3 The facts are the same as above but ABC also
sells and distributes the oven cleaner to a
public school maintenance department How if
at all will this change ABCs liability under
the FHSA andor PPPA
Thanks in advance for your assistance in this matter
Very truly yours
GRAHN GRAHN LTD
of
Frederick S Grahn
PSGha
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WASHINGTON 0 C 20207
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t
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or
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Comments Processed
Frederick S Grahn Esq
Grahn Grahn Ltd
Suite 1204
134 North La Salle
Chicago Illinois 60602
Dear Mr Grahn
This is in response to your letter of October 15
1986 in
which you ask for an advisory opinion concerning whether a hypo
thetical firm would have any liability under either the Federal
Hazardous Substances Act FHSA or
the Poison Prevention
Packaging Act PPPA because of a heavyduty oven cleaner sold
to restaurants landlords and janitorial services
In order to be regulated under the FHSA a ha4ardous sqb
stance must be intended or packaged in a form suitable
Tor
use in the household or by children 15 USC 5 1261f
p q 1 While use by the employees for landlords
and
janitorial services could involve use of the oven cleaner in t
homes of consumers the Commission regulations at 16 CFR n
15003c 10istate that the term azardous bs anrP i
tended or packaged in a form suitable
for use in 1K ousehold
does not include industr al supplies that might be taken in
a home by a serviceman air article labeled as and marketed
solely for industrial use does not become subject to the FHS a
because of the possibility that an industrial wnrkpr av take n
supply for his own use A copy
of 5 15003i is e
closed for your information
ADVISORY OPINION
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Frederick S Grahn Esq
Grahn Grahn Ltd
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The theoretical facts that you describe indicate that the
oven cleaner is never sold or distributed for other than
commercial purposes Thus under the principles described in the
preceding paragraph the oven cleaner would not be subject to the
FHSA by virtue of its use by landlords restaurants or
janitorial services The addition of the fact of sale for use by
a public school maintenance department would not bring the
product within the scope of the FHSA since that use is not one
involving use in the household or by children
The PPPA applies only to substance which are amon
other things customarily produced or distributed for sale f
consumption or use or customarily stored by individuals in o
about the household 15 USC S 14712 The fact that the
PPPA applies only to acts performed by individuals indicat s
that the Act is not intended to apply to substances that ae
present in the home only when being used by the employees f
landlords or janitorial services Since use by a school
maintenance department is not in or about the household that
additional fact would not bring the product within the scope of
the PPPA
I should note however that if claims such as that the
oven cleaner killsgerms or sanitizes are made in connection with
the distribution of the product the product would be considered
a pesticide under the Federal Insecticide Fungicide and
Rodenticide Act FIFRA which is administered by the U S En
vironmental Protection Agency 7 USCS 136 There may be la
beling or child resistant packaging requirements applicable to
the product under FIFRA
The views expressed in this letter are based on the most
current interpretation of the law by this office However they
could be changed or superseded subsequently by the Commission
In addition in appropriate circumstances the judicial system
would be the ultimate interpreter of the law in this area
1J Therefore under the facts hypothesized in your letter we
would conclude that this oven cleaner is not subject to the re
quirements of either the FHSA or the PPPA In making this deter
mination we consider it significant that the product would never
be available in a retail store
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I hope this letter is helpful Please do not hesitate to
contact me if you have further questions
Sincerely
P
John P Mackey
Acting General Counsel
Enclosure
J
000953
· . 
r ri  . r , s . 
 & r , t . 
a e  
 e s  s l f l. e   t   
    e t  ti s. 
i erely; 
 .  
s re 
 nera~_~~-· 
CPL 0202038 CPL 238D Insp ion Procedure http wwwos iovpisoshawebowadispshowd
Al DOL
r
OSHA Advanced Search
I 1 1
A to Z Index I En Espanol I Contact Us I About OSHA
OSHA Newsletter 3 RSS Feeds Q Print This Page Q Q Text Size
Occupational Safety Health Administration We Can Help whats New I Offices
Home Workers Regulations Enforcement Data Statistics Tr P Newsroom Small Business OSHA
Directives Dblleof Contents
Record Type Instruction
Directive Number CPL 0202038
Old Directive Number CPL 238D
Title Inspection Procedures for the Hazard Communication Standard
Information Date 03201998
Standard Number 191020
DIRECTIVE NUMBER CPL 238D EFFECTIVE DATE March 20 1998
SUBJECT Inspection Procedures for the Hazard Communication Standard 29
ICFR 191020 191599 191728 191890 192659 and 192821
ABSTRACT
Purpose This instruction establishes policies and provides clarifications to ensure
uniform enforcement of the Hazard Communication Standard HCS
Scope This instruction applies OSHAwide
References OSHA Instruction CPL 2111 Citation Policy for Paperwork and Written
Program Requirement Violations
OSHA Instruction CPL 243A Chemical Information Manual Refer to the
OCIS Chemical Information Database
OSHA Instruction STP 2117 State Standards
Hazard Communication Standard HCS 29 CFR 191020
Cancellations
State Impact
Action
Originating Office
Contact
By and Under the Authority of
Charles N Jeffress
Assistant Secretary
I Puroose
II Scope
III Cancellation
IV Action Information
V References
OSHA Instruction CPL 238C October 22 1990
This instruction describes a Federal Program change for which State adoption
is not required See paragraph I
OSHA Regional Administrators and Area Directors shall use the guidelines in
this instruction to ensure uniform enforcement of the HCS
Office of Health Compliance Assistance Directorate of Compliance Programs
DCP
OSHA DCP Office of Health Compliance Assistance
200 Constitution Avenue NW Room N3467
Washington DC 20210
TABLE OF CONTENTS
1 of 27 762011316PM
000954
 ·02·038 • L ·2.38D • I sp . ion cedure ••• tt ://www.os· 10V/pls/oshaweb/o adisp.show _d ••• 
   
.JJ l  • OSHA v c  rc  
 !OSHA QuickTakes e sle ter ~  s e ri t i   a a  i  
ccupational Safety & lt  i i t i  e can Help W at's w  i  
o e ork r    l ti s 
.. Directiv  - Tab e f t ts 
• r  : 
• ir ti  r: 
• l  ir ti  r: 
• itl : 
• Infonnation t : 
• tandard u ber: 
 
I struction 
 -02-03  
 -2.38D 
 & t ti ti  raining ublications 
I s ecti n  f r  r  unication t r  
03/20/1998 
910.1200 
sr  
I DIRECTIVE NUMBER: CPL 2-2.38D [EFFE  : r  ,19  
!S : I ti  r r  f r t  r  i ti  t r ,  
I  910. 2 0, 915.99, 917.28, 918.90, 926.59,  928.21 
Purpose: 
: 
s: 
i : 
t t  I t: 
i : 
Originating Office: 
t ct: 
By and nder the uthority of 
l  .  
Assistant Secretary 
I. p  
II. S£QQe 
. QlnceliatiQ!J 
.   
v. f r  
 
his instruction establishes poliCies and provides clarifications to ensure 
if r  f r t    i ti   ( S). 
i  i t ti  li  A-wi . 
 I t ti   . 1 , it ti  li  f    itt  
rogra  equire ent iolations. 
 I t ti   -2.43 , i l I f ti  l - f  t  t  
I  l  t base. 
 i   - . 1 , t t  r s. 
 i ti  t  (H S),   910. 200. 
 I t ti   -2.38 , t  , . 
i  i t ti  i   r l   f  i  t t  ti  
is not required. ee paragraph I. 
OSHA Regional Ad inistrators and Area Directors shall use the guidelines in 
        . 
Office of Health Co pliance Assistance, Directorate of Co pliance Progra s 
(D P). 
SHA, DCP, ffice of ealth o pliance Assistance 
 tit ti  ue, ,   
i ton,   
   
ll usiness Cl)Sl-i  
/6/20 1 :16  
CPL 0202038 CPL 238D Insp ion Procedure httpwwwos Govpisoshawebowadispshowd
VI Action
VII State Impact
VIII Federal Proaram Change
IX Backgrou
X Organization of this Instruction
XI Inspection Guidelines
A Scope and Application Paragraph b
1 Inspection Guidelines
2 CitationGuidelines
B Hazard Determination Paragraph d
1 Inspection Guidelines
2 Citation Guidelines
C Written Hazard Communication Prooram Paragraph e
1 Inspection Guidelines
D Labels and Other Formsof Warning Paragraph f
1 Inspection Guidelines
2 Citation Guidelines
E Material Safety Data Sheets Paragraph a
1 Inspection Guidelines
2 CitationGuidelines
F Employee Information and Training Paragraph h
1 Inspection Guidelines
2 Citation Guidelines
G Trade Secrets Paragraph i
1 Inspection Guidelines
a Non emergencies
b Medical emergencies
2 Citation Guidelines
a Non emergencies
b Medical emergencies
XII Classification and Grouping of Violations
III Interf WithOtherStandar
A Access to Exposure Records
B 29 CFR 191045
C Other Health Standards
Appen A
CLARIFICATIONS AND INTERPRETATIONS OFTHE
HAZARD COMMUNICATION STANDARD HCS
PURPOSE Paragraph a
a
SCOPE AND APPLICATION Paragraph b
b
b
b
b5
b
Hazardous waste
Consumer Products
2 of 27 762011316PM
000955
 ·02·038 . L ·2.38D . I sp . ion edure •.. 
   
I. Acti  
V I. State I act 
VIII. Federal r gr  hange 
I . B roulli! 
X. rganization of this Instruction 
. Inspecti  ui li  
A. cope and pplication - r r  (b) 
1. I s cti n ui eli s 
2. i i  uidelines 
. azard eter ination - r gr'l  (d) 
1. I ti n i li s 
2. O  i l  
. ritten azard Ommunication rogram. r r  (e) 
. I ction uideli es 
. l   t er  f i .  (0 
. I ction uideli es 
. it  i l  
. aterial fety ata ts. aragraph (g) 
1. Inspection uidelines 
. i  i l  
. l  I f ti   r i i .  (h) 
1. Inspection uidelines 
. it ti  i li  
.  rets.  (i) 
1. Inspection Guidelines 
a. on-e ergencies 
b. Medical e ergencies 
.   
a. Non-e ergencies 
b. ic l r ci s 
II.    f  
XIII. Interface ith ther. Standards 
.     
.   910. 4S0 
. t  lt   
Appendix  
QARIFIC I   I I  F  
 I I   (H ) 
PURPOSE, Paragraph (a) 
(a)(2) 
 D lICATION, r r  (b) 
(b)(2) 
(b)(3) 
(b)(4) 
(b)(S) 
(b)(6) 
Hazardous waste 
Onsu er r cts 
ttp://ww .os· 10V/pls/oshaweb/o adisp.show _d ... 
/6/2011 3:16 P  
CPL 0202038 CPL 238D Insp ion Procedure http wwwos Govpisoshawebowadispshowd
Articles
Wood and wood products
Particulates not otherwise regulated PNOR
DEFINITIONS Paragraph c
Article
Chemical
Chemical Manufacturer
Container
Distributor
Employee
Employer
Exposure
Foreseeable emergency
Hazardous chemicals
Hazard Warning
Produce
HAZARD DETERMINATION Paragraph d
d1
dZ
d3
d4
d5
d6
WRITTEN HAZARD COMMUNICATION PROGRAM Paragraph e
e
eZ
e4
LABELS AND OTHER FORMS OF WARNING Paragraph f
f
fZ
f
f
CARCINOGEN LABELING Subpart Z
TABLE Al
GUIDANCE FOR MSDS AND LABEL NOTATIONS
FOR CARCINOGENS
f
MATERIAL SAFETY DATA SHEETS Paragraph g
g
gZ
g
g
g
g
g
gB
g
EMPLOYEE INFORMATION AND TRAINING Paragraph h
3 of 27 762011316PM
000956
 -02-038 -  -2.38D -  "ion cedure ... 
   
BLE  
rticles 
ood  ood r  ucts 
ti l t  not other is  r gulated (PN ) 
A m , aragraph (e) 
rti  
Ol  
Ol  f  
 
 
l  
l y r 
r  
r l  r  
r s c e icals 
rd i  
 
 I I , r r  (d) 
(d)(l) 
(d)(2) 
(d)(3) 
(d)(4) 
(d)(5) 
(d)(6) 
I   I I  , r r  (e) 
(e)(l) 
(e)(2) 
(e)(4) 
     I , r r  (f) 
(f)(1) 
(f)(2) 
(f)(5) 
(f)(6) 
O  U  (Subpart ) 
      
 O  
(f)(11) 
I    , r raph (g) 
(g)(l) 
(g)(2) 
(g)(3) 
(g)(4) 
(g)(5) 
(g)(6) 
(g)(7) 
(g)(8) 
(g)(9) 
L  I I   I I G, r r  (h) 
://w w.os· IOV/pls/oshaweb/o adisp.show _d ... 
/6/2011 :16  
CPL 0202038 CPL 238D Insp
tw
TRADE SECRETS Paragraph i
i1
i
Appen
SAMPLE LETTER MSDSLABEL QUERY
Appendix
HAZARD EVALUATION PROCEDURES
Internet addresses
Appendix D
GUIDE FOR REVIEWING MSDS COMPLETENESS
ADDendix E
SAMPLE HAZARD COMMUNICATION PROGRAMS
INDEX
ion Procedure httpwwwosr Govplsoshawebowadispshowd
I Purpose This instruction establishes policies and provides clarifications to ensure uniform enforcement of the Hazard Communication
Standard HCS
II Scope This instruction applies OSHAwide
III Cancellation
A OSHA Instruction CPL 238C October 22 1990
B Compliance Instruction Hazard Communication Standard Documentation of Citations Related to the Exposure to Hazardous
Substances and Consumer Products dated March 21 1995 to OSHA Regional Administrators from John B Miles Jr
IV Action Information
A Responsible Office Office of Health Compliance Assistance
B Action Offices OSHA Regional Area and District Offices State Designees
C Information Offices Consultation Project Managers
V References
A OSH A Instruction CPL2111 Citation Policy for Paperwork and Written Program Requirement Violations dated November 27
1995
B OSHA Instruction CPL 243A Chemical Information Manual Refer to the OCIS Chemical Information Database dated July 1
1991
C 0 SHA Instruction STP 2117 State Standards dated August 31 1984
D Hazard Communication Standard HCS 29 CFR 1910 1200 was published in the Federal Register on November 25 1983 48
FR 53280
VI Aom OSHA Regional Administrators and Area Directors shall use the guidelines in this instruction to ensure uniform enforcement of
the HCS The Directorate of Compliance Programs Office of Health Compliance Assistance will provide support as necessary to assist
the Regional Administrators and Area Directors in enforcing the HCS
VII State Impact This instruction describes a Federal Program Change for which State adoption is not required See paragraph I
VIII Federal Program Chance This instruction describes a Federal Program change for which State adoption is not required
A In order to effectively enforce safety and health standards guidance to compliance staff is necessary Therefore although
adoption of this instruction is not required States are expected to have standards enforcement policies and procedures which
are at least as effective as those of Federal OSHA A Statesprocedures for enforcement of its hazard communication standard
should address the means by which the State will handle referrals from Federal OSHA or other State plans concerning
inadequate or deficient MSDSs prepared by a manufacturer within its jurisdiction See paragraphE1dofthis instruction
IX Background A final Hazard Communication Standard HCS 29 CFR 191020 covering the manufacturing sector Standard Industrial
Classification Codes SIC 2039 was published in the Federal Register on November 25 1983 48FR 53280 As a result of a court
challenge OSHA was ordered by the US Court of Appeals for the Third Circuit to expand the scope of the standard without further
rulemaking
A On August 24 1987 a final rule covering all employers was published in the Federal Register Due to subsequent court and
administrative actions OSHA was prevented from enforcing the rule in the construction industry and from enforcing in all
industries three requirements dealing with providing and maintaining material safety data sheets MSDSs on multi employer
worksites coverage of consumer products and the coverage of drugs in the non manufacturing sector
B As a result of the February 21 1990 Supreme Court decision see Dole Secretary of Labor et al v United Steelworkersof
America et al No 881434 all provisions of the rule are now in effect for all industrial segments including the three
previously stayed provisions mentioned above OSHA extended the compliance date until March 17 1989 for programmed
inspections in the construction industry
4 of 27 762011316PM
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B. o pliance Instruction, "Hazard o unication Standard: ocu entation of itations Related to the Exposure to azardous 
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B. S A Instruction CPL 2-2.43 , he ical Infor ation anual - efer to the IS he ical Infor ation atabase, dated July 1, 
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c.   I tr ti   - . 1 , t t  t rds, t  t 1, 4. 
D. Hazard Co unication Standard (HCS), 29 CFR 1910 1200 was published in the Federal Register on Nove ber 25, 1983 (48 
F.R. 53280). 
I. ctll . S A egional d inistrators and rea irectors shall use the guidelines in this instruction to ensure unifor  enforce ent of 
the HCS. The Directorate of Co pliance Progra s, ffice of Health Co pliance Assistance, will provide support as necessary to assist 
the Regional Administrators and Area Directors in enforcing the HCS. 
II. t t  I ct. is i str cti  scri s  r l r r   f r ic  t t  tion is t r quired. ee r r  I. 
VIII. Federal Progra  Change. This instruction describes a Federal Progra  change for which State adoption is not required. 
A. In order to effectively enforce safety and health standards, guidance to co pliance staff is necessary. Therefore, although 
adoption of this instruCtion is not required, States are expected to have standards, enforcement policies and procedures which 
are at least as effeCtive as those of Federal OSHA. A State's procedures for enforce ent of its hazard co unication standard 
should address the eans by which the State will handle referrals fro  Federal OSHA or other State plans concerning 
inadequate or defiCient MSDSs prepared by a anufacturer within its jurisdiction. (See paragraph E.1.d. of this instruction.) 
I . Background.  final azard o unication tandard (HCS), 29 CFR 1910.1200, covering the anufacturing sector, Standard Industrial 
Oassification Codes (SIC) 20-39, as published in the Federal egister on ove ber 25, 1983 (48 F.R. 53280). As a result of a court 
challenge, OSHA was ordered by the U.S. Court of Appeals for the Third Circuit to expand the scope of the standard without further 
rule aking. 
A. On August 24, 1987, a final rule covering all e ployers was published in the Federal Register. Due to subsequent court and 
administrative actions, OSHA was prevented from enforcing the rule in the construction industry, and fro  enforcing in all 
industries, three requirements dealing with providing and maintaining material safety data sheets (MSDSs) on multi-employer 
worksites, coverage of consumer products, and the coverage of drugs in the non-manufacturing sector. 
B. As a result of the February 21, 1990, Supreme Court decision (see Dole, Secretary of Labor, et. al., v. United Steelworkers of 
America et. aI., No. 88-1434), all provisions of the rule are now in effect for all industrial segments, including the three 
previously t  provisions ti  ove.  exte  t  co plianc  t  til rc  17, 1989, f r progra  
inspeCtions in the construction industry. 
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C On February 9 1994 OSHA published the final rule for Hazard Communication 59FR 6126 This modified final rule included
a number of minor changes and technical amendments to further clarify the requirements of the standard
X Organization of this Instruction Compliance guidelines are addressed within the main part of this instruction Clarifications
interpretations review aids and other information are provided in Appendices A through E This directive will include references which
will allow the interpretative provisions to be accessed through the OSHA Web Site
A Appendix A of this instruction provides clarifications of provisions of the standard where significant interpretations have been
necessary to ensure uniform enforcement and understanding
B Appendix B provides a sample letter for inquiries regarding missing or deficient MSDSs and labels
C Appendix C provides general guidelines for evaluation of hazards
D Appendix D provides a guide for reviewing MSDSs
E Appendix E provides a sample Hazard Communication Program
XI Inspection Guidelines The following guidelines apply to all inspections conducted to determine compliance with the HCS
Inspection Guidance Although the HCS contains some specification requirements it is largely a performance oriented standard
The standard establishes a goal that allows employers wide flexibility to develop a program suitable to their facility CSHOs
should weigh particular HCS deficiencies in light of the effectiveness of an employers overall hazard communication program
Citations should be written to reflect the degree that the employer failed to meet this goal and the hazard the deficiency
represents
Documentation In addition to those items required by the FIRM when citations are recommended the CSHO shall document
the following on the OSHA1B or as appropriate elsewhere in the case file
Name of the chemicals
Name of the person preparing the hazard determination written program label MSDS etc and the company for whom they
work
CSHOs shall ensure that the number of employees who may be exposed including potential exposure or foreseeable
emergencies to the chemical in the establishment is documented
Health and physical hazards of the chemical
If practical include a photocopy or a photograph of inaccurate andor any incomplete labelsMSDS or video footage of
unlabeled containers in the case file Otherwise document the specific deficiency in the case file If the volume of
inaccuratecomple MSDSs cannot reasonably be included in the file then a representative number should be documented
indexing those referenced in the citation
A Scope and Application ParagraphbThe scope paragraph clearly states that the HCS applies to any chemical which is known
to be present in the workplace in a manner that employees may be exposed regardless of whether the employer has created
the chemical exposure The mere presence of a hazardous chemical in the workplace does not trigger coverage under the
standard There must be actual or potential exposure to an employee
1 Inspection Guidelines
a A complete exemption from all requirements of the HCS applies for only those items listed underb6and
should not be confused with the labeling exemptions atb5The b5exemptions only apply to chemicals
which are subject to the labeling requirements of certain other Federal agencies
b Laboratory coverage is dealt with in paragraphb3Workoperations where employees only handle chemicals in
sealed containers such asfound in marine cargo handling warehousing and retail sales are covered to the
extent as explained in paragraphb4
2 Citation Guidelines
a Consumer Products 191020b6ixItis the Agencys policy not to issue citations for consumer products
unless the CSHO can document that the product was used in the workplace in a manner not intended by the
manufacturer or the frequency and duration of use results in exposures that are significantly greater than those
experienced by a normal consumer To ensure that citations of the HCS for consumer products are adequately
documented the following elements must be included in the case file
What information established the chemical as a consumer product For instance was the container label
subject to the Consumer Product Safety Act provisions The term consumer product means any article
or component part thereof produced or distributed i for sale to a consumer for use in or around a
permanent or temporary household or residence a school in recreation or otherwise or ii for the
personal use consumption or enjoyment of a consumer in or around a permanent or temporary household
or residence a school in recreation or otherwise 15USCA2052
What is are the hazardous chemical present in the product towhich employees were exposed What
isare the concentration of the hazardous chemical present Was the product included in the
employer hazardous chemical inventory
What is the duration of use of the product iefor what period of time did the employees use the
chemical during the workshift and workweek Did it greatly exceed normal or expected use by a
consumer
Was the frequency of employee use significantly greater than that of a normal consumer See Appendix
A
How was the product used and in what amounts Was the product used in the workplace for the purpose
intended by the manufacturer
When available include in the file the MSDS for the cited product to aid in determining coverage and
intended uses
1The above instruction regarding consumer products cancels and supersedes the Agencys March 21
1995 compliance instruction to OSHA Regional Administrators entitled HCS Documentation of Citations
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. n bruary 9, , A li   fi l r l  f r r  i ti  (59 .R. 6). his odifi  l l  i l  
 u ber of inor s  t ical t  t  f rther l rif  the r ir nts f t  rd. 
X. Q' i ti  f this I t . o pliance i li es are r d it i  t  ain  f t is i t . O , 
i t r t ti , revie  i s  other i f r ation  r i  i  i   t r  . i  i ti  ill i l  f r s i  
ill l  the i t r r t tive r visi s to  ccessed t r     i . 
. Appendix  f t is i struction r i  l rifi ti  f provisions f  t r  r  i i i t i terpretations   
r  to re unifor  enforce ent  r t i . 
. ppendix  i  a l  l t r f r i iri s r i  i i  r fi i t   l . 
. ppendix  r i  general i elines r l ti  f s. 
. ppendix  pr vi s  g i  r r i i  . 
. ppendix  r i  a ple zard i ti  r r . 
. I ti  .  ll i  idelines l  to l i spections   t i  li    : 
I ti  ce. l  t   t i   ifi ti  , t  l   rf -  r . 
he  li   l t ll  l  ide i ili  t  velop  r r   t   it . s 
l     fi i i  i  light f t   f  loyer's   i ti  . 
it ti  l   ritt  t  l t   t  l  i  t  t i  l d  r   Ci  
represents. 
t ti . I  iti  t  t  it  r ir   t  I ,  it ti  r  r ed, t   ll t 
 f l i    A-1B , s i te,     le: 
• e f  mical(s) 
• e f   r ri  t  r  i ti ,  , l l, , tc.,  t      
. 
• s ll sure t t t   f l      (inclu i  t ti l   f l  
r i ) t  t e i l i  t  t li t is t . 
• lt   i l  f t  l. 
• If r ti l, i l de  t  r  t raph f i r t  d/or  i l te label(s)/ , r i  f t  f 
l beled  i  t   f . t er ise t  Cifi  Ci     l .     
i a curate/incompl te  t r l      l ,       , 
indexing those referenced in the citation. 
.   li ti  - r r  (bl.   r r  l rl  t t  t t t   li  t   i l i  i   
t   r t i  t  r l  i   r t t l y s y  x s , r r l  f t r t  l r s r t  
t  i l r .  r  r  f  r  i l i  t  r l   t tri r r  r t  
.  t  t l r t ti l    . 
1. Inspection uidelines 
.  l t  ti  fr  ll r ir t  f t   li  f r l  t  it  li t  r (b)(6)  
 t   i  t    t (b )(5).  (b )(5)  l    i l  
  j t t   l li  i t   i   r l . 
. r t r  r  i  lt it  i   (b)(3). r  r ti s  l  l  l  i l  i  
l  t i r  (su   f  i  ri  r  li , r i ,  r t il l s) r  r  t  t  
xt t s x l i  in r r  (b)(4). 
. Ot ti   
.  t , 910.120 (b)(6)(ix) -    ncy's  t   Cit ti    r  
l     t      i    i     i t   t  
f t r r        l  i   t   Si ifi  r    
ri    r l r.  r  t t it ti  f t   f r r r t  r  t l  
t , t  f ll i  l t  t  i l  i  t   file: 
•     l    duct? r i tance,   t i r  
    t   visions? (The  "cons  duct"   i l , 
or co ponent part thereof, produced or distributed (i) for sale to a consu er for use in or around a 
per anent or te porary household or reSidence,  school, in r cr tion, r other ise, r (ii) f r the 
l , i   j     i       t  l  
r r i ,  l, i  r r tion, r t r i  ... (1  .S.CA 52» 
• t is/ar  the hazardous chemical(s) r s t in the r ct t  ic  e ployees ere exposed? t 
i /ar   ncentration(s)    hemical(s) sent?    i l  i  t  
ployer's r  i l i ntory? 
• t is the r ti  f use f t  r uct, i.e., f r t period f ti e did t  e ployees use the 
i l i   i   rkwe k? i  i  l   l      
sumer? 
•       Si ifi tl       l nsumer? (S   
.) 
•  s t  r ct used  in t ounts? as t  r ct used in t  rk l c  f r t  r s  
i t  by the facturer? 
•  il le, i l  i  t  fil  t   f r t  it  r t t  i  i  t r i i  r   
i t  sers). 
( )   i tr ti  r r i  r r t  l   r  t  ncy's r  1, 
95, li  i tr ti  t   i l i i tr t r  titled, " S: t ti  f it ti  
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Related to the Exposure to Hazardous Substances and Consumer Products This document is included as
Appendix A of OSHA Instruction CPL2111
b Articles 191020b6vFor HCS violations involving manufactured items which under normal conditions of
use may release hazardous chemicals and are not otherwise exempted from coverage as articles the following
shall be documented in the case file
What is the hazardous chemical in the item to which employees were exposedWas this item included in
the employer hazardous chemical inventory
What were the activitiesoperation that resulted in employee exposure to the hazardous chemical Did
the release of the covered chemicals pose any potential physical hazard or health risk to the employees
Include a copy of the MSDS where available for the cited product
c For both consumer products and items not meeting the article exemption the specific hazardous chemical in the
productitemshall be described in the citation In the case of mixtures the concentration of the hazardous
chemical shall also be noted For example the Agency shall not issue citations simply stating that glue or
dishwashing liquid was the hazardous consumer product or that brick was the hazardous chemical in a
manufactured item The citation must state the name of the hazardous chemical for example silica methyl ethyl
ketone sodium hydroxide etc
B Hazard Determination Paragraph Only chemical manufacturers and importers are required to perform hazard
determinations on all chemicals they produce or import although distributors and employers may also choose to do so Hazard
determination procedures must be in writing and made available upon request to employees the National Institute for
Occupational Safety and Health NIOSH and OSHA Appendix C is provided as a guide for use when assessing appropriate
hazard evaluation procedures
1 Inspection Guidelines The adequacy of a companys hazard determination program should be assessed primarily by
examining the outcome of that determination ie the accuracy and adequacy of the information on labels and MSDSs
and by reviewing the manufacturersdistributor written hazard evaluation procedures The written procedures
generally describe the process followed they do not have to address individually each chemical evaluated
a The hazard evaluation must include an assessment of both physical and health hazards The chemical
manufacturer or importer must consider the potential exposures that may occur when downstream employers use
the product and address the hazards that may result from that use on the label and MSDS prepared for the
product
b Hazard determination procedures do not have to be maintained on site consequently the CSHO may have to
request them The CSHO may allow the manufacturer importer distributor employer up to five working days to
produce the procedures
c In the event that there are any questions concerning the adequacy of the scientific data underlying a chemical
manufacturershazard determination the Area Director AD should refer those findings to OSHAs Salt take
Laboratory for review
2 Citation Guidelines
a Citations for violations of paragraphd1shall be issued when the preparer has failed to perform a hazard
determination Paragraphsd2d3d4andd5of the standard shall be used as appropriate
b If the preparer has not developed an MSDS and no written procedures are available then violations of both
paragraphsd1andd6exist and shall be recommended for citation Refer to paragraph E2 of this
instruction for guidance
c Failure to provide the hazard determination procedures within five working days shall result in the issuance of a
citation underd6
C Written Hazard Communication Program Paragraph e CSHOs shall review the employerswritten hazard communication
program to determine if all applicable requirements of paragraph e have been addressed The HCS obligates all employers
including those on multi employer worksites who may expose their employees or employees of other employers to hazardous
chemicals to develop a written program
1 Inspection Guidelines
a The written program should be reviewed first prior to ascertaining whether the elements of the program have
been implemented in the workplace In general the written program should consider the following elements
where applicable
1 Labels and Other Forms of Warning
Designation of persons responsible for ensuring labeling of inplant containers
Designation of persons responsible for ensuring labeling on shipped containers
Description of labeling system used
Description of written alternatives to labeling of inplant containers where applicable
Procedures to review and update label information when necessary
2 Material Safety Data Sheets
Designation of persons responsible for obtainingmaintaining the MSDSs
How the data sheets are to be maintained eg in notebooks in the work areas in a pickup truck at the
jobsite via telefax procedures on how to retrieve MSDSs electronically including backup systems to be used in
the event of failure of the electronic equipment and how employees obtain access to the MSDSs
Procedures to follow when the MSDS is not received at the time of the first shipment
For chemical manufacturers or importers procedures for updating the MSDS when new and significant health
information is found
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   r  t   t s   ducts."   i  i l   
ndix  f    . 11. 
. ti l s, 910.120 (b)(6)(v) -   i l ti s i l i  f t  it  i   l iti  f 
se  l  r us i l    t i  t  f    "a i les,"  ll i  
ll   i    f : 
• t   r s        r  xposed?   it   i  
t  loyer's   tory? 
• t   ctivitieS/operations    l y e     hemical(s)?  
t   f  r  emical(s)    i l       l ees? 
•    f t  ,  l ,  t   ct. 
. r   t    t ti    i ,  Ci      
roduct/item l   i  i   it ti n.     i tures,      
i  l  l   t . r l ,          "g e"  
"dishwashing i id"    r ct   "br k"       
f t  .   t      r s i  (for ple, li a,  l 
t , i  i , tc.). 
. r   - aragraph (d).     t r   i     
i ti   l i l     rt.          . r  
i ti  r s st   riting   l ,  t,  l ,  l   
ti l   lt  (NI H),  . i   i  i     r   i   
rd l i  . 
. I ti  i li s.   f  pany's r  t r i ti  r r  l    ri ril   
i i    f t t ti ; i.e.,  r cy          
    turer's/dist tor's i    .    
r lly scri  t  r c ss f ll ; t y  t v  t  r ss, i ivi lly, ch c ic l v l t . 
.  r  l ti  st i l   t f t  i l  lt  r s.  i l 
f ct rer r i orter t i r t  t ti l r  t t  r  tr  l r   
t  r t,  r  t  r  t t  r lt fr  t t   t  l l   r r  f r t  
r t. 
. r  i ti    t e t   i t i   it , ently, t      
r t t .   y ll  t  f t r r (i p rt r, i tri t r, loyer)  t  fi  r i   t  
r  t  r r . 
.  t   t t    ti  i  t   f  i tifi  t  l i   i l 
facturer's  t i ti , t   i t  (A ) l  f  t  fi i  t  SHA's lt La  
r t r  f r r i . 
. Ot tio  li s. 
. it ti s f r i l ti ns f  (d)(1) ll  i   t    f il  t  f   r  
t r i ti . r r s (d)(2), (d)(3), (d)(4),  (d)(S) f t  t r  ll  ,  r riate. 
.   r r r        i    ,  i  f  
 (d)(1)  (d)(6) i t  ll    ti n. (Ref    .2.   
i i  r i nce.) 
c. il r  t  r vi  t  z r  t r i ti  r c r s it i  fiv  rki  ys s ll r s lt i  t  iss c  f  
 r (d)(6). 
. ritt n r  i ti  r r , r r  (e).  ll r i  t  ployer's ritt  r  i ti  
r r  t  t r i  if all lic l  r ir ts f r r  (e) v   r ss .   li t s all l yers, 
i l i    lti- l  ,     l  (or l    loyers) t   
i l   l   rit  . 
. I ti  i li . 
.  ritt   l   i  i t, i r  i i    l      
been i ple ented in the orkplace. In general, the ritten progra  should consider the follo ing ele ents, 
 : 
(1) ls  t r r  f r i . 
• i ti  f rson(s) r i l  f r ri  l li  f i -pla t t i rs. 
• i i  f rson(s) i  r     t iners. 
• ri ti   l li  tem(s) . 
• ri ti    l   i   -plant t iners,  l . 
• r r  t  r i   t  l l i f r ti   c ss ry. 
(2) t ri l f ty t  ts. 
• i ti  f rson(s) i l  r / ai t i i  t  . 
•        i t i  (e.g.,    t   rea(s),   i -u     
jobsite, via telefax), procedures on how to retrieve SDSs electronically, including back-up syste s to be used in 
t  t f f il r  f t  l tr niC i t,   l s t i   t  t  . 
• r c r s t  f ll   t   is t r c iv  t t  ti  f t  fir t i nt. 
• r i l f t r r  r i rt r , r r s f r ti  t      i ifi t lt  
i f ti   . 
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3 Training
Designation of persons responsible for conducting training
Format of the program to be used audiovisuals classroom instruction etc
Elements of the training program check to see if the written program addresses how the duties outlined inh2
andh3will be met
Procedures to train new employees at the time of their initial assignment and to train employees when a new
hazard is introduced into the workplace
Procedures to train employees regarding new hazards to which they may be exposed when working on or near
another employer worksiteie hazards introduced by other employers
4 Additional Topics To Be Reviewed
Is a list of the hazardous chemicals part of the written program
Are methods the employer will use to inform employees of the hazards of non routine tasks outlined Do those
methods include procedures regarding how employees will be informed of potential hazards at other worksites
they may visit and at multi employer worksites
Are employees informed of the hazards associated with chemicals contained in unlabeled pipes in their work
areas
Does the written plan include the methods the employer will use on multi employer worksites to provide other
employers with on site access to MSDSs
Does the plan include the methods the employer will use at multiemployer worksites to inform other employers of
any precautionary measures that need to be taken to protect employees
For multiemployer workplaces are the methods the employer will use to inform the other employersof the
labeling system used clearly described
Is the written program made available to employees and their designated representatives upon request
2 Citation Guidelines
a Generally all violations of paragraph e shall be grouped with the violated elements listed in the subparagraphs
of e andor violations of paragraphs fg and h as appropriate since e1 is the only provision under
paragraph e which addresses the development implementation and maintenance of the written hazard
communication program Speck citation guidance is given below
1 If an employer has done nothing to comply with the HCS citations for violations of paragraphse fg
and h of the standard may be issued as separate items with separate penalties Normally these employers will
be cited for violations ofe1f1g1andh2 3
2 Where employees are exposed or potentially exposed to a hazardous chemical and labeling MSDS chemical
inventory and training requirements are met but there is no written plan violations of 191020 shall be
noted as De Minimisand no citations shall be issued
3 On multiemployer worksites MEW the CSHOsshould refer to enforcement policies for MEW in the FIRM
Employers on such sites who do not use hazardous chemicals but whose employees are exposed to the chemicals
used by other employers are required to have a program and train their employees on the hazards of the
chemicals in the work areas If an employer fails to comply with this the employer should be cited for paragraphs
e1and appropriate sections of h Paragraphe2is used to cite employers on MEWwho have a program
but have failed to include the methods to be used to provide other employers on site access to MSDSs labeling
systems used in the workplace or to explain the precautionary measures which need to be taken to protect other
employees on the worksite
D Labels and Other Formsof Warning Paragraph fLabels or other markings on each container must include the identity and
appropriate hazard warnings including target organ effects of the hazardous chemical Labels on shipped containers must also
include the name and address of the chemical manufacturer importer or other responsible party
1 Inspection Guidelines
a CSHOs shall determine that containers are labeled that the labels are legible and that the labels are prominently
displayed
b Labels must be in English Labels and MSDSs may also be printed in additional languages
c The CSHO shall determine whether the label identity can be cross referenced with the MSDS and the list of
hazardous chemicals
d CSHOs must consider alternate labeling provisions for example tags or markings for containers which are of
unusual shape or proportion and do not easily accommodate a legible label
e CSHOs shall evaluate the effectiveness of in plant labeling systems through a review of the employerstraining
program and MSDS procedures Such evaluation shall include interviews with employees to determine their
familiarity with the hazards associated with chemicals in their workplace An effective labeling system is one that
ensures that employees are aware of the hazardous effects including target organ effects of the chemicals to
which they are potentially exposed SeeAppendix A for a discussion of effective labeling systems
f Guidelines for referrals regarding inadequate labels are dealt with in this instruction see paragraphE1d
2 Citation Guidelines
a Chemical manufacturers importers and distributors shall be cited for appropriate paragraphsf1ithrough
f1iiiof the standard when deficiencies are found relating to products that are shipped downstream
Paragraphs5if5iiandf6of the standard shall be cited when a hazardous chemical is created
andor used inhouse only See paragraphE2bof this instruction
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(3) i . 
• i ti  f rson(s) i l   cti g i ing. 
• r t f   t   sed (a i ls,  ti , tc.). 
• l ts f t   r --ch            l  i  (h)(2) 
 (h)(3) ill  . 
•           i i l         
r     t  . 
•   i  l  i     i       i     
t r loyer's r it  (i.e., r  i tr   t r loyers). 
(4) iti l  o  . 
•   t f   i l  rt    gram? 
•    l  ill    l      -  t ks tlined?   
t   r ures   l y es ill  i  f i l  t  it  
t  y i it  t lti- l r rksites? 
• r  l  i f r  f t  r  i t  it  i l  t i  i  l l  i  i  t ir r  
r as? 
• s  i  l  l         lti-      
l  it  -sit   t  Ss? 
• s   l         lti-  rksites      
 r ti nary  t       l yees? 
• r lti-  ,     l  il       ployer(s) f  
l li  te   l l  ribed? 
• I  t  ritt  r r   il l  t  l   t ir Sig t  r r t ti   r uest? 
. Ot ti  i li es. 
. l , l  f  (e)       lement(s)  i    
f (e) /or i l ti  f r r  (f), (g),  (h)  r ri te, i  (e)(l) i  t  l  r i i  r 
r r  (e) i  r   , i l t ti        
i ti  . cific  i    l : 
(1)   l    t i  t  l  it  t  , it ti  f  i l ti  f  (e), (f), (g), 
 (h) f t  t r    i   r t  it s, it  r t  lties. r ll  t  l r  ill 
 it  f r i l ti s f (e)(l), (f)(l), (g)(l)  (h)(2) & (3). 
(2)  ployees    i ll        l ling, ,  
i t ry,  i i  i t   t, t  i   i  l , i l i   910. 1200(e) ll  
         . 
(3)  lti-  it  (M ),  HO's  r t  t l      . 
   it          l       
  r l  r  i       i  i  l   t    t  
i l  i  t  r  . f  l  f il  t  l  it  t is, t  l  l   Cit  f   
(e)(l)  ri t  ti s f (h).  (e)(2) i    i  l        
 ve   l e  t         -sit    s, i  
syste s used in t  rk l c , r t  x l i  t  r c ti ry s r s ic   to  t k  t  r t ct t r 
l    . 
. l l   t r r  f r i . r r  m. l  r t r r i    t i r t i l  t  i tit   
appropriate hazard warnings, including target organ effects of the hazardous chemical. labels on shipped containers must also 
i l e t    r  f t  i l f t rer, i rt r, r t r r i l  rt . 
1. Inspection uidelines. 
.  ll t r i  t t t i r  r  l l , t t t  l l  r  l i l ,  t t t  l l  r  r i tl  
i l . 
. la l  t  i  li . la l   DS's  l   i t  i  iti l l es. 
.   ll i  t   l l    s-         
 . 
. s st c si r lt r t  l li  r visi s (for x l  t s r rki s) f r c t i rs ic  r  f 
al      t     l. 
. s ll l t  t  ff ti s f i -pl t l li  t  t r   r i  f t  ployer's tr i i  
r r    r r .  l ti  ll i l  i t r i  it  l  t  t r i  t ir 
ili rit  i   r  i      .   li   i    
r  t l        (incl    ts)     
hich they are potentially exposed. (See ppendix  for a discussion of effective labeling systems.) 
f. i li  f r r f rr ls r r i  i t  l l  r  lt it  i  t i  i tr tion, s  r r  .1.d .. 
. O i  i li es. 
a. he ical anufacturers, i porters, and distributors shall be cited for appropriate paragraphs (f)(l)(i) through 
(f)(l)(iii) f t  t r   fi i i  r  f  r l ti  t  r t  t t r  i  trea . 
r graphs (f)(S)(i), (f)(S)(ii),  (f)(6) f t  t r  ll  it    r  i l i  r t  
d/or  i -house l . (Se  r r  .2.b. f t i  i truction.) 
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b No citations shall be issued on paragraphf11An indefinite stayof enforcement has been placed on the
requirement that manufacturers update label information within 90 days of becoming aware of significant
information regarding the hazards of the chemical OSHA will alert the regulated community at the time that the
stay is lifted
E Material Safety Data Sheets Paragraph g The standard requires chemical manufacturers and importers to develop or obtain a
material safety data sheet for each hazardous chemical they produce or import
1 Inspection Guidelines CSHOs shall evaluate the compliance status of this provision by examining a sample of MSDSs to
determine that the MSDSs have been obtained or developed and prepared in accordance with the requirements of
paragraphsg25of the standard and to ensure that the information regarding the health and physical hazards is
accurate If MSDSs are not updated when new information becomes available the initial hazard determination
performed by the chemical manufacturer or importer is deficient
a The CSHO is to complete this review by following the procedures outlined in Hazard Evaluation Procedures
Appendix C of this instruction The CSHO shall also use available literature and computer references in the Area
Office as well asAppendix D Guide to Reviewing MSDS Completeness in reviewing MSDS
b The following items shall be considered when reviewing MSDSs
Do employers have an MSDS for each hazardous chemical used
Does each MSDS contain information which adequately addresses at least the 12 elements required by the
standard atg2ixii
Are all sections of the MSDS accurately completed
c The CSHO shall ensure compliance with the MSDS transmission provisions of the standard by reviewing the
chemical manufacturer importersor distributor program for transmitting the MSDSs including updated
MSDSs to downstream customers
d The following procedures apply in situations where the employersMSDSlabel is inadequate or deficient and the
employer relied upon the information supplied by chemical manufacturer or importer
1Employers are not to be held responsible for inaccurate information on the MSDSlabel which they did not
prepare and they have accepted in good faith from the chemical manufacturer importer or distributor
2CSHOs shall take copies of any MSDSlabel with inaccurate or deficient information back to the Area Office for
referral to the appropriate State Plan State or Area Office
3The Area Office within whose jurisdiction the upstream supplier or manufacturer is located shall then ensure
that referral procedures outlined herein are followed State Plan States shall follow referral procedures as required
by the State
4The Area Office or State Plan State towhich the referral was made shall notify the referring office of the
outcome of the referral
5Area Offices should expect to receive requests from employers to assist them in obtaining MSDSs or labels in
situabons when an inspection has not been conducted If the Area Director determines that the employer has
tried to obtain the information and has not been able to do so a letter andor telephone call from the Area Office
to the supplier or manufacturer is the appropriate action in this situation
6In the event that the CSHO needs MSDS information quickly as part of a current inspection heshe may
contact the manufacturer directly prior to making the referral to the AO in whose jurisdiction the manufacturer is
located
7Referral Procedures for Distributors When a distributor has not received an MSDS from the supplier the
CSHO shall recommend that the distributor write to the chemical manufacturer or supplier of the chemical If the
distributor fails to receive the MSDS within a reasonable period of time for example five working days the Area
Director shall follow the referral procedures outlined herein
2 Citation Guidelines Citations shall be issued to the employer only when MSDSs or labels are missing Citations to
manufacturers or importers for incomplete or inaccurate MSDSs or labels shall include an abatement requirement for the
transmittal of corrected MSDSs or labels to all customers with the next shipment of the chemical
a IfMSDSs or labels are missing or have not been received the employer shall be cited unless a good faith effort
has been made to obtain the information
1Ifa citation is issued to the employer for lack of an MSDS label and the employer has failed to document that
a good faith effort has been made to obtain them CSHOs shall recommend that the employer write to both the
supplier distributor and to the manufacturer for the MSDS or label
b Any party who changes the label or MSDS for example changing the name or identity of the chemical becomes
the responsible party for the change regardless of whether they are a chemical manufacturer distributor or
employer Where a distributor adds its name to an MSDS or label which is inaccurate or incomplete but makes no
other changes to the information on the data sheet or label citations shall not be issued to the distributor
Distributors however who substitute their names on the MSDS or change it in any way become the responsible
party and must be able to supply the required additional information on the hazardous chemical and appropriate
emergency procedures if necessary Failure to provide the additional information will result in a violation of
g2xiiof the standard if noted upon inspection
c CSHOs shall citeg1whenever an inspection reveals that an employer does not have an MSDS Ifan employer
possesses an MSDS but it is not readily accessible to employees while in their work area then a violation ofg8
shall be cited Violations ofg8shall also be cited when an employer using electronic access as an integral part
of the hazard communication program does not have an adequate backup system to address emergency
situations
d On MEW citations for violations ofg8of the standard shall be issued to the employer responsible for making
the MSDSsreadily accessible as discussed below A citation for violation of2ishall be issued if an
employer fails to include the methods by which the employer will inform other employers about on site access to
data sheets
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b. No cit ti s sha l be issued on paragraph (f)( 1). An indefinite stay-of- f r ent has en placed on th  
require ent that anufacturers update l l information it i   days f beco ing a r  f i ifi t 
i f r ation regarding t  zar s f th  i l.  ill l rt t  r l t  it  at t  ti e t t t  
stay is lifted. 
. Material Safety Data Sheets. aragraph (g). Th  standard r ir  i l f t r rs d i porters t  develop r t i  a 
material safety t  sh t for ach hazardous c ic l t  produce r i rt. 
1. Inspection uidelines. (s s shall evaluate the co pliance status of this provision by exa ining a sa ple of S Ss to 
t r i  that the SDSs have been tained r v l  and repared in accordance it  t e requirements f 
r r  (g)(2)-(5) of t  standard  t  nsure that t  i f r ation r r i  t  lt  an  i l r  i  
r t . If s are ot up t    i f r ti  beco es il l , t  i itial r  t r ination 
rf r ed by the che ical ufacturer r i orter i  fiCi t. 
. The (s  is to plete this review  fo l ing t  r cedures tli  i  azard valuation res, 
ppendix C, of this instruction. The (  shall also use available literature and co puter references in the rea 
fice as l  Appendix 0, uide t  i i   Co pl t , i  i i  . 
.  f ll i  it s ll be i r  he  r vi i  s: 
•  e pl y r  ve an  r h hazardous ch i l d? 
• es each  contain i f r ti  i  t ly r s t l t the  l t  ir   t  
t r  t (g)(2)(i)-(xiiJ? 
•  all sections f the S ccurately l ted? 
.  (s  sha l nsure li  i  t       t r     
che ical anufacturer's, i porter's, or distributor's progra  for trans itting the S Ss (including updated 
S Ss) to do nstrea  custo ers. 
. e f ll ing r ures l  i  it ti  r  t  loyer's SDS/label is i t  r fi i t  t  
e ployer r li   t e i f r ti  s li  y c ic l facturer r i rt r: 
(1) E ployers are not to be held responsible for inaccurate infor ation on the SDS/label which they did not 
r r   t   t  i   f it  fr  t  i l f t r r, i rter, r i tri tor. 
(2) (s s shall take copies of any S/label ith inaccurate or defiCient infor ation back to the Area ffice for 
referral to the appropriate State Plan State or Area ffice. 
(3)  r  ffi  it i  s  j ri i ti  t  tr  li r r f t r r is l c t  s ll t  r  
t t r f rral r c ures tli  r i  r  f ll . t t  lan t t s s ll f ll  r f rr l r c r s as r ir  
by the tate. 
(4)  r  ffi  r t t  l  t t  t  i  t  r f rr l   ll tif  t  r f rri  ffi  f t  
   rral. 
(5) Area ffices should expect to receive requests fro  e ployers to assist the  in obtaining SDSs or labels in 
situations when an inspection has not been conducted. If the Area irector deter ines that the e ployer has 
tried to obtain the infor ation, and has not been able to do so, a letter and/or telephone call fro  the Area ffice 
t  t  li r r f t r r i  t  r ri t  ti  i  t i  it ti . 
(6) I  t  v t t t t  (s  s  i f r ti  ickly as rt f  c rr t i spection, /sh  y 
c t ct t  f ct rer ir ctiy ri r t  aking t  r f rr l t  t   in hose j ris icti  t  f ct r r is 
l . 
(7) Referral Procedures for Distributors. hen a distributor has not received an SDS fro  the supplier, the 
(s      i tri t r          i l. I   
i t i t r        r l   f i e,  le,   ys,   
irector shall follo  the referral procedures outlined herein. 
. it ti  i li s. it ti  ll  i  t  t  l r l    r l l  r  issing. it ti  t  
f t r r  r i rt r  f r i l t  r i r t  s r l l  ll i l   t t r ir t f r t  
tr s itt l f c rr ct  s r l ls t  ll c st rs it  t  xt s i t f t  c e ical. 
a. If MSDSs or labels are issing or have not been received, the e ployer shall be Cited unless a good faith effort 
    i  t  r ation. 
(1) If a citation is issued to the e ployer for lack of an /label and the e ployer has failed to docu ent that 
a good faith effort has been ade to obtain them, (sHOs shall reco end that the e ployer rite to both the 
li  ( i i tor)    f t      l bel. 
b. Any party ho changes the label or S S (for exa ple, changing the na e or identity of the chemical) beco es 
the responsible party for the change regardless of hether they are a che ical anufacturer, distributor or 
e ployer. here a distributor adds its na e to an S S or label hich is inaccurate or incomplete, but akes no 
other changes to the infor ation on the data sheet or label, citations shall not be issued to the distributor. 
Distributors, however, who Sl.!bstitute their na es on the MSDS or change it in any way become the "responsible 
party" and ust be able to supply the required additional infor ation on the hazardous che ical and appropriate 
emergency procedures, if necessary. Failure to provide the additional information will result in a violation of 
( )(2)(xii) f t  st r  if noted  inspection. 
c. (sHOs shall cite (g)(l) whenever an inspection reveals that an e ployer does not have an MSDS. If an e ployer 
possesses an MSDS but it is not readily accessible to employees while in their work area, then a violation of (g)(8) 
shall be cited. Violations of (g)(8) shall also be Cited when an employer using electronic access as an integral part 
of the hazard co unication progra  does not have an adequate back-up syste  to address e ergency 
situations. 
d. On MEW, citations for violations of (g)(8) of the standard shall be issued to the employer responsible for making 
the SDS(s) readily acceSSible, as discussed below.  citation for violation of (e)(2)(i) shall be issued if an 
employer fails to include the methods by which the employer will inform other employers about on-site access to 
ata ets. 
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1 For example if an employer on a multi employer worksite brings hazardous chemicals onto that site and fails
to inform other employers about the presence of those chemicals andor the availability of the MSDSs that
employer shall be cited for violation ofg8grouped with2
2Controlling Employer If the employer uses a general contractor or other employer as an intermediary for
storage of the MSDSs and that intermediate employer has agreed to hold and provide ready access to the
MSDS then the intermediate employer becomes the controlling employer and is responsible for ensuring the
availability of the MSDSs
3The controlling employereggeneral contractor shall therefore normally be cited for violation ofg8if
the MSDSs are not available however
4Ifthe MSDSsare not available because the subcontractor failed to make them readily accessible then the
subcontractor shall be cited for violation ofg8
F Employee Information and Traininci Paragraph h The standard requires the training of all employees exposed or potentially
exposed to hazardous chemicals
1 Inspection Guidelines Training programs must be evaluated through program review and discussion with management
and employees
a Employee interviews will provide general information to the CSHO regarding the training program It cannot be
expected that employees will recall all information provided in the training and be able to repeat it Employees
must be aware of the hazards to which they are exposed know how to obtain and use information on labels and
MSDSs and know and follow appropriate work practices If the CSHO detects a trend in employee responses that
indicates training is not being conducted or is conducted in a cursory fashion that does not meet the intent of the
standard a closer review of the written program and its implementation may be necessary The following
questions may be used by the CSHO in determining the adequacy of the training program
Has a training and information program been established for employees exposed to hazardous chemicals
Is this training provided at the time of initial assignment and whenever a new hazard is introduced into
work areas
Have all new employees at this location received training equivalent to the required initial assignment
training
If electronic access to MSDSs is being used at a workplace have employees been adequately trained to
retrieve theinformation
b Paragraph h requires that information and training be provided to employees regarding the hazards of all
chemicals in their work areas including by products and hazardous chemicals introduced by another employer
provided that they are known to be present in such a manner that employees may be exposed under normal
conditions of use or in a foreseeable emergency
c CSHOs should determine if employees are employed by outside contractors such as temporary employment
agencies or the inspected employer For guidance concerning an employers responsibility for training temporary
employees see Appendix A To establish if an employer employee relationship exists the CSHO should determine
the following
Who controls the manner and means by which work is accomplished
Who supervisesevaluat the work quality
What and where is the location of the work
Who determines the workers schedule Time of arrivaldays worked
Who provides required instruments tools and equipment
What is the history and duration of the relationship between the parties
To what extent can the clienthos employer choose a particular worker
Who has the right to assign new projects to the worker
What is the extent of the partys control over when and how long the employee works
Who provides payment and method of payment
Who provides nonsalary benefits if any
Who determines whether a worker gets a raisebonus
2 Citation Guidelines If no form of employee training has been provided citations shall be issued underh1Citations
shall be issued under paragraphh2andh3of the standard as appropriate if there is a deficiency in an otherwise
existing program The employer is always ultimately responsible for ensuring that employees are adequately trained
regardless of the method relied upon to comply with the training requirements
G Trade Secrets Paragraph i1 Only specific chemical identities may be withheld under the HCS trade secrets provisions Even
when a chemicals identity is rightfully withheld as a trade secret its release may be required by the trade secret access
provisions in paragraph i
1 Inspection Guidelines CSHOs evaluating MSDSs and hazard determination programs may request disclosure of trade
secret identities under paragraphi12of the HCS OSHA shall take all steps feasible to protect trade secret identities
including secure filing and return of information when its use is complete
a Non emergencies Health professionals are entitled to trade secret information when providing medical or other
occupational health services to exposed employees Likewise the employees themselves andor their designated
representatives are entitled to trade secret information If these individuals are denied access to trade secret
information the matter may be referred to OSHA for enforcement proceedings
1 As stipulated in the standard OSHA should receive from the referring health professional employee or
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(1) r l , if  l    l i- l  i  i   i l   t  it   f il  
 i f    t      /or   f  SDS(s),  
 l   i   i l ti  f (g)(8)  i  (e)(2)(i). 
(2) t lli  l r.  t  l r   l t t   t  l    i t i  f  
 f  SDS(s),  t t i      l        
SDS(s), t   i t      r,  i      
i    SDS(s). 
(3)  t lli  l  (e.g., l t t r) ll, t f , ll   it  f  i l ti  f (g)(8) if 
 DS(s)  t le; : 
(4) If the SDS(s) are not available because the subcontractor failed to ake the  readily accessible, then the 
t t r ll  it  f  i l ti  f (g)(8). 
. l  ti   r i ing.  (h).     t i i  f ll l    ti l  
   i ls. 
.  i .  r  t          
 l . 
. l  i t i         i    r gra . t t  
t   l s ill ll l  i         t .  
t          ,           
,    f ll  r ri t   ti .  t   t t   t  i  l   t t 
 i     t d,  i  t              
rd,  l r i  f   r    i    ary.   
ti      t   i  t r i i  t   f t  tr i i  r r : 
•          l     icals? 
• I  t i  t i i  i  t t  ti  f i iti l i t      i  i t  i t  
 as? 
•  ll  l s t i  l i  i  i i  i l    i  i iti l i  
tr i ing? 
•           ,  l      
  i ation? 
b. r r  (h) r ir s t t i f r ti   tr i i   r vi  t  l y s r r i  t  z r s f all 
  t ir  r s l i  -    i     l er, 
i d   r           l s      
conditions of use or in a foreseeable e ergency. 
.  l  t r i  if l  r  l   t i  tr t r  (suc   t r r  l t 
i ) r t  i t  l r. (For i  r i   ployer's r i ilit  f r tr i i  t r r  
l ,  i  .) o t li  if  l r- l  r l ti i  i t , t   l  t r i  
 i : 
•  tr l  t  r    i   i  lished? 
•  upervises/evaluates   lity? 
•         ork? 
•  t r i   rker'S dule? (TI  f l/day  ?) 
•  r i  r ir  i tr t , t l ,  i ent? 
• t   i         ties? 
•  t t t  t  lient/host l r   rti l r rker? 
•   t  i t  i   j    rker? 
• t is t  xt t f t  rty's c tr l v r  and  l  t  l y e orks? 
•   t   f ent? 
•  r i  -salar  fit , if y? 
•  t r i s t   r t   i /b us? 
. m ti  Ui li . f   f l  i i    i , i i  ll  i   (h)(l). O i  
ll  i  r r r  (h)(2)  (h)(3) f t  t r ,  r ri t , if t r  i   fiCi  i   t r i  
i ti  r r .  l r i  l  lti t l  r i l  f r ri  t t l  r  t l  tr i ed, 
r r l ss f t  t  r li   t  l  it  t  tr i i  r ir t . 
.  ts,  (i). l  Cifi  i l i titi    it l  r t   t  r t  isions.  
  ical's i tit  i  i tf ll  Wit l    t  r t, it  r l    i   t  t  t  
r i i  i  r r  (i). 
. ti  i . s l     i ti     l r    
t i titi    (i)(12) f t  .  ll t  ll t  f i l  t  t t t  t i tities, 
i l i   ili    f i i   i   i  l . 
a. Non-e ergencies. Health professonals are entitled to trade secret infor ation when providing edical or other 
ti l lt  r i  t   l . U ise, t  l  t l  /o  t i  Si t  
r r sentatives r  titl  t  tr  r t i f r ti n. If t  i i i l  r  i  cc ss t  tr  r t 
i f r tion, t  tt r y  r f rr  t   f r f r t r c i s. 
(1)  ti l t  i  t  t ,  l  r i  f  t  f i  lt  rofeSSi nal, l ,  
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designated representative a copy of the written request for the trade secret information as well as a copy of the
written denial provided by the holder of the trade secret These two written documents shall be reviewed by the
Area Director to determine the validity of the request and the trade secret claim The Regional Solicitor may be
consulted to provide assistance in this regard
a If the Area Director does not believe that there is enough information upon which to base a decision heshe
may contact either the trade secret requester or the trade secret holder for further information Such requests
shall be documented in thecase file
b Medical emergencies The HCS permits a treating physician or nurse to designate the existence of a medical
emergency requiring the immediate disclosure of trade secrets Referrals received from treating physicians and
nurses relating to a medical emergency shall normally be classified as imminent danger or serious in accordance
with the FIRM Due to the potential risk to life andor health the Area Director shall ensure that these referrals
are processed as soon as received The Area Director or hisher designee shall contact the manufacturer of the
chemical by telephone Telephone numbers are required on the MSDS The manufacturer shall be informed of
the standard requirements and requested to immediately provide the needed information directly to the treating
physician or nurse
2 Citation Guidelines
a Non emergencies In response to non emergencies where OSHA believes that the chemical manufacturer
importer or employer will not be able to support the trade secret claim the withholding of a specific chemical
identity shall be cited as a violation of paragraphg2Where OSHA does not question the claim that a specific
chemical identity is a trade secret but the employer has failed to comply with paragraphi1iiiiior iv
or withi2ori3such failure shall be grouped with 191020 stating the deficiency in the AVD For
example the employer claims a trade secret exists but failed to indicate on the MSDS that the specific chemical
was being withheld for that reason as required under paragraph1iii
b Medical emergencies For medical emergencies failure to disclose the information shall result in the issuance of a
willful citation if the elements of a willful citation can be established The chemical manufacturer will frequently
be located under a different Area Office jurisdiction Apparent violations shall be referred to the office of
jurisdiction for investigation and the issuance of citations Concurrently the Area Director of jurisdiction shall
coordinate obtaining an administrative subpoena ordering the immediate disclosure of the needed information
Federal Court Orders shall be sought immediately if the administrative subpoena is not effective in obtaining the
information
XII Classification and Grouping of Violations The procedures in the FIRM shall be followed except as modified by this instruction
A Citations for violations of paragraphs efg and h of the standard shall be issued as separate items only when there is a
pervasive lack of compliance with the Hazard Communication Standard Otherwise specific guidance in this instruction shall be
followed
B Generally HCS violations shall be classified as non serious Serious violations shall be issued only when the deficiency can
contribute to a potential exposure capable of causing death or serious physical harm In addition the CSHO must document
that the employer knew or should have known of the violation
1 Documentation of a HCS violation for a chemical manufacturer or importer could be in the form of a referral generated
as a result of OSHAs observation of conditions of use resulting in employee exposure to the hazardous chemical at a
downstream user workplace
XIII Interface With Other Standards In some cases an employersduties under other OSHA standards dovetail with requirements of the
HCS resulting in simplified compliance
A Access to Exposure Records The Access to Employee Exposure and Medical Records Standard 29 CFR 191002 and the HCS
overlap with regard toMSDSs MSDSs are specifically identified as exposure records under 29 CFR 191002c5iiiEach
MSDS received by an employer must be maintained for at least 30 years as required at191002i The access
standard does offer an alternative to keeping the MSDSs at 191002iBwhich reads as follows
Material safety data sheets and paragraphc5iv records concerning the identity of a substance or agent need not be
retained for any specified period as long as some record of the identity chemical name or trade name if known of the
substance or agent where it was used and when it was used is retained for at least thirty 30 years
1 Employers might simplify their responsibilities as they relate to the overlap between these two standards by incorporating
the requirements under 29 CFR 191002iBwith those for the HCS paragraph1iThat is the list of
hazardous chemicals could include information on where chemicals were used and when they were used These lists
would then have to be kept for at least 30 years
2 Section e4of the HCS requires employers to make the written hazard communication program available upon request
to employees their representatives OSHA or NIOSH in accordance with the requirements at 191002eThe
standard 191002 requires the employer to provide a copy of the requested record in this case a copy of the
written hazard communication program in a reasonable time but in no event later than fifteen 15 days Some
employers have incorrectly interpreted this to mean that they have 15 days to produce a copy of the written program
and make it available at the worksite The intent behind thee4 requirements of the HCS is to allow the employer up
to 15 days to provide a written photo or other copy of the program to employees who request it This does not mean
the employer has 15 days in which to get the program to the worksite for employees to access The written program
must be available to employees at the worksite at all times as per 191020 e1
B 29 CFR 1910 1450 Occupational Exposure to Hazardous Chemicals in Laboratories Quality control laboratories are usually
adjuncts of production operations and are not covered under the Laboratory Standard but are covered under the HCS For
laboratories covered under the Laboratory Standard the requirements of the HCS are superseded the more specific standard
191045 takes precedence Both the training and information and the hazard identification requirements of the Laboratory
Standard are more extensive than the HCS laboratory requirements
C Other Health Standards Paragraphf4ofthe HCS references labeling requirements of substance specific standards
Employers must comply with these substance specific standards For example the ethylene oxide ETO standard provides a
different labeling requirement than the HCS Labels do not have to be affixed to containers of ETO unless the product is capable
of producing employee exposure at or above the action level of05ppm as an 8 hour time weighted average 29 CFR
1910047
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i t d t ti    f t e ritt  st f r    i ,  ll   py f t e 
i  i l r i   t  l r f   .  t  ri  t    i   t  
r  ir t r to t r i  t  validity f  t  t  t   l .  i  l  y  
l  t  r i  ssi t  i   . 
(a) If   ir t r does t l  t t t r  i  enough i f r ti   i  t    i , /sh  
ay t ct either t e tr de  r t r r t  tr  r t l r f r f rt r i .  t  
all   i  t  case f . 
b. edical r . e  r it   tr ting i i  r r   i te the i     
r  iri  t  i i t  i l r  f t  ts. f rr ls r i   i  i i s  
r s l i  t   i l r cy ll ll   l ifi  s i i t   ri s i   
it  t  I . ue t  t e t ti l i  t  lif  /or lt , t e r  i t  ll r  t t t  f l  
r  r c ss d s on  r .   i t r  i /her i  l t t  f ct r r f  
i l  . l  r   r ir   t  .      f 
t  dard's i ts  t  t  i tely i   ed i      
i i  r . 
2.  i s. 
. on- . In  t  - , r       , 
i porter r l yer ill ot  l  t  rt t e tr  t cl i , t  it olding   ifi  i l 
i ntity ll  it  as  i l ti  f r r  (g)(2).  A s t    t  Cifi  
i l i ntity i   tr e t, t t  l r  f il  t  ply it   (i)(1)(i), (ii), (iii) r (i ), 
r i  (i)(2) r (i)(3),  f il  ll   i  910.12oo(g)(2), i   iCie  i   . r 
l ,  l  l i     i t   il  t  i i     t  ifi  i l 
 i  it l  f r t t r , s r ir  r r r  (i)(1)(iii). 
. i l i . r i l ies, f il   i l   i i  ll l  i   i    
ill l Citati , if t  l    ill l i i    t li .  i l t  ill l  
 l t  r  iff r t r  ffi  j ri i ti . r t i l ti s ll  r f rr  t  t  ffi  f 
j ri i ti  f r i ti ti   t  i  f Citati . rr tl , t  r  ir t r f j ri i ti  ll 
r i te t i i g    ri  t   l r  f t   r tion. 
r l rt r  ll  t i i t l  if t  i i t ti   i  t ff ti  i  t i i  t  
i f . 
. O i   i  f i .  r s i    l  f ll  t     . 
. it ti  f  i l ti ns f  (e), (f), (g)  (h) f t  t  ll  i   t  it  l   t  i   
r i  l ck  pliance it   r  unic ti  rd. i  Cifi  i  i  i  i ti  ll  
f ll . 
. r ll   i l ti  ll  l ifi   - ri . ri  i l ti  ll  i  l   t  fi i   
t i         t  r i  i l .  ition, t   st  
that the e ployer kne  or should have kno n of the violation. 
. t ti  f      l f t r r  t r          
   f A's   iti      l         
do nstrea  user's orkplace. 
III. I t rf ce it  t r t r . I   ,  ployer's ti  r t r  t r  t il it  r ir t  f t  
, r lti  i  i lifi  li ce. 
   
A. Access to Exposure Records. The Access to E ployee Exposure and edical Records Standard (29 CFR 1910.1020) and the HCS 
overlap with regard to MSDSs. MSDSs are specifically identified as exposure records under 29 CFR 1910.1020(c)(5)(iii). Each 
 r i    l r t  i t i  f r t l t  r  s r ir  t 910.1020(d)(1)(ii).  "ac  
t rd"  ff r  lt r ti  t  i  t   t 910.1020(d)(1)(ii)(B), i  r   f ll s: 
"Material safety data sheets and paragraph (c)(S)(iv) records concerning the identity of a substance or agent need not be 
retained for any specified period as long as some record of the identity (che ical name or trade name, if known) of the 
substance or agent, where it was used, and when it was used is retained for at least thirty (30) years." 
1. ployers i t si lify t ir responsibilities as t y relate to t  overlap bet een these t  st r s by i c r r ti  
the require ents under 29 F  1910.1020(d)(1)(ii)(B) ith those for the S paragraph (e)(1)(i). hat is, the list of 
 i l  l  i l e i f ti    i l      t   .  li t  
l       f r  l   rs. 
2. ection (e)(4) of the S requires e ployers to ake the ritten hazard co unication progra  available upon request 
t  l y s, t ir r r s t tiv s,  r I , in cc r c  it  t  r ir ts t 91 .1020(e).  
standard, 1910.1020(e), r ir s t  l y r to provide  copy f the requested record (i  t is case,  copy f t  
i   i ti  ra ) "in  l  i  ...  i    l  t  i  (1 ) ays .... "  
e ployers have incorrectly interpreted this to ean that they have 15 days to produce a copy of the ritten progra  
  it il l  t t  r it .  i t t i  t  (e)(4) r ir t  f t   is t  ll  t  l r  
to 15 days to provide a written (photo or other) copy of the program to employees who request it. This does not mean 
t  l y r s 15 ys in ic  t  t t  r r  t  t  rksit  f r l y s t  access.  ritt  r r  
t     t    ll s,  r 910. 2 0 ( )(1). 
B. 29 CFR 1910.1450. Occupational Exposure to Hazardous Chemicals in Laboratories. Quality control laboratories are usually 
adjuncts of production operations and are not covered under the Laboratory Standard, but are covered under the HCS. For 
l r t ri  r  r t  r t r  t r , t  r ir t  f t   r  r  (t  re ifi  t ard, 
1910.1450, takes precedence). oth the training and infor ation and the hazard identification require ents of the Laboratory 
t r  r  r  xt siv  t  t   l r t r  r ir ts. 
C. Other Health Standards. Paragraph (f)(4) of the HCS references labeling requirements of substance-specific standards. 
ployers ust co ply ith these substance speCific standards. or exa ple, the ethylene oxide (E ) standard provides a 
different labeling require ent than the S. Labels do not have to be affixed to containers of ET  unless the product is capable 
of producing e ployee exposure at or above the action level of 0.5 pp  as an 8-hour ti e weighted average (29 CFR 
910. 047 W(1)(ii». 
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Appendix A
CLARIFICATIONS AND INTERPRETATIONS OF THE
HAZARD COMMUNICATION STANDARD HCS
This appendix includes clarifications and interpretations which answer the most frequently asked questions
regarding the HCS Clarifications are keyed to the most applicable paragraph of the HCS
PURPOSE Paragraph a
a2OSHAsposition is that State standards can be enforced only under the auspices of an OSHA approved State plan States without
State plans are preempted from addressing the issue of Hazard Communication Community right tokn w standards are outside the
jurisdiction of OSHA and are not affected by this position Inquiries regarding preemption that require indepth knowledge of this
subject shall be referred through the Directorate of Compliance Programs to the Office of State Programs for response
The Agencysposition regarding State standards has been described in OSHA Instruction STP 2117 This should be consulted when
answering questions regarding State standards
SCOPE ANDAPPLIG4TION Paragraph b
b2The phrase known to be present is essential to the scope of the standard If a hazardous chemical is known to be present by
the chemical manufacturer or the employer it is covered by the standard This includes chemicals to which employees may be exposed
during normal operations or in a foreseeable emergency This means that even though an employer was not responsible for the
manufacture of the hazardous chemical the employer has the responsibility for conveying hazards to hisher employees For example
the standard applies in the following situations if employees are exposed to chemicals brought onto a multi employer worksite by other
employer or if service personnel are exposed to natural gas during furnace repair An employer whose employees are exposed to
chemicals known to be present must include in their hazard communication program information concerning the hazards of those
chemicals
By productscovered by the HCS A manufacturersor importershazard determination procedures must anticipate the full
range of downstream uses of their products and account for any hazardous byproducts which may be formed For example a
manufacturer of gasoline must inform downstream users of the hazards of carbon monoxide since carbon monoxide is a
hazardous chemical and is known to be present as a byproduct resulting from the use of gasoline Similarly manufacturers of
diesel must inform downstream users of the potential human carcinogenicity of diesel exhaust on the MSDSs for diesel fuel
The terminology exposed under normal conditionsof use or in a foreseeable emergencyexcludes substances for which the
hazardous chemical is inextricably bound or is not readily available and therefore presents no potential for exposure
Exposure includes accidental or possible exposure see definition under paragraph c of the standard Further employees
such as office workers or bank tellers who encounter chemicals only in nonroutine isolated instances are not covered
However an employee in a graphic arts department who routinely uses paints adhesives etc would be covered by the HCS
OSHA does not consider either radiation hazards or biological hazards to be covered by the HCS If however the radiological or
biological agent is accompanied by an otherwise covered hazardous chemical ega container with a biological sample packed
in an organic solvent then the container would be subject to the requirements of the HCS for the hazardous chemical only
b3The coverage of lab is limited under the HCS and includes quality control laboratories laboratories whose function is to
produce commercial quantities ofmaterials and all laboratories connected with production processes The CSHOs may want to refer to
29 CFR 191045 Occupational Exposure to Hazardous Chemicals in Laboratories the Lab Standard The operating definition of a
laboratory is not the same for both standards The Lab Standard covers only laboratories meeting the criteria of laboratory use and
laboratory scale and excludes procedures that are part of a production process 55FR 3328 The preamble to 29 CFR 191045
statesmost quality control laboratories are not expected to meet the qualification for coverage under the Laboratory Standard
Quality control laboratories are usually adjuncts of production operations 55FR 3312 Quality control laboratories would
therefore generally be covered by the HCS
Some manufacturers of chemical specialty products have interpreted the laboratory provisions as exempting them from
coverage These operations are considered to be manufacturing processes and are not exempted Furthermore a pilot plant
operation is also considered to be a manufacturing operation and is covered under the HCS Establishments such as dental
photo finishing and optical laboratories clearly are not considered laboratory operations for the purposes of this standard since
they are engaged in the production of a finished product
Laboratories covered under the HCS do not have to have a written hazard communication program Therefore when the
required training is performedemployees would be informed that written programs are not required for laboratories
Paragraphb3iiiwas revised to clarify the intent of the standard Employers are required to provide laboratory employees
with information and training as outlined in paragraph hMerely providing MSDSs to employees is not considered training for
purposes of the standard
Paragraphb3ivwas added to cover laboratory employers who ship hazardous chemicals A laboratory shipping hazardous
chemicals is considered a chemical manufacturer and must meet the hazard evaluation requirements of paragraph d the
labeling requirements of1and MSDS requirements ofg6andg7In the event that the shipment is of a newly
developed chemical OSHA would expect the laboratory to provide all available information on that chemical As stated in the
preamble the HCS is based upon currently available information If a new chemical is developed and has not been tested to
determine its hazardous effects then there is no information to transmit The rule does not require testing of chemicals to be
performed
Quality control samples taken in a plant must be labeled tagged or marked unless the person taking the sample is also going to
be performing the analysis and thus the sample would come under the portable container exemption A handwritten label may
be utilized as long as the required label information is present The rack in which samples are placed could be labeled in lieu of
labeling individual samples if the contents and hazards are similar
b4Since all containers are subject to leakage and breakage employees who work in operations where they handle only sealed
containerssuch as warehousing are potentially exposed to hazardous chemicals and therefore need access to information as well as
training The training required for employees who handle sealed containers is dependent upon the type of chemicals involved the
potential size of any spills or leaks the type of work performed and what actions employees are expected to take when a spill or leak
occurs
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ppendix  
ARIFICATIONS AN  INTERP TIONS F E 
 C U IC ION  (HC ) 
This appendix i cl s clarifications and i t r r t ti  ic  ans er t  ost frequently sk  sti s 
regarding t  S. larifications are keyed t  t  st applicable r r  f the S. 
E aragraph (a) 
 f  
(a)(2)OSH 's position is t t State standards can  forced onl  r t  uspices f an A-a proved t t  l . t t  it t 
State plans are pree pted fro  addressing the issue of Hazard Co unication. Co unity right-te-know standards are outside the 
jurisdiction of  and r  not affected y this iti . I iri  r r i  r ption t t require i -depth l  f t i  
subject shall  r f rr  t  t  irectorate of o pli  r gra s t  t e ffi  f t t  r r s f r . 
The Agency's pOSition regarding State standards has been described in OSHA Instruction STP 2-1.117. This should be consulted when 
ans ering sti  r r i  t t  st r . 
(b)(2) The phrase "known to be present"is essential to the scope of the standard. If a hazardous che ical is known to be present by 
the i l ufacturer r t  e l , it i  r   t  t rd. i  i l  i l  t  i  l y s    
during r al r ti  or i   f r l  r . i  s t t  t   l r  t r i l  f r t  
f  f t  r  i , t  e pl y r   r i ili  f r i  r s t  i /her . r l , 
the t r  plies i  t  f ll i  it ti s: if l  r   t  i l  r t t   lti- l r r it   t r 
e loyer(s) r if r ice r l re ex s  t  t r l  ri  f r c  r ir. n ployer  l  r   t  
i l  "known t   r " st i l de i  i  r    i f ti  r i g    t  
i l . 
,v-pr ducts are r   t  .  f turer's r i rter's r  t r i ti  r r  t ti i t  t  f ll 
r  f tr   f t ir r t   t f r  r  - r t  i    f r d. r le,  
f cturer f s li  st i f r  str  s rs f t  z r s f c r  onOXide, si c  c r  xi  is  
r s i l  i  "known t   "   - r uct l i     f li . i il l , f t r r   
i l t i   r  f  i l  i i i  f i l t     i l l. 
The terminology "exoosed under nor al conditions ofuse or in a foreseeable emerqencv" excludes substances for which the 
hazardous che ical is i xtric ly bound r is not readily available, and, t r f r , presents no t ti l f r exposure. 
(" xposure" includes aCCidental or possible exposure, see definition under paragraph (c) of the standard). urther, e ployees 
  O fice r r  r k t ll     l   "n - tine,"     vered. 
o ever, an e ployee in a graphic arts depart ent ho "routinely" uses paints, adheSives, etc., ould be covered by the HCS. 
 s   it r i ti    i laqical      . f, r,  r i l i   
i l ic l t is cc i  y  t r is  c v r  z r s c ic l, (e.g.,  c t i r it   i l ic l s l  ck  
i   r i  l ent), t  t  t i r l   j t t  t  r ir t  f t   f r t  r  i l l . 
(b )(3) The coverage of laboratories i  li i    S,  i l  li  l l ratories, l i   i  i  t  
produce co ercial quantities of aterials, and all laboratories connected with production processes. The CSHOs ay want to refer to 
  910. 450, ti l r  t  r  i l  i  r t ri  (th   t ndard).  r ti  fi iti  f  
l r t ry i  t t   f r t  t ards.   t r  r  l  l r t ri  ti  t  rit ri  f "la r t r  "  
"laboratory scale" and excludes procedures that are part of a production process (55 F.R. 3328). The preamble to 29 CFR 1910.1450 
t t  " ... most lit  tr l l r t ri  r  t t  t  t t  lifi ti  f r r  r t  r t r  t rd. 
lity tr l l r t ri  r  ll  j t  f r ti  erations ... " (5  .R. 12). lit  tr l l r t ri  uld, 
therefore, generally be covered by the HCS. 
 f t r r  f i l i lt  r t   i t r r t  t  l r t r  r i i  s ti  t  fr  
c v r . s  r ti  r  i r  t   f t ri  r c sses,  r  t pted. rther ore,  il t l t 
operation is also conSidered to be a manufacturing operation and is covered under the HCS. Establishments such as dental, 
photo finishing, and optical laboratories clearly are not considered laboratory operations for the purposes of this standard since 
they are engaged in the production of a finished product. 
r t ri s c v r  r t    t v  t  v   ritt  z r  c ic ti  rogram. refore,  t  
required tr i i  is erformed, e ployees ould be inf r  t t ritt  r r s are n t r ired f r laboratories. 
Paragraph (b )(3)(iii) was revised to clarify the intent of the standard. E ployers are required to provide laboratory e ployees 
with infor ation and training as outlined in paragraph (h). erely providing MSDSs to e ployees is not considered training for 
purposes of the standard. 
aragraph (b)(3)(iv) as added to cover laboratory e ployers ho ship hazardous che icals.  laboratory shipping hazardous 
i l  i  i   i l f t   t t t  r  l ti  r i t  of  ( ), t  
labeling require ents of (f)(l) and MSDS require ents of (g)(6) and (g)(7). In the event that the ship ent is of a newly 
developed chemical, OSHA would expect the laboratory to provide all available infor ation on that chemical. As stated in the 
preamble, "the HCS is based upon currently available information. If a new chemical is developed, and has not been tested to 
deter ine its hazardous ffects, then t r  is no i f r ti  to transmit. he rule does t r ir  t sti  f che icals t  be 
performed." 
Quality control samples taken in a plant must be labeled, tagged, or marked unless the person taking the sample is also going to 
be rf r i  th  nalysis,  t  t  l  l  c  r t e p rt l  t iner tion.  ha - ritt  l l  
be utilized as long as the required label infor ation is present. The rack in hich sa ples are placed could be labeled in lieu of 
labeling individual sa ples if the contents and hazards are si ilar. 
(b)(4) Since all containers are subject to leakage and breakage, employees who work in operations where they handle only sealed 
containe~ (such as arehousing) are potentially exposed to hazardous che icals, and, therefore, need access to infor ation as well as 
training. The training required for e ployees who handle sealed containers is dependent upon the type of che icals involved, the 
potential size of any spills or leaks, the type of work performed and what actions employees are expected to take when a spill or leak 
curs. 
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Employers are required to obtain an MSDS for chemicals in sealed containers if an employee requests one and to maintain and
make available to employees all MSDSs received The employer attempt to obtain an MSDS must begin promptly normally
within a day
b5The exemptions described underthis paragraph apply to labeling requirements only and are not intended to provide a complete
exemption from the standard
b6This paragraph totally exempts certain categories of substances from coverage under the HCS
Hazardous waste Hazardous waste is exempted from the standard when subject to regulation by the Environmental Protection
Agency EPA under the Resource Conservation and Recovery Act RCRA If the waste is not regulated under RCRA then the
requirements of the standard apply Once the material is designated as hazardous waste as defined under RCRA it is totally
exempted Other chemicals which are used by employees at a hazardous waste site that are not hazardous waste are covered
under the HCS An example would be an acid brought on site by the employer to neutralize a waste product
Consumer Products Ordinarily OSHA will not cite for employee use of consumer products A substance is considered a
consumer product if it is 1 defined as such under the Consumer Products Safety Act 2 used in the workplace as intended by
the manufacturer and 3 used with the same frequency and duration of exposure expected of a typical consumer The CSHO
must consider whether use of consumer products in the workplace greatly exceeds normal conditions of use or if the use is
different than originally intended for the product As an example windshield wiper fluid which contains methanol is meant to
be used in a closed system and sprayed onto the windshield for cleaning An employee using windshieldwiper fluid on a daily
basis to clean windows or other glass surfaces would be covered by the standard as use of this fluid differs from the intended
purpose and the frequency and duration of exposure is significantly greater than that of a normal consumer See paragraph
A2afor guidelines
Articles By definition a manufactured item is exempted as an article if under normal conditions of use it does not release
more than very small quantitiesegminute or trace amounts of a hazardous chemical and does not pose a physical hazard
or health risk to employees See paragraphd5of this appendix for a discussion regarding the terms health risk versus
health hazard An item may appear to meet the definition of an article but produces a hazardous by product during normal
processing If the cutting burning heating or otherwise processing the article results in employee exposure to a hazardous
chemical but such processes are not considered part of its normal conditions of use the item would be an article under the
standard and thus be exempted
Absent evidence that releases of very small quantities could cause health effects in employees the article exemption would
apply The following items are examples of articles
Stainless steel table
Vinyl upholstery
Tires
Adhesive tape
The following items are examples of products which would NOT be considered articles under the standard and would thus
not be exempted from the requirements
Metal ingots that will be melted under normal
Conditions of use
Bricks for use in construction operations since under normal condition of use bricks may be dry cut drilled or
sawed and the clay slurry of wet cutting when dried releases dust that contains crystalline silica
Switches with mercury in them that are installed in a maintenance process when it is known that a certain percent
break under normal conditions of use
Lead acid batteries which have the potential to leak spill or break during normal conditions of use including
foreseeable emergencies In addition lead acid batteries have the potential to emit hydrogen which may result in
a fire or explosion upon ignition
CSHOs have to consider the hazardous chemical in the item The only information that has to be reported in these situations is
that which concerns the hazard of the released chemical Hazardous chemicals which are still bound in the article would
continue to be exempted under the article exemption
Wood and wood araducts The wood and wood products exemption wasnever intended by OSHA to exclude wood dust from
coverage This has been clarified in the final rule published February 9 1994 See Federal Register Vol 59 page 6145 As
stated in the preamble Wood dust does not share solid wood products self evident hazard characteristics that supported the
exemptionThe potential for exposure to wood dust within the workplace especially with regard to respirable particles is not
selfevident nor are its hazards through inhalation so wellknown that hazard communication programs are unnecessary The
permissible exposure limits for wood dust must be included on the MSDS which will generally be developed by the sawmill or
the first employer which handles or processes the rawmaterial in such a way that the hazardouschemical is produced and
released into the work environment Further any chemical additives present in the wood which present a health hazard must
also be included on the MSDS andor label as appropriate
Parbcuiatesnototherw5e regulated PNOR1 Particulates not otherwise regulated are exempt unless evidence exists that they
present a health or physical hazard For these chemicals the PNOR PEL must be included on the MSDSs
DEFINITIONS Paragraph c
The definitions of the HCS must be consulted to properly interpret and apply the standard
Artic The definition has been amended to permit the release of very small quantities egminute or trace amounts of a hazardous
chemical and still qualify as an article provided that a physical or health risk is not posed to the employees 59FR 6146 In evaluating
an article one must consider the health risk which exposure to that article presents The term risk as opposed to hazard is used
here since the hazard is an inherent property of the chemical and exists no matter the quantity of exposure To be exempted as an
article exposure must not pose a risk to employee health
OSemica The standard definition of chemical is much broader than that which is commonly used Thus steel coils which are cut
and processed castings which are subsequently ground or welded upon bricks that are dry sawed or drilled carbide blades which are
sharpened are all examples of products which contain chemicals which if available for exposure are covered by the HCS
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Employers are required to obtain an MSDS for chemicals in sealed containers if an employ e requests one and to aintain and 
make available to employees all MSDSs received. The e ployer's attempt to obtain an MSDS ust begin promptly (normally 
within a d ). 
(b)(5) The exemptions described under this paragraph apply to labeling require ents only and are not intended to provide a complete 
exemption from the standard. 
(b)(6) This paragraph totally exempts certain categories of substances fro  coverage under the HCS. 
Hazardous waste - Hazardous waste is exempted from the standard when subject to regulation by the nviron ental Protection 
Agency (EPA), under the Resource Conservation and ecovery Act (RCRA). If the waste is not regulated under RCRA, then the 
requirements of the standard appl . nce the material is deSignated as hazardous aste as defined under R , it is t t ly 
ex . ther chemicals which are used by employees at a hazardous waste sit  that are not hazardous st  are r  
under the HC . (An example would be an acid brought on site by the e ployer to neutralize a waste pr t.) 
Consumer Pro t - rdi ril ,  will not cite for employ e use of consu er pr t . A substance is considered  
consu er product if it is 1) defined as such under the Consumer Products Safety ct, 2) used in the orkplace s intended y 
the manufacturer and 3) used with the same frequency and duration of x s r  x ected of a typical c s r. The  
must consider whether use of c s er products in t  orkplace reatly exceeds normal nditi ns of use or if the use is 
different than originally intended for the product. As an exa ple, indshield wiper flUid, hich contains ethanol, is eant to 
be used in a closed system and sprayed onto the indshield for cleaning. An e ployee using indshield-wiper fluid on a dally 
basis t  clean windo s r t r glass surfaces l  be covered  t  t r , s se f this fl i  iff rs fro  t  int  
purpos , and the fr uency an  duration of x r  is i ificantly r ter than th t f a r al r. (See r r  
A.2.a. for gui li s.) 
Ar JCl  - By definiti , a anufactured it  is exe pted s  rticle if "und  normal iti  of use it does not l  
or  t  ry small i , .g., i ute or tr ce a ounts f  zardous e ical...   not e  i  azard 
or lt  ri  t  e l es." (S e r r  (d)(5) f t i  endix for  i i  regarding t  t r  "health i k" versus" 
alth haz r .") An ite  ay appear to t th  finition f  "arti le," but r c s  r  - r t ri  r al 
~. If the cutting, burning, heating, or otherwise processing the article results in e ployee exposure to a hazardous 
che ical but  pr c ss  re ot conSidered rt of its r l conditions f , t  it  ould be  "arti l " r t  
t r ,  thus  t . 
Absent i nce t t r l  f "very all titi s" could  health ff t  i  l , t  rti l  ti  l  
apply. The following ite s are exa ples of articles: 
t i l ss t l  
Vinyl upholstery 
ires 
Adhesive tape 
The follOWing items are examples of products which would NOT be considered "articles" under the standard, and would thus 
not be exe pted fro  the req uire ents: 
t l i t  t t ill  lt d r r l 
iti  f . 
ricks for use in construction operations, since, under nor al condition of use, bricks ay be dry cut, drilled, or 
s ,  t  cl y sl rry f t c tti  (wh  ri d) releases st t t c t i s cryst lli  silica. 
it  it  r r  i  t  t t r  i t ll  i   i t  r   it i   t t  rt i  r t 
r  r r l iti  f e. 
Lead acid tt ri s ic  v  t  t ti l t  leak, spill or r k ri  r l c iti s f use, i cl i  
foreseeable e ergencies. In addition, lead acid batteries have the potential to e it hydrogen hich ay result in 
a fire or explosion upon ignition. 
s have t  c si r t  z r s c ic l in t  it . he ly i f r ti  t t has t  be r rt  in these sit ti s is 
that hich concerns the hazard of the released che ical. azardous che icals hich are still bound in the article ould 
continue to be exe pted under the "article" exe ption. 
   oroducts -     r t  ti  s r i t ed   t  l   t fro  
coverage. This has been clarified in the final rule published February 9, 1994, (See Federal Register, Vol. 59, page 6145.) As 
stated in the preamble, "Wood dust does not share solid wood products' 'self-evident' hazard characteristics that supported the 
exemption .... The potential for exposure to wood dust within the workplace, especially with regard to respirable particles, is not 
self-eVident, nor are its hazards through inhalation so ell-kno n that hazard co unication progra s are unnecessary." The 
permissible exposure li its for wood dust ust be included on the MSDS, which will generally be developed by the sawmill (or 
the first employer which handles or processes the raw material in such a way that the hazardous chemical is "produced" and 
r l  i t  t  r  nvironment). rther,  i l iti  r t i  t   hich pres t  h lth haz r  u t 
ls   i l   t   /or l l s r riate. 
Particulates not otherwise requlated (PNOR) - Particulates not otherwise regulated are exe pt unless evidence exists that they 
present a health or physical hazard. For these che icals, the "PNOR" PEL ust be included on the MSDSs. 
DERNmON5. Paragraph (c) 
The definitions of the HCS must be consulted to properly interpret and apply the standard. 
~. The definition has been a ended to per it the release of "very small quantities, e.g., inute or trace amounts" of a hazardous 
chemical and still qualify as an article provided that a physical or health risk is not posed to the employees (59 F.R. 6146). In evaluating 
an article, one must consider the health risk which exposure to that article presents. (The term "risk" as opposed to "hazard" is used 
here, since the hazard is an inherent property of the chemical and exists no matter the quantity of exposure. To be exempted as an 
article, exposure must not pose a risk to employee health.) 
07emical. he standard's definitio  of "c ical" is uch broader than that hich is commonly used. hus, steel coils which are cut 
and processed, castings which are subsequently ground or welded upon, bricks that are dry sawed or drilled, carbide blades which are 
sharpened, are all examples of products which contain chemicals which, if available for exposure, are covered by the HCS. 
7/6/2011 3:16 P  
CPL 0202038 CPL 238D Insp tion Procedure http wwwos qovpisoshawebowadispshowd
aemicaManufacturer Based on this definition and that of its related terms an employer that manufactures processes formulates or
repackages a hazardous chemical is considered a chemical manufacturer This includes those companies which blend or mix
chemicals Such companies can comply with the standard by transmitting the relevant labelMSDS for the components of their mixture
which they in turn received in good faith from their suppliers to their downstream customers Oil and gas producers are considered
chemical manufacturers because they process hazardous chemicals for use or distribution
Con h rThis definition includes tank trucks and rail cars A room or an open area is not to be considered a container and therefore
a hazardous chemical such as wood dust on the Floor of a workplace or a pile of sand at a construction site would not have to be
labeled Since only containers need to be labeled under the HCS if there is no container there is no requirement to label
Pipes or piping systems engines fuel tanks or other operating systems in a vehicle are not considered to be containers Thus
LP cylinders that serve as the source of fuel used to operate lift trucks for example would not have to be labeled once the fuel
tank is installed although the spare LP cylinders in storage must be labeled since they are containers Even though containers
of fuel such as gasoline and UP clearly are within the scope of the HCS no requirement exists to label those containers operating
the lift truck The producer still has an obligation to assess the hazards associated with the fuels including their byproducts
Bricks that are palletized and bound by metal bands are considered to be containers that are to be tagged with an appropriate
label
The standard requires all containers of hazardous chemicals leaving the workplace to be labeled with the required information
Even very small containers must be tagged or marked in a fashion that fulfills the intent of the standard
Distributor A distributor who blends mixes or otherwise changes the composition of a chemical is considered a chemical manufacturer
under the HCS Employees in these operations are considered to use hazardous chemicals Under these conditions the distributor will
not be able to claim the sealed container provision in paragraphb4and will need to meet all applicable provisions of the HCS
including hazard determinations MSDSs labeling training and a written program
Paragraph 1200g7distinguishes between a distributor and a retail distributor This distinction has been made to
recognize that retail establishments primarily deal with the general public This type of operation makes it difficult to determine
at the point of purchase whether a customer is an employer who needs a material safety data sheetMSDS The onrequest
system has been permitted to preclude the necessity of determining every customer need for an MSDS at the time of purchase
or of providing an MSDS to every customer
Em Employees such as office workers or bank tellers who encounter hazardous chemicals only in non routine isolated instances
are not covered For example an office worker who occasionally changes the toner in a copying machine would not be covered by the
standard However an employee who operates a copying machine as part of her hiswork duties would be covered by the provisions of
the HCS
Training provisions for temporary employees are addressed under h1
Ematover An employer who brings hazardous chemicals into the country for use in their own workplace becomes an importer and is
therefore responsible for conducting a hazard determination of the chemical producing the MSDS ensuring appropriate labeling and
all other applicable provisions of the standard
Wosure It is important to note for purposes of chemical manufacturers hazard determinations and downstream use by employees
that exposure includes any route of entry such as inhalation ingestion skin contact or absorption and potential exposure including
exposure that could result in the event of a foreseeable emergency
Foreseeable emergencv Foreseeable emergency does not include employee exposures in the event of an accidental fire but does
include equipment failure rupture of containers or failure of control equipment which could result in an uncontrolled release
Hazardous chemicals Hazardous chemicals as defined by the HCS which are grown cultivated or harvested such as cotton lumber
and grain are covered by the HCS at the first point of processing or manufacture The first employer meeting the definition of a
chemical manufacturer will be responsible for performing the hazard determination developing or obtaining the MSDSs and labeling
containers of the hazardous chemicals For example saw mills are considered to be the chemical manufacturer since they are the
first employers who process the product A saw mill processes timber into lumber thereby creating wood dust which is a hazardous
chemical under the HCS Grain elevators also meet the definition of a chemical manufacturer since they treat dry and move grain
creating grain dust a hazardous chemical under the standard
Based on a manufacturer hazard determination if a fire extinguisher is classified as a hazardous chemical then it would be
subject to the HCS labeling requirement Under the standard a compressed gas is considered a physical hazard and is
therefore covered Similarly several extinguishing agents are also considered hazardous chemicals by nature of their associated
health hazards
Hazard Wamino The definition has been amended to include target organ effects on labels in order to convey the specific physical and
health hazards of a chemical
Produce The definition of produce has been expanded and now includes blend extract generate and emit in addition to
manufacture process formulate and repackage This would include the extraction of naturally occurring substances such as clay and
stone which contain crystalline silica
HAZARD DETERMINATION Paragraph d
d1Although the chemical manufacturer and the importer have the primaryduty for hazard evaluation some employers may choose
to do their own evaluations Whoever does the evaluation is responsible for the accuracy of the information The evaluation must assess
the hazards associated with the chemicals including hazards related to any anticipated or known use which may result in worker
exposure
Known intermediates and byproducts are covered by the HCS and must be addressed in the hazard determination
Decomposition products which are produced during the normal use of the product or in foreseeable emergenciesegplastics
which are injection molded diesel fuel emissions are covered
An employer may rely upon the hazard determination performed by the chemical manufacturer Normally the chemical
manufacturer possesses knowledge of hazardous intermediates byproducts and decomposition products that can be emitted
by their product
d2The preparer of the MSDSlabel is required to consider all available scientific evidence concerning the hazardsofa chemical in
addition to consulting the Floor of reference sources listed in paragraphd3which establishes which chemicals are hazardous under
the standard See Appendix C of this instruction for further guidance on evaluating health effects No testing of chemicals to
determine hazards is required the evaluation may be based on information currently available in chemicalscientific literature
Where at least one positive scientific study exists which is statistically significant and demonstrates adverse health effects the
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MSDS must include the adverse health effects found This does not necessarily mean that the results of all such studies would
also appear on the label See Appendix A which discuss label information
Any substance which is inextricably bound in a product is not covered under the HCS For example a hazard determination for
a product containing crystalline silica may reveal that it is bound in a rubber elastomer and under normal conditions of use or
during foreseeable emergencies cannot become airborne and therefore cannot present an inhalation hazard In such a
situation the crystalline silica need not be indicated as a hazardous ingredient since it cannot result in employee exposure
d3Any chemical regulated in part 1910 Subpart Z including those listed in the Z Tables or for which there is a TLV in the latest
edition of the ACGIH Threshold Limit Values listing is considered to be part of the floor of hazardous chemicals covered by the
standard
d4A chemical manufacturerimporter has the option of reporting negative findings regarding carcinogenicity but is required to
report any positive findings of NTP andor IARC on the MSDS Itshould be noted that negative evidence generated by a producer does
not nullify the positive finding by IARC or NTP
On December 20 1985 OSHA published an interpretive notice in the Federal Register regarding the carcinogenicity of
lubricating oils Vol 50 FR 51852 The notice was published in response to a number of inquiries which were received
regarding the applicability of the HCS requirements to naphthenic lubricating oils which are refined using a hydrotreatment
process These types of oils may be found in a number of industrial operations including ink manufacture and the production of
synthetic rubber
Positive findings of carcinogenicity by the International Agency for Research on Cancer IARC must be reported under the HCS
The IARC Monograph 33 concludes that there is sufficient evidence to indicate that mildly hydrotreated and mildly solvent
refined oils are carcinogenic Therefore under the requirements of the HCS producers of such materials must report such
findings on the MSDS for the substance and include appropriate hazard warnings on labels
IARC also stated that there is inadequate evidence to conclude that severely hydrotreated oils are carcinogenic and that there is
no evidence to indicate that severely solvent refined oils are carcinogenic In the absence of any valid positive evidence from
sources other than IARC regarding the carcinogenicity of severely hydrotreated or severely solvent refined oils no reference to
carcinogenicity need be included on the MSDS and label for such materials IARC has also concluded that when an oil is refined
using sequential processing ofmild hydrotreatment and mild solvent refining there is no evidence of carcinogenicity
The questions posed to OSHA concerned the process parameters used for mild hydrotreatment OSHA examined the studies
upon which IARC based its positive findings and concluded that any oil will be considered to be mildly hydrotreated if the
hydrotreatment process was conducted using pressure of 800 pounds per square inch or less and temperatures of 800 degrees
Fahrenheit or less independent of other process parameters If the oil is produced within these parameters it must be
considered to be potentially carcinogenic under the requirements of the HCS
d5While the HCS does not require testing of chemicals to determine their individual hazards this is allowed and some preparers of
MSDSs may choose this option Ifa chemical manufacturer chooses to test a mixture as a whole a full range of tests would have to be
performed including tests to determine health risks and physical hazards Another accepted approach to hazard determinations is for
the manufacturer to test certain properties of a chemical and to rely on the literature for others
If the mixture has not been tested as a whole it is assumed to present the same hazards as its individual component parts and
themanufacturer of a mixture may rely on the upstream chemical manufacturers hazard determinations for those constituent
substances This must be stated in the hazard determination procedures of the manufacturer who is producing the mixture The
MSDS for the mixture would then be comprised of the MSDSs for each component and must be physically grouped together
Information such as the product identity the manufacturer name address etc must be provided on the new MSDS If the
physical characteristics of a mixture have not been objectively determined the employer may present data in ranges egflash
points range from 70 to 100 degrees Fahrenheit
The language in paragraphd5ivwas amended in the February 9 1994 Final Rule The new language indicates that the
manufacturer must consider the health risk to downstream users when components of a mixture could be released The
previous language used the term hazard This language was changed since a hazard is an inherent property of the chemical
and exists no matter what quantity of the chemical is present Health risk is a function of the inherent hazard and the exposure
level In accordance with scientific principles concentrations which pose a health risk are always covered by HCS even though
the concentrations in the mixture may be below the cutoff levels
d6Employers who are not planning to evaluate the hazards of chemicals they purchase can satisfy the requirements for written
hazard evaluation procedures by stating in their written program that they intend to rely on the evaluations of the chemical
manufacturer or importer
WRITTENHAZARD COMMUNICA77ON PROGRAM Paragraph e
e1All employers with employees who are or may be exposed to hazardous chemicals known to be present in their workplaces
must develop implement and maintain at each workplace a written hazard communication program Programs must be developed
whether the employer generates the hazard or the hazard is generated by other employers
e2Multi employer worksites are those establishments where employees of more than one employer are performing work The MSDS
information exchange or access requirements pertain to employers who introduce hazardous chemicals into the worksite and expose
another employers employees
Paragraphe2irequires an employer on a multi employer worksite to include the methods heshe will use in hisher
program to provide other employers with on site access to MSDSs This covers each hazardouschemical to which the other
employers employees may be exposed Therefore one employer does not have to physically give the other employer the MSDSs
but rather must inform others of the location where the MSDSs will be maintainedeg in the general contractors trailer The
HCS allows employers to decide on the method of information exchange
e4Paragraph e4requires employers to make the written program available upon request to employees OSHA and NIOSH in
accordance with the requirements of 29 CFR 191002 This requirement means that the employer must provide a copy of the
written program within the time periods discussed in 191002 ieno later than 15 working days after the request for access is
made
LABELSAND OTHER FORMS OF WARNING Paragraph f
f1Labels provide an immediate warning of the hazards to which employees may be exposed and also provide a link to other sources
of more detailed information Labels must contain the identity of the chemical the name and address of the responsible party and
appropriate hazard warnings The standard definition of hazard warning has been amended to specifically include target organ
effects any words pictures symbols or combination thereof appearing on a label or other appropriate form of warning which convey
the specific physical or health hazard including target organ effects of the chemicalsin thecontainersAppendix A of the HCS
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The questions posed to OSHA concerned the process para eters used for mild hydrotreatrnent. OSHA exa ined the studies 
upon which !ARC based its positive findings and conCluded that any oil will be considered to be ildly hydrotreated if the 
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the anufacturer of a ixture may rely on the upstream chemical anufacturers' hazard deter inations for those constituent 
t . i  t  t t  i  t  r  t i ti  r s f t  f t   i  i  t  ixture.  
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i l r t ri ti  f  i t r   t  j ti l  t r i d, t  l r  r t t  i  r ; .g., fl  
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The language in paragraph (d)(5)(iv) was a ended in the February 9, 1994, Final Rule. The new language indicates that the 
f t  t i  t  lt  l kt  t  r   t  f  i t  l   r l .  
previous language, used the ter  "hazard". This language was changed since a hazard is an inherent property of the che ical, 
and exists no matter what quantity of the chemical is present. Health risk is a function of the inherent hazard and the exposure 
l l. I  r  it  SCie tifi  ri i les, tr ti  i    lt  ri  r  l  r     t  
the concentrations in the ixture ay be belo  the cut-off levels. 
(d)(6) Employers who are not planning to evaluate the hazards of chemicals they purchase can satisfy the requirements for written 
hazard v l ti  r c r s by st ti  in t ir ritt  r r  t t t y i t  t  r ly on t  v l ti s f t  c ic l 
manufacturer or importer. 
RJ7TEN HAZARD CO UNICATION PROGRA . Paragraph (e) 
(e)(l) ll e ployers it  e ployees ho are, r ay be, exposed t  hazardous che icals kno n to be present in t ir orkplaces, 
st v l p, i l t,  i t i  t c  r l   ritt  z r  i ti  r ra . r r s t  l  
whether the employer generates the hazard or the hazard is generated by other employers. 
(e)(2) ulti-e ployer worksites are those establish ents where e ployees of more than one e ployer are perfor ing work. The MSDS 
i f r ti   r cc ss r ir t  rt i  t  l r   introduce r  ch ic ls i t  t  r ite  x s  
t r ployer's l y s. 
Paragraph (e)(2)(i) requires an e ployer on a ulti-e ployer worksite to include the ethods he/she will use in his/her 
program to provide other employers with on-site access to MSDSs. This covers each hazardous chemical to which the other 
employers' employees may be exposed. Therefore, one employer does not have to physically give the other employer the MSDSs 
b  r t   i f r     l ti  r  t   il   intained. (e.g., i  t   ontractor's railer).  
HCS allows employers to decide on the method of information exchange. 
(e)(4) Paragraph (e)(4) requires employers to make the written program available upon request to employees, OSHA and NIOSH, in 
accordance with the requirements of 29 CFR 1910.1020(e). This requirement means that the employer must provide a copy of the 
ritten progra  ithin the ti e periods discussed in 1910.1020 (i.e., no later than 15 orking days after the request for access is 
made). 
     ARNING, r r  (f) 
(f)(1) Labels provide an i ediate arning of the hazards to which e ployees ay be exposed and also provide a link to other sources 
of more detailed information. Labels must contain the identity of the chemical, the name and address of the responsible party, and 
appropriate hazard warnings. The standard's definition of hazard warning has been amended to speCifically include target organ 
effects: "any ords, pictures, sy bols, or co bination thereof appearing on a label or other appropriate for  of arning hich convey 
the specific physical or health hazard(s), including target organ effects, of the chemical(s) in the container(s)." Appendix A of the HCS 
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clearly states that employees exposed to health hazards must be apprised of both changes in body functions and the signs and
symptoms that may occur to signal those changes
The definitions for physical and health hazard explain which hazards must be covered The hazard warning must convey the
particular hazards of the chemical including target organ effects Statements such as Hazardous if Inhaled Caution
Danger are precautionary statements and are not to be considered appropriate hazard warnings If when inhaled a
chemical causes lung damage then the appropriate hazard warning is lung damage not inhalation
The label is intended to be an immediate visual reminder of the hazards of a chemical It is not necessary however that every
hazard presented by a chemical be listed on the label The data sheet is used for this purpose Manufacturers importers and
distributors will have to assess the evidence regarding the productshazards and must consider exposures under normal
conditions of use or in foreseeable emergencies when evaluating what hazards shall be put on the label This is not to say that
only acute hazards are to be listed on the label or that well substantiated hazards should be left off the label because they
appear on the data sheet
As an example of the above IARC published Monograph No 44 entitled Alcohol Drinking in which the carcinogenicity of
ethanol was determined based on chronic exposure to ethanol through human consumption Manufacturers and importers must
consider this information in performing the hazard determination of a product which contains ethanol The MSDS would have to
list ethanol as a hazardous ingredient along with the findings published in the IARC monograph However under normal
conditions of use or in a foreseeable emergency ingestion should not be a route of exposure therefore the product would not
be listed as a carcinogen on the label
The Agency believes that the American National Standards Institute ANSI Standard Z129 1994 provides much useful
information for employers regarding product labels and will generally be very helpful in complying with the HCS The Agency
has one concern however regarding ANSIs health hazard evaluation process The ANSI standard states that labeling
recommendations are not based only on the inherent properties of the chemical but are directed to the avoidance of hazardous
exposures resulting from customary and reasonably foreseeable occupational use misuse handling and storage
The Agency has stated from the outset that the HCS is based on the premise that chemicals have inherent characteristics that
pose potential hazards and workers have the right to know what those potential hazards are
Exposure calculations are not permitted in determining whether a hazard must appear on a label If there is a potential for
exposure other than in minute trace or very small quantities a hazard warning must be included when substantiated Chemical
manufacturers distributors or importers may not exclude hazards based on presumed or perceived levels of exposure
downstream ieomitting a carcinogenic hazard warning because in the supplier estimate presumed exposures will not be
high enough to cause the effect Exposure determines the degree of risk and should be addressed in training programs by the
downstream employer
CSHOs should note that a label incorporating a rating system is not permitted for shipped containers unless specific hazard
warning information is affixed to the container
In situations where a tank truck rail car or similar vehicle comprise the container for the hazardous chemical the labeling
information may either be posted on the outside of the vehicle or attached to the accompanying shipping papers or billof
lading A label may not be shipped separately even prior to shipment of the hazardous chemical since to do so defeats the
purpose of providing an immediate hazard warning Mailing labels directly to purchasers bypasses employees involved in
transporting and handling the hazardous chemical Note the exemption inf2for solid metals plastic items shipments of
whole grain and untreated lumber
Labeling requirements apply for shipped containers leaving the workplace regardless of whether the intended destination is
interstate or intrastate Sealed containers intended for export must comply with the labeling provisions if these containers leave
the workplace and if downstream employees such as dock workers may be exposed to the hazardous chemical
f2Solid metal solid untreated wood plastic items and shipments of whole grain do not result in an exposure or potential
exposure to employees during shipment Therefore labels for such items may be transmitted with the initial shipment itself or with the
MSDS that is to be provided prior to or at the time of the first shipment and need not be included with subsequent shipments unless
the information changes This applies only to solid materials which would not fall under the article exemption due to downstream use
Chemicals shipped with these materials remain covered by all labeling provisions of the standard For example treated lumber is
covered since the lumber is not completely cured at the time of shipment and the hazardous chemical will to a varying degree offgas
during shipment and be available for exposure to employees
f5An employers obligation to label inplant containers and of hazardous chemicals requires that appropriate hazardf6warnings
appear on the label pursuant tof5iiAlternatively an employer may provide general information regarding the hazards of
chemicals as long as other information required by the HCS is immediately available to employees
The standard recognizes the use of alternative inplant labeling systems such as the HMIS Hazardous Material Information
System NFPA National Fire Protection Association and others which may be used in industry These systems rely on
numerical andor alphabetic codes to convey hazards and are generally non specific OSHA has permitted these types of
inplant labeling systems to be used when an employers overall HCS program is proven to be effective despite the potential
absence of target organ information on container labels Under these circumstances the employer should assure through
more intensified training that its employees are fully aware of the hazards of the chemicals used Additionally employers must
ensure that their training program instructs employees on how to use and understand the alternative labeling systems so that
employees are aware of the effects including target organ effects of the hazardous chemicals to which they are potentially
exposed CSHOs should determine whether workers can recognize what hazards correspond to what code ratings symbols This
can be achieved through employee interviews
Employers using alternative labeling systems must ensure that their employees are aware of a information required to be
conveyed under the HCS OSHA will make a plant specific determination of the effectiveness of the complete program when an
inspection is conducted Any employer who relies on one of these types of alternative labeling systems instead of using labels
containing complete health effects information will in any enforcement action alleging the inadequacy of the labeling system
bear the burden of establishing that it has achieved a level of employee awareness which equals or exceeds that which would
have been achieved if the employer had used labels containing complete health effects information 59 FR 6156
The key to evaluating the effectiveness of any alternative labeling method is to determine whether employees can correlate the
visual warning on the inplant container with the applicable chemical and its appropriate hazard warnings The alternative
labeling system must also be readily accessible to all employees in their work area throughout each work shift For purposes of
this provision the term other such written materials does not include material safety data sheets used in lieu of labels
CARCINOGEN LABELING Subpart Z
The labeling provisions of OSHAscomprehensive substance specific standards Subpart Z of 1910 contain requirements which may
pre empt HCS labeling provisions Therefore containers of hazardous chemicals labeled in accordance with the substance specific
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che icals, as long as other infor ation required by the HCS is i ediately available to e ployees. 
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-plant l li  t  t   d   loyer's ll   i     i  i   ti l 
 f t   i ti   i  l l .   i t ces,  l  l   -  
 i t sified t i i  - t t it  l   f ll   f t   f t  i l  . iti lly, l  t 
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     ti ss f             
visual arning on the in-plant container ith the applicable che ical and its appropriate hazard arnings. The alternative 
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standard will be deemed to be in compliance with the health effects labeling requirements of the standard
Those chemicals identified as being known to be carcinogenic and those substances that may reasonably be anticipated to be
carcinogenic by NTP must have carcinogen warnings on the label and information on the MSDS Appearing on NTPs annual list
constitutes a positive finding of suspect or confirmed carcinogenicity
IARC evaluates chemicals manufacturing processes and occupational exposures as to their carcinogenic potential The IARC criteria
for judging the adequacy of available data and for evaluating carcinogenic risk to humans were established in 1971 Volumes 116 and
revised in 1977 Volumes 17 and following
IARC monographs contain evaluations on specific chemicals or processes At the conclusion of each evaluation IARC provides a
summary evaluation Periodically IARC publishes supplements in which chemicals that have already been evaluated in previous
monographs are reevaluated In cases where a chemical has been re evaluated the most recent IARC evaluation shall be relied upon
IARC provides a summary in Supplement 7 of the chemicals which have been evaluated in Volumes 142 Table I of Supplement 7
provides a summary evaluation of all chemicals for which human and animal data were considered Table I of Supplement 7 also
provides a summary classification of a chemicalscarcinogenic risk
Group 1 The agent is carcinogenic to humans
Group 2A The agent is probably carcinogenic to humans
Group 2B The agent is possibly carcinogenic to humans
Group 3 The agent is not classifiable as to its carcinogenicity to humans
Group 4 The agent is probably not carcinogenic to humans
All IARC listed chemicals in Groups 1 and 2A must include appropriate entries on both the MSDSs and on the label Group 2B chemicals
need be noted only on the MSDS
Individual monographs have been published subsequent to Supplement 7 For purposes of compliance with the MSDS and labeling
requirements the IARC monograph summary evaluation for the chemical can generally be relied upon but it may be necessary to
review the evaluations In some cases a group of compounds may be listed in the summary as carcinogenic but closer examination of
the appropriate monograph will reveal that IARC had data to support the carcinogenicity of only certain compounds Those compounds
are the only ones covered by the HCS IARC also evaluates specific industrial processes or occupations for evidence of increased
carcinogenicity Findings that an occupation is at increased risk of carcinogenicity without identification of specific causative agents do
not affect label or MSDS requirements
Table Al below represents a general guide regarding the labeling and MSDS requirements under the HCS The existence of positive
human evidence of carcinogenicity always requires carcinogen warnings on the label In addition the existence of one valid positive
study indicating carcinogenic potential in either animals or humans is sufficient basis for a notation on the MSDS
TABLE Al
UJDANCE FOR MSDS AND LABEL NOTATIONS
FOR CARCTNOGENS
5CE MS
Requiated by OSHA X X
as a Carcinogen
Listed on NT X X
Carcinogen Report
ARCGroup I X X
ARCGroup 2A X X
ARCGZUup 2B X Not Required
FARCGroup 3 Not Required Not Required
1ARCGroup 4 Not Requircd NLRequired
Ore Positive X jet Required
StudyAnima i Only
Multiple Aaitcal X Depends 017
Studies evidence NO
review needed
One Pasitive x X
StudySome Human
Evidence
Cational Office There may be instances where a carcinogen
warning may be required for a chefnica that is not listed by
IAR or NTP but multiple animal studies indicated
carcinogenicity Such cases shall be reviewed by the Regional
Administrator and coordinated by the Directors of compliance
and Health Standards Pregramis
Given the above criteria benzene which is regulated by OSHA as a carcinogen and for which several valid positive human studies
exist would require carcinogen hazard warnings on both the MSDS and the label Polyvinyl chloride resin must be labeled as a
carcinogen but final molded and extruded products do not need to be as per 29 CFR 19100 7
f11A stayofenforcement has been placed on the requirement for revision of container labels within three months of becoming
aware of significant hazard information OSHA will alert the regulated community at the time that the stay is lifted
MATERIAL SAFETY DATA SHEETS Paragraph g
g1Chemical manufacturersimporters who choose to purchase data sheets for their products through information services or
sources such as but not limited to Internet providers or MSDS repositories rather than developing the MSDSs themselves retain
responsibility for the downstream Flow of information and for assuring MSDS accuracy Distributors and employers who in good faith
choose to rely upon the sheets provided to them by the chemical manufacturerimporter assume no responsibility for the content and
accuracy of the MSDSs
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(g)(l) Ole ical anufacturers/importers who choose to purchase data sheets for their products through infor ation services (or 
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choose to rely upon the sheets provided to the  by the che ical anufacturer/importer assu e no responsibility for the content and 
accuracy f t  s. 
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The MSDS requirements apply to free samples provided by chemical manufacturers and importers since the hazards remain the
same regardless of the cost to the employer
Even though solid metals wood plastic items and whole grains are covered differently under the labeling requirements the full
MSDS requirements pertain to these items
Chemical manufacturers and importers are not required to provide MSDSs for chemicals or articles which are not covered under
HCS If the chemical manufacturer importer chooses to provide an MSDS for a non covered chemical as a customer service it
should be noted on the sheet that the chemical or article has been found by the company not to be covered by the rule For
example
Thisproduct is not considered to be or to contain hazardous chemicals based on evaluations made by our
company under the OSHA Hazard Communication Standard 29FR191020
Distributors and employers are not required to maintain MSDSs for chemicals not covered by the HCS No MSDS shall indicate
that OSHA hasmade any findingsfor a product since the Agency does not make caseebe case hazard determinations
Scrap dealers are generally considered distributors and since their products are not articles would NOT be exempt from the
HCS If their suppliers are furnishing articles which they did not manufacture such as a broken refrigerator the supplier is not
required to provide a label or MSDS However if their suppliers added hazardous chemicals to the article as would be the case
if an employer scraps pipes containing a hazardous chemical or its residue the supplier must provide a label and MSDSs to the
scrap dealer Similarly manufacturers are also required to pass on any information they have regarding known contaminants of
the scrap as would be the case if cutting fluids were present In addition article manufacturers that sell for scrap those
produced items that fail specification or suppliers who provide for example metal tailings from a manufacturing process are
considered by OSHA to have the required knowledge of the itemsconstituents and must develop and transmit MSDSs and
labels to downstream scrap dealers
Generally the only requirement that the HCS places on non manufacturing scrap dealers is that they send their downstream
users those labels and MSDSs received from employers who have scrapped the materials
g2Information provided on MSDSs must be accurate The safety and health precautions must be consistent with the hazards of the
chemical
The standard allows any MSDS format as long as all of the required information is included The OSHA Form 20 obsolete since
May 1986 does not meet all requirements of the current standard The OSHA Form 20 may be used provided all additional
information required by the standard is included OSHA has published an optional form OSHA174 which may be used to
comply with the HCS Additionally the ANSI Z40011993 standard for the preparation of MSDSs is a consensus standard which
provides an order of presentation for MSDS information and is becoming internationally accepted Itprovides guidance for
preparers on the agreed order of information document design and other issues related to the usability of the completed
MSDS The ANSI standard provides valuable assistance to MSDS preparers particularly small manufacturers and is
recommended for the preparation of MSDSs Given the multitude of uses and users for which MSDSs provide information the
ANSI standard provides a uniform approach to addressing HCS concerns while meeting the diverse needs of the regulated
community
MSDSs must be in English This requirement was included to prevent importers of chemicals from supplying MSDSs in a foreign
language This requirement however does not prevent a chemical manufactureremployer from translating MSDSs from
English into foreign languages in order to assist non English speaking employees with training comprehension and hazard
recognition
If a hazardous chemical is present in the mixture in reportable quantitiesie01percent for carcinogens and 1 percent for
other health hazards it must be reported on the MSDS unless the mixture has been tested as a whole or unless the material is
bound in such a way that employees cannot be exposed For example if crystalline silica is present in a wet mixture it is
possible that when the mixture dries there is a potential for the silica to become airborne and thus create a potential for
exposure In this case the presence of silica must be indicated on the MSDS for the liquid mixture
Mixtures which have not been tested as a whole are assumed to have the same hazards as each of its hazardous components
The data sheets for each component may satisfy the requirements of the standard These MSDSs must be physically attached to
one another and identified in a manner where they can be clearly crossreferenced with the label Alternatively the
manufacturer or distributor of the mixture may create a distinct MSDS which lists the individual chemical components of the
mixture and their associated hazards
If the components of a mixture could be released in concentrations which would exceed an OSHA PEL an ACGIH TLV or could
present a health risk to employees information on these components must be included on the MSDS regardless if their final
concentration in the mixture is less than 1 or01for carcinogens For instance TDI is a sensitizer at very small
concentrations and despite its low concentration in a mixture can be offgassed in quantities which may present a health risk
that must be noted on the MSDS
MSDSs do not have to report negative findings of carcinogenicity However if the MSDS format provides a space for a
carcinogen entry this space must be filled with accurate information as no blank spaces may be present on the MSDS
MSDSs must include a telephone number for emergency information There is no requirement that the responsible party staff a
telephone line with personnel who can respond to an emergency 24 hoursaday The hours of emergency line operation are
determined by the chemical manufacturer and should be set after considering the thoroughness of the MSDS the
healthphysical hazards of the chemical the frequency of use and immediacy of information needs and the availability of
information through alternative sources
g3MSDS preparers are required to mark all blocks on a form even if no relevant information has been found for a given category
Computergenerated MSDSs however do not have to follow this requirement due to electronic formatting considerations
g4Where the evidence supports similar health hazards for a class or family of chemicals it is acceptable for the MSDS to report
those findings with respect to the entire class or family Thus a generic MSDS may address a group of complex mixtures such as
crude oil natural gas or bricks which have similar hazards and characteristics because their chemical ingredients are essentially the
same even though the specific composition varies in each mixture
g5The MSDS must be updated only when its preparer becomes newly aware of significant hazard information or ways to protect
against the hazards of a chemical The standard requires that these changes be added within three months of becoming aware of the
information
g6Chemical manufacturers and importers have an affirmative duty to provide MSDSs to distributors and employers upon initial
shipment and also upon request Thus a chemical manufacturer andor importer shall be cited underg6if they withhold sending
MSDSs to downstream users with an initial shipment with the first shipment after updating an MSDSs or upon request pending a
separate payment for the MSDSs
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sa e even t  t  speCific c siti  v ri s i  each ixt re. 
(g)(5)   t  t  l   it  r r r  l  r  f i ifi t r  i f r ti  r  t  r t t 
against the hazards of a che ical. he standard requires that these changes be added ithin three onths of beco ing a are of the 
ti . 
(g)(6) he ical f ct r rs and i rt rs have an ffir tiv  ty t  provide s to istri t rs and e ployers  i iti l 
ship ent and also upon request. hus, a che ical anufacturer and/or i porter shall be cited under (g)(6) if they ithhold sending 
S Ss to do nstrea  users ith an initial ship ent, ith the first ship ent after updating an S Ss, or upon request pending a 
separate pay ent for the s. 
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g7As in paragraphg6distributors have an affirmative duty to provide MSDSs to other distributors and downstream employers
and cannot withhold sending the MSDSs pending separate payment CSHOs should be aware of various changes regulating the
relationship between distributors both retail and wholesale and employers in the standard
g8MSDSs must be readily accessible and there must be no barriers to employee access during the work shift The Agency
interprets the term readily accessible to mean immediate access to MSDSs The employer has flexibility to determine how this will be
accomplished The use of electronic means such as computers with printers microfiche machines the Internet CDROMS fax
machines etc is acceptable Employers using electronic means to supply MSDSs to their employees must ensure that reliable devices
are readily accessible in the workplace at all times that workers are trained in the use of these devices including specific software that
there is an adequate backup system for rapid access to MSDSs in the event of an emergency including power outages equipment
and online access delays and that the system is part of the overall hazard communication program of the workplace Additionally
employees must be able to access hard copies of the MSDSs and in the event of medical emergencies employers must be able to
immediately provide copies of MSDSs tomedical personnel Mere transmission of the requested information orally via telephone is not
acceptable
Employers may use offsite MSDS management services to meet the requirements of the HCS only if MSDSs are readily available
to employees either as hard copies in the workplace or through electronic means and as long as the provisions outlined in the
previous paragraph are ensured Despite the use of an MSDS management service the employer maintains primary
responsibility for the hazard communication program including receipt and use of the information to develop and implement a
sitespecific hazard communication program under paragraph e of the HCS
When immediate access to paper or hard copy MSDSs does not exist CSHOs should evaluate the performance of the employers
system by requesting a specific MSDS Ultimately the evaluation of an adequate system will rely on the professional judgement
of the CSHO Factors that may be appropriate to consider when determining if MSDSs are readily accessible include
1 Are the sheets or alternative methods maintained at a location and under conditions where employees can
access them during each work shift when they are in their work areas
2 If an electronic system is used for MSDS access computer fax etcdoemployees know how to operate and
obtain information from the system CSHOs should request an employee to retrieve MSDSs using the electronic
system
3 Was there an emergencyaccident where immediate access was critical
4 How quickly did the employer respond to the employees request
Employees must have immediate access to MSDSs and be able to get information when they need it in order for an employer to
be in compliance
On multi employer job sites employers who produce use or store hazardous chemicals in such a way that other employers
employees are exposed or potentially exposed must communicate to other employers how the means of access to MSDSs will
be accomplished
g9Employees who work at more than one site during the work shift must be able to obtain MSDS information immediately in an
emergency MSDSs may be kept at the primaryworkplace facility as long as the employer has a representative available at all times to
ensure ready accessto this information This is the only situation in which an employer is allowed to transmit hazard information via
voice communication The employer must address in the written hazard communication program how MSDS information will be
conveyed to remote worksites
EMPLOYEE INFORMATION AND TRAINING Paragraph h
h Employees are to be trained at the time they are assigned to work with a hazardous chemical The intent of this provision is
to have information prior to exposure to prevent the occurrence of adverse health effects This purpose cannot be met if
training is delayed until a later date
The training provisions of the HCS are not satisfied solely by giving employee the data sheets to read An employerstraining
program is to be a forum for explaining to employees not only the hazards of the chemicals in their work area but also how to
use the information generated in the hazard communication program This can be accomplished in many ways audiovisuals
classroom instruction interactive video and should include an opportunity for employees to ask questions to ensure that they
understand the information presented to them
Furthermore the training must be comprehensible If the employees receive job instructions in a language other than English
then the training and information to be conveyed under the HCS will also need to be conducted in a foreign language
Additional training is to be done whenever a new physical or health hazard is introduced into the work area not a new
chemical For example if a new solvent is brought into the workplace and it has hazards similar to existing chemicals for which
training has already been conducted then no new training is required As with initial training and in keeping with the intent of
the standard the employer must make employees specifically aware which hazard category iecorrosive irritant etc the
solvent falls within The substance speck data sheet must still be available and the product must be properly labeled If the
newly introduced solvent is a suspect carcinogen and there has never been a carcinogenic hazard in the workplace before
then new training for carcinogenic hazards must be conducted for employees in those work areas where employees will be
exposed
It is not necessary that the employer retrain each new hire if that employee has received prior training by a past employer an
employee union or any other entity General information such as the rudiments of the HCS could be expected to remain with
an employee from one position to another The employer however maintains the responsibility to ensure that their employees
are adequately trained and are equipped with the knowledge and information necessary to conduct their jobs safely It is likely
that additional training will be needed since employees must know the specifics of their new employers programs such as where
the MSDSs are located details of the employer inplant labeling system and the hazards of new chemicals to which they will
be exposed For exampleh3iiirequires that employees be trained on the measures they can take to protect themselves
from hazards including specific procedures the employer has implemented such as work practices emergency procedures and
personal protective equipment to be used An employer therefore has a responsibility to evaluate an employeeslevel of
knowledge with regard to the hazards in the workplace their familiarity with the requirements of the standard and the
employershazard communication program
Training need not be conducted on each specific chemical found in the workplace but may be conducted by categories of
hazardeg carcinogens sensitizers acutely toxic agents that are or may be encountered by an employee during the course
of his duties
The training requirements also apply if the employer becomes aware via the multi employer worksite provision of exposures of
hisher employees to hazards for which they have not been previously trained
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(g)(7)As in r r  (g)(6), istri utors v   ffir tiv  ty t  r vi  s t  t r istri t rs  str  l y rs 
 t i l  i      t.     f     
r l ti i    (bot  il  le)     r . 
(g)(8)  st  i    r  t        t   ift.   
i t r r ts   "readily i le"      .           
i d.    C    ters  i t r , i fi  i s,  t, -R ,  
, .,  l .   troniC   l     l  t   l   
are r ily accessible in t  rk l c  t all ti s; t t rk rs r  tr i  in t  use f t s  vices, i cl i  s cific s ft r ; t t 
t  i    -u  t  f r i     i    f  cy, i l i   es, i t, 
d -lin   ;  t t  t    f  ll      l . itional y, 
l  t  l  t    i  f t  s,  i  t  t f i l i , l  t  l  t  
i i t l  i  i     i l l.  i i     i n ti  ll  i  l  i   
. 
   -site  nt     t     l  i     l  
 l , it r   i  i   l    l iC    l    i i  li  i   
  r  r d.  t      t ,  l  i   
i ilit  f r t  r  i ti  r , i l i  i t   f t  i f ti  t  l   i l t  
- i i   i ti     (e) f  . 
 i   t  r      t ,        ployer's 
t     ifi  . t ly,  l ti  f   te        
f  . tors    r ri t     t r i i     il   l : 
) r  t  t  r lt r ti  t  i t i  t  l ti   r iti s r  l   
     t,       s? 
)   l i   i      (co r, , tc.)do l       
t i  i f ti  f  t  tem? (  l  t  l  t  t i   i  t  l t i  
tem.) 
)  t r   /acci   i i    ritical? 
)  ickly i  t  l y r r s  t  t  loyee's r est? 
l  t  i i t   t     l  t  t i f n ti   t   it i  r r f r  l r t  
 i  li . 
 lti-   ,   ce,            l r ' 
l     ti lly , t i    l     f    ill 
 . 
(g)(9) ployees  rk t r  t  one site ri  t  rk s ift st be able t  t i   i f r ti  i i t ly in an 
.        r l  t ,  l          l i   
s r    t  i  ti . i      i  i   l r        
ice i .  l r t  i   i  r         
c   r t  i . 
E PL YEE I F TI   T I I , aragraph (h) 
(h) l  r  t   t i  t t  ti  t  r  i  t   it   r  ical.  i t t f t i  r i i  i  
 ve  i r       f   f cts.   t  t i  
tr i i  i  l  til  l t r t . 
  i i  f t     i i  l l    l      .  ployer's  
 i      r l i i   l  t l    f  i l  i  i   r ,  l    
 t  i f ti  t  i  t   i ti  . i    li  i    (audi i l , 
l r  i tr tion, i t r ti  i o),  l  i l   rt it  f r l  t   ti  t  r  t t t  
r t  t  i f r ti  r t  t  t . 
t , t  t i i  st  i l .  t  l  i  j  i t ti  i   l  t  t  lish, 
t  t  t i i   i f r ti n t     t   ill l   t   t  i   f i  l ge. 
 i i  i     r   i l   r    i    ,    
che ical. For exa ple, if a ne  solvent is brought into the orkplace, and it has hazards si ilar to existing che icals for hich 
t i i   l   t , t    t i i  i  i .  it  i iti l t i ing,  i  i  it  t  i t t f 
 ,  l r t  l  ifi ll   i   t r  (Le., i , i i t, tc.)  
l t f ll  it i .  t - ecific t  t t till  ilable,  t  r t st  r rl  l led. If t  
l  i tr  l t i   t r i n,  t r   r   r i i  r  i  t  r l  f r , 
t   tr i i  f r rCi i  r s st  t  f r l  i  t  r  r  r  l  ill  
x s d. 
It i  t r  t t t  l r r tr i    ir  if t t l y e  r i  ri r tr i i    t l r,  
l  i , r  t r tit . r l i f r ti ,  s t  r i t  f t   l   t  t  r i  it  
 l y  fr   siti  t  t r.  l yer, ever, i t i s t  r s si ility t  s r  t t t ir l y s 
 t l        l      ct   f ly. I    
 i i l i i  ill  ded i  l  t   Cifi  f i   l r '     
   , t il  f  loyer's -plant  ,           
 d. r le, (h)(3)(iii) i  t t l   t i   t   t   t  t  t t t l  
fr  r , i l i  ifi  r r  t  l r  i l t    r  r ti , r  r dures,  
personal protective equip ent to be used. An employer, therefore, has a responsibility to evaluate an e ployee's level of 
l  it  r r  t  t  r  i  t  r l , t ir f ili rit  it  t  r ir t  f t  t rd,  t  
loyer's r  i ti  r r . 
r i i   t  t   ch Cifi  i l f  i  t  r l , t   t   t ri  f 
z r  (e.g., c rci ns, s sitiz rs, c t ly t xic ts) t t r  r y  c t r  y  l y  ri  t  c rs  
f  . 
 tr i i  r ir t  lso l  if t  l r c s r  vi  t  lti- l r r it  r i i  f r  f 
is/her l y s t  z r s f r ic  t y have t  r vi sly tr i d. 
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HCS training of temporary employees is a responsibility that is shared between the temporary agency and the host employer
The hostemployer holds the primary responsibility for training since the host employer uses or produces chemicals creates and
controls the hazards and is therefore best suited to inform employees of the chemical hazards specific to the workplace
environment The temporary agency in turn maintains a continuing relationship with its employees and would be at a
minimum expected to inform employees of the requirements of the standard Contracts between the temporary agency and the
host employer should be examined to determine if they set out the training responsibilities of both parties in order to ensure
that the employers have complied with all requirements of the regulation
A frequently overlooked portion of the training provisions is that dealing with emergency procedures The HCS training is
expected to be proportional to the hazards of the workplace If a chemical is very hazardous more information would be
expected to be provided on the MSDS Therefore the training for emergency procedures including information about the
characteristics of the chemical and precautions to be taken would need to be more extensive Section 191020hrequires
training of employees on among other things the measures employees can take to protect themselves from hazards including
emergency procedures and an explanation of the information on the MSDSs
Questions have arisen regarding the interface of 29 CFR 19102 training requirements for emergency procedures and those
for the HCS The scope and extent of employee training regarding emergency procedures will depend upon the employer
emergency response plan If the employer merely intends to evacuate the work area the training in emergency procedures
could be limited for example to information on the emergency alarm system in use at the worksite evacuation routes and
reporting areas
In situations where employees are expected to moderate or control the impact of the emergency in a manner similar to an
emergency responder training under 19102 would be required Employers who fall under the scope of HAZWOPER must
have either a written emergency response plan or an emergency action plan If employers expect their own employees to
respond to a potential emergency involving a hazardous substance then the employer must create an emergency response plan
and the employees must be trained to perform the duties expected HAZWOPER does not cover response to incidental spills that
do not have the potential for becoming an emergency Training for responding to such incidental spills would be under the HCS
and would include at a minimum leak and spill cleanup procedures and the use of appropriate PPE
Employees that are required to respond to spills that have the potential for becoming an emergency are covered by the
provisions of 19102qSee definition of emergency response in 191023Therefore in workplaces where there is a
potential for emergencies the employersHCS training program would have to address the HAZWOPER emergency response
plan andor emergency action plan Training under the HCS can be adapted to encompass all of the required training
competencies in 29 CFR19102q6the first responder awareness level and a single training session could be fashioned
to satisfy the requirements of both standards
TRADE SECRETS Paragraph i
i1Despite the claim that a hazardous chemical or a constituent thereof is a trade secret the PEL TLV or other designated
exposure limit must be included on the MSDS
i2 The designation of an incident as a medical emergency is left to the discretion of the treating physician or nurse
Appendix B
SAMPLE LETTER MSDSLABEL QUERY
Date
Company Name
Street Address
City State ZIP Code
Dear Name or Position of Responsible Employer Representative
Representatives of the Occupational Safety and Health Administration OSHAor State plan designated agency recently visitedor
corresponded with company name which purchases the following chemicals from your company
List chemicals products
OPTION 1
At the time of the visit company name did not have material safety data sheetslab l for the above listed products despite a prior
request to your company
OPTION 2
At the time of the visit material safety datasheetslab l supplied by your company were found to be deficient in the following areas
Describe the specific deficiencies
You are required under OSHAsHazard Communication Standard 29CFR 191020 or your Statesrighttoknow law to perform
hazard determinations label containers and provide the MSDS for all hazardous chemicals which you produce or import A copy of the
standard is provided for your reference
Please immediately send properly completed material safety data sheetslabels for the chemicals listed above to your customer and a
copy tome If the MSDSs were deficient you are required to send revised copies to all of your customers with the first shipment after a
MSDS label is revised If this information is not received within 30 days an inspection of your establishment may be conducted by
OSHA
Thank you for your assistance If you have any questions regarding this matter please feel free to contact me at
Sincerely
Area Director
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 t i i  f t  l yees i   i ilit  t t i   t  t  t    t  t l r. 
 t- l  l   ri  r i ilit  r         i als, r t   
tr l   ,  , t , t    l s        l  
.  t r r  cy,  r , i   ti i    i  ,  l  e,   
, ct d   l  f  i ts f t  rd.    r r     
t- l r l   i ed     t    i ili    ,     
  l r  ve li   l t    l tion. 
  rl k d i      i    it   .     
t        f  .   l   ,  i    
t       . ,     res,   t  
t ri ti    i l  ti    n,      ive. i  910. 12oo(h)  
  l s  (amon  t  t )           i l  
    l i  f t  i i   t  . 
ti          910.120  t   r     
r  .    t t f l   i        loyer's 
r   . f  l  l       ,   i    
l   it ,  le,      l  t  i     ite,  t s,  
rti  . 
I  it ti  r  l s r  t  t  r t  r trol t  i t f t  r  i   r i il r t   
r cy ,   910.120   .   l     f   
ve   ritt         .    i   l   
r    ti l r     ,         l  
  l  t  i      .   t    l il   
    t ti l  i   cy.  f r    t l i     t   
  ,   i , l          ri t  . 
l  t r      ill     ti l  i   cy,     
r i i  f 910. 120(q). (Se  fi iti  f r  r  i  910. 120(a)(3).) r f re, i  r l  r  t r  is  
t ti l  , t  loyer's  i           
l  d/or r  ti  .  r t      t   l     
t ci s i    910.120(q)(6)(i),  i  r r  l l,   i l  i i  i  l   i  
 ti f   i  f  t r s. 
E s.  (i) 
(i)(l) it  t  l i  t t  r  i l, r  tit t t r f, i   tr  r t, t  L, , r t r Si t  
r  li it t  i l   t  . 
(i)(2)  i ti    i i    "medi  ncy" i  ft      ti  i i   . 
ate 
  
 r  
Oty, , I   
i   
 , /L   
ear (Na e or Position of esponsible ployer epresentative): 
epresentatives f the ccupational afety and ealth i istr ti  (O )/or tate plan designated agency r c tly visit /or 
 i  (company e), i     emical(s)   y: 
(List i als, ts) 
I  : 
t t  ti  f t  i it, (company ) i  t  t i l f t  t  heets/labels f r t  -li t  ts, it   i r 
request to your co pany. 
I  : 
t t  ti  f t  i it, t ri l f t  t  heets/labels li   r  r  f  t   fiCi t i  t  f ll i  r : 
(Descri  t  Cifi  fi iencies.) 
You are required under SHA's azard o unication tandard (29 CFR 1910.1200) or your tate's right-to-kno  la  to perfor  
r  i ti , l l ,             i port.     
t      . 
lease i i t ly s d r rl  c l t  t ri l s f ty t  s ts/lab ls f r t  c ic ls list  v  t  r c st r   
copy t  e. If t  s r  defiCient, you re r ir  t  send revised copies t  all f y r c st rs it  t  first s i t ft r  
SDS/label is revised. If this infor ation is not received ithin 30 days, an inspection of your establish ent ay be conducted by 
. 
  f r r i t ce. If    ti  r r i  t i  tt r, l  f l fr  t  t t  t ___ . 
incerely, 
r   
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Appendix C
HAZARD EVALUATION PROCEDURES
Govpisoshawebowed i spshowd
The hazard evaluation procedures required by the standard are performance oriented Basically OSHAsconcern is that the
information on labels and data sheets and in the training program is adequate and accurate Although specific procedures to follow
and sources of consultation cannot be definitively established general guidance will be provided herein The hazard evaluation process
can be characterized as a tiered approach the extent to which a chemical must be evaluated depends to a large degree upon the
common knowledge regarding the chemical whether its health effects are under review and how prevalent it is in the workplace
1 The first step for CSHOs evaluating chemicals is to determine whether the chemical is part of the floorof chemicals to be
considered hazardous in all situations
a The floor of chemicals consists of three sources
1Any substance for which OSHA has a permissible exposure limit PEL in 1910 1000 or a comprehensive
substancespecific standard in Subpart Z This includes any compound of such substances where OSHA would
sample to determine compliance with the PEL
2Any substance for which the American Conferenceof Governmental Industrial Hygienists ACGIH has a
Threshold Limit Value TLV in the latest edition of their annual list Any mixture or combination of these
substances would also be included
3Any substance which the National Toxicology Program NTP or the International Agency for Research on
Cancer IARC has found to be a suspect or confirmed carcinogen or which OSHA regulates as a carcinogen
b Sources to generally establish hazards of the chemicals that are part of the floor of hazardous chemicals covered by the
standard
The OSHA Chemical Information Manual
OSHA Instruction CPL 243A October 20 1987
NIOSHOSHA Occupational Health Guidelines
Documentation for theThreshold Limit Values
NTP Summary of the Annual Report on Carcinogens
IARC Monographs
In addition the CSHOs should check the NIOSH Registry of Toxic Effects of Chemical Substances RTECS to see if any
hazards are indicated which do not appear in these sources If there are further study should be done to evaluate the
hazards RTECS should never be considered a definitive source for establishing a hazard since it consists of data that has
not been evaluated It is however a useful screening resource
2 The second step is to consult other generally available sources to see what has been published regarding the chemical Pattys
Industrial Hygiene and Toxicology would be one such source OCIS contains a number of other chemical information sources
Material Safety Data Sheets available through information services would also be useful
3 The third step for those chemicals where information is not readily available or where such available information is not
complete is to perform searches of bibliographic data bases In general the National Library of Medicine NUM services should
be used These include the Toxicology Data Bank TDB TOWNE and MEDLARS The information generated by these data
bases should be evaluated using the criteria in Appendix B of the HCS ietoqualify as an acceptable study it must be
conducted according to scientific principlesegin animal studies the number of subjects is adequate to do statistical analyses
of the results a control group is used and the study must show statistically significant results indicating an adverse health
effect This evaluation obviously requires a subjective professional assessment Any questions should be referred to the
Directorate of Compliance Programs Office of Health Compliance Assistance through the Regional Office for assistance In
general uncorroborated case reports and in vitro studies such as Ames tests areuseful pieces of information but not definitive
findings of hazards Animal studies involving species other than those indicated in the acute hazard definitions must be
evaluated as well The acute hazard definitions are not included in the standard to categorize chemicals but rather to establish
that chemicals meeting those definitions fall under the coverage of the standard
4 In some cases the only information available on a substance may be employer generated data If the employer indicates that
such information is the basis for the hazard evaluation the CSHO shall ask to see it in order to complete the OSHA evaluation
5 In cases where the employer denies the CSHO access to its own hazard data and no published data on the chemical can be
found to review the sufficiency of the hazard determination the Regional Office shall be contacted for assistance in obtaining an
administrative subpoena The Directorate of Compliance Programs shall be contacted if assistance is required in order to obtain
unpublished chemical hazard information available from other Federal agencies such as Environmental Protection Agency
6 Ifan employer has found any chemical to be non hazardous and the CSHO has reason to believe it is hazardous further
investigation is required The definitions of hazard in the standard are very broad and it is not expected that many chemicals
can be considered nonhazardous under this approach Those most likely to be exempted would be chemicals that pose no
physical hazards and which have lethal dose findings above the limits found in the acute hazard definitions
7 In some cases the employer may not have addressed in the Hazard Communication Program a specific chemical that the CSHO
knows to be present through knowledge of the process or through sampling or other investigation of the workplace This
situation should also be further investigated If the CSHO has information to indicate that there is a hazard the employer must
be able to defend the finding of no hazard
8 Internet addresses for the above mentioned organizations are
ACGIH http wwwacgihorg
NTP http ntpserverniehsigov
IARC http wwwiarcf
OSHA http wwwoshagov
Appendix D
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ppendix  
 I  CEDURES 
The hazard evaluation procedures required by the standard r  perfor ance- . l , A's concern is that t  
information on labels and d t  t ,  in t  traini  , is dequate and t . Although specific rocedures t  f ll  
and sources of consultation cannot be definitively t li , general i  ill be provided r i . he zard l ti  r ss 
can be characterized as a "tier " approach -- the xtent t  hich a che ical ust be evaluated ends to  l r  gree  t e 
co on knowledge r r i  t  c ic l, hether its health ff cts re r r vi , and ho  r valent it is i  t  rk l c . 
. he fir t t  for CSHOs evaluati g i l  is t  i  t  t  c i l is rt f t  "fl r" of icals t   
considered hazardous in all i . 
a.  flo r f i l  consists of t r  s : 
(1) Any substance for hich OSHA has a per issible exposure li it (PEL) in 1910.1000, or a co prehensive 
t - ecific t ard i  Subpart Z. is i cludes  co pound of c  substanc s r   l  
ple t  deter ine compliance it  t  PEL 
(2) Any substance for hich the A erican onferenceof overn ental Industrial ygienists (AC IH) has a 
Threshold Li it Value (TLV) in the latest edition of their annual list. Any ixture or co bination of these 
bstances l  l   i . 
(3) ny substance hich the ational oxicology rogra  (NT ) or the International gency for esearch on 
cancer (IA ) has found to be a suspect or confir ed carcinogen or hich S A regulates as a carcinogen. 
. r  t  r ll  t li  r  f t  i l  t t r  rt f t  fl r f r  i l  r   t  
t : 
   I for ation . 
A i   -2.43 , t r , . 
I HjOSHA cc ti al lt  i li s. 
   r ld it . 
TP u ary of the nnual eport on carcinogens. 
!  r . 
 i i , t   l   t   i   i  ff t   e ical t  ( )   i   
  i i ted i   t r i  t  .  t  ,  t  l     l t  t  
.  l  r  i   fi iti  r  f r t li i    i e it i t  f t  t t  
t  l t . It i , er,  f l r ing r r . 
2. The second step is to consult other generally available sources to see hat has been published regarding the che ical. Patty's 
Industrial ygiene and Toxicology ould be one such source. OS contains a nu ber of other che ical infor ation sources. 
aterial Safety ata Sheets available through infor ation services ould also be useful. 
3.  t ir  st , f r t s  c ic ls re i f r ti  is t r ily v il l  r r  s c  v il l  i f r ti  is t 
complete, is to perform searches of bibliographic data bases. In general, the National Library of Medicine (NLM) services should 
be used. hese include the oxicology ata ank (T B), XU , and L . he infor ation generated by these data 
bases should be evaluated using the criteria in ppendix  of the S; i.e., to qualify as an acceptable study, it ust be 
conducted according to scientific principles (e.g., in ani al studies, the nu ber of subjects is adequate to do statistical analyses 
f t  r lts;  trol r  i  ,  t  t  t  t ti ti ll  Si ifi t r lt  i i ti   r  lt  
ffect). i  l ti  i l  r ir   j tive, r f i l s ent.  ti  l   r f rr  t  t  
Directorate of Compliance Programs, Office of Health Compliance Assistance (through the Regional Office), for assistance. In 
general, uncorroborated case reports and in vitro studies, such as Ames tests, areuseful pieces of information, but not definitive 
findings of hazards. Animal studies involving species other than those indicated in the acute hazard definitions must be 
l t   ll.  t   fi iti   t i l  i  t  t  t  "c t rize" i l  t t r t  t lis  
that che icals eeting those definitions fall under the coverage of the standard. 
4. In so e cases, the only infor ation available on a substance ay be e ployer-generated data. If the e ployer indicates that 
such infor ation is the basis for the hazard evaluation, the CSH  shall ask to see it in order to co plete the S A evaluation. 
. I   r  t  l r i  t    t  it   r  t    li  t   t  i l c   
f  t  r i  t  ffiCi  f t  r  t r i ti , t  i l ffi  ll  t t  f r i t  i  t i i   
administrative subpoena. The Directorate of Compliance Programs shall be contacted if aSSistance is required in order to obtain 
li  i l r  i f r ti  il l  fr  t r r l i   s ir t l r t ti  ncy. 
6. If an e ployer has found any che ical to be non-hazardOUS, and the CSHO has reason to believe it is hazardous, further 
investigation is required. The definitions of hazard in the standard are very broad, and it is not expected that many chemicals 
  i r  r  r t i  r ch.  t li l  t   t  l   i l  t t   
ysic l zards,  i  v  l t l s  fi i  v  t  li it  f nd in th  t  z r  finitions. 
7. In some cases, the employer may not have addressed in the Hazard Communication Program a speCific chemical that the CSHO 
 t   r t t r  l  f t e proc  r through li  r t r i ti ti  f t  orkplace. i  
it ti  s l  ls   f rt r i ti ated. If t   s i f r ti  to i i t  t t t r  is  azard, t e l r t 
 l  t  f  t  fi i  f  z rd. 
. I t r t r  f r t  - ti  r i ti  re: 
A I  - http:// ww.acgih.org 
NTP - http://ntp-server.niehs.nih.gov 
IARC - http:// w .iarc.fr 
OSHA - http://www.osha.gov 
ppendix D 
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GUIDE FOR REVIEWING MSDS COMPLETENESS
NOTE This guide has been developed for use as an optional aid during inspections
During CSHO review for Material Safety Data Sheet completeness the following questions may be helpful
1 Do chemical manufacturers and importers have an MSDS for each hazardous chemical produced or imported into the United
States
2 Do employers have an MSDS for each hazardous chemical used
3 Is each MSDS in at least English
4 Does each MSDS contain at least the
aIdentity used on the label
b Chemical and common names for single substance hazardous chemicals
c For matures tested as a whole
1 Chemical and common names of the ingredients which contribute to the known hazards
2 Common names of the mixture itself
d For mixtures not tested as a whole
1 Chemical and common names of all ingredient which are health hazards 1 percent concentration or
greater including carcinogens 01 percent concentration or greater
2 Chemical and common names of all ingredients which are health hazards and present a risk to employees
even though they are present in the mixture in concentrations of less than 1 percent or01 percent for
carcinogens
eChemical and common namesof all ingredients which have been determined to present a physical hazard when
present in the mixture
fPhysical and chemical characteristics of the hazardous chemical vapor pressure flash point etc
g Physical hazards of the hazardous chemical including the potential for fire explosion and reactivity
h Health hazards of the hazardous chemical including signs and symptoms and medical conditions aggravated
IPrimary routes of entry
jOSHA permissible exposure limit PEL The American Conference of Governmental Industrial Hygienists ACGIH
Threshold Limit Value TLV Other exposure limits including ceiling and other short term limits
k Information on carcinogen listings reference OSHA regulated carcinogens those indicated in the National Toxicology
Program NTP Annual Report on Carcinogens andor those listed by the International Agency for Research on
Carcinogens IARC
NOTE Negative conclusions regarding carcinogenicity or the fact that there is no information do not have to be
reported unless there is a specific space or blank for carcinogenicity on the form
1 Generally applicable procedures and precautions for safe handling and use of the chemical hygienic practices
maintenance and spill procedures
mGenerally applicable control measures engineering controls work practices and personal protective equipment
n Pertinent emergency and first aid procedures
o Date that the MSDS was prepared or the date of the last change
p Name address and telephone number of the responsible party
5 Are all sections of the MSDS completed
Appendix E
SAMPLE HAZARD COMMUNICATION PROGRAMS A B
NOTE The following model programs are provided only as guidelines to assist in complying with 29 CFR 191020 They are not
intended to supersede the requirements of 29 CFR 191020 Employers should review the Hazard Communication Standard for
particular requirements which are applicable to their workplaces
SAMPLE WRITTEN HAZARD COMMUNICATION PROGRAM A
1 Company Policy
To ensure that information about the dangers of all hazardous chemicals used by Name of Company are known by all affected
employees the following hazardous information program has been established
All work units of this company will participate in the hazard communication program This written program will be available in the
location for review by any interested employee
2 Container Labeling
The person position will verify that all containers received for use will be clearly labeled as to the contents note the appropriate
hazard warning and list the name and address of the manufacturer
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I   I I    
: i  i    l      i l i  i  i i . 
i      f ty t   ,      l: 
.  i l f t   i rt rs    f    i l   i t  i t  t  it  
t tes? 
.      f r    ed? 
.  h    t lish? 
.    i  t  e: 
(a) I tit     l el? 
(b) i l  n me(s)  l    icals? 
(c) r ixtur     : 
(1) i l   me(s)    i      zards? 
(2)  me(s)    itself? 
(d) r i t  t t t    l : 
(1) i l   me(s)    i   l   (1 t   
ter), i   (0.1    eater)? 
(2) i l   me(s) f ll i r i t  i  r  lt  r   r t  ri  t  l , 
ven      t    t ti  f      .1  r 
c rci ns? 
(e) ical   ame(s) f ll i r i t  i    t r i  t  r t  i l r   
r t i  t  i ture? 
(f) i l  i  t ri ti      (vap r r ,  i t, tc.)? 
(g) i l r  f t  r  i l i l i  t  t ti l f r fir , l i ,  r ctivity? 
(h) l   f  r s  (incl i        ravated)? 
(I) ri r  r t  f try? 
(j)  r i si l   li i  (P L)?  i  f r ce  l i l i i  (A ) 
l  U it l  (T V)? t r  limit(s) (incl i  ili   t  t t  li its)? 
(k) I f r ti n   li ti s (refer    i ns,     l  
 (NT ) l rt   d/or     l     
rci s (IA C)? 
: ti  l i  r r i  r i i ity, r t  f t t t t r  i   i f r tion,  t  t   
r rt  l  t r  i   Cifi   r l  f r r i i it   t  f r . 
(I) ll  li l     r     f   (hygieni  r tices, 
i   ill cedures)? 
(m) r ll  li l  tr l r  (engineeri  tr ls, r  r ti   r l r t ti  Uipment)? 
(n) ti t r   fi t i  r ures? 
(0) ate that the  as prepared or the date of the last change? 
(p) , r   t l  r f t  r i l  rty? 
.  l     leted? 
i   
    (A & 8) 
:  f ll i  l r r s r  r i d l   i li  t  i t i  l i  it    910. 200.  r  t 
i t  t  r  t  r ir ts f   910. 2 0. l r  l  r i  t  r  i ti  t r  f r 
rti l r r ir ents i  r  li le t  t ir r l . 
 I   I I   (A) 
1. o pany Policy. 
o r  t t i f r ti  t t  r  f ll r  i l  s   (Name f any) r    ll ff t  
l y s, t  f ll i  z r s i f r ti  r r  s  st lis : 
ll r  it  f t i   ill rti i t  i  t  r  i ti  r r . i  ritt  r r  ill  il l  i  t  
(loc ti n) f r r i    i t r t  l . 
2. Container Labeling. 
 (person/po n) ill  t l     ill  l rl      t ts, t   i t  
hazard arning and list the na e and address of the anufacturer. 
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The personposition in each section will ensure that all secondary containers are labeled with either an extra copy of the original
manufacturers label or with labels that have the identity and the appropriate hazard warning For help with labeling see
personposition
On the following individual stationary process containers we are using description of labeling system used rather than a label to
convey the required information
We are using an inhouse labeling system which relies on provide a description of any inhouse system which used numbers or
graphics to convey hazard information
The personposition will review the company labeling procedures every providea time period and will update labels as required
3 Material Safety Data Sheets MSDSs
The personposition is responsible for establishing and monitoring the company MSDS program Heshe will make sure procedures
are developed to obtain the necessary MSDSs and will review incoming MSDSs for new or significant health and safety information
He she will see that any new information is passed on to affected employees The procedure below will be followed when an MSDS is
not received at the time of initial shipment
Enter procedure to be followed here
Copies of MSDSs for all hazardous chemicals to which employees are exposed or are potentially exposed will be kept in state location
MSDSs will be readily available to all employees during each work shift If an MSDS is not available contact person position
MSDSs will be readily available to employees in each work area using the following format
Describe company format here
Note Ifalternatives to paper copies ofmaterial safety data sheets is used describe the format used and how to access the MSDSs
When revised MSDSs are received the following procedures will be followed to replace old MSDSs
Describe procedures
4 Employee Training and Information
The personposition is responsible for the Hazard Communication Program Heshe will ensure that all program elements specked
below are carried out
Prior to starting work each new employee will attend a health and safety orientation that includes the following information and
training
An overview of the requirements contained in the Hazard Communication Standard
The hazardous chemicals present at hisher work area
The physical and health risks of the hazardous chemicals
Symptoms of overexposure
How to determine the presence or release of hazardous chemicals in the work area
How to reduce or prevent exposure to hazardous chemicals through use of control procedures work practices and personal
protective equipment
Steps the company has taken to reduce or prevent exposure to hazardous chemicals
Procedures to follow if employees are overexposed to hazardous chemicals
How to read labels and MSDSs to obtain hazard information
Location of the MSDS file and written hazard communication program
Prior to introducing a new chemical hazard into any section of this company each employee in that section will be given information
and training as outlined above for the new chemical hazard The training format will be as follows
Enter format such as audiovisuals interactive computer
programsclassroom instruction etc
5 Hazardous Non Routine Tasks
Periodically employees are required to perform non routine tasks which are hazardous Some examples of non routine tasks are
confined space entry tank cleaning and painting reactor vessels Prior to starting work on such projects each affected employee will
be given information by the personposition about the hazardous chemicals he or she may encounter during such activity This
information will include specific chemical hazards protective and safety measures the employee can use and steps the company is
taking to reduce the hazards including ventilation respirators the presence of another employee buddy systems and emergency
procedures
Examples of non routine tasks performed by employees of this company are
Task Hazardous Chemical
6 Informing other Employers
It is the responsibility of personposition to provide other employers with information about hazardous chemicals their employees may
be exposed to on a job site and suggested precautions for employees It is the responsibility of person position to obtain information
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The (person/positi ) i  ach section will ensure that all secondary containers are l eled ith either an xtra c y of t e original 
a f t rer's l l or it  labels that ave the identity  the ropriate hazard ar i . For l  it  l li , see 
(person/positi n). 
On the follo ing individual stationary process containers, e are using (description of labeling system used) rather than a label to 
convey t  r ir  i f . 
We are using an in-house labeling system which r li  on (provid  a description of  in-house system i  sed bers r 
graphics to convey hazard infor ation.) 
The (person/position) ill revie  the co pany labeling procedures every (provide a ti e period) and ill update labels as required. 
3. aterial f ty  Sheets (MS ) 
The (person/position) is responsible for establishing and onitoring the co pany SDS progra . e/she ill ake sure procedures 
are developed t  obtain t  r  s and will r i  i co ing s f r  or i nificant lt   f t  i f r ti . 
He/she will see that any new infor ation is passed on to affected e ployees. The procedure belo  will be followed when an SDS is 
not received t the ti e f i iti l i t: 
(Enter r   be  .) 
Copies of MSDSs for all hazardous che icals to which e ployees are exposed or are potentially exposed will be kept in (state location). 
MSDSs ill be readily available t  all e ployees ring each rk s ift. If an  is t available, c t ct (pers / sition). 
MSDSs will be readily available to employees in each work area using the following for at: 
(Descri   f r at re.) 
t : If alternatives t  r copies f t ri l f t  t  t  i  , ri  t  f r t    t   t  . 
hen revised S Ss are received, the follo ing procedures ill be follo ed to replace old S Ss: 
(Descri  res.) 
. l  r i i   I f r ti  
The (person/position) is responsible for the Hazard Communication Program. He/she will ensure that all program elements specified 
l  re ried t. 
Prior to starting work, each new employee will attend a health and safety orientation that includes the following infor ation and 
tr i i g: 
*      t i     i ti  r . 
*  r  i l  r t t is/her r  r . 
*  i l  lt  i   t   i l . 
* Symptoms of overexposure. 
* How to deter ine the presence or release of hazardous che icals in the work area. 
*  t  r c  r r t r  t  r  c ic ls t r  s  f tr l r r , r  r ti   r l 
r t ctiv  i t. 
* Steps the co pany has taken to reduce or prevent exposure to hazardous che icals. 
* rocedures to follo  if e ployees are overexposed to hazardous che icals. 
*          f r ation. 
* Location of the SDS file and ritten hazard co unication program. 
Prior to introducing a new chemical hazard into any section of this company, each employee in that section will be given information 
and tr i i  as outlined above f r the ne  che ical hazard. he tr i i  f r t ill be as follows: 
(Ent r f r at,   i i ls, i t r ti  t r 
rogram ,cl ssroom i tr tion, tc.) 
.  - i   
Periodically, employees are required to perform non-routine tasks which are hazardous. Some examples of non-routine tasks are: 
confined space try, t k cl i g, and i ti  r ct r vessels. rior to st rti  rk on such rojects, each ff ct  e l y  ill 
be given infor ation by the (person/pOsition) about the hazardous che icals he or she ay encounter during such activity. This 
infor ation will include speCific che ical hazards, protective and safety easures the e ployee can use, and steps the co pany is 
taking to reduce the hazards, including ventilation, respirators, the presence of another e ployee (buddy systems), and e ergency 
procedures. 
Examples of non-routine tasks performed by employees of this company are: 
  
****** **************** 
****** **************** 
6. I f r i  t r l r  
It is the responsibility of (person/position) to provide other employers with information about hazardous chemicals their employees may 
be exposed to on a job site and suggested precautions for employees. It is the responsibility of (person/ position) to obtain information 
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about hazardous chemicals used by other employers to which employees of this company may be exposed
Other employers will be provided with material safety data sheets for hazardous chemicals generated by this company operations
Material safety data sheets will be provided to other employers in the following manner
Provide company policy here
In addition to providing a copy of an MSDS to other employers other employers will be informed of precautionary measures needed to
be taken to protect their employees who are exposed to operations performed by this company
Also other employers will be informed of the hazard labels used by the company If symbolic or numerical labeling systems are used
the other employees will be provided with information to understand the labels used for hazardous chemicals for which their employees
may have exposure
7 List of Hazardous Chemicals
The following is a list of all known hazardous chemicals used by our employees This list includes the name of the chemical
manufacturer the work area the chemicals are used in the dates of use and the quantity used Further information on each chemical
may be obtained from the MSDSs which are located state location
HAZARDOUS CHEMICAL INVENTORY
hemical man facturer XQr U Start Date inifih Date 21an tt
include hero theohomioal list dcv elapod during the tmcntoty Arrange this list so that ynu am able to crass
reference it with your WDS file and thelabels anyour containers Additimwl information such as the
ruanufaeWCrstelephone nsnnbar alt enurgeacy wm64r arienrik name CAS number the associated tasketc
couldbe included and might be found useful to employees and the emploJ
When new chemicals are received this list is updated including date the chemicals were introduced within 30 days of introduction
into the workplace To ensure that the chemical is added in a timely manner the following procedures shall be followed
State procedures to be followed
The hazardous chemical inventory was compiled and is maintained by
Name and Telephone Number of Responsible Party
8 Chemicals in Unlabeled Pipes
Work activities are sometimes performed by employees in areas where chemicals are transferred through unlabeled pipes Prior to
starting work in these areas the employee shall contact personposition for information regarding
The chemical in the pipes
Potential hazards
Safety precautions to be taken
Include here the chemical list developed during the inventory Arrange this list so that you are able to cross reference it with your
MSDS file and the labels on your containers Additional information such as the manufacturer telephone number an emergency
number scientific name CAS number the associated task etc could be included and might be found useful to employees and the
employer 9 Program Availability
A copy of this program will be made available upon request to employees and their representatives
Notes for Chemical Manufacturers Importers
and Distributors
1 Hazard Determination Chemical manufacturers and importers are to detail the methods they will use to conduct a hazard
determination for the chemicals produced or imported in their work places The procedures should identify the system in place
to conduct hazard determinations The system should identify the person or department responsible for conducting the hazard
determination and the research strategy involved Chemical manufacturers which rely on information from upstream suppliers
should state this in their written program
2 Transmittal of MSDSs Chemical manufacturers importers and distributors should develop a system to ensure that material
safety data sheets are transmitted to customers The system should identify the person or department responsible for ensuring
the transmittal ofmaterial safety data sheets and should include a method to ensure that transmittal is accomplished as required
by 29 CFR 191020
3 Labels Chemical manufacturers importers and distributors should have a system for ensuring appropriate labeling of
hazardous chemicals
4 Updating LabelsMSDSs A system should be detailed assigning responsibility and periodic review of scientific information
required to update material safety data sheets and labels as required by 29 CFR 191020
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about hazardous che icals used by other e ployers to hic  l s of this co pany ay be ex . 
ther employers ill be provided it  aterial safety dat  ets f r r s ic l  generated y this pany's r ti . 
aterial safety data sheets i l be provided to other e ployers i  the fo lo ing : 
(Provide y li y ) 
In addition to providing a copy of an SDS to other e pl , t  l  i l  i f r ed of r ti r  r s ed t  
be tak  to protect t ir ployees who r  expos  t  operations perfor ed by this co pa . 
Also, other employers will be informed of the hazard labels used by the company. If symbolic or numerical labeling systems are used, 
the ot r pl y s will be provided with i f r ati n t  derstand t  l els d for h z r  che icals f r i  t ir l yees 
may have exposure. 
7. ist of zardous icals 
The follo ing is a list of all known hazardous che icals used by our e ployees. his list includes the na e of the che ical 
anufacturer, the work area the che icals are used in, the dates of use, and the quantity used. urther infor ation on each che ical 
ay  t ined fro  the s hich r  l ted (state l tion). 
ZA.o.oous  INVENTORY 
~ MaDuhc:turg[ 
(k1dude hete the- -tbt"ml(:llilifi deveIrJpod d\lring the InvcntOry. Art3flgl: mill Iu.t $Q Ih!J.t you ate able to e-l0S,· 
n:r.eftnce it with your M.~{)S me and the lilbel:\ on your c;:ontajncrs, Additioo:aJ in(ormati('J11 ~  a.~ the 
manufacture('s telephone ntunhcr. an CliltCl'Sel)CY liumt..er. ~~i(!f1tifl"c M e, S nu ber, tbe ll!lsociated tasolt., de., 
..-:;ould be included and iGht be found usdul1Q e ployees and Ihe tUlplnrI:T,) 
hen  i  r  r , t i  li t i  t  (includi  t   i l  ere ced), it i    f i  
i t  t  r l . o nsure t t t  i l i   i   ti l  er, t  f ll i g r r s ll  f ll : 
(Stat  r r  t   f ll ) 
The hazardous che ical inventory was co piled and is aintained by: 
(Na e    f si le ) 
8. i l  i  l l  i s 
ork ctiviti s are so eti es rf r  y e ployees in areas r  c icals are tr sf rr  t r  l l  pipes. rior t  
starting ork in these areas, the e ployee shall contact (person/position) for infor ation regarding: 
*  i l i  t  i . 
*  ards. 
* Safety precautions to be taken. 
(Include here the che ical list developed during the inventory. rrange this list so that you are able to cross-reference it ith your 
SDS file and the labels on your containers. Additional infor ation such as the anufacturer's telephone nu ber, an e ergency 
r, SCi tifi  e,  r, t  i t  t k, tc., l   i l   i    f l t  l    
loyer.) . r r  il ilit  
 copy of this progra  ill be ade available, upon request, to e ployees and their representatives. 
  Ole i  t rers, rters. 
  
1. Hazard eter ination - Che ical anufacturers and i porters are to detail the ethods they ill use to conduct a hazard 
deter ination for the chemicals produced or imported in their work places. The procedures should identify the system in place 
to conduct hazard deter inations. The syste  should identify the person or depart ent responsible for conducting the hazard 
t r i ti   t  r r  tr t  i lved. i l f t r r  i  r l   i f r ti  fr  u tr  s li r  
should state this in their written progra . 
2. rans ittal f s - Ole ic l f cturers, i rters, and istri t rs should develop  syste  t  ensure t t aterial 
safety data sheets are trans itted to custo ers. The syste  should identify the person or depart ent responsible for ensuring 
the trans ittal of aterial safety data sheets and should include a ethod to ensure that trans ittal is acco plished as required 
by 29 CFR 1910.1200. 
3. Labels - Ole ical anufacturers, i porters, and distributors should have a syste  for ensuring appropriate labeling of 
 i als. 
4. pdating Labels/ s -  syste  should be detailed assigning responsibility and periodic revie  f SCientific i f r ti  
required to update material safety data sheets and labels as required by 29 CFR 1910.1200. 
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lla and Connmunicadian Checklist
I Has a list of all haAtdous chemicals inthe wmitplactbeen prepare r
2 Diics the cornparty Mee x method for updating the htaratiWu chemical hin
J Has the company obtained or dmgop d a material safety shirt fix exh haxardotnm
chemical iwed
S Has a system been develnped to ensure that all incoinitig haratdans chemicals have
label ant datx towels
5 Are pmeedurcx inplW rnssirclabeling fix enitaiters ref hartdouschea
6 rUe employees aware of theriWitenents of the llarard Cammmonmat Standard a j
initxrrcavt specific W iheir workplace
7 Arc cmpkayen tamdtar 11tthe ltazatds of the chemicals to their workptax7
k Have rmplocabeenmotnncd of the hazardsassiatcdwith perfgneatnnnirm
taske
S Ikemploy mkd tarrd how indetm the prtseoce ae relearnorlitrdouachemical
in thew oorkpiace
to erexmptoyces tratrwdabort proper work praelcim and persemxl proInetyu proem
in relation to talehazx4oehevnreahs in theirwork area
It Ithe training pingnnt prnvide i ototmamoon appropriate first aA enrrgency
procsxlurex and the likely xymptoms arosrrexpowrc
12 lbws the training pix grata inchiAe an explanation of labels and warninthat are axed
in each wwkarea
13 tXvi the training dewnbt where employees obtain data shccts and how emphsycause
them
14 la a xatom inplaceW ensure that new cnipkyccs are Imimil before beginning work
13 Is it y9em inplace to idenlifynew harardaus chcrateals befoir theyare intmducni
into awarkarea
16 1s akIem inplace to informmjal yceothc livards amsoaaied with newly
introduea3chemicals
SAMPLE HAZARD COMMUNICATION PROGRAM B
Introduction
The Hazard Communication Standard requires you to develop a written hazard communication program The following is a sample
hazard communication program that you may use as a guide in developing your program
Our Hazard Communication Program
General Company Policy
The purpose of this notice is to inform you that our company is complying with the OSHA Hazard Communication Standard Title 29
Code of Federal Regulations 191020 by compiling a hazardouschemicals list by using MSDSS by ensuring that containers are
labeled and by providing you with training
This program applies to all work operations in our company where you may be exposed to hazardous chemicals under normal working
conditions or during an emergency situation
The safety and health SH manager Robert Jones is the program coordinator acting as the representative of the plant manager
who has overall responsibility for the program Mr Jones will review and update the program as necessary Copies of the written
program may be obtained from Mr Jones in Room SD10
Under this program you will be informed of the contents of the Hazard Communication Standard the hazardous properties of
chemicals with which you work safe handling procedures and measures to take to protect yourselves from these chemicals You will
also be informed of the hazards associated with non routine tasks such as the cleaning of reactor vessels and the hazards associated
with chemicals in unlabeled pipes
List of Hazardous Chemicals
The safety and health manager will make a list of all hazardous chemicals and related work practices used in the facility and will
update the list as necessary Our list of chemicals identifies all of the chemicals used in our ten work process areas A separate list is
available for each work area and is posted there Each list also identifies the corresponding MSDS for each chemical A master list of
these chemicals will be maintained by and is available from Mr Jones office Room SD10
Material Safety Data Sheets MSDSs
MSDSs provide you with specific information on the chemicals you use The safety and health manager Mr Jones will maintain a
binder in his office with an MSDS on every substance on the list of hazardous chemicals The plant manager JeffOBrien will ensure
that each work site maintains MSDSs for the hazardous chemicals in each work area MSDSs will be made readily available to you at
your work stations during your shifts
The safety and health manager Mr Jones is responsible for acquiring and updating MSDSS Hewill contact the chemical
manufacturer or vendor if additional research is necessary or if an MSDS has not been supplied with an initial shipment All new
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I tr ction 
The azard o unication tandard requires you to develop a ritten hazard co unication progra . The follo ing is a sa ple 
r  i i         Ui  i  l i   . 
Our Hazard Communication Program 
General Co pany Policy 
 r  f t i  ti  is t  i f r   t t r  i  l i  it  t   r  i ti  t ndard, itl   
ode of Federal egulations 1910.1200, by co piling a hazardous che icals list, by using , by ensuring that containers are 
labeled, and by providing you with training. 
i  r r  li  t  ll r  r ti  i  r  r      t  r  i l  r r l r i  
conditions or during an emergency situation. 
The safety and health (S&H) anager, obert Jones, is the progra  coordinator, acting as the representative of the plant anager, 
ho has overall responsibility for the progra . r. Jones ill revie  and update the program, as necessary. Copies of the ritten 
progra  may be obtained fro  Mr. Jones in Room SD-lO. 
nder this progra , you ill be infor ed of the contents of the azard o unication tandard, the hazardous properties of 
che icals ith hich you ork, safe handling procedures, and easures to take to protect yourselves fro  these che icals. You ill 
l   i f  f t   i t  i  - i  t sks,   t  l i    ls,  the  SSOCiat  
with chemicals in unlabeled pipes. 
U    i l  
The safety and health manager will make a list of all hazardous chemicals and related work practices used in the facility, and will 
update the list as necessary. Our list of chemicals identifies all of the chemicals used in our ten work process areas. A separate list is 
available for each ork area and is posted there. ach list also identifies the corresponding  for each che ical.  aster list of 
these che icals ill be aintained by, and is available fro  r. Jones' office, Roo  SD-lO. 
aterial af ty ata ts ( Ss) 
MSDSs provide you with specific information on the chemicals you use. The safety and health manager, Mr. Jones, will maintain a 
binder in his office with an MSDS on every substance on the list of hazardous chemicals. The plant manager, Jeff O'Brien, will ensure 
t t each rk site i t i s s f r t  z r s che icals in each rk area. s ill be  readily available t  you at 
your ork stations during your shifts. 
The safety and health manager, Mr. Jones, is responsible for acquiring and updating MSDSS. He will contact the chemical 
f cturer or vendor if iti l r s rc  is necessary or if an  has t been s li  ith an i iti l shipment. ll new 
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procurements for the company must be cleared by the safety and health manager A master list of MSDSs is available from Mr Jones
in Room SD10
Labels and Other Formsof Warning
The safety and health manager will ensure that all hazardous chemicals in the plant are properly labeled and updated as necessary
Labels should list at least the chemical identity appropriate hazard warnings and the name and address of the manufacturer importer
or other responsible party Mr Jones will refer to the corresponding MSDS to assist you in verifying label information Containers that
are shipped from the plant will be checked by the supervisor of shipping and receiving to make sure all containers are property labeled
If there are a number of stationary containers within a work area that have similar contents and hazards signs will be posted on them
to convey hazard information On stationary process equipment regular process sheets batch tickets blend tickets and similar written
materials will be substituted for container labels when these documents contain the same information as labels These writtenmaterials
will be made readily available to you during your work shift
If you transfer chemicals from a labeled container to a portable container that is intended only for your immediate use no labels are
required on the portable container Pipes or piping systems will not be labeled but their contents will be described in training sessions
Non Routine Tasks
When you are required to perform hazardous non routine tasks egcleaning tanks entering confined spaces etc a special training
session will be conducted to inform you of the hazardous chemicals to which you might be exposed and the precautions you must take
to reduce or avoid exposure
Training
Everyone who works with or is potentially exposed to hazardous chemicals will receive initial training on the Hazard Communication
Standard and the safe use of those hazardous chemicals The safety and health manager will conduct these training sessions A
program that uses both audiovisual materials and classroomtype training has been prepared for this purpose Whenever a new hazard
is introduced additional training will be provided Regular safety meetings will also be used to review the information presented in the
initial training Foremen and other supervisors will be extensively trained regarding hazards and appropriate protective measures so
they will be available to answer questions from employees and provide daily monitoring of safe work practices
The training program will emphasize these items
A summary of the standard and this company written program
The chemical and physical properties of hazardous materialseg Flash point vapor pressure reactivity and methods that
can be used to detect the presence or release of chemicals including chemicals in unlabeled pipes
The physical hazards of the chemicals in your work area eg potential for fire explosion etc
The health hazards including signs and symptoms of exposure of the chemicals in work area and any medical condition
known to be aggravated by exposure to these chemicals
Procedures to protect against chemicals hazards eg required personal protective equipment and its proper use and
maintenance work practices or methods to ensure appropriate use and handling of chemicals and procedures for emergency
response
Work procedures to follow to assure protection when cleaning hazardous chemical spills and leaks
The location of the MSDSs how to read and interpret the information on labels and MSDSS and how employees may obtain
additional hazard information
The safety and health manager or hisher designee will review the employee training program and advise the plant manager on
training or retraining needs Retraining is required when the hazard changes or when a new hazard is introduced into the workplace
It will be company policy to provide training regularly in safety meetings to ensure the effectiveness of the program As part of the
assessment of the training program the safety and health manager will obtain input from employees regarding the training they have
received and their suggestions for improvement
Contractor Employers
The safety and health manager Robert Jones upon notification by the responsible supervisor will advise outside contractors in
person of any chemical hazards that may be encountered in the normal course of their work on the premises the labeling system in
use the protective measures to be taken and the safe handling procedures to be used In addition Mr Jones will notify these
individuals of the location and availability of MSDSs Each contractor bringing chemicals onsite must provide Mr Jones with the
appropriate hazard information for these substances including MSDSs labels and precautionary measures to be taken when working
with or around these chemicals
Additional Information
All employees or their designated representatives can obtain further information on this written program the hazard communication
standard applicable MSDSs and chemical information lists at the safety and health office Room SD10
INDEX
acute hazards L 2 3
appropriate hazard warnings 1 23 4 5
bank tellers 1 2
benzene 1
bill of lading 1
bricks L 2 145 5
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carbide blades 1
castings 1
categories of hazard 1
chemicals not covered 1
complete exemption 12
consensus standard 1
constituent substances 1
Consumer Product Safety Act 1
Controlling Employer 1 2
copying machine 1 2
diesel fuel emissions 1
emergency procedures 1 2 345 6
Environmental Protection Agency EPA 1
ethanol 1 2 11
Exposure calculations 1
fire extinguisher 1
first point of processing 1
floor of hazardous chemicals 1
floor of reference sources 1
foreign language 12 3
free samples 1
Grain elevators 1
HAZWOPER 1 23
Hazardous Materials Information System HMIS 1
International Agency for Research on Cancer IARC 1 2
Immediate access 1 2 3 4
incidental spills 1 2
inherent property 1 2
Lab Standard 1
labeling exemptions 1
labeling systems 12345 6 78 9
laboratory coverage 1
laboratory operations 1
LP cylinders 1 2
lubricating oils 1 2
Multiple Animal Studies
multiemployer worksites MEW 123 4 56 7
National Toxicology Program NTP12
National Fire Protection Association NFPA 1
normal conditions of use 12 34 56 78 9
office workers 12
oil and gas producers 1
OSHA Form 2012
Permissible Exposure Limit PEL12
pipes or piping systems 1 2
portable container 1 2 3
positive human evidence 1
rail car 12
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Standard Number 191020 191020b6ix
April 14 2005
Ms Beverly Cohen
Special Counsel
Hinman Straub Attorneys at Law
121 State Street
Albany NY 122071693
DearMs Cohen
This is in response to your February 25 2005 correspondence to the Occupational Safety and Health Administration OSHA Your letter was
transferred to our Directorate of Enforcement Programs DEP for a response This letter constitutes OSHA interpretation of only the
requirements discussed and may not be applicable to any questions not delineated within your original correspondence Your letter requested
clarification regarding OSHAHazard Communication Standard HCS 29 CFR 191020 You specifically asked about requirements for
maintaining material safety data sheets MSDSs for consumer art products and office cleaning products
You have referenced twodifferent types of chemical products and asked questions related to these materials In order to clearly answer your
questions the scenarios and questions you presented will be paraphrased below followed by OSHAs answers
Question 1 The employees of my client may create visual aids and presentation displays where they would use commercial art chemical
products such as thinners adhesives and paints Could you please clarify whether or not the use of consumer art products by my clients
employees would meet the consumer products exemption under 29 CFR 191020b6ix
Answer The consumer product exemption of the HCS applies to the use of those products only if the employer can demonstrate they are
used in the same manner egwith the same frequency and duration of use as a normal consumer would utilize them In the scenario you
provided the employees of your client are performing operations related to their normal work requirements During the execution of these
duties they may be utilizing art chemicals such as paints thinners and adhesives If the employees are routinely exposed to these hazardous
chemicals then they would be required to be afforded the chemical hazard information available through MSDS and hazard communication
training It is the responsibility of the employer to determine employee exposure and ascertain if the frequency of useexposure is indeed not
more than that which would be experienced by a normal consumer
Question 2 Additionally the offices of my client purchase products such as Windex and Office Cleaner so that their employees may clean
their work stations Would the office cleaning products used by my clients employees come under the consumer products exemption of the
HCS
Answer You have indicated that these products are provided by your client for their employees to use for the occasional cleaning of work
stations and not in situations related to a required work assignment Ifyour clientsemployees utilize the office cleaning products you mention
Windex and Office Cleaner with the frequency and duration as that of a normal consumer then the use of those cleaning chemicals would
fall under the HCS exemption for consumer products 29 CFR 191020b6t
You included different types of chemical products in your inquiry The products in question are being used for a variety of purposes and in a
variety of quantities A consumer product that is used in a workplace in such a way that the duration and frequency of use are the same as
that of a consumer is not required to be included in an employers hazard communication program Again it is your clients responsibility to
make this determination for his workplace by assessing the exposure potential of the consumer products he may utilize and ensuring that the
frequency and duration of use of these products by his employees are not greater than that of normal consumer use
Thank you for your interest in occupational safety and health We hope you find this information helpful OSHA requirements are set by
statute standards and regulations Our interpretation letters explain these requirements and how they apply to particular circumstances but
they cannot create additional employer obligations This letter constitutes OSHA interpretation of the requirements discussed For further
information on this subject you may go to OSHAsweb site athttiwwwosha If you have any further questions please feel free to
contact the Office of Health Enforcement at 202 6932190
Sincerely
Jonathan L Snare
Acting Assistant Secretary
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April 14, 2005 
Ms. Beverly Cohen 
Special Counsel 
Hinman Straub Attorneys at Law 
121 Stat  Street 
lbany, NY 12207-1693 
r Ms. : 
Enforce ent Data & Statistics Training Publicati s Ne sr  
1910.12 0; 910. 12QQ(b )(6)(ix) 
This is in response to your February 25, 2005, correspondence to the ccupational Safety and ealth d inistration (O ). our letter as 
tr sf rr  to r irectorate of f r t r r s (D ) f r  res . This l tt  nstitutes A's i t r r t ti  of l  t  
require ents discussed and ay not be applicable to any questions not delineated within your original correspondence. Your letter requested 
cl rifi ti n r r i  A's azard i ti  t rd (H ),   910. 2 0. ou specifically asked t r ir t  f r 
aintaining aterial safety data sheets (MS Ss) for consu er art products and office cleaning products. 
You have referenced t o different types of che ical products and asked questions related to these aterials. In order to clearly ans er your 
questions, the scenariOS, and questions you presented will be paraphrased below, followed by OSHA's answers. 
Question 1: The employees of y client ay create visual aids and presentation displays where they would use co ercial art che ical 
products such as thinners, adhesives, and paints. Could you please clarify whether or not the use of consumer art products by my client's 
employees would meet the consumer products exemption under 29 CFR 1910.1200(b)(6)(ix)? 
Answer: The consumer product exemption of the HCS applies to the use of those products only if the employer can demonstrate they are 
used in the same manner (e.g., with the same frequency and duration of use) as a normal consumer would utilize them. In the scenario you 
provided, the e ployees of your client are perfor ing operations related to their nor al ork require ents. uring the execution of these 
duties they ay be utilizing art che icals such as paints, thinners, and adhesives. If the e ployees are routinely exposed to these hazardous 
chemicals, then they would be required to be afforded the chemical hazard information available through MSDS and hazard communication 
training. It is the responsibility of the e ployer to deter ine e ployee exposure and ascertain if the frequency of use/exposure is indeed not 
more than that which would be experienced by a nonmal consumer. 
Question 2: Additionally, the offices of my client purchase products such as index and Office Cleaner so that their employees may clean 
their work stations. Would the office cleaning products used by my client's employees come under the consumer products exemption of the 
HCS? 
Ans er: You have indicated that these products are provided by your client for their e ployees to use for the occasional cleaning of ork 
stations and not in situations related to a required ork assign ent. If your clien~s e ployees utilize the office cleaning products you ention 
(Windex and Office Cleaner) with the frequency and duration as that of a normal consumer, then the use of those cleaning chemicals would 
fall under the HCS exemption for consumer products, 29 CFR 191O.12oo(b)(6)(ix). 
You included different types of chemical products in your inquiry. The products in question are being used for a variety of purposes and in a 
variety of quantities. A consumer product that is used in a workplace in such a way that the duration and frequency of use are the same as 
that of a consu er is not required to be included in an e ployer's hazard co unication progra . Again, it is your client's responsibility to 
make this determination for his workplace by assessing the exposure potential of the consumer products he may utilize and ensuring that the 
frequency and duration of use of these products, by his employees, are not greater than that of normal consumer use. 
Thank you for your interest in occupational safety and health. We hope you find this information helpful. OSHA requirements are set by 
statute, standards, and regulations. Our interpretation letters explain these requirements and how they apply to particular Circumstances, but 
they cannot create additional employer obligations. This letter constitutes OSHA's interpretation of the requirements discussed. For further 
infor ation on this subject you ay go to OSHA's web site at http://www.osha.gov. I     f t  questions, please feel fr  to 
contact the ffice of ealth Enforce ent at (202) 693-2190. 
Sincerely, 
Jonathan L. Snare 
Acting Assistant Secretary 
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Standard Number 191020x7
January 9 1990
MrSteven Schatzow
Attorney at Law
Morgan Lewis and Bockius
1800 M Street NW
Washington DC 20036
Dear Mr Schatzow
This is in response to your letter of December 4 1989 to the Occupational Safety and Health Administration
OSHA regarding the requirement of chemical manufacturers to provide material safety data sheets MSDS
under the Hazard Communication Standard HCS 29 CFR 191020
In your letter you correctly summarized OSHAs requirement regarding the provision of MSDS for consumer
products OSHA does not require that MSDS be provided to purchasers of household consumer products when
the products are used in the workplace in the same manner that a consumer would use themiewhere the
duration and frequency of use and therefore exposure is not greater than what the typical consumer would
experience This exemption in OSHAs regulation is based however not upon the chemical manufacturers
intended use of his product but upon how it actually is used in the workplace Employees who are required to
work with hazardous chemicals in a manner that results in a duration and frequency of exposure greater than
what a normal consumer would experience have a right to know about the properties of those hazardous
chemicals
In your letter you describe a situation that occurs in some institutional settings where employees use your
clients household products pesticides in a manner different than how a homeowner would use them
Regarding this type of situation you stated myclient does not intend that its products be used except as a
consumer would use the product Should an institutional customer contact my client regarding the need for a
MSDS for a particular product where the customer intends to use the product in a manner dissimilar to that in
which a homeowner would use the same product my client intends to inform the customer that such use is not
appropriate and to decline to provide the customer with a MSDS for the product Such action on the part of
your client would constitute a violation of OSHAs HCS which requires all employers to provide information to
their employees about the hazardous chemicals to which they are exposed by means of a hazard
communication program labels and other forms of warning material safety data sheets and information and
training See 191020 Furthermore sectiong7requires retail distributors that sell hazardous
chemicals to commercial customers to provide MSDS to such employees upon request Distributors obtain the
MSDS of course from the chemical manufacturer the preparer of the MSDS Additionally the chemical
manufacturer of the pesticide your client in the situation you portray would have to have developed and have
available at his manufacturing worksite location MSDS for his own employees at that site who are exposed to
the pesticide in question during their formulation and production Sharing the MSDS with downstream
employers upon request for distribution to their employees who are also exposed meets the intent of the
standard
I hope this has been responsive to your concern Please feel free to contact me again if you have any further
questions
Sincerely
Thomas J Shepich Director
Directorate of Compliance Programs
0 Standard Interpretations Table of Contentr
Freedom of Information Act I Privacy Security Statement I Disclaimers I Customer Survey I Important Web Site Notices I International I Contact Us
1 of 2 762011312PM
000982
1/09/ 990 -      rod ... t ://www.os· /pls/oshaweb/owadisp.sho  _d ... 
   
• 
11 \ cr f:J" 
:r 
rl::Le 
[:': 'f 'J:' 
l  o  ed ar  
 OSHA QuickTakes l tt r m   ED    II    
ti l f t  &    c  l  
e r r   
• tandard I t r r t ti s - able f tents 
•  r: 
r  ,  
r. t  t20  
tt  t  
, i   i  
  t, .W. 
ton, .C.  
 r. 2 : 
nforcement t  & t ti ti  i i  
910.12 0(9)(7) 
  
is is i  r s s  t  r l tt r f r , 9, t  t  ti l f t   lt  i i tr ti  
(O A)             (M ) 
under the azard o unication tandard (H S), 29 F  1910.1200. 
In your letter, you correctly su arized HA's require ent regarding the provision of S S for consu er 
products.  does not require that  be provided to purchasers of household consu er products hen 
the products are used in the orkplace in the sa e anner that a consu er ould use the , i.e.; here the 
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This is in response to your memorandum of May 15 requesting clarification of the application of 29 CFR
191020 to retail establishments which use consumer products for cleaning purposes This is also in followup
to several telephone conversations between our staff members on the specific case involved Safeway Inc
Store 914 for which a hearing date of August 13 has been set
Your memo requested National Office guidance regarding citation strategy and litigation priorities for violations
of consumer product use in a workplace which is not specifically exempted under 191020b6viiie
employee use of consumer products which is of a greater frequency and duration than normal consumer use
The performanceoriented nature of the Hazard Communication Standard HCS makes it difficult to draw clear
exacting lines for the number of times a consumer product can be used in a workplace before the provisions of
the rule apply However where an employer is uncertain whether the duration and frequency of exposure to
these products is comparable to that of a consumer he or she should obtain or develop the MSDS and make it
available to employees see 52 FR pg 31862 August 24 1987 It is the employers responsibility to assess
his workers exposures and determine if and when the requirements of the standard apply
During the course of an inspection it is imperative that the compliance officer document that any employee use
of a consumer product containing hazardous ingredients at his or her workplace is of a frequency or duration
that clearly exceeds what a reasonable person would concede to be normal consumer use in a home or
household environment Situations where employee use of a product is close or similar to the way or to the
amount of times a consumer could be envisioned to use a product should not be cited as violations of the HCS
It is important to note that the use of consumer products can be hazardous The fact that a product is labeled
in accordance with the provisions of the Consumer Product Safety Act and exempt from OSHA HCS
labelingdoes not render that product safe to use by workers This is especially pertinent when as a
condition of employment an employee must utilize a hazardous consumer product with a greater frequency
and resultant greater duration of exposure than what is typical of a normal consumer or household use In
these situations the employee has a right to know about the hazards of the chemicals he or she is expected
to work with and therefore is exposed to This is the obvious intent of the standard with regard to workplace
consumer product exposure
We have been advised by the Solicitors Office that in cases involving employee workplace exposures to
hazardous consumer products the employer has the initial burden of proving that the product is used in its
workplace in a manner contemplated by the exemption language of 191020b6viiThat is the employer
must demonstrate that the consumer product is used by employees in the same manner as normal consumer
use and that the duration and frequency of exposure is not greater than that experienced by the general public
Employers must be able to demonstrate that an employee is using for example a can of sink cleanser with the
same frequency or duration of use as would be expected at home If it is the employeesjob to clean sinks all
day or part of the day with such frequency that is greater than one would be expected to be experienced at
home then the employee is entitled to the hazard communication information available through the MSDS and
required employee training provisions of the HCS Under this example it is essential that OSHA establish
through employee interviews that the worker did in fact repeatedly clean sinks throughout his or her workshift
in a manner that any reasonable person would agree resulted in exposures significantly greater than those of a
consumer This evidence would be used to rebut the employer potential offer of proof that his or her
employees used the hazardous cleanser in a manner similar to that of a normal consumer
While we agree that clear lines delineating when the HCS applies and when it would not apply may be difficult to
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define for all workplace situations and depends on specific workplace conditions the intent of the HCS to
provide employees information on hazardous chemicals they work with is clear
We hope this discussion will be useful to you in this pending case and in future situations
Stanaara Interpretations i aole or t ontents
Freedom of Information Act I Privacy Security Statement I Disdaimers I Customer Survey I Important Web Site Notices I International I Contact Us
USDepartment of tabor I Occupational Safety HealthAdmhstratiln 1 200 Constitutbn Ave NW Washington DC 20210
Telephone 800321OSHA6742 I TfY8778895627
wwwOSHAgov
2of 2 762011313PM
000985
8/15/1991 .   
• 
 nsumer ... ://www.os· 10V/pls/oshaweb/o adisp.show _d ... 
.. . 
0  
fi  f r ll r l  Situatio s d  o  ifi  r l c  iti , t  i t t f t  , t  
r i  l  i f r ti   r  ch ic l  t  r  it , i  l r. 
 hope t is i i  ill e f l t   i  t i  i    i  f t  it ti  . 
• Standard Interpretations· Table f Contents 
r do  f Infor ation t  Priv  & rity t  cl i   usto er   t t  it  ti   m ti al  t ct s 
u.s. epartment oflil r I atb i fEt  &  I' ili;tratbn I  onstl tbn ., tiN, l9ton,   
elephone: 800-32HlSHA(6742) I TTY: 877-889-5627 
ww.OSHA.gov 
/6/2011 :13  
ORIGI IVO 7LED2AM PM
JUL 1 1 2011
CHRISTOPHER L RIC cleric
By Lfi1A ARIES
DE
Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise Idaho 83702
Tel 208 3192600
Fax 208 3192601
Attorneys for Defendant
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
V
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
CaseNo CVPI1003515
SECEXPARTEMOTION TO STRIKE
AMENDED AFFIDAVIT OF JP
PURSWELL PHDPECPE FILED IN
OPPOSITION TO DEFENDANTS
MOTION FOR SUMMARY JUDGMENT
Defendant
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA pursuant to Idaho Rules of Civil Procedure 7 and 56c
objects to and hereby moves this Court ex parte to strike the Amended Affidavit ofJPPurswell
PhDPE CPE Amended Purswell Affidavit which was filed by Plaintiff Billie Jo Major
Plaintiff on July 7 2011 with absolute disregard for this Courts Order Governing
Proceedings and Setting Trial Scheduling Order and the applicable Idaho Rules of Civil
Procedure
This Motion to Strike is made on the following grounds
1 The Amended Purswell Affidavit was filed twentyseven 27 days after
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Attorneys for Defendant 
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IST PHER D. R~CH, Clerk 
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v. 
SEC RIT  E IP E T 
CORPORATION, a issouri corporation, 
nt. 
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EC'S   I   I  
E    .P. 
ELL, H.D., .E., , I  I  
I   FENDANT'S 
    
f t rit  i t r r ti  ("SE "),       
rec r , ree er r e e a er P.A., rs a t t  I a  les f i il r ce re  a  6(c), 
objects to and hereby moves this Court ex parte to strike the Amended Affidavit of J.P. Purswell, 
Ph.D., P.E., CPE ("Amended Purs ell ffidavit"), i  s fil   l i tiff illie J  j r 
("Plaintiff') on July 7, 2011 with absolute disregard for this Court's Order Governing 
Proceedings and Setting Trial ("Scheduling Order")  t  appli l  I  l  f ivil 
r dure. 
This otion to Strike is ade on the follo ing grounds: 
. he ended urs ell ffidavit as filed t enty-seven (27) days after 
EC'S  E I   T I   FI I  OF J.P. PURSWEL , PH.D., P.E., 
CPE, FILED IN OPPOSITION TO DEFENDANT'S OTION FOR SU ARY JUDG ENT - Page 1 
14542-011 (401602) 
Plaintiffs opposition to SECs motion for summary judgment was due and filed
on June 10 2011 in accordance with this Court Scheduling Order
2 Further the Amended Purswell Affidavit was filed thirteen 13 days after SECs
reply brief on the motion for summary judgment was due and filed on June 24
2011 in accordance with this Court Scheduling Order
3 The Amended Purswell Affidavit was filed six 6 days after SECs counsel
deposed Dr Purswell regarding his opinions and writings in this case including
his original Affidavit
4 IRCP56c requires that any affidavits relied upon in opposition to a motion
for summary judgment be filed with the partysbriefing and
5 SEC does not have an adequate opportunity to respond to Plaintiffsuntimely
filed Affidavit either by operation of the time limits for summary judgment
briefing imposed byIRCP 56c and this Courts Scheduling Order or by
operation of the briefing permitted underIRCP56 See Sun Valley Potatoes
Inc v Rosholt Robertson Tucker 133 Idaho 1 6 981 P2d 236 241 1999
This motion is further supported by the Idaho Rules of Civil Procedure this Courts
Scheduling Order the Register of Actions in this case and applicable Idaho law
Oral argument is not requested and a proposed Order is submitted herewith If
desired by this Court SEC will present oral argument on this motion at the July 14 2011 hearing
already set in this matter
DATED this 11 day ofJuly 2011
GREENER BURKE SHOEMAKER PA
Christopher C Burke Thomas J Lloyd III
Attorneys for Defendant
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing SECEXPARTE MOTION TO
STRIKE AMENDED AFFIDAVIT OFJPPURSWELL PHDPECPE FILED IN
OPPOSITION TO DEFENDANTSMOTION FORSUMMARY JUDGMENT on the following
named personson the date indicated below in the manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
P O Box 7808
Idaho 83707
ViaUSMail
Via Hand Delivery
is Facsimile2084898988
I Via Overnight Delivery
DATED this 11 day ofJuly 2011
Christopher C Burke
Thomas J Lloyd III
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na ed person(s) on the date indicated belo , in the anner indicated belo : 
Darwin Overson, Esq. 
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
I Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
JUL 12 2011
CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Case No CV PI 1003515
Plaintiff
VS
MOTION FOR ORDER SHORTENING
TIME FOR FILINGTHE AMENDED
AFFIDAVIT OF DR PURSWELL
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
COMES NOW the Plaintiff Billie JoMajor by and through her counsel of record Darwin L
Overson of the firm Jones Swartz PLLC and pursuant toIRCP6d56cand 56e moves this
Court for an order shortening time for Plaintiff to file the Amended Affidavit ofJP Purswell PhD
PE CPE in Opposition to DefendantsMotion for Summary Judgment filed July 7 2011
DefendantsMotion for Summary Judgment and PlaintiffsCross Motion for Partial Summary
Judgment are scheduled to be heard by this Court on July 14 2011
MOTION FORORDER SHORTENING TIME FOR FILING
THE AMENDED AFFIDAVIT OF DR PURSWELL 1
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ES  the Plaintiff, illie Jo ajor, by and through her counsel of record, ar in L. 
,  t  ir  s & S artz PLLC, and pursuant to IR.C.P. 6(d), 56(c) and 56(e) oves this 
ourt for an order shortening ti e for Plaintiffto file the ended ffidavit of J.P. Purs ell, Ph.D., 
P.E., CPE, in pposition to efendant's otion for Su ary Judg ent, filed July 7, 2011. 
efendant's otion for Su ary Judg ent and Plaintiffs ross- otion for Partial Su ary 
Judg ent are scheduled to be heard by this ourt on July 14, 2011. 
       
    .  -  
Good cause exists for granting this Motion which is supported by the records and pleadings on
file herein and the Affidavit of Counsel in Opposition to DefendantsEx Parte Motion to Strike
Dr PurswellsAmended Affidavit and in Support ofPlaintiffsMotion to Shorten Time for Filing
the Amended Affidavit ofDr Purswell filed concurrently herewith
DATED this 12th day ofJuly 2011
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 12th day of July 2011 a true and correct copy of the
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
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BySTEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
STATE OF IDAHO
ss
County ofAda
Case No CV PI 1003515
AFFIDAVIT OF COUNSEL IN
OPPOSITION TO DEFENDANT
EXPARTE MOTION TO STRIKE
DR PURSWELL AMENDED
AFFIDAVIT AND IN SUPPORT OF
PLAINTIFFSMOTION TO SHORTEN
TIME FOR FILING THE AMENDED
AFFIDAVIT OF DR PURSWELL
I Darwin L Overson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
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I, ar in . verson, being first duly s orn upon oath, depose and state upon y o n 
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practice law before this and all courts of the State of Idaho. 
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2 I am counsel of record for Plaintiff Billie Jo Major in the above action and have
firsthand knowledge of the documents materials and all other discovery that has been produced
by either party in this case Furthermore I have firsthand personal knowledge of the taking of
Dr Purswellsdeposition all the filings with the Court and other communications discussed in
this Affidavit
3 Defendant moved for summary judgment on April 22 2011
4 On May 26 2011 Defendant filed a Supplemental Affidavit of Counsel in
Support of DefendantsMotion for Summary Judgment attaching thereto the deposition
transcript ofPlaintiffsexpert Dr Pacheco
5 Trial in this case was continued in order to allow time for DefendantsMotion to
be heard due to this Court busy calendar and limited availability to hear the Motion prior to
trial I attended the status conference by telephonic means
6 Plaintiff filed her opposition to DefendantsMotion for Summary Judgment on
June 10 2011 along with the supporting Affidavits of Dr Yost Dr Purswell and Plaintiffs
counsel Along with her opposition memorandum Plaintiff filed her Motion for Partial
Summary Judgment supported by the same memorandum as that filed in opposition to
DefendantsMotion for Summary Judgment Both filings were accomplished byme
7 On June 24 2011 Defendant moved to strike portions of the affidavit ofDr Yost
Also on June 24 2011 Defendant filed its Reply Memorandum in Support of Defendants
Motion for Summary Judgment In its Reply Memorandum Defendant took the position for the
first time that its SABRE Red Law Enforcement 10 OC Spray Cell Buster was a product
governed in its labeling requirements by the Federal Hazardous Substance Act and not OSHAs
Hazard Communication Standard since law enforcement may use the product to perform
AFFIDAVIT OF COUNSEL IN OPPOSITION TO DEFENDANTSEXPARTE MOTION TO STRIKE
DR PURSWELLSAMENDED AFFIDAVIT AND IN SUPPORT OFPLAINTIFFSMOTION TO
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. efendant oved for su ary judg ent on pril 22, 2011. 
.  a  , , efe t file   l t l ffida it  l i  
Support of efendant's otion for Su ary Judg ent, attaching thereto the deposition 
tra scri t f laintiffs e ert, r. ac eco. 
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be heard due to this ourt's busy calendar and li ited availability to hear the otion prior to 
trial. I attended the status conference by telephonic eans. 
. Plaintiff filed her opposition to efendant's otion for Su ary Judg ent on 
June 10, 2011, along ith the supporting ffidavits f r. ost, r. urswell, and laintiffs 
el. lon  it  er siti  e ra , lai tiff file  er ti  f r artial 
Su ary Judg ent supported by the sa e e orandu  as that filed in opposition to 
efendant's ti  f r ar  J ent. t  filings ere acc lis e  rne. 
. n June 24, 2011, efendant oved to strike portions of the affidavit f r. ost. 
lso on June 24, 2011, efendant filed its eply e orandu  in Support of efendant's 
otion for Su ary Judg ent. In its eply e orandu , efendant took the position for the 
first ti  t t its    f r t 0%  ray, ll ster, s  r t 
governed in its labeling require ents by the ederal azardous ubstance ct and not SHA's 
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extractions in a home I received the filings mentioned in this paragraph and reviewed the
same
8 On June 30 2011 Defendant took the deposition of Dr Purswell a labeling
expert for the Plaintiff I personally defended the deposition
9 During that deposition defense counsel questioned Dr Purswell extensively about
the basis of his opinion that SECsSABRE Red Law Enforcement 10 OC Spray would be
governed by the OSHA Hazard Communication Standard 29CFR 191020 and not by the
Federal Hazardous Materials Act 15USCA 1261 et seq and 16CFR 1500 et seq
There was extensive questioning of Dr Purswell regarding the use of SABRE Red Law
Enforcement 10 OC Spray in and around households by police Dr Purswell testified that it
would not remove the products for labeling purposes from being governed by OSHAsHazard
Communication Standard because according to guidance and opinion letters of both OSHA and
the Consumer Product Safety Commission where a consumer product is used with greater
frequency and duration in the workplace than what would reasonably be expected of a typical
consumersuse in the household it is governed by OSHAsHazard Communication Standard
Several OSHA and Consumer Product Safety Commission guidance and opinion publications
were included as exhibits to the deposition ofDr Purswell
10 Also during the deposition it came to the attention of both Dr Purswell and
Plaintiffs counsel that the Affidavit of Dr Purswell initially filed in opposition to Defendants
Motion for Summary Judgment was absent a notary stamp Dr Purswell was asked about the
circumstances of his executing the Affidavit and he explained how the error was likely to have
occurred
11 Defense counsel also questioned Dr Purswell about the use of the word
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ould not re ove the products for labeling purposes fro  being governed by SHA's azard 
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the Consu er Product Safety Co ission, where a consu er product is used with greater 
frequency and duration in the orkplace than hat ould reasonably be expected f a typical 
c sumer's se i  t e sehold, it is er e   HA's azar  icati  ta ard. 
Several S  and onsu er Product Safety o ission guidance and opinion pUblications 
ere included as exhibits to the deposition of r. Purswell. 
. Also during the deposition, it came to the attention of both Dr. Purswell and 
laintiffs counsel that the ffidavit f r. urs ell initially filed in opposition to efendant's 
otion for Su ary Judg ent as absent a notary sta p. r. Purs ell as asked about the 
circu stances of his executing the ffidavit, and he explained ho  the error as likely to have 
. 
. efense counsel also questioned r. Purs ell about the use of the ord 
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industrial in paragraph 5 of his Affidavit where he stated that the express standard in the
industry for labeling of hazardous industrial chemicals was OSHA Hazard Communication
Standard Dr Purswell explained that the use of the term industrial was unfortunate and
should not have been used in the Affidavit because the Hazard Communication Standard applies
to all hazardous chemicals used in the workplace and not just industrial chemicals
12 At the end of the deposition defense counsel requested of the court reporter an
expedited transcript which was produced to the parties later that same day I was present in the
room for this conversation
13 Also at the end of the deposition defense counsel served on Plaintiffs counsel a
Memorandum the Affidavit ofChris Burke the Affidavit ofNicholas J Roberts and the Second
Affidavit ofRobert Nance all in opposition to PlaintiffsMotion for Partial Summary Judgment
I was the person served
14 At 45pm on June 30 2011 the court reporter who handled the deposition of
Dr Purswell emailed a rough draft of the deposition transcript to both parties counsel At
538pm by email defense counsel served on Plaintiffscounsel the Affidavit of Thomas J
Lloyd III in Support ofOpposition to PlaintiffsCross Motion for Summary Judgment
15 On July 7 2011 Plaintiff filed her Reply to DefendantsOpposition to Plaintiffs
Cross Motion for Partial Summary Judgment Concurrently with the Memorandum Plaintiff
filed the Amended Affidavit of J P Purswell PhDPE CPE in Opposition to Defendants
Motion for Summary Judgment with attached Exhibit C which consisted of OSHA and
Consumer Product Safety Commission guidance and opinion documents discussed during
Dr Purswellsdeposition In his Amended Affidavit Dr Purswell explained that he had relied
on those publications in formulating his opinions expressed in his report and that the OSHA
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ffidavit of obert ance, all in opposition to Plaintiff's otion for Partial Su ary Judg ent. 
I as the person served. 
. t 4:45 p.m. on June 30, 2011, the court reporter ho handled the deposition of 
r. rs ll ailedar gh r ft fth depositi ntr scriptto th rties. unsel.  
:38 .m.,  e ail, efense c sel ser e   laintiff's c sel t e ffida it f as J. 
loyd III in Support of pposition to Plaintiff's ross otion for Su ary Judg ent. 
. n July 7, 2011, Plaintiff filed her eply to efendant's pposition to Plaintiffs 
ross otion for Partial Su ary Judg ent. rr tl  it  t  r u , l i tiff 
filed the A ended Affidavit of J. P. Purswell, Ph.D., P.E., CPE, in Opposition to Defendant's 
ti    t it  tt  i it , i  i t     
onsu er Product Safety o ission guidance and opinion docu ents discussed during 
r. Purswell's deposition. In his ended ffidavit, r. Purs ell explained that he had relied 
on those publications in for ulating his opinions expressed in his report and that the OSHA 
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Hazard Communication Standard was the standard in the industry for labeling of hazardous
substances intended for and packaged for occupational use which was also extensively discussed
in his deposition testimony I prepared filed and caused these documents to be served
16 On July 11 2011 Defendant filed SECsEx Parte Motion to Strike Amended
Affidavit of JP Purswell PhDPE CPE Filed in Opposition to DefendantsMotion for
Summary Judgment I received this document and reviewed the same
FURTHER YOUR AFFIANT SAYETH N
SUBSCRIBED AND SWORN TO before me this 12th day of July 2011
wS Notary Public forIdaho
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foregoing document was served on the following individualsby the method indicated
Christopher C Burke
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USMail
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By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
Case No CV PI 1003515
PLAINTIFFSOBJECTIONS AND
OPPOSITION TO SECEXPARTS
MOTION TO STRIKE AMENDED
AFFIDAVIT OFJPPURSWELL PHD
PECPE FILED IN OPPOSITION TO
DEFENDANTSMOTION FOR
SUMMARY JUDGMENT
Plaintiff by and through her counsel of record respectfully submits the following
objections and opposition to the exparte motion filed by SEC to strike the Amended Affidavit of
JPPurswell PhDPECPE in Opposition to DefendantsMotion for Summary Judgment
L BACKGROUND
1 Defendant moved for summary judgment on April 22 2011
The Background facts stated herein are supported by paragraphs 3 through 16 of the Affidavit of
Counsel in Opposition to Defendant Ex Parte Motion to Strike Dr Purswell Amended Affidavit and
in Support ofPlaintiff Motion to Shorten Time
PLAINTIFF OBJECTIONS AND OPPOSITION TO SEC EXPARTE MOTION TO STRIKE
AMENDED AFFIDAVITOF JP PURSWELL PHDPECPE FILED IN OPPOSITION TO
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a issouri corporation, 
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laintiff,  a  t r  er c sel f rec r , res ectfull  sub its t e f ll i  
objections and opposition to the ex parte motion filed by SEC to strike the Amended Affidavit of 
J.P. Purswell, Ph.D., P.E., PE, in pposition to efendant's otion for Su ary Judg ent. 
I. ROUND} 
. efendant oved for su ary judg ent on pril 22, 2011. 
1 The Background facts stated herein are supported by paragraphs 3 through 16 of the Affidavit of 
Counsel in pposition to efendant's Ex Parte otion to Strike r. Purswell's ended ffidavit and 
in Support of Plaintiffs Motion to Shorten Time. 
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2 On May 26 2011 Defendant filed a Supplemental Affidavit of Counsel in
Support of DefendantsMotion for Summary Judgment attaching thereto the deposition
transcript ofPlaintiffsexpert Dr Pacheco
3 Trial in this case was continued in order to allow time for DefendantsMotion to
be heard due to this Court busy calendar and limited availability to hear the Motion prior to
trial
4 Plaintiff filed her opposition to DefendantsMotion for Summary Judgment on
June 10 2011 along with the supporting Affidavits of Dr Yost Dr Purswell and Plaintiffs
counsel Along with her opposition memorandum Plaintiff filed her Motion for Partial
Summary Judgment supported by the same memorandum as that filed in opposition to
DefendantsMotion for Summary Judgment
5 On June 24 2011 Defendant moved to strike portions of the affidavit ofDr Yost
Also on June 24 2011 Defendant filed its Reply Memorandum in Support of Defendants
Motion for Summary Judgment In its Reply Memorandum Defendant took the position for the
first time that its SABRE Red Law Enforcement 10 OC Spray Cell Buster was a product
governed in its labeling requirements by the Federal Hazardous Substance Act and not OSHAs
Hazard Communication Standard since law enforcement may use the product to perform
extractions in a home
6 On June 30 2011 Defendant took the deposition of Dr Purswell a labeling
expert for the Plaintiff
7 During that deposition defense counsel questioned Dr Purswell extensively about
the basis of his opinion that SECsSABRE Red Law Enforcement 10 OC Spray would be
governed by the OSHA Hazard Communication Standard 29CFR 191020 and not by the
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Federal Hazardous Materials Act 15USCA 1261 et seq and 16CFR 1500 et seq
There was extensive questioning of Dr Purswell regarding the use of SABRE Red Law
Enforcement 10 OC Spray in and around households by police Dr Purswell testified that it
would not remove the products for labeling purposes from being governed by OSHAsHazard
Communication Standard because according to guidance and opinion letters of both OSHA and
the Consumer Product Safety Commission where a consumer product is used with greater
frequency and duration in the workplace than what would reasonably be expected of a typical
consumersuse in the household it is governed by OSHAsHazard Communication Standard
Several OSHA and Consumer Product Safety Commission guidance and opinion publications
were included as exhibits to the deposition ofDr Purswell
8 Also during the deposition it came to the attention of both Dr Purswell and
Plaintiffscounsel that the Affidavit of Dr Purswell initially filed in opposition to Defendants
Motion for Summary Judgment was absent a notary stamp Dr Purswell was asked about the
circumstances of his executing the Affidavit and he explained how the error was likely to have
occurred
9 Defense counsel also questioned Dr Purswell about the use of the word
industrial in paragraph 5 of his Affidavit where he stated that the express standard in the
industry for labeling of hazardous industrial chemicals was OSHA Hazard Communication
Standard Dr Purswell explained that the use of the term industrial was unfortunate and
should not have been used in the Affidavit because the Hazard Communication Standard applies
to all hazardous chemicals used in the workplace and not just industrial chemicals
10 At the end of the deposition defense counsel requested of the court reporter an
expedited transcript which was produced to the parties later that same day
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r l a r s aterials t,  .S.c.A. §§ , t q.,   .F.R. § 50 .1, t. q. 
ere as e te sive esti i  f r. rs ell re ar i  t e se f  e  a  
nforce ent 10%  pray in and around households  police. r. urs ell testified that it 
ould not re ove the products for labeling purposes fro  being governed by HA's azard 
i ti  t  , i  t  i a   i i  l tt   t    
t  r r t f t  i i , r   r r t i   it  r t r 
frequency and duration in the orkplace than hat ould reasonably be expected of a typical 
c sumer's se i  t e sehold, it is er e   SHA's azar  icati  ta ard. 
r l   s er r t f t  i i  i   i i  li ti  
ere included as exhibits to the deposition of r. Purs ell. 
. ls  ri  t e siti , it  t  t  tt ti  f t  r. rs ll  
Plaintiffs counsel that the ffidavit of r. Purs ell initially filed in opposition to efendant's 
otion for Su ary Judg ent as absent a notary sta p. r. Purs ell as asked about the 
circu stances f his executing the ffidavit, and he explained ho  the error as likely to have 
. 
. efense counsel also questioned r. Purs ell about the use of the ord 
"industrial" in paragraph 5 of his ffidavit here he stated that the express standard in the 
industry for labeling of "hazardous industrial che icals" was OSHA's Hazard Co unication 
rd. r. ll l i  t t t    t  t  "indu trial"  t t   
should not have been used in the ffidavit because the azard Co unication Standard applies 
to all hazardous che icals used in the workplace and not just industrial che icals. 
. t t   f t  siti , f s  s l r st  f t  rt r rt r  
expedited transcript, which was produced to the parties later that same day. 
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11 Also at the end of the deposition defense counsel served on Plaintiffs counsel a
Memorandum the Affidavit of Chris Burke the Affidavit ofNicholas J Roberts and the Second
Affidavit ofRobert Nance all in opposition to PlaintiffsMotion for Partial Summary Judgment
12 At 45pm on June 30 2011 the court reporter who handled the deposition of
Dr Purswell emailed a rough draft of the deposition transcript to both parties counsel At
538pm by email defense counsel served on Plaintiffscounsel the Affidavit of Thomas J
Lloyd III in Support of Opposition to PlaintiffsCross Motion for Summary Judgment
13 On July 7 2011 Plaintiff filed her Reply to DefendantsOpposition to Plaintiffs
Cross Motion for Partial Summary Judgment Concurrently with the Memorandum Plaintiff
filed the Amended Affidavit of J P Purswell PhDPECPE in Opposition to Defendants
Motion for Summary Judgment with attached Exhibit C which consisted of OSHA and
Consumer Product Safety Commission guidance and opinion documents discussed during
Dr Purswellsdeposition In his Amended Affidavit Dr Purswell explained that he had relied
on those publications in formulating his opinions expressed in his report and that the OSHA
Hazard Communication Standard was the standard in the industry for labeling of hazardous
substances intended for and packaged for occupational use which was also extensively discussed
in his deposition testimony
14 On July 11 2011 Defendant filed SECs Ex Parte Motion to Strike Amended
Affidavit of JP Purswell PhDPECPE Filed in Opposition to DefendantsMotion for
Summary Judgment
II SUMMARYOF ARGUMENT
1 A Motion to Shorten Time has been filed concurrently with this Opposition to
SECs Motion to Strike Dr PurswellsAmended Affidavit
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11. s       ositi n,     laintif s   
e ,  fida   is ,  id   ic la  . rt ,    
ffidavit of obert ance, all in opposition to Plaintiffs otion for Partial Su ary Judg ent. 
. t 4:45 p.m. on June 30, 2011, the court reporter ho handled the deposition of 
r. Purs ell e ailedaroughdraftofthedepositiontranscripttobothparties.counsel.  
:38 .m.,  ail, fe se s l s r   laintiffs s l t  ffi it f s J. 
lo d III i  rt f siti  t  laintiffs r ss ti  f r ar  J ent. 
.  J l  , , lai tiff file  er e l  t  efendant's siti  t  laintiffs 
r ss tion f r artial ar  J ent. tl    ndu , l i ti  
filed the ended ffidavit f J. . urs ell, h.D., .E., , in pposition to efendant's 
tio  f r r  t it  tt  i it , i  i t  f   
s r r t f t  issi  i   i i  ts is ss  ri  
Dr. Purswell's deposition. In his A ended Affidavit, Dr. Purswell explained that he had relied 
 t se lications i  f r lati  is i io s e resse  i  is re rt a  t at t e  
azar  icati  ta ar  as t e sta ar  i  t e i str  f r la eli  f azar s 
substances intended for and packaged for occupational use, hich as also extensively discussed 
in his deposition testi ony. 
.  J l  , 1, efe a t file  C's x rte ti  t  tri e e e  
ffidavit of J.P. Purs ell, Ph.D., P.E., P , Filed in pposition to efendant's otion for 
r  t. 
.    
.  otion to horten i e has been filed concurrently ith this pposition to 
C's    . rswell's e  vit. 
I TIFF'S   I   EC'S  PAR    I  
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S2 SEC has not been prejudiced in any manner since the statements contained in
Dr PurswellsAmended Affidavit and attached exhibits were extensively discussed in his
deposition andorin his initial Affidavit
3 Plaintiff filed the Amended Affidavit ofDr Purswell for the following reasons
a To correct the technical error ofnot having a notary stamp affixed to his initial
Affidavit
b To help clarify a very rough transcript ofDr Purswellsdeposition and
c To provide the exhibits to Dr Purswellsdeposition consisting of the OSHA
and Consumer Product Safety Commissionsguidance and opinion letters discussed in his
deposition
4 Dr PurswellsAmended Affidavit was also filed in support ofPlaintiffsMotion
for Partial Summary Judgment and filed concurrently with her Reply Memorandum
III ARGUMENT
Defendants ex parte motion should be denied It is within this Court discretion to
consider supplemental affidavits in support of or in opposition to a motion for summary
judgment when a motion to shorten time has been filed Sun Valley Potatoes v Rosholt
Robertson Tucker 133 Idaho 1 1999 Rhodehouse v Stutts 125 Idaho 208 214 1994 In re
John 201020 Doe I v Dept ofHealth and Welfare 150 Idaho 491 248P3d 742 747 2011
As provided inIRCP56e the court may permit affidavits to be supplemented or opposed by
depositions answers to interrogatories or further affidavits Id The mandatory period for
filing supporting or opposing affidavits set out inIRCP56cmay be shortened for good cause
shown Sun Valley Potatoes 133 Idaho at 5 Similarly it is within the Courtsdiscretion to
extend the time for the Plaintiff to obtain and file affidavits depositions and interrogatories in
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.  s t  r j i  i   r si  t  st t ts t i  i  
r. urswell's e e  ffi a it a  attac e  ex i its ere extensivel  isc sse  i  is 
siti  nd/or i  is i iti l ffi vit. 
3. lai tiff file  t e e e  ffi a it f r. rs ell f r t e f ll i  reasons: 
. o correct the technical error f not having a notary sta p affixed to his initial 
vit; 
.  l  l rif   r  r  tr ri t  r. urswell's position;  
.  r i  t  i it  t  r. urswell's osition, i ti  f t   
a  s er r ct afet  mission's i a ce a  i i  letters isc sse  i  is 
siti n. 
. r. rswell's  ffid it s ls  fil  i  s rt f laintiff's ti  
f r artial ar  J e t a  file  c c rre tl  it  er e l  e ra . 
I.  
f ndant's   o    i d.     ourt's   
c si er s le e tal affi a its i  s rt f r i  siti  t  a ti  f r s ar  
    t      . Sun Valley Potatoes v. Rosholt, 
t  & ker,  I   (1 9); s  v. t tts,  I  8,  (1 4); I  r  
John (2010-20) Doe I v. Dept. of Health and elfare, 150 Idaho 491, 248 P.3d 742, 747 (2011). 
s provided in I.R.C.P. 56(e), the "court ay per it affidavits to be supple ented or opposed by 
depositions, ans ers to interrogatories, or further affidavits." Id. The andatory period for 
filing supporting or opposing affidavits set out in I.R.C.P. 56( c) ay be shortened for good cause 
sho n. Sun alley otatoes, 133 Idaho at 5. i ilarly, it is ithin the ourt's discretion to 
extend the ti e for the Plaintiff to obtain and file affidavits, depositions and interrogatories in 
I TIFF'S J I S    C'S  PART  I    
E    .P. , H.D., .E., ,   I   
ENDANT'S I     -  
opposition to the Defendantsmotion for summary judgment SeeIRCP56fwhen affidavits
unavailable In exercising its discretion this Court should apply the rules liberally to secure
just speedy and inexpensive determination of this action IRCP1a
Here a Motion to Shorten Time has been filed concurrently herewith supported by
affidavit showing good cause PltfsMotion to Shorten Time Aff ofPltf s Counsel in Support
of Motion to Shorten Time 1136 Defendant has not been prejudiced as the Amended
Affidavit is consistent with both Dr Purswellsprior Affidavit and his deposition testimony
The Amended Affidavit merely corrects a technical error and supplements and clarifies what can
only be described as a very rough transcript of Dr Purswellsdeposition submitted by the
Defendant
The Amended Affidavit of Dr Purswell was also filed in support of PlaintiffsReply
Memorandum in support of her Cross Motion for Partial Summary Judgment Where the issue of
whether the possible use of SECsSABRE Red Law Enforcement 10 OC Spray could possibly
be used in or around a household and thereby subject to the Federal Hazardous Substance Act
was raised for the first time in Defendantsopposition to PlaintiffsCross Motion for Summary
Judgment the Plaintiff was entitled to file additional supporting evidence on that issue As such
the filing of the Amended Affidavit was perfectly acceptable underIRCP56
Furthermore Dr PurswellsAmended Affidavit could be submitted on a motion for
reconsideration should this Court grant DefendantsMotion for Summary Judgment
IV CONCLUSION
DefendantsMotion should be denied in order to do substantial justice This case should
not be decided on a technicality or on the basis of a rough deposition transcript submitted without
its exhibits Defendant has not been surprised or otherwise prejudiced in any way by
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i    f ndant's    nt.  LR.C.P. 6(f) (whe  f  
available). I  e ercisi  its iscreti n, t is rt s l  a l  t e r les li erall  t  "sec re 
just, speedy and inexpensive deter ination" ofthis action. LR.C.P. 1 (a). 
r ,  ti  t  rt  i    file  rr tl  erewith, rt   
ffi it s i   se. ltfs ti  t  rt  i e; ff. f ltfs s l i  rt 
f ti  t  rt  i , ~~ 3-16. f t s t  r j i  s t   
ffida it is c siste t it  t  r. rswell's ri r ffida it a  is e siti  testi ny. 
he ended ffidavit erely corrects a technical error and supple ents and clarifies hat can 
l   ri    r  r  tr ri t f r. rswell's iti  itt   t  
f nt. 
he ended ffidavit f r. urs ell as also filed in support f laintiffs eply 
e orandu  in support of her ross otion for Partial Su ary Judg ent. here the issue of 
t r t  ssi l  s  f C's    f r t 0%  r  l  ssi l  
 s  i  r r   s hold,  t r  s j t t  t  r l r s st  t, 
as raise  f r t e first ti e i  efe dant's siti  t  laintiffs r ss ti  f r ar  
Judg ent, the Plaintiff as entitled to file additional supporting evidence on that issue. s such, 
the filing ofthe ended ffidavit as perfectly acceptable under LR.C.P. 56. 
, . urswell's e  id         
reconsideration, should this Court grant efendant's otion for Su ary Judg ent. 
.  
efendant's otion should be denied in order to do substantial justice. his case should 
not be decided on a technicality or on the basis of a rough deposition transcript sub itted ithout 
ts . efendant has not been surprised or other ise prejudiced in any ay by 
I TIFF'S S  I   EC'S     I  
E E  I I   J.P. , H.D., .E., , I  I  I I   
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Dr PurswellsAmended Affidavit Accordingly DefendantsMotion should be denied
DATED this 12th dayofJuly 2011
JONES SWARTZ
DARWINL OVERSON
ERIC B SwARTz
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 12th day of July 2011 a true and correct copy of the
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
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By JOHN WEATHEfaY
DEPUry
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICTOF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
V
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
Defendant
Case No CVPI 1003515
ORDERRE PENDING MOTIONS FOR
SUMMARY JUDGMENT AND TO
STRIKE AFFIDAVIT OF GERALD
YOST
On July 14 2011 the Court held its hearing on the following motions
1 Defendant Security Equipment CorporationsSEC Motion for Summary
Judgment
2 Plaintiff Billie Jo Majors Major Cross Motion for Summary Judgment
3 SECs Motion to Strike the Affidavit of Gerald Yost and
4 SECs Ex Parte Motion to Strike the Amended Affidavit of DrJPPurswell
Each party filed briefs and affidavits in support and in opposition to these motions After
considering the written submissions of the parties and hearing oral argument by counsel on the
motions on July 14 2011 the Court HEREBY ORDERS as follows
The Court did not consider the Amended Affidavit ofJPPurswell or consider or
rule on SECsEx Parte Motion to Strike that affidavit because the Amended Affidavit was not
timely filed
2 SECsMotion for Summary Judgment is GRANTED in all respects on the
grounds and for the reasons recited by the Court on the record during the hearing on the Motion
ORDER RE PENDING MOTIONS FOR SUMMARY JUDGMENT AND MOTION TO STRIKE AFFIDAVIT OF
GERALD YOST Page 1 14542011 402462doc
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n July 14, 2011, the Court held its hearing on the follo ing otions: 
. efendant ecurity quip ent orporation's ("SE ")    
Judg ent; 
. Plaintiff Billie Jo ajor's ("Major") ross- otion for u ary Judg ent; 
. C's o     id    t;  
. EC's       e  i   r. .P. rswel . 
Each party filed briefs and affidavits in support and in opposition to these motions. After 
considering the written submissions of the parties and hearing oral argument by counsel on the 
otions on July 14,2011, the Court HEREBY ORDERS as follows: 
1.   i  t    id  f .P. urswell, r i  r 
r l   EC's  rt  ti  t  tri  t t ffi avit, s  t   ffi it s t 
timely filed. 
. EC's ti  f r r  J t is  i  ll r s ts  t  
grounds and for the reasons recited by the Court on the record during the hearing on the otion. 
  PENDI   F R SUM  JU T A  I  T  T I  Fl A I  F 
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3 MajorsCross Motion for Summary Judgment is DENIED on the grounds and for
the reasons stated by the Court on the record during the hearing on the Motion
4 SECsMotion to Strike the Affidavit of Gerald Yost is DENIED on the grounds
and for the reasons stated by the Court on the record during the hearing on the Motion The
Court considered the Affidavit of Dr Yost but found that it was insufficient to create a material
dispute of fact to preclude summary judgment in favor of SEC
The Court reserves and did not decide the issue of whether or not Major has any
viable claim arising out of the Federal Hazardous Substances Act FHSA The Court will
permit the parties to file further motions on this last issue should they deem such motions
appropriate
G
DATED this r day ofJuly 2011
Honorable Cheri C Copsey istrict Judge
Fourth Judicial District Ada County
ORDER RE PENDING MOTIONS FOR SUMMARY JUDGMENTANDMOTION TO STRIKE AFFIDAVIT OF
GERALD YOST Page 2 14542011 402462doc
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing ORDER ON PENDING
MOTIONS FOR SUMMARY JUDGMENT AND MOTION TO STRIKE AFFIDAVIT OF
GERALD YOST on the following named personson the date indicated below in the manner
indicated below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O BOX 7808
Boise Idaho 83707
Christopher C Burke Esq ViaUS Mail
Thomas J Lloyd III Esq Via Hand Delivery
GREENER BURKE SHOEMAKERPA Via Facsimile 2083192601
950 W Bannock Street Suite 900 ViaOvernight Delivery
Boise Idaho 83702
DATED this I I day of July 2011
CHMSTOPVEr D RICH
LN
Clerk o
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ORIGINAL
Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise Idaho 83702
Tel 208 3192600
Fax 208 3192601
Attorneys for Defendant
P
JUL 2 2 2011
CHRISTOPHER D RICH ClerkBy JAMIE RAIMDALL
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
V
SECURITY EQUIPMENT CORPORATION a
Missouri corporation
Defendant
Case No CVPI 1003515
DEFENDANT SECURITY
EQUIPMENT CORPORATION
SECOND MOTION FOR
SUMMARY JUDGMENT
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA pursuant to Rule 56 of the Idaho Rules of Civil
Procedure hereby respectfully moves this Court for an order granting summary judgment against
Plaintiff Billie Jo Major Plaintiff on all remaining claims asserted by Plaintiff with respect to
SECs compliance with the Federal Hazardous Substances Act 15USC 1261 et seq
The basis for this Motion is that following this Court entry of summary judgment in
open court on July 14 2011 and in a subsequent written Order issued on July 19 2011
Plaintiffs only remaining claim is limited to the question of whether SEC complied with the
Federal Hazardous Substances Act FHSA in labeling its product As the FHSA does not
DEFENDANT SECURITY EQUIPMENT CORPORATIONSSECOND MOTION FOR SUMMARY
JUDGMENT Page 1 14542 011 403153001007
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efendant Security quip ent orporation ("SE "),   t  it  l  
r rd, r r r  r  .A., rs t t  l   f t  I  l s f i il 
Procedure, hereby respectfully oves this Court for an order granting su ary judg ent against 
Plaintiff Billie Jo ajor ("Plaintiff') on all remaining claims asserted by Plaintiff with respect to 
SEC's compliance with the Federal Hazardous Substances Act, 15 U.S.c. § , t q. 
he basis for this otion is that, follo ing this ourt's entry f su ary judg ent in 
open court on July 14, 2011 and in a subsequent written Order issued on July 19, 2011, 
Plaintiff s only re aining clai  is li ited to the question of hether S  co plied ith the 
r l    ("FHS ") in labeling its product. s the F S  does not 
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JUDG ENT - Page 1 14 -  ( 53) 
provide a private cause of action Plaintiff is further limited to causes of action in common law
negligence strict liability andornegligence per se
This Court has already determined that SEC neither knew nor could have known of the
risks of longterm chronic adverse health effects as a result of exposure to its product On that
basis Plaintiff cannot establish the requisite duty element for either a claim in common law
negligence or strict liability and summary judgment is appropriate in favor of SEC on those
claims
Plaintiffsremaining possible claim for negligence per se must also fail A claim for
negligence per se requires the existence of an applicable statute or law that clearly defines the
required standard of conduct The FHSA however is vague and ambiguous on its face in that it
fails to define material terms and to otherwise instruct a product manufacturer in the precise
labeling requirements imposed by its provisions Moreover nothing in the statute would require
a product manufacturer to differentiate between a chronic versus an acute adverse health
condition and to the extent that Plaintiff seeks to impose such a requirement that claim is
preempted by the FHSA Finally Plaintiffsclaim for negligence per se must fail due to the fact
that any additional warning that could have been placed on the label of the product container
would only have covered information about which Plaintiff was already wellaware and given
that Plaintiff did not even see the product label about which she complains she cannot as a
matter of law establish any argument that the alleged defect in the product label was a proximate
cause of her alleged injuries
This Motion is supported by the pleadings filed with the Court in this action the
Memorandum in Support of this Motion the Second Affidavit of Christopher C Burke filed
DEFENDANT SECURITY EQUIPMENT CORPORATIONSSECOND MOTION FOR SUMMARY
JUDGMENT Page 2 14542011403153001008
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negligence or strict liability, and su ary judg ent is appropriate in favor of S  on those 
. 
laintiffs re aining possible clai , for negligence per se, ust also fail.  clai  for 
negligence per se requires the existence of an applicable statute or la  that clearly defines the 
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condition, and to the extent that Plaintiff seeks to i pose such a require ent, that clai  is 
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t at lai tiff i  t e e  see t e r ct la el a t ic  s e c lai s, s e ca t as a 
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his otion is supported by the pleadings filed ith the ourt in this action, the 
e orandu  in Support of this otion, the Second Mfidavit of Christopher C. Burke, filed 
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concurrently herewith and certain other memoranda and affidavits previously filed in support of
SECsprior Motion for Summary Judgment and in opposition to PlaintiffsCross Motion for
Summary Judgment
Oral argument is requested
DATED this 22 day ofJuly 2011
GREENER BURKE SHOEMAKERPA
d7qR9
Christopher C Bur e
Thomas J Lloyd III
Attorneys for Defendant
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing DEFENDANT SECURITY
EQUIPMENT CORPORATIONSSECOND MOTION FORPARTIAL SUMMARY JUDGMENT on
the following named personson the date indicated below in the manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
P O Box 7808
Idaho 83707
ViaUSMail
x Via Hand Delivery
Via Facsimile 2084898988
Via Overnight Delivery
DATED this 22 day of July 2011
Christopher C Burke
Thomas J Lloyd III
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DATED this 22nd day of July, 2011. 
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Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
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Fax 208 3192601
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
Wins
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
CaseNo CVPI 1003515
SECOND AFFIDAVIT OF
CHRISTOPHER CBURKE IN
SUPPORT OF SECsSECOND MOTION
FOR SUMMARY JUDGMENT
Defendant
STATE OF IDAHO
ss
County ofAda
I Christopher C Burke being first duly sworn upon oath state as follows
I am one of the attorneys of record for Defendant Security Equipment Corporation
SEC or Defendant and make this Affidavit in support of SECsSecond Motion for
Summary Judgment based upon personal knowledge
2 Attached to this Affidavit Exhibit A are true and correct excerpts of the March
17 2011 Rule 30b6deposition of SEC given by Robert Nance in this case March 17 2011
Deposition Transcript
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001010
hristopher . urke, IS  #2098 
ho as J. loyd III, IS  #7772 
E   KER  
 . a  tr t, ite  
is , Idaho  
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
: 'uosz : 
   
I ER D. RICH C' ........ 
 JAMIE RANDA l.' "'1\ 
0iPUTY 
           
  I , I        
I IE J  J , an individual, 
Plaintiff, 
v. 
S I  IP  
P RATI , a issouri corporation, 
nt. 
   ) 
)ss. 
ounty f da ) 
 .: - I-  
 I   
 .   
  EC's   
   
I, Christopher C. Burke, being first duly sworn upon oath, state as follows: 
1. I a  e f t e att r e s f rec r  f r efe a t ecurit  i e t r rati  
("S "  "Defend "), and ake this ffidavit in support of SEC's Second otion for 
Su ary Judg ent, based upon personal kno ledge. 
. ttached to this ffidavit xhibit  are true and correct excerpts of the arch 
17,2011 Rule 30(b)(6) deposition of SEC given by Robert ance in this case ("March 17,2011 
Deposition Transcript"). 
 FI AVI   I  .   S   EC'S SEC  I   
SUMMARY JUDGMENT - Page I 14542-  ( 03655.doc) 
3 Attached hereto as Exhibit B is a true and accurate copy of deposition Exhibit D
attached to the March 17 2011 Deposition Transcript That exhibit was identified and discussed
by Mr Nance in that deposition
DATED this 22 day of July 2011
By
Christopher C Burke
I hereby certify that I caused to be served the foregoing Second Affidavit of
Christopher C Burke in Support ofSECsSecond Motion for Summary Judgment to be
served on the following named personson the date indicated below in the manner indicated
below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
P O Box 7808
Boise Idaho 83707
DATED this 22 day of July 2011
ViaUSMail
X ViaHand Delivery
Via Facsimile 2084898988
Via Overnight Delivery
OL qk
Christopher C Burke
SECOND AFFIDAVIT OF CHRISTOPHER C BURKE IN SUPPORT OF SEC SECOND MOTION FOR
SUMMARY JUDGMENT Page 2 14542011 403655doc
SUBSCRIBED AND SWORN TO before me this7xsday of July 2011
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TAR x Residing at Star Idaho
Commission Expires0622012
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attached to the arch 17, 2011 eposition Transcript. That exhibit as identified and discussed 
by Mr. Nance in that deposition. 
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I hereby certify that I caused to be served the foregoing Second Affidavit of 
Christopher C. Burke in Support of SEC's Second otion for Summary Judgment to be 
served on the following na ed person(s) on the date indicated below, in the anner indicated 
elow: 
Darwin Overson, Esq. 
Eric B. Swartz, Esq. 
J S & S ARTZ, PLLC 
1673 . Shoreline Drive, Suite 220 
. .   
Boise, Idaho 83707 
 this 22nd day of July, 2011. 
[ ]  .S. il 
[ ] ia and elivery 
[ ] ia Facsi ile (208/489-8988) 
[ ] i  r i t li r  
hristopher . urke 
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Page 90
A I believe so
MR OVERSON Okay
Exhibit D marked
Q BY MR OVERSON Do you recognize
Exhibit D thatsbeen handed to you as three pages of
materials that youve produced in response to our
discovery requests
A Yes
Q And can you tell us what those three pages
are beginning with the first
A Theyr the labels for the products that
the Idaho DOC purchased from us
Q What is this first product
A Thatsan MK6 Sabre Red H Imsorry
Thats the second product The this one thats an
MK6 Sabre Red Stream H2O product
Q Okay And by purchased IDOC purchased
you mean during the period of 2004 to 2008
A Yes
Q Okay And then the next one
A Thatsthe MK4 size that Ms Major
carried
Q Okay Is that an H2O
A Yes
Q Okay And the next one
Page 91
A That is the Aerosol Grenade the MK3 size
Aerosol Grenade
Q Okay Six seconds deployment time six
seconds is that what it says or five
A I think its six
Q Six Im sorry You said that was the
A MK3Aerosol Grenade
Q Aerosol Okay Okay I have some
questions on that Okay And then the next one
A Thats the MK4 Cone delivery
Q Whatsthat
A Its like a fogger Its a cone and
fogger are two names that are used interchangeably
Q Okay But for purposes of your product
line do you sell it as a separate product
A Well typically in MK9 size people call
it a fogger In the smallerdutybelt size they call
it a cone
Q Okay So all Id have to do is go to a
bigger can and now I got the logger on my hands
A Yeah People tend to call it a fogger
rather than a cone
Q Okay I see why And then the next page
is the MK9 Fogger
A Yes
Page 92
1 Q And this product was sold to IDOC in the
2 period of 2004 to 2008
3 A Yes
4 Q Okay
5 A But I don see a label for the Cell
6 Buster which would mean that we didntsell them the
7 Cell Buster during that period
8 Q Okay Bu t you did sell them the MK9
9 Fogger
10 A Thatswhy I would have provided that
11 label yes
12 Q And it delivers the same thing except for
13 without the wand
14 A Yes
15 Q Okay I cantread the first one the
16 MK6
17 A Uhhuh
18 Q Tell me if I were able to read it from the
19 Active ingredients portion down to the part there
20 where youve got your Security Equipment Corporation
21 and your address if I were to read that and then read
22 the one for the MK4 H2O right below it would they be
23 the same verbiage
24 A Yes
25 Q Okay I t doesn say anything about don
Page 93
1 use this product if youresuffering from my type of
2 respiratory illness does it
3 A No
4 Q Okay And youre familiar with the other
5 products other OC products on the market that do
6 A No Im not
7 Q Youre not familiar with any products that
8 have that warning
9 A No
10 Q Okay
11 A Most products on the market have less
12 warning information than we do
13 Q Okay The training manual here Lets
14 just get this in front of you
15 Exhibit E marked
16 Q BY MR OVERSON Youvebeen provided
17 Exhibit E
18 Do you recognize that as material that you
19 produced in response to our request for production
20 A Yes
21 Q And it is an Instructor Certification
22 Manual
23 A Yes sir
24 Q Produced by your firm or your company
25 A Yes sir
24 Pages 90 to 93
2083459611 M M COURT REPORTING 2083458800 fax
001014
age 90 age  
1 .  li  s .  . nd t i  r uct as l  t  lO  i  the 
2 . : . 2 riod f  t  ? 
3 (Exhibit D arked.)  . . 
 . (BY MR. OVERSON): Do you recognize  . . 
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 discovery requests?  ll uster ri  t t ri . 
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 . They're the labels for the products that  l l, . 
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3 . hat is this first product?  it t  nd? 
4 . at's  K-6   - -- 'm .  . . 
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7 Q. Okay. And by "purchased, IDOC purchased,"  . -h . 
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 . t is t  r l r , t  -3 i ,  use this product if you're suffering fro  y type of 
  .  i t  ill ss,  it? 
 Q. Okay. Six seconds, deployment time six  . . 
 seconds, is that what it says, or five?  . y.  ou're il     
 .  i  it's ix.  t ,        o? 
 . ix. I'm sorry. ou said that as the --  . , I'm ot. 
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 . Aerosol. kay. kay. I have so e    rning? 
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Attorneys for Defendant
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
0
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
Defendant
CaseNo CVPI1003515
MEMORANDUM IN SUPPORT OF
DEFENDANTSSECOND MOTION FOR
SUMMARY JUDGMENT
Defendant Security Equipment Corporation SEC or Defendant by and through its
counsel of record Greener Burke Shoemaker PA pursuant to IRCP 56 submits this
Memorandum in support of its Second Motion for Summary Judgment Motion In addition
to this Memorandum SEC relies on the following additional pleadings previously filed in this
action to supports its Motion
1 Affidavit of Counsel in Support of DefendantsMotion for Summary Judgment
filed April 22 2011 Counsel AM
2 Affidavit of Robert Nance in Support of DefendantsMotion for Summary
Judgment filed April 22 2011 NanceAff
3 Affidavit of Christopher A Reilly PhD in Support of Defendants Motion for
MEMORANDUM IN SUPPORT OF DEFENDANTSSECOND MOTION FOR SUMMARY
JUDGMENT Page 1 14542 011 403122doe
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rist er . r e, I  #2098 
as 1. loyd III, I  # 772 
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: (2 ) -2601 
ttorne s  e a t 
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I  . I  l r  
By JA IE AANOAU. I 
CIPUTY 
       I I     
  ,        
IE  J ,  i i i al, 
laintiff, 
v. 
  
ORATI N, a issouri corporation, 
nt. 
 o.: -PI-  
    
FENDANT'S    
  
: 
efendant ecurity quip ent orporation ("S " or "Defendant"), by and through its 
counsel of record, reener urke Shoe aker P.A., pursuant to I.R.C.P. 56, sub its this 
e orandu  in support of its Second otion for Su ary Judg ent ("Motion").  i  
to this e orandu , S  relies on the follo ing additional pleadings, previously filed in this 
ti , t  s rts its ti : 
. Affidavit of Counsel in Support of Defendant's otion for Summary Judgment, 
file  ril ,  ("Couns l ff."); 
. Affidavit of Robert Nance m Support of Defendant's otion for Summary 
J ent, file  ril ,  ("Nance ff."); 
. ffidavit of hristopher . eilly, Ph.D. in Support of efendant's otion for 
    ENDANT'S     
J E T - Page 1 14542-011 (403122.doc) 
Summary Judgment filed April 22 2011 Reilly AM
4 Affidavit of Christopher C Burke in Opposition to Plaintiffs Cross Motion for
Summary Judgment filed June 30 2011 Burke Aff
5 Second Affidavit of Robert Nance in Support of DefendantsOpposition to
PlaintiffsCross Motion for Summary Judgment filed June 30 2011 2d Nance AM
6 Affidavit of Nicholas J Roberts in Support of DefendantsOpposition to
Plaintiff s Cross Motion for Summary Judgment filed June 30 2011 Roberts Aff
7 Second Affidavit of Christopher C Burke in Support of SECsSecond Motion for
Summary Judgment 2 Burke AM
8 SECsMemoranda in Support of its original in Motion for Summary Judgment
and in Opposition to Plaintiff s Cross Motion for Summary Judgment and
9 The other pleadings and documents on file with this Court
I INTRODUCTION AND PROCEDURAL BACKGROUND
The Court is wellaware of the issues presented in this case Nonetheless in order to
maintain a complete record SEC restates the procedural background of this case as follows
Plaintiff filed this products liability action on February 24 2010 asserting causes of
action against SEC under theories of Strict Liability and Negligence based on SECs alleged
failure to provide an adequate warning on its Sabre Red oleoresin capsicum OC pepper
spray See Plaintiffs Complaint and Demand for Jury Trial Complaint p 67 Plaintiff
1 As pled Plaintiffs cause of action for Strict Liability is not premised on an alleged failure to
provide an adequate warning on the OC Spray SEC previously sought summary judgment on Plaintiffs
Strict Liability claim and in light of the Courtsruling that the risk of Plaintiff claimed injury was
neither known nor foreseeable at the time Plaintiff was exposed to SECs OC spray summary judgment
was granted on that issue Nonetheless under Idaho law failure to warn may be a basis for liability under
theories of either Negligence or Strict Liability Mico Mobile Sales Leasing Inc v Skyline Corp 97
Idaho 408 414 546 P2d 54 1975 For purposes of this motion SEC addresses the strict liability claim
as if it had also alleged inadequate warnings
MEMORANDUM IN SUPPORT OF DEFENDANTSSECOND MOTION FOR SUMMARY
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u ary Judg ent, filed pril 22, 2011 ("Reilly ff."); 
. ffidavit of Christopher C. Burke in pposition to Plaintiffs Cross- otion for 
Su ary Judg ent, filed June 30, 2011 ("Burke ff."); 
.  ffida it  t a  in t  dant's iti  t  
laintiffs ross- otion f r ar  J e t, file  J e ,  ("2nd a ce ff."); 
. ffida it  icholas . ts in t  ndant's i   
lai tiffs ross- otion f r ar  J ent, file  J e ,  ("Roberts ff."); 
.  ffida it  rist r . r e i  rt  EC's  ti  f r 
ar  J e t ("2nd r e ff."); 
. C's e ra  i  rt f its ri i l i  ti  f r r  J t 
and in Opposition to Plaintiffs Cross- otion for Su ary Judg ent; and 
. he other pleadings and docu ents on file ith this ourt. 
.     
e rt is ell-a are f t e iss es rese te  i  t is case. et eless, in r er to 
maintain a complete record, SEC restates the procedural background of this case as follows: 
Plaintiff filed this products liability action on February 24, 2010, asserting causes of 
action against SEC under theories of Strict Liability and Negligence based on SEC's alleged 
failure to provide an adequate warning on its Sabre Red oleoresin capsicum ("OC") r 
spray.! (See Plaintiffs' Co plaint and De and for Jury Trial ("Co plaint"), p. -7.) lai tiff 
1 s pled, laintiffs cause of action for trict iability is not pre ised on an alleged failure to 
provide an adequate arning on the  Spray. SE  previously sought su ary judg ent on Plaintiffs 
Strict Liability clai  and, in light of the Court's ruling that the risk of Plaintiffs clai ed injury was 
neither kno n nor foreseeable at the ti e Plaintiff as exposed to SEC's  spray, su ary judg ent 
as granted on that issue. onetheless, under Idaho law, failure to arn ay be a basis for liability under 
theories of either Negligence or Strict Liability. Mica Mobile Sales & Leasing, Inc. v. Skyline orp., 97 
Idaho 408,414,546 P.2d 54 (1975). For purposes of this otion, SEC addresses the strict liability clai  
as if it had also alleged inadequate warnings. 
 I    FENDANT'S  I   U  
 - Page 2 14542-  ( 03122 doc) 
alleges that as a result of her exposuresto OC spray she suffers from chronic respiratory
symptoms and illness Complaint 10
On April 22 2011 SEC filed its first Motion for Summary Judgment on each of
Plaintiff s claims asserting that SEC had no duty to warn against the adverse health effects that
were unknown and unforeseeable at the time it distributed the product that was ultimately sold to
Plaintiffs former employer the Idaho Department of Corrections IDOC SEC also sought
summary judgment on Plaintiffs failure to warn claims based on the Occupational Safety
Health Act OSHA on grounds that such claims were preempted by application of the Federal
Hazardous Substances Act FHSA 15USC 1261 et seq
Plaintiff opposed SECs motion and additionally filed a cross motion against SEC
asserting liability for an alleged failure to comply with OSHA standards The briefing on these
motions progressed according to this Court May 13 2011 Order Governing Proceedings and
Setting Trial and the applicable Rules of Civil Procedure Notably Plaintiff did not assert any
argument that SEC had failed to comply with the labeling requirements of the FHSA until her
Reply in support of her own Cross Motion for Summary Judgment the last filing in the line of
briefing prompted by these motions
At oral argument on the parties competing motions for summary judgment held on July
14 2011 this Court granted summary judgment to SEC on all issues presented Since the Court
did not believe that an issue had been properly or timely raised by Plaintiff that SEC had not
complied with the labeling standards of the FHSA that sole issue was left undecided However
the Court invited further briefing on this limited remaining issue Accordingly SEC files this
present motion seeking summary judgment on the last ofPlaintiffs theories in this case
HI
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alleges that, as a result of her exposure(s) to OC spray, she suffers from "chronic respiratory 
symptoms and illness." (Complaint, ~ 1 .) 
On April 22, 2011, SEC filed its first otion for Summary Judgment on each of 
Plaintiff s clai s, asserting that SEC had no duty to arn against the adverse health effects that 
were unkno n and unfores eable at the time it istributed the product that as ultimately ld to 
Plaintiffs former e ployer, the Idaho epart ent of orrections ("IDOC").  ls  s ght 
summary judgment on Plaintiffs failure to warn claims based on the Occupational Safety & 
ealth ct ("OSH ") on grounds that such clai s ere pree pted by application of the Federal 
azar s sta ces ct ("FHS "),  .S.c. § , t . 
Plaintiff opposed SEC's otion, and additionally filed a cross- otion against SEC, 
asserting liability for an alleged failure to comply with OSHA standards. The briefing on these 
motions progressed according to this Court's May 13, 2011 Order Governing Proceedings and 
Setting Trial and the applicable Rules of Civil Procedure. Notably, Plaintiff did not assert any 
argument that SEC had failed to comply with the labeling requirements of the FHSA until her 
Reply in support of her own Cross-Motion for Summary Judgment -        
briefing prompted by these motions. 
At oral argument on the parties' competing motions for summary judgment, held on July 
14, 2011, this Court granted summary jUdgment to SEC on all issues presented. Since the Court 
did not believe that an issue had been properly or ti ely raised by Plaintiff that SEC had not 
complied with the labeling standards of the FHSA, that sole issue was left undecided. However, 
the ourt invited further briefing on this li ited, re aining issue. ccordingly, SE  files this 
present motion seeking summary judgment on the last of Plaintiff s theories in this case. 
II I 
E RANDUM I  SUPPORT OF DEFENDANT'S SECOND M TI  FOR SUMMARY 
JUDGMENT - Page 3 14542-011 ( 03122.doc) 
II STATEMENT OF UNDISPUTED FACTS
In the interest of maintaining a complete record on the instant motion though the
following recitation of facts has been briefed before SEC restates the relevant facts on which it
relies to support this Motion
A The Parties
1 Plaintiff Billie Jo Major Ms Major or Plaintiff claims that she suffered
injuries following exposure to OC spray also referred to as pepper spray during a training
session she was attending as an employee of the IDOC Complaint 8 She specifically
claims that she suffers from a longterm or chronic respiratory illness such as RADS chronic
cough syndrome vocal cord dysfunction esophageal dysmotility andor gastrointestinal reflux
andora long term chronic aggravation or exacerbation of an existing health condition as a result
ofher exposure to OC spray Complaint T 11 and 19 Counsel Aff 9 and Ex H p 14
2 SEC is a manufacturer and retailer of self defense products including a line of
pepper sprays or OC sprays SEC sells its products to law enforcement agencies as well as
civilians Nance Aff 2
3 The SEC product line upon which Plaintiff bases her allegations in her Complaint
is SEC SABRE Red law enforcement 10 OC spray Complaint 8
B Plaintiffs Employment at IDOC
4 Major was employed as a correctional officer with the IDOC from July 2004
through May 2008 Burke Aff 2 Ex AMajor Dep 35216
5 During her employment for the IDOC Major worked at two different correctional
facilities the Idaho Maximum Security Institution IMSI and the South Boise Womens
Correctional Facility SBWCF Burke Aff 2 Ex A Major Dep 351725 Major
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II. S TE ENT F UNDISPUTED FACTS 
In the interest of maintaining a co plete record on the instant otion, though the 
following recitation of facts has been briefed before, SEC restates the relevant facts on which it 
relies to support this otion: 
. he P ties 
1. Plaintiff illie Jo ajor ("Ms. ajor" or "Plaintiff') clai s that she suffered 
injuries following exposure to OC spray, also referred to as pepper spray, during a training 
session she as attending as an e ployee of the I C. (Co t, ~ .)  ly 
clai s that she suffers fro  a long-term or chronic respiratory illness, such as S, chronic 
cough syndrome, vocal cord dysfunction, esophageal dysmotility and/or gastrointestinal reflux, 
and/or a long term chronic aggravation or exacerbation of an existing health condition, as a result 
of her exposure to OC spray. (Co plaint, ~~ 11 and 19; Counsel Aff. ~   x. , . 4.) 
.  s    i   l   ,     
pepper sprays or OC sprays.  sells its r cts t  la  e f rce e t a e cies as ell as 
civilians. (Nance Aff. ~ 2.) 
. The SE  product line upon hich Plaintiff bases her allegations in her o plaint 
is EC's  e  la  e f rce e t 0%  spray. (C laint, ~ .) 
. Plaintiff's Employment at IDOC 
. ajor as e ployed as a correctional officer ith the I C fro  July 2004 
through May 2008. (Burke Aff. ~ 2, x. " " ( ajor ep. 35:2-16).) 
. During her employment for the IDOC, Major worked at two different correctional 
facilities: the Idaho axi u  Security Institution ("I SI") an  t  South B i  omen's 
Correctional Facility ("SBWCF"). (Burke Aff. ~ 2, Ex. " " ( r ep. 35:17- 5).) jor 
E RANDUM I  SUPPORT OF DEFENDANT'S SECOND MOTI N FOR SUMMAR  
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worked at IMSI from July 2004 to July 2006 and there again from August or September 2007 to
May 2008 Id at 35173612 46612 Major worked at SBWCF from roughly July 2006
through August or September 2007 the time frame between her different positions at IMSl Id
351725 4120427
6 While employed at IDOC Major was required to attend different training courses
which were taught by other IDOC personnel Burke Aff T 2 3 and 5 Ex A Major Dep
92109317 Ex B Kimmel Dep 9059213 and Ex D Dep Ex 8 Bates Nos
D00000005658 The training courses included among other training courses annual training
regarding the use of OC Spray Id
C Plaintiffs Use and Exposure to OC Products
7 IDOC did not actually issue any of SECs OC pepper spray products to its
employees or mandate their use in all IDOC facilities until some time in late spring or summer
of 2007 Burke Aff 67 Ex F Overgaard Dep 56245721 Ex E Schaffer Dep
43214422 Prior to that time IDOC employees were issued and were using pepper spray
products from a competitor manufacturer Defense Technologies Id IMSI has records of
purchases of Defense Technologies pepper spray products in 2004 and 2005 Id at 3 Ex B
Kimmel Dep 7113 7210 Defense Technologies OC pepper spray products were issued to
and carried by correctional officers at IMSI from at least 2001 through 2005 Id 75237620
Burke Aff 9 Ex H Dep Ex 10 Major received heronthejob training with Defense
Technologies OC pepper spray and was issued and used Defense Technologies OC pepper spray
during her first six eight 68 weeks of work at IMSI in 2004 Id at T 2 9 Ex A Major
Dep 1421 1442 Ex HDep Ex 10
8 Major attended IDOC OC training sessions wherein she received minor acute
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worked at IMSI from July 2004 to July 2006, and there again from August or September 2007 to 
May 2008. (Jd. at 35:17-36:12; 46:6-12.) Major worked at SBWCF from roughly July 2006 
through August or September 2007, the time frame between her different positions at IMSI. (Jd. 
35:17-25; 41 :20-42:7.) 
6. hile e ployed at ID C, ajor as required to attend different training courses 
which were taught by other IDOC personnel. (Burke Aff. ~~ 2, 3 and 5, Ex. "A" (Major Dep. 
92:10-93:17), Ex. "B" (Kimmel Dep. 90:5-92:13), and Ex. "D" (Dep. Ex. 8, Bates Nos. 
OC0000056-58).) he training courses included, a ong other training courses, annual training 
regarding the use of OC Spray. (Jd.) 
. Plaintiff's Use and Exposure to OC Products 
. I  did not actually issue any of SEC's  pepper spray products to its 
employees, or mandate their use, in all IDOC facilities, until some time in late spring or summer 
 7. (Burke Aff. ~~ 6-7, x. "F" (Overgaard ep. 56:24-57:21); x. "E" (Schaffer ep. 
43:21-44:22).) Prior to that time, IDOC employees were issued and were using pepper spray 
products from a competitor manufacturer, Defense Technologies. (I .) I I has records of 
purchases of Defense Technologies pepper spray products in 2004 a  05. (I . t ~ 3, x. "B" 
(Kimmel Dep. 71:13-72:10).) Defense Technologies OC pepper spray products were issued to 
and carried by correctional officers at I SI from at least 2001 through 2005. (Jd. (75:23-76:20); 
urke ff. ~ 9 Ex. " " ( ep. Ex. 10).) ajor received her on-the-job training ith efense 
Technologies OC pepper spray and was issued and used Defense Technologies OC pepper spray 
during her first six-eight (6-8) weeks of work at IMSI in 2004. (Jd. at ~~ 2, 9, Ex. "A" (Major 
Dep. 142:11-144:12); Ex. "H" (Dep. Ex. 10).) 
8. ajor attended IDOC OC training sessions wherein she received minor acute 
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Level 2 and 3 exposures to OC spray on only five 5 occasions in almost five 5 years namely
0820402146022170713 1807 and 038 Burke Aff 28 and 10 Ex B
Kimmel Dep 1824195 119251218 Ex D Dep Ex 8 Ex J Dep Ex 33 Ex
C Dep Ex 24 Ex E Schaffer Dep 4317442563126612 672681270137223
Ex G Doan Dep 2142214 239 2413 27162915 4022411 4517508 Ex F
Overgaard Dep 41174517 7858216 Ex A Major Dep 921010125 10751089
1109 1128 11291194 119525 1231340 These exposures generally lasted
only seconds a minute at most Id Major was only exposed to SEC pepper spray at three 3
of these five 5 trainings on 021470713 1807 and 038 Id 3 4 and 68 Ex B
Kimmel Dep 119251218 1341385Ex C Dep Ex 24 Ex E Schaffer Dep
43174425 6312 6612 6726812 70137223 Ex G Doan Dep 2142214 239
2413 27162915 4022411 4517 508 Ex F Overgaard Dep 41174517 785
8216 On the other two 2 trainings Major was exposed to OC pepper spray products
manufactured by Defense Technologies Id
9 Major received her first exposure to OC during the August 20 2004 OC training
Burke Aff 2 Ex A Major Dep 9318944 97623 98251012 She entered a six
foot by eight foot 6x 8 room which had been previously sprayed by her trainer with a white
canister of MK9 fog Id at 98251012 She stayed in the room about 20 seconds until she
started to cough and then walked outside Id She stopped coughing after the training session
ended Id She does not know what brand of OC was sprayed in the room Id She did not
see the writing on the OC canister Id
10 Majorsnext OC training took place on February 14 2006 Her instructor was
Sgt Brett Kimmel Burke Aff 2 and 3 Ex B Kimmel Dep 1344 1385 Ex A
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e l    s res t   r   l  fi  (5) casions i  l st fi  (5) rs: l  
8/2 /04, 211 /06, 02121107, 7/13- 8/07, a  3/0 /08. (Burke ff. ~~ -8  ,  "B" 
(Kimmel ep. 18:24-19:15; 119:25-121:18; x. "D" (Dep. x. 8); x. "J" (Dep. x. 33); x. 
"C" (Dep. Ex. 24); Ex. "E" (Schaffer ep. 43:17-44:25; 63:12-66:12; 67:2-68:12; 70:13-72:23), 
. "G" (Doa  e . 1:24- 2:14; 3:9- 4:13; 7:16- 9:15; 0: 2- 1: 1; 5:17- 0:8), . "F" 
(Overgaard ep. 41:17-45:17; 78:5-82:16), x. "A" (Major e . 2:10- 01:25; 07:15- 08:9; 
10:19- 12:18; 12:19- 19:14; 19:15-2 ; 23:12- 34:10).)  r  r ll  l t  
only seconds, a inute at ost. (Jd.) ajor as only exposed to SE  pepper spray at three (3) 
f t ese fi e (5) trai i s,  211 /07, 7113- 8/07, a  3/0 /08. (I . ~~ ,   -8, x. "B" 
(Kimmel Dep. 119:25-121:18; 134:14-138:5), Ex. "C" (Dep. Ex. 24), Ex. "E" (Schaffer Dep. 
3:17- 4:25; 3:12- 6:12; 7:2- 8:12; 0:13- 2: 3), . "G" (Doa  . 1:24- 2:14; 3:9-
24:13; 27:16-29:15; 40:22-41:11; 45:17-50:8), x. "F" (Overgaard ep. 41:17-45:17; 78:5-
82:16).) n the other t o (2) trainings ajor as exposed to  pepper spray products 
anufactured by efense Technologies. (Jd.) 
. aj r recei e  er first e s re t   ri  t e st ,20   trai i g. 
(Burke Aff. ~ 2, Ex. "A" ( ajor ep. 93:18-94:4; 97:6-23; 98:25-101:12).) She entered a six 
f t  ei t f t (6'x ') r  ic  a  ee  re i sl  s ra e   er trai er it  a ite 
canister f -9 fog. (Jd. at 98:25-101: 12.) he stayed in the roo  about 20 seconds until she 
started to cough and then alked outside. (Jd.) She stopped coughing after the training session 
e ed. (J .) e es t  at ra  f  as s ra e  i  t e r . (J .) e i  t 
see the writing on the OC canister. (Jd.) 
0. ajor's next  training took place on ebruary 14, 2006. er instructor as 
Sgt. rett i el. (Burke ff. ~~ 2 and 3, Ex. "B" (Kim el ep. 134:14-138:5), Ex. "A" 
    FENDANT'S     
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Major Dep 10751089Major does not recall anything about this training or whether or not
she was exposed to OC Id Ex AMajor Dep 10751089
11 Major received OC training from Sgt Dan Schaffer at SBWCF on February 21
2007 Burke Aff Tj 2 and 6 Ex E Schaffer Dep 63126612 Ex A Major Dep
11091128 Major recalls the training It was classroom training She did not get exposed
to OC in that training Id Ex AMajor Dep 11091128
12 Major received OC training from Sgt Dan Schaffer on July 13 andor 18 2007 at
SBWCF Burke Aff T 2 and 6 Ex A Major Dep 1129 1194ExE Schaffer Dep
6726812 70137223 Major received a 15second Level 2 exposure to OC during this
training where she was required to pick up and move an object sprayed with OC pepper spray
Id Ex A Major Dep 1129 1194 Major started coughing when the OC was sprayed
on the object but the cough was temporary Id Following her own exposure she watched and
laughed as other correctional officer trainees came out of the building coughing after they
received their exposures to OC Id She does not know the brand name or color of the OC
spray canister that was used in the training Id
13 Major last had OC training at IMSI with Sgts Nick Doan and Joshua Overgaard
on March 3 2008 Burke Aff T 2 7 and 8 Ex A Major Dep 119525 12321340
Ex G Doan Dep 2392413 27162915 4022411 4517508 Ex F Overgaard
Dep 41174517 7858216 This was a Level 3 exposure where Major entered a room
which had previously been sprayed with an MK9 OC fog Id Major did not see the canister
of MK9 OC fog used in this training and doesntknow its color shape size or brand Id Ex
AMajor Dep 13321340
14 In June 2007 before providing Major with OC training Sgts Schaffer Doan and
MEMORANDUM IN SUPPORT OF DEFENDANTSSECOND MOTION FOR SUMMARY
JUDGMENT Page 7
14542011 403122doc
001025
(Major Dep. 107:5-108:9).) Major does not recall anything about this training or whether or not 
she was exposed to ~C. (Id., Ex. "A" (Major Dep. 107:5-108:9).) 
1 . ajor received OC training from Sgt. Dan Schaffer at SB CF on February 21, 
2 . (Burke Aff. ~~ 2 and 6, Ex. "E" (Schaffer Dep. 63:12-66:12), Ex. "A" (Major Dep. 
110:19-112:18).) ajor recalls the training. It was classroom training. She did not get exposed 
to OC in that training. (Id., Ex. "A" (Major Dep. 110:19-112:18).) 
. ajor received C training fro  Sgt. an Schaffer on July 13 and/or 18, 2007 at 
SB CF. (Burke Aff. ~~ 2 and 6, Ex. "A" (Major Dep. 112:19-119:14), Ex. "E" (Schaffer Dep. 
67:2-68:12; 70:13-72:23).) ajor received a 15-second Level 2 exposure to C during this 
training, where she was required to pick up and move an object sprayed with OC pepper spray. 
(Id., Ex. "A" (Major Dep. 112:19-119:14).) ajor started coughing when the OC was sprayed 
on the object, but the cough was temporary. (Jd.) Following her own exposure, she watched and 
laughed as other correctional officer trainees came out of the building coughing after they 
received their exposures to ~C. (Id.) She does not know the brand name or color of the OC 
spray canister that was used in the training. (Id.) 
3. ajor last had OC training at I SI with Sgts. Nick Doan and Joshua Overgaard 
on March 3, 2008. (Burke Aff. ~~ 2, 7 and 8, Ex. "A" (Major Dep. 119:15-25; 123:12-134:10), 
Ex. "G" (Doan Dep. 23:9-24:13; 27:16-29:15; 40:22-41:11; 45:17-50:8), Ex. "F" (Overgaard 
Dep. 41:17-45:17; 78:5-82:16).) i   a l  ex ur  r  j r ent r   r o  
which had previously been sprayed with an K-9 OC fog. (Id.) ajor did not see the canister 
of MK-9 OC fog used in this training and doesn't know its color, shape, size or brand. (Id., Ex. 
"A" (Major Dep. 133:12-134:10).) 
14. In June 2007, before providing ajor ith OC training, Sgts. Schaffer, oan and 
E RANDU  IN SUPPORT OF DEFENDANT'S SECOND MOTI  FOR SUMMA Y 
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Overgaard received OC instructor training from a representative of SEC and were certified by
SEC as OC instructors Burke Aff 6 7 and 8 Ex E Schaffer Dep 1542419ExG
Doan Dep 1551924 Ex F Overgaard Dep 20324 They were instructed by SEC
using the Sabre Instructor Certification Manual SEC Manual Id T 6 7 and 11 Ex F
Overgaard Dep 248253ExE Schaffer Dep 751676 Ex J Dep Ex 41 Page 7
of the SEC Manual Bates No SEC000338 provides in part
OC oleoresin capcasum red pepper OC produces rapid
physiological affects complete recovery and restricts immunity buildup
because it is an inflammatory agent
Physiological affects
Eyes tear and blink repeatedly
Eyes close
Respiration of OC causes inflammation of the respiratory tract
Inflammation causes coughing gagging and a loss of breath
sensation
Facial areas may also become inflamed and will burn
Swelling may occur around the eyes mouth and nose
The nose will run and produce excessive mucus
Affects may differ with each case Common symptoms include light
headedness uncontrollable shaking of the body weakening legs tightness
of the chest and hearing impairment The affects are all temporary
ExJDep Ex 41 SEC000338
15 In providing annual OC training to IDOC correctional officers including Major
the IDOC instructors including Sgts Kimmel Schaffer Overgaard and Doan used a
PowerPoint presentation that was prepared and provided to them by SEC Burke Aff 3 68
and 12 Ex B Kimmel Dep 13271342 16131633Ex ESchaffer Dep 7421756
7727820 Ex G Doan Dep 5210 5422 Ex F Overgaard Dep 2542917 668
6723 Ex K Dep Ex 35 The SEC PowerPoint was shown to Major and other
correctional officers during their annual OC trainings Id The PowerPoint Ex KDep Ex
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Overgaard received OC instructor training from a representative of SEC, and were certified by 
SEC as OC instructors. (Burke Aff. ~~ 6, 7 and 8, . "E" (Scha fer e . 5:14-24:19), . "G" 
(Doan Dep. 15:5-19:24), Ex. "F" (Overgaard Dep. 20:23-24:2).) They were instructed by SEC 
using the Sabre Instructor Certification Manual ("SEC Manual"). (Id. ~~ ,  a d , . "F" 
(Overgaard Dep. 24:8-25:3), Ex. "E" (Schaffer Dep. 75:16-76:7); Ex. "J" (Dep. Ex. 41).) Page 7 
of the  anual (Bates o. 000338) provides in part: 
oc - oleoresin capcasu  - re  e per ...  duces ra id 
physiological affects, co plete recovery, and restricts i unity build-up 
because it is an infla atory agent. 
Physiological affects 
es tear a  li  re eate l  
Eyes close 
espiration of  causes infla ation of the respiratory tract 
Infla ation causes coughing, gagging and a loss of breath 
 
acial areas ay also beco e infla ed and ill bum 
elling ay occur around the eyes, outh and nose 
The nose ill run and produce excessive ucus 
Affects ay differ with each case.     
ea e ess, c tr lla le s a i  f t e y, ea e i  le s, ti t ess 
of the chest and hearing i pair ent. The affects are all te porary. 
(Ex. "J" (Dep. Ex. 41, SEC000338).) 
5. In providing annual OC training to IDOC correctional officers, including Major, 
the I  instructors, including Sgts. i el, Schaffer, vergaard and oan, used a 
PowerPoint presentation that was prepared and provided to them by SEC. (Burke Aff. ~~ , -8 
and 12, Ex. "B" (Kimmel Dep. 132:7-134:2; 161:13-163:3), Ex. "E" (Schaffer Dep. 74:21-75:6; 
77:2-78:20), Ex. "G" (Doan Dep. 52:10-54:22), Ex. "F" (Overgaard Dep. 25:4-29:17; 66:8-
67:23); Ex. "K" (Dep. Ex. 35).)   o r oi t s shown t  j r an  t r 
correctional officers during their annual C trainings. (Id.) The PowerPoint, (Ex. " " ( ep. Ex. 
 I    EFENDANT'S SECOND M TI  FOR SUMMARY 
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35 provides in part
PHYSIOLOGICAL AFFECTS
Eyes tear up and close involuntarily
OC causes inflammation of the respiratory tract
Inflammation causes coughing gagging and a loss of breath
sensation
The skin exposed to OC may also become inflamed and will burn
Swelling may occur around the eyes nose and mouth
The nose will run and produce excessive mucus
Ex K Dep Ex 35IDCRecords 000053
16 As part of their annual OC training IDOC correctional officers including Major
were administered written tests Burke Aff 3 7 and 1315 Ex B Kimmel Dep 197
2112132217 Ex F Overgaard Dep 1141153Dep Ex 28 Ex LDep Ex 25
ExM Dep Ex 26 ExNDep Ex 28
17 Majors test results for the 08204 OC training are reflected in Ex L Dep
Ex 25 Burke Aff T 3 and 13 Ex B Kimmel Dep 197211Ex LDep Ex 25
Question 14 of that test and Majorscorrect answer state
14 What are the 3 distinct physical affects when contaminated with
OC
A Facial burning eye closure respiratory
Id
18 Majors test results for the 02147OC training are reflected in Ex M Dep
Ex 26 Burke Aff 3 and 14 Ex B Kimmel Dep197212132ExMDep
Ex 26 Question 12 of that test and Majorscorrect answer state
12 What are the physiological affects of OC
A Redness of the eyes running nose shortness of breath
Id
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35), provides in part: 
 FFECTS 
• Eyes tear up and close involuntarily 
•  causes inflammation f the res irat r  tract 
• Inflammation auses c i , ga ing   loss f breath 
s s ion 
• he s in ose  to  a  ls  beco e infla e   ill m 
• ling   d the , s   t  
• he s  ill ru   roduce ces ive c s 
(Ex. "K" (Dep. Ex. 35, I.D.C. Records 000053).) 
. s part of their annual C training, I C correctional officers, including ajor, 
were ad inistered written tests. (Burke Aff. '11'113,   -1 , . "B" (Kimme  . 9:17-
21:1; 21:3-22:17), Ex. "F" (Overgaard ep. 114:1-115:3; ep. Ex. 28), Ex. "L" (Dep. Ex. 25), 
Ex. "M" (Dep. Ex. 26), Ex. "N" (Dep. Ex. 28).) 
. ajor's test results for the 08120104  training are reflected in x. "L" (Dep. 
Ex. 25). (Burke ff. '11'113 and 13, Ex. "B" (Kimmel ep. 19:17-21:1; Ex "L" (Dep. Ex. 25).) 
Question 14 of that test, and ajor's correct answer, state: 
(Id.) 
. t  t   i ti t i l t   t i t  it  
? 
. acial burning, eye closure, respiratory 
. ajor's test results for the 02114/07 C training are reflected in Ex. "M" ( ep. 
Ex. 26). (Burke Aff. '11'113 a  4, x. "B" (Kim el ep. 9:17-21:12 :3-22:17), x. "M" ( e . 
Ex. 26).) Question 12 of that test, and Major's correct answer, state: 
2. t r  t  ysi l i l ff ts f C? 
. edness of the eyes, running nose, shortness of breath. 
(Jd.) 
 I    EFENDANT'S  I  F  SUM  
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19 Majorstest results for the 038 OC training are reflected in ExN Dep
Ex 28 Burke Aff 3 7 and 15 Ex B Kimmel Dep 2112217 Ex FOvergaard
Dep 1141153Ex NDep Ex 28 Test question 9 and Majorscorrect answer state
9 The physiological affects of being sprayed with OC spray are
A Running nose with mucus discharge
B Eyes tear and involuntarily close
C Respiration of OC causes of inflammation of the respiratory tract
D All of the above
The bold of D indicates Major correct answer Id
20 During the time Major was employed by IDOC IDOC kept and maintained as
part of its business records Material Safety Data Sheets MSDS for the SEC Sabre Red and
Defense Technologies First Defense OC pepper spray products purchased and used by IDOC in
order to identify hazards for health reactivity and fire Burke Aff 3 and 16 Ex B
Kimmel Dep 10151048 Ex O Dep Ex 32 A true and accurate copy of the SEC
Sabre Red MSDS is contained within Ex O Dep Ex 32 Bates IDCRecords 0004647
That MSDS provides in part
SECTION 6 HEALTH HAZARDS
Signs and symptoms of exposure Ingredients cause irritation through all routes
of entry Repeated contact may cause dermatitis Ingestion may cause nausea
vomiting andor diarrhea
Medical conditions aggravated by exposure May cause more severe temporary
effects on those persons who are asthmatics or suffer from emphysema
Emergency and first aid procedures Remove victim from contaminated area and
remove contaminated clothing Provide fresh air irrigate with copious amounts
of cool water Obtain medical advice is sic symptoms persist
1 Inhalation Provide fresh air
Id
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. ajor's t t r lts f r t  3/0 /08  tr i i  r  r fl t  i  x. "N" (De . 
Ex. 28). (Burke Aff. ~~ ,  a  , x. "B" (Kim el e . 1:1- 2:17), x. "F" (Overgaar  
ep. 114:1-115:3), x. "N" (Dep. x. 28).) est question 9, and ajor's correct ans er, state: 
.  si l i l ff ts f i  s r  it   s r  r : 
. unning nose ith ucus discharge 
. yes tear and involuntarily close 
. i ti      i la ti   t  i t  t t 
.     
[The l  f  i icates jor's rr t swer.] (J .) 
0. ri  t e ti e aj r as e l e   I , I  e t a  ai tai e  as 
part of its business records aterial Safety ata Sheets ("MSDS")       
efe se ec l ies irst efe se  e er s ra  r cts rc ase  a  se   I  i  
order to identify hazards for health, reactivity and fire. (Burke ff. ~~   , x. "B" 
(Kimmel ep. 101:15-104:18); Ex. "0" (Dep. Ex. 32).)  true and accurate copy of the SE  
Sabre Red S S is contained ithin Ex. "0" (Dep. Ex. 32, Bates I.D.C. Records 00046-47). 
at  r ides i  art: 
(Jd.) 
  -  S 
Signs and sy pto s of exposure: Ingredients cause irritation through all routes 
of entry. Repeated contact ay cause der atitis. Ingestion ay cause nausea, 
vo iting and/or diarrhea. 
edical conditions aggravated by exposure: ay cause ore severe, te porary 
effects on those persons ho are asth atics or suffer fro  e physema. 
Emergency and first aid procedures: Remove victim from contaminated area and 
r  t i ate  l t i g. r i  fr  ir, irrigat  it  i  t  
of cool ater. btain edical advice is (sic) sy pto s persist. 
. l ti n:    
    ENDANT'S     
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21 The affects of OC pepper spray exposure to individuals are acute transient
reversible and recoverable within a short period of time typically wearing off within minutes
Burke Aff 3 and 68 Ex B Kimmel Dep 36133725 Ex E Schaffer Dep 35
376Ex F Overgaard Dep 5113 564Ex G Doan Dep 2517266Reilly Aff 7
Nance Aff 2 The affects include mucous production redness of the eyes watery eyes or
crying involuntary closing of the eyes burning sensation of the skin such as a sunburn
inflammation of the skin sneezing and coughing and slightly restricted airways Id Complete
recovery from respiratory symptoms occurs within no longer than thirty sixty 3060 minutes
Id OC sprays are designed and intended to have theses acute effects as they are made for self
defense and protection and are used by law enforcement officers to subdue criminal suspects
and inmates without the need for more lethal forms of force Id Major was aware of the acute
affects of OC exposure having experienced them at least four 4 times in annual OC trainings
between 2004 and 2007 prior to her 038 OC training Burke Aff 2 Ex A Major
Dep 921010125 11291194
D OC Spray Generally Notice ofHazard
22 The manufacture and sale of OC spray is regulated by the United States
Consumer Product Safety Commission under the Federal Hazardous Substances Act as a self
pressurized irritant Nance Aff 6
23 There is no published literature that definitively states or otherwise establishes
within a reasonable degree of scientific probability a conclusive or casual association between
exposure to OC spray and chronic or long term health conditions or disease Reilly Aff 37
Nance Aff 817 Aff Counsel 10 and 11 Ex I 9411953and Ex J 12891314
24 Based upon available scientific and medical literature published prior to 2008 a
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. he fects f  e per s ra  os re to in ividuals e t , t i t, 
re ersi le a d rec era le ithin a s rt eriod f ti e, t icall  eari  ff ithin i tes. 
(Burke Aff. ~~  d -8, . "B" (Kimme  . 6:13- 7:25), . "E" (Scha fer . 5:3-
37:6), Ex. "F" (Overgaard ep. 51: 13-56:4), Ex. "G" (Doan ep. 25: 17-26:6); eilly ff. ~ ; 
ance ff. ~ 2.) The affects include ucous production, redness of the eyes, watery eyes or 
crying, involuntary closing f the eyes, burning sensation f the skin (such as a sunburn), 
infla ation ft e s i , i   i ,  li tl  r tricte  ir . (ld) lete 
recovery fro  respiratory sy pto s occurs within no longer than thirty-sixty (30-60) inutes. 
(Id.)  sprays are designed and intended to have theses acute effects as they are ade for self 
defense and protection, and are used by la  enforce ent officers to subdue cri inal suspects 
and in ates ithout the need for ore lethal for s f force. (Id.) ajor as a are f the acute 
affects of  exposure, having experienced the  at least four (4) ti es in annual  trainings 
bet een 2004 and 2007, prior to her 03/03/08  training. (Burke ff. ~ , x. "A" (Major 
ep. 92:10-101:25; 112:19-119:14).) 
.  ray e erally -    
2. e a fact re a  sale f  s ra  is re late   t e ite  tates 
onsu er Product Safety o ission under the Federal azardous Substances ct as a "self-
pressurized irritant." (Nance Aff. ~ 6.) 
3. here is no published literature that definitively states or other ise establishes 
within a reasonable degree of scientific probability a conclusive or casual association between 
exposure to C spray and chronic or long ter  health conditions or disease. (Reilly ff. ~~ -7; 
 f . ~~ -1 ; ff. l ~~   1, x. I, 4:11-95:3  x. , 28:9-131:4.) 
4. ased upon available scientific and edical literature published prior to 2008, a 
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manufacturer of OC spray products such as SEC could not know or have been put on notice that
exposure to OC spray was a foreseeable cause of any of the chronic medical conditions
complained of by Plaintiff Reilly Aff 10 Aff Counsel 10 Ex I 14421467
III LEGAL STANDARD
Summary judgment is appropriate if the pleadings depositions and admissions on file
together with the affidavits if any show that there is no genuine issue as to any material fact and
that the moving party is entitled to a judgment as a matter of lawIRCP56c Only
disputes over facts that might affect the outcome of the suit under the governing law will
properly preclude the entry of summary judgment Factual disputes that are irrelevant or
unnecessary will not be counted Anderson v Liberty Lobby Inc 477 US242 1986 citing
10A C Wright A Miller M Kane Federal Practice and Procedure 2725 pp 9395
1983 When a motion for summary judgment has been supported by depositions affidavits or
other evidence the adverse party may not rest upon the mere allegations or denials of that
partys pleadings but the partys response by affidavits or as otherwise provided in this rule
must set forth specific facts showing that there is a genuine issue for trial IRCP56e see
also Gardner v Evans 110 Idaho 925 929 719P2d 1185 1189 1986
The party seeking summary judgment bears the initial burden to show that there is no
genuine issue of material fact and that he or she is entitled to judgment as a matter of law
McCorkle v Northwestern Mut Life Ins Co 141 Idaho 550 554 112 P3d 838 842 CtApp
2005 The movant may meet this burden by establishing the absence of evidence on an element
that the nonmoving party will be required to prove at trial Dunnick v Elder 126 Idaho 308
311 882 P2d 475 478 CtApp 1994 This may be accomplished either by an affirmative
showing with the moving partysown evidence or by a review ofthe nonmovantsevidence and
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anufacturer of OC spray products, such as SEC, could not know or have been put on notice that 
exposure to OC spray was a foreseeable cause of any of the chronic medical conditions 
complained of by Plaintiff. (Reilly Aff. ~IO; Aff. Counsel ~ 1 , . I, 44:2- 46:7.) 
I . E   
Summary judgment is appropriate "if the pleadings, depositions, and admissions on file, 
together with the affidavits, if any, show that there is no genuine issue as to any material fact and 
that the oving party is entitled to a judg ent as a atter of law." .R.c.P. 6(c). "Onl  
disputes over facts that might affect the outcome of the suit under the governing law will 
properly preclude the entry of summary judgment. Factual disputes that are irrelevant or 
unnecessary will not be counted." Anderson v. Liberty Lobby, Inc., 477 U.S. 242 (1986) (citing 
lOA C. Wright, A. Miller, & . a e, e eral ractice a  r ce re § , . -95 
(1983)). When a motion for summary judgment has been supported by depositions, affidavits or 
other evidence, the adverse party "may not rest upon the ere allegations or denials of that 
party's pleadings, but the party's response, by affidavits or as otherwise provided in this rule, 
must set forth specific facts showing that there is a genuine issue for trial." I.R.C.P. 56(e); see 
ls  r er v. v s,  I a  , 9,  .2d ,  (1 86). 
The party seeking summary judgment bears the initial burden to show that there is no 
genuine issue of material fact, and that he or she is entitled to judgment as a matter of law. 
cCorkle v. Northwestern ut. Life Ins. Co., 141 Idaho 550, 554, 112 P.3d 838, 842 (CLApp. 
2005). The movant may meet this burden by establishing the absence of evidence on an element 
that the nonmoving party will be required to prove at trial. Dunnick v. Elder, 126 Idaho 308, 
311, 882 P.2d 475, 478 (Ct.App. 1994). his ay be acco plished either by an affir ative 
sho ing ith the oving party's o n evidence or by a revie  of the non- ovant's evidence and 
E R  I  SUPPORT F EFENDANT'S SECOND TI  FOR SUMMARY 
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the contention that the required proof of an element is lacking Heath v HonkersMiniMart
Inc 134 Idaho 711 712 8 P3d 1254 1255 CtApp 2000 Once such an absence of evidence
has been demonstrated the burden shifts to the opposing party to show through further
depositions discovery responses or affidavits that there is indeed a genuine issue for trial Id
In a products liability action the standard on summary judgment is well settled
To prevail over a defendants motion for summary judgment a
plaintiff who alleges product liability based on either negligence or
strict liability must establish that there are material issues of fact as
to 1 injury 2 whether the injury was proximately caused by a
defect and 3 whether the defect existed at the time the product
left the control of the manufacturer
Tuttle v Sudenga Indus Inc 125 Idaho 145 14950 868 P2d 473 47778 1994 citing
Corbridge v Clark Equip Co 112 Idaho 85 87 730 P2d 1005 1007 Farmer v International
Harvester Co 97 Idaho 742 74647 553 P2d 1306 131011 1976
A plaintiff who produces a mere scintilla of evidence or otherwise
raises only a slight doubt as to these facts will not withstand
summary judgment rather the plaintiff must respond to the
summary judgment motion with specific facts showing there is a
genuine issue for trial
Id at 150 citingIRCP56eCorbridge 112 Idaho at 87
IV ARGUMENT
As this Court has previously determined that the FHSA is the proper legislative
pronouncement of the labeling requirements applicable to SECs OC spray the questions
pertinent to this motion are
A Whether Plaintiffmay assert a cause of action under the FHSA
B Whether Plaintiffmay support a state law cause of action under a theory of negligence
or strict liability for an alleged violation of the FHSA and
CWhether Plaintiff may support a state law cause of action under a theory of negligence
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the contention that the required proof of an ele ent is lacking. eath v. onker's ini-Mart, 
Inc., 134 Idaho 711, 712, 8 P.3d 1254, 1255 (Ct.App. 2000). nce such an absence of evidence 
has been de strate , t e burden s ifts to the pposing party to s  t rough further 
depositions, discovery responses, or affidavits that there is indeed a genuine issue for trial. Id. 
In a products liability action, the standard on su ary judgment is ell-settled: 
o prevail over a defendant's otion for su ary judg ent, a 
plaintiff who alleges product liability based on either negligence or 
strict liability ust establish that there are aterial issues of fact as 
to (1) injury, (2) hether the injury as proxi ately caused by a 
efect, a  (3) hether t e efect e iste  at t e ti e t e r ct 
t  l   r. 
Tuttle v. Sudenga Indus., Inc., 125 Idaho 145, 149-50, 868 P.2d 473, 477-78 (1994) (citing 
Corbridge v. Clark Equip. Co., 112 Idaho 85, 87, 730 P.2d 1005, 1007; Far er v. International 
arvester o., 97 Idaho 742, 746-47,553 .2d 1306,1310-11 (1976)). 
 plaintiff ho produces a ere scintilla of evidence, or other ise 
raises only a slight doubt as to these facts, ill not ithstand 
su ary judg ent; rather, the plaintiff ust respond to the 
su ary judg ent otion ith specific facts sho ing there is a 
genuine issue for trial. 
!d. at 150 (citing LR.C.P. 56(e); Corbridge, 112 Idaho at 87). 
.  
s this ourt has previously deter ined that the F S  is the proper legislative 
pronouncement of the labeling requirements applicable to SEC's OC spray, the questions 
pertinent to this motion are: 
) hether Plaintiff ay assert a cause of action under the F SA; 
B) hether Plaintiff ay support a state law cause of action under a theory of negligence 
or strict liability for an alleged violation of the F SA; and 
C) hether Plaintiff may support a state law cause of action under a theory of negligence 
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per se for an alleged violation of the FHSA
A The FHSA Provides No Private Right Of Action
There is no express private right of action conferred by either the text of the FHSA 15
USC 1261 et seq or by the regulations governing the FHSA 16USC 1500 et seq As
such whether a private right of action should be implied is determined by analyzing the criteria
set forth in Cort v Ash 422US66 78 1975
First is the plaintiff one of the class for whose especial benefit
the statute was enacted that is does the statute create a federal
right in favor of the plaintiff Second is there any indication of
legislative intent explicit or implicit either to create such a
remedy or to deny one Third is it consistent with the underlying
purposes of the legislative scheme to imply such a remedy for the
plaintiff And finally is the cause of action one traditionally
relegated to state law in an area basically the concern of the States
so that it would be inappropriate to infer a cause of action based
solely on federal law
Riegel Textile Corp v Celanese Corp 649F2d 894 897 2d Cir 1981 citing Cort 422US
at 78 In applying the Cort analysis courts should be reluctant to imply private rights of
action Riegel 649 F2d at 897 citations omitted Furthermore the Cort factors are not
necessarily to be accorded equal weight Id Rather the central inquiry remains whether
Congress intended to create either expressly or by implication a private cause of action
Touche Ross Co v Redington 442US 560 575 1979
Applying the Cort factors courts addressing the question of whether a private right of
action exists under the FHSA have uniformly rejected that contention instead deferring to state
law causes of action which may only be premised on the standards promulgated under the
FHSA See In re Mattel Inc 588 F Supp 2d 1111 CDCal 2008 Milanese v RustOleum
Corp 244 F3d 104 110 2d Cir 2001 Pennsylvania Gen Ins Co v Landis 96 F Supp 2d
408DNJ2000 affd 248F3d 1131 3d Cir 2000 The FHSA does not provide a private
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    ll  i l ti   t  . 
. e  ide   ivate i t f ti n. 
here is no express private right f action conferred by either the text f the , 15 
.S.C. § 1261, et seq., or by the regulations governing the F S , 16 .S.C. § 0,  q.  
s h, t r  ri ate ri t f ti  s l   i lie  is t r i   l i  t  rit ri  
    . ,  .S. ,  (1 5): 
ir t, i  t  l i tiff "one f t  lass f r  i l fit 
   acted,"  ,       
ri t i  f r f t  l intiff? , is t r   i i ti  f 
l isl ti  i t t, li it r i li it, it r t  r t  s   
re e  r t  e  e? ir , is it c siste t it  t e erl i  
purposes of the legislative sche e to i ply such a re edy for the 
plaintiff? nd finally, is the cause of action one traditionally 
r l t  t  st t  l , i   r  si ll  t  r  f t  t t s, 
s  t at it l  e i a r riate t  i fer a ca se f acti  ase  
s lel   fe eral la ? 
Riegel Textile orp. v. elanese orp., 649 F.2d 894,897 (2d ir. 1981) (citing ort, 422 .S. 
at 78). I  l i  t  rt l sis, "courts s l   r l t t t  i l  ri ate ri ts f 
action." Riegel, 649 F.2d at 897 (citations o itted). Further ore, "[t]he Cort factors are not 
necessarily to be accorded equal eight." Id. ather, "[t]he central inquiry re ains hether 
Congress intended to create, either expressly or by i plication, a private cause of action." 
  & Co. v. Redington, 442 U.S. 560, 575 (1979). 
pplying the ort factors, courts addressing the question of hether a private right of 
action exists under the F S  have unifor ly rejected that contention, instead deferring to state 
la  causes of action (which ay only be pre ised on the standards pro ulgated under the 
SA). ee I  re ttei, I c.,  . .   (C.D. al. 08); ilanese v. st-Oleu  
orp., 244 F.3d 104, 110 (2d ir. 2001); ennsylvania en. Ins. o. v. Landis, 96 F. Supp. 2d 
408 (D.N.J. 2000) aff'd, 248 F .3d 1131 (3d Cir. 2000) ("[T]he FHSA does not provide a private 
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judicial remedy to a party injured by the introduction of a misbranded hazardous substance into
the stream of commerce Christenson v St MarysHospital et al 835FSupp 498DMinn
1993 Palmer v Liggett Group Inc et al 635FSupp 392DMass 1984 Riegel 649 F2d
894 2d Cir 1981 Wallace v Parks Corp et al 629NYS2d570NYApp Div 1995
For these reasons SEC contends that this Court should similarly find that no private right
of action exists under the FHSA Thus the remaining questions concern whether Plaintiff can
support a state law cause ofaction for inadequate warning
B Plaintiff Cannot Establish The Requisite Duty Under Theories Of Either Negligence
Or Strict Liability
Without a specific right of action under the FHSA Plaintiff is confined to general
theories of Negligence and Strict Liability under Idaho law utilizing the FHSA merely as
evidence of an allegedly inadequate warning Accord Milanese v RustOleum Corp 244 F3d
104 110 2d Cir 2001 Although there is no federal private right of action under the FHSA
Riegel Textile Corp v Celanese Corp 649 F2d 894 903 2d Cir 1981 a state negligence
claim lies for failure to comply with the federal FHSA mandated labeling requirements In
such an instance Plaintiff must be able to establish each element of a cause of action for
Negligence or Strict Liability including that SEC had a duty to warn of the risk of the specific
2 It should be further noted that as pled Plaintiffscause of action for inadequate warning is
inconsistent with the standards required by the FHSA Plaintiffs Complaint includes three 3 sentences
that begin with the phrase Said warnings should have consisted of all three of which suggest a warning
label that is inconsistent with the requirements ofthe FHSA Compare Complaint 19 with 15USC
1261pWhile a state law cause of action for failure to comply with the FHSA may be permissible
the FHSA preempts any state cause of action that seeks to impose a labeling requirement different from
the requirements found in the FHSA and the regulations promulgated thereunder Milanese v Rust
Oleum Corp 244 F3d 104 109 2d Cir 2001 As pled then Plaintiffs Complaint is actually still
preempted by the FHSA See Leibstein v LaFarge N Am Inc 689 F Supp 2d 373 381EDNY
2010Insofar as the Complaint is read to impose labeling requirements that are not identical to
the FHSA requirements such causes of action are preempted by the FHSA Regardless of the
deficiencies in Plaintiffs Complaint in this regard however for all of the reasons stated herein even a
properly pled or amended complaint under the facts of this case could not survive summary judgment
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ju icial re e  t  a art  i jure   t e introd ction f a is ra e  azar s s sta ce i t  
   ."); hristenson v. St. ary's ospital, et. ai., 835 .Supp. 498 (D.Minn. 
93); l  . i tt , I c., t. l.,  .Sup .  (D.Mass. 84); i l,  .2d 
 (2d ir. 81); llace v. rks orp., et. l.,  .Y.S.2d  (N.Y. . i . 95). 
F or these reasons, S  contends that this ourt should si ilarly find that no private right 
f ti  ists r t  . , t  r i i  ti ns r  t r l i tiff  
support a state la  cause of action for inadequate arning. 2 
. Plaintiff annot stablish he equisite uty nder heories f ither egligence 
r trict ia ility. 
it t a s ecific ri t f acti  er t e , lai tiff is c fi e  t  e eral 
t e ries f e lige ce a  trict ia ilit  er I a  la , tilizin  t e  erel  as 
evidence of an allegedly inadequate arning. ccord ilanese v. ust-Oleu  orp., 244 F.3d 
,  (2d ir. 1) ("Althoug  t r  is  f r l ri ate ri t f ti  r t  , 
ie el extile rp. v. el ese rp.,  .2d ,  (2  ir. 981), a state e li e ce 
clai  lies for failure to co ply ith the federal, F S - andated labeling require ents."). I  
  , i ti        l        
egligence or Strict iability, including that S  had a duty to arn of the risk of the specific 
2 It should be further noted that, as pled, Plaintiffs cause of action for inadequate arning is 
inconsistent ith the standards required by the F SA. Plaintiffs o plaint includes three (3) sentences 
t at e i  it  t e rase, "Said ar i s s l  a e c siste  f," all t ree f ic  s est a ar i  
label that is inconsistent ith the require ents f the A. (Compare o plaint, ~  it  IS .S.c. § 
1261(p)(I).) hile a state la  cause of action for failure to co ply ith the F S  ay be per issible. 
"the  ree ts a  state ca se f acti  t at see s t  i ose a la eli  re ire e t iffere t fr  
the require ents found in the F S  and the regulations pro ulgated thereunder." ilanese v. ust-
leu  Corp., 244 F.3d 104, 109 (2d Cir. 2001). s pled, then, Plaintiffs Co plaint is actually still 
preempted by the FHSA. See Leibstein v. LaFarge N Am. Inc., 689 F. Supp. 2d 373, 381 (E.D.N.Y. 
2010) ("[I]nsofar as the Co plaint is read to [ ... ] i pose labeling require ents that are not identical to 
the  require ents, [ ... ] such causes f action are pree pted by the .") egardless f the 
deficiencies in Plaintiffs o plaint in this regard, ho ever, for all of the reasons stated herein, even a 
properly pled or amended complaint under the facts of this case could not survive summary judgment. 
    FENDANT'S     
JUDG ENT-Page 15 -  (4 3122.doc) 
injuries complained of See Puckett v Oakfabco Inc 132 Idaho 816 823 quoting Rindlisbaker
v Wilson 95 Idaho 752 519 P2d 421 1974 and Restatement Second of Torts 402A cmt
h As noted above factual disputes that are irrelevant or unnecessary will not be counted
Anderson v Liberty Lobby Inc 477US 242 1986 Thus evidence that SEC knew or should
have known or that SEC was obligated to andor did not warn of risks of acute respiratory
health effects is irrelevant and insufficient to withstand summary judgment
As this Court has previously determined that there can be no duty imputed to a defendant
in a products liability suit where the risk of the plaintiffsalleged injuries was neither known nor
foreseeable at the time the product was sold the same reasoning precludes any attempt by
Plaintiff to resurrect a Negligence or Strict Liability claim utilizing the FHSA Nothing in the
FHSA supplants the general tenet of Idaho law already addressed and confirmed by this Court
that a duty to warn does not arise unless the risk of harm is known or foreseeable See
Restatement Second of Torts 388 This Court has already analyzed the evidence submitted
by Plaintiff attempting to suggest that SEC knew or should have known of potential longterm
chronic adverse health effects associated with exposure to OC spray and has rejected the
contention that SEC had a duty to warn on that basis In line with the Courtsprevious rulings
then Plaintiff still cannot sustain a cause of action for Negligence or Strict Liability based on an
alleged violation of the FHSA because SEC neither knew nor should have known that exposure
During oral argument on the initial motions for summary judgment heard by this Court SEC
argued and this Court agreed that it is possible to conceive of a warning against the known acute
adverse health effects of exposure to OC spray but that such an exercise would have no bearing on the
outcome of this case At its most fundamental level PlaintiffsComplaint asserts that SEC should have
warned against a chronic adverse health effect that was neither known nor foreseeable at the time it sold
the product to which Plaintiffwas ultimately exposed
4 Because SEC has previously briefed at length Idaho and hornbook law on when a duty to warn
will arise and has presented evidence that such a duty did not arise in this instance and in the interest of
brevity SEC incorporates those arguments and that evidence herein by reference See SECs
Memorandum in Support of its original Motion for Summary Judgment filed April 22 2011
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injuries co plained of. See uckett v. akfabco, Inc., 132 Idaho 816,823 (quoting indlisbaker 
. il n,  I  ,  .2d  (1 4),  t t t (S nd)  rt  § 2A, t. 
). s te  a e, "[fJact al is tes t at are irrele a t r ecessar  ill t e c unted." 
nderson v. iberty obby, Inc., 477 .S. 242 (1986). hus, evidence that  kne  or should 
have kno n, or that SE  as obligated to andlor did not arn, of risks of acute respiratory 
lt  ff ts, is irrele a t  i s ffi ie t t  it st  s r  j ent.3 
s t is rt as re i sl  eter i e  t at t ere ca  e  t  i te  t  a efe a t 
in a products liability suit here the risk of the plaintiffs alleged injuries as neither kno n nor 
f reseea le at t e ti e t e r ct as s l , t e sa e reas i  recl es a  atte t  
Plaintiff to resurrect a egligence or Strict Liability clai  utilizing the F S .4 othing in the 
 s la ts t  r l t t f I  l , lr  r ss   fir e   t is urt, 
t at a t  t  ar  es t arise less t e ris  f ar  is  r f reseeable.  
estate ent (Second) of orts § 388. his ourt has already analyzed the evidence sub itted 
by Plaintiff, atte pting to suggest that SEC kne  or should have kno n of potential long-ter , 
chronic adverse health effects associated with exposure to OC spray, and has rejected the 
contention that SEC had a duty to arn on that basis. In line ith the Court's previous rulings, 
then, Plaintiff still cannot sustain a cause of action for egligence or Strict Liability based on an 
alleged violation of the F S , because SEC neither kne  nor should have kno n that exposure 
3 ri  r l r t  t  i iti l ti s f r s r  j t r   t is rt,  
ar e , a  t is rt a ree , t at it is ssi le t  c cei e f a ar i  a ai st t e n, ac te 
erse lt  ffe ts  re t   r y, t t t   r is  l    ri   t  
outco e of this case. t its ost funda ental level, Plaintiffs Co plaint asserts that SEC should have 
arned against a chronic adverse health effect that as neither kno n nor foreseeable at the ti e it sold 
the product to hich Plaintiff as ulti ately exposed. 
4 s    r i l  ri f  t l t  I   r  l     t  t  r  
ill arise, and has presented evidence that such a duty did not arise in this instance, and in the interest of 
brevity, S  incorporates those argu ents and that evidence herein by reference. (  EC's 
e orandu  in Support of its original otion for Su ary Judg ent, filed pril 22, 2011.) 
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to its OC spray products would cause any longterm chronic adverse health conditions of the
type of which Plaintiff complains SEC is therefore entitled to judgment as a matter of law on
PlaintiffsNegligence and Strict Liability claims for the same reasons previously cited by the
Court in granting Summary Judgment to SEC with respect to alleged OSHA violations
C Plaintiff Cannot Support A Cause Of Action For Negligence Per Se
Plaintiff has not asserted anything in her pleadings that would suggest she is pursuing an
action for Negligence Per Se based on alleged violations of FHSA requirements Nevertheless
SEC anticipates that she may assert such a theory in an effort to avoid the fact that she cannot
otherwise establish a duty to warn of longterm chronic adverse health effects based on the then
existing scientific knowledge andor literature
Negligence per se which results from the violation of a specific requirement of law or
ordinance is a question of law Obendorfv Terra Hug Spray Co Inc 145 Idaho 892
897 188 P3d 834 839 2008 citingOGuin v Bingham County 142 Idaho 49 51 122 P 3d
308 310 2005
In order to replace a common law duty of care with a duty of care
from a statute or regulation the following elements must be met
1 the statute or regulation must clearly define the required
standard of conduct 2 the statute or regulation must have been
intended to prevent the type of harm the defendantsact or
omission caused 3 the plaintiff must be a member of the class of
persons the statute or regulation was designed to protect and 4
the violation must have been the proximate cause of the injury
Id As Plaintiff cannot establish as a matter of law the first and fourth requirements for a claim
of negligence per se SEC is entitled to summary judgment on Plaintiffsonly remaining claim
1 The FHSA does not clearly define the required standard of conduct as it
relates to Plaintiffs allegations
The FHSA sets forth the following requirements for labeling hazardous substances
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t  its  r  r ts l    l -ter , r i  r  lt  iti s f t  
type of which Plaintiff co plains. SEC is therefore entitled to judg ent as a atter of law on 
l intiffs lige   tri t i ilit  l i , f r t   r  r i l  it   t  
rt i  ra ti  ar  J e t t   it  res ect t  alle e   i lati s. 
. l i tiff t rt  a se f cti  r e ligence r e. 
laintiff has not asserted anything in her pleadings that ould suggest she is pursuing an 
action for egligence Per Se based on alleged violations of F S  require ents. evertheless, 
 anticipates that she ay assert such a theory in an effort to avoid the fact that she cannot 
other ise establish a duty to arn of long-ter , chronic adverse health effects based on the then-
e isti  scie tific le e a /or literat re. 
"Negligence per se, hich results fro  the violation of a specific require ent of la  or 
r i a ce, is a esti  f la  .... " bendorfv. Terra ug Spray Co., Inc., 145 Idaho 892, 
897, 188 P.3d 834,839 (2008) (citing 'Guin v. ingha  ounty, 142 Idaho 49,51, 122 P 3d 
,  (2 05)). 
I  r er t  re lace a c  la  t  f care it  a t  f care 
fro  a statute or regulation, the follo ing ele ents ust be et: 
(1) the statute or regulation ust clearly define the required 
t r  f uct; (2) t  t t t  r r l ti  t   
intended to prevent the type of har  the defendant's act or 
issi  s d; (3) t  l i tiff st   r f t  l ss f 
persons the statute or regulation was designed to protect; and (4) 
the violation ust have been the proxi ate cause of the injury. 
I . s l i tiff t st blish, s  tt r f l , t  first  f rt  r ir ts f r  l i  
of negligence per se, SEC is entitled to su ary judg ent on Plaintiffs only re aining clai . 
. e   t l l  i  t  i  t   t  it 
relates to Plaintiff's allegations. 
he  sets forth the follo ing require ents for labeling hazardous substances: 
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A the name and place of business of the manufacturer packer
distributor or seller B the common or usual name or the
chemical name if there be no common or usual name of the
hazardous substance or of each component which contributes
substantially to its hazard unless the Commission by regulation
permits or requires the use of a recognized generic name C the
signal word DANGER on substances which are extremely
flammable corrosive or highly toxic D the signal word
WARNING or CAUTION on all other hazardous substances
E an affirmative statement of the principal hazard or hazards
such as Flammable Combustible Vapor Harmful Causes
Burns Absorbed Through Skin or similar wording descriptive
of the hazard F precautionary measures describing the action to
be followed or avoided except when modified by regulation of the
Commission pursuant to section 1262 of this title G instruction
when necessary or appropriate for firstaid treatment H the word
poison for any hazardous substance which is defined as highly
toxic by subsection h of this section 1 instructions for
handling and storage of packages which require special care in
handling or storage and J the statement i Keep out of the
reach of children or its practical equivalent
15USCA 1261p Based on the argument previously set forth in Plaintiffs Reply
memorandum on her Cross Motion for Summary Judgment SEC understands that Plaintiffs
contention is that SEC failed to comply with section E above However because section E is
extremely vague it fails to meet the requisite burden of clearly defining the required standard
of conduct sufficient to support a negligence per se claim
First a definition of principal hazard does not exist anywhere in the text or regulations
of the FHSA See 15USC 1261 et seq 16CFR1500 et seq What then distinguishes
a principal hazard from a secondary hazard such that a manufacturesduty to label would
arise under the FHSA This type of ambiguity is exactly the same type of statutory ambiguity
which led the Idaho Supreme Court to previously reject a similar negligence per se claim See
Ahles v Tabor 136 Idaho 393 34P3d 1076 2001 InAhles the court was faced with deciding
whether the language contained within IC 49633 set forth with sufficient clarity to sustain a
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(A) the name and place of business of the anufacturer, packer, 
distributor or seller; (B) the c on or s al a e or the 
che ical na e (if there be no co on or usual na e) of the 
hazardous substance r f ea  co ponent hich ibutes 
substantially to its hazard, unless the o ission by regulation 
permits or requires the use of a recognized generic name; (C) the 
signal ord "DANGER" on substances hich are extre ely 
fla l , c rr si , r ighly t i ; (D) the si al ord 
"WAR "  "CAUTI "  l t e  s s; 
(E) an affirmative state ent of the principal hazard or hazards, 
s  as "Flammable", "Combustible", "Vapor l", "Causes 
rns", "Absorbed Through Skin", r i ilar r in  ri ti e 
of the hazard; (F) precautionary easures describing the action to 
e f llowed r i , ce t  ified  r l ti  f t  
Co ission pursuant to section 1262 of this title; (G) instruction, 
he  ecessar  r a r riate, f r first-aid treat ent; (H) t e r  
"poison" for any hazardous substance hich is defined as "highly 
toxic" by subsection (h) of this section; (I) instructions for 
handling and storage of packages hich require special care in 
handling or storage; and (J) the state ent (i) "Keep out f the 
reach f children" or its practical equivalent 
 .S.C.A. § 1261(p)(1). ased on the argu ent previously set forth in Plaintiffs eply 
r   r ross- ti  f r r  J nt,  rst s t t l i tiffs 
contention is that  failed to co ply ith section (E), above. o ever, because section (E) is 
extremely vague, it fails to meet the requisite burden of "clearly defin[ing] the required standard 
of conduct" sufficient to support a negligence per se clai . 
First, a definition of "principal hazard" does not exist any here in the text or regulations 
  A.   .S.C. § 1261, et seq.; 16 C.F.R. 1500.1 et seq. hat, then, distinguishes 
a "principal" hazard from a "secondary" hazard, such that a manufacture's duty to label would 
arise under the F SA? This type of a biguity is exactly the sa e type of statutory a biguity 
hich led the Idaho upre e ourt to previously reject a si ilar negligence per se clai . See 
l s v. abor,  I  3,  .3d  ( 01). I  l s, t  court s f  it  ci i  
whether the language contained within I.C. § -6  t f rth, it  uffi i t l rit  t  sustai   
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negligence per se claim the required standard of conduct for passing a slower vehicle on Idaho
roads Id at 396 In particular the statute utilizes two different terms highway and
roadway which carry conflicting definitions in other areas of Title 49 Id On that basis the
court found that the statute was too vague The standard of conduct described in IC 49633
however is far from clear and requires statutory interpretation including consideration of
problematic definitions of terms used in the statute Id With no clear definition of the material
terms the court concluded that liability in negligence per se cannot lie Id at 397 The court
remanded the case to the district court to determine anew the issue of Ahles negligence ie
whether Ahles conduct breached the standard of reasonable care under the circumstances Id
Here the Court does not have the benefit of any definition of principal hazard and is
confronted with even greater ambiguity than in Ahles Thus the same result should follow
Plaintiff cannot maintain a claim for negligence per se because the statute is too vague to provide
the requisite clarity under the first Obendorffactor
Moreover assuming arguendo that the known acute adverse respiratory health effects of
OC Spray do constitute a principal hazard under the FHSA the text of the statute is
nevertheless ambiguous as to what warning would be required to address those effects 6 As
quoted above the statute requires an affirmative statement of the principal hazard or hazards
such as Flammable Combustible Vapor Harmful Causes Burns Absorbed Through
Skin or similar wording descriptive of the hazard 15USC 1261pEemphasis
5 Unlike the Ahles court this Court need not allow a general negligence claim to proceed as that
issue has already been briefed extensively and this Court has already decided that Plaintiff cannot
establish that a duty existed to warn against unknown and or unforeseeable chronic health effects
6 To be clear whether the known acute respiratory health effects of OC Spray constitute a
principal hazard of the product and whether that question is a question of fact for the jury is irrelevant
for purposes of this motion The threshold inquiry at hand which must be addressed as a matter of law
before Plaintiff is even permitted to take a negligence per se case before a jury is whether the FHSA
unambiguously defines the standard ofconduct required of SEC Obendorf 145 Idaho at 897
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negligence per se claim, the required standard of conduct for passing a slower vehicle on Idaho 
roa s. ! . at 39 . In particular, the statute utilizes two different ter s, "highway" and 
"roadway", which carry conflicting definitions in other areas of Title 49. Id. On that basis, the 
court found that the statute was too va : "The standard f conduct e ribed in I.C. § 49-63 , 
however, is far from clear and requires statutory interpretation including consideration of 
problematic definitions of terms used in the statute." Id. With no clear definition of the material 
terms, the court concluded that liability in negligence per se cannot lie. Id. at 397. The court 
e a de  the ase to t e s ct rt "to ne   ss e  le ' , .e., 
hether le ' t re  t e t r  f rea le are r t  ir tances." I . 
Here, the Court does not have the benefit of any definition of "principal hazard", and is 
confronted ith even greater a biguity than in hles. ,     : 
Plaintiff cannot aintain a c1ai  for negligence per se because the statute is too vague to provide 
the requisite clarity under the first Obendorf factor. 5 
oreover, assuming arguendo that the known, acute adverse respiratory health effects of 
OC Spray do constitute a "principal hazard" under the FHSA, the text of the statute is 
nevertheless ambiguous as to what warning would be required to address those effects. 6 As 
quoted above, the statute requires "an affirmative statement of the principal hazard or hazards, 
s c  as "Fla a le", "Co b ", "Vapor Har ful", "Ca s  ms", "Absor   
ki ", or si ilar ording descriptive f the hazard."  .S.C. § 261(p)(1)(E) ( i  
5 nlike the hles court, this ourt need not allo  a general negligence clai  to proceed, as that 
issue has already been briefed extensively and this Court has already decided that Plaintiff cannot 
establish that a duty existed to arn against unknown and/or unforeseeable chronic health effects. 
6   clear, t r t  nown, acute r spiratory health eff ts of  Spray constit t  a 
principal hazard of the product, and whether that question is a question of fact for the jury, is irrelevant 
for purposes of this motion. The threshold inquiry at hand, which must be addressed as a matter of law 
before Plaintiff is even permitted to take a negligence per se case before a jury, is whether the FHSA 
unambiguously defines the standard of conduct required of SEC. Obendorf, 145 Idaho at 897. 
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added None of the suggested terminology of the statute is relevant here thus the proper
question is whether the phrase similar wording descriptive of the hazard is sufficiently
unambiguous to give rise to a duty under a negligence per se analysis
Notably again assuming only for the sake of argument that the temporary respiratory
effect of SECsOC spray is a principal hazard the FHSA labeling requirement is hazard
specific not organ specific Id The language suggested by the text of the statute itself
demonstrates this point the warning Vapor Harmful does not indicate what it is harmful to
Causes Burns does not indicate whether those burns may be to the eyes skin respiratory tract
or otherwise Accordingly labeling the product with the statement Causes Irritation or
Causes Inflammation may well suffice under the FHSA but such a warning would not comply
with the standards urged by Plaintiff to warn against longterm chronic effects Plaintiff s
claim is therefore problematic in two respects First Plaintiff seeks a finding of negligence per
se that imposes a burden greater than that which is required by the FHSA and thus her claim is
preempted second she seeks a finding of negligence per se that is premised on only one of many
plausible interpretations of the vague requirements of the FHSA thereby necessarily nullifying
any negligence per se argument For all of these reasons summary judgment is appropriate
More specifically the fact that SECsOC Spray may constitute an acute temporary
hazard to the respiratory tract does not give rise to a duty to warn against any possible andor
unknown chronic adverse effects on the respiratory tract Plaintiffs counsel admitted during
SECsproduct labels did warn that OC was an irritant See label 2d Burke Aff T 2 3 and
ExB attached The word irritant may by itself be sufficient to comply with the principal hazard
requirement of Section E of 15USC 1261p
8 As previously briefed in SECs Opposition to PlaintiffsCross Motion for Summary Judgment
pp 19 21 incorporated herein by reference the distinction between acute and chronic adverse health
effects implicates the second Obendorf factor in determining whether a finding of negligence per se is
appropriate Restated in brief Plaintiff cannot sustain a claim based on the contention that the statute was
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added). one f t  s gested t r i log  f the st t te is rele a t r ; t s, t  r r 
question is whether the phrase "similar wording descriptive of the hazard" is sufficiently 
una biguous to give rise to a duty under a negligence per se analysis. 
otably, again assu ing only for the sake of argu ent that the te porary respiratory 
effect f C's  spray is a "principal hazard", e     -
specific, not organ-specific. .  la guage este   t  t t  t e t t t , it lf, 
de onstrates this point: the arning "Vapor ar ful" does not indicate what it is har ful to; 
"Causes ms"  t icat  het e  s  m      , i , i t  ct, 
 . Accordingly, labeling the product with the state ent "Causes Irritation" or 
"Causes Inflammation" may well suffice under the FHSA, but such a warning would not comply 
ith the standards urged by Plaintiff to arn against long-ter , chronic effects. 7 lai tiff s 
clai  is therefore proble atic in t o respects: First, Plaintiff seeks a finding of negligence per 
se that i poses a burden greater than that hich is required by the , and thus her clai  is 
preempted; second, she seeks a finding of negligence per se that is premised on only one of many 
plausible interpretations of the vague requirements of the FHSA, thereby necessarily nullifying 
any negligence per se argu ent. For all of these reasons, su ary judg ent is appropriate. 
ore specifically, the fact that SEC's C Spray ay constitute an acute, te porary 
hazard to the respiratory tract does not give rise to a duty to warn against any possible (and/or 
unknown) chronic adverse effects on the respiratory tract.s Plaintiffs counsel admitted, during 
7 SEC's product labels did arn that  as an "irritant." (See label, 2d urke ff., ~~ 2-3 and 
Ex. "B" attached.) The word "irritant" may by itself be sufficient to comply with the "principal hazard" 
requirement of Section E of 15 U.S.C. § 1261(p)(1). 
8 As previously briefed in SEC's Opposition to Plaintiffs Cross- otion for Summary Judgment, 
pp. 19-21 (incorporated herein by reference), the distinction bet een acute and chronic adverse health 
effects implicates the second Obendorf factor in determining whether a finding of negligence per se is 
appropriate. Restated in brief, Plaintiff cannot sustain a claim based on the contention that the statute was 
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oral argument on July 14 2011 that a conclusive study establishing a causal association between
Plaintiffs exposure to OC spray and her alleged chronic condition does not exist As such a
warning that specifically warns only against the acute temporary effect such as Causes
Temporary Coughing or Temporary Respiratory Irritant may likely be sufficient under the
FHSA but would have no relevance to Plaintiffscomplaints of longterm chronic effects
Plaintiff simply cannot establish that the FHSA clearly defines a required standard of conduct
that is relevant to the injuries she has alleged thus a claim for negligence per se cannot stand
2 Any alleged FHSA violation was not the proximate cause of Plaintiffs injury
Finally no reasonable juror will be able to find that any alleged violation of the FHSA
proximately caused Plaintiffsalleged injuries In Idaho proximate cause is split into two
components
First there is actual cause and second there is true proximate
cause sometimes known as legal cause Munson v State Dept
of Highways 96 Idaho 529 531 531 P2d 1174 1176 1975
Sisters of the Holy Cross 126 Idaho at 103940 n 1 895 P2d at
123233 n 1 Actual cause is the factual question of whether a
particular event produced a particular consequence Sisters of the
Holy Cross 126 Idaho at 1039 40 n 1 895P2d at 1232 33 n 1
True proximate cause focuses upon legal policy in terms of
whether responsibility will be extended to the consequences of
conduct which has occurred
Newberry v Martens 142 Idaho 284 288 127 P3d 187 191 2005 When there are multiple
possible causes of an injury the defendantsconduct or omission amounts to proximate cause if
it was a substantial factor in bringing about the damage Id Further in a products liability
action the defect which makes the product unreasonably dangerous and allows the imposition
of liability without proof of fault must itself be the actual cause of the injury Nelson v
Brunswick Corp 503 F2d 376 379 9 Cir 1974 Thus if despite a deficient warning the
designed to prevent a type of harm that was not known or foreseeable the alleged chronic longterm
respiratory illness complained of in this litigation
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ral ar e t  J l  , , t at a c cl si e st  esta lis i  a ca sal ass ciati  et ee  
Plaintiff s exposure to  spray and her alleged chronic condition does not exist. s such, a 
arning that specifically arns only against the acute, te porary effect, such as "Causes 
e rar  i g" r "Temporary es irat r  Irrita t", a  li el  e s fficie t er t e 
 t l    l  t  laintif  s l i t   l -te , i  f ts. 
l i tiff si l  t st lis  t t t   l rl  fi s  r ir  st r  f t 
that is relevant to the injuries she has alleged; thus, a clai  for negligence per se cannot stand. 
. ny alleged  violation as not the proxi ate cause f lai tiffs injury. 
i lly,  r s le j r r ill  l  t  fi  t t  ll  i lati  f t   
proxi ately caused Plaintiffs alleged injuries. In Idaho, "proximate cause" is split into t o 
co ponents: 
irst there is actual cause, and second there is true proxi ate 
cause, so eti es kno n as "legal cause." unson v. State, ept. 
f igh ays, 96 Idaho 529, 531, 531 P.2d 1174, 1176 (1975); 
Sisters f the oly ross, 126 Idaho at 1039-40 n. 1, 895 P.2d at 
1232-33 n. 1. ctual cause is the factual question of hether a 
rti l r t r   rti l r s . isters f t e 
ly r ss,  I a  at -40 . ,  .2d at -3  . 1. 
rue proxi ate cause "focuses upon legal policy in ter s of 
hether responsibility ill be extended to the consequences of 
   cur ed." 
Newberry v. artens, 142 Idaho 284,288, 127 P.3d 187, 191 (2005). hen there are ultiple 
ssi le ca ses f a  i j r , t e efendant's c ct r issi  a ts t  r i ate ca se if 
"it as a substantial factor in bringing about the da age." Id. Further, in a products liability 
action, "the defect hich akes the product 'unreasonably dangerous' and allo s the i position 
of liability ithout proof of fault ust itself be the actual cause of the injury." l  . 
r s ick orp.,  .2d ,  (9th ir. 74). "Th s, if es ite a eficie t ar i  t e 
designed to prevent a type of harm that was not known or foreseeable - the alleged chronic, long-ter  
respiratory illness co plained of in this litigation. 
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user is fully aware of the danger of which a reasonable warning should apprise him then the
deficiency is not a cause of the ensuing accident Id
Based on the evidence of record SEC contends that no reasonable juror could determine
that SECs conduct in allegedly not complying with FHSA labeling standards with respect to its
OC products was a substantial factor leading to Plaintiffsalleged injuries Therefore this is a
legal cause issue which the Court can decide on summary judgment See Nelson v Brunswick
Corp 503 F2d 376 9 Cir 1974 Plaintiffstestimony makes manifest the conclusion that
he knew all that an adequate warning would tell him and that a cause of the explosion was not
his lack of appreciation of the danger
The Statement of Undisputed Facts SOF at the beginning of this memorandum
provides an accounting of Plaintiffsknowledge of and experience with how OC affects the
human body Much of Plaintiffs knowledge and experience was obtained prior to Plaintiff
having any exposure to OC manufactured by SEC SOF 411 Throughout the course of her
employment with various Idaho correctional institutions Plaintiff received a number of trainings
regarding the use and effects of OC Id As a part of the training Plaintiff was educated on the
use and effects of OC from the IDOC instructors that had received direct training from SEC
SOF 1315 The IDOC instructors that trained Plaintiff used both a training manual and a
PowerPoint presentation provided by SEC each of which identified the known acute adverse
respiratory effects of exposure to OC SOF 1415 As a part of her training through IDOC
Plaintiff was administered written tests on the use and effects of OC and through those tests
Plaintiff was able to correctly identify the known adverse respiratory effects of exposure to OC
SOF 1619 Also as a part of her training Plaintiff was exposed to OC and witnessed first
hand the respiratory effects ofOC exposure SOF 913
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user is fully a are of the danger of hich a reasonable arning should apprise hi , then the 
deficiency is not a cause of the ensuing accident." Id. 
ase   t e idence f ,  t s t at  l  juror ld t ine 
that SEC's conduct in allegedly not co plying ith F S  labeling standards ith respect to its 
C products as a substantial factor leading to Plaintiffs alleged injuries. Therefore, this is a 
legal cause issue which the Court can decide on summary judgment. See Nelson v. Brunswick 
Corp., 503 F.2d 376 (9th Cir. 1974) ("[Plaintiffs] testimony makes manifest the conclusion that 
he kne  all that an adequate arning ould tell hi  and that a cause of the explosion as not 
his lack of appreciation of the danger."). 
The State ent of ndisputed Facts ("SO ") at t e e i i  f t is e ra  
provides an accounting of Plaintiff s knowledge of and experience with how OC affects the 
hu an body. uch of laintiffs kno ledge and experience as obtained prior to laintiff 
having any exposure to  anufactured by SE . (S F #4-11.) Throughout the course of her 
e l e t it  ari s I a  c rrecti al i stit ti s, lai tiff recei e  a er f trai i s 
regarding the use and effects of ~C. (ld.) As a part of the training, Plaintiff was educated on the 
  ts      t rs t  i  i    EC. 
(SOF #13-15.) The IDOC instructors that trained Plaintiff used both a training manual and a 
PowerPoint presentation provided by SEC, each of which identified the known acute adverse 
respiratory effects of exposure to ~C. (S F #14-15.) s  rt f r tr i i  t r  I , 
Plaintiff as ad inistered ritten tests on the use and effects of ~C, and through those tests 
lai tiff as a le t  c rrectl  i e tif  t e  a erse res irat r  effects f e s re t  C. 
(S  #16-19.) lso as a part of her training, laintiff as exposed to  and itnessed, first-
hand, the respiratory effects of C exposure. (S F #9-13.) 
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Having obviously known well the acute adverse respiratory effects of OC Plaintiff
cannot now reasonably argue that her conduct would have changed had the OC container
contained any different label Importantly Plaintiff cannot recall having ever had the
opportunity to review the OC canisters used in any of her training exposures SOF 9 12 13
In short she never saw the labels on SEC canisters from which she alleges OC exposure
Despite having known of and been trained in the adverse respiratory effects of exposure to OC
and despite having previously experienced the respiratory effects of OC exposure from earlier
trainings using OC pepper spray manufactured by manufacturers other than SEC Plaintiff
nonetheless voluntarily participated in the trainings without regard for the warnings or lack of
warnings on canisters of SEC OC products Thus even if SEC violated an FHSA labeling
standard which SEC disputes there can be no reasonable argument that such a violation was the
proximate cause of Plaintiffs injuries Clearly it was not As Plaintiff will therefore be unable
to provide more than a mere scintilla of evidence regarding the question of proximate cause if
that SEC is entitled to entry of judgment as a matter of law in its favor on Plaintiff s theory of
negligence per se
V CONCLUSION
To properly grant a manufacturersmotion for summary judgment the district court
must rule as a matter of law that the product was not defective and that if defective such defect
nonetheless did not proximately cause the injury Tuttle 125 Idaho 145 In this case Plaintiff
cannot prove that SECs OC spray was defective the defect alleged an inadequate warning is
not actually a defect based on the previously determined and admitted fact that SEC had no
notice of or duty to warn against the risk of Plaintiffs alleged chronic injuries Moreover
Plaintiff cannot produce more than a scintilla of evidence or raise any more than a slight doubt
MEMORANDUM IN SUPPORT OF DEFENDANTSSECOND MOTION FOR SUMMARY
JUDGMENT Page 23 14542011 403122doc
001041
aving obviously kno n ell the acute adverse respiratory effects of D , laintiff 
t  reas l  argue t at r c nduct o ld a e a e   t  D  t iner 
contained any different label. I portantly, laintiff cannot recall having ever had the 
opportunity to review the DC canisters used in any of her training exposures. (SOF #9, 12, 13.) 
I  rt,    t  la ls   isters  ic   ll  D  . 
espite having kno n of and been trained in the adverse respiratory effects of exposure to C, 
and despite having previously experienced the respiratory effects of DC exposure from earlier 
trainings using D  pepper spray anufactured by anufacturers other than S , Plaintiff 
nonetheless voluntarily participated in the trainings without regard for the warnings, or lack of 
warnings, on canisters of SEC DC products. ,  i   i lat    l li  
standard, hich SEC disputes, there can be no reasonable argu ent that such a violation as the 
proximate cause of Plaintiff s injuries. Clearly it was not. As Plaintiff will therefore be unable 
to provide ore than a ere scintilla of evidence regarding the question of proxi ate cause, if 
that, SEC is entitled to entry of judg ent as a atter of la  in its favor on Plaintiff s theory of 
negligence per se. 
v.  
"To properly grant a manufacturer's motion for summary judgment, the district court ... 
ust rule as a atter of la  that the product as not defective and that, if defective, such defect 
nonetheless did not proxi ately cause the injury." Tuttle, 125 Idaho 145. In this case, Plaintiff 
cannot prove that SEC's DC spray was defective: the defect alleged, an inadequate warning, is 
not actually a defect, based on the previously deter ined (and ad itted) fact that SEC had no 
notice of or duty to arn against the risk of Plaintiffs alleged, chronic injuries. er, 
Plaintiff cannot produce ore than a scintilla of evidence or raise any ore than a slight doubt 
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that the allegedly inadequate warning was a proximate cause of her alleged injuries Plaintiff
was actually warned of the known risks of the product was instructed on the known and
intended effects of the product was tested on the known and intended effects of the product had
personally been exposed to the product andor similar products on several prior occasions and
was instructed to sustain exposure to the product by IDOC personnel over her objection
Moreover Plaintiff never saw the warning label that she claims was defective so any deficiency
in that label could not have had any causal influence in her exposure Summary judgment
against Plaintiff is therefore appropriate on all of these grounds Id
DATED this 22 day of July 2011
GREENER BURKE SHOEMAKER PA
Christopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing document on the following
named personson the date indicated below in the manner indicated below
Darwin Overson Esq ViaUSMail
Eric B Swartz Esq x Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O Box 7808
Boise Idaho 83707
DATED this 22 day of July 2011
Christopher C Burke
Thomas J Lloyd III
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that the allegedly inadequate warning was a proximate cause of her alleged injuries. Plaintiff 
was actually warned of the known risks of the product, was instructed on the known and 
intended effects of the product, as tested on the kno n and intended effects of the product, had 
personally been exposed to the product (and/or si ilar products) on several prior occasions, and 
as instructed to sustain exposure to the product by I O  personnel over her objection. 
oreover, Plaintiff never sa  the arning label that she clai s as defective, so any deficiency 
in that label c ld t a e had a  ca sal influence i  er e s re.  judg e t 
against Plaintiff is therefore appropriate on all of these grounds. Id. 
TE  t is nd day of July, 2011. 
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THE DISTRICT COURTOF THE FOURTH JUDICIAL DISTRICTua
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR
Plaintiff
VS
SECURITY EQUIPMENT CORP
Defendant
Case No CVPI201003515
SCHEDULING ORDER
The Court set Security Equipment Corporations Motion for Summary Judgment for
hearing on September 15 2011 at 230pmEach side will be given no more than fifteen 15
minutes oral argument See Local Rules Pursuant to the Courts authority underIRCP7b3
the following schedule shall apply
a A party opposing this Motion shall file any opposition by August 12 2011 The
original brief any attachments or affidavits shall be filed with the Court by the close of
business with copies of all materials sent by email in a Word document to
dcdanseladawebnetPursuant to the local rules the brief shall not exceed twenty
five 25 pages without order of the Court for good cause No separate statement of
undisputed facts may be filed
b The moving party shall file any reply by August 26 2011 The original brief and any
attachments or affidavits shall be filed with the Court by the close of business with
copies of all materials sent by email in a Word document or PDF file to
dcdanselaa webnetPursuant to the local rules the brief shall not exceed fifteen
15 pages without order of the Court for good cause
IT IS SO ORDERED
Dated this 25 day of July 2011
Cheri C Copsey
District Judge
SCHEDULINGORDER
CASE NO CVPI201003515 1 001043
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950W BANNOCK STREET SUITE 900
BOISE IDAHO 83702
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZPLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawc m
Attorneys for Plaintiff Billie Jo Major
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CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
vs
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
CaseNo CV PI 1003515
NOTICE OF COMPLIANCE
TO THE CLERK OF THE ABOVE ENTITLED COURT
PLEASE TAKE NOTICE that on the 26 day ofJuly 2011 Plaintiff by and through her
counsel of record Jones Swartz PLLC served Plaintiffs Supplemental Answers and
Responses to Defendants Second Set of Interrogatories and Requests for Production of
Documents together with a copy of this Notice of Compliance upon counsel for the Defendant
as follows
NOTICE OF COMPLIANCE 1
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ocu ents, together ith a copy of this otice of o pliance, upon counsel for the efendant 
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OTICE F CE - 1 
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
DATED this 26 day ofJuly 2011
USMail
ax 192601 041jsenger Delivery
Email cburke@greenerlawcom
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By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
CaseNo CV PI 1003515
Plaintiff
VS NOTICE OF COMPLIANCE
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
TO THE CLERK OF THE ABOVE ENTITLED COURT
PLEASE TAKE NOTICE that on the 26 day of July 2011 Plaintiff by and through her
counsel of record Jones Swartz PLLC served Plaintiffs Fifth Supplemental Answers and
Responses to DefendantsFirst Set of Interrogatories and Requests for Production together
with a copy of this Notice of Compliance upon counsel for the Defendant as follows
NOTICE OF COMPLIANCE I
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post OfficeBox 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
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Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
DATED this 26 day ofJuly 2011
taxMail3192601
Messenger Delivery
Email cburke@greenerlawcom
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawc m
Attorneys for Plaintiff Billie Jo Major
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By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Case No CV PI 1003515
PLAINTIFFSMOTION FOR
RECONSIDERATION OF THE
COURTSORDER GRANTING
DEFENDANT MOTION FOR
SUMMARY JUDGMENT
Defendant
Plaintiff respectfully moves pursuant to Idaho Rule of Civil Procedure 11a2bfor
reconsideration of this Court July 19 2011 Order granting DefendantsMotion for Summary
Judgment as to the foreseeability of injury element ofPlaintiffsfirst and second causes of action
Plaintiff seeks reconsideration on the issue of whether there was sufficient scientific
evidence in existence at the time SEC sold its SABRE Red Law Enforcement 10 OC Spray
MK9 Fogger to IDOC to give rise to a genuine issue ofmaterial fact to whether SEC knew or
should have known that danger to users could result from a particular use of the product or
PLAINTIFFSMOTION FOR RECONSIDERATION OF THE COURTSORDER GRANTING
DEFENDANTMOTION FOR SUMMARY JUDGMENT 1
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I TIFF'S   
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l i tiff r s tf ll  s, rs t t  I  l  f i il r r  1(a)(2)(b), f r 
rec si erati  f t is ourt's J l  ,  r er ra ti  efendant's tio  f r ar  
Judg ent as to the foreseeability of injury ele ent of Plaintiff s first and second causes of action. 
i  s    s      ie  ti  
e idence i  e iste ce at t e ti e  s l  its  e  a  f rce e t 0%  ray, 
-9 Fogger, to I , to give rise to a genuine issue of aterial fact to hether S  kne  or 
should have kno n that danger to users could result fro  a particular use of the product; or, 
I TIFF'S I   I    URT'S   
NDANT'S OTION    -  
more specifically whether SEC knew or should have known their product posed a risk of chronic
injury such as that suffered by the Plaintiff
This motion is supported by the pleadings papers affidavits and depositions on file as
well as the Memorandum Affidavit of Garold S Yost PhDand Affidavit of Counsel filed
concurrently herewith
DATED this 26th day ofJuly 2011
J01
1
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 26th day of July 2011 a true and correct copy of the
foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
PLAINTIFFSMOTION FOR RECONSIDERATION OF THE COURTSORDER GRANTING
DEFENDANT MOTION FOR SUMMARY JUDGMENT 2
DARWINL OVERSON
ERIC B SWARTZ
ERIC B SWARTZ
001050
ore specifically, hether SE  kne  or should have kno n their product posed a risk of chronic 
injury such as that suffered by the Plaintiff. 
his otion is supported by the pleadings, papers, affidavits, and depositions on file, as 
  e e , ffida it   . t, h.D.,  fida t  s  ile  
concurrently here ith. 
 this 26th day of July, 2011. 
By~~~~~~~~~ __ 
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I  I  that on this 26th day f July, 2011, a true and correct copy f the 
foregoing docu ent as served on the follo ing individual(s) by the ethod indicated: 
Christopher C. Burke 
     
950 . annock treet, uite 900 
oise, I  83702 
DARWIN L. OVERSO 
 .  
L INTIF 'S   I    OURT'S  RA TI  
FENDANT'S     -  
NO
PILE
AM PM
JUL 2 6 2011
CHRIcTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
STATE OF IDAHO
County ofAda
ss
Case No CV PI 1003515
AFFIDAVIT OF COUNSEL IN
SUPPORT OF PLAINTIFFSMOTION
FOR RECONSIDERATION AND IN
OPPOSITION TO DEFENDANT
SECOND MOTION FOR SUMMARY
JUDGMENT
I Darwin L Overson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFSMOTION FOR RECONSIDERATION
AND IN OPPOSITION TO DEFENDANT SECOND MOTION FORSUMMARY JUDGMENT I
9Z
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
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I, ar in . verson, being first duly s orn upon oath, depose and state upon y o n 
personal knowledge as follows: 
. I a  a  att r e  it  t e la  fir  f J es & r  LL ,   ut r  t  
practice law before this and all courts of the State ofldaho. 
I   L I    LAINTIF 'S   NSIDERATION, 
 I  POSITI   FENDANT'S E  I  F R U  JUDG  - 1 
2 I am counsel of record for Plaintiff Billie Jo Major in the above action and have
firsthand knowledge of the documents materials and all other discovery that has been produced
byeither party in this case
3 Attached hereto as Exhibit 1 is a true and correct copy of the label of SECs
SABRE Red Law Enforcement 10 OC Spray MK9 Fogger The identical label has been filed
as an exhibit to the affidavit of Mr Lloyd but the copywas difficult to read Exhibit 1 hereto is
a clearer copy that was produced by SEC during discovery
FURTHER YOUR AFFIANT SAYETH N A TT TTT
SUBSCRIBED AND SWORN TO before me this 26 day of July 2011
Notary Public for Idaho
G i My Commission expiresPUBUN
E Og 1
AFFIDAVIT OF COUNSEL IN SUPPORTOF PLAINTIFFSMOTION FOR RECONSIDERATION
AND IN OPPOSITION TO DEFENDANT SECOND MOTION FOR SUMMARY JUDGMENT 2
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firsthand kno ledge of the docu ents, aterials, and all other discovery that has been produced 
by either party in this case. 
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 26th day of July 2011 a true and correct copy of the
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
TMessenger Del
Email c r e c
ERIC B SWARTZ
com
AFFIDAVIT OF COUNSEL IN SUPPORTOF PLAINTIFFSMOTION FOR RECONSIDERATION
AND IN OPPOSITION TO DEFENDANT SECOND MOTION FOR SUMMARY JUDGMENT 3
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I  IF  that  this th  f J l , ,  true  rrect  f the 
foregoing docu ent as served on the follo ing individual(s) by the ethod indicated: 
Christopher C. Burke 
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I I    I    PLAINTIF 'S I   CONSIDERATION, 
 I  SI I   EFENDANT'S SEC  I   SUMMARY JUD  -  
EXHIBIT 1
TO AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFS
MOTION FOR RECONSIDERATION AND IN OPPOSITION TO
DEFENDANTSSECOND MOTION FOR SUMMARY JUDGMENT
EXHIBIT I
TO AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFS
MOTION FOR RECONSIDERATION AND IN OPPOSITION TO
DEFENDANTSSECOND MOTION FOR SUMMARY JUDGMENT
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ACTIVE INGREDIENTS Approx133Major
Capsaicinoids and an invisible ultraviolet light
sensitive dye for suspect identification
We DIRECTIONS To be used by Law Enforcement
Corrections Military or Security Personnel
trained in the proper use of aerosol projectors
Reduce injuries by following these instructions
Remove pin and press actuator to fire at
subject face in 12to 1second bursts Aim
for the eyes forehead if wearing glasses nose
Q
andmouth To stop firing release pressure from
MK9Fggep hie
actuator Caution thargeintoow backwinds or s ld face to prevent bl
exposure Do not discharge at distances of less
than six feetmay cause injuries to soft body
Non Flammable tissue Ifyou are unable to restrain the subject
Electronic Immobilization after3112to1 second bursts employ the next
appropriate force option Test fire periodically
Device Compatible to assure performance and familiarity of spray
pattern DO NOT puncture or incinerate can
DO NOT expose to heat orstore above120 F
Active Ingredient DO NOT use after canisters expiration date It
is the user responsibility to keep the canister
133 Major CapSaicinoldS from accidentally firing WARNINGKEEP OUT
OF REACH OF CHILDRENThe contents are
10 Oleoresin Capsicum dangeroususe with care
tJI IU FIRST AID Begin decontamination process2000 immediately after restraining subject Remove
subject fromcontaminated area to area of fresh
CAUTION
air Verbally reassure subject If available rinse
affected areas with clean cool running water
and soap Repeat if necessary Do not rub orSEVERE SKIN AND EYE IRRITANT
use creams lotions oils or salves For eye
CONTENTS UNDER PRESSURE contact flushwith coldwater for 15 minutes
or longer Only qualified medical personnel
SEE OTHER WARNINGS ON should remove contacts Periodically monitor
BACK LABEL subject until they are fully recovered Get
medicat attention if symptoms persist
920060 MADE IN USA Security Equipment Corporation
747Sun Park Drive
NET 185OZS J Fenton MO 63026
001055
SEC000128 
SEC000126
001056
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SEC000126 
Approx133Major Capsakinoids
To beused by Law Enforcement Corrections or Military Personnel
trained in the proper use of aerosol grenades Reduce injuries by following these
instructions Remove cap positioned on topotgrenode Direct thegrey lever ontop
of thecanister away from yourselfand press lever until it snaps into place The
canister will begin to discharge immediately Tostop the dischargeuse ascrew
driver to lift the lever to its original position Direct thedischarge away from you
wten releasing its contents Manufacturer suggests using a mask whendischarging
this unit Proper training isrequired for the mosteffective use of this product
Caution Avoiddeploying into head winds orshield face to prevent blow back
exposure 00 NOTpuncture or incinerate call 00 NOTexpose to temperatures
exceeding 120 degrees F 50 degreesC 00NOT use aftercanistets expiration date
It isthe user responsibility to keep thecanister from accidentally firing WARNING
KEEP OUT OFTHE REACH OFCHILDREN Thecontents are dangeroususe with rare
Begin decontamination process as soon as possible after restraining
subject Remove subject from contaminated area toarea of fresh air Verbally
reassuresubject Ifavailable dnse affectedareas with cleancool runningwater and
soap Repeat ifnecessary Do notrub oruse creams lotions oKsor salves For eye
contact flush with cold water for15 minutes or longerOnly qualified medical
personnel should removecontacts Periodicallymannersubject until they are fully
recovered Get medical attention ifsystems persist
Security Equipment Corporation 330Sun Valley Clmle Fenton MO 63026
FOR LAW
ENFORCEMENT ONLY
SF1131
133Major Capsaicinoids
109Cleoresin Capsicum
CAUTION
SEVERE SKIN ANDEYE IRRITANT
CONTENTS UNDER PRESSURE
SEE OTHER WARNINGS ON BACKLABEL
AG 10 MADE INUSA
NET 20OZS TOTALWEIGHT 125 OZS
N OIII O 0T C nL CA yj
Ortscm4CbNrL
N
mcmm
w2m 3moo
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133Major Capsaicinoids a 3t a ao z QZt9d 6 z r
109Capsicum a o g o 0 en a y a 0r Qc o
2000r000SHUs amrNmoamom
V X0000 Ntem 0U NC7Q 3 p
i
r
nMOBI ZATION Q a P 0 aO S H 5NELECTRONIC NtY 9 U0 3 9 8 R
DEVICE COMPATIBLE 0 00t m m b ci v m a E cio
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CAUTION 0a 2 auKm
War
1
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Approx. 1.33% j r Capsaicinoids. 
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CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Case No CV PI 1003515
AFFIDAVIT OF BILLIE JO MAJOR IN
SUPPORT OF PLAINTIFFSMOTION
TO RECONSIDER AND IN
OPPOSITION TO DEFENDANT
SECOND MOTION FOR SUMMARY
JUDGMENT
Defendant
STATE OF IDAHO
SS
County of Ada
I Billie Jo Major being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am the Plaintiff in the above captioned lawsuit
2 I was employed as a guard at IDOC in July 2004 Prior to working at IDOC I had
a history of respiratory illness but nothing to the extent that prevented me from performing work
AFFIDAVIT OF BILLIE JO MAJOR IN SUPPORT OF PLAINTIFFSMOTION TO RECONSIDERAND IN
OPPOSITION TO DEFENDANTSSECONDMOTION FOR SUMMARY JUDGMENT 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post OfficeBox 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
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I, illie Jo ajor, being first duly s orn upon oath, depose and state upon y o n 
personal kno ledge as follo s: 
. I a  the Plaintiff in the above-captioned la suit. 
. I as e ployed as a guard at I C in July 2004. Prior to orking at I C, I had 
a history of respiratory illness but nothing to the extent that prevented e fro  perfor ing work, 
  I   J     L I TIFF'S   I    
  ENDANT'S      -  
caring for myself or otherwise participating in recreational activities and enjoying my life
When I took the job at IDOC I was physically able to perform my duties as a correctional guard
at IDOC I worked at the Idaho Maximum Security Institution IMSI from July 2004 to July
2006 and again from August or September 2007 to May 2008 During the intervening periods I
worked at the South Boise Women Correctional Facility
3 I was exposed to OC Spray at IDOC as OC Spray was used for training and
prisoner control While at IMSI I was frequently exposed to OC at various levels of exposure
such as instances where I had deployed an OC Spray product where others had and I was in the
area or as part of a training course While working at IDOC I developed a chronic cough
Other employees and some of the prisoners would make comments about my coughing thinking
I was a smoker I was not a smoker Even though I had a chronic cough I was able to perform
the work continue to care for myself and participate in recreational activities much as I had
always done before I was an avid cyclist rode horses and generally was physically fit and
active during most all of the period that I worked at IDOC In late February early March 2008 I
developed bronchitis and was placed on light duty by my doctor On March 3 2008 I
participated in an OC Spray training where I was exposed to SECs MK9 Fogger The MK9
Fogger produces an aerosol of widely disbursed micro droplets Other of SECs OC Spray
products used at IDOC were streams and foams that in my experience mostly caused eyes and
skin irritation although there would be some coughing too By comparison the MK9 Fogger
had less effect on my eyes and skin and more effect on my respiratory system During the
training I experienced a strong burning sensation in my lungs and could not stop coughing The
coughing continued even after the training When the coughing continued into the next day I
went to my doctor and was placed on medical leave Before starting that training session I asked
AFFIDAVITOF BILLIE JO MAJOR IN SUPPORT OF PLAINTIFFSMOTION TO RECONSIDER ANDIN
OPPOSITION TO DEFENDANTSSECOND MOTION FOR SUMMARY JUDGMENT 2
001059
canng for yself, or other ise participating in recreational activities and enjoying y life. 
hen I took the job at I , I as physically able to perfor  y duties as a correctional guard 
t I . I r  t t  I  i  ecurit  I tit ti  ("IMSI") fro  July 2004 to July 
2006 and again fro  ugust or Septe ber 2007 to ay 2008. uring the intervening periods, I 
r  t t  t  is  omen's rr ti l cility. 
3. I as exposed to  Spray at I  as  Spray as used for training and 
prisoner control. hile at I SI, I as frequently exposed to C at various levels of exposure 
such as instances here I had deployed an  pray product, here others had and I as in the 
,       . hile orking at I C, I developed a chronic cough. 
ther e ployees and so e of the prisoners ould ake co ents about y coughing, thinking 
I as a s er. I as t a s er. e  t  I a  a c r ic c gh, I as a le t  erf r  
t e r , c ti e t  care f r self a  artici ate i  recreati al acti ities c  as I a  
al ays done before. I as an avid cyclist, rode horses, and generally as physically fit and 
ti  i  t ll  t  i  t t   t .  l t  r ry, l   ,  
l e  r itis  as lace   li t t    tor.  r  , , I 
participated in an C Spray training here I as exposed to SEC's -9 Fogger. The -9 
Fogger produces an aerosol of idely disbursed icro-droplets. Other of SEC's OC Spray 
products used at IDOC were streams and foams that, in my experience, mostly caused eyes and 
s i  irritati , alt  t ere l  e s e c i  t .  c aris n, t e -9 er 
had less effect on my eyes and skin and more effect on my respiratory system. During the 
training I experienced a strong burning sensation in my lungs and could not stop coughing. The 
coughing continued even after the training. hen the coughing continued into the next day, I 
went to my doctor and was placed on medical leave. Before starting that training session, I asked 
 F I LIE J  AJOR I  S PP  F I F'S ION    IN 
  NDANT'S S  ION F R  J  - 2 
to be excused but was told that I would not be excused from the training Had I known that the
kind of exposure I was going to receive posed a risk of the kind of chronic respiratory injuries I
suffered I would have refused to participate but I was assured by all the training materials I had
had prior to and during that training that any effects of OC Spray were purely temporary and did
not pose a health risk
4 The March 3 2008 training session consisted of the trainer spraying multiple
bursts of MK9 Fogger into a confined cell into which a trainee would enter and remain until
they had breathed in the OC aerosol fully enough to experience the full effects of the MK9
product The trainee would then exit the cell and engage in physical exercises to demonstrate
that they could perform their job under the effects of the OC Once the trainee completed the
exercises the trainee would assist another trainee going through the same cycle of events The
exposure portion of the training waiting to enter the cell entering the cell performing the
exercises and assisting another trainee lasted approximately twoandahalf hours which was
conducted entirely indoors with poor ventilation
5 After the March 3 2008 training I was unable to work due to my coughing
becoming so bad that I could not communicate with others or otherwise physically do my job
The coughing became very severe to the point that it prevented me from working inhibited my
ability to care for myself and has prevented me from participating in the recreational and social
activities as I had done previous to March 3 2008
6 While I had several trainings on OC Spray and generally understood that OC
Spray causes respiratory irritation and inflammation nothing in my training experience or
observations at IDOC regarding OC Spray informed me that there was a risk of health injury
from the product I was not made aware that chronic exposure could result in hypersensitivity to
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t    t  t l  t t I l  t   fr  t  tr ining.  I  t t t  
i  f e s re I as i  t  recei e se  a ris  f t e i  f c r ic respirat r  i j ries I 
suffered, I ould have refused to participate, but I as assured by all the training aterials I had 
a  ri r t  a  ri  t at trai i  t at a  effects f  ra  ere rel  te rar  a  i  
t s   lt  ris . 
.   ,  t i i  ssi  i t   t  t i  r i  lti l  
rsts f -9 r i t   fi  ll i t  i   tr i  l  t r  r i  til 
t e  a  reat e  i  t e  aer s l f ll  e  t  e erie ce t e f ll effects f t e -9 
product. he trainee ould then exit the cell and engage in physical exercises to de onstrate 
that they could perfor  their job under the effects f the . nce the trainee co pleted the 
r i s, t  tr i  l  i t t r tr i  i  t r  t   l  f ts.  
e s re rti  f t e trai i g, aiti  t  e ter t e cell, e teri  t e cell, erf r i  t e 
exercises and assisting another trainee, lasted approxi ately t o-and-a-half hours hich as 
conducted entirely indoors ith poor ventilation. 
5. fter t e arc  ,  trai i , I as a le t  r  e t   c i  
beco ing so bad that I could not co unicate ith others or other ise physically do y job. 
 i   r  r  t  t  i t t t it r t   fr  r i g, i i ite   
a ilit  t  care f r self, a  as re e te  e fr  artici ati  i  t e recreati al a  s cial 
activities as I had done previous to arch 3, 2008. 
. hile I had several trainings on  Spray and generally understood that  
Spray causes respiratory irritation and infla ation, nothing in y training, experience or 
observations at moc regarding  pray infor ed e that there as a risk f health injury 
fro  the product. I as not ade a are that chronic exposure could result in hypersensitivity to 
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capsaicinoids and other irritants commonly confronted in the environment I was not aware that
overexposure to OC Spray was dangerous and could cause respiratory illness or aggravate an
existing respiratory illness As presented in the trainings and on the labeling of the SABRE Red
products I understood that all the effects from OC Spray were temporary and generally safe I
was repeatedly instructed that the effects were all temporary I understood the effects of OC
Spray exposure to be temporary and safe based on how I had been trained and what I had been
told I was never provided a copy of SECsor any other OC product manufacturersMSDS for
OC Spray products prior to March 3 2008 During my employment at IDOC I read the label of
one of SECsSABRE Red OC Spray canistersan OC Spray stream product Nothing on the
label indicated a risk of respiratory injury Nothing warned against overexposure Nothing on
the label said anything about ventilation in the area other than saying that the sprayed subject
should be moved to fresh air after being exposed
7 Had I been informed of the health risks associated with OC Spray and the MK9
Fogger in particular I would have insisted that I be permitted to opt out of the March 3 2008
training and would have taken steps to protect myself I believe that if the negative health effects
of the MK9 Fogger were made known to IDOC employees it is likely the trainers I had would
have designed the training on March 3 2008 differently in order to provide ventilation in the
area in order to avoid spraying so much of the MK9 Fogger in the cell and that they would
have been more open to excusing me from the training due to the fact I had bronchitis at the time
During none of those trainings did I see or hear anything that would have informed me of the
risks of acute and chronic respiratory illness such as I have experienced during and after the
March 3 2008 training at IDOC I was informed during trainings that OC Spray would cause
irritation and inflammation of the respiratory tract but was always told and in everything I read
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ca saici i s a  t er irrita ts c l  c fr te  i  t e envir ent. I as t a are t at 
overexposure to  pray as dangerous and could cause respiratory illness or aggravate an 
i ti  i t  illn .  t  i  t  t i i    t  l li   t    
products, I understood that all the effects fro   Spray ere te porary and generally safe. I 
 r t dl  i tr t  t t t  "effects r  ll t porary." I r t  t  ff t  f  
      f              
told. I as never provided a copy f EC's or any other  product anufacturer's  for 
 pray products prior to arch 3, 2008. uring y e ploy ent at I , I read the label f 
one of SEC's S  ed  Spray canisters-an  Spray strea  product. othing on the 
label indicated a risk of respiratory injury. othing arned against overexposure. othing on 
t  l l s i  t i  t til ti  i  t  r  t r t  s yi  t t t  s r  s j t 
s l  e e  t  fres  air after ei  e sed. 
. ad I been infor ed of the health risks associated ith  Spray and the -9 
Fogger in particular, I ould have insisted that I be per itted to opt out of the arch 3, 2008 
training and ould have taken steps to protect yself. I believe that if the negative health effects 
f t e -9 er ere a e  t  I  e l ees, it is li el  t e trai ers I a  l  
a e esi e  t e trai i   arc  ,  iffere tl  i  r er t  r i e e tilati  i  t e 
area, in order to avoid spraying so uch f the -9 ogger in the cell, and that they ould 
have been ore open to excusing e fro  the training due to the fact I had bronchitis at the ti e. 
uring none of those trainings did I see or hear anything that ould have infor ed e of the 
risks of acute and chronic respiratory illness such as I have experienced during and after the 
arc  ,  trai ing at I . I as i f r e  ri  trai ings t at  ra  l  ca se 
irritation and infla ation of the respiratory tract but as al ays told, and in everything I read, 
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that those effects were purely temporary I was never informed either by spoken word or by
written materials that chronic exposure could lead to a respiratory condition where I would be
hypersensitive to OC Spray andor other irritants in the environment I was never informed
either by spoken word or by written material that an acute overexposure to OC Spray could lead
to a respiratory condition where I would be hypersensitive to OC Spray andor other
environmental irritants I was not informed in any manner during my employment at IDOC that
exposure to OC Spray could put me at risk for the kinds of respiratory illnesses that I have
sustained Had I been informed of those risks and exposure could not be avoided while still
doing my job I would have found a different job rather than risk aggravating my respiratory
problems even further
FURTHER YOUR AFFIANT SAYETH NAUGHT
BILLI Jo MAJOR
SUBSCRIBED AND SWORN TO before me this ZS day ofJuly 2011
w OTAR Notary Public for Idaho
aw k c MyCommission expires 7
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t at t  fects  l  t ry.    i d, it       
ritten aterials, that chronic exposure could lead to a respiratory condition here I ould be 
r iti e t   r  ndlor t r irrita t  i  t  ir t.    d, 
it r  s  r  r  ritte  t ri l, t t  t  r s r  t   r  l  l  
t  a res irat r  c itio  ere I l  e erse siti e t   ra  andlor t er 
ir e tal irrit ts. I as t i f r  i   r ri   l t t moc t t 
e s re t   ra  c l  t e at ris  f r t e inds f res irat r  illnesses t at I a e 
sustained. ad I been infor ed f those risks, and exposure could not be avoided hile still 
doing y job, I ould have found a different job rather than risk aggravating y respiratory 
proble s even further. 
    . 
       ,ts.T:f-  f July, 1. 
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I  IF  that on this 26th day f July, 2011, a true and correct copy f the 
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AFFIDAVIT OF GAROLD S YOST
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MOTION TO RECONSIDER COURTS
ORDER ON DEFENDANTMOTION
FOR SUMMARY JUDGMENT
I GAROLD S YOST PhDbeing first duly sworn upon oath depose and state of my
own personal knowledge that if called upon to testify I would competently testify to the
following
1 I am a professor of Pharmacology and Toxicology and an adjunct professor of
Medical Chemistry at the University of Utah Department of Pharmacology and Toxicology I
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I, GAROLD S. YOST, Ph.D., being fIrst duly sworn upon oath, depose and state of y 
own personal knowledge that, if called upon to testify, I would competently testify to the 
f ll i : 
. I am a professor of Pharmacology and Toxicology and an adjunct professor of 
Medical Chemistry at the University of Utah, Department of Pharmacology and Toxicology. I 
I A IT F  . , P . .,  S RT  I TIFF'S I   ER 
C RT'S ER N E E 'S OTION  AR  J G ENT - 1 
hold a BachelorsofScience in Chemistry a MastersofScience in Organic Chemistry and a
PhDin Organic Chemistry I have been recognized internationally as an authority on toxicology
in the respiratory tract with particular expertise on the cytochrome P450mediated mechanisms
of lung injury Attached as Exhibit A to the previously filed Affidavit of Garold S Yost PhD
In Opposition to DefendantsMotion for Summary Judgment is a true and correct copy of my
curriculum vitae
2 I have conducted extensive research into the mechanisms responsible for human
lung disease caused by particulate matter in air pollution In my lab my research team and I have
cloned expressed and characterized multiple irritant receptors that are expressed on human
lung epithelial cells and are activated by particulates in polluted air and by capsaicinoids that are
present in pepper sprays This work has provided compelling evidence for the relevance ofthese
receptors in human lung disease
3 I have reviewed the discovery materials produced by the parties to the litigation
identified above including the medical records of the Plaintiff and the depositions taken
According to the Plaintiffsmedical and employment records and according to the deposition
testimony of her former coworkers the Plaintiff was employed with the Idaho Department of
Correction IDOC for a number of years as a prison guard During her employment with the
IDOC the Plaintiff had numerous exposures to OC Spray In March 2008 the Plaintiff was
exposed during an IDOC trainingsession usingone of SECsSabre Red Law Enforcement 10
OC Spray products that produces a fine aerosol disbursement of the OC material in the air The
two IDOC employees who conducted the March 2008 training testified in their depositions that
the SEC Sabre Red product that was used was the fog As indicated in the deposition of SEC
Vice President Robert Nance the Sabre Red fog products are specifically designed toincrease
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hold a achelor's of Science in he istry, a aster's of Science in rganic he istry, and a 
Ph.D. in rganic hemistry. I have been recognized internationally as an authority on toxicology 
i  t  r spir t r  tr ct, it  rti l r rtis   t  t r  450- i t  is s 
 l  i j ry. tt   i it  t  t  i l  il  i it  r l  . st, h.D., 
In pposition to efendant's otion for Su ary Judg ent is a true and correct copy of y 
curriculu  vitae. 
2. I  t  t si  r s r  i t  t  is s r s si l  f r  
l  is s  s   rti lat  tt r i  ir ll ti . I   l ,  r s r  t   I  
cloned, expressed, and characterized ultiple "irritant receptors" that are expressed on hu an 
lung epithelial cells and are activated by particulates in polluted air and by capsaicinoids that are 
present in pepper sprays. his ork has provided co pelling evidence for the relevance of these 
r t r  i   l  i e. 
. I have revie ed the discovery aterials produced by the parties to the litigation 
identified above, including the edical records of the Plaintiff and the depositions taken. 
ccording to the Plaintiff's edical and e ploy ent records, and according to the deposition 
testi  f er f r er c - r ers, t e lai tiff as e l e  it  t e I a  e art e t f 
 ("IDOC") for a number of years as a prison guard. During her employment with the 
I , the Plaintiff had nu erous exposures to  Spray. In arch 2008, the Plaintiff as 
os  ri   moc trainingsession si gone f C's r   a  f rc t 0% 
 ra  r cts t at r duces a fine aer s l is urse e t f t e  aterial i  t e air. e 
two IDOC e ployees who conducted the arch 2008 training testified in their depositions that 
the SEC Sabre Red product that was used was the fog. As indicated in the deposition of SEC 
ice President obert ance, the Sabre ed fog products are specifically designed toincrease 
AFFIDAVIT   . Y , ., IN   'S ION   
T'S ER N 'S TION FOR S ARY J G ENT -  
respiratory tract deposition when compared to their stream and foam products Increased
respiratory tract exposure to capsaicin would be expected to producegreater respiratory tract
irritation and inflammation facilitated by activation of TRP receptors in the respiratory tract
4 According to the records and other documents I reviewed after the Plaintiff
completed the March 2008 OC Spray training session she was not able to return to work due to a
severe chronic cough and other adverse respiratory problems The records also indicate the
Plaintiff suffered a much milder form of chronic cough prior to the March 2008 training butit
was only after the exposure in the March 2008 training that her condition worsened to the point
that she was no longer able to work whether at the IDOC or in other similar employment
settings
5 I have expressed my expert opinions as to the cause of the Plaintiffsacute
adverse health responses to the OC Spray and how it greatly exacerbated her underlying
respiratory diseases which could be characterized as a chronic aggravation of her respiratory
disease Attached as Exhibit B to the previously filed Affidavit of Garold S Yost PhDIn
Opposition to DefendantsMotion for Summary Judgment is a true and correct copy of my
expert report in this case in which I set forth my conclusions as to the acute and chronic effects of
Ms Major exposure to OC Spray during her employment with IDOC
6 In reaching my opinions in addition to the records and discovery materials
already mentioned I relied on a body of scientific literature and studies relating to the effects of
capsaicinoids on human and animal tissues In assisting the Plaintiff in responding to one of
Defendantsdiscovery requests I identified several research articles that support my opinions
including the following
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r s ir t r  tr t position,  r  t  t ir str   f  r ts.  
r s ir t r  tr t s r  t  s i i  l   t  t  r r t r r s ir t r  tr t 
t   la  t   ti       pir t r  ct. 
. ccording to the records and other docu ents I revie ed, after the laintiff 
l t  t      t i i  ssion,   t l  t  t  t    t   
 i    t  s  i t r  l s.   l  i   
Plaintiff suffered a uch ilder for  of chronic cough prior to the arch 2008 training, butit 
 l  t  t   i  t    t i i  t t  iti   t  t  i t 
t at s e as  l er a le t  rk, et er at t e I  r i  t er si ilar e l e t 
s tti s. 
. I a e e resse   e ert i i s as t  t e ca se f t e laintiff's ac te 
a erse ealt  res ses t  t e  ray, a   it reatl  e acer ate  er erl i  
respiratory diseases hich could be characterized as a chronic aggravation f her respiratory 
i e. tta   i it  t  t  i l  ile  fida it  l  . t, h.D.,  
siti  t  f ndant's ti  f r r  J t is  tr   rr t  f  
e ert re rt i  t is case i  ic  I set f rt   c cl si s as t  t e ac te a  c r ic effects f 
s. ajor's exposure to  pray during her e ploy ent ith I . 
. In reaching y opinions, in addition to the records and discovery aterials 
lr  ti , I r li     f i tifi  liter t r   t i  r l ti  t  t  ff t  f 
s i i ids    i l tiss s. In assisting the Plaintiff in responding to one of 
efendant's discovery requests, I identified several research articles that support y opinions, 
including the follo ing: 
   . , H. ., I    'S    
RT'S ER  DANT'S     -  
a M Hayman and P Kam CAPSAICIN A REVIEW OF ITS PHARMACOLOGY AND
CLINICAL APPLICATION Current Anesthesia and Critical Care Vol 19 pp 338343 2008
b K Alawi and J Keeble THE PARADOXICAL ROLE OF TRPVI RECEPTOR IN
INFLAMMATION Pharmacology and Therapeutics Vol 125 pp 189195 2010
c CA Reilly DJ Crouch GS Yost and A Fatah DETERMINATION OF
CAPSAICIN NONIVAMIDE AND DIHYDROCAPSAICIN IN BLOOD AND TISSUE BY LIQUID
CHROMATOGRAPHYTANDEM MASS SPECTROMETRY J Anal Toxicol 26 313319 2002
d CA Reilly JL Taylor DL LanzaBA CarrDJ Crouch andGS Yost
CAPSAICINOMS CAUSE INFLAMMATION AND EPITHELIAL CELL DEATH THROUGH ACTIVATION OF
VANILLOID RECEPTORS Tox Sci 73 170181 2003
e CA Reilly and GS Yost STRUCTURAL AND ENZYMATIC PARAMETERS THAT
DETERMINE ALKYL DEHYDROGENATIONHYDROXYLATI OF CAPSAICINOIDS BY P450 ENZYMES
DrugMetab Dispos 33 530536 2005
f CA Reilly ME Johansen DL Lanza J Lee JO Lim and GS Yost
CALCIUM DEPENDENT AND INDEPENDENT MECHANISMS OF CAPSAICIN RECEPTOR TRPV1
MEDIATED CYTOKINE PRODUCTION AND CELL DEATH IN HUMAN BRONCHIAL EPITHELIAL CELLS
J Biochem Molec Toxicol 19266752005
g ME Johansen CA Reilly and GS Yost TRPV1 ANTAGONISTS ELEVATE
CELL SURFACE POPULATIONS AND RECEPTOR FUNCTION TO EXACERBATE TRPV1MEDIATED
ToxicITiES IN HUMANLUNG EPITHELIAL CELLS Toxicol Sci 89 27886 2006
h CAReilly andGS Yost Metabolism OF CAPSAICINOIDS BY P450 ENzYMEs
A REVIEW OF RECENT FINDINGS ON REACTION MECHANISMS BIoACTIVATION AND
DETOXIFICATION PROCESSES Drug Metab Rev 38 685 706 2006
i KCThomasAS SabnisMEJohansen DL LanzaPJMoosGSYost
andCA Reilly TRPV 1 AGONISTS CAUSE ENDOPLASMIC RETICULUM STRESS AND CELL DEATH
IN HUMAN LUNG CELLS J Pharmacol Exp Ther 321 830838 2007
j BF Bessac and SE Jordt Breathtaking TRP CHANNELS TRPA1 AND
TRPV I IN AIRWAY CHEMOSENSATION AND REFLEX CONTROL Physiology 23 360370 2008
k DAGroneberg A Niimi Q Thai Dinh B Cosio Mark Hew A Fischer
andKFChung INCREASED EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID1 IN
AIRWAY NERVES OF CHRONIC COUGH American Journal of Respiratory and Critical Care
Medicine Vol 170276802004
7 As I stated inmy earlier affidavit filed with this Court the articles cited above are
just a few ofmany that support my opinions as expressed in my report in this case Based on my
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I N NG S,J. r col. x . er. , -838 (2 7). 
j. B.F. Bessac and S.E. Jordt, Breathtaking TRP CHANNELS: TRP 1 AND 
1 I  I  S S I    L, ysi l y, ,3 -37  (2 8). 
k. .A. roneberg, . ii i, . hai inh, . osio, ark e , . Fischer, 
and .F. hung, I CRE SE  E PRESSI  OF TR SIE T RECEPT R P TE TI L  ILLOI -1 IN 
I  E ES F I  , erican Journal f espiratory and ritical are 
i i , l. 70, 12 6-1280 (20 4). 
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review of the abovecited articles and my education training research and knowledge of the
scientific literature and studies in the relevant area it is my opinion that the risks to the
respiratory tract posed by exposure to SECsSabre Red Law Enforcement 10 OC Spray MK9
Fogger MK9 Fogger were known and foreseeable risks at the time SEC sold its product to
the IDOC
8 1 understand that my testimony in my earlier affidavit left a confusing impression
with this Court about the rationale for my opinion regarding the time frame in which it was
known or should have been known that SECsMK9 Fogger posed a risk ofchronic respiratory
injury such as that described in the medical records of Ms Major I understand that this Court
was left with the impression that my conclusion was reached only after relying on those articles
cited above that were published in 2008 or later In reviewing my earlier affidavit I can see how
this Court was left with that impression and I therefore submit this affidavit to clarify both my
opinion and the basis on which I have reached it
9 First I believe it best to state unequivocally that it is my expert opinion based on
my education research and training that the scientific literature and studies in existence prior to
2008 was such that when viewed as a body of literature and human and animal studies it was
known that a product such as SECs MK9 Fogger posed a risk of both acute and chronic
respiratory injury such as that described in MsMajor medical records
10 There is no doubt that the literature and studies had established prior to 2008
within a reasonable degree of scientific certainty that the inflammatory properties associated
with exposure to capsaicinoids greatly enhances the sensitivity ofneuronal and respiratory tissues
to an array of irritants by an increase in the number andor responsiveness of TRP receptors
populating those tissues Once a higher sensitivity develops in an affected individual the
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revie  of the above-cited articles and y education, training, research, and kno ledge of the 
sci ntifi  lit r t r   st i s i  t  r l v nt rea, it is  opi i  t t t  ris s t  t  
respiratory tract posed by exposure to SEC's Sabre Red La  Enforce ent 10% C Spray, -9 
Fogger ("MK-9 Fogger") were known and foreseeable risks at the ti e SEC sold its product to 
the I . 
8. I understand that y testi ony in y earlier affidavit left a confusing i pression 
it  t is rt a t t e rati ale f r  i i  re ar i  t e ti e fra e i  ic  it as 
n, r s l  a e ee   t at EC's -9 er se  a ris  f c r ic res irat r  
i j r  s  s t t s ri  i  t  i l r r s f s. j r. I rst  t t t is rt 
as left ith the i pression that y conclusion as reached only after relying on those articles 
ite   t t r  lis  i   r l t r. I  r i i   arli r ffi vit, I  s   
this Court was left with that impression and I therefore submit this affidavit to clarify both my 
io    s  ic     . 
9. First, I believe it best to state unequivocally that it is y expert opinion, based on 
y education, research, and training, that the scientific literature and studies in existence prior to 
2008 as such that hen vie ed as a body of literature and hu an and ani al studies, it as 
kno n that a product such as SEC's -9 Fogger posed a risk of both acute and chronic 
respiratory injury such as that described in s. ajor's edical records. 
. There is no doubt that the literature and studies had established prior to 2008, 
within a reasonable degree of scientific certainty, that the infla atory properties associated 
with exposure to capsaicinoids greatly enhances the sensitivity of neuronal and respiratory tissues 
to an array of irritants by an increase in the number and/or responsiveness of TRP receptors 
populating those tiss s. nce a higher sensitivity develops in an affected individual, the 
AFFIDAVIT F AR LD S. Y S , H. ., IN   IN IFF'S TION  R NSIDER 
C RT'S OR ER ON DE ANT'S MOTION FOR S ARY J G ENT - 5 
neurogenic inflammatory response in the respiratory tissues will occur at a lower threshold than
in the general non sensitized population Once an individual has become sensitized to capsaicin
the threshold for activation of the neurogenic inflammatory response by exposure to irritants
other than capsaicin is also lowered Capsaicin and its involvement in the sensitization process
was well understood prior to 2008 Thus even prior to 2008 people with asthma andorchronic
cough including Ms Major would have been expected to be much more sensitive to the
pathological effects of pepper sprays That is a person such as Ms Major who is already
sensitized to some extent would be expected to become increasingly sensitized by repeated
andorhigh levels of respiratory exposure to OC spray People with asthma andorchronic cough
are simply more sensitive to the effects ofpepper spray than other people with normal respiratory
function
11 People with greater sensitivity to capsaicin are expected to have increased TRPV 1
receptor populations Other important TRP channels exist and several of them particularly
TRPAI are activated by irritants such as those that exist in cigarette smoke and other
environmental sources Thus it is reasonable to expect the multiple TRP channels to act in
concert with each other to result in higher acute respiratory responses to a multitude of
respiratory irritants particularly in people with increased sensitivity to pepper sprays That is to
say that once the TRP receptor population is upregulated and hypersensitivity occurs the
individual will thereafter experience acute respiratory responses to respiratory irritants whether
from capsaicin cigarette smoke or other environmental sources at exposures that would not
evoke a major response in persons who have not been similarly sensitized The hypersensitivity
of affected individuals to a whole array of respiratory irritants would be expected to elicit
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in the general non-sensitized population. nce an individual has beco e sensitized to capsaicin, 
the threshold for activation of the neurogenic infla atory response by exposure to irritants 
t r t  i i  i  l  l r d. saici   it  i l t i  t  nsiti ti  r  
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cough, including s. ajor, ould have been expected to be uch ore sensitive to the 
    . That is, a person such as s. ajor ho is already 
sensitized to so e extent ould be expected to beco e increasingly sensitized by repeated 
and/or high levels of respiratory exposure to OC spray. People with asthma and/or chronic cough 
are si ply ore sensitive to the effects of pepper spray than other people ith nor al respiratory 
ti . 
. People ith greater sensitivity to capsaicin are expected to have increased T P I 
r t r l ti s. ther i portant TRP channels exist, and several of the , particularly 
TRP l, are activated by irritants such as those that exist in cigarette s oke and other 
environ ental sources. s, it is reas a le t  e ect t e lti le  c a els t  act i  
concert ith each other to result in higher acute respiratory responses to a ultitude of 
respiratory irritants, particularly in people ith increased sensitivity to pepper sprays. hat is to 
say, that once the T P receptor population is up-regulated and hypersensitivity occurs, the 
in ividual ill t r fter rie ce t  r s ir t r  r s s s t  r s ir t r  irrita ts, t r 
fro  capsaicin, cigarette s oke, or other environ ental sources, at exposures that ould not 
evoke a ajor response in persons ho have not been si ilarly sensitized. he hypersensitivity 
of affected individuals to a whole array of respiratory irritants would be expected to elicit 
IDA IT   S. , ., I    I TIFF'S TION  S ER 
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respiratory symptoms that are for all intents and purposes chronic due to the frequency of
recurrence of acute respiratory responses to irritants typically encountered in every day life
12 After being informed that it was perceived that the 2008 and more recent articles
were required to support my conclusion that it was known prior to 2008 that a product like SECs
MK9 Fogger posed a risk of causing acute and chronic injury to the respiratory system I
identified additional literature and studies that were published prior to 2008 that also support my
conclusions The pre2008 articles previously identified upon which I base my conclusion that
SECs MK9 Fogger product posed a risk of respiratory injury such as experienced by Ms
Major are as follows
a CA Reilly DJ Crouch GS Yost and A Fatah DETERMINATION OF
CAPSAICIN NONIVAMIDE AND DIHYDROCAPSAICIN IN BLOOD AND TISSUE BY
LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY J Anal Toxicol
26 313319 2002
b CA Reilly JL Taylor DL Lanza BA Carr DJ Crouch and GS Yost
CAPSAICINOIDS CAUSE INFLAMMATION AND EPITHELIAL CELL DEATH
THROUGH ACTIVATION OF VANILLOID RECEPTORS Tox Sci 73 170181
2003
c CA Reilly and GS Yost STRUCTURAL AND ENZYMATIC PARAMETERS THAT
DETERMINE ALKYL DEHYDROGENATIONHYDROXYLATI OF CAPSAICINOIDS
BY P450 ENZYMES DrugMetab Dispos 33 530536 2005
d CA Reilly ME Johansen DL Lanza J Lee JO Lim and GS Yost
CALCIUMDEPENDENT AND INDEPENDENT MECHANISMS OF CAPSAICIN
RECEPTOR TRPV1MEDIATED CYTOKINE PRODUCTION AND CELL DEATH IN
HUMAN BRONCHIAL EPITHELIAL CELLS J Biochem Molec Toxicol 19 266
275 2005
e ME Johansen CA Reilly and GS Yost TRPVI ANTAGONISTS ELEVATE
CELL SURFACE POPULATIONS AND RECEPTOR FUNCTION TO EXACERBATE
TRPV1MEDIATED TOXICITIES IN HUMAN LUNG EPITHELIAL CELLS Toxicol
Sci 89 27886 2006
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ere required to support y conclusion that it as kno n prior to 2008 that a product like EC's 
 -9 F ogger posed a risk of causing acute and chronic injury to the respiratory system, I 
identified additional literature and studies that were published prior to 2008 that also support my 
l i .  r -200  rti les r i l  i tifi ,  i  I   l i  t t 
SEC's -9 Fogger product posed a risk of respiratory injury such as experienced by s. 
j r,   l s: 
a. .A. eilly, .J. rouch, .S. ost, and .A. Fatah, ETE I TI  OF 
AI IN, I  ,   I      
LI I  T P -T E  ss SPE T ET , J. nal. oxieol., 
,3 -31  (2 2). 
b. .A. eilly, lL. aylor, .L. anza, .A. arr, .l rouch, and .S. ost, 
I I I     I I    
 I I   I I  , . ci., , -18  
(20 3). 
. .A. eill  a  .S. st,   I    
  EHYDROGENATIONIHYDROXYLATION   
B  450 E Z ES, rug etab. ispos. 33, 530-536 (2005). 
d. .A. eilly, .E. Johansen, .L. anza, J. ee, J.-O. i , and .S. ost, 
I -       
E EPT  (TRP 1)-ME I  C T INE PR CTI   ELL E T  IN 
 BR C I L EPIT ELI L ELLS, J. ioehe . olee. Toxieol. 19,266-
 (20 5). 
. .E. J a sen, .A. eill , a  .S. st, l IS   
 CE I S      
V1-MEDI  I ITIES I    PI I  S, oxieol. 
Sci. 89, 278-86 (2006). 
A IDAVIT   S. Y , ., IN   I TIFF'S ION   
'S R ER N DANT'S TION FOR   -  
CAReilly andGS Yost Metabolism OF CAPSAICINOIDS BY P450 ENZYMES
A REVIEW OF RECENT FINDINGS ON REACTION MECHANISMS BIOACTIVATION
AND DETOXIFICATION PROCESSES DrugMetab Rev 38 685706 2006
g KCThomasAS SabnisMEJohansen DL Lanza PJMoosGSYost
and CAReilly TRPV I AGONISTS CAUSE ENDOPLASMIC RETICULUM STRESS
AND CELL DEATH IN HUMAN LUNG CELLS J Pharmacol Exp Ther 321 830
838 2007
h DA Groneberg A Niimi Q Thai Dinh B Cosio Mark Hew A Fischer
andKFChung INCREASED EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL
VANILLOID1 IN AIRWAY NERVES OF CHRONIC COUGH American Journal of
Respiratory and Critical CareMedicine Vol 170 12761280 2004
Those articles cited subparagraphs a through h provide sufficient support for my conclusion
but as I stated in my prior affidavit these articles are just a part of a much larger body of literature
and studies that support my conclusion Additional compelling support may be found in the
following pre2008 articles
i JEMitchel A P Campbell NE New LRSadofsky JA Kastelik SA
Mulrennan SJ Compton and AH Morice Expression AND
CHARACTERIZATION OF THE INTRACELLULAR VANILLOID RECEPTOR TRPV I
IN BRONCHI FROM PATIENTS WITH CHRONIC COUGH Experimental Lung
Research 31295306 2005
j T Higenbottam CHRONIC COUGH AND COUGH REFLEX IN COMMON LUNG
DISEASES Pulmonary Pharmacology Therapeutics 15241247 2002
k Pierangelo Geppetti Serena Materazzi Paola Nicoletti THE TRANSIENT
RECEPTOR POTENTIAL VANILLOID 1 ROLE IN AIRWAY INFLAMMATION AND
DISEASE European Journal ofPharmacology 533207214 2006
1 W J Meggs NEUROGENIC INFLAMMATION AND SENSITIVITY TO
ENVIRONMENTAL CHEMICALS Environ Health Prospect 101234238 1993
Again the articles cited here are just a small part of a larger body of literature and scientific
studies as I will explain further below
13 I have also identified three articles reviewing the scientific literature regarding
capscaicin TRP receptors sensitization and respiratory illness Even though these articles are
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but as I stated in y prior affidavit these articles are just a part of a uch larger body of literature 
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follo ing pre-2008 articles: 
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Research, 31 :295-306 (2005). 
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ISE SES, ul onary har acology & Therapeutics, 15:241-247 (2002). 
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DISEASE, European Journal o/Phar acology 533:207-214 (2006). 
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gain, the articles cited here are just a s all part of a larger body of literature and scientific 
st ies as I ill e lai  f rt er el . 
. I have also identified three articles revie ing the scientific literature regarding 
capscaicin, T P receptors, sensitization, and respiratory illness. Even though these articles are 
   . T, . .,    AINTIF 'S    
URT'S   NDANT'S     -  
published in 2009 and 2010 they provide a fair overview of the state ofknowledge prior to 2008
Of the fifty eight cited in in LuYuan Lee and Qihai Gu Role of TRPV 1 in Inflammation
Induced Airway Hypersensitivity Current Opinion in Pharmacology9243249 2009 in which
the authors provided a review of some of the literature and studies of TRPV 1 and its role in
airway hypersensitivity and related airway diseases only eight were published in 2008 or later
A similar review was published in Pulmonary Pharmacology Therapeutics 22 6570 2009
by John J Adcock entitled TRPV 1 Receptors in Sensitization of Cough and Pain Reflexes Of
the fifty nine articles cited in the review only three were published in 2008 and none of them
were published after 2008 Another valuable review was by K Alawi and J Keeble in
Pharmacology and Therapeutics 125 181 195 2010 The paradoxical role of the transient
receptor potential vanilloid 1 receptor in inflammation Of the 226 articles cited in the
review only fourteen were published inafter 2008 All three of these reviews support my
conclusion about the state of the science at the time SEC sold its MK9product to IDOC by their
citation to much of the same body of literature that I have relied upon in reaching my conclusion
14 I have attached hereto as Exhibit 1 a true and correct copy of each of the articles
cited to in this affidavit
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SUBSCRIBED AND SWORN TO before me this ZIdayof 2011
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METABOLISM OF CAPSAICINOIDS BY P450 ENZYMES
A REVIEW OF RECENT FINDINGS ON REACTION
MECHANISMS BIOACTIVATION AND DETOXIFICATION
PROCESSES
Christopher A Reilly and Garold S Yost
Department of Pharmacology and Toxicology University of Utah Salt Lake City
Utah USA
Capsaicinoids are botanical irritants present in chili peppers Chili pepper extracts and
capsaicinoids are common dietary constituents and important pharmaceutical agents Use
of these substances in modern consumer products and medicinal preparations occurs
worldwide Capsaicinoids are the principals of pepper spray selfdefense weapons and
several over the counter pain treatments as well as the active component of many dietary
supplements Capsaicinoids interact with the capsaicin receptor akVRl or TRPVI to
produce acute pain and cough as well as longterm analgesia Capsaicinoids are also toxic
to many cells via TRPVI dependent and independent mechanisms Chemical modifications
to capsaicinoids by P450 enzymes decreases their potency at TRPVI and reduces the phar
macological and toxicological phenomena associated with TRPVI stimulation Metabolism
of capsaicinoids by P450enzymes also produces reactive electrophiles capable ofmodifying
biological macromolecules This review highlights data describing specific mechanisms by
which P450 enzymes convert the capsaicinoids to novel products and explores the relationship
between capsaicinoid metabolismand its effects on capsaici imilpharmacology andtoxicology
CAPSAICINOID PHARMACOLOGY TOXICOLOGY AND HUMAN
EXPOSURE SOURCES
The capsaicinoids are a family of natural products isolated from the fruits of hot
peppers Govindarajan 1985 Govindarajan and Sathyanarayana 1991 These substances
produce the characteristic sensations associated with the ingestion of spicy food Capsaici
noids elicit multiple characteristic pharmacological responses that include severe irrita
tion inflammation erythema and transient hyper and hypoalgesia at exposed sites
capsaicinoids are particularly irritating to the eyes skin nose tongue and respiratory
tract where large numbers of sensory nerve fibers C and AS terminate that express
high quantities of the capsaicin receptor ieVRl or TRPV1 TRPVI has been cloned
and its pharmacological properties and physiological roles characterized Caterina et al
Presented at the Seventh International Symposium on Biological Reactive Intermediates Tucson
Arizona January 472006
Address correspondence to Dr Christopher A Reilly Department of Pharmacology and Toxicology
University of Utah 30 S 2000E Room 201 Skaggs Hall Salt Lake City UT 84112 USA Fax 801 5853945
Email ChrisReilly@pharmutahedu
685
001075
rug etabolism Re i s. 3 : 5-70 . 2006 
Copyright © Informa ealthcare 
ISS : 0360-2532 print 1 1097-9883 online 
l: 0.108010 60253 600 59 57 
forma 
healthcare 
IS   I I I    S: 
 I    I I   I  
, - ,  I  
 
isto  . ill   l  . ost 
epartment of Phar acology and Toxicology, niversity of tah, Salt Lake ity, 
t ,  
apsaicinoids are botanical irritants present in chili peppers. hili pepper extracts and 
capsaicinoids are co on dietary constituents and i portant phar aceutical agents. se 
 these e       i i    
orld ide. apsaicinoids are the principals f pepper spray self-defense eapons and 
several over-the-counter pain treat ents as ell as the active co ponent f any dietary 
supplements. Capsaicinoids interact with the capsaicin receptor (a.k.a., VRI or TRPVl) to 
produce acute pain and cough as well as long-term analgesia. Capsaicinoids are also toxic 
to y cells via l-dependent  independent echanis s. he ical odifications 
to capsaicinoids by P450 enzymes decreases their potency at TRPVl and reduces the phar-
macological and toxicological phenomena associated with TRPVl stimulation. etabolism 
of capsaicinoids by P450 enzy es also produces reactive electrophiles capable of oditying 
biological acro olecules. This review highlights data describing specific echanis s by 
hich P450 enzy es convert the capsaicinoids to novel products and explores the relationship 
bet een capsaicinoid etabolis  and its effects on capsaicinoid phar acology and toxicology. 
 L Y, I ,   
  
The capsaicinoids are a family of natural products isolated from the fruits of "hot" 
peppers ( ovindarajan, 1985; ovindarajan and Sathyanarayana, 1991). These substances 
produce the characteristic sensations associated ith the ingestion of spicy food. apsaici-
noids elicit ultiple characteristic phar acological responses that include severe irrita-
tion, infla ation, erythe a, and transient hyper- and hypoalgesia at exposed sites; 
capsaicinoids are particularly irritating to the eyes, skin, nose, tongue, and respiratory 
tract, here large nu bers of sensory nerve fibers ( - and S-) t i t  t t  
high quantities of the capsaicin receptor (Le., 1 or PV1). PV1 has been cloned 
and its phar acological properties and physiological roles characterized ( aterina et aI., 
Presented at the Seventh International Symposium on Biological Reactive Intermediates. Tucson, 
Arizona, January 4-7.2006. 
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Capsaicinoid A1kyl5ideChain
Capsaicin OH
Homocapsaicin C0
Nordihydrocapsaicin C0H
Dihydrocapsaicin C0H
Homodihydrocapsaicin CO
Nonivamide COH
Figure I The chemical structure of capsaicin and related capsaicinoid analogs The chemical structure of capsaicin
is shown and the vanilloid ring and variable acyl termini potions of capsaicinoid analogs are highlighted The
structures of the alkyl termini of the major naturally occurring capsaicinoids are also represented in text form
1997 TRPVl is a calcium channel that when activated by capsaicinoids produces the
characteristic sensations previously described and causes toxicity in many mammalian
cell types Lee et al 2000 Maccarrone et al 2000 Macho et al 2000 Surh 2002
Reilly et al 2003b Agopyan et al 2004 Reilly et al 2005 Johansen et al 2006 Sev
eral excellent and comprehensive reviews dedicated to TRPV1 have been published
Szallasi and Blumberg 1999 Caterina and Julius 2001
There are numerous naturally occurring capsaicinoid analogs Kozukue et al 2005
Thompson et al 2005a Thompson et al 2005b but six most abundant analogs are capsaicin
dihydrocapsaicin nordihydrocapsaicin nonivamide homocapsaicin and homodihydrocapsai
cin Reilly et al 2001a Reilly et al 2001b The chemical structures of themajor capsaicinoid
analogs are depicted in Fig 1 All analogs have the capacity to bind to and activate TRPV1
albeit with different potencies depending primarily upon the alkyl chain structure Pyman
1925 Hayes 1984 Gannett 1990 Walpole et al 1993a Walpole et al 1993b Walpole et al
1993c and a 3methoxy4hydroxybenzylamine vanilloid ring Capsaicin and nonivamide
are the most potent and pungent analogs followed by dihydrocapsaicin and the remaining ana
logs Common sources for human exposure to capsaicinoids include ingestion of spicy foods
and use of oral dietary supplements application of topical creams to treat chronic pain neural
gia and psoriasis and inhalation by exposure to cooking fumes and pepper spray aerosols
Szallasi and Blumberg 1993 Szallasi and Blumberg 1999 Robbins 2000 Reilly et al
2001a Reilly et al 2001b Szallasi and Appendino 2004 Reilly 2006 Capsaicinoids in the
form of oleoresin capsicum are classified as GRAS Generally Regarded As Safe substances
by the United States Food and Drug Administration FDA and are approved as food additives
or as topical analgesics without extensive toxicological profiling
Early studies of capsaicinoid toxicity demonstrated extreme differences depending
upon the route of exposure Oral and topical capsaicin exposures yielded LD values in
mice at 190 and 500 mgk respectively whereas intravenous and intratracheal instillation
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There are nu erous naturally occurring capsaicinoid analogs (Kozukue et aI., 2005; 
Tho pson et aI., 2005a; Tho pson et aI., 2005b), but six ost abundant analogs are capsaicin, 
i r i i , r i r i i , i i , saicin,  i roca i-
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1993c) and a 3- ethoxy-4-hydroxybenzyla ine (vanilloid) ring. apsaicin and noniva ide 
are the ost potent and pungent analogs, follo ed by dihydrocapsaicin and the re aining ana-
logs. o on sources for hu an exposure to capsaicinoids include ingestion of spicy foods 
and use of oral dietary supple ents; application of topical crea s to treat chronic pain, neural-
gia, and psoriasis; and inhalation by exposure to cooking fu es and pepper spray aerosols 
(Szallasi and lu berg, 1993; SzaIlasi and lu berg, 1999; obbins, 2000; eilly et al., 
2001a; Reilly et aI., 2001b; SzaIlasi and Appendino, 2004; Reilly, 2006). Capsaicinoids, in the 
form of oleoresin capsicum, are classified as GRAS (Generally Regarded As Safe) substances 
by the United States Food and Drug Administration (FDA) and are approved as food additives 
r as t ical a al esics itho t e te si e t ic logical r fili . 
Early studies of capsaicinoid toxicity demonstrated extreme differences depending 
upon the route of exposure. ral and topical capsaicin exposures yielded LDso values in 
ice at  a  0 g/kg, res ecti el , ereas i tra e ous a  i tratrac eal i stillation 
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routes produced LD values of056 and 16 mgkg respectively Glinsukon et al 1980
Regardless of the route of exposure the cause of death for the animals was rapid onset of
convulsions within 05ivto 38 po minutes due to cardiovascular and pulmo
nary dysfunction and failure Routine use of capsaicinoidcontaining products by humans
in various forms on a daily basis by large numbers of diverse people suggest that capsaici
noids are safe under normal conditions via topical and oral routes However extreme
exposure scenarios resulting in acute toxicity severe injury and fatality have occurred
Heck 1995 Steffee et al 1995 Billmire et al 1996 Busker and van Helden 1998
Smith and Stopford 1999 Olajos and Salem 2001 Granfield 1994
Excessive ingestion of oleoresin capsicum by a child undergoing homeopathic treatment
of a digestive disorder resulted in death Snyman 2001 Severe cardiovascular and
pulmonary toxicities have also been observed in subjects exposed to pepper sprays partic
ularly in those individuals who had preexisting respiratory or cardiovascular diseases or
in individuals under the influence of illicit drugs eg methamphetamine The precise
mechanisms by which the capsaicinoids precipitated these responses and the relationship
if any between drug metabolism activation of TRPV1 and pharmacological activity have
been essentially unexplored
Metabolism of Capsaicin by P45O Enzymes Past and Present
Initial studies on the metabolism of capsaicin by P450 enzymes demonstrated the
formation of multiple products arising from aromatic and alkyl hydroxylation Lee 1980
Kawada et al 1984 Gannett 1990 Surh et al 1995 Surh and Lee 1995 Because of the
state and availability of modern sophisticated bioanalytical technologies at the time of
these studies typically little definitive structural information for the observed metabolites
was presented
Recent studies performed in our laboratory have confirmed the initial conclusions
regarding the formation of aliphatic and aromatic hydroxylated products In addition a
number of new metabolites arising from multiple and novel metabolic processes were
identified Reilly et al 2003a Metabolites arising from alkyl dehydrogenation and
oxygenation aromatic hydroxylation and Odemethylation were described Based on
extensive characterization of the metabolites by liquid chromatography tandem mass
spectrometry LCMSMS UVvisible absorbance spectroscopy and 1D and 2D
proton and carbon13 NMR a scheme for the metabolism of capsaicin by human liver
microsomal P450 enzymes was proposed Fig 2 Products included the formation of an
unusual macrocyclic metabolite M1 that was postulated to be formed through covalent
bond formation between the amide nitrogen of capsaicin and a uniquely stable tertiary
allylic carbocation at the penultimate c01 carbon of the alkyl side chain a dehydroge
nated alkyl diene M4 and a dehydrogenated imide metabolite M9 The formation of
w and w1 alcohols M2 and M3 respectively two aromatic phenols M5 and M7
and an 0demethylated metabolite M6 was also observed Tentative structural identifi
cation for a metabolite that was formed by Ndehydrogenation and subsequent aromatic
hydroxylation M8 was also presented M8 exhibited UVvisible absorption characteris
tics consistent with a molecule with extended conjugation The proposed structure and a
potential mechanism for the formation of M8 via sequential oxidation processes involv
ing the imide M9 as the secondary substrate are presented in Fig 3 The relative amounts
of each metabolite were dependent on the P450 enzymes that were used as presented in
Table 1
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Figure 2 Schematic representation of the primary metabolites of capsaicin produced by P450 enzymes and the
associated metabolic pathways underlying their formation Each metabolite has been given a reference number
M1M9 which is used throughout the review Specific details on the characterization of these metabolites and
methods used to determine their structures can be found in Reilly et al 2003a
Detoxification and Bioactivation of Capsaicin by P450s
Structure activity studies employing models of acute pain and altered pain sensitiv
ity in mice have demonstrated a strict structural requirement for both the vanilloid ring
pharmacophore and a hydrophobic alkyl sidechain consisting of 812 carbon atoms that
may be saturated or unsaturated and branched or unbranched to havemaximum potency at
TRPV1 Walpole et al 1993b Walpole et al 1993a Walpole et al 1993c Modifica
tions to either of the pharmacophores of capsaicin or its analogs were shown to reduce
potency drastically Based on these data and studies of the proposed capsaicinbinding site
of TRPV1 Jordt and Julius 2002 Gavva et al 2004 one would predict that P450
dependent metabolism of capsaicinoids to produce the metabolites shown in Fig 2 would
limit the pharmacological and toxicological effects of these molecules via reduction in
their affinity for TRPV1
However early research exploring the relationship between metabolism of capsaici
noids and capsaicinoid toxicity yielded conflicting results Some studies have demon
strated that bioactivation of capsaicinoids by S9 liver fractions produced metabolites
capable of inducing genetic mutations in the form of His reversions Salmonella typh
imurium strains TA98 TA100 TA1535 azaguanine resistance in Chinese hamster V79
cells micronuclei formation in Swiss and albino mice and chromosomal aberrations in
human lymphocytes Surh and Lee 1995 Proposed mechanisms for the mutagenicity of
capsaicinoids involved the formation of an electrophilic epoxide 1 electron oxidized
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noids and capsaicinoid toxicity yielded conflicting results. Some studies have demon-
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Figure 3 Proposed metabolic pathway for the formation ofM8 from M9 via a sequential P450dependent oxida
tion process Capsaicin is initially metabolized to generate an imide M9which subsequently undergoes epoxi
dation and tautamerization to generate M8 Reilly et al 2003a Sun 2006
Table 1 Relative metabolite abundance pooled human liver microsomes and the principal P450 enzymes
responsible for producing each metabolite ofcapsaicin
Metabolite
Approx Total
Metabolites HLM Principal P450 Enzyme
M1 Macrocycle 22 2C9 2CI9 2E1
M2 toOH 26 2E1 2C8
M3w1OH 65 3A4 2C8
M4 Diene 26 2C9 2C19 2E1
M5 AromaticOH 13 1A2 2C 19
M6 0Demethyl 5 1A2 2C19 3A4 2D6
M7AromaticOH 75 2B6 2C8 2E1
M8 Oxygenated and Dehydrogenated 29 3A4 lAl 2E1 2C8 2D6 2B6
M9Imide 26 3A4 lAl 2136
phenoxyl radical intermediates as observed for peroxidasemediated metabolism of cap
saicinoids andor redox cycling of catecholquinone metabolites arising from aromatic
hydroxylation andor Odemethylation Unfortunately definitive evidence for the forma
tion of these metabolites by S9 fractions and detailed mechanistic toxicity studies were not
performed Furthermore subsequent experiments to validate the mutagenicity findings
failed to repeat the initial results completely Lawson and Gannett 1989
Additional studies investigating the formation of electrophiles from capsaicin by
P450 enzymes provided more direct evidence for the formation of metabolites capable of
modifying biological macromolecules Miller 1983 Gannett 1990 The authors of these
studies proposed that the ability of radiolabeled capsaicinoids to bind microsomal
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phenoxyl radical inter ediates (as observed for peroxidase- ediated etabolis  of cap-
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dditional studies investigating the for ation of electrophiles fro  capsaicin by 
P450 enzy es provided ore direct evidence for the for ation of etabolites capable of 
odifying biological acro olecules (Miller. 1983; annett. 1990). he authors of these 
studies proposed that the ability of radiolabeled capsaicinoids to bind icroso al 
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proteins including CYP2E1 and possibly other P450 enzymes occurred through an elec
trophilic arene oxide or quinone methide The latter metabolite is a common type of
metabolite generated from structurally similar 0methoxy4alkylphenols Thompson
et al 1995 Unfortunately neither the formation of the epoxide nor the quinone methide
was clearly demonstrated With the discovery of TRPV 1 in 1997 research on the relation
ship between capsaicinoid toxicity pharmacology and metabolism has gained new
momentum and a number of detailed studies have demonstrated a direct relationship
between the metabolic transformation of capsaicinoids and the role of the TRPV1 in cap
saicinoid pharmacology and toxicity
Recent studies in our laboratory of capsaicin metabolism by P450 enzymes has confirmed
many of the hypotheses presented by earlier reports regarding electrophile formation It
has been demonstrated that at least four separate electrophilic metabolites are produced
from capsaicin by P450 enzymes Addition of the endogenous nucleophile glutathione
GSH to in vitro metabolic incubations of capsaicin and human liver microsomes
revealed that the Odemethylated M6 the aromatic hydroxylated M5 and M7 and the
oxygenated imide metabolite M8 were amenable to depletion by GSH whereas many
other metabolites egM1 M2 and M3 were produced at significantly higher quantities
Corresponding GSH adducts of three of these metabolites have been identified by LCMS
MS Fig 4 G1G3 In addition evidence for the formation of a quinone methide metab
olite generated from P450mediated oxidation of the 4OH group of the vanilloid ring
has been obtained This adduct G4 exhibited properties consistent with addition of GSH
to the benzylic position of the quinone methide metabolite as would be predicted based on
prior studies of related alkyl phenols and catechols Iverson et al 1995 All GSH adducts
were identified using LCMSMS and neutral loss scanning of pyroglutamate 129 u and
scanning for the loss of GSH 307 u from precursor ions Baillie 1993 A general
scheme for the formation of electrophilic metabolites and GSH adducts of capsaicin by
P450 enzymes is shown in Fig 4
Unpublished studies from our laboratory have also demonstrated significance for
P450 metabolism with respect to toxicity via the formation of electrophilic species from
capsaicinoids One or more of these reactive metabolites has been shown to cause the
time concentration and NADPH dependent inactivation of CYP2E1 Fig 5 as pre
viously described Miller 1983 Gannett 1990 Miller et al 1993 Although not speci
fically tested the inactivation of CYP2E1 and possibly other P450 enzymes by
capsaicinoids may have the potential to cause toxicities through a variety of mechanisms
including deleterious drug drug interactions arising from deficiencies in drug clearance
capacity Alternatively inhibition of P450 enzymes such as CYP2Elmay prove to be
beneficial such as that shown for bioactivation of known pro carcinogens that are bio
activated by P450 enzymes Miller et al 1993 Zhang et al 1993 Zhang et al 1997
Tanaka 2002
Preliminary studies from our laboratory also suggest that metabolism of capsaicino
ids by P450s can alter toxicity Assessment of capsaicinoid toxicity through activation of
TRPV1 in a lung cell model was used to assess this process The results demonstrated a
decrease in toxicity when cells were treated with extracts of capsaicin metabolites extra
cated from in vitro incubations containing human liver microsomes with and without
NADPH or added P450 Table 2 Complimentary studies demonstrated an increase in
toxicity with inhibition of P450dependent metabolism in these cells with 1aminmoben
zotriazole 1ABT Table 2 Results demonstrating identical LD values for the Odem
ethylated metabolite M6 in normal and TRPV1overexpressing cells Table 2 implied a
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to the benzylic position of the quinone met hide metabolite. as would be predicted based on 
prior studies of related alkyl phenols and catechols (Iverson et a1.. 1995). ll  adducts 
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ti e. concentration. and P -dependent inactivation of C P2El (Fig. 5). as pre-
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fically tested. the inactivation of CYP2El, and possibly other P450 enzy es. by 
capsaicinoids may have the potential to cause toxicities through a variety of mechanisms. 
including deleterious drug-drug interactions arising from deficiencies in drug clearance 
capacity. Alternatively. inhibition of P450 enzymes such as CYP2Elmay prove to be 
beneficial. such as that sho n for bioactivation f kno n pro-carcinogens that are bio-
activated by P450 enzymes ( iller et a1.. 1993; Zhang et a1.. 1993; Zhang et a1.. 1997; 
Tanaka. 2002). 
reli inary studies fro  our laboratory also suggest that etabolis  of capsaicino-
ids by P450s can alter toxicity. Assess ent of capsaicinoid toxicity through activation of 
TRPVl in a lung cell odel was used to assess this process. The results de onstrated a 
decrease in toxicity when cells were treated with extracts of capsaicin etabolites extra-
cated fro  in vitro incubations containing hu an liver icroso es with and without 
NADPH or added P450 (Table 2). Co pli entary studies de onstrated an increase in 
toxicity with inhibition of P450-dependent metabolism in these cells with l-aminmoben-
zotriazole (I- BT) (Table 2). Results de onstrating identical LDso values for the -de -
ethylated metabolite (M6) in normal and TRPVl-overexpressing cells (Table 2) implied a 
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Figure 4 Representative metabolic pathways that lead to the formation of glutathione adducts of capsaicin Spe
cific metabolic processes and resulting metabolites that are amenable to trapping by glutathione are shown The
corresponding MHion for each adduct is also provided Identification and preliminary structural assignments
were generated by interpretation of liquidchromatographic tandem mass spectrometric data and comparison to
predicted mass spectra MassFrontier 40
nonTRPV1 dependent mechanism of toxicity This alternate mechanism likely involved
redox cycling of the catechol with oxygen to form electrophilic quinoid metabolites and
reactive oxygen species ROS Either of these products could then alter critical biomole
cules and associvated cellular processes to promote toxicity Hence metabolism of capsa
icinoids by P450 enzymes may play a dual role in capsaicioid toxicity and pharmacology
These studies provide support for the prior work on capsaicinoid toxicity and provide sig
nificant new data that illustrate the complex interactions between these metabolites and
mechanisms of capsaicinoid bioactivity
Alkyl Dehydrogenation and Oxygenation of Capsaicinoids by
P450 Enzymes
P450 enzymes are notorius for catalyzing the hydroxylation oxygenation of sub
strates This process occurs via a welldefined series of chemical reactions involving the
sequential transfer of electrons and protons between the P450 heme substrate and molec
ular oxygen During substrate oxygenation reactions P450 enzymes catalyze the site
specific abstraction of hydrogen from the substrate to generate intermediate substrate rad
icals that subsequently undergo oxygen rebound to form the corresponding hydroxylated
product The overall reaction can be summarized by the following equations where R
represents the substrate
NADPH HO R NADP H R OH 1
This catalytic process has been extensively characterized and is widely accepted
Many comprehensive reviews dedicated to this subject are available Lewis and Pratt
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lkyl e y r e ati  a  xy e ati  f a saici i s y 
 z  
 e z es are t rius f r catal zi  t e r lation (oxyge ati n) f sub-
strates. his process occurs via a ell-defined series f c e ical reacti s i l ing t e 
s ti l tr sf r f l tr s  r t s t ee  t   e, s str t ,  l c-
lar e . rin  s strate e ati  reacti s,  e z es catal ze t e site-
s ifi  str ti  f r  fr  t  s str te t  r t  i t r iate s str t  r d-
i ls t t s s tl  r o  r  t  f r  t  rr s i  r late  
r t.  r ll r ti    s ri   t  f ll i  ti s, r   
r re t  t  tr te: 
DPH+W02 + ~NADP+ +H20+R-O  (1) 
his catalytic process has been extensively characterized and is idely accepted. 
any co prehensive revie s dedicated to this subject are available (Le is and Pratt, 
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Figure 5 Time and concentration dependent inactivation of recombinant CYP2E1 by capsaicin Incubations
contained CYP2E1 NADPH and various concentrations of capsaicin At various time points after the addition
of NADPH aliquots were removed from the primary incubation mixture and assayed for residual p nitrophenol
PNP oxidase activity Data are expressed as Log remaining activity versus samples with no pre incubation
Additional studies yielded the following criteria for inactivation rate of inactivation 02 min apparent K
25 pM and a partition ratio 7 Smeal 2002
Table 2 Approximate LD values for capsaicin in various cell lines treated with P450 inhibitors and P450
derived metabolites
Treatment BEAS213
TRPV 1 Over
expressing BEAS 213 HepG2
Capsaicin 100 8 RM I 03pM 200 pM
05mM 1ABT 90 6RM Not Determined 180 8 pM
Extracted capsaicin Not Determined 4pM Not Determined
Extracted capsaicin metabolites HLM Not Determined 10 pM Not Determined
M6 synthetic 5 1 pM 5 2 pM Not Determined
1998 Guengerich 2001a Guengerich 2001b Parkinson 2001 This catalytic cycle is
also depicted in Fig 6 steps 1 6a
A less common and frequently overlooked pathway for xenobiotic metabolism by
P450 enzymes involves the desaturationehydrogenatio of chemicals to produce oxi
dized products including alkenes Numerous examples of substrate dehydrogenation reac
tions exist in the literature including the formation of alkenes from fatty acids Guan
et al 1998 Haining et al 1999 a toxic alkene of valproic acid Rettie et al 1987 Rettie
et al 1988 Kassahun and Abbott 1993 Rettie et al 1995 Sadeque et al 1997 ezlopitant
Obach 2001 and reactive eneimine metabolites of the leukotriene receptor antagonist
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c tai e  l. . a  ari s c ce trati s f ca saici . t ari s ti e i ts after t e additi  
of NADPH. aliquots were removed from the primary incubation mixture and assayed for residual p-nitrophenol 
(P ) idase ti it . at  r  ress  s og% r i i  ti it  rs s s les it   r -i ti n. 
Additional studies yielded the following criteria for inactivation: rate of inactivation = 0.02 min-I. apparent Kr = 
25 /l . and a partition ratio = 7 (S eal. 2002). 
able 2 pproxi ate Dso values for capsaicin in various cell lines treated ith P450 inhibitors and P450-
e  t oli s. 
I- er-
re t t -2B r ssi  -2B ep 2 
s i i   ± /l   ± .3/l  >200/l  
+0.5  I-AB   ± /l  t t r i   ± /l  
Extracted capsaicin t t r i  -4/l  t t r i  
Extracted capsaicin etabolites ( L ) t eter i e  >IO/l  t t r i  
6 (synthetic) ±I/l  ±2/l  t t r i  
1998; Guengerich. 2001a; Guengerich. 2001b; Parkinson. 2001). This catalytic cycle is 
also depicted in Fig. 6. steps 1-6a. 
 less co on and frequently overlooked path ay for xenobiotic etabolis  by 
P450 enzy es involves the desaturationldehydrogenation of che icals to produce oxi-
dized products. including alkenes. u erous exa ples of substrate dehydrogenation reac-
tions exist in the literature. including the for ation of alkenes fro  fatty acids (Guan 
et a1.. 1998; aining et a1.. 1999). a toxic alkene ofvalproic acid ( ettie et a1.. 1987; ettie 
t 1.. ;   tt. ; tti  t 1.. 95;  t 1.. 997). l it t 
(Obach. 2001). and reactive enei ine etabolites of the leukotriene receptor antagonist 
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Figure 6 Schematic representation of the P450 catalytic cycle and specific features that dictate substrate
hydroxylation and dehydrogenation Each step is numbered and described in the text
zafirlukast Kassahun et al 2005 and of the pneumotoxicant 3methylindole Adams
et al 1987 Yost 1989 Ruangyuttikarn et al 1991 Skiles and Yost 1996 Skordos et al
1998a Skordos et al 1998b Loneragan et al 2001 Interestingly many dehydrogenated
products of xenobiotics exhibit unique toxicity that is not observed for hydroxylated products
Mechanistically there are a number of similarities between substrate hydroxylation
and dehydrogenation reactions but distinct differences exist Dehydrogenation of a sub
strate is electronically equivalent to substrate hydroxylation with the exception that water
does not balance the stoichiometry Guengerich 2001a The dehydration process follows
identical pathways as those previously described for hydroxylation However these pathways
diverge and a distinct feature of the desaturation process is the subsequent reduction of
the ironoxo heme to form a substrate carbocation intermediate Fig 6 steps 6b and 7
which ultimately surrenders an additional proton to P450 to form a dehydrogenated prod
uct Fig 6 step 8b This final step does not occur during the hydroxylation of substrates
which typically proceed by direct oxygen rebound with the intermediate substrate radical
or by addition of a hydroxide equivalent to the carbocation intermediate Because both
hydroxylation and dehydrogenation of substrates occur via a similar catalytic process the
formation of these metabolites from a substrate typically coincides However in some
instances steric or substrate structural features unique to the enzyme and substrate pair
skew the relative rates of the competing oxygen rebound and secondary hydrogen abstrac
tion processes to increase or decrease the relative amounts of product formed This aspect
of P450 cataysis will be discussed in greater detail since this phenomenon appears to be a
prominent feature of capsaicin metabolism by certain P450 enzymes A schematic repre
sentation summarizing the biochemical processes that result in the formation of dehydroge
nated and hydroxylated metabolites of xenobiotics by P450 enzymes is presented in Fig 6
As previously described the initial characterization of metabolites produced from
capsaicin by P450s revealed the formation of several alkyl dehydrogenated and hydroxy
lated metabolites M1M4 It was noted in these initial studies that there was a significant
difference between the types and relative amounts of alkylderived metabolites generated
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ske  the relative rates of the co peting oxygen rebound and secondary hydrogen abstrac-
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pro inent feature of capsaicin etabolis  by certain P450 enzy es.  sche atic repre-
sentation su arizing the bioche ical processes that result in the for ation of dehydroge-
nated and hydroxylated etabolites of xenobiotics by 450 enzy es is presented in ig. 6. 
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capsaicin by 450s revealed the for ation of several alkyl dehydrogenated and hydroxy-
lated etabolites (MI-M4). It as noted in these initial studies that there as a Significant 
difference bet een the types and relative a ounts of alkyl-derived etabolites generated 
694 C A REILLYAND G S YOST
from capsaicin and its unsaturated straightchain analog nonivamide Reilly and Yost
2005 Specifically the relative amounts of corresponding macrocyclic c01hydroxy
lated alkene metabolites of nonivamide were much lower some were not produced at all
than those of capsaicin These preliminary results elicited a number of questions regarding
the underlying chemical and biochemical processes and the criteria that dictated the for
mation of these metabolites from each substrate These questions were addressed by a
series of experiments that compared the alky metabolism of multiple natural and synthetic
capsaicinoid analogs having variable alkyl terminal structure and were used to construct
models describing the alkyl metabolism of capsaicinoids by P450 enzymes
The effects of alkyl chain structure on the production of various metabolites from
capsaicin and its analogs are described in detail in Reilly and Yost 2005 These capsaici
noid analogs used in this study varied in the degree of saturation at the023 position the
presence or absence of a branched carbon chain at the w1 carbon and altered alkyl chain
length The structures are shown in Fig 1 with the exception of n vanillyloctanamide and
nvanillyldecanamide which differed from nonivamide nvanillylnonanamide by 1 and
1 carbon in the alkyl chain respectively Results for the production of alkyl hydroxylated
and dehydrogenated metabolites M1M4 from these variable substrates by human liver
microsomes are summarized in Table 3 In general the following trends were observed
Formation of macrocyclic colhydroxylated and dienealkene metabolites was strictly
dependent upon the configuration of the alkyl terminal structure Specifically substrates
with a tertiary carbon atom and an unsaturated bond at the w23 position capsaicin and
homocapsaicin exhibited the greatest propensity to form M1 M3 and M4 but substrates
lacking the unsaturated bond at the w23 position eg nordihydrocapsaicin dihydrocap
saicin and homodihydrocapsaicin or straightchain analogs egnonivamide and other
nacylvanillamides produced markedly lower to nondetectable quantities of these metab
olites respectively These data were consistent with the concept that the relative free
energy and stability of the radical and carbocation intermediates formed at the tertiary
allylic carbon atom of capsaicin were much lower than those associated with formation of
primary secondary or tertiary intermediates from straightchain or saturated branched
chain analogs The exceptional stability of the tertiary allylic intermediates formed with
capsaicin ultimately dictated the formation of the macrocyclic M1 diene M4 and co1
hydroxylated M3 metabolites from these diverse substrates Decreases in the formation
of M1 M3 and M4 from the other capsaicinoids paralleled the predicted stability and rel
ative free energies associated with these molecules and supported the mechanism shown
Table 3 Relative production of alkyl derived metabolites ofmultiple capsaicinoid analogs with different alkyl
terminal structure by pooled human liver microsomes
Capsaicinoid Analog Relative Metabolite Production Versus Capsaicin
Saturated analogs Macrocycle wOH olOH Terminal Alkene
Nordihydrocapsaicin 3 09 90 14 ND 15 4
Dihydrocapsaicin 6 2 180 15 ND 23 9
Homodihydrocapsaicin 10 2 193 7 ND 29 6
Straight chain analogs Macrocycle toOH olOH Terminal Alkene
nVanillyloctanamide ND 54 5 ND 3 1
Nonivamide ND 135 8 ND 6 3
nVanillyldecanamide ND 170 15 ND 14 5
Increased chain lengths Macrocycle oOH o1OH Diene
Homocapsaicin 48 8 50 13 60 12 8 1
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capsaicin and its analogs are described in detail in eilly and ost (2005). hese capsaici-
noid analogs used in this study varied in the degree f saturation at the w-2.3 position. the 
presence or absence f a branched carbon chain at the -l carbon. and altered alkyl chain 
length. he structures are sho n in ig. 1. ith the exception f n-vanillyloctana ide and 
n-vanillyldecana ide. hich differed fro  noniva ide (n-vanillylnonana ide) by -1 and 
+ 1 carbon in the alkyl chain. respectively. esults for the production f alkyl hydroxylated 
and dehydrogenated etabolites (MI-M4) fro  these variable substrates by hu an liver 
icroso es are su arized in able 3. In general, the follo ing trends ere observed. 
r ti  f r cycli . w-I- r l t .  ie e/alkene t lit s s stri tl  
t  t  fi r ti  f t  l l t r i l str t r . ecifi all . s str t s 
it   t rti r  r  t    s t r t  d t t  -2.3 siti  (caps i i   
i i ) i ite  t  re te t r it  t  f r  l. .  . t tr t  
la in  t  t r t   t t  -2.3 iti  (e.g .. r i r saicin. i r p-
saicin. and ho odihydrocapsaicin) or straight-chain analogs (e.g .. noniva ide and other 
- l ill i s) r  r l  l r t  t t l  tities f t  t b-
lit . ectively.  t  ere i t t ith t  t t t t  l ti   
energy and stability of the radical and carbocation inter ediates for ed at the tertiary 
allylic carbon ato  of capsaicin ere uch lo er than those associated ith for ation of 
pri ary. secondary. or tertiary inter ediates fro  straight-chain or saturated branched-
chain analogs. he exceptional stability f the tertiary allylic inter ediates for ed ith 
capsaicin ultimately dictated the formation of the macrocyclic (MI), diene (M4), and w-I-
hydroxylated (M3) metabolites from these diverse substrates. Decreases in the formation 
f I. .   fr  t  t r s i i i s r ll le  t  r i te  st bilit   r l-
ti e fre  r i s ss i t  it  t s  l l s  s rt  t  is  s  
le  l ti  ti   l l- ri  t lit   ltiple i i i  l s it  i fere t l l 
ter inal structure by pooled hu an liver icroso es. 
i i id l  l ti e t lit  r ti  r  i i  (%) 
at rate  a al s r cyd  ro-OH ro-l-0  r i l lkene 
ordihydrocaps icin .3 ± .9 ±  .D.  ±  
ihydrocapsaicin ±   ±  .D.  ±  
o o ihydrocaps i in  ±  3±  .D.  ±  
Straight -chain analogs acrocyde ro-OH ro-l-0H  lkene 
fl- anillyloctana ide .D. 4±  .D. ± I 
o iva ide .D.  ±  .D. ±  
fl- anillyldecana ide .D.  ±  .D.  ±  
Increased chain lengths acrocyde ro-OH 00-1-0H e e 
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Figure 7 Proposed reaction mechanism for the metabolism of capsaicin by P450 enzymes to generate the alkyl
derived metabolites M1 M2 M3 and M4 Capsaicin is initially activated at the alkyl terminus to generate an
unstable terminal methyl radical This species rapidly undergoes oxygen rebound to yield M2 a primary product
of all capsaicinoids Alternatively this unstable intermediate can rearrange and surrender an additional electron
to the high valent iron oxygen heme complex of the enzymes to yield a carbocation intermediate at the w car
bon atom This process primarily occurs for capsaicinoids with a tertiary allylic carbon atomwhere the carboca
tion is highly stabilized Little to no rearrangement products are observed for capsaicinoids having a tertiary or
secondary carbon only Formation of the tertiary allylic carbocation is requisite for the formation ofsignificant
quantities ofMl M3 and M4 Additional details for these mechanisms are presented in Reilly and Yost 2005
in Fig 7 As represented graphically in Fig 7 rearrangement of a primary terminal methyl
radical intermediate is proposed to describe the product profiles observed and occurs prior
to rearrangement to yield tertiary allylic intermediates and Ml M3 and M4 It is likely
that a formal primary radical or carbocation intermediate did not form during metabo
lism by P450s Rather a transition state wherein the radical character was initially pro
duced and primarily localized at the terminal position resulted in the formation of the
terminal alcohol via rapid oxygen rebound processes Subsequently with some substrates
in which the transition state charge density could be delocalized to more stable positions
with lower free energy rearrangement to w1 position and formation of a carbocation
occurred and ultimately produced M1 M3 and M4 via intramolecular trapping hydroxide
addition and loss of a second proton respectively As such itwas concluded that forma
tion of radical and carbocation intermediates that can be stabilized and rearranged to more
stable positions on the capsaicinoid molecule eg the tertiary allylic position of capsai
cin would produce greater quantities of products attributed to formation of the metabolic
intermediate at the co1 carbon Conversely substrates that lack the tertiary allylic motif
do not exhibit large favorable changes in free energy upon rearrangement of the terminal
methyl radical to the w1 position and would only form products derived from metabo
lism of the alkyl terminal carbon atomieM2
The exclusive formation of ohydroxylated metabolites from many of the capsaici
noid analogs supported the mechanism presented in Fig 7 In general metabolism of all
capsaicinoid analogs resulted in the formation of large quantities of 0hydroxylated M2
metabolites essentially independent of alkyl terminal structure One interpretation of
these data suggests a catalytic mechanism that involves the initial abstraction of hydrogen
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from the terminal carbon atom by the ironoxo heme prosthetic group of P450 enzymes as
shown in Fig 7 However based on the relative activation energies associated with
abstraction of hydrogen from either the w or w1 carbon atom and the relative stability of
the resulting radical intermediate one would predict that products derived from formation
of a metabolic intermediate at the co1 carbon atom egM1M3 or M4 would dominate
the product profiles This trend has been shown for a number of lipids and substrates shar
ing structural similarity to capsaicin and its straightchain analogs Rettie et al 1987
Rettie et al 1988 Kassahun and Abbott 1993 Rettie et al 1995 Sadeque et al 1997
Adas et al 1998 Bylund et al 1998a Bylund et al 1998b Guan et al 1998 Adas et al
1999 Haining et al 1999 Chuang et al 2003 but it was not observed for the capsaici
noid analogs These data suggest that not only do the chemical structure of the alkyl ter
minus of the capsaicinoids and the propensity to form stable rearrangement products
dictate the types of metabolites that are formed but specific enzyme substrate interactions
unique to capsaicinoids in many P450 enzymes also contribute to metabolic fate Hence
certain features of the capsaicinoids likely restrict access of the w1 carbon to the P450
heme thus favoring initial substrate activation at the terminal carbon atom In such a sce
nario the unusual obligate abstraction of hydrogen from the terminal methyl position of
capsaicinoids would occur as previously discussed and products derived from formation
of a radical or carbocation intermediate at the w1 position would form indirectly This
scenario appears to be the case for capsaicinoids
Enzyme Substrate Interactions that Govern Capsaicinoid Metabolism
Unique metabolite profiles are observed when using individual recombinant P450
enzymes Reilly and Yost 2005 The most explicit examples of this phenomenon are the
near exclusive formation of the alkyl dehydrogenated products M1 and M4 by CYP2C9
the preferential production of the ohydroxylated metabolite M2 and M1 and M4 by
CYP2E1 and the formation of only alkylderived metabolites arising from formation of
metabolic intermediates at the or1 carbon atom Ml M3 and M4 by CYP3A4 Fig 8
The metabolite profile observed for CYP3A4 represents what would be predicted based on
thermodynamicenergetic principles that typically govern themetabolism of lipids and other
substrates and are consistent with published data for the P450 dependent metabolism of
other alkanes shown to undergo activation preferentially at the co1 positions Adas et al
1998 Bylund et al 1998a Bylund et al 1998b Guan et al 1998 Adas et al 1999
Haining et al 1999 Chuang et al 2003 As such CYP3A4 appears to demonstrate a
lack of steric restriction for substrate access to the P450 heme whereas CYP2C9 and
CYP2E1 demonstrate unexpected metabolite profiles that strongly suggest that specific
enzyme substrate interactions between capsaicin and these enzymes play a definitive role
in determining both the types of reactions that can occur iepartitioning between dehy
drogenation vs oxygenation reactions and the specific site at which initial hydrogen
abstraction occursie o vs co1 Detailed reviews describing the concept of orienta
tiondirected dehydrogenation and hydroxylation reactions by P450s can be found in
Meunier et al 2004 and Kumar et al 2004
To further address the concept of sterically directed reaction mechanisms and to
address the hypothesis that specific interactions between P450 active site residues dictated
substrate access to the P450 heme and associated metabolic mechanisms the metabolism
was evaluated for a series of nonivamide analogs having 1 altered alkyl chain length and
2 specific modifications to the vanilloid ring structure It was found that increasing the
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fro  the ter inal carbon ato  by the iron-oxo he e prosthetic group of P450 enzy es, as 
sho n in ig. 7. o ever, based on the relative activation energies associated ith 
abstraction of hydrogen fro  either the (0- or (0-1 carbon ato  and the relative stability f 
the resulting radical intermediate, one would predict that products derived from formation 
f a etabolic inter ediate at the (0-1 carbon ato  (e.g., l, 3, or 4) ould do inate 
the product profiles. This trend has been shown for a nu ber of lipids and substrates shar-
ing str t ral Si ilarity t  s i i   its str i t-chain l s ( ttie t I., ; 
tti  t I., ; assa n  tt, ; tti  t aI., ;  t I., ; 
Adas et aI., 1998; Bylund et aI., 1998a; Bylund et aI., 1998b; Guan et aI., 1998; Adas et aI., 
1999; aining et aI., 1999; Chuang et aI., 2003), but it as not observed for the capsaici-
i  l s. es  t  est t t, t l   t  i l t t re  t  l l t r-
inus  t  i i i   t  it  t   t l  t ts 
dictate the types of metabolites that are formed, but specific enzyme substrate interactions 
ique t  ca saici ids i  a   e z es als  c tri te t  eta lic fate. e ce, 
certain feat res f t e ca saici i s li el  restrict access f t e (0-1 car  t  t e  
heme, thus favoring initial substrate activation at the terminal carbon atom. In such a sce-
nario, the unusual obligate abstraction of hydrogen from the terminal methyl position of 
capsaicinoids would occur, as previously discussed, and products derived from formation 
f a radical or carbocation inter ediate at the (0-1 position ould for  indirectly. his 
scenario appears to be the case for capsaicinoids. 
Enzy e Substrate Interactions that overn apsaicinoid etabolis  
nique etabolite profiles are observed hen using individual reco binant P450 
enzy es (Reilly and ost, 2005). The ost explicit exa ples of this pheno enon are the 
near exclusive for ation of the alkyl dehydrogenated products (Ml and 4) by C P2C9; 
the preferential production of the (O-hydroxylated etabolite (M2) and l and 4 by 
P2El; and the for ation of only alkyl-derived etabolites arising fro  for ation of 
etabolic inter ediates at the (0-1 carbon ato  (Ml, 3, and 4) by P3 4 (Fig. 8). 
The metabolite profile observed for CYP3A4 represents what would be predicted based on 
thermodynamic/energetic principles that typically govern the metabolism of lipids and other 
substrates and are consistent ith published data for the P450-dependent etabolis  of 
other alkanes sho n to undergo activation preferentially at the (0-1 positions (Adas et aI., 
1998; Bylund et aI., 1998a; Bylund et aI., 1998b; Guan et aI., 1998; Adas et aI., 1999; 
Haining et aI., 1999; Chuang et aI., 2003). As such, CYP3A4 appears to demonstrate a 
          , e    
P2El e strate e ecte  eta lite r files t at str l  s est t at s ecific 
enzy e substrate interactions between capsaicin and these enzy es playa definitive role 
in deter ining both the types of reactions that can occur (Le., partitioning bet een dehy-
drogenation vs. oxygenation reactions) and the specific site at which initial hydrogen 
a stracti  cc rs (Le., (0- s. (0-1). etaile  re ie s escri i  t e c ce t f rie ta-
tion-directed dehydrogenation and hydroxylation reactions by P450s can be found in 
i r t I. (2 )  r t I. (2 4). 
To further address the concept of sterically directed reaction echanis s and to 
address the hypothesis that specific interactions bet een P450 active site residues dictated 
t         t boli  ni s, t  l  
as evaluated for a series of noniva ide analogs having 1) altered alkyl chain length and 
2) specific modifications to the vanilloid ring structure. It was found that increasing the 
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Figure 8 Selective production of metabolites M1M4 by CYP2El 2C9 and 3A4 Data represent the relative
abundance peak areas of each metabolite obtained from the analysis of in vitro metabolic incubations by liquid
chromatographytandem mass spectrometry using acquisition parameters specific for the detection of each
metabolite Reilly et al 2003a Reilly and Yost 2005 All peak areas were normalized to that of an internal
standard For clarity data for CYP2E1 are amplified by a factor of 5 and those for CYP3A4 by 10 Equal quanti
ties of recombinant P450 enzymes were used
alkyl chain lengthof the capsaicinoid increased the formation of 0 alcohols see Table 3
These data implied that one of two processes was operational 1 the increased hydropho
bicity of the substrate favored partitioning into the enzyme andor 2 longer alkyl chain
lengths allowed for the alkyl terminus to penetrate more freely into the active site of P450s
such that interactions between the substrate terminus and the ironoxo heme became more
favorable Additional studies to elucidate this phenomenon will be required in order to
understand fully the significance of these results Specifically the possibility will be
investigated that even greater alkyl chain lengths 10 carbon atoms will promote meta
bolic switching to the w1 position or that shorter lengths 8 carbon atoms will prevent
terminal alcohol formation These data would ultimately support the hypothesis that the
vanilloid ring moiety of capsaicinoids dictates metabolism of the alkyl terminus of these
molecules by P450 enzymes
Additional studies using nonivamide analogs with altered vanilloid ring structures
were also performed to address the previously stated hypothesis Elimination or alkylation
of the 4011 group on the vanilloid ring of nonivamide as in nbenzylnonanamide 34
dimethoxynbenzylnonanamide or 3methoxynbenzylnonanamide drastically altered
the apparent ability of P450 enzymes to catalyze intra chain oxidation and dehydrogena
tion reactions For these three variant substrates a number of metabolites were observed
having MS properties consistent with modifications to the alkyl chain at multiple
positions along the chain Fig 9 depicts selectedreaction monitoring LCMSMS chro
matograms showing metabolite peaks that exhibit precursor toproduct ion transitions
specific to either addition of oxygen to the alkyl chain M 16 unchanged aromatic
ring or dehydrogenation of the alkyl chain M 21unchanged aromatic ring The
chromatograms show that essentially one product is formed from nonivamide but that
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e      ere d. 
l l i  l t  f t  s i i i  i crease  t  f r ti  f £O-alcoh ls (se  l  ). 
These data i plied that one of two processes was operational: 1) the increased hydropho-
i it  f t e trate f r  rtiti i  i t  t   /or ) l r l l i  
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  te        -oxo    
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li  itc ing t  t  £0-1 iti   t t t  l t s «8  t s) ill t 
ter inal alcohol for ation. hese data ould ulti ately support the hypothesis that the 
vanilloid ring moiety of capsaicin aids dictates metabolism of the alkyl terminus of these 
olecules by 450 enzy es. 
Additional studies using nonivamide analogs with altered vanilloid ring structures 
ere als  erf r e  t  a ress t e re i sl  state  t esis. li inatio  r al lation 
of the 4-0H group on the vanilloid ring of noniva ide. as in n-benzylnonana ide. 3,4-
di ethoxy-n-benzylnonana ide. or 3- ethoxy-n-benzylnonana ide. drastically altered 
the apparent ability of P450 enzy es to catalyze intra-chain oxidation and dehydrogena-
 . r    t t s.    t   r  
having SIMS properties consistent with odifications to the alkyl chain at ultiple 
itions l g t  i . i .  i ts l t d-r tion it ring /MS/MS ro-
atogra s sho ing etabolite peaks that exhibit precursor-to-product ion transitions 
i ic t  ithe  ition  ge  t  t  l l i  ([M + 16 j+ ~unchanged aro atic 
ring) or dehydrogenation of the alkyl chain ([M - 21 + ~unchanged aro atic ring). The 
chro atogra s sho  that essentially one product is for ed fro  noniva ide but that 
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Figure 9 Representative liquid chromatographic tandem mass spectrometric chromatograms from the analysis
of alkyl derived metabolites M1M4 and similar produced by dehydrogenation left panel and hydroxylation
right panel of structural variants of nonivamide From top to bottom Nonivamide nvanillylnonanainide 34
dimethoxynbenzylnonanamide 3methoxy nbenzylnonanamide nbenzylnonanamide and a 4methoxy3
hydroxynonivamide analog Specific criteria for the analysis of these metabolites by tandem mass spectrometry
are provided in the figures Known metabolites of nonivamide are labeled The series of peaks present for the
nonivamide analogs exhibit chromatographic and mass spectrometric properties consistent with the formation of
multiple metabolites derived from dehydrogenation and hydroxylation of the alkyl chain at multiple locations
from the terminal carbon inward These data are consistent with the elution profiles for such metabolites derived
from capsaicin suggesting that multiple metabolic sites occur on the alkyl side chains of these nonivamide
vanilloid ring variants
multiple products are formed from the other analogs Although the identities of these
metabolites have not been confirmed the preliminary LCMS data strongly support
the conclusion that the 4 OH group of capsaicinoids controls binding in P450 enzymes
and ultimately dictates alkyl metabolism Ablation of specific interactions between the
vanilloid ring OH group and P450 active site residues allows for conformations that favor
oxidation at multiple locations along the alkyl chain as opposed to obligate metabolism of
the alkyl terminus of nonivamide or capsaicin Additional support for this conclusion
was obtained using a 4methoxy3hydroxy nonivamide analog Changes in alkyl metabo
lism of this substrate were not observed relative to nonivamide suggesting a hydroxyl
group at either the 3 or 4 position on the vanilloid ring serves as a requisite hydrogen
bond donors to direct terminal oxidation of the alkyl terminus of the capsaicinoid mole
cule Hence it is likely that for many P450 enzymes particularly those with relatively
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noniva ide analogs exhibit chro atographic and ass spectro etric properties consistent ith the for ation of 
iple ites e  r    lation     t tiple  
fro  the ter inal carbon in ard. These data are consistent ith the elution profiles for such etabolites derived 
fro  capsaicin. suggesting that ultiple etabolic sites occur on the alkyl side-chains of these noniva ide 
(vani loid g) . 
ultiple products are for ed fro  the other analogs. lthough the identities of these 
etabolites have not been confir ed. the preli inary / SIMS data strongly support 
the conclusion that the 4-0  group of capsaicinoids controls binding in 450 enzy es 
and ulti ately dictates alkyl etabolis . blation of specific interactions bet een the 
vanilloid ring -O  group and P450 active site residues allo s for confor ations that favor 
oxidation at ultiple locations along the alkyl chain. as opposed to obligate etabolis  of 
the alkyl terminus of nonivamide (or capsaicin). Additional support for this conclusion 
was obtained using a 4-methoxy-3-hydroxy-nonivamide analog. Changes in alkyl metabo-
lis  of this substrate were not observed relative to noniva ide. suggesting a hydroxyl 
group at either the 3- or 4-position on the vanilloid ring serves as a requisite hydrogen 
bond donors to direct ter inal oxidation of the alkyl ter inus of the capsaicinoid ole-
cule. ence. it is likely that. for any P450 enzy es. particularly those ith relatively 
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restricted active sites eg CYP2E1 and CYP2C9 specific interactions between the
4OH group on the vanilloid ring of capsaicinoids and key residues in the active sites of
certain P450 enzymes control substrate binding in a way that prevents the intrachain
oxidation of the capsaicinoids
An illustration of how the 4OH group may restrict access of the alkyl chain to the
ironoxo heme of CYP2C9 is shown in Fig 10 This model represents one of several similar
and energetically favorable poses that were predicted for capsaicin in CYP2C9 This
model depicts an endon orientation for capsaicin in the active site of CYP2C9 where
the 4OH group of the vanilloid ring is positioned near Glu104 Phe114 and Leu208 in a
pocket distal to the heme iron As a result the alkyl terminus extends toward the heme
iron and the w and w1 carbon atoms reside 47and 512 A away from the heme iron
center respectively Analysis of space filling renderings of this model suggest that substi
tution of the Phe114 with a more bulky residue such as Trp may potentially limit the
three dimensional space of the vanilloid ring binding pocket Indeed site directed
mutagenesis studies in which Phe114 of CYP2C9 was substituted with Trp demonstrated
a shift in the relative ratio ofM1 to M4 produced by the mutant enzyme The ratio of M1
M4 produced by the Phel14Trp mutant was27versus 05for the wildtype enzyme
This marked change in distribution was attributable to an increase in the k for M4 forma
tion from 3 gM to 40 gM with the mutant enzyme Only minor changes were observed
for M1 formation k 2 gM to 7 gM These data imply that metabolism of capsaicin by
CYP2C9 to produce M1 and M4 can be selectively altered by mutations that have the
capacity to alter a predicted binding site for the vanilloid ring and that loss of a second
Figure 10 Hypothetical docking models representing capsaicin bound in the active site of human CYP2C9
Energy minimized and high probability docking poses were generated in collaboration with Dr Eric Johnson
The Scripps Research Institute The pose on the left suggests an endon motif where the terminal carbon
atom of capsaicin is in close proximity to the P450 heme center The alternative pose right places capsaicin in a
folded confirmation with the alkyl terminus in close proximity to the P450 heme center with similar distances
separating the amide nitrogen of capsaicin and the proposed site at which the stabilized intermediate carbocation
forms These representations in combination with the data presented in the text provide novel insights into the
formation ofMIM4 by CYP2C9
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restricted active sites (e.g .. CYP2E 1 and CYP2C9). specific interactions between the 
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CYP2C9 to produce l and 4 can be selectively altered by mutations that have the 
capacity to alter a predicted binding site for the vanilloid ring and that loss of a second 
Figure 10 ypothetical docking odels representing capsaicin bound in the active site of hu an P2 9. 
Energy minimized and high probability docking poses were generated in collaboration with Dr. Eric Johnson 
(The Scripps Research Institute). The pose on the left suggests an "end-on" motif where the terminal carbon 
atom of capsaicin is in close proximity to the P450 heme center. The alternative pose (right) places capsaicin in a 
"folded" confir ation ith the alkyl ter inus in close proxi ity to the 450 he e center ith si ilar distances 
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proton to produce M4 was more favorable than intramolecular trapping of the tertiary
allylic carbocation to form M1
Another energetically favorable and predicted position places capsaicin in a
folded conformation where the alkyl terminus of capsaicin resides 5354 A from
the heme iron center while the distance between the proposed metabolic tertiary allylic
intermediate of capsaicin that precedes M1 and M4 formation and the amide nitrogen
atom of capsaicin are separated by a mere 63 A Site directed mutagenesis studies using
single and double mutants of CYP2C9 APhe476TrpCYP2C9 and OPhe114Trp
Phe476Trp CYP2C9 demonstrated similar shifts in the relative ratio of M1 to M4 pro
duced Ratios of 116 and 63 were observed for the two mutant enzymes respectively
For the OPhe476Trp CYP2C9 enzyme an increase was observed in the k for M1
formation from2Mto 30Mand a concomitant 6 fold increase in the Vmax for M1
formation and 5fold decrease in M4 formation One interpretation of these data is that
substitution of Phe476 with Trp creates a new lower affinity substrate binding site
whereby the folded conformation becomes favored and thus intramolecular trapping
of the proposed tertiary allylic carbocation intermediate of capsaicin within the active
site of CYP2C9 is facilitated This idea may be particularly germane to the double
mutant where the possible binding location of the vanilloid ring in the endon posi
tion is also restricted Collectively these studies provide mechanistic rationale to
explain the differences between capsaicinoid metabolism on the alkyl chain versus that
of other molecules
CONCLUSIONS
This review highlights a number of interesting concepts about the biological fate of
capsaicinoids and how metabolism by P450 enzymes contributes to both detoxification
and bioactivation processes in humans It was a goal of this review to provide new insights
into critical aspects of P450dependent metabolic processes that dictate substrate metabo
lism and to relate these processes to molecular mechanisms of xenobiotic toxicity
Although far from a complete story the data discussed in this review present a number of
new and intriguing findings that may be important for the interpretation of future studies
involving the metabolism of structurally related chemicals by P450 enzymes Further
more these data may serve as preliminary insights to support new avenues of research
related to the pharmacological and toxicological properties of capsaicinoids in humans
Specifically do polymorphisms or individual differences in phase 1 or phase II drug
metabolizing enzyme expression profiles predispose certain types of cells tissues or indi
viduals to infrequent but potentially significant idiosyncratic responses to capsaicin It is
well known that individual susceptibility to capsaicin can be highly variable However
the mechanism remains unclear Is this due to differences in metabolism where bioactiva
tion to toxic intermediates that alter biological macromolecule function promotes reactiv
ity Alternatively is erratic sensitivity the result of deficient or excessive clearance of
these molecules such that more or less agent is available to activate TRPV 1 Recent
studies have described a potential benefit of capsaicinoids as chemotherapeutic agents to
reduce certain types of cancer eg prostate Mori 2006 Meanwhile others have
shown that capsaicinoids may increase the risk of certain types of cancers Toth and
Gannett 1992 Lopez Carrillo et al 1994 Archer and Jones 2002 What if any is the
role of drug metabolism in carcinogenesis and chemoprevention by capsaicinoids Are
differences in the metabolism of capsaicinoids responsible for these phenomena These
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ity? lternatively, is erratic sensitivity the result of deficient (or excessive) clearance of 
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reduce certain types of cancer (e.g., prostate) (Mori, 2006). Meanwhile, others have 
sho n that capsaicinoids ay increase the risk of certain types of cancers (Toth and 
annett, 1992; Lopez- arrillo et aI., 1994; rcher and Jones, 2002). hat, if any, is the 
role of drug metabolism in carcinogenesis and chemoprevention by capsaicinoids? Are 
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questions have only begun to be addressed by investigators and it will be fascinating to
learn what current studies will reveal in the near future
ABBREVIATIONS
BEAS213 immortalized human bronchial epithelial cells
CYP Cytochrome P450
Glu Glutamic acid
GSH Glutathione
HepG2 human hepatoma cells
Lv intravenous dosage
LCMS Liquid Chromatography Tandem Mass Spectrometry
LD50 lethal dose for 50 of the test population
Leu Leucine
NADPH NADP Nicotinamide adenine dinucleotide phosphate
reduced and oxidized forms
Phe Phenylalanin
PO oral dosage
ROS Reactive oxygen species
S9 Supernatant fraction after centrifugation at 9000 x g for 30 minutes
Trp Tryptophan
TRPV1 Transient Receptor Potential Vanilloid 1
UV Ultraviolet
1ABT 1Aminobenzotriazole
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TRPV1 Antagonists Elevate Cell Surface Populations of Receptor
Protein and Exacerbate TRPV1Mediated Toxicities in Human
Lung Epithelial Cells
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TRPV mediates cell death and pro inflammatory cytokine
production in lung epithelial cells exposed to prototypical receptor
agonists This study shows that NHBE BEAS2B and TRPV
over expressing BEAS2B cells pretreated with various TRPV
antagonists become sensitized to the prototypical TRPV agonist
nonivamide via a mechanism that involves translocation of
existing receptor from the endoplasmic reticulum to the plasma
membrane As such typical cellular responses to agonist treat
ment as measured by calcium flux inflammatory cytokine gene
induction and cytotoxicity were exacerbated These data were in
contrast to the results obtained when TRPV 1 antagonists were co
administered with nonivamide conditions which inhibited
TRPVmediated effects The antagonists LJO328 SC0030
and capsazepine increased the cytotoxicity of nonivamide by
20fold and agonistinduced calcium flux by 6fold Inflamma
torycytokine gene induction by nonivamide was also increased
significantly by pretreatment with the antagonists The enhanced
responses were inhibited by the coadministration of antagonists
with nonivamide confirming that increases in sensitivity were
attributable to increased TRPVassociated activity Sensitization
was attenuated by brefeldin A a golgi transport inhibitor but not
cycloheximide a protein synthesis inhibitor or actinomycin D a
transcription inhibitor Sensitized cells exhibited increased cal
cium flux from extracellular calcium sources while unsensitized
cells exhibited calcium flux originating primarily from intracellu
lar stores These results demonstrate the presence of a novel
mechanism for regulating the sub cellular distribution of TRPV
and subsequent control of cellular sensitivity to TRPV agonists
Key Words capsaicin TRPVl calcium translocation cytotox
icity inflammation
The lung epithelium is the initial barrier that xenobiotics
encounter upon inhalation and is a frequent target for toxicants
Burgel and Nadel 2004 Damage to the respiratory epithe
lium compromises respiratory function by increasing the
ITo whom correspondence should be addressed at University of Utah
Department of Pharmacology and Toxicology 30 S 2000 E Room 201 Skaggs
Hall Salt Lake City UT 84112 Fax 801 585 3945 EmailChrisReilly@
pharmut hedu
susceptibility of individuals to subsequent lung injury and
infections and ultimately contributes to hypersensitivity dis
orders such as asthma and COPD Kasper and Haroske 1996
Kuwano et al 2001 Selman et al 2001 Witschi 1991
Activation of TRPV1 the capsaicin receptor VRI in lung
epithelial cells by certain types of airborne particulate pollut
ants and prototypical agonists initiates inflammatory re
sponses and promotes cell death Agopyan et al 2003ab
2004 Oortgiesen et al 2000 Reilly et al 2003 Veronesi
et cal 1999b
TRPV 1 is a cation selective channel that has been shown to
be expressed by lung epithelial cells It is a member of the
Transient Receptor Potential TRP family of ion channels
Clapham 2003 that detect and respond to many types of
stimuli There are five major subfamilies TRPC canonical
TRPV vanilloid TRPMmelastatin TRPAAnktM1 TRPP
polycystins and TRPML mucolipins TRPV1 the founding
member of the TRPV subfamily is activated by low pH
noxious temperature xenobiotics such as capsaicin and resin
iferatoxin RTX Caterina et al 1997 as well as by the
endogenous agonists anandamide Szallasi and Di Marzo
2000 Narachidonoyldopamine NADA Huang et al
2002 Noleoyldopamine OLDA Chu et al 2003 and
12Shydroperoxyeicosatetraenoic acid 12SHPETE
Hwang et al 2000
TRPV 1 function is regulated by a variety of mechanisms
including desensitization by accumulation of excess intracel
lular calcium and subsequent calciumdependent dephosphor
ylation Dray et al 1990 Marsh et al 1987 Williams and
Zieglgansberger 1982Wood et al 1988 binding ofcalmodulin
Rosenbaum et al 2004 and phosphatydylinositol45
bisphosphate PiP Chuang et al 2001 direct phosphory
lation by protein kinase A PKA Di Marzo et al 2002
Puntambekar et al 2004 or protein kinase C PKC Bhave
et al 2003 Premkumar and Ahern 2000 and phosphoryla
tion by CAM kinase H Jung et al 2004
Recently the spatialtemporal regulation of TRP channels
has been shown to be a control mechanism for TRP channel
function Regulated cell surface expression of TRPV2 by
Published by Oxford UniversityPress 2005
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ENHANCEMENT OF TRPVIMEDIATED TOXICITIES
insulinlikegrowth factor first indicated that changes in cellular
location could impact TRP channel function Kanzaki et al
1999 TRPV2 has also been shown to be translocated to the
cell surface of neurons by treating with neuropeptide head
activator Boels et al 2001 and by forskolin in mast cells
Barnhill et al 2004 In Drosophila photoreceptor cells light
induced the shuttling of TRPL receptors between the rhab
domeral photoreceptor membrane and an intracellular com
partment controlling channel function Bahner et al 2002
The sub cellular distribution and function of TRPM1 has also
been shown to be regulated by translocation mechanisms Xu
et al 2001 There have also been a number of studies that
demonstrate the translocation of TRPC channels including
workwhich established that TRPC 1 was translocated to the cell
surface upon treatment with thrombin in endothelial cells
Mehta et al 2003 Similarly epidermal growth factor
promoted the translocation and insertion of TRPC5 into the
plasma membrane Bezzerides et al 2004 while the trans
location of TRPC6 was initiated by muscarinic receptor
activation or thapsigargin induced endoplasmic reticulum
ER calcium depletion Cayouette et al 2004 A Caeno
rhabditis elegans TRPC homologue TRP3 was suggested to
translocate to spermatide cell surfaces in response to a store
operated calcium entry SOLE signal Xu and Sternberg
2003 In other studies simply internalizing the channels
through cytoskeletal disruption revealed a loss of function for
TRP3 Lockwich et al 2001 and several other TRPC
channels 1 2 and 4 Itagaki et al 2004 demonstrating
further the functional importance of the cellular location of
TRP channels
Additional studies have demonstrated the presence of multi
ple pools of TRPV 1 in cells including plasma membrane and
ERassociated populations Karai et al 2004 Olah et al
2001 TRPV 1 has been shown to increase at the cell surface
with no increase in mRNA as aresult of inflammation in dorsal
rootganglion neurons Ji et al 2002 a process that appears to
be controlled by protein kinase C snapin and synaptotagmin
IX MorenillaPalao et al 2004 It is not known whether sim
ilar control mechanisms exist in lung epithelial cells or whether
this phenomenon affects prototypical responses to agonists
In the present study we show that prolonged treatment of
cells with TRPV 1 antagonists induced translocation ofTRPV l
to the cell surface significantly increasing typical responses to
receptor agonists Characterization of this unique mechanism
provides new information on TRPVI function and regulation in
human lung epithelial cells and highlights the potential for side
effects due to prolonged use of TRPV1 antagonists as
therapeutic agents
MATERIALS AND METHODS
Chemicals Nonivamide 99 capsazepine CPZ sulfinpyrazone and
ionomycin were purchased from Sigma Chemical Corporation St Louis MO
279
Thapsigargin was purchased from Alexis Biochemicals San Diego CA
Fluo4 AM was purchased from Molecular Probes Eugene OR SC0030
N4tertbutylbenzylN3fluoro4methylsulfonylamino benzyl thiourea
Wang et al 2002 and LJO328 N4tert butylbenzylNIt3fluoro4
methylsulfonylaminophenylethythiourea were generously provided by
Dr Jeewoo Lee Seoul National University Seoul Korea
Cell culture BEAS 26human bronchial epithelial cells CRL9609 were
purchased from ATCC Rockville MD TRPVIoverexpressing cells were
generated by transfecting BEAS213 cells with human TRPVI cDNA cloned
into the pcDNA 3IDV5His6 mammalian expression vector InVitrogen
Carlsbad CA and selecting for stably transformed cells as previously
described Reilly et al 2003 BEAS26 and TRPV Ioverexpressing BEAS
213 cells were cultured in LHC9 media BioSource Camarillo CA Normal
human bronchial epithelial NHBE cells a primary cell line were purchased
from Cambrex Walkersville MD and cultured in BEGM media Culture
flasks for BEAS213 and TRPVIoverexpressing BEAS213 cells were coated
with LHC basal media fortified with collagen 30 pgml fibronectin 10 g
ml and bovine serum albumin 10 gml Cells were maintained between
309 confluency and were passaged every 24days by trypsinization
Cytotoxicity assays Cells were sub cultured into coated multiwell cell
culture plates and allowed to reach 95 confluence within 2448hThe cells
were treated for 24 h with the various agonists and antagonists prepared in the
appropriate culture media Cell viability was assessed using the Dojindo Cell
Counting Kit8 Dojindo Laboratories Gaithersburg MD according to the
supplier recommendations Briefly WST8 a tetrazolium salt is reduced by
cellular NAD and NADP dependent dehydrogenases to an orange formazan
product that is soluble in tissue culture medium The amount of formazan
produced k 450 nm is directly proportional to the numberof living cells
Data are expressed as the percentage of viable cells relative to untreated control
cells calculated using the absorbance ratio All experiments were performed in
triplicate
Fluorometric calcium assays Cells were sub cultured into coated 96well
culture plates and grown to 95confluence within 2448hPrior to analysis
the cells were loaded with membrane permeable fluorogenic calcium indicator
Fluo4AM 25ltM for 90 min at room temperature 22C in LHC 9
media containing 200 pM sulfinpyrazone Cells were washed with media and
incubated at room temperature for an additional 20 min to permit methyl ester
hydrolysis and activation of Fluo4 AM within the cells Changes in cellular
fluorescence in response to agonist and antagonist treatments were assessed
microscopically IOX objective on cell populations 500 cells field using
a Nikon Diaphot inverted microscope equipped with a fluorescence filter set
designed to visualize green fluorescent protein Fluoromicrographs were
captured at high resolution using a SPOT Insight QE digital camera interfaced
with the SPOT data system software Diagnostic Instruments Inc Sterling
Heights MI Images were collected immediately prior to the addition of the
various substances and 30 s after treatment All agonist and antagonist solutions
were prepared in culture media and were added to the cells in 50 l volumes at
room temperature Image quantitation was achieved using the NIH Image J
software package Briefly the brightness of the images was normalized the
background fluorescence subtracted and the mean fluorescence intensity of the
images determined Data was normalized to maximize fluorescence values
obtained by treating cells with ionomycin 15 gM
RTPCR analysis of cytokine gene expression Cells were subcultured
into coated 25 cm cell culture flasks and grown to a density of 8090
followed by the procedure to enhance TRPV 1 responses by antagonists Cells
were washed with PBS and then treated with nonivamide for4 h at 37CTotal
RNAwas extracted from the cell pellets using the RNeasy mini RNA isolation
kit Qiagen Valencia CA and 5 g of total RNA was transcribed into cDNA
using Poly T and Superscript II Invitrogen Carlsbad CA IL6 IL8and P
actin cDNA was selectively amplified by PCR from 25 l of the cDNA
synthesis reaction using the following primers IL6 sense 5CTTCTCCA
CAAGCGCCTTC3and antisense 5GGCAAGTCTCCTCATTGAATC3
325 nt IL8 sense 5TGGCTCTCTTGGCAGCCTTC3 and antisense
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actin c  as selectively a plified by P  fro  2.5 III of the e  
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5CAGGAATCTTGTATTGCATCTG 3 410 nt and fi actin sense 5GAC
AACGGCTCCGGCATGTGCA3and antisense5TGAGGATGCCTCTCT
TGCTCTG 183 nt The PCR program consisted of an initial 2 min
incubation at 94C and 28 cycles of 94C 30s 55C30 s and 72C 30s A
final extension period of 10 min at 72C was also included PCR products were
resolved on a 1 SB agarose gel and images were collected using a BioRad
GelDoc imaging system Product quantification was achieved by determining
the band intensities for each PCR product relative to 3actin the internal PCR
control using the Gel Doc density analysis tools
Cellular sensitization and inhibition assays Characteristic TRPV1
mediated calcium responses were established using nonivamide as the agonist
Enhanced calcium responses were initiated by treating cells up to 24 h with
antagonists prior to loading with Fluo4AMBrefeldin A actinomycin D and
cycloheximide were coincubated with antagonists at various concentrations to
identify cellular processes that controlled cell sensitization Inhibition of
normal and enhanced responses to nonivamide was achieved by addition of
TRPVI antagonists 30 s prior to the addition of nonivamide For enhanced
cytotoxicity cells were treated with the antagonist up to 24 h washed once with
sterile phosphate buffered saline PBS and treated with nonivamide for an
additional 24 h Brefeldin A actinomycin D and cycloheximide were co
incubated with the antagonists during the pretreatment period to assessmecha
nisms that controlled sensitization Inhibition of enhanced cytotoxicity was
achieved by cotreating cells with nonivamide and LJO328 5 PM for 24 h
Intracellularextracellular calcium flux determination Depletion of ER
calcium was accomplished by treating cells with thapsigargin 15Mfor
5 min or until the baseline fluorescence intensity returned to basal levels This
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was followed by addition of nonivamide to observe the influx ofcalcium from
extracellular sources Inhibition of calcium flux due to cell surface TRPV 1 was
accomplished using a solution of the calciumchelator EGTA 100M and the
calcium channel blocker ruthenium red 10Mboth of which are plasma
membrane impermeable This was followed by treatment with nonivamide to
observe calcium flux originating from the ER Differences in fluorescence
responses observed between the treatments were used to assess the relative
contribution of ERbound and cell surface TRPV 1 in total calciumfluxinitiated
by nonivamide
Statistical analysis ofdata ECand LDvalues were obtained by non
linear regression analysis Prism 4GraphPad Software Inc San Diego CA
using the sigmoidal dose response variable slope equation Statistical testing
utilized ANOVA and Dunnett multiple comparison posttest to determine
significance The unpaired ttest was also used where appropriate
RESULTS
Calcium flux induced by the prototypical TRPV 1 agonist
nonivamide was significantly increased following a 24 h pre
treatment with the antagonists LJO328 SCO030 and capsa
zepine in a dose dependent manner Figs la and lb Increases
in sensitivity were observed at 05 h and were maximized at 6 It
data not shown EC values for the enhancement of calcium
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FIG 1 Pre treatment 24 h of TRPV Ioverexpressing BEAS2B cells with TRPV1 antagonists enhanced TRPV Imediated calcium flux a and b and
cytotoxicity c and d induced by nonivamide a Dose related increases in nonivamide induced 25Mcalcium flux by 24 h antagonist pretreatment LJO328
triangles SCO030 inverted triangles and capsazepine diamonds bCalcium flux initiated by nonivamide squares and following 24 h pre treatment with
I M UO328 triangles 02pM SCO030 inverted triangles and 3M capsazepine diamonds for 24 h Calcium flux curves for the sensitized cells were
significantly different than nonivamide only ANOVA p 01 n 4 The data are presented as an increase in fluorescence relative to fluorescence values
observed using ionomycin 15McDose response cytotoxicity curves 24h for LJO328 open triangles SCO030 open inverted triangles and capsazepine
open diamonds all dashed lines and with subsequent nonivamide075pM treatment with LJO328 triangles SCO030 inverted triangles and capsazepine
diamonds dDoseresponse cytotoxicity curves for nonivamide alone squares and following a 24 h pre treatment with 1 MLJO328 triangles 02gM
SCO030 inverted triangles and 3 pM capsazepine diamonds Cytotoxicity curves for sensitized cells were significantly different than nonivamide only
ANOVA p 01n 3 The error bars are expressed as the standard deviation
0
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FI .1. Pre-treatment (24 h) ofTRPVI-overexpressing BEAS-2B cells with TRPVI antagonists enhanced TRPVI-mediated calcium flux (a and b) and 
cytotoxicity (c and d) induced by noniva ide. (a) ose-related increases in noniva ide-induced (2.5 11M) calciu  flux by 24 h antagonist pre-treat ent: J -328 
(triangles), S 0030 (inverted triangles), and capsazepine (dia onds). (b) alciu  flux initiated by noniva ide (squares) and follo ing 24 h pre-treat ent ith 
I 11M UO-328 (triangles), 0.2 11M SC0030 (inverted triangles), and 3 11M capsazepine (diamonds) for 24 h. Calcium flux curves for the sensitized cells were 
significantly different than noniva ide only ( , p < 0.01, II = ).    t     i  res  r l ti  t  oresce ce  
observed using iono ycin (15 11M). (c) ose-response cytotoxicity curves (24 h) for J -328 (open triangles), S 0030 (open inverted triangles), and capsazepine 
(open dia onds) (all dashed lines) and ith subsequent noniva ide (0.75 11 ) treat ent ith LJ -328 [triangles], S 0030 [inverted trianglesJ, and capsazepine 
[dia ndsJ. (d) se-r s s  t t i it  r s f r i i  l  (sq r s)  f ll i     r -tr t t it  I 11M J -3  (tria gles), .2 11  
S 0030 (inverted triangles), and 3 11  capsazepine (dia onds). ytotoxicity curves for sensitized cells ere significantly different than noniva ide only 
(ANOVA, p < 0.01, II = ). e rr r r  r  r   t  t r  i ti . 
ENHANCEMENT OF TRPV IMEDIATED TOXICITIES
flux by LJO328 SC0030 and capsazepine were 07 gM
01095 gM 004 and 18 gM 04 respectively Fig
la Pre treatment with concentrations of LJO328 SC0030
and capsazepine that produced maximum increases in sensi
tivity from Fig la amplified calcium flux by 70 and
shifted the EC value for nonivamide induced calcium flux
from 3 gM 1 to044 gM 09 05 gM 02 and044 gM
04respectively Fig lb
TRPVI overexpressing BEAS 2B cells pre treated with
TRPV I antagonists for 24 h also exhibited greater cytotoxicity
when treated with nonivamide Figs lc and ld All three
antagonists ie LJO328 SC0030 and capsazepine en
hanced TRPVImediated cell death Sensitization was ob
served at 05 h reached a maximum at 2 h and persisted for
greater than 72 h data not shown The approximate EC50
values for exacerbation of nonivamide toxicity by LJO328
SC0030 and capsazepine were 030 M 08037 gM
05and 125 gM 09respectively Fig lc Pre treatment
with concentrations of LJO328 SC0030 and CPZ that
produced maximum increases in sensitivity from Fig lc
decreased the LD of nonivamide from 089 gM 03 to
045 004 gM 053 003 ltM and041 004 gM
respectively Fig ld
Previous studies showed that treatment of cells with non
ivamide or other TRPV 1 agonists increased the expression of
IL6 and IL8 mRNA and cytokine secretion via a process that
was dependent upon influx of extracellular calcium via TRPV 1
Oortgiesen et al 2000 Reilly et al 2003 2005 Veronesi
et al 1999b Pre treatment of cells with LJO328 for 24 h
markedly increased the degree of IL6 and IL8 gene induction
produced by nonivamide treatment relative to cells that were
not pretreated with the antagonist Figs 2a and 2b Quanti
tation of the magnitude of this response demonstrated signif
icant 12 IL6 and 17fold IL8 increases relative to
responses induced by nonivamide alone Fig 2b
a
lane 1 2 3 4
LJO 328 10 10
pretreated
x x
NM PM
nonivamide x 1 PM 1 PM x
IL8
IL6
0 actin
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Previous work has also shown that LJO328 is a potent
competitive inhibitor of calcium flux and cell death initiated by
nonivamide when coadministered to cells Reilly et al 2005
Addition of LJO328 to cells during treatment with nonivamide
prevented both basal and enhanced cell death Fig 3a and
calcium flux Fig 3b in response to nonivamide treatment
Similarly both normal and antagonistinduced increases in
calcium flux were blocked by SCO030 and CPZ Fig 3b
consistent with inhibition of TRPVI
The increases in cytotoxicity and calcium flux due to antag
onist pre treatment could occur from an elevation in TRPV 1
expression changes in cellular distribution post translational
modifications or combinations of the three Increased sensi
tivity was not attenuated by cycloheximide or actinomycin D
Figs 4a and 4b RTPCR analysis of TRPV 1 expression levels
demonstrated no change in mRNA concentrations following
24 h antagonist pretreatment data not shown Co treatment
with brefeldin A a Golgi transport inhibitor significantly re
duced the ability of the antagonists to sensitize cells Figs 4a
and 4b suggesting that sensitization was related to protein ex
port to the cell surface Accordingly calcium flux in un
sensitized cells was only slightly attenuated by ruthenium red
EGTA 5 yet was completely inhibited by prior depletion
of intracellular ER calcium stores with thapsigargin Fig 5
Conversely sensitized cells exhibited calcium flux that was
only partially attenuated by ruthenium redEGTA 20 or
thapsigargin 20 Only when ruthenium redEGTA was
used in conjunction with thapsigargin conditions which would
prevent calcium flux originating from both intracellular stores
and the media was a near complete block 66 of calcium
flux observed Fig 5 Collectively these data suggested that
translocation of TRPVI from the ER to the cell surface was
responsible for sensitization of the cells
NHBE and BEAS213 cells primary and immortalized cell
lines from which the TRPVIoverexpressing cells were
b
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c
T
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FIG 2 Pre treatment 24 h of TRPVIoverexpressing BEAS 213 cells with TRPVI antagonists enhanced TRPVImediated IL6 and IL8 gene induction
a TRPV Ioverexpressing BEAS 213 cells were pre incubated with 10 M LJO328 for 24 h washed with media treated with I ltM nonivamide for an additional
4 h and the abundance of IL6 and IL8 mRNA assessed by RTPCR Untreated control lane 1 nonivamide only lane 2 LJO328 pre treatment and nonivamide
lane 3 and LJO 328 only control lane 4b Normalized 3actinPCR product intensities Each set of bars corresponds to the gel lane designated below the graph
Band intensities for sensitized cells were saturated following exposure level adjustments made to allow for visualization of lower intensity bands basal control
Values are significantly different from IL6 and IL8controls respectively p 05 Mest n 3The error bars are expressed as the standard deviation
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flu  b  J -328, , a  ca saze i e ere .07 11M ± 
0.01,0.095 11M ± 0. 04, a d 1.8 11M ± 0.4, respectively (Fig. 
la). Pre-treat ent ith concentrations of LJ -328, SC0030, 
and capsazepine that produced maximum increases in sensi-
tivity (from Fig. I a) amplified calcium flux by -70% and 
shifted the ECso value for noniva ide-induced calciu  flux 
fro  3 ~lM ± 1 to 0.44 11M ± 0.09, 0.5 J.lM ± 0.2, and 0.44 11M ± 
0.04, respectively (Fig. lb). 
T  I-overexpressing S-2B cells pre-treated ith 
P  I antagonists for 24 h also exhibited greater cytotoxicity 
when treated with noniva ide (Figs. Ic and Id). All three 
antagonists (i.e., J -328, 0030, and capsazepine) en-
a  Vl-   t . i  a  -
served at 0.5 h, reached a axi u  at 2 h, and persisted for 
reater tha    (data t s n). e r imate so 
values for exacerbation of noniva ide toxicity by J -328, 
S 0030, and capsazepine ere 0.30 11M ± .08, .37 11M ± 
.05, a  .25 J.lM ± .09, res ecti el  (Fi . Ic). re-treat e t 
it  trations f J -32 , 30,   t t 
produced maximum increases in sensitivity (from Fig. Ic) 
decreased the LDso of noniva ide fro  0.89 11  ± .03 t  
.045 ± 0.004 11M, 0.053 ± 0.003 ~LM, and 0.041 ± . 04 11 , 
respectively (Fig. Id). 
ious ies   re     n-
iva ide, or other TRPVI agonists, increased the expression of 
IL-6 and IL-8 mRNA and cytokine secretion via a process that 
as dependent upon influx of extracellular calciu  via P  I 
(Oortgiesen et aI., 2000; Reilly et aI., 2003, 2005; Veronesi 
et aI., 1999b). re-treat ent of cells ith J -328 for 24 h 
arkedly increased the degree of IL-6 and IL-8 gene induction 
produced by noniva ide treat ent, relative to cells that were 
not pre-treated ith the antagonist (Figs. 2a and 2b). uanti-
tation of the agnitude of this response de onstrated signif-
ica t -1.2 (I -6) a  -1.7-fol  (IL-8) i creases, relati e t  
responses induced by nonivamide alone (Fig. 2b). 
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FIG. 2. Pre-treatment (24 h) of TRPVI-overexpressing BEAS-2B cells with TRPVI antagonists enhanced TRPVI-mediated IL-6 and IL-8 gene induction. 
(a) I-overe ressi  -2B cells ere re-i c ate  it   JlM J -3  f r  , as e  it  edia, treated it  I Jl  i a i e f r an additi al 
4 h, and the abundance of I -6 and I -8  assessed by -P : ntreated control (lane I), noniva ide only (lane 2), J0-328 pre-treat ent and noniva ide 
(lane 3) and LJ -328 only control (lane 4). (b) or alized (p-actin) PCR product intensities. Each set of bars corresponds to the gel lane designated belo  the graph. 
(#) Band intensities for sensitized cells were saturated following exposure level adjustments made to allow for visualization of lower intensity bands (basal control). 
alues are significantly different fro  IL-6 and IL-8 controls, respectively (I' < 0.05 (*), t-t st, 11 = 3). The error bars are expressed as the standard deviation. 
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G o FIG 4 Brefeldin A but not cycloheximide or actinomycin D inhibited
ti R A sensitization ofcytotoxicity aand calcium fluxbby TRPV 1 antagonist prelL treatment a TRPVI overexpressing BEAS213 cells were pre incubated
FIG 3 Coincubation of TRPV I antagonists with nonivamide inhibited
with or without I M LJO328 and with or without brefeldin A
antagonist induced sensitization ofcytotoxicity aand calcium fluxbinduced cycloheximide or actinomycin D for 24 h washed with PBS and treated with
by 24hpretreatment withantagonistTRPVIoverexpressingBEAS 2B cells
05 M nonivamide for an additional 24 h to assess TRPVImediated
were pre incubated with media normal or 1 MLJO328 sensitized for 24h cytotoxicity Values are significantly different from brefeldin Afree control
washed with PBS and treated with I Mnonivamide in the presence or absence p
05 nest n 3 The error bars are expressed as the standard
of 5MLJO328 for an additional 24h Values are significantly different from
deviation bTRPV Ioverexpressing BEAS2Bcells were pre incubated with
control p 01 and p 05Orespectively ttest n 3The error bars
media normal or 1 MLJO328 sensitized and brefeldin A cycloheximide
are expressed as the standard deviation b TRPVIoverexpressing BEAS2B
or actinomycin D for 24 h washed with PBS and loaded with the calcium
cells were pre incubated with media normal or 3 MCPZ sensitized for 24 h
indicator Flou4 AM in order to assess TRPV I mediated calcium flux
washed and loaded with the calcium indicator Flou4 AM Calcium flux was
Calcium flux was induced with 25Mnonivamide Images were collected
induced with 25Mnonivamide and blocked by antagonist addition 30 s prior to
before and 30 s after the addition of agonist Data represent changes in
the addition of nonivamide Data are represented as the increase in mean
fluorescence intensity relative to ionomycin 15MValues are significantly
fluorescence intensity relative to ionomycin 15MValues are significantly
different from normal flux control p 05 Mest n 4 The error bars
different from the normal and enhanced response control p 05
are expressed as the standard deviation
respectively ttest n 4The error bars are expressed as the standard deviation
in NHBE cells with some cytotoxicity to BEAS2B 16 and
derived were also assessed for antagonist induced sensitiza NHBE cells 28 due to LJO328 itself Fig 6b Similarly
tion Pre treatment with LJO328 30 and 50 gM in BEAS2B inflammatory cytokine gene induction by nonivamide treat
and NHBE cells for 24 h increased the cytotoxicity of ment was markedly increased in BEAS2B cells 24 h pre
nonivamide by 50o in BEAS2B cells Fig 6a and 68 treatment with LJO328 Figs 6c and 6d
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i fla t r  t ine  i tio   i i  tr t-
ent as arkedly increased in S-2  cells 24 h pre-
treat ent ith LJ -328 (Figs. 6c and 6d). 
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FIG 5 Cells sensitized by LJO 328 pretreatment demonstrated intracel
lular and extracellular calcium flux while unsensitized cells showed primarily
intracellular calcium flux TRPV1overexpressing BEAS2B cells were pre
incubated with media normal or 1 pM LJO328 sensitized for 24 h washed
with PBS and loaded with the calcium indicator Flou4 AM inorder to assess
TRPV1mediated calcium flux Calcium fluxwas induced with 20 pM normal
or 2 pM sensitized nonivamide Thapsigargin 15 pM was used to deplete
ER calcium stores before addition of nonivamide An EGTA 100 PM and
ruthenium red 10 ltM solution was used to inhibit calcium flux originating
from extracellular sources Images were collected before and 30 s after the
addition of agonist Data represent changes in fluorescence intensity relative to
ionomycin 15 pM Values are significantly different from normal and
enhanced flux p 05 respectively nest n 4 The error bars are
expressed as the standard deviation
DISCUSSION
The lung epithelium is a frontline barrier to inhaled xeno
biotics and pathogens This important cell layer is often subject
to damage possibly causing airway inflammation pulmonary
edema various systemic responses and respiratory dysfunc
tion Barnes 2002 Cohn et al 2004 Morrison and Bidani
2002 It has been shown that several xenobiotics selectively
damage the lung epithelium by interacting with specific
receptors on the cellular surface One such receptor is TRPV 1
which has been shown to produce inflammatory responses and
cell death when activated by certain types of particulate
materials Agopyan et al 2003ab 2004 Oortgiesen et al
2000 Veronesi et al 1999a or the prototypical TRPV 1
agonist capsaicin Reilly et al 2003 Therefore the identi
fication and characterization of specific factors that modulate
the sensitivity of these cells to specific toxicants either via
inhibition of responses or by sensitizing cells is an important
task Here we demonstrate that TRPV l antagonists enhanced
typical responses to nonivamide in lung epithelial cells via
a novel mechanism that correlated to an increase in cellsurface
receptor function
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Cytotoxicity inflammatory cytokine gene induction and
calcium flux induced by the TRPV 1 agonist nonivamide were
used to evaluate the effects of lowdose longterm pre
treatment of TRPV1 antagonists on basal TRPV 1 functions
Previously we demonstrated that the antagonists LJO328 and
SCO030 attenuated the cytotoxicity ofTRPV 1 agonists when co
administered Reilly et al 2005 Similarly LJO328 SCO030
and the prototypical TRPV1 antagonist capsazepine inhibited
TRPV 1mediated calcium flux and calciumdependent
cytokine gene induction and secretion Reilly et al 2003
2005 In this study we found that TRPV 1 antagonists were
able to enhance the sensitivity of these cells to subsequent
agonist exposures when applied for extended periods of time
prior to agonist treatment LJO328 was the most potent
sensitizing agent followed by SCO030 and CPZ Co treatment
of cells with these antagonists and nonivamide attenuated both
basal and enhanced responsiveness to agonist treatment
indicating that modulation of TRPV1 was responsible for the
changes in sensitivity observed with antagonist pretreatment
Increased cellular sensitivity was observed within 05 h of
antagonist treatment and was maximized at 26 h depending
upon the endpoint used Elevated sensitivity remained for 72h
data not shown Overlapping kinetics for the enhancement
of cytotoxicity and calcium flux suggested that these two
TRPV1mediated processes were augmented through the same
mechanism
A potential explanation for the observed increases in
sensitivity produced by antagonist pretreatment was that the
TRPV 1 antagonists promoted increases in TRPV 1 expression
by inhibiting basal TRPV 1 functions in the cells Previous
studies that characterized the TRPV1overexpressing cell line
demonstrated that increased levels of receptor expression
selectively promoted cytotoxicity and inflammatory cytokine
responses similar to the enhanced responses observed in this
study Reilly et al 2003 However we found that neither
cycloheximide a protein synthesis inhibitor nor actinomycin
D and transcription inhibitor prevented sensitization by the
antagonists Analysis ofTRPV I mRNA abundance by RTPCR
following 24 h antagonist treatments supported this conclusion
data not shown
Brefeldin A a Golgi transport inhibitor drastically reduced
cellular sensitization produced by antagonists pre treatment
These data suggested that translocation of TRPV 1 from the
intracellular locations ER to the plasma membrane caused
sensitization Quantification of calcium flux originating from
intracellular stores and extracellular sources provided compel
ling evidence that the abundance of TRPV 1 at the cell surface
was increased by antagonist pretreatment These data con
firmed the existence of two distinct populations of TRPV 1
which can be dynamically regulated by longterm inhibition of
basal TRPV1mediated processes How translocation initiation
signals are processed in cells remains unclear but modifica
tions to extracellular calcium content calcium EDTA alone
had no effect on sensitivity data not shown
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FIG 6 BEAS 2B and NHBE cells also demonstrated enhanced sensitivity following 24 h TRPV I antagonist pretreatment BEAS213 a and NHBE cells
b were pre incubated with increasing concentrations of LJO 328 for 24 h washed and treated with 100 Mor 125 Mnonivamide respectively for an additional
24 h All cell treatments were performed in the appropriate cell culture media Cytotoxicity values are significantly different from the control where cells did not
receive LJO328 pre treatmentp 01 and p 05 ANOVAwith Dunnettsttest n 3The error bars represent the standard deviation c BEAS 213
cells were pre incubated with 20 gM LJO328 for 4 h washed treated with 100 M nonivamide for an additional 4 h and the abundance of IL6 and IL8 mRNA
assessed by RTPCR Untreated control lane 1 nonivamide only lane 2 LJO328 and nonivamide lane 3 and LJO328 only control lane 4 d Normalized
0actinPCR product intensities Each set of bars corresponds to the gel lane designated below the graph Values are significantly different from IL6 and IL8
controls respectively p 05 t test n 3The error bars are expressed as the standard deviation
It is significant to note that the BEAS213 cells as well as
a primary lung epithelial cell line NHBE neither of which
artificially over express TRPV 1 also responded to TRPV l
antagonist pre treatment in a similar manner albeit the degree
of sensitization observed was much lower We presume that the
subtle changes in cell sensitivity produced by antagonists pre
treatment in these cells was the result of lower basal expression
levels of TRPV 1 compared to the TRPV 1overexpressing
cells and thus less protein was available to redistribute
between the ER and cell surface over the duration of the assay
The fact that a maximum effect was attainable in all cell types
including the over expressing line suggests that the rate and
degree of sensitization was ultimately dependent upon the level
of TRPV I expression the duration of the agonist treatment
and the rate of translocation relative to protein recycling and
degradation
These intriguing results highlight potential negative effects
that may be encountered with therapeutic use of TRPV 1
antagonists to treat various malaise including chronic pain
bladder dysfunction or lung inflammatory diseases Similarly
substances such as DHEA and aminoglycoside antibiotics
which have also been shown to inhibit TRPVI Chen et al
2004 Raisinghani and Premkumar 2005 may also promote
sensitization although this possibility was not investigated
A more detailed investigation of the precise biochemical mech
anisms and cellular pathways that govern TRPV1 translocation
will ultimately provide additional understanding of how this
receptor is regulated to control threshold responses to endog
enous and foreign agonists Such knowledge may ultimately
provide insights into individual variability to toxicant suscep
tibility and uncover potential unanticipated drug interactions
Collectively these data add to our current understanding of
how TRPV 1 influences respiratory cell toxicities by providing
novel insights into biological factors that control TRPVI
mediated processes in respiratory epithelial cells
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ABSTRACT Activation of the capsaicin receptor VR1
or TRPV1 in bronchial epithelial cells by capsaicinoids
and other vanilloids promotes pro inflammatory cy
tokine production and cell death The purpose of this
study was to investigate the role of TRPV1mediated
calcium flux from extracellular sources as an initia
tor of these responses and to define additional cel
lular pathways that control cell death TRPV1 an
tagonists and reduction of calcium concentrations in
treatment solutions attenuated calcium flux induction
of interleukin6 and 8 gene expression and IL6 se
cretion by cells treated with capsaicin or resinifera
toxin Most TRPV1 antagonists also attenuated cell
death but the relative potency and extent of protec
tion did not directly correlate with inhibition of total
calcium flux Treatment solutions with reduced cal
cium content or chelators had no effect on cytotox
icity Inhibitors of arachidonic acid metabolism and
cyclooxygenases also prevented cell death indicating
that TRPV1 agonists disrupted basal arachidonic acid
metabolismand altered cyclooxygenase function via a
TRPV1dependent mechanism in order to produce tox
icity These data confirm previous results demonstrat
ing calcium flux through TRPV1 acts as a trigger for
cytokine production by vanilloids and provides new
mechanistic insights on mechanismsof cell death pro
ducedby TRPV1 agonists in respiratory epithelial cells
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INTRODUCTION
The capsaicin receptor VR1 or TRPVI has been
described as a temperature 42C pH 64 at
37Cand vanilloidsensitive homotetrameric cation
channel exhibiting moderate selectivity for calcium
pCa pNa 96 13 TRPVI expression was ini
tially demonstrated in peripheral afferent sensory
nerve fibers C and AS originating from dorsal root
ganglia 1 but ongoing studies have also revealed
expression and function in a variety of nonneuronal
tissues and cell types 4 including keratinocytes 5
and lung epithelial cells 68TRPV1 subunits con
sist of six transmembrane domains a putative pore
loop region and cytosolic N and Cterminal domains
that possess a variety of regulatory features including
multiple phosphorylation sites 912 subcellular lo
calization sequences 13 a calciumcalmodulin bind
ing site 14 and a phosphatidylinositol diphosphate
PiP2 binding site 15 Differences in binding of reg
ulatory constituents at these sites negatively and posi
tively regulate channel gating thresholds and calcium
flux It has been proposed that these features play a
definitive role in finetuning receptor responses to ag
onists under diverse physiological states The relevance
of these structural and functional aspects of TRPVI to
vanilloid induced cell death and cytokine production
is essentially unknown
In human airway epithelial cells TRPV1 has been
shown to regulate inflammatory cytokine production
26600110
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The capsaicin receptor (VRI or TRPVl) has been 
described as a te perature- (>42°C), p - «6.4 at 
°C),  nil oid- e o-  t  
channel exhibiting oderate selectivity for calciu  
(pCa++:pNa+ =9.6) [1-3]. TRP l expression as ini-
tially de onstrated in peripheral afferent sensory 
nerve fibers (C- and 8-) originating fro  dorsal root 
ganglia [1], but ongoing studies have also revealed 
expression and function in a variety of nonneuronal 
tissues and cell types [4] including keratinocytes [5] 
and lung epithelial cells [6-8]. T P l subunits con-
sist f si  tr s ra e i s,  t ti  r  
l  re i , a  c t s lic - a  -ter i al ai s 
that possess a variety of regulatory features including 
ltiple s r lati  sites [9-1 ], s cell lar l -
calization sequences [13], a calciu /cal odulin bind-
ing site [14], and a phosphatidylinositol diphosphate 
(PiPz) binding site [15]. Differences in binding of reg-
ulatory constituents at these sites negatively and posi-
tively regulate channel gating thresholds and calciu  
flux. It has been proposed that these features playa 
definitive role in llfine-tuning" receptor responses to ag-
onists under diverse physiological states. The relevance 
of these structural and functional aspects of TRPVl to 
vanilloid-induced cell death and cytokine production 
is essentially unknown. 
In human airway epithelial cells, TRPVl has been 
sho n to regulate infla atory cytokine production 
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following exposure to concentrated ambient particu
late pollutants and TRPV1 agonists 8 16 191 A direct
relationship was shown for TRPV1 activation by nega
tivelycharged particles and the productionof cytokines
and apoptotic cell death in several respiratory epithe
lial cell lines including BEAS213 A549 NHBE and a
small alveolar epithelial cell SAEC line
Our laboratory has investigated mechanisms by
which pepper sprays produce toxicity in respiratory
tissues the active ingredients in pepper spray prod
ucts are the capsaicinoids 7Rats exposed to capsaicin
by noseonly inhalation exhibited marked inflamma
tion the appearance of neutrophils and proliferating
macrophages and extensive damage to tracheal epithe
lial bronchial epithelial and alveolar cells 7 Com
plimentary in vitro studies demonstrated that TRPVI
could mediate both proinflammatory cytokine pro
duction and cell death It was found that the level of
TRPV1 expression in multiple cell typesie BEAS
2B A549 and HepG2 correlated to their relative sen
sitivity to TRPV1 agonistinduced toxicities Further
more selective overexpression of TRPVl in BEAS213
cells conferred greater 100200fold sensitivity to
agonists using IL6 production and cell death as end
points However a confounding outcome of these stud
ies was that capsazepine the prototypical TRPVl an
tagonist and EGTAa calcium chelator did not prevent
the cytotoxicity of capsaicin or resiniferatoxin RTX
in either BEAS213 or TRPV1 overexpressing cells de
spite inhibiting cytokine production Inhibition of al
ternate TRPVI independent mechanisms of cell death
egcapsaicindependent inhibition of protein synthe
sis ROS production etc 2023 was investigated but
was not involved in this unique cell death process
In this study we used a number of novel selec
tiveand potentantagonists of TRPV1 2427 and overt
manipulations to extracellular calcium content to de
fine the precise role of TRPVImediated calcium flux
from extracellular sources in the production of pro
inflammatory cytokines and cell death in response to
treatment with prototypical TRPVl agonists Many of
these antagonists have been shown to exhibit greater
potency affinity and selectivity for TRPV1 than cap
sazepine and thus may provide additional insights
into the biochemical basis of TRPV1mediated toxici
ties Additional studies to identify specific components
of the cell death process following TRPV1 activation
were also performed
MATERIALSAND METHODS
Chemicals
Capsaicin nvanillylnonanamide 97 cap
sazepine CPZ ionomycin58114 eicosatetraynoic
acid ETYA indomethacin acetylsalicylic acid
etodolac diclofenac ABTS2azinobisethylbenzo
thiazoline6sulfonic acid diammonium salt sulfin
pyrazone Tween20 thapsigargin EGTA ruthenium
red and 30 hydrogen peroxide H2O2 were pur
chased from Sigma Chemical Corporation St Louis
MO RTX and 5iodoRTX were purchased from
Alexis Biochemicals San Diego CA Fluo4AM was
purchased from Molecular Probes Eugene OR The
synthesis and characterization of SCO030 W44tert
butylbenzylN3fluoro4methylsulfonylamino
benzylthiourea JYL1433 and KMJ642 have been
previously described 267 Synthesis of LJO328
N4tert butylbenzyl N13fluoro4methylsul
fonylaminophenyl ethylthiourea an usubstituted
SCO030 analogue is presented in the following patent
document WO 2005003 84 Two proprietary com
petitive TRPV1 antagonists having structures similar to
KMJ642 LJO328 JYL1433 and SCO030 antagonists
A and B were also obtained from Dr Jeewoo Lee For
reference the chemical structures of LJO328 SCO030
JYL1433 KMJ 642 5iodoRTX and capsazepine are
shown in Figure 1 structures for antagonists A and B
are proprietary All other chemicals were purchased
from established chemical suppliers
Cell Culture
BEAS213 bronchial epithelial cells CRL9609
were purchased from ATCC Rockville MD TRPV1
overexpressing cells were generated by transfecting
BEAS213 with the human TRPV1 cDNA cloned into
the pcDNA31DV5His6 mammalian expression vec
tor InVitrogen Carlsbad CA and selecting for sta
bly transformed cells as previously described 7Cells
were cultured in LHC9 media BioSource Camarillo
CA in coated polystyrene cell culture flasks The plate
coat consisted ofLHC basal media fortifiedwith colla
gen 30gml fibronectin 10gmland bovine
serum albumin 10 gmU Cells were maintained be
tween 3090confluence and werepassaged every24
days Some experiments assessing the effects of calcium
on cytotoxicity and cytokine responses wereperformed
in keratinocyte growth medium KGM complete with
calcium and deficient in calcium KGM 2 Cambrex
Bioscience Walkersville MD Cells were cultured for
2 h in complete or calciumfree KGM prior to treat
ments
Fluorometric Calcium Assays
Cells were subcultured into coated 96 well cell cul
ture plates and grown to 90 confluence over 48 h
Cells were loaded with Fluo4AM 25Ma mem
brane permeable fluorogenic calcium indicator for
001107
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pli entary in vitro studies de onstrated that TRPVl 
could mediate both pro-inflammatory cytokine pro-
on   t .        
 e ressi  i  ltiple cell t es (i.e., -
2B, 549, and ep 2) correlated to their relative sen-
sitivity to TRP 1 agonist-induced toxicities. Further-
ore, selective overexpression of P 1 in S-2B 
cells conferred greater (~100-200-fold) sensitivity to 
agonists using IL-6 production and cell death as end-
points. However, a confounding outcome of these stud-
ies was that capsazepine, the prototypical TRPV1 an-
tagonist, and E T , a calciu  chelator, did not prevent 
the cytotoxicity of capsaicin or resiniferatoxin (RTX) 
in either BEAS-2B or TRPV1-overexpressing cells, de-
spite inhibiting cytokine production. Inhibition of al-
t r te l-independe t is s f ll t  
(e.g., capsaicin-dependent inhibition of protein synthe-
sis, S production, etc.) [20-23] as investigated, but 
as not involved in this unique cell death process. 
In this study, we used a number of novel, selec-
tive, and potent antagonists of TRPV1 [24-27] and overt 
manipulations to extracellular calcium content to de-
fine the precise role of T PVl- ediated calciu  flux 
fro  extracellular sources in the production of pro-
infla atory cytokines and cell death in response to 
treatment with prototypical TRPV1 agonists. Many of 
these antagonists have been shown to exhibit greater 
potency, affinity, and selectivity for TRPV1 than cap-
sazepine and, thus, may provide additional insights 
  i l   -  xici-
ties. dditional studies to identify specific co ponents 
of the cell death process following TRPV1 activation 
were also performed. 
I    
i  
Capsaicin (n-vanilly1nonanamide) (97%), cap-
sazepine (CPZ), iono ycin, 5,8,ll,14-eicosatetraynoic 
id (E A), t acin, t l ic i , 
t l , i l f ,  (2,2'- i o- is-[eth 1be -
iazo1ine-6- 1  i ]-dia  alt), u1fi -
pyrazone, een-20, thapsigargin, , rutheniu  
red, and 30% hydrogen peroxide (H20 ) ere pur-
chased fro  Sig a Che ical Corporation (St. Louis, 
).  and 5-iodo-  ere purchased fro  
lexis ioche icals (San iego, A). F1uo-4-A  as 
purchased fro  olecular Probes (Eugene, OR). The 
synthesis and characterization of 0030 (N-(4-tert-
buty1benzyD- ' -[3-fluoro-4-(methy1sulfony1amino)-
enzyl]thioure ), J -14 ,  J-64  e  
previously described [26,27]. Synthesis of J -328 
(N-(4-tert-butylbenzyD- ' -(1-[3-fluoro-4-( ethy1su1-
f 1a in )phe 1] thyDthioure ),  a-s stit t  
0  a al e, is rese te  i  t e f ll i  ate t 
 (W  0 5/0 308 ). o  -
titive  t ists i  str t res si il r t  
J-64 , J -3 , -14 ,  0  (antagonists 
  ) r  l  t i e  fr  r.  .  
, e  t res  -3 , 0 , 
J -1433, J-642, 5-iodo- , and capsazepine are 
sho n in Figure 1; structures for antagonists  and  
are proprietary. All other che icals were purchased 
fro  established che ical suppliers. 
ll lt r  
BE S-2B bronchial epithelial cells (C L-9609) 
were purchased fro  ATCC (Rockville, D). TRPV1-
r ressi  lls r  r t   tr sf ti  
-2B it  t     l  i t  
the pcDNA 3.10-V5 /His6 a alian expression vec-
tor (InVitrogen, arlsbad, A) and selecting for sta-
bly transfor ed cells, as previously described [7]. Cells 
e  i  -9  (Bio r e, aril o, 
) in coated polystyrene cell culture flasks. The plate 
 i  f  l a   ol a-
gen (30 f.Lg/mL), fibronectin (10 f.Lg/mL), and bovine 
seru  albu in (10 f.Lg/mL). ells ere aintained be-
t een 30-90% confluence and ere passaged every 2-4 
days. So e experi ents assessing the effects of calciu  
on cytotoxicity and cytokine responses were performed 
in keratinocyte growth ediu  (KG ) co plete with 
l   fi t  l  (  ) (Ca  
, l rsvil e, D). l    f r 
2 h in co plete or calciu -free KG  prior to treat-
ts. 
l r etric alci  ssa s 
  l     l  l  ul-
ture plates and grown to ~90% confluence over 48 h. 
    l -4-A  (2.5 f.LM),  em-
brane per eable fluorogenic calciu  indicator, for 
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FIGURE 1 Chemical structuresof LJO328 SC0030 JYL1433 KMJ642 5iodoRTX and capsazepine
90 min at room temperature 22C in LHC9 me
dia containing 200 M sulfinpyrazone washed with
LHC9 and incubated at room temperature for an ad
ditional 203 min to permit methyl ester hydrolysis
and activation of Fluo 4 within the cells All loading
steps were performed in the dark Changes in cellu
lar fluorescence in response to agonist and antagonist
treatments were assessed microscopically at 10x mag
nification on cell populations 500 cells in a field us
ing a Nikon Diaphot inverted microscope equipped
with a filter set designed to visualize green fluorescent
protein Fluoromicrographs were captured at high res
olution using a SPOT Insight QE digital camera inter
faced with the SPOT data system software Diagnostic
Instruments Inc Sterling Heights MI Images were
collected immediately prior to the addition of the var
ious substances and 1 min after treatment All agonist
and antagonist solutions were prepared in LHC9 or
KMG and KGM 2 and were added to the cells in 50
100 L volumesat room temperature Antagonists were
added to cells 1 min prior to agonist exposure Data are
presented as the mean fluorescence intensity and stan
dard deviation for cell populations is determined using
the NIH Image J software package
Cytotoxicity Assays
Cells were subcultured into coated multiwell cell
culture plates and allowed to reach 80 confluence
over 24 h The cells were washed once with sterile
phosphatebuffered saline and treated for 24 h with the
various agonists and antagonists Treatment solutions
were prepared in LHC9 or KGM and KGM2 Cells
were treated withantagonists for 30 min prior to agonist
treatments and were included in the agonist treatment
solutions Cell viability wasassessed using the Dojindo
Cell Counting Kit8 Dojindo Laboratories Gaithers
burgMD according to thesupplier recommendations
Cell viability was determined spectrophotometrically
assaying for the formationof a water soluble formazan
dye product produced by active mitochondria dehy
drogenase enzymes in viable cells Data are expressed
as the percentage of viable cells relative to untreated
control cells
RTPCR Analysis of Cytokine
Gene Expression
Cells were subcultured into coated 25 cm cell cul
ture flasks and grown to a density of 80 over 48 h
Cells were treated with capsaicin in the presence and
absence of various antagonists for 4 hat37C Treatment
solutions were prepared in LHC9 Cells were treated
with antagonists for 30 min prior to agonist exposure
and were also included in the treatment solutions at
the specified concentrations Total RNA was extracted
from the cells using the RNeasy mini RNA isolation
kit Qiagen Valencia CAquantified using the UV ab
sorbance ratio at 2608 nm and 5 g of total RNA
transcribed into cDNA using Superscript II InVitro
gen Carlsbad CA IL6 IL8and Ractin cDNA was
selectively amplified by PCR from 25L of the cDNA
synthesis reaction and the following primers IL6 sense
5CTTCTCCACAAGCGCCTTC3 and antisense 5
GGCAAGTCTCCTCATTGAATC3325ntIL8 sense
5lodoKI X
HO
Cl
HO ISI
NJ
I
H
001108
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I  1. he ical structures of J -328, 0030, J -1433, J-642, 5-iodo-R , and capsazepine. 
90 min at room temperature (~22°C) in LHC-9 me-
dia containing 200 f.LM sulfinpyrazone, washed with 
LHC-9, and incubated at room temperature for an ad-
ditional 20-30 in to per it ethyl ester hydrolysis 
and activation of Fluo 4 ithin the cells. ll loading 
steps were performed in the dark. Changes in cellu-
lar fluorescence in response to agonist and antagonist 
treatments were assessed microscopically at lOx mag-
nification on cell populations (~500 cells in a field) us-
ing a Nikon Diaphot inverted microscope, equipped 
ith a filter set designed to visualize green fluorescent 
protein. Fluoromicrographs were captured at high res-
olution using a SPOT Insight QE digital camera inter-
faced ith the SP T data syste  soft are (Diagnostic 
Instru ents, Inc., Sterling Heights, I). I ages were 
collected immediately prior to the addition of the var-
ious substances and 1 in after treat ent. ll agonist 
and antagonist solutions were prepared in LHC-9 (or 
 and  2) and ere added to the cells in SO-
100 f.LL volu es at roo  te perature. Antagonists were 
added to cells 1 min prior to agonist exposure. Data are 
presented as the mean fluorescence intensity, and stan-
dard deviation for cell populations is determined using 
the NIH Image J software package. 
Cytotoxicity Assays 
l    i   ulti el  l  
culture plates and allowed to reach ~80% confluence 
r  .  c ll  r    it  t ril  
phosphate-buffered saline and treated for 24 h with the 
various agonists and antagonists. Treatment solutions 
were prepared in LHC-9 (or KGM and KGM 2). Cells 
were treated with antagonists for 30 in prior to agonist 
treat ents and ere included in the agonist treat ent 
solutions. ell viability as assessed using the ojindo 
Cell Counting Kit-8 (Dojindo Laboratories, Gaithers-
burg, D), according to the supplier reco endations. 
ell viability as deter ined spectrophoto etrically 
ss i  f r t  f r ti  f  t r-s l le f r  
dye product produced by active itochondrial dehy-
drogenase enzy es in viable cells. ata are expressed 
as the percentage of viable cells relative to untreated 
 l . 
-  l sis  t i  
ene Expression 
l   l  i t    2  ul-
ture flasks and gro n to a density of ~80% over 48 h. 
Cells were treated with capsaicin in the presence and 
absence of various antagonists for 4 h at 37°C. Treat ent 
solutions were prepared in LHC-9. Cells were treated 
ith antagonists for 30 in prior to agonist exposure 
  l o  i  t  t t  ol t  t 
the specified concentrations. Total RNA was extracted 
 t  ll  i  t   i i  i l ti  
kit (Qiagen, Valencia, CA), quantified using the UV ab-
s r  r ti  t 60/280 ,   f.Lg f t t l  
transcribed into c  using Superscript II (In itro-
gen, Carlsbad, CA). IL-6, IL-8, and i3-actin cDNA was 
selectively a plified by P  fro  2.5 f.LL of the c  
synthesis reaction and the follo ing pri ers: IL-6 sense 
'- -3'  anti se '-
CAAGTCTC TCAT GA TC-3' (  t), I -8 sen  
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5GTGGCTCTCTTGGCAGCCTTC3 and antisense
5CAGGAATCTTGTATTGCATCTG 3 410 nt and
Ractin sense5GACAACGGCTCCGGCATGTGCA3
and antisense 5TGAGGATGCCTCTCTTGCTCTG3
183 nt The PCR program consisted of an initial 2 min
incubation at 94 C and 28 cycles of 94C 30 s 55C
30 s and 72C 30 s A final extension period of
10 min at 72C was also included PCR products were
resolved ona 1 sodium borate agarose gel and the im
ages were analyzed using a BioRad GelDoc imaging
system Relative band intensities for each PCR prod
uct relative to the internal PCR control 3actin are
reported
IL6ELISA
Cells were subcultured into 24 or 48well coated cell
culture dishes at 40confluence and maintained for
48 h until a confluence of 80was achieved Treat
ments were performed in LHC9 or KGM KGM 2
fortified with capsaicin and the various modulators of
TRPV1 function for 24 h Cells were treated with antag
onists for 30 min prior to agonist treatment After 24 h
themedia was collected clarifiedbycentrifugation and
stored at 20C until assayed for IL6 content
IL6 production was quantified using a validated
ELISA assay developed in our laboratory BrieflyNunc
MaxiSorb 96well plates FischerScientific were coated
for 12 h at 4C using a rat IgG1 monoclonal anti
human IL6 antibody eBioscience San Diego CA at
a concentration of 1 gmL in 100 mM sodium car
bonate buffer pH 95 The coating solution was re
moved washed three times with phosphatebuffered
salinePBS containing05 Tween20 and incubated
for 1 h at room temperaturewith PBS containing 10 fe
tal bovine serum FBS Hyclone Laboratories Logan
UT Samples and standards 100 RL were aliquoted
into the wells and incubated at room temperature for
2 h The samples were removed the plate was washed
five times and incubated for an additional 2 hat room
temperature with PBS FBS containing 1 gmL of
an affinity purified biotinylated rat IgG2A monoclonal
antihuman IL6 antibody eBioscience The plate was
washed five times and incubated for 30 min at room
temperaturewith a horseradish peroxidase avidin con
jugate eBioscience diluted 1 1000 in PBS FBS The
wells were washed five times and developed for 30
60 min at room temperature by incubating with 03
H2O2 and 055 mMABTS in 100 mMcitrate buffer pH
4 Reactions were terminated by addition of 50 L of
20 SDS 50 dimethyformamide and the concentra
tion of IL6 calculated using the absorbance at 405 nm
and a semilog calibration curve constructed using re
combinant human IL6 as the standard RDSystems
Minneapolis MN The limit of quantitation LOQ for
this assay was 20 pgmL All experiments were per
formed in triplicate
Statistical Analysis
Data were analyzed for statistical significance us
ing ANOVA paired ttests and posttesting using Dun
netts test Statistically significant differences in re
sponses are represented within the figures and are de
scribed in the figure legends
RESULTS
TRPVIoverexpressing BEAS2B cells treated with
the prototypical TRPV1 agonists RTX and capsaicin
exhibited dose dependent increases in cellular fluores
cence relative to untreated control cells Figure 2A
EC values for the induction of calcium flux were
A
B
e
i
O
v I
3
i
1rgouistlPI
FIGURE 2 A Dose response data for the induction of intracellu
lar calcium flux in TRPVl overexpressing cells by RTX squaresand
capsaicin triangles Data represent themean fluorescence values for
cell populationsand standard deviation n 4 EC values were ob
tained by nonlinear regression analysis Prism4GraphPad Software
Inc San Diego CA using the onesite binding model B Attenu
ated capsaicininduced 20 Mcalcium flux open bars in TRPVl
overexpressing cells using reduced calcium solutions left group
depletion of ER calcium stores with thapsigargin 15 M 5 min
gray bars and treating with 100 M EGTA and 10 Mruthenium
red black bars Data represent the mean fluorescence values for cell
populations and standard deviation n 4 Statistically significant
decreases relative to complete media significant decreases due to
depletion of ER calcium stores and additional decreases afforded
by EGTA and ruthenium red p 05 are identified
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 s  '- -3' 
(183 nt). The PCR progra  consisted of an initial 2 in 
incubation at 94c C and 28 cycles of 94°C (30 s), 55°C 
(30 s), and neC (30 s). A final extension period of 
10 in at noc as also included.  products ere 
e     % sodiu  borate agarose gel, and the i -
 r  l zed i   io-Ra  l-Doc i i  
system. Relative band intensities for each PCR prod-
   e te    (f3-a tin)  
r rt . 
-6 S  
lls e ltured i t    -well t  ll 
ture s e   ~4 % lue c     
  ti     ~8 %  i . at-
ents ere perfor ed in L C-9 (or ,  2) 
f rtifie  it  ca saici  a  t e arious lat rs f 
T P l function for 24 h. ells ere treated ith antag-
onists for 30 in prior to agonist treat ent. fter 24 h, 
the media was collected, clarified by centrifugation, and 
stored at -20cC until assayed for IL-6 content. 
IL-6 production as quantified using a validated 
ELISA assay developed in our laboratory. Briefly, Nunc 
MaxiSorb 96-well plates (Fischer Scientific) were coated 
for 12 h at 4°C using a rat Ig l onoclonal anti-
hu an IL-6 antibody (eBioscience, San Diego, CA) at 
a concentration of 1 tJ..g/mL in 100 m  sodium car-
ate ff r,  .5.  ting s l tio  s r -
e , as e  t ree ti es ith s ate- ffere  
saline (PBS) containing 0.05% T een-20, and incubated 
f r   at r  te erat re ith  c tai ing 0% fe-
tal bovine seru  (F S) (Hyclone Laboratories, Logan, 
T). Sa ples and standards (100 tJ..L) ere aliquoted 
into the ells and incubated at roo  te perature for 
2 h. The samples were removed; the plate was washed 
 e   ncubated   i      
te perature ith PBS + FBS containing 1 tJ..g/ mL of 
an affinity purified biotinylated rat Ig 2  onoclonal 
anti-human IL-6 antibody (eBioscience). The plate as 
  i es        
temperature with a horseradish peroxidase-avidin con-
jugate (eBioscience) diluted 1/1000 in PBS + .  
wells were washed five times and developed for 30-
60 in at roo  te perature by incubating ith 0.03% 
20 2  . 5   i    itrate ff r,  
4.4. eacti s ere ter i ate   a iti  f  tJ..L f 
20% 50S: 50% dimethyformamide and the concentra-
tion of IL-6 calculated using the absorbance at 405 n  
and a se ilog calibration curve constructed using re-
co binant hu an IL-6 as the standard (R&D Syste s, 
Minneapolis, MN). The limit of quantitation (LOQ) for 
t is assa  as 20 / m . ll e eri e ts ere er-
for ed in triplicate. 
t ti ti l lysis 
ata ere analyzed for statistical significance us-
ing , paired t-tests, and posttesting using un-
ett's test. tatisticall  si ifica t iffere ces i  re-
sponses are represented ithin the figures and are de-
scribed in the figure legends. 
 
Vl- r r i  -2  lls tr t  ith 
t e r t t i l l ists, ,  saicin, 
exhibited dose-dependent increases in cellular fluores-
cence relative to untreated control cells (Figure 2A). 
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FIGURE 2. (A) Dose-response data for the induction of intracellu-
lar calci  fl  i  V1- ere ressi  cells   (sq ares) a  
capsaicin (triangles). ata represent the ean fluorescence values for 
cell populations and standard deviation (Il = 4). ECso values ere ob-
tained by nonlinear regression analysis (Prism 4, GraphPad Software, 
Inc., San Diego, CAl using the one-site binding model. (8) Attenu-
ated capsaicin-induced (20 J.lM) calciu  flux (open bars) in TRPV1-
overexpressing cells using reduced calciu  solutions (left group), 
depletion of ER-calcium stores with thapsigargin (1.5 J.lM, 5 min) 
(gray bars), and treating ith 100 J.lM  and 10 J.lM rutheniu  
red (black bars). Data represent the ean fluorescence values for cell 
populations a  standard deviation (Il = 4). ' tatistically significant 
decreases relative to co plete edia, "significant decreases due to 
depletion of ER calcium stores, and "'ad iti l eases f  
by  and rutheniu  red (p :s 0.05) are identified. 
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04 f01 and 10 f 04 M for RTX and capsaicin re
spectively Agonist induced calcium flux wasdecreased
by 45 in reduced calcium media open bars and
further decreased by6when EGTA 100 gM and
the polar nonselective calcium channel blocker ruthe
nium red 10 M were included in the treatment so
lutions solid bars Figure 213 Depletion of endoplas
mic reticulum stores of calcium with thapsigargin gray
bars decreased calcium fluxby 65 and 85 in calcium
deficient and complete media respectively Figure 213
These data indicated that 4550ofthe total calcium
flux observed was attributable to uptake from the treat
ment solutions All TRPV1 selective antagonists inhib
ited calcium flux in a dose dependent manner IC val
ues for the antagonists are presented in Table 1 The
rank order for inhibition of calcium flux was SCO030
capsazepine and 5iodoRTX antagonist A JYL1433
KMJ642 antagonist B and LJO328
Inhibition of cell death by various TRPV1selective
antagonists was also assessed Figures 3A and 313
present dose response data for the inhibition of cell
death by TRPV1 antagonists 5IodoRTX was the
most potent inhibitor of capsaicin toxicity followed by
A
n
e
C
r
e
Volume 19Number 4 2005
TABLE 1 IC50 Values for the Inhibition of RTXand
CapsaicinInduced Calcium Flux Using Various TRPV1
Antagonists
TRPV1 Inhibitor ICM
SCO030 03f01
Capsazepine 05f03
5IodoRTX 06f03
Antagonist A 08t02
JYL1433 3 f 2
KMJ642 30f05
Antagonist B 5 f 2
LJO328 7 f4
LJO328 Capsaicin 08t01
IC50 values were determined from semilog plots using the onesite compe
tition model provided in theGraphPad Software package Data represent the
mean and standard deviation n 4
SCO030 KMJ642antagonist AJYL1433 LJO328 and
antagonist B The rank order for the degree of protec
tion provided by the effective antagonists was 5iodo
RTX LJO328 antagonist A SCO030 antagonist B JYL
1433 KMJ642 and capsazepine decreases in cell vi
ability at high antagonist concentrations were due to
the toxicity of the antagonists themselves Interestingly
B
100
80
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D
Z
0
0 02505075 01 1 10 20 30
Antagonistj gM
FIGURE 3 AInhibition of cell death G Mcapsaicin in TRPVIoverexpressing cells by various TRPV1 selective antagonistsSCO030 upside
down open triangles solid line JYL1433 filled diamonds dashed line capsazepine stars dashed line and 5iodoRTX open diamonds
solid line B Inhibition of cell death by LJO328 stars dashed line KMJ642 filled diamonds solid line antagonist A upsidedown open
triangles solid line and antagonist B filled diamonds dashed line Data are representative of the mean viability and standard deviation
n 3 For claritystatistical significance has not been noted in the figures CThe effects of LJO328 and 5 iodoRTX on cell death induced by
vanilloid treatment TRPVIoverexpressing cells were treated with 1 Mcapsaicin or 10 nMRTX with increasing concentrations of LJO328 or
5iodoRTX for 24 h Data represent the mean and standard deviation n 3 Data are as follows 10 nM RTX plus 5iodoRTX circles 10 nM
RTX plusLJO328 triangles and 1 Mcapsaicin plus LJO328 squares Statistically significant changes in cell viabilityrelative to capsaicin or
RTX treated controls p 05 are identified with an asterisk D Dose response cytotoxicity data for TRPVIoverexpressing cells treated with
increasing concentrations of capsaicin in the presence triangles and absence of 20M LJO328 squares Data represent the mean and standard
deviation n 4
01 1 10 100
Log Antagonist gM
001 01 01 1 10 100
Log Antagonistj lM
Log Capsaicin gM
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.4±0.1  .0± .4 ..,..M    saicin, e-
s ectively. ist i ce  calci  fl  as ecrease  
 ~4 % i  r  l i  i  (ope  ars),  
f rt er ecrease   ~6% e   (10  ..,.. ) a  
the polar, nonselective calciu  channel blocker, ruthe-
i   (1  ..,..M),  i lude  i  t e t t t o-
l tio s (soli  ars) (Figure B). e leti  f e oplas-
ic reticulu  stores of calciu  ith thapsigargin (gray 
bars) decreased calciu  flux by ~65 and 85% in calciu  
eficie t  c lete edia, res ecti el  (Figure B). 
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SC0030, K J-642, antagonist A, JYL-1433, LJO-328, and 
antagonist B. The rank order for the degree of protec-
ti  r ide   t  ff ti  t ists s -iod -
, J -328, antagonist , S 0030, antagonist , J -
1433, J-642, and capsazepine; decreases in cell vi-
a ilit  at i  a ta ist c ce trati s ere e t  
the toxicity of the antagonists themselves. Interestingly, 
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FIGURE 3. (A) Inhibition of cell death (111M capsaicin) in TRPV1-overexpressing cells by various TRPVl selective antagonists. SC0030 (upside-
down open triangles, solid line), JYL-1433 (filled diamonds, dashed line), capsazepine (stars, dashed line), and 5-iodo-RTX (open diamonds, 
solid line). (B) Inhibition of cell death by J -328 (stars, dashed line), J-642 (filled dia onds, solid line), antagonist  (upside-down open 
triangles, solid line), and antagonist B (filled dia onds, dashed line). Data are representative of the ean viability and standard deviation 
(11 = 3). For clarity, statistical significance has not been noted in the figures. (C) The effects of LJO-328 and 5-iodo-RTX on cell death induced by 
vanilloid treat ent. P l-overexpressing cells ere treated ith 1 11M capsaicin or 10 n   ith increasing concentrations of J -328 or 
-i -R  for 2  . ata represe t the ea   sta ard i tion (11 = ). t  re s f ll s:    l s -i -R  (cir l s),   
 lus J -328 (tria les), a  11M ca saicin lus J -328 (sq ares). tatisticall  si ificant c a es i  cell ia ilit  relative t  ca saici - r 
T -treated controls (p:s 0.05) are identified ith an asterisk. (D) ose-response cytotoxicity data for T PVl-overexpressing cells treated ith 
increasing concentrations of capsaicin in the presence (triangles) and absence of 20 11M LJ -328 (squares). ata represent the ean and standard 
e iation (11 = ). 
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capsazepine did not prevent cell death while KMJ642
provided only minimal protection despite the ability
of both antagonists to prevent calcium flux Figure 3C
compares the inhibition of capsaicin and RTXinduced
cell death by 5iodoRTX and LJO328 Threshold con
centrations of LJO328 that prevented cell death were
575Mfor capsaicin and 10 RM for RTX consis
tent withRTX being a more potent and selective TRPV1
agonist with a lower Kd than capsaicin 28915Iodo
RTX was the mostpotent inhibitor of cell death induced
by RTX but also required a minimum ratio of 51
to be effective despite having a Kd similar to RTX it
self Figure 30An approximate 25fold increase in the
LD50 for capsaicin wasobserved when LJO 328was in
cluded in treatment solutions Figure 3D confirming
results from Figure 3B that a minimum ratio of 510
LJO328capsaicin was required to compete for TRPV1
binding and to mitigate toxicity by this antagonist A
ratio 510 was also required for all of the other an
tagonists tested Figures 3A and 3B
Several TRPV1 antagonists were also assessed for
modulation of agonist induced cytokine responses
IL6 and 8 are common biomarkers of cellular injury
and the induction of acute pro inflammatory processes
Cells treated with capsaicin exhibited significant 25
and 8fold increases in the relative abundance of IL6
and IL8 mRNA transcripts Figure4A in response to
capsaicin treatment IL6 and IL8 gene induction was
markedly suppressed by LJO328 Figure 4A as well
as by capsazepine SC0030 EGTA and ruthenium red
Figure 4B Differences in the inhibition patterns for
IL6and IL8were observedwith EGTA and ruthenium
red These effects appeared to be a direct result of an
tagonistchelator treatment rather than influences on
TRPV1mediated functions since increases in IL6oc
curred in control samples data not shown Addition
of LJO328 to treatment solutions completely blocked
the induction of IL6 secretion by cells treated with cap
saicin and RTX in a concentration dependent manner
Figure 40 Concentrations of LJO328 that blocked
IL6 production were approximately twofold lower for
capsaicin than RTX similar to the trends observed for
inhibition of cell death
Additional experiments to fully elucidate the
significance of extracellular to intracellular calcium
flux in TRPV1 agonist induced cell death and cy
tokine production were performed by treating TRPV1
overexpressing cells with increasing concentrations
of capsaicin in either complete KGM or calcium
deficient KGM 2 cell culture media Inhibition of cell
death was not observed in reduced calcium media
Figure 5A while IL6 production was completely
prevented Figure 5B
Cotreatment of cells with capsaicin and inhibitors
of arachidonic acid metabolism ETYA and cyclo
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FIGURE 4 AInduction of IL6and IL8 gene expression inTRPV1
overexpressing cells by capsaicin and inhibition by LJO 328 Cells
were treated as shown in the figure for 4 hharvested and changes in
gene expression assessed by RTPCRas described under the materi
als and methods section Represents a statistical increase over un
treated control cells while W represents significant differences from
treated and control cells B The effects of multiple TRPV1 antag
onists and modulators of TRPV1 function or calcium concentration
on the induction of IL6 open bars and IL8 shaded bars genes
in TRPV1overexpressing cells treatedwith capsaicin 1M for 4 h
at 37 C Concentrations of antagonist were SCO030 100 nM cap
sazepine 15MEGTA 75Mand ruthenium red 150MPoints
at which statistically greater levels of gene expression were observed
versus untreated control cells are indicated by an asterisk 1while
lower levels of expression relative tocapsaicin treated cells are rep
resented with an open circle Data represent the mean and stan
dard deviation n 5C Inhibition of capsaicin andRTX induced
IL6 secretion by TRPV1overexpressing cells with LJO 328 Cells
were treatedwith increasing concentrations of LJO328 and capsaicin
1 M squares or RTX 10 nM triangles for 24 h at 37CIL6
concentration in media was determined by ELISA using pooled sam
ples n 3 The concentration of IL6 in untreated control cells was
265 pgmL
oxygenase COX enzymes indomethacin etodolac
aspirin and diclofenac also showed significant inhi
bition of cell death Figure 6 LJO328 and capsazepine
were evaluated for inhibition of recombinant human
COX1 and COX2 in vitro however neither TRPVl
antagonist was active data not shown demonstrating
that LJO328 and the other TRPV1 antagonists exerted
their protective effects through TRPV1 inhibition and
not by altering associated cell death pathways
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RTX as the ost potent inhibitor of cell death induced 
by RTX, but also required a minimum ratio of ~5:1 
to be effective despite having a Kd similar to RTX it-
self (Figure 3C). An approxi ate 25-fold increase in the 
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cluded in treatment solutions (Figure 3D), confirming 
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binding and to mitigate toxicity by this antagonist. A 
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tagonists tested (Figures 3  and 38). 
Several T P l antagonists ere also assessed for 
l tion f ist-i duce  t ine r s s s. 
I -6 and 8 are co on bio arkers of cellular injury 
and the induction of acute pro-infla atory processes. 
Cells treated with capsaicin exhibited significant (2.5-
 -fol ) i creases i  t e l ti  e  -6 
and IL-8 R  transcripts (Figure 4 ) in response to 
capsaicin treat ent. IL-6 and IL-8 gene induction as 
markedly suppressed by LJO-328 (Figure 4A), as well 
as by capsazepine, SC0030, EGTA, and ruthenium red 
(Figure 48). Differences in the inhibition patterns for 
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red. These effects appeared to be a direct result of an-
tagonist/ chelator treatment rather than influences on 
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curred in control samples (data not shown). Addition 
of LJO-328 to treatment solutions completely blocked 
the induction of I -6 secretion by cells treated ith cap-
saicin and RTX in a concentration-dependent anner 
(Figure 4C). Concentrations of LJO-328 that blocked 
IL-6 production were approximately twofold lower for 
capsaicin than RTX, si ilar to the trends observed for 
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Additional experiments to fully elucidate the 
significance of extracellular to intracellular calcium 
flux in TRPV1 agonist-induced cell death and cy-
tokine production were performed by treating TRPVl-
overexpressing cells with increasing concentrations 
of capsaicin in either complete (KG ) or calcium-
fi i t (KG  ) ll lt re dia. I i iti  f ll 
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(Figure 5A), while IL-6 production was completely 
prevented (Figure 58). 
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of arachidonic acid etabolis  (ETYA) and cyclo-
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bition of cell death (Figure 6). LJO-328 and capsazepine 
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FIGURE 5 A Dose response cytotoxicity data for TRPVl
overexpressing cells treated with increasing concentrations of cap
saicin in complete diamonds and calcium deficient squarescell cul
ture media Data represent the mean and standard deviation n 4
Statistical differences p05were not observed B Inhibition of
IL6 production by cells treated with capsaicin 1 M in complete
and calciumdeficient cell culture media The concentration of IL6
in media collected from untreated cells was 270f50 pgmL IL6
was lower than complete cell culture media and in cells treated
with capsaicin p05Data represent the mean and standard
deviation n 3
DISCUSSION
TRPV1 is a vital component ofmammalian sensory
function However definitive physiological functions
a
j
e
Log lInhibitorl M
FIGURE6 Inhibition of cell death by inhibitors ofarachidonic acid
metabolism and COX activity Inhibition of cell death induced by
capsaicin 1MinTRPVIoverexpressing cells using ETYA upside
down triangles indomethacin squares etodolac triangles acetyl
salicylic acid diamonds and diclofenac circles Error bars less than
5are not shown Data represent the mean and standard deviation
n 3The lowest concentrations of inhibitor atwhich statistical sig
nificance p 05was observed are indicated with an asterisk C
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of TRPV1 and the consequences of activation in respi
ratory epithelial cells have not been fully established
It has been suggested that TRPV1 serves as a molecu
lar sensor of potentially noxious inhaled environmen
tal substances whose activation acts in concert with
neuronal TRPV1 to initiate protective defense mech
anisms including cough and immune responses Data
presented here support this idea and confirm an es
sential role for TRPV1 in promoting pro inflammatory
cytokine production by bronchial epithelial cells via
a mechanism that was dependent upon the ability of
TRPV1 tomediate the transfer of calcium ions from the
extracellular matrix into the cytosol
Data are also presented that highlight the exis
tence of ancillary deleterious TRPV1mediated pro
cesses that ultimately lead to cell death These pro
cesses were independent of extracellular calcium con
tent and cellular uptake through TRPV1 These results
contrasted with the neurotoxic mechanism of capsaici
noids which involves agonist induced influx and pro
longed accumulation of calcium termed excitotoxicity
30Excitotoxic mechanisms have also been shown for
Jurkat HEK293 and CHOcells that transiently overex
pressed recombinant rat TRPV1 3133 In all instances
toxicity was inhibited by capsazepine and treatments
that interfered withTRPVlmediated calcium fluxand
accumulation in cells Here we clearly demonstrate
the existence of an alternate mechanism for cell death
by TRPV1 agonists one that was not influenced by
changes in extracellular calcium content or inhibited
by capsazepine Rather cell death involved disruption
of normal COX function following TRPV1 activation
Our previous studies 7 provided preliminary
evidence that the cytotoxicity of capsaicinoids and
other TRPV1 agonists to BEAS 213 and TRPV1
overexpressing cells occurred via a mechanism that
was independent of calcium These studies provide ad
ditional mechanistic insights and support this conclu
sion Most TRPV1 antagonists prevented cell death to
some degree Figures 3A and 3B However inhibition
of cell death by TRPV1selective antagonists did not di
rectly correlate with their ability to attenuate calcium
flux Table 1 and Figures 3A and 3B For example cap
sazepine and KMJ 642 were potent inhibitors of cal
cium flux yet little to no protection against cytotoxicity
was observed using these two antagonists FigureW
Similarly removal of calcium from the treatment so
lutions had no effect on cell death by TRPV1 agonists
Figure 5 despite having significant impact on overall
agonist induced calcium flux and cytokine responses
Three hypotheses to describe the mechanismsof
cell death were considered A concomitant increase in
intracellular sodium as a result of TRPV1 activation
has been suggested as a possible mechanism for cell
death However this hypothesis was dismissed because
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ciu  flux, yet little to no protection against cytotoxicity 
was observed using these two antagonists (Figure 3A). 
Similarly, removal of calcium from the treatment so-
lutions had no effect on cell death by TRPV1 agonists 
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TRPVI inhibitors egcapsazepine have been shown
to concomitantly inhibit both calcium and sodium flux
33 If the influx of sodium ions through TRPVI caused
cell death then inhibition of cell death would corre
late directly with the relative IC50 values of the an
tagonists This correlation was not observed A second
potential calcium independent mechanism of cytotox
icity that also account for the level of TRPV1 expres
sion as a determinant of sensitivity was that agonist
induced tetramerization of TRPVI subunits 2 served
as an intrinsic cell death signal However tetramer for
mation has also been shown to be blocked by TRPVI
antagonists such as capsazepine and calcium chela
tors such as EGTA 2 Unfortunately neither of these
substances prevented cell death A third hypothesis to
explain the data presented in this study stated that cell
death occurred via the activation of intracellular ER
bound TRPV1 to promote toxicity This mechanism ex
plains data that shows a strong correlation between
TRPVI expression and the inability of extracellular
modifications to calcium content to alter cell death pro
cesses Data presented in Figure 2B support the exis
tence of two distinct populations of TRPVI in these
cells and provide significant support for this proposed
mechanism
Additional studies to identify prodeath pathways
associated with TRPVI signaling demonstrated a role
for altered arachidonic acid homeostasis and COX
metabolism Figure 6 Previous research has demon
strated the selective upregulation of COX2 and PGEZ
by BEAS213 cells following treatment with residual oil
fly ash ROFA 17345 an activator of TRPVI 17
and in keratinocytes treated with capsaicin 5 Non
specific inhibition of arachidonic acid metabolism us
ing ETYA and COX inhibition using various NSAIDs
prevented cell death by capsaicin Figure 6 These data
indicate that changes in COX mediated metabolism via
a TRPVI mediated process contribute to the cell death
cascade
Collectively these studies expand our current un
derstanding of the mechanism bywhich TRPVI me
diates proinflammatory and cell death processes in
BEAS213 cells exposed to capsaicin RTX and likely
other TRPVI agonists The presence of multiple func
tionally distinct subcellular pools of TRPVI has been
shownand processes integrally related to TRPV1 func
tion in cells have been identified The proposed mech
anisms of cytokine induction and cell death are pre
sented graphically in Figure 7 Based on our results
it may be reasonable to predict that variations in the
regulation of TRPV1 functioneg PIP2 or calmodulin
binding phosphorylation etc that can be influenced
by genetic andor environmental factors may have a
significant impact on the toxicities of various TRPVI ag
onists in vivo depending upon which pool of TRPV1
Ca
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Ruthenium Red
Agonist I ReducedCa
Death
Cox
IL8 Ca
itratransc ription Z
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IL6 and IL 8secretion
FIGURE 7 Schematic representation of the proposed mechanism
for extracellular calcium dependent cytokine production and extra
cellular calciumindependent cell death in TRPVIoverexpressing
cells TRPVI is represented as shaded ovals on theplasma membrane
and endoplasmic reticulum of cellsTRPVIselective antagonists and
overt modifications to extracellular calcium content selectively in
hibit cytokine responses but not cell death Only lipophilic TRPVI
antagonists prevent cell death presumably by inhibiting intracellu
lar thapsigarginsensitive TRPVImediated activities
that becomes activated Likewise differences in TRPVI
expression and location rather than differences in chan
nel gating thresholds and receptor activity will likely
govern the cytotoxic potential of lipophilic TRPVI ag
onists in vivo Together these data elicit a number of
intriguing hypotheses regarding the potential role of
TRPVI in mediating airway toxicities by chemically
and physically distinct substances and suggest a poten
tial role for this receptor in mediating environmentally
influenced airway diseases such as asthma COPD or
ARDS
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ABSTRACT
Previous studies on themetabolismof capsaicinoids natural prod
ucts isolated from chili peppers demonstrated the production of
unique macrocyclic alkyl dehydrogenated w and ceihydroxy
lated products This study investigated the structural and enzy
matic parameters that direct selective alkyl dehydrogenation and
hydroxylation of capsaicinoids using a variety of structurally re
lated capsaicinoid analogs and cytochrome P450 P450 enzymes
CYP2C9 preferentially catalyzed alkyl dehydrogenation whereas
CYP2E1 and 3A4catalyzed w and wlhydroxylation respectively
Analysis of incubations containing various P450s and structural
variants of capsaicin by liquid chromatography tandem mass
spectrometry demonstrated similarities in the rate of capsaicinoid
metabolism but marked differences in the metabolite profiles
Production of macrocyclic and wlhydroxylated metabolites from
the various capsaicinoids was dependent on the structure of the
alkyl terminus and P450 enzyme A tertiary carbon at the w1
position coupled to an adjacent unsaturated bond at the w23
position enhanced the formation of themacrocyclic and dehydro
genated metabolites and were requisite structural features for
wlhydroxylated product formation Conversely substrates lack
ing these structural features were efficiently oxidized to the w
hydroxylated metabolite These data were consistent with our hy
pothesis that metabolism of the alkyl portion of capsaicinoids was
governed in part by the stability and propensity to form an inter
mediate radical and a carbocation and a direct interaction be
tween the alkyl terminus and the heme of many P450 enzymes
These results provided valuable insights into potential mecha
nisms by which P450s metabolize capsaicinoids and highlight crit
ical chemical features that may also govern the metabolism of
structurally related compounds including fatty acids monoter
penes and isoprenoids
The capsaicinoids are a family of natural products isolated from the
dried fruits of chili peppers Capsiceun annum and Capsicum frute
scens Govindarajan 1985 Govindarajan and Sathyanarayana 1991
Caterina et at 1997 These substances are the principals that produce
the characteristic sensations associated with the ingestion of spicy
cuisine as well as the agents responsible for causing severe irritation
inflammation erythema and transient hyper and hypoalgesia at sites
exposed to capsaicinoids capsaicinoids are particularly irritating to
the eyes skin nose tongue and respiratory tract There are six
naturally occurring capsaicinoid analogs capsaicin dihydrocapsaicin
nordihydrocapsaicin nonivamide homocapsaicin and homodihydro
capsaicin Fig 1 Reilly et al 2001 All capsaicinoid analogs
possess a 3hydroxy4methoxybenzylamide vanilloid ring pharma
cophore but differ from capsaicin in their hydrophobic alkyl side
chain Differences in the side chain moiety include saturation of
This work was supported by grants from the National Heart Lung and Blood
Institute HL069813 and HL13645 and a contract from the National Institute of
Standards and Technology Department of Commerce Contract 60NAN
Boo0006
Article publication date and citation information can be found at
hftpdmdaspetjournalsorg
doi10124md104001214
CIS the w23position deletion of a methyl group at C loss of
the tertiary carbon and changes in the length of the hydrocarbon
chain Fig 1Previous structure activity studies using models for the
study of acute pain and altered pain sensitivity in mice have demon
strated a strict structural requirement for both the vanilloid ring
pharmacophore and a hydrophobic alkyl chain that may be saturated
or unsaturated branched or unbranched and consisting of 8 to 12
carbon atoms for optimal binding and activation of the capsaicin
receptor TRPV I Walpole et al 1993abc
Capsaicinoids particularly in pepper spray or overthecounter pain
relief productsegCapsazin Chattem Inc Chattanooga TN are
frequently associated with undesirable effects including localized
dermal erythema tissue inflammationegskin mucous membranes
and eyes painful burning and itching sensations and uncontrollable
cough Caterina et al 1997 Olajos and Salem 2001 NIJ March
1994 In animals the toxicity LD of capsaicinoids has been
shown to be related to the route of exposure with intravenous and
intratracheal administration being the most lethal forms of exposure
approximately 100 to 600 times more lethal than oral or topical doses
Glinsukon et al 1980 In all cases however the cause of death was
attributed to severe respiratory depression and cardiovascular dys
function Glinsukon et al 1980 One hypothesis for the apparent
ABBREVIATIONS TRPV1 capsaicin receptor transient receptor potential V1 NADPH reduced nicotinamide adenine dinucleotide phosphate
P450 cytochrome P450 HPLC high performance liquid chromatography LCMSMS liquid chromatography tandem mass spectrometry amu
atomic mass units
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Fie I Chemical structures of the capsaicinoids and alkyl derived metabolites of capsaicin dihydrocapsaicin and nonivamide The structure of capsaicin is shown in the
upper left panel The compositions of the alkyl side chain groups Rgroups of the capsaicmoid analogs used in this study are represented in text fortnat below the structure
of capsaicin The right panel shows the alkyl derived metabolites that are under investigation
tissue selective nature of the toxicity of the capsaicinoids proposed
that unique cytotoxic metabolites were produced in respiratory tissues
and that these metabolites were responsible for the ensuing cellular
damage organ dysfunction and ultimate failure However previous
studies that characterized the P450dependent metabolism of capsa
icin demonstrated that biotransfonnation serves as a protective mech
anism against cell death in lung and liver cells as demonstrated by an
increase in cytotoxicity when cellular P450s were inhibited by the
mechanism based inactivator laminobenzotriazole Reilly et at
2003a Inhalation of pepper spray aerosols capsaicinoids by rats
caused exposuredependent acute tissue inflammation and selective
damage to various airway epithelial cell types Reilly et al 2003a
Additional studies confirmed that capsaicin and its analogs produced
these adverse effects through the activation of calciumdependent
inflammation and calciumindependent cytotoxic TRPVI medi
ated processes Reilly et al 2003b Thus capsaicinoids have been
classified as moderately toxic substances with an apparent selectivity
for respiratory and cardiovascular tissues However the mechanisms
for cellular damage and possibly organ dysfunction are not dependent
upon the P450 mediated bioactivation to cytotoxicants Rather the
toxic effects of capsaicinoids appear to be highly dependent upon the
ability of capsaicin and its analogs to bind and activate TRPVI
ultimately promoting cellular inflammation and cell death
Previous studies on the metabolism and subsequent amelioration
ofcapsaicin toxicity through metabolism by P450 enzymes identified
a unique alkyl dehydrogenated metaboliteiea diene of capsaicin
M4 in addition to the expected or and colhydroxylated M2 and
M3 respectively metabolites Fig 1 An unusual macrocyclic me
tabolite M1 was also identified and was postulated to arise through
covalent bond formation between the amide nitrogen and a uniquely
stable tertiary allylic radical at the penultimate w I carbon of the
alkyl side chain Reilly et al 2003x Fig 1 The macrocyclic and
01hydroxylated metabolites were not formed from the straight
chain capsaicin analog nonivamide Nonivamide lacks the tertiary
allylic structural feature Fig 1 and thus does not have ability to
form a stabilized radical intermediate which was postulated to be a
requisite intermediate in the production of these three metabolites
However our previous work did not answer many questions re
garding substrate structure requirements for individual metabolite
production or elucidate whether specific cytochrome P450 enzymes
imposed active site constraints that might control the formation of
these unique metabolites Could a capsaicinoid with a tertiary carbon
but without the unsaturation at the co23position form these types of
metabolites Could capsaicinoids with longer or shorter alkyl chains
form macrocyclic products consisting of more or less carbon atoms
Would longer or shorter straightchain analogs serve as substrates for
both co and Ihydroxylation Therefore the current research was
conducted to determine which structural features of the capsaicinoids
controlled the P450mediated production of these alkyl hydroxylated
and dehydrogenated metabolites and to establish rational mechanis
tic hypotheses for their formation Our working hypothesis was the
presence of a tertiary allylic carbon was crucial for the formation and
stabilization of a tertiary allylic radical intermediate that ultimately
produced the macrocyclic terminal dehydrogenated and w1hy
droxylated metabolites Conversely in the absence of this structural
configuration the alkyl chain binds to most P450s in an orientation
wherein the alkyl terminus interacts directly with the P450 heme and
substrates are preferentially oxidized at the terminal methyl position
to form an whydroxylated metabolite
Materials and Methods
Chemicals and Reagents Capsaicin and its natural andspnthetic analogs
are potent derntal ocular and respiratory irritants that cause severe irrita
tion painful burning sensations and uncontrollable cough Use caation when
handling concentrated solutions or powdered forms of these chemicals 3Hy
droxy4methoxyben zylamine HCl vanillamine HCI decanoyl chloride oc
tanoyl chloride nonivamide iivanillylnonanamide capsaicin 97 capsa
icin 60 dihydrocapsaicin 90 NADPH sodium carbonate sodium
hydroxide DOand methanolDl were purchased from Sigma Aldrich St
Louis MO OWater 95 was purchased from Cambridge Isotope Lab
oratories Andover MA Anhydrous diethyl ether n butyl chloride ethyl
acetate HPLC grade methanol and 88 formic acid were purchased from
J T Baker Phillipsburg NJ Homocapsaicin homodihydrocapsaicin and
nordihydrocapsaicin were purified from a mixture of capsaicinoids 60
capsaicin by HPLC Purity values for the isolated and synthesized capsaici
noid analogs ranged from 85 to 95 Purified water for buffer and sample
preparation was generated using a Millipore Milli Q Plus water purification
system Millipore Corporation Billerica MA
Synthesis of Capsaicinoids Synthesis of iivanillyloctanamide and n
vanillyldecanamide was achieved using a method based on those described by
Nelson 1919 and Jones and Pyman 1925 Briefly the free base form of
vanillamine HCl was prepared by dissolving 02 g of vanillamine HCl in 3 ml
of 03 N NaOH and adding 1 N NaOH drop wise until a precipitate formed
The precipitate was collected by vacuum filtration dissolved in methanol
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,  f nction,  lti t  il . r, i  
ies  e   0-  s   a-
i i  tr t  t t i tr f ti  r    r t ti  ch-
anis  against cell death in lung and liver cells, as de onstrated by an 
increase i  t t i it  he  ll lar s r  i i it   t  
e is -base  i cti ator, I- i t i l  (Reilly t L, 
3a).     ls (caps i i s)   
 r - t t  ti  i fla ti   l tive 
  s a     (Re  t L, 03 a), 
itio l t ies fir e  t t i in  its l  r ce  
ese s  fects   a io   l i -  
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  (Re   L, 03b). , i ids e  
i     sta ces th   l ti  
 i   iovascular s. r,   
r ll lar a e  i l   ti  e t t 
 t  -    . ,  
t i  ffects f i i ids r t   ig ly t  t  
il  f   ts ogs t  ind  ate PY I, 
ti a  ing lular fla ation  ll t . 
e ious ies  e l ,  t li ti , 
f ca saicin t icit  t r  eta lis    e z es i e tified 
a unique alkyl-dehydrogenated etabolite (i.e., a diene of capsaicin, 
4), in    te  W-,  w-I- late  (M2  
, res ectively) eta lites (Fi . I).  s al acr c clic e-
tabolite (M I) was also identified and was postulated to arise through 
   e        
st le t rtiar  allylic r i l t t  ltimate (w-l) r  f t  
alkyl side chain (Reilly et aL, 2003a) (Fig. I), The acrocyclic and 
w-l-hydroxylated eta lites ere n t fonne  fr  the strai t-
chain capsaicin analog, noniva ide. oniva ide lacks the tertiary 
allylic structural feature (Fig. I) and, thus, does not have ability to 
fonn  t ilized r i l intenn i t , ic  as t late  t    
te intermediate   ion f  t ree li . 
o r, r r ious r  i  t a s er  stions r -
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ca saici )  . rit  alues f r t e is late  a  s t esize  ca saici-
id l s  ro   t  %. tified t  r fer  le 
preparation as generated using a illipore illi-Q Plus ater purification 
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crystallized by drying at 40C under a stream of air and dried at 7080C
for 10 to 20 min The molar equivalents of solid vanillamine were deter
mined and the powder was mixed with 5 ml of anhydrous ethyl ether to
produce a suspension The appropriate acyl chloride was added to this sus
pension in a drop wise manner to a total molar ratio of051Themixture was
gently heated in a water bath removed capped and mixed The mixture was
then permitted to react overnight at room temperature 22C with gentle
rocking The next day 50 Al of I M HCI and 2 m1 of H2O were added and
mixed to remove the excess unreacted vanillamine The ether fraction was
transferred and washed with 2 nil of 50 saturated sodium carbonate to
decompose the remaining acyl chloride The ether fraction was collected and
dried under a stream of air at 40Cand the product was dissolved in methanol
The molecular mass of the two capsaicinoid products was confirmed by direct
infusion of a 10 nglAl solution of each of the products in methanol01
formic acid 703 into the mass spectrometer and were verified as ntz 280
and 308 for the octyl and decyl forms respectively The structural features
were detennined using tandem mass spectrometry and comparison to the mass
spectra of other capsaicinoid standards Purity and retention properties were
assessed by HPLC and UV detection at 230 nm using nonivamide as the
quantitative standard Products were 90 to 95 pure with an approximate
yield of 25 to 30 r
In Vitro Metabolism The metabolism of capsaicin and its chemical
analogs see Fig 1 for structures was performed as previously described
Reilly et al 2003a using pooled human liver microsomes 100 pmolml
025 mgml and various recombinant human P450 enzymes 50 pmolml
BDGentest Woburn MA Briefly 100 AM capsaicinoid wasincubated with
each P450 sample and 2 mM NADPH in phosphate buffered saline pH72
for various time points up to I It at 37C 05ml total volume 100 M
capsaicin appeared to be a saturating concentration for these enzymes The
metabolites were extracted from the incubations using 4 ml of 50 r nbutyl
chloride50ethyl acetate fortified with 50 Mcapsaicin or nonivamide as
an internal standard based on a 500Al incubation volume mixed and
centrifuged and the organic layer was collected and concentrated by drying at
40C under a stream of air Prior to LCMS analysis the dried residues
were reconstituted in 50 Al of 60methanol40 purified H2O
Analysis ofMetabolite Formation by Liquid ChromatographyTandem
Mass Spectrometry Electrosprayionization LCMSMS analysis was per
formed using a Finnegan TSQ 7000 tandem mass spectrometer Thermo Elec
tron Waltham MA interfaced with a Hewlett Packard Series 1100 solvent
delivery system Hewlett Packard Palo Alto CA The metabolites were
resolved using a MetaSil Basic CC 150 X 303 mreversephase HPLC
column Varian Inc Palo Alto CA with isocratic conditions consisting of
methanol and aqueous formic acid 01 v The chromatographic condi
tions used for the analysis of each analog and its metabolites were as follows
n vanillyloctanamide 57methanol nordihydrocapsaicin capsaicin and
nonivamide 60 methanol dihydrocapsaicin and ti vanillyldecanamide
64 methanol and homocapsaicin and homodihydrocapsaicin 68 These
concentrations were chosen to produce overlapping retention times for the
individual analogs and their respective metabolites relative to capsaicin The
HPLC flow rate was set at025 mlmin and the column was maintained at a
temperature of 40C The mass spectrometer was programmed to monitor for
precursortoproduct ion transitions corresponding to the internal standard
capsaicin or nonivamide parent compounds QM H dehydrogenated
M H 2 amu and oxygenatedM H 16 auto metabolites and
the primary capsaicinoid product ion derived from the vanilloid ring moiety
inz 137 The parent compound n ratios were 280 nvanillyloctanamide
294 nonivamide and nordihydrocapsaicin 306 capsaicin 308 dihydrocap
saicin nvan illy ldecanamide 320 homocapsaicin and 322 homodihydro
capsaicin The identity of each capsaicinoid metabolite was verified by
analysis in 6013methanolDI and by full scan MS analysis as
previously described for capsaicin Reilly et al 2003a Incorporation of
from OWater 50 and 95 v in incubations was assessed by fullscan
mass spectrometry and monitoring for increases in the 2 arm isotope peak
The parameters for the mass spectrometer were optimized using nonivamide
and the optimize function within the instrument operating system All other
parameters were as follows collision gas argon 30 mT collisionoffset
voltage 20 eV auxiliary gas nitrogen 10 units and sheath gas nitrogen
50 psi
Relative metabolite production was determined by dividing the normalized
metabolite peak area ratios by the corresponding ratios obtained for capsaicin
Semiquantitative analysis ofmetabolite production was assessed by integration
of the selected metabolite peaks in the LCMSMS chromatogram and nor
malizing the peak area to the internal standard peak area capsaicin or noni
vamide Absolute quantitation of the metabolites was not feasible because
analytical standards are not available Quantitative analysis to assess metabolic
rates for capsaicin and nonivamidewas achieved by monitoring the disappear
ance of the substrate and determining the change in substrate concentration
using peak area ratios analyteinternal standard and a standard curve con
structed with the specific capsaicinoid analog
Results
Analysis of capsaicin its analogs and the production of their
respective metabolites was achieved using the analytical methods
described above The rates and extent of capsaicin and nonivamide
metabolism by human liver microsomes were identical and quickly
10 min became nonlinear during the 60min incubation period
Fig 2A The initial rate of substrate disappearance due to P450
turnover in human liver microsomes was 4 1 pmolmin pmol P450
for both capsaicin and nonivamide Production of the alkyl hydroxy
lated w o I and dehydrogenated macrocyclic and terminal alk
ene metabolites MI4 from capsaicin and nonivamide Ml
M4N was also nonlinear Fig 2 B and Q The rates of formation
and final concentrations of the four alkyl derived capsaicin metabo
e
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FIG 2 Quantitative kinetic analysis of the metabolism of capsaicin open triangles
and nonivamide open squares by human liver microsomes A Semiquantitative
kinetic data representing the relative formation of macrocyclic open diamonds
whydroxylated open squares wlhydroxytated open triangles and terminal
dehydrogenated crosses metabolites from capsaicin B and nonivamide C by
human liver microsomes Incubations were prepared and assayed as described under
Materials and Methods using either capsaicin or nonivamide as an internal standard
ie nonivamide was used as the internal standard for incubations containing
capsaicin Data are representative of the mean relative metabolite peak area and
standard deviation for three separate incubations at each time point For clarity error
bars7have been omitted from the figure these error bars were encompassed by
the symbol
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DEHYDROGENATION AND HYDROXYLATION OF CAPSAICINOIDS
lites were different Surprisingly the dehydrogenated alkene M4 was
produced at the fastest rate and highest final concentration M3 was
the least abundant metabolite produced whereas MI and M2 were
similar in their rate of formation and abundance Fig 213 The
relative production of each metabolite from capsaicin is presented in
Table 1
The production of alkyl derived metabolites from nonivamide was
strikingly different from that for capsaicin Fig 2C Specifically the
putative macrocyclic MIN and wlhydroxylated M3N metabo
lites were not detected and the production of the dehydrogenated
product M4Nwas minimal The w hydroxylated metabolite M2N
was the principal product of this straightchain capsaicinoid Interest
ingly the formation of M4N was not observed until the 20min time
point suggesting that either the rate of M4N production by P450 was
minimal and product accumulation was not detectable until 20 min or
M4N was produced via a secondary perhaps nonenzymatic process
such as dehydration of M2N Regardless significant differences in
the production of the alkyl hydroxylated and dehydrogenated metab
olites were observed for these structurally diverse capsaicinoid
analogs
Incubations with capsaicin and a variety of recombinant P450
enzymes also demonstrated significant differences in metabolite pro
duction Fig3CYP2C9 2C19 2C8 and 2EI efficiently catalyzed
FABLE I
Relative metabolite abundance producedf m the inetabolisnt of capsaicin and
nonivamide by human liver microsomes and recombinant human CYP2C9
Incubations were performed as described under Materials and Methods Relative
metabolite abundance was determined as the percentage of totall metahohte peak area obtained
from selected ion monitoring I0MS for MI to M9 in 31 Reilly et al 2003
HLM human liver microsomesNDnot detected
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the formation of the dehydrogenated metabolites M1 and M4 from
capsaicin However CYP2E1 produced M2 with the highest relative
turnover and M3 production was highest with CYP3A4 and 2C8
Additional P450 enzymes that produced metabolites included
CYPIA1 IA2 2D6 and 2A6 however their catalytic efficiency was
markedly lower than that of human liver microsomes or the enzymes
discussed previously Because CYP2C9 was the most active enzyme
for catalyzing the alkyl dehydrogenation of capsaicin to form M 1 and
M4 coupled with the low amounts of M2 and M3 formed it was
chosen for additional studies to identify similar metabolites from a
variety of structurally diverse capsaicinoid analogs
Data showing the relative production of metabolites corresponding
to M IM4 from capsaicin by human liver microsomes and CYP2C9
from structural analogs of capsaicin see Fig 1 are shown in Tables
2 and 3 respectively The production of macrocyclic metabolites was
limited to those capsaicinoid analogs that contained a tertiary carbon
atom at the wIposition In addition the production of these metab
olites was markedly enhanced by the presence of a double bond at the
w23position iecapsaicin and homocapsaicin Small amounts
7of capsaicin of MIlike metabolites were observed with the
saturated capsaicin analogs nordihydrocapsaicin dihydrocapsaicin
and homodihydroeapsaicin formation of macrocyclic metabolites
from these analogs was verified by deuterium exchange MSMS
analysis and the presence of a single exchangeable proton Reilly et
al 2003a Significant production of MI from capsaicin and its
corresponding macrocyclic metabolite from homocapsaicin was also
observed Formation of macrocyclic metabolites was not observed
when the straightchain analogs of capsaicin ievanillyloctana
mide nonivamide and nvanillyldecanamide were the substrates
wHydroxylated metabolites were produced from all of the capsaici
noid analogs However significantly greater amounts of these metab
olites were observed when straightchain or branchedchain saturated
capsaicinoid analogs were the substrates
Similar to the macrocyclic metabolites significant quantities of
wthydroxylated metabolites were only produced from capsaicin and
homocapsaicin The terminal dehydrogenated metabolites were pro
duced from all of the capsaicinoid analogs with the rank order for
production of analogs with a tertiary allylic carbon analogs with a
300
HLM CYP2C9
Metabolite Identification
011
Capsaicin Nonivamide Capsaicin Nonivamide
1 of torn nterobolites 7c of total metabolites
Macrocycle Ml 22 4 ND 34 i 3 ND
oOH M2 18 4 24 4 102 0801
wIOHM3 8 2 ND 0I ND
Diene or alkeneM4 28 5 4 1 63 i 5 5 2
Others M5M9 28 14 71 14 2 95 4
N11 Macrocycle 50 i
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FIG 3 Formation of M1 M2 M3 and M4 from capsaicin by individual recombinant P450 enzymes and human liver microsomes HLM Note that theYaxis for M4
is approximately 2 10 and 30fold higher than the relative responses for M1 M2 and M3 Incubations containing individual P450 enzymes were prepared and assayed
as described tinder Materials and Methods using nonivamide as in internal standard Data represent the normalized metabolite peak area analyteinternal standard from
individual samples that were incubated for 20 open bars it 1 or 60 min gray bars n 1
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TABLE 2
Production ofmetabolites relaied to MI M2 M3 and M4 brown capsaicin from
various capsaicinoid analogs by hianan liver rnicrosomes
Values represent the average percentage and standard deviation for metabolite production
relative w capsaicin from three separate incubations Incubations were performed as
described under Materials and Methods using the semiquanusnive method for assessing
metabolite formation
Capsaicinoid Analog Relative Metabolite
and Description Production Versus Capsaicin
Saturated analogs Macrocycle wOH urlOH Terminal alkene
Nordihydrocapsaicin 3i09 90 14 ND 154
Dihydrocapsaicin 6 2 180 15 ND 23 i 9
Ho modihydroc apsaici n 10 2 193 7 ND 29 i 6
Straightchain analogs Macrocycle wOH w1OH Terminal alkene
nVan illyloctanamide ND 54 t 5 ND 3 1 1
Nonivamide ND 135 8 ND 6 3
n Vanillyldecanamide ND 170 15 ND 14 15
Increased chain lengths Macrocycle ur ail OH Diene
Homocapsaicin 48 8 50 1 13 60 12 8 1
NDnot detected
TABLE 3
Production of metabolites related to Ml M2 M3 and M4 from capsaicin from
various capsaicinoid analogs by recombinant iuonan CYP2C9
Values represent the average percentage of metabolite produced relative to capsaicin
from two separate incubations Incubations were performed as described under Materials and
Methods using the semiquamitative method for assessing metabolite formation
Capsaicinoid Analog Relative Metabolite
and Description Production Versus Capsaicin
11
Saturated analogs Macrocycle o0H to I OH Terminal alkene
Nord ihydrocapsaicin 09 103 ND 6
Dihydrocapsaicin 45 349 ND 40
Homodihyd rocapsaicin 4 285 ND 26
Straight chain analogs Macrocycle u oii a l OH Terminal alkene
wtVanillyloctanamide ND 30 ND 1
Nonivamide ND 267 ND 17
n VaniIIyldecanamide ND 247 ND 8
Increased chain lengths Macrocycle arOH wIOH Diene
lomocapsaicin 24 106 64 53
NDnot detected
tertiary carbon only straightchain analogs Table 2 Similar data
for metabolite production were observed when CYP2C9 was utilized
instead of human liver microsomes albeit produced at different ab
solute and relative amounts Table 3
Discussion
The ability of cytochrome P450 enzymes to metabolize capsaici
noids to a number of distinct metabolites has been shown to be an
important determinant of the pharmacology and toxicology of these
compounds P450dependent metabolism of capsaicinoids has been
shown to mitigate capsaicinoid toxicity in cell culture Reilly et al
2003a Likewise metabolites of capsaicin did not prolong phenobar
bitalinduced sleep as observed for the parent capsaicinoids Surh et
al 1995 Structureactivity studies with capsaicin nonivamide
structural variants and their metabolites have also demonstrated
marked differences in pain producing potential and hyper and hy
poalgesic properties Chemical modifications to the alkyl terminus
substantially decreased biological responses presumably due to de
creased interactions between themetabolites and TRPV I Walpole et
al 1993abc
The biological activities of capsaicinoids are distinctly reliant on
the chemical structure of the alkyl terminus Likewise structural
variants of capsaicin in the form of multiple capsaicinoid analogs
exhibit unique metabolite profiles and provide an interesting set of
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Frc 4 Proposed metabolic schemes describing the production of macrocyclie
whydroxylated colhydroxylated and terminal dehydrogenated metabolites from
various capsaicinoid analogs by P450 enzymes Metabolic scheme for the metab
oism of capsaicin A and metabolic scheme for the metabolism of dihydrocap
saicin B and nonivamideC
probes to investigate aliphatic hydroxylation and dehydrogenation
mechanisms by P450 enzymes Incubations containing capsaicin or
nonivamide exhibited similarities in the overall rate of metabolism by
human liver microsomes Fig 2A However significant differences
in the formation ofalkyl derived metabolites were observed Fig 2 B
and Q Specifically macrocyclic and wlhydroxylated metabolites
were not produced from nonivamide and the terminal dehydrogenated
metabolite of nonivamide M4Nwas formed in very low amounts
relative to capsaicin Similar data were observed using a variety of
structurally diverse capsaicinoid analogs Fig l Tables 2 and 3
which also illustrated a critical role for branched andor unsaturated
alkyl tennini for selected metabolite formation
Hydroxylation and dehydrogenation of alkanes via the formation of
w I radicals and subsequent hydroxyl rebound to generate the corre
sponding alcohol product is a widely accepted P450 mechanism that
has been described for a number of P450catalyzed reactions Rettie
et al 1988 Obach 2001 Kumar et al 2004 Meunier et al 2004
However the formation of whydroxylated products is typically lim
ited by unfavorable energetic barriers for substrate activation at the
terminal position unless the reactions are sterically directed to the
terminal carbon within the P450 active site Although our data support
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DEHYDROGENATION AND HYDROXYLATION OF CAPSAICINOIDS
a mechanism of hydroxyl rebound and sterically controlled activation
of the alkyl terminus for the formation of hydroxylated metabolites
from capsaicinoids this mechanism does not fully account for the
product profiles observed for all of the analogs Therefore we present
an alternate mechanism Fig 4 to explain our data This mechanism
proposes that capsaicinoid metabolism proceeds through an initial
hydrogen atom abstraction from the terminal carbon sterically di
rected substrate activation by the high valent FeO species fol
lowed by either oxygen rebound to produce walcohols from Fe
OH or oneelectron oxidation by FeOH to form carbocation
intermediates that rearrange to the more energetically stable w1
tertiary carbon atoms of certain capsaicinoid analogs These stabilized
tertiary carbocation intermediates then undergo one of three reactions
Kumar et al 2004 Meunier et al 2004 1 lose a proton to produce
terminal alkenes 2 become trapped by the amide nitrogen to form
macrocyclic metabolites or 3 undergo oxygen rebound from the
reduced Fe 0Hheme to produce wI alcohols Fig 4 A to Q We
concluded that the latter reaction most likely occurred as a result of
oxygen rebound from the heme rather than hydration of the carboca
tion by H2O since we did not observe 80labeling of the hydroxy
lated metabolites when HOWater was included at 50 or 90 vv in
incubations data not shown The relative amounts ofdehydrogenated
and hydroxylated products produced from the various capsaicinoid
analogs support this alternate mechanism in which the relative stabil
ity of the rearranged intermediate carbocation governed the relative
production of w w1 macrocyclic and terminal dehydrogenated
metabolites
Preferential activation of the terminal methyl position appeared to
be favored for many P450 enzymes despite the higher energetic
barriers associated with activation of the primary carbon atom Ter
minal activation was due presumably to steric restrictions that limit
the access and orientation of the substrate relative to the active site
ironoxo highvalent heme Preferential oxidation of the terminal
carbon versus w ioxidation is not uncommon but is less favorable as
alluded to above Here we provide evidence for direct activation of the
terminal methyl carbon and subsequent formation of hydroxylated
alcohols a process that appears to be inversely related to the predicted
stability of the rearranged product iestraightchain analogs form
greater amounts of hydroxylated products than do saturated capsa
icinoids and capsaicinoids with a tertiary allylic motif due presum
ably to lower propensities for rearrangement to secondary carboca
tions that are not highly stabilized like the tertiary allylic carbocation
of capsaicin Deuterium isotope effects in the formation of 5hydroxy
valproic acid by CYP413 I Rettie et al 1995 and the formation of
20hydroxyeicosatetraenoic acid by 4F2 and 4Al I Powell et al
1998 also support the concept of sterically controlled terminal hy
drogen abstraction
Formation of the respective w I hydroxylated metabolites from the
various capsaicinoid analogs also exhibited a strict requirement for the
tertiary allylic configuration Surprisingly no secondary or tertiary
alcohols were produced from the straightchain or branched chain
saturated capsaicinoids Tables 2 and 3 These data along with other
aspects of the observed product profiles suggest that the formation of
the w I alcohols from capsaicin and homocapsaicin was also accom
plished through formation of a terminal methyl carbocation rapid
rearrangement of the primary carbocation to the more stable tertiary
allylic carbocation and facile oxygen rebound minor pathway This
mechanism was consistent with the finding that incorporation of
Olabeled water was not observed and no secondary alcohols were
formed from straightchain capsaicinoids despite the observation that
terminal alkenes were formed albeit in very small amounts from
these analogs This mechanism also explains why the analogs with ao
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tertiary carbon but without a double bondienordihydrocapsaicin
dihydrocapsaicin and homodihydrocapsaicin were not metabolized
to produce wlalcohols but did produce small amounts of their
respective macrocyclic metabolites and large amounts of their respec
tive whydroxylated metabolites
Terminal dehydrogenated metabolites M4 could potentially form
by dehydration of the hydroxylated products However several results
confirmed that dehydrogenation was directly catalyzed by P450 en
zymes and not formed by dehydration of the alcohols Specifically
the production of terminal dehydrogenated metabolites from straight
chain analogs was very low despite extensive formation of why
droxylated metabolites that surpassed that of capsaicin Comparable
results were observed for branched chain metabolites lacking the
double bond at the w23 position If M4 was formed by chemical
dehydration of either the w or w I alcohol much greater amounts of
the alkene should have been produced from these analogs similar to
the relative formation of M4 versus M2 or M3 from capsaicin Thus
terminal dehydrogenation appeared to be a direct P450catalyzed
process similar to that which has been shown for valproic acid
another saturated alkane and ezlopitant Rettie et al 1988 1995
Obach 2001
As with most P450catalyzed processes the ability of specific
enzymes to catalyze certain metabolic reactions can be highly variable
and specific Several P450 enzymes selectively catalyzed the alkyl
hydroxylation and dehydrogenation of capsaicin Fig 3 Based on
these data the relative percentages of individual P450 enzymes in
livermicrosomes and data presented in Figs 2B and C and 3 it may
be reasonable to conclude that the most active enzymes for production
of specific metabolites ultimately dictate the formation of these me
tabolites in microsomes For example CYP2C9 20of total liver
microsomal P450 Guengerich 2003 was likely the enzyme that
produced the majority of the macrocyclic and alkene products ob
served in microsomal incubations since it was the most active en
zyme and enzymes such as CYP2C8 2C19 and 2E1 20total
P450 combined produced only small quantities of these metabolites
Similar conclusions may be made regarding whydroxylated metabo
lites by CYP2E1 andw1hydroxylated products by CYP3A4 Based
on the mechanistic conclusions discussed above and those repre
sented by Fig 4 A to C several general conclusions can be made
regarding the underlying biochemistry for the enzyme selective pro
duction of the metabolites Depending upon the specific active site
orientation of the capsaicinoids within the individual P450s the
relative production of metabolites will vary For example CYP2C9
was capable of producing all four alkyl metabolites in various
amounts with a distinct preference for catalyzing the metabolism of
capsaicin to M I and M4 These were the major products of CYP2C9
metabolism Fig 3 Table 1 and appeared to be produced via the
mechanisms discussed above Likewise CYPIA2 appeared to be
unique in its ability to only produce the alkyl dehydrogenated metab
olites albeit at very low amounts suggesting an unusual mechanism
similar to that of CYP2C9 where dehydrogenation of the alkyl chain
was more favorable than hydroxylation Conversely CYP3A4 pro
duced large amounts of the w I alcohol Fig 3 This difference in
relative metabolite production may be due to the fact that CYP3A4
has a relatively spacious active site relative to other P450s and
therefore may be the most likely enzyme to permit the binding of
capsaicin in a manner that favors the initial abstraction of hydrogen
and one electron oxidation to produce the energetically more favor
able tertiary allylic carbocation rather than formation of this inter
mediate by rearrangement of the terminal carbocation Despite the
possibility that capsaicinoids were initially activated by CYP3A4 at
the w1 position to produce M3 very little Ml or M4 was observed
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a echanis  of hydroxyl rebound and sterically controlled activation 
of the alkyl tenninus for the fonnation of w-hydroxylated etabolites 
fro  ca saici ids, this echa is  oes not fully account for the 
product profiles observed for all of the analogs, Therefore, we present 
an alternate mechanism (Fig, 4) to explain our data, This mechanism 
proposes that capsaicinoid metabolism proceeds through an initial 
hydrogen ato  abstraction fro  the ter inal carbon (sterically di-
rected substrate activation) by the high-valent [Fe]Y =0 species, fol-
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, or one-electron oxidation by [FellY -OH to fonn carbocation 
intermediates that rearrange t  t  ore ti lly sta le -I 
tertiary carbon atoms of certain capsaicinoid analogs, These stabilized 
tertiary carbocation intennediates then undergo one of three reactions 
(Kumar et aI., 2004; eunier et aI., 2004): I) lose a proton to produce 
tenni l alkene , ) e e tra e   the ide itroge  t  fonn 
acrocyclic etabolites, or 3) undergo oxygen rebound fro  the 
reduced [Fellll-OH heme to produce w-I alcohols (Fig. 4, A to C). We 
lude  t at t  latter re tion ost li l  cc rre    lt  
oxygen rebound from the heme rather than hydration of the carboca-
tion by H20, since we did not observe IgO-labeling of the hydroxy-
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incubations (data t s n). he relative a ts f e drogenated 
and hydroxylated products produced fro  the various capsaicinoid 
analogs SUpp0l1 this alternate mechanism in which the relative stabil-
ity of the rearranged intennediate carbocation governed the relative 
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Preferential activation of the tenninal methyl position appeared to 
be favored for any P450 enzy es despite the higher energetic 
arriers ass ciate  ith acti ati  f t e ri ar  car  at . er-
inal activation was due presu ably to steric restrictions that li it 
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iron-oxo high-valent he e. Preferential oxidation of the ter inal 
  -I-  is      ble, , 
alluded to above. Here we provide evidence for direct activation of the 
terminal methyl carbon and subsequent formation of w-hydroxylated 
alcohols, a process that appears to be inversely related to the predicted 
stability of the rearranged product (i.e., straight-chain analogs for  
greater amounts of w-hydroxylated products than do saturated capsa-
icinoids and capsaicinoids with a tel1iary allylic motif, due, presum-
ably, to lower propensities for rearrangement to secondary carboca-
tions that are not highly stabilized, like the tertiary allylic carbocation 
of capsaicin). Deuterium isolope effects in the fonnation of 5-hydroxy 
valproic acid by CYP4B I (Rettie et aI., 1995) and the fonnation of 
20-hydroxyeicosatetraenoic acid by 4F2 and 4AII (Powell et aI., 
1998) also support the concept of sterically controlled ter inal hy-
drogen abstraction, 
For ation of the respective lu-I-hydroxylatecl etabolites fro  the 
various capsaicinoid analogs also exhibited a strict requirement for the 
tcrtiary allylic configuration. Surprisingly, no secondary or tertiary 
alcohols were produced from the straight-chain or branched-chain, 
saturated capsaicinoids (Tables 2 and 3), These dala, along with other 
aspecls of the observed product profiles, suggest that thc for ation of 
the w-l-alcohols from capsaicin and homocapsaicin was also accom-
plished through fonnation of a tenninal methyl carbocation, rapid 
rearrange ent of the pri ary carbocation to the ore stable tel1iary 
allylic carbocation, and facile oxygen rebound (minor pathway). This 
echanis  as consistent ith the finding that incorporation of 
IgO-Iabeled ater as not observed, and no secondary alcohols ere 
formed from straight-chain capsaicinoids, despite the observation that 
terminal alkenes were fonned (albeit in very small amounts) from 
these analogs, This mechanism also explains why the analogs with a 
te tiary c , but ithout  double  (i.e., ih droc i , 
ih dr i i , a d h ro i ) ere t et lized 
to produce -l-alcohols, but did produce s all a ounts of their 
res tive a r lic t lites d l r e ts f their r -
tive -hydroxylated li . 
er inal e drogenated et lites (M ) ld t ti lly f nn 
   t e roxylated pr . r,   
c firmed that e r e ati  as irectl  catalyzed b  0 en-
zy es a d t fonne     t e l . cif ll , 
the production f ter inal dehydrogenated etabolites fro  straight-
ain l gs as  l , it  te sive fonnation  -h -
r ylated eta lites t at s r asse  t at f ca saici , ara le 
res lts e e s  r ra ched  tes a   
uble  t e -2,3 i .   as nn    
r ti  f it er t e ltl- r ltl-I- l l,  r t r ts f 
the alkene s ld   ce  fro   l , lar  
the  or a io         aici . , 
tenninal ti   t    ire t 0- t l  
process, si ilar to that hich has been sho n for valproic acid, 
ther t rated l ,  l itant (Rettie t I., 8, 5; 
, 0 I). 
s ith st -catal ze  r cesses, t e a ilit  f s ecific 
enzy es to catalyze certain etabolic reaclions can be highly variable 
and specific. everal 450 enzy es selectively catalyzed the alkyl 
r l ti   r ti  f s i i  (Fi . ). s   
t  t , t  l ti  t   i i idual  es i  
iv  icros ,   te   . ,  ,  ,   
   e     es r  
of specific etabolites ulti ately dictate the for alion of these c-
ta lites in icr s es. r e a le,  (~20Cfc f t tal li er 
icroso al P450) (Guengerich, 20(3) was likely the enzy e lhat 
produced the ajority f the acrocyclic and alkene products ob-
   ti , i       n-
zy e, and enzy es such as P2 8, 2 19, and 2 l (-20% total 
, bi ed) r ce  l  s all tities f t  tabolit s. 
a      r i  - a  tabo-
lites   I  -I-hydroxylated r ts  3 4, s  
 t  anisti  l i  is ss  v ,  t  re-
sented by ig. 4,  to , several general conclusions can be ade 
r i  t  rl i  i i t  r t  - l ti e ro-
duction of the etabolites. epending upon the specific active site 
orientation of the capsaicinoids ithin the individual 450s, the 
r l ti  r ti  f t lites ill ry. r l ,  
as capable of producing all four alkyl etabolites in various 
a unts, it  a isti ct refere ce f r catal zi  t e etabolis  f 
capsaicin to  I and 4. These were the ajor products of CYP2C9 
etabolis  (Fig. 3; able I) and appeared to be produced via the 
i   bove. i ise, P I   t   
unique in its ability lo only produce the alkyl-dehydrogenated etab-
lit s, l it at r  l  ounts, s sti   s l c anis  
i il  t  t t  9,  ti  of t  l l c i  
 r  f v r bl  t  ydroxylalion. rsely, 3  ro-
duced large a ounts of the w-I-alcohol (Fig, 3). This difference in 
relative etabolite production ay be due to the fact that P3 4 
s  r l ti l  s i s acti  sit  relati  t  t r s and, 
therefore, ay be the ost likely enzy e to per it the binding of 
capsaicin in a anner that favors the initial abstraclion of hydrogen 
 - l tr  i ti  t  r  t  energeticall  r  f vor-
l  t rti r  al l  carbocation, ral r t an ti  f this inter-
ediate by rearrange ent of the tenninal carbocation. espite the 
possibility that capsaicinoids were initially activated by CYP3A4 at 
the -l position to produce 3, very little  I or 4 as observed. 
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These data indicate that specific interactions between individual P450
enzyme and capsaicinoids work in concert with the structuraldepen
dent mechanisms described in Fig 4 A to C to direct the ultimate
metabolite profile
Overall the metabolism of capsaicin and its analogs by human
P450 enzymes presents unique insights into possible mechanisms by
which P450s metabolize various chemicals and exemplify a number
of theoretical aspects of P450 metabolism The metabolism of capsa
icinoids provides valuable information on chemical features that can
influence the hydroxylation and dehydrogenation of certain chemical
entities as well as highlight the importance of steric interactions in
governing metabolite formation
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Capsaicinoids found in lessthan lethal self defense weapons
have beenassociated with respiratory failure and death in exposed
animals and people The studies described herein provide evidence
for acute respiratory inflammation and damage to epithelial cells
in experimental animals and provide precise molecular mecha
nisms that mediate these effects using human bronchiolar and
alveolar epithelial cells Inhalation exposure of rats to pepper
sprays capsaicinoids produced acute inflammation and damage
to nasal tracheal bronchiolar and alveolar cells in a dose related
manner In vitro cytotoxicity assays demonstrated that cultured
human lung cells BEAS213 and A549 were more susceptible to
necrotic cell death than liver HepG2 cells Transcription of the
human vanilloid receptor type1 VRl or TRPV1 was demon
strated by RTPCR in all of these cells and the relative transcript
levels were correlated to cellular susceptibility TRPV1 receptor
activationwas presumably responsible for cellular cytotoxicity but
prototypical functional antagonists of this receptor were cytotoxic
themselves and did not ameliorate capsaicinoid induced damage
Conversely the TRPV 1 antagonist capsazepine as well as calcium
chelation by EGTA ablated cytokine IL6 production after cap
saicin exposure To address these seemingly contradictory results
recombinant human TRPV1 was cloned and overexpressed in
BEAS213 cells These cells exhibited dramatically increased cel
lular susceptibility to capsaicinoids measured using IL6 produc
tion and cytotoxicity and an apoptotic mechanism of cell death
Surprisingly the cytotoxic effects of capsaicin in TRPV1 overex
pressing cells were also not inhibited by TRPV1 antagonists or by
treatments that modified extracellular calcium Thus capsaicin
interacted with TRPV1 expressed by BEAS213 and other airway
epithelial cells to cause the calcium dependent production of cy
tokines and conversely calciumindependent cell death These
results have demonstrated that capsaicinoids contained in pepper
spray products produce airway inflammation and cause respira
tory epithelial cell death The mechanisms of these cellular re
sponses to capsaicinoids appear to proceed via distinct cellular
pathways but both pathways are initiated by TRPV1
Key Words capsaicinoids vanifloid receptors TRPVlcytokines
pepper sprays inflammation bronchiolar epithelial cells BEAS213
cells
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cology and Toxicology University of Utah 30 South 2000 East Room 201
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Capsaicinoids are the active components of the less than
lethal selfdefense weapons used by law enforcement officers
Ryder 1996 Reilly et al 2001a These pepper sprays are
produced by aerosolization of lipidsoluble dilute oily extracts
of hot peppers Capsicum annum and C frutescens Al
though pepper sprays are extensively utilized for individual
self defense and law enforcement purposes the respiratory
toxicity of these sprays has not been adequately evaluated In
particular very little is known about the effects and mecha
nisms by which capsaicinoids interact with airway epithelial
cells This paucity of knowledge was particularly surprising
after examining reports Billmire et al 1996 of respiratory
failure and death Steffee et al 1995 in humans who have
been exposed to these sprays Recent clinical studies Chan et
al 2002 have shown no overt respiratory effects after brief
1 2 s low dose exposures to pepper spray However capsa
icinoids have also been shown to be lethal by all routes of
exposure causing severe respiratory depression and failure
and ultimately death Glinsukon et al 1980 in animals such
as mice and rats Intravenous administration was the most toxic
route of exposure while intratracheal was slightly less Glin
sukon et al 1980 Surprisingly studies that have carefully
documented the pathology produced by inhalation of pepper
sprays in experimental animals are lacking
The recent cloning and characterization of a capsaicinsen
sitive receptor from animal Caterina et al 1997 and human
Hayes et aL 2000 tissues has provided a long awaited mo
lecular target for the capsaicinoids Structure activity studies of
capsaicin and structural variants have demonstrated a strict
requirement for both the 4 hydroxy3methoxybenzylamide
vanilloid ring pharmacophore and acyl chain moieties for
pharmacologic activity Caterina and Julius 2001 Szallasi and
Blumberg 1999 Similarly a variety of other receptor ligands
resiniferatoxin olvanil capsazepine phorbol 20 homovanil
lates etc required the presence of the vanilloid ring Because
of this apparent structural requirement the capsaicin receptor
has been named the vanilloid receptor type1 VR1 A new
nomenclature has recently been suggested for the superfamily
of transient receptor potential TRP cation channels Montell
et al 2002 This nomenclature renames vanilloid receptor
typeI VR1 as TRPV1 and this new designation is used
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The recent cloning and characterization of a capsaicin-sen-
sitive receptor from animal (Caterina et al., 1997) and human 
(Hayes et a1., 00) tiss es as r Vi e  a l -a aite  o-
lecular target for the capsaicinoids. Structure-activity studies of 
capsaicin (and structural variants) have de onstrated a strict 
require ent for both the 4-hydroxy-3- ethoxybenzyla ide 
(vanilloid ring phar acophore) and acyl chain oieties for 
phar acologic activity (Caterina and Julius, 2001; Szallasi and 
l er , 999). i ilarly. a ariet  f t er rece t r li a s 
(resiniferatoxin, olvanil, capsazepine, phorbol 20-ho ovanil-
lates, etc.) required the presence of the vanilloid ring. ecause 
of this apparent structural require ent, the capsaicin receptor 
has been na ed the vanilloid receptor type-l (  1).  ne  
no enclature has recently been suggested for the superfa ily 
of transient receptor potential (TRP) cation channels ( ontell 
et I., 002). is e clat re re a es a ill i  rece t r 
type-l (VRl) as 1, and this ne  designation is used 
 
CAPSAICINOIDS AND LUNG VANILLOID RECEPTORS
hereafter TRPV1 was the first member of the growing family
of vanilloid receptors to be characterized Caterina and Julius
2001 Montell et al 2002 Szallasi 2001 and has been de
scribed as a cell membranebound ligandgated calcium chan
nel with high selectivity for capsaicin and other vanilloidlike
compounds TRPV1 has also been shown to be activated by
acidic pH and temperatures 42C Caterina and Julius 2001
Montell et al 2002 Szallasi 2001
Since the discovery of TRPV1 a variety of other vanilloid
receptorlike proteins egVRL1 VRL2 VROAC SIC
TRPM8 and VR5sv have been identified Caterina et al
1999 Delany et al 2001 Schumacher et al 2000 Recent
data have placed the vanilloid receptors in an ever expanding
family Montell et al 2002 of TRP ion channels that includes
not only ligand heat and pHactivated calcium channels but
receptors that are activated by cold McKemy et al 2002
extracellular osmolarity Liedtke et al 2000 Strotmann et al
2000 and cell volume Suzuki et al 1999 Some of these
receptorsie VR5sv and VRL2 do not have known func
tions andor agonists Delany et al 2001 Schumacher et al
2000 This intriguing family of genes presents the scientific
community with a cornucopia of receptors that appear to re
spond to an amazing variety of environmental stimuli includ
ing noxious irritants environmental pollutants and tempera
ture Caterina and Julius 2001
Perhaps the most intriguing facet of the identification of the
vanilloid receptor family of ion channels has been that their
functions do not appear to be limited only to the perception of
noxious stimuli e capsaicin pH or heat through activation
of nerve fibers but that several of the vanilloid receptors eg
the VRL2 and VR5sv receptors are highly expressed in
non neuronal cells Hayes et al 2000 Inoue et al 2002
Sanchez et al 2001 including epithelial cells of the kidney
and respiratory tissues Delany et al 2001 Hayes et al
2000 To date however a physiological role for these recep
tors in non neuronal tissues has not been established
Previous research has demonstrated that the activation of
TRPV 1 expressed by cultured neurons isolated from rat dorsal
root ganglia promoted cell death Szallasi and Blumberg
1999 The cytotoxic properties of capsaicinoids in peripheral
sensory A8 and Cfiber neurons have been well documented
Szallasi and Blumberg 1999 Wood et al 1988 and are
exploited for the treatment of chronic pain McMahon et al
1991 The mechanism of neurotoxicity by vanilloid receptor
ligands has been shown to be calcium dependent inhibited by
capsazepine and ruthenium red and thus mediated by
TRPVL The role of TRPV1 in the cytotoxicity of capsaicin in
non neuronal cell lines has also been investigated but not fully
elucidated For example HEK293 cells engineered to overex
press rat TRPV1 demonstrated enhanced calcium flux and cell
death that was inhibited by capsazepine ruthenium red and by
removal of calcium from the media Caterina eta 1997 Jordt
et al 2000 However a variety of other cell lines including
monkey kidney Vero Creppy et al 2000 human neuroblas
toma SHSY5Y Richeux et al 1999 and human endothelial
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ECV340 Richeux et al 2000 were not protected from cy
totoxicity by capsazepine or modulators of calcium flux unless
rat TRPV 1 was transfected into these cells Similarly human
glioblastoma Al 72 cells Lee et al 2000 were not protected
by capsazepine or modulators of calcium flux despite the
apparent endogenous expression of TRPV L Therefore a gen
eral mechanism to explain the TRPV 1 mediated cytotoxicity of
capsaicin and other vanilloid compounds has not been estab
lished Rather it appears that different cell lines respond in
unique manner to TRPV1mediated signaling induced by li
gand binding
Capsaicinoids have also been used to study the cough reflex
and neurogenic inflammation in respiratory tissues In neuro
genic inflammation capsaicin promotes the calcium and
TRPV 1 dependent release of Substance P and other neuropep
tides from neurons in the airway tissues Veronesi et al 1999
2000 to stimulate inflammatory responses to potentially
harmful stimuli including particulate material Recent work at
the United States Environmental Protection Agency has dem
onstrated that capsaicin particulate matter and neuropeptides
acted synergistically to promote the production of inflamma
tory mediators IL6 IL8 and tumor necrosis factora TNF
a by human respiratory epithelial cells human bronchiolar
epithelial cells BEAS 213 human lung adenocarcinoma cell
line A549 and normal human bronchiolar epithelial cells
Quay et al 1998 Veronesi et al 1999 2000 Cytokine
production by BEAS 213 cells was ameliorated by capsazepine
and by removal of calcium from the treatment solutions Vero
nesi et al 1999 2000 Similar cytokine responses were also
observed in rats intratracheal instillation and humans bron
choscope treated with concentrated ambient particulate mate
rial Carter et al 1997 Lay et al 1999 Thus direct activa
tion of TRPV1 in these cells by various stimuli can cause
calciumdependent cytokine production and acute respiratory
inflammation
Although these data provided evidence for the expression of
functional TRPV1 in these cells direct evidence of TRPV1
expression was not provided Also the influence of TRPVI on
cellular susceptibility to cytotoxicity by these substances was
not investigated despite observation in vivo that demonstrated
increases in lactate dehydrogenase LDH activity in bron
choalveolar lavage fluid of treated animals and humans Carter
et al 1997 Lay et al 1999 Therefore it seems likely that
activation of vanilloid receptors presumably TRPV1 in respi
ratory epithelial cells by capsaicinoids initiates the production
of proinflammatory cytokines to mount a host defense re
sponse to protect against potentially harmful inhaled cytotoxic
substances including capsaicin and particulate material Unfor
tunately this response may lead to cell death
Thus a hypothesis is formulated that capsaicinoids which
are present in pepper spray products induce acute inflamma
tion and respiratory epithelial cell injury through activation of
TRPV 1 in rat and human respiratory tissues Activation of
TRPV 1 may induce cell death through the production of cy
tokines that are toxic to the same cells that have produced
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increases in lactate dehydrogenase (L ) activity in bron-
l lar l  fl i  f tr t  i ls  s (Carter 
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are present in pepper spray products, induce acute infla a-
tion and respiratory epithelial cell injury through activation of 
T P l in rat and hu an respiratory tissues. ctivation of 
TRP l ay induce cell death through the production of cy-
t ines t at are t ic t  t e sa e cells t at a e r ce  
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them alternatively cell death may be independent of cytokine
effects This hypothesis was addressed by nose only inhalation
exposure of rats to pepper sprays capsaicinoids by in vitro
studies with human lung epithelial BEAS213 and A549 or
liver cells the human hepatoma cell line HepG2 and by the
production and characterization of a TRPV1 overexpressing
human lung epithelial cell line
MATERIALS AND METHODS
Reagents Capsaicin 97 nonivamide 99 resiniferatoxin RTX
anandamide capsazepine ruthenium red EGTA ketamine hydrochloride and
acetopromazine maleate were purchased from Sigma Chemical Corp St
Louis MO Olvanil scutigeral phorbol12henylacetate3acetate20ho
movanillate PPAHV and isovelleral were purchased form Alexis Biochemi
cals Inc San Diego CA Cell culture media was purchased from BioSource
International Camarillo CA Pepper spray canisters were purchased from
independent distributors and sampled as previously described Reilly et al
2001bc Briefly pepper spray canisters were cooled to 20C overnight in a
freezer shaken and gently discharged into a silanized glass tube that had been
previously equilibrated to 80C using dry ice Cooling the tubes with dry ice
was necessary to prevent evaporation of the solvent during collection The
sample was immediately capped and thawed on ice The sample volume was
determined and the volatile components were permitted to evaporate at room
temperature for 1 h with gentle agitation The original sample volume was
established by addition of dehydrated ethanol and the capsaicinoid concentra
tions were determined by LCMS as previously described Reilly et al
2001bc
Noseonly inhalation Male Sprague Dawley rats 125 g were purchased
from Charles River Laboratories Wilmington MA Prior to exposure to the
capsaicinoids the rats were anesthetized by ip injection of 80 mgk ketamine
and 5 mgk acetopromazine The animals were placed inside a noseonly
exposure apparatus InTox Products Albuquerque NM and exposed 30
min to aerosols generated from ethanolic solutions of capsaicinoids that were
collected from pepper spray canisters Reilly et al 2001a Aerosols were
generated using a Lovelace nebulizer operated at a flow rate of approximately
05 1min The chamber flow was approximately 10 Imin and was maintained
under a vacuum of05 psi approximately 26 mm Hg Using this protocol
approximately 85of the generated aerosol particles were between 17and 02
m median mass aerodynamic diameter determined using a sevenstage
cascade impactor An estimate of the delivered dose was achieved by quanti
tative analysis Reilly et al 2001abofa paper filter 02mthat collected
aerosol from a sampling orifice The sampling rate for the filter was approx
imately 05 Imin The delivered dose was calculated using a minute volume of
02 1min and an approximate deep lung deposition factor of 10 Edward
Ban Lovelace Respiratory Research Institute Albuquerque NM personal
coin inunication Prior to each experiment all gas flows were calibrated The
concentrations of capsaicinoids in lung and blood of rats exposed to capsaici
noids using this protocol was recently published Reilly et al 2002
Following exposure the animals were removed from the chamber and
permitted to recover Following the predetermined recovery periods the ani
mals were sacrificed by COinduced asphyxiation and the nasal passages
trachea and lungs were excised A catheter tipped syringe was used to man
ually infuse approximately 250 500 1A of 10 neutral buffered formalin into
the trachea and lungs until they increased approximately twofold in volume
This degree of inflation was sufficient to observe small airway architecture
The respiratory tissues were treated for 23 days in fixative prior to sample
preparation and sectioning through the major bronchiolar and distal alveolar
regions Nasal samples were obtained by sectioning through the first and
second palatal ridges of decalcified heads Young 1981 prepared by treating
the heads for approximately 36 h in CaIExIIdecalcifying fixing solution
Fisher Scientific Fairlawn NJ The samples were sectioned stained with
hematoxylin and eosin and evaluated using both qualitative and semiquanti
tative criteria ie a numerical score was used to represent the frequency
andor severity of the lesions For example the degree of inflammation
congestion and edema was scored 04 based on the size of the lesion ie
the entity was not present versus an entity greater than 05mm Cellular
infiltrate was scored 04 by counting the number and type of cells observed
in four different fields at 45X while epithelial loss was scored 04 based on
the presence or absence of the lesion its continuity and its frequency
Necrosis epithelial dysplasia squamous metaplasia inflammation congestion
and edema epithelial loss cellular infiltrate lymphocytes plasma cells
macrophages neutrophils and eosinophils fibroendothelial proliferation fi
brosis giant cells goblet cell hyperplasia hemorrhage and alveolar emphy
sema were all evaluated by semiquantitative criteria Lesions that appeared at
a high frequency and atmoderate to marked severity ascore of 1 4 in at least
50of the treated population were identified and described below
Cell culture Immortalized human bronchiolar epithelial BEAS213 hu
man lung adenocarcinoma A549 and human hepatoma HepG2 cell lines
were obtained from American Type Culture Collection Rockville MD
BEAS 213 cells were cultured in Lechner and LaVeck media LHC9 con
taining retinoic acid 33 nM and epinephrine 275M using plastic cell
culture dishes precoated with LHCbasal medium containing BSA 100 g
ml collagen 30gml and fibronectin 10gml for 4 h at 37C A549 cells
were cultured using DMEMT12 media containing 10 FBS HepG2 cells
were cultured in EaglesMEM Gibco BRL supplementedwith 1 mM sodium
pyruvate 2 mM sodium bicarbonate and 10 FBS All cells were maintained
in 75em flasks at 37C in an air ventilated and humidified incubator main
tained at5 CO Culture media was renewed every 23 days and cells were
subcultured every 56days using025trypsin
Cytotoxicity assays Cells were subcultured into 96 well cell culture plates
at 75 confluency and permitted to adhere for 8 12 h at 37C The cells
were washed once with sterile phosphatebuffered saline and treated with
increasing concentrations of capsaicin 0200 uM prepared in 100 ethanol
and maintained at 05v in the treatment solutions or other TRPVI
ligands in serumfree cell culture medium minus FBS for 24 h at 37C
Where specified inhibitors of TRPV 1 were added 30 min prior addition ofthe
treatment solutions Cell viability was assessed using the Dojindo Cell Count
ing Kit8 Dojindo Laboratories Gaithersburg MD according to the supplier
recommendations Cell viability was expressed as the percentage of viable
cells relative to untreated cells using the absorbance at 450 run All experi
ments were performed in triplicate on three separate occasions
ELISA assays for IL6 BEAS213 cells were subcultured into 24well
coated cell culture dishes at 50 confluency and permitted to adhere for
8 12 It at 37C Prior to treatment the cells were washed once with fresh
media Treatments were performed in cell culture media containing capsaicin
and various modulators of TRPVI function for 24 It at 37C After 24 h the
media was collected clarified by centrifugation and stored at 20C until
assayed for IL6 content To ensure consistent results the cell viability for each
well was determined using the Dojindo Cell Counting Kit 8Samples exhib
iting unusual values for cell viability were discarded Cytokine production was
assessed using commercial ELISA kits for IL6 RDSystems Minneapolis
MN and performed as outlined by the manufacturer All experiments were
repeated on three separate occasions
RTPCR screening for TRPVI expression RTPCR was used to assess
the expression of TRPV I mRNA in BEAS2A549 and HepG2 cells Total
RNA was isolated from cultured cells approximately 10 x 10 cells using
the RNeasy total RNA isolation kit Qiagen Valencia CA as described by the
manufacturer protocols Total RNA was quantified using the ultravioletabs r
bance ratio A2806 and 5 gwere used as a template for cDNA synthesis
using Superscript IIreverse transcriptase InViuogen Carlsbad CA and
PolyT as a primer Five 1A of the firststrand synthesis reaction were used as
a template for PCR Primers specific for the published human TRPV1 sequence
Hayes et al 2000 GenBank numberXM008512 Sense 5GCAAGAA
CATCTGGAAGCTGC3and AntisenseYCTTCTCCCCGGAAGCG
GCAGG3 were used to amplify a 436 nucleotide nt 3fragment of
TRPVI 3Actin 180 nt was also amplified by PCR as an internal control
Following an initial 25min melting step PCR was performed using a PTC
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repeated on three separate occasions. 
RTIPCR screening for TRPVI expression. RT-PCR was used to assess 
the expression of T P  I  in E S-2B, 549, and ep 2 cells. Total 
R  as isolated fro  cultured cells (approxi ately 1.0 x 107 cells) using 
the RNeasy total RNA isolation kit (Qiagen, Valencia, CAl as described by the 
anufacturer protocols. otal  as quantified using the ultraviolet-absor-
bance ratio (A2801 A260) and 5 fJ.g were used as a template for cDNA synthesis 
using Superscript II-reverse transcriptase (InVitrogen, Carlsbad, CAl and 
l  s a pri r. Five /-tl f the first-str  s thesis re ti  ere s  s 
a te late f r . Primers s ecific f r t e lishe  a   I se e ce 
(Hayes et a1., 2000; en ank nu ber M_00SS12; Sense: 5' - AA-
AAGCTGC-3' d ntise : S'-CTTCT CCG -
GCAGG-3') were used to amplify a 436 nucleotide (nt) 3' -fragment of 
T PV1. J3-Actin (1S0 nt) as also a plified by P R as an internal control. 
Following an initial 2.5-min melting step, PCR was performed using a PTC-
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100 Programmable Thermal Controller MJ Research Inc Watertown MA
and the following cycling program 94C for 1 min 53C for 1 min and 72C
for 15min PCR was performed for 34 cycles and was followed by a 20min
incubation at 72C PCR products were resolved using a 1 Trisacetate
EDTA TAEagarose gel containing ethidium bromide 3Actin was used to
normalize the PCR product band intensity during scanning densitometry using
a BioRad GelDoc 1000 System Hercules CA The relative intensities for
the PCR products were linear in relation to cycle number The TRPVI
fragment was also cloned into a TOPOTAvector Invitrogen Carlsbad CA
the sequence determined and verified by comparison to published sequences
Cloning and overexpression ofTRPVI The full length cDNA encoding
TRPVI was amplified by PCR from total RNA isolated from human fetal brain
Stratagene La Jolla CA using pwo proofreading DNA polymerase and the
following primers Forward 5CACCATGAAGAAATGGAGCAGCAC3
containing a 5CACC Kozac sequence followed by the translation start site
and Reverse 5CTTCTCCCCGGAAGCGGCAGG3The antisense primer
was designed to amplify TRPVI but omit the stop codon This strategy
permitted the fusion of the V5 epitopeHis6 tag contained within the expres
sion vector sequence to the recombinant TRPV1 protein The amplified cDNA
2517 nt was purified by agarose gel electrophoresis 1 TAE agarose gel
containing ethidium bromide and cloned into the pcDNA 31 DV5His6
TOPO mammalian expression vector as directedby the manufacturer Invitro
gen Positive bacterial clones were selected by ampicillin resistance and
screened for the presence and orientation of TRPVI by Apal restriction
digestion Plasmid DNA was isolated from positive clones and the sequence of
the construct verified Vector containing the TRPVI insert was transformed
into BEAS 213 cells using FuGene6 Transfection Reagent Roche Molecular
Biochemicals Indianapolis IN 31FuGene6DNAfor 8 h at 37C in DMEM
F12 media containing 10 FBS Transfected cells were selected by resistance
to Genetici0 400 Agml BEAS2B colonies originating from singlecell
clones were readily visible about 23 weeks post transfection These colonies
were harvested using trypsintreated filter disks cloning disks subcultured
expanded and screened for overexpression of TRPVI by RTPCR using the
following primers to amplify a 510 nt fragment corresponding to the 5end
of TRPVI as well as primers selective for the presence of the V5 epitope
fusion protein 364 nt TRPVI Forward5CACCATGAAGAAATGG
AGCAGCAC3TRPVI Reverse CCGTCATGCAGGTTGAGCATG
T TRPVIV5 Forward 5CTGGACCACCTGGAACACCAA3 and
TRPVIV5 Reverse 5GAGGGTTAGGGATAGGCTTAC3 A single
clone that overexpressed TRPVI and the mRNA for the V5fusion protein
from approximately 26 colonies screened was identified Additional Geneti
cinresistant colonies that did not overexpress TRPVI or V5epitope mRNA
were also used as controls in experiments that were designed to assess the
influence ofTRPV 1 on cellular responses to capsaicin Since suitable antibod
ies for the detection of human TRPVI protein are not available functional
overexpression of TRPVI in BEAS213 TRPVI overexpressing cells and
Geneticinresistant but not TRPVI overexpressing cells was assessed using
capsaicin induced cobalt and calcium flux that was blocked by capsazepine
Enhanced capsaicin induced calcium flux was subjectively monitored with
the intracellular calcium chelator Fluo4AM Molecular Probes Eugene OR
as described by the manufacturer and microscopic evaluation of cellular
fluorescence Quantitative assays for cobalt influx was achieved by treating
cells 6 well plate 10 X 10 cells with 10 AM capsaicin for 10 min at 37C
in calcium and magnesiumfree HanksBalanced Salt SolutionIBSS con
taining 25mM CoCl After incubation the cells were placed on ice washed
twice in HBSS and solubilized in 05 mL HBSS containing 2 SDS Cellular
cobalt concentration was determined using ICPMS performed by the Veter
inary Diagnostic Laboratory at Utah State University Logan UT The use of
cobalt as a measure for calcium flux through TRPVI has previously been
described by Wood et al 1988
Analysis of apoptosis and necrosis by flow cytometry Differentiation
between apoptosis and necrosis was assessed using the Vybrant apoptosis
assay kit Molecular Probes containing fluorescein isothiocyanate FITC
Annexin V and propidium iodide and monitoring for cellular fluorescence due
to the exposure of phosphatidylserine on extracellular membrane surfaces
173
FITC Annexin V binding to assess apoptosis and nuclear staining due to loss
of membrane integrity propidium iodide staining to assess necrosis using
low cytometry fluorescence microscopy and an ELISA assay measuring
histoneassociated DNA strand breaks For flow cytometry and fluorescence
microscopy human bronchiolar epithelial cells BEAS213 or TRPVI over
expressing cells were treated with various concentrations of capsaicin for up to
24 h washed once with calcium and magnesiumfree phosphate buffered
saline harvested by trypsinization and centrifugation and resuspended in 50
mM flEPES pH 74containing 700 mM NaCl and 125mM CaCi annexin
binding buffer The cells were washed once by centrifugation at 500 g for 5
min and resuspended in the same buffer Aliquots of approximately 1 X 10
cellsml were prepared pelleted by centrifugation and resuspended in 5 Al
FITC Annexin V as provided in the assay kit and 1 Al propidium iodide 100
Agml and incubated at room temperature for 15 min After 15 min 400 AI
of the HEPES buffer was added and the cells placed on ice until assayed by
flow cytometry using a Becton Dickenson FACScan fluorescence activated
cell sorter and established methods for the analysis of Annexin Vpropidium
iodide staining A total of 10000 events cells were counted for each sample
The ELISA assay that was used to measure histone associated DNA strand
breaks was performed according to the manufacturer protocols Roche Mo
lecular Biochemicals
Statistical analysis Statistical analysis was performed using theMicrosoft
Excel software package Statistical differences between samples were estab
lished using the two sampletest and a 95 confidence interval p 025
RESULTS
Rats exposed to aerosols of capsaicinoids for 30 min ap
proximately 1012 mgkg exhibited a variety of lesions
including infiltration of inflammatory cells alveolar macro
phage proliferation damage to nasal tracheal bronchiolar and
alveolar cells epithelial dysplasia rounding of columnar epi
thelial cells and loss of ciliated and nonciliated epithelial cells
in the trachea and nasal turbinates along with hemorrhage and
congestion Fig 1 The most severe lesions were observed at
the 24 It recovery period although evidence of inflammation
was present as early as 4 h At 48 72 h inflammation appeared
to resolve while altered cell morphology and cell damage in
trachea and alveolar airways were still apparent
In the upper airways mild patchy epithelial necrosis and
sloughing of cells were observed in nasal turbinates and tra
chea Figs IA and 1C These lesions were often accompanied
by mild infiltrates of mixed inflammatory cells while some
epithelial cells were more cuboidal than columnar Mild cuboi
dal metaplasia was occasionally present in the epithelial cells
of the bronchi and bronchioles In some lung tissues mild
epithelial cell necrosis and sloughing were evident in terminal
bronchioles Fig 1F The most extensive lesions were present
in the air sacs and alveoli In general septal walls were
thickened by mild but occasionally marked infiltrates of
mixed inflammatory cells Fig 1D Moderate to marked cap
illary congestion with frequent mild to marked hemorrhage and
occasional edema was also present in alveolar walls and spaces
Fig IE In some tissues mild to marked proliferations of
foamy macrophages filled air sacs and alveoli Fig 1D Gran
ulomatous inflammation with small focal areas ofnecrosis was
occasionally observed Although ethanol may potentiate the
effects of capsaicinoids Trevisani et al 2002 and ethanol
vapor was probably inhaled by the animals the control animals
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that were exposed to ethanol vapors did not demonstrate re
spiratory lesions Low 07 mgkg and intermediate 03
mgkg doses of capsaicinoids or pepper sprays produced very
mild and moderate lesions respectively while higher doses
08 mgkg produced more severe and frequent lesions These
pathologies appeared to occur in a doseresponsive manner
unpublished data manuscript in preparation
The precise molecular mechanisms by which the pepper
sprays capsaicinoids caused inflammation and cell damage in
vivo were further investigated in vitro using various cell lines
derived from human lung and liver tissues BEAS 2B cells are
an SV 40 transfected immortalized human bronchiolar epi
thelial cell line that has frequently been used to study the
mechanisms of airway toxicants in vitro Similarly A549 cells
are derived from human adenocarcinoma and serve as an
additional model for studying airway toxins The A549 cells
serve as a surrogate for human alveolar epithelial cells Human
hepatoma HepG2 cells were used to represent liver cell re
sponses BEAS 2B cells treated with increasing concentrations
of capsaicin 0 200 AM for 24 h exhibited a dose dependent
decrease in cell viability Fig 2A The approximate LC
value was 100 AM Approximately 80 of the decrease in cell
viability was observed within 8 h data not shown however
a 24 h exposure period was used to ensure the complete loss of
cell viability and to minimize variability Similar decreases in
cell viability were also observed for A549 and HepG2 cells
Fig 2A The LC value for capsaicin in A549 and HepG2
cells was approximately 110 and 200 AM respectively To
ensure that very brief exposures to capsaicin would also cause
cell death cells were treated for 30 min washed extensively to
remove capsaicin and the cell viability determined 24 h later
BEAS2B cells treated with 100 M capsaicin in this manner
demonstrated an approximate 40 50 loss in cell viability
data not shown Thus the LC values did not significantly
change even with very short exposures to capsaicin provided
that cytotoxicity was assessed 24 h after the initial treatment
TRPV 1 has been implicated as a key mediator of various
cellular responses to capsaicinoids in vivo and in vitro There
fore we investigated the hypothesis that the relative levels of
expression of this receptor in several cell lines would mirror
the extent of cellular damage that was caused by exposure of
the cells to capsaicin Expression of TRPV1 in BEAS 213
FIG 1 Photomicrographs of nasal A and B tracheal C alveolar D and E and terminal bronchiolar F tissues from rats exposed 30 min by noseonly
inhalation to an aerosolized pepper spray extract 1012 mgkg L epithelial loss D epithelial dysplasia N normal epithelium M macrophages Cl
mononuclear cell infiltrate BI bronchiolar hemorrhage AI1 alveolar hemorrhage CM cuboidal metaplasia Figures represent characteristic lesions observed
at a moderate to marked degree scored 1 4 in a minimum of 50 of the treated animals following a 24 h recovery n 6
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FIG. 1. Photomicrographs of nasal (A and B). tracheal (e), alveolar (D and E). and terminal bronchiolar (F) tissues from rats exposed (30 min) by nose-only 
inhalation to an aerosolized pepper spray extract (1.0-1.2 g/kg). L, epithelial loss; , epithelial dysplasia; , nor al epitheliu ; , acrophages; e1, 
ononuclear cell infiltrate; BU, bronchiolar he orrhage; H, alveolar he orrhage; e , cuboidal etaplasia. Figures represent characteristic lesions observed 
at a moderate to marked degree (scored 1-4) in a minimum of 50% of the treated animals following a 24-h recovery (Il = ). 
that were exposed to ethanol vapors did not demonstrate re-
spiratory lesions. Low (0.07 mg/kg) and intermediate (0,3 
g/kg) doses of capsaicinoids or pepper sprays produced very 
ild and oderate lesions. respectively. hile higher doses (> 
0.8 mg/kg) produced more severe and frequent lesions, These 
pathologies appeared to occur in a dose/responsive manner 
(unpublished data. manuscript in preparation), 
The precise molecular mechanisms by which the pepper 
sprays (capsaicinoids) caused inflammation and cell damage in 
vivo were further investigated in vitro using various cell lines 
derived fro  hu an lung and liver tissues. S-2  cells are 
an S  -40-transfected. i ortalized. hu an bronchiolar epi-
thelial cell line that has frequently been used to study the 
echanis s of air ay toxicants in vitro, Si ilarly. 549 cells 
r  ri  fr   r i   r  s  
additional odel for studying airway toxins. The A549 cells 
serve as a surrogate for human alveolar epithelial cells. Human 
hepatoma. HepG2 cells. were used to represent liver cell re-
sponses, BEAS-2B cells treated with increasing concentrations 
of capsaicin (0 -200 p.M) for 24 h exhibited a dose-dependent 
decrease in cell viability (Fig. 2A). The approximate LC oo 
l  s  p. . r Xi at l  0% f t  r s  i  ll 
viability as observed ithin 8 h (data not shown); ho ever. 
a 24-h exposure period as used to ensure the co plete loss of 
cell viability and to minimize variability. Similar decreases in 
cell viability ere also observed for 549 and ep 2 cells 
(Fig. 2A). The LC so value for capsaicin in 549 and ep 2 
lls  r i t l     p. . r spectively.  
e s re t at er  rief e s res t  ca saici  l  als  ca se 
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r  psaicin,  t  ell i ilit  t r i    l ter. 
-2  cells. treated ith 100 p.M capsaicin in this anner. 
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(dat  t shown). s. t e C so l  i  t Si ifi tl  
change even ith very short exposures to capsaicin. provided 
that cytotoxicity as assessed 24 h after the initial treat ent. 
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cellular responses to capsaicinoids in vivo and in vitro. There-
fore. e investigated the hypothesis that the relative levels of 
expression of this receptor in several cell lines would irror 
t e e te t f cell lar da a e t at as ca se   e s re of 
the cells to capsaicin. Expression of T P 1 in E S-2B. 
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FIG 2 A Cytotoxicity of capsaicin to BEAS 213 filled circles A549
open squares and HepG2 open triangles cells Data represent the mean cell
viability and SD at a given concentration of capsaicin from three independent
experiments B Normalized densitometric traces for TRPVI and 3actin
transcripts amplified by RTPCR from total RNA isolated from BEAS 213
solid line A549 dotted line and HepG2 dashed line cells The inset of
panel B shows the agarose gel used to generate the densitometric traces Std
Molecular weight standards B BEAS213 A A549 and H HepG2
An asterisk represents data points that were significantly greater p
025 than the values for both A549 and BEAS 213 cells
A549 and HepG2 cells was assessed using RTPCR and DNA
sequence analysis RTPCR and densitometric analyses of the
agarose gels were used to compare the relative abundance of
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TRPVI message in BEAS 2B A549 and HepG2 cells In
general BEAS213 cells expressed the highest levels of tran
scripts and HepG2 cells the least Fig 2B These data dem
onstrated a correlation between TRPV1 expression and cellular
susceptibility to cytotoxicity The densitometric data for the
levels of TRPVI expression in these cells are presented in
Figure 2B Analysis of BEAS 2B cells exposed to 0 50 and
100 M capsaicin for 24 h and treated with FITC annexin V
and propidium iodide by flow cytometry demonstrated exten
sive doserelated increases in staining by both fluorophores
These data were consistent with necrotic mechanisms of cell
death Fig 3 These results were verified by fluorescence
microscopy cells were stained by both fluorophores and by an
ELISA assay that showed a lack of enrichment of histone
associated DNA fragments in the cells data not shown Ne
crotic mechanisms of cell death were also observed for resinif
eratoxin RTX anandamide and capsazepine
Surprisingly the cytotoxic effects of capsaicin were not
ameliorated by the TRPVI functional antagonists capsazepine
and isovelleral Uerman et al 2000 or by modulators of
calcium flux ruthenium red and EGTA Table 1 These
results were particularly intriguing because none of the proto
typical modulators of TRP receptor function decreased suscep
tibility of the cells to the cytotoxicity caused by capsaicin
Unexpectedly capsazepine and isovelleral were also toxic to
BEAS213 cells at concentrations that were much lower than
capsaicin Table 1 Although Substance P has been shown to
exacerbate calcium flux into and IL6 production by BEAS 213
cells that were treated with capsaicin Veronesi et al 1999
this neuropeptide did not modulate cellular death from capsa
icin exposure a result that provided additional support for the
conclusion that cell death was calcium independent
BEAS 2B cells treated with capsaicin also exhibited a dose
dependent increase in the production and release of IL6 a
common cytokine used to assess proinflammatory responses
Maximum induction of IL6 47Fold was observed at 24 h
Q
ss Untreated Control
0
a
Apoptosis Apoptosis
FITC Annexin V AU
142 408 Capsaicin 100M 2ts
6
62Necrosis
1 o
Apoptosis
FIG 3 Flow cytometric analysis of FITCAmtexin V and propidium iodide staining of BEAS 213 cells treated with 0 untreated control 50 and 100 M
capsaicin for 24 h Data are representative of a single experimental population of cells However the experiments were reproduced on three separate occasions
to ensure consistent results The percentage of cells exhibiting apoptotic and necrotic characteristics is shown within the figure
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TABLE I
REILLY ET AL
Modulators of TRPVI Function and Cellular Calcium Flux Do
Not Ameliorate the Cytotoxic Effects of Capsaicin in BEAS2B
Bronchiolar Epithelial Cells or TRPV1 Overexpressing Cells
Treatment BEAS 213
Cell viability
TRPV1 overexpressing
No additions capsaicin only 51 7 56 1
Capsazepine
10M 33 5 58 1
30 M 24 5 31 3
EGTA
500 M 54 8 53 2
1rum 395 41 5
Ruthenium Red
500M 52 3 53 4
CaCl
100 M 52 9 ND
500 M 41 5 ND
Substance P
500M 58 9 ND
Note All treatments contained capsaicin BEAS213 cells were treated with
100 Mcapsaicin and TRPVI overexpressing cells were treated with 10M
capsaicin ND not determined
Known inhibitors of calcium flux through TRPVI
Significant difference versus cells treated with capsaicin only p 025
with a concentration of 100 M capsaicin Fig 4 although
significant induction of IL6 was observed in as little as 2 h
with 100 M capsaicin data not shown Addition of excess
calcium chloride slightly increased IL6 release not statisti
cally significant while chelation of free extracellular calcium
in the media 110 AM by EGTA or blocking calcium flux
into cells by the TRPVI antagonist capsazepine drastically
decreased IL6 production Fig 4 Therefore these results
demonstrate a requirement for calcium influx into cells through
TRPVI in order to promote IL6 release Release was also
observed using LC concentrations of RTX but not anandam
ide or capsazepine data not shown
The importance of TRPVI in cell death and proinflamma
tory processes was addressed by overexpression of TRPVI in
BEAS213 cells Human TRPVI was cloned from fetal brain
mRNA and transfected into BEAS 213 cells Overexpression of
TRPV1 in BEAS 2B cells was assessed using RTPCR and
densitometric analysis of the PCR product intensity for nor
mal and TRPVI overexpressing cells Fig 5A The overex
pressing cells also possessed mRNA coding for the TRPV1V5
epitope fusion protein Expression of this mRNA was not
observed in BEAS2B cells Fig 5A or in control cells that
expressed Geneticin resistance but did not show enhanced
susceptibility to cytotoxicity by capsaicin data not shown
Overexpression of functional TRPVI was also determined
TRPV1 overexpressing cells based on overexpression of
mRNA previously loaded with Fluo 4AM displayed in
creased cellular fluorescence when treated with capsaicin due
to CaFluo4 complex formation The percentage of
BEAS 2B or TRPVI overxpressing cells that exhibited fluo
rescence in the absence ofcapsaicin were less than 1 for both
cell types Upon exposure to 100 AM capsaicin 15 min
approximately 3 of the BEAS 213 cells showed increased
fluorescence while approximately 61 of the TRPV1 overex
pressing cells were fluorescent Calcium influx was dosede
pendent since fluorescence was demonstrated in 7 and 18 of
the overexpressing cells with 1 M and 10 AM concentrations
of capsaicin respectively The TRPV1 overexpressing cells
also showed elevated cobalt uptake twofold compared to
normal BEAS 213 cells when exposed to capsaicin Geneticin
resistant control cells that did not show overexpression of V5
or TRPVI mRNA were identical to BEAS2B cells in both
experiments Further confirmation of the role of TRPV1 in
these cellular responses in either cell line was demonstrated
by the inhibition 95 of calcium or cobalt uptake by
capsazepine
Overexpression of TRPV1 resulted in an approximate 100
fold increase in the susceptibility to cytotoxicity Fig 5B
Similarly the cytotoxicity of several other TRPV1 ligands was
increased in TRPV1 overexpressing cells Table 2 The LC
values for olvanil and RTX decreased 15Fold and 75000fold
respectively although the LC values for various other
TRPVI ligands decreased a mere 1 2 Fold suggesting that
different mechanisms are involved in the cytotoxicity of these
diverse compounds
100
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FIG 4 Induction and inhibition of IL6 production by BEAS 213 cells
treated with capsaicin 100 M or capsaicin 100 M plus various modula
tors of TRPVI function for 24 h Capsazepine was used at a concentration of
10 AM EGTA at 100 Mand CaCI at 10M Data represent the mean and
SDof triplicate determinations for fold increases in IL6 concentrations versus
untreated cells control values approximately 175 pgml Statistically signif
icant difference p 025 versus untreated control cells Statistically
significant difference p 025 from cells treated with capsaicin only
untreated uapsalctn Capsaicin Capsaicin Capsaicin
Control EGTA CaCl
Capsazepine
Treatment
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FI . 4. Induction and inhibition of IL-6 production by BE S-2B cells 
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icant difference (p < 0.025) versus untreated control cells. "Statistically 
significant difference (p < 0.025) fro  cells treated ith capsaicin only. 
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FIG 5 A Normalized densitometric traces for TRPVI V5 fusion and
iactin transcripts amplified by RTPCR from total RNA isolated from
BEAS213 dashed line and TRPV 1 overexpressing solid line cells The inset
represents the agarose gel used to generate the densitometric traces B
Cytotoxicity of capsaicin to BEAS213 cells circles compared to TRPVI
overexpressing squares and Geneticin resistant control squares cells Data
represent the mean cell viability and SD at a given concentration of capsaicin
for three independent experiments For the Geneticinresistant cells the data
represent the mean and SD from experiments using four different clones cell
lines Values significantly lower p 025 than the values obtained for both
normal BEAS 213 and Geneticinresistant but not TRPV1 overexpressing
control cell lines
The effects of TRPV1 overexpression in BEAS 213 cells on
the proinflammatory responses to capsaicin treatment were also
assessed Overexpression of TRPV1 also caused a shift in the
dose response curve for IL6 production and release to lower
doses of capsaicin Figure 6 Decreased IL6 production by
cells exposed to 100 M capsaicin was presumably due to
the extensive cell death Maximum production of IL6 24 h
treatment by TRPV1 overexpressing cells was observed at
approximately 05 M capsaicin versus approximately 100
M for BEAS213 cells
The LC values for RTX olvanil and capsaicin appeared to
correlate to literature data Smart et al 2001 Szallasi et al
1999 on TRPVI binding affinity ie RTX olvanil
capsaicin determined by 3HRTX binding as well as the
ability of the compounds to cause calcium influx through
TRPVI ie RTX olvanil capsaicin Flow cytometric
and fluorescence microscopic analysis of TRPVI overexpress
ing cells exposed to capsaicin 0 05 and 10 M for 24 h
demonstrated marked dose related increases in FITC annexin
V staining without concomitant increases in propidium iodide
TABLE 2
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Diverse TRPVI Ligands Exhibit Different Cytotoxic Potencies
in BEAS2B and TRPVI Overexpressing Cells
LCM
TRPVI ligands BEAS 2B TRPV1 overexpressing
Capsaicin 100 10 10102
RTX 75 3 0001 00005
Olvanil 08 09 05 007
Scutigeral 45 1 25 05
Anandamide 125 3 1003
Capsazepine antagonist 25 5 100 2
Isovelleral antagonist 06 01 03 03
Ruthenium Red 1000 ND
Substance P 1000 ND
PPAHV 702 25 02
Note ND not determined
Represents a significant difference versus BEAS 213 cells p 025
staining Fig 7 These data were consistent with apoptotic not
necrotic mechanisms of cell death Similar to BEAS213 cells
however the cytotoxic effects of capsaicin in TRPV1 overex
pressing cells were not ameliorated by functional antagonists
of TRPVI modulators of calcium flux or extracellular calcium
concentrations Table 1
a
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Capsaicin gM
FIG 6 Induction of IL6 production by normal BEAS 213 solid bars
and TRPVI overexpressing cells dotted bars treated with increasing concen
trations of capsaicin for 24 h Data represent the mean and SD of triplicate
determinations for fold increases in IL6 concentration versus untreated cells
control values for IL6 were approximately 175 pgml and 850 pgml for
BEAS 213 and TRPVI overexpressing cells respectively Statistically sig
nificant difference p 025 between treated and untreated control cells
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0 0105 01025 05 1 5 25 50 100 200
001130
I S      177 
4 
.-., 
;::J 
-< .~ 3 
~ 
'(ji 
I::  <IJ 
i:: 
-~ 
I:: 
'" CO 
0 
..-..  g 
I:: 100 
o 
 80 
~  .~ 
. -  
.g 
:;  
A 
I3 - 13 
0 
B 
TRPVI t . 13  13  
VI 
5-Fusion 
(I-Actin 
0.2 0.4 0.6 0.8 
  (A ) 
  1000 
 [Ca saici ] (!AM) 
. S. (A) liz  it t i  t es  VI. ·f sion.  
{.l-acti  tra s ripts lified  /P  fro  t t l  i late  fr  
-2B (dashed line) and I overexpressing (solid line) cells. he inset 
represents the agarose gel used to generate the densito etric traces. ( ) 
t t i it   i i  t  -2B lls (circl ) are  t   
r r i  (squar )  ti i  r i t t tr l (sq r s) ll . t  
re rese t t e ea  cell ia ilit  a   at a i e  c ce trati  f ca saici  
for three independent experi ents. or the eneticin·resistant cells. the data 
represent the ean and S  fro  experi ents using four different clones/cell 
. *Values ica   (p < .02 )  t e    t  
"nor l" S-2B  ti i ·r sist t (but t I r r ssi g) 
  i . 
The effects of TRPYI overexpression in BE S-2B cells on 
the proinflammatory responses to capsaicin treatment were also 
assessed. verexpression of T PYI also caused a shift in the 
dose-response curve for IL-6 production and release to lo er 
ses f ca saici  (Figure ). ecrease  I -6 r cti   
cells exposed to > 100 J1.M capsaicin as presu ably due to 
t  t ive ll th. i  r ti  f I -6 (2   
tr t nt)  PYI r re i  ll  as r  t 
approxi ately 0.5 J1.M capsaicin. versus approxi ately 100 
J1.M  -2B l . 
The LC 30 values for RTX, olvanil, and capsaicin appeared to 
correlate to literature data (S art et a1.. 2001; zallasi et a1., 
1999) on T PYI binding affinity (Le., T  > l il > 
capsaicin), deter ined by 3H-RTX binding, as well as the 
a ilit  f t e c unds to ca se calci  i fl  t r  
PYI (Le ..  > l il > capsaicin). Flo  cyto etric 
and fluorescence icroscopic analysis of TRPYI overexpress-
ing cells exposed to capsaicin (0, 0.5, and 1.0 J.LM) for 24 h 
tr t  r , -r l t  i reas  i  I - i  
Y staining, without concomitant increases in propidium iodide 
  
ivers  l iga  i it iffer t t t i  t ies 
 -2   l re  s 
C:.o (,...M) 
 igands -2  TRP I overexpressing 
i  00:': 10 .0 ± .2' 
 7.5 == 3 . 00  ± . 0 5* 
l il .8 == .09 .05 ± 0.007* 
cutigeral .5 ==  .5 ± 0.5 
na de 2.5 == 3 0.0 ± 3 
s i  (anta ist) ::,:  0.0 ±  
Isovelleral (antagonist) .6::,: .1 .3 ± .03 
utheniu  ed > 1000  
sta ce  >   
 .0 ±  .5 == .2 
te. . t . 
*Represe ts  ficant fere   S-2B ls (p < .025) . 
staining (Fig. 7). hese data ere consistent ith apoptotic, not 
r ti ,    th. i   -2B l . 
e er, t e c t t ic effects f ca saici  i  YI erex-
pressing cells were not a eliorated by functional antagonists 
PYl,   l  ,  l  l  
t tions (Table ). 
5 
4 
3 
2 
[J YR.l Over-expressing 
• BEAS-2B 
-.:' 
",,:. 
;; ~:.i., ~i:'::"':":: 
::::.::-:~.:.:: ::', ::::::::. :::~. 
;::: :~;i :'~'::'I Ii:.: .. ::.:.:.: .. . I 
I':{: I ::::. I :>::~ It 
* 
o .01 .05 .1 .25 .5 I   
[Ca saici ] (11M) 
* 
* 
I 
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FIG 7 Flow cytometric analysis of FITC Annexin V and propidium iodide staining of TRPV1 overexpressing cells treated with 0 left05 middle and
10Mright capsaicin for 24 h Data are representative of a single experimental population of cells However the experiments were reproduced on three
separate occasions to ensure consistent results The percentage of cells exhibiting apoptotic and necrotic characteristics is shown within the figure
DISCUSSION
Capsaicinoids have been known for centuries to produce
severe irritation coughing and respiratory inflammation in
experimental animals and man The use of pepper extracts for
the production of pepper spray self defense weaponry has
utilized this dramatic acute response to incapacitate attackers
and uncooperative suspects Although vast literature exists
concerning the responsiveness of many different types of cells
to capsaicinoids including respiratory epithelial and neuronal
cells the precise molecular mechanisms that governed the
physiological and pathological responses to capsaicinoids have
not been identified or characterized With the recent cloning of
TRPV1 and several other members of the TRPvanilloid re
ceptor family of ion channel receptors scientists have begun to
understand the molecular basis for these diverse physiological
responses produced by capsaicin and other TRPV1 agonists
Gunthorpe et al 2002 The studies presented here have
demonstrated that acute inhalation of capsaicinoids in the form
of pepper sprays by noseonly administration to rats produced
acute inflammation moderate epithelial cell dysplasia and
necrosis in the upper and lower respiratory tract However the
most severe lesions were present in the terminal bronchioles
and alveoli where the capsaicinoids produced marked inflam
mation multifocal macrophage proliferation bronchiolar and
alveolar epithelial cell injury and mild to marked vascular
congestion with septal and alveolar hemorrhage In order to
elucidate the molecular mechanisms responsible for these
pathological effects and to predict the potential effects of
capsaicinoids in humans we utilized immortalized human lung
epithelial cells to evaluate cellular deathcytotoxicity and
proinflammatory cytokine production
The doses used for animal inhalation experiments approx
imately 1012 mgk in a 30 min exposure are similar to
doses that humans would receive during a 510 s exposure of
pepper spray Pepper sprays contain approximately 1 to 32 Ag
total capsaicinoids per At of condensed spray depending upon
the product and formulation Reilly et al 2001ab If one
assumes that the pepper spray canisters contain between 5 and
50 ml of condensed spray unpublished observations then
each canister would contain approximately 5 mg to 16 g total
capsaicinoids Therefore it is reasonable to predict that a dose
of 1 mgkg or more could be inhaled by people exposed to
large amounts of pepper spray Our previous research Reilly et
al 2002 has shown that the concentrations of capsaicinoids in
the blood of rats exposed to 057 mgkg approximately half of
the dose used in the current studies were as high as 125 ngml
in blood and 174 ngmg for lung tissues Extrapolation of these
values to the dose used in the current studies 1012 mgkg
would predict a concentration of approximately 1 M vide
supra which happens to be the LC of capsaicin in the
TRPV 1 overexpressing cell line Concentrations much higher
than 1 AM concentration in blood would be expected at the
site of delivery particle deposition in respiratory cells after an
inhalation exposure Thus it is also reasonable to assume that
humans exposed to pepper sprays could have nasal tracheal
bronchiolar andor alveolar capsaicinoid exposures similar to
the concentrations that elicited cellular death andor cytokine
release in these cell culture studies even if the subject did not
receive a total dose of 1 mgkg Since capsaicinoids can pro
duce significant cell death and IL6 production in very short
time periods 052 h it is also reasonable to predict that
inhaled doses of pepper sprays in humans could cause adverse
respiratory inflammatory responses similar to those character
ized in this study
Recent work at the USEPA has demonstrated a key role for
TRPV 1 in mediating inflammatory responses to capsaicin and
various forms of airborne particulate material in airway tissues
Veronesi et al 1999 2000 Given these data and the knowl
edge that TRPV 1 and other TRP receptors are expressed in
respiratory tissues including the trachea bronchi and alveoli
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Apoptosis
19 Untreated Control
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physiological and pathological responses to capsaicinoids have 
not been identified or characterized. ith the recent cloning of 
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understand the olecular basis for these diverse physiological 
responses produced by capsaicin and other TRPVl agonists 
(Gunthorpe et aI., 2002). The studies presented here have 
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elucidate the olecular echanis s responsible for these 
pathological effects, and to predict the potential effects of 
capsaicinoids in humans, we utilized immortalized human lung 
epithelial cells to evaluate cellular death/cytotoxicity and 
pro infla atory cytokine production. 
e s s s  f r i l i l ti  ri ents (a r x-
i ately 1.0 -1.2 g/kg in a 30-min exposure) are si ilar to 
doses that hu ans ould receive during a 5-10 s exposure of 
pepper spray. Pepper sprays contain approxi ately 1 to 32 /-lg 
total capsaicinoids per /-ll of condensed spray, depending upon 
the product and for ulation (Reilly et aI., 2001a,b). If one 
assu es that the pepper spray canisters contain bet een 5 and 
 l  e se  r  (unpublishe  ervations), t  
each canister ould contain approxi ately 5 g to 1.6 g total 
capsaicinoids. Therefore, it is reasonable to predict that a dose 
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l r  ts  r r y. r r i  r r  (R i11  t 
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supra), i  s t   t  so f s i i  i  t  
  ere ressi  cell li e. ce trati s c  i er 
than 1 /-l  (concentration in blood) ould be expected at the 
site of delivery (particle deposition) in respiratory cells after an 
inhalation exposure. hus. it is also reasonable to assu e that 
hu ans exposed to pepper sprays could have nasal, tracheal, 
bronchiolar, and/or alveolar capsaicinoid exposures si ilar to 
the concentrations that elicited cellular death and/or cytokine 
s    l   i s.  f     
receive a total dose of 1 g/kg. Since capsaicinoids can pro-
duce Significant cell death and IL-6 production in very short 
ti e periods (0.5-2 h), it is also reasonable to predict that 
inhaled doses of pepper sprays in hu ans could cause adverse 
respiratory infla atory responses si ilar to those character-
i  i  t i  t y. 
Recent work at the USEPA has de onstrated a key role for 
TRP l in ediating infla atory responses to capsaicin and 
various for s of airborne particulate aterial in airway tissues 
(Veronesi et I., , 000). i e  t ese ata, a  t e owl-
edge that TRPVl and other TRP receptors are expressed in 
respiratory tissues, including the trachea, bronchi. and alveoli, 
CAPSAICINOIDS AND LUNG VANILLOID RECEPTORS
we investigated the role of TRPVI in these pathologies by the
use of human airway and hepatic cell lines The use of RTPCR
techniques confirmed the expression of TRPVI mRNA tran
scripts in human lung epithelial A549 and BEAS 213 and
liver HepG2 cells Capsaicininduced cell death was greater
in the two lung epithelial cell lines than the liver hepatoma cell
line Furthermore the relative rank order of susceptibility to
cytotoxicity by capsaicinoids correlated to the relative levels of
TRPV 1 transcripts in the three cell lines These data suggested
that TRPVI may be a key mediator of the cytotoxic effects of
capsaicin in these cells
The mechanism of cell death in BEAS2B cells was shown
to be necrosis not apoptosis Surprisingly several experimen
tal variables designed to block cell death including removal
and chelation of calcium and the use of functional antagonists
to TRPVI were ineffective in ameliorating cell death In
addition other TRPV1 ligands both prototypic agonists such
as RTX olvanil and anandamide as well as prototypic antag
onists such as capsazepine and isovelleral were also cytotoxic
at concentrations less than capsaicin Thus ligand binding to
TRPV1 appears to trigger key cytotoxic responses that are
independent of calcium flux into the cell through TRPVI as
required for IL 6 production
In order to elucidate the mechanisms that produced cellular
toxicities we cloned the human TRPVI cDNA and overex
pressed this receptor in BEAS 213 cells These engineered cells
expressed much higher levels of TRPVI transcripts than the
parent cell line as well as much higher capsaicininduced ion
flux that was ameliorated by capsazepine Additional control
cell lines were also produced in these studies These cell lines
showed stable incorporation of the Geneticin resistance expres
sion cassette but did not overexpress mRNA for TRPVI or the
TRPVIV5 fusion protein In addition these cells did not
exhibit functional increases in ion flux cobalt and calcium in
the presence of capsaicin The lack of TRPVI overexpression
despite expression of Geneticin resistance was likely due to
the incorporation of the TRPVI expression cassette into a
silent portion of the genome or from interruption of the gene
during recombination However the cells that did overexpress
TRPV1 were dramatically more susceptible to capsaicin in
duced cell death approximately 100fold than either normal
BEAS 213 or other control cell lines Several other TRPVI
ligands were also evaluated for enhanced cytotoxicity but only
RTX and olvanil caused marked increases in toxicity in the
overexpressing cells Surprisingly cytotoxicity in the overex
pressing cells was again not blocked by TRPV 1 antagonists or
dependent on calcium flux from extracellular media
Unexpectedly the overexpressing cells were killed by cap
saicin through apoptotic not necrotic mechanisms A shift in
the mechanism of cell death may indicate that TRPVImedi
ated cellular injury in the TRPVI overexpressing cells was
truly occurring through programmed cell death mediated by
TRPVI However the cytotoxicity observed in the parent cell
line by a necrotic mechanism may have been the result of a
composite response of several biochemical targets We specu
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late that other vanilloid receptors eg VRL2 VR5sv
TRPM8 VRL1 etc or vanilloid receptors comprised of
mixed populations of vanilloid receptor family protein sub
unitsTRPV1 and others exist as tetramers that appear to form
in response to agonist exposure Delany et al 2001 Kedei et
al 2001 Kuzhikandathil et aL 2001 Schumacher et al
2000may be activated by these structurally diverse xenobi
otics These mixed receptors may also participate in the regu
lation of the responses that were observed in these studies For
example activation of these mixed receptors or other vanilloid
receptors may contribute to both pro and antiapoptotic re
sponses in BEAS 213 cells with anti apoptotic responses dom
inating The net result could be necrotic cell death produced
primarily from non TRPVImediated processes However
overexpression of TRPVI may dilute these alternate targets
for cytotoxicity either by altering the subunit composition of
mixed receptor complexes or by increasing the density of
homogenous TRPV1 tetramers such that TRPV1mediated
proapoptotic signals dominate the cellular responses to capsa
icin exposure Regardless of the mechanism these data rein
forced the concept that cell death in lung epithelial cells treated
with capsaicin was calcium independent but related to TRPVI
expression These results also demonstrated that the TRPVI
overexpressing cells are a valuable tool for differentiating
cytotoxicities and proinflammatory responses that are truly
mediated by TRPV1 as observed for capsaicin RTX and
olvanil versus toxicities that occur as a result of other pro
cesses that are probably independent of TRPVI binding eg
capsazepine anandamide and others
Another significant finding was that the TRPVI overex
pressing cells were also more responsive to proinflammatory
stimuli IL6 production by normal BEAS 2B cells increased
dramatically 457fold in the presence of 100 1xM capsaicin
Increases in IL6 production were also observed with 75 M
RTX twofold but not in the presence of 125 M anan
damide or 25 M capsazepine The TRPV1 overexpressing
cells doubled IL6 production in response to capsaicin concen
trations that were approximately 1002foldlower than the
concentrations that produced this response in the parent cell
line Interestingly the only ligands that increased cytokine
production in BEAS213 cells were the same ligands that ex
hibited enhanced cytotoxicity in the TRPVI overexpressing
cells Cytokine production by these cells was also inhibited by
capsazepine and EGTA These data confirmed the vital role of
TRPVI and calcium flux through TRPVI in the induction of
cytokine production by lung epithelial cells that are exposed to
capsaicin
From these data we conclude that TRPV1 activation medi
ated cell death and cytokine production by BEAS 213 cells
treated with capsaicin and other selected TRPV 1 ligands How
ever these data may also suggest that the cytotoxicity observed
in normal BEAS213 cells treated with capsaicin and other
TRPVI ligands that do not exhibit enhanced cytotoxicity in
TRPV1 overexpressing cells was probably caused by interac
tion with additional biochemical targets Although we have not
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identified the alternate biochemical targets that mediated the
cytotoxicity of these xenobiotics one hypothesis is that other
members of the TRP receptor superfamily whose function has
not been evaluated in human lung epithelial cells may mediate
these responses These hypotheses may help explain the ap
parent discrepancies between the cytotoxicity and cytokine
data and the inability of capsazepine to block cytotoxicity as
well as provide insight into the unique nature of the cytotox
icity of capsaicin in BEAS 213 and possibly other lung cells
For example it may be possible that heterogeneous receptor
complexes that mediate cell death are activated by capsaicin
but are not inhibited by capsazepine Similarly alternate re
ceptor complexes probably homogeneous TRPV1 tetrameric
complexes that mediate cytokine production may be activated
by capsaicin and inhibited by capsazepine Studies to charac
terize the other vanilloid receptors and the potential functional
significance of heteromeric complexes of vanilloid receptors
are underway in our laboratory
In summary these studies demonstrated that capsaicinoids
produced acute pulmonary inflammation and respiratory cell
injury in experimental animals and in human lung epithelial
cells These pathologies and toxicities appeared to occur
through activation of TRPV1 and possibly other related va
nilloid receptor proteins through complex processes that ap
pear at least in part to be mediated by unique and separate
calcium dependent and calcium independent mechanisms
Thus the cytotoxic and proinflammatory response mechanisms
emerge as distinct processes in human lung epithelial cells that
are mediated at least in part by TRPV I These studies provide
a fascinating foray into the precise molecular mechanisms that
control respiratory responsiveness to a large number of envi
ronmental irritants including pepper sprays and possibly other
respiratory irritants and toxicants such as ambient particulate
matter Additional characterization of other TRPvanilloid re
ceptor proteins that may also be expressed in respiratory epi
thelial cells should help clarify the relative contributions made
by the plethora of vanilloid receptors that control airway re
sponsiveness to various environmental stimuli
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Increased Expression of Transient Receptor Potential
Vanilloid1 in Airway Nerves of Chronic Cough
David A Groneberg Akio Niimi Q Thai Dinh Borja Cosio Mark Hew Axel Fischer and K Fan Chung
Division of Allergy Research Department of Pediatric Pneumology and Immunology Charite Faculty of Medicine Humboldt Universitat zu
Berlin Berlin Germany and Thoracic Medicine National Heart and Lung Institute Imperial College London United Kingdom
Transient receptor potential vanniloid1 TRPV1 mediates the cough
response induced by the pepper extract capsaicin and is expressed
in sensory nerves that innervate the airway wall We determined
the expression of TRPV1 in the airways of patients with chronic
persistent cough of diverse causes and with an enhanced capsaicin
cough responseWe obtained airway mucosal biopsies by fiberoptic
bronchoscopy in 29 patients with chronic cough and 16 healthy
volunteers without a cough Immunostaining for nerve profiles with
anti protein geneproduct PGP95antibody showed no increase
in nerve profiles in the airway epithelium of patients with chronic
cough however with an anti TRPV1 antibody there was a fivefold
increase of TRPV1 staining nerve profiles p 001There was
a significant correlation between capsaicin tussive response and
the number of TRPV1positive nerves within the patients with
cough Our findings indicate that TRPV1 receptors may contribute
to an enhanced cough reflex and the cough response in chronic
persistent cough of diverse causes
Keywords airway nerves capsaicin cough transient receptor potential
vanniloid1
Chronic cough that persists over many months is a disorder that
is often distressing and debilitating In many patients this may
be associated with asthma or related conditions such as cough
variant asthma and eosinophilic bronchitis gastroesophageal re
flux disease and rhinosinusitis 12Very often no associated
cause can be determined as specific treatments do not control
the cough 3 The cough reflex measured with inhalation of
the pungent ingredient of chili peppers capsaicin is usually
augmented in patients with chronic persistent cough 4 Little
is known about the abnormalities of the cough receptor itself
in these patients with chronic persistent cough Nerve profiles
in the airway submucosaof patients with chronic persistent cough
are not increased although the number of the neuropeptide
calcitonin generelated peptide CGRPcontaining nerve pro
files were increased 5 It has been hypothesized that cough
sensitization may occur either centrally within the brain stem or
spinal cord afferents or peripherally in cough receptors Cough
itself is mediated by the activation of myelinated Aa fibers as
well as possibly unmyelinated C fibers 6
The cloned capsaicin receptor subtype termed transient re
ceptor potential vanniloidITRPV1 is a nonselective ionchan
nel subunit of 838amino acid sequence cloned in 1997 7
Capsaicin and endogenous agonists anandamide eicosanoids
and bradykinin stimulate TRPV 1 89 TRPV 1 is expressed in
sensory and afferent fibers innervating the airway wall emanating
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from vagal ganglia 10 Activation of TRPV I by agonists such
as capsaicin induces Ca influx resulting in cough 11 We
postulated that airway nerves of patients with chronic persistent
cough could express more TRPV I receptors which could be
the basis for the increased cough reflex and cough symptoms
The aim of this study was therefore to identify whether TRPV 1
immunoreactivity was augmented in the airways of patients with
chronic cough
METHODS
Patients
We investigated 29 consecutive patients referred with chronic cough
through a standard protocol to diagnose and treat the cause of the
cough The mean duration of cough was 67years SD12and the
causes were asthma n 6gastroesophageal reflux n 4rhinosinus
itis n 4bronchiectasis n 1 and unexplained n 14We also
enrolled 16 healthy subjects with no history of cough Table 1 Patients
and volunteers underwent capsaicin cough challenge and fiberoptic
bronchoscopy The study was approved by the Royal Brompton and
National Heart and Lung Institute Ethics Committee and patients gave
informed consent
Capsaicin Challenge
Coughs were counted for 1 minute after singlebreath inhalation of
09NaCl and capsaicin solutions of increasing concentrations098
500MAerosols were generated from a dosimeter attached to a
nebulizer set at a dosing period of 1 minute Increasing concentrations
of capsaicin were inhaled until five or more coughs were counted The
concentration at which this occurs was recorded as the concentration
that causes five or more coughs PC
Fiberoptic Bronchoscopy
Fiberoptic bronchoscopy was performed according to established guide
lines Oxygen 3 Lminute was administered via nasal prongs and
oxygen saturation was monitored with a digital oximeterIpical anes
thesia of the upper airways and larynx was obtained using lidocaine
2 Bronchial biopsies were taken from the segmental and subseg
mental carinae in the right lung and were immediately placed in optimal
cutting temperature embedding media snap frozen in isopentane pre
cooled with liquid nitrogen and stored at 70C before sectioning and
immunostaining
Immunohistochemistry
Immunohistochemistry was performed on cryostat cut 8pm sections
obtained from one subsegmental biopsy from each subject Sections
were preincubated with 01M phosphate buffer containing Ibovine
serum albumin and 10 normal swine serum for l hour to block
nonspecific binding and incubated with polyclonal rabbit antibody
against the pan neuronal marker protein gene product PGP25
1400 Biotrend Cologne Germany To assess epithelialIRPV1
expression alternate sections were incubated with a previously de
scribed polyclonal rabbit antibody against TRPV1 1115000GlaxoS
mithKline HarlowUK12Signaling was detected by incubation with
biotinylated goat antirabbit IgG1200 Amersharn Braunschweig
Germany in combination with a StreptavidinTexas Red conjugate
1150 Amersham or with a fluorescein isothiocyanateconjugated goat
anti rabbit IgG1400 Cappel OH Fluorescence signaling was ana
lyzed using an epifluorescence microscope and the combination of an
001135
Increase  ressi  f ra sie t ece t r te ti l 
anilloid-l in irway erves of hronic ough 
David . roneberg, kio ii i, . hai inh, orja osio, ark e , xel Fischer, and . Fan hung 
ivision of llergy esearch, epart ent of Pediatric neu ology and I unology, harM aculty of edicine, u boldt- niversitat zu 
Berlin, erlin, er any; and Thoracic edicine, ational eart and Lung Institute, I perial ollege, London, nited ingdo  
Transient receptor potential vanniloid-1 (TRPV-1) ediates the cough 
response induced by the pepper extract capsaicin and is expressed 
in sensory nerves that innervate the air ay all. e deter ined 
the expression of TRPV-1 in the airways of patients with chronic 
persistent cough of diverse causes and with an enhanced capsaicin 
cough response. e obtained airway ucosal biopsies by fiberoptic 
bronchoscopy in 29 patients ith chronic cough a d 16 healthy 
volunteers without a cough. I unostaining for nerve profiles with 
anti-protein gene product (PGP)-9.5 antibody showed no increase 
in nerve profiles in the airway epithelium of patients with chronic 
cough; however, with an anti-TRPV-l antibody, there was a fivefold 
increase f -l staining nerve profiles (p < 0.001). here as 
a significant correlation bet een capsaicin tussive response and 
the number of TRPV-l-positive nerves within the patients with 
cough. ur findings indicate that P -l receptors ay contribute 
to an enhanced cough reflex and the cough response in chronic 
persistent cough of diverse causes. 
Keywords: airway nerves; capsaicin; cough; transient receptor potential 
-1 
Chronic cough that persists over many months is a disorder that 
is often distressing and debilitating. In any patients, this ay 
 i t  it  t  r l t  itions   -
variant asth a and eosinophilic bronchitis, gastroesophageal re-
Ilux disease. and rhinosinusitis (1, 2). ery often. no associated 
cause can be deter ined, as specific treat ents do not control 
the cough (3). he cough reflex easured ith inhalation of 
the pungent ingredient of chili peppers, capsaicin. is usually 
aug ented in patients with chronic persistent cough (4). Little 
is kno n about the abnor alities of the cough receptor itself 
in these patients ith chronic persistent cough. erve profiles 
in the airway submucosa of patients with chronic persistent cough 
are not increased, although the number of the neuropeptide 
calcitonin gene-related peptide (CGRP)-containing nerve pro-
files were increased (5). It has been hypothesized that cough 
sensitization ay occur either centrally within the brain ste  or 
spinal cord afferents or peripherally in cough receptors. Cough 
itself is mediated by the activation of myelinated Ai) fibers, as 
ell as possibly un yelinated  fibers (6). 
The cloned capsaicin receptor subtype termed transient re-
ceptor potential vanniloid-I (TRPV-I) is a nonselective ion chan-
nel subunit of 838-amino acid sequence cloned in 1997 (7). 
Capsaicin and endogenous agonists, anandamide, eicosanoids, 
and bradykinin sti ulate TRP -I (8,9). TRP -I is expressed in 
sensory and afferent fibers innervating the airway wall emanating 
(Received in original form February 9, 2004; accepted in final form September 20,2004) 
Supported by a research scholarship from the Deutsche Atemwegsliga. 
Correspondence and requests for reprints should be addressed to K. Fan Chung, 
.D., D.Sc., ational eart Lung Institute, I perial College, ovehouse Street, 
London SW3 6L Y, UK. E-mail: f.chung@imperial.ac.uk 
A  J Respir (rit Care ed Vol 170. pp 1276-1280, 2004 
Originally Published in Press as 001: 10.1164/rccm.200402-1740C on September 24,2004 
Internet address: www.atsjournals.org 
fro  l lia (1 ). tivatio  f  -1  ists s  
s  induces H i l  l    (1 ). e 
lated at a  erves  ients it  c  
 l  pre s r   -1 r t r , i  ld  
the i   t  increase   l    t . 
e i   t is t  as therefore t  i ti  t  -l 
i r ti ity as e ted i  t e ir a s f tie ts it  
i  . 
S 
ti ts 
e investigated  ti  tie ts  it  i  gh 
through  t rd r t l t  i s   tr t t  se f t  
. e     as .7 e rs (S . .2),   
auses ere  (n = ),   (n = ), i us-
itis (n ,~ ), e  (n" I),   (n= 4).   
e r lled  ealt  s jects it   ist r  f c  (Table I). atie ts 
 te     e   ibe  
bronchoscopy. The study as approved by the oyal ro pton and 
l e t   t te ics it .  s  
onne  ent. 
i  e  
s ere c te  f r I i te after si le- reat  i alati  f 
.9% el  s i in sol ti s f i r si  tr ti s (0.98-
 [lM). eros ls r  r t  fr   i t r tt  t   
izer  t  i    I i te. re  t t  
of capsaicin ere inhaled until five or ore coughs ere counted. he 
concentration at which this occurs was recorded as the concentration 
t t s s fi  r r  s (PC). 
i er tic r c sc  
i li    rf  accor i  t  establi  uide-
s.  (  l te)  stere   al r s.  
 at r ti   i  l   i i l ximeter. Topical anes-
thesia of the upper air ays and larynx as obtained using lidocaine 
(2%). ronchial biopsies ere taken fro  the seg ental and subseg-
ental carinae in the right lung and were i ediately placed in opti al 
tti  t r t  i  dia, s  f  i  i t  -
cooled ith liquid nitrogen, and stored at -7(rc. before sectioning and 
i unostaining. 
i t i t  
I unohistoche istry as perfor ed on cryostat-cut. 8-[lm sections 
t i  fr   eg nt l i  fr   subject. ti  
r  r i t  it  O.I-  ph sp t  ff r containi  I % ovi  
r  al i   10% nor al  ser   I h r t  l  
ci  i i   i  i  l 1  r bbit nti  
a ai st t e a - e r al arker protei  gene pr ct (P P)-9.  
( /40 : i tre d, l e. ermany).  assess epit elial TRPY-I 
r ssion, lt r t  secti s r  i t  it  a previously de-
scribed polyclonal rabbit antibody against TRPY-I (1115,000: GlaxoS-
ithKline, arlow. K) ( 2). i ali   det ct  hy i ti  it  
bi ti l t  t anti-r hhit I  ( 120 : r m, r unschweig, 
ennany) i  i ti  i   Streptavidin-   co j  
(1150: ersham) or ith a fluorescein isothiocyanate-conjugated goat 
anti-rabbit-Ig  (l/400; Cappel, H). Fluorescence signaling as ana-
lyzed using an epifluorescence microscope and the combination of an 
Groneberg Niimi Dinh et al TRPV1 Expression in Chronic Cough 1277
TABLE 1 CHARACTERISTICS OF NORMAL VOLUNTEERS WITHOUT COUGH AND OF PATIENTS
WITH COUGH
PC
Age Sex FEV Capsaicin Smoking
n yrx MaleFe Predicted m00 Exsmokers
Normal volunteers 16 37 154 97 1037133 125 39250 0
Patients with cough 29 50 146 920 97 15 39098250 7
Definition of abbreviation PC concentration of capsaicin causing five coughs or more
Median range
Participants were current nonsmokers and exsmokers were defined as those that stopped smoking for 3 or more years at
the time of study with less than 5 packyears of smoking
t Mean SD
p 02
excitation filter with a band pass of 54610nut and a barrier filter with
a longpass of 590 rim Images of epithelium were captured using an
image system and computerized by SPOT Advanced software SPOT
Insight QE version351Visitron Systems Puchheim Germany The
observers were unaware of the clinical details of the participating sub
jects Images of the epithelium were captured and the area of specific
immunostaining and the total area were measured The PGP95or
TRPV1positive nerve densities were expressed as the percentage of
the epithelial area 5 12 The immunoreactive nerves were distin
guished from any background staining
Data Analysis
For statistical analysis of the immunoreactive percentage of nerve fibers
the Mann Whitney U test was applied as the data were not normally
distributed Pearson rank correlation was used to determine correla
tions A p value of less than 05 was taken as significant
RESULTS
Both normal volunteers and patients with cough showed no
evidence of airflow obstruction but the patients with cough
were on average 30 fold more sensitive to the tussive effects of
capsaicin Table 1
Staining for PGP95revealed specific staining of nerve pro
files in the biopsies TRPV 1 immunohistochemistry also led to
specific staining of nerve profiles in the subepithelial and epithe
lial layers of the biopsies Occasional staining of epithelial cells
was present and consisted of less than 1 of epithelia cells
there were no differences between normal and patients with
cough Nerve fiber profiles were measured only in the epithelium
Nerve fibers immunostained for the general nerve marker
PGP95and for TRPV1 varied in their density among cases
and between groups The median range total nerve density
PGP95positive fibers was 1680 to405 in the patients
and was not significantly different at 1400 to294 in the
control group Figure I in agreement with an earlier study
5However significant differences were found for TRPV1
positive nerve fibers which were higher in cough biopsies with
values of150 to39in the patients versus0230123
in the control group p 0003 Figure 2 We have also
quantified the expression of TRPV1 in the biopsies as a ratio
of the PGP95 expression measured in the adjacent section for
each subject Thus the TRPV1 to PGP95 ratio was 0170
065in normal volunteers and 075 0096in the patients with
chronic cough p 0001This indicates a 4fold increase in
the staining of epithelial nerves in patients with chronic cough
There were no significant differences in the expression of
PGP95 or of TRPV 1 between the patients with unexplained
cough and those in which the cough was associated with a cause
Within the 29 patients with cough the number of TRPV1
positive fibers were inversely correlated to PC r 041
p 05there was no significant correlation between PGP95
expression and PC Figure 3
We have shown in a cohort of patients with chronic cough an
increase in the nerve profiles expressing TRPV1 although the
nerve profiles stained with the neuronal marker PGP95 were
not increased as compared with healthy volunteers who do not
suffer from chronic cough The area of positive staining with
the antiTRPV 1 antibody was 75 of the PGP95positive
staining indicating that 75 of the nerve profiles detected in
the epithelium expressed TRPV1 compared with only 17 in
the normal control subjects We found an inverse correlation
between the capsaicin cough responsiveness and the nerve pro
files stained with those expressing TRPV1 within the group of
patients with a cough These results indicate that TRPV 1 may
be important in the pathogenesis of chronic cough
The cohort of patients with a chronic cough that we studied
had a wide spectrum of associated causes that included asthma
gastroesophageal reflux and rhinosinusitis but the majority of
these cases had unexplained cough in that none of the putative
causes of cough was found to be causing the cough These pa
tients were referred to our cough clinic from a wide area of
southern United Kingdom and have often been seen by other
colleagues and received treatment In nearly half of the patients
48 in this small cohort we could not identify a cause in
contrast to previous series 13All patients with cough had a
sensitive cough response to capsaicin In addition we found that
there was no difference in the expression of either PGP95 or
ofTRPV 1 between the patients with unexplained cough and
those in whom the cough was associated with a cause
The comparative group of normal control subjects that we
recruited was not equally balanced with the group of patients
with cough in terms of sex and age The predominance of females
in the patients with a chronic cough is as one may expect The
influence of sex and age on the degreeof expression ofPGP95
and TRPV1positive neural fibers in the airway epithelium is
unknown Within the group of normal volunteers and the those
with a cough we found no significant differences between men
and women in terms of the PGP95 and TRPVI expression
and there was no significant correlation between age and the
capsaicin response and TRPV1 expression within the normal
volunteers The lack of relationship between these factors in our
study would suggest that these may not have influenced the
results we found
The phenotypic expression of airway nerves in patients with
chronic cough was changed in that there was a fivefold greater
expression of TRPV1 TRPV1 gene expression is found pre
dominantly in nociceptive like primary afferent neurones whose
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atie ts ith a c h. ese res lts i icate t at -l a  
be i portant in the pathogenesis of chronic cough. 
 rt f ti ts it   r i   t t  st i  
had a wide spectru  of associated causes that included asth a, 
gastroesophageal reflux, and rhinosinusitis, but the ajority of 
these cases had "unexplained" cough in that none of the putative 
causes of cough as found to be causing the cough. hese pa-
tie ts ere referred t  r c  cli ic fr  a i e area f 
southern United Kingdo  and have often been seen by other 
llea e   e ived t t ent.  l  l   t  tie ts 
(48%) i  t i  ll hort,  l  t i tif   se, i  
contrast to previous series (13). ll patients ith cough had a 
sensitive cough response to capsaicin. In addition, e found that 
there as no difference in the expression of either -9.5 or 
of TRPV-I between the patients with "unexplained" cough and 
t se i   t   s ss i t  it   se. 
The co parative group of nor al control subjects that we 
recruited as not equally balanced ith the group of patients 
ith cough in ter s of sex and age, The predo inance of fe ales 
in the patients ith a chronic cough is as one ay expect. The 
influence of sex and age on the degree of expression of P P-9.5-
and P -l-positive neural fibers in the air ay epitheliu  is 
. ithin     unteers    
with a cough, we found no significant differences between men 
and o en in ter s of the P P-9.S and T P -l expression, 
 t    i i ica t l ti  t    t  
capsaicin response and T P  -I expression ithin the nor al 
volunteers. he lack of relationship bet een these factors in r 
st  l  s est t at t ese a  t a e i flue ce  t e 
  . 
The phenotypic expression of airway nerves in patients with 
chronic cough was changed in that there was a fivefold greater 
expression of TRPV-l. TRPV-l gene expression is found pre-
dominantly in nociceptive-like primary afferent neurones whose 
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TRPV1Immunofluorescence staining of airway nerves in a bronchial
8 biopsy with an anti TRPV1 antibody in a normal noncoughing volunteer
norm panel 1 and in a patient with cough cough panel 2 Panel 3
0 4 0
cough control positive for TRPV 1 was significantly greater in patients with chronic cough
than in the control group panel 4 Arrows denote positive neuronal
staining Original magnification x250
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v1 Figure 1 Airway staining for protein gene product
PGP95 Immunofluorescence staining of airway nerves
CL
V e in a bronchial biopsy with the pan neuronal marker
PGP95in a normal noncoughing volunteer norm panel
1 and in a patient with cough cough panel 2Panel 3
shows no staining with the negative control when the
0 0 0 primary antibody was not added Individual percentages
Chronic Health
of bronchial epithelial area staining positive for PGP95of
shown between patients with a chronic cough and
Cou Contro healthy control subjects panel4 The arrows denote posi
tive neuronal staining Original magnification x250
Figure 2 Airway staining for transient receptor potential vanniloid 1
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Figure 3 Correlation between PGP95 expression percentage of epi
thelial area and the concentration of capsaicin causing fivecoughs or
more PC responseMupperpaneO and between TRPV expres
sion percentage of epithelial area and the capsaicin PC response
Mlower paned in the 29 patients with chronic cough There was a
significant correlation between TRPV1 expression and the PC response
but not between PGP95expression and the PCs response
cell bodies reside in the dorsal root trigeminal and nodose
ganglia Antibodies directed against TRPV1 have revealed the
cellular distribution of TRPV 1 in sensory neurones 14 It is
not excluded that there may also be upregulation in airway
ganglia which would not be accessible from the mucosal biopsy
method The cause of the increasednumber ofTRPV1positive
nerve fibers in patients with chronic cough is unknown Expres
sion of TRPV1 receptors is known to be regulated by growth
factors such as nerve growth factor and glial cell line derived
neurotrophic factor 15 Immunoreactivity to CGRP which is
regulated by nerve growth factor has been reported to be in
creased in epithelial nerves in chronic cough5 making the role
for nerve growth factor and other growth factors more likely Such
CGRP positive nerve profiles may also be expressing TRPV1
TRPVI mediates the cough induced by capsaicin as in stud
ies in guinea pigs the capsaicin antagonist capsazepine inhibits
capsaicin induced cough and the endogenous TRPV1 ligand
anandamide causes cough an effect inhibited by capsazepine
and resinoferatoxin which are both TRPV1 antagonists 11
Although an increase in the number ofTRPV 1 receptors may
contribute to the enhanced cough reflex to capsaicin other fac
tors may also be involved The activation of A8 fibers and C
fibers in the airways of guinea pigs or rats induced by decreasing
pH involves TRPV 1 because protons can increase the TRPV 1
ion channel opening 16 Heat activated currents in TRPV1
can be potentiated by relatively small changes in pH 17 and
this would indicate the potential for low pH to augment capsaicin
cough sensitivity in situations such as gastroesophageal reflux
of gastric acid An increase in the content of protons in exhaled
breath condensate of the order of halflog in chronic cough has
been reported 18In addition the reported increase in CGRP
immunoreactive nerves in this condition 5also indicates the
presence of a neuropeptide that could sensitize visceral afferents
19 Nerve growth factor could also act on mast cells which
we have found to be increased in biopsies from patients with
1279
nonasthmatic cough 20 to release lipoxygenase products that
could activate TRPV1 receptors 21
In summary we found increased expression of TRPV1 in
airway epithelial nerves of patients with chronic cough and a
significant correlation of this expression with the capsaicin cough
sensitivity Thus TRPV1 expression may be one of the determi
nants of the enhanced cough reflex found in patients with chronic
cough TRPV I antagonists have been described22 and these
could be effective in the treatment of chronic cough irrespective
of the type or cause of chronic cough
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cell bodies reside in the dorsal root, trige inal. and nodose 
ganglia. Antibodies directed against TRPY-I have revealed the 
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been reported (18). In addition, the reported increase in CGRP-
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Abstract
TRPV 1 is a calciumselective ion channel expressed in human lung cells We show that
activation of the intracellular sub population of TRPV1 causes endoplasmic reticulum ER
stress and cell death in human bronchial epithelial and alveolar cells TRPV 1 agonist
nonivamide treatment caused calcium release from the ER and altered the transcription of
GADD153 GADD45a GRP78BiP ATF3 CCND1 and CCNG2 in a manner comparable to
prototypical ER stress inducing agents The TRPV1 antagonist LJO328 inhibited mRNA
responses and cytotoxicity EGTA and ruthenium red inhibited cell surface TRPV 1 activity but
did not prevent ER stress gene responses or cytotoxicity Cytotoxicity paralleled EIF2a
phosphorylation and the induction of GADD153 mRNA and protein Transient over expression
of GADD153 caused cell death independent of agonist treatment and cells selected for stable
over expression of a GADD153 dominant negative mutant exhibited reduced sensitivity
Salubrinal an inhibitor of ER stress induced cytotoxicityvia the EIF2aK3EIF2a pathway or
stable over expression of the EIF2aS52A dominant negative mutant also inhibited cell death
Treatment of the TRPV 1 null HEK293 cell line with TRPV 1 agonists did not initiate ER stress
responses Similarly n benzylnonanamide an inactive analogue of nonivamide failed to cause
ER calcium release an increase in GADD153 expression and cytotoxicity We conclude that
activation of ERbound TRPVI and stimulation of GADD153 expression via the
EIF2aK3EIF2a pathway represents a common mechanism for cytotoxicity by cell permeable
TRPV 1 agonists These findings are significant within the context of lung inflammatory diseases
where elevated concentrations of endogenous TRPV 1 agonists are likely produced in sufficient
quantities to cause TRPV1 activation and lung cell death
4
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prototypical ER stress-inducing agents. The TRPVl antagonist LJO-328 inhibited mRNA 
responses and cytotoxicity. EGTA and ruthenium red inhibited cell surface TRPVl activity, but 
did not prevent ER stress gene responses or cytotoxicity. Cytotoxicity paralleled EIF2a 
phosphorylation and the induction of GADD153 mRNA and protein. Transient over-expression 
of 153 caused cell death independent of agonist treat ent, and cells selected for stable 
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stable over-expression of the EIF2a-S52  do inant negative utant also inhibited cell death. 
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quantities to cause TRPVl activation and lung cell death. 
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Introduction
Lung cell damage causes acute respiratory distress and contributes to the pathogenesis of
chronic lung diseases Knight and Holgate 2003 Evidence suggests that the transient receptor
potential vanilloid type1 receptor TRPV1 capsaicin receptor VR1 Hs 268202 may be a
mediator of lung pathologies caused by xenobiotic toxicants and endogenous agonists as well as
a therapeutic target for treating and or preventing lung disorders Jia et al 2005 Szallasi et al
2006
TRPV1 is widely expressed in the respiratory tract including nasal mucosal cells Seki et
al 2006 Cfiber neurons and airway smooth muscle cells Mitchell et al 2005 Watanabe et
al 2005 and alveolar and bronchial epithelial cells Veronesi et al 1999 Reilly et al 2003
Agopyan et al 2004 TRPV1 is selectively activated by capsaicin the primary pain producing
chemical in hot peppers and a variety of exogenous and endogenous respiratory toxicants
including anandamide Van Der Stelt and Di Marzo 2004 products of arachidonic acid
metabolism by lipoxygenases Hwang et al 2000 H2S Trevisani et al 2005 ethanol
Trevisani et al 2004 acids Tominaga et al 1998 Ricciardolo et al 2004 and particulate
pollutants Veronesi et al 1999 Agopyan et al 2004 Capsaicin and other TRPVI agonists
are routinely used to study the TRPV1 pharmacology and have proven instrumental in defining
the physiological roles of TRPV1 in the lung and other organs Here we use capsaicin to
elucidate toxicological phenomena associated with TRPV1 activation in lung cells
Capsaicin is used clinically to induce cough Morice et al 2001 and to treat rhinitis van
Rijswijk and Gerth van Wijk 2006 However numerous case reports have described adverse
respiratory effects and death in humans following exposures to concentrated capsaicinoid
aerosols Heck 1995 Steffee et al 1995 Billmire et al 1996 In animal models high doses of
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ntro : 
Lung cell da age causes acute respiratory distress and contributes to the pathogenesis of 
chronic lung diseases (Knight and olgate, 2003). vidence suggests that the transient receptor 
potential vanilloid type-1 receptor (TR 1, capsaicin receptor, 1; s. 2) ay be a 
e iat r f l  at logies ca se   e i tic t ica ts a  e e s a ists as ell as 
a therapeutic target for treating and/or preventing lung disorders (jia et ai., 2005; Szallasi et ai., 
). 
 i  i l  e  i  t  i t  t t i l i  l l ll  (S i t 
ai., 2006), -fiber neurons and air ay s ooth uscle cells (Mitchell et ai., 2005; atanabe et 
ai., 2005), and alveolar and bronchial epithelial cells (Veronesi et ai., 1999; eilly et ai., 2003; 
gopyan et ai., 2004). P 1 is selectively activated by capsaicin, the pri ary pain producing 
chemical in hot peppers, and a variety of exogenous and endogenous respiratory toxicants 
i cl ing a a a i e (Van er telt a  i arz , 004), r cts f arac i ic aci  
eta lis   lipoxygenases (Hwang et ai., 00), z  (Trevisa i et ai., 05), et a l 
(Trevisani et ai., 2004), acids (Tominaga et ai., 1998; icciardolo et ai., 2004), and particulate 
lluta ts (Veronesi et ai., ; a  et ai., 004). a saici  a  t er 1 a ists 
are routinely used to study the TRP 1 phar acology and have proven instru ental in defining 
the physiological roles of T P 1 in the lung and other organs. ere e use capsaicin to 
elucidate toxicological pheno ena associated ith T P 1 activation in lung cells. 
Capsaicin is used clinically to induce cough (Morice et ai., 2001) and to treat rhinitis (van 
ijs ijk and erth van ijk, 2006). o ever, nu erous case reports have described adverse 
respiratory effects and death in hu ans follo ing exposures to concentrated capsaicinoid 
aerosols (Heck, 1995; Steffee et ai., 1995; ill ire et ai., 1996). In ani al odels, high doses of 
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capsaicin cause acute respiratory and cardiovascular failure independent of the route of
administration Glinsukon et al 1980 Inhalation of capsaicinoids by rats causes lung
inflammation and widespread damage to tracheal bronchial and alveolar cells Reilly et al
2003 In vitro studies with human bronchial epithelial cells have demonstrated two principal
outcomes associated with TRPV 1 activation proinflammatory cytokine IL6 and IL8
production and oncotic cell death Reilly et al 2003 Reilly et al 2005 Cytokine synthesis
and cell death were inhibited by TRPV1 antagonists that prevented calcium release from the
endoplasmic reticulum ER and included LJO328 SC0030 5 iodoRTX Conversely
inhibition of the cell surface population of TRPV 1 using EGTA ruthenium red and calciumfree
media only prevented cytokine responses
In mammalian cells depletion of ER calcium initiates a homeostatic stress response
program termed ER stress ER stress is generally initiated by a reduction in protein processing
efficiency in the ER and its roles in human diseases and xenobiotic toxicities have been reviewed
Cribb et al 2005 Schroder and Kaufman 2005 Zhang and Kaufman 2006 ER stress is
predominantly regulated by three sensors Activating transcription factor 6 ATF6 Hs 492740
eukaryotic initiation factor 2a kinase3 EIF2ocK3 or PERK Hs 59158 and ER to nucleus
signaling 1 and 2 ERN1 and 2 ak IRE Ia and p Hs 133982 and Hs 592041 Schroder and
Kaufman 2005 Activation of one or more of these proximal sensors is dependent upon the
type of cellular stress For example the prototypical ER stress inducing agent thapsigargin
preferentially activates the translational branch involving EIF2uK3 Activated EIF2aK3
catalyzes the phosphorylation of cytosolic EIF2a Hs 15177 Lu et al 2004 Boyce et al
2005 Heterodimerization of EIF2aP with EIF23 promotes ATF4 translation Hs 49648 and
inhibits the translation of nonessential genes Wek et al 2006 ATF4 translocates to the
0
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capsaicin cause acute respiratory and cardiovascular failure, independent of the route of 
ad inistration (Glinsukon et ai., 1980). Inhalation of capsaicinoids by rats causes lung 
inflammation and widespread da age to tracheal, bronchial and alveolar cells (Reilly et ai., 
3). I  itr  st dies ith a  r c ial e it elial cells a e e strated t o rincipal 
tco es ass ciate  ith  acti ati : r -i fla at r  c t ine (IL-6 a  I -8) 
r tion  tic ll e t  (Reilly t i., ; ill  t i., 05). t in  s t esis 
and cell death ere inhibited by T P 1 antagonists that prevented calciu  release fro  the 
endoplas ic reticulu  (E ) and included LJ -328, S 0030, 5-iodo-RT . onversely, 
inhibition of the cell surface population ofT P 1 using E T , rutheniu  red and calciu -free 
edia only prevented cytokine responses. 
I  li  lls, l ti  f  l i  i itiat s  st ti  str ss r s s  
program termed ER stress. ER stress is generally initiated by a reduction in protein processing 
efficiency in the  and its roles in hu an diseases and xenobiotic toxicities have been revie ed 
(Cribb et ai., 2005; chroder and auf an, 2005; hang and auf an, 2006).  stress is 
predominantly regulated by three sensors: Activating transcription factor 6 (ATF6; Hs. 49274(1), 
eukaryotic initiation factor a kinase-3 (EIF2a 3 or RK; s. 9),   t  l  
signaling 1 and 2 (ERN1 and 2, a.k.a. IRE1a and p; Hs. 133982 and Hs. 592041) (Schroder and 
auf an, 2005). ctivation of one or ore of these proxi al sensors is dependent upon the 
type of cellular stress. For exa ple, the prototypical ER stress-inducing agent thapsigargin 
preferentially activates the "translational branch" involving EIF2aK3. Activated EIF2aK3 
catalyzes the phosphorylation of cytosolic EIF2a (Hs. 151777) (Lu et aI., 2004; oyce et ai., 
2005). eterodi erization of IF2a-P ith EIF2~ pro otes F4 translation ( s. 496487)  
inhibits the translation of "non-essential" genes ( ek et aI., 2006). TF4 translocates to the 
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nucleus where it modulates the expression of a subset of stress response genes that include
ATF3 GADD153 CCND1 and BiPGRP78 see Table 1 for UniGene IDs Phosphorylation of
EIF2a is considered protective Lu et al 2004 Boyce et al 2005 but increased expression of
GADD153 as a consequence of EIF2a phosphorylation causes cell cycle arrest at Gl S and cell
death Oyadomari and Mori 2004
In this study we tested the hypothesis that activation of the intracellular ER sub
population of TRPV 1 byprototypical and endogenous TRPV 1 agonists would disrupt ER
calcium homeostasis and activate EIF2aK3dependent ER stress responses to cause cytotoxicity
The data obtained from this work implies that a common mechanism of cytotoxicity exists for
cell permeable TRPV1 agonists and that conditions that promote TRPV1 activation in vivo eg
inflammation inhalation of polluted air etc may promote lung pathologies through TRPV l
and EIF2aK3dependent pro cytotoxic ER stress pathways
Methods
Chemicals Structures of the TRPV 1 agonists and antagonists used in this study are
shown in Figure 1 Nonivamide nvanillylnonanamide sulfinpyrazone dithiothreitol DTT
hydrogen peroxide H2O2 ruthenium red ethylene glycolbis2aminoethyletherN
tetraacetic acid EGTA benzylamineHCI and nonanoyl chloride were purchased from Sigma
Chemical Corporation St Louis MO N4tertbutylbenzylN13fluoro4
methylsulfonylaminophenylethythiourea LJO328 was generously provided by Dr Jeewoo
Lee Seoul National University Seoul Korea Thapsigargin and 5iodo resiniferatoxin were
purchased from Axxora San Diego CA Salubrinal EIF2xinhibitor was purchased from
Calbiochem San Diego CA PCR primers were purchased from Integrated DNA Technologies
7
001146
J # 19412 
nucleus here it odulates the expression of a subset of stress-response genes that include 
, , , a  iP/GRP78 (see a le  f r i e e I s). s r lati  f 
IF2a is nsidered r t tive (Lu t i., ; oyce t I., 05), t i reas  r ssi  f 
, as a c nse uence f I 2a s r lati , ca ses cell c cle arrest at 1/S a  cell 
death (Oyado ari and ori, 2004). 
I  t is st  e t st  t e pothesis t t ti ti  f t  i tr ll lar  s -
l ti  f   r t t pical  s  ist  l  isr t  
l i  e stasis  ti t  I aK3- t  tr  r ses t   t t xi it . 
The data obtained fro  this ork i plies that a co on echanis  of cytotoxicity exists for 
cell-per eable TRP 1 agonists and that conditions that pro ote TRP 1 activation in vivo (e.g., 
i fla ti , i l ti  f ll te  ir, tc.)  r te l  t l ies t r  1-
and EIF2aK3-dependent pro-cytotoxic E  stress path ays. 
s: 
Chemicals: Structures of the TRPV1 agonists and antagonists used in this study are 
shown in Figure 1. Nonivamide (n-vanillylnonanamide), sulfinpyrazone, dithiothreitol (DTT) , 
hydrogen peroxide (H20 2), ruthenium red, ethylene glycol-bis(2-aminoethylether)-N,N,N,N-
tetraacetic acid (EGTA), benzyla ine-HCl, and nonanoyl chloride were purchased fro  Sig a 
Chemical Corporation (St. Louis, MO). N-(4-tert-butylbenzyl)-N' -(1-[3-fluoro-4-
(methylsulfonylamino)phenyllethyl)thiourea (LJO-328) was generously provided by Dr. Jeewoo 
Lee (Seoul ational niversity, Seoul, orea). Thapsigargin and 5-iodo-resiniferatoxin ere 
purchased from Axxora (San Diego, CA). Salubrinal (EIF2a-inhibitor) was purchased from 
albioche  (San iego, A). P  pri ers ere purchased fro  Integrated  Technologies 
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Coralville IA nBenzylnonanamide was synthesized by reacting benzylamineHCI and
nonanoyl chloride in01M NaOH and collecting the precipitate Product structure was verified
by liquid chromatographytandem mass spectrometry mz 248HandNMR Purity was
estimated to be 98 by HPLCUV analysis 230 nm Chemical analysis data are included in
supplemental data file 1 figure 1 All other chemicals and reagents were purchased from
established suppliers
Cell culture BEAS2B human bronchial epithelial cells CRL9609 were purchased
from American Type Culture Collection ATCC Rockville MD TRPV1overexpressing cells
were generated as previously described Reilly et al 2003 BEAS2B and TRPVl
overexpressing cells were cultured in LHC9 media BioSource Camarillo CA Normal human
bronchial epithelial NHBE cells a primary cell line were purchased from Cambrex
Walkersville MD and cultured in BEGM media HEK293 human embryonic kidney CRL
1573 and A549 human lung carcinoma CCL185 cells were purchased from ATCC and were
cultured in DMEMT12 containing 10 FBS Hyclone Laboratories Logan UT Culture flasks
for BEAS2B and TRPV1overexpressing BEAS2B cells were coated with LHC basal media
fortified with collagen 30 gml fibronectin 10 gml and bovine serum albumin 10 gml
Cells were maintained between 3090 maximum density and were sub cultured every 2 4 days
Fluorometric Calcium FluxAssays TRPV1 overexpressing cells were used to evaluate
calcium flux Flux in BEAS2B A549 and NHBE cells was not detectable Functional
evidence provided here and in previous studies Reilly et al 2003 Reilly et al 2005 Johansen
et al 2006 demonstrates that the TRPV1overexpressing cells model responses of BEAS213
and other lung cells when treated with diverse TRPV 1 agonists with the exceptions that TRPV1
dependent calcium flux is quantifiable and dose responses for TRPV 1 agonists are shifted to
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(Coralville, I ). n- enzylnonana ide as synthesized by reacting benzyla ine-HCI and 
nonanoyl chloride in O.lM a  and collecting the precipitate. Product structure as verified 
by liquid chro atography-tande  ass spectro etry (rn/z 248), IH-and !3C-N R. Purity as 
esti ated to be -98% by P C/UV analysis (230 n ). he ical analysis data are included in 
supplemental data file 1, figure 1. All other chemicals and reagents were purchased from 
established suppliers. 
ell c lt re: S-2  a  r c ial e it elial cells (CR -96 ) ere rc ase  
fro  erican pe lture lle ti  (AT ) (Ro ill , ). l- r r ssi  lls 
were generated as previously described (Reilly et aI., 2003). BEAS-2B and TRPVl-
overexpressing cells ere cultured in L C-9 edia (BioSource, Ca arillo, CA). or al hu an 
bronchial epithelial (NHBE) cells, a primary cell line, were purchased from Cambrex 
( alkersville, ) and cultured in  edia. 293 hu an e bryonic kidney (C -
1573) and 549 hu an lung carcino a (CC -185) cells ere purchased fro   and ere 
cultured in D E :F12 containing 10% FBS (Hyclone Laboratories, Logan UT). Culture flasks 
f r -2  a  l-o ere ressi  -2  cells ere c ate  it   asal e ia 
fortified with collagen (30 /lg/ l), fibronectin (10 /lg/ I), and bovine seru  albu in (10 /lg/ I). 
ells ere aintained bet een 30-90% axi u  density and ere 'sub-cultured every 2-4 days. 
Fluorometric Calcium Flux Assays: TRPVl-overexpressing cells were used to evaluate 
calci  fl x. l  i  -2 , , a   cells as t etectable. cti al 
evidence provided here and in previous studies (Reilly et aI., 2003; Reilly et aI., 2005; Johansen 
et aI., 6) e strates t at t e PVl-overex ressi  cells el res ses f -2B 
and other lung cells when treated with diverse TRPVl agonists, with the exceptions that TRPVl-
dependent calciu  flux is quantifiable and dose-responses for T P l agonists are shifted to 
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lower concentrations To assay calcium flux TRPV1overexpressing cells were sub cultured
into 96well culture plates and grown to 90 maximum density Cells were loaded with the
fluorogenic calcium indicator Fluo4AM 25M Invitrogen Carlsbad CA for 90 min at
room temperature 22C in LHC9 media containing 200 gM sulfinpyrazone Cells were
washed and incubated for an additional 20 min at room temperature to permit methyl ester
hydrolysis and activation of Fluo4 Changes in cellular fluorescence in response to agonist and
antagonist treatments were assessed microscopically on cell populations 1 min after treatments
using methods previously described Reilly et al 2005 Johansen et al 2006 ER calcium flux
was evaluated by pretreating cells with thapsigargin 25M for 5 min followed by addition of
nonivamide 25 gM Calcium flux due to cell surface TRPV1 activity was assessed by treating
cells with nonivamide in calcium free media containing EGTA 50 M and ruthenium red 250
M Differences in fluorescence responses observed between the treatments and controls were
used to assess the relative contribution of ERbound and cell surface TRPV1 in total calcium
flux initiated by agonists Data are expressed as fold change in fluorescence intensity
Cytotoxicity Assays Cells were sub cultured into multiwell plates and allowed to reach
90 confluence The cells were treated for 24h with various agonists and antagonists prepared
in the appropriate culture media without FBS Cell viability was assessed using the Dojindo Cell
Counting Kit 8 Dojindo Laboratories Gaithersburg MD according to the supplier
recommendations Loss of cell monolayer integrity due to treatment with toxic TRPV1 agonists
was confirmed microscopically Toxicity data are expressed as the percentage of remaining
viable cells relative to untreated controls calculated using the absorbance ratio of the formazan
dye product generated from the Dojindo reagent
Q7
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lo er co ce trati s. o assa  calci  fl . I- ere ressing cells ere s b-c ltured 
i t  6-well lture lates  r  t  -9 % i  sit . lls er  l a e  it  t  
flu orogenic calciu  indicator Fluo-4-AM (2.S IlM) (Invitrogen. arlsbad. A). for 90 in at 
r  te perature (-22°C) in C-9 e ia c tai ing 0 Il  s lfin raz e. ells ere 
as e  a  incubate  f r a  a iti al  i  at r  te erat re t  er it et l ester 
hydrolysis and activation of Fluo-4. hanges in cellular fluorescence in response to agonist and 
antagonist treatments were assessed microscopically on cell populations I min after treatments 
using ethods previously described (Reilly et aI.. 200S; Johansen et aI.. 2006).  calciu  flux 
as evaluated by pre-treating cells ith thapsigargin (2.S IlM) for S in follo ed by addition of 
i a ide (2.S Il ). alci  fl  e t  cell s rface I acti it  as assesse   treati  
cells ith noniva ide in calciu  free edia containing  (SO IlM) and rutheniu  red (2S0 
IlM). ifferences in fluorescence responses observed bet een the treat ents and controls ere 
    e   -bound    I   l  
flux initiated by agonists. Data are expressed as fold change in fluorescence intensity. 
Cytotoxicity Assays: Cells were sub-cultured into ulti-well plates and allowed to reach 
-90% confluence. he cells ere treated for 24h ith various agonists and antagonists prepared 
in the appropriate culture edia without FBS. Cell viability was assessed using the Dojindo Cell 
Counting Kit-8 (Dojindo LaboratOries. Gaithersburg. MD), according to the supplier 
reco endations. Loss of cell onolayer integrity due to treat ent with toxic TRPVI agonists 
as confir ed icroscopically. Toxicity data are expressed as the percentage of re aining 
viable cells relative to untreated controls, calculated using the absorbance ratio of the for azan 
dye product generated from the Dojindo reagent. 
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RTPCR analysis Cells were sub cultured into 25 cm cell culture flasks grown to a
density of 90 and treated with TRPV 1 agonists and antagonists Total RNA was extracted
from cells using the RNeasy RNA isolation kit Qiagen Valencia CA and 25g of total RNA
was transcribed into cDNA using PolyT and Superscript III Invitrogen Carlsbad CA cDNA
corresponding to GADD153 GADD45a ATF3 CCND1 CCNG2 BiPGRP78 and0actin was
amplified by PCR from 1 gL of the cDNA synthesis reaction using the primers listed in Table 1
and GoTaq green PCR mastermix Promega MadisonM The PCR program consisted of an
initial 2 min incubation at 94C and 28 cycles of 94C 30 s 55C 30 s and 72C 30 s A
final extension period of 10 min at 72C followed PCR products were resolved on 1 SB
agarose gels and images were captured using a BioRad Gel Doc imaging system Product
quantification was achieved by determining the band intensities for each PCR product relative to
Ractin the internal PCR control using the Gel Doc density analysis tools in the Quantity One
software Experiments were reproduced a minimum of three times on different passages of cells
Cloning ofER Stress Gene cDNA The full length cDNA for human GADD153 ATF3
EIF2a and ATF4 were amplified from BEAS213 cells using Phusion GC rich PCR supermix
New England Biolabs Ipswich MA The following primers were used GADD153 5
CACCATGGCAGCTGAGTCATTGCCTTTC and5TGCTTGGTGCAGATTCACCATTC
ATF3 5 CACCATGATGCTTCAACACCCAG and 5
ATACTGAAGCTGCAGGCACTC EIF2a 5CACCATGCCGGGTCTAAGTTGTAG and
5ATCTTCAGCTTTGGCTTCCATTTC AT1 5
CACCATGACCGAAATGAGCTTCCTG and 5GGGGACCCTTTTCTTCCCCCTTG
These primers incorporated a 5 CACC sequence immediately prior to the ATG start site to
permit directional cloning into the pcDNA31V5His6 mammalian expression vector
10
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RT-PCR analysis: Cells ere sub-cultured into 25 c z cell culture flasks, gro n to a 
sit  f -90%,  tre te  it  l ists  t ists. t l  as tr t  
fro  cells using the easy  isolation kit (Qiagen, alencia, ) and 2.5 J..lg of total  
s tra s ribed i t   si  l   rs ri t III (Invitro , rls , A).  
corresponding to 153, 45a, TF3, CC l, CC 2, BiP/GRP78 and p-actin as 
a plified by P  fro  1 ~LL of the c  synthesis reaction using the pri ers listed in Table 1 
and oTaq green P  aster ix (Pro ega, adison, WI). The P  progra  consisted of an 
initial 2 in incubation at 94°C and 28 cycles of 94°C (30 s), 55°C (30 s), and 72°C (30 s).  
final extension period of 10 in at 72°C follo ed. P  products ere resolved on 1 % S  
agarose gels and i ages ere captured using a io-Rad el-Doc i aging syste . Product 
quantification as achieved by deter ining the band intensities for each P  product relative to 
p-actin, the internal P  control, using the el oc density analysis tools in the uantity ne 
s ft are. eri ents ere re r ce  a i i  f t ree ti es  iffere t assa es f cells. 
Cloning of ER Stress Gene eDNA: The full-length cDNA for human GADD153, ATF3, 
I ,   r  lifie  fr  -2B lls si  si  -rich  s r i  
(New England Biolabs, Ipswich, A). The following primers were used: GADD153 (+) '-
  (-) '-TGC T GTGCAGATTC , 
 (+) ' -   (-) '-
, 2a (+) ' -   
(-) '- A , F4 (+) '-
GC TC   (-) ' - . 
These pri ers incorporated a 5' -C CC sequence i ediately prior to the T  start site to 
permit directional cloning into the pcDNA3.1-V5/His6 mammalian expression vector 
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Invitrogen Carlsbad CA and eliminated the stop codon to allow for epitope tagging with V5
His6 An expression plasmid for p58 pcDNAI p581PK was generously provided by Dr
Michael G Katze University of Washington Seattle WA The pMaxGFP expression vector
was purchased from Amaxa Biosystems Gaithersburg MD All clones were sequence verified
by comparison to the appropriate GenBank sequences Plasmids used in the transient
transfection assays were simultaneously purified using the Qiagen Plasmid DNA MidiPrep kit
and further purified using the GeneElute HP Plasmid Miniprep kit Sigma St Louis MO
Site DirectedMutagenesis The GADD153L134A41 Matsumoto et al 1996 and
EIF2aS52A Srivastava et al 1998 dominant negative mutants were constructed using the
QuickChange XL Site Directed Mutagenesis Kit Stratagene Madison WI and the following
primers GADD153L134A41 5
GGCACAGGCAGCTGAAGAGAATGAACGGGCCAAGCAGG and 5
CCTGCTTGGCCCGTTCATTCTCTTCAGCTGCCTGTGCC and EIF2aS52A 5
CTTCTTAGTGAATTAGCCAGAAGGCG and 5
GGATACGCCTTCTGGCTAATTCACTA
Transient Over Expression Assays and Stable Over Expressing Cell Lines A459 cells
respond to TRPV1 agonists similar to BEAS2B NHBE and TRPV1overexpressing cells with
the exception that they exhibit slightly reduced sensitivity to agonists due to lower levels of
TRPV1 expression Reilly et al 2003 A549 cells were used as transfection hosts to evaluate
the protoxic effects of ER stress induced gene products in lung cells because they exhibited
reproducibility in transfection efficiency and limited toxicity due to transfection reagents
Transfection efficiency typically reached 80 using A549 cells versus 510 with BEAS2B
cells or1 using NHBE cells This level of transfection was necessary to evaluate the effects
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(Invitrogen, Carlsbad, C ) and eli inated the stop codon to allo  for epitope tagging ith 5-
His6. An expression plas id for p58 IPK (pc NA1-p58 IPK) was generously provided by Dr. 
ichael . at , iversity f s i t , ttl , .  ax FP ressi  t r 
was purchased from Amaxa Biosystems (Gaithersburg, D). All clones were sequence verified 
by co parison to the appropriate en ank sequences. las ids used in the transient 
transfection assays were si ultaneously purified using the Qiagen Plas id DNA idi-Prep kit 
and further purified using the GeneElute HP Plasmid iniprep kit (Sigma, St. Louis, O). 
ite- irecte  t e esis: e -U34A1U41A (Matsu t  et aI., ) a  
EIF2a-S52A (Srivastava et aI., 1998) dominant negative mutants were constructed using the 
Quick-Change XL Site -Directed utagenesis Kit (Stratagene, adison I) and the following 
pri ers: GADD153-U34A1U41A (+) '-
TG ACGGGC AGCAGG  (-) ' -
T ,   (+) '-
G   (-) '-
CTA . 
Transient ver-Expression Assays and Stable ver-Expressing ell Lines: 459 cells 
respond to T P 1 agonists si ilar to E S-2 , E, and T P 1-overexpressing cells, ith 
the exception that they exhibit slightly reduced sensitivity to agonists due to lo er levels of 
TRPV1 expression (Reilly et aI., 2003). A549 cells were used as transfection hosts to evaluate 
the pro-toxic effects of ER stress-induced gene products in lung cells because they exhibited 
reproducibility in transfection efficiency and li ited toxicity due to transfection reagents. 
Transfection efficiency typically reached -80% using 549 cells versus -5-10% ith BE S-2B 
cells, or <1 % using NHBE cells. This level of transfection was necessary to evaluate the effects 
 
JPET119412
of ER stress genes on cell populations A549 cells were sub cultured into 48well cell culture
plates and grown to a density of 7080 Cells were washed with OptiMem media and
transfected for 18h using Lipofectamine 2000 Invitrogen Carlsbad CA at a ratio of 31
lipidplasmid DNA Following transfection cells were washed with OptiMem and allowed to
grow for an additional 24h Cell viability was assessed as described above All experiments
were performed in triplicate and were normalized to control cells transfected with equal
quantities of the pMaxGFP plasmid
Stably over expressing cell lines were generated by culturing transfected A549 cells in
media fortified with Geneticin 600 ggmL Invitrogen Carlsbad CA for 3 weeks Resistant
foci were isolated and expanded in selective media Individual clones were screened for over
expression of the target genes by assaying for V5His6 expression by RTPCR and subsequently
used for cytotoxicity screening
Western blotting BEAS2B cells were grown to 90 maximum density in 25 cm
flasks Prior to treatment cells were cultured in fresh media for 2h Cells were treated for 0 1 2
4 and 8h rinsed with PBS and immediately lysed on ice using 20 mM HEPES pH 75
containing 150 mM NaCl 1 Triton X100 1 mM EDTA 10 mM sodium pyrophosphate 100
mM sodium fluoride 175 mM 3glycerophosphate 1 mM phenylmethylsulfonyl fluoride
PMSF 4 mgmL aprotinin and 2 mgLpepstatin A The lysates were clarified by
centrifugation at 20000 xg for 15 min at 4Cand the concentration of protein determined using
the BCA Assay Pierce Rockford IL 50 gg of soluble protein from each sample was resolved
on a 10 NuPAGE gel Invitrogen Carlsbad CA and subsequently transferred to PVDF
membrane The blots were probed for EIF2ocP using a rabbit polyclonal IgG fraction specific to
EIF2ocpS52 BioSource International Camarillo CA according to supplier protocols
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of R stress genes on cell populations. 549 cells ere sub-cultured into 48-well cell culture 
plates and grown to a density of -70-80%. ells ere ashed ith pti e  edia and 
transfected for -18h using Lipofecta ine 2000 (Invitrogen, Carlsbad, CA) at a ratio of 3: 1 
lipid:plasmid DNA. Following transfection, cells were washed with Opti e  and allowed to 
gro  for an additional 24h. ell viability as assessed as described above. ll experi ents 
ere perfor ed in triplicate and ere nor alized to control cells transfected ith equal 
quantities of the p axGFP plasmid. 
tably over-expressing cell lines ere generated by culturing transfected 549 cells in 
edia fortified ith eneticin (600 J..lg/mL) (Invitrogen, arlsbad, ) for -3 eeks. esistant 
foci ere isolated and expanded in selective edia. Individual clones ere screened for over-
expression of the target genes by assaying for 5-His6 expression by -P  and subsequently 
used for cytotoxicity screening. 
ester  l tti g: S-2  cells ere r  t  -90% a i  e sit  i   c 2 
s. ri    ls  re      . l     , , , 
,  , ri s  it  ,  i i t l  l s   i  si    ,  .5 
containing 150 mM NaCI, 1 % Triton X100, 1 mM EDTA, 10 mM sodium pyrophosphate, 100 
 sodiu  fluoride, 17.5  ~-glycerophosphate, 1  phenyl ethylsulfonyl fluoride 
(P SF), 4 mg/mL aprotinin, and 2 mglmL pepstatin A. The lysates were clarified by 
centrifugation at -20,000 xg for 15 in at 4 DC and the concentration of protein deter ined using 
the  ssay (Pierce, ockford, I ). 50 J..lg of soluble protein fro  each sa ple as resolved 
on a 10% NuPAGE gel (Invitrogen, Carlsbad, CA) and subsequently transferred to PVDF 
e brane. he blots ere probed for I 2a-P using a rabbit polyclonal Ig  fraction specific to 
IF2a-pS52 ( ioSource, International, amarillo, A) according to supplier protocols. 
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GADD153 expression was determined using an antiGADD153 antibody from Biolegend San
Diego CA and the protocol provided by the supplier
Statistical Analysis Statistical testing utilized the paired ttests and ANOVA with post
hoc testing using Dunnettstest to determine significance A 95 confidence interval was used
as the limit for significance Specific details on statistical analyses are presented in the figure
legends
Results
Treatment of TRPV1 overexpressing cells with nonivamide 25M produced marked
increases in cytosolic calcium due to release of calcium from ER stores Figure 2A EGTA and
ruthenium red cotreatment had little to no effect on calcium flux but cotreatment with LJO328
or prior depletion of ER calcium stores with thapsigargin completely prevented calcium flux n
Benzylnonanamide failed to elicit ER calcium release at 25 M Figure 2A or at concentrations
up to 25 M data not shown Treatment of TRPV1overexpressing cells with 1 M
nonivamide caused an approximate 50 loss in cell viability after a 24h period Figure 213
Cell death corresponded to a loss of monolayer consistency data not shown and was inhibited
by LJO328 cotreatment but not by EGTA and ruthenium red nBenzylnonanamide did not
cause cell death consistent with a lack of TRPV 1 activation
Analysis of collective genetic responses in TRPVIoverexpressing and BEAS2B cells
exposed to 1 and 100 M LC50 concentrations nonivamide respectively for 4h in the presence
of or absence of LJO328 by microarray yielded preliminary insights into cellular processes that
constituted the cell death process data are provided in supplemental data files 2 and 3
Increased expression of GADD153 GADD45u ATF3 CCNG2 and BiPGRP78 mRNA and a
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153 expression as deter ined using an anti- 153 antibody fro  iolegend (San 
ie o, ) a  t e r t c l r ide   t e s pplier. 
Statistical Analysis: Statistical testing utilized the paired t-tests and  ith post-
hoc testing using unnett's test to deter ine significance.  95% confidence interval as used 
as the li it for significance. Specific details on statistical analyses are presented in the figure 
legends. 
sults: 
reat ent of P 1-overexpressing cells ith noniva ide (2.5 /-lM) produced arked 
i creases i  t lic l i   t  r l   l i  fr   t r  (Figur  A).   
  - e t  ttle   e t   x,  -  t  -328 
or prior depletion of  calciu  stores ith thapsigargin co pletely prevented calciu  flux. n-
enzylnonana ide failed to elicit  calciu  release at 2.5 /-lM (Figure 2A) or at concentrations 
up to 25 /-lM (data not shown). reat ent of PV1-overexpressing cells ith 1 /-lM 
noniva ide caused an approxi ate 50% loss in cell viability after a 24h period (Figure 2B). 
ell death corresponded to a loss of onolayer consistency (data not shown) and as inhibited 
by LJ -328 co-treat ent, but not by E T  and rutheniu  red. n-Benzylnonana ide did not 
se ll th. i t t it   l  1 ti ti . 
nalysis of collective genetic responses in PV1-overexpressing and -2  cells 
exposed to 1 and 100 /-lM (LC50 concentrations) noniva ide. respectively. for 4h. in the presence 
of or absence of LJO-328, by microarray yielded preliminary insights into cellular processes that 
constituted the cell death process (data are provided in supple ental data files 2 and 3). 
Increased expression of 153. 45a. F3. 2. and iP/GRP78  and a 
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decrease in CCND1 mRNA were observed and these responses were validated byRTPCR
Figure 3A Cotreatment of cells with the TRPV1 antagonist LJO328 prevented changes in
gene expression while little to no inhibition was observed using EGTA and ruthenium red
Figure 3A Treatment of BEAS2B cells with the prototypical ER stress inducing agents
thapsigargin and DTT produced similar changes in the expression of GADD153 GADD45a
ATF3 CCND1 CCNG3 and BiPGRP78 Figure 3B mRNA
BEAS2B cells treated with nonivamide 100 and 200 M also exhibited a shift in the
relative amount of EIF2aP and an increase in the expression of GADD153 mRNA and protein
Figure 4AC EIF2a phosphorylation and GADD153 expression was inhibited by LJO328
but not by EGTA and ruthenium red Figure 4A The kinetic and dose dependent features of
GADD153 induction and EIF2aP accumulation paralleled cytotoxicity Figures 4AC The
highest levels of EIF2a phosphorylation and GADD153 protein were detected at Ahwith 200
M nonivamide For GADD153 increases in mRNA in BEAS2B cells was maximal at Ah and
occurred at concentrations 150 luM Similar responses were observed using the TRPV1
overexpressing cells but maximum increases in protein and mRNA were observed with a dose
of 1 2 gM data not shown
Transient over expression of GADD153 in A549 cells produced an approximate 50
loss in cell viability relative to pMaxGFPtransfected control cells in the absence of cytotoxic
TRPV1 agonists Figure 5A Transient over expression of ATF4 which stimulates GADD153
transcription also produced 20 cell death GADD153L134A41 ATF3 or p58
not cytotoxic Transient cotransfection of A549 cells with ATF3 and GFP 10 yielded a high
proportion of viable GFPexpressing cells 48h after the transfection procedure Figure 5B No
ethidium bromide EtBr stained nuclei were observed in these cells indicating cellular integrity
14
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decrease in DI  ere observed and these responses ere validated by -PCR 
(Figure 3 ). o-treat ent of cells ith the PVl antagonist J -328 prevented changes in 
gene expression. hile little to no inhibition as observed using  and rutheniu  red 
(Figure 3 ). reat ent f S-2B cells ith the prototypical  stress-inducing agents 
thapsigargin and TI produced si ilar changes in the expression of I53. 45a. 
3. I. 3. and iP/GRP78 (Figure 3 ) . 
S-2  cells treated ith noniva ide (100 and 200 /lM) also exhibited a shift in the 
relative a ount of EIF2a-P and an increase in the expression of 153  and protein 
(Figure 4 -C). EIF2a phosphorylation and 153 expression as inhibited by LJ -328. 
but not by EGTA and rutheniu  red (Figure 4A). The kinetic and dose-dependent features of 
 i ctio  a  I 2a-P acc lati  arallele  c t t icit  (Figures -C). e 
highest levels of EIF2a phosphorylation and GADD153 protein were detected at -8h with 200 
/lM noniva ide. For I53. increases in  in S-2  cells as axi al at -4h and 
occurred at concentrations> 150 /l . Si ilar responses ere observed using the l-
overexpressing cells. but axi u  increases in protein and  ere observed ith a dose 
of 1-2 /lM (data not shown). 
Transient over-expression of 153 in 549 cells produced an approxi ate 50% 
loss in cell viability relative to p ax FP-transfected control cells in the absence of cytotoxic 
TRPVl agonists (Figure 5A). Transient over-expression of ATF4. which stimulates GADD153 
transcription. also produced -20% cell death. GADDI53-L134A1L141A. ATF3. or p58IPK were 
not cytotoxic. Transient co-transfection of 549 cells ith TF3 and FP (10:1) yielded a high 
proportion of viable GFP-expressing cells 48h after the transfection procedure (Figure 5B). No 
ethi i  r i e {Et r)-stai e  clei ere ser e  i  t ese cells. i icati  cell lar i tegrity. 
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Conversely very few cells transfected with GADD153 and GFP 10 survived while those that
remained attached to the culture dish exhibited intense nuclear staining with EtBr These data
were consistent with a loss of cell viability cell membrane integrity and oncotic cell death as
previously reported for BEAS2B and A549 cells treated with capsaicin Reilly et al 2003
Inhibition of cytotoxicity using dominant negative forms of EIF2a EIF2xS52Aand
GADD153 GADD153L134A41 was also evaluated Figure 6 Figure 6A shows that
both the EIF2aS52A and GADD153L134A41 over expressing A549 cells were less
susceptible to cytotoxicity by nonivamide Similarly addition of salubrinal to treatment
solutions containing nonivamide 1 or 100 M inhibited cell death in TRPV1over expressing
and BEAS213 cells with a maximum effect between 25 and 5 M Figure 6B Salubrinal
inhibits EIFUMinduced cytotoxicity Lu et al 2004 Boyce et al 2005
Induction of the pro apoptoticoncotic ER stress induced gene GADD153 was also
compared in TRPV1overexpressing BEAS213 A549 and NHBE lung cells as well as human
embryonic kidney HEK293 cells Table 2 All four lung cell types express TRPV1 but
HEK293 cells do not Significant 68fold GADD153 mRNA induction was observed
following 4h treatment of BEAS2B TRPV1overexpressing A549 and NHBE cells with LC50
concentrations of nonivamide resiniferatoxin and anandamide but not with n
benzylnonanamide Interestingly nbenzylnonanamide inhibited cell death caused by
nonivamide in the TRPV1overexpressing cells at concentration ratios51 data not shown
Induction of GADD153 transcription was attenuated by LJO328 in all cells types exhibiting a
response as well as by 5iodoRTX in the TRPV1overexpressing line GADD153 induction was
not observed in HEK293 cells treated with nonivamide or resiniferatoxin
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r ely, r  f  lls tr f t  it     (10:1) rvi d, ile t  t t 
r i e  tt  t  t  lt re i  i ite  i te s  l r t i i  it  t r.  t  
r  iste t it   l   ll i ility, ll r  i t rity,  e ti  ll ath,  
previously reported for S-2  and 549 cells treated ith capsaicin (Reilly et aI., 2003). 
tion     t    2a (EIF2a-S5 A)  
153 (GAD I53- 134A!L141A) as also evaluated (Figure 6). igure 6  sho s that 
both the I 2a-S52  and I53- 134A!L141A over-expressing 549 cells ere less 
susceptible to cytotoxicity by nonivamide. Similarly, addition of salubrinal to treatment 
solutions containing noniva ide (1 or 100 IlM) inhibited cell death in P l-over-expressing 
and E S-2B cells ith a axi u  effect bet een 2.5 and 5 IlM (Figure 6B). Salubrinal 
i i its IF2aK3-i  t t i it  (Lu t I., 4;  t I., 5) 
Induction of the pro-apoptotic/oncotic E  stress-induced gene  153 as also 
co pared in TRP l-overexpressing, BE S-2B, 549, and BE lung cells as ell as hu an 
e bryonic kidney (HE -293) cells (Table 2). ll four lung cell types express T P l, but 
-293 cells do not. ignificant (6-8-fold) 153  induction as observed 
follo ing 4h treat ent of S-2 , Vl-overexpressing, 549, and  cells ith so 
t ti s  i i , i i t xi ,  i , t t it  -
benzylnonana ide. Interestingly, n-benzylnonana ide inhibited cell death caused by 
noniva ide in the TRP l-overexpressing cells at concentration ratios >5:1 (data not shown). 
Induction of 153 transcription as attenuated by LJ -328 in all cells types exhibiting a 
response as ell as by 5-iodo-RT  in the TRP l-overexpressing line. 153 induction as 
    s  t    i if ratoxin. 
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Discussion
Previous studies of TRPV1 and the effects of its agonists on cultured lung cells and in
animal models of airway injury support the hypothesis that TRPV1 is a mediator of lung injury
and inflammation Reilly et al 2003 Vargaftig and Singer 2003 Li et al 2005 Reilly et al
2005 Trevisani et al 2005 Bhatia et al 2006 Geppetti et al 2006 However precise
molecular mechanisms of cell death have not been established
Quantitation of calcium flux in TRPV1overexpressing cells demonstrated that 8590
of functional TRPV1 existed in the ER membrane Figure 2A Selective inhibitors of TRPV1
and treatments that reduced the passage of calcium ions from extracellular sources into cells
Figure 2A and B confirmed previous data demonstrating a correlation between ER calcium
release and cytotoxicity in TRPV1overexpressing cells Reilly et al 2005 Although calcium
flux was not detected in BEAS2B NHBE or A549 cells results presented here demonstrate
that the TRPV1 overexpressing cells model the TRPV 1 agonist induced effects in these cell
types
cDNA microarray analysis supplemental data files 2 and 3 demonstrated that TRPV 1
activation was associated with changes in the expression of several prototypical ER stress genes
in lung cells Comparisons between gene expression changes elicited by nonivamide in the
presence and absence of LJO328 and EGTAruthenium red Figure 3A and changes elicited by
the prototypical ER stress inducingagents thapsigargin and DTT Figures 313 support our
conclusion that TRPV1 activation causes ER stress Furthermore ER stress proceeded via
pathways similar to those activated by thapsigargin and DTT Schroder and Kaufman 2005
ER stress responses are compensatory responses Upregulation of specific gene products
through dedicated signaling pathways coupled with cell cycle arrest and a temporary halt of
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i sion: 
re i s st ies f l a  t e effects f its a ists  c lt re  l  cells a  i  
ani al odels of air ay injury support the hypothesis that TRP l is a ediator of lung injury 
a  i fla ati  (Reill  et aI., 3; ar afti  a  i er, 3; i et aI., 5; eill  et aI., 
; r is i t I., ; tia t I., ; tti t I., 006). r, r is  
 s s       t bli ed. 
a titati  f calci  fl  i  1- ere ressi  cells e strate  t at -90% 
f f ctio al P l e iste  i  t e  e ra e (Figure A). electi e i i itors f l 
and treat ents that reduced the passage of calciu  ions fro  extracellular sources into cells 
(Figure 2  and ) confir ed previous data de onstrating a correlation bet een  calciu  
release and cytotoxicity in P 1-overexpressing cells (Reilly et aI., 2005). lthough calciu  
fl  as t etecte  i  -2 , , r  cells, res lts rese te  ere e strate 
that the TRP 1-overexpressing cells odel the TRP l agonist-induced effects in these cell 
types. 
c  icroarray analysis (supple ental data files 2 and 3) de onstrated that T P l 
ti ti  as ss i t  it  s i  t  r ssi  f s r l r t t ical  str ss s 
in lung cells. o parisons bet een gene expression changes elicited by noniva ide in the 
presence and absence of J -328 and GTAIruthenium red (Figure 3 ) and changes elicited by 
the prototypical  stress inducing-agents thapsigargin and  (Figures 3B) support our 
conclusion that P l activation causes  stress. Further ore,  stress proceeded via 
path ays si ilar to those activated by thapsigargin and  (Schroder and auf an, 2005). 
ER stress responses are co pensatory responses. Up-regulation of specific gene products 
through dedicated signaling path ays, coupled ith cell cycle arrest and a te porary halt of 
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general transcription and translation are coordinated processes that have evolved to help cells
overcome inefficiencies in protein processing Schroder and Kaufman 2005 Alterations in ER
processing efficiency occur with nutrient deprivation viral infection disruption of cellular redox
state changes in ER folding environmenteg alterations in calcium homeostasis redox state
expression of unstable polymorphic variant proteins and toxicant exposures Cribb et al 2005
Schroder and Kaufman 2005 If cells cannot compensate for a specific stress they die
ER stress induced cell death has been primarily attributed to the expression of GADD153
following EIF2aK3 activation Matsumoto et al 1996 McCullough et al 2001 Oyadomari
and Mori 2004 GADD153 inhibits cell proliferation by reducing the expression of CCND1
and causes cell death bysequestering the anti apoptotic Bcl2 protein and inhibiting ofNFKB
and AktPKBmediated cytoprotective processes McCullough et al 2001 Hu et al 2004
Hyoda et al 2006 The balance between cell death and survival ultimately depends upon the
level of GADD153 expression and the coexpression of other pro and anti cytotoxic gene
products that participate in ER stress responses
Treatment of BEAS213 cells with nonivamide promoted the phosphorylation of EIF2a at
serine 52 Figure 4A This was indicative of EIF2aK3 activation EIF2a phosphorylation was
associated with increased expression of GADD153 expression Figure 3A 4A and 413
Increased concentrations of EIF2aP and GADD153 correlated with the onset of cell death in
BEAS2B cells as determined using dose and temporal response correlations with protein and
mRNA Figure 4AC These trends were reproduced using the TRPV I overexpressing line
EIF2a phosphorylation and GADD153 expression were attenuated by LJO328 but not by
EGTA or ruthenium red nBenzylnonanamide a pharmacologically inactive nonivamide
analogue did not promote ER calcium release or induce GADD153 expression in BEAS2B or
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general transcription and translation, are coordinated processes that have evolved to help cells 
overco e inefficiencies in protein processing (Schroder and auf an, 2005). lterations in  
r ssi  fficien  r it  tri t ri ti n, ir l i f ti , isr ti  f ll l r r  
state, changes in ER folding environ ent (e.g., alterations in calciu  ho eostasis, redox state), 
e ressi  f sta le l r ic aria t r tei s, a  t ica t e s res (Crib  et aI., 05; 
Schroder and auf an, 2005). If cells cannot co pensate for a specific stress, they die. 
 stress-induced cell death has been pri arily attributed to the expression of 153 
follo ing EIF2a 3 activation (Matsu oto et aI., 1996; c ullough et aI., 2001; yado ari 
and ori, 2004). GADD 153 inhibits cell proliferation by reducing the expression of CCND 1 
a  ca ses cell eat   se esteri  t e a ti-a t tic cl-2 r tein, a  i i itin  f F-KB 
and ktlPKB- ediated cytoprotective processes (McCullough et aI., 2001; u et aI., 2004; 
 t I., 06).  l  t  ll t   s r i l lti t l  s  t  
level of 153 expression and the co-expression of other pro- and anti-cytotoxic gene 
products that participate in  stress responses. 
r t t  -2B lls it  i a ide r t  t  r l ti    t 
serine 52 (Figure 4A). This was indicative of EIF2aK3 activation. EIF2a phosphorylation was 
ass ciate  it  i crease  e ressi  f  e ressi  (Figure , , a  B). 
creas  ons  -P    t        
BE S-2B cells, as deter ined using dose- and te poral-response correlations ith protein and 
RNA (Figure 4A-C). These trends were reproduced using the TRPV1-overexpressing line. 
I  s r l tion   r ssi  r  tt t   J -3 , t t  
EGTA or rutheniu  red. n-Benzylnonana ide, a phar acologically inactive noniva ide 
analogue, did not pro ote ER calciu  release or induce GADD153 expression in BEAS-2B or 
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any other cells tested and was nontoxic at concentrations equal to or in 2 fold excess of
nonivamide Figures 2A and B Table 2 These data support our conclusion that TRPV1
activation promotes cytotoxicity via activation of EIF2aK3 phosphorylation of EIF2a and
expression of GADD153
To substantiate the role of GADD153 in cell death we cloned this gene and transiently
transfected A549 cells with the expression construct Performing transient transfection studies in
the BEAS213 and NHBE cells were hampered by variable transfection efficiency and high levels
of toxicity due to transfection reagents As such we used A549 cells as the model for these
experiments We have previously shown that A549 cells respond to TRPV1agonists similar to
BEAS2B cells Reilly et al 2003 Cells transfected with GADD153 exhibited reduced
viability due to loss of cells from the culture wells Figure 5A and B Cytotoxicity and cell loss
relative to controls were not observed with GADD153L134A41 ATF3 or p58 but
toxicity was observed with ATF4 These results were consistent with the established roles of
these proteins Schroder and Kaufman 2005 Specifically ATF3 and p58 limit ER stress
responses by inhibiting ATF4dependent gene transcription and the phosphorylation of EIF2a by
EIF2aK3 respectively Conversely ATF4 promotes GADD153 transcription and GADD153 is
pro cytotoxic Additional support for GADD153 as the ultimate mediator of cytotoxicity was
obtained by treating A549 cells that stably over expressed the GADD153L134A41
dominant negative mutant Matsumoto et al 1996 Overexpression of GADD153
L134A41 markedly reduced cytotoxicity caused by nonivamide Figure 6A Data in
Figures 5 and 6 imply that GADD 153 was the primary cause of cytotoxicity in lung cells treated
with TRPV 1 agonists
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any other cells tested, and as non-toxic at concentrations equal to or in 2-fold excess of 
i a ide (Figures  a  , a le ). ese ata s rt r c cl si  t at l 
activation pro otes cytotoxicity via activation f I 2a 3, phosphorylation f I 2a, and 
expression of I53. 
o s st ti t  the r le f 1  i  ll t ,  l  t is e  tr si tl  
transfected 549 cells ith the expression construct. Perfor ing transient transfection studies in 
the E S-2B and E cells ere ha pered by variable transfection efficiency and high levels 
of toxicity due to transfection reagents. s such, e used 549 cells as the odel for these 
experi ents. e have previously sho n that 549 cells respond to P l-agonists si ilar to 
S-2B cells (Reilly et aI., 2003). ells transfected ith 153 exhibited reduced 
viability due to loss of cells fro  the culture ells (Figure 5  and ). ytotoxicity and cell loss 
relati e t  c tr ls ere t ser e  it  I53-L134A1L 41A, 3, r 58 IPK, t 
t icit  as ser e  it  . ese res lts ere c siste t it  t e esta lis e  r les f 
these proteins (Schroder and auf an, 2005). Specifically, TF3 and p58 IPK li it ER stress 
responses by inhibiting ATF4-dependent gene transcription and the phosphorylation ofEIF2a by 
I 2a 3, respectively. onversely, 4 pro otes 153 transcription, and 153 is 
pro-cytotoxic. Additional support for GADD153 as the ultimate mediator of cytotoxicity was 
obtained by treating 549 cells that stably over-expressed the I53-L134A1L141A 
do inant negative utant (Matsu oto et aI., 1996). ver-expression of I53-
134A1L141A r l  r  t t i it  s   i i  (Figur  A). t  i  
Figures 5 and 6 i ply that  153 as the pri ary cause of cytotoxicity in lung cells treated 
ith P l agonists. 
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The effects of modifying the EIF2aK3EIF2a signaling were also evaluated Two
approaches were used stable over expression of the EIF2aS52A dominant negative mutant in
A549 cells Srivastava et al 1998 and pharmacological stabilization of EIF2aP in BEAS2B
and TRPV 1overexpressing cells using salubrinal Boyce et al 2005 Interestingly squelching
of EIF2a phosphorylation Figure 6A and inhibition of EIF2a dephosphorylation Figure 6B
protected cells from toxicity Initially these data seemed contradictory but literature supports a
dual role for EIF2aP in regulating cell survival and death during ER stress Thus the results in
Figures 6A and B highlight this dual effect of the EIF2aK3EIF2a pathway However the
molecular basis for these antithetical responses remains enigmatic
We also investigated whether ER stress represented a common mechanism of
cytotoxicity for structurally diverse TRPV 1 agonists Table 2 shows that transcriptional
activation of GADD153 occurred in BEAS213 A549 NHBE and TRPV1overexpressing cells
treated with LD50 concentrations of nonivamide resiniferatoxin and anandamide As predicted
TRPV1 agonists failed to induce GADD153 expression in the TRPV1null HEK293 cell line
Table 2 Similarly nbenzylnonanamide failed to elicit GADD153 expression confirming the
direct link between TRPV1 activation GADD153 expression and cell death This conclusion
was also supported by the inhibition of GADD153 expression by LJO328 and 5 iodoRTX
Table 2 The inability of 5 iodoRTX to completely inhibit GADD153 expression in the
BEAS213 cell line was consistent with our previous findings that 5iodoRTX like capsazepine
causes cytotoxicity at elevated concentrations Reilly et al 2003 Reilly et al 2005
Collectively the results presented by this study support the following mechanism of
cytotoxicity for TRPV1agonists in lung and possibly other cells First activation of
intracellular TRPV 1 leads to a decrease in ER calcium content an accumulation of
19
001158
# 194l2 
he effects f odifying the I /EIF  signaling ere also evaluated. o 
approaches ere used: stable over-expression of the IF2a-SS2  do inant negative utant in 
549 cells (Srivastava et aI., 1998) and phar acological stabilization of IF2a-P in S-2  
and T P  l-overexpressing cells using salubrinal (Boyce et aI., 2005). Interestingly, squelching 
of IF2a phosphorylation (Figure 6 ) and inhibition of IF2a dephosphorylation (Figure 6 ) 
protected cells from toxicity. Initially, these data seemed contradictory, but literature supports a 
al r le f r I a-P i  re lati  cell s r i al a  eat  ri   stress. s, t e res lts i  
Figures 6  and  highlight this dual effect of the IF2a 3/EIF2a path ay. o ever, the 
olecular basis for these antithetical responses re ains enig atic. 
e also investigated hether E  stress represented a co on echanis  of 
cytotoxicity for structurally diverse P l agonists. able 2 sho s that transcriptional 
acti ati  f  cc rre  i  -2B, 9, , a  V1- ere ressi  cells 
tr t  it   tr ti s f i i , r si if r toxi ,  nda i . s r i t , 
TRP l agonists failed to induce GADD153 expression in the TRPV1-null HEK293 cell line 
(Table 2). Si ilarly n-benzylnonana ide failed to elicit 153 expression confir ing the 
direct link between TRPVl activation, GADD153 expression, and cell death. This conclusion 
as also supported by the inhibition of 153 expression by LJ -328 and 5-iodo-RT  
(Table 2). The inability of 5-iodo-RTX to completely inhibit GADD153 expression in the 
S-2B cell line as consistent ith our previous findings that 5-iodo-R  (like capsazepine) 
causes cytotoxicity at elevated concentrations (Reilly et aI., 2003; eilly et aI., 2005). 
Collectively, the results presented by this study support the following mechanism of 
cytotoxicity for V1-agonists in lung (and possibly other) cells. irst, activation of 
 l    reas    l i  t nt,  l   
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unfoldedpartially folded proteins in the ER lumen and an overall decrease in protein processing
efficiency As a result EIF2aK3 is activated resulting in the phosphorylation of EIF2a and an
increase in the expression of ATF4 GADD153 and other ER stress related genes Ultimately
increased transcription and expression of GADD 153 causes cell death
The translational facets of the results presented in this study are twofold First the near
uniform response elicited by structurally diverse TRPV1 agonists in all four lung cell types
suggests that this mechanism of toxicity is applicable to many other TRPV1 agonists
Specifically environmental TRPV1 agonists that promote lung inflammation and injuryeg
particle pollutants and endogenous TRPV1 agonists eg leukotrienes HzS etc that are
produced during inflammation or infection may also cause lung cell death and tissue damage via
the EIF2xK3dependent ER stress pathway As such future clinical research targeting TRPV1
andor theEIF2aK3dependent ER stress pathways may prove beneficial in the treatment andor
prevention diverse respiratory maladies Second our results indicate that the effects of a TRPV1
ligand on a cell will depend upon both the relative sub cellular distribution of TRPV1 and the
relative permeability of the ligand Hence it must be stressed that the sub cellular location of
TRPVI should be established and multiple TRPV1 agonists and antagonists preferably not
capsazepine should be utilized in future research studies evaluating the role of TRPV1 in
specific biological outcomes Although we have not specifically tested whether cell
impermeable agonists of TRPV1 eg pH or environmental particle pollutants exhibit different
mechanisms of cytotoxicity evidence supports this hypothesis Specifically inhibition of the
cell surface TRPV1 in lung cells has no effect on cytotoxicity by TRPV1 agonists despite
inhibition of pro inflammatory cytokine synthesis Reilly et al 2005 and sensory neurons
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unfolded/partially folded proteins in the E  lu en, and an overall decrease in protein processing 
ffi i y. s  r sult, I  is ti t  r s lti  i  t  s r l ti  f I    
increase in the expression of ATF4, GADD153, and other ER stress-related genes. Ulti ately, 
increased transcription and expression of  153 causes cell death. 
The translational facets of the results presented in this study are t o-fold. First, the near 
unifor  response elicited by structurally diverse l agonists in all four lung cell types 
s ests t at t is ec a is  f t icit  is a lica le t  a  t er l a ists. 
pecifically, environ ental l agonists that pro ote lung infla ation and injury (e.g., 
particle pollutants) and endogenous l agonists (e.g., leukotrienes, 2 , etc.) that are 
produced during infla ation or infection ay also cause lung cell death and tissue da age via 
the IF2aK3-dependent  stress path ay. s such, future clinical research targeting l 
a /or t e IF2aK3-dependent  stress at a s a  r e e eficial i  t e treat e t a /or 
prevention diverse respiratory aladies. Second, our results indicate that the effects of a P l 
ligand on a cell ill depend upon both the relative sub-cellular distribution of l and the 
relative per eability of the ligand. ence, it ust be stressed that the sub-cellular location of 
l should be established and ultiple l agonists and antagonists (preferably not 
capsazepine) should be utilized in future research studies evaluating the role of TRPVl in 
specific biological outco es. lthough e have not specifically tested hether cell-
i per eable agonists of TRP l (e.g. p  or environ ental particle pollutants) exhibit different 
echanis s of cytotoxicity, evidence supports this hypothesis. Specifically, inhibition of the 
cell surface T P l in lung cells has no effect on cytotoxicity by T P l agonists, despite 
inhibition of pro-infla atory cytokine synthesis (Reilly et aI., 2005), and sensory neurons, 
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which primarily express TRPV 1 on the cell surface are protected against cytotoxicity by
inhibiting cellular influx of calcium Wood et al 1988
Overall these results provide novel insights into mechanisms by which diverse
exogenous and endogenous TRPV1 agonists affect lung cell physiology These findings provide
fundamental knowledge that will facilitate future basic science and clinical research on TRPV 1
in an array of physiological and pharmacological models including models of acute lung injury
and inflammatory lung injury
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hich pri arily express P 1 on the cell surface, are protected against cytotoxicity by 
i i itin  ll lar i fl   l i  (Wood t I., 88). 
verall, these results provide novel insights into echanis s by hich diverse 
exogenous and endogenous P 1 agonists affect lung cell physiology. hese findings provide 
funda ental kno ledge that ill facilitate future basic science and clinical research on 1 
in an array of physiological and phar acological odels, including odels of acute lung injury 
a  i fla at ry l  i j r . 
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Legends for Figures
Figure 1 Chemical structures for the TRPV 1 agonists and antagonists used in this study
Figure Z Relationship between calcium flux panel A and cell death panel B in TRPV1
overexpressing cells Cells were assayed for calcium flux and cell death as described under the
materials and methods section In panel A the treatments were nonivamide 25 gM nonivamide
EGTA and ruthenium red 50250 gM nonivamide following 5 minute pretreatment with
25 gM thapsigargin 25 gM nbenzylnonanamide and nonivamide20 gM LJO328 Identical
treatments were used in panel B with the exception that ruthenium red and EGTAwere used
separately Represents statistical significance paired ttest p025 n3
Figure 3 Modulation of ER stress response gene expression in BEAS213 cells treated with
nonivamide panel A and prototypical ER stress inducing agents panel B All treatments were
performed for 4h at 37C in 6well plates using LHC9 as the vehicle Panel A BEAS213 cells
treated with fresh media Ct 100 gM nonivamide N nonivamide and 30 gM LJO328 NL
or nonivamide and EGTA 50 gM and ruthenium red 250 gM NER Total RNA was
extracted for analysis of gene expression as described in the materials and methods section
Images showing changes in the expression of GADD153 GADD45u ATF3 CCND1 CCNG2
and BiPGRP78 as well as quantitative results for changes in gene expression bar graph are
shown All data are normalized to 3actin the smaller PCR product shown for each image panel
White bars represent untreated control cells light grey bars represent cells treated with 100 gM
nonivamide for 4h at 37C medium grey bars represent cells treated with nonivamide and 20 gM
LJO328 and black bars represent cells treated with nonivamide and EGTAruthenium red
all
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egends for igures: 
Figure 1: he ical structures for the T P 1 agonists and antagonists used in this study. 
igure 2: elationship bet een calciu  flux (panel ) and cell death (panel ) in P 1-
ere ressi  cells. ells ere assa e  f r calci  fl  a  cell eath, as escri e  er t e 
aterials a  et ds secti . I  a el  t e treat e ts ere i a ide .5 Il , i a ide 
+  a  r t e i  re  (50+250 Il ), i a ide f ll i   i te re-treat e t it  
.5 Il  i argi , .5 Il  - l namide,  de+20 Il  -3 .  
treat ents ere used in panel  ith the exception that rutheniu  red and E T  ere used 
separately. *Represents statistical significance (paired t-test, p<0.025, n=3). 
Figure 3: odulation of ER stress response gene expression in BEAS-2B cells treated with 
noniva ide (panel ) and prototypical  stress-inducing agents (panel ). ll treat ents ere 
rf r  f r  t °C i  -well lates si  -9 s t  i l . l : -2B lls 
treated ith fresh edia (Ct), 100 Il  noniva ide (N), noniva ide and 30 Il  LJ -328 (NL), 
or noniva ide and EGTA (50 Il ) and rutheniu  red (250 Il ) (NER). Total RNA was 
extracted for analysis of gene expression, as described in the aterials and ethods section. 
I ages showing changes in the expression of GADD153, GADD45a, ATF3, CCND1, CCNG2, 
and i /GR 78, as ell as quantitative results for changes in gene expression (bar graph) are 
shown. All data are normalized to ~-actin, the smaller PCR product shown for each image panel. 
hite bars represent untreated control cells, light grey bars represent cells treated with 100 Il  
noniva ide for 4h at 37°C, ediu  grey bars represent cells treated ith noniva ide and 20 Il  
J -3 , a  lac  ars re rese t cells treate  it  i a ide a  +rutheniu  re  
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50250 gM Panel B BEAS213 cells were treated with fresh media Ct thapsigargin 25
M DTT 1 mM or H202 1 mM processed and assayed by RTPCR as described for panel
A White bars represent untreated cells light grey bars represent cells treated with thapsigargin
medium grey bars represent cells treated with DTT and black bars represent cells treated with
H202 Represents significant changes in expression relative to control cells and represents
statistically significant changes relative to nonivamide treatment ANOVA 95 confidence
interval n3
Figure 4 Concentration and time dependent changes in GADD153 expression EIF2oc
phosphorylation and cell viability in BEAS2B cells Panel A Western blot analysis showing
the time and dose dependent changes in GADD153 expression and EIF2oc phosphorylation in
BEAS213 cells treated with 100 M nonivamide N1 200 gM nonivamide N2 100 gM
nonivamide plus 30 M LJO328 NIL or 100 gM nonivamide plus 50 gM EGTA and 250 M
ruthenium red N1ER Panel B Dose response relationship between cell death and GADD153
induction Dose response cytotoxicity curve for nonivamide in BEAS2B cells solid circles
solid line and induction of GADD153 open circles dashed line right axis Panel C Time
dependent loss of cell viability and increased expression of GADD153 mRNA BEAS2B cells
solid squares cell viability open squares GADD153 expression were treated with 100 gM
nonivamide All data are relative to control cells treated in an identical manner using media only
n3
Figure 5 Panel A Viability of A549 cells transiently transfected with ER stress induced
genes Cells were sub cultured into 48well plates and transfected for 18h with mammalian
31
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(50+250 ,.1 ). anel : -2B cells ere treated ith fresh edia (Ct). thapsigargin (2.5 
llM). I (1 ) or 2 2 (1 M). processed. and assayed by -P , as described for panel 
. hite bars represent untreated cells. light grey bars represent cells treated ith thapsigargin. 
e i  re  ars re rese t cells treate  it  . a  lac  ars re rese t cells treate  it  
20 2. *Represents significant changes in expression relative to control cells and # re rese ts 
st tisti ll  si ifica t es r l ti  t  i i e tr t t (A  , 5% fide ce 
i t r l. =3). 
Figure 4: Concentration- and ti e-dependent changes in Dl53 expression. EIF2a 
horyl ti .  ll i ilit  i  -2B ll . l : e t r  l t l i  i  
the ti e- and dose-dependent changes in l53 expression and EIF2a phosphorylation in 
S-2B cells treate  it   llM i a ide (Nl).  ll  i a i e (N ).  ll  
noniva ide plus 30 llM J -328 (NIL). or 100 ll  noniva ide plus 50 ll   and 250 llM 
rutheniu  red (NI R). anel : ose-response relationship bet een cell death and 153 
induction. ose-response cytotoxicity curve for noniva ide in BE S-2B cells (solid circles. 
solid line) and induction of GADD153 (open circles. dashed line. right axis). Panel C: Time-
e e e t l ss f cell ia ilit  a  i crease  e ressi  f  . -2  cells 
(solid squares = ll i bility;  s r s = 153 expression) ere treated ith 100 ll  
i a i e. ll ata are relati e t  c tr l cells treate  i  a  i e tical a er si  e ia l  
(n=3). 
Figure 5: Panel A: Viability of A549 cells transiently transfected with ER stress -induced 
genes. Cells ere sub-cultured into 48-well plates and transfected for 18h ith a alian 
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expression plasmids harboring cDNA for EGFP GADD153 ATF3 ATF4 and p58
Following a 24h recovery period cell viability was determined Represents a statistically
significant decrease in viability 95 confidence interval by ANOVA n3 Panel B Bright
field and fluorescence micrographs of A549 cells cotransfected with ATF3 EGFP and
GADD153EGFP 10 target gene plasmidMaxGFP LightBright field image
GFPfluorescence image using a filter set to image GFP expression EtBr fluorescence image
using a filter set to visualize propidium iodide or ethidium bromide stained cell nuclei
Following transfection and a 24h recovery period cells were sequentially imaged to assess the
survival of GFP transfected cells and deaddamaged cells EtBr resulting from transfection of
either ATF3 control or GADD153 A total of 25 ng plasmid DNA was used for each
transfection Represents statistical significance paired t tests p025 n3
Figure 6 Panel A Dose response cytotoxicity curves for A549 open triangles and stably
over expressing cell lines harboring the dominant negative EIF2aS52A open squares and
GADD153L134A41 open circles genes Panel B Inhibition of cell death in BEAS213
and TRPV1overexpressing cells using salubrinal Cells were treated with nonivamide 1 gM
TRPV1overexpressing cells or 100 M BEAS2B cells in the presence and absence of
salubrinal for 24h at 37 in LHC9 media CirclesTRPV1overexpressing cells and
triangles BEAS2B cells treated with nonivamide and increasing concentrations of salubrinal
Data representing changes in viability due to treatment of BEAS2B and TRPV1overexpressing
cells with salubrinal only are represented as squares and dots respectively Cell viability was
determined as described in the materials and methods section Data n6 are relative to
untreated controls
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expression plasmids harboring cDNA for EGFP, GADDI53, ATF3, ATF4, and p58JPK• 
ollo ing a 24h recovery period, cell viability as deter ined. * res ts  ti ti l  
significant decrease in viability (95% confidence interval by ) (n=3). anel : right 
field a  fluoresce ce icrographs f  cells c -tra sfecte  it   + EGFP a  
DI +EGFP (1 :1 t r et  lasmid:pMax-G P). i ht= ri t fi l  i , 
FP=fluorescence i age using a filter set to i age FP expression, t r=fluorescence i age 
using a filter set to visualize propidiu  iodide- or ethidiu  bro ide stained cell nuclei. 
llo ing tr f ti     r r  ri d, lls r  ti ll  i  t   t  
survival of FP-transfected cells and dead/da aged cells (Et r+) resulting fro  transfection of 
ther  (-control) or I53.  total of 25 ng plas id  as used for each 
transfection. *Represents statistical significance (paired t-tests, p<0.025, n=3) 
igure : anel : ose-response cytotoxicity curves for 549 (open triangles), and stably 
over-expressing cell lines harboring the do inant negative IF2a-S52  (open squares) and 
I53- 134A1L141A (ope  circles) e es. a el : I i iti  f cell eat  i  -2B 
and TRPV l-overexpressing cells using salubrinal. Cells were treated with nonivamide 111M 
(TRP 1-overexpressing cells) or 100 11M (BE S-2B cells) in the presence and absence of 
salubrinal for 24h at 37°C in L -9 edia. ircles= T PV1-overexpressing cells and 
triangles= S-2  cells treated ith noniva ide and increasing concentrations of salubrinal. 
ata representing changes in viability due to treat ent of E S-2  and T PV1-overexpressing 
cells ith salubrinal only are represented as squares and dots, respectively. ell viability as 
        cti n.  (n=6)  l t   
 . 
 
JPET 119412
Table 1 Primer Sequences used for RTPCR analysis of selected ER stress responsive genes
Gene Name PCR
UniGene ID Product Size nt Primer Sequence
GADD153 395 5GACCTGCAAGAGGTCCTGTC
Hs 505777 5TCGCCTCTACTTCCCTGGTC
GADD45a 258 5TCTCGGCTGGAGAGCAGAAG
Hs 80409 5 CGCGCAGGATGTTGATGTCG
GRP78BiP 296 5CGTGGAATGACCCGTCTGTG
Hs 605502 5CTGCCGTAGGCTCGTTGATG
CCND1 480 5AGTGCGAGGAGGAGGTCTTC
Hs 523852 5AGCGTGTGAGGCGGTAGTAG
CCNG2 744 5 AGGGCTGAGTTTGATTGAGG
Hs 13291 5 TAGCTGTTGTGGAGGTTCTG
ATF3 302 5 CTCGGAAGTGAGTGCTTCTG
Hs 460 5 CCGTCTTCTCCTTCTTCTTG
RActin 183 5GACAACGGCTCCGGCATGTGGCA
Hs 520640 5TGAGGATGCCTCTCTTGCTCTG
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Table 2: Induction of GADD153 expression by multiple TRPV1 agonists and inhibition by antagonists in various cell lines. 
GADD153 Induction (Fold Control) 
Treatment (4h) TRPVI-OE# BEAS-2B NHBE A549 HEK-293 
Nonivamide 1 /lM 8.1 ± 0.8* - - - -
Nonivamide 100 /lM - 7.9 ± 0.5* 6.0 ± 0.4* 5.5 ± 0.3* 0.88 ± 0.07 
Nonivamide 200 uM - - - - 1.19±0.06 
Resiniferatoxin O.Ol/lM 7.9 ± 0.8* - - - -
Resiniferatoxin 7.5 "..1M - 6.4 ± 0.8* 6.3 ± 0.3* 4.8 + 0.4* 0.77 + 0.08 
Anandamide 12.5 /lM 7.4 ± 0.6* - - -
Anandamide 25 uM - 6.9 ± 0.5* - 3.3 + 0.2* -
n-Benzylnonanamide l/lM 1.3 ± 0.2 - - -
n-Benzylnonanamide 100/lM - 2.2 ± 0.3 2.6 ± 0.2* 0.65 ± 0.07 0.78 ± 0.04 
Capsaicin I/lM + 5-I-RTX l/lM 0.6 ± 0.4 - - - -
Capsaicin 100UM + 5-I-RTX 30/lM - 10.4 ± 0.9* 4.2 ± 0.4* - -
Capsaicin I/lM + LJO-328 20 /lM 1.34 ± 0.03 - - - -
Capsaicin 100UM + LJO-328 50 /lM - 1.4 ± 0.2 1.0 ± 0.1 0.75 ± 0.09 0.84 ± 0.07 
TRPVl over-expressing cells. *Statistically significant increase relative to control (t-test, p<0.05, n=3). 
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Figure 3A and B 
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Figure 4A-C A. 
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Figure 6A and B 
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Keywords The transient potential receptor vanilloid 1 TRPV1 receptor is a non selective cation channel that is
TRPVI chemically activated by capsaicin the pungent component of hot peppers In addition endogenous
Sensory nerves compounds in particular the endogenous cannabinoid receptor activator anandamide have been
Pain
demonstrated to activate TRPVI in vivo TRPV1 receptors are also activated by temperatures within the
Inflammation
Neuropeptides
noxious range 43C and low pH pH 60TRPV1 receptors are predominantly expressed in primary
afferent fibreswhich are peptidergic sensory neurones such as the thinly myelinated A fi and unmyelinated
Cfibres TRPVI receptors have also been demonstrated to be present in non neuronal cells Historically
TRPVI has been considered as a pro inflammatory receptor due to its key role in several conditions
including neumpathic pain joint inflammation and inflammatory bowel disease amongst others However
the purpose of this review is to underline the emerging new evidence which demonstrate paradoxical
protective functions for this unique receptor in vivo For example in experimentally induced sepsis TRPVI
null mice demonstrated elevated levels of pathological markers in comparison to wild typemice In addition
to the pro inflammatory and protective roles of TRPVI in pathophysiological states TRPVI has also been
shown to have important functions under normal physiological conditions for example in urinary bladder
function thermoregulation and neurogenesis The emerging functions of TRPVI highlight the necessity for
further research in light of increasing reports of potential TRPVI antagonists undergoing pre clinical
experimentations
2009 Elsevier Inc All rights reserved
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The transient receptor potential vanilloid I TRPVI receptor is a
non selective cation channel which belongs to the TRP family of ion
channels Starowicz et al 2007 This TRP family now includes more
than 30 cation channels the majority of which are permeable for
divalent and monovalent cations including Ca Na and Mg2
Pedersen et al 2005 These ion channels mediate the receptor
induced response of a cell to external transient stimuli such as
temperature light mechanical and osmotic pressures These stimuli
act to increase or decrease the selective permeability ofTRP channels
to specific ions subsequently altering the cell membrane potential
and leading to depolarisation Piper et al 1999
Traditionally TRPVI has been considered as a pathological
receptor it has a significant role in the pain transduction pathway
and has awell defined pro inflammatory role in avariety ofdisease and
injury states For example mice genetically modified to lack the TRPVI
receptor demonstrated an increased threshold to noxious heat a
reduction in pathological biomarkers egcytokines and decreased
tissue swelling in a model ofmurine joint inflammation Caterina etal
2000 Keeble et al 2005 However recent studies are challenging this
pro inflammatory deleterious role of TRPVI in disease and are
presenting a new insight into a paradoxical protective role for TRPVI
in certain disease states Banvolgyi et al 2005 For example there is
increasing evidence of a protective role for this receptor in organ
systems such as the cardiovascular system and thegastrointestinal tract
amongst others Birder etal 2001 WangandWang 2005 In addition
toprotective roles forTRPVI in disease theTRPVI receptor also appears
to play an important part in normal physiological functions such as
urinary bladder function Birder et al 2002 thermoregulation Gavva
etal 2007x and neurogenesis Jinet al 2004 It now seems essential
that the paradox surrounding the role of TRPVI in different diseases and
physiological states is elucidated in order to determine the future of this
receptor as a therapeutic target for anti inflammatory drugs
The purpose of this review is firstly to review the history of TRPVI
and extensive literature showing that TRPVI plays a deleterious role
in disease However the emerging evidence of protective and
physiological roles for TRPVI will then be examined which puts this
receptor into a novel perspective Indeed just as we thought that the
role ofTRPV1 was established it would appear that westill have far to
go before we completely understand this intriguing receptor
1 Transient Receptor Potential receptors background
TRP receptors ion channels are named after the role of these
proteins in the Drosophila photo transduction mutant which shows a
transient instead of a sustained response to bright light Montell
2005 On the basis of amino acid sequence homology the TRP
superfamily can be divided into seven subfamilies the TRPC
Canonical family the TRPM Melastatin family the TRPV
vanilloid family the TRPP Polycystin family the TRPML
Mucolipin family the TRPA Ankyrin family and the TRPN
NOMPC family Pedersen et al 2005 TRP receptors show broad
tissue distribution and may participate in divergent functions such as
visual and auditory functions speech pain signal transduction
regulation of blood circulation gut motility mineral absorption and
fluid balance airway and bladder hypersensitivities cell survival
growth and death Inoue et al 2006 Such wide functional diversity
ofTRP receptors seems toarise in addition to the multiplicity of their
activation mechanisms from the complex regulation of transcription
and splicing Clapham 2003 Monte 2005 Pedersen et al 2005
12The Transient Receptor Potential Vanilloid receptor subfamily
The TRPV subfamily contains six mammalian receptors TRPVI
TRPV6 in addition to two receptors in non mammals the Osm9
C elegans and Nanchung Nan from Drosophila Kim etal 2003 It
should be noted that only TRPVI from the TRPV subfamily is activated by
vanilloids such as capsaicin hence theVanilloid subtype term From the
TRPV subfamily TRPVITRPV4 are heat activated receptors that are
non selective for cations including Ca2 Chung etal 2005 Clapham
2003 Additionally TRPVI TRPV4 function as polymodal chemo
sensors fora broad rangeofendogenous and synthetic ligands discussed
later in detail with respect to TRPV1 McNamara etal 2005 Moqrich et
al2005 Nilius et al2004The last twomembers ofthe TRPV subfamily
TRPV5 andTRPV6 have different properties from those of TRPV1 TRPV4
Nilius et al 2000 Nilius et al 2001 Vennekens et al 2000 They are
highly Ca selective channels unlike the other members and are both
firmly regulated by Ca iThese properties allow TRPV5 and TPRV6 to
play an important role as regulators in epithelial Ca transport and also
as selective Ca entry pathways in non excitable cells Van Abel et al
2005 Contrary to the TRPVITRPV4 channels TRPV5 and TRPV6 have
relatively low temperature sensitivity Nilius etal 2001
2The Transient Receptor Potential
Vanilloid 1 receptor history and overview
Formerly known as the vanilloid receptor type 1 VRI Caterina
et al 1997 the TRPVI receptor is unique in that it is activated by
capsaicin the main pungent principle of hot chilli peppers capsicum
spp Morita et al 2006 The excitatory and neurotoxic properties of
capsaicin were used to define and study nociceptive neurones
Electrophysiological and biochemical studies demonstrated that capsa
icin excites sensory neurones by increasing the plasma permeability of
the plasma membrane to cations However the molecular mechanisms
underlying this action were unclear Bevan Szolcsanyi 1990
Prior to the critical study by Caterina et al 1997 which determined
and molecularly identified the capsaicinVRVreceptor in the rat much
was unknown of the molecular structure of the receptor However the
hypothesis of a capsaicin receptor existing in the plasma membrane ofa
subgroup of sensory neurones which detect noxious chemical
mechanical and thermal stimuli was raised over thirty years ago
Szolcsanyi Jancs6 Gabor 1975Over half a century ago the exciting
pharmacology of capsaicin was the focus of attention of the Hungarian
pharmacologist Jancs6 who demonstrated that capsaicin acts exclu
sively on nociceptive afferent neurones Jancso 1960 Holzer 2008
Further extensive research followed which provided dramatic results
demonstrating the selectivity ofcapsaicin effects on afferent neurones
which indicated the presence ofa specific capsaicin receptor Szolcsanyi
Jancs6Gabor 1975 Subsequent studies followed providing further
critical evidence supporting the theory of a capsaicin receptor and
specific vanilloid binding sites were determined Szallasi Blumberg
1999 Previously in 1992 Bevan and colleagues presented the first
competitive capsaicin antagonist capsazepine The latter study dem
onstrated the ability of capsazepine to reversibly reduce the current
response to capsaicin in dorsal root ganglion DRG neurones from rats
while the current responses to control compounds were not affected by
capsazepine Bevan et al 1992 Thus these studies provided critical
steps towards precise identification of the vanilloid receptor
Therefore when the VR1 receptor was first cloned and demon
strated to be a non selective cation channel activated by capsaicin and
also by increasing temperatures within the noxious range Caterina
et al 1997 it laid the foundation for further discoveries and
knowledge regarding this receptor In 2000 Hayes et al cloned and
identified TRPVI in humans and shortly after that in 2002 Savidge
et al identified TRPVI in guineapigs
21Transient Receptor Potential
Vanilloid I molecular structure and functions
TRPVI is a non specific cation channel with relatively modest Ca
permeability Piper et al 1999 It is a single polypeptide of 838 amino
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(,NO P ) fa ily (Pedersen et aI., 2005). TRP receptors sho  broad 
tissue distribution and ay participate in divergent functions such as 
is al a  a it r  f cti s, s eech, ai  si al tra sduction, 
regulation of blood circulation, gut motility, mineral absorption and 
l i  l , i   l  ensitiviti , ll urvival, 
gro th and death (Inoue et aI., 2006). Such ide functional diversity 
of  receptors see s to arise, in addition to the ultiplicity of their 
activation mechanisms, from the complex regulation of transcription 
a  s lici  (Clapha , 03; ontell, 05; e erse  et al.. 005). 
1.2. The Transient Receptor Potential Vanilloid receptor subfamily 
  f il  t ins i  lia  r t rs (TR 1-
T PV6) , in addition to t o receptors in non- a als; the s -9 
(C s)  a  (Na ) ro  ros  (Kim  I., 03).  
  ted that  l ro  the P   s ate   
ill i ,   i i , e the 'Vanilloid' t pe t r . r  t e 
 s f mily, 1-TRP 4 r  t- ti t  r tors t at r  
- ive  , including ( + (Chung  I., ; . 
03). iti ally, 1-TRP  ti   l l o-
  a    s   igands (discu se  
  l ith es t  ; a ara  I., ;   
I., ; ilius t I., 04). e   ers  t   family, 
  TR , a e iffere t r rtie  fr  t se f 1-TRP  
(Nilius  I., ; lius  l.. ; e e ens  I., 00).   
i l  a2 I- l ti e l , li  the t  ,  e t  
fir ly regulated by [Ca2 I- ]i. hese properties allo  P 5 and P 6 to 
  i portant le  rs  ial 2 + t   
 e a2 +  a s  -  ls (Van bel  I., 
05). tr r  t  t e 1-TRP  l ,     
   iti  ( lius  I., 0 I). 
. e a s e   t  
  e  -    
r rl    t  ' ill i ' r t r t e  (V 1; t ri a 
t aI., 997), t e l rece t r is i ue i  t t it is acti ate   
aici , t  i  t ri i l   t illi ers (ca i  
p.; ta  l.. 06).     e   
capsaicin ere used to define and study nociceptive neurones. 
   ies t   a-
 tes  rones     r abili   
t e la  rane t  ti . r, t  l l  i  
underlying this action ere unclear (Bevan & Szolcsanyi, 1990). 
   l t     l. (19 )  e  
and olecularly identified the capsaicin ' R1' receptor in the rat, uch 
s n    t    t r. r,  
            
s r p f r  r es i  t t i s e ical, 
  l ti li  s      
(Szolcsanyi & jancso-Cabor. 1975). ver half a century ago, the exciting 
ar ac l  f ca saici  as t e f c s f atte ti  f t e aria  
r l ist j so,  tr t  t t saicin, t  xclu-
sively on nociceptive afferent neurones (Jancso. 1960; olzer, 2008). 
t e       ti  l  
ng  l cti i   saicin's f     
hich indicated the presence of a specific capsaicin receptor (Szo!csanyi 
&jancso-Cabor, 975).   f ll ed,   
critical e i e ce s rti  t e t e r  f a ca saici  rece t r a  
s ecific a ill i  i i  sites ere eter i e  (Szallasi & l erg, 
999). r viously, i     ll  r t  t  fir t 
co petitive capsaicin antagonist, capsazepine. The latter study dem-
onstrated the ability of capsazepine to reversibly reduce the current 
r s s  t  s i i  i  rsal r t li  (O C) r es fr  r ts, 
      s     
i  (Be a  t I., 992). , t  t ie  r ide  riti l 
steps to ards precise identification of the vanilloid receptor. 
refore,   ' ' t   t   on-
t     -selecti  ti   ate   ai i   
als   i creasi  te erat res it i  t  i s ra e (Cateri a 
t I., 97), it l i  t  f ti  f r f rt r is ri s  
l  r i  t i  r ceptor.  00,  t l. l   
i ti  l    hortl   t, i  02, vi  
et al. identified PV1 in guinea-pigs. 
.1. r si t ece t r t ti l 
nilloid 1 - l l r str t r   f ti s 
TRPV1 is a non-specific cation channel with relatively modest Ca2+ 
per eability (Piper et aI., 1999). It is a single polypeptide of838 a ino 
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acids with a predicted molecular mass of 95 kD TRPV receptors have
large intracellular amino N and carboxy C terminal cytosolic
domains and six putative transmembrane TM segments with an
additional short hydrophobic stretch between TM5 and TM6 TRPVI
subunits are thought toassemble as tetramers Caterina et al 1997The
Nterminus 432 amino acids contains at least three ankyrin repeats
Tominaga Tominaga 2005 which are essential for channel function
Jung etal2002whilethe Cterminus 154 amino acids contains a TRP
domain Tominaga Tominaga 2005 consisting of 25 amino acids
Nakagawa Hiura2006 proposed toserve as amolecular determinant
of subunit tetramerization GarciaSanz etal 2004
The C terminuscontains amino acid residues essential for phospha
tidylinositol 45bisphosphate PIP binding Prescott Julius 2003
On the other hand protein kinase APKA and protein kinase C PKC
have been proposed to act on various sites in the Nterminal the C
terminal and the intracellular loop connecting TM2 and TM3 Bhave
et al 2002 Mohapatra Nau 2003 Tominaga Tominaga 2005
The predicted membrane topology ofTRPVI Fig 1 and the presence of
multiple Nterminal anlcyrin repeats are the characteristics that
distinguished the significant similarities between TRPVI and other
TRP channels particularly the TRP and TRPL from theDrosophila retinal
receptors in addition to amino acid sequence conservation between
TRPVI and other TRP receptors within and adjacent toTM5 and TM6
which contribute to the ion permeability path Caterina et al 1997
Tominaga et al 1998
TRPVI undergoes two types ofdesensitization upon activation by
capsaicin or protons acute desensitization and tachyphylaxis or loss
of sensitivity to repeated stimulations Koplas et al 1997 The
regulatory lipid PIP2 is a putative intracellular modulator of TRPV1
although there is some debate as to whether it sensitizes or
desensitizes the channel Mutations in a C terminal cytosolic region
ofTRPVI indicate an inhibitory role for PIP2 Prescott Julius 2003
However others have found that PIP sensitizes TRPVI and that
depletion leads to desensitization Liu et al 2005 Stein et al 2006
An increase in intracellular calcium concentration causes TRPVI
desensitization and calmodulin CaM a ubiquitous calciumsensor
may play a role in mediating this effect Nurnazaki et al 2003
Rosenbaum et al 2004 CaM interacts in vitro with isolated peptides
from the TRPVI Nterminal region in a Cadependent manner
Rosenbaum et al 2004 and also binds to the TRPVI C terminal
region in a Ca independent manner Numazaki et al 2003
2Expression of Transient Receptor Potential Vanilloid 1
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fibres Caterina et al 1997 These are characteristic peptide
containing sensory neurones mainly thinly myelinated A6 and
unmyelinated C fibres such as small diameter DRG and trigeminal
ganglion neurones In addition non neuronal cells have been
demonstrated to express TRPVI such as keratinocytes Southall et
al 2003 bladder urothelium Lazzeri et al 2004 smooth muscle
Birder et al 2001 liver Reilly et al 2003 polymorphonuclear
granulocytes Heiner et al 2003 pancreatic cells Akiba et al
2004 endothelial cells Golech et al 2004 lymphocytes Saunders
et al 2007 and macrophages Chen et al 2003 TRPVI has also
been found in the brain such as in dopaminergic neurones of the
substantia nigra hippocampal pyramidal neurones hypothalamic
neurones and neurones in the locus coeruleus in addition to various
layers of the cortex Mezey et al 2000
23Neurogenic inflammation
TRPVI expression on sensory nerves in particular C and AS
fibres is intrinsically associated with neurogenic inflammation
Neurogenic inflammation is defined as the oedema formation
increased blood flow and inflammatory cell recruitment observed
after stimulation of sensory nerves and release of neuropeptides
Fig2The neuropeptides that are released include substance P and
calcitonin gene related peptide CGRP amongst others Substance P
and CGRP cause plasma extravasation Lembeck Holzer 1979 and
increased blood flow Brain et al 1985 respectively in addition to
other effects on leukocyte accumulation Cao etal 2000 Costa et al
2006 and cell signalling Zhao et al 2002 On the whole their
effects have been considered to be largely pro inflammatory Table
1contributing to a variety of the pathophysiological states discussed
later in this review There is also evidence that the anti inflammatory
neuropeptide somatostatin SST is released under some circum
stances Helyes et al 2003 Pinter et al 2006 SST acts on sensory
nerve endings to inhibit not only its own release but that of other
neuropeptides In addition it inhibits the actions of pro inflammatory
neuropeptides and other inflammatory mediators at their effector
siteegvascular smooth muscle and mast cells Pinter et al 2006 It
is unclear what causes pro inflammatory versus anti inflammatory
neuropeptides to be released from sensory nerves but it is clear that it
Table 1
Summary of the paradoxical effects of TRPVI
Consistent with its role in pain and nociception TRPVI expression
has been confirmed in small to medium diameter primary afferent
Nociception and pro inflammatory effects
Diabetic painful neuropathy Rashid et al 2003 Kamei et al 2001 Hong and
Wang and Wang 2005
Wiley 2005
Peripheral neuropathic pain Hudson et al 2001 Kanai et al 2005
Cancer pain Ghilardi et al 2005
Rheumatoid arthritis Engler et al 2007
Osteoarthritis Fernihough et al 2005 Engler et al 2007
Chronic persistent cough Groneberg et al 2004
Faecal incontinence Chan et al2003
Oesophageal reflux disease
Physiological functions
Cystitis Charrua et al 2007 Wang et al 2008 Dints et al
Birder et al 2002 Daly et al 2007
2004
Protective effects
Ischaemia and reperfusion
injury
Hypertension Vaishnava Wang 2003 Wang and Wang 2006
Inflammatory bowel disease Massa et al2006 Sibaev et al 2006
Sepsis Clark et al 2007 Wang et al 2008 Helyes et al
2007
Allergic contact dermatitis Banvolgyi et al 2005
Obesity Zhang et al2007
Urinary bladder function
Thermoregulation Gavva et al2007a
Neurogenesis Jin et al 2004
Fig 1 Membrane topology of the TRPVI receptor showing significant domains
binding sites and phosphorylation sites C Ankyrin repeat domain C TRP domain
rPIP2 binding domain PKAPKC phosphorylation sites A CaM binding sites
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Proinflammatc
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Fig 2 A simplified diagram showing activation of TRPVI on sensory nerves leading to
release of neuropeptides It is unclear what causes pro inflammatory versus anti
inflammatory neuropeptides to be released but it may depend on the site of action and
the disease process involved
may contribute to the paradoxical role of the TRPV1 receptor under
pathophysiological conditions
24Transient Receptor Potential Vanilloid I pharmacology
241Exogenous agonists
TRPVI receptors are activated by diverse exogenous stimuli
including chemical activatorsagonists temperatures within the
noxious range 43 C Caterina et al 1997 and acid 60at room
temperature Jordt et al 2000 Activation of TRPVI by any of the
stimuli causes a rapid rise in Ca 7 Tominaga et al 1998
Chemical activators ofTRPV1 include capsaicin olvanil whichwas
the first synthetic capsaicin analogue and the exceedingly potent
capsaicin analogue plant toxin resiniferatoxin RTX Piper et al
1999These three ligands display structure activity relationship and
share a common structure of a group of acid amides ofvanillylamine
and fatty acids linked to a nonpolar side chain Morita etal 2006
Uniquely and perhaps only a property of capsaicin and related
vanilloid compounds application of capsaicin results in TRPV1
activation depolarisation of the membrane followed by rapid and
profound desensitization of the TRPVI receptor Caterina etal 1997
Physiologically TRPVI desensitization can lead to adaptation of
peripheral neurons to pain perception This desensitization caused
in part by the acute increase in intracellular Ca explains the
analgesic effect of capsaicin which is contrary to the acute pain and
neurogenic inflammation it results in Szallasi Blumberg 1999
24Endogenous agonists endovanilloids
The possibility of endogenous agonist acting at TRPVI in vivo
was raised whenTRPVI was demonstrated to be present in the central
nervous system and other organ systems Capsaicin the chemical
activator of TRPVI that enabled the determination of TRPVI
expression historically is not produced endogenously and so could
not account for activation in vivo In addition under normal
physiological conditions TRPVI is Unlikely to be activated by heat
or low pHTherefore the existence of endogenous agonists using this
receptor for inter or intracellular signalling was suggested and they
have been termedtheendovanilloids Di Marzo et al 2001 van der
Stelt Di Marzo 2004
The first endogenous activator of TRPVI was identified due to its
chemical similarity with capsaicin the endogenous cannabinoid
receptor ligand Narachidonoyl ethanolamine anandamide AEA
Zygmunt et al 1999 Smart et al 2000 Additionally the chemical
similarity between the potent Nacylvanillylamide agonist atTRPVI
receptors and theprototypic inhibitor of AEA cellular uptake AM404
marked the beginning of research correlating the endocannabinoid
and vanilloid signalling systems Di Marzo etal 1998 Thus AEA was
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Sensory nerve first identified and subsequently other derivatives of longchain
unsaturated fatty acids such as the N acyldopamines Chu et al
2003 Huang et al 2002 were demonstrated to act as endogenous
activators for TRPV1 van der Stelt Di Marzo 2004 Other
endogenous agonists of TRPVI were described by Hwang et al
2000 who reported that several products of lipoxygenases were
able to activate TRPVI receptors in isolated membrane patches of
sensory neurones Table 2 Of these lipoxygenase compounds 12
Shydroperoxyeicosatetraenoic acid15Shydroperoxyeicosate
traenoic acid and leukotriene B demonstrated the highest efficacy
Additionally TRPVI is either activated or sensitised by other
inflammatory mediators such as protons nerve growth factor NGF
Chuang et al 2001 bradykinin Chuang et al 2001 and adenosine
triphosphate Tominaga et al 2001 Tominaga Caterina 2004
243Antagonists
The analgesic potential of TRPVI antagonists was initially studied
using the first TRPVI antagonist capsazepine which is a reversible
competitive antagonist Bevan et al 1992
Although efficacious this compound is far from an ideal TRPVI
antagonist for various reasons for instance it has well documented
actions at a range of other channels including voltagegated Ca 21
channels Docherty et al 1997 and nicotinic acetylcholine receptors
Liu Simon 1997 Furthermore capsazepine has a poor pharma
cokinetic profile Lopez Rodriguez et al 2003 In recent years a
number of more selective TRPVI antagonists have appeared the first
ofwhich was iodo resiniferatoxin Wahl etal 2001 Although iodo
resiniferatoxin is a potent and selective inhibitor of TRPVI it has
limited utility in vivo Almasi et al 2003 Rigoni et al 2003 and has
recently been shown to have partial agonist actions at TRPVI in vitro
Shimizu et al 2005 SB366791 Gunthorpe etal 2004 in addition
to AMG9810 Gavva et al 2005 and A425619 El Kouhen et al
2005 amongst others are synthetic potent inhibitors of TRPVI
activation by heat acid and capsaicin A number of these have been
shown to possess efficacy in in vivo animal models of pain such as
capsaicin induced eye wiping capsaicin and Complete Freund
Adjuvant CFA induced hyperalgesia and in neuropathic pain
models including partial sciatic nerve injury and chronic constriction
injury Gavva etal 2005 Honore et al 2005 Kanai et al 2005Varga
etal 2005
Table 2
Exogenous and endogenous activators agonists of TRPV 1
Exogenous agonistsactivators
Temperature43 C Caterina et al 1997
Low pH acid 60 Jordt et al 2000
Capsaicin Caterina et al 1999
Vanilloidsegolvanil Brand et al 1987
Resiniferatoxin M Szallasi and Blumberg 1989
Endogenous agonistsactivators
Narachidonoyl ethanolamine Zygmunt et al 1999 Smart et al
anandamide AEA 2000
Nacyldopamines and other longchain Huang et al 2002 Chu et al 2003
unsaturated fatty acids
Lipoxygenases compounds
Leukotriene B Huang et al 2002
12Shydroperoxyeicosatetraenoic acid Hwang et al 2000
15Shydroperoxyeicosatetraenoic acid Hwang et al 2000
Inflammatory mediators
Prostaglandins Huang et al 2002
Protons Chuang et al 2001
Nerve growth factor NGF Chuang et al 2001
Bradykinin Chuang et al 2001
Adenosine triphosphate Tominaga et al2001 Tominaga
Caterina 2004
Somatostatin
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3 Pathophysiological functions
of Transient Receptor Potential Vanilloid 1
As mentioned previously the TRPV1 receptor has historically been
considered a proinflammatory receptor with adverse effects in various
disease states This concept was supported by studies in which TRPVI
receptors were impaired either genetically as in TRPVI knockout mice
Catering et al 2000 by means of RNA interference techniques
Christoph et al 2006 or following treatment with selective antago
nists Christoph etal 2007 From our knowledge of TRPV1 receptors it
has been suggested and indeed demonstrated that several pathological
conditions appear to be characterised by increased expression or
changes in the expressionand distribution ofTRPV1 This results in the
alteration of its normal physiological functioning contributing to the
pathophysiology of a specific condition The following section will
address the range of studies that support the view that TRPV1 causes
profound pro nociceptive and pro inflammatory effects
31Nociception andpro inflammatory
roles of Transient Receptor Potential Vanilloid I
31Nociception and associated pain conditions
The first process with which TRPV1 was strongly linked is that of
pain perception Szolcsanyi Jancso Gabor 1975 Painproducing
stimuli are detected by specific primary afferent nerve fibres namely
small unmyelinated polymodal nociceptive Cfibres and thinly
myelinated A6 sensory nerve fibres Holzer 1991 which cause a
dull nagging pain and sharp pricking pain respectively Capsaicin
and related molecules bind to TRPV1 receptors on the peripheral
terminals of nociceptive neurons Szolcsanyi Jancso Gabor 1975
with receptor occupancy resulting in cation influx action potential
firing and consequent pain sensation Szallasi Blumberg 1999
Concomitantly neuropeptides such as substance P and CGRP are
released from their peripheral endings and exert local neurogenic
inflammation Banvolgyi et al 2004 as discussed previously In
accordance with the proposed role of TRPV1 in the processing of
multiple pain producing stimuli Tominaga et al 1998 Tominaga
Julius 2000 it was first noted that TRPVI knockout mice exhibit an
impaired thermal and inflammatory nociception Caterina et al
2000 There are several diseases associated with pain in which a role
for TRPVI has been implicated as discussed in the following sections
31Painful diabetic neuropathy Painful diabetic neuropathy is one
of the most common complications in early to intermediate stages of
diabetes mellitus Hong Wiley 2005 Diabetic patients often
demonstrate one or more types of stimulusevoked pain including
increased responsiveness to noxious stimuli hyperalgesia in
addition to hyper responsiveness to normally innocuous stimuli
allodynia Similar to human diabetic neuropathy animal models
such as the streptozotocin STZinduced diabetic micerats exhibit
early functional and biochemical abnormalities including thermal
hyperalgesia and mechanical allodynia Hong et al 2004 Khan et al
2002 Rashid et al 2003 It has been reported that hyperactivity of
TRPVIexpressing Cfibres results in hyperalgesia and allodynia in
this model Kamei et al 2001 Rashid et al 2003
Hong and Wiley 2005 presented a study which employed STZ
induced diabetic rats to investigate the expression and function of the
TRPVI receptor The study reported that TRPVI protein levels were
down regulated while the function of TRPVI was increased in the
DRG neurones isolated from early diabetic rats The expression of
TRPV1 was decreased in DRG neurones from diabetic rats which is
consistent with the down regulation of total TRPVI proteins
Therefore it is possible that the down regulation ofTRPVI in C fibres
was due to a compensatory mechanism to reduce the observed
increased activity of TRPV1 receptors in painful diabetic neuropathy
as C fibres are the primary conveyers of pain in diabetes mellitus
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Hong Wiley 2005 Hong et al 2008 have more recently shown
that DRG neurons from diabetic rats exhibit increased levels of
oxidative stress in vitro an effect that is reduced by incubation ofcells
with theTRPVI antagonist capsazepine With regard to theA fibre
neurones the expression of TRPV1 was increased in large myelinated
mechanosensory Afibre neurones while control animals exhibited
low levels of TRPVI expression in this subpopulation of afferent
neurones Hong Wiley 2005 It is possible that this increased
TRPVI expression may act tomodulate transmission ofpain signals or
maintain the peripheral sensitisation in neuropathic states as
desensitization of nociceptors by RTX did not prevent the develop
ment of hyperalgesia in diabetic rats Khan et al 2002
Facer et al 2007 demonstrated a similar finding to the
aforementioned studies in human diabetic patients It was observed
that in diabetic patients skin samples the number of TRPV1
expressing fibres was decreased as was expression of TRPV1 in
surviving fibres In addition TRPVI was also decreased in non
diabetic neuropathic nerves as this study investigated a multitude of
neuropathic pain conditions including diabetic neuropathy Hence
early diabetic neuropathy is associated with enhanced function of
TRPVI in DRG neurones Hong Wiley 2005 which may result in
compensatory down regulation of TRPVI receptor expression
312Peripheral neuropathic pain Peripheral neuropathic pain most
often occurs as a result of peripheral nerve injury resulting in
symptoms such as hyperalgesia and allodynia Hudson et al 2001
The mechanisms underlying hyperalgesia and allodynia are not fully
elucidated but include an alteration in the phenotype of primary
afferent neurones in addition to changes in responsiveness of central
nociceptive neurones Gold 2000 With respect to expression levels
total expression levels of TRPV1 in the DRG tend to be decreased in
most neuropathic pain models Rasband et al 2001 Schafers et al
2003 Ithas been demonstrated that TRPV1 mRNA levels were down
regulated in the somata of damaged sensory neurones following
sciatic nerve axotomy Michael Priestley 1999
Hudson et al 2001 reported that after total or partial sciatic
nerve transection or spinal nerve ligation TRPVIimmunoreactivity
was significantly reduced in the somata of damaged DRG neuronal
profiles compared to controls However after partial transection or
spinal nerve ligation TRPVI expression was increased in the
undamaged DRG somata compared to controls It was also reported
that TRPV1 was expressed in the injured sciatic nerve proximal to the
lesion despite its down regulation in the damaged neuronal somata
Hudson et al 2001
The persistence ofTRPVI expression in sites close to nerve injury
although down regulated in injured nerves is possibly due to
depletion of growth factors such as NGF in injured nerves Indeed it
has been demonstrated that NGF modulates the expression of TRPVI
mRNA and protein Ogun Muyia et al 1999 This together with
TRPV1 upregulation in DRGs left undamaged after partial nerve
injury may be crucial to the development or maintenance of
neuropathic pain Hudson et al 2001
In a separate study Kanai et al 2005 reported that the
expression level of TRPV1 protein in the spinal cord which is critical
to pain transduction was significantly increased in the lumbar spine
after induction of a chronic constriction injury CCI in sciatic nerves
of rats in comparison to controls A specific TRPV1 antagonist
administered intrathecally significantly attenuated mechanical allo
dynia in animals with CCI induced neuropathic pain In addition in
vitro investigations in the same study demonstrated that a specific
TRPVI antagonist inhibited capsaicininduced release of substance P
and CGRP from a rat spinal cord preparation A further striking result
obtained by Kanai et al 2005 is that the upregulation of TRPV1
expression occurred with onset of mechanical allodynia in the CCI
rats and that the increased expression was also observed in the
undamaged lumbar spine
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All these studies suggest that TRPVI is an essential receptor in
peripheral neuropathic pain production mechanisms The increase in
TRPVI expression particularly in healthy undamaged nerves
possibly occurs to compensate for the down regulation of TRPVI
expression in injured nerves This increase in expression can present
at the same time as the onset of neuropathic pain following nerve
injury Kanai et al 2005 The ability of an antagonist of TRPVI to
attenuate the mechanical allodynia exhibited by CCI rats Kanai et al
2005 further confirms its involvement in the nociceptive pathway
involved in the neuropathy and this may provide a therapeutic goal
for neuropathic painassociated conditions
31Cancer pain Cancer pain is a significant clinical problem as it is
the first symptom of the disease in approximately 2050of all cancer
patients Mercadante Arcuri 1998 Malignant bone tumours occur
in patients with primary bone cancer but also more commonly occur
as distant metastases of nonbone primary tumours particularly
those in breast prostate and lung Coleman 1997 Accordingly the
bone is the most common siteof origin of chronic pain in patients with
metastatic lung breast or prostate cancers Ghilardi et al 2005
Osteoclasts the principal bone resorbing cells have been implicated
in bone cancer pain Adami 1997 and osteoclast induced bone
remodelling is accompanied by the robust production of extracellular
protons which are known to be potent activators of primary afferent
neurones Bevan Geppetti 1994 Reeh Steen 1996 This raises
the possibility that the acidic microenvironment produced by
osteoclasts contributes significantly to bone cancer associated pain
via activation of acid sensitive nociceptors which innervate the
marrow and mineralised bone Reeh Steen 1996 While tissue
acidosis may activate nociceptors through multiple mechanisms one
definitemechanism is activationof TRPV1which as stated previously
is activated by protonslow pH Tominaga et al 1998 In light of the
clinical significance and severity of bone cancer pain it was necessary
to examine the role of TRPVI in this pathophysiological setting
Ghilardi et al 2005 demonstrated that TRPVI receptors were
expressed on sensory fibres present in mineralised bone and bone
marrow close in proximity to blood vessels in the femur ofmice with
2472 osteolytic sarcoma cell inducedbone cancer model The study
investigated this model in TRPVI knockout mice wildtype control
mice and with the administration of a selective TRPVI antagonist to
observe the effects on pain related behaviours It was reported that
TRPVI knockout mice and TRPV1 antagonist treated mice demon
strated reduced ongoing and movement evoked pain related behav
iour and attenuation of bone cancer severity although neither the
antagonist of TRPV1 or gene knockout affected tumour growth In
bone cancer pain at least three mechanisms contribute simulta
neously to activation and sensitisation of TRPVI receptors expressed
by sensory fibres innervating the tumourbearing joint including
inflammation tumourreleased products and tumour induced injury
to primary afferent neurones Ghilardi et al 2005 All of these
mechanisms centre on the activation and sensitisation of TRPVI in
pain generation and it may be that TRPVI presents as a novel target
for pharmacological treatment of pain states associated with bone
cancer metastasis Ghilardi et al 2005
312Acute and chronic arthritis
The involvement of TRPVI in arthritic conditions has been the
subject of extensive research due to the intrinsic involvement of
sensory nerves in inflammation Szolcsanyi 2004 With TRPVI
receptors having a strong role as integrators of multiple noxious
stimuli TRPVI receptors would clearly have detrimental effects in
arthritic conditions which are characterised by chronic debilitating
pain amongst other symptoms Carlton Coggeshall 2001 It has
long been known that treatmentwith large doses of capsaicin causes a
depletion of neuropeptides and adecrease in the severity ofadjuvant
induced joint disease Colpaert et al 1983 Furthermore it has been
known that neuropeptidecon Laining nerve fibres are present in the
knee joint synovium and adjacent bone Iwasaki et al 1995 and that
adjuvantinduced joint inflammation induces a very rapid transcrip
tion of betapreprotachykinin and alpha CGRP genes in innervating
sensory ganglia with a subsequent increase in substance P and CGRP
Bulling et al 2001 Moreover levels of neuropeptides have been
demonstrated to be significantly increased in samples of synovial fluid
from patients with rheumatoid arthritis Larsson et al 1991
Such studies paved the way to determine a role for TRPVI in joint
disease Accordingly increased expression of TRPVI on unmyelinated
nerves was demonstrated during CFA induced hind paw inflammation
Carlton Coggeshall 2001 Myelinated axons were not affected
during inflammation indicating that an increase in the number of
unmyelinated sensory axons expressingTRPV1 is one of the mechan
isms underlying peripheral sensitisation in inflammation Carlton
Coggeshall 2001 More recently Keeble et al 2005 demonstrated
the pathophysiological involvement of TRPV1 in a murme joint
inflammation model acutely and chronically The study examined
the vascular and hyperalgesic components of joint inflammation in
wildtype mice and TRPVI knockout mice after intraarticular
injection of CFA and demonstrated that knee swelling and vascular
hyperpermeability were significantly higher in the CFA treated joints
of wildtype mice in comparison to TRPVI null mice although
leukocyte accumulation and cytokine production were not affected
Additionally thermal hyperalgesia and joint swelling were decreased
inTRPV1 knockout micecompared withwild type controls after intra
articular injection of mouse recombinant tumour necrosis factora
TNFx demonstrating that this important cytokine which has a
critical role in the pathophysiology of rheumatoid arthritis requires
the presence of TRPV1 receptors to function Keeble et al 2005
31Airway hypersensitivity
In addition to pain disorders TRPVI has been implicated in airway
disorders such as chronic coughing Groneberg et al 2004 The initial
analysis of the augmented cough reflex measured with inhalation of
capsaicin in patients with chronic persistent cough Choudry Fuller
1992 resulted in a number ofstudies investigating TRPVI involvement
in airway hypersensitivity Groneberg etal 2004Little is known about
the abnormalities of the cough receptor itself in these patients with
chronic persistent cough although the number of neuropeptide CGRP
containing nerves in the airway submucosa of patients with chronic
persistent cough was shown to be increased in one studyOConnell
et al 1995 As the cough reflex is mediated by the activation of Afi
fibres in addition to C fibres Widdicombe 1995 and with the TRPVI
receptor shown to be expressed in sensory and afferent fibres
innervating the airway wall emanating from vagal ganglia Michael
Priestley 1999 this indicates a strong involvement of TRPVI in the
underlying mechanisms in chronic persistent cough conditions Indeed
it was demonstrated that the expression of TRPVI in the airways of
patients with persistent cough was increased significantly almost five
fold compared to normal volunteers Groneberg et al 2004 In the
same study there was a significant correlation between the capsaicin
response and the number of TRPV1 expressing nerves within the
patients with cough The TRPVIdependence of capsaicin induced
cough has also been demonstrated in guineapigs where the TRPVI
antagonist capsazepine inhibited the capsaicin induced cough and the
endogenous TRPV1 ligand anandamide induced coughing an effect
that was also abolished by capsazepine and RTX Jia et al 2002
Although the increase in TRPVI receptors may contribute to the
enhanced cough reflex to capsaicin other factors may additionally be
involved The activation of A6 fibres and C fibres in the airways of
guineapigs or rats induced by decreasing pH involves TRPVI as
protons increase the TRPVI channel function Tominaga etal 1998
An increase in the content of protons in exhaled breath condensate in
chronic cough has been reported Niimi et al 2004 providing
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further evidence that TRPV1 may play a central role in airway
hypersensitivity
314Faecal incontinence
A different disorder which TRPVI has been suggested and
demonstrated to be involved in is that of faecal urgency and
incontinence Chan et al 2003 Faecal urgency is a distressing
debilitating disorder which is not fully understood It is a well
recognised featureof disorders such as rectal cancer and inflammatory
bowel disease although in many patients faecal urgency has no
underlying cause Sun et al 1992 Rectal sensation is thought to be
conveyed by the polymodal C fibres and AS fibres Indeed most
primary colonic afferents are polymodal sensory fibres that can encode
all types of stimulation Duthie Gaims 1960 Su Gebhart 1998
Chan et al 2003 demonstrated that in patients suffering from rectal
hypersensitivity the number of TRPV1expressing nerve fibres was
increased in muscle submucosal and mucosal layers of rectal biopsy
samples Inaddition the increase in TRPV1 correlated significantly with
the decrease in rectal heat and distension sensory thresholds The
thresholds for heat and distension were also significantly correlated
Chan etaL 2003Therefore faecal urgency and rectal hypersensitivity
may arise from increased numbers of sensory fibres expressing TRPVI
and thatmay result in sensitisation sprouting or phenotypic changes of
sensory nerves in transmission of visceral sensation Sun et al 1992
315Oesophageal reflux disease
Altered TRPVI receptor expression has been also demonstrated in
the pathophysiology of non erosive reflux disease NERD Bhat
Bielefeldt 2006 NERD and gastro oesophageal reflux disease GERD
cause symptoms of heart burn and are common acid regurgitation
pathologies Martinez et al 2003 NERD has been considered a mild
form of GERD and thus has been treated conservatively with lifestyle
modifications and standard histamine receptor antagonists H2
blockers Recent studies indicate that at least a subgroup of these
patients are most likely to perceive oesophageal acid exposure as
painful suggesting that changes in visceral sensation possibly
visceral hyperalgesia may contribute to their symptoms Martinez
et al2003 Visceral hyperalgesia has been increasingly recognised as
an important factor in the pathogenesis of functional disorders of the
gastrointestinal tract Mayer 1994 Studies on animals and patients
demonstrate that inflammation of the gastrointestinal tract enhances
responses to mechanical and chemical stimulation Ozaki et al 2002
Lamb et al 2003 The altered behavioural responses are associated
with enhanced excitability of visceral sensory neurones which may
be caused at least in part by changes in the properties and expression
of ion channels Bielefeldt et al 2002 Dang et al 2004 Hence the
potential involvement of TRPVI has attracted significant attention
due to its relevance to nociception Caterina et al 1997
A recent study demonstrated that activation of TRPVI receptors by
capsaicin injection into the oesophageal wall resulted in severe chest
pain and heartburn in healthy volunteers Bllalla et al 2004 In
addition TRPV 1 immunoreactive fibres were increased in patients with
erosive oesophagitis supporting a role for TRPVI in symptoms of
gastrointestinal reflux Matthews et al 2004 Bhat and Bielefeldt
2006 subsequently reported that in patients with reflux symptoms in
the absence of macroscopic mucosal injury free nerve endings were
found in the human oesophageal mucosa and that increased acid
exposure is associated with an increase in the density of nerve fibres
expressing TRPVI As TRPV1 is activated by protons Tominaga et al
1998 it is likely that increased oesophageal acid exposure will cause an
excitation and possibly sensitisation of TRPVI receptors in sensory
nerve fibres innervating the oesophageal mucosa Furthermore it seems
that theover expression of the TRPV1 receptor Bhat Bielefeldt 2006
and all increase in the number of TRPV1 immunoreactive fibres in
patients with reflux diseases could further exacerbate the symptoms
187
316Urinary bladder function
The discovery of specific binding sites for capsaicin in the rat
urinary bladder initiated extensive research into the roles of TRPV1
receptors in the urinary tract Szallasi et al 1993 In the lower
urinary tract TRPVI expression is now widely documented not only
concerning theTRPV1 expressing nerve fibre subpopulations butalso
non neuronal tissues Avelino Cruz 2006 The expressionofTRPV1
receptors in the urinary tract was detected for the first time using
radioactive RTX binding in the urinary bladder Szallasi et al 1993
Acs et al 1994 andurethra Parlani etal 1993 of the rat Following
this extensive immunohistochemical studies in rodents demonstrat
ed the presence of TRPVIexpressing nerve fibres throughout the
entire urinary tract with the exception of the kidney parenchyma
Birder et al 2001 Avelino et al 2002 In the rat bladder the
majority ofTRPVI fibres coexpressed the neuropeptides substance P
and CGRP Avelino etal 2002 In the human urinary bladder TRPV1
expressing nerve fibres were detected in the suburothelial connective
tissue and in the mucosal layer Apostolidis et al 2005 Brady et al
2004 Lazzeri etal 2004TRPVIexpressing fibres were also found in
urothelial cells Lazzeri et al 2004
As in other systems pain perception was the first pathophysio
logical role attributed to TRPV1 in the urinary tract Avelino Cruz
2006 For example Charrua et al 2007 demonstrated that TRPVI is
essential for the generation of noxious bladder input associated with
lipopolysaccharide induced cystitis in addition to the bladder over
reactivity Furthermore Wang et al 2008 have shown that both
cyclophosphamide and acolein induced cystitis cause bladder me
chanical hyperreactivity and mechanical allodynia of the mouse hind
paws that is abolished in TRPVI knockout mice A similar role for
TRPV1 in cyclophosphamide induced bladder inflammation was
determined using the TRPVI receptor antagonist capsazepine Dinis
et al 2004 Overall these studies clearly show a role for TRPVI in a
painrelated bladder condition
The recent detection of the receptor in urothelial prostate cells
prostate cancer cells in addition to transitional cell tumours raises the
further possibility that TRPVI is involved in cell differentiation Dinis
et al 2005 Lazzeri et al 2005 It can be hypothesised that in the
normal urinary tract and bladder the role of TRPV1 is that of a
regulatory and perhaps mechanosensory but this changes in lower
urinary tract dysfunctions where it contributes to the nociceptive
element of the disease state Accordingly desensitization of the
receptor by capsaicin and RTX has been investigated for therapeutic
purposes and some benefit was obtained in painful bladder syndrome
and overactive bladder ofneurogenic and non neurogenic origins De
Groat 1997 Lazzeri et al 1998 2000 2004
317Summary
The role ofTRPV1 in the disease processes discussed above strongly
supports a pro inflammatory role for TRPVI Thus it can clearly be
seen why there has been an enormous pharmaceutical effort to
produce TRPV1 antagonists with an effective therapeutic profile
Albeit the process has not been as simple as was originally conceived
A number of TRPVI antagonists are reported to be in clinical
development for pain and related conditions including SB 705498
which is aimed at providing therapeutic analgesia against migraine
and dental pain states Szallasi et al 2006 However since the role of
TRPVI in pain and neurogenic inflammation was discovered a
plethora of research has been carried out to determine the full anti
nociceptiveanti inflammatory potential of these drugs Therefore a
multitude of disease states have been investigated and paradoxically
the absence or antagonism of TRPVI receptors has recently been
shown to exacerbate the inflammatory state by a numberof authors
This paradoxical effect ofTRPVI was initially considered an exception
to the norm However the number ofdiseases in which TRPV1 plays a
protective role is continually expanding Consequently our view of
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TRPV1 has been put into a whole new perspective and highlights new
issues in the generation of treatments that target this receptor
32Protective roles of Transient
Receptor Potential Vanilloid 1 in inflammation
321TRPVI in the cardiovascular system
The function of the circulation is to supply a sufficient blood flow to
peripheral tissues and organs according to their metabolic demands
Inoue et al 2006 This is accomplished by the constantly changing
haemodynamics determined by cardiac output vascular resistance
and renal fluid regulation The TRPV1 receptor is expressed on afferent
nerve fibres that innervate the epicardial surface of the hearts
ventricle Zahner et al 2003 These fibres mediate the cardiogenic
sympathoexcitatory reflex that is essential during cardiac ischaemia a
condition that is associated with chest pain increased blood pressure
and enhanced sympathetic nerve activity Schultz 2003 Zahner et al
2003 It has been proposed that by an ischaemia induced direct
activation of sensory nerve endings in the heart which probably
involves increased tissue levels of bradykinin TRPV1 participates as a
sensor of tissue ischaemia Pan Chen 2004 With respect to this
role TRPVI has been shown to protect against ischaemiareperfusion
injury of the heart Bolli AbdelLatif 2005 Furthermore TRPVI
protects against ischaemiareperfusion induced inflammation of the
liver Harada et al 2005 and kidneys Mizutani et al 2009
TRPV1 has also been shown to protect the cardiovascular system
against hypertension The administration of capsaicin to neonatal rats
to cause the degeneration of sensory neurons that express TRPV1 has
been performed to investigate the functions of TRPVI in this disease
Vaishnava Wang 2003 The animals displayed an exaggerated
increase in blood pressure following salt loading suggesting a
protective role forTRPV1 in the development ofhypertension Further
support for a role of TRPVI in opposing hypertension evoked by salt
loading has been provided by a comparison of Dahl saltsensitive and
Dahl salt resistant rats maintained on high or lowsalt diets for a
period of 3 weeks Wang Wang 2006 Inthe saltresistant animals
high salt intake was found to activate and upregulate the expression
of TRPVI which acted to prevent salt induced increases in blood
pressure Wang Wang 2006 In contrast the expression and
function of TRPVI were impaired in salt sensitive animals and the
protective effect of the channel was lost
32Sepsis
A novel protective role for TRPVI in the systemic disease sepsis
has recently been reported by Clark et al 2007 In humans this
condition is characterised by substantial vasodilatation low systemic
vascular resistance compensatory changes in cardiac output and
severe hypotension Parrillo 1993 Plasma levels of the neuropep
tide such as CGRP are increased in patients with sepsis Joyce et al
1990 Furthermore in experimental models of sepsis such as
endotoxininduced shock in rats elevated plasma CGRP and neuro
peptide Y were observed Wang et al 1992 A role of TRPVI in
infection has not been characterised in the past although it has been
reported that tolllike receptor 4 andCD14 both ofwhichare proteins
of the immune system are colocalised with TRPV 1 in sensory nerves
Wadachi Hargreaves 2006
To investigate the potential involvement ofTRPVI in sepsis Clark
et al 2007 injected the gramnegative bacterial cell wall compo
nent lipopolysaccharide endotoxin to TRPV1 knockout and wild
type mice to induceendotoxic shock It was reported that hypotension
was potentiated in the TRPV1 null mice in comparison to wildtype
controls This indicates that TRPVI receptors possibly have vascular
protective roles in shock In addition specific symptoms characteristic
ofseptic shock such as early hyperthermiaand late hypothermia were
both exhibited by both wild type and knockout mice but the latter
response was significantly enhanced in TRPVI null mice This further
confirms a protective role for TRPVI in sepsis Furthermore levels of
TNFct and nitric oxide in peritoneal lavage were assessed after
lipopolysaccharide injection It was observed that both TNFX and
nitric oxide levels were significantly raised in TRPV1 null mice
indicating that TRPVI protects against an acute increased immune
response in the peritoneal cavity in vivo Therefore in a thorough
analysis of all pathological elements in sepsis TRPV1 appears to be
protective in this model
32TRPVI functions in the lower gastrointestinal tract
The pro inflammatory role of TRPVI in the gastrointestinal tract
was discussed in Sections 314and 315Considering the pro
inflammatory role ofTRPV1 in this system it is particularly intriguing
that the role of TRPV1 in the large bowel is also proposed to be
protective Sibaev et al 2006 It has been reported by Sibaev et al
2006 that TRPVI is protective in the pathological condition ofcolitis
one of the disorders under the branch of collective gastrointestinal
disturbances termed chronic inflammatory bowel diseases 1131 In
these disorders impaired intestinal motility has been reported and
alterations of motor function are often associated with theseverity of
inflammation Bossone et al 2001 Koch et al 1988 Intestinal
inflammation is accompanied by functional and trophic alterations of
the gastrointestinal tract with additional phenotypic changes such as
hypertrophy hyperplasia and myeloperoxidase activity Moreels
et al 2001 Moreels et al 2004 Weisbrodt et al 1994 TRPV1
immunoreactive fibres have been detected on nerve terminals within
the myenteric ganglia and interganglionic fibre tract throughout the
gastrointestinal tract Ward et al 2003
One animal model of IBD involves the infusion of24dinitrobenzene
sulfonic acid DNBS through the rectum of micerats Massa et al
2004 Massa etal 2006 showed protective effects ofTRPVI receptors
in DNBSinduced colitis in mice in astudy involving TRPV1 null mice It
was reported that the TRPVI null mice exhibited increased levels of
DNBSinduced inflammation strongly indicating a protective role of
TRPVI receptors during the initiation of inflammation In addition
increased spontaneous spiking activity of smooth muscle cell mem
brane of DNBStreated colons from TRPV1 null mice was readily visible
after eight hours of DNBS treatment indicating that inflammation
induced irritationof smooth muscle occurs atanearlier stage compared
to wild type animals
Further studies by this group confirmed the above findings Sibaev
et al 2006 reported that electrophysiological results of isolated
colonic sections differed significantly between TRPV1 knockout mice
and wildtype mice in that inflammation caused spontaneous
atropine insensitive rhythmic action potentials in TRPVI knockout
mice but not in wildtype animals This indicates that membrane
stability is disturbed due to a lack of protective mechanisms Twenty
four hours after induction of inflammation electricallyinduced
inhibitory junction potentials of circular smooth muscle cells were
significantly extended in mutant mice in comparison to wild type
controls again suggesting absent protective mechanisms in the
mutant mice This suggests a protective role for TRPVI in colitis in
addition to a physiological role in gastric motility Myers et al 1997
Hosseini et al 1999 De Man et al 2001 This was observed in
altered electrophysiological recordings of inflamed colonic tissue
from TRPVI null mice and wild type littermates Sibaev et al 2006
324Allergic contact dermatitis
Contact dermatitis CD is a chronic allergic condition typified by
skin inflammation and itching Banvolgyi etal 2005 CD is one of the
most common skin diseases with a great socio economic impact
Krasteva et al 1999 According to the pathophysiological mechan
isms involved two main types of CD may be noted allergic contact
dermatitis ACD and irritant contact dermatitis CD can be induced by
a number of irritants in addition to allergens which are influenced by
a multitude of environmental aspects Banvolgyi et al 2005 The
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involvement of C and A6sensory nerve fibres in this condition and
their potential to modulate allergic dermatitis responses are well
established although the exact mechanisms have not been defined
yet Brain 1997 Elevated levels of neuropeptides have been
observed in the effector phase of ACD in humans and murine models
Krasteva et al 1999 However the mechanisms responsible for the
stimulation of sensory fibres and release of neuropeptides are to date
unclear
To investigate the potential involvement of TRPVI in the
pathogenesis of contact dermatitis Banvolgyi et al 2005 employed
the ear model of oxazaloneinduced ACD in TRPVI null mice and in
mice pretreated with RTX to block TRPVI responses It was reported
that in this model of ACD TRPVI demonstrates protective roles as
inflammatory markers such as oedema and TNF cx levels were all
significantly elevated in the TRPVI knockout mice in comparison to
wild type mice Therefore it was demonstrated that pathophysiolog
ical activation of TRPVI is associated with a protective regulatory role
in ACD although it was also demonstrated that accumulation of
inflammatory cells such as neutrophils are not influenced by TRPVI
gene deletion Banvolgyi et al 2005
325Adipogenesis
The role of TRPV1 in adipogenesis and obesity has been the subject
of interest due to the documented effects of red peppers on
thermogenesis where it has been demonstrated to elevate thermo
genesis in humans on high fat and carbohydrate diet Yoshioka et al
1988 Interestingly obesity is now classed as a chronic mild
inflammatory condition Trayhurn Wood 2005 A number of
other studies followed and recently it was demonstrated that a non
pungent capsaicin analogue promoted energy metabolism and
suppressed body fat increase in mice Ohnuki et al 2001 However
the effects of capsaicin have not been assessed in obesity in humans or
animal models until recently Zhang et al 2007 Visceral obesity
depends on the proliferation and growth of preadipocytes which are
closely regulated by several genes and extracelullar factors Flier
2004 Among these factors capsaicin has been shown to affect lipid
metabolism Yoshioka et al 1988 Ohnuki et al 2001 The
mechanisms by which capsaicin affects visceral adipose tissue has
not been fully clarified However with the identification of the
receptor for capsaicin TRPVI it provided an insight into one of the
mechanisms
Zhang et al 2007 reported a novel role for TRPVI having
identified for the first time TRPVI transcripts and channel protein in
preadipocytes and adipose tissue in mice and humans It was
demonstrated that TRPVI activation by capsaicin and the consequent
increase in cytosolic Ca21 prevented adipogenesis the growth of
preadipocytes into adipose cells in vitro Additionally the adminis
tration of capsaicin prevented obesity in wild type mice but not
TRPVI knockout mice assigned to high fat diet in vivo Zhang et al
2007 The role of Ca in adipogenesis has been studied and it has
been reported that adipogenesis is regulated by Ca elevated Ca21
levels significantly suppressed adipogenesis with a decrease in
triglyceride accumulation Miller et al 1996 Shi et al 2000 In
vitro application of capsaicin reduced intracellular lipid droplets and
triglyceride levels and fatty acid synthase in stimulated preadipocytes
all of which are key processes in the generation of obesity Therefore
Zhanget al 2007 demonstrated both in vitro and in vivo that TRPV1
receptors prevent adipogenesis partly through increasing cytosolic
Ca and prevents obesity This indicates that TRPVI functions
physiologically to regulate adipogenesis and it would be interesting
to determine ifTRPVI receptor expression is altered in obese humans
or murine models of obesity against appropriate controls
326Mechanisms underlying the protective effects of TRPVI
Thus far it is clear that there is a wide range of diseasesconditions
in which TRPV1 is protective against disease progression Within the
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remit of our understanding of TRPV1 it is conceivable that this
protection could be affected by one or a combination of the following
ian altered profile of neuropeptide release from sensory nerves eg
release of somatostatin as opposed to pro inflammatory neuropep
tides ii activation of a different subset of TRPVI channels for
example non neuronal TRPVI receptors or iii the effect ofneuronal
release ofpro inflammatory neuropeptides has a beneficial effect on
disease outcome Of course it is possible that there are other
explanations too that are beyond the scope of this review
3261Altered profile of neuropeptide release from sensory nerves To
date all of the pro inflammatory effects of TRPVI are thought to be
mediated by the release of pro inflammatory neuropeptides princi
pally substance P and CGRP However it is conceivable that in certain
diseases the profile of neuropeptide release is altered to favour the
antiinflammatory neuropeptide SST As mentioned previously in
this review SST is a neuropeptide that has long been known to have
anti inflammatory properties Szolcsanyi et al 1998 It has been
shown that SST is colocalised with substance P in Cfibres Kashiba
et al 1996 and acts prejunctionally at afferent nerve terminals to
inhibit the release of pro inflammatory neuropeptides Green et al
1992 There is a plethora of research showing that exogenous SST or
its synthetic analogues exert a significant anti inflammatory and anti
nociceptive effect in various disease states including chronic airway
inflammation Elekes et al 2008 endotoxininduced airway disease
Helyes et al 2007 streptozotocin induced diabetic mechanical
allodynia Szolcsanyi et al 2004 and adjuvant induced chronic
arthritis Helyes et al 2004 For example Helyes et al 2007 have
shown that endotoxininduced airway inflammation in mice signif
icantly increased lung and plasma concentrations of SST in TRPVI
wild type but not knockout mice Furthermore a SST analogue
diminished bronchial inflammation and hyperreactivity in TRPVI
knockout mice whereas a SST receptor antagonist increased inflam
mation and hyperreactivity in wild type counterparts Helyes et al
2007
However there is minimal evidence linkingTRPV1 activation to SST
release from sensory nerves in vivo Indeed thereare numerous sources
of SST in addition to Cfibres including monocytesmacrophages
lymphocytes and neuroendocrine cells amongst others Helyes
et al 2006 and it is not yet known whether TRPVI is even expressed
on all of these cell types Furthermore exogenous SST was pro
inflammatory against ACD Gutwald et al 1991 suggesting that SST
did not mediate the protective role of TRPVI in this disease
326Activation of a different subset of receptors Until recently
TRPV1 receptors were thought to be expressed uniquely on sensory
nerves However it is now clear that this is not the case In fact as
discussed in Section 2 non neuronal expression has been detected
in epithelial cells vascular endothelium and immune cells amongst
others Gunthorpe Szallasi 2008 Table 3Furthermore a study
by Kark et al 2008 showed that neuronal TRPVI can behave
differently to non neuronal TRPVI capsaicin was shown to cause
vasoconstriction or vasodilation depending on the concentration
used the tissue of interest dilation in skin constriction in skeletal
muscle and the site of TRPVI expression Intraarterial administra
tion of capsaicin 011pM to the perfused rat hind limb caused a
concomitant dilation of skin vessels and constriction of skeletal
muscle resistance vessels Conversely at lower concentrations of
capsaicin up to 10 nM it caused a vasodilation of skeletal muscle
vessels Functional expression of TRPV1 in vascular smooth muscle
cells was shown to mediate vasoconstrictor responses of the skeletal
muscle resistance arteries whereas TRPVI on sensory nerves
mediated the vasodilation Interestingly Keeble and Brain 2006
showed that topical application of capsaicin to the synovial mem
brane of the mouse knee joint caused a TRPV1dependent vasocon
striction Conversely a similar dose of capsaicin caused a vasodilation
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Table 3
A comparison of neuronal and non neuronal expression of TRPVI receptors
Neuronal expression
LocationCell type Function
Cfibres Ab fibres Neurogenic inflammation Caterina et al 1997
Various CNS structures
Dopaminergic neurones in substantia nigra Enhancement of locommorbehaviour peripheral Mezey et al 2000 Dawbarn et al 1981
vasodilatation and hypothermia response
Hippocampal pyramidal neurones Enhancement of pairedpulse depression AIHayani et al 2001
Neurones in the locus coeruleus Analgesicantinociception activity of capsaicin Marinelli et al 2002
Striatal neurones Peripheral vasodilatation and subsequent hypothermia response Hajos et al 1988
Hypothalamic neurones Stimulation of glutamate release and enhancement Karlsson et al 2005
of postsynaptic currents
Non neuronal expression
Location Cell type Function
Epithelial cells
Keratinocytes Release of pro inflammatory mediator sensor for noxious Southall et al 2003
cutaneous stimulation
Bladderurothelial cells Regulation of bladder reflex contractions Lazzeri et al 2004 Birder et al 2001
Vasculature
Smooth muscle Vasoconstriction Kark et al2008
Cerebromicrovascularendothelial cells Contribution to the regulation of cerebral blood Flow and BBB permeability Golech et al 2004
Immune cells
polymorphonuclear granulocytes Possible pro inflammatory role yet the role of TRPVI on cells of the Heiner et al 2003
lymphocytes immune system is currently elusive Saunders et al 2007
macrophages Chen et al 2003
Preadipocytes and adipose tissue Regulation of adipogensis Zhang et al 2007
PancreaticAcells Modulation of insulin secretion as a Ca channel Akiba et al2004
when applied topically to the mouse ear Grant et al 2002 due to
TRPV1induced substance P and CGRP release These findings are
especially interesting as they show functional differences ofTRPV1 in
vascular tissue that may be due to neuronal versus non neuronal
TRPVI activation and which could have implications for the role of
TRPVI in different disease states
As yet there is no direct evidence to show that non neuronal
TRPVI can have a protective effect against inflammatory disease but
it is worth speculating that this is a distinct possibility For instance all
of the diseases mentioned in the section on pro inflammatory effects
of TRPVI are intrinsically associated with pain andor have a distinct
neuronal involvement On the other hand diseases in which TRPVI is
protective are not generally associated with pain and have no
significant link with the nervous system Indeed as mentioned in
Section325adipogenesis may be associated with TRPVI expression
on preadipocytes Zhang et al 2007
326Proinflammatory neuropeptides improve disease outcome
The neuropeptides substance P andCGRP are intrinsically associated
with pro infla m matory outcomes and it is generally considered that
inhibiting these neuropeptides will relieve inflammation However
there is evidence to the contrary depending on the disease For
example inhibitionof thevasodilator effect of CGRP is beneficial to the
relief ofmigraine Goadsby et al 1990 Lassen et al 2002However
the same vasodilator mechanism is believed to mediate the protective
effect of sensory nerve activation against colonic inflammation
Reinshagen etal 1998 This is because CGRPinduced vasodilation
protects the mucosa against acid back diffusion Holzer 1991 Li et al
1992 In contrast inhibition of substance P effects does notprotect
against colonic injury Reinshagen et al 1998 The release of CGRP
from sensory nerves causing vasodilation is also considered to be
responsible for the protective role of TRPVI in hypertension
Vaishnava Wang 2003 Wang 2005 and reperfusion induced
tissue inflammatory responses Okajima Harada 2006 For
example CGRP mediates the anti thrombininduced reduction of
ischaemiareperfusion induced liver injury Harada et al 2005 and
CGRP induced PGI production mediates theprotective effect ofCGRP
against ischaemiareperfusion induced renal injury Mizutani et al
2009 in rats In the heart substance P and CGRP cause negative
inotropic and chronotropic effects in addition to vasodilation to
alleviate the effects of ischaemia and reperfusion injury in this organ
Bolli AbdelLatif 2005 Indeed TRPVI gene deletion decreases the
release of substance P in response to ischaemia and impairs the
recovery of cardiac function after the insult Wang Wang 2005
Protective effects of pro inflammatory neuropeptides could also
contribute to the protective effect of TRPVI in sepsis For example
Okajima et al 2005 have shown that CGRP may protect against
endotoxin induced hypotension via increased production of endo
thelial PGI Moreover Wang et al 2008 showed that the TRPVI
mediated protection against endotoxin induced hypotension and
mortality was possibly due to substance P release and subsequent
effects on sympathetic nerve activity Furthermore Verdrengh
Tarkowski 2008 have shown that macrophages from NK receptor
knockout mice are less efficient at phagocytosing bacteria suggesting
a role for substance P in clearance ofbacteria In contrast symptoms of
sepsis were notaffected by the use of neurokinin receptor antagonists
in the study by Clark et al 2007 However this study involved the
use of a cocktail of NKI NK2 and NK3 receptor antagonists which
may have masked the effect of an individual receptor subtype
There is therefore mounting evidence that substance P and CGRP
mediate TRPVIinduced protection However it is unlikely that this is
always the case as demonstrated by their role in ACD For example
topical application of substance P and CGRP to the site ofoxazolone
induced ACD increases both the intensity of the swelling Gutwald
et al 1991 and the number of leukocytes recruited to the site of
challenge Goebeler et al 1994 However an alternative reason for
the protection afforded by TRPV1 may lie with the neuropeptide
neurokinin A NKA Inhibition of the NKA receptor NK2 enhances
dinitrofluorobenzeneinduced ACD and NK2 receptor agonists have
been shown to diminish ACD inflammation Scholzen et al 2004
327Summary
Overall it is clear that the findings relating to the protective
effects of TRPV1 put this receptor into a new perspective especially
in relation to the therapeutic potential of drugs that target this
receptor However it is not only the protective effects of TRPV1 that
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are paradoxical in terms of our classical view of this receptor but
also the emerging roles for TRPVI in normal physiological conditions
The prospect of physiological roles of TRPVI was raised by the
discovery of theendogenous activatorsof the receptor and the broad
expression of TRPVI receptors suggesting that TRPVI may notonly
be activated under pathophysiological conditions
4 Physiological functions of
Transient Receptor Potential Vanilloid 1
41Thermoregulation
Detection of noxious heat was one of the first functions attributed
to the TRPVI receptor Blockade of this function has since become a
classic screen test for TRPVI antagonists However through the use of
TRPVI antagonists in vivo a new and highly significant function for
this receptor in physiological temperature regulation has been
discovered Most selective TRPVI antagonists regardless of their
molecular structure cause an increase in body temperature Gavva
et al 2007a Intriguingly a single oral dose of the antagonist A
425619 induces a transient period of hyperthermia followed by a
period of hypothermia but this characteristic is unique to this drug
Millsetal 2008 Furthermore AMG8562 blocks capsaicin activation
of TRPVI does not affect heat activation of TRPVI potentiates pH 5
activationof TRPVI in vitro and does not cause hyperthermia in vivo
in rats Lehto et al 2008 In this case therefore the loss of heat
activation is concomitantly observed with protection against hyper
thermia However this does not necessarily mean that the two
phenomena are intrinsically related
AMG517 has been well characterised in terms of thermoregula
tion As with all TRPVI antagonists this drug causes hyperthermia
This effect is conserved between species as the same effect is seen in
rats dogs and monkeys Gavva et al 2007aband perhaps most
importantly humans Gavva et al 2008 Modifications of AMG517
to restrict its site of action to peripheral TRPVI did not prevent
hyperthermia demonstrating that the site of agonist induced hyper
thermia is outside of the bloodbrain barrier Gavva et al 2007a
Tamayo et al 2008 Furthermore protons are not involved as
antagonists that are ineffective against proton activation still cause
hyperthermia Gavva et al 2007a However the hyperthermia is
attenuated by acetaminophen Gavva et al 2007b and repeated
administration of AMC517 attenuates the hyperthermia response
without attenuating inhibition of capsaicin induced pain responses
Gavva et al 2007b Similarly repeated dosing of ABT102 induced
hyperthermia is attenuated upon repeated dosing Honore et al
2009 This effect of repeated administration of antagonist perhaps
explains why hyperthermia is not observed in TRPVI knockout mice
Interestingly in the case of ABT102 repeated dosing also enhances
its analgesic effect Honore et al 2009 although the reason for this is
far from clear Overall the exact cause of the TRPVI antagonist
induced hyperthermia is still to be elucidated but this effect
highlights the importance of normal physiological functions of
TRPVI in the generation ofTRPVI antagonists
42Urinary bladder function
As mentioned previously the TRPVI receptor plays an essential
role in the pain associated with urinary bladder infections such as
cystitis Charrua et al 2007 In addition to this pathophysiological
function of TRPVI it is becoming increasingly clear that this receptor
plays a role in normal bladder function although some studies have
been conflicting as to the precise role For example Dinis et al 2004
showed that capsazepine had no effect on bladder reflex activity in
normal rat bladders even at extremely high concentrations However
other authors have reported that the deletion of the TRPVI gene
increases bladder capacity and the frequency of non voiding bladder
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contractions and of low volume micturitions in mice Birder et al
2002 Albeit TRPVI knockout mice only exhibited this increased
response under anaesthesia and not in conscious mice Therefore
voluntary bladder control is unlikely to be influenced by the TRPVI
receptor Invitro Daly et al 2007 have carried out studies showing a
clear role for TRPVI in the excitability of low threshold bladder
afferent nerve fibres taken from mice Bladder distension induced
afferent discharge in TRPVI wild type mice was attenuated in TRPVI
knockout mice Furthermore afferent discharge was also decreased in
the presence of capsazepine Dinis et al 2004 and Daly et al 2007
therefore found conflicting results concerning TRPVI and bladder
function This may reflect a species difference or a difference in the
degree ofbladder distension between the two studies
43Roles in the brain neurogenesis
Finally and with the TRPVI receptor having been discussed in
various peripheral organs it is fitting to conclude on the role ofTRPVI
in the brain TRPVI receptors have been demonstrated tocontribute to
a pivotal physiological process within the brain neurogenesis or the
birth of new neurones Jin etal 2004 As TRPVI has been detected in
the brain Mezeyet al2000 it has been proposed that it is involved in
normal physiological processes within this organ and this has been
recently investigated Jin et al 2004 reported that TRPVI mediates
CBI induced regulation of neurogenesis Neurogenesis was deter
mined by intraperitoneal injection of bromodeoxyridineBrdUwhich
stains new neurones and it was demonstrated that the number of
BrdUpositive cells were approximately 50 lower in the specified
brain regions in CBI receptor null mice in comparison to control
Paradoxically the administration of specific CBI receptor antagonists
SR141716A andAM251 in wild type andCBl null mice increased the
number of BrdUlabelled cells by 50 in the subventricular zone
indicating that they were acting via different mechanisms To
investigate this discrepancy the authors administered these CB1
receptor antagonists toTRPVI null mice and interestingly the effects
of these antagonists were abolished in these mice in comparison to
TRPVI wild type mice The exact cause of this discrepancy seems
uncertain The authors suggest that SR141716A may block TRPVI
receptors hence producing this effect in the wild type mice Jin etal
2004 However there seems to be more complex underlying
mechanisms Additional studies have demonstrated thatCBI receptor
antagonists seem to act onTRPVI receptors concomitantly Pegorini et
al 2006 Pegorini et al 2006 demonstrated that the capsazepine
reserved the neuroprotective effects exhibited by the CBI receptor
antagonist rimonabant in experimentally induced ischaemia in
gerbils An alternative explanation to the results observed by
SR141716A and its possible interaction with TRPVI receptors in vivo
is that during the presence of CBI receptor blockade compensatory
mechanisms may result in the increase of production of endocanna
binoid such as anandamide which can activate and quickly desensitise
TRPVI receptors At present this is speculative but there are strong
evidence of interactions between the cannabinoid signalling pathway
and the vanilloid signalling pathway
5 Concluding remarks
It is clear that the TRPVI is a paradoxical receptor that has
expanded from being thecapsaicin receptor to a crucial integrator of
multiple stimuli leading to pro inflammatory or protective effects
depending on the disease state Pro inflammatory effects are
intrinsically associated with sensory nerve activation and subsequent
release ofneuropeptides such as substance P and CGRP Indeed all of
the pro inflammatory effects involve neuronal TRPVI channels On
the other hand protective effects ofTRPVI may be associated with i
SST release presumably also from sensory nerves ii TRPVI receptors
on non neuronal cell types or iii protective actions of pro
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inflammatory neuropeptides amongst other reasons In addition to
the pathophysiological roles for TRPV1 it is now also clear that TRPV1
exerts significant functions under normal physiological conditions
Indeed it has been suggested that body temperature maintenance is
the predominant function of TRPV1 Gavva 2008Thus the fact that
TRPVI antagonism is a potential therapeutic target for a variety of
disease states renders it an important goal to differentiate the effects
of TRPV1 so that certain pathophysiological and physiological states
are not adversely affected Will this be possible The generation of
TRPVI antagonists that do not cause hyperthermia are already in the
pipeline suggesting that the paradoxical effects of TRPVI can to at
least some degree be differentiated This is encouraging since TRPVI
antagonist induced hyperthermia has been the greatest stumbling
block to date in the progress of these drugs through clinical trials Can
the effects of TRPVI in pathophysiological states also be differenti
ated Furthermore do we know whether TRPVI antagonists
will adversely affect disease states in humans These questions
remain to be answered butmay be critical to the future ofTRPVI as a
therapeutic target
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Role of TRPV1 in inflammation induced airway hypersensitivity
LuYuan Lee and Qihai Gu
Airway hypersensitivity is a common pathophysiological
feature in various airway inflammatory diseases Increasing
evidence suggests that activation of the transient receptor
potential vanilloid type 1 receptor TRPV1 plays an important
part in the manifestation of various symptoms of airway
hypersensitivity This mini review focuses on recent studies
that have revealed several potential contributing factors to the
increase in TRPV1 sensitivity in pulmonary sensory neurons
during airway inflammatory reaction In addition chronic
allergic airway inflammation induces a pronounced
overexpression of TRPV1 in neurofilamentpositive pulmonary
sensory neurons in nodose ganglia A better understanding of
the mechanisms underlying the increase in sensitivity andor
expression of TRPV1 during acute and chronic airway
inflammation should generate the necessary information for
developing effective therapeutic interventions to alleviate
airway hypersensitivity
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Introduction
Transient receptor potential vanilloid type 1 receptor
TRPVI is a polymodal transducer and belongs to the
superfamily of TRP ion channels 1 TRPVI is a tetra
meric membrane protein with four identical subunits
and each subunit contains six transmembranespanning
domains which form a nonselective cation channel with
a high permeability to Ca Since it was cloned in 1997
21 the TRPVI expressed on the sensory nerve term
inals has been recognized as a molecular gateway to
nociceptive sensation in somatic and visceral tissues 3
In the last several years the expression ofTRPV1 on the
sensory nerves in the respiratory tract and its important
role in the regulation of the airway function especially in
disease conditions have been increasingly recognized
4
The involvement of TRPV1 in the manifestation of
various symptoms in airway diseases has been extensively
discussed in several recent reviews457This mini
review is intended to focus specifically on more recent
findings of the involvements of TRPV1 in the develop
ment of airway hypersensitivity associated with inflam
matory reactions in the respiratory tract We will further
discuss the mechanisms possibly underlying the upregu
lation of TRPV1 sensitivity and expression under these
pathophysiological conditions
TRPV1expressing sensory nerves in airways
The afferent activities arising from sensory terminals in
the lung and airways are conducted primarily by branches
of vagus nerves and project to the nucleus tractus soli
tarius in the medulla Among these sensory nerves
TRPV1 is expressed predominantly in nonmyelinated
Cfiber afferents 8 which represent 75 of the
afferent fibers in the pulmonary branch of the vagus
nerve One unique feature of these nerves is the exten
sive coexpression of TRPV1 with certain sensory neuro
peptides namely tachykinins and calcitonin gene related
peptide CGRP 9 that are synthesized in the cell
bodies of these neurons located in the nodose and jugular
ganglia 10 Another prominent anatomical feature of
these sensory nerves is the axonal arborization of their
endings that either extend into the space between epi
thelial cells or form networklike plexus immediately
beneath the basement membrane of epithelium 911
Figure 1 suggesting a role of these afferents in regulat
ing the airway responses to inhaled irritants 123When
these TRPV I expressing nerve endings are activated
either by inhaled irritants or by endogenous TRPV1
activators see details in a later section centrally
mediated reflex responses are elicited which include
reflex bronchoconstriction and mucus hypersecretion
via the cholinergic pathway accompanied by the sen
sation of airway irritation and urge to cough Figure 1 In
anesthetized animals it also elicits the classical pulmon
ary chemoreflexes characterized by the triad of apnea
bradycardia and hypotension 12 Activation of TRPV1
also triggers Ca2 influx and release of tachykinins and
CGRP from the sensory terminals These sensory neuro
peptides can act on a number of effector cells in the
respiratory tracteg smooth muscles cholinergic ganglia
mucous glands and immune cells and elicit the local
axon reflexes such as bronchoconstriction protein extra
vasation and inflammatory cell chemotaxis 10
Figure 1 These actions generated by tachykinins and
CGRP have been well documented in rodents but the
degree of their relative importance in human airways
remains to be fully established 103
wwwsciencedirectom Current Opinion in Pharmacology 20099243249
001195
il l  li  t ww.sciencedirect.com Current Opinion in 
,  Pharmacology 
ELSEVIE  
l  f  i  i fl tion-i  i  r siti it  
-Yu      
ir  r iti it  i    t i l i l 
f t r  i  ri  ir  i fl t r  i ses. I r i  
      i t  
i l ill i     (T ) l   i  
t i  t  if t ti  f i  t  f i  
sitivity.  i-      
   l t      
   it      
  t r  tion.  iti n,  
      
   i  r fil ent-   
  i   li .  tt  t i  f 
t  i  rl i  t  i r  i  iti it  /or 
    t     
i l i  l  r t    i i   
l i  ff ti  t ti  i t ti  t  ll i t  
ir  r itivity. 
r  
rt t f i logy, i r it  f t , lexington,  36, 
 
rr i  t r: lee, lu-  (Iylee@uky.edu) 
r t i i  i  nn l gy , :243-249 
is i   f   t  i   
i  
it    l   li   
vailable online 5th arch 2009 
1- 8921$ -  front ter 
(D  l i r .   . 
001 0.1016/j.coph.20 9.02.002 
I t ti  
ransient receptor potential vanilloid type 1 receptor 
(TR V1) is   r,  gs t  e 
s rf il  f P io  a els [l]. l is  t tra-
i  ra e tein ith  i ti l it , 
  it t i s si  tr s r e-s i  
i , ich or   s l tive ti  l it  
a high per eability to az+. ince it as cloned in 1997 
[2], the l pressed  t e s s r  erve t r -
inals as een rec nized as 'a lecular ate a ' t  
ce tive on  s tic  iscera  iss  [3]. 
 he a   ,  res on l  e 
sensory nerves in the respiratory tract and its i portant 
role in the regulation of the air ay function, especially in 
disease conditions, have been increasingly recognized 
[4 °,s°,6, 7]. 
ww.science irect.com 
 ve  f l   i t   
various sy pto s in air ay diseases has been extensively 
i s  i  everal t r i  [4°,5.,7]. is i i-
revie  is intended to focus specifically on ore recent 
fi ings f t  i lve t  f l i  t  evelop-
t f ir  rsensitivit  ss i t  it  i fl -
t r  r ti s i  t  r s ir t r  tr ct. e ill f rt r 
discuss the echanis s possibly underlying the upregu-
l ti  f l s nsiti it   r ssi  r t s  
i  it . 
- r i  r  r  i  ir  
he afferent activities arising fro  sensory ter inals in 
    r   ri    
  ,  je t t  t  l  t t  li-
tarius in the edulla. ong these sensory nerves, 
l is r ss  r i tl  i  li t  
(C-fiber) affere ts [8], ic  re rese t >75% f t e 
afferent fibers in the pulmonary branch of the vagus 
er e. e i e feat re f t ese er es is t e e ten-
si e c e ression f  ith certai  se s r  e ro-
ti s, l  t i i s  l it i  -r l t  
peptide (C ) [9], that are synthesized in the cell 
bodies of these neurons located in the nodose and jugular 
l  [[0].   t i l t   
  es       
endings that either extend into the space bet een epi-
thelial cells or for  net ork-like plexus i ediately 
t  t e t ra e f it li  [9,11] 
(Figure 1), suggesting a role of these afferents in regulat-
i  t e air a  res ses t  i ale  irritants [12,13]. e  
these TRPVl-expressing nerve endings are activated 
ither  i l  irritants r  s l 
ti ators (see t ils i   l t r s ction), tr ll  
e iate  refle  res ses are elicited, ic  i clu e 
reflex bronchoconstriction and mucus hypersecretion 
via the cholinergic pathway, accompanied by the sen-
sation of airway irritation and urge to cough (Figure 1). In 
anesthetized ani als, it also elicits the classical 'pul on-
ary che oreflexes', characterized by the triad of apnea, 
bradycardia, and hypotension [12]. ctivation of T P l 
l  t iggers ci+ i lu   n:lcasc  t i ins  
 RP fr  the r  t r i l . hese r  r -
 tides ca  act  a r f effect r cells i  the 
respiratory tract (e.g. s ooth uscles, cholinergic ganglia, 
cous la s, a  i une cells), a  elicit t e l cal 
'axon refle es' s c  as r c c stricti , r tei  e tra-
t ,  i fla at r   is [1 ] 
(Figure 1). These actions generated by tachykinins and 
 RP e   te   t , t e 
degree of their relative i portance in hu an air ays 
re ains to be fully established [10, U]. 
urrent i i  i  r cology , :243-249 
244 Respiratory
Figure 1
activators
H heat
LO metabolites
endovanilloids
Endogenous
TRPV1
modulators
PGEBKN F
t
proteases
hyperthermia
polycations c
higher centers
vagal
Inns afferent
medulla
vag
efferent
100i11111
Centrally mediated Reflexes Mlilr
reflex bronchoconstriction mucus TKs CGRP
smooth muscle
secretion airway irritation cough Axon Reflexescardiorespiratory depression
chemotaxis protein
extravasation mucosal
edema bronchoconstriction
current Opinion in Pharmacology
Schematic illustration of the function of TRPV1 expressing sensory nerves and their interaction with other cell types in airway mucosa EO eosinophil
LO lipooxygenase PGE prostaglandin E BK bradykinin NGF nerve growth factor TKs tachykinins CGRP calcitonin gene related peptide See
text for details adapted from Ref 13
Airway hypersensitivity plasticity of TRPV1 in
airway diseases
Airway hypersensitivity characterized by exaggerated
sensory eg airway irritation and dyspnea and reflexo
genic responses eg cough and bronchoconstriction to
inhaled irritants and certain endogenously released
mediators is a common pathophysiological feature in
patients with airway inflammatory diseases such as
asthma bronchitis and viral infection Increasing and
compelling evidence reported in recent studies suggests
that the TRPV1 channel plays a pivotal role in the
manifestation of various symptoms of airway hypersensi
tivity in these patients 45For example cough sen
sitivity to TRPV1 activators capsaicin or citric acid
aerosol was markedly elevated in patients with asthma
or airway inflammation 145 Endogenous TRPV1
activators such as H and lipooxygenase metabolites
are consistently detected in the bronchoalveolar lavage
fluid sputum andor exhaled breath condensate of
patients with inflammatory airway diseases 5 In
addition certain endogenous inflammatory mediators
egprostaglandin E and bradykinin though notTRPV1
activators themselves can markedly enhance the sensi
tivity ofTRPV1 and lower its threshold for activation 5
Furthermore cough sensitivity to acute inhalation chal
lenge of ovalbumin aerosol was elevated in sensitized
guinea pigs and the enhanced response was significantly
attenuated by TRPV1 antagonists suggesting the involve
ment ofTRPV1 in the airway hypersensitivity induced by
chronic allergic inflammation 16 Recent studies further
revealed that the increased TRPV1mediated responses
are associated with increased expression of the TRPV1
channel in bronchopulmonary sensory nerves in certain
chronic airway diseases 178 These observations
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collectively suggest that plasticity of TRPV1 develops
upon the action of various inflammatory mediators and
cytokincs during airway inflammatory reaction At the
presence of either an enhanced sensitivity or an increase
in expression of TRPV1 a given level of stimulation is
expected to evoke a greater afferent discharge of the
TRPV1expressing sensory nerves in the airways and
consequently more severe sensory and reflex responses
resulting in airway hypersensitivity
Increased sensitivity of TRPV1
The sensitivity of TRPV1 can be elevated by the actions
of a number of chemical physical and biological factors
as discussed in detail in several comprehensive reviews
13456In this mini review we will focus our atten
tion on three of these factors because recent investi
gations have revealed new information about their
involvements in the development of airway hypersensi
tivity associated with airway inflammatory reaction
Increase in airway temperature
Tissue inflammation is known to lead to local hyperemia
and an increase in temperature in the inflamed area A
recent study reported that the end expiratory tempera
ture plateau was 2YC higher in mild allergic asthmatic
children than in healthy children and the difference was
closely correlated with the exhaled nitric oxide concen
tration as well as the sputum eosinophil percentage 19
An earlier study in adult patients also showed a faster rise
of exhaled temperature in asthmatics than matching
controls 20These findings seem to suggest that exhaled
breath temperature is related to the degree of airway
inflammation in asthma
The four subtypes of TRPV channels TRPV14 are
generally considered as the primary sensors for warm and
hot temperatures in mammalian species and each is
activated in a different temperature range 43Cfor
TRPV1 52C for TRPV2 3438Cfor TRPV3 27
35Cfor TRPV4 21 A recent study has demonstrated
the expression of both mRNA and receptor proteins ofall
these four subtypes of TRPVs in the cell bodies of
sensory neurons innervating the lung structures in rats
22 These neurons isolated in primary culture also
exhibit distinct temperature sensitivity in wholecell
patch clamp electrophysiological recording experiments
22 When the temperature was raised from normal
36Cto hyperthermic 406Clevel of the rat body
temperature and held constant the inward currents
evoked by capsaicin and 2aminoethoxydiphenyl borate
2APB a nonselective activator of TRPV13 receptors
were both significantly increased 23This potentiating
effect was clearly present even at a moderate level of
hyperthermia 39CHowever it was largely attenu
ated by selective TRPV1 antagonists eapsazepme or
AMG 9810 23 and completely absent in pulmonary
nodosejugular neurons isolated from TRPV1null mice
24 suggesting the possible involvement of a positive
interaction between hyperthermia and these chemical
activators at the TRPV1 channel Surprisingly although
hyperthermia also potentiated the TRPV1mediated
response to H it inhibited the responses mediated
through the acidsensing ion channels 23 The specific
site and mechanism underlying this interaction are not
known but an involvement ofcytoplasmic COOHterm
inal domain of the TRPV1 receptor in the conformational
changes has been suggested 25 Furthermore in a
recent study Voets etal 26 have clearly demonstrated
that increasing temperature to 42Cshifted the TRPV1
channel activation curve open probability versus voltage
from a non physiological positive voltage range toward the
negative potential Figure 2 This large shift of voltage
dependent activation curve to a physiologically relevant
voltage range with a relatively small gating charge may
explain in part the hyperthermiainduced hypersensitiv
ity in pulmonary sensory neurons expressing the TRPV1
2627 This positive interaction between hyperther
mia and chemical activators of TRPV1 is particularly
relevant because an increase in tissue temperature during
inflammatory reaction may occur concurrently with the
release of several endogenous TRPV1 activators such as
proton polycations and certain lipoxygenase metabolites
of arachidonic acideg 12S hydroperoxyeieosatetraenoie
acid and 15S hydroperoxyeicosatetraenoic acid in the
airways 5
Proteaseactivated receptors2PAR
PAR belongs to a family of Gprotein coupled seven
transmembrane domain receptors named PARs that are
uniquely activated by proteolysis 28 PAR activation
occurs after cleavage of its extracellular Nterminal
domain by specific proteases revealing a newNterminus
that acts as a tethered ligand bindingto and activating the
receptor Figure 3 Expression ofPAR has been demon
strated in a variety of cells in the lung and airways
including TRPV1 positive sensory neurons 29 Mast
cell tryptase trypsin and trypsinlike proteases and
coagulation factors VIIa and Xa are considered as the
endogenous agonists of PAR 2930PAR can also be
activated by certain airborne allergens such as house dust
mite Der P1 P3 and P9 31 In addition tissue kallik
reins a large family of secreted serine proteases with
tryptic or chymotryptic activity are recently proposed as
Physiological regulators of PAR 32
Compelling evidence indicates that PAR plays a critical
role in the pathogenesis of airway inflammation and air
way hyperresponsiveness The elevated levels ofboth the
endogenous agonists and the expression of PAR have
been reported from patients and animals under airway
inflammatory conditions 303Activation of PAR in
the lung induces airway constriction lung inflammation
and proteinrich pulmonary edema 3436 These effects
are inhibited by either perineural capsaicin treatment of
wwwsciencedirectom Current Opinion in Pharmacology 20099243249
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Voltage shifts of TRPV1 activation curves by temperature and capsaicin
a Voltage dependence of the open probability of TRPV1 channels at
17Ctriangles and 42C circles The inset shows the respective current
families obtained from a voltagestep protocol holding potential 0 mV
voltage steps of 100 ms duration from 120 to 160 mV in 40mV
increments Note the leftward shift of the activation curve toward
negative potentials by increasing the temperature b The same voltage
protocol as in a and the temperature was held at 24CActivation of
TRPV1 by capsaicin 100 nM circles also caused a pronounced leftward
shift of the activation curve adapted from Ref 271
both vagi and the combination of neurokinin1 NK1
NK2 and CGRP receptor antagonists indicating the
involvement of neuropeptides released from TRPVI
containing C fiber afferents Indeed a recent study
showed that PAR activation upregulates the excitability
of rat pulmonary chemosensitive neurons and potentiate
the capsaicininduced TRPV1mediated pulmonary che
moreflex responses 37 PAR activation also exaggerates
the TRPV1 dependent tussive response in guinea pigs
38 Furthermore PAR activation is often associated
with release of various proinflammatory mediators in
eluding prostanoids such as prostaglandin E and cyto
kines such as interleukin IL6 and IL8 29340
These mediators are known to have potential regulatory
effects on the sensitivity of TRPV1 5
The signaling mechanisms of PAR are not fully under
stood In a number of cell systems PAR has been
reported to be coupled to G11 protein to activate phos
pholipase C resulting in generation of second messen
gers inositol145triphosphate and diacylglycerol which
further trigger mobilization of Ca2 and activation of
protein kinase C 28 Involvements of PKC PKA and
possibly PKD have recently been proposed in PAR
induced sensitization of TRPV1 as well as other TRP
channels in sensory neurons374123Figure 3
Polycations
Recent studies have reported that extracellular cations
such as Mg2 and Ca can sensitize and gate TRPV1 44
A similar effect can also be generated by polyamines
such as spermine spermidine and putrescine the
organic polycations that are known to modulate inflam
mation and nociception 45 More importantly it has
been reported that the blood levels of these polyamines
were significantly elevated in patients during asthmatic
attack 46 The study by Ahern et al further suggested
that the extracellular acidic residues ASP646 and Glu
648 which are located near the pore forming region of
TRPV1 play an important role in polyamine regulation
Their hypothesis was supported by the finding that
spermine failed to increase the wholecell current evoked
by protons in TRPV1expressing oocytes 45
Airway infiltration of eosinophils and the release of their
granulederived low molecular weight and highly
cationic proteins ie major basic protein eosinophil
cationic protein eosinophil peroxidase and eosinophil
derived ncurotoxin occur in a variety of airway inflam
matory diseases including asthma 47 Furthermore the
increases in both the number of eosinophils and levels of
eosinophil derived cationic proteins in the bronchoalveo
lar lavage fluid of asthmatic patients are correlated with
the severity of the disease 48 Recent studies have
demonstrated that these eosinophil derived cationic
proteins can directly sensitize the capsaicinevoked
TRPV1mediated wholecell responses in isolated rat
pulmonary sensory neurons the effect of these proteins
was completely abolished when their cationic charges
were neutralized by mixing with a polyanion 49
Whether these eosinophil granule proteins increase the
sensitivity of TRPV1 via a similar mechanism as poly
amines remains to be determined
Overexpression of TRPV1 in chronic airway
inflammation
In addition to increased excitability of the channel an
increase in the TRPV1 receptor protein expression can
Current Opinion in Pharmacology 2009 9243249 wwwsciencedirectom
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Schematic illustration of the hypothesized interaction between PAR and TRPV1 in pulmonary sensory neurons PAR proteaseactivated receptor2
FVlla coagulation factor Vila FXa coagulation factor Xa PARAP synthetic PAR activating peptide TM transmembrane domain Garr and G G
proteins PLC phospholipase C PIP phosphatidylinositol 45bisphosphate IP inositol145triphosphate DAG diacylglycerol PKC protein
kinase CCa intracellular Ca concentration TKs tachykinins AC adenylate cyclase PKA protein kinase A PGE prostaglandin E IL
interleukin See text for details
also contribute to the airway hypersensitivity particularly
in chronic airway diseases For example the TRPV 1
immunoreactive nerve profile was fivefold higher in the
biopsies of bronchial tissue from patients with chronic
cough than healthy individuals 17 Furthermore there
was a significant correlation between the cough sensitivity
to capsaicin inhalation challenge and the density of
TRPV1expressing nerves in the mucosa of patients with
chronic cough 175 These observations have provided
strong evidence to suggest an increase in expression of
TRPV1 in the sensory endings of airway mucosa may be
involved in the development of chronic cough A recent
study showed that after chronic airway inflammation was
induced by allergen sensitization capsaicin evoked a
pronounced stimulatory effect on vagal bronchopulmon
ary myelinated afferents which normally exhibit no or
very little sensitivity to capsaicin 18 Immunohisto
chemical experiments further indicated a pronounced
increase in the proportion of TRPV1 expressing bronch
opulmonary neurons in nodose ganglia of sensitized rats
and the increased TRPV1 expression was found mainly in
neurofilamentpositive neurons myelinated neurons
18 This observation is in general agreement with
another recent finding of an increased number of
TRPV1 immunoreactive axons within the tracheal epi
thelium and around smooth muscles of ovalbuminsen
sitized guinea pigs by Watanabe et al 51 The
mechanism underlying the phenotypic change in TRPV1
expression in pulmonary myelinated neurons was not
known However a possible involvement of neurotro
phins such as brain derived ncurotrophic factor and nerve
growth factor should be considered These neurotrophins
are known to upregulate the expression of TRPV1 in
sensory neurons 5255 or promote translocation of the
TRPV1 to cell membrane 56 and their synthesis and
release have been shown to increase in allergic airways
578
Conclusion
Airway hypersensitivity is a common and debilitating
problem for patients with various airway inflammatory
diseases Cumulative evidence indicates that TRPV1
plays a key part in the manifestation of various symptoms
of airway hypersensitivity suggesting that TRPV1 is an
important target for pharmacological interventions To
obtain the necessary information for developing new
wwwsciencedirectom Current Opinion in Pharmacology 20099243249
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kinase ; [Ca2+1;, intracellular a2+ concentration; s, tachykinins; , adenylate cyclase; , protein kinase ; E2, prostaglandin 2 ; IL, 
i l kin.  t  ils. 
also contribute to the air ay hypersensitivity, particularly 
i  r i  ir a  is s s. r l , t  -l 
i r ti  r e r file as fi f l  i er i  the 
i psies f r i l tissue fro  tie ts it  r ic 
 t a  lt  individuals [1 ]. rt r r , t r  
as  si ificant rr lation h  t e  t e  s nsiti it  
to capsaicin inhalation challenge and the density of 
l-ex ressi  erves in the c sa f atie ts ith 
chronic cough [17,.10]. hese observations have provided 
strong evidence to suggest an increase in expression of 
T P l in the sensory endings of air ay ucosa ay be 
involved in the develop ent of chronic cough.  recent 
study showed that, after chronic airway infla ation was 
induced y llergen siti ti , i in ed  
ronounce  sti lat ry effect  a al r c l -
r  linate  ffer ts, ich r ll  i it  r 
very little sensitivity to capsaicin [lS00]. histo-
c e ical e eriments further indicated a r ounced 
increase in the r rtion f l-ex ressi  r c -
  n odose a  ized r , 
and the increased T P l expression as found ainly in 
r fil nt- itive r  (myelinated r s) 
[lS00j. This observation is in general agreement with 
ww.science irect.com 
another recent finding of an increased nu her of 
T P l-i unoreactive axons ithin the tracheal epi-
t liu   r  t  s les f valbumin-se -
itized inea i   ata a e t l. [51°].  
echanis  underlying the phenotypic change in P l 
expression in pul onary yelinated neurons as not 
kno n. o ever, a possible involvement of neurotro-
phins such as brain-derived neurotrophic factor and nerve 
r t  fact r s l  e c si ere . ese e r tr i s 
are kno n to upregulate the expression of l in 
sensory neurons [52-55], or pro ote translocation of the 
l to cell e brane [56], and their synthesis and 
release have been sho n to increase in allergic air ays 
[57,SS]. 
l i  
Airway hypersensitivity is a co on and debilitating 
proble  for patients with various airway infla atory 
s s. e e  icates  l 
plays a key part in the anifestation of various sy pto s 
of air ay hypersensitivity, suggesting that P l is an 
i portant target for phar acological interventions. o 
obtain the necessary infor ation for developing new 
rrent    , :243-249 
248 Respiratory
effective therapeutic strategy further investigations on
the mechanisms involved in the increase in sensitivity
andor expression of TRPV1 during both acute and
chronic airway disease conditions are required In
addition it is evident that the interaction between
TRPV1 and other ion channels and regulatory receptor
proteins that are also expressed on these airway sensory
nerves is important in modulating the function of airway
sensory neurons Thus TRPV1 functions not only as a
transducer but also as an integrator of actions generated
by multiple endogenous activators and modulatory mol
ecules A better understanding of the overall role of
TRPV1 in regulating the excitability of these neurons
during airway inflammatory reaction is probably one of
the most important steps in uncovering the underlying
mechanism of airway hypersensitivity
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Abstract
The transient receptor potential vanilloid I TRPV 1 is an excitatory cation channel rather selectively expressed in a subpopulation of nociceptive
primary sensory neurons that promote neurogenic inflammation via neuropeptide release TRPV I is activated by noxious temperature tow
extracelhtlar pll and diverse lipid derivatives and is uniquely sensitive to vanilloid molecules including capsaicin TRPVI expression and sensitivity
is highly regulated by diverse G protein coupled and tyrosine kinase receptors Other exogenous or endogenous chemical agents including reactive
oxygen species ethanol and hydrogen sulphide sensitizeactivate TRPVI In the airways TRPV1 agonists cause cough bronchoconstriction
microvascular leakage hypetreactivity and hypersecretion Patients with asthma and chronic obstructive pulmonary disease are more sensitive to the
tussive eftect of TRPV I agonists and TRPV l activation may contribute to respiratory symptoms caused by acidic media present in the airways during
asthma exacerbation gastroesophageal reflux induced asthma or in other conditions TRPVI antagonists may be useful in the treatment of these
diseases
C 2005 ElsevierBVAll rights reserved
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The transient receptor potential TRP family of proteins is
currently under intense investigation in health and disease
because these ion channels have been recognized to sense a vast
range ofstimuli and because of their wide distribution in different
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tissues and organs TRPs are putative six transmembrane pro
teins that assemble as tetramers to form cation permeable
pores TRPs have been subdivided in three main subclasses
TRPC TRPM and TRPV V stands for vanilloid Clapham
2003 Montell et al 2002 TRPP TRPML and TRPN are
additional and newly proposed subtypes of TRPs More recently
a novel TRPlike channel that responds to cold temperature
15 C has been cloned and termed ANKTMI or TRPA1
McKemy et al 2002 Peier et al 2002
Uncertainty exists as regard to the precise and multiple roles
ofTRPs Their localization in the plasma membranes ofneurons
or other cells and a large body of evidence collected using a
plethora of stimuli indicates that they are sensors of chemical
and physical stimuli TRP channels are the molecules used by
mammals and humans to appreciate sweet and bitter tastes and
to discriminate warmth heat and cold However intracellular
localization eg in the endoplasmic reticulum Karai et al
2004 and evidence obtained about the cellular regulation
of ion flux has suggested a role as modulators of Ca2 ho
meostasis Clapham 2003 Montell 1997 downstream to G
protein coupled receptors most probably via the phospholipase
C pathway However this otherwise fascinating hypothesis is not
supported yet by the identification of a messenger molecule
which directly binds and activates the channel Clapham 2003
Phosphatidylinositol45bisphosphate PIP binding and PIP
hydrolysis inhibits and activates respectively TRPL in the
Drosophila Hardie 2003 and the mammalian TRPV1 Chuang
et al 2001 Prescott and Julius 2003 However a major role of
PIP as TRP regulator has been challenged by the observation
that constitutive activity of TRPM7 is increased by PIP binding
and reduced by PIP hydrolysis Runnels et al 2002 Finally
TRPs have been proposed to regulate the so called capacitance
Ca entry or store operated Ca entry SOCE Store operated
Ca entry channels are considered channels that link Ca store
depletion with Ca entry However final proof that one or more
TRPs are the exclusive and selective mechanism that mediate
store operated Ca entry is still lacking Clapham 2003 Al
though there is no evidence for one or more specific and high
affinity endogenous ligands for TRPs a series of lipid derivatives
including arachidonic acid metabolites have been claimed to gate
TRPs For example the endocannabinoid anandamide and its
metabolite arachidonic acid activates directly TRPV l Zygmunt
et al 1999 and via a cytochrome P450 epoxygenasedependent
formation of epoxyeicosatrienoic acids TRPV4 Watanabe et
al 2003
2 The transient receptor potential vanilloid 1
TRPV 1 a 426 in the rat amino acid protein Caterina et al
1997 uniquely sensitive to vanilloid molecules including cap
saicin the hot principle contained in the plants of the genus
Capsicum Szallasi and Blumberg 1999 is activated by low
extracellular pH pH 6 5 Bevan and Geppetti 1994 Geppetti
et al 1991 Tominaga et al 1998 and elevated concentrations
in the micromolar range of the endocannabionid anandamide
Zygmunt et al 1999 the lipoxygenase metabolites of
arachidonic acid leukotriene B LTB or 12hydroperoxyei
cosatetraenoic acids 12HPETE Hwang et al 2000 and
Narachidonoyldopamine Huang et al 2002 TRPV I is
also a thermosensor activated by moderate noxious temper
ature between 42 and 53 C Caterina et al 1997 TRPV 1
together with other TRP channels TRPA1 TRPM8 TRPV3
TRPV4 and TRPV2 enables mammals to discriminate
different temperatures from noxious cold to noxious heat
Clapham 2003 Montell 1997 Montell et al 2002
TRPVI is highly expressed in a subset of primary sensory
neurons of the trigeminal vagal and dorsal root DRG ganglia
with C and A6 fibers These neurons have been defined as
polymodal nociceptors because of their ability to detect noxious
chemical thermal and high thresholdmechanical stimuli TRPV 1
mRNA is also expressed in diverse areas of the central nervous
system including the limbic system striatum hypothalamus
thalamic nuclei substantia nigra reticular formation locus
coenileus and cerebellum Mezey et al 2000 There is also
evidence that TRPV I mRNA and protein are expressed in non
neuronal cells including epithelial cells ofthe urothelium Birder
etal 2001 keratinocytes Inoue et al 2002 and epithelial cells
of the palatal rugae Kido et al 2003 see also below The
investigation of the physiological and pathophysio logical func
tion if any ofTRPV l in non neuronal cells as well as in non
sensory neuronal cells may elucidate broader functions than pain
perception However it should be underlined that there is not clear
evidence for such roles yet
TRPV 1 gating excites terminals of primary sensory neurons
and causes their depolarization and the initiation of action
potentials Orthodromic propagation of the depolarizing stim
ulus contributes to reflex responses including cough urinary
bladder voiding peristalsis in the gut and other responses
Antidromic conduction of action potential to collateral nerve
fibers or direct gating of TRPV 1 itself allow Ca2 influx into
the nerve endings a phenomenon that results in the local release
of neuropeptides including calcitonin gene related peptide
CGRP and the tachykinins substance P SP and neurokinin
A NKA Activation of CGRP receptors and tachykinin NK
NK and NK receptors on effector cells particularly at the
vascular levels causes a series of inflammatory responses col
lectively referred to as neurogenic inflammation Geppetti and
Holzer 1996
The putative role of TRPV I as a sensor of noxious tem
perature and acidic pH justifies the channel enrichment on
peripheral terminals ofprimary sensory neurons Less clear is the
significance of the high TRPV I expression on central terminals
of primary sensory neurons in the dorsal horn of the spinal cord
and medulla oblongata two anatomical sites where noxious tem
perature or low pH can unlikely be encountered However lipid
derivates that potentially may be produced in the spinal cord have
been shown to stimulate the channel within the dorsal spinal cord
Tognetto et al 2000 thus suggesting TRPV I expressed on
central terminals of primary sensory neurons may exert an
homeostatic role at this level Whereas TRPV l is not required for
appropriate temperature sensing its genetic deletion impairs the
development of thermal hyperalgesia Davis et al 2000 Urinary
bladder function was also found altered in TRPV 1 knockout mice
Birder et al 2002 Pharmacological studies with the first
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generation capsazepine Walker et al 2003 and more recent
TRPVI antagonists Lee et al 2003 Pomonis et al 2003
support the hypothesis that TRPVI also contributes to mechanical
hyperalgesia
3 Activation of TRPVI and neurogenic inflammatory
responses
The term neurogenic inflammation refers to a series of re
sponses mainly present at the vascular level but that also occur in
other tissues and organs with a large variability according to
the mammal species under investigation At the vascular level
neurogenic inflammation in parenthesis the neuropeptide in
volved consists of vasodilatation CGRP plasma protein
extravasation and leukocyte adhesion to the vascular endothelium
ofpostcapillary venules substance Pneurokinin A Geppetti and
Holzer 1996 In non vascular tissues neurogenic inflammatory
responses include cardiac positive chonotropic effects CGRP
contraction of the smooth muscle ofthe iris sphincter substance P
neurokininA ureter bladder and urethra substance Pneurokinin
A relaxation of bladder CGRP exocrine gland secretion
substance Pneurokinin A and other effects The bronchomotor
response in the airways illustrates the marked speciesrelated
variation in the effect produced by sensory nerve activation
tachykinins Excitation of TRPVIexpressing nerve terminals
causes direct bronchoconstriction in the guinea pig NK21
and indirect mainly mediated by epithelial nitric oxideprosta
noids bronchodilatation in the rat and mouse NKI In man
mainly NK2 but also tachykinin NKI receptors mediate a robust
bronchoconstriction Amadesi et al 2001 Ofparticular interest is
the ability of tachykinins NKI to stimulate seromucous secretion
Geppetti et al 1993 fiom bronchial glands and to excite NK3
postganglionic cholinergic nerve terminals in the human bronchus
Myers et al 2005
Neurogenic inflammation markedly contributes to inflam
matory responses both at the somatic and visceral levels in dif
ferent mammal species In the human skin there is strong evidence
that capsaicin or histamine cause a flare response that being
blocked by local anesthetics or by repeated application of topical
capsaicin capsaicin desensitization is mediated by stimulation
of terminals of TRPVIexpressing neurons and the subsequent
release of neuropeptides Less clear is however whether in man
neurogenic inflammation plays a pathophysiological role at the
visceral level There is evidence that CGRP is released by
capsaicin from human tissues in vitro FrancoCereceda 1991
Geppetti et al 1992 and during migraine attacks Goadsby et
al 1990 A major role of CGRP released from trigeminal
perivascular nerve fibers derived from the observation that BIBN
409613S a peptoid with high affinity for the CGRP receptor
Doods et al 2000 that does not cross the blood brain barrier
reduces the pain and other symptoms associated with migraine
attacks Olesen et al 2004
4 Sensitization and regulation of TRPV1 function
Expression of mRNAprotein and function of TRPVI as
those of other TRP channels undergo marked plasticity by a
209
series of regulatory and inflammatory mediators TRPVI
plasticity more than its normal expression underlines its pos
sible role in disease Nerve growth factor NGF is required for
survival of newborn rat dorsal root ganglia neurons and for
expression of the TRPVIphenotype in adult rat dorsal root
ganglia neurons in culture Bevan and Winter 1995 NGF via a
p38 mitogen activated protein MAP kinase increases TRPVI
protein transportation to the peripheral endings of sensory neu
rons a phenomenon associated with an increase in heat hyper
sensitivity Ji et al 2002 Thus upregulation ofTRPV 1 could
contribute to the proinflammatory role of NGF released from
mast cells during asthma exacerbations Bonini et al 1996
Protein kinases A and C PK and phospholipase A and C
metabolites also regulate TRPVI by diverse mechanisms The
threshold temperature for TRPVI stimulation is lowered by
anandamide through a protein kinase C PKCc dependent
pathway Premkumar and Ahern 2000 The major proin
flammatory peptide bradykinin via activation of the B receptor
sensitizes TRPVI by diverse intracellular mechanisms includ
ing PKCs Premkumar and Ahern 2000 Sugiura etal 2002
displacement of PIP from TRPVI binding Chuang et al
2001 and 12 and 5 lipoxygenase metabolites production
Carr et al 2003 Shin et al 2002 In vagal afferent Cfibers
bradykinin evokes membrane depolarization and action poten
tial discharge through the additive effects of TRPVI activation
Lee etal 2005 Prostaglandins may induce cough Costello et
al 1985 and one major adverse effect of angiotensin
converting enzyme inhibitors is cough Israili and Hall
1992 The interesting hypothesis that protein kinase Cprotein
kinase Adependent pathways are involved in TRPVI sensiti
zation that results in a lowered tussive threshold to capsaicin is
currently under intense scrutiny
Protease activated receptor2 PAR2 is stimulated though
cleavage of its extracellular tail by proteases such as trypsin
and tryptase PAR2 is expressed in a large variety of cells
including TRPVIpositive sensory neurons and PAR2 stimu
lation promotes neurogenic inflammation and hyperalgesia
Steinhoff et al 2000 Vergnolle et al 2001 A large body
of evidence indicates that in the lung PAR2 activation is as
sociated with inflammatory responses including exaggeration
of allergic reaction Schmidlin et al 2002 bronchoconstriction
and plasma protein extravasation Su et al 2005 all effects
mediated in large part by a sensory neurogenic mechanism The
recent finding that PAR2 stimulation upregulates the function of
TRPVI through a PKCdependent mechanism adds PAR2 to
the list of G protein coupled receptors that regulating TRPVI
orchestrate the neural components of the inflammatory response
in the airways Amadesi et al 2004
Sensitization of TRPVI by PKC and cAMP dependent pro
tein kinase PKA pathways seems to be promiscuously used
by different stimuli including capsaicin anandamide heat and
protons Bhave et al 2002 De Petrocellis et al 2001
Premkumar and Ahem 2000 Vellani et al 2001 but it is not
unique to endogenously generated agents The common notion
that exposure to mucosal surfaces or wounds to alcoholic tinc
tures causes burning pain has remained without an explanation
until the observation that ethanol excites TRPVI expressing rat
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sensory neurons and human embryonic kidney HEK293 cells
transfected with the human TRPVI but not wild type HEK293
cells Trevisani et al 2002 TRPVI usually stimulated at 42 C
in the presence ofethanol is activated by lower temperatures as
the physiological temperature of 37 C because ethanol lowers
the threshold temperature for TRPVI activation by about 8 C
Trevisani et al 2002 In the presence of ethanol effects of
TRPV 1 agonists including anandamide and protons are marked
ly potentiated Trevisani et al 2002 Ethanol induced asthma is
still a poorly understood condition where a primary role for ac
etaldehyde has been proposed Vally and Thompson 2003
Exposure to ethanol of isolated guinea pig bronchi and intragastric
ethanol in vivo caused bronchoconstriction and bronchial micro
vascular leakage through a capsaicinsensitive TRPVIdependent
and tachykinin mediated mechanism Trevisani et al 2004a This
finding supports the hypothesis that ethanol by lowering the
temperature threshold for TRPV 1 activation causes a series of
neurogenic proinflammatory responses of relevance for alcohol
induced asthma
5 Localization and function of TRPV 1 in the airways
In a large variety ofdiseases including migraine osteoarthr
titis cystitis and detrusor hyperreflexia fecal urgency and
inflammatory bowel diseases postherpetic neuralgia and post
mastectomy pain and many others diseases a role for TRPVI
expressing neurons and neurogenic inflammation has been
proposed Geppetti and Holzer 1996 Geppetti and Trevisani
2004 Neurogenic inflammation has been proposed also to
contribute to asthma previous reviews have covered this issue
Barnes 1986 Bertrand and Geppetti 1996 Joos and Pauwels
2001 Contribution of neurogenic inflammation in chronic
obstructive pulmonary disease COPD is suggested by the
findings that cigarette smoke the major causative agent of the
disease produces an early inflammatory response completely
mediated by sensory neuropeptides Baluk et al 1996 Lundberg
and Saria 1983 The hypothesis that TRPVI contributes to
some of the major symptoms of asthma and COPD is cor
roborated by a series of anatomical physiological and patho
physiological findings reported below
In the guinea pig TRPVIpositive nerve fibers localized
within the epithelium of the trachea and around smooth muscle
and blood vessels and within the lower airways in the vicinity
of bronchi and bronchioles and around alveolar tissue Al
though TRPVI immunoreactive and neuropeptide negative
axons were also seen TRPV 1 in the tracheal epithelium mostly
colocalized with substance P Watanabe et al 2005 Of in
terest for further discussion is the finding that in the guinea pig
no TRPVI was found localized to airway epithelial cells
Watanabe et al 2005 In contrast with this immunohisto
chemical observation RTPCR revealed that TRPVI together
with acid sensing ion channel la ASIC 1 a and ASIC3 subunits
of proton gated ion channels are expressed in immortalized
human bronchial epithelial cells normal human bronchial tra
cheal epithelial cells and normal human small airway epithelial
cells from the distal airways Agopyan et al 2003 TRPV 1
seemed to be associated to Ca 2 regulation and apoptosis in
these cells as apoptotic response and large part of the Ca 2
response caused by exposure of these cells to particulate matter
PM was inhibited by capsazepine and because particulate
matter exposure induced apoptosis in mouse sensory neurons
but not in those pretreated with capsazepine in the absence
of extracellular calcium or in sensory neurons from TRPV 1
knockout mice Agopyan et al 2004 Thus the hypothesis
was advanced that capsaicin and acid sensitive irritant re
ceptors located on somatosensory cell bodies and their nerve
fiber terminals subserve particulate matter induced airway in
flammation Veronesi et al 2000
Neuropeptides tachykinins and CGRP released from
terminals of TRPVI expressing neurons have been proposed
to contribute to the immune response van Hagen et al 1999
However recent evidence suggests that mouse dendritic cells
DC a key cell type of the vertebrate immune system ex
presses TRPVI and its activation by capsaicin or heat leads to
dendritic cells maturation and draining lymph nodes Base and
Srivastava 2005 The intriguing hypothesis that TRPV I and its
putative ligands orchestrate an early immune response is
however challenged by additional observations that failed to
detect the occurrence of a functional TRPV I in mouse dendritic
cellsOConnell et al 2005 TRPVI expression has been
recently detected in many other non neuronal human cells
in skin human mast cells epidermal keratinocytes Stander
et al 2004 and liver HepG2 cells Vriens et al 2004 in
prostate epithelial cell lines PC3 and LNCaP and prostate tissue
Sanchez etal 2005and in intracytoplasmatic granulesmatching
mitochondria structures of gastric parietal cells Faussone
Pellegrini et al 2005 It is possible that also in the airways
TRPVI occurs in extmneuronal cells from where it may con
tribute to homeostasis and inflammation However it should be
underlined that conclusive evidence that non neuronal TRPVI
is functional and exerts defined biological roles is still absent
Fig t
6 Cough and TRPV1
Activation of afferent nerve fibers with rapidly adapting
receptors RAR that conduct action potentials in the A 6 range
initiates the cough reflex RARs are exquisitely sensitive to
mechanical perturbation of their receptive fields but are
unaffected by a variety of chemical agents or messengers
including bradykinin and capsaicin In contrast C fibers are
activated by capsaicin and bradykinin but are much less
sensitive to mechanical stimulation Undem et al 2002 How
ever capsaicin and bradykinin substantially reduce the elec
trical threshold for initiating the cough reflex and capsazepine
prevents the increased cough sensitivity induced by capsaicin
Mazzone et al in press A series of experiments with
tachykinin receptor antagonists suggested that TRPVICfiber
activation sensitizes the cough reflex via central mechanisms
Mazzone et al in press
A key role played by airway inflammation in the upregula
tion of the cough reflex is strengthened by the following recent
observations i inflammation substantially increases the mech
anical sensitivity of RAR fibers and ii causes a phenotypic
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Fig 1 Schematic representation of cell types that putatively express functional TRPV I and the biological functions produced by the channel following exposure to its
putative ligands
switch in neuropeptide innervation of the airways as RAR
neurons synthesize tachykinins and calcitonin generelated
peptide and finally iii the proinflammatory peptide bradyki
nin seems to activate Cfiber by stimulating TRPV 1 Undem et
al 2002 In addition the pivotal function of TRPVI in the
cough response in chronic airway inflammatory disease is
underlined by the lower threshold to cough induced by cap
saicin a common tussive stimulus in experimental animals and
in man in patients with asthma cough variant asthma and
COPD Doherty et al 2000 Fujimura et al 1994 Millqvist
2000 Wong and Morice 1999 Although channels known to
sense low extracellular pH include ASICs and electrophysio
logical studies propose that the tussive response to citric acid is
mediated by ASICs Kollarik and Undern 2002 phannaco
logical evidence with two TRPVI antagonists capsazepine
Lalloo et al 1995 and iodo resineferatoxin Trevisani et al
2004b gives robust support to the role of this channel to
mediate citric acid induced cough Thus TRPV 1 may be con
sidered as a major molecular entity involved in the tussive
response in health and disease and its targeting may represent a
novel therapeutic strategy in treating cough
Increased expression of TRPV 1 has been found in inflam
matory diseases of the gut where its exaggerated expression
was associated with the severity of the symptoms Chan et al
2003 Similar findings have been obtained in the respiratory
tract Whereas PGP95positive nerve fibers were not increased
in the airway epithelium of patients with chronic cough a five
fold increase in TRPVIpositive nerve profiles was found in
these patients A significant correlation between capsaicin tussive
response and the number of TRPVIpositive nerves was also
found in patients with chronic cough Groneberg et al 2004
Expression of TRPV 1 has been also found increased in the
airway smooth muscle of patients with chronic cough where
it localized in a thapsigargin insensitive compartment Mitchell
et al 2005 In line with this latter observation the bronchocon
strictive eicosanoid 20hydroxyeicosatetraenoic acid 20HETE
a product of cytochrome P450 CYP450 omegahydroxylase
and capsaicin have been found to produce a capsazepinesensitive
tonic contraction in airway smooth muscle cells Thus 20HETE
could be added to the series of putative endogenous TRPV 1
agonists that in the present case contributes to bronchoconstriction
by stimulation ofnon neuronal TRPV 1 channels Rousseau et al
2005
7 Putative endogenous TRPVI agonists and the therapeu
tic potential of TRPVI antagonists in airway disease
The current active search for high affinity and selective
TRPV 1 antagonists has yielded a series of molecules tested in
various models of disease that include different types of neuro
pathic pain and urinary bladder dysfunction TRPVI antago
nists are under intense investigation in several other animal
models ofdisease The identification of the endogenous ligand
that during inflammation or injury activates TRPV 1 is of para
mount importance to make the channel a valuable therapeutic
target Lipid substances as anandamide Tucker et al 200 1 or
Narachidonoyl dopamine Harrison et al 2003 have been
shown to cause bronchoconstriction in guinea pigs entirely via
a TRPVIdependent pathways In addition to lipid derivatives
protons seem to play a major role as putative ligands of
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TRPV1 in the airways The original proposal Bevan and Geppetti
1994 that low extracellular pH might activate the capsaicin
receptor was fully confirmed following TRPVl cloning Tominaga
et al 1998
Exposure to endogenous and exogenous acids in the airways
acidopnea evokes cough bronchoconstriction airway hyper
reactivity microvascular leakage and heightened production of
mucous all effects mediated by neurogenic inflammation The
role ofacidity to the mechanism ofasthma is being increasingly
appreciated Harding 2003 and now the contribution of in
halation of acidic media because of gastroesophageal reflux
disease and following exposure to acid fog pollution or work
place exposure in asthma seems widely confirmed Harding
2003 In addition a marked decrease in pH in the exhaled
breath condensate that seems to reflect the lining fluid pH ofthe
lower airways via the activation of TRPV 1 and the release of
sensory neuropeptides has been proposed to contribute to the
mechanisms of obstructive airway diseases Hunt et al 2000
Ricciardolo et al 2004
In addition to protons temperature and a large variety of
lipids recent studies have added novel molecules to the stimuli
known to produce airways inflammation via TRPV 1 activation
and neurogenic mechanisms The odorous and irritant gas hy
drogen sulfideHShas been recently described as an endo
genous mediator with diverse biological effects Li et al 2005
NaHS that non enzymatically generates HSincreased sensory
neuropeptide release in the airways and caused in vivo bron
choconstriction and microvascular leakage in a capsazepine
sensitive manner This novel mechanism may contribute to the
irritant action ofHS in the respiratory system possibly through
TRPV 1 activation Trevisani et al 2005 Electrophysio logical
results suggest that both the TRPV 1 and the purinergic PX
receptors mediate the sensory transduction of reactive oxygen
species ROS especially H2O and OH by capsaicin sensitive
vagal lung afferent fibers Ruan et al 2005 This finding is of
particular relevance when considering the role ofreactive oxygen
species in the mechanism of cigarette smoke induced injury and
of COPD Finally stimulation of afferent fibers in the upper
airways eg in the nose may modulate the responsiveness of the
same type of nerve terminals in the lower airways The role of
NGF to upregulate TRPVI described previously in isolated
neurons Ji et al 2002 has received support from recent data
in man in vivo Patients sensitive to scents and chemicals with
respiratory symptoms showed a significant increase in NGF in
the nasal lavage fluid a phenomenon associated with an increased
tussive response to capsaicin Milldvist et al 2005 In another
study intranasal capsaicin enhanced the cough response provoked
by inhalation of a tussigen in humans Plevkova et al 2004
8 Conclusions
Enhancement of the cough response to capsaicin and citric
acid is reported in patients suffering from two respiratory illness
asthma and COPD widely distributed in the general population
Cough by capsaicin and most likely cough by citric acid are
mediated by TRPV l activation Thus it is possible that chronic
inflammation changes the phenotype of sensory neurons and
possibly of other cells exaggerating the function of TRPV 1
Associated to TRPV 1 upregulation a sort ofsensory hypersen
sitivity a phenomenon that may resemble thermalmechanical
hyperalgesia may develop in the airways during chronic in
flammation and may represent one of the underlying mech
anisms ofmany symptoms including irritation chest tightness
breathlessness discomfort sneezing and cough The introduc
tion ofTRPV 1 antagonists in clinical investigation will test this
hypothesis soon as well as the usefulness ofthese molecules for
the treatment of inflammatory airway diseases
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1 Introduction
A B S T R A C T
Preclinical studies suggest that the vanilloid receptor TRPVI is an important component of several
disease areas such as pain inflammatory visceral cancer and neuropathic airway disease including
chronic cough inflammatory bowel disease IBD interstitial cystitis urinary incontinence pancreatitis
and migraine TRPVI is a member ofa distinct subgroup of the transient receptor potential TRP family
of ion channels The neuronally expressed TRPVI is a non selective Ca preferring cation channel In
addition to capsaicin this channel is activated by a number of different stimuli including heat acid
certain arachidonic acid derivatives and direct phosphorylation via protein kinase C PKC Moreover
there is also evidence that various inflammatory mediators such as adenosine triphosphate ATP bra
dykinin nerve growth factor NGF or prostaglandin E2 PGE2 may indirectly lead to activation of the
TRPVI channel via activation of their respective receptors There is strong experimental evidence that the
combination of direct and indirect mechanisms finely tune the TRPVI activity Each of the different
known modes of direct TRPVI activation protons heat and vanilloids is capable of sensitising the
channel to other agonists Similarly inflammatory mediators from the external milieu found in disease
conditions can indirectly sensitise the receptor It is this sensitisation of the TRPVI receptor in inflam
matory disease that could hold the key and contribute to the transduction of noxious signalling for
normally innocuous stimuli ie either hyperalgesia in the case of chronic pain or airway hyper
responsivnesshypertussive responses in patients with chronic cough Itseems reasonable to suggest that
the various mechanisms for sensitisation provide a scenario for TRPVI to be tonically active and this
activity may contribute to the underlying pathology providing an important convergence point of
multiple pain producing stimuli in the somatosensory system and multiple coughevoking irritants in the
airways The complex mechanisms and pathways that contribute to the pathophysiology of chronic pain
and chronic cough have made it difficult for clinicians to treat patients with current therapies There is an
increasing amount of evidence supporting the hypothesis that the expression activation and modulation
of TRPVI in sensory neurones appears to be an integral component of pain and cough pathways
although the precise contribution of TRPVI to human disease has yet to be determined So the question
remains open as towhether TRPVI therapeutics will be efficacious and safe in man and represent a much
needed novel pain and cough therapeutic
The vanilloid 1 TRPVI or VRl receptor is a member of
a subgroupsuperfamily of transient receptor potential TRP ion
channels which subserve a whole host of cellular roles including
many features of sensory transduction 1 The neuronally
expressed TRPVI is a non selective Ca preferring cation
channel The TRPVI channel is activated by a diverse range of
chemical ligands such as capsaicin the hot component of chilli
peppers and other vanilloids resiniferatoxin and the cannabinoid
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anandamide as well as acid protons H physical stimuli such as
heat certain arachidonic acid derivatives and direct phosphoryla
tion via protein kinase C PKC 25 In addition TRPVI is also
activated directly and indirectly by a variety ofmediators thought
to contribute to neuroinflammation 67Moreover various
endogenous mediators such as bradykinin substance 1P glutamate
prostaglandins hydroperoxy fatty acids and adenosine triphos
phate ATP sensitise TRPVI 7
It is this sensitisation of the TRPVI receptor in inflammatory
diseases that could hold the keyand contribute to the transduction
of noxious signalling for normally innocuous stimuli ie either
hyperalgesia in the case of chronic pain or airway hyper
responsivnesshy ertussive responses in patients with chronic
cough It seems reasonable to suggest that the various mechanisms
1094 5539 see front matter 2009 Elsevier Ltd All rights reserved
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for sensitisation provide a scenario for TRPVI to be tonically active
and this activity may contribute to the underlying pathology
providing an important convergence point of multiple pain
producing stimuli in the somatosensory system and multiple
cough evoking irritants in the airways Whilst there is evidence
that this is indeed the case in pain producing pathways there is no
direct evidence that there is tonic activity of TRPVI in cough
receptors However as discussed in Section 4 it seems likely that
TRPVI plays a critical role in the sensory regulation andor sensi
tisation of the cough reflex in animals and humans and in so doing
may be tonically active in airway sensory nerves This review
examines the various mechanisms that can activate and sensitise
TRPVI receptors and the evidence that suggests that these recep
tors are important in pain and cough pathways Adecade after the
first reported cloning ofthe receptor2TRPVI research has moved
into another era The availability of novel potent and selective
TRPVI antagonists together with agreater understanding ofTRPVI
physiology and pharmacology should enable crucial questions
with respect to the potential therapeutic benefits of targeting this
mechanism in disease To date the foremost application of TRPVI
receptor antagonistsagonists has been understandably in pain
However the potential therapeutic benefit of targeting TRPVI for
a wide range of other disease areas including asthma and cough 8
has recently been highlighted
2 Activation and sensitisation of TRPV1 receptors
Sequence analysis of the cloned capsaicin receptor VRl
revealed that it belongs to the TRP superfamily characterised by
having six transmembrane domains and having a pore region
between the fifth and sixth transmembrane domains 2 Once
activated by vanilloid molecules the channel allows the influx of
the cations Ca 2 and Na TRPVI mRNA is highly expressed in
a subset of primary sensory neurones with AS and Cfibres that
respond to chemical mechanical and thermal stimuli and
therefore they are classified as polymodal nociceptors Fig 1
Recent studies have demonstrated that several endogenous
Brady B
PAR
NGF P
chemical substances can activate TRPVI in various tissues The
most prominent feature of TRPVI is its responsiveness to physi
cochemical agentsnoxiou stimuli such as temperature and
protons TRPVI can be activated by acidic solutions with a pH of
56 which can be produced in tissues during pathological
conditions with inflammation 9TRPVI is a thermosensor on
afferent nerves activated by temperatures between 42 and 53 C
2 which coincides with the threshold temperature of thermal
pain perception 9The effect of temperature on airway afferent
nerves has not been as widely studied as the cutaneous
temperature sensors However it is probably unlikely that these
temperatures are achieved in the lower airways even in the
inflamed lung Whilst it is known that noxious cold air can induce
coughwhich may implicate TRPM8 receptors there appears to be
little or no evidence to show whether hot air can cause or
sensitise the cough reflex Recently several members of the TRP
family including TRPVI and TRPV4 have been implicated in
sensory nerve mechanotransduction 10 Nonetheless the
molecular basis of mechanical transduction in the sensory
terminals of the airways is little understood but it would be
fascinating to determine if TRPVI receptors in airway sensory
nerves can respond to mechanical stimuli that can cause cough
Additional stimuli of TRPVI include elevated concentrations of the
endocannabinoid anandamide 11 the lipoxygenase metabolites
of arachidonic acid leukotriene B4 LTB4 12S and 15S
hydroperoxyeicostetraenoic acid 125 and 15S HPETE 12
which can also sensitise TRPVI receptors Recently N arach
idonoyl dopamine NADA has been recognised as a TRPVI
stimulant apparently more potent than anandamide 134
It is well known that bradykinin activates sensory neurones
however the mechanism by which this occurs is not well under
stood although possible sensitisation pathways have beensuggested
Bradykinin releases diacylglycerol DAG inositol145triphos
phate IP3 and arachidonic acid from sensory neurones 9
Thus it is likely that arachidonic acid generated by bradykinin
would in turn activate phospholipase A2 PLA2 and result in
the production of lipoxygenase products from arachidonic acid
QGv2
Heat
PLC
G PIP
AA a z
1 1 PGs
IP DAG
HPETEs
HETEs C4
LTB
1 Ethanol
NaCaz
Ff
r
Capsaicin
N unilloids
Anandamide
Fig 1 Diversity of mechanisms either directly indirectly or sensitising TRPVI receptors in the terminals of primary sensory neurones For explanation see text
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A PLA2 lipoxygenaseTRPVI pathway for excitation of sensory neu
rones by bradykinin is therefore possible Fig1
It is well documented that a number of endogenous inflam
matory mediators can modulate the sensitivity of TRPV1 during
tissue inflammation The exact mechanisms underlying the sensi
tisation of TRPV1 are not yet fully understood but several signal
transduction pathways are known to be involved Fig 1TRPV1 has
several consensus phosphorylation sites that can be phosphory
lated by protein kinases A C and G PKA C and G and tyrosine
kinase Trk 15181 which ultimately results in sensitisation of
TRPV1 receptors PKC activation increases neuronal current
responses to noxious heat and the activation of PKC by phorbol
esters enhances the responses ofTRPV1 to capsaicin anandamide
acid and heat 1719 Thus for example bradykinin which as
already mentioned could indirectly activate TRPV1 receptors via
the production ofarachidonic acid metabolites could also sensitise
the TRPV1 receptor by an indirect action on PKC also via the
production of lipoxygenase products such as 15 SHPETE which in
turn activates PKC Furthermore bradykininvia activation oftheB2
receptor Fig 1 is known to stimulate phospholipase C PLC and
increase the production of DAG which in turn activates PKC 201
Prostaglandin E2 PGE2 also sensitises sensory neurones via an
effect on TRPV1 receptors Fig 1 Evidence suggests that PGE2
activates the G proteincoupled EP2 prostanoid receptor present on
the membranes ofthese neurones which upon activation increases
the enzyme activity of adenyl cyclase The resulting rise in cAMP
may then stimulate PKA which in turn increases the phosphory
lation of TRPV1 and enhances its excitability 1162 1 A further
example is nerve growth factor NGF administration of NGF in
somatic tissues induces a longlasting increase in the sensitivity of
TRPV1 receptors This effect is believed to be mediated through the
Gprotein coupled TrkA receptors which in turn activates
mitogenactivated protein kinase and the PLC signalling pathway
resulting in potentiation of the TRPV1 channel 202
Another pathway for sensitising TRPV1 involves the disinhibi
tion of the receptor PLC cleaves phosphatidylinositol45
biphosphate PIP2 toyield IP3 and DAG PIP2 constitutively inhibits
TRPV1 such that removal of PIP2 from TRPV1 results in disinhibi
tion of the receptor When PLC is activated by bradykinin or NGF
PLC sequesters PIP2 which release TRPV1 from the constitutive
inhibition Fig 19
3 TRPV1 receptors in pain
Depending on its origin pain can be classified as follows pain
caused by the activation of nociceptive receptors and transmitted
over intact neuronal pathways is termed nociceptive pain pain
caused by damage to neural structures that disrupts the ability of
the sensory nerves to transmit correct information to the brain is
termed neuropathic pain finally pain with no clear physiological
origin can be termed psychological pain
Growing evidence suggests several members of the TRP super
family are involved in the detection of acute noxious mechanical
and chemical as well as in neuropathic pain 1231 The first evidence
for the involvement ofTRP channels in the pain pathway came with
the cloning of the vanilloid receptor TRPV1 which is arguably the
most extensively studied of the entire TRP superfamily 24
The appropriate expression of the receptor in target tissues and the
unmistakable pungency of capsaicin and many other agonists at
the vanilloid receptor clearly define TRPV1 as a key transducer in
the pain pathway and as an important integrator of responses to
inflammatory mediators Moreover sensitisation of TRPV1 recep
tors during chronic pain is believed to contribute to the trans
duction of noxious signalling for normally innocuous stimuli
67
Furthermore TRPV1 has a unique expression profile in peripheral
nociceptors and the ability to show polymodal activation
Thus the expression ofTRPV1 in the dorsal root ganglion DRG
and nodose ganglion neurones particularly in association with
nociceptive afferent fibres together with its activation by heat
43C acid and pungent vanilloid compounds strongly indicate
that TRPV1 plays an important role in the detection and integration
of noxious stimuli 23 In genebased disruption experiments
analysis ofTRPV1 geneknockout mice revealed that the channel
contributes to the detection ofacute painful chemical and thermal
stimuli 256 In particular trpvl mice showed reduced
responses to noxious heat stimuli and complete indifference to
pungent vanilloids
In addition to theirnormal role as detectors of harmful stimuli
several pathological conditions lead to changes in the expression
level andor sensitivity of pain TRP channels This can lead to
exaggerated pain when the experienced pain overestimates the
harmfulness ofthestimulus or chronic pain when the pain persists
after the noxious stimulus has terminated Many pathological
conditions are characterised by hyperaesthesia ie enhanced
sensitivity to sensory stimuliWith respect to pain a distinction can
be made between allodynia when pain is experienced in response
to nonnoxious stimuli and hyperalgesiawhenexaggerated pain is
experienced in response to noxious stimuli
Mechanisms leading to allodynia and hyperalgesia are well
described for TRPVI The trpvl mice are notonly less sensitive
to acute painful thermal stimuli and chemical stimuli but are also
unable to develop inflammatory thermal hyperalgesia 256
Several mechanisms have been elucidated that contribute to the
increased sensitivity ofTRPV1 during inflammation and have been
discussed earlier in this review Fig 1
The well established role of TRPV1 in the pain pathway has
given rise to the development of TRPV1 selective antagonists as
new therapeutic targets for the treatment of clinical pain 271
Recently SB705498 was reported as a potent selective TRPV1
antagonist with good oral bioavailability and effectiveness in
reducing hyperalgesia and allodynia in animal models 28301
Furthermore encouraging pharmacodynamic effects including an
effect on heat pain threshold and a reduction in W burn induced
flare in the skin indicating on target activity of SB705498 and
activity versus inflammatory hyperalgesia have been reported in
Phase 1 healthy volunteer studies This demonstrates that this
compound is pharmacologically active in humansat the dose tested
and provides further confidence in the progression and design of
clinical trials to assess the efficacy ofTRPV1 antagonists in patients
31 Similarly AMG8562 a novel second generation TRPV1
antagonist was shown to cause effective anti nociceptive effects in
several models of inflammatory and surgical pain 1321 Importantly
this compound did not cause hyperthermia increase in body
temperature an effect that has been observed previously with
other TRPVI antagonists in animal and human studies 334
These examples illustrate the potential ofTRPV1 antagonists in the
treatment of varied forms ofpain in humans and with the devel
opment ofeven more selective agents further understanding of the
role of TRPV1 in pain is within reach
4 TRPV1 receptors in cough
Cough is arguably the most common symptom associated with
pulmonary diseases such as asthma bronchitis chronic obstruc
tive pulmonary disease COPD and the common cold Chronic
cough is a symptomatic manifestation of airway hyper
responsiveness Receptors present on airway sensory nerve endings
and in cell bodies of Cfibres and AS fibres are drug targets for
chronic cough Increasing evidence has suggested a significant role
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Fig 2 Current status of novel TRPV1 antagonists for drug development
ofTRPV1 in the genesis ofcough First good evidence suggests that
airway sensory nerves expressingTRPV1 receptors are involved in
eliciting cough reflexes 2135and that TRPV1 plays a critical role
in the sensory regulation andor sensitisation of thecough reflex in
animals 3537 In animals and in humans experimental cough
can be induced by inhalation of citric acid capsaicin and ananda
mide all of which are potent TRPV1 activators 3843 Second
a number of endogenous inflammatory mediators that are known
to upregulate TRPV1 sensitivity such as PGE2 bradykinin and
histamine can also enhance the cough sensitivity in experimental
animals as well as in humans 4446 Indeed PGE2 at low doses
markedly enhances the excitability of vagal pulmonary Cfibres in
anaesthetised rats 47In cultured nodose and jugular pulmonary
neurones PGE2 markedly increased the whole cell current density
and numberofaction potentials evoked by capsaicin which suggest
a sensitising effect of PGE2 on TRPV1 receptors 116 Likewise it has
recently been reported that activation of protease activated
receptor2 PAR2 upregulates the excitability of isolated rat
pulmonary chemosensitive neurones 48 and also increases
TRPV1mediated cough in guineapigs via activation of PKC and
PKA signal transduction pathways 49 Thus PGE2 and PAR2
released during airway inflammation may cause airway hyper
responsiveness and exaggerated cough reflexes via sensitisation of
TRPV1 receptors in a similar manner to that described for the
generation ofthermal hyperalgesia in inflammatory pain Third in
humans TRPV1 is upregulated in patients with chronic cough
5011and a significant correlation between the cough sensitivity
to capsaicin inhalation challenge and the density of TRPV1
expressing nerves in the mucosa of patients with chronic cough
was also observed 50 Moreover capsaicinevoked cough
responses are increased in patients with inflammatory lung
diseases such as asthma bronchitis COPD and upper respiratory
tract infection which could be a result of TRPVI sensitisation
Clearly there is a growing body ofevidence linking an important
role ofTRPV1 in airway inflammation airway hyperresponsivness
and cough Thus as in thepain arena this potential role ofTRPV1 in
the cough pathway has given rise to studies examining the phar
macological antitussive activity of TRPV1 antagonists Several
studies have used the TRPV1 antagonist capsazepine and iodo
resiniferatoxin iodoRTX These studies demonstrated antitussive
activity but the agents were not fully efficacious 4052Unfortu
nately capsazepine and iodoRTX are not particularly good phar
macological tools with limited selectivity and potency 53 More
encouragingly preclinical studies have demonstrated clear anti
tussive efficacy with the more potent and more selective TRPV1
antagonists BCTC and JNJ17203212 in a number ofrodent models
including capsaicin and citric acid evoked cough in guineapigs
534Furthermore the TRPVI antagonist BCTC was also shown
to possess antitussive activity in an antigenevoked cough model in
guineapigs 54 and also attenuated the hyperresponsiveness to
capsaicinevoked cough that develops following airway inflam
mation induced by the noxious gas sulphur dioxide 55Together
these findings provide convincing evidence to suggest that an
increase in expression andor sensitivity of TRPV1 in the airway
sensory nerves may be involved in the development of chronic
cough Unquestionably the emergent evidence implicating
a fundamental role for TRPV1 in airway inflammation means that
TRPVl antagonists may have important benefit for the treatment of
patients suffering from chronic cough asthma COPD and allergic
rhinitis
S Current status of novel TRPV1 antagonists for drug
development
To date the foremost application ofTRPV1 receptor antagonists
agonists has been understandably in pain Several synthetic
antagonists of the TRPV1 channel are being developed and are
currently under investigation focused primarily for use in pain in
particular dental pain and migraine However authoritative infor
mation regarding the exact progress of these molecules through
preclinical and early clinical development is often difficult to
acquire A number of pre clinical Phase I and Phase 11 clinical
studiestrial are currently in progress emanating from various
different pharmaceutical companies and collaborations Fig 2 As
discussed previously encouraging pharmacodynamic effects have
been obtained with SB 705498 demonstrating that this agent is
pharmacologically active in humans 1311 Likewise MerckNeuro
gen and Glenmark have also recently announced completion of
successful Phase 1 clinical trials with MK2295 NGD8243 and
GRC6211 respectively and are now in the process of assessing
proofofconcept studies in dental pain 56 Unfortunately Amgen
recently announced that their molecule AMG517 caused marked
hyperthermia in humans and stated that this would prevent it from
further development 34 Interestinglyhyperthermia has not been
highlighted as a major issue in the other Phase I studies completed
so far Notwithstanding Amgen have another second generation
TRPV1 antagonist AMG8562 in pre clinical development which
does not cause hyperthermia but retains pharmacological efficacy
in ontarget agonist challenge models and rodent pain models
There are many other companies operational in this area Fig 2
578and no doubt further clinical trials will soon be underway
Indeed Evotec AG very recently announced the initiation of a Phase
I clinical trial of a TRPVI antagonist under partnership with Pfizer
Inc To date the emphasis for TRPV1 antagonists from a clinical
development viewpoint has been on pain however there is
increasing preclinical and clinical evidence which suggests that
TRPV1 antagonists may have potential for the treatment ofcough as
well as a variety ofother human disorders
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tussive efficacy ith the ore potent and ore selective P 1 
antagonists. T  and J J17203212. in a nu ber of rodent odels 
including capsaicin- and citric acid-evoked cough in guinea-pigs 
[53.54). rt r re. t  PV1 t i t   l   
to possess antitussive activity in an antigen-evoked cough odel in 
guinea-pigs [54) and also attenuated the hyperresponsiveness to 
aicin-   at ps lo ing  -
    s  l   [55). r. 
ese indings   e ce  t   
i creas  in r ssi  nd/or s siti it  f  i  t  ir  
 es   e    e t   
. ti bl . e    
       la    
1 a ta ists a  a e i rta t e efit f r t e treat e t f 
  r   . t a.   l  
i . 
5.    l l    
 
 t  t  f r t li ti  fT  r t r t gonists/ 
sts  en. t ndably.  in.  t  
          
rr tl  r i sti ti n. f s  ri ril  f r s  i  i . i  
ti l  t l i   i i e. r. t rit ti  i f r-
      ese les  
pre-clinical and early clinical develop ent is often difficult to 
ac ire.  er f re-cli ical. ase I a  ase II clinical 
tudies/trials  tl   res     
iffere t ar ace tical c a ies a  c lla rati s (Fi . ). s 
is ss  r i sl . r i  r ic ff ts  
   58- 05498. str ti  t t t i    
r col i ll  ti  i   [ ). i i e. rck- uro-
  l r   l  r tl   pl ti  f 
sf   I l    -22  (N -82 3)  
11. res ectively. a  are  i  t e r cess f assessi  
r f-of- t st i s i  t l i  [56). f rt ately.  
recently announced that their olecule 517 caused arked 
hyperther ia in hu ans and stated that this ould prevent it fro  
  [34). restingly.     
highlighted as a ajor issue in the other hase I studies co pleted 
 r. t nding.   ther. - rati . 
1 t ist (AMG8 ) i  r -cli i l evelop ent. i  
s t s  rt er ia. t r t i s r cologi l ffi  
i  n-t t (a nist) ll  l   t i  odels. 
 r   t  i  r ti l i  t i   (Fi . ) 
[57.58). and no doubt further clinical trials ill soon be underway. 
ed.    tl       e 
 l     PV1  r  i  f r 
Inc. o date the e phasis for P 1 antagonists fro  a clinical 
develop ent viewpoint has been on pain. however. there is 
increasing preclinical and clinical evidence hich suggests that 
 t i t    t ti l f r t  tr t t f   
    f   r ers. 
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6 Conclusions
Preclinical studies suggest that the TRPV1 receptor is an
important component of several disease areas such as pain
inflammatory visceral cancer and neuropathic and airway
disease including chronic cough In addition to capsaicin this
channel can be activated directly indirectly and also sensitised by
a number of different stimuli and mechanisms including heat acid
and various inflammatory mediators There is strong experimental
evidence that the combination of direct indirect and sensitising
mechanisms finely tune the TRPVI activity It is this sensitisation of
the TRPVI receptor in inflammatory disease that could hold the key
and contribute to the transduction of noxious signalling for nor
mally innocuous stimuli ie either hyperalgesia in the case of
chronic pain or airway hyperresponsivnessyp rtu siveresponses
in patients with chronic cough It seems reasonable to suggest that
the various mechanisms for sensitisation provide a scenario for
TRPVI to be tonically active and this activity may contribute to the
underlying pathology providing an important convergence point
of multiple pain producing stimuli in the somatosensory system
and multiple coughevoking irritants in the airways There is an
increasing amount of evidence supporting the hypothesis that the
expression activation and modulation of TRPV1 in sensory neu
rones appears to be an integral component of pain and cough
pathways although the precise contribution of TRPV1 to human
disease has yet to be determined So the question remains open as
to whether TRPVI therapeutics will be efficacious and safe in man
and represent a much needed novel pain and cough therapeutic
The availability of novel potent and selective TRPVI antagonists
together with a greater understanding of TRPV1 physiology and
pharmacology should enable crucial questions with respect to the
potential therapeutic benefits oftargeting this mechanism in disease
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Chronic Cough and the Cough Reflex in Common
Lung Diseases
T Higenbottam
Clinical Science AstraZeneca RD Charnwood Bakewell Road Loughborough
Leicestershire LEI 5RH UK
SUMMARY Following the experience of asthma characterised by the presence of bronchial hyper
responsiveness the notion has been accepted that the chronic cough of disease occurs as a result of altered sensitivity
of the afferent limb of the cough reflex
Methods for testing for the threshold for eliciting the cough reflex have also been borrowed from asthma care
In the main aerosols are inhaled that contain the relevant stimulus
A number of factors influence the cough response to inhaled aerosols The distribution of the inhaled aerosol is
important as certain chemically sensitive receptors are distributed in different regions of the lungs The larynx and
central airways are important but so too are the peripheral airways The degree of bronchodilatation is also
important as airway narrowing can itself induce coughing in man
Asthma oesophageal reflux and rhinitis patients experience increased coughing that is associated with increased
sensitivity to inhaled capsaicin In syndromes of chronic obstructive pulmonary disease COPD and interstitial lung
disease ILD increased sensitivity to coughing with capsaicin is common This appears a specific effect of the
pathogenic process of the disease Modification of the disease process can lessen coughing and the sensitivity to
capsaicin c 2002 Published by Elsevier Science Ltd
KEYWORDS CoughAirway infection Lung transplants Induced coughs Asthma Gastrooesophageal reflux
INTRODUCTION Tablet Common causes of chronic cough are shown
The symptom of chronic cough often diagnosed
when coughing persists for more than 10 days may
signify one of many serious illnesses see Table 1
A persistent cough commonly occurs with upper
respiratory tract infections but this usually recovers
over a period of 610 days
In parallel with ideas developed to explain bron
chial hyperresponsiveness the chronic cough of
disease was considered a result of increased sensitivity
of the reflex mechanism of coughing Unlike reflex
bronchoconstriction while the normal cough reflex
is initiated by vagal afferent nerve the effector limb of
I Infectious disease Viral Common cold influenza
Bacterial Pneumonia
Bordetella pertussis
Tuberculosis
2 Airway disease Asthma and allergic rhinitis
Chronic bronchitis
Bronchiectasis
Lung cancer
3 Mechanical Inhaled foreign bodies
Auricular hair
4 Interstitial Sarcoidosis
lung disease Diffuse pulmonary fibrosis
Connective tissue disease
5 Drug induced Angiotensin converting enzyme inhibitors
6 Gastro intestinal Gastro oesophageal reflux
7 Psychogenic Nervous habit anxiety states
Author for correspondence T Higenbottam Clinical Science There are a number of serious diseases that cause chronic cough
AstraZeneca RD Charnwood Bakewell Road Loughborough together with the socalled psychogenic cough associated with
Leicestershire LEI 15RH UK depression and anxiety
1094553902 see front matter 241 c 2002 Published by Elsevier Science Ltd
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the reflex is a complex coordinated musculoskeletal
response Coughing is a perturbation of the normal
breathing pattern that can also be initiated voluntar
ily These attributes make the objective study of the
cough reflex problematic in man
Returning to the analogy of asthma and the mea
surement of the heightened bronchial responsiveness
rapid advances in the field were characterised by
development of standardised methods of measure
ment These standards involved selection of the
measurement of airway calibre and the means ofpro
voking the reflex Inhalation of an aerosol was the
preferred route of delivery for the provocation agent
and threshold bronchoconstriction doses defined The
study of the cough reflex in man also involves inha
lation ofan aerosol of the provocation agent and as
means of recording the subsequent coughing
As with the measurement of bronchial responsive
ness in asthma a number of different chemicals have
been used to provoke the cough reflex By contrast
with cough there is evidence that the provocative
agents act on distinct sets of receptors on the afferent
nerves and introduce a number important factors that
alter the cough responses
FACTORS THAT INFLUENCE THE COUGH
REFLEXES IN DISEASE
Distribution of the airway afferent receptors
One of the early means of provoking cough was
the use of an aqueous aerosol containing a low
concentration of the chloride anion A parallel
experimental study of laryngeal afferents had
demonstrated that the afferents myelinated nerves
were responsive specifically to aqueous solutions
that contained low concentrations of chloride anions
and low pH
In man it is necessary to deliver the aqueous aerosol
using an ultrasonic nebuliser that has an output
of 10 mUmin and a particle size of at least 10p It is
usual to inhale the aerosol from an unsealed dead
space volume of 400ml see Fig 1 During the
inhalation the expiratory breathing pattern can be
recorded and coughing detected by the characteristic
high expiratory flow rate The frequency ofcoughing
is the measurement used to determine the sensitivity
of the cough reflex
The cough reflex initiated by aqueous low chloride
solutions depends on stimulation of receptors loca
lised in the larynx and in the major airways such as
the bronchi When the same solution is nebulised at
the same rate but with an aerosol with a particle
size less than 5m then coughing is not provoked
This aerosol of large particles when inhaled is
distributed to the major airways while the small
particle aerosol is distributed to the alveoli and
smaller airways Fig 2
Patients who have undergone successful heart lung
transplants fail to respond to inhaled ultrasonically
nebulised aqueous solutions low in chloride anions
While they still respond by coughing when drops of
low chloride solutions are applied to the larynx There
is no histological evidence of airway afferent nerves
up to three years after surgery in these patients below
the level of the tracheal anastomosis between their
tittrsaonlc Cough Challenge
Methods for measuring the cough reflex
Eeuiornent Bronchoscreen Dosimeter
Integrator
Shutter
1
Pneumotachograph Heater
connection
w
Pressure I
Air Its
OlTransducer
2Channel pMichChart Recorder Placebo1 lilts Cone Low
Resistance
o CompressorValve
Computer with
Nebulizer Thermal Printer
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Cassette
Fig 1 The delivery of inhaled aerosols that contain tussive compounds make use of two delivery systems The ultrasonic nebuliser that
can aerosolise up to 10mlin and produces amist with a large mass median diameter It is usual to provideadead space volume into which
the mist is continuously delivered and from which the subject intermittently inhales This ensures a constant quality to the mist that is
inhaled Jet nebulisers offer an alternative aerosol generator with a lower volume output than the ultrasonic nebuliser It does however
produce a mist with smaller particles In addition it can be linked to a breathactuated system that delivers a single burst ofmist each
time a breath is taken Accurate dosing is a particular advantage of this type ofdevice
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Fig 2 The ultra sonic nebuliser provides a means to record the frequency of coughing during the inhalation of the tussive agents
The inhalation ofaerosols with different sized particles containing the same aqueous solution of low chloride solution distributes
to different regions of the lungs The small particle aerosol produced by a jet nebuliser when radiolabelled with technetium 99 is
largely distributed to the periphery of the lungs By contrast the ultrasonic nebuliser aerosol is by comparison distributed to the
central airways Using matched outputs of large and small particle aerosols the aqueous solution only causes cough when large particle
aerosols are inhaled
native airway and the donated lung airway Above
the anastomosis the normal afferent innervation of
the mucosa remains
Breath triggered jet nebulisers are used to provide
specific aerosolised doses of chemical stimuli and
mediators to induce coughing see Fig 1 Again
there is evidence that the receptors may have a unique
distribution in the lungs For example using jet nebu
lisers and ultrasonic nebulisers it is possible to show
that receptors sensitive to prostaglandin E PGE
and capsaicin have quite distinct distributions The
receptors sensitive to PGE are found in the large
airways in a similar distribution to those responsive
to water while the capsaicin receptors are found in
central and peripheral airways Fig 3
The effect of airway calibre on the cough reflex
Experimental studies indicate that airway calibre
increases the sensitivity of the afferents involved in
the cough reflex In man this has proved difficult to
demonstrate
Inhalation of aerosols of leukotriene D LTD
causes in normal subjects and asthmatic patients
significant airway obstruction The forced expired
volume in 1 s FEV can fall by over 50 When
this occurs coughing occurs late rather than during
the inhalation at the time of maximum broncho
constriction Use of an antagonist to the LTD
receptor blocks not only the airflow obstruction
but also the cough Fig 4 The degree of airflow
obstruction as measured by the fall of in FEV
correlates with the frequency of coughing induced
by LTD4 Fig 5
Similarly use of a P2 agonist also blocks the fall in
FEV i and coughing induced by LTD 7
These data support the idea that in man
airway obstruction could indeed enhance the
sensitivity of some of the receptors involved in
coughing
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Fig 3 Using match output nebulisers with large or small particles and the same solutions it is possible to demonstrate that large and
small particle aerosols equally provoke coughing with solutions containing capsaicin By comparison prostaglandin E2 only provokes cough
with large particle aerosols
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Drop in FEV1
The myelinated nerve afferents involved in the
response to aqueous solutions low in chloride anions
are affected by airway calibre Pre treatment with
either a X3 agonist or ananticholinergic agent
increases the FEV and the degree of bronchodilata
tion correlates with the capacity to inhibit ultrason
ically induced cough Fig 6 This is in keeping with
the observation that pulmonary stretch receptors may
influence the cough reflex
However it is not possible to inhibit cough induced
by capsaicin with bronchodilators
The effect of respiratory tract infections
Normal and non asthmatic individuals studied from
the onset of an upper respiratory tract infection
Fig 5 There is a clear correlation between the fall in FEV and
the frequency of coughing after LTD has been inhaled
URTI show a characteristic pattern of changes in
symptoms and lung function
The symptom of coughing lasts for a median of 10
days during which time the peak expiratory flow
PEF is reduced Although it is possible to cause
bronchodilatation and improve the PEF with regular
anticholinergic therapy the severity of the cough
symptom is not affected see Fig 7 Of special inter
est is the observation that during an URTI the cough
reflex from inhaled ultrasonically aqueous low chlor
ide solution is not enhanced By contrast URTI
increases the sensitivity to inhaled capsaicin
This further emphasises the differences between the
response to water and to capsaicin indicating dis
tinct populations of receptors are involved in the two
0 10 20 30 40 50
Fig 4 Inhalation of Leucotriene D LTD causes a fall in FEV
unless the subjects had first inhaled a specific LTD receptor
antagonist Associated with the fall in FEV there is sustained
coughing
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Fig 7 A study of normal volunteers who were recruited before
winter They were instructed to attend on the first day of symptoms
characterising an upper respiratory tract infection Half were
treated with regular inhaled anti cholinergic drug and the other
halftreated with a placebo inhaler The URTI resulted in a fall in
peak expiratory flow PF that slowly recovered over ten days
The same slow improvement of symptoms was seen but while
the bronchodilators im roved PF but had no effect on the
frequency of cough Cough l Cough 2 is the difference
between the pre and post treatment values of transformed cough
frequencies and the log FEV 2 IFEV 1 is the transformed
ratio of pre to post treatment FEV
reflex responses It also indicates that inflammation
enhances responses of the capsaicin receptors but not
the water receptors
The distinction between the water and capsaicin
receptors in socalled normal and pathological cough
reflex responses is further emphasised by the obser
vation that in patients with chronic cough after taking
Angiotensin converting enzyme inhibitors ACE
inhibitors the capsaicin induced cough is enhanced
while the water cough response is not affected i 1
ALTERED COUGH REFLEX TO CAPSAICIN
IN COMMON LUNG DISEASE
Of all the various agents used to induce the cough
reflex only for capsaicin is there evidence that the
pathophysiological mechanism involved in common
diseases affects the sensitivity of the reflex response
In asthma oesophageal reflux and rhinitis chronic
cough is associated with increased sensitivity to
inhaled capsaicin Treatment of the disease asthma
therapy antiacid therapy and rhinitis therapy causes
the response to capsaicin to diminish Fig 8 An
interpretation would be that the loss of airway
inflammation that results from the specific therapy
restores the sensitivity of the capsaicin receptors to
normal 12
In COPD as in asthma capsaicin induced coughing
is increased Fig9There is also evidence that the
reported symptomatic cough is correlated with the
sensitivity of the capsaicin induced cough reflex
Fig 10
Similarly in ILD patients there is also evidence of
increased sensitivity to inhaled capsaicin in producing
cough see Fig 11 This effect was not a result of
smaller lungs as aged matched normal subjects with
strapped chests to reduce lung volume had no
evidence ofenhanced capsaicin responsiveness
It can be concluded that symptomatic chronic
cough associated with common diseases is reflected
in an enhanced airway response to inhaled capsaicin
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Fig 8 The use of inhaled capsaicin to study chronic cough in patients with asthma rhinitis and gastro oesophageal reflux shows that
the patients have increased sensitivity to their cough reflex With specific treatment of asthma rhinitis and gastrooesophageal reflux the
response to inhaled capsaicin lessened significantly This would suggest that the presence of the disease caused the increased sensitivity to
the inhaled capsaicin
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This observation could provide not only a means to
study the efficacy of therapies for chronic cough but
could have diagnostic value
CONCLUSION
Chronic cough associated with a range of common
diseases is associated with enhanced responsiveness of
a
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Fig 10 Compared with an aged matched and in a young control
population the patients with cryptogenic fibrosing alveolitis
CFA ILD the proportion who coughed with capsaicin was
significantly higher in the CFA group
airway receptors to inhaled capsaicin Treatment of
the specific disease normalises the capsaicin response
A reduction in airway calibre can cause spontan
eous cough and increases the response to aqueous
solutions low in chloride anions This stimulus may
be acting on the mechanoreceptors the myelinated
afferent nerves of the airway mucosa By contrast
these receptors are not affected by development of
URTI nor treatment with ACE inhibitors
Fig 9 The use of a different method to detect the proportion of
patients with asthma and chronic obstructive pulmonary disease
COPD and control subjects who cough with inhaled capsaicin
increasing doses were inhaled The proportion who coughed four
times was ultimately 100 of all the asthma and COPD patients
significantly more than in the control population
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Fig l l The increased sensitivity to inhaled capsaicin in the
patients was associated with the frequency with which patients
reported their chronic cough
Both as a diagnostic test and a means to investigate
the impact of treatment on the disease enhanced
cough reflex to inhaled capsaicin offers the best
means of studying cough in humans
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EXPRESSION AND CHARACTERIZATION OF THE INTRACELLULAR
VANILLOID RECEPTOR TRPV1 IN BRONCHI FROM PATIENTS
WITH CHRONIC COUGH
Jennifer E Mitchell Anne P Campbell and Norman E New Department
of Cellular Pathology Hull Royal Infirmary Hull United Kingdom
Laura R Sadofsky Jack A Kastelik Siobhan A Mulrennan
Steven J Compton and Alyn H Morice University of Hull
Academic Medicine Castle Hill Hospital Hull United Kingdom
TRPV1 is a modulator of noxious stimuli known to be important in the cough reflex We have
compared the expression of 7RPVI in normal human airways and thosefrom patients with chronic
cough and found that there is up regulation in airways smooth muscle in disease This increased
expression appears to be intracellular and we have therefore examined the role of intracellular rat
and human 7 RPV1 activity was found using intracellular calcium signalling with human intra
cellular LfWI being located in a thapsigargin insensitive compartment Increase in YRPVI
activity may have a role in the airway hypersensitivity seen in chronic cough
Keywords bronchial smooth muscle chronic cough endoplasmic reticulum immuno
histochemistry TRPV1 vanilloid receptor
The vanilloid receptor TRPVI plays an important role in the response to
noxious stimuli Stimulation ofTRPVI by agonists such as protons and heat
leads to depolarization of afferent sensory nerves and the central appreci
ation of the stimulus In the airways the physiological effect of TRPVI acti
vation is demonstrated by the response to inhalation of two potent agonists
of TRPVI capsaicin and resiniferatoxin which are the most potent protus
sive agents known 1 Indeed TRPV1 is a strong candidate for the major
pharmacological receptor of the cough reflex in both man and animals 2
TRPVI also has a role in the inflammatory cascade Neurogenic inflam
mation triggered by activation ofTRPVI causes airway edema inflammatory
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cell infiltration and bronchial hyperresponsiveness Proinflammatory med
iators such as bradykinin and nerve growth factor require TRPVI for the full
expression of response 3 We sought to determine the microscopic distri
bution ofTRPV1 in human bronchus and hypothesized that 1 differential
expression of TRPVI would be observed in patients with chronic cough as
compared with asymptomatic controls and 2 this differential expression
would correlate with the presence or absence of bronchial inflammation
Recently it has been shown that the localization ofTRPV1 within cells is
not limited to the cell membrane TRPV1 tagged with green fluorescent
protein and TRPVI immunostaining has been used to demonstrate the
presence of the channel in intracellular organelles such as the endoplasmic
reticulum 47We therefore documented the pattern of subcellular stain
ing within our human bronchial specimens In addition using a human
embryonic cell line expressing cloned rat and human TRPVI we sort to
explore the functional consequences of the subcellular distribution of
TRPV1 in a calcium signaling model
MATERIALS AND METHODS
Ethical approval for this study was obtained from the Hull and East Rid
ing Local Ethics Committee
Patient and Specimen Details
Bronchoscopic biopsies from 24 patients with chronic cough see Table 1
were compared with 21 bronchial biopsies from 18 asymptomatic indivi
duals who had undergone fluorescent bronchoscopy as a potential screen
ing procedure for bronchogenic carcinoma The bronchial resection
margin from a lobectomy specimen was used as a positive control
TABLE 1 Patient Details and Inflammatory Status ofBiopsies
Diagnosis No of patients Adequate biopsies No with inflammation Degree
FB 21 21 5 Mild
Idiopathic cough 9 5 3 Mild
Postinfectivc cough 2 2 1 Mild
GER 6 6 2 Mild
Chronic allergic rhinitis 2 2 1 Moderate
Interstitial lung disease 1 1 0 NA
ABPA I 1 I Mild
Bronchiectasis 1 0 NA NA
Tourettessyndrome 1 l I Mild
Asthma and GER 1 I 1 Mild
FB fluorescent bronchoscopy GER gastroesophagcal reflux ABPA allergic bronchopulmonary
aspergillosis
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Biopsy Inflammatory Status
Five micrometer sections routinely stained with hematoxylin and eosin
were assessed for the presence or absence of inflammation and if present
its degree mild moderate or severe by an experienced histopathologist
with a special interest in respiratory pathology APC
Immunohistochemistry
Formalinfixed paraffinembedded sections were investigated by
immunohistochemistry for TRPVI Tissue sections were dewaxed in xylene
dehydrated in alcohol and taken down to water Endogenous peroxidase
was blocked using 3 hydrogen peroxide Heat mediated antigen retrieval
was performed by microwaving the slides in a pH 60 citrate buffer for 10
minutes The slides were placed in cold water to prevent the sections drying
out and were then loaded on to a Shandon Sequenza An Avidin Biotin
blocking kit Vector Laboratories Peterborough UK was used to block
any endogenous biotin present The slides were rinsed in Trisbuffered sal
ine TBS and incubated overnight at 4C in primary antibody VR1
Chemicon International Harrow UK at a concentration of14000 For
each biopsy asection incubated with TBS without primary antibodywas used
as a negative control The following day the primary antibody was washed off
in TBS The primary antibody was detected using biotinylated anti mouse
rabbit antibodies Dako Cytomation Ely UK at a concentration of100
The antigen antibody complex was then visualized by the enzymatic
reduction of 3 3diaminobenzidine tetrahydrochloride DAB Sigma
Aldrich Poole UK and enhanced darkened with copper sulphate Sec
tions were counterstained with hematoxylin then dehydrated andmounted
Interpretation of Immunohistochemistry Results and
Statistical Analysis
TRPVI staining was recorded as either positive or negative and its dis
tribution noted by two independent investigators Discrepancies in the
results were resolved by consensus following reassessment of the slide by
both investigators
Significant differences in staining pattern between the fluorescent
bronchoscopy and chronic cough patients and between the biopsies with
and without inflammation were evaluated by Fisher exact test
Cloning and Expression of Human and Rat TRPV1
Rat and human TRPVI rTRPVl hTRPVI were cloned from rat dorsal
root ganglia cDNA and MRC5 human lung fibroblasts cDNA respectively
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into the mammalian expression vector pcDNA3 Invitrogen The cloned
PCR products were sequenced and compared to the published rTRPVI
and hTRPVI sequences accession numbers AF029310 and AY131289
respectively For tranfections semiconfluent HEK cells 40 to 60 in
60 mm Petri dishes were transfected using the LipofectAMINE method
according to the manufacturer protocol Gibco Transfected HEK cells
were subcloned in geneticin 06mgmL containing medium Dulbeccos
modified Eagle medium DMEM containing 10 fetal calf serum FCS
100 UmL penicillin 100 gmL streptomycin and 250 ngmL amphoteri
cin B To obtain cell lines permanently expressing receptors singlecell
colonies were grown and subsequently tested for capsaicin responsiveness
by measuring increases in intracellular calcium see Calcium Signaling
The final clones selected were taken through three rounds of singlecell
cloning to ensure the cell lines were derived from a single cell
Calcium Signaling
Calcium signaling was performed using methods based on those by
Compton and colleagues 8Cells at 90 confluence in 75cm2 flasks were
washed and harvested with phosphatebuffered saline PBS without cal
cium or magnesium The cells were pelleted and resuspended in 1 mL
of DMEM culture medium containing 10 FCS 100 UmL penicillin
100 ggmL streptomycin and 250 ngmL amphotericin B containing
025 mM sulphinpyrazone and 25 g of Fluo3 acetoxymethyl ester Fluo3
AM The cells were then incubated at room temperature RT for 25 min
utes whilst gently shaking The cells were then washed by centrifugation
and resuspended in Calcium Assay Buffer CAB 150mM sodium chlor
ide 250M sulphinpyrazone 3 mM potassium chloride 10 mM glucose
20mM HEPES and 280mM calcium chloride CaC1 pH 74
Increases in intracellular calcium levels were measured at RT using a fluoro
spectrometer Photon Technology International The fluorospectrometer
was set to emit an excitation wavelength of 480 nm and record light emitted
with a wavelength of 530 nm Each cuvette contained 2 ml of suspended
cells in CAB and a small magnetic flea Capsaicin concentration effect
curves were constructed for rTRPVI HEK cells and hTRPVIHEK cells in
the presence and absence of extracellular calcium by adding increasing
concentrations of capsaicin to separate cellcontaining cuvettes The
increase in fluorescence at 530 nm was recorded and expressed as a per
centage of the maximum fluorescence signal after the addition of 6M cal
cium ionophore A23187 Results were analysed using GraphPad Prism
software
To determine the dependence of the capsaicin response on thapsigar
gin sensitive intracellular calcium stores cells were preincubated for
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cells in  and a s all agnetic flea. apsaicin concentration effect 
es e cte   I-HE  s  -HE  ll ,  
the presence and absence of extracellular calcium, by adding increasing 
concentrations of capsaicin to separate cell-containing cuvettes. he 
increase in fluorescence at 530 nm was recorded and expressed as a per-
centage f the axi u  fluorescence signal after the addition f 6 ~M cal-
ciu  ionophore (A23187). esults ere analysed using raph ad ris  
t . 
o eter ine t e e e e ce f t e capsaicin res se  thapsigar-
gin sensitive intracellular calcium stores, cells were preincubated for 
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4 minutes with 1 tM thapsigargin prior to the addition of capsaicin either
in the presence or absence of extracellular calcium
RESULTS
Five of the biopsies from the chronic cough patients had insufficient
material for adequate assessment and were excluded from the study
Biopsy Inflammatory Status
Five of the 21 biopsies from the fluorescent bronchoscopy patients
showed a mild degree of inflammation whereas 10 out of 19 biopsies from
the chronic cough patients were inflamed Table 1 Figure 1
FIGURE I Normal bronchial biopsy from a fluorescent bronchoscopy control A and an inflamed
bronchial biopsy from a chronic cough patient B Hernatoxylin and eosin stain
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4 inutes ith 1 ~IM thapsigargin prior to the addition of capsaicin either 
in the presence or absence of extracellular calciu . 
 
Five of the biopsies fro  the chronic cough patients had insufficient 
aterial for adequate assess ent and ere excluded fro  the study. 
i  I fl t r  t t  
Five f the 21 biopsies fro  the fluorescent bronchoscopy patients 
showed a ild degree of infla ation, whereas 10 out of 19 biopsies fro  
t e c r ic c  patients ere i fla e  (Table 1, igure 1). 
FIGURE 1 Normal bronchial biopsy from a fluorescent bronchoscopy control (A) and an inflamed 
r c ial i s  fr  a c r ic c  atie t (B). ematoxyli  a  e si  stain. 
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Immunohistochemistry
Bronchial resection margin used as the positive control showed positive
staining for TRPVI in ganglia and small nerves In addition staining of
chondrocytes within bronchial cartilage was observed
The test biopsies showed positive staining for TRPVI within cartilage
whenever this was present 9 cases In addition some biopsies showed
positive staining of small nerves Figure 2 and smooth muscle myocytes
Figure 3 The latter tended to have a perinuclear distribution
No significant differences were observed between the fluorescent bron
choscopy controls and the chronic cough patients in neural expression of
TRPVI Table2 In contrast a highly significant difference was observed in
FIGURE 2 Positive immunohistochcmical staining for TRPVl in a nerve arrow from the bronchial
biopsy of a fluorescent bronchoscopy control patient A and with negative control 6
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00 J E. itchell et al. 
I ist c e istry 
ronchial resection argin used as the positive control sho ed positive 
staining for TRPVl in ganglia and small nerves. In addition, staining of 
chondrocytes within bronchial cartilage was observed. 
The test biopsies sho ed positive staining for TRPVl within cartilage 
whenever this was present (9 cases). In addition, so e biopsies showed 
positive staining of s all nerves (Figure 2) and s ooth uscle yocytes 
(Figure 3). The latter tended to have a perinuclear distribution. 
 si ifica t ifferences ere s r ed t e  t  fluores t r -
s  trols  t  r ic h tie ts i  r l r ssi  f 
TRPVl (Table 2). In contrast a highly significant difference was observed in 
FIGURE 2 Positive immunohistochemical staining for TRPVI in a nerve (arrow) from the bronchial 
biopsy of a fluorescent bronchoscopy control patient (A) and with negative control (E). 
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FIGURE 3 Positive immunohistochemical staining for TRPV1 in the cytoplasm of smooth muscle arrows
from the biopsy of a chronic cough patient A with negative control I3and negative staining of smooth
muscle for TRPVl in the biopsy ofa fluorescent bronchoscopy control G
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I  3 Positive i unohistoche ical staining for P l in the cytoplas  of s ooth uscle (arro s) 
from the biopsy of a chronic cough patient (A), with neg-ative control (B), and neg-ative staining of smooth 
uscle for l in the biopsy f a fluorescent bronchoscopy control (C). 
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TABLE 2 Positive Staining for TRPVl
Patient group n Smooth muscle Nerve
FB controls 21 1 2
Idiopathic cough 5 3 0
Postinfective cough 2 1 0
GER 6 4 1
Chronic allergic rhinitis 2 0 0
Interstitial lung disease I 1 0
ABPA 1 0 0
Bronchiectasis 1 0 0
Tourettessyndrome 1 1 0
Asthma and GER 1 0 0
Total chronic cough 19 11 1
Versus FB control 0003 NS
FB fluorescent bronchoscopy GER gastroesophageal retlux ABPA allergic bronchopulmon
ary aspergillosis
the stainingof smooth muscle myocytes between the 2 groups 1 of the fluor
escent bronchoscopy controls compared with 11 of the biopsies from
chronic cough patients P 0003 Table 2 and Figure 3 No positive
staining was noted in any of the negative controls
Correlation with Inflammation
There was no significant difference in the expression of TRPVI
between the biopsies with nerve 0 smooth muscle 4 and without nerve
2 smooth muscle 8 inflammation
Calcium Signaling in Rat and Human TRPV1 HEK293
Capsaicin concentration effect curves for HEK cells transfected with
human and rat TRPVI generated ECvalues of 8 nM and 424 nM respect
ively with a greater magnitude of response in hTRPVI Figure 4A and B
In rTRPV1 in the presence of extracellular calcium pretreatment of the
cells with 1 gM thapsigargin resulted in a 38 reduction in capsaicin
response 30 gM compared to controls Figure 4A In contrast hTRPVI
under the same conditions displayed no reduction in the capsaicin
response Figure 4B The maximal response of hTRPVI to capsaicin
1 gM in calciumfree buffer was reduced by 28 compared to the
response obtained in calciumcontaining buffer with no further reduction
detected with pretreatment of 1 gM thapsigargin Figure 4B For rTRPV1
removal of extracellular calcium resulted in a complete loss in the capsai
cin response up to 3 gM Figure 4A At 10 gM and 30 gM capsaicin a 79
and 67 reduction in capsaicin response was observed respectively
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the staining of s ooth uscle yocytes between the 2 groups (1 of the fluor-
esce t r c sc  c trols re  it   f t e i sies fr  
chronic cough patients P = .00 ) (Table   igure ).  siti e 
stai i  as te  i  a  f t e e ati e c tr ls. 
  ti  
here as no significant difference in the expression f l 
bet een the biopsies ith (nerve 0, s ooth uscle 4) and ithout (nerve 
2, s t  uscle 8) i fla ati . 
l i  i li  i       
Capsaicin concentration-effect curves for HEK cells transfected with 
hu an and rat T P l generated ECso values of 8 n  and 424 n , respect-
ively, with a greater magnitude of response in hTRPVl (Figure 4A and B). 
In r P l, in the presence of extracellular calciu , pretreat ent of the 
cells ith 1 J.l  thapsigargin resulted in a 38% reduction in capsaicin 
response (30 ~IM) compared to controls (Figure 4A). In contrast, hTRPVl 
under the sa e conditions displayed no reduction in the capsaicin 
response (Figure 4B). The maximal response of hTRPVl to capsaicin 
(l J.l ) in calciu -free buffer as reduced by 28% co pared to the 
response obtained in calcium-containing buffer, with no further reduction 
detected with pretreatment of 1 J.lM thapsigargin (Figure 4B). For rTRPVl, 
re oval of extracellular calciu  resulted in a co plete loss in the capsai-
cin, response up to 3 J.lM (Figure 4A). At 10 J.lM and 30 J.lM capsaicin a 79% 
and 67% reduction in capsaicin response was observed, respectively 
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FIGURE 4 Capsaicin concentration effect curves for A rTRPV1 and B hTRPV1 transfected HEK293
cells either with or without extracellular calcium andor thapsigargin 1gM With extracellular
calcium A With cxtracellular calcium and 1 M thapsigargin 0 Without extracellular calcium
0 Without extracellular calcium and with I gM thapsigargin 0 Without extracellular calcium in
the presence of 10 gM capsazepine The results are expressed as the mean f SEM of 3 to 6 separate
experiments each performed in duplicate
Figure 4A The rTRPV1 specificity of this remaining response was
confirmed by the addition of 10 M capsazipine Figure 4A The com
bination of extracellular calcium removal and 1 M thapsigargin pre
treatement resulted in a negligible capsaicin response even at 30M
Figure 4A and B
1 2 3 4
Log Capsaicin Concentration nM
1 0 1 2 3
Log Capsaicin Concentration nM
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FIGURE 4 Capsaicin concentration effect curves for (A) rTRPV1 and (8) hTRPV1 transfected HEK293 
lls it r it  r it t tr ll lar l i  /or t si r i  (l flM). (0) it  extr cell l r 
calcium. (6) ith extracellular calcium and 1 IlM thapsigargin. ('7) ithout extracellular calcium. 
(O) ithout extracellular calcium and with 1 IlM thapsigargin. (0) ithout extracellular calcium in 
the presence of 10 Il  capsazepine. The results are expressed as the mean ± SE  of 3 to 6 separate 
experiments each performed in duplicate. 
(Figure 4A). The rTRPVI specificity of this remammg response was 
confir ed by the addition of 10 ~IM capsazipine (Figure 4A). he com-
bination f extracellular calciu  re oval and 1 ~M thapsigargin pre-
treatement resulted in a negligible capsaicin response, even at 30 ~M 
(Figure 4A and B). 
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DISCUSSION
The distribution of TRPV1 has been previously studied by immunohis
tochemistry and in the periphery is localized to small diameter nerve
fibres and ganglia 9 Our findings of positive staining of nerves and gang
lia in normal human lung supports the idea of constitutive TRPV1
expression and provides further evidence for a role for TRPV1 in afferent
respiratory reflexes Regulation of the TRPVI occurs in disease states and
increased TRPV1 immunoreactivity localized to nerve fibers has been
demonstrated in inflammatory bowel disease 10 The human airway is
relatively sparsely innervated and within individuals there is marked varia
bility in nerve density and distribution This coupled with the necessity of
using small biopsy specimens provides the opportunity for sampling error
In addition our fluorescent bronchoscopy control group differed signifi
cantly in age and smoking status to our chronic cough group However
despite these limitations our findings suggest that there is no gross
up regulation of TRPVI positive nerves in chronic cough but as with many
studies in the literature 11 subtle changes cannot be commented on with
certainty
The observed positive staining of chondrocytes is similar to that seen
with S100 protein a calcium flux regulator first isolated from the central
nervous system 12 The significance in this case is uncertain
Perhaps the most surprising finding was the observation of positive
staining of bronchial smooth muscle cytoplasm in eleven of our biopsies
from patients with chronic cough and in only one of the fluorescent bron
choscopy controls Technical failure in the control specimens is unlikely
because TRPV1 immunoreactivity was detected in airway nerves To our
knowledge this is the first report of TRPVI immunoreactivity in nonneuro
nal tissue within the lungs Expression of functional TRPVI has been
described in human keratinocytes where they contribute to the inflamma
tory cascade 13 14
We explored the functional consequences of this cytoplasmic TRPV1
staining in stably transfected cell lines expressing both human and rat
TRPVl We found hTRPVI to be significantly more sensitive to the effects
of capsaicin stimulation both in terms of threshold concentration and
peak effect Stimulation of both human and rat TRPVI by capsaicin in
the absence of extracellular calcium still led to an increase in intracellular
calcium signaling which presumably represents release of calcium from
intracellular calcium stores In the case of rTPRVI these stores were thap
sigargin sensitive indicating a reliance on endoplasmic reticulum Ca2
ATPase In contrast hTRPVI was less sensitive to depletion of extracellular
calcium and the response was thapsigargin insensitive It therefore appears
that intracellular activity has a greater importance in hTRPVI and this may
001232
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he distribution of RPVl has been previously studied by i unohis-
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expression and provides further evidence for a role for TRPVl in afferent 
respiratory reflexes. Regulation of the TRPVl occurs in disease states and 
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e strated in inflam at r  el isease [1 ]. e an air a  is 
relatively sparsely innervated and within individuals there is arked varia-
bility in erve e sit  a  istri ti . is c led ith t e necessity f 
using s all biopsy speci ens provides the opportunity for sa pling error. 
In addition, r fluorescent bronchoscopy control r  differed signifi-
cantly in age and smoking status to our chronic cough group. However, 
despite these limitations our findings suggest that there is no gross 
up-regulation of TRPVl positive nerves in chronic cough, but as with many 
t ies in e iterature [ ], subtle changes cannot be co ented on ith 
certainty. 
The observed positive staining of chondrocytes is similar to that seen 
with S100 protein, a calciu  flux regulator first isolated fro  the central 
nervous syste  [12]. The significance in this case is uncertain. 
Perhaps the ost surprising finding was the observation of positive 
staining of bronchial s ooth muscle cytoplasm in eleven of our biopsies 
fro  patients with chronic cough and in only one of the fluorescent bron-
choscopy controls. Technical failure in the control speci ens is unlikely 
because TRPVl i unoreactivity was detected in airway nerves. To our 
kno ledge this is the first report ofT P I i unoreactivity in non-neuro-
nal tissue ithin the lungs. Expression of functional TRP l has been 
escri e  i  a  erati c tes ere t e  c tri te t  t e i fla a-
tory cascade [13, 14]. 
e explored the functional consequences of this cytoplas ic TRPVl 
staining in stably transfected cell lines expressing both hu an and rat 
TRPVl. e found hTRP l to be significantly ore sensitive to the effects 
of capsaicin sti ulation, both in ter s of threshold concentration and 
peak effect. Stimulation of both human and rat TRPVl by capsaicin in 
  f xt ell  l  till  t   i   l  
calciu  signaling, which presu ably represents release of calciu  fro  
i tr ll l r l i  st r s. I  t  s  f r I t s  st r s r  t p-
sigargin sensitive, indicating a reliance on endoplasmic reticulum Ca2+ 
e. I  ntrast, l  l  sensiti  t  pl ti  f xtr cell l r 
calcium and the response was thapsigargin insensitive. It therefore appears 
that intracellular activity has a greater importance in hTRPVl and this may 
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give more weight to our observation of TRPVI staining in the cytoplasm of
smooth muscle from patients with chronic cough
Our patients reflected the mixed pattern of disease seen in chronic
cough In all forms of chronic cough there is evidence of airway inflam
mation with an increase in inflammatory cells in bronchoalveolar lavage
fluid and on histology an increase in epithelial desquamation inflamma
tory cells particularly mononuclear cells with associated submucosal
fibrosis squamouscell metaplasia and loss of cilia 15 Physiologically
there appears to be upregulation of the TRPVI system as evidenced by cap
saicin hypersensitivity 16 17 Thus even in cough caused by isolated gas
troesophageal reflux cough sensitivity to inhaled capsaicin is enhanced
18 This demonstrable hyperresponsiveness may reflect increased
expression of TRPVI How and why any such increased expression is seen
in smooth muscle is unknown Given the role of TRPVI in the inflamma
tory cascade it is tempting to postulate that upregulation of TRPVI in
smooth muscle may occur in the response to inflammation However the
findings of the present study do not support the simple relationship of
cellular inflammation to TRPV1 upregulation
In conclusion we have demonstrated increased expression ofTRPVI in
patients with chronic cough and this expression is uniquely found in the
cytoplasm of bronchial smooth muscle hTRPVI is shown to have an impor
tant cytoplasmic component of activity suggesting a pathophysiological
role for our findings
REFERENCES
1 Laude EA Higgins KS Morice AH A Comparative study of the effects of citric acid capsaicin and
resiniferatoxin on the cough challenge in guinea pig and man Pulm Pharmacol 1993671175
2 Morice NH Geppetti P Cough 5 The type 1 vallinoid receptor a sensory receptor for cough
Thorax2004593578
3 Chuang HH Prescott ED KongHShields S Jordt SE BasbaumAI ChaoMVIuliusD Bradykinin
and nerve growth factor release the capsaicin receptor from Ptdlns452mediated inhibition
Nature 200141957962
4 Olah Z Szabo T Karai L Hough C Fields RD Caudle RNI Blumberg PM Iadarola MJ Ligand
induced dynamic membrane changes and cell deletion conferred by vanilloid receptor 1 I Biol
Chem 2001761102 11030
5 Liu M Liu MC Magoulas C Priestley JV Willmott NI Versatile regulation of cytosolic Ca by
vanilloid receptor I in rat dorsal root ganglion neurons Biol Chem 20037854625472
61 Wisnoskey BJ SinkinsWG Schilling WP Activation of vanilloid receptor type I in the endoplasmic
reticulum fails to activate store operated Ca21 entry Biochem J2003372517528
7 Karai LIRussellITIadarolaMl Olah Z Vanilloid receptor 1 regulatesmultiple calcium compartments
and contributes toCa l induced Ca release in sensory ncuronsJBiol Chem200479163778
8 Compton Si Cairns lA Palmer KJ Al Ani B Hollenberg MD Walls AF A polymorphic protease
activated receptor 2 PAR2 displaying reduced sensitivity to trypsin and differential responses to
PAR agonists J Biol Chem 2000753920739212
9 Guo A Vulchanova L Wang J Li X Elde R ILnmunocytochemical localization of the vanilloid
receptor 1 TRPVl relationship to neuropeptides the P2X3purinoceptor and I134 binding
sites Eur J Neurosci 19991946958
001233
illoid t  in o c i 305 
give ore eight to our observation of TRP l staining in the cytoplas  of 
s ooth uscle fro  patients ith chronic cough. 
ur patients reflected the ixed pattern of disease seen in chronic 
cough. In all forms of chronic cough there is evidence of air ay infla -
ation ith an increase in infla atory cells in bronchoalveolar lavage 
fluid, and on histology an increase in epithelial desqua ation, infla a-
tory cells, particularly ononuclear cells ith associated sub ucosal 
fibrosis, squa ous-cell etaplasia, and loss of cilia [15]. Physiologically 
there appears to be up-regulation of the TRPVl system as evidenced by cap-
saicin hypersensitivity [16, 17]. hus even in cough caused by isolated gas-
troesophageal reflux, cough sensitivity to inhaled capsaicin is enhanced 
[18]. his de onstrable hyperresponsiveness ay reflect increased 
expression of TRPVl. How and why any such increased expression is seen 
in  uscle is . e   le  l   la a-
tory cascade, it is tempting to postulate that upregulation of TRPVl in 
smooth muscle may occur in the response to inflammation. However, the 
findings of the present study do not support the simple relationship of 
cellular infla ation to P l up-regulation. 
In conclusion, e have de onstrated increased expression of l in 
patients with chronic cough and this expression is uniquely found in the 
cytoplasm of bronchial s ooth muscle. hTRPVl is shown to have an impor-
tant cytoplasmic co ponent of activity, suggesting a pathophysiological 
role for our findings. 
 
[1] aude , iggins S, orice :  o parative study of the effects of citric acid, capsaicin and 
resiniferatoxin on the cough challenge in guinea pig and an. Pul  har acal. 1993;6:171-175. 
[2] orice A , eppetti P: ough. 5: he type 1 vallinoid receptor: a sensory receptor for cough. 
rax. 004;59(3):257-258. 
[3] Chuang HH, Prescott ED, Kong H, Shields S,Jordt SE, Basbaum AI, Chao MY,Julius 0: Bradykinin 
and nerve gro th factor release the capsaicin receptor fro  Ptdlns(4,5)P2- ediated inhibition. 
t . 001 ;411 :957-96 . 
[4] Olah Z, Szabo T, Karai L, Hough C, Fields RD, Caudle RM, Blumberg PM, Iadarola tvU: Ligand-
induced dyna ic e brane changes and cell deletion conferred by vanilloid receptor 1. J ioi 
rn. 00 ;276:11021-11030. 
[5] Liu M, Liu MC, Magoulas C, Priestley.lV, Willmott N.J: Versatile regulation of cytosolic Ca2 f by 
vanilloid receptor [ in rat dorsal r t ganglion e r s . .J ioi hern. 2003;278:5462-5472. 
[6] isnoskey ~J, Sinkins G, Schilling P: Activation ofvanilloid receptor type I in the endoplasmic 
reticulum fails to activate store-operated Ca2f entry. Biochem J. 2003;372:517-528. 
[7] Karai q, Russell.JT, Iadarola MJ, Olah Z: Vanilloid receptor 1 regulates multiple calcium compartments 
and contributes to a2 I -induced a2 f release in sensory neurons . .J ioi hern. 2004;279: 16377-16387. 
[8] Compton ~J, Cairns .lA, Palmer 1<:1, AI-Ani B, Hollenberg MD, Walls AF: A polymorphic protease-
activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to 
PAR agonists . .J Bioi Chern. 2000;275:39207-39212. 
[9] Guo A, Vulchanova L, Wang.J, Li X, Elde R: Immunocytochemical localization of the vanilloid 
receptor I (TRPV1): relationship to neuropeptides, the P2X(3) purinoceptor and IB4 binding 
sites. ur . .J. eurosci. 1999;11:946-958. 
306 J 1J Mitchell et al
10 Yiangou Y Facer P Dyer NH Chan CL Knowles C Williams NS Anand P Vanilloid receptor
1 immunoreactivity in inflamed human bowel Lancet 200135713381339
11 OConnell F Springall DR MoradoghliHaftvani A KrauszT Pri D Fuller RW PolakJM Pride NB
Abnormal intraepithelial airway nerves in persistent unexplained cough Am J Respir Crit Care
Med 19953220682075
12 Nakamura S Nakamura T Kawahara H 5100 protein in human articular cartilage Arta Orthop
Scand 19885943 440
131 Inoue K Koizumi S Fuziwara S Denda S Denda M Functional vanilloid receptors in cultured
normal human keratinocytes Biochem Biophys Res Commun 2002911249
14 Southall MD Li T Gharibova LS Pei Y Nicol GD Travers JB Activation of epidermal vanilloid
receptor1 induces release of proinflammatory mediators in human keratinocytes J Pharmacol
Exp Ther 20033 417222
151 Boulet LP MilotJ Boutet M St Georges F Laviolette M Airway inflammation in nonasthmatic
subjects with chronic cough Am J Respir Crit Care Med 199449482489
16 OConnell F ThomasVE Studham JM Pride NB Fuller RW Capsaicin cough sensitivity increases
during upper respiratory infection Respir Med 199690279286
17 Choudry NB Fuller RW Sensitivity of the cough reflex in patients with chronic cough Eur
RespirJ 199252 6300
181 Nieto L de Diego A Perpina M Compte L Garrigues V Martinez E Poncc Cough reflex testing
with inhaled capsaicin in the study of chronic cough Respir Med 20039739 400
001234
06  E. itchell et l. 
[10] iangou , Facer P, yer , han , no les , illia s , nand : anilloid rece t r 
1 i unoreactivity in inflamed a  bo el. ancet. 2001;337:1338-1339. 
[11] ell F, rin all , ra ghli- aftvani , ra sz , ri 0, ller , la ] , ride : 
Abnormal intraepithelial airway nerves in persistent unexplained cough? Am J Respir Crit Care 
. 1995; 132:2068-207 . 
[1 ] aka ura , aka ura , awahara : S-1 0 rotein in u an rtic lar c rtila . cta rthop 
. 988;39:438- 40. 
[13] Inoue , oizu i , Fuziwara , enda ,  : tio l V"anilloid r t rs in lt re  
nor al hu an keratinocytes. Biochem Biophys Res Co un. 2002;291:124-129. 
[l4] Southall D, Li T, Gharibova LS, Pei Y, Nicol GO, Travers .JB: Activation of epider al vanilloid 
receptor-l induces release of proinflammatory ediators in hu an keratinocytes . .J Phar acol 
Exp Ther. 2003;304:217-222. 
[13] oulet LP, ilotJ, outet , St eorges F, Laviolette : irway inflam ation in nonasth atic 
subjects ith chronic cough. ] espir rit are ed. 1994;149:482-489. 
[l6] onnell F, ho as , Studha .J , Pride , Fuller : apsaicin cough sensitivity increases 
during upper respiratory infection. espir ed. 1996;90:279-286. 
[17] houdry , Fuller : Sensitivity of the cough reflex in patients ith chronic cough. Eur 
espir J. 1992;3:296-300. 
[18] Nieto L, de Diego A, Perpina , Co pte L, Garrigues V, artinez E, Ponce.J: Cough reflex testing 
with inhaled capsaicin in the study of chronic cough. Respir ed. 2003;97:393-400. 
Copyright of Experimental Lung Research is the property of Taylor Francis Ltd and
its content may not be copied or emailed to multiple sites or posted to a listsery
without the copyright holdersexpress written permission However users may print
download or email articles for individual use
001235
opyright f xperi ental Lung esearch is the property f aylor & r i  t   
its content ay not be copied or e ailed to ultiple sites or posted to a listserv 
ithout the copyright holder's express ritten per ission. o ever, users ay print, 
l , r il rticles f r i i i l . 
Neurogenic Inflammation and Sensitivity to Env ental Chemicals h vwwhercorgnewsmcsarticlesmeggs fullhtiA
Back NIEHS
Research Advance
Environmental Health Perspectives Volume 101 Number 3 August 1993
Neurogenic Inflammation and Sensitivity to Environmental Chemicals
William J Meggs
Department ofEmergency Medicine East Carolina University School ofMedicine Greenville NC 27858
USA
Introduction
Discussion
Abstract
Neurogenic inflammation as a pathway distinct from antigen driven immune mediated inflammation may
play a pivotal role in understanding a broad class of environmental health problems resulting from chemical
exposures Recent progress in understanding the mediators triggers and regulation of neurogenic
inflammation is reviewed Evidence for and speculations about a role for neurogenic inflammation in
established disorders such as asthma rhinitis contact dermatitis migraine headache and rheumatoid arthritis
are presented The sick building syndrome and multiple chemical sensitivity syndrome have been defined as
clinical entities in which exposure to chemical inhalants gives rise to disease Current data on the existence of
chemical irritant receptors in the airway and skin are discussed neurogenic inflammation arising from
stimulation of chemical irritant receptors is a possible model to explain many of the aspects of chemical
sensitivities Keywords asthma indoor air pollution multiple chemical sensitivity syndrome neurogenic
inflammation neutral endopeptidase reactive airways dysfunction syndrome reactive upper airways
dysfunction syndrome rhinitis substance P sick building syndrome Environ Health Perspect 101
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Introduction
Sensitivity to environmental chemicals in general and in particular to volatile organic chemicals VOCs in
indoor air needs to be elucidated The lack of an established mechanism to explain how exposure to
concentrations ofVOCs that are well tolerated by the population at large can produce the array of symptoms
seen in sensitized individuals has hampered progress in understanding these disorders Over the past few years
progress has been made in understanding neurogenic inflammation chemical irritant receptors and the
regulation of neurogenic inflammation Here I review these topics emphasizing those aspects that may be
applicable to elucidating the mechanism of chemical sensitivity as a disorder of the regulation of neurogenic
inflammation Possible application to specific clinical entities is discussed with suggestions for clinical
research to study the association
1 of 10 721011250PM
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are presented. The sick building syndro e and ultiple che ical sensitivity syndro e have been defmed as 
clinical entities in hich exposure to che ical inhalants gives rise to disease. urrent data on the existence of 
c e ical irrita t rece t rs i  t e air a  a  s i  are isc ssed; e r e ic i fla ati  arisi  fr  
sti l ti  f i l irrita t r t rs is  ssi l  l t  l i   f t  s ts f i l 
sensitivities. ey ords: asth a, indoor air pollution, ultiple che ical sensitivity syndro e, neurogenic 
i fla ati n, e tral e e ti ase, reacti e air a s sf cti  s r e, reacti e er air a s 
sf ti  s r , r i itis, s st  , si  il i  s r . ir  lt  rs t : 
234-238(1993) 
ttp://ehpnet1.niehs.nih.gov/docs/J99 /JOl-3/meggs.htm! 
Address correspondence to . 1. eggs, Room 4 54, Brody Building, Department of Emergency edicine, East 
ar li a i ersit  c l f e ici e, reenville,   . 
ro  
e siti it  t  e ir e tal c e icals i  e eral, a  i  artic lar t  latile r a ic c e icals (V s) i  
i r ir, s t   l i t d.  l  f  st lis  is  t  l i   s r  t  
concentrations of Cs that are ell tolerated by the population at large can produce the array of sy pto s 
seen in sensitized individuals has ha pered progress in understanding these disorders. ver the past fe  years 
progress has been made in understanding neurogenic inflammation, chemical irritant receptors, and the 
re lati  f e r e ic i fla ati n. ere I re ie  t ese t ics, e asizi  t se as ects t at a  e 
applicable to elucidating the echanis  of che ical sensitivity as a disorder of the regulation of neurogenic 
infla ation. Possible application to specific clinical entities is discussed, ith suggestions for clinical 
research to study the association. 
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Neurogenic Inflammation
Inflammation is an abnormal condition of redness swelling heat and pain localized to a tissue Histologically
inflammation is characterized by edema vasodilatation and infiltrates of leukocytes A number of chemical
mediators of inflammation have been identified biochemically Inflammation may be triggered by the immune
system in which foreign materials interact with leukocyte receptors created after a sensitizing exposure to
trigger an inflammatory cascade Neurogenic inflammation is a welldefined process by which inflammation is
triggered by the nervous system
Early in the study of neurogenic inflammation chemical stimulation was recognized as a trigger of neurogenic
inflammation As early as 1910 it was recognized that the application of mustard oil to the conjunctival sac in
experimental models produces inflammation that can be blocked by sensory nerve ablation12 The
neuropeptides substance P SP neurokinen A NA and calcitonin generelated peptide CGRP are now
known to coexist in sensory neurons and to have potent vasodilatory properties 36 Direct stimulation of
sensory nerves produces vasodilatation78which can be blocked by depletion of substance P with
capsaicin 911 The sensory fibers involved in neurogenic inflammation have been identified as Cfibers
with a slow velocity of 12msec 12
Progress has been made in understanding the regulation of neurogenic inflammation 13 A cell surface
enzyme neutral endopeptidase NEP downregulates neurogenic inflammation bydegradating substance P
In the lung this enzyme is inhibited by cigarette smoke viral infections and toluene diisocynate whereas
corticosteroids increase NEP
Neurogenic inflammation is now a welldefined physiological mechanism by which mediators are directly
released from sensory nerves to produce vasodilatation edema and other manifestations of inflammation
The nerve fibers have been identified as slow velocity Cfibers and the regulation of neurogenic
inflammation has been studied
Chemical Irritant Receptors
The common chemical sense is a nasal sensation provoked by airborne chemicals which is distinct from taste
and smell 14 This sense is experienced as a burning and painful sensation in the upper airways and eyes
upon exposure to irritant substances and results from exposure of trigeminal nerve endings to the irritants
The skin and other mucous membranes have similar responses to irritant chemicals Recent studies in anosmic
subjects have separated the common chemical sense from olfaction IS The common chemical sense and
olfaction are depicted in Figure 1 There is evidence that protein receptors on cell membranes are the
activation site for chemical irritants It is thought that sensory nerves act as both afferent and efferent nerves
for neurogenic inflammation triggered by chemical irritants In the nose substance P release has been verified
for exposures to nicotine capsaicin ether formaldehyde and cigarette smoke 167Hence stimulation of
the chemical irritant receptors leads to neurogenic inflammation The relationship among chemical irritants
sensory nerves substance P and NEP is summarized in Figure 2
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eurogenic Inflammation 
Inflam ation is n nn  tion  re , l , t, a   ize  t   is . i al y, 
inflammation is characterized by ede a, vasodilatation, and infIltrates of leukocytes.  nu ber f che ical 
at rs  fla ation have been ide tified i l . Infla ation  e triggere    i une 
syste , in hich foreign aterials interact ith leukocyte receptors created after a sensitizing exposure to 
trigger an inflammatory cascade. Neurogenic inflammation is a well-defmed process by which inflammation is 
triggered by the nervous syste . 
arly in the study f neurogenic infla ation, che ical sti ulation as recognized as a trigger f neurogenic 
inflammation. As early as 1910, it was recognized that the application of mustard oil to the conjunctival sac in 
experi ental odels produces infla ation that can be blocked by sensory nerve ablation (1,2). The 
neuropeptides substance P (SP), neurokinen  (N ), and calcitonin gene-related peptide (CG P) are no  
kno n to coexist in sensory neurons and to have potent vasodilatory properties (3-6). irect sti ulation of 
s s r  r es r duces s il t ti  (7,8), ich   locke   l ti  f s st ce  it  
capsaicin (9-11). The sensory fibers involved in neurogenic infla ation have been identified as C-fibers 
ith a slo  velocity of 1-2 lsec (12). 
Progress has been made in understanding the regulation of neurogenic inflammation (13). A cell-surface 
enzy e, neutral endopeptidase (NEP), downregulates neurogenic infla ation by degradating substance P. 
In the lung this enzy e is inhibited by cigarette s oke, viral infections, and toluene diisocynate, hereas 
icost ids ncrease . 
Neurogenic inflammation is now a well-defmed physiological mechanism by which mediators are directly 
released fro  sensory nerves to produce vasodilatation, ede a, and other anifestations of infla ation. 
he nerve fibers have been identified as slo  velocity -fibers, and the regulation f neurogenic 
fla o    i d. 
Che ical Irritant Receptors 
he co on che ical sense is a nasal sensation provoked by airborne che icals hich is distinct fro  taste 
and s ell (14). This sense is experienced as a burning and painful sensation in the upper air ays and eyes 
upon exposure to irritant substances and results from exposure of trigeminal nerve endings to the irritants. 
he skin and other ucous e branes have si ilar responses to irritant che icals. ecent studies in anos ic 
subjects have separated the common chemical sense from olfaction (15). The common chemical sense and 
olfaction are depicted in Figure 1. There is evidence that protein receptors on cell e branes are the 
activation site for che ical irritants. It is thought that sensory nerves act as both afferent and efferent nerves 
for neurogenic inflammation triggered by chemical irritants. In the nose, substance P release has been verified 
for exposures to nicotine, capsaicin, ether, fonnaldehyde, and cigarette smoke (16,17). Hence, stimulation of 
the che ical irritant receptors leads to neurogenic infla ation. he relationship a ong che ical irritants, 
sensory nerves, substance P, and NEP is summarized in Figure 2. 
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Figure 1 Olfaction and the common chemical sense Olfaction is the sensation of odor transmitted by cranial nerve I
the olfactory nerve The common chemical sense is a sensation of burning and irritation in the airway produced by
irritant chemicals and transmitted by cranial nerve V the trigeminal nerve
Figure 2 Schematic diagram ofneurogenic inflammation triggered by chemical irritants Chemical irritants C bind
chemical irritant receptors on sensory nerves to release substance PPand other mediators from nerve endings
Substance P binds receptors on effector cells to trigger inflammation Neutral endopeptidase nep an enzyme located
on the membranes of effector cells degrades substance P and downregulates neurogenic inflammation It is proposed
that chemical sensitivity syndromes are disorders of the regulation of neurogenic inflammation
Regulation of Neurogenic Inflammation
Neutral endopeptidase degrades substance P 13 NEP is located on the surfaces of cells with substance P
receptors ie the target cells of substance P Substances that decrease neutral endopeptidase levels increase
neurogenic inflammation while substances that increase neutral endopeptidase suppress neurogenic
inflammation Human recombinant NEP suppresses neurogenic inflammation 1820 Exogenous substances
that inhibit NEP include cigarette smoke 21 respiratory viruses 2225 and the volatile organic chemical
toluene diisocyanate 26
Possible Roles ofNeurogenic Inflammation
Neurogenic inflammation may play a role in a variety of disorders from asthma and rhinitis to migraine
headache rheumatoid arthritis and fibromyalgia Such a role is supported by a combination of animal studies
pharmacological responses of these disorders and circumstantial evidence At the current time these
associations are somewhat speculative but there is sufficient evidence to justify investigations
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Figure 1. Olfaction and the common chemical sense. Olfaction is the sensation of odor, transmitted by cranial nerve I, 
the olfactory nerve. The co on che ical sense is a sensation of burning and irritation in the air ay, produced by 
irritant che icals and trans itted by cranial nerve , the trige inal nerve. 
Figure 2. Sche atic diagra  of neurogenic infla ation triggered by che ical irritants. he ical irritants (C) bind 
che ical irritant receptors on sensory nerves to release substance P (P) and other ediators fro  nerve endings. 
Substance P binds receptors on effector cells to trigger inflammation Neutral endopeptidase (nep), an enzyme located 
on the membranes of effector cells, degrades substance P and downregulates neurogenic inflammation. It is proposed 
that che ical sensitivity syndro es are disorders of the regulation of neurogenic infla ation. 
Regulation of Neurogenic Inflammation 
eutral endopeptidase degrades substance P (13). EP is located on the surfaces of cells ith substance P 
receptors, i.e., the target cells of substance P. Substances that decrease neutral endopeptidase levels increase 
neurogenic inflammation, while substances that increase neutral endopeptidase suppress neurogenic 
inflammation. Human recombinant NEP suppresses neurogenic inflammation (18-20). Exogenous substances 
that inhibit NEP include cigarette s oke (21), respiratory viruses (22-25), and the volatile organic che ical 
toluene diisocyanate (26). 
Possible oles of eurogenic Infla ation 
Neurogenic inflammation may playa role in a variety of disorders, from asthma and rhinitis to migraine 
headache, rheu atoid arthritis, and fibro yalgia. Such a role is supported by a co bination of ani al studies, 
pharmacological responses of these disorders, and circumstantial evidence. At the current time these 
associations are somewhat speculative, but there is sufficient evidence to justify investigations. 
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It is now known that the neuropeptides of neurogenic inflammation reproduce the pathology of asthma 27
and the role of neurogenic inflammation has been documented in animal models of asthma 28 Barnes 29
has recently reviewed the current evidence for the role of neurogenic inflammation in asthma and has
suggested strategies for reducing neurogenic inflammation in this disease It is increasingly recognized that
respiratory irritants such as VOCs and environmental tobacco smoke can exacerbate asthma and rhinitis
3032 A number of studies have documented an increase in the incidence of asthma in industrialized
countries over both the long term and during the 1980s 33 In addition studies during the 1980s established
that the American population is exposed to VOCs in the indoor air 34
The role of neurogenic inflammation and chemical irritants in these respiratory disorders and the upregulation
of neurogenic inflammation by inhalant irritants discussed above indicate that there may be a relationship
between indoor air pollution with VOCs and the worsening asthma epidemic Pursuit of this relationship
should be a research priority In the past asthma was divided into extrinsic asthma triggered by protein
aeroallergens and intrinsic asthma ofunknown cause This distinction was made before the role of
neurogenic inflammation in asthma was appreciated It may be that asthma would be better classified as
immunogenic or neurogenic Table 1 The distinction between neurogenic and immunologic asthma is limited
to the catalysts because the two types cross over after the release ofmediators in that the mediators of
neurogenic inflammation trigger mast cell degranulation and mast cell mediators stimulate peripheral nerves
This bidirectional regulatory circuit has recently been reviewed 35
Table 1 Immunogenic vers neurogenicasthma
Immunogenic Neurogenic
Triggered by Protein aeroallergens Volatile organic chemicals
Interacting with IgE antibody Chemical irritant receptors
Located on Mastcells Sensory nerve C fibers
Releasing Histamine leukotriena4 Neuropeptides substance P
prostoglandins chematactic neurokinen A calcitonin
factors gene related peptide
Stimulating Sensory nerve C fibers Mastcell degranulation
Producing Bronchial inflammation Bronchial inflammation
Manifesting as Asthma Asthma
This crossover phenomenon does not mean that neurogenic inflammation and immunologic inflammation are
clinically identical in all cases In the upper airways and skin the initial complaint associated with exposure to
chemical irritants is burning or pain whereas itching is the initial complaint associated with immunemediated
exposures It maybe that there is individual variability in the degree to which crossover is clinically
manifested The two mechanisms might be differentiated by testing patients with challenging doses of
antigens and nonallergenic chemical irritants while monitoring clinical symptoms and measuring mediators
This research would best be carried out by studying upper airway responses as nasal washings can be easily
obtained for quantifying mediators
Another disorder that increased significantly during the 1980s is migraine headaches 36 Headache is an
early and consistent consequence of exposure to VOCs On the basis of pharmaceutical responses ofmigraine
and animal experiments Nicolodi and Sicuteri proposed that neurogenic inflammation plays a role in the
pathophysiology ofmigraine headaches 37 Silberstein argued that both tension headaches and migraine
may be generated by neurogenic inflammation 38 Buzzi and Moskowitz demonstrated that stimulation of
trigeminal sensory fibers leads to changes consistent with those ofmigraine in a rat model and these changes
can be blocked by the antimigraine drugs sumatriptan and dihydroergotamine 39 Hardebo has pointed out
that the postulate that neurogenic inflammation mediates migraine provides a rational explanation for why
serotonin antagonists are effective in treating migraine 40 Challenge studies with VOCs on migraine
patients with and without specific pharmacological blockage of relevant receptors is needed to elucidate the
role of neurogenic inflammationand chemical irritants in migraine
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 t  r l  f r ic i fla ti  s  e te  i  i l ls f st  (2 ). r s (2 ) 
has recently revie ed the current evidence for the role of neurogenic infla ation in asth a and has 
suggested strategies for reducing neurogenic infla ation in this disease. It is increasingly recognized that 
res irat r  irritants s c  as s a  e ir e tal t acc  s e ca  e acer ate ast a a  r i itis 
(30-3 ).  r f st ies  t   i re s  i  t  i i e  f st  i  i stri lize  
countries, over both the long ter  and during the 1980s (33). In addition, studies during the 1980s established 
that the erican population is exposed to s in the indoor air (34). 
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neurogenic infla ation trigger ast cell degranulation, and ast cell ediators sti ulate peripheral nerves. 
his "bidirectional regulatory circuit" has recently been revie ed (35). 
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is cr ss er e e  es t ea  t at e r e ic i fla ati  a  i l ic i fla ati  are 
clinically identical in all cases. In the upper air ays and skin, the initial co plaint associated ith exposure to 
i l irrita t  is r i  r in, r  it i  is t  i iti l l i t i t  it  i - i t  
exposures. It ay be that there is individual variability in the degree to hich crossover is clinically 
a ifested. e t  ec a is s i t e iffere tiate   testi  atie ts it  c alle i  ses f 
antigens and nonallergenic che ical irritants hile onitoring clinical sy pto s and easuring ediators. 
his research ould best be carried out by studying upper air ay responses, as nasal ashings can be easily 
obtained for quantifying ediators. 
t er is r er t at i crease  si ifica tl  ri  t e s is i rai e ea ac es (3 ). ea ac e is a  
early and consistent consequence of exposure to s. n the basis of phar aceutical responses of igraine 
and ani al experi ents, icolodi and Sicuteri proposed that neurogenic infla ation plays a role in the 
pathophysiology of migraine headaches (37). Silberstein argued that both tension headaches and migraine 
a  e e erate   e r e ic i fla ati  (3 ). zzi a  s itz e strate  t at sti lati  f 
trige i l s s r  fi rs le s t  s sist t it  t s  f i r i  i   r t l,  t s  s 
can be blocked by the anti igraine drugs su atriptan and dihydroergota ine (39). ardebo has pointed out 
that the postulate that neurogenic infla ation ediates igraine provides a rational explanation for hy 
s r t i  t ists r  ff ti  i  tr ti  i r i  (4 ). lle  st i s it  s  i r i  
atie ts, it  a  it t s ecific ar ac l ical l c age f rele a t receptors, is ee e  t  el ci ate t e 
role of neurogenic infla ation and che ical irritants in igraine. 
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A comparison of neuropeptide staining in the synovium of patients with rheumatoid arthritis osteoarthritis
and controls found weaker staining in the nerve filaments of the rheumatoid arthritis group 41 The authors
suggest that this weaker staining is evidence of release from nerve fibers in rheumatoid arthritis and
neurogenic inflammation may play a role in this disorder Zimmerman has suggested that neurogenic
inflammation may play a role in fibromyalgia 42
Role of Neurogenic Inflammation in Chemical Sensitivity Syndromes
Sick building syndrome SBS is a term used to designate an outbreak of illness associated with indoor air
contaminants in new and tightly sealed buildings Symptoms include irritation of the eyes nose and throat
skin irritation and neurotoxic symptoms including mental fatigue and difficulty concentrating 43 The
syndrome is an acquired disorder with onset related to moving into a new or renovated building and there is
wide individual variability in onset and symptoms after exposure
Multiple chemical sensitivity syndrome MCS is a related syndrome with onset related to an environmental
exposure most commonly a solvent or pesticide After the initial exposure individuals become sensitive to
lowlevel chemical exposures with symptoms involving more than one organ system Though this syndrome
was described four decades ago 445 it remains highly controversial
Reactive airways dysfunction syndrome RADS is an asthmalike illness that develops within minutes to
hours after an acute exposure to dust smoke or solvent There is persistent bronchial hyperreactivity with
positive methacholine challenge The asthma becomes chronic after the initial exposure and can be difficult to
treat 46
Reactive upper airways dysfunction syndrome RUDS also follows a chemical exposure and there is
persistent chronic rhinitis The chief complaint of patients with RUDS is chemical sensitivity 47 Unlike
patients with RADS medical attention is not sought on the day of exposure which probably reflects the fact
that breathing is compromised in RADS but not in RUDS Preliminary study of the nasal mucosa found
lymphocytic infiltrates and electron microscopy has shown thickening of the basement membrane and
desquamation of the respiratory epithelium 48
There are many similarities between SBS MCS RADS and RUDS Fig 3 In each snydrome a highdose
exposure induces the syndrome and subsequent exacerbations are associated with lowlevel exposures SBS
and MCS include symptoms involving more than one organ system with the respiratory mucosal and central
nervous system being prominently involved The major difference between SBS and MCS is that SBS refers to
a cluster of cases associated with a building while MCS patients have more generalized complaints RADS
and RUDS have prominent airway involvement with the difference between the two being that RADS
involves the lower airway asthma and RUDS involves the upper airway rhinitis In one small series 100
ofpatients with RUDS had extra airway manifestations and met the Cullen case definition 49 for MCS
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 c parison f e r e tide stai ing in the s i  f atie ts ith rhe at id art ritis, ste art ritis, 
d trols found ea er st i ing in the rve fIlaments f the rhe t id rt ritis r p (4 ). he t rs 
suggest that this eaker staining is evidence of release fro  nerve fibers in rheu atoid arthritis, and 
neurogenic inflammation may playa role in this disorder. Zimmerman has suggested that neurogenic 
infla ation ay playa role in fibro yalgia (42). 
Role of Neurogenic Inflammation in Chemical Sensitivity Syndromes 
"Sick ilding s r e" (SB ) is a ter  se  t  esi ate a  tbrea  f illness ass ciate  it  in r air 
ta inants in e   ti tl  s le  il i s. t s include irritation f the s, s ,  t r t, 
skin irritation, and neurotoxic sy pto s including ental fatigue and difficulty concentrating (43). The 
syndrome is an acquired disorder with onset related to moving into a new or renovated building, and there is 
ide i i id al aria ilit  in set a  s t s after e s re. 
ultiple che ical sensitivity syndro e (M S) is a related syndro e ith onset related to an environ ental 
exposure, ost co only a solvent or pesticide. After the initial exposure, individuals beco e sensitive to 
lo -level che ical exposures ith sy pto s involving ore than one organ syste . Though this syndro e 
as described four decades ago (44.45), it re ains highly controversial. 
eactive air ays dysfunction syndro e (R ) is an asth alike illness that develops ithin inutes to 
rs after a  ac te e s re t  st, s e, r s l ent. ere is ersiste t r c ial erreacti it  it  
positive ethacholine challenge. The asth a beco es chronic after the initial exposure and can be difficult to 
treat (46). 
Reactive upper-air ays dysfunction syndro e (R S) also follo s a che ical exposure, and there is 
persistent chronic rhinitis. The chief co plaint of patients ith S is che ical sensitivity (47). nlike 
patients with RADS, medical attention is not sought on the day of exposure, which probably reflects the fact 
that breathing is co pro ised in RADS but not in RUDS. Preli inary study of the nasal ucosa found 
ly phocytic infIltrates, and electron icroscopy has sho n thickening of the base ent e brane and 
desquamation of the respiratory epithelium (48). 
There are any si ilarities between SBS, CS, RADS, and RUDS (Fig. 3). In each snydro e, a high-dose 
exposure induces the syndro e, and subsequent exacerbations are associated ith lo -level exposures. SBS 
and CS include sy pto s involving ore than one organ syste , ith the respiratory ucosal and central 
nervous syste  being pro inently involved. The ajor difference bet een S S and S is that S S refers to 
a cluster of cases associated with a building, while CS patients have more generalized complaints. RADS 
and RUDS have pro inent airway involve ent, with the difference between the two being that RADS 
involves the lo er air ay (asthma), and R S involves the upper air ay (rhinitis). In one s all series, lOO% 
of patients with RUDS had extra-airway manifestations and met the Cullen case definition (49) for MCS. 
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Figure 3 Chemical sensitivity syndromes The multiple chemical sensitivity syndrome MCS sick building syndrome
SDS reactive airways dysfunction syndrome RADS the reactive upper airways dysfunction syndromeRUDS
have many features in common These syndromes may all be disorders of the regulation ofneurogenic inflammation
These syndromes may be related at a deeper level All of these illnesses may be disorders of the regulation of
neurogenic inflammation The inducing exposure may alter the respiratory mucosa in one or more ways The
regulation of neurogenic inflammation may be disturbed by the depletion of NEP or other enzymes which
would result in a heightened response to subsequent exposures The desquamation of the respiratory
epithelium seen in RUDS may remove a barrier to chemical irritants so that chemical irritants may reach and
trigger the irritant receptors at lower concentrations
Patients with these illnesses complain of symptoms in organ systems in addition to the airways and some
patients have no airways symptoms at all Mechanisms to explain how airway irritants can trigger systemic
symptoms must be considered First it is common for inflammatory illnesses primarily arising in one organ or
tissue to produce systemic manifestationseg the extra articular manifestations of rheumatoid arthritis and
the systemic manifestations ofCrohnsdisease Viral infections of the upper airway produce systemic
symptoms including myalgias fever fatigue and malaise
Both the mediators and regulators of inflammation may be released from the site of inflammation and affect
distant sites Two important regulators of inflammation interleukin 1 and interleukin 2 suppress central
nervous system activity501 Another possibility is that some form of neural switching may take place
That is triggering of chemical irritant receptors in one organ could lead to an efferent signal traveling to
another site through an aberrant or conditioned crossing of the pathways A combination of these two
mechanisms may be operative
The hypothesis that neurogenic inflammation is the mechanism of chemical sensitivity syndromes is amenable
to scientific study Biopsies of the airways of chemically sensitive individuals should be abnormal with signs
of inflammation Immunofluorescent monoclonal antibodies could be used to detect NEP which should be
decreased and substance P which should be elevated relative to controls Nasal washings should contain
increased levels of the mediators of neurogenic inflammation relative to controls and the levels should
increase after chemical challenge in patients but not controls Heightened neuronal firing of sensory fibers
should occur after chemical challenges
Discussion
Neurogenic inflammation leads to inflammation independent of the immune system Polypeptide mediators
are stored in nerve endings and released when irritant receptors on nerves are stimulated by chemicals The
role of neurogenic inflammation in a number of inflammatory conditions is currently under investigation
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Figure 3. Chemical sensitivity syndromes. The multiple chemical sensitivity syndrome (MCS), sick building syndrome 
(SDS), reactive airways dysfimction syndrome (RADS), the reactive upper airways dysfimction syndrome (RUDS) 
have any features in co on. hese syndro es ay all be disorders ofthe regulation of neurogenic infla ation. 
ese s r es a  e relate  at a ee er le el. ll f t ese illnesses a  e is r ers f t e re lati  f 
e r e ic i fla ati . e i ci  e s re a  alter t e res irat r  c sa i  e r re a s. e 
regulation of neurogenic inflammation may be disturbed by the depletion of NEP or other enzymes, which 
ould result in a heightened response to subsequent exposures. he desqua ation of the respiratory 
epithelium seen in RUDS may remove a barrier to chemical irritants, so that chemical irritants may reach and 
trigger the irritant receptors at lower concentrations. 
Patients ith these illnesses co plain f sy pto s in organ syste s in addition to the air ays, and so e 
patients have no air ays sy pto s at all. echanis s to explain ho  air ay irritants can trigger syste ic 
symptoms must be considered. First, it is common for inflammatory illnesses primarily arising in one organ or 
tissue to produce syste ic anifestations (e.g., the extra-articular anifestations of rheu atoid arthritis and 
the syste ic anifestations of rohn's disease). Iral infections of the upper air ay produce syste ic 
sy pto s, including yalgias, fever, fatigue, and alaise. 
oth the ediators and regulators of infla ation ay be released fro  the site of infla ation and affect 
distant sites. Two important regulators of inflammation, interleukin 1 and interleukin 2, suppress central 
nervous system activity (50,51). Another possibility is that some form of neural switching may take place. 
That is, triggering of che ical irritant receptors in one organ could lead to an efferent signal traveling to 
another site through an aberrant or conditioned crossing of the path ays.  co bination of these t o 
mechanisms may be operative. 
The hypothesis that neurogenic inflammation is the mechanism of chemical sensitivity syndromes is amenable 
to scientific study. iopsies of the air ays of che ically sensitive individuals should be abnormal, ith signs 
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ecreased, a  s sta ce , ic  s l  e ele ate  relati e t  c trols. asal as i s s l  c tai  
increased levels of the ediators of neurogenic infla ation relative to controls, and the levels should 
increase after che ical challenge in patients but not controls. eightened neuronal firing of sensory fibers 
should occur after che ical challenges. 
 
Neurogenic infla ation leads to infla ation independent of the i une system. Polypeptide ediators 
are stored in nerve endings and released hen irritant receptors on nerves are sti ulated by chemicals. The 
role of neurogenic infla ation in a nu ber of infla atory conditions is currently under investigation. 
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There is strong evidence that neurogenic inflammation is operative in asthma and rhinitis There is
circumstantial evidence that neurogenic inflammation may play a role in migraine headache Evidence for a
role in rheumatoid arthritis and fibromyalgia is not as compelling at this time The significance of these
associations for environmental health is that neurogenic inflammation can be triggered in the airways by
environmental chemicals such as cigarette smoke and solvents Hence any disorder mediated by neurogenic
inflammation can potentially be exacerbated by environmental chemicals Study of the hypothesis that
chemical sensitivity syndromes such as SBS and MCS may result from neurogenic inflammation arising from
stimulation of irritant receptors by environmental chemicals may lead to an understanding of these disorders
It is of interest that the symptoms ofheadache myalgia arthralgias and arthritis and airway symptoms
reported by MCS patients overlap with those disorders for which a role for neurogenic inflammation has been
reported
The hypothesis that neurogenic inflammation triggered by environmental chemicals plays a role in human
health is amenable to scientific study Research should focus on noninvasive methods for detecting
biomarkers of neurogenic inflammation Are there degradation products of substance P or other mediators of
neurogenic inflammation that are elevated in the urine or serum of patientswith activation of this system Are
there evoked potentials or nerve conduction parameters that can be used to detect activation of neurogenic
inflammation Two groups of patients should be studied with challenge tests patients with disorders in which
neurogenic inflammation is suspected to play a role ie asthma rhinitis migraine rheumatoid arthritis
fibromyalgia and patients with chemical sensitivity syndromes These patients should be isolated from VOCs
in a specially constructed clinical research unit and monitored for resolution of their symptoms Chemical
challenges should be conducted while patients are monitored for provoked symptoms Biomarkers of
neurogenic inflammation should be measured throughout the course of these challenges
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Abstract
A sensitive and selective liquid chromatography tandem mass
spectrometry LCMS method for the analysis of capsaicin
nonivamide and dihydrocapsaicin in blood and tissue has been
developed The method utilized aonestep liquid liquid extraction
that yielded an approximate 90 recovery of capsaicinoids from
blood Chomatographic separation of the capsaicinoids was
achieved using a reversedphase high performance liquid
chromatography column and a stepwise gradient of methanol and
distilled water containing01vv formic acid Identification and
quantitation of the capsaicinoids was achieved using electrospray
ionization tandem mass spectrometry monitoring the precursorto
production transitions for the internal standard octanoyl
vanillamide mz280 137 capsaicin mz306 137
dihydrocapsaicinmz 308 137 and nonivamide mz 294
137 Calibration curves 10 to 250 ngmL were constructed by
plotting concentration versus peakarea ratio analyteintemal
standard and fitting the data with aweighted quadratic equation
The accuracy of the assay ranged from 90to 107 for all
analytes The infra assay precision RSD for capsaicin was 4 at
25ngmL 3at 10ngmL and 7at 100ngmL The interassay
precision RSDfor capsaicin was 6 at 25 ngmL61o at 10
ngmL and7 at 100 ngmL Similar values for inter and intra
assay precision were obtained for nonivamide and dihydrocapsaicin
This method was used toassay for capsaicinoids in blood and tissue
samples collected from rats exposed to capsaicinoids via noseonly
inhalationThe concentration of capsaicin in these samples ranged
from 10to904ngmL in the blood 50to 167 pgm in the
lung and 20 to34pgm in the liver
Introduction
Capsaicinoids are chemical irritants isolated from hot
peppers Capsicum annum and C fmtescens 13 These
compounds have been widely used in modern society forvarious
Author to whom correspondence should beaddressed
E mail christopherreitly@yahoocom
purposes including the preparation of spicy foods production
of medicinal creams for treatment of chronic pain and arthritis
and in the preparation of self defense products ie pepper
sprays 13 Exposure to capsaicinoids or pepper sprays
elicits a variety of physiological responses that include coughing
and gagging disorientation erythema and reddening of the
skin lacrimation temporary blindness and an intense burning
sensation 4 The pharmacologic responses to the capsaici
noids are the result of capsaicin dihydrocapsaicin nordihy
drocapsaicin nonivamide homocapsaicin and homodihydro
capsaicin 14These compounds are found in hot peppers
and oleoresin capsicum OC the concentrated extract of
hot peppers that is typically used to prepare products that
utilize capsaicinoids as the active ingredient 34The biolog
ical target of the capsaicinoids has been shown to be the
vanilloid receptor type1 or VRI present primarily on the
termini of peripheral sensory neurons that respond to cap
saicin exposure 57 Excitation of VRI by capsaicinoids
causes a Ca dependent release of substance R and various
other cytokines and tachykinins89which ultimately causes
the sensation of burning and pain and the development of
localized inflammation 59 Capsaicin dihydrocapsaicin
and nonivamide exhibit the greatest potency of the capsaici
noids and typically represent 8595 of the total capsaicinoid
content in hot peppers OC and pepper spray products
13
Previous research has demonstrated that the concentration
of the capsaicinoids in fresh peppers OC and pepper spray
products was variable 13101 This variability was hy
pothesized to contribute to the unpredictable performance
and efficacy of the pepper spray products when used as less
thanlethal deterrents 12 14 In addition variability in cap
saicinoid concentrations may contribute to the potential for
undesirable effects such as ocular damage respiratory dis
tress and dermal irritation resulting from exposure to capsai
cinoids 1216 Differences in the concentrations of capsaici
noids in pepper extracts may also affect the efficacy of
potentially beneficial preparations of capsaicinoids including
Reproduction photocopying of editorial content of thisjournal is prohibited without publisherspermission 313
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I bstra  I 
A sensitive and selective liquid chro atography-tande  mass 
spectrometry (LC-MS-MS) method for the analysis of capsaicin, 
nonivamide. and dihydrocapsaicin in blood and tissue has been 
developed, The ethod utilized a one-step liquid-liquid extraction 
that yielded an approximate 90% recovery of capsaicinoids from 
blood. Cho atographic separation of the capsaicinoids as 
achieved using a reversed-phase high-perfor ance liquid 
chro atography colu n and a stepwise gradient of ethanol and 
distilled water containing 0.1% (v/v) formic acid. Identification and 
quantitation of the capsaicinoids was achieved using electrospray 
ionization-tandem mass spectrometry monitoring the precursor-to-
product-ion transitions for the internal standard octanoyl 
vanilla ide (mlz 280 ... 137). capsaicin (mlz 306 ... 37), 
dihydrocapsaicin (m/z 308 ... 137), and noniva ide (mlz 294 ... 
137). Calibration curves. 1.0 to 250 nglmL. were constructed by 
plotting concentration versus peak-area ratio (analyte/internal 
standard) and fitting the data with a weighted quadratic equation. 
The accuracy of the assay ranged from 90% to 107% for all 
analytes. The intra-assay precision (%RSD) for capsaicin was 4% at 
2.5 nglmL. 3% at 10 nglmL. and 7% at 100 nglml. The interassay 
precision (%RSD) for capsaicin was 6% at 2.5 nglmL. 6% at 10 
nglrnL. and 7% at 100 nglml. Similar values for inter- and intra-
assay preciSion were obtained for nonivamide and dihydrocapsaicin. 
This ethod as used to assay for capsaicinoids in blood and tissue 
samples collected from rats exposed to capsaicinoids via nose-only 
inhalation. The concentration of capsaicin in these sa ples ranged 
from < 1.0 to 90.4 nglmL in the blood, < 5.0 to 167 pglrng in the 
lung. and < 2.0 to 3.4 pglrng in the liver. 
i  
Capsaicinoids are chemical irritants isolated from "hot" 
peppers (Capsicum annum and C. frutescens) (1-3), These 
compounds have been widely used in modern society for various 
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r s  i l i  t  re r ti  f s i  f s. r ti  
f e icinal crea s f r tr t t f c r ic ain a  rt ritis, 
and in t e re arati  of self-defense r cts (Le., pepper 
sprays) (1-3). xposure to capsaicinoids (or pepper sprays) 
elicits a variety of physiological responses that include coughing 
a  a i , is ri t ti , er t e a a  re e i  f t e 
i , ti ,  i ,   t s   
ti  (4).      saici-
noids are the result of capsaicin, dihydrocapsaicin, nordihy-
r aici , i i , saicin.  dihydro-
ca saici  (1-4). ese c s are f  i  "h t" e ers 
 l r si  si  (O ), t  tr t  tr t f 
"hot" peppers t at is typically used to prepare r cts t at 
utilize capsaicinoids as the active ingredient (3,4). he biolog-
ical target of the capsaicinoids has been sho n to be the 
ill i  r t r t - , r 1, r t ri ril   t  
ter i i of peripheral sensory e r s t at respond to cap-
saicin exposure (5-7). Excitation of VR1 by capsaicinoids 
s s  ++-depe t r l s  f s st  p,  ri s 
other cytokines and tachykinins (8,9), which ultimately causes 
the sensation of burning and pain and the develop ent of 
 i  (5-9). psaicin, saicin, 
 i i  x i it t  t t t  f t  psaici-
noids and typically represent 85-95% of the total capsaicinoid 
content in "hot" peppers, OC, and pepper spray products 
(1-3). 
 r earc   tr ted t  ntrati  
of the capsaicinoids in fresh peppers, C, and pepper spray 
products was variable (1-3,10,11). This variability was hy-
pothesized to contribute to the unpredictable performance 
and efficacy of the pepper spray products hen used as less-
t an-l t al t rr t  (1 -14). I  addition, ri bilit  i  -
saicinoid concentrations ay contribute to the potential for 
sirabl  ff ts such as ocular a age, respiratory is-
tress, and er al irrit ti  resulti  fr  ex sure to capsai-
i  ( -1 ).  i  the concentr ti  of capsaic -
noids in pepper extracts ay also affect the efficacy of 
potentially beneficial preparations of capsaicinoids, including 
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medicinal creams and dietary supplements
Since the advent of capsaicinbased productsie pepper
sprays medicinal creams etc there have been many reports
of adverse physiological responses following exposure 12 16
Respiratory complications particularly in asthmatics and oc
ular and dermal irritation are the most common complaints
1216 In most reports ofexposures the symptoms were tran
sient however several exposed subjects have required extended
medical treatment 12 18 For example an infant acciden
tally exposed to 5 pepper spray gas required treatment for
acute lifethreatening respiratory distress which included
manual ventilation and suction to alleviate airway congestion
17 In a separate incident several hospital employees required
treatment for respiratory complications and irritation to mu
cosa resulting from accidental discharge of pepper spray in an
emergency facility 18 There also have been several reports of
deaths following exposure to pepper spray products 19 Un
fortunately the role of the pepper spray or capsaicinoids in
these fatalities was not evaluated because of other complicating
factors including concomitant use of illicit drugs typically
methamphetamine or cocaine intoxication physical injury or
physical restraint 19
The purpose of our research was to develop sensitive and se
lective methods for the analysis of capsaicin nonivamide and
dihydrocapsaicin in blood and tissue such that the concentra
tions of capsaicinoids could be determined following a con
trolleddose exposure These data are being used to evaluate the
role of capsaicinoids in eliciting adverse physiological responses
and to serve as a basis to develop safer products Because non
ivamide is often used as a synthetic substitute for OC in various
pepper products and because it can be improperly identified as
capsaicin or nordihydrocapsaicin 20 it has been included in
this assay To assess the effectiveness of this assay we have an
alyzed blood and tissue samples collected from rats exposed to
aerosolized solutions of capsaicinoids
Experimental
Reagents
Capsaicin 97 and 60 dihydrocapsaicin 97 non
ivamide nvanillylnonanamide 99 ketamine hydrochlo
ride and acetopromazine maleate were purchased from Sigma
Chemical Corp St Louis MO Octanoyl vanillamide
internal standard was synthesized by condensation of octanoyl
chloride and 4hydroxy3 methoxy vanillylamine hydrochlo
ride as previously described 21 Octanoyl chloride and vanil
lylamine hydrochloride were purchased from Aldrich Chemical
Co Milwaukee WIMethanol was purchased from Fisher Sci
entific Fair Lawn NJ USPgrade ethanol was purchased
from Quantum Chemical Corp Tuskola IL nButyl chloride
and 88 formic acid were purchased from JTBaker Phillips
burg NJ Distilled water specific resistance 182Mf2cm
was prepared using a Millipore MilliQ Plus water purification
system Millipore Corp Burlington MA Bovine blood con
taining sodium citrate was purchased from Pel Freez Biologi
cals Rogers AR
Analytical standards
Analytical standards were prepared by weighing 10 mg of
each capsaicinoid using a Cahn model 4700 analytical balance
Cahn Instruments Cerritos CA and dissolving the compound
in 10 mL of methanol Prior to weighing each compound the
balance was calibrated to ensure accuracy Standard solutions
were prepared in methanol by serial dilution of the 01mgL
standard using volumetric pipettes and flasks All standards
were stored protected from light at 20C for the duration of the
study Quality control samples were prepared at 25 ngmL 10
ngmL and 100 ngmL in bovine blood Aliquots 1 mL were
stored at 20C
LCMSMS analysis
Analysis of the capsaicinoids was performed using a Ther
moQuest TSQ tandem MS ThermoQuest Instruments San
Jose CA combined with a Hewlett Packard series 1100 HPLC
Agilent Technologies Palo Alto CA Chromatographic sepa
ration of the analytes and the internal standard was achieved
using a MetaSil Basic 100 x 30 mm 3pm particle size CC
reversedphase HPLC column MetaChem Technologies Tor
rance CA and a stepwise gradient of methanol and distilled
water containing 01 vv formic acid The column was equi
librated at a flow rate of025 mLminwith a mobile phase con
sisting of57 methanol and 425 distilled water containing
01 vv formic acid at 40C The mobile phase was main
tained at this composition for 79 min and then the methanol
was increased to 65 over the duration of01min At 102
min the concentration of methanol was increased to 75
After 160 min the concentrations of methanol and formic acid
were returned to their initial concentrations for the durationof
the analysis 22 min The autosampler was maintained at 4C
and the injection volume was 15 pL
The MS was equipped with an electrospray ionization source
and operated in selected reaction monitoring mode for pre
cursortoproduct ion transitions for octanoyl vanillamide mz
280 137 nonivamide mz 294 137 capsaicinmz306
137 and dihydrocapsaicin m2308 137 The capillary and
lens voltages were optimized for maximum signal intensity
using the optimize function of the data system and the pre
cursortoproduct ion transition for capsaicin 306 137
nearly identical optima were observed for nonivamide and di
hydrocapsaicin The precursor ion resolution Q1 was set such
that 50 of peak height was observed at 15 amu and the
product ion resolution set to default tune values 50 peak
height at 07 amu Additional instrument settings were as fol
lows capillary temperature 250 C ESI spray voltage 45 kV
auxiliary gas nitrogen 10 U and sheath gas nitrogen 50 psi
The collision gas argon was set to a pressure of30 mT and the
collision energy was 20 eV
Integration and quantitation of the data were performed
using the Xcalibur LCQuan software package version 1
ThermoQuest Statistical analyses were performed using Mi
crosoft Excel 2000 Microsoft Redmond WA
Preparation of samples
Samples 1 mL of blood were prepared in 16 x 100mm
screwcap culture tubes For tissue samples 250500 mg of
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edicinal crea s and dietary supple ents. 
Since the advent of capsaicin-based products (Le., pepper 
sprays, edicinal crea s, etc.), there have been any reports 
of adverse physiological responses following exposure (12-16). 
Respiratory co plications, particularly in asth atics, and oc-
ular and dermal irritation are the most common complaints 
(12-16). In most reports of exposures, the symptoms were tran-
sient; ho ever, several exposed subjects have required extended 
edical treat ent (12-18). For exa ple, an infant acciden-
tally exposed to 5% pepper spray gas required treat ent for 
acute life-threatening respiratory distress, which included 
manual ventilation and suction to alleviate airway congestion 
(17). In a separate incident. several hospital e ployees required 
treat ent for respiratory co plications and irritation to u-
cosa resulting from accidental discharge of pepper spray in an 
e ergency facility (18). There also have been several reports of 
deaths folloWing exposure to pepper spray products (19). n-
fortunately, the role ofthe pepper spray (or capsaicinoids) in 
t  at lities as t l t  ecause  t er li ti  
factors including c c ita t use of illicit drugs (typically 
methamphetamine or cocaine). intoxication, physical injury, or 
physical restraint (19). 
The purpose of our research was to develop sensitive and se-
lective ethods for the analysis of capsaicin, noniva ide, and 
dihydrocapsaicin in blood and tissue such that the concentra-
tions of capsaicinoids could be determined following a con-
trolled-dose exposure. These data are being used to evaluate the 
role of capsaicinoids in eliciting adverse physiological responses 
and to serve as a basis to develop safer products. Because non-
ivamide is often used as a synthetic substitute for OC in various 
pepper products, and because it can be improperly identified as 
capsaicin or nordihydrocapsaicin (20), it has been included in 
this assay. To assess the effectiveness of this assay, we have an-
alyzed blood and tissue sa ples collected fro  rats exposed to 
aerosolized solutions of capsaicinoids. 
Experimental 
eagents 
Capsaicin (97% and 60%), dihydrocapsaicin (97%), -
ivamide (n-vanillylnonanamide) (99%), ketamine hydrochlo-
ride, and acetopro azine maleate were purchased from Sigma 
Che ical Corp. (St. Louis, O). ctanoyl vanilla ide 
(internal standard) was syntheSized by condensation of octanoyl 
chloride and 4-hydroxy-3-methoxy-vanillylamine hydrochlo-
ride, as previously described (21). Octanoyl chloride and van il-
lylamine hydrochloride were purchased from Aldrich Chemical 
Co. (Milwaukee, WI). ethanol was purchased from Fisher Sci-
entific (Fair Lawn, NJ). U.s.P.-grade ethanol was purchased 
from Quantum Chemical Corp. (Tuskola, IL). n-Butyl chloride 
and 88% formic acid were purchased from ].T. Baker (Phillips-
burg, NJ). Distilled water (specific resistance =18.2 Q.cm) 
was prepared using a illipore illi-Q Plus water purification 
system (Millipore Corp., Burlington, MA). Bovine blood con-
taining sodium citrate was purchased from Pel-Freez Biologi-
cals (Rogers, AR). 
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Integration and quantitation of the data ere perfor ed 
using the calibur uan soft are package (version 1.1) 
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cr soft cel  ( icr soft. ed ond, A). 
Preparation of sa ples 
Sa ples (1 mL) of blood were prepared in 16 x 100-  
scre -ca  lt r  tubes. r tiss e sa ples, -5  g of 
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tissue was homogenized in 1 mL dH Prior to extraction
each sample was fortified with internal standard octanoyl vanil
lamide at a concentration of 50 ngmL vortex mixed and di
luted with 1 mL OlM sodium phosphate buffer pH 70 The
samples were then extracted with 5 mL of nbutyl chloride by
shaking for 20 min at room temperature centrifuged for 10 min
at 2500 x g and the upper organic layer transferred to clean
tubes The solvent was evaporated to dryness under a stream of
air at 40nC and the dried sample residues containing the cap
saicinoids stored at 20C Prior to the analysis the dried
residues were reconstituted in 50 pL 70 methanol30 dis
tilled water and transferred to autosampler vials for analysis
Accuracy and precision
The accuracy of this assay was determined as the percentage of
the target analyte concentration using the mean n 5 assayed
concentration in a single batch of samples Intraassay precision
was expressed as percent relative standard deviation RSD and
was calculated for each batch using the standard deviation of the
assayed concentrations ofeach analyte at each concentration di
vided by the mean assayed concentration n 5 Interassay pre
cision RSDwas determined by dividing the standard deviation
of the assayed concentrations n 15 for three separate replicate
batches by the mean concentration n 15
Stability
The effect of various storage conditions on sample stability
was determined for each analyte using quality control samples
Quality control samples n 5 at 25 10 and 100 ngmLwere
stored at either room temperature for 24 h subjected to a
freeze thaw cycle or stored overnight at 4C in autosampler
vials 70 methanol30 distilled water The samples were
then analyzed as described Stability was
assessed by comparing the mean assayed
concentration n 5 for the stability con
trols to the mean concentration of un
treated quality control samples
Recovery
The recovery of the capsaicinoids from
blood was determined using quality control
samples n 5 at 25 10 and 100 ngmL
Recovery was assessed by comparing the
concentrations obtained for quality con
trol samples processed as described to sam
ples that were extracted and the internal
standard added immediately prior to evap
oration of the solvent n 5 The ratio of
the two concentrations represented the
percentage of analyte recovered by the ex
traction
Animal exposures and sample collection
Male Sprague Dawley rats 125 g were
purchased from Charles River Laboratories
Wilmington MA Prior to exposure to the
capsaicinoids the rats were anesthetized
by intraperitoneal injection of 80 mgk
ketamine and 5 mgk acetopromazine To simulate exposures
to pepper sprays the animals n 2 for control and high dose ex
posures and n 1 for low and medium dose exposure were
placed inside the noseonly exposure apparatus InTox Products
Albuquerque NM and exposed to aerosols generated from so
lutions of capsaicinoids for 15 min The aerosol was generated
from solutions of 0 1 5 and 50 mgL capsaicin approxi
mately 55 capsaicin 35 dihydrocapsaicin 43 nordihy
drocapsaicin 28 nonivamide 15 homodihydrocapsaicin
and 14 homocapsaicin dissolved in 55 USPgrade
ethanol45 dH using a Lovelace nebulizer operated at a
flow rate of05Lmin The chamber flow was 10 Lmin and was
maintained under a vacuum of05 psi 26 mm Hg Using this
protocol approximately 85 of the generated aerosol particles
were 17 mm in diameter determined using a sevenstage
cascade impactor An estimate ofthe delivered dose was achieved
by quantitative analysis of a paper filter 02 pm that collected
aerosol from a sampling orifice The sampling rate for the filter
was 05 LminThe delivered dose was calculated using a minute
volume of 02 Lmin and an approximate lung deposition factor
of 10 Prior to each experiment all gas flowswere calibrated
Following exposure the animals were removed from the
chamber and either sacrificed by COinduced asphyxiation or
permitted to recover Blood 5 mL was collected by syringe
from the abdominal aorta and immediately transferred to hep
arinizedvacutainer tubes gently shaken and placed on ice
Aliquots 1 mL were prepared and stored at 80nC in 16 x 100
mmscrew cap tubes Liver and lung tissue were also collected
rinsed with icecold saline and stored at 80C until assayed All
experimental protocols were approved by the University of Utah
Animal Review Board and performed in accordance with current
IACUC regulations
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Figure 1 Mass spectrum showing the product ions produced from collision induced dissociation of
capsaicin The data were generated by introducing a 10 ngmL solution of capsaicin at a rate of
10 pUmin into the LC flow consisting of 57 methanol425distilled water containing 01
formic acid using a syringe pump The LC flow was directed into the MS at a flow rate of025 mUmin
and data collected for 25 scans The inset represents the proposed fragmentation pathway for the
precursor ion of capsaicin mz306
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 t  c ll ct  f r 25 scans.  i s t r r s ts t  r s  fr t ti  t y f r t  
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Results
LCMS
The analysis of capsaicin dihydrocapsaicin and nonivamide
in blood by LCMSMS exhibited a limit of detection LOD of
025 ngmL and a lower limit of quantitation LOQ of 10
ngmLA mass spectrum showing the product ions generated by
collision induced dissociation of capsaicin mz306 is shown
in Figure 1 An ion having a masstocharge ratio of 137 was the
predominant product ion produced by the capsaicinoids A typ
ical selectedreaction monitoring profile obtained from the
analysis of an extracted 25 ngmL calibrator by LCMSMS is
shown in Figure 2 As shown in Figure 2 all analytes were sep
arated either chromatographically or differentiated by MSMS
using selected reaction monitoring
The plot of the ratio of analyte and internal standard peak
areas versus calibrator concentration was nonlinear over the
range of 10250 ngmL Calibration curves were fit to a
quadratic equation weighted 1Y where Y was the peakarea
ratio Calibration curves generated in this manner exhibited a
correlation coefficientrthat was typically 0980 The accu
racy of the LCMSMS assay was 2 90 n 5 and the intra
assay precision 8RSD for all analytes at the three quality con
trol concentrations The interassay precision was 9RSDand
the accuracy n b was 88 for all analytes at all quality con
trol concentrations The data for intra and interassay precision
and accuracy are summarized in Table I
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Figure 2 Representative selected reaction monitoring profile obtained from the analysis of an ex
tracted 25ngmLcalibrator containing capsaicin dihydrocapsaicin and nonivamide by LCMS
The identities of the peaks are octanoyl vanillamide mz280 137 nonivamide mz294 137
capsaicin mz 306 137 and dihydrocapsaicin mz308 137
Table I Accuracy and Intra and Interassay Precision RSD for Quality
Control Standards Containing Capsaicin Nonivamide and Dihydrocapsaicin
Capsaicin Nonivamide Dihydrocapsaicin
Target Concentration Accuracy RSD Accuracy RSD Accuracy RSD
ngmL Target Target Target
Intra assay n 5
25 104 4 99 4 102 6
10 104 3 107 3 102 2
100 90 7 96 8 96 4
Interassay n 15
25 108 6 107 7 105 9
10 100 6 101 7 100 4
100 88 7 90 9 96 5
Recovery of the capsaicinoids from blood
was 8595 for all three analytes at the
concentrations tested Table II
The effects of various storage conditions
on the stability of the analytes are sum
marized in Table III The experimentally
determined concentrations of capsaicin
in samples n 5 that were stored at ei
ther room temperature in autosampler
vials in 70methanol30distilledH
at 4C or subjected to a freeze thaw
cycle were essentially not affected How
ever nonivamide and dihydrocapsaicin
exhibited an approximately 50 decrease
in concentration when stored in blood at
room temperature for 24 h Data for the
stability of the capsaicinoids are presented
in Table III
Analysis of biological samples
Data from the analysis of capsaicinoids
in blood lung and liver collected from
rats exposed to aerosols of capsaicinoids
are presented in Table IV These analyses
demonstrated that we could detect capsai
cinoids in blood lung and liver specimens
collected from rats dosed with doses of
capsaicinoids 045 mgk n 2 In
addition to detecting capsaicin dihydro
capsaicin and nonivamide nordihydro
capsaicin was also observed in the m12294
137 selected reaction monitoring profile
Figure 3 Identification of nordihydro
capsaicin in these samples was based on
similarities in the precursor toproduct ion
transition retention time and proportion
45 relative to capsaicin dihydrocap
saicin of this analyte versus authentic
nordihydrocapsaicin found in the purified
mixture of capsaicinoids used for the in
halation studies Nordihydrocapsaicin an
other naturally occurring capsaicinoid was
not quantitated in this assay because stan
dard reference material for this analogue
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lt  
l - S-MS 
e a al sis f ca saicin, i r ca saici , a  i a ide 
i  l  by -MS-MS e i ite   li it f t ti  (L ) f 
0.25 ng/  and a lo er li it of a titati  (L ) of 1.0 
ng/mL.  ass spectru  sho ing the product ions generated by 
collision-induced dissociation of capsaicin (mlz 306) is sho n 
i  i r  . n i  i   ss-t - r  r ti  f  as t  
re i a t r t i  r uce  by t  ca saici i s.  t -
ical selecte -reacti  it ri  profile obtained fro  the 
analysis of an extracted 25-ng/ L calibrator by LC-MS-MS is 
sho n in Figure 2. As sho n in Figure 2, all analytes ere sep-
100-
80~ 
60~ 
40~ 
 a lami  
/z=280 -> 7 
8.5 
l   l y, ol. 6,   
r t  it r r t r i ll  r iff r tiat  by -MS 
using selected-reaction onitoring. 
The plot of the ratio of analyte and internal standard peak 
  l   as -line    
r  f .0-250 / . li r ti  r s ere fit t   
quadratic equation, eighted l1Y2, here  as the peak-area 
ratio. alibration curves generated in t is a er exhibited a 
l ti  f i i t (ft) t t a  t i ll  2 .98 .  -
r  f t  -MS-MS  as  0% (n = )  t  i tra-
assa  recisi  :s; 8%RS  for all a al tes at t e t ree alit  c n-
trol concentrations. he interassay precision as:S; 9%RSD and 
the accuracy (n = S) as 2 88% for all analytes at all quality con-
trol concentrations. The data for intra- and interassay precision 
and accuracy are su arized in Table I. 
r  f t  ai i i  fr  l  
as -95% f r all t r  a al tes t t  
 t  ( a l  I). 
The effects of various storage conditions 
20-; \. 
o~---------------L~-------------------------  t  t ilit   t  l t   um-ri  i  a le III. e ri t ll  
eter i e  c ce trati s of capsaicin 
in sa ples (n = 5) that ere stored at ei-
ther roo  te perature, in autosa pler 
 (in 0% ethanol!30%  20 
at 4°C), or subjected to a freeze-tha  
cycle ere essentially not affected. o -
ever, noniva ide and dihydrocapsaicin 
exhibited an approxi ately 50% decrease 
   t     
roo  te perature for 24 h. ata for the 
stability of the capsaicinoids are presented 
i  l  III. 
100 I Nonivamide i E mH94-m 
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Figure 2. Representative selected·reaction monitoring profile obtained from the analysis of an ex-
tracted 25-ng/ L calibrator containing capsaicin, dihydrocapsaicin, and noniva ide by L - S-MS. 
 i i i     r  l ill i  (mil  -> 7), i i  (mil  -> 37), 
capsaicin (mil 306 -> 137), and dihydrocapsaicin (mil 308 -> 137). 
Table I. Accuracy and Intra- and Interassay Precision (%RSD) for Quality 
tr l t r s t i i  saicin, i i , a  i droc s i i  
apsaicin i i  ihydroca saici  
arget oncentration ccuracy  r   r   
(ng/ L) (% Target) (%) (% arget) (%) (% arget) (%) 
a-a say (n = ) 
.5 4      
  3 107    
 90  96  96  
te as  (n = ) 
.5       
       
       
 
al sis f i l ical sa les 
ata fro  the analysis of capsaicinoids 
in blood, lung, and liver collected fro  
rats exposed to aerosols of capsaicinoids 
are presented in Table IV. These analyses 
de onstrated that e could detect capsai-
cinoids in blood, lung, and liver speci ens 
     s   
capsaicinoids 2 0.045 mglkg (n = 2). I  
addition to detecting capsaicin, dihydro-
capsaicin, and noniva ide, nordihydro-
capsaicin as also observed in the lz294 
-+ 137 selected-reaction onitoring profile 
(Figure 3). Identification of nordihydro-
capsaicin in these samples was based on 
si ilarities in the precursor -to-product ion 
transition, retention ti e, and proportion 
(4-5% relative to capsaicin + dihydrocap-
saicin) of this analyte versus authentic 
nordihydrocapsaicin found in the purified 
ixture of capsaicinoids used for the in-
halation studies, ordihydrocapsaicin, an-
other naturally occurring capsaicinoid, was 
not quantitated in this assay because stan-
dard reference material for this analogue 
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was not available The concentrations of capsaicinoids in blood
lung and liver were dependent upon the dose received by the
animal The total concentration of capsaicin dihydrocapsaicin
and nonivamide in blood samples ranged from 10 to 1256
ngmL 50 to 1739pgmg for lung and 20 to 34 pgm for
liver for all three doses used in this study Capsaicin repre
sented 7080 ofthe total capsaicinoids present in blood sam
ples and 90 100 in lung and liver due presumably to the in
ability to detect dihydrocapsaicin and nonivamide at very low
concentrations dihydrocapsaicin and nonivamide comprise
only 35 and 28 of the capsaicinoids present in the dose of cap
saicinoids respectively No capsaicinoids were detected in blood
lung or liver collected from control animals or animals per
mitted to recover for 24 or 48 h after the
exposure data not shown
Discussion
The development of sensitive and selec
tive methods to accurately quantitate the
concentrations of capsaicinoids in biolog
ical matrices is needed to evaluate the re
lationship between dose and physiological
effects of capsaicinoids For example the
ability to generate dose response rela
tionships will be beneficial in the devel
opment and assessment of medicinal
products that contain capsaicinoids The
methodology may also be beneficial in un
derstanding the risks and ramifications of
exposure and the development of safer
more effective products
We developed sensitive and selective
methods for the detection and accurate
quantitation of capsaicin nonivamide and
dihydrocapsaicin in biological samples
using LCMSMS Using this method the
assayed concentrations for the fortified
quality control samples were 90107 of
the target concentrations for all analytes
Table I The method produced nearly
identical values for the quality control
samples on separate days exhibiting an in
terassay precision of less than 9 RSD
Table 1 In general capsaicin was not af
fected by different sample storage and han
dling conditions However nonivamide
and dihydrocapsaicin were significantly
decreased 50 in blood samples stored
at room temperature for 24 h Table II1
These data are significantly different than
what we have previously observed for sta
bility of capsaicinoids on cloth samples in
which approximately 70 of the predicted
amounts of capsaicin nonivamide and
dihydrocapsaicin were detected even after
storage for six months at room temperature 22 These data
demonstrate that different matrices that may be assayed for
the presence of capsaicinoids require different storage and
Table II Recovery of Capsaicin Nonivamide and
Dihydrocapsaicin from Blood
Target concentration Capsaicin Nonivamide Dihydrocapsaicin
ngmL Target Target Target
25 95 2 864 91 4
10 95 6 90 6 939
100 88 1 85 2 878
Table III Stability of Capsaicin Nonivamide and Dihydrocapsaicin in Standards
Stored Under Various Conditions
Treatment and target Capsaicin Nonivamide Dihydrocapsaicin
concentration ngmL Control Control Control
24 hRoom temperature
Dihydrocapsaicin
Blood 0 0000
25 937 49 10 52 10
10 99 9 48 9 78 7
100 97 7 41 7 6911
24 hAutosamplerat4C
500 057 904332ngmL
25 99 14 101 12 103 9
10 104 10 107 11 102 8
100 97 2 100 3 94 4
Freezethaw
045 85 pgmg NDT
25 101 1 102 1 101 17
10 108 10 110 9 100 12
100 93 5 89 4 95 7
Table IV Concentrations of Capsaicin Nonivamide and Dihydrocapsaicin in
Blood Lung and Liver Collected from Rats Exposed to Aerosols of Capsaicinoids
Sample Solution Dose
TissueConcentrations
Tissue mgL mgk Capsaicin Nonivamide
NDtND NDTND NDtND
1 ml 10 0038 LOQT NDt NDt
50 045 82ngmL LOQT LOQT
1 A 10ngmL 334148ngmL
Lung 0 0000 NDtND NDtND NDtND
200mg 10 0038 LLOQT U Dt NDt
50 LOQT
500 057 167 153 pgmg LOQT LOQ 69 pgmg LOQ
Liver 0 0000 NDt ND NDtND NDtND
500mg 10 0038 NDt NDt NDt
50 045 30pgmg ND LOQT
500 057 31 pgmg LOQT LOW LOQ LOQT LOQ
N 2 for control and high doses of capsaicin N 1 for low and medium doses
t ND The capsaicinoid analogue was not detected in this sample
t LOQ The capsaicinoid wasdetected however the concentration was below the lower limit of quantitation
317
001250
 f l  logy, l. , t r  
as t a aila le. e tr ti s f s i i i s i  l , 
lung, and liver ere dependent upon the dose received by the 
ani al. The total concentration of capsaicin, dihydrocapsaicin, 
 i a ide i  l  l  r  fr  < .0 t  25.6 
glmL, < .0 t  73.9 /m  f r l , a  < .0 t  .4 glmg f r 
liver for all t ree doses used in t is study. apsaicin repre-
sented 70-80% of the total capsaicinoids present in blood sa -
les  -10 % i  l   li r, e r s l  t  t  i -
a ilit  t  etect i roca saici  a  i a ide at er  lo  
c ce trati s; dihydrocapsaicin and noniva ide co prise 
only 35 and 2.8% of the capsaicinoids present in the dose of cap-
saicinoids, respectively. No capsaicinoids ere detected in blood, 
l , r liver llecte  fr  tr l i ls r i l  r-
st r  f r si  t s t r  t r t r  (2 ), ese t  
e strate t at iffere t atrices t at ay be assayed for 
the presence of capsaicinoids require different storage and 
 I.  f saicin, ,  
ihydroca   l  
r t t ti  i i  i i  i r i i  
(nglmL) % r t % r t % r t 
2.5 95 ± 2 86 ± 4 91 ± 4 
  ± 6  ± 6  ± 9 
  ± 1 85 ± 2 87 ± 8 
tte           
exposure (data not shown). able III. tability of apsaicin, oniva ide, and ihydrocapsaicin in ta ar s 
i  
The develop ent of sensitive and selec-
tive methods to accurately quantitate the 
concentrations of capsaicinoids in biolog-
i l atrices is  t  l t  t  r -
lationship bet een dose and physiological 
effects of capsaicinoids. For exa ple, the 
ability to generate dose-response rela-
tionships ill be beneficial in the devel-
op ent and assess ent of edicinal 
products that contain capsaicinoids. The 
ethodology may also be beneficial in un-
derstanding the risks and ramifications of 
exposure and the develop ent of safer, 
ore effective products. 
e developed sensitive and selective 
      
quantitation of capsaicin, noniva ide, and 
dihydrocapsaicin in biological sa ples 
using LC- S-MS. Using this ethod, the 
assayed concentrations for the fortified 
quality control sa ples were 90-107% of 
the target concentrations for all analytes 
(Table I). he ethod produced nearly 
identical values for the quality control 
sa ples on separate days, exhibiting an in-
terassay precision of less than 9%RSD 
(Table I), In general. capsaicin as not af-
fected by different sa ple storage and han-
dling conditions. However, noniva ide 
and dihydrocapsaicin were significantly 
 (-5 %) in blood samples stored 
at room temperature for 24 h (Table III), 
These data are Significantly different than 
hat we have previously observed for sta-
bility of capsaicinoids on cloth sa ples, in 
which approximately 70% of the predicted 
amounts of capsaicin, nonivamide, and 
dihydrocapsaicin were detected even after 
  arious  
t t  t t i i  oniva ide r c  
tr ti  (ng/mL) % l % tr l % ontrol 
   te erat re 
,5  ± 7  ± 10  ± 10 
  ± 9  ± 9  ± 7 
  ± 7  ± 7 9 ± 11 
24 h utosa pler at4'C 
.5  ± 14 101 ± 12 3±9 
  ± 10 107 ± 11 102 ± 8 
  ± 2  ± 3  ± 4 
reez -thaw 
.5 101 ± 1  ± 1 101 ± 17 
  ± 10 110 ± 9 100 ± 12 
  ± 5  ± 4  ± 7 
 .   ici , ,  r i   
l , ,  li  le t   t    l   i i  
ple! l ti   issue oncentrations 
s  (rngImL) (rngIkg)' apsaicin i i  i droca saici  
l  .0 . 00 .D.t, .D. .D.!, .D. .D.!, .D. 
(1 L) .0 . 038 <LOQI .Dt .D.! 
.0 .045 8.2 ng/mL < I < I 
0.0 .57 0 4, 3.2 /  .8, .0 glmL 3.4, 4.8 /  
Lung .0 . 00 .D.t, .D. .D.t, .D. .D.t, .D. 
(2oo g) .0 . 038 < I N. .t .D.t 
.0 .045 8.5 pg/mg .D.! < I 
0.0 .57 ,  /m  < I, <  .9 / , < ' 
liv r .0 . 0 .D.!, .D. .D.t, .D. .D.t, .D. 
(5OO g) .0 . 038 .D.t .D.t .D.! 
.0 .045 .0 /m  bN.D. < I 
0.0 .57 3.1 pg/ g, < L I < QI, <  < I, <  
*  =  f r tr l  i   f i in.  =  f r l   i  . 
t .D. =  i i i  l   t t t d i  t iS le. 
I < O =  i i i  s t t ; r, t  t ti   l  t  l  li it f tit ti . 
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handling conditions Hence if blood and tissue samples are to
be assayed for capsaicinoids they should be immediately frozen
and stored frozen until analysis to ensure accurate determina
tion of capsaicinoids in the sample Another important factor
that may affect the analysis of capsaicinoids in biological sam
ples is the time between sample collection and exposure Un
fortunately we have not investigated toxicokinetics in this
study nor have we evaluated other routes ofexposure However
we did show that the capsaicinoids were not detectable in sam
ples collected 24 or 48 It after exposure suggesting the ability
to detect capsaicinoids in biological samples was affected by
time Collectively our data suggest that care must be used
when collecting storing and handling biological samples that
are to be assayed for capsaicinoids and that knowledge of these
parameters is important for interpretation of the data
Unlike previous analytical methods for the analysis of cap
saicin and its analogues this method permitted the unique
identification of nonivamide in the presence of capsaicin In ad
dition this method had the sensitivity and selectivity necessary
to accurately identify and quantitate the capsaicinoids in com
plex and diverse biological matrices including blood lung and
liver Previous workusing GCMS or HPLC for analysis of cap
saicinoids in pepper products and biological samples has been
limited by the inability to detect chromatographically sepa
rate or to differentiate the individual capsaicinoid analogues
2327 Specifically nonivamide may only exist in very low
concentrations relative to capsaicin and dihydrocapsaicin and
may not be detectable in less sensitive methods suchas HPLC
with UV detection In addition nonivamide may be misidenti
fied as either nordihydrocapsaicin because of the same mass in
GCMS or capsaicin because ofsimilar chromatographic prop
erties in HPLC 2327 The method described here permitted
the simultaneous detection and unique identification of all
three capsaicinoids that are commonly used to prepare com
mercial pepper products as well as the qualitative identification
of nordihydrocapsaicin another naturally occurring capsaici
noid This sensitivity and selectivity may be beneficial in as
sessing the contribution of individual capsaicinoids particularly
if the exposure involves a complex mixture of naturally occur
ring capsaicinoids
Our results also suggest that the concentration of capsaici
noids in blood lung and liver is strongly related to the dose
Table IV None of the capsaicinoids were detected in blood
lung or liver collected from control animals n 2 or animals
exposed to the lowest dose n 1 38mgk but all three cap
saicinoids were detected in blood 904 and 332 ngmL lung
167 and 153 pgm and liver 30 and 20 pgm in animals
exposed to the highest dose n 2 057mgk Nordihydro
capsaicin was also qualitatively identified in blood samples col
lected from the high dose animals Figure 3 The most likely
reasons for the differences between the concentrations of cap
saicinoids in the samples collected from the high dose animals
are differences in the rate of respiration positioning in the ex
posure chamber or inherent differences in absorption elimi
nation or metabolism of capsaicin All of these parameters
could cause differences in the delivered dose and thus the
capsaicinoid concentrations detected in the various tissues
The doses of capsaicinoids used in this study were intended to
represent an approximate dose received by an animal or human
sprayed with a typical pepper spray weapon for several seconds
1020 ml at 1030 mgmL capsaicin Assuming efficient in
halation and dermal absorption of the capsaicinoids it is rea
sonable to predict that in addition to the
100
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Figure 3 Representative selected reaction monitoring profile obtained from the analysis of a 1 mL
blood sample from a rat exposed to057mgkg capsaicinoids via inhalation The identities of the
peaks are octanoyl vanillamide mz 280 137 nonivamide and nordihydrocapsaicinmz294
137 capsaicin mz 306 137 and dihydrocapsaicin mz 308 137
skin and clothing capsaicinoids will be
present in blood lung and possibly liver at
detectable concentrations following an ex
posure to pepper spray Therefore anal
ysis of these samples by LCMSMS may
be beneficial in demonstrating pepper
spray exposure in medico legal investiga
tions in addition to assessing efficacy of
the capsaicinoids in controlled dose expo
sure studies
Conclusions
This method for the analysis of cap
saicin nonivamide and dihydrocapsaicin
permitted the identification and quantita
tion of the three principal capsaicinoids
found in various pepper products in
cluding pepper spray self defense weapons
as well as the qualitative identification of
nordihydrocapsaicin The LOQ of 10
ngmLand upper limit of quantitation of
250 ngmLwere sufficient for the simul
taneous quantitation all three capsaici
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(23-27). Specifically, noniva ide ay only exist in very lo  
concentrations relative to capsaicin and dihydrocapsaicin and 
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it   etecti . I  a iti , i a ide a  be isi enti-
fied as either nordihydrocapsaicin (because of the sa e ass in 
-MS) or capsaicin (because of si ilar chro atographic prop-
 la ide 
/z~280 -+  
.5 
  l ti l xicology, l. 6, pte ber  
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t r  s i i i s t t r  l  sed t  r r  -
r i l r r ts, s ll as t  lit ti  i tifi ti  
of nordihydrocapsaicin, a t er naturally occurring capsaici-
noid. his sensitivity and selectivity ay be beneficial in as-
sessing the contribution of individual capsaicinoids, particularly 
if t  s r  i l s  l  i t r  f turall  ur-
ri  aici i . 
r r s lts als  s st t t t  tr ti  f capsaici-
noids in blood, lung, and liver is strongly related to t e dose 
(Table IV). one of the capsaicinoids ere detected in blood, 
l g,  li  ll t   t l i l  (  = )  i l  
s  t  t  l st s  (n = 1) ( .8 g/k ) , t ll t r  ap-
saicinoids ere detected in blood (90.4 and 33.2 ng/ L) , lung 
(167 and 153 pg/mg) , and liver (3.0 and < 2.0 pg/mg) in ani als 
exposed to the highest dose (n = 2) (0.57 g/kg). ordihydro-
i i   l  lit ti l  i ti i  i  l  l  ol-
lecte  fr  t e i  se a i als (Fig re ). e st li el  
reasons for the differences bet een the concentrations of cap-
saicinoids in the sa ples collected fro  the high dose ani als 
are differences in the rate of respiration, positioning in the ex-
posure cha ber, or inherent differences in absorption, eli i-
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l   ere  i   l   nd, s,  
capsaicinoid concentrations detected in the various tissues. 
The doses of capsaicinoids used in this study ere intended to 
represent an approxi ate dose received by an ani al or hu an 
s ra e  it   t ical e er s ra  ea  f r se eral sec s 
(10-20 L at 10-30 g/ L capsaicin). ssu ing efficient in-
halation and der al absorption of the capsaicinoids, it is rea-
sonable to predict that, in addition to the 
skin and clothing, capsaicinoids will be 
rese t in l , l , a  ssi l  li er at 
detectable concentrations follo ing an ex-
posure to pepper spray. herefore, anal-
o~----------------~~-------------------------- ysis of these sa ples by LC-MS- S ay be beneficial in de onstrating pepper 
spray exposure in medico-legal investiga-
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tions in addition to assessing efficacy of 
the capsaicinoids in controlled dose expo-
 . 
l i  
his ethod for the analysis of cap-
saicin, noniva ide, and dihydrocapsaicin 
per itted the identification and quantita-
tion of the three principal capsaicinoids 
found in ari s pepper r cts in-
cluding pepper spray self-defense eapons, 
as ell as the qualitative identification of 
nordihydrocapsaicin. The LOQ of 1.0 
nglmL and upper limit of quantitation of 
250 nglmL ere sufficient for the si ul-
taneous quantitation all three capsaici-
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noids in blood lung and liver isolated from rats exposed to cap
saicinoids via inhalation Extending the dynamic range of the
assay to lower concentrations of all three analytes may be de
sirable to account for the substantially lower concentrations of
nonivamide and dihydrocapsaicin in mixtures of capsaicinoids
as well as all capsaicinoids in blood and tissues from low dose
exposures or human exposures where the body mass and
thus volume of distribution is larger Also a more sensitive
method would be helpful to account for potential differences in
the concentrations of capsaicinoids in blood and tissues fol
lowing different routes of exposureie inhalation versus oral
or dermal doses which would likely affect the amount andor
rate of absorption Although we have not focused on the anal
ysis of capsaicinoids inon other matrices eg clothes skin
etc our previous research suggests that this assay would be ap
plicable 228As such this assay or a modified version of this
assay may represent a valuable tool for medical and forensic sci
entists who study the mechanisms by which capsaicinoids elicit
specific physiological responses or use capsaicinoids as a marker
of pepper spray exposure
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noids in blood, lung, and liver isolated fro  rats exposed to cap-
saicinoids via inhalation. Extending the dyna ic range of the 
assay to lo er concentrations of all three analytes ay be de-
sirable to account for the substantially lo er concentrations of 
noniva ide and dihydrocapsaicin in ixtures of capsaicinoids, 
as ell as all capsaicinoids in blood and tissues fro  low dose 
exposures, or hu an exposures, where the body ass, and 
thus, volume of distribution is larger. Also, a more sensitive 
ethod ould be helpful to account for potential differences in 
the concentrations of capsaicinoids in blood and tissues fol-
lo ing different routes of exposure (i.e., inhalation versus oral 
or der al doses), hich ould likely affect the a ount and/or 
rate of absorption. Although we have not focused on the anal-
sis f ca saici ids i ion t r atrices (e.g., cl t es, s i , 
etc.), our previous research suggests that this assay ould be ap-
plicable (22,28). As such, this assay, or a odified version of this 
assay, ay represent a valuable tool for edical and forensic sci-
entists who study the echanis s by which capsaicinoids elicit 
s ecific si l ical res nses r se ca saici ids as  ar er 
of pepper spray exposure. 
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Reconsideration and in Opposition to Defendants Second Motion for Summary Judgment
Plaintiff incorporates the Statement of Undisputed Facts and Statement of Disputed Facts set
forth in her Memorandum in Opposition to DefendantsMotion for Summary Judgment and
Memorandum in Support of Plaintiffs Cross Motion for Partial Summary Judgment In further
support of her Motion for Reconsideration and in opposition to Defendants Second Motion for
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l i ti    following   t f   f r 
Reconsideration and in Opposition to Defendant's Second otion for Summary Judgment. 
Plaintiff incorporates the Statement of Undisputed Facts and Statement of Disputed Facts set 
forth in her e orandu  in pposition to efendant's otion for Su ary Judg ent and 
e orandu  in Support of Plaintiffs ross otion for Partial Su ary Judg ent. In further 
support of her otion for Reconsideration and in opposition to Defendant's Second otion for 
Su ary Judgment, Plaintiff files concurrently here ith the ffidavit of arold S. ost, Ph.D., 
 I    LAINTIF 'S I   I I    OURT'S 
  FENDANT'S    MENT,  I  POSITI   
FENDANT'S    U   - 1 
in Support of Plaintiffs Motion to Reconsider Courts Order on Defendants Motion for
Summary Judgment Second Yost Affidavit the Affidavit of Billie Jo Major in Support of
Plaintiffs Motion to Reconsider and in Opposition to DefendantsSecond Motion for Summary
Judgment and the Affidavit of Counsel Support of Plaintiffs Motion to Reconsider and in
Opposition to DefendantsSecond Motion for Summary Judgment
I SUMMARY OF ARGUMENTS
A Motion for Reconsideration
Plaintiff seeks reconsideration of this Court Order granting summary judgment as to the
foreseeability of harm issue In the Second Yost Affidavit Dr Yost explains that the studies
published in and after 2008 cited in his first affidavit were not necessary to his conclusion
regarding the foreseeability issue He explains why the risk of acute and chronic respiratory
injury such as that suffered by Ms Major which was posed by SECs SABRE Red Law
Enforcement 10 OC Spray MK9 Fogger MK9 Fogger were known prior to 2008 He
identifies the body of scientific literature that supports his conclusion by citation to numerous
articles that make up but a part of the body of literature he was referring to in his earlier affidavit
B Opposition to DefendantsSecond Motion forSummary Judgment
Plaintiff opposes Defendant Second Motion for Summary Judgment on the grounds that
the causes of action are not federal claims brought under the FHSA Rather they are state tort
claims where the FHSA defines the label warning standard So long as state law warning
requirements do not conflict with the FHSA warning requirements there is no preemption And
in this case a violation of those standards was the proximate cause of the Plaintiff s injuries
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In Support of Plaintiffs otion to econsider ourt's rder on efendant's otion for 
Su ary Judg ent ("Second ost ffidavit");  ffida it  llie  a   t  
l i tiff s otion t  si r  i  siti  t  f dant's  ti  f r r  
Judg ent, and the ffidavit of ounsel Support of Plaintiffs otion to econsider and in 
pposition to efendant's Second otion for Su ary Judg ent. 
.    
. tion   
l i tiff s r i r ti  f t is ourt's r r r ti  r  j e t s t  t  
foreseeability of har  issue. In the Second ost ffidavit, r. ost explains that the studies 
published in and after 2008 cited in his first affidavit ere not necessary to his conclusion 
regarding the foreseeability issue. e e lai s  t e ris  f ac te a  c r ic res irat r  
injury, such as that suffered by s. ajor, hich as posed by SEC's S BRE Red La  
force e t 0%  r y, -9 r ("M -9 og er"), r   ri r t  8.  
identifies the body of scientific literature that supports his conclusion by citation to nu erous 
articles that ake up but a part ofthe body ofliterature he as referring to in his earlier affidavit. 
. pposition to efendant's Second otion for Su ary Judg ent 
Plaintiff opposes efendant's Second otion for Su ary Judg ent on the grounds that 
t  s s f ti  r  t f r l l i s r t r t  A. ther, t  r  st t  t rt 
clai s ere t e  efi es t e la el ar i  standard.  l  as state la  ar i  
require ents do not conflict ith the F S  arning require ents, there is no preemption. nd 
i  t is case, a i lati  f t se sta ar s as t e r i ate ca se f t e laintiff's i j ries. 
 I    LAINTIF 'S I   NSIDERATI    OURT'S 
  EFENDANT'S    JUDGMENT,  I  POSITI   
FENDANT'S     JUD NT - 2 
II FACTS GIVING RISE TO A GENUINE ISSUE OFMATERIAL FACT
A Plaintiffs Employment Exposure Injuries and Knowledge
1 Ms Major was employed as a guard at the IDOC in July 2004 Medical records
indicate she had suffered periodic bouts of respiratory illnesses She was however physically
able to perform her job as a guard She worked at the Idaho Maximum Security Institution
IMSI from July 2004 to July 2006 and again from August or September 2007 to May 2008
During the intervening periods she worked at the South Boise Women Correctional Facility
2 Ms Major was frequently exposed to OC Spray at the IDOC Ms Majors
respiratory problems became worse and she developed a chronic cough She was however still
able to work care for herself and participate in recreational activities as she had done before In
late February early March 2008 Ms Major developed bronchitis and was placed on light duty
On March 3 2008 she participated in an OC Spray training where she was exposed to SECs
MK9 Fogger The MK9 Fogger produces a widely dispersed aerosol The MK9 Fogger was
designed specifically to irritate and inflame the respiratory tract Other of SECs OC Spray
products include streams and foams which are specifically designed to cause irritation and
inflammation of the eyes and skin By function of design the stream and foam products have
less effect on the respiratory system than does the fogger Conversely the fogger has less effect
on the skin and eyes
1 All citations to the record in support of each numbered paragraph in II of this Memorandum appear at
the end of the numbered paragraph Quotations from the record that may appear within a numbered
paragraph may be located within those cited portions ofthe record
2 Aff of Major T 2 Aff of Counsel in Opp to DefsMSJ and in Supp of Pltfs CrossMPSJ 13 Ex 1
Pacheco Dep 543 5522 731 751 120221 12225 1275 142917 Ex 72 T 9 Ex 7
Schaffer Dep9016 9116 T 11 Ex 9 Link Dep 60513
3 Aff of Counsel in Opp to DefsMSJ 110 Ex 8 Nance Dep 5122 5420 Aff ofMajor T 3
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3 In the March 3 2008 training the trainer sprayed a random number of bursts of
MK9 Fogger into a cell where trainees entered individually and remained until they breathed in
the aerosol to experience the respiratory effect of the MK9 Fogger The instructions limit the
bursts to three Trainees then exited the cell and performed exercises under the effects of OC
Next the trainees helped others through the same procedure The exposure portion of the
training lasted approximately two andahalf hours and was conducted indoors with poor
ventilation
4 After March 3 2008 Ms Major was unable to work due to a severe chronic
cough that also prevented her from caring for herself and engaging in other activities While she
had several trainings on OC Spray and generally understood that OC Spray causes respiratory
irritation nothing in her training experience or observations at the IDOC regarding OC Spray
informed her that there was a respiratory risk associated with the products She was not aware
that chronic exposure could cause hypersensitivity to capsaicinoids and other irritants She was
not aware that overexposure to OC Spray was dangerous and could cause respiratory illness or
aggravate an existing respiratory illness As presented in the trainings and on the labeling of the
SABRE Red products she believed that all the effects from OC Spray were temporary and
generally safe She was never provided a copy ofSECsorany other OC product manufacturers
MSDS for OC Spray products prior to March 3 2008 During her employment at the IDOL
Ms Major read the label of one of SECs SABRE Red OC Spray canistersan OC Spray stream
products
4 Aff of Major 4 Aff ofCounsel in Opp to Defs MSJ 11 Ex 9 Link Dep 571 5825 6014
6215
5 Aff ofMajor 57
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5 Had she been informed of the health risks associated with OC Spray and the MK
9 Fogger in particular Ms Major would have insisted that she be permitted to opt out of the
March 3 2008 training Had the negative health effects been made known to IDOC employees
it is likely the trainers would have designed the training on March 3 2008 differently Had the
risks of OC Spray been made known to her but could not be avoided in the job Ms Major would
have found another job
6 Ms Major was diagnosed as having 1 irritant triggered vocal cord dysfunction
secondary cough attributable to OC exposure at IDOC 2 esophageal dysmotility and reflux
aggravated by occupational exposure to OC weight gain due to lack of exercise and
medications 3 chronic severe cough multifactorial and 4 restless leg syndrome Dr Pacheco
testified regarding a study from 1998 that recognized a condition referred to as irritant associated
vocal cord dysfunction
B SECsKnowledge of Risks Posed by OC Spray
7 Defendant marketed its MK9 Fogger to law enforcement to be used for crowd
control cell extractions and situations requiring a lot of cross contamination The MK9 Fogger
was designed to have more of an impact on the respiratory tract than the stream and foam
products SEC understood how OC caused irritation and inflammation of the respiratory tract
through nerve receptors and had reviewed research on the effects of capsicum on the respiratory
tract SECsVice President decided to test its OC products for the effects on the eyes and skin
and for acute effects of acute exposure to the respiratory tract SEC did not test for health effects
6 Af ofMajor 57
Aff of Counsel in Opp to DefsMSJ 13 Ex 1 Pacheco Dep 2822 341 3811 471 641
and Exs 69 72 Bates Nos NJH 48 63 8087 73
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secondary cough, attributable to  exposure at I ; (2) esophageal dys otility and reflux 
r t   ti l s r  t  , i t i   t  l  f rcise,  
edications; (3) chronic severe cough- ultifactorial; and (4) restless leg syndro e. r. Pacheco 
t stifie  r r i   st  fr   t t r i   iti  r f rr  t  s irrit t ssoci t  
l r  sf nction. 7 
. C's o ledge  is      
. f t r t  its -9 r t  l  f r t t   s  f r r  
tr l, ll tr ti ,  it ti  r iri   l t f r - t i ti .  -9 r 
as si e  t   "more f  i t  t  r s ir t r  tr ct" t  t  str   f  
products. SE  understood ho   caused irritation and infla ation of the respiratory tract 
through nerve receptors, and had revie ed research on the effects of capsicu  on the respiratory 
tract. C's ice resi e t eci e  t  test its  r cts f r t e effects  t e e es a  s i  
 f r t  ffects f t  s re t  t  r s ir t r  tr t.  i  t t st f r lt  ffects 
6 f .  r, ~~ -7. 
7 ff. of Counsel in pp. to ef's SJ, ~ 3, Ex. 1 (Pacheco ep., 28:2-22, 34:1 - 8: 1, 7:1 - 64:14, 
 s. ,  (Bates s. J  , , -8 ), & 3). 
    I TIFF'S I      URT'S 
 I  ENDANT'S I    T,  I  I I   
NDANT'S  I    J  -  
of chronic exposure or for chronic health effects from acute exposure SEC knew a safety
concern existed with OC Spray when used on people with respiratory illness
Q Okay Particularly there are concerns with the safety ofOC
products when used on individuals with pulmonary issues
generally
Q Respiratory issues
A The effects may be greater
SECsVice President considered other manufacturers selling 145 20 and maybe even30
capsaicinoids OC Spray products as irresponsible because they are dangerous The risks of those
products according to SECsVice President were that they Cause could cause some could
possibly cause longterm damage or extremely long recovery periods
8
C Second Yost Affidavit
8 In the Second Yost Affidavit Dr Yost testifies unequivocally that it is his expert
opinion based on his education research and training that the scientific literature and studies in
existence prior to 2008 was such that when viewed as a body of literature and human and animal
studies it was known that a product such as SEC MK9 Fogger posed a risk of both acute and
chronic respiratory injury such as that described in Ms Major medical records
9 Dr Yost explains that the articles he cited previously as a basis for his opinions in
his report that were published in 2008 and later were not necessary to that part of his opinion
relating to the foreseeability of acute and chronic injury such as those documented in
Ms Major medical history as being caused by exposure to OC Spray He explains that based
8 Aff of Counsel in Opp to Def s MSJ 10 Ex 8 Nance Dep 214 4311 441217 501 5917
6322 643 654 1307 13725 1390 1402 1574 1635and Exs B LO Substance P is
the neuropeptide that binds with the capsaicinoid receptor TRVPI as discussed in Dr Yosts opinion
report
9 Second Yost Affidavit 19
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 r i  r , r f r r i  lt  ff t  fr  t  ure.    f t  
cern ist  it   r   s   l  it  r s ir t r  illn ss: 
. y. rti l rl  t r  r  r s it  t  s f t  f  
r ts  s   i i iduals it  l r  iss s, 
erally? 
* * * 
. espiratory issues. 
. he effects ay be greater. 
SEC's ice President considered other anufacturers selling 1.45%,2.0% and aybe even 3.0% 
i i ids   ts  i i le  t   r s.  i   t  
products, according to SEC's ice President, ere that they "Cause --    --  
possibly cause long-ter  da age or extre ely long recovery periods."g 
c.   i  
. In the Second ost ffidavit, r. ost testifies unequivocally that it is his expert 
opinion, based on his education, research, and training, that the scientific literature and studies in 
iste e ri r t     t t,  i     f literat r     i l 
studies, it as kno n that a product such as SEC's -9 Fogger posed a risk of both acute and 
chronic respiratory injury such as that described in s. ajor's edical records.9 
. r. ost l i s t t t  rti les  ite  r i sl  s  sis f r is i i s i  
his report that were published in 2008 and later were not necessary to that part of his opinion 
relati  t  t e f reseeabilit  f ac te a  c r ic i j r  s c  as t se c e te  i  
s. ajor's e ical ist r  as ei  ca se   e s re t   ray. e e lai s t at ase  
8 ff. f sel i  . t  fs J, ~ , .  (Nance ep., 1 :24 - 3: 1, 4:12-17, 0:10 - 9:17, 
3:6-22, 4:3 - 5:4, 30:7 - 37:25, 39:10 - 40:12, 57:14 - 63:5 a  s. , -O). sta ce  is 
t  r tide t t in s it  t  s i i i  r t r 1 s is ss  i  r. st's i i  
re ort. 
9 Second Yost Affidavit, ~ 9. 
    I TIFF'S   I    OURT'S 
 I  FENDANT'S I    J T,  I  I I   
ENDANT'S  I     -  
on what was known prior to 2008 about capsaicinoids TRP Receptors and neurogenic
inflammation of the respiratory tissues the risk posed by a product like the MK9 Fogger of
acute and chronic respiratory injury such as documented in Ms Major medical records would
be known Dr Yost explains that his opinion is based on a whole body of scientific literature
that predates 2008 He identifies four additional publications from 1993 2002 2005 and 2006
which support his opinion relating to foreseeability of acute and chronic respiratory injury He
also provides three separate reviews that cite several hundred pre2008 studies that support his
opinion regarding the known risk of acute and chronic respiratory injury posed by products like
the MK9 Fogger
10 According to Dr Yost there is no doubt that the literature and studies existing
prior to 2008 established within a reasonable degree of scientific certainty that the inflammatory
properties associated with capsaicinoids greatly enhance the sensitivity of neuronal and
respiratory tissues to an array of irritants by an increase in the number andor responsiveness of
TRP receptors populating respiratory tissues Once a higher sensitivity develops in an affected
individual the neurogenic inflammatory response in the respiratory tissues will occur at a lower
threshold than in the non sensitized population Once an individual has become sensitized to
capsaicin the threshold for activation of the neurogenic inflammatory response by exposure to
irritants other than capsaicin is also lowered Capsaicin and its involvement in the sensitization
process were well understood prior to 2008 Thus even prior to 2008 people with asthma andor
chronic cough including Ms Major would have been expected to be muchmore sensitive to the
pathological effects of pepper sprays That is a person such as Ms Major who was already
10 Second Yost Affidavit IT 1013
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 t a   n r t   t i i i ,  t r   r i  
infla atio  f t e r ir t r  tis , t  ris     r t like t  -9 r f 
t   r i  r ir t r  i j r    t  i  . jor's i l r r  l  
 . r. ost l i s t t i  i i  i     l    i tifi  literat r  
t at t  . e i ti ies  iti l lications  , , ,   
ic  rt is i i  r l ti  t  f r abilit  f t   r i  r ir t r  i j r .  
ls  r ides t re  s r t  r i s t t it  s r l r  r -20  st i s t t s rt is 
i io  r r i  t   ri  f t   r i  r ir t r  i j r    r t  li  
t e -9 gger. 1O 
. cc r i  t  r. st, t ere is  t t at t e literat re a  st ies e isti  
prior to 2008 established ithin a reasonable degree f scientific certainty that the infla atory 
r erties ass ciate  it  ca saici i s reatl  e a ce t e sensiti it  f e r al a  
respiratory tissues to an array of irritants by an increase in the nu ber and/or responsiveness of 
 rece t rs lati  res irat r  tiss es. ce a i er se siti it  e el s i  a  affecte  
i i i al, t e e r e ic i fla at r  res se i  t e res irat r  tiss es ill cc r at a l er 
threshold than in the non-sensitized population.      i   
capsaicin, the threshold for activation of the neurogenic infla atory response by exposure to 
irritants other than capsaicin is also lo ered. apsaicin and its involve ent in the sensitization 
process ere ell understood prior to 2008. hus, even prior to 2008, people ith asth a and/or 
chronic cough, including s. ajor, ould have been expected to be uch ore sensitive to the 
pathological effects of pepper sprays. hat is, a person such as s. ajor ho as already 
10 Second Yost Affidavit, ~~ 10-13. 
    L INTIF 'S   I    OURT'S 
 I  FENDANT'S I    J ENT,  I  SI I   
FENDANT'S      -  
sensitized to some extent would be expected to become increasingly sensitized by repeated
andorhigh levels ofrespiratory exposure to OC sprayI1
11 People with greater sensitivity to capsaicin are expected to have increased TRPV1
receptor populations Other important TRP channels exist and several of them particularly
TRPA1 are activated by irritants such as those that exist in cigarette smoke and other
environmental sources Thus it is reasonable to expect the multiple TRP channels to act in
concert with each other to result in higher acute respiratory responses to a multitude of
respiratory irritants in people with increased sensitivity to capsaicinoids That is to say once the
TRP receptor population is upregulated and hypersensitivity occurs the individual will
thereafter experience acute respiratory responses to respiratory irritants whether from capsaicin
cigarette smoke or other environmental sources at exposure levels that would not evoke a
significant response in persons who have not been sensitized The hypersensitivity of affected
individuals to a whole array of respiratory irritants would be expected to elicit respiratory
symptoms that are for all intents and purposes chronic due to the frequency of recurrence of
acute respiratory responses to irritants encountered in everyday life
12
12 After being informed that it was perceived that the 2008 and more recent articles
were required to support his conclusion that it was known prior to 2008 that a product like the
MK9 Fogger posed a risk of causing acute and chronic respiratory injury Dr Yost identified
additional literature and studies that were published prior to 2008 that also support his
conclusion However the pre2008 articles previously cited by Dr Yost were sufficient to
11 Second Yost Affidavit 1013
12 Second Yost Affidavit 1013
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i    t      i l  nsit   t  
nd/or i  l ls f r s ir t r  s r  t   spray. I I 
1. l  it  r t r nsiti it  t  ai i  r  t  t   i r  l 
r t r l ti s. ther i portant P channels exist, and several of the , particularly 
 I,  ti t   i ita t    t  t t i t i  i tt    t  
ir t l s r s. s, it i  r l  t  t t  lti l   l  t  t i  
rt it   t r t  r lt i  i r t  r ir t r  r  t   ltit   
i t  i ita ts i  le it  i re  siti it  t  aici i s. t i  t  y,  t  
 r t r l ti  i  -r l t   r ensitivit  rs, t  i i i l ill 
thereafter experience acute respiratory responses to respiratory irritants, hether fro  capsaicin, 
i r tt   r t r ir t l r , t r  l l  t t l  t   
i ifica t r s  i  r s   t  siti d.  r nsiti it  f ff t  
individuals to a hole array of respiratory irritants ould be expected to elicit respiratory 
t s t t ,  ll i te t   , i   t  t      
t  r ir t r  r  t  irrita ts t r  i  r  lif . 12 
. fter being infor ed that it as perceived that the 2008 and ore recent articles 
r  r ir  t  rt is l i  t t it   ri r t   t t  r t li  t  
-9 r   ris  f i  t   r i  r ir t r  i j ry, r. t i tifie  
additional literature and studies that ere published prior to 2008 that also support his 
l i n. o ever, the pre-2008 articles previously cited by r. ost ere sufficient to 
 d ost ffida , ~~ -1 . 
2 d ost ffida , ~~ -1 . 
    I IFF'S IO   I    URT'S 
 I  FENDANT'S I  F  S  J T,  I  PP SI I   
NDANT'S  I     -  
support his conclusion regarding the foreseeability issue As he stated in his prior affidavit those
articles are just part of a much larger body of literature and studies that support his conclusion
13
13 For instance Dr Yost has identified three reviews of the science regarding
capsaicinoids TRP receptors sensitization and respiratory illness Even though each of the
three were published in 2009 and 2010 they provide a fair overview of the state of knowledge
prior to 2008 because they are based on pre2008 research Of the fiftyeight cited studies in Lu
Yuan Lee and Qihai Gus ROLE OF TRPV1 IN INFLAMMATION INDUCED AIRWAY
HYPERSENSITNITY Current Opinion in Pharmacology 9243249 2009 in which the authors
provided a review of some of the literature and studies of TRPV1 and its role in airway
hypersensitivity and related airway diseases only eight studies were published in 2008 or later
A similar review was published in Pulmonary Pharmacology Therapeutics 226570 2009
by John J Adcock entitled TRPV 1 RECEPTORS IN SENSITIZATION OF COUGH AND PAIN REFLEXES
Of the fiftynine articles cited in the review only three were published in 2008 and none of them
were published after 2008 Another informative review was by K Alawi and J Keeble
published in Pharmacology and Therapeutics12581195 2010 THE PARADOXICAL ROLE OF
THE TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 RECEPTOR IN INFLAMMATION Of the 226
studies cited in this review only fourteen were published in or after 2008 All three of these
reviews support Dr Yosts conclusion about the state of the science at the time SEC sold the
MK9 Fogger to IDOC
13 Id
14 Second Yost Affidavit 13 See also Aff of Counsel in Opp to Defs MSJ 3 Ex 1 Pacheco
Dep 47 552 8811 90 121024 Ex 73 discussing known relationship between respiratory
irritants such as capsicum and vocal cord dysfunction including an article published in 1998 and
Ms Major case
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support his conclusion regarding the foreseeability issue. s he stated in his prior affidavit, those 
articles are just part f a uch larger body f literature and studies that support his conclusion. 13 
.  or instance, r. ost has identified three revie s f the science regarding 
capsaicinoids,  receptors, sensitization, and respiratory illness. ven though each f the 
three ere published in 2009 and 2010, they provide a fair overvie  f the state f kno ledge 
        -200  arch.   -eig   t  i  -
 Lee  i ai u's   l I  -   
SITNIT , rr t i i  i  r ol y, :243-24  (2 9), i  i  t  t rs 
provided a revie  f so e f the literature and studies f l and its role in air ay 
hypersensitivity and related air ay diseases, only eight studies ere published in 2008 or later. 
 si ilar revie  as published in ul onary har acology & herapeutics, 22:65-70 (2009), 
by John J. dcock entitled l P S I  S SI I I  F   P I  F S. 
f the fifty-nine articles cited i  the revie , only three ere published in 2008 and none f the  
ere published after 2008. nother infor ative revie  as by . la i and J. eeble 
published in har acology and herapeutics,125:181-195 (2010),  P I   F 
        I .    
studies cited in this revie , only fourteen ere published in or after 2008. ll three f these 
re ie s t r. st's s on t            
-9 er t  OC. 14 
3 . 
4  ost id it, ~ 13. See also, ff. f ounsel in pp. to ef's J, ~ 3, x. 1 (Pacheco 
p., 7:4 - 5:25, 8: 1 - :, 21: 0-24 & . ) (discussing  relations ip et ee  res irat r  
irritants such as capsicu  and vocal cord dysfunction, including an article published in 1998, and 
s. ajor's case). 
    IFF'S I      URT'S 
 I  ENDANT'S    ,   I I   
NDANT'S  I     -  
D SECs MK9 Fogger Label
14 SECsMK9 Fogger label does not provide a warning that it is an irritant or an
inflammatory to the respiratory tract The label states Caution Severe Skin and Eye Irritant
Contents Under Pressure and See Other Warnings On Back Label The back label provides
no warnings relating to inhalation And while SECsVice President testified that if a person is
suffering asthma emphysema or bronchitis they recommend that they not be exposed such a
warning does not appear on the label Even though SEC knew OC is a respiratory irritant that
the MK9 Fogger was designed specifically to cause respiratory tract inflammation and that
overexposure could be dangerous the label has nothing warning of respiratory irritation the
risks ofoverexposure or what action to take or avoid in order for users to protect themselves
15 SEC developed an MSDS for each of its OC Spray products that identified the
product as causing irritation through all routes of entry and identifying it as a severe skin and
eye irritant SEC identified its product as being a hazard to the eyes Liquid or vapors may
cause redness burning tearing swelling andorpain And it identified the product as a hazard
to the skin Frequent or repeated contact with skin may cause skin irritation and dermatitis
And a hazard when ingested Ingestion may cause nausea vomiting andordiarrhea The
MSDS stated that when inhaled the product may cause irritation of the respiratory tract
Finally the MSDS warned under Medical Conditions Aggravated that the product may cause
1s Id
16 Aff of Counsel in Opp to DefsMSJ 10 Ex 8 NanceDep 4412 486 904 942 and Exs B
D E 9 Ex 7 Schaffer Dep 764 771Affidavit ofCounsel in Support of PlaintiffsMotion for
Reconsideration and in Opposition to DefendantsSecond Motion for Summary Judgment 13 Ex 1
clean copy ofMK9 Fogger label
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. C's -9  a e  
. C's -9  l l  t i e  i  t t it i   i ita t   
infla atory to the respiratory tract. he label states "Caution: evere kin and ye Irritant," 
"Contents nder ressure" and "See ther arnings n ack abel." he back label provides 
 a ings l ti  t  i alation. 15  ile C's ice i t t ti i  t t i    i  
suffering asth a, e physe a, or bronchitis, they "recommend that they not be exposed," such a 
warning does not appear on the label. Even though SEC knew OC is a respiratory irritant; that 
 -9    cif    i   ti ;   
overexposure could be dangerous: t  l l  t i  r i  f r ir t r  irrit ti , t  
risks of overexposure, or hat action to take or avoid in order for users to protect the selves. 16 
.  l    f r  f its  r  r t  t t i tified t  
product as causing "irritation through all routes of entry" and identifying it as a severe skin and 
eye irritant. SE  identified its product as being a hazard to the eyes: "Liquid or vapors ay 
s  r , r i , t ri g, lli , nd/or ain."  it i tifie  t  r t   r  
t  t  s i : "Freque t r r t  t t it  s i   s  s i  irritati   rmatitis." 
nd a hazard hen ingested: "Ingestio  a  ca se a sea, iti g, and/or iarrhea." e 
 state  t at, e  i aled, t e r ct "ma  ca se irritati  f t e res irat r  tract." 
Finally, the SDS warned, under "Medical Conditions Aggravated," that the product "may cause 
15Id. 
16 ff. f ounsel in pp. to ef's J, ~ 10, x. 8 (Nance ep., 44:12 - 8:6,90:4 - 4:24  xs. , 
 & E), ~ 9, Ex. 7 (Schaffer ep., 76:4 -7 :1); ffid it f s l i  rt f laintiff's ti  f r 
ec si erati n, a  i  siti  t  efendant's ec  ti  f r ar  J ent, ~ , x.  
(clean copy of -9 Fogger label). 
    LAINTIF 'S   I    OURT'S 
  FENDANT'S    MENT,  I  SI I   
FENDANT'S      -  
more severe temporary effects on those persons who are asthmatics or suffer from
emphysema
III ARGUMENT
A Motion for Reconsideration Standard
Motions for reconsideration are matters for the trial courtsdiscretion A party making
a motion for reconsideration is permitted to present new evidence but is not required to do so
B Motion for Summary Judgment Standard
Summary judgment is proper when there are no genuine issues of material fact and the
moving party is entitled to judgment as a matter of law
20
All controverted facts are to be
liberally construed in favor of the nonmoving party
21
C AMaterial Issue of Fact Exists Precluding Summary Judgment on Plaintiffs
First and Second Causes ofAction
On July 14 2011 this Court explained why Dr Yostsaffidavit did not present a genuine
issue of material fact This Court said that Dr Yostsaffidavit would have to 1 conclude that
prior to 2008 there existed sufficient knowledge of a risk posed by SECsproduct of acute and
chronic respiratory illness such as that claimed by Ms Major and 2 identify the scientific basis
for such conclusion that does not depend on publications from 2008 or later This Court also
expressed concern that Dr Yost had concluded that SECs product posed a risk of acute
respiratory injury but made no conclusions regarding chronic respiratory injury
17 Aff of Counsel in Opp to DefsMSJ 10 Ex 8 Nance Dep 12425 12721 and Ex J Bates Nos
SEC 2224
18 Jordan v Beeks 135 Idaho 586 592 21 P3d 908 914 2001
19 Johnson v Lambros 143 Idaho 468 147 P3d 100 Ct App 2006
20IRCP56c
21 Heath v HonkersMiniMart Inc 134 Idaho 711 712 Ct App 2000
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re , ry, fects  s  s   cs   r  
e physe a."I? 
I.  
. otion    
otions  i ti   tt s  t e t ial urt's i cretion. 18 "A t  i  
 ti  f r r si r ti  is r itt  t  r s t  i , t is t r ir  t   SO.,,19 
. otion for u ary Judg ent tandard 
 j e t is   t    i  i   t i l t  t  
oving party is entitled to judg ent as a atter of la ?O       
liberally construed in favor ofthe non oving party?1 
.  aterial Issue of Fact Exists Precluding Su ary Judg ent on Plaintiff's 
   ses   
 l  , , t is rt l i   r. st's ffi it i  t r t  i  
i   t ri l f t. i  rt i  t t r. st's ffi it l   t  (1) l de t t 
prior to 2008, there existed sufficient kno ledge of a risk posed by SEC's product of acute and 
r i  r ir t r  illness  s t t l i   . j r;  (2) i tif  t  i tifi  i  
f r s c  c cl si  t at es t e e   licati s fr   r later. is rt als  
expressed concern that r. ost had concluded that SEC's product posed a risk of acute 
respiratory injury but ade no conclusions regarding chronic respiratory injury. 
17 ff. f s l i  . t  ef's J, ~ 10 Ex. 8 (Nance ep., 124:25 - 27:21  x. J, t s s. 
 -2 ). 
18 r  v. s,  I a  , ,2  .3d ,9  (2 01). 
19 J s  v. r s,  I a  ,  .3d  (Ct. p. 006). 
20 LR.C.P. 56(c). 
21 e t  v. nker's i i-M rt I c.,  I a  1,  (Ct. . 000). 
    LAINTIF 'S   I    OURT'S 
  FENDANT'S    ENT,   SITI   
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Dr Yost has clarified that his conclusion regarding the known risks ofOC Spray products
was that of acute and chronic respiratory injury He explains how persons who have respiratory
illness are more sensitive to the pathological effects of exposure to OC and that hypersensitivity
can develop through an increase in TRP receptor populations caused by capsaicinoid exposure
Hypersensitivity lowers the individuals threshold for acute respiratory responses to common
irritants Due to that lowered threshold a recurrent acute reaction to common irritants takes
place The end result is a chronic hypersensitivity to common irritantsa chronic respiratory
illness
The Second Yost Affidavit clarifies that the publications cited in his initial affidavit
published in 2008 or later were not necessary to his conclusion regarding whether the risk of
acute and chronic respiratory injury was known prior to 2008 He explains that for that
conclusion he was relying on an entire body of publications that existed prior to 2008 along
with his own research education and experience His second affidavit identifies a multitude of
pre2008 publications supporting his conclusion as to the foreseeability of acute and chronic
respiratory injury caused by OC exposure
As this Court stated in its ruling whether an injury is foreseeable is normally an issue of
fact for the jury When viewed in a light most favorable to the Plaintiff a genuine issue of
material fact exists to preclude summary judgment
1 Negligent Failure to Warn
A genuine issue ofmaterial fact exists as to the failure to warn claim The elements are
22 See Sliman v Aluminum Co of America 112 Idaho 277 283 1986 The factual question of
foreseeability is for the jury to determine IProducts Liability supra 8031 This being an area
in which judges find it difficult to agree the issue should ordinarily be left to the common sense of the
jury
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r. st s l rifi  t t is l si  r r i  t   ris s f  r  r ts 
s t t f t   r i  r spir t r  i j ry.  l i s  rs s   r s ir t r  
illness r  r  s nsiti  t  t  t l i l ff ts f s r  t    t t rsensiti it  
ca  e el  t r  a  i crease i   rece t r lati s ca se   ca saici i  e sure. 
rs siti it  l rs t  i i i ls' t r s l  f r t  r s ir t r  r s s s t   
i it t .     shold,    t    ta  t  
l .   r s lt is  r i  rs nsiti it  t   irritants-a r i  r s ir t r  
illne . 
e ec  st ffida it clarifies t at t e licati s cite  i  is i itial affi a it 
published in 2008 or later ere not necessary to his conclusion regarding hether the risk f 
t   r i  r s ir t r  i j r  s  ri r t  .  l i s t at, f r t t 
c cl si , e as rel i   a  e tire  f licati s t at e iste  ri r t  , al  
it  is  research, e cati  a  e erie ce. is sec  affi a it i e tifies a ltit e f 
r -20  lic ti s s rti  is l si  as t  t  f r s eabilit  f t   r i  
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s t is rt state  i  its r li , et er a  i j r  is f reseea le is r all  a  iss e f 
fact for the jury?2 hen viewed in a light ost favorable to the Plaintiff, a genuine issue of 
t ri l f t ists t  r l  s r  j t. 
.  e   
             i .  ts : 
22 See Sliman v. Aluminum Co. of America, 112 Idaho 277, 283 (1986) ("The factual question of 
f res bilit  is f r t  j r  t  t rmine); IA r cts i ilit , s r , § 8.03[1] ("This being an area 
i  ic  judges fin  it iffic lt t  a ree, t e iss e s l  r i aril  e left t  t e c  se se f t e 
j ry"). 
    I TIFF'S I      URT'S 
 I  ENDANT'S I    J T,  I  I I   
ENDANT'S  I     -  
a The defendant manufactured the product
b The defendant knew or should have known that danger to users
or bystanders could result from a particular use of the product
c The defendant failed to give adequate warning of such danger
d The failure to give adequate warning was a proximate cause of
the injury and
e The damages
The first element is undisputed As to the second element a genuine issue of material
fact exists based on the expert report of Dr Yost Dr Yostsprior affidavit the Second Yost
Affidavit the testimony of Dr Pacheco and testimony of SECs Vice President24 As to the
third element it is undisputed that the MK9 Fogger label did not identify any risk of injury from
inhalation or what actions should be taken or avoided in order to protect the user from respiratory
injury The MK9 Fogger label violates FHSA warning standards SEC is not entitled to
summary judgment on the second or third elements
A genuine issue of material fact exists on the fourth element The expert report of
Dr Yost his prior affidavit the Second Yost Affidavit the expert report ofDr Pacheco and her
deposition present a genuine issue of material fact as to the cause in fact ie whether the
respiratory injuries were caused by OC Spray exposure A genuine issue of material fact also
exists as to proximate cause iewhether the failure to include an FHSA compliant label was the
23 SeeIDJ1006 Product Liability Failure to WarnIssues Puckett v Oakfabco Inc 132 Idaho
816 979 P2d 1174 1999 Rindlisbaker v Wilson 95 Idaho 752 519 P2d 421 1974 RESTATEMENT
SECOND TORTS 402A comment h 1977
24 See supra at IICT 813 II13 7 IID 1415
25 See supra at IID 1415 infra IIID2
26 See infra at IIID2
27 See supra at IIC 813 113 7 IID 1415
MEMORANDUM IN SUPPORT OF PLAINTIFFSMOTION FOR RECONSIDERATION OF THE COURTS
ORDERGRANTING DEFENDANTMOTION FOR SUMMARY JUDGMENT AND IN OPPOSITION TO
DEFENDANTSSECOND MOTION FOR SUMMARY JUDGMENT 13
001265
(a) The defendant anufactured the product; 
(b) e fe t  r ld e  t t er t  r  
r bystanders c ld res lt fro  a artic lar se f t e r ct; 
(c) he f t faile  t  i e ate r i  f s  r; 
(d) he failure t  i e t  ar ing as  r i ate se f 
the injury; and 
( e) The da ages.23 
he first ele ent is undisputed. s to the second ele ent, a genuine issue of aterial 
t ists   t  t t  r. t, . st's i  i vit, t   t 
ffidavit, the testi ony of r. Pacheco, and testi ony of S C's ice President.24 s   
third ele ent, it is undisputed that the -9 Fogger label did not identify any risk of injury fro  
i l ti  r t ti s l   t  r i  i  r r t  r t t t  r fr  r ir t r  
injury?5 The -9 Fogger label violates F S  arning standards.26 SE  is not entitled to 
su ary judg ent on the second or third ele ents. 
 genuine issue of aterial fact exists on the fourth ele ent.  rt r rt f 
r. ost, his prior affidavit, the econd ost ffidavit, the expert report of r. acheco, and her 
deposition present a genuine issue of material fact as to the cause in fact, i.e., whether the 
respiratory injuries ere caused by  Spray exposure?7  genuine issue of aterial fact also 
exists as to proxi ate cause, i.e., hether the failure to include an F S  co pliant label as the 
23 See I.D.J.I. 10.06 (Product Liability - ail re t  arn-Issues); tt v. lif bco, I c.,  I a  
816,979 P.2d 1174 (1999); Rindlisbaker v. ilson, 95 Idaho 752, 519 P.2d 421 (1974); RESTATE ENT 
(SECOND) TORTS, § 2A, c e t  (1 7). 
24 See supra, at §§ II.C, ~~ 8-13, II.B, ~ , & II.D, ~~ -1 . 
25 See supra, at §§ II.D, ~~ -1  & i fra, III.D.2. 
26 See infra, at § III.D.2. 
27 See supra, at §§ II.C, ~~ 8-13, II.B, ~ 7, & I.D, ~~ -1 . 
 I    LAINTIF 'S I   SI A I    OURT'S 
 I  EFENDANT'S I   U  ENT,  I  OSITI   
FENDANT'S     JU  - 13 
proximate cause ofPlaintiffsinjuries 28 SEC is not entitled to summary judgment on the fourth
element or on the fifth element which is traditionally amatter for the jury
2 Strict Liability
A genuine issue ofmaterial fact exists on the strict liability claim The elements are
a The defendant was the manufacturer of the product
b The product was defective
c The defect existed when the product left the defendants
control
d The defect was a proximate cause of injury to the plaintiff and
e The damages
The first element is undisputed A genuine issue of material fact exists on the second
element a product may be defective in its design manufacture or due to a failure to adequately
warn the consumer of a hazard involved in the foreseeable use of the product A product has
a defect when it exposes a user or bystander to an unreasonable risk of physical injury or if it is
more dangerous than would be expected by an ordinary person who may reasonably be expected
to use it
Here the issue is whether a defect existed in the following respects 1 a failure to
adequately warn of a hazard from the foreseeable misuse of the MK9 Fogger and 2 the design
of the MK9 Fogger The product was uniquely designed when compared to SECsother OC
products to primarily cause respiratory irritation The canister is also much larger than most of
the other products SEC designed for law enforcement and thus it poses a greater risk of
28 See supra at ILA 1 6 infra at IIID3
29 SeeIDJ1004 Product LiabilityStrict LiabilityIssues IC 61401 et seq RESTATEMENT
2D OF TORTS 402A Toner v Lederle Lab 112 Idaho 328 1987
soIDJ1001Puckett v Oakfabco Inc 132 Idaho 816 979 P2d 1174 1999
31IDJ1001Puckett v Oakfabco Inc 132 Idaho 816 979 P2d 1174 1999
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r i ate   laintiffs i j ri .28  i  t title  t  r  j t  t  f rt  
l t, r  t  fift  l t, i  is tr iti ll   tt r f r t  j r . 
.   
 genuine issue of aterial fact exists on the strict liability clai . he ele ents are: 
(a) he defendant as the "manufacturer" of the product; 
(b) he product as "defective"; 
(c)  t i t   t  t l t t  fendant's 
tr l; 
(d) The defect as a proxi ate cause of injury to the plaintiff; and 
( e) The da ages?9 
he first ele ent is undisputed.  genuine issue of aterial fact exists on the second 
l t:  r t   f ti  i  its sign, f t r , r  t   "failure t  t l  
ar  t e c s er f a azar  i lve  i  t e f reseea le se f t e r duct.,,30 "A r ct as 
a defect hen it exposes a user or bystander to an unreasonable risk of physical injury, or if it is 
r  r s t  l   t    r i r  rs    r s l   t  
t   it.,,31 
ere, the issue is hether a defect existed in the follo ing respects: (1) a failure to 
a e atel  ar  f a azar  fr  t e f reseea le is se f t e -9 er; a  (2) t e esi  
f t e -9 er. e r ct as i el  esi e  e  c are  t  EC's t er  
products to pri arily cause respiratory irritation. The canister is also uch larger than ost of 
t e t er r cts  esi e  f r la  e f rce e t a , t s, it ses a reater ris  f 
28  s r , t § II. , " -6, & i fr , t § II.D.3. 
29 See I.DJ'!. 10.04 (Product iability-Strict iability-Issues); I.e. §§ 6-1401, et. seq.; EST TE E T 
(20) OF TORTS § ; r v. rl  b.,  I a   (1 7). 
3°I.D.J.!. 10.01.1; Puckett v. Oakfabco, Inc., 132 Idaho 816, 979 P.2d 1174 (1999). 
311.DJ.1. 10.01.1; Puckett v. Oakfabco, Inc., 132 Idaho 816, 979 P.2d 1174 (1999). 
    I TIFF'S   I    URT'S 
 I  FENDANT'S I    J NT,  I  I I   
ENDANT'S  I     -  
overexposure when misused in a foreseeable way such as was the case here The MK9
Fogger contains133 capsaicinoids placing it at or near the hottest products on the market
A jury could reasonably conclude that the combination of these factors resulted in a product that
exposes a user or bystander to an unreasonable risk of physical injury or it is more dangerous
than would be expected by an ordinary person who may reasonably be expected to use it That is
due to the way it is designed the MK9 Fogger is likely to result in overexposure to OC when
misused in a foreseeable waywhich SECs Vice President admitted can be dangerous
Combined with a failure to warn of the health risks of overexposure a reasonable jury could
easily find that the product was defective Accordingly summary judgment would be
inappropriate on the second element
As for the third element if the second element is proven there would be little dispute
over whether the product was in the same condition when it was used by the IDOC as when it left
SECspossession For the reasons already stated supra the fourth and fifth elements present
issues offact
3 Conclusion
For the above stated reasons Plaintiff respectfully requests that this Court reconsider its
Order granting DefendantsMotion for Summary Judgment
D SECsMK9Fogger Label Violates FHSA Standards Which Was a Proximate
Cause of Plaintiffs Injuries
Defendant seeks summary judgment on the following issues 1 Whether the FHSA
provides an independent cause of action distinct from state law tort claims 2 Whether the
32 Aff of Counsel in Opp to DeFs MSJ 10 Ex 8 Nance Dep 5923 6016 Ex B SEC 27579
showing sizes as low as 1 ounce and the MK9 Fogger at 185ounces per canister
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  is s    re  ,      ere.32  -9 
er c tai s .3 % ca saici i s, laci  it at r ear t e "hottest" r cts  t e arket. 
 j r  c l  reas a l  c cl e t at t e c i ati  f t ese fact rs res lte  i  a r ct t at 
exposes a user or bystander to an unreasonable risk f physical injury, or it is ore dangerous 
than ould be expected by an ordinary person ho ay reasonably be expected to use it. hat is, 
due to the ay it is designed, the -9 ogger is likely to result in overexposure to  hen 
isused in a foreseeable ay-which EC's ice resident ad itted can be dangerous. 
i e  it  a fail re t  ar  f t e ealt  ris s f ere s re, a reas a le j r  c l  
easily find that the product as defective. ccordingly, su ary judg ent ould be 
inappropriate on the second ele ent. 
s f r t  t ir  l t, if t   l t i  r n, t r  l   little i t  
over hether the product as in the sa e condition hen it as used by the I  as hen it left 
SEC's possession. For the reasons already stated supra, the fourth and fifth ele ents present 
is   t. 
. s  
For the above-stated reasons, Plaintiff respectfully requests that this ourt reconsider its 
rder granting efendant's otion for Su ary Judg ent. 
. C's K-9  l i l   t ar s, i    i  
s  f l i tiffs juries 
efendant seeks su ary judg ent on the follo ing issues: (1) t r t   
provides an independent cause of action distinct fro  state la  tort clai s; (2) hether the 
32 ff. of Counsel in pp. to efs SJ, ~ 10, Ex. 8 (Nance ep., 59:23 ~ 0:16 & Ex. B (SEC 275-79)) 
(sho ing sizes as lo  as 1 ounce and the -9 Fogger at 18.5 ounces per canister). 
    I TIFF'S   I    OURT'S 
  FENDANT'S I    ,   SI I   
FENDANT'S  I     -  
Plaintiff can prove negligence or strict liability and 3 Whether the Plaintiff can prove
negligence per se
1 The Maiority View is That the FHSA Does Not Provide a
PrivateRight ofAction
The parties agree that the FHSA does not provide an independent cause of action separate
and distinct from state tort claims The majority view is that stated by the Eighth Circuit in
Mattis v Carlon Electrical Products 33
The FHSA was enacted in 1960 to provide nationally uniform
requirements for adequate cautionary labeling of packages of
hazardous substances which are sold in interstate commerce and
are intended or suitable for household use As enacted the
FHSA did not mention federal preemption but the 1966
Amendments to the Act added a provision to preempt any state
cause of action that seeks to impose a labeling requirement
different from the requirements in the FHSA or the regulations
promulgated thereunder Other circuits interpreting this provision
have held that a plaintiffmay not bring a claim for failure to warn
based on state requirements that are more elaborate than the FHSA
however a common law tort action based on failure to warn may
be brought for noncompliance with the federal labeling
requirements Similarly our circuit has held that when a statute
only preempts state requirements that are different from or in
addition to those imposed by federal law plaintiffs may still
recover under state tort law when defendants fail to comply with
the federal requirements Therefore in order to prevail on his
failure to warn claim Mattis had the burden of proving the Carlon
cement label did not comply with the FHSA
The pertinent question is whether the Plaintiff can proceed with her state law claims employing
the FHSA as the relevant standard for adequate warning labels
33 295 F3d 856 2002
34 Id at 861 62 citing Milanese v RustOleum Corp 244F3d 104 10910 2d Cir 2001
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l i tiff  r  li  r stri t li bility;  (3) t r t  l intiff  r  
l   e. 
.  j         r i   
r    ti n. 
 rties r  t t t   s t r i   i t s  f cti  s r t  
     i .  j rit  i  i  t t t t   t  i t  ir it i  
 .  tr  cts:33 
   t  i   t  '''provide ti ll  i  
i t   t  ti  l li     
    l      
   e  l  se. ", s cted, t  
 i  t ti  f r l r e ption,    
ts t  t  t   r isi  t  r t  st t  
s  f ti  t t s s t  i s   l li  r ir t 
different fro  the require ents in the F S  or the regulations 
pro ulgated thereunder. ther circuits interpreting this provision 
 l  t t  l i tiff  t ri   l i  f r f il r  t  r  
  t t  i t  t t   l t  t  t  ; 
ho ever, a co on la  tort action based on failure to arn ay 
 r t f r nonco pliance t    labeling 
r ir t . i il rly, r ir it  l  t t "when  t t t  
l  r t  t t  r ir ts t t r  iffer t fr  r i  
iti  t  t  i s   f r l l , l i tiffs  till 
r r r t t  t rt l   f ts f il t  l  it  
t  fe r l r ir ents." Therefore, in order to prevail on his 
f ilur  t  r  l i , attis  t  r  f r i  t  rl  
ce e t la el i  t c l  it  t e SA. 34 
The pertinent question is hether the Plaintiff can proceed ith her state la  clai s e ploying 
t e  s t e r l t st r  f r t  r i  l ls. 
33295 F.3d 856 (2002). 
34 Id. at 861-62 (citing ilanese v. Rust-Oleum Corp., 244 F.3d 104, 109-10 (2d Cir. 2001). 
 I  P  F I TIFF'S I   I   E RT'S 
 I  NDANT'S IO    J ,  I  I I   
NDANT'S  ION F   J  -  
2 Violation of FHSA Warning Label Standards is Evidence of a Failure to
Warn Under Theories of Negligence Negligence Per Se and Strict Liability
An FHSA warning label violation is evidence of a failure to warn and of a defective
product in state tort product liability cases
35
Violation of a statute or regulation may be
negligence per se where the statute or regulation was intended to prevent the type of harm the
defendantsact or omission caused and the plaintiff is a member of the protected persons the
statute or regulation aims to protect
36
The FHSA requires manufacturers of hazardous substance products to include on the
label certain warnings and directions A hazardous substance means
1AAny substance or mixture of substances which i is toxic
ii is corrosive iii is an irritant iv is a strong sensitizer v is
flammable or combustible or vi generates pressure through
decomposition heat or other means if such substances or
mixture of substances may cause substantial personal injury or
substantial illness during or as a proximate result of any
customary or reasonably foreseeable handling or use including
reasonably foreseeable ingestion by children
It is undisputed that the MK9 Fogger contains an irritant ie OC It also appears that it is
undisputed that OC is also toxic The FHSA states Toxic shall apply to any substance
which has the capacity to produce personal injury or illness to man through ingestion inhalation
or absorption through any body surface
38
According to Dr Yost Dr Pacheco and SECs
35 Sanchez v Galey 112 Idaho 609 61718 1987 OSHA violation may be evidence of negligence per
se citing Dixon v International Harvester Co 754 F2d 573 581 5th Cir 1985 we reiterated that a
violation of an OSHA regulation can be evidence of negligence or even in appropriate circumstances
negligence per se see Leibstein v Lagarge North Amer 689 F Supp2d 373 38090EDNY2010
state claim using FHSA
36 Walton v Potlach Corp 116 Idaho 892 898 n1 1989
37 15USC 1261fAemphasis added
16CFR 15003bDefinitions
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. iolation    a dards  idence   re  
arn e  e ries  , igence  ,   i . 
  r i  l l i l ti  is i  f  f il r  t  r   f  f ti  
product in state tort product liability cases.  iolati    t t te  l ti    
ligence    t e t t te  l tion  i t  t  t t  t    t  
f ndant's t r ission   t  l i tiff i   r  t  r t t  r  t  
statute or regulation ai s to protect. 36 
e  ires a t rers  s t  t  t  i l   t  
label certain arnings and directions.  "hazardous substance" eans: 
(1 )(A) ny substance or ixture of substances hich (i) is toxic, 
(ii) is corrosive, (iii) is an irritant, (iv) is a strong sensitizer, (v) is 
fla able or co bustible, or (vi) generates pressure through 
deco position, heat, or other eans, if such substances or 
i ture f s st s  s  s st ti l rs l i j r  r 
s sta tial illness ri  r as a r i ate res lt f  
custo ary or reasonably foreseeable handling or use, including 
r s l  f r s l  i sti   ildren.37 
It is undisputed that the -9 Fogger contains an irritant, i.e., . It ls  rs t t it is 
is t  t t  is ls  t i .   st tes: "Toxic s ll l  t   s st  ... 
ic  as t e ca acit  t  r ce ers al i j r  r illness t  a  t r  i esti , i alati n, 
or absorption through any body surface".38 ccording to r. ost, r. acheco, and EC's 
35 c ez v. ley, 112 Idaho 609, 617-18 (1987) (O  violation ay be evidence f negligence per 
se) (citing ixon v. International arvester o., 754 .2d 573,581 (5th ir. 1985) ("we reiterated that a 
i lati  f a   re lati  ca  e e i e ce f e li e ce r e en, i  a r riate circ sta ces, 
negligence per se")); see eibstein v. agarge orth er., 689 . upp.2d 373, 380-90 (E.D.N.Y. 2010) 
(state clai  using FHSA). 
36 alton v. Potlach Corp., 116 Idaho 892, 898 & n.1 (1989). 
37  .S.C. § 1261(f)(1)(A) (emphasis added). 
38  .F.R. § 1500.3(b)(5) (Definitions). 
    LAINTIF 'S   I    URT'S 
  FENDANT'S    NT,   SITI   
FENDANT'S      -  
Vice President OC is a substance which has the capacity to produce personal injury or illness
through inhalation
39
The FHSA requires manufacturers of products containing irritant andor toxic
substances to include conspicuous warnings and instructions on the label that among others
includes 1 an affirmative statement of the principal hazard or hazards such as Flammable
Combustible Vapor Harmful Causes Burns Absorbed Through Skin or similar
wording descriptive of the hazard 2 precautionary measures describing the action to be
followed or avoided 3 instruction when necessary or appropriate for firstaid treatment
and 4 instructions for handling and storage of packages which require special care in handling
or storage 40 The statements must be located prominently in conspicuous and legible type
in contrast by typography layout or color with other printed matter on the label
41
As to what is actually required by the FHSA label standards the Mattis case is very
instructive and by comparison demonstrates that a genuine issue of material fact exists in this
case Mattis involved a young electrician who inhaled chemical vapors from piping cement that
contained respiratory irritants The electrician became ill as a result and was diagnosed as
suffering from reactive airway syndrome RADS
In Mattis
the district court held that there was a question of fact for the jury
about whether these requirements were met because the label did
not statekeep out of the reach of children and because the
evidence about the harmful effects of Carlon cement called into
39 See supra HA 6 ILB 17 IIC 813
40 15 USC 1261pdefining misbranded hazardous substance see 15 USC 1263
prohibiting introduction into interstate commerce of misbranded hazardous substance
41 15USC 1261p
42 295F3d at 85960
43 id
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ice resi ent,  is a s sta ce ic  as t e ca acit  t  r ce ers al i j r  r illness 
t r  i alati .  
e  re ires a facturers f r cts c tai i  "irritant" and/or "to ic" 
s sta ces t  i cl e c s ic s ar ings a  i str ctions  t e la el t at, a  t ers, 
i cl es: (1) "an affir ati e state e t f t e ri ci al azar  r azar s, s c  as "Flam a le", 
"Combustible" "Vapor ar f l" "Causes " "Absorbed r  i "  i  , " , 
r i  escri ti e f t e azar "; (2) "preca tionar  eas res escri i  t e acti  t  e 
lo e   e "; (3) "instr ,    r ri t ,  r -ai  "; 
and (4) "instructions for handling and storage of packages hich require special care in handling 
r st r ge.,,   st t ts st  "locate  r i tl  ... in conspicuous and legible type 
in contrast by typography, layout, or color ith other printed atter on the label.,,41 
s to hat is actually required by the F S  label standards, the attis case is very 
instructive and, by co parison, de onstrates that a genuine issue of aterial fact exists in this 
case. attis involved a young electrician ho inhaled che ical vapors fro  piping ce ent that 
contained respiratory irritants.42 The electrician beca e ill as a result and as diagnosed as 
s fferi  fr  reacti e air a  s r e (R DS).43 
In attis, 
[t ]he i tri t rt l  t t t r    ti  f f t f r t  j r  
about hether these require ents ere et because the label did 
not state "[k]eep out of the reach of children" and because the 
e e t  r f l     l   
39 See supra, §§ IlA, ,-r 6, II.B, ,-r 7, & II.C, ,-r,-r -1 . 
40  .S.C. § 1261(p)(I) (defining "misbranded hazardous substance");   .S.C. §  
(prohibiting introduction into interstate co erce of "misbranded hazardous substance"). 
  .S.c. § 261(P)(2). 
42  .3d  -6 . 
43 [ . 
 I    I TIFF'S I   I I    URT'S 
  ENDANT'S I    NT,   I I   
ENDANT'S      -  
question whether the labels statements about principal hazards
precautionary measures or instructions for handling were
inadequate We agree Although the label stated vapor harmful
this warning was followed by the statements may irritate eyes and
skin and vapors may cause flash fires The label does not make
it clear that inhalation of the vapors is harmful The label did not
state handling instructions or specify any precautionary measures
regarding inhalation of fumes from the cement other than to say
if inhaled get fresh air
Here a jury could reasonably conclude that the FHSA requirements were not met by the MK9
Fogger label because there is evidence of the harmful effects of capsaicinoids which calls into
question whether the statement of principal hazards precautionary measures or instructions for
handling were adequate Nothing on the label indicates either an acute or chronic respiratory
hazard The label fails to identify measures to take or avoid that would prevent either acute or
chronic respiratory injury There are no instructions on the label for special handling The
product contains133 capsaicinoids SEC recognized that the MK9 Fogger would specifically
target the respiratory system SEC recognized that for people with respiratory illness OC Spray
products can pose a danger Finally SEC recognized that overexposure to strong OC Spray
products can cause respiratory injury or at least aggravation of an existing respiratory injury
The MK9 Fogger label reads as follows
CAUTION
SEVERE SKIN AND EYE IRRITANT
CONTENTS UNDER PRESSURE
SEE OTHER WARNINGS ON BACK LABEL
ACTIVE INGREDIENTS Approx 133 Major Capsaicinoids
and an invisible ultraviolet light sensitive dye for suspect
identification DIRECTIONS To be used by Law Enforcement
Corrections Military or Security Personnel trained in the proper
as
Mattis 295F3d at 862 emphasis in original
45 See Leibstein 689FSupp2d at 38488 finding issue of facts as to whether manufacturer of cement
products label included the principal hazards or precautionary measures
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ti  et r t e l el's t t ts t ri i l r , 
precautionary r s, r i str tions for li  r  
ina t . e r . ltho  t  l l st t  "vapor rmful," 
t is r i  as f llo e   t  st t ts, "ma  irritate es  
s i "  "vapors  s  flas  fir s."  l l s t  
it le r t at i l tio  f t  a rs is r ful.  l l i  t 
state handling instructions or specify any precautionary easures 
r r i g i l ti  f f  fr  t  t t r t  t  , 
"if inhaled, get fresh air. ,,44 
r ,  jur  ld r s l  lude t t t e  r ire e ts er  t t  t  -9 
r l l s  t ere is i e ce f t  r f l ffects f s i i i s i  lls i t  
question hether the state ent of principal hazards, precautionary easures, or instructions for 
a lin  ere a equate.45 t i   t e la el i dicates eit er a  ac te r c r ic res irat r  
azar . e la el fails t  i e tif  eas res t  ta e r a i  t at l  re e t eit er ac te r 
chronic respiratory injury. here are no instructions on the label for special handling.  
r ct c tai s .3 % ca saici i s.  rec ize  t at t e -9 er l  s ecificall  
target the respiratory syste .  recognized that for people ith respiratory illness,  pray 
products can pose a danger. i ally,  rec ize  t at ere s re t  str   ra  
r ts  s  r s ir t r  i j r  r t l st r ti  f  isti  r s ir t r  i j r . 
he -9 ogger label reads as follo s: 
: 
    I T. 
S  . 
     L. 
 I : r x. .3 % aj r a saici i s 
and an invisible ultraviolet light sensitive dye for suspect 
identification. DIRECTIONS: To be used by Law Enforce ent, 
rrecti s, ilitar  r ec rit  ers el trai e  i  t e r er 
44 attis, 295 F.3d at 862 (e phasis in original). 
45 See Leibstein, 689 .Supp.2d at 384-88 (finding issue of facts as to hether anufacturer of ce ent 
product's label included the principal hazards or precautionary easures). 
    LAINTIF 'S   I    OURT'S 
  FENDANT'S    T,   POSITI   
FENDANT'S      -  
use of aerosol projectors Reduce injuries by following these
instructions Remove pin and press actuator to fire at subject
face in 12 to 1second bursts Aim for the eyes forehead if
wearing glasses nose and mouth To stop firing release pressure
from actuator Caution Avoid discharge into head winds or shield
face to prevent blowback exposure Do not discharge at distances
of less than six feetmay cause injuries to soft body tissue If you
are unable to restrain the subject after 3 12 to 1 second bursts
employ the next appropriate force option Test fire periodically to
assure performance and familiarity of spray pattern DO NOT
puncture or incinerate can DO NOT expose to heat or store above
120 F DO NOT use after canistersexpiration date It is the
user responsibility to keep the canister from accidently firing
WARNING KEEP OUT OF REACH OF CHILDREN The
contents are dangeroususe with care
FIRST AID Begin decontamination process immediately after
restraining subject Remove subject from contaminated area to
area of fresh air Verbally reassure subject If available rinse
affected areas with clean cool running water and soap Repeat if
necessary Do not rub or use creams lotions oils or salves For
eye contact flush with cold water for 15 minutes or longer Only
qualified medical personnel should remove contacts Periodically
monitor subject until they are fully recovered Get medical
attention ifsymptoms persist
By comparison the label in Mattis was described by the court as
Danger extremely flammable harmful or fatal if swallowed
vapor harmful may irritate eyes and skin may be absorbed
through the skin Vapors may cause flash fires Read precaution
on back label With regard to vapors the back of the label stated
Vapors may ignite explosively Prevent buildup of vapors open
all windows and doorsuse only with cross ventilation Close
container after use If inhaled get fresh air If ill feelings persist
seek medical attention
47
Unlike the label in Mattis the MK9 Fogger label did not include any warning like vapor
harmful or similar wording to alert users that under certain circumstances exposure could cause
respiratory injury To the contrary SECstraining materials and MSDS assured users that any
46 Aff of Counsel in Support ofPltfs Mtn for Reconsideration 3 Ex 1
47
Mattis 295 F3d at 859 n2 emphasis added
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use f aerosol projectors. educe injuries by follo ing these 
ins .  i    t t  t  ir  t bject's 
 in 12  I-  . i   t   (forehea  i  
earing glasses), nose and outh. o stop firing, release pressure 
 t tor. ti n: i  is  i t   i   i l  
face to prevent blo -back exposure. o not discharge at distances 
f less than six feet-may cause injuries to soft body tissue. If you 
 le t  t i  t  j t ter , 12 t    ts, 
l  t  t iat   ti . t ir  i i ll  t  
assure perfor ance and fa iliarity of spray pattern.   
t re  i ine t  .   s  t  t  t   
0 .   use after canister's expiration date.    
user's responsibility to keep the canister fro  accidently firing. 
      N.  
contents are dangerous-use ith care. 
 : egin deconta ination process i ediately after 
restraining subject. e ove subject fro  conta inated area to 
   ir. erbally reassure subject.  il l , i s  
affected areas ith clean, cool running ater and soap. epeat if 
necessary. o not rub or use crea s, lotions, oils, or salves. For 
eye contact, flush ith cold ater for 15 inutes or longer. nly 
qualified edical personnel should re ove contacts. Periodically 
onitor subject until they are fully recovered.  l 
tt ti  if t s ersist. 46 
y co parison, the label in attis as described by the court as: 
"Dan er: e tre el  fla a le • r f l  t l  ll  • 
r r f l •  irritat  s  s i  •    
through the skin. apors ay cause flash fires. ead precaution 
on back label." ith regard to vapors, the back ofthe label stated: 
"Vapors ay ignite explosively. Prevent build-up of vapors-open 
all indo s and doors-use only ith cross-ventilation. ... lose 
container after use .... If inhaled get fresh air. If ill feelings persist, 
  t ntion.,,47 
nlike the label in attis, the -9 Fogger label did not include any arning like "vapor 
harmful" or si ilar ording to alert users that under certain circu stances exposure could cause 
respiratory injury. o the contrary, SEC's training aterials and S S assured users that any 
46 ff. of ounsel in Support ofPltfs tn for econsideration, -,r  . . 
47 attis, 295 F.3d at 859 n.2 (e phasis added). 
    LAINTIF 'S   I    OURT'S 
  ENDANT'S    MENT,   SI I   
FENDANT'S      -  
respiratory effects were temporary The label failed to state that inhalation of the OC aerosol
may be harmful There are no handling instructions or identification of precautionary measures
other than Remove subject from contaminated area to area of fresh air
As in Mattis a genuine issue ofmaterial fact exists as to whether SEC complied with the
warning label requirements of the FHSA SEC acknowledges that its products contain
capsaicinoids and those are respiratory irritants SEC acknowledges that its products have an
acute toxicity when inhaled SEC submitted to this Court the following statement
Security Equipment Corporation manufactures self pressurized
irritant products for personal protection under the SABRE and
SABRE Red brand names These products are regulated under
the Federal Hazardous Substances Act FHSA 15USC 1261
and its implementing regulation 16 CFRPart 1500 The
following sections of the regulation determine the hazards
associated with the use of this product and determine the
appropriate labeling statements
16CFR 15003b
16CFR 150041
16CFR 150042
Acute Toxicity Inhalation
Test for Skin Irritant
Test for Eye Irritant
49
Despite its knowledge that the MK9 Fogger contained substances considered as being a
respiratory irritant and toxic
50
when inhaled as defined under the FHSA regulations SEC put
nothing on its label to warn of those two principal hazards
Under the FHSA a product having more than one principal hazard must include on its
label an affirmative statement of each such hazard the precautionary measures describing the
action to be followed or avoided for each hazard and instructions for handling and storage
48 Aff ofR Nance in Support ofDef s MSJ 7 Ex B
49 Id
0 16CFR 15003bDefinitions Toxic shall apply to any substance which has the capacity
to produce personal injury or illness to man through ingestion inhalation or absorption through any body
surface
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r ir t r  ff ts r  t r ry.  l l f il  t  t t  t t i l ti   t   r l 
  r ful. r  r   li  i tr ti  r i tifi ti  f r ti r  r  
t r t n: "Remove j t fr  t i t  r  t  r   fr  ir." 
s in attis, a genuine issue of aterial fact exists as to hether S  co plied ith the 
i  l l ire e ts  t  . S  ackno ledges that its products contain 
i i ids  t s   i t  i it t .  ackno ledges that its products have an 
t  t i it  e  i aled.48  itt  t  t i  t t  ll i  t t t: 
Security quip ent orporation anufactures self-pressurized 
irrita t r ts f r r l r t ti  r t  ABRE®  
 ed®  . These products are regulated under 
t  r l r  t es t (F )  .S.C. §  
and its i ple enting regulation, 16 .F.R. Part 1500.  
f llo i  ti  f t  r l ti  t r i  t  r  
associated ith the use of this product and deter ine the 
appropriate labeling state ents. 
 .F.R. § 1500.3(b)(5) 
 .F.R. § 50 .41 
 .F.R. § 50 .42 
cute oxicity (Inhalation) 
   t  
t f r  Irrita t  
espite its kno ledge that the -9 Fogger contained substances considered as being a 
respiratory irritant and toxic  hen inhaled (as defined under the F S  regulations), S  put 
nothing on its label to arn of those t o principal hazards. 
nder the F S , a product having ore than one principal hazard ust include on its 
label "an affir ative state ent of each such hazard; the precautionary easures describing the 
acti  t  e f ll e  r a i e  f r eac  azard," a  i str cti s f r a li  a  st ra e 
48 ff. f . a ce i  rt f f's J, ~  & . . 
49 !d. 
50  .F.R. § 1S00.3(b)(S) (Definitions) ("Toxic shall apply to any substance ... hich has the capacity 
to produce personal injury or illness to an through ingestion, inhalation, or absorption through any body 
"). 
    INTIF 'S   I    URT'S 
 I  FENDANT'S I    J NT,  I  SITI   
ENDANT'S      -  
necessitated by the existence of more than one hazard5 The regulations define principal
hazardsas wording descriptive of the principal or primary hazardsassociated with a
hazardous substance 52 SEC was required by FHSA standards to include the statement
Harmful if Inhaled or words of similar import but no such warning is on the label
Nor did the label include any measures or instructions to avoid respiratory injury which
could have been as easy as a statement regarding the respiratory dangers of overexposure
respiratory injury or aggravation of existing respiratory injury And given that there was a
significant body of scientific literature prior to 2008 that chronic respiratory injury could occur
through the sensitization process a warning of the risk of both acute and chronic respiratory
injury should have been included It should have contained a statement similar to the following
Risk to your health depends on level and duration of exposure Furthermore a statement
regarding the necessity of ventilation and limitation of exposure to avoid acute and chronic
respiratory injury is required under the FHSA The MK9 Fogger label contained no such
warnings or direction
The FHSA is neither vague nor difficult to comply with All that is required is a
balanced perspective of the potential hazards of the product Many products which may
cause chronic health effects may also be acutely toxic and present physical hazards such as
flammability
55
The product labeling must take into consideration both the acute and chronic
inhalation hazards
56
Here SEC failed to include a balanced perspective of the potential hazards
16CFR 150027 15USC 1261p
51 16CFR 150021avii
53 See Busch v Graphic Color Corp 644 NE2d 839 843 44 Ill App 1995 statement on label of
methylene chloride was sufficient to warn against acute and chronic injury from inhalation
54
Busch 644NE2d at 844 quoting 57 Fed Reg 46 664 1992
55 Id
56 Id
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it t   t  iste ce  r  t   r . 51  r l ti  fi  ri i l 
hazard(s) as "wording descriptive of the principal or pri ary hazard(s) associated ith a 
s tance.,,   s r ire    st r s t  i l  t  st t t 
"Harmful if Inhaled" or ords of si ilar i port, but no such arning is on the label. 
or did the label include any easures or instructions to avoid respiratory injury, hich 
ld       t t t i  t  i t    sure: 
respiratory injury or aggravation of existing respiratory injury.  i  t t t r    
significant body of scientific literature prior to 2008 that chronic respiratory injury could occur 
t r  t  iti ti  r s,  r i  f t  ris  f t  t   r i  r ir t r  
injury should have been included. It should have contained a state ent si ilar to the follo ing: 
"Risk to your health depends on level and duration of exposure.,,53 urther ore, a state ent 
re ar i  t e ecessit  f e tilati  a  li itati  f e s re t  a i  ac te a  c r ic 
respiratory injury is required under the FHSA. e -9 er la el c tai e   s c  
warnings or direction. 
  i  it r  r iffic lt t  l  it . ll that is required is "a 
balanced perspective f the potential hazards of the product.,,54 "Many products hich ay 
cause chronic health effects may also be acutely toxic and present physical hazards, such as 
fla ability.,,55 he product labeling ust take into consideration both the acute and chronic 
 r s. 56 Here, SEC failed to include a balanced perspective of the potential hazards. 
51  .F.R. § 1500.127; 15 .S.C. § 1261(p). 
52  .F.R. § 1500.121(a)(2)(vii). 
53 See usch v. raphic olor orp., 644 .E.2d 839, 843-44 (Ill. pp. 1995) (state ent on label of 
ethylene chloride as sufficient to arn against acute a  chronic injury fro  inhalation). 
54 Busch, 644 N.E.2d at 844 (quoting 57 Fed. Reg. 46, 664 (1992». 
5I . 
56 d. 
    I TIFF'S   I    URT'S 
 I  ENDANT'S I    J ,  I  SI I   
ENDANT'S      -  
Since there is substantial evidence in the record on which a reasonable jury could
conclude that SEC violated the FHSA summary judgment is precluded
3 A Genuine Material Issue of Fact Exists on the Issue of Proximate Cause
That Precludes Summary Judgment
Defendant argues that the Plaintiff cannot establish proximate cause because 1 she
received training on OC Spray products 2 she observed others who were exposed to OC Spray
3 she did not see the label of the product used during her March 3 2008 training and 4 SECs
MSDS identified temporary respiratory effects of OC Spray However the training Plaintiff
received according to the evidence presented by SEC identified the effects of OC Spray as
purely temporary All the reactions Plaintiff observed according to the evidence presented by
SEC outwardly appeared to be temporary Plaintiff was lured into believing that this was a safe
product with no respiratory risks Based on the Second Yost Affidavit it was not safe Because
nothing in the training served to warn Plaintiff of the danger and she was assured the effects she
observed in herself and others were temporary SECsfirst and second arguments are unavailing
since they present factual issues for the jury to decide
Defendantsthird argument is similarly unavailing because it does not take into account
that had the trainers known the risk of injury to the respiratory tract that information would have
been conveyed to the Plaintiff during her training It is a reasonable inference for the jury to
make that the trainers who conducted Plaintiffs OC Spray trainings did see the product and as
trainers they would have read any warnings on the label before exposing their trainees to the
substance But that was not the case
Defendantsthird argument also fails to account for the fact that the Plaintiff had read the
label of other SABRE Red OC Spray products that had the same label as the MK9 Fogger
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    I TIFF'S   I    URT'S 
 I  ENDANT'S I    J T,  I  I I   
NDANT'S  I    J  -  
Had the Plaintiff been warned that the MK9 Fogger posed a risk to her health she would
have insisted on being excused from the training Furthermore had she been instructed as to the
acute and chronic risks associated with the product she would have taken steps to protect her
healtheven ifit required finding a different job
Finally Defendantsargument regarding its MSDS fails for two reasons first the
Plaintiff never saw SECsMSDS during her employment with IDOC and second SECsMSDS
does not provide the information necessary to comply with FHSA labeling standards It does not
identify acute and chronic respiratory injury as principal hazards It does not identify measures
for avoiding injury And it does not provide a cautionary statement for the handling of the
product Even if she had seen the MSDS it is quite clear that there is nothing contained therein
that would have alerted Ms Major or her trainers to the risk ofboth acute and chronic respiratory
injury
For the above stated reasons whether SECs failure to warn was a proximate cause of
Plaintiffsinjuries presents a genuine issue ofmaterial fact Summary judgment must be denied
IV CONCLUSION
For the reasons set forth herein Plaintiff s Motion for Reconsideration should be granted
and DefendantsSecond Motion for Summary Judgment should be denied
DATED this 26th day of July 2011
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ad the laintiff been arned that the -9 ogger posed a risk to her health, she ould 
 i i t   i    t  t ining. rt r ore,    i t t   t  t  
acute and chronic risks associated ith the product, she ould have taken steps to protect her 
lth-eve  i  it r ir  fi i   iff r t j b. 
i ally, fendant's t i  it   il   t  sons: first, the 
l i ti    EC's  ri  r l t it  ;  second, EC's  
does not provide the infor ation necessary to co ply ith F S  labeling standards. It does not 
identify acute and chronic respiratory injury as principal hazards. It does not identify easures 
f r i i  i j r . nd, it does not provide a cautionary state ent for the handling of the 
product. Even if she had seen the S S, it is quite clear that there is nothing contained therein 
that ould have alerted s. ajor or her trainers to the risk of both acute and chronic respiratory 
I J . 
For the above stated reasons, hether SEC's failure to arn as a proxi ate cause of 
Plaintiffs injuries presents a genuine issue of aterial fact. Su ary judg ent ust be denied. 
.  
For the reasons set forth herein, Plaintiffs otion for econsideration should be granted, 
and efendant's Second otion for Su ary Judg ent should be denied. 
TE  t is t   f J l , . 
DARW RSON 
 . W Z 
E O  I  PP T F P I F'S IO   I   E URT'S 
R ER I  NDANT'S IO    ,     
D DANT'S  OTION    - 24 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
vs
SECURITY EQUIPMENT CORPORATION
aMissouri corporation
Defendant
Case No CV PI 1003515
PLAINTIFFSSECOND
SUPPLEMENTAL EXPERT
WITNESS DISCLOSURE
PRELIMINARY STATEMENT
Discovery in this matter is ongoing This disclosure is made and based upon the
Plaintiffscurrent understanding of the facts claims and defenses at issue in this litigation It is
anticipated that further discovery investigation and consultation with witnesses and experts may
supply additional facts add meaning to known facts and establish new factual conclusions and
legal contentions all ofwhich may lead to additions to modifications of and variations from the
disclosures set forth herein This disclosure is therefore made without prejudice to Plaintiffs
PLAINTIFFSSECOND SUPPLEMENTAL EXPERT WITNESS DISCLOSURE 1
001278
... 
-.I 
« 
z: 
-CJ 
-a: 
o 
n n,  #588  
 . artz,  #639  
J  &   
 . l  i ,   [83702] 
    
,   
ne: (2 ) -89  
si il : (2 ) -898  
ail: i jonesandswartzlaw.com 
ri jonesandswartzlaw.com 
ttorne s  l intif , illie  j  
. 'ILEO, ~ NO a'l~A.M. ___ --P.M.--=I~-"-""-
    
CHRISTOPHER D. RICH, Clerk 
By STEPHANIE VIDAK 
 
       I I    
   I , I        
  ,  i i al, 
l intif , 
. 
  A I , 
 iss ri r r ti , 
f nt. 
 .  I  
I TIFF'S  
L   
ES   
  
iscovery in this atter is ongoing. This disclosure is ade and based upon the 
laintiff's current understanding f the facts, clai s, and defenses at issue in this litigation. It is 
anticipated that further discovery, investigation, and consultation ith itnesses and experts ay 
supply additional facts, add eaning to kno n facts, and establish ne  factual conclusions and 
le al c te ti s, all f ic  a  lea  t  a itions t , ifications f, a  ariations fr  t e 
disclosures set forth herein. his disclosure is therefore ade ithout prejudice to laintiff's 
I TIFF'S   P  ITNESS IS S RE -  
right to disclose evidence of subsequently discovered facts or opinions thereon Subject to and
without waiving the right to supplement the scope of the testimony disclosed herein based upon
information learned or documents acquired through the completion of discovery in this action
Plaintiff makes the following disclosure
Original Disclosure
Garold S Yost PhD
Professor of Pharmacology and Toxicology
College ofPharmacy
University ofUtah
30 North 1900 East 201
Salt Lake City Utah 84112
80158 7956
Dr Yost is a Professor of Pharmacology and Toxicology at the University ofUtah He is
internationally recognized as an authority on toxicology in the respiratory tract with particular
expertise on the cytochrome P450mediated mechanisms of lung injury Research in the Yost
laboratory is largely focused on the elucidation of the chemical biochemical and cellular
mechanisms of toxicity to lung tissues that are caused by exposure to environmental pollutants
There are a number of chemicals that cause selective damage to lung tissues after inhalation or
from ingestion followed by systemic exposure to circulating chemicals He is also an expert in
lung diseases drug induced toxicities and adverse drug reactions His expertise extends also to
the analysis chemistry receptor activation and biological effects including toxicities of
capsaicinoids
Dr Yost is expected to testify regarding the human bodysreaction to and toxicity of
capsaicinoids and oleoresin capsicum OC spray as well as similar compounds Dr Yost will
testify that within a reasonable degree of certainty it was Plaintiff s exposure to DefendantsOC
spray products while performing her duties as a correctional officer with the Idaho Department of
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right t  iscl se e ide ce f s se e tl  isc ere  facts r i i s t ere . ject t  a  
ithout aiving the right to supple ent the scope f the testi ony disclosed herein based upon 
infor ation learned or docu ents acquired through the co pletion of discovery in this action, 
l i tiff a es t  f ll i  i l r : 
iginal is l r : 
d . , h.D. 
r fessor f ar ac l  a  ic lo  
ollege f har acy 
niversity of tah 
   st #20  
Salt ake ity, tah 84112 
(801)581-7956 
r. st is a r fess r f ar ac l  a  ic l  at t e i ersit  f ta . e is 
internationally recognized as an authority on toxicology in the respiratory tract, ith particular 
expertise on the cytochro e 450- ediated echanis s of lung injury. esearch in the ost 
laboratory is largely focused on the elucidation of the che ical, bioche ical, and cellular 
echanis s of toxicity to lung tissues that are caused by exposure to environ ental pollutants. 
r  r   r  i ls t t  l ti   t  l  ti  ft r i l ti  r 
fro  ingestion follo ed by syste ic exposure to circulating che icals. e is also an expert in 
l  iseases, r -i ce  t icities, a  a erse r  reacti s. is e ertise e te s als  t  
the analysis, che istry, receptor activation, and biological effects (including toxicities) of 
capsaicinoids. 
r. st is e ecte  t  testif  re ar i  t e a  dy's reacti  t , a  t icit  f, 
capsaicinoids and oleoresin capsicum (OC) spray, as well as similar compounds. Dr. Yost will 
testify that ithin a reasonable degree of certainty it as Plaintiffs exposure to efendant's D  
spray products hile perfor ing her duties as a correctional officer ith the Idaho epart ent of 
I TIFF'S  PLE   I  I  -  
Corrections that caused an acute and chronic adverse health response and greatly exacerbated
Plaintiffsunderlying respiratory illness He will testify to how such injury takes place by
explaining the physiological and chemical mechanisms by which the compounds found in the
DefendantsOC Spray products affect the relevant human tissues He will testify about the
research in this area explaining to the jury what is known of these mechanisms and physiological
responses
Dr Yosts opinions are based upon his review of records produced in discovery
including but not limited to Plaintiffs medical records NJHR 1 59 Hendrickson 16
Moldenhauer DC 23 St Als 14 other experts reports Idaho Department of Correction
records IDC Records 35120 Sabre Red product information Sabre Red 12 Material Safety
Sheet 14 and deposition testimony Billie Major Robert Nance Bret Kimmel Daniel J
Schaffer Joshua Overgaard Nicholas Doan and Sara AnneMarie Link His opinions are also
based on his professional experience education observations and the research of his own and
others including research articles entitled Increased Expression of Transient Receptor Potential
Vanilloid1 in Airway Nerves of Chronic Cough and Breathtaking TRP Channels TRPAJ and
TRPVI in Airway Chemosensation and Reflex Controltrai ing
Dr Yost has not prepared any trial exhibits at this time In the event that any of those
items are prepared they will be produced in accordance with this Court June 1 2010
Scheduling Order and Rule 26a4of the Idaho Rules of Civil Procedure Dr Yostsinitial
report outlines his opinions in part and is produced herewith as Exhibit A In the event further
depositions are taken in this matter Dr Yosts opinions may change based on his subsequent
review of such deposition testimony and ifso this disclosure will be supplemented accordingly
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orrections t at s      ers  t  s    ated 
laintiff's underlying respiratory illness. e ill testify to ho  such injury takes place by 
explaining the physiological and che ical echanis s by hich the co pounds found in the 
efendant's  pray products affect the relevant hu an tissues. e ill testify about the 
research in this area explaining to the jury hat is kno n of these echanis s and physiological 
responses. 
r. st's OpInIOnS are ase   is reVIe  f rec r s r ce  i  isc very, 
including but not li ited to Plaintiff's edical records (NJ R 1-59, endrickson 1-6, 
oldenha er  -3, t. I's -4), t er e erts' re rts, I a  e art e t f rrecti  
records (ID  ecords 35-120), abre ed product infor ation (Sabre ed 1-2, aterial afety 
Sheet 1-4), and deposition testi ony (Billie ajor, obert ance, ret i el, aniel J. 
ff r, J s  r rd, ic las   r  - ari  ink). is i i s r  ls  
ase   is r fessi al e erie ce, e cati n, ser ati s, a  t e researc  f is  a  
t rs, i l in  r s r  rti l s title  I reas  r ssi  f r si t t r t ti l 
ill i -l i  ir  r s f r i    r t t i   nels: l  
TRPVl in Airway Chemosensation and Reflex Controltraining,. 
r. ost has not prepared any trial exhibits at this ti e. In the event that any of those 
ite s are prepared, they ill be produced in accordance ith this ourt's June 1, 2010 
Scheduling rder and ule 26(a)(4) of the Idaho ules of ivil Procedure. r. ost's initial 
report outlines his opinions in part and is produced here ith as Exhibit A. In the event further 
depositions are taken in this matter, Dr. Yost's opinions may change based on his subsequent 
revie  of such deposition testi ony, and if so, this disclosure ill be supple ented accordingly. 
LAINTIF 'S  PLEMENT     -  
Exhibits Dr Yost may utilize during trial may include medical records deposition
testimony deposition exhibits photographs monographs research articles material safety data
sheets package inserts and any other document or thing produced by any party or any nonparty
to this matter or which is referred to by any party in discovery or referred to in any document or
answers or response to discovery in this matter Illustrative exhibits demonstrative exhibits and
anatomical models may also be utilized Discovery is ongoing in this matter and additional
information may yet be discovered Plaintiff reserves the right to utilize other presently
unidentified exhibits at trial which will be timely disclosed at a later date
Dr Yostsqualifications are further outlined in his Curriculum Vitae and his profile and
biosketch on the University ofUtah College of Pharmacy website which includes a list of his
publications all of which are attached hereto as Exhibits B and C respectively Dr Yosts
agreedupon compensation for analysis of the issues in this case and to testify is 450 per hour
A copy of the signed agreement is attached hereto as Exhibit D
Plaintiff reserves the right to elicit opinion testimony from any expert non retained
treating medical provider and any other witnesses disclosed in discovery or deposition by the
Plaintiff or Defendant Further Plaintiff reserves the right to supplement or amend this
disclosure and to list rebuttal experts
Supplemental Disclosure
1 Karin PachecoMDMSPH
National Jewish Hospital
1400 Jackson Street Room G 211
Denver CO 80206
303 3981520
Dr Pacheco is an Assistant Professor of Preventative Medicine and AllergyImmunology
at the University of Colorado Denver where she teaches courses regarding bioaerosols in
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ibits . s   lize  ia     ,  
testi ony, deposition exhibits, photographs, onographs, research articles, aterial safety data 
sheets, package inserts, and any other docu ent or thing produced by any party or any non-party 
t  t is atter r ic  is referre  t   a  art  i  isc er  r referre  t  i  a  c e t r 
ans ers or response to discovery in this atter. Illustrative exhibits, de onstrative exhibits and 
t i l els  l   tili . iscovery is ongoing in this atter and additional 
infor ation ay yet be discovered. Plaintiff reserves the right to utilize other, presently 
unidentified, exhibits at trial hich ill be ti ely disclosed at a later date. 
r. st's lifications r  f rt r tli  i  is rric lu  itae  is r fil   
biosketch on the niversity f tah - ollege of har acy ebsite, hich includes a list f his 
publications, all of hich are attached hereto as xhibits  and , respectively. . st's 
agreed-upon co pensation for analysis of the issues in this case and to testify is $450 per hour. 
 copy of the signed agree ent is attached hereto as xhibit . 
Plaintiff reserves the right to elicit opinion testi ony fro  any expert, non-retained 
tr ti  i l r i r,   t r itness s is l s  i  is r  r siti   t  
l i ti   ant. Further, Plaintiff reserves the right to supple ent or a end this 
i l s r   t  li t r tt l rts. 
l l i l ur : 
. ri  , .D.,  
ati al Je is  s ital 
1400 Jackson Street, oo   211 
enver,  80206 
(303) 398-1520 
r. acheco is an ssistant rofessor f reventative edicine and llergy/Immunology 
at the niversity of olorado, enver, here she teaches courses regarding bioaerosols in 
I TIFF'S  PLE     -  
occupational medicine and the history of occupational medicine Dr Pacheco is an expert in
environmental and occupational diseases Dr Pacheco is expected to testify to a reasonable
medical certainty that Plaintiffscurrent medical condition has been caused by Plaintiffs
exposure to DefendantsOC spray products while employed by the Idaho Department of
Corrections Dr Pacheco will testify that Plaintiff suffers from irritant triggered vocalcord
dysfunction and chronic cough caused by Plaintiffsexposure to OC spray while performing her
duties as a correctional officer at the Idaho Department of Corrections Dr Pacheco is further
expected to testify that Plaintiff suffers from esophageal dysmotility and reflux exacerbated by
weight gain due to Plaintiffs inability to exercise ever since the occupational injury took place
In addition to her education training and experience Dr Pachecosopinions are based upon
examinations and testing of Plaintiff on March 31 2009 and October 6 2010 her review of
Plaintiffsmedical records and test results Dr Yostsinitial report dated January 13 2011 and
her review and knowledge of the relevant research and medical knowledge
Dr Pacheco has not prepared any trial exhibits at this time but it is anticipated that Dr
Pacheco may use any materials relied upon in the drafting of her Impairment Rating report as
exhibits at trial Additional exhibits Dr Pacheco may utilize during trial may include any of
the medical records deposition testimony deposition exhibits photographs monographs and
material safety data sheets Illustrative exhibits demonstrative exhibits and anatomical models
may also be utilized along with relevant research articles and scholarly publications
Discovery is ongoing in this matter and additional information may yet be discovered
Dr Pacheco has prepared an initial report which summarizes her opinions in whole or in
part and is produced herewith as Exhibit E In Dr Pachecosreport she requests Plaintiff receive
a psychological evaluation which would be factored into Dr Pachecosimpairment rating The
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ti l i i   t  ist r  f ti l i i . r.  is  rt i  
ir t l  ti l is s s. r.  is t  t  t stif  t   r s l  
e ical certai t  t at laintiffs c rre t e ical c iti  as ee  ca se   laintiffs 
  f ndant's       t     
ti s. r. acheco ill testify that laintiff suffers fro  irritant triggered vocal-cord 
ti   i     laintif  s  t    il  r i  r 
tie    ti l ic  t t   t t  r cti s. r.  i  t  
expected to testify that Plaintiff suffers fro  esophageal dys otility and reflux exacerbated by 
weight gain due to Plaintiffs inability to exercise ever since the occupational injury took place. 
In addition to her education, training, and experience, r. Pacheco's opinions are based upon 
exa inations and testing f laintiff on arch 31, 2009 and ctober 6, 2010; her revie  f 
l intif s i l   t t lt ; . st's i iti l t t   , 1,  
r r i   le  ft  r l t r s r   i l l . 
r. ac ec  as t re are  a  trial e i its at t is ti e t it is a tici ate  t at r. 
acheco ay use any aterials relied upon in the drafting of her I pair ent ating report as 
exhibits at trial. dditional exhibits r. Pacheco ay utilize during trial ay include any of 
the edical records, deposition testi ony, deposition exhibits, photographs, onographs, and 
t ri l s f t  t  s ts. Illustrative i its, str ti  i its  t i l ls 
a  als  e tilize , al  it  rele a t researc  articles a  sc larl  licati s. 
is r  is i  i  t is tt r  iti l i f r ti   t  i r . 
r. Pacheco has prepared an initial report hich su arizes her opinions in hole or in 
art a  is r ce  ere it  as i it . I  r. acheco's re rt s e re ests lai tiff recei e 
a psychological evaluation hich ould be factored into r. acheco's i pair ent rating. he 
I TIFF'S    ITNES  IS  -  
psychological evaluation has been performed by Plaintiffsother expert witness Dr Negron and
has been forwarded to Dr Pacheco but Dr Pacheco has not yet had time to prepare a
supplemental report regarding the increase in Plaintiffsimpairment rating Dr Pacheco reserves
the right to revise her opinions to include the information found in Dr Negronspsychological
assessment As discovery is ongoing in this matter additional information may yet be
discovered Dr Pacheco further reserves the right to revise her opinions as new information
becomes available
Dr Pachecosqualifications are outlined in her Curriculum Vitae containing a list of her
scholarly works publications and lectures attached hereto as Exhibit F Dr Pachecosagreed
upon compensation for analysis of the issues in this case and to testify is 480 per hour A copy
ofDr Pachecosfee schedule is attached hereto as Exhibit G A copy of Dr Pachecosretention
letter is attached hereto as Exhibit H Attached hereto as Exhibit I is a list of all cases in which
Dr Pacheco has testified going back ten years
2 Mary BarrosBailey PhD CRC CDMS CLCP NCC DABVE
Intermountain Vocational Services
PO Box 7511
Boise ID 837071511
208 2298484
Dr BarrosBailey is a Bilingual Rehabilitation Counselor Vocational Expert and Life
Care Planner Dr BarrosBailey is the former Chair of the Commission on Rehabilitation
Counseling Certification and also served as the Ethics Committee Chair Dr BarrosBailey is
also one of the founding members of the Inter organizational ONET Task Force Dr Barros
Bailey received her doctorate in Counseling with a cognate in Rehabilitation Counseling from
the University of Idaho Dr BarrosBailey serves on the editorial board of several peer review
journals including Journal of Counseling Development Journal of Forensic Vocational
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l i l l ti    rf r   laintiffs t r rt it  r. r   
as ee  f r ar e  t  r. acheco, t r. ac ec  as t et a  ti e t  re are a 
s le e tal re rt re ar i  t e i crease i  laintiffs i air e t rati g. r. ac ec  reser es 
t  i t t  is   i i  t  i l  t  i ti   i  r. gron's l i l 
ss ent. s discovery is ongoing in this atter, additional infor ation ay yet be 
i , r.  t r  t  i t t  i  r i i    i ti  
beco es available. 
r. Pacheco's qualifications are outlined in her urriculu  itae, containing a list of her 
s l rl  r s, li tio s  l t r s, tt  r t  as i it . r. acheco's reed-
 c e sati  f r a al sis f t e iss es i  t is case a  t  testif  is $480 er r.  c  
f r. acheco's fee schedule is attached hereto as xhibit .  copy f r. acheco's retention 
t       . tta          l     
r. Pacheco has testified, going back ten years. 
. r  rr s- il y, , , , , , /A  
I t r t i  ti l r i s 
   
is , I  -151  
(20 ) -8484 
r. arros- ailey is a ilingual ehabilitation ounselor, ocational xpert and ife 
 r. . r s- ile  i  t   i   t  is i   abilit ti  
ounseling ertification and also served as the thics o ittee hair. r. arros- ailey is 
also one f the founding e bers f the Inter-organizational *NE  ask orce. r. arros-
aile  recei e  er ct rate i  seling ith a c ate i  e a ilitati  seli  fr  
the niversity of Idaho. r. arros- ailey serves on the editorial board of several peer revie  
journals including Journal of ounseling & l t, r l f r i  ti l 
I TIFF'S  L  ITNES  S  -  
Analysis and the Journal of Mixed Methods Research Dr BarrosBailey is expected to testify
regarding Plaintiffsearning capacity and life care plan Dr BarrosBailey will testify that due
to Plaintiffs current medical condition caused by the exposure to Defendants OC spray
products Plaintiff has no probable future earning capacity or residual work life Dr Barros
Bailey will also testify that Plaintiff will need aggressive vocational rehabilitation that could take
years in order to have the chance at a possible future earning capacity In addition to her
education training and experience Dr BarrosBailey opinions are based upon her meeting
with Plaintiff on February 2 2011 her review of Plaintiffscomplete set ofmedical records and
bills Bates Nos BSG 15 DHC 1 21 IPA 150 MPT 1 26 Moldenhauer 1 196 NJH 170 NA
110 OBGYN 128 OA16 OSCI 123 SARMC 1352 SLFH 196 SLRMC 1145 SWEINT
120 BSG BILL 1 DHC BILL 12 GSR BILL 1 IPA BILL 16MOLDENHAUER 1 27 NJH
BILL 14 SAPG BILL 1 SARMC BILL 16 SLFH BILL 19 SLRMC BILL 13 SWIENT
BILL 1 SLMBS 12 SURGEON FEES FOR CASH PAY PATIENTS Dr Yostsinitial report
dated January 13 2011 Dr Pachecosinitial report dated January 11 2011 PACHECO 17
24 Dr Negronsinitial report and Plaintiffsfederal tax returns for the years 2003 through
2009 all of which were produced in discovery by Plaintiff with the exception of Dr Pachecos
report Dr Negronsreport and the surgeon fees which are produced herewith as Exhibits E L
and J respectively
Dr BarrosBailey has not prepared any trial exhibits at this time but it is anticipated that
Dr BarrosBailey may use any materials relied upon in the drafting of her Earning Capacity
Evaluation and Life Care Plan or such documents themselves as exhibits at trial Additional
exhibits Dr Barros Bailey may utilize during trial may include any of the medical records
deposition testimony deposition exhibits photographs monographs material safety data
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l i   t  r l  i e  t  arch. r. rr s- il  i  t  t  t stif  
r r i  laintiffs r i  it   lif  r  l n. r. arros- ailey ill testify that due 
to Plaintiffs current edical condition caused by the exposure to efendant's C spray 
r cts, lai tiff as  r a le f t re ear i  ca acit  r resi al r  life. r. rros-
aile  ill als  testif  t at lai tiff ill ee  a ressi e cati al re abilitati  t at c l  ta e 
ears i  r er t  a e t e c a ce at a ssi le f t re ear i  capacity.  i    
ation, tr i i ,  ri , r. rr s- iley's i i  r    r ti  
ith Plaintiff on February 2,2011; her revie  of Plaintiffs co plete set of edical records and 
ill  (Bates .  -5,  -2 , I  -5 ,  -2 , lden a r -1 ,  -7 ,  
-1 ,  -2 , l-6, I -2 ,  -35 ,  -9 ,  -1 , I  
-2 ,  I  ,  I  -2,  I  , I  I  -6,  -2 , J  
 -4,   ,   -6,   -9,   -3,  
I  1,  1-2,      IENTS); r. ost's initial report 
dated January 13, 2011; r. Pacheco's initial report dated January 11, 2011 (P CHE  17-
4); r. gron's i iti l r ort;  laintiff's f r l t  r t r  f r t  r   t r  
2009; all of hich ere produced in discovery by Plaintiff ith the exception of r. Pacheco's 
r rt, r. ron's r rt,  t  s r  f s i  r  r  r it  s i its , , 
 J r s ectiv l . 
r. arros- ailey has not prepared any trial exhibits at this ti e but it is anticipated that 
r. arros- ailey ay use any aterials relied upon in the drafting of her Earning apacity 
l ti   ife r  l , r s  e ts t s l s, s i its t tri l. iti l 
exhibits r. arros- ailey ay utilize during trial ay include any f the edical records, 
deposition testi ony, deposition exhibits, photographs, onographs, aterial safety data 
I TIFF'S    ITNESS IS OS RE -  
sheets and her reports Illustrative exhibits demonstrative exhibits and anatomical models
may also be utilized along with other scholarly materials Discovery is ongoing in this matter
and additional information may yet be discovered
Dr BarrosBailey has prepared an initial report which summarizes her opinions in whole
or in part and is produced herewith as Exhibit K Once Dr Pachecosreport has been revised to
include the information found in Dr Negronsreport a copy will be forwarded to Dr Barros
Bailey Dr BarrosBailey reserves the right to revise her opinions to include the information
found in Dr Pachecosrevised impairment rating report As discovery is ongoing in this
matter additional information may yet be discovered Dr Barros Bailey further reserves the
right to revise her opinions as new information becomes available
Included in her report as appendices are copies of Dr BarrosBailey Curriculum Vitae
which includes a list of all ofDr BarrosBailey publications fee schedule and list of all cases
in which Dr BarrosBailey has testified going back ten years
3 Roberto Negron MD
Sage Health Care
413 N Allumbaugh St Ste 101
Boise ID 83704
208 3231125
Dr Negron is the Clinical Medical Director of Behavioral Health and Chairman of the
Department ofPsychiatry at St Alphonsus Regional Medical Center Dr Negron is the Program
director of Adolescent Services at Intermountain Hospital and is the Clinical Medical Director at
Allumbaugh HouseDetox Center Dr Negron is expected to testify regarding Plaintiffscurrent
psychiatric state as a result of her current medical condition Dr Negron is expected to testify
that Plaintiffscurrent medical condition has prevented Plaintiff from participating in activities
that previously were her major coping skills Plaintiff has become withdrawn and isolated as a
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ets,   rt . lustr e xhibits, tr ti  i   t i l l  
a  als  e tilize  al  it  t er scholarl  aterials. isc er  is i  i  t is atter 
and additional infor ation ay yet be discovered. 
r. - e      rt    i    
r i  art a  is r ce  ere it  as i it . ce r. acheco's re rt as ee  re ise  t  
i l  t  i f r ti  f  i  r. gron's r ort,   ill  f r r  t  r. rros-
il y. r. rr s- il   t  i t t  i   i i  t  i l  t  i ti  
f  i  r. acheco's r i  i ir t r ti  r ort. s discovery is ongoing in this 
tt r, iti l i f r ti   t  is r d, r. rr s- il  f rt r r s r s t  
  is      r   il l . 
Included in her report as appendices are copies f r. arros- ailey's urriculu  itae 
ic  i cludes  list  ll  . rr s- iley's li ti ,  l ,  list  ll  
i  i  r. rr s- ile   t tifi d, i   t  rs. 
. rt  r ,  
 lt  r  
 . llumbaugh t., t   
,   
(2 ) -1125 
r. e r  is t  li ical i l ir t r  i r l lt   ir   t  
e rt e t f i tr  t t. lphons  i l i l t r. r. r  i  t  r r  
ire t r f dolesce t r ices t I t r t i  s it l  is t  li ic l e i l ire t r t 
llumbaugh ouselDetox enter. r. egron is expected to testify regarding laintiffs current 
psychiatric state as a result of her current edical condition. r. egron is expected to testify 
t at laintiffs c rre t e ical c iti  as re e te  lai tiff fr  artici ati  i  acti ities 
that previously ere her ajor coping skills. Plaintiff has beco e ithdra n and isolated as a 
I TIFF'S   P  ITNES  IS S  -  
result and that isolation has caused Plaintiff to become progressively more depressed with
significant suicidal ideation Dr Negron is also expected to testify that if Plaintiffsdepressive
illness goes untreated it could negatively affect the physical recovery from her injuries In
addition to his education training and experience Dr Negronsopinions are based upon his
psychiatric evaluation of Plaintiff on February 4 2011 his review of Plaintiffscomplete set of
medical records Bates Nos BSG 15 DHC 1 21 IPA 150 MPT 126 Moldenhauer 1196
NJH 170 NA 110 OBGYN 1 28 OAl6 OSCI 1 23 SARMC 1352 SLFH 196 SLRMC I
145 SWEINT 120 BSG BILL 1 DHC BILL 12 GSR BILL 1 IPA BILL 16
MOLDENHAUER 127 NJH BILL 1 4 SAPG BILL 1 SARMC BILL 16 SLFH BILL 19
SLRMC BILL 13 SWIENT BILL 1 SLMBS 12 SURGEON FEES FOR CASH PAY
PATIENTS Dr Yostsinitial report dated January 13 2011 and Dr Pachecosinitial report
dated January 11 2011 all of which were produced in discovery by Plaintiff with the exception
ofDr Pachecoswhich is produced herewith as Exhibit E
Dr Negron has not prepared any trial exhibits at this time but it is anticipated that Dr
Negron may use any of the material relied upon in the drafting ofhis Psychological Evaluation as
exhibits at trial Additional exhibits Dr Negron may utilize during trial may include any of
Plaintiffs medical records deposition testimony deposition exhibits photographs
monographs material safety data sheets and his report Illustrative exhibits demonstrative
exhibits anatomical models and other scholarly materials may also be utilized Discovery is
ongoing in this matter and additional information may yet be discovered
Dr Negronsinitial report is produced herewith as Exhibit L As discovery is ongoing in
this matter additional information may yet be discovered Dr Negron reserves the right to
revise his opinions as new information becomes available
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re lt  t at i l ti   se  l i ti  to e i l  e  it  
significant suicidal ideation. r. egron is also expected to testify that if Plaintiffs depressive 
illness es treate  it l  ti l  ff t t  si l r r  fr  r i j ri s. I  
iti  t  is ti , tr i i ,  ri , r. gron's i i s r  s   is 
s i tric l ti  f l i tiff  r r  , ; is r i  f l intiffs lete s t f 
e ical re r s (Bates .  -5,  -2 ,  -5 ,  -2 , lden a  -19 , 
J  1-70,  1-10,  1-28, I-6, S I 1-23, S  1-352, S F  1-96, S  1-
145, S I  -2 ,  I  ,  I  -2,  I  , I  I  -6, 
E  -27, J  I  -4,  I  ,  I  -6,  I  -9, 
  -3,   ,  -2,      
P I NTS); r. ost's initial report dated January 13, 2011; and r. Pacheco's initial report 
dated January 11, 2011; all of hich ere produced in discovery by Plaintiff ith the exception 
of r. acheco's hich is produced here ith as xhibit . 
r. egron has not prepared any trial exhibits at this ti e but it is anticipated that r. 
egron ay use any of the aterial relied upon in the drafting of his Psychological Evaluation as 
exhibits at trial. dditional exhibits r. egron ay utilize during trial ay include any of 
laintiff's  records, deposition t sti ony, deposition xhibits, photographs, 
monographs, material safety data sheets and his report. Illustrative xhibits, tr ti  
exhibits, anato ical odels and other scholarly aterials ay also be utilized. iscovery is 
ongoing in this matter and additional information may yet be discovered. 
r. egron's initial report is produced here ith as xhibit . s discovery is ongoing i  
this atter, additional infor ation ay yet be discovered, r. egron reserves the right to 
revise his opinions as ne  infor ation beco es available. 
I TIFF'S  PL     -  
Dr Negronsqualifications are outlined in his Curriculum Vitae which includes a list of
all of his publications attached hereto as Exhibit M A copy of Dr NegronsRetainer
Agreement is attached hereto as Exhibit N Attached hereto as Exhibit O is a list of all cases in
which Dr Negron has testified going back four years
4 Gary R Couillard CPA
131 l st Ave Ste 706
Salt Lake City UT 84103
801 8245566
Mr Couillard is a forensic accountant with 38 years of experience providing economic
loss appraisals fraud investigations insurance claims business interruptions lost personal
earnings and benefits life expectancy andwork life lost household services personal injury and
wrongful death wrongful termination and discrimination lost commercial profits intellectual
property infringement business and professional practice valuation utility rate and regulations
analysis reasonable compensation tax issues divorce asset analysis arbitration mediation and
structured settlements In this case he has provided analysis opinions and conclusions
pertaining to the economic damages in connection with the injuries sustained by the Plaintiff
which were caused by the Defendantswrongful conduct complained of in this case He has
prepared a report setting forth his opinions and conclusions relating to the economic damages
sustained by the Plaintiff in this case which is attached hereto along withMr Couillardsas
Exhibit R His Curriculum Vitae is attached hereto as Exhibit S His fee schedule is attached
hereto as Exhibit T A list of articles Mr Couillard has authored is attached hereto as Exhibit U
Attached hereto as Exhibit V is a list of all cases in which Mr Couillard has testified going back
four years
Mr Couillard is expected to testify that the economic loss to the Plaintiff resulting from
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r. ron's lifications r  tline  i  is rriculu  it , ic  i cludes  list f 
all of his publications, attached hereto as Exhibit .  c  f r. egron's etai er 
gree ent is attached hereto as xhibit . ttached hereto as xhibit 0 is a list f all cases in 
hich r. egron has testified, going back four years. 
. ary . ouillard, P  
 1st , t .  
Salt ake ity,  84103 
(801) 824-5566 
r. illar  i   f r i  t t it   r  f rie  r i i  i  
l ss a raisals, fra  i esti ati s, i s ra ce clai s, si ess i terr ti s, l st ers al 
earnings and benefits, life expectancy and ork life, lost household services, personal injury and 
rongful death, rongful ter ination and discri ination, lost co ercial profits, intellectual 
property infringe ent, business and professional practice valuation, utility rate and regulations 
l sis, r s l  s ti  t  iss s, i r  ss t alysis, r itr ti n, i ti   
str ct re  settle e ts. I  t is case, e as r i e  a al sis, i i s a  c cl sions 
pertaining to the economic damages in connection with the injuries sustained by the Plaintiff 
hich ere caused by the efendant's rongful conduct co plained f in this case. e has 
prepared a report setting forth his opinions and conclusions relating to the econo ic da ages 
sustained by the Plaintiff in this case hich is attached hereto along ith r. ouillard's as 
 .   ita       .      
  t .  s   e  r.     t     . 
ttached hereto as xhibit  is a list of all cases in hich r. ouillard has testified, going back 
four years. 
r. Couillard is expected to testify that the econo ic loss to the Plaintiff resulting fro  
LAINTIF 'S  PL     -  
her injuries in this case ranges from12639 2 to14706 plus medical expenses incurred
through the date of his report In addition to the information in his report Mr Couillard will
testify to the medical expenses incurred to the date of his report are663221 plus the costs of
various prescription medications and interest on all past medical expenses The components of
economic loss to the Plaintiff include past lost earnings future lost earning capacity lost
employment benefits lost household services past medical expenses and a life care plan
including necessary future medical expense and household services He will testify that the
calculations performed in his report that are in part based on a remaining work life expectancy
for the Plaintiff of 57 years of age based on standard work life tables He will further testify that
the standard work life tables for calculating work life expectancy understate the Plaintiffsactual
work life expectancy He will discuss the wealth of recent economic studies that support his
conclusion that the Plaintiff would have worked beyond age 57 and how that impacts the
Plaintiffstotal economic losses beyond that which he has set forth in his report
In addition to his education training and experience Mr Couillardsopinions are
based upon his review ofPlaintiffsfederal tax returns from the years 2003 through 2009
PERSI policies and benefits documents State of Idaho 1373 functional capacity household
service and economic loss questionnaires a copy ofPlaintiffsComplaint Plaintiffs
employment history PlaintiffsSocial Security Summary PlaintiffsSocial Security Statement
Plaintiffsjob responsibilities at SCP and Plaintiffsdisability benefits documents and the
initial expert reports ofDr Pacheco dated January 11 2011 Dr Negron and Dr BarrosBailey
dated March 24 2011 all ofwhich were produced in discovery by Plaintiff with the exception of
Dr Pacheco Dr BarrosBailey reports Dr Negron questionnaires and the PERSI policies and
benefits documents which are produced herewith as Exhibit E L K P and Q respectively
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 e       $1,263,962 t  $1,470,670  i l   
t r  t  t   i  r port. I  iti  t  t  i f r ti  i  i  r port, r. ill r  ill 
t stif  t  t  i l s s i rr  t  t  t  f is r rt r  $66,322.12 l s t  sts f 
ri s r s ri ti  i ti s  i terest  ll st i l s s.  ts f 
i  l s  t  t  l i tiff i l  t l t r i s, f t r  l t r i  pacity, l t 
l t efits, l st s l  s rvi s, st i l s s,   lif  r  l  
i l i  ss r  f t r  i l s   s l  s r i s.  ill t stif  t t t  
calculations perfor ed in his report that are in part based on a re aining ork life expectancy 
f r t  l i tiff f  r  f    t r  r  lif  t l .  ill f rt r t stif  t t 
t  t r  r  life t l  f r l l ti  r  lif  t  r t t  t  laintiffs t l 
ork life expectancy. e ill discuss the ealth of recent econo ic studies that support his 
l i  t t t  l i tiff l   r e       t t i t  t  
laintiff s total econo ic losses beyond that hich he has set forth in his report. 
In addition to his education, training, and experience, r. ouillard's opinions are 
based upon his revie  f laintiffs federal tax returns fro  the years 2003 through 2009 ; 
P SI policies and benefits docu ents (State ofldaho 1-373); functional capacity, household 
service and econo ic loss questionnaires; a copy of Plaintiffs o plaint; Plaintiffs 
e ploy ent history; laintiffs ocial ecurity u ary, laintiffs ocial ecurity tate ent 
laintiffs job responsibilities at  ; and laintiffs disability benefits docu ents; and the 
initial expert reports of r. Pacheco, dated January 11, 2011, r. egron, and r. arros- ailey, 
dated arch 24, 2011; all of hich ere produced in discovery by Plaintiff ith the exception of 
Dr. Pacheco, Dr. Barros-Bailey's reports, Dr. Negron, questionnaires, and the PERSI policies and 
benefits docu ents, hich are produced here ith as Exhibit E, L, , P, and  respectively. 
IFF'S    ITNESS IS S  -  
Mr Couillard has prepared his report which may use as a trial exhibit along with this
Curriculum Vitae and scholarly articles relating to the issue of the standard tables for work life
expectancy of the Plaintiff being understated Other exhibits that may be used at trial include the
tables for work life expectancy the above listed material that have been provided to him by
Plaintiff as exhibits at trial as well as his report Additional exhibits Mr Couillard may utilize
during trial may include any of Plaintiffsmedical records deposition testimony deposition
exhibits photographs monographs material safety data sheets charts tables and other
materials used to calculate the damages set forth in his report and he may use tables charts
and information in his report as well Illustrative exhibits demonstrative exhibits and models
may also be utilized Discovery is ongoing in this matter and additional information may yet
be discovered that may be used as exhibits
To the extent further investigation discloses additional pertinent information Mr
Couillard reserves the right pursuant to applicable rules to supplement his report Mr Couillard
also reserves that right to revise his report to include additional elements of damage including
damages based on additional or supplemental information received from other experts in this
case
5 JPPurswell PhD
2035 Mulligan Drive
Colorado Springs CO 80920
719 3300126
Dr Purswell is the Vice President ofPurswell Purswell Engineering Ergonomics
Inc Dr Purswell was the Chair of IE PE exam from 20052009 and he currently serves on the
IE PE Exam committee Dr Purswell also teaches ergonomics and safety engineering at
Colorado State University His Curriculum Vitae which includes a list of his publications is
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r. illar   r re  is r rt i   s    trial i it l  it  t is 
rriculu  itae  s l rl  rticles r l ti  t  t  iss  f t  st r  t les f r r  life 
expectancy of the Plaintiff being understated. ther exhibits that ay be used at trial include the 
ta les f r r  life t cy, t   liste  t ri l t t   r i e  t  i   
lai tiff as e i its at trial as ell as is re rt. itional e i its r. illar  a  tilize 
during trial may include any of Plaintiff's medical records, deposition testimony, deposition 
exhibits, photographs, onographs, aterial safety data sheets, charts, tables and other 
aterials se  t  calc late t e a a es set f rt  in is re rt, a  e a  se ta les, c arts 
and infor ation in his report as ell. Illustrative exhibits, de onstrative exhibits and odels 
 ls   tili . is r  is i  i  t is tt r  iti l i f r ti   t 
 is r  t t   s  s i its. 
o the extent further investigation discloses additional pertinent infor ation, r. 
illar  reser es t e ri t, rs a t t  a lica le r les, t  s le e t is re rt. r. illar  
also reserves that right to revise his report to include additional ele ents of da age, including 
da ages based on additional or supple ental infor ation received fro  other experts in this 
e. 
. J.P. urs ell, h.D. 
2035 ulligan Drive 
olorado Springs,  80920 
(719) 330-0126 
r.    ic  i    l  & Purs ell, Engineering & r o ics, 
I c. r. rs ell as t e air f I   e a  fr  -20  a  e c rre tl  ser es  t e 
   itt . r. r ll l  t  i   f t  i i  t 
Colorado State niversity. is Curriculu  itae, hich includes a list of his publications, is 
LAINTIF 'S  PLE     -  
attached hereto as Exhibit W His fee schedule is attached hereto as Exhibit X A list of cases in
which Dr Purswell has testified is attached hereto as ExhibitY
Dr Purswell has prepared an initial report of his conclusions and opinions relating to the
adequacy or lack thereof ofwarnings on the Defendantsproducts labels His initial report is
attached hereto as Exhibit BB Specifically he is expected to testify regarding Defendants
warning label on its Sabre Red OC spray products Mr Purswell is expected to testify that
Defendantswarning labels found on their Sabre Red products are inadequate and do not
properly warn of real and potential dangers their products pose to people suffering from
respiratory impairment Mr Purswell is also expected to testify that due to the inadequacy ofthe
warning label found on DefendantsSabre Red products Plaintiff was and the general public
continues to be at risk of suffering from illness due to using DefendantsSabre Red products
because they are not being properly warned on the potential health risks
It is anticipated that Dr Purswell will testify regarding MSDSs in general and SECs
product MSDSs SEC competitor product MSDSs and SECs chemical suppliers MSDSs He is
anticipated to testify that based upon the foregoing respiratory inflammation and illness as a
result of OC exposure were known to or should have been known to SEC and that SEC did not
disclosure ofthe same
In addition to his education training and experience Dr Purswellsopinions are based
upon his review of Material Safety Data Sheets for various Sabre Red Products including
MK9 First Defense HV Stream Sabre 50CFT Sabre 50 Foam Sabre 50Sabre Red H2O
Sabre Red Gernade Cell Buster Sabre Red MK9 Fogger Sabre Red CFT and Sabre Red
Cone Dr Purswell also reviewed Material Safety Data Sheets from Defendantssuppliers
for material used in the making of Sabre Red products product and warning labels for the
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attached eret   ibit . is fe  e is ta e  e et   it .  list  ases in 
hich . l has te fied is attached   t . 
r. rs ell as repared a  i itial re rt f is c clusions a  i ions relati  t  t e 
adequacy r lack thereof f arnings on the efendant's products labels. is initial report is 
attached hereto as xhibit . pecifically he is expected to testify regarding efendant's 
arning label on its Sabre ed  spray products. r. Purs ell is expected to testify that 
f dant's r i  l l  f   t ir r  e  r ts r  i a t    t 
properly warn of real and potential dangers their products pose to people suffering from 
respiratory i pair ent. r. urs ell is also expected to testify that due to the inadequacy ft e 
arning label found on efendant's Sabre ed products, Plaintiff as, and the general public 
continues to be, at risk of suffering fro  illness due to using efendant's Sabre ed products 
because they are not being properly arned on the potential health risks. 
It is anticipated that r. Purs ell ill testify regarding S Ss, in general, and SEC's 
product S Ss, SEC co petitor product S Ss, and SEC's che ical suppliers' S Ss. e is 
anticipated to testify that based upon the foregoing, respiratory infla ation and illness as a 
result of C exposure ere kno n to, or should have been kno n to SEC and that SEC did not 
s    e. 
I  a iti  t  is e ucation, trai i , a  e erie ce, r. urswell's i i s are ase  
upon his review of aterial Safety Data Sheets for various Sabre Red Products including: 
 ir t fe s   tr , r  .0 , r  .0 a , r  .0, r   0, 
Sabre Red ernade, Cell Buster, Sabre Red 9 Fogger, Sabre Red CFT, and Sabre Red 
Cone. r. Purs ell also revie ed; aterial Safety ata Sheets fro  efendant's suppliers 
for aterial used in the aking of Sabre ed products; product and arning labels for the 
LAINTIF 'S ECON  SUPPLEMENTAL  I   - 1  
various Sabre Red products the promotional literature regarding Defendants Sabre Red
product line and the product and warning labels for various SEC competitor products
Material Safety Data Sheets for various SEC competitors Products SEC training manual and
training presentation Deposition transcripts of Bob Nance and Nicholas Doan Dr Pachecos
initial report dated January 11 2001 Dr Yostsinitial report dated January 13 2011 a copy
of PlaintiffsComplaint and two articles entitled Increased Expression of Transient Receptor
Potential VanilloidI in Airway Nerves of Chronic Cough and Breathtaking TRP Channels
TRPAI and TRPV1 in Airway Chemosensation and Reflex Control all ofwhich were produced
in discovery either by Defendant or byPlaintiff with the exception ofDr Pachecosreport
MSDS sheets of competitor products product warnings and labels for competitor products all of
which are being produced herewith as Exhibits E Z and AA
Dr Purswell has not prepared any trial exhibits at this time but it is anticipated that Dr
Purswell may use his report and Curriculum Vitae along with any of the above listed material
that have been provided to him by Plaintiff as exhibits at trial Additional exhibits Dr Purswell
may utilize during trial may include any of Plaintiffsmedical records deposition testimony
deposition exhibits photographs monographs and material safety data sheets Illustrative
exhibits demonstrative exhibits and anatomical models may also be utilized Discovery is
ongoing in this matter and additional information may yet be discovered
To the extent further investigation discloses additional pertinent information Mr
Purswell reserves the right pursuant to applicable rules to supplement his report Mr
Purswell also reserves that right to revise his report to include additional opinions and
conclusions based on additional or supplemental information received from other experts and
medical providers in this case
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various Sabre ed products, the pro otional literature regarding efendants Sabre ed 
r t li ;  t  r t  r i  l l  f r ri   tit r r ts; 
t ri l f t  t  ts f r ri s  tit rs r ts;  tr i i  l  
trai ing resentation; e siti  tra scri ts f  a ce a  ic las an; r. acheco's 
i itial re rt ate  Ja ar  , 001; r. st's i itial re ort, ate  Ja ar  , 1; a c  
f laintiff's lai t; a  t  articles e title  I crease  x ressi  f r sie t ece t r 
otential anilloid-l in ir ay erves f hronic ough and reathtaking  hannels: 
T I and T I in ir ay he osensation and eflex ontrol all of hich ere produced 
in discovery either by efendant or by Plaintiff ith the exception of r. Pacheco's report, 
S S sheets of co petitor products, product arnings and labels for co petitor products, all of 
i  r  i  r  r it  s i its , ,  . 
r. rs ell as t re are  a  trial e i its at t is ti e t it is a tici ate  t at r. 
Purs ell ay use his report and urriculu  itae, along ith any of the above listed aterial 
that have been provided to hi  by Plaintiff as exhibits at trial. dditional exhibits r. Purs ell 
ay utilize during trial ay include any of Plaintiff's edical records, deposition testi ony, 
deposition exhibits, photographs, onographs, and aterial safety data sheets. llustra e 
e i its, e strati e e i its a  a at ical els a  als  e tilize . Discovery is 
ongoing in this atter and additional infor ation ay yet be discovered. 
To the extent further investigation discloses additional pertinent infor ation, r. 
Purs ell reserves the right, pursuant to applicable rules, to supple ent his report. r. 
Purswell also reserves that right to revise his report to include additional opinions and 
conclusions based on additional or supple ental infor ation received fro  other experts and 
edical providers in this case. 
I TIFF'S  L    S  -  
6 Garold S Yost PhD
Professor of Pharmacology and Toxicology
College ofPharmacy
University ofUtah
30 North 1900 East 201
Salt LakeCity Utah 84112
80158 7956
Attached hereto as Exhibit CC is a list of all cases in which Dr Yost has testified going
back four years Plaintiff further supplements her disclosure of Dr Yost by stating that Dr Yost
has additionally been provided for his review the deposition transcripts of Joshua Overgaard
Bret R Kimmel Nicholas Doan Daniel J Schaffer Billie Major Vols I II with errata sheets
Sara AnnMarie Link and the rough transcript from Bob Nances deposition Dr Yosts
publication have previously been disclosed along with his Curriculum Vitae
Dr Yost has not prepared any trial exhibits at this time but it is anticipated that Dr Yost
may use any materials relied upon in the drafting of his initial report as exhibits at trial
Additional exhibits Dr Yost may utilize during trial may include any of Plaintiffsmedical
records deposition testimony deposition exhibits photographs monographs and material
safety data sheets Illustrative exhibits demonstrative exhibits and anatomical models may
also be utilized Discovery is ongoing in this matter and additional information may yet be
discovered Dr Yost reserves the right to revise his opinion as additional information becomes
available
In addition to the retained experts identified herein the Plaintiff hereby discloses as
non retained treating physicians the following medical professionals who may be called upon
to testify consistent with their medical records and deposition testimony
7 JanetODonnell
William Loveland
Danny J Hendrix
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. ld . , h.D. 
e    nn      
llege f annac  
i ersit  f ta  
    #201 
alt ake ity, tah 84112 
(801)581-7956 
ttached hereto as xhibit  is a list of all cases in hich r. ost has testified going 
 f r r . l i tiff f rt r l t  r i l r  f r. t  t ti  t t r. t 
s iti ally,  r ide  f r is r i , t  siti  tr s ri ts f J s  r ard, 
 . l, ic las ,  . ff r, lie  l .  & IT it  errata s eets, 
a -Marie i ,  t   t i t   nce's siti n. r. st's 
pUblication have previously been disclosed along ith his urriculu  itae. 
r. ost has not prepared any trial exhibits at this ti e but it is anticipated that r. ost 
ay use any aterials relied upon in the drafting of his initial report as exhibits at trial. 
dditional exhibits r. ost ay utilize during trial ay include any of Plaintiff's edical 
rec r s, e siti  testi , e siti  e i its, t ra s, ra s, a  aterial 
safet  ata s eets. Illustrati e e i its, e strati e e i its a  a at ical els a  
  ti d. iscovery is ongoing in this atter and additional infor ation ay yet be 
i . . t  t  i t t  i  i  i i   iti l i ti   
il l . 
In addition to the retained experts identified herein, the Plaintiff hereby discloses as 
non-retained treating physicians the follo ing edical professionals ho ay be called upon 
to testify consistent ith their edical records and deposition testi ony. 
.  'Do ne  
llia  a  
Danny J. Hendrix 
I TIFF'S     S  -  
Idaho Pulmonary Associates Boise
1075 Curtis Road
Boise ID 83706
208 3230031
8 Glenn W Moldenhauer DC
Chiropractic Center
228 Holly
Boise ID 83686
208 4675759
208 4674510 Fax
9 Dr Reese A Verner
6140 West Curtisian Ave
Ste 102
Boise ID 837040109
208 3672834
10 Dr Matthew Schwarz
South West Idaho Ear Nose Throat
900 North Liberty St
Ste 400
Boise ID 83704
208 3673320
Plaintiff also discloses that she may call at trial other medical experts identified in the
previously disclosed medical records to testify consistent with the medical records and
deposition testimony
Plaintiff reserves the right to utilize as exhibits documents that are as yet unknown to
him and any and all materials produced incident to discovery whether produced by a party or
non party any and all pleadings answers and responses to discovery responses to subpoenas
deposition transcripts and deposition exhibits Plaintiff also reserves the right to utilize as
exhibits illustrative and demonstrative materials and anatomical models Plaintiff may utilize
any and all medical records relied upon by the treating physicians and other medical service
providers along with their own records
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laintiff also discloses that she ay call at trial other edical experts identifie d in the 
previously disclosed edical records to testify consistent ith the edical records and 
deposition testi ony. 
l i tiff r s r s t  ri t t  tiliz  s i its ts t t r  s t  t  
hi , and any and all aterials produced incident to discovery, hether produced by a party or 
non-party, any and all pleadings, ans ers and responses to discovery, responses to subpoenas, 
deposition transcripts, and deposition exhibits. Plaintiff also reserves the right to utilize as 
exhibits illustrative and de onstrative aterials, and anato ical odels. Plaintiff ay utilize 
a  a  all e ical rec r s relie    t e treati  sicia s a  t er e ical ser ice 
providers along ith their o n records. 
I TIFF'S  L   S  S  -  
Plaintiff reserves the right to elicit opinion testimony from any person duly qualified
who has been disclosed by Defendants in this action
Plaintiff reserves the right to elicit opinion testimony from any expert non retained
treating medical provider and any other witnesses disclosed in discovery or deposition by the
Plaintiff or Defendants Further Plaintiff reserves the right to supplement or amend this
disclosure and to list rebuttal experts In the event further depositions are taken in this matter
the testimony of non retained medical providers who provided care and treatment to Plaintiff
as a result of the incident at issue in this case may change based on subsequent review of such
deposition testimony and if so this disclosure will be supplemented accordingly
As discovery and Plaintiffstreatment remains ongoing there may be other persons not
identified herein who may fall within the scope of this disclosure that are not yet known If such
persons are identified Plaintiff reserves the right to seasonably disclose such persons and to call
them as witnesses at the time oftrial
Any of the persons identified above may be called for purposes of rebuttal andor
impeachment Plaintiff also reserves the right to seasonably supplement this list with other
rebuttal andor impeachment witnesses
Plaintiff reserves the right to alter amend or supplement this disclosure as the Idaho
Rules of Civil Procedure and the Court may allow
Second Supplemental Disclosure
Plaintiff further supplements her disclosure ofDr Yost by stating that Dr Yost has relied
on the following articles and the articles cited therein in forming his expert opinion
I Hamyman Mark Kam Peter CAPSAICIN A REVIEW OF ITS PHARMACOLOGY
AND CLINICAL APPLICATION Vol 19 Journal Current Anesthesia and Critical Care pp 338343
2008
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l i tiff reserves t e rig t t  licit i ion t ti  fr   r , l  lifi , 
ho as ee  isclosed  efendants in this ti . 
lai tiff reser es the rig t t  elicit i i  testi  fr  a  e ert, -retaine  
treating edical provider, and any other witnesses disclosed in discovery or deposition by the 
f  ts. Further, Plaintiff reserves the right to supple ent or a end this 
isclosure  t  list tt l t .  t  t t  iti   t  i  t is tt r, 
the testi ony of non-retained edical providers ho provided care and treat ent to Plaintiff 
s  r s lt f t e i ide t t iss  i  t is ase  e s   s s t r i  f s  
deposition testimony, and if so, this disclosure will be supplemented accordingly. 
s discovery and Plaintiff s treat ent re ains ongoing, there ay be other persons not 
identified herein ho ay fall ithin the scope 6fthis disclosure that are not yet kno n. If such 
persons are identified, Plaintiff reserves the right to seasonably disclose such persons and to call 
  itness    e  l. 
 f t e ers s i e tifie  a e a  e calle  f r r ses f re ttal a /or 
i peach ent. Plaintiff also reserves the right to seasonably supple ent this list ith other 
rebuttal and/or i peach ent witnesses. 
lai tiff reser es t e ri t t  alter, a end, r s le e t t is iscl s re as t e I a  
ules of ivil rocedure and the ourt ay allo . 
  : 
Plaintiff further supple ents her disclosure of r. ost by stating that r. ost has relied 
on the follo ing articles and the articles cited therein in for ing his expert opinion: 
1. Ha y an, ark & a , eter, PSAICIN:  I  F ITS PHA L  
 I I  PPLI ATI N, ol. 19, Journal urrent nesthesia and ritical are, pp. 338-343 
(2008). 
LAINTIF 'S  PPLEMENT   I   - 17 
2 Alawi Khadija Keeble Julie THE PARADOXICAL ROLE OF TRPV1 RECEPTOR IN
INFLAMMATION Vol 125 Pharmacology and Therapeutics pp 189195 2010
3 CAReillyDJCrouch GS Yost andA Fatah Determination of Capsaicin
NONIVAMIDE AND DIHYDROCAPSAICIN IN BLOOD AND TISSUE BY LIQUID CHROMATOGRAPHY
TANDEM MASS SPECTROMETRY J Anal Toxicol 26 313319 2002
4 CA Reilly JL Taylor DL Lanza BA Carr DJ Crouch and GS Yost
CAPSAICINOIDS CAUSE INFLAMMATION AND EPITHELIAL CELL DEATH THROUGH ACTIVATION OF
VANILLOID RECEPTORS Tox Sci 73 170181 2003
5 CA Reilly and GS Yost STRUCTURAL AND ENZYMATIC PARAMETERS THAT
DETERMINE ALKYL DEHYDROGENATIONHYDROXYLATION OF CAPSAICINOIDS BY P450 ENZYMES
DrugMetab Dispos 33 530536 2005
6 CA Reilly ME Johansen DL Lanza J Lee JO Lim and GS Yost
CALCIUMDEPENDENT AND INDEPENDENT MECHANISMS OF CAPSAICIN RECEPTOR TRPV1
MEDIATED CYTOKINE PRODUCTION AND CELL DEATH IN HUMAN BRONCHIAL EPITHELIAL CELLS
J Biochem Molec Toxicol19266752005
7 MEJohansenCAReilly and GS Yost TRPV1 ANTAGONISTS ELEVATE CELL
SURFACE POPULATIONS AND RECEPTOR FUNCTION TO EXACERBATE TRPV1MEDIATED
TOXICITIES IN HUMAN LUNG EPITHELIAL CELLS Toxicol Sci 89 278286 2006
8 CAReilly andGS Yost METABOLISM OF CAPSAICINOIDS BY P450 ENZYMES A
REVIEW OF RECENT FINDINGS ON REACTION MECHANISMS BIOACTIVATION AND
DETOXIFICATION PROCESSES DrugMetab Rev 38 685706 2006
9 KCThomasASSabnisMEJohansenDLLanza PJ Moos GSYost and
CA Reilly TRPV1 AGONISTS CAUSE ENDOPLASMIC RETICULUM STRESS AND CELL DEATH IN
HUMAN LUNGCELLS J Pharmacol Exp Ther 321 830838 2007
10 BF Bessac and SEJordt BREATHTAKING TRP CHANNELS TRPA1 AND TRPV1
IN AIRWAY CHEMOSENSATION AND REFLEX CONTROL Physiology 23 360370 2008
11 DAGroneberg A Niimi Q Thai Dinh B Cosio Mark Hew A Fischer and
KF Chung INCREASED EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID1IN
AIRWAY NERVES OF CHRONIC COUGH American Journal of Respiratory and Critical Care
Medicine Vol 170 12761280 2004
12 JE Mitchel AP Campbell NE New LR Sadofsky JA Kastelik SA
Mulrennan SJ Compton and AHMorice EXPRESSION AND CHARACTERIZATION OF THE
INTRACELLULAR VANILLOID RECEPTOR TRPV1 IN BRONCHI FROM PATIENTS WITH CHRONIC
COUGH Experimental Lung Research 31295306 2005
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2. i, ja & l , l ,     l   
, l. ,   r uti s, . -19  (2 0). 
. .A Reilly, .J. Crouch, .S. ost, and A Fatah, eter ination of Capsaicin, 
,         -
 S  ,  l. xico!., , -319 (2 2). 
. .A eilly, J.L. aylor, .L. anza, .A arr, .J. rouch, and .S. ost, 
  I   I I       
I I  , x. ci., , -18  (2 3). 
. .A eilly and .S. ost, S   I  P S T T 
   I /HYDR  TIO      , 
 t b. i . , -53  (2 5). 
. .A ill , .E. J s , .L. , J. , J.-O. i ,  .S. st, 
I -   I P  IS S F PS I I   (TR l)-
        I  I LI  , 
J ioche . olec. oxicol. 19,266-275 (2005). 
. .E. Johansen, .A. eilly, and .S. ost, P l T ISTS ELE TE ELL 
       PVI-MEDIA  
T ICITIES IN  L  EPIT ELI L CELLS, Toxico!. Sci. 89,278-286 (2006). 
. .A eill  a  .S. st, I  F I I I    :  
   I I   I  , I - TI I ,  
 ,  t b. v. , -70  (2 6). 
. .C. , S. bnis, .E. en, .L. , .J. , .S. t,  
.A eilly, l IS   I  I      I  
  S, J har acol. xp. her. 321, 830-838 (2007). 
. .F.   .E. r t, I   LS: I  l 
IN AIR AY CHE OSENSATION AND REFLEX CONTROL, Physiology, 23, 360-370 (2008). 
. .A r erg,  ii i, . i i , . sio, r  ,  is r,  
.F. hung, I S  P SSI  F SI  P  P I  ILLOID-l I  
I  S F I  , erican Journal f espiratory and ritical are 
edicine, ol. 170, 1276-1280 (2004). 
. J.E. itchel, P. a pbell, .E. e , .R. Sadofsky, J.A astelik, S.A. 
ulrennan, S.J. o pton, and H. orice, E PRESSI  AND C R CTERIZ TI  OF THE 
I  I I   (TRP l) I  I  I  I  I  
COUGH, Experi ental Lung Research, 31 :295-306 (2005). 
I TIFF'S  L     -  
13 T Higenbottam CHRONIC COUGH AND COUGH REFLEX IN COMMON LUNG
DISEASES Pulmonary Pharmacology Therapeutics 15241247 2002
14 Pierangelo Geppetti Serena Materazzi Paola Nicoletti THE TRANSIENT
RECEPTOR POTENTIAL VANILLOID 1 ROLE IN AIRWAY INFLAMMATION AND DISEASE European
Journal ofPharmacology 533207214 2006
15 WJMeggs NEUROGENIC INFLAMMATION AND SENSITIVITY TO ENVIRONMENTAL
CHEMICALS Environ Health Prospect 101234238 1993
16 John J Adcock TRPV 1 RECEPTORS IN SENSITIZATION OF COUGH AND PAIN
REFLEXES Pulmonary Pharmacology Therapeutics 226570 2009
17 LuYuan Lee and Qihai Gu ROLE OF TRPV1 IN INFLAMMATION INDUCED AIRWAY
HYPERSENSITIVITY Current Opinion in Pharmacology 9243249 2009
18 K Alawi and J Keeble THE PARADOXICAL ROLE OF THE TRANSIENT RECEPTOR
POTENTIAL VANILLOID 1 RECEPTOR IN INFLAMMATION Pharmacology and Therapeutics
12581195 2010
Plaintiff further supplements this disclosure by stating that copies of all of the above
listed articles have previously been produced in discovery
DATED this 25th dayof July 2011
JOl
ERIC B SWARTZ
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. . ige tt , I      I    
DISEASES, Pul onary Phar acology & . ti , 5:241-247 (20 2). 
. iera elo e etti, a a i,  tti,  S  
   :    I TI   I , ope  
Journal of Pharmacology 533:207-214 (2006). 
. .J. eggs, E IC I F ATION  S SI I I  T  I  
I S, nviron. ealth rospect, 101:234-238 (1993). 
. J  . d ,  S I  I I I     I  
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laintiff further supple ents this disclosure by stating that copies f all f the above 
listed articles have previously been produced in discovery. 
DATED this 25th day of July, 2011. 
By~~~~~~~~ __ __ 
DARWIN . VERSON 
 .  
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Case No CV PI 1003515
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SECURITY EQUIPMENT CORPORATION
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FOR SUMMARY JUDGMENT will be called for hearing before The Honorable Cheri C Copsey at
the Ada County Courthouse inBoise Idaho
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DATED this 29th day ofJuly 2011
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foregoing document was served on the following individualsby the method indicated
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USMail
X Fax 3192601
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Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise Idaho 83702
Tel 208 3192600
Fax 208 3192601
Attorneys for Defendant
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By JERI HEATON
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
V
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
Case No CVPI1003515
SECMOTION TO STRIKE
PORTIONS OF SECOND AFFIDAVIT
OF GEROLD S YOST PHDFILED IN
SUPPORT OF PLAINTIFF MOTION
FOR RECONSIDERATION
Defendant
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA pursuant to Idaho Rules of Civil Procedure 7 and 56c
objects to and hereby moves this Court to strike portions of the Second Affidavit of Gerold S
Yost PhD Second Yost Affidavit which was filed by Plaintiff Billie Jo Major Plaintiff
on July 26 2011 in support of PlaintiffsMotion for Reconsideration
This Motion to Strike is made on the following grounds
1 The Second Yost Affidavit directly contradicts deposition testimony and should
be stricken pursuant to the sham affidavit rule
SEC MOTION TO STRIKE SECOND AFFIDAVIT OF GEROLD S YOST PHDFILED IN SUPPORT OF
PLAINTIFF MOTION FOR RECONSIDERATION Page 1 14542011 408382doc
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JR\G\NAl 
A.M·· ____ :.:._It,.,L, t;27 , 
AUG  8 2011 
CHRJSTOPHER O. RI , Cieri( 
By JERI HEATON 
Christopher C. Burke, ISB #2098 
Thomas 1. Lloyd III, ISB #7772 
GREENER BURKE S OE AKER P  
950 . annock Street, Suite 9  
Boise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
DEPUTY 
I  E IS    E     E 
  I , I    E    
I LIE J  J , an individual, 
Plaintiff, 
v. 
SECURITY EQUIP ENT 
CORPORATION, a issouri corporation, 
nt. 
s  o.: -P -I  
EC'S    
   I  
  . , H.D   
  LAINTIF 'S  
 I  
Defendant Security Equip ent Corporation ("SE "),  a  t r  its c sel f 
record, Greener Burke Shoemaker P.A., pursuant to Idaho Rules of Civil Procedure 7 and 56(c), 
objects to and hereby moves this Court to strike portions of the Second Affidavit of Gerold S. 
Yost, Ph.D. ("Second Yost Affidavit"), ic  as file   laintiff illie J  aj r ("Plaintiff') 
on July 26,2011 in support of Plaintiffs otion for Reconsideration. 
is ti  t  tri e is a e  t e f ll i  r unds: 
. he Second ost ffidavit directly contradicts deposition testi ony and should 
be stricken pursuant to the sha  affidavit rule; 
SEC'S TI  T  STRIK  SECON  AFFIDAVI   GEROL  S. Y ST, PH.D FIL  I  SUPPOR  OF 
PLAINTIFF'S OTION FOR RECONSIDERATION - Page I 14542-  ( 08382 doc) 
2 The Second Yost Affidavit does not provide any explanation as to why his
testimony has changed from that testimony given during his deposition on April
19 2011 and
3 The Second Yost Affidavit relies on facts and data not previously disclosed in
discovery in violation of Idaho Rules of Civil Procedure 26
This Motion is further supported by the Idaho Rules of Civil Procedure this Court
Scheduling Order the Register of Actions in this case and applicable Idaho law
Oral argument is requested
DATED this
T
day of August 2011
GREENER BURKE SHOEMAKER PA
7
Christopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
SECMOTION TO STRIKE SECOND AFFIDAVIT OF GEROLD S YOST PHDFILED IN SUPPORT OF
PLAINTIFF MOTION FOR RECONSIDERATION Page 2 14542 011 408382doc
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing SEC MOTION TO STRIKE
PORTIONS OF SECOND AFFIDAVIT OF GEROLD S YOST PHDFILED IN SUPPORT OF
PLAINTIFFSMOTION FOR RECONSIDERATION on the following named personson the
date indicated below in the manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
ViaUS Mail
Via Hand Delivery
Via Facsimile 2084898988
Via Overnight Delivery
P O Box 7808
Boise Idaho 83707
DATED thisZ day ofAugust 2011
76a
Chri topher C Burke
Thomas J Lloyd III
SEC MOTION TO STRIKE SECOND AFFIDAVIT OF GEROLD S YOST PHDFILED IN SUPPORT OF
PLAINTIFF MOTION FOR RECONSIDERATION Page 3 14542 011 408382doc
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ByJERIHEATON
DEPUTY
Christopher C Burke ISB 42098
Thomas J Lloyd III ISB 47772
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise Idaho 83702
Tel 208 3192600
Fax 208 3192601
Attorneys for Defendant
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
V
SECURITY EQUIPMENT
CORPORATION a Missouri corporation
CaseNo CVPI1003515
AFFIDAVIT OF THOMAS J LLOYD III
IN SUPPORT SECMOTION TO
STRIKE PORTIONS OF THE SECOND
AFFIDAVIT OF GAROLD S YOST PhD
Defendant
STATE OF IDAHO
ss
County of Ada
I Thomas J Lloyd III being first duly sworn upon oath state as follows
1 I am one of the attorneys of record for Defendant Security Equipment Corporation
SEC or Defendant and make this Affidavit in support of DefendantsMotion to Strike
Portions of the Second Affidavit of Garold S Yost PhDbased upon personal knowledge
2 I attended and argued at the hearing held before this Court on July 14 2011 in the
above captioned matter Attached hereto as Exhibit A is a true and correct copy ofthe
Transcript of Proceedings from the July 14 2011 hearing
AFFIDAVIT OF THOMAS J LLOYD III IN SUPPORT SEC MOTION TO STRIKE PORTIONS OF THE
SECOND AFFIDAVIT OF GAROLD S YOSTPhDPage 1 14542 011 407782doc
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Christopher C. Burke, ISB #2098 
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I, Thomas 1. Lloyd III, being first duly sworn upon oath, state as follows: 
. I a  one of the attorneys of record for efendant Security Equip ent Corporation 
("S "  "Defen t"), and ake this ffidavit in support f efendant's otion to trike 
ti   t   id it  r l  . st, h.D.,   r l l dge. 
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above-captioned matter. Attached hereto as Exhibit A is a true and correct copy ofthe 
Transcript of Proceedings from the July 14,2011 hearing. 
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DATED this LD day of August 2011
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OF 1P
Notary Public f bD
Residing at I
Commission Expires
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Affidavit of Thomas J Lloyd
III in Support of SECsMotion to Strike Portions of the Second Affidavit ofGarold S
Yost PhDto be served on the following named persons on the date indicated below in the
manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
P O Box 7808
Boise Idaho 83707
r
DATED this 1 day of August 2011
Y
Thomas J Lloyd III
AND SWORN TO before me this lW day of August 2011
ViaUS Mail
Via Hand Delivery
Via Facsimile 2084898988
Via Overnight Delivery
Christopher C Burk
Thomas J Lloyd III
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In The District Court of the Fourth Judicial District
In and for the County of Ada
BILLIE JO MAJOR an individual Case No CV PI 1003515
Plaintiff
Vs
SECURITY EQUIPMENT CORPORATION
A Missouri corporation
Defendant
TRANSCRIPT OF PROCEEDINGS
Held on July 14 2011 before Cheri C Copsey district court
judge
For the Plaintiff Darwin Overson
JONES SWARTZ
1673 W Shoreline Drive Suite 200
Boise Idaho 83707
For the Defendant Christopher C Burke
Thomas J Lloyd
GREENER BURKE SHOEMAKER
950 W Bannock Street Suite 900
Boise Idaho 83702
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1 BOISE IDAHO JULY 141H 2011 1 cases every year Thatsby and large a lot more
2 THE COURT All right Counsel I decided 2 than almost all of the other districts There are
3 to go forward with this hearing but I can tell 3 some districts that only get 100 The caseload
4 you that the cross motion for summary judgment was 4 here is horrendous
5 really not properly filed Now Imgoing to 5 So I would suggest to both sides to
6 consider it in an exercise of discretion 6 take that in mind because youregoing to have
7 Let me explain something When I set a 7 that problem with every single judge We are
8 schedule I expect the parties to complywith the 8 extremely overloaded I cannot read things and
9 schedule You can set a cross motion without 9 Imsomebody who likes to come in having read all
10 the courts consent And you certainly dontjust 10 of the material And when you put me in that
11 notice it up forhearing Its not proper and I 11 position it is very difficult
12 could as I said just ignore it Imnot going 12 So yesterday when my clerk pointed out
13 to 13 that we had these additional documents filed and
14 Iri addition in addition when people 14 I know wehad stuff filed on July 11th as well so
15 file things at49 less than 48 hours before the 15 its both sideshere I decided initially I
16 hearing Imnot going to consider it And the 16 decided that I just was going to change the whole
17 reasonImnot is this I donthave time to read 17 motions However Ive read all of the motions
18 it I have been working lets see 60hour 18 not the documents that were filed July 11th and
19 weeks Ive been coming in at600 in the 19 July 12th I haventread them I cannot rule on
20 morning Imon the bench all day as I was 20 them
21 yesterday I didntsee this document I do not 21 Idecided I think this is straight
22 have time to read it 22 forward enough that I should be able to address it
23 NowImgoing to I want you to 23 without additional time But I really need you to
24 understand this judicial district is getting 24 understand what is going on here in the 4th
25 approximately each judge approximately 600 new 25 Judicial District
4 5
1 In addition to all of that we have one 1 that yesterday initially we said wer not going
2 judge who is being used by the Supreme Court for 2 to hear this today welljust reschedule it And
3 education purposes Hes only here two days a 3 if we rescheduled it were really talking about
4 week So when thathappens the caseload goes up 4 probably the first week in September because of
5 This up until June 30th every one of the 5 whatsgoing on
6 district court judges got almost 300 its 290 6 Imin a little more unique position
7 some newcases filed and those are new cases 7 than some of the other district court judges
8 filed 8 because one of the cases thatImworking on the
9 So youneed to take that into 9 legislature by legislation requires it to be given
10 consideration when youre filing all of this 10 priority over all cases every single case out
11 Itsthe reason weadopted some page limitations 11 there to the point if necessaryImsupposed to
12 and things of that nature We just have to 12 cancel trials to take care of the case So I
13 because and Imnot just talking about myself 13 again apologize there was that confusion but I
14 Imtalking about all of the judges Thatswhy 14 should be able to address this here
15 youregoing to see a lot more a lot more 15 Now one thing I did want to make sure
16 control being placed by the judges on the schedule 16 that I understood and Ihave read all of the
17 and by whatsbeing filed Thatswhy I know I 17 material other than the things from July 11th on
18 and at least two other judges that Imaware of 18 I justhaven read it and I believe those are
19 require you to file your documents request a 19 motions to strike in any event
20 hearing date allow me to look at them to 20 As I understand it there the
21 determine if itssomething that can be handled on 21 plaintiff in this case agrees that there should be
22 just regular civil rules so it is 28 days or if 22 a dismissal of the express warranty claim
23 its something that really needs more time 23 MR OVERSON Thats correct YourHonor
24 SoImgoing to go ahead and hear both 24 THE COURT Okay Andat least I got that
25 the motion and the cross motion And I apologize 126 right All right Now if each side and I
Kim Madsen Official Court Reporter boise ldano ua15Zu11 u1s0c rrl001307
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1 think the way I read it the motions and cross 1 THE COURT Not only was it tardy itsan
2 motions are really dealing with pretty similar 2 amendment of an earlier affidavit and I didn
3 issues So Idontknow I dontreally care 3 read the motions to strike but generally amended
4 which one of you wants to go first but total 15 4 affidavits are not considered
5 minutes both sides total because I have another 5 MRLLOYD Okay
6 matterat400oclock So who would like to 6 THE COURT Okay And not only that if I
7 initiate it 7 were to do that then that reopens your ability
8 MRLLOYD Your Honor with your permission 8 this thing can go on forever And so generally
9 Iwould like to initiate it 9 unless the amendment doesn materially change
10 THE COURT Sure 10 anything if itsjust just a matter of
11 MR LLOYD Your Honor just one point of 11 formatting then thats one thing But otherwise
12 clarification First an introduction I dont 12 the reason we dontdo that especially if theres
13 believeIve ever been before you My name is Tom 13 an objection filed is that at some point you got
14 Lloyd Im with the firm of Greener Burke 14 to be able to make a decision
15 Shoemaker here on behalf of Security Equipment 15 SoIm at this point and is it
16 Corp 16 Mr Overson whosgoing to argue for
17 One point of the clarification on your 17 MR OVERSON Yes Your Honor
18 comments just before we began or as we began 18 THE COURT Okay And I did not know that
19 today One of the motions to strike that was 19 that was the basis of the motion to strike but
20 filed in fact the one that was filed on July 20 unless there a good reason and unless its
21 11th was amotion to strike an affidavit that was 21 not a material change Imjust considering the
22 served very tardy And soIm trying to 22 affidavits as I read them at the verybeginning
23 understand if the court will be considering that 23 Go ahead
24 affidavit on the motion for summary judgment or 24 MR LLOYD Okay
25 not It will just help me frame my argument 25 THE COURT And I feel bad for you counsel
8 9
1 this is not a good way to be introduced to me 1 For purposes of our motion for summary
2 MR LLOYD I completely 2 judgment Your Honor we are I guess focusing on
3 THE COURT So I apologize 3 the question of whether ornot a duty exists that
4 MR LLOYD No apology is necessary Your 4 SEC which is Security Equipment Corp which I
5 Honor To take up our motion for summary 5 will refer to as SEC whether SEC had a duty to
6 judgment initially whenwe filed this and the 6 in fact warn against an effect that was really
7 court is well aware of well aware of the facts 7 not a chronic effect a longterm effect
8 1 trust that youveread thebriefing albeit 8 And before we get to that I should
9 under under the schedule that you have and I 9 mention briefly on the issue of the warranty
10 also understand that Your Honor has additional 10 claims now when discovery was still going on in
11 hearings beyond this one today 11 this case Your Honor as we have briefed there
12 So in the interest of brevity I would 12 was a discovery question put out an interrogatory
13 like to sort of truncate the factual basis 13 put out asking for the basis for the warranty
14 factual background of this case I believe it is 14 claims There also a request for production of
15 well briefed byboth sides 15 documents asking for any documents that support
16 And so more to the point what wer 16 the warranty claims
17 dealing with is in fact whatsknown as a 17 In response to that we received an
18 defensive weapon I mean wer dealing with a 18 indication from opposing counsel and from the
19 product that is used by law enforcement by 19 plaintiff that the warranty that the plaintiff
20 military and by consumers worldwide to ward off 20 would no longer be pursuing the warranty claim
21 individuals assailants to keep crowd control to 21 Now the way we interpreted that
22 maintain control of prisons everything of that 22 because there was no there was no language
23 nature All known effects of this particular 23 clarifying warranty claim was number one it was
24 product are temporary They are reversible 24 sort of perhaps odd phrasing of it but I dont
25 theyr transitory and theyr recoverable 25 think uncommon to refer to all warranty claims as
uts1szull01362PM Kim Madsen Official Court Reporter Boise Idaho 001308
AJOR VS SEQUIRTY EQUIP ENT CORP CVPI1003515 
  
1      it,       URT: ot only as it tardy, it's an 
2 ti s r  r all  ali  it  r tt  si il r 2 t f  earli r affi vit  I didn't 
3 issues. So I don't kno  -- I on't r ll  c r  3 read the otions to strike, but generally a ended 
4   f     t, t t t l  4 f  r  t onsidered. 
5 i t s,   tal,      R. LL YD: kay. 
6 tt r t :00 'clo k.   l  li  t    URT: kay. nd not only that, if I 
7 initiate it? 7 r  t   t t, t  t t r s r abilit  --
8 R. YD:  r, t   r i i   this thing can go on forever. nd so generally 
9 I ould like to initiate it.  unless the a end ent doesn't aterially change 
10 T E T: Sure.  anything, if it's just -- just a atter of 
11 . D: r r, j st  i t f  for atting, then that's one thing. But otherwise 
12 l ri i ti . i t  i t cti n,  on't  the reason we don't do that, especially if there's 
13 elie e I've e er ee  ef re .  a e is   an objection filed, is that at some point you got 
14 l . I'm it  t  fir  f r ner, r  &        cision. 
15 r re  lf f curit  i t   I'm -- t t is i t -- a  is it 
16 r .  r. verson ho's going to argue for --
17 e    ication    . : s,  nor. 
18 c e ts j st ef re e e a  r as e e a    RT: ay.  I i  t  t at 
19 .    s   t as  t t as t  i  f t  ti  t  tri e, t 
20 ,  t,    as ile     unless there's a good reason --   t's 
21    ion  e  f     not a aterial change, I'm just considering the 
22 served very tardy. nd so I'm trying to  affidavits as I read them at the very beginning. 
23 rst  if t  rt ill  si ri  t t 23  a ead. 
 affidavit on the otion for su ary judg ent or  . D: kay. 
 not. It ill just help e fra e y argu ent.  T E C RT: nd I feel bad for you, counsel, 
  
 is s       roduced  .  or purposes of r otion for su ary 
2 . : I l t l  --  judgment, Your Honor, we are, I guess, focusing on 
  : o I apologize.  the question of whether or not a duty exists that 
4 . : o l  is ss r , r 4 SEC, which is Security Equip ent Corp., which I 
5 r.  t   r tion f r r   will refer to as SEC, whether SEC had a duty to, 
 jud t, i itially  e ile  is --  t e  in fact, warn against an effect that was really 
  is l are  --  are   .  not a chronic effect, a long-ter  effect. 
8 I trust that you've read the briefing, albeit  nd before e get to that, I should 
9 under -- er the schedule that ou have, a  I 9 mention briefly on the issue of the warranty 
  erstand  o  onor s   claims, now when discovery was still going on in 
11 hearings beyond this one today.  this case, our onor, as e have briefed, there 
12  in t e i terest f re it , I l   was a discovery question put out, an interrogatory 
 like t  s t f truncate the fa t  i ,  put out asking for the basis for the arranty 
14 factual a ground  this .  lie e it is  clai s. here's also a request for production of 
15 ell riefe   both si es.  documents asking for any documents that support 
1  nd so ore to the point, hat e're  the arranty clai s. 
17 dealing ith is, in fact, at's no n as a  In response to that we received an 
18 defensive eapon. I ean, e're dealing ith a  indication from opposing counsel and from the 
 product that is sed  a  t,   plaintiff that the arranty -- that the plaintiff 
20 ilitary and by nsu ers rld-wide to a  f 20 would no longer be pursuing the warranty claim. 
21 individuals, assailants, to keep cro d control, to 21 o , the ay e interpreted that, 
22 aintain control of prisons, everything of t at 2  because t e  as  -- there was no language 
2  nat r . ll kno n ffects f this rticular 23 clarifying warranty clai , was, nu ber one, it was 
24 product are te porary. hey are reversible, 2  sort of perhaps odd phrasing of it, but I don't 
25 t ey're transitory and t ey're reco era le. 25 think uncommon to refer to all warranty claims as 
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1 Now there is a slight difference there
2 on the cross motion and exactly what wer
3 talking butIm going to save that perhaps until
4 my final comments
5 And so with respect to that duty we
6 also have to establish furtherframing this debate
7 that there is in fact a difference between acute
8 and chronic adverse health effects because the
9 ultimate question here is what is the plaintiffs
10 injury If we were here to discuss whether the
11 plaintiff had suffered an acute adverse reaction
12 toOCspray I dontthink in fact we would be
13 here there would be no injury there would be no
14 damage
15 And so by plaintiffsown admission
16 this has to be in order for this case to even
17 be in this courtroom today has to be about a
18 chronic adverse effect And this I think goes
19 across many lines not just limited to the context
20 ofOC spray
21 As I mentioned inthe briefing if we
22 have a drug manufacturer who knows that its
23 product is going to cause an acute reaction
24 perhaps temporary blindness light sensitivity
25 stiffness of joints theres not going to be th
1 attendant responsibility of that manufacturer to
2 warn against something that is chronic something
3 that has never happened a complete blindness a
4 permanent blindness a loss of limb for example
5 a permanent paralysis
6 And so I think we have to look at every
7 quote thatsput in the briefing in that context
8 because I think taken out of context we start to
9 blur the lines of actually what wer discussing
10 here We start to blur what is the plaintiffs
11 ultimate injury
12 With that in mind we go to perhaps the
13 first basis and what we contend is the primary
14 basis for our motion for summary judgment both to
15 the strict liability and to the failure to warn
16 claims
17 Now as we stated in the briefing a
18 requirement forstrict liability and failure to
19 warn is that the injury complained of had to have
20 been known or foreseeable at the time the product
21 was sold so that the manufacturer has basically a
22 fair opportunity to warn against that particular
23 injury Or you know there are circumstances to
24 design around that particular risk And so this
25 concept applies to both the third and fourth
Kim Madsen Official Court Reporter Boise Idaho 0815201101367PM
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1 a warranty claim 1 simply has no privity of contract here The
2 Now in response to this to our motion 2 product was not sold directly to the plaintiff
3 for summary judgment I understand that the 3 The product was not even sold directly to the
4 plaintiff has asked that we go back in time and 4 plaintiffsemployer The product wassold to a
5 understand that not only was perhaps a letter if 5 third party who then sold it to the plaintiff
6 anything was omitted from that answer of warranty 6 And we contend the privity the lack of privity
7 claims but actually an entire word which did 7 there destroys any potential warranty claims
8 demonstrate for us that we should have been able 8 But I think maybe more to the heart of
9 to divine that information through no othermeans 9 the matter and before I do this and this goes
10 but our best guessing 10 to the strict liability claim and this goes to the
11 On thatbasis we did not pursue any 11 failure to warn claim Counts Three and Four of
12 additional discovery This wasa representation 12 the plaintiffscomplaint what I would like to do
13 made ina court document We didntpursue any 13 is perhaps frame the duty or frame the rest of
14 additional discovery based on the warranty claim 14 the debate
15 that was going to be dismissed and we weoppose 15 Number one as Ive already mentioned
16 the plaintiff about the warranty claim anything 16 what wer talking about here is a duty whether a
17 of that nature And so we do we domaintain 17 duty exists under the applicable law that SEC
18 and thiswill all this will be all I say about 18 should have had an obligation to have warned
19 this that the principle of judicial estoppel 19 against chronic longterm health effects adverse
20 truly does prevent the plaintiff from coming back 20 health effects to the plaintiff Whatwer not
21 in now after the deadlines for motions for summary 21 talking about here is causation Wer not
22 judgment to further litigate the warranty claim 22 talking whether the plaintiff injuries actually
23 notwithstanding the fact that even if the warranty 23 were caused by exposure to Oleoresin Capsicum
24 claim were to come in were to come into this 24 spray which Ill refer to asOC spray for ease
25 courtroom today and into trial the plaintiff 25 of reference
001309
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   i .  si l  as  ri it  f c tract ere. e 
2 , i  r s se t  t is, t  r ti  2 r t s t s l  ir tl  t  t  l intiff. 
   t,      he product as not even sold directly to the 
4 l i tiff s s  t t    i  ti   4 plaintiff's e ployer. The product was sold to a 
 understand that not only as perhaps a letter, if  third party ho then sold it to the plaintiff. 
6 a ything, as itte  fr  t at a s er f arra t     t  t  ri it  -- t  l  f ri it  
7 l i s, t t ll   tire r , i  i   there destroys any potential arranty clai s. 
8      l      But I think maybe more to the heart of 
 to divine that infor ation through no other eans   tt r -- and before I do this, and this goes 
 t r est essi g.  t  t e strict lia ilit  clai  a  t is es t  t e 
       s       l i ,     f 
 iti l is ry. is s  r r s t ti   the plaintiff's co plaint, hat I would like to do 
 ade in a court docu ent. e didn't pursue any  is perhaps fra e the duty --  f    f 
14 a iti al isc er  ase   t e arra t  clai   t  te. 
15 t t  i  t   i iss    --    r e,  I've lr  ti , 
 t  l i ti  t t  t  l i , t i   hat e're talking about here is a duty, hether a 
   t re.     -- e  i tain,  duty exists under the applicable law that SEC 
18 a  t is ill all -- this ill be all I say about 18 should have had an obligation to have arned 
 t i  -- that the principle of judicial estoppel  against chronic long-ter  health effects, adverse 
 tr l  s r t t  l i tiff fr  i    health effects to the plaintiff. hat e're not 
 in no  after the deadlines for otions for su ary  talking about here is causation. e're not 
22 judg ent t  f rt r litigate t  rr t  l i , 22 talking hether the plaintiff's injuries actually 
 not ithstanding the fact that even if the arranty  ere caused by exposure to leoresin apsicu  
 l i  r  t   i  -- ere      spray, hich I'll refer to as .c. spray for ease 
 t  t a   i t  t i l, t  l i ti    . 
12 13 
1 , t ere is a sli t iffere ce t ere  attendant responsibility of that anufacturer to 
  t  r s  ti   tl  t e're  warn against something that is chronic, something 
 tal i , t I'm i  t  sa e t at er a s til 3 that has never happened, a co plete blindness, a 
4  fi l ts.  per anent blindness, a loss of li b, for exa ple, 
5 nd so ith respect to that duty, e  a per anent paralysis. 
 ls   t  st lis  f rt r fra i  t is t   nd so I think e have to look at every 
 t a   , n t,  ference    quote that's put in the briefing in that context 
   rse  e t  s  e  s       text,    
 ltimate sti  ere is hat is t  l i tiff's 9 blur the lines of actually hat e're discussing 
 i j r . If e r  re t  is ss ether t   here. e start to blur hat is the plaintiff's 
 plaintiff a  suffered a  acute adverse reaction  ultimate injury. 
 t  .c. s ra , I n't t i , in fact, e ld   ith that in ind, we go to perhaps the 
13 , t e l  e  i j , t  l  e   first basis and hat e contend is the pri ary 
14 da age.  basis for our motion for summary judgment, both to 
 nd so by plaintiff's o n ad ission  the strict liability and to the failure to arn 
 t is as t   -- in rder  t i   t    i s. 
 be in this courtroo  today has to be about a  o , as e stated in the briefing, a 
 chronic adverse effect. nd this, I think, goes  require ent for strict liability and failure to 
 acr ss a  li es, t just li ite  t  t e c te t  warn is that the injury complained of had to have 
 of o.c. spray.  been known or foreseeable at the time the product 
 s I entioned in the briefing, if e  was sold so that the manufacturer has basically a 
 a e a r  a fact rer  s t at its  fair opportunity to arn against that particular 
 ro t is i  t  se  te r ti ,  injury. Or, you know, there are circumstances to 
 perhaps temporary blindness, light sensitivity,  design around that particular risk. And so this 
 stiffness of joints, there's not going to be the  concept applies to both the third and fourth 
i  s , ffiCial rt rt r, is , I  8/15/2011 01:36:27  
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causes of action the plaintiff has raised
Now in our briefing papers we have
brought forth affidavit testimony of experts in
the field particularly that of Dr Reilly who
indicates what somewhat difficult to do in
certain circumstances and that is hes proven the
absence of something He has indicated that there
is in fact no scientific knowledge no
definitive study no case study case report
test anything of that nature that would give rise
to an inference that there is a known foreseeable
risk of chronic longterm adverse health effects
Now in response the plaintiff has
filed well they plaintiffs failed to meet
her burden frankly In response what she has done
is she has filed the affidavit of Dr Yost One
ofDr Yosts biggest contentions is well Dr
Reilly overgeneralized He made hemade
statements too much in the absolute
But what he doesntdo notably
throughout his affidavit is actually contrast He
doesn he doesn look at those articles that
were in some casescoauth red by the two of them
and say no actually this article says it and
heres where it says it He doesn meet that
is saying that this is this the possible
effect on chronic condition that would cause a
chronic condition in fact was well known How
do I I mean how do I ignore that
MR LLOYD Well YourHonor its not a
matter of making a credibility decision
determination what we contend and this goes
along with the motion that we haventquite hit on
yet and thatsour motion to strike his affidavit
as being a sham affidavit Now the law is well
settled on this that when a deponent or when a
witness has been deposed under oath and has made
affirmative statements regarding certain topics
he cantcome back and say something thats
completely contrary to that
Now on that basis wev moved to
strike certain of Dr Yoststestimony Now
wer not seeking to strike the entire thing In
fact the entire thing with the exception of the
three particular parts we believe is actually
opining as to the actual causation between
exposure toOC spray and in other words the
medical diagnosis plaintiff chronic longterm
health effects
And on those three points Your Honor
1
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we do consider this to be a sham and that is
because prior to this affidavit in coming forth
he was deposed on these issues
One of the other things that I think we
made a point of in our motion to strike his
testimony is that again we have to make the
distinction between acuteeffects and chronic
effects Some of his statements are in fact too
vague to be able to determine whether hes
referring to chronic effects or acute effects
Paragraph six for example he does say
that the risks of the risks to the respiratory
trackwere known and foreseeable Well that begs
the question which risks are we talking about
Yes the risk to the acute effects the acute
reaction that was known and foreseeable But
thatsnot what plaintiff is complaining about and
so thatsnot relevant
To the extent thathe is saying that
chronic effects were known and foreseeable that
those risks were known and foreseeable thats
directly contrary to his affidavit testimony or
to his deposition testimony where he said I
dontthink that existed then referring to any
scientificknowledge in March of 2008 when the
08152011013627PM Kim Madsen Official Court Reporter Boise taano 001310
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1 causes of action the plaintiff has raised. 1 burden of showing there is actually a genuine 
2 o , in our briefing papers we have 2 issue. He says Dr. Reilly overgeneralizes, but he 
3 brought forth affidavit testimony of experts in 3 doesn't say how and he doesn't point to where in 
4 the field, particularly that of Dr. Reilly, who 4 any of that documentation there is evidence of a 
5 indicates at's s e hat d fficu t to d  in  known or foreseeable risk of long-term chronic 
6 certain circu stances, and that is he's proven the  health conditions. 
7 absence of so ething. e has indicated that there  THE COURT: Well, he doesn't use that 
 is, in fact, no scientific knowledge, no  language, but doesn't he -- I'm looking at his 
 definitive study, no case study, case report, 9 affidavit now. This is Dr. Yost? 
10 test, anything of that nature that would give rise  MR. LLOYD: Right. 
11 to  inference t at there is  no n forese   THE COURT: And he cites to these articles 
12 risk of chronic, long-term adverse health effects.  and he says, and this is -- here's my problem, 
13 Now, in response, the plaintiff has  because the biggest problem I have is I can't make 
 filed -- well, they -- plaintiff's failed to meet  credibility determinations. I mean, that's a -- I 
 her burden frankly. In response hat she has done  just can't do that. 
 is   file  t e ida it  r. t. e  He says it's now known -- it's known 
 of Dr. Yost's biggest contentions is, well, Dr.  now and it was known prior to 2008 that people 
 Reilly overgeneralized. He made --  a e  with asthma and chronic cough are more sensitive 
19 e ts   n e l .  to pepper spray than others. And he says people 
 But hat he doesn't do notably  with greater sensitivity to capsacin would be 
 throughout his affidavit is actually contrast. He  expected to have increased TRPVl receptor 
 n't -  sn't  t s  cles   populations. And then he talks about how they are 
 ere in so e cases co-authored by the t o of the   activated by irritants including cigarette smoke 
 and say, no, actually this article says it and  and other environmental sources. 
 re's ere it s it.  sn't t t t  And he goes -- it seems to me that he 
16 17 
1 is saying that this is --  -- the possible    i  t i  t      t t i  
 ff t  r i  ition --  d    because prior to this affidavit in co ing forth, 
 chronic condition, in fact, as ell kno n. o   he as deposed on these issues. 
   -- I mean, how do I ignore that?   f t  t r t i s t t I t i   
5 . : ll,  or, it's t   ade a point of in our otion to strike his 
 matter of making a credibility decision --  testi ony is that, again, e have to ake the 
 determination, what we contend, and this goes  i t   t    i  
 along with the motion that we haven't quite hit on  ff cts.    t  re,  ct,  
 yet, and that's our motion to strike his affidavit  vague to be able to determine whether he's 
 as being a sham affidavit. Now, the law is well  referring to chronic effects or acute effects. 
 settled on this, that when a deponent --     Paragraph six, for exa ple, he does say 
 witness has been deposed under oath and has made  t   f --   t  t  pir t r  
 affirmative statements regarding certain topics,  tr  r    f r seeable. ell, t t s 
 he can't come back and say something that's  the question, hich risks are e talking about. 
 completely contrary to that.  s,      ff cts,   
 o , on that basis e've oved to  r cti , t t    f r eeable. t 
 strike certain of Dr. Yost's testi ony. Now,  that's not what plaintiff is co plaining about and 
18 we're not seeking to strike the entire thing. In 18 s  that's t l vant. 
19 fact, the entire thing, with the exception of the 19  t   t at  i  sayi  t t 
 three particular parts, we believe is actually 20 r i  f    an  f eeable, t  
21 opining as to the actual causation between 21 t      f seeable, that's 
22 exposure to O.c. spray and -- i  ot r rds, t  22 irectl  c trar  t  his affi a it testi ny -- or 
23 medical diagnosis, plaintiff's chronic long-term 23 to his deposition testi ony here he said, "I 
 health effects. 24 on't t i  t t exi t  then," r f rri  t  any 
25 And on those three points, Your Honor, 25 scientific knowledge in arch of 2008 when the 
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plaintiff was last exposed to this product
He furtherexplained that even today
its not definitively known But he opines that
based on his gathering of a variety of
circumstantial evidence some of which he cited
and some of which was not available in March of
2008 But it was unequivocal in his deposition
testimony Idontthink that existed then
So to the extent that he is making an
alternative statement now we domove to quash
that We contend itsasham We believe itsa
sham and it is directly contrary to what he
testified to in his deposition
And whileImon this point I will hit
those two other categories Paragraph six is
is really referring to the known and foreseeable
standard Paragraph ten is where inDr Yosts
affidavit thatswhere he talks about death
the couple of instances of death that were
apparently the result of exposure toOC spray
We contend this is a non starter And the reason
this is a non starter is because frankly again
wer talking about apples and oranges
In these few instances again looking
back to Dr Yosts deposition testimony hes
20
We have now done that And again the
court can review this in the context ofDr Yosts
testimony during his deposition At that time he
made clear that that article simply referred to
greater acute effects in people with existing
with existingchronic cough He did not make any
statement then was in fact asked and asked
if that was a fair representation of what the
article was about He said yes it was That
article was solely relating to what increase acute
effects would happen to somebody who is in fact
already suffering from chronic cough Now thats
theresanother sort of internal
THE COURT Is that the part where he
testifies substantial evidence he testifies in
his deposition substantial evidence that the pain
irritation lacrimation et cetera that we talked
about before is not long It doesn persist for
weeks and months in other words it is acute not
chronic
MR LLOYD Yes Your Honor I believe that
is the the exact testimony
And so to the extent that getting
back to our motion for summary judgment To the
extent that Dr Yost has presented testimony that
1 admitted that these were products of acute
2 reactions with aggravating factors drugs
3 alcohol physical confinement physical restraint
4 These were not however instances of death that
5 followed a long chronic degradation or failing
6 health of the individual
7 So again to the extent that Dr Yost
8 is opining that death is a longterm effect of
9 exposure toOCspray I really think thatsa
10 strong argument and at the end of the day thats
11 not what were here for Plaintiff was sitting
12 here I believe in the courtroom when we began
13 this hearing and to my knowledge has not deceased
14 since she left this courtroom
15 Paragraph 12 goes to what I think is
16 probably the most contentious article and thats
17 the Groneberg 2004 article Now that article
18 wev now presented to the court Plaintiff
19 well the plaintiff and Dr Yost relied heavily on
20 this 2004 article as sort of the cornerstone the
21 light at the end of the tunnel as to whether there
22 was a known and foreseeable risk to exposure to
23 OC spray However neither Dr Yost nor the
24 plaintiff presented that article to the court for
25 the courtsown review
21
1 would call into question this known and
2 foreseeable standard thatwev presented all of
3 that testimony is a sham because all of that
4 testimony is directly contrary to what he
5 testified to duringhis deposition Itwas clear
6 It was unequivocal that in 2008 when plaintiff was
7 last exposed toOC spray manufactured by SEC
8 therewasno scientific available scientific
9 literature demonstrating that longterm chronic
10 effects would occur as a result of exposure to
11 OCspray According to Dr Yost I dont think
12 that existed then
13 So I guess again getting back to
14 the point of what Dr Yost then further contends
15 in his in his affidavit He disagrees with Dr
16 Reilly saying that Dr Reillysmade statements
17 that are too absolute and that you cant you
18 cantnecessarily make those statements based on
19 the articles that existed that hes listed and
20 thereseleven articles
21 However whats interesting about Dr
22 Yosts statement is that he then proceeds to make
23 the very absolute statement that in 2008 this was
24 known and foreseeable Again we believe thats a
25 sham and we dontbelieve that it should be
Kim Madsen Official Court Reporter Boise Idaho uts11JLull u1SOLrm001311
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 plaintiff as last exposed to this product. 1 itted that these ere roducts f te 
2 He further explained that even today 2 reactions ith aggravating factors; drugs, 
3 it's not definitively known. But he opines that 3 alc l, sical c fine e t, sical restrai t. 
4 based on his gathering of a variety of  hese e t, , instances f th t at 
 circu stantial evidence, so e of hich he cited  followed a long chronic degradation or failing 
6 d s e  ich as t la le n a  f 6 th   l. 
7 2008. ut it as unequivocal in his deposition  So, again, to the extent that r. ost 
8 testi ony, "I don't think that existed then."  is opining that death is a long-term effect of 
 So to the extent that he is making an  exposure to .c. spray, I really think that's a 
 alternative state ent now, we do ove to quash  strong argu ent and at the end of the day that's 
11 t . e te  t's  . e ieve t's    at 're ere . i  s  
 sha  and it is directly contrary to what he  , I , in e  e  e  
 testified to in his deposition.  this hearing and to y kno ledge has not deceased 
 And while I'm on this point, I will hit  ce    . 
 those t o other categories. Paragraph six is --  r r   es t  t I t i  is 
 is really referring to the known and foreseeable  probably the ost contentious article and that's 
 standard. Paragraph ten is here in r. ost's  the roneberg 2004 article. o , that article 
 ida t -- t at's ere  t l s t t ,  e've no  presented to the court. Plaintiff--
 the couple of instances of death, that were  ell, the plaintiff and r. ost relied heavily on 
 apparently the result of exposure to .c. spray. 20 is  e     t ,  
  te     - rt r.  e   light at the end of the tunnel as to hether there 
 this is a non-starter is because, frankly, again,  as    f res l  ris  t  s re t  
 we're talking about apples and oranges.  .c. spray. o ever, neither r. ost nor the 
 In these few instances, again looking 24 plaintiff presented that article to the court for 
 back to Dr. Yost's deposition testimony, he's  t  urt's  i . 
 21 
 e have now done that. And, again, the  ld ll i t  sti  t is   
        f r. st's  e  t   e've nted, l   
 testi ony during his deposition. t that ti e he  t t t sti  is  s  s  ll f t t 
 made clear that that article simply referred to  testi ony is directly contrary to hat he 
 greater acute effects in people with existing --  testifie  t  ri  is eposition. It as clear. 
 with existing chronic cough. He did not make any  It as unequivocal that in 2008 hen plaintiff as 
 t t ent,  ,  ct,   --   last exposed to .c. spray anufactured by S , 
 if that was a fair representation of what the  r    ci ntif  -- il l  scientifi  
 article was about. He said, yes, it was. That  literature de onstrating that long-ter  chronic 
 article was solely relating to what increase acute  effects ould occur as a result of exposure to 
 effects would happen to somebody who is, in fact,  .c. spray. ccording to r. ost, I don't think 
 already suffering from chronic cough. Now, that's  t i  n. 
 -- ere's    l --  o I guess -- again, getting back to 
 THE COURT: Is that the part where he  the point of what Dr. Yost then further contends 
 ti  stanti l  --  stif      -- in his affidavit. e disagrees ith r. 
 his deposition substantial evidence that the pain,  eill  sayi  t at r. eilly's a e state e ts 
 irritation, lacri ation, et cetera, that e talked  that are too absolute and that you can't --  
 about before is not long. It doesn't persist for  can't ecessaril  a e t se state e ts ase   
 s  t s, i  t r r s, it is cute, t  t  rt  t xi  t  e's   
 hronic.  there's l  articl s. 
 R. LLOYD: Yes, Your Honor. I believe that 1 However, what's interesting about Dr. 
 i  t  -- the exact testimony.  ost's state ent is that he then proceeds to ake 
   t   t  t t -- getting  the very absolute statement that in 2008 this was 
 back to our motion for summary judgment. To the  kno n and foreseeable. gain, e believe that's a 
 extent that Dr. Yost has presented testimony that     on't l  t t i  shoul  be 
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considered But the fact of the matter is Reilly
Dr Reilly has been consistent throughout his
testimony both in his deposition and in his
affidavit Dr Yost on the other hand has
changed his position and we believe that the
reason hes changed his position is that his
affidavit testimony is a sham and should be
disregarded by this court
The final argument and IknowIm
running short on timehere Your Honor soIm
going to fast forward it The final argument that
wev presented with respect to the claims
asserted by defendant on the failure to warn by
the plaintiff on the failure to warn is that the
Federal Hazardous Substances Act the FHSA as
Illrefer to it preempts plaintiff cause of
action here Now again this is the one that
sorts to sort ofstarts to bleed between the
motion for summary judgment and the plaintiffs
crossmotion for partial summary judgment
We first raised this in our motion I
understand plaintiff in one of the recent filings
made a representation to the court that we did not
wedid not raise the issue of the Federal
Hazardous Substances Act the FHSA until our
24
And so the questionhas arisen then
what is the scope of the FHSA Because if the
scope of the FHSA includes the law enforcement
brandedOC spray products manufactured by SEC
then its going to preempt And plaintiffs
causes of action whether they be state law causes
of action or something under the federal OSHA
standard they are going to be preempted and she
not going to be able to litigate them here
The FHSA in the regulation is very
clear Its expanded to show any product that
under any reasonably foreseeable use could be
brought into around or used within a home or
other place where people dwell
Plaintiffsexpert Dr Purswell has
focused a lot of time on what the intended use of
this product is Dr Purswell fortunately is
was apparently not aware of the fact that this
product is also marketed to law enforcement who go
outside of the correctional facility
Ithinkwithin that issue itself we
have a bit of a debate because the regulations are
expansive and they do have abroad scope to any
place where people dwell
What it doesn include is something
UyrlIuyaal
23
1 reply brief on our motion for summary judgment
2 In fact it was as the court is well aware it
3 was briefed the preemption argument was briefed
4 in the motion for summaryjudgment
5 Now in response plaintiff came and
6 filed her own cross motion for summaryjudgment
7 going to the very heart of this matter And so to
8 speak of that what we have now is sort of a
9 debate between the FHSA and the OSHA standards
10 Well as we said in the briefing the
11 OSHA standards do not provide a private cause of
12 action And so plaintiff cannot bring a claim
13 necessarily on under OSHA She cantbring a
14 claim to federal court state court asserting a
15 violation of OSHA What she has to do is say
16 common law cause of action which is as I
17 understand it negligence per se in this instance
18 supported by with the evidence of the OSHA
19 standards
20 So the question again is not whether
21 FHSA preempts OSHA The question is whether the
22 FHSA preempts that state law cause of action which
23 would impose a different standard a greater
24 standard than thatwhich we contend is included
25 in the FHSA
1 where an individual goes to work works with the
2 product nobody else is really around and then
3 they go home they leave the product behind
4 Thatsnot what wer dealing with here Even
5 under Dr Purswellsformer understanding that
6 this was solely to be used within correctional
7 facilities frankly thats a place where people
8 dwell I mean that is a place where people eat
9 where they sleep where they live where they do
10 all of their exercises where they do their chores
11 and they do they do their work
12 This is not a product that is solely
13 foruse by an occupational person in for example
14 a manufacturing plant This is product that is
15 both intended and actually used based on the
16 affidavit testimony weprovided from Nick Roberts
17 now intended and actually used in and out of
18 correctional facilities in apartments in homes
19 wherever necessary Frankly wherever an
20 individual again a criminal or what have you
21 wherever that person can be found thatswhere
22 this product is going to be thatswhere this
23 product going to be used The plaintiff herself
24 has testified to having an officer come into her
25 home carrying the product and you know that she
08152011013627PM Kim Madsen Official Court Reporter Boise Idaho 001312
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 considered. But the fact of the atter is Reilly  re l  rief  r ti  f r r  j t. 
 -- r. eilly has been consistent throughout his  In fa t, t as -  e t   r , t 
 testi ony, both in his deposition and in his  as riefe  -- the ree tio  ar e t as riefe  
 it. . ,  e  ,   in the tion f r r  ju t. 
 changed his position and we believe that the  o , in response plaintiff ca e a  
 reason he's changed his position is that his  file  r  ross- tion f r r  judg ent 
 affidavit testi ony is a sha  and should be  going to the very heart of this atter. nd so to 
 disregarded by this court.  s  f t t, t  e  is s rt f  
 The final argument --    'm  te t ee  t    t   t rds. 
 running short on ti e here, Your Honor, so I'm  ell, as e said in the briefing, the 
 going to fast for ard it. he final argu ent that   standards do not provide a private cause of 
 e've rese ted ith res ect to t e clai s  ti . nd s  l i tiff t rin   l i  
 asserted by defendant on the failure to arn --   ril   - er A.  an't ing  
 the plaintiff on the failure to warn is that the  clai  t  fe eral c rt, state c rt asserti  a 
    t, e A,   iolation  A. t   t   i   
 I'll refer to it, pree pts plaintiff's cause of   a    ti ,  ,   
 tion r . , i , t is is t e e t t  rsta d it, li  r  i  t is i t , 
 ts  --   ts  ee  ee  t   supported by -- t   de ce f   
 otion for su ary judg ent and the plaintiff's  r s. 
 cross-motion for partial su ary judg ent.  So the question, again, is not hether 
 e irs  aise   in  .    ree ts . e esti  is et er t e 
 understand plaintiff in one of the recent filings  F S  pree pts that state la  cause of action hich 
 ade a representation to the court that e did not  l  i pose a iffere t sta ard, a reater 
 --  d  ise  s     24 r ,   c      
   t, e ,    i  t  . 
 25 
 nd so the question has arisen, then,  here an individual goes to ork, orks ith the 
 at is t e sc e f t e A? eca se if t e  r ct,  ls  is r ll  r ,  t  
 scope of the F S  includes the la  enforce ent  they go ho e, they leave the product behind. 
 branded o.c. spray's products manufactured by SEC,  That's not what we're dealing with here. Even 
 then it's going to pree pt. And plaintiff's 5 r r. rswell's f r r rst i  t t 
 causes of action, hether they be state la  causes  this as solely to be used ithin correctional 
 of action or so ething under the federal S   facilities, frankly, that's a place where people 
 standard, they are going to be pree pted and she's  ell. I n, t t is  l  r  le at, 
 not going to be able to litigate the  here.  where they sleep, where they live, where they do 
 he  in the regulation is very  all f t eir e ercises, ere t e   t eir c res 
 clear. It's expanded to show any product that  and they do -- they do their ork. 
 under any reasonably foreseeable use could be  his is not a product that is solely 
 brought into, around or used within a home or  for use by an occupational person in, for exa ple, 
 other place where people dwell.  a anufacturing plant. This is product that is 
 Plaintiff's expert, r. Purs ell, has  both intended and actually used, based on the 
       t  te   f  affidavit testi ony e provided fro  ick Roberts 
 this product is. Dr. Purswell fortunately is--  now, intended and actually used in and out of 
 was apparently not aware of the fact that this  correctional facilities, in apart ents, in ho es, 
 product is also arketed to la  enforce ent ho go  herever necessary. Frankly, herever an 
 outside of the correctional facility.  individual, again, a criminal or what have you, 
      l    wherever that person can be found, that's where 
 have a bit of a debate because the regulations are  this product is going to be -- at's   
 expansive and they do have a broad scope to any  product's going to be used. The plaintiff herself 
 place here people d ell.  has testified to having an officer co e into her 
 hat it doesn't include is something  home carrying the product, and, you know, that she 
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1
1 had her episode of coughing as a result of that 1
2 So again this isnta product that is 2
3 solely designed for what you would call 3
4 occupational use in the manufacturing plant 4
5 setting This is a product that goes out into the 5
6 public 6
7 Furthermore as we can see from the 7
8 the second affidavit ofRob Nance Bob Nance we 8
9 have a product thatSEC doesntparticularly sell 9
10 to the general consumers but thats solely the 10
11 result of arrangements they have with many of 11
12 their distributors What they do not do is they 12
13 do not put any stops on that product being 13
14 purchased by consumers And in fact he is 14
15 aware as he testified of at least 50 15
16 distributors that do sell that to the general 16
17 public 17
18 So this is a product that is very 18
19 reasonably foreseeable will make it out into the 19
20 general public will be used in homes apartments 20
21 places where people dwell even if that place 21
22 where people dwell is a correctional facility 22
23 itself 23
24 And so we believe very strongly that 24
25 the FHSA does apply in this situation And what 25
Now Iwant to close with one comment
2 briefly And Your Honor this arose as a result 2
3 of the final reply briefing to which we did not 3
4 have an opportunity to respond thatwas filed by 4
5 the plaintiff For the first time in that reply 5
6 briefing the plaintiff suggested that we did not 6
7 also comply with the FHSA Now Imnot going to 7
8 ask the courts permission to file additional 8
9 briefing I understand that the court is 9
10 overburdened and would not 10
11 THE COURT Well I may give you that 11
12 opportunity 12
13 MR LLOYD Well Your Honor I dontknow 13
14 that itsnecessary because there is there 14
15 is a case on point for this and the case thatIm 15
16 referring towev actually already cited but it 16
17 discusses the FHSA well and thats Chemical 17
18 Specialties Manufacturing Association Inc 18
19 versus Allenby 19
20 THE COURT And the citation I recognize 20
21 the name but what is the citation 21
22 MR LLOYD This is 958F2d941 Itsa 22
23 2000 or a 1992 case out of the 9th Circuit 23
24 And what this case establishes is and 24
25 1 quote Under the FHSA perhaps Ill preview 25
thats going to do is that going to do with
respect to plaintiffs cause actionunder the FHSA
and plaintiff cause of action for Im sorry
plaintiffs cause of action for negligent failure
to warn and plaintiff negligence per se cause of
action underOSHA because OSHA is very
specific its right in the regulations and it
says this this in the scope section of the
OSHA regulations it says this standard does not
apply if and one of those things is if the FHSA
applies
So we contend YourHonor andIll
wrap up my comments now we contend thatits a
legal question as to whether the FHSA applies We
contend that Dr Purswell opinions that it does
not when instead OSHA applies those are legal
opinions thathe is not qualified to make and
thats really a determination for this court to
make
And so on that basis webelieve that
those two causes of action whether they be under
a general negligence standard or a negligence per
se standard but based on alleged failure to warn
that those particular causes of action are
preempted by the FHSA
29
it thiswith one with one additional sentence
What I understand the plaintiffscontention to be
is under the FHSA we have not complied with the
labeling requirement And this case states
Under the FHSA and this would be in contrast to
OSHA all accompanying literature where there are
directions for usewritten or otherwise is
defined as cautionary labeling 15USCSection
1261 and 1262
Accompanying literature is thereafter
defined as follows Any placard pamphlet
booklet book signed or other written printed or
rapid matter or visual device and it provides
direction for use written or otherwise and that
is used in connection with display sale
demonstration or merchandizing of a hazardous
substance intended foruse in the household or by
children
So basically what its saying is that
the labeling requirement under the FHSA is not
like the labeling requirement under OSHA Under
OSHA as the plaintiff has contended that
labeling requirement means it has to be right on
that cannister it has to be on directly on the
product itself
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1 had her episode of coughing as a result of that.  that's going to do is that's going to do -- i  
2 o, gain, t is isn't  r t t t is  respect to plaintiffs cause action under the F SA 
3 l l  i     l  l  3 and plaintiff's cause of action for -- I'm sorry, 
4 ti l s  i  t  nuf cturi  l t 4 plaintiff's cause of action for negligent failure 
5 setting. his is a product that goes out into the  to arn and plaintiffs negligence per se cause of 
6 blic.  cti  r  -- because OSHA is very 
7 ,     f   -- 7 specific, it's right in the regulations, and it 
8 t e sec  affi a it f  a ce --  ce,   says this -- i  -- in the scope section of the 
9 have a product that S  doesn't particularly sell  S  regulations, it says this standard does not 
10 t  t e e eral c su ers, t t at's solel  t e  apply if, and one of those things is if the FHSA 
11 lt  t  t   it     applies. 
 i  tri t rs.           t nd, r nor,  'l  
13  t t  t   t t r t i   rap up y co ents now, e contend that it's a 
 purchased by consu ers. nd, in fact, he is  legal question as to hether the  applies. e 
15 r ,   stifi ,      contend that r. Purswell's opinions that it does 
 t s   l       not hen instead S  applies, those are legal 
 li .  opinions that he is not qualified to make and 
18 So this is a product that is very  that's really a deter ination for this court to 
 l  abl , ill e it t i t  t e  . 
20 e eral lic, ill e se  i  es, a art ents,         t  
 la  ere l  ell,  if t t l   those t o causes of action, hether they be under 
 ere e le ell is a c rrecti al facilit   a general negligence standard or a negligence per 
23 itself.  se standard, but based on alleged failure to arn, 
 nd s  e elie e er  str l  t at  that those particular causes of action are 
      is ti .    preempted by the FHSA. 
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1  I t t  l s  ith  t    th  -- t   it l t ce. 
 ri fl . , r r, t is r se   r lt  hat I understand the plaintiff's contention to be 
 of the final reply briefing to hich e did t  is under the FHSA we have not complied with the 
4 e  rt it  t  r  t t as file    labeling require ent. And this case states, 
 the plaintiff. For the first time in that reply  "Under t e ,  t is l   i  tr st t  
6 riefi  t e lai tiff s ested t at e id t  OSHA, all accompanying literature where there are 
 ls  l  ith t  . , I'm t ing t   re ions  e, i ten  r ,  
 ask the court's per ission to file additional  defined as cautionary labeling. 15 U.S.c. Section 
 riefi . I erstand t at t e c rt is    62." 
 overburdened and ould not --  "Accompanying literature is thereafter 
 E : ell, I a  i e  t at  defined as follows: Any placard, pamphlet, 
 rt it .  booklet, book signed or other written, printed or 
13 . : ll, our r, I n't no   rapid matter or visual device and it provides 
 t at it's e es  ecause -- t  is --   ire tion  , itte   t r i ,  t t 
15 is a case  int f r t is a  t e case t at I'm  is used in connection with display, sale, 
 referring to e've actually already cited, but it  demonstration or merchandizing of a hazardous 
 iscusses the S  l  at's   substance intended for use in the household or by 
18 Specialties anufacturing Association, Inc.  il ren." 
9 s s le .  So basically what it's saying is that 
20 E : nd the itation -- I recognize  the labeling requirement under the FHSA is not 
21 the , t hat is the cit ti ? 21 like the labeling requirement under OSHA. Under 
22 . : his is 958 .2d . It's   OSHA, as the plaintiff has contended, that 
23 2000 - r   as    e th i . 23 labeling require ent eans it has to be right on 
24 nd hat this ase lishes i ,  24 that r, it  to e  -- directly on the 
25 I quote, "Under the FHSA" -- perhaps I'll preview 25 product itself. 
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1 What the FHSA stands for is you know 1 particular occasion Ive been a little sick I
2 wer not quite as strict there So long as this 2 dontknow that I should be going forward with
3 information is conveyed alongwith the sale of the 3 this Instructed to go forward anyway and then
4 product thats going to suffice to meet the 4 went forward nonetheless
5 labeling standard under the FHSA 5 With all of these things combined
6 Now again this goes back to the heart 6 perhaps capstoned by the fact that plaintiff has
7 of plaintiffs crossmotion for summary judgment 7 testified that on none of these occasions that she
8 and really the question of whether there 8 was exposed to OCspray during training did she
9 whether theyare able to meet thatproximate cause 9 actually see the cannister that was sprayed In
10 requirement under a which Iunderstand that in 10 other words she didntsee that which she claims
11 the reply briefing the plaintiff backed off from 11 there should have been a label on
12 but nevertheless that fourth requirement under 12 All of this begs the questioncan that
13 the negligence per se requiring that proximate 13 under any reasonable juror analysis establish
14 cause be established between the alleged violation 14 proximate cause when wehave all of these other
15 and the injury itself 15 factors The plaintiff herself even though the
16 In thisparticular case we have an 16 plaintiff was instructed by her superiors the
17 individual who was trained by SEC actually 17 plaintiff had on previous occasions watched other
18 trained by IDOC people who were trained by SEC 18 people go through training and in fact laughed
19 with a PowerPoint presentation supplied by SEC 19 at them
20 their MSDS sheets supplied along with the sale of 20 All of these things built together
21 this product This individual took written tests 21 and then essentially what she doing is she
22 and scored correctly that there are in fact 22 hinging her claim on the idea that had a label
23 respiratory effects alerted because she knew 23 been affixed to something that she never saw that
24 that the product had respiratory effects alerted 24 she would have never been exposed to and then
25 her superiors and said I dontknow on this 25 suffer the injury that she is now contending
32 33
1 The fact ofthe matter is all of this 1 point me to a single definitive study that shows
2 information whether it be through the MSDS 2 OCspray causes chronic effects complained of by
3 sheets throughthe training manuals through the 3 Miss Major
4 Power Point presentation all of all of this 4 THE COURT Youre talking about in the
5 information was conveyed to the plaintiff as per 5 depositions
6 requirements under the FHSA 6 MROVERSON Whatsthat
7 1 think unless the court has any 7 THE COURT Youretalking about in the
8 questions I think I will reserve a little bit of 8 depositions
9 time if it is okay with Your Honor for reply 9 MROVERSON Correct Correct
10 argument 10 THE COURT But isnthat the issue
11 THE COURT Okay Thank you Mr Overson 11 MROVERSON Well and what he explains
12 MROVERSON Thank you 12 in his affidavit is that no he cantpoint to a
13 THE COURT Probably the most important 13 single study that would demonstrate that
14 thing that youregoing to have to address is the 14 definitively Okay
15 motion to strike your expertsaffidavit in 15 THE COURT So you would agree that there
16 certain places because of the inconsistencies 16 you have not identified any study that this
17 between what he testified to in the deposition and 17 company should have been aware of thatOC spray
18 he says in the affidavit 18 had the had the it was foreseeable that it
19 MROVERSON Thank you Your Honor I 19 could cause chronic lung problems like your client
20 apologize 20 claims
21 THE COURT Thatsokay 21 MROVERSON The okay Theresno study
22 MR OVERSON I think on the surface a brief 22 where theyv taken subjects exposed them toOC
23 look at it it looks inconsistent but we need to 23 spray and found that it caused the symptoms and
24 look closely at the questions that defense counsel 24 condition that my client has But thats not
25 was asking Dr Yost They were asking him can you 25 whats required under the law Dr Yost explained
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 hat the  stands for is, you kno ,  articular ccasi n I've ee  a little sic . I 
 e're not quite as strict there. So long as this 2 don't kno  that I should be going for ard ith 
 information is conveyed along ith the sale of the  this. Instructed to go for ard any ay and then 
 product, that's going to suffice to eet the  e  for ard l s. 
 labeling standard under the F S .  ith all of these things co bined, 
 o , again, this goes back to the heart  er a s ca st ned  t e fact t at lai tiff as 
 of plaintiff's cross-motion for su ary judg ent 7 ied      s   
 and really the question of whether there -  as exposed to .c. spray ri  training i  she 
 hether they are able to eet that proximate cause  actually see the cannister that as sprayed. In 
 requirement under a -- ich  a      ,  i n't   c   s 
1 the reply briefing the plaintiff backed off fro ,    e    . 
 but, nevertheless, that fourth require ent under  ll of this begs the question can t at 
 the negligence per se requiring that proximate  under any reasonable juror analysis establish 
 cause be established bet een the alleged violation  proxi ate cause hen e have all of these other 
 a d t e i jury itself.  fact rs. e lai tiff erself, e e  t  t e 
 In this particular case e have an 16 l i tiff as i tr te   r ri r , t  
 individual ho as trained by S , actually  plaintiff had on previous occasions atched other 
 trained by IDOC people who were trained by SEC  people go through training, and, in fact, laughed 
 ith a Po erPoint presentation supplied by SEC,   . 
 their S S sheets supplied along ith the sale of  ll f t ese t ings ilt t et er --
 this product. This individual took written tests  and then essentially hat she's doing is she's 
 and scored correctly that there are, in fact,  hinging her claim on the idea that had a label 
 respiratory effects, alerted - s  e   been affixed to so ething that she never saw, that 
 that the product had respiratory effects alerted  she ould have never been exposed to and then 
 her superiors and said, I don't know --    suffer the injury that she is no  contending. 
  
 e  f   s     point e to a single definitive study that sho s 
 i f r ati , et er it e t r  t e   .c. s r  s s r i  ffe ts l i  f  
 sheets, through the training anuals, through the  iss ajor. 
 Power Point presentation, all of --     m  T: ou're talking about in the 
 infor ation as conveyed to the plaintiff as per  positions? 
 require ents under the F S .  . N: hat's t at? 
 I think unless the court as any  m  COURT: You're talking about in the 
 questions, I think I will reserve a little bit of  depositions? 
 ti e, if it is okay ith our onor, for reply  . : rrect. rrect. 
 argument.  m  T:  n't t t  ue? 
 mE COURT: Okay. Thank you. Mr. Overson.  . : l --  t  l i  
 . S : hank you.  in his affidavit is that no, he can't point to a 
 m  COURT: Probably the most important  single study that would de onstrate that 
 thing that you're going to have to address is the  definitively. kay. 
 otion to strike your expert's affidavit in  m  T: So you ould agree that there -
 certain places because of the inconsistencies  you have not identified any study that this 
 between what he testified to in the deposition and  company should have been aware of that O.c. spray 
 he says in the affidavit.   t  -  t  -   bl    
 . E S : Thank you, our onor. I  could cause chronic lung proble s like your client 
 apologize.  l i s. 
 m  COURT: That's okay.  . N:  - y. here's  t  
 . :  i   t  ace    where they've taken subjects, exposed them to O.c. 
 look at it, it looks inconsistent, but e need to  spray and found that it caused the sy pto s and 
 look closely at the questions that defense counsel  condition that my client has. But that's not 
 was asking Dr. Yost. They were asking him can you  hat's required under the law. r. ost explained 
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1 in his affidavit and it goes to his criticism of 1 seems to be the primary irritant Once youre
2 Dr Reilly who theywork in the same lab 2 sensitized to do that youresensitized at a
3 ironically is that Dr Yost is taking a view of 3 greater level to other irritants such as dust and
4 the entire area of study and he is combining that 4 itskindof a core irritant
5 to draw conclusions And as he does that hes 5 All hes saying here though is this
6 followinghis scientific method based on his 6 is one of the studies he looked at and it explains
7 education research and involvement in this area 7 the it explains part of the picture
8 and hes saying that given the conglomeration of 8 THE COURT Well isntthat though when
9 studies that existed at the time SEC and 9 I was reading that it seemed to me what hes
10 companies like SEC should have knownthat there 10 really talking about is causation which is really
11 was a risk associated with their product of 11 different from the foreseeable nature of the
12 causing an individual with who is susceptible 12 potential dangers And I think thatswhat
13 to having a greater sensitivity to capsacin which 13 counselsgetting at Hes talking about yeah
14 would result in the type of injury that she has 14 this caused her thiswould cause this But at
15 Counsel made a point of talking about 15 the same time I didn read what the studies
16 the Groneberg study and Dr Yost talked about it 16 showed as saying that at the time that she was
17 andhe said yeah theyr talking about acute 17 exposed to this that the literature would have
18 effects He says our findings indicate that the 18 put someone on notice that it is a foreseeable
19 TrpV1 receptors may contribute to an enhanced 19 one of the foreseeable dangers of the use of this
20 cough reflex and cough response and chronic 20 material
21 persistent cough of diverse causes 21 MR OVERSON And see I think thatswhat
22 Those TrpV1 receptors according to Dr 22 hes saying inhis report and in his affidavit
23 Yost as it was written in his report as an 23 THE COURT Okay Where in his affidavit
24 individual is exposed to capsacin which is really 24 are you talking about
25 a unique chemical for the humanbody because it 25 MROVERSON Okay
36 37
1 THE COURT Which paragraph 1 says Based on my review of the above cited
2 MR OVERSON Based on my review of the 2 articles and my education training research and
3 above Imsorry In answer to your question 3 knowledge of the scientific literature in the
4 paragraph six the article cited and this is 4 relevant area it is my opinion that the risk to
5 after he lays out the number of let me just go 5 the respiratory trackposed by exposure to SEC
6 through the whole thing 6 SABRE Red law enforcement ten percent OC spray
7 In reaching my opinion in addition to 7 specifically the MK9 Fogger were known and
8 the records and discovery materials already 8 reasonably foreseeable were known and
9 mentioned I relied on a body of scientific 9 THE COURT But thatsa legal honestly
10 research relating to the effects of capsacin on 10 counsel thats a legal conclusion and he is
11 human and animal tissue 11 like I said what concerns me is that he is
12 In assisting the plaintiff in 12 relying on 2008 and 2010 to some degree articles
13 responding to one of the defendantsdiscovery 13 And one of them is fairly significant Its the
14 requests I identified several research articles 14 one thatsthe its B the paradoxical role of
15 that support my opinion including the following 15 TrpV1 receptors and inflammation which is
16 16 precisely the issue thathe uses to opine that
17 THE COURT You donthave to read those 17 capsacin is one of those triggers for all of these
18 MROVERSON Okay And then it says The 18 chronic effects That certainly wasntwell known
19 articles cited above are just a few of many 19 at the time
20 THE COURT Okay But to the extent he 20 MROVERSON I think hesnot relying on
21 cites articles that are after her exposure those 21 any I think what hes really trying to say is
22 are clearly irrelevant 22 hes not relying on any one of these studies
23 MROVERSON I would agree 23 THE COURT But how can to be honest with
24 THE COURT Okay 24 you counsel I dont I dontthink its proper
25 MROVERSON I would agree And but he 125 for him to rely on anything that was not in
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 in his affidavit, and it goes to his criticis  of  see s to be the pri ary irritant. nce you're 
2 Dr. Reilly, who -- they work in the sa e lab  sensitized to do that, you're sensitized at a 
3 ironically -- is that r. ost is taking a vie  of 3 reater l l t  t r irritants s  s st  
4 the entire area of study and he is co bining that 4 t's    re t t. 
 to  i .    es t, e's  ll e's sa i  ere, t , is t is 
 following his scientific method based on his  is one of the studies he looked at and it explains 
 e cati , researc  a d i olve e t i  t i  area   -- it e lai s art f t e ict re. 
 and he's saying that given the conglo eration of 8  : ll, i n't t t, t  -- hen 
 ies t iste   e ,    I as rea i  t at, it see e  t  e at e's 
 companies like SEC should have known that there  really talking about is causation, hich is really 
 as a risk associated ith their product of  fere   e re    e 
 causing an individual ith -- ho is susceptible  t ti l rs.  I t in  t at's t 
 to having a greater sensitivity to capsacin which  counsel's getting at. e's talking about, yeah, 
 ould result in the type of injury that she has.     - t is l  s  t is. t t 
 ounsel ade a point of talking about   e e  i n't    es 
 the roneberg study and r. ost talked about it  s e  as sa i  t at at t e ti e t at s e as 
 and he said, yeah, they're talking about acute  s  t  t i , t t t  liter t r  l   
 effects. He says, our findings indicate that the  put so eone on notice that it is a foreseeable --
 TrpVl receptors ay contribute to an enhanced  one of the foreseeable dangers of the use of this 
 cough reflex and cough response and chronic  t rial. 
 persistent cough of diverse causes.  . : , e,  i  at's  
 Those TrpVl receptors, according to Dr.  he's saying in his report and in his affidavit. 
 Yost as it was written in his report, as an   T: kay. here in his affidavit 
 individual is exposed to capsacin, hich is really  are you talking about? 
 a unique che ical for the hu an body because it  . : a . 
  
 THE COURT: hich paragraph?  says, "Based on y revie  of the above-cited 
 R. ERS : Based on y revie  of the  articles a   e cation, trai i , researc  a  
  -- I'm sorry. In ans er to your question,  kno ledge of the scientific literature in the 
 paragraph six, the article cited --     relevant area, it is y opinion that the risk to 
 after he lays out the number of -- let e just go  the respiratory track posed by exposure to SEC 
 through the whole thing.  S  ed la  enforce ent ten percent o.c. spray, 
 "In reaching y opinion in addition to  s ecificall  t e -9 er, ere  a  
 the records and discovery aterials already  reasonably foreseeable --   nd" --
 mentioned, I relied on a body of scientific   T: ut that's a legal-- estly, 
 research relating to the effects of capsacin on  counsel, that's a legal conclusion and he is--
 a    sue."  li  I id, t r   i  t t  i  
 "In assisting the plaintiff in  relying on 2008 and 2010 to so e degree articles. 
 responding to one of the defendant's discovery  nd one of the  is fairly significant. It's the 
 requests, I identified several research articles   at's  -- it's B, the paradoxical role of 
 that support y opinion including the follo ing"  r  I rece t rs a  i fla ation, ic  is 
 --  precisely the issue that he uses to opine that 
  RT:  on't    .  capsacin is one of those triggers for all of these 
 R. ERS : kay. nd then it says, "The  chronic effects. That certainly wasn't well known 
 articles cited above are just a few of many" -  t  . 
 THE COURT: Okay. But to the extent he  . : I t i  e's t rel i   
 cites articles that are after her exposure, those  any -- I think hat he's really trying to say is 
 are clearly irrelevant.  he's not relying on anyone of these studies. 
 R. ERS : I ould agree.   URT:    --     
 THE COURT: Okay.  you, counsel, I don't -- I don't think it's proper 
 MR. OVERSON: I would agree. And - but he 25 for hi  to rely on anything that was not in 
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1 existence at the time that he was exposed which
2 would be anything from 2008 on Because
3 presumably the manufacturer would not have that
4 information which goes to whether this was a
5 foreseeable danger at the time of exposure
6 MR OVERSON And maybe we didntdo a very
7 good job in presenting the evidence in terms of
8 because his report obviously was in support of
9 causation and foreseeability
10 THE COURT Right but then how do you
11 and this is the reason it seems to me it goes back
12 to the motion to strike Because youvegot the
13 deposition material where he in direct
14 question do you have studies that show this
15 chronic this chronic that it can cause these
16 chronic effects and he says no Thatswhat he
17 says He says no So that
18 MR OVERSON The question ismore pointed
19 though
20 THE COURT I think thatsa pretty pointed
21 question
22 MR OVERSON Well itsalmost too pointed
23 Theyr asking him and I wish I had the
24 deposition readily handy here But theyr asking
25 him specifically is there a specific study that
40
1 really irrelevant as towhether this company
2 should have foreseen the potential danger to your
3 client And thats the issue
4 And thatswhy I think what counsel is
5 saying is right theres you have to
6 distinguish between his statements on causation
7 which really at this point is not relevant to the
8 issues that are before the court or whether
9 because this is a products liability case whether
10 it was foreseeable to the company that they should
11 have foreseen these kinds of injuries as
12 potential
13 And just him saying the conclusion
14 thatsa conclusory statement just like when
15 as far asIm concerned their expert having a
16 conclusory statement that it wasn foreseeable
17 thatsreally a legal conclusion I think the
18 more important thing iswhat do youbase that on
19 Whatsthebasis for that statement
20 MROVERSON And I dontknow that they
21 ever asked him that question
22 THE COURT But but counsel hesyour
23 expert Presumably you with himwould work on an
24 affidavit Thatswhatsnecessary in the
25 affidavit And I dontsee anything in any of his
1 definitively concludes that exposure toOCspray
2 causes her injuries the types of injuries that
3 she suffering And asIve already said thats
4 true But he goes on to explain the totality of
5 the evidence when you look at it And he says so
6 in paragraph seven of his affidavit It is known
7 now and it was known prior to 2008 that people
8 with asthma and chronic cough are more sensitive
9 to pepper stray than other people with normal
10 respiratory functions and he goes on and explains
11 how that sensitivity comes about
12 THE COURT Thats true but he doesnt
13 hesthe one who doesntdistinguish between
14 chronic and acute That affidavit really doesnt
15 it says result in higher acute respiratory
16 responses And the issue here is chronic Thats
17 his affidavit
18 And I guess the point is that if I take
19 that paragraph as true it doesn support his
20 conclusion And thatswhatsreally important
21 is does he have anything to support his conclusion
22 which is completely conclusory And hesin
23 when hes asked for very specific do you have
24 any studies because the fact that hesarrived at
25 some sort of conclusion back here in 2010 is
41
1 affidavits that really definitively point to
2 whether he whetherstudies existed at the
3 time that this product was used whether studies
4 existed that would have identified chronic this
5 chronic condition as a result of exposure
6 And thatsthe problem because it is
7 in his depositions that what he says He said
8 there arenthe cantpoint to any studies that
9 show that
10 MR OVERSON Yes he I looked at that
11 testimony over and over again and I see him saying
12 that do I have one that says if you expose
13 somebody to OCspray that this will happen I
14 mean thats exactly one studywhere they exposed
15 people and this happened and the answer no
16 THE COURT Okay
17 MR OVERSON But I don know that thats
18 necessary to proceed forward on this case And
19 the Idaho Supreme Court has acknowledged that
20 there are certain situations where its
21 permissible for the expert to to expand on just
22 what Dr Yost has been talking about looking at
23 the entire area or field of study and drawing
24 scientific conclusions from that
25 In Weeks for instance the Supreme
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 e istence at t e ti e t at e as e se , ic   efi iti el  c cl es t at e s re t  .c. s ra  
2 l  e t i  fr   .  2  r i j ri , t  t  f i j ries t t 
 re   a turer    t  e's f ri .   've  i , at's 
 infor ation ich es t  et er t is as a  true. But he goes on to explain the totality of 
 foreseeable danger at the ti e of exposure.  the evidence hen you look at it. nd he says so 
6 . :  a e e i n't  a er  6 i  r r  s  f is ffi vit. It is  
7  job i  r ti  t  ide ce i  t r  f -- 7   it   ri r t   t t l  
 eca se is re rt i sl  as in s rt f  ith ast a  c r ic c  are re sensiti e 
 causation and foreseeability.  to pepper stray than other people ith nor al 
10  T: i t, t t e     -- 10 r s ir t r  f ti s,   s   l i s 
 and this is the reason it see s to e it goes back  ho  that sensitivity co es about. 
 to the otion to strike. ecause you've got the   RT: at's e,   esn't --
 deposition aterial here he --  r   he's the one ho doesn't distinguish bet een 
 question, do you have studies that sho  this  chronic and acute. hat affidavit really doesn't 
15 chronic -- this chronic - that it can cause these 15 -- it  r lt i  i r t  r ir t r  
 chronic effects, and he says no. hat's hat he  responses. nd the issue here is chronic. hat's 
 .   .  t t --  his affidavit. 
 . E S : The question is ore pointed  nd I guess the point is that if I take 
 t .  t at ara raph as tr e, it esn't s rt is 
  : I t i  t at's  r tt  i t   conclusion. nd that's hat's really i portant, 
 question.  is does he have anything to support his conclusion 
 . : ll, it's l st t  i t .  hich is co pletely conclusory. nd he's in --
 They're asking hi  --   ish      e's  f r -- very specific do you have 
 deposition readily handy here. ut they're asking   st i s s  t  f t t t e's rri e  t 
 hi  specifically is there a specific study that           
  
 r ll  irrele a t s t  ether t is a  1 ffid its t at r ll  fi iti l  i t t  
 should have foreseen the potential danger to your  t r  --  es  -- t  
 .  at's  .  ti e that this product as used hether studies 
 nd that's hy I think hat counsel is  iste  t t l   i tifie  r i  -- t is 
 sa ing is ri t, t ere's --  a e t  5 r i  iti  s  r s lt f s r . 
 distinguish between his state ents on causation,  nd that's the proble  because it is --
 hich really at this point is not relevant to the  in his depositions that's hat he says. e said 
 ss es    e urt,   --   ren't -- he can't point to any studies that 
 eca se t is is a r cts lia ilit  case, et er   t. 
 it as foreseeable to the co pany that they should  . N: ,  -- I l  t t t 
 have foreseen these kinds of injuries as  testi ony over and over again and I see hi  saying 
 potential.  that do I have one that says if you expose 
 nd just hi  saying the conclusion --  so ebody to .c. spray that this ill happen. I 
 t at's a c cl s r  state ent, j st like e  --  mean, that's exactly one study where they exposed 
 as far as I'm concerned, their expert having a  people and this happened and the answer's no. 
 conclusory state ent that it asn't foreseeable,  THE COURT: Okay. 
 that's really a legal conclusion. I think the  . :   on't   at's 
 ore i portant thing is hat do you base that on.  necessary to proceed for ard on this case. nd 
 at's  s   t ent?  t  I  re e rt s le  t t 
 . S : nd I don't kno  that they     s  t's 
 ever asked hi  that question.  permissible for the expert to - to expand on just 
  : t -- but counsel, he's your  hat r. ost has been talking about, looking at 
 expert. Presu ably you ith hi  ould ork on an  the entire area or field of study and dra ing 
 affidavit. That's what's necessary in the  i ntif    t. 
 affidavit. nd I don't see anything in any of his  In eeks, for instance, the Supre e 
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1 Court recognized that it wasn necessary for that 1 asked that question in the deposition
2 type of study to be present before you could show 2 THE COURT But what is thebasis for that
3 proximate cause 3 opinion Theyr entitled to know what the basis
4 THE COURT No I understand that and I 4 is They asked him for those questions He
5 agree with you about that The problem youvegot 5 doesntgive a basis for it
6 is when asked specifically whether there were any 6 And actually the like I said other
7 studies that showed exactly what the issue is he 7 than the conclusory statement that he makes when
8 says no Thatsthe problem He cant he 8 he gives an he gives a inhis affidavithe
9 cantsay no and then turn around but I conclude 9 talks about result in higher acute not higher
10 that infact it was foreseeable Hes got to 10 chronic respiratory responses He says acute
11 say whatsthe basis for that 11 MROVERSON Yes He acknowledges
12 MR OVERSON I I 12 throughout the deposition that for the general
13 THE COURT Thats the problem 13 population it is going to be acute Thenhe goes
14 MR OVERSON I understand I hear the 14 on and he talks about you know it can happen
15 concern and I guess in my mind and Ihate to be 15 there is a risk of it being chronic
16 repetitive but I keep coming back to the idea 16 And even Mr Nance the vice president
17 though that that is not the question that he was 17 of the company he acknowledged inhis deposition
18 asked but itsthe question he answers in his 18 that you know he understood that there would be
19 affidavit 19 risks of you know overexposure that you might
20 THE COURT But how does he come to the 20 have a complication of an already existing illness
21 conclusion that it was reasonably foreseeable at 21 or you may become M
22 the time your client was exposed if there are no 22 And I understand the courtsconcern on
23 studies to support that conclusion 23 that andImvery itsa very pointed issue
24 MR OVERSON Well one I think thats 24 that the court has raised and I
25 what hes saying in his affidavit He wasnt 25 THE COURT Actually opposing counsel raised
44 45
1 it Imjust following up on it 1 THE COURT Except thatsnot what he says
2 MR OVERSON Yeah And Im really 2 because that the studies that he lists were not
3 struggling because I did read his deposition as 3 available
4 being answering the questions that were put to 4 MR OVERSON Well some of them were
5 him 5 THE COURT Some were But he hasn
6 Now can he present an affidavit or a 6 distinguished between what he if he if he
7 deposition and further expand on that if hes 7 was going to do this he should have excluded
8 asked that question Certainly But they didnt 8 anything in 2008 a bust because he doesntexplain
9 ask him that question And itstheir burden and 9 howhewould have answered ifhe hadn had access
10 motion for summary judgment to come forward and 10 to the studies from 2008 through 2010 He doesnt
11 say we asked the question and this is his answer 11 say that He doesntsay based on the existing
12 And they didntask the right question Their 12 which would have been the 2002 2003 the 2005
13 question was too specific And its 13 the 2005 2006 2006
14 THE COURT Dontforget this is a 14 And Illjust point out that if you
15 crossmotion for summary judgment So just don 15 I haventgone and looked at these but if you
16 forget that 16 just look at the title of some of these the only
17 MR OVERSON Okay 17 ones that seem to be very specific to his later
18 THE COURT Okay 18 testimony about the receptor and its role in
19 MR OVERSON And the expert for the 19 inflammation are all 2008 and later Those are
20 defense Mr Reilly thatsMrYosts Dr 20 the ones hes talking about The earlier ones
21 Yostscriticism of him over and over again is 21 have to do with the exception I guess of the
22 hes too specific And he explains the general 22 capsaicinoids cause inflammation in epithelial
23 way that he reaches his conclusion is by looking 23 cell depth through activation of vanilloid
24 at the totality of the science that was available 24 receptors Thatsthe only one that I can see
25 in 2008 25 here that possibly has something to do with it
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1 rt r i  t t it sn't ss r  f r t t  asked that question in the deposition. 
2  f       l   2  URT: t t i  t  i  f r t t 
3 i ate  --  opinion? hey're entitled to kno  hat the basis 
4  T: ,       is. hey asked hi  for -- those questions. e 
 a ree it   a t t at. e r le  ou've t  esn't i e a asis f r it. 
 is hen asked specifically hether there ere any  nd actually the -- l   aid,  
 ies   t     ,   t a  the conclusory state ent that he akes hen 
 s . at's t  r l .  an't -- he   i   --  i   -- i  i  f i vit  
9 n't     m r d,   de  talks about result in higher acute, not higher 
10 t t, i  f t, it s f r s bl . e's t t   chronic respiratory responses. e says acute. 
  hat's  s  t.  . S : es. e ackno ledges 
 R. OVERSON: I -- I --  throughout the deposition that for the general 
  T: hat's the proble .  population it is going to be acute. hen he goes 
14 . N: I ersta  --        t l s out,  , it  n, 
    ess    --   t  t    there is a risk of it being chronic. 
16 titi ,   e  ng    ,  nd even r. ance, the vice-president 
 t , t t t t is t t  ti  t t   17 of the co pany, he ackno ledged in his deposition 
18 , t it's t e ti    i  i   that, you kno , he understood that there ould be 
 affidavit.  ris s f,  , ere s re t at  i t 
  RT:   s        li ti  f  lr  i ti  illness 
 l i  t t it as l  e l  t  or you ay beco e ill. 
 t e ti e r clie t as e se  if t ere are       ourt's r   
 t ies t  t t at l sion?    'm  -- it's a very pointed issue 
24 . : l ,  --   at's         --
 hat he's saying in his affidavit. e asn't  THE COURT: Actually opposing counsel raised 
  
1 it. I'm just f ll i    it.   T: t t at's t t  s s 
 . : . nd 'm ll   s  t t --  e    s    
 str li  eca se I i  rea  is e siti  as  a aila le. 
4 i  -- ans ering the questions that ere put to 4 . N: ell, s  f t  r . 
5 i .   :  r . t  sn't 
 , ca  e rese t a  affi a it r a  istinguishe  et een -- t  -- if  -- if  
7 deposition and further expand on that if he's  as going to do this, he should have excluded 
 asked that question? ertainly. ut they didn't  anything in 2008 a bust because he doesn't explain 
 as  i  t at esti . nd it's t eir rden a          dn't   
 tion   udg e t  e or ard   to the studies from 2008 through 2010. He doesn't 
 say e asked the question and this is his ans er.  s  t t.  esn't s  s   t e isti , 
 And they didn't ask the right question. Their  ic  l  a e ee  t e 2, , t e , 
 e tion  t  i i . d it's --  t  5, 6, 6. 
  T: n't  is    nd I'll just point out that if you -
 ross-motion f r s r  ju t.  just n't  I en't   l e  t t s , t if  
 forget t t.  just look at the title of so e of these, the only 
 . : a .  ones that see  to be very specific to his later 
18 E : .  testi ony about the receptor and its role in 
 R. OVERSON: And the expert for the  fla  re il   r.   
 defense, r. eilly, that's r. ost's -- .  the ones he's talking about. The earlier ones 
 ost's criticis  of hi  over and over again, is  e   -- ith the exception, I guess, of the 
 he's too specific. nd he explains the general  capsaicinoids cause infla ation in epithelial 
23 ay that he reaches his conclusion is by looking  cell depth through activation of vanilloid 
 at the totality of the science that as available  receptors. That's the only one that I can see 
 in .  here that possibly has so ething to do ith it. 
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But Imean thatsthe problem is
that hes that your expert and your
affidavit and when he gives whenhe has the
paragraph where he comes to his conclusion he
bases it on studies that were not available to the
defendant at the time that your client was
exposed And thats I think thatsa
significant problem
And then the paragraph that you point
to as talking about that about being known in
2008 he says acute He doesn say chronic
MROVERSON Youre referring to
THE COURT Thats paragraph seven And to
be honest with you paragraph six I mean you
keep saying it needs to be specific paragraph
six even the part where he says were known and
foreseeable he doesnttalk about chronic He
just says respiratory track the risk to the
respiratory trackposed by exposure were known and
foreseeable Well I dontknow what that means
MROVERSON Well I think that ties back
to his statements in his report that those
that this product caused her injuries and thats
the risk of
THE COURT But he didntsay that counsel
MROVERSON position
THE COURT just need answers to that
Thatswhat I really need
So what about the argument on Ill
let you briefly talk about this the argument
about the preemption issue
MROVERSON Yeah You know the thing
Id like to back up just a little bit on that
because the Supreme Court has laid out the US
Supreme Court has laid out a very specific way
thatwer supposed to deal with these and I dont
see that the defense has walked through that
analysis The federal law whether it be OSHAor
FHSA is only going to prevent if the state law is
asking for something different
Well you know here the and mind
you its defense burden to prove preemption
They haven shown that theyv complied with the
FHSA and
THE COURT I dontthink they have to yet
I think all they have to do is I think the only
issue before me is not whether they complied I
know you raised that in your reply but Imnot
going to address that The issue here is does the
I hate acronyms
avr i
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1 MROVERSON In in the last one
2 THE COURT Not in that affidavit And I
3 think the to be honest with you I think the
4 reason he didntsay that is because of his
5 answers in his deposition where hes asked about
6 the existence of these studies
7 The defendant isn an expert The
8 defendant has to rely on the scientific knowledge
9 at the time that they that theymarket this
10 product I donthave anything before me that
11 says that at the time this product was your
12 client was using it that in fact the scientific
13 literature should have alerted them to the fact
14 thiswas a foreseeable risk and thats the core of
15 their argument But I think I understood your
16 position
17 MROVERSON Well and Ibelieve that if
18 we a fair reading of Dr Pachecosdeposition
19 along with the vocal cord study that was discussed
20 there I think you know I think that would
21 probably also provide a basis for the SEC at the
22 timeknowing that this is the type of risk that
23 their product poses But you know I understand
24 the courts
25 THE COURT Well I
49
1 MR OVERSON Yeah the
2 THE COURT The federal law does it
3 MR OVERSON Yeah the consumer one
4 THE COURT Right The OSHA requirements
5 And Ithink thats its a legal issue It is
6 pretty straight forward
7 MR OVERSON Well it is its a legal
8 and factual issue because the factual issue thats
9 tied up in it and I think counsel acknowledged
10 this is whetheror not this product is a
11 household product as that term is defined under
12 the consumer product version And the fact that a
13 law enforcement officer would carry it on their
14 belt or that a SWAT team going out to a home where
15 somebody has boarded themselves up or other
16 officers trying to control a crowd would use this
17 MK9
18 THE COURT But the question is it says
19 under any customary or reasonably foreseeable
20 condition purchase storage or use may be
21 brought into or around a house apartment or other
22 placewhere people dwell I think their point is
23 the prison they may be dwelling their against
24 their will but they clearly they do dwell
25 there
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 ut -- I ean, that's the proble , is  . : I  -- in the last ne-
 that he's -- that -- your expert and your  m  : t in t t ffi it. nd I 
 affidavit and hen he gives - he  he as the  t i  the -- to e nest ith , I t i k t e 
 paragraph where he comes to his conclusion, he  reason he didn't say that is because of his 
 bases it  st dies t t ere t ila le to t e  a s ers in is e siti  ere e's as e  a t 
 defendant at the time that your client was  the iste ce f t ese t i . 
 exposed. And that's --  t i  t at's   he efendant isn't a  e ert. e 
8 significant proble .  fe a t as to r l   t e i tific le  
9 And then the paragraph that you point  at the ti e that they -- that they arket this 
 to as talking about that, about being known in  product. I don't have anything before e that 
 2008, he says acute. He doesn't say chronic.  sa s t at at t e ti e t is r ct as --  
 . E S : ou're referring to-  lient as si  it, t t, i  f t, t  s i tific 
 m  COURT: That's paragraph seven. And to  literature      e a  
 be honest with you, paragraph six -- I ean, you   as  re  s   at's    
 keep saying it needs to be specific, paragraph  their argu ent. ut I think I understood your 
 six, even the part here he says ere kno n and  siti . 
 foreseeable, he doesn't talk about chronic. e  . : l-- and I believe that if 
 just says respiratory track --  ris  to t e   - a fair reading of r. Pacheco's deposition 
 respiratory track posed by exposure were known and  along with the vocal cord study that was discussed 
 foreseeable. ell, I don't kno  hat that eans.  ,   --  , I t i  t t l  
 . S : ell, I think that ties back  probably also provide a basis for the SEC at the 
 to his statements in his report, that those --  ti e kno ing that this is the type of risk that 
 that this product caused her injuries and that's  their product poses. ut, you know, I understand 
    --   urt's--
 m  : ut he didn't say that, counsel.  m  : l , 1--
48  
 . E S : -- position.  . : h, e--
 m  T: - j st ee  a s ers t  t at.  m  T:   ,  t -
 That's what I really need.  . : h,   e. 
 o hat about the argu ent on -- I'll  m  T: ight. he S  require ents. 
 let you briefly talk about this, the argument     at's - it's a le al iss e. It is 
 about the preemption issue.  pretty straight for ard. 
 R. OVERSON: Yeah. You know, the thing--  . : el ,   -- it's  l l 
 I'd like to back up just a little bit on that       t l i  at's 
 because the Supreme Court has laid out --  .S.  tied up in it, and I think counsel ackno ledged 
 Supreme Court has laid out a very specific way  this, is hether or not this product is a 
 that we're supposed to deal with these and I don't  household product as that ter  is defined under 
 see that the defense has walked through that  the consu er product version. nd the fact that a 
 analysis. The federal law, whether it be OSHA or  la  enforce ent officer ould carry it on their 
 FHSA, is only going to prevent if the state law is  elt r t at a  tea  i  t t  a e ere 
 asking for something different.  so ebody has boarded the selves up or other 
 Well, you know, here the -   16 ffi rs tr i  t  tr l  r  l  s  t is 
 you, it's defense burden to prove preemption. 17 -  --
 They haven't shown that they've co plied with the 8 m  URT: t t e esti  is it sa s 
 -- 9 under any custo ary or reasonably foreseeable 
 m  COURT: I don't think they have to yet. 20 ndition, r se, st r  r se,   
 I think all they have to do is -- I think the only 21 brought into or around a house, apartment or other 
 issue before me is not whether they complied. I  place where people dwell. I think their point is 
 kno  you raised that in your reply, but I'm not  the prison, they ay be dwelling their against 
 going to address that. The issue here is does the  their ill, but they clearly -- t   ll 
 -- I hate acronyms.  re. 
08/15/2011 01:36:27 P  .. Ki  adsen, ffiCial Court Reporter, BOise, Idaho 
MAJOK
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
V5StUUIKI r tVUIrmtmUKr
50
MROVERSON Right I understand but the
problem is that OSHA has looked at their
regulations and theyv said that the purpose of
the OSHA let me back up here
THE COURT Okay
MROVERSON This is this a quote from
Martin vs American Cyanamid and we quoted this in
ourbrief 6th Circuit 1993 Congress enacted
the OSHA regulations to insure safe and healthy
working conditions The purpose of the act is
forward looking ie to prevent first injury
Now as we lookat the OSHA
regulations theyv interpreted that and so has
the Consumer Product Safety Commission to mean a
product brought in or around or stored or used at
the household by basically a consumer versus
OSHA which its purpose is to protect employees in
the workplace I dontthink that theresany
contention here that this product is designed and
used in law enforcement and military in the
workplace It is not a product that a consumer is
likely to bring into their home
THE COURT Can I ask you a question I
dontknow enough about the product but I know
that consumers can purchase
52
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And the interpretations thatIvebeen
our position is supported by the
interpretations of both agencies and that the
court has available in the deposition of Dr
Purswell We went through some of those and
previously at the hearing we discussed this Last
night we received or I guess it was yesterday
morning or before we got the we finally got
the actual copies instead of a rough version
THE COURT Okay But this is but this
was not used in the this is the this is
this is a new deposition June 30th
MR OVERSON Yeah this is this is from
the deposition was taken on June 30th But the
rough transcript was obtained by Mr Lloyd and
submitted that day And I think Mr Lloyd would
agree it was a pretty rough transcript
MR LLOYD It was pretty rough
MROVERSON So we both agreed to
substitute this one
And I draw your attention to page 207
throughout my examination of Dr Purswell and he
goes through and he explains specifically how the
agencies have interpreted the OSHA regulation the
51
1 MROVERSON Right
2 THE COURT this Its its generally
3 available for consumers
4 MR OVERSON Well this one isnt Yeah
5 this one isntAndif I mayapproach
6 THE COURT All right
7 MR OVERSON This is material thatsin
8 there but I think it highlights may I
9 approach
10 THE COURT Yes most certainly Imnot
11 that formal
12 MROVERSON This is the MK Fogger product
13 that we have been talking about
14 THE COURT Okay Now is this for law
15 enforcement only
16 MR OVERSON It is for law enforcement
17 only And the second sheet shows that you know
18 this the testimony ofMr Nance was that the
19 MK9 Fogger and the Cell Buster are the same
20 product except you put a different top on it on
21 the Cell Buster so you can stick it under the door
22 and fog open the cell or even a home he talked
23 about that for extraction purposes But again
24 all of that usage is still in the employment
25 context It is not in the consumer product
53
1 hazard communication standard versus the consumer
2 version the FHSA and how he has looked at those
3 in reaching his conclusion as to the standard in
4 the industry
5 THE COURT Okay This is page 206 you
6 said
7 MR OVERSON 207
8 THE COURT 207
9 MROVERSON And Imsorry I need to give
10 you the range because we go through the number
11 and unfortunately we donthave the exhibits to
12 this The court reporter has not provided that
13 yet
14 I was just looking to see if there was
15 a really good example that I could show the court
16 But it goes on to it looks like we
17 go through 258
18 THE COURT I hope you guys arentintending
19 that this be made part of the record
20 retrospectively so thatImbound by it for the
21 purposes of summary judgment because I cant read
22 280some pages
23 MR OVERSON Well and Imnot submitting
24 it to the court for that purpose
25 THE COURT All right
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1 MR. OVERSON: Right. I understand, but the 1 . O ERS : ig t. 
2 problem is that OSHA has looked at their 2 THE T: -- this. It's -- i 's ge ly 
3 regulations and they've said that the purpose of 3 available for cons . 
4 the  - let me back up here. 4 . : ll, this one is 't. ea , 
5 THE COURT: Okay. 5 this one isn't. n  if I a  a r ach? 
6 . E : his is -- this a quote from  E : ll rig t. 
7 artin vs. American Cyanamid and we quoted this in  . : his is at rial t at's in 
8 our brief, 6th Circuit 1993. "Congress enacted  t , but I think it g lights -- ay I 
9 the OSHA regulations to insure safe and healthy  approach? 
10 working conditions. The purpose of the act is  THE : , ost t i l . 'm t 
11 forward looking, i.e., to prevent first injury."  that f r al. 
12 , as e lo  at the   . : his s the  gger ct 
 regulations, they've interpreted that and so has 1  that e e een ta ing t. 
 the Consu er Product Safety Co ission to ean a  E : y. , is t is for la  
5 product brought in or around or stored or used at  rce e t ly? 
 the household by basically a consu er, versus  . : It is f r la  e f rce e t 
 OSHA, which its purpose is to protect employees in  l .  the  t s t t, u , 
 the workplace. I don't think that there's any  t is -- the testi ony of r. ance as that the 
 contention here that this product is designed and  -9 er a  t e ell ster are t e sa e 
 used in la  enforce ent and ilitary in the  product except you put a different top on it on 
21 workplace. It is not a product that a consumer is  t e ell ster s   ca  stic  it r t e r 
 likely to bring into their home.  and fog open the cell or even a ho e, he talked 
 T E C RT: Can I ask you a question? I  t t t, f r tr ti  r s s. t, in, 
 don't know enough about the product, but I know  all of that usage is still in the e ploy ent 
 that consu ers can purchase --  .     e   
 53 
 xt.    rd, s    
 And the interpretations that I've been  r i n,  ,        
 -- our position is supported by the  i  i  i  l i   t  t  t  i  
 interpretations of both agencies and that the  t e i stry. 
 court has available in the deposition of r.   T: . is is    
 Purswell. e ent through so e of those and  said? 
 previously at the hearing we discussed this. Last  . N: 7. 
 night we received - or, I guess, it was yesterday   T: . 
9 morning or before -- we got the -- e finally got  . : , 'm or y,   t  i  
 the actual copies instead of a rough version.   t  r  s    t r  t  r --
 THE COURT: Okay. But this is -  t i   and unfortunately e don't have the exhibits to 
      --   t  -- t   --  this. he court reporter has not provided that 
 this is a ne  deposition, June 30th?  et. 
 . N: h, t is is --     I s j st l i  t  s  if t r  s 
 -- the deposition was taken on June 30th. But the  a really good exa ple that I could sho  the court. 
 rough transcript was obtained by Mr. Lloyd and  But it goes on to -- it looks like e 
 submitted that day. And I think r. Lloyd would  go through 258. 
 agree, it was a pretty rough transcript. 18  URT: I   s ren't i t i  
19 R. LLOYD: It was pretty rough. 19 t  t  b   rt f t  recor  
 R. OVERSON: So we both agreed to 20 retr spectivel  s  t at I'm   it f r t e 
 stit t  t i  ne. 21 purposes of su ary judg ent because I can't read 
22 And I draw your attention to page 207 22 280-so e pages. 
23 throughout my examination of Dr. Purswell and he 23 . SON: ell-- an  I'm not sub itt  
24 goes through and he explains specifically how the 24 it to the court for that purpose. 
25 agencies have interpreted the OSHA regulation, the 25  COURT: ll right. 
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1 MR OVERSON Okay But I just simply ask 1 guidance material in order to determinewhat
2 the court draw attention to that particular 2 industry standard is for labeling of products and
3 portion where Dr Purswell explains and its 3 similar to the defendant and then applying
4 consistent with the opinion that he provided 4 that standard and concluding that the label it
5 earlier by affidavit why the OSHA standards apply 5 was a breach of that standard
6 in terms of the hazard communication standard 6 But whats important is that he
7 versus the FHSA standard 7 explains why you know he explains these
8 And if I might 8 opinion letters and guidance from OSHA and the
9 THE COURT Well just to the extent that he 9 consumer protection consumer product safety
10 appears a littlebit Imreading very quickly 10 commission
11 but he appears to be giving legal opinions about 11 THE COURT Fromwhat I can seehere he
12 the effects of agency opinions and regulations 12 says hes not aware of anything thats specific to
13 Imnot accepting what he says 13 this kind of spray in the OSHA regulations Im
14 MROVERSON Well absolutely 14 just reading here at pages 217 through 220 And I
15 THE COURT Okay So I dontknow what 15 dontknowwhat years he is talking about for the
16 relevancy it is 16 data base but
17 MROVERSON Well and I tried to make 17 MROVERSON Well he testified that he
18 that clear when I was asking him these questions 18 checked that it was during the
19 and I think a fair reading of the deposition it 19 THE COURT The relevant periods
20 will be clear that hes heslooking to that 20 MROVERSON But I think the data base is a
21 And yeah hes hesmaking some legal 21 different data base I dontknow how to explain
22 conclusions and thats fine the court can 22 that portion
23 disregard that 23 THE COURT I dontwant to go too far into
24 But what hesdoing is hesrelying on 24 this because I haventread his deposition and Im
25 the agencys interpretations and opinion and 25 not going to sit here and read 200 and some pages
56 57
1 MR OVERSON Right I understand There 1 MR OVERSON Yeah in the first paragraph
2 is however an admission by Mr Nance in his 2
3 affidavit Lets see it is 3 THE COURT Right
4 THE COURT Let me find it 4 MROVERSON right above the line that
5 MROVERSON It was filed on April 22nd 5 was stricken out the following sections of the
6 THE COURT His affidavit youre talking 6 regulation determine the hazards associated with
7 about 7 the use of this product and determine the
8 MR OVERSON Yeah Exhibit B Affidavit of 8 appropriate labeling statements And he includes
9 Robert Nance in Support of DefendantsMotion for 9 portions of the FHSA but then he also includes
10 Summary Judgment Its filed under seal 10 the OSHA communication standard
11 THE COURT I left my copies in the where 11 THE COURT Yeah
12 is it 12 MR OVERSON So hesacknowledging there at
13 MR OVERSON It is itsExhibit B and it 13 least at some level that the OSHA standards are
14 is a July 29 2009 letter by Mr Nance and it says 14 applicable to their product
15 that the following sections of the regulation 15 THE COURT Probably in some instance but
16 THE COURT Are you talking about the 16
17 email Exhibit B 17 MROVERSON And those well this
18 MR OVERSON It is an attachment to the 18 wouldntbe his admission but the testimony is
19 email And the email has been represented by 19 this stuff is used by law enforcement whether
20 Mr Nance as being correspondence with the 20 its in corrections or by military or law
21 Consumer Protection Safety Agency And there he 21 enforcement having to clear out buildings
22 acknowledges that their products are governed by 22 Because this Fogger isntthe spray thatwe have
23 29 CFR part 1910 23 on a chain Okay This is a different product
24 THE COURT Are you Imlooking at the 24 and it is designed for filling a roomwith
25 letter 126 capsacin microscopic droplets and its designed to
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1 R. OVERSON: Okay. But I just si ply ask 1 guidance material in order to ete ine what 
2 the court dra  attention to that particular 2 industry standard is for labeling of products  
3 portion where Dr. Purswell explains -- and it's 3 -- s ilar to the d nt's d then a ing 
4 consistent with the opinion that he provided 4 that standard and c cluding that the la , it 
5 earlier by affidavit why the OSHA standards apply 5 as a breach  that s . 
6 in terms of the hazard co unication standard  But w at's important is that e 
7 versus the  s .  e plains hy -- ou , he e lains these 
8 And if I ight --  opinion letters a d idance from   the 
9 THE COURT: ell, just to the extent that he  consu er protection -- s er roduct ety 
10 appears a little bit -- I'm reading very quickly, 10 c issi . 
11 but he appears to be giving legal opinions about 11 E :  hat I   e , he 
12 the effects of agency opinions and regulations,  s s h 's  are  t ing t at's ic to 
13 I'm not accepting what he says.  this ind f s ray in the  r l ti . I'm 
 . : ell, absolutely.  just reading here at pages 217 through 220. nd I 
 T E C RT: kay. So I don't kno  hat 15 n't  hat rs e is t l i  t f r t e 
 relevancy it is.  ta , ut --
 . : l--   tried  a e  . : l ,  t ie  t   
 that clear hen I as asking hi  these questions  e  t t it as ring t e --
 and I think a fair reading of the deposition it   T: e e a t . 
   e  t e's -- he's looking to that. 20 . : t I t i  t  t  s  is  
 And, yeah, he's - he's aking so e legal  fe  a .  n't     
 c clusions a  t at's fi e, the c rt ca   t at rti . 
 disregard that.   T: I n't t t   t  f r i t  
 ut hat he's doing is he's relying on  s a se  ven't   i   'm 
 the agency's interpretations and opinion and  t i  t  it r   r     . 
  
 R. OVERSON: Right. I understand. There  . : ,     
 is, ho ever, an ad ission by r. ance in his  --
3 affidavit. et's see, it is --   RT: t. 
  RT:    t.  . N: --      
 . E S : It as filed on pril 22nd.   t i  t, t  ll i  ti   t  
6 THE COURT: His affidavit, you're talking 6 re lati  eter i e t e azar s ass ciate  it  
 out?  the use of this product and deter ine the 
 . : h, i it , ffi it f  appropriate labeling state ents. nd he includes 
9 Robert Nance in Support of Defendant's otion for  portions of the SA, but then he also includes 
 Summary Judgment. It's filed under seal.    i t  t ndard. 
11 THE COURT: I left my copies in the -- r    URT: h. 
12  t?  . :  e's ackno l i  t r  t 
 . ON:   -- t's    i    at  l l t  t   st r  r  
 is a July 29, 2009 letter by Mr. Nance and it says 14 applicable to their product. 
 that the following sections of the regulation -- is  RT: r a l  i  s e i stance, t 
 T E C URT: re you talking about the 16 -
 e-mail, Exhibit B? 17 R. SON:  t  -- ell, t  
 . ON: t i   tt t t    ouldn't  is dmission, t t  testi ny is 
 e-mail. And the e-mail has been represented by 1  this stuff is used by la  enforcement, hether 
 r. Nance as being correspondence with the  it's i  rr ti s or  ilit r  r l  
 Consumer Protection Safety Agency. And there he 21 enforce ent having to clear out buildings. 
22 acknowledges that their products are governed by  ecause this ogger isn't the spray that e have 
 29 CFR, part 1910.  on a chain. kay. This is a different product 
24 THE COURT: Are you -- I'm looking at the  and it is designed for filling a roo  ith 
 l t er. 25 capsacin icroscopic droplets and it's designed to 
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Theresreally no dispute of fact in
this case that that is the purpose of this law
enforcement product that it is sold to law
enforcement for that purpose Andwhen it is used
by an employee with a greater frequency than what
would be expected of the average consumer then
its going to fall under the OSHA regulations
That would be true of even a bottle of
bleach Your Honor Under the regulations if you
went down and boughtClorox bleach and you put it
on your shelf and you did your laundry like any
typical person would that is going to the
labeling requirements of that product are going to
be governed by the FHSA Okay
But if you buy that product and you
take it into your work environment and you got
people using it to clean the floor to do the
dishes to clean the bathrooms for any number of
reasons that you would use it in a work area And
theyr usingit on a daily basis say four hours
a day now that chemical that would otherwise just
be a household chemical is going to be a chemical
falling under the OSHA regulations and in order to
60
THE COURT Lets just go back and address
his the Ivegot CloroxIve got Dial soap
MRLLOYD Sure
THE COURT Okay
MRLLOYD Sure
THE COURT I got Dial soap Now its in
the correctional facility Does the
manufacturersresponsibilities changebecause
itsused in a workplace
MR LLOYD No Your Honor
THE COURT Thank you
MR LLOYD The easy answer is no And the
reason for that is quite simple Imean the
standard itself the FHSA is very clear that
whenever products can be reasonably anticipated to
be used in on or around the household or a place
where people dwell then the FHSAapplies The
OSHA standard is very clear that whenever the FHSA
applies the OSHA standard does not
Dr Purswell in his during his
deposition and it was toward the end of the
deposition andIm not going to belabor the
court with finding the specific citation at this
moment but the fact of the matter is he
maintained throughout the entire deposition that
59
1 comply theyr going to have to comply with the
2 hazardous communication standard
3 AndImnot sure where Im at onmy
4 time but
5 THE COURT I think we have all blown
6 through the time at this point Thank you
7 counsel If you want to briefly respond because
8 Mr Strother is back there I think hesenjoying
9 it
10 MR STROTHER Not very much
11 MR LLOYD I wouldntanticipate
12 THE COURT I mean its really interesting
13 Go ahead Mr Lloyd
14 MRLLOYD Thank you Your Honor
15 THE COURT Why dontyou start with a
16 response to the last one
17 MR LLOYD Okay In response to the last
18 one I think when we were looking at the letter
19 the July 29 2009 letter that Mr Overson just
20 just brought to the courtsattention frankly to
21 the same extent that Dr Purswell is attempting to
22 make legal conclusions that won hold weight in
23 this courtroom I think the same thing could be
24 said ofthis letter
25 Furthermore to the extent
61
1 this was the case What Mr Overson has contended
2 now is the case that both of them can apply to a
3 particular product
4 At the end of the deposition when we
5 started going through the opinion letters on which
6 he relies andIll get to that issue in just a
7 moment that the opinion letters on whichhe
8 relies they specifically say that its not a
9 for any particular product that its not an
10 eitheror standard that one of its not a
11 bothand standard Its an eitheror either one
12 is going to apply or the other one is going to
13 apply He admits this at the end of his
14 deposition
15 Another thing that he admits during his
16 deposition and this one I will point the
17 courtsattention to is on page near where
18 Mr Overson was pointing the courtsattention
19 its on page 209 of his deposition Because I
20 asked him about these opinion letters on which he
21 relied because frankly as we presented to the
22 court we presented case after case after case
23 that establishes that when the FHSA applies it
24 preempts any state law causeof action and
25 combined with the fact that OSHA has not provided
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1 go after the lungs as opposed to the eyes and the 1 co ply, they're going to have to co ply ith the 
2 s . 2 hazardous ca ion sta . 
3 There's really no dispute of fact in 3 nd I'm ot re here I'm t   
4 this case that that is the purpose of this law 4 ti , but--
5 enforcement product, that it is sold to law  THE :  t i  e have ll blown 
6 enforcement for that purpose. nd when it is used 6 through the ti e at this p i t. ha  y , 
7 by an employee with a greater frequency than what 7 counsel. If you ant to briefly respond because 
8 would be expected of the average consu er, then 8 . trother is ack th . I t ink 's  
9 it's going to fall under the OSHA regulations. 9 it. 
1  hat  e true f en  tle of  . : ot ery . 
11 bleach, our onor. nder the regulations, if you 11 . : I l n't cipate --
12 went down and bought Clorox bleach and you put it  E :  , i 's l  inter . 
13 on your shelf and you did your laundry like any  o , . . 
14 typical person would, that is going to -- t e  . : a  , our r. 
 labeling requirements of that product are going to  E :  n't   ith  
 be governed by the FHSA. Okay.  response to the last one. 
 But if you buy that product and you  . : .  res onse t  t  last 
 take it into your work environment and you got  one, I t i k hen e ere looking at the letter, 
 people using it to clean the floor, to do the  the July 29, 2009 letter that r. verson just--
20 dishes, to clean the bathrooms, for any number of  just brought to the court's attention, frankly, to 
 reasons that you ould use it in a work area. nd  e e   r. l s   
 they're using it on a daily basis, say, four hours  a e l l lusions t t n't l  i t i  
 a day, now that chemical that would otherwise just   rt ,        
 be a household chemical is going to be a chemical  i  f t i  l tt r. 
 falling under the OSHA regulations and in order to  ,  e  --
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 THE COURT: Let's just go back and address  t i   t  e. t r. s   t  
  --  -- I've got Clorox, I've got Dial soap. 2  s  ,      l    
 . D: r .  rti l  ct. 
 THE COURT: Okay.  t the end of the deposition hen e 
 . : re. 5 started going through the opinion letters on hich 
 THE COURT: I got Dial soap. Now it's in  he relies, and I'll get to that issue in just a 
 the correctional facility. Does the  o ent, that the opinion letters  hich e 
 manufacturer's responsibilities change because  relies, they specifically say that it's not a --
9 it's used in a workplace?  for any particular product, that it's not an 
 . : , r nor.  i /o     f -- it's t a 
11 THE COURT: Thank you.  oth/and t ndard. t's  i r/ r; i   
12 MR. LLOYD: The easy answer is no. And the  is going to apply or the other one is going to 
 reason for that is quite simple. I mean, the  apply. He ad its this at the end of his 
 standard itself, the F S  is very clear that  deposition. 
 whenever products can be reasonably anticipated to  nother thing that he ad its during his 
 be used in on or around the household or a place 6 siti  --    I ill i  t  
 where people dwell, then the FHSA applies. The 7 ourt's tt nti  t  -- is on page -- r r  
 OSHA standard is very clear that whenever the FHSA  r. ers  as i ti  t e court's attention, 
19 applies, the OSHA standard does not.  it's on page 209 of his deposition. ecause I 
 r. r ll i  i  -- during his  ask  i  abo t t s  i i  l tt rs  i   
 deposition and it was toward the end of the  r li  cause, frankly, as  pr t  t  t  
22 deposition -- and I'm not going to belabor the  court, e presented case after case after case 
 court with finding the specific citation at this 23 t  stabli  t   t   applies, it 
24 e t -- but t  f ct f t  tt r i  h  24 pree pts any state la  cause of action and 
25 maintained throughout the entire depOSition that 25 i  it  t  f ct that OSHA h  not pr vi  
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a private cause of action and therefore has to be
subsumed into a state law cause ofaction FHSA
therefore preempts anything in which OSHA would be
used as a evidentiary basis
On page 209 I asked if theresa
conflict between an opinion letter issued and I
use random dates here just put some chronological
order on it if theresa conflict between an
opinion letter issued in 1990 and a court opinion
on the same subjectmatter issued in 2000 which
in your mind carries more legal effect His
answer The binding aspect of that is whatever
the court rules is the courts is the courts
correct interpretation of the regulation
EvenDr Purswell admits thatwhen in
conflict with the case law that we have presented
to the court which itself has not been disputed
and no case law to the contrary has been
presented that case law is going to apply Its
the courts interpretation not the opinion
letters
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1 already indicated the court will not be
2 THE COURT I didnteven read it
3 MR OVERSON Exactly All of those opinion
4 letters on which he relies are contained nowat
5 the end of that amended affidavit They werent
6 presented to the court before But the fact of
7 the matteris and to potentially ward off any
8 motion for reconsideration based on this
9 information the fact of the matter is the case
10 law uniformly holds that the FHSA is going to
11 apply whenever under any reasonably foreseeable
12 standard of use or you know bringing along
13 what have you that the FHA the FHSA is going
14 to apply
15 Now within that discussion a
16 representation was made to the court just now by
17 Mr Overson that this product this law
18 enforcement grade or brand product the
19 specific Fogger that thatsnot available to the
20 general consumers Frankly that statement just
21 not true We have affidavit testimony from Bob
22 Nance and there frankly is no affidavit
23 testimony to the contrary from from the
24 plaintiff that while SEC does not sell this
25 particular product on the open market to consumers
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1 that FHSA does in fact apply to that product
2 We have the same thing here SEC
3 doesntsell it but one of their distributors
4 perhaps 50 of their distributors sells it to the
5 general public And there is no dispute including
6 through Dr Purswell at this point that the
7 product itself is therefore available to the
8 general public The general public can find it
9 It can be used in and in and around places
10 where people dwell whether that be a correctional
11 facility or a household and all of this really
12 comes to the head that the FHSA does apply And
13 by OSHAsown admission essentially if thatsthe
14 case then OSHA will not apply
15 Now Iwant to now I guess were
16 going in reverse of the argument that Mr Overson
17 had presented One thing I think is important
18 here to note and that is this distinction that
19 Mr Overson has tried to make between what is the
20 known and foreseeable standard Is that that
21 there has to be a definitive study out there a
22 definitive article or rather can it be the
23 collaboration of a number of things that sort of
24 hint around it and therefore SEC should have
25 been on knowledge in 2008 on notice in2008
22 Now the opinion letters on which he
23 baseshis his opinion is theyr frankly
24 included in that last affidavit that amended
25 affidavit of Dr Purswell that the court has
1
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again as I mentioned in my open comments that
is merely a product of an agreement that they have
with their distributors to not to not compete
with them onthe consumer market
Notwithstanding that the product is
available for consumer purchase through what he
estimatesto be around 50 distributors that he was
aware of at the time he made his affidavit
And so what this brings in is I
suggest Your Honor the case Canty versus
Everlast Supply Co which is wev cited in
our briefing 685 A2d Ill slow down 685
A2d 1365 And Im looking at pages 1370 through
1371
In this case the evidence reveals that
Everlast one of the stores where lacquer seal is
sold again this is a product that is intended
for industrial use but the question is whether
the FHSA nevertheless applies In this case the
evidence reveals that Everlast one of the stores
where lacquer seal is sold is open to the general
public as well as trades people Any Everlast
customer whether professional or not may
purchase lacquer seal for household use And on
this basis the New Jersey Supreme Court decides
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2  
1     t   t   t   1 alrea  i icate  t e c rt ill t e --
2  i    l  c  f cti n,  2  OURT: I didn't  r  it. 
   t     l   3 R. SON: xactly. ll of those opinion 
4    vi ti  sis.  l   i   r l  ar    t 
5      i  ere's   the end of that a ended affidavit. They eren't 
6 fl     l t  d,    rese te  t  t e c rt efore. t t e fact f 
7  r  t  r , j t t  r l i l 7  at r  --  t  t nti ll  r  ff an  
8   it,  ere's  fli  t     f r si rati    t i  
 opinion letter issued in 1990 and a court opinion  i f r ti n, t  f ct f t  att r i  t  c  
10    j t t    0,   la  unifor ly holds that the F S  is going to 
11       ff ct?   apply whenever under any reasonably foreseeable 
 r, ''Th  i i  t  t t i  t   standard of use, or, you know, bringing along, 
13   e    ourt's --  t  ourt's  hat have you, that the F  - the F S  is going 
  t    gulation."  to apply. 
15 e  r. rs ell a its t at e  i   ,     
16 conflict ith the case la  that e have presented  representation as ade to the court just no  by 
17   urt,  l     s te   r. verson that this product, this la  
18   s  l  t  t  tr r  s   e f rce e t ra e -- or brand product, the 
19 r t , t t  l  i  i  t  pply. It's  specific Fogger, that that's not available to the 
20 the court's interpretation, not the opinion  general consu ers. rankly, that statement's just 
21 letters.  not true. e have affidavit testi ony fro  Bob 
 o , the opinion letters on hich he  Nance, and there, frankly, is no affidavit 
23  s -- is i i  i  -- t ey're, fr kly,  testi ony to the contrary fro  -- r   
 lude   at  vit,    plaintiff that hile  does not sell this 
 i it  . ll t t t  t   particular product on the open market to consumers 
  
1 -- a ain, as I e ti ne  i   e  c e ts, t at  that FHSA does, in fact, apply to that product. 
2 is erely a product of an agree ent that they have  e have the sa e thing here. SEC 
3 ith t ir i tributors t  t -- to not co pete  sn't  , t    ibutors --
4 th   t e  t. 4 r a s  f t ir istrib tors s lls it t  t  
 t ithstanding t,  ct s  general public. nd there is no dispute including 
6 available for consu er purchase through hat he  through r. urs ell at this point that the 
  to    stributors   a   product itself is therefore available to the 
 are    ti e   s i .  general public. he general public can find it. 
9 nd s  hat this rings in is -- I  t  e    - in and around places 
 t, r r, the se    here people d ell, hether that be a correctional 
11 verlast ly o., ich is -- e've cite  in  facility or a household, and all of this really 
12 r bri fi , 85 .2d -- I'll  .   co es to the head that the F S  does apply. nd 
 .2d 1365. nd I'm looking at pages 1370 through  by SHA's o n ad ission essentially if that's the 
14 .  case, t e   ill t a l . 
 I  t is  e idence e e s   ,   t  - now, I guess we're 
6 verlast, one of the stores here lacquer seal is  going in reverse of the argument that Mr. Overson 
 sold -- i , this is  product that is intended  had presented. ne thing I think is i portant 
 for industrial use, but the question is hether  ere t  te   s s istinction at 
 the  e ertheless li s. In this ase t   . ers  as tried t   e   is the 
20 evidence re e ls that E e , one  the res  kno n  res  r . Is  tha  
21 here lacquer seal is s l , is pen to the general 21 there has to be a definitive study out there, a 
 public as ell as trades people. ny Everlast  d finitive rti l , r rather  it  the 
23 custo er, hether professional or not, ay  collaboration of a nu ber of things that sort of 
 purchase lac er seal for se ld se. nd   hint around it, and, therefore,  should have 
25 this basis the ew Jersey re e Court decides 25 been on knowledge in 2008 --  tice i  08 
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that this particular product could cause the
longterm chronic health effect
I think Your Honor through your
questioning is well aware of the dispute here I
would only add because the representation was made
by Mr Overson that there is no requirement that a
single definitive study exists the problem with
that argument is that itsin direct conflict with
the very statute on which he relies for the bulk
of his argument OSHA
And the OSHA standard pointing the
courtsattention for ease most of ease of
reference was discussed in Dr Purswells
affidavit The only way that the OSHA standard
going to apply is if theresa physical hazard and
thats something like combustion something that
can do actual physical harm to something or if
itsahealth hazard And this comes from 29 CFR
Section 191020 specifically the definition of
health hazard
That definition has that definition
requires a chemical for which there is
statistically significant evidence based on at
least one study conducted in accordance with
established scientific principles
68
on at least one study conducted in accordance with
established scientific principles that acute or
chronic health effectsmay occur in exposed
employees
So the argument I suspect will be
well the acute effects are known and therefore
it falls under health standard and you have to
warn against that particular target
But again that doesn get to the
heart of what were talking about here I can
conceive inmy mind a warning that would go on
that label that would say Warning Acute
temporary reversible respiratory effects will
result from
THE COURT Andwestill be here
MRLLOYD Andwestill behere It
doesntget to the heart ofwhere we are
And with that Your Honor again
unless you have any questions Ithink Your Honor
has already identified many of the other issues I
would discuss
THE COURT Counsel very brief response and
then then what Imgoing to do is take up
Mr Strother so he can get out of here well take
a brief recess and Ill come back in
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1 And so to the extent thatMr Overson
2 is arguing that theresnot a requirement for a
3 single definitive study frankly under OSHA there
4 is There is in fact there is very clearly a
5 requirement in order for OSHA to even apply to the
6 product
7 Now the admission has now been made on
8 the record here today that Dr Yost couldn point
9 to one single definitive study none of
10 plaintiffsexperts could point to one single
11 definitive study So to that extent OSHA is not
12 even going to apply
13 Now I suspect that the argument in
14 response to that if wehad time for an argument
15 in response to that
16 THE COURT Imgoing to give him five
17 minutes
18 MRLLOYD Okay All right
19 THE COURT AndId like you to kind of wrap
20 it up before Mr Strother jumps up and starts
21 screaming
22 MR LLOYD Sure I expect that the
23 argument in response to that is that that
24 definition says in totality a chemical for which
25 there is statisticallv significant evidence based
1 Go ahead counsel
2 MR OVERSON just in terms of the
3 standardId just encourage the court to take a
4 look at the Coombs case Coombs versus Curnow
5 Its219P3d453 The Idaho citation is 148
6 Idaho 129 Its a 2009 Supreme Court case
7 Then also another Idaho Supreme Court
8 case 2007143 Idaho 834 There letssee
9 Both of them deal with the proximate cause issue
10 and scientific evidence thats necessary to
11 support their proximate cause link And they both
12 recognize that an expert can look at the
13 overall grouping of evidence likeIve been
14 talking about as Mr Yost did and draw valid
15 scientific conclusions from that
16 On 145 ofDr Yosts deposition and 146
17 I
18 THE COURT Ido have that Let me make
19 sure that I have that Ive got a lot of
20 deposition material here Ive got Yost Okay
21 145 you said
22 MROVERSON Uhhuh
23 THE COURT Okay
24 MROVERSON Okay Nowhesjust been
25 asked a few questions about letssee Im
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1 that this particular product could cause the    t  t  ext t t t r.  
2 -ter   l  f ct. 2 is ar i  t at t ere's t a re ire e t f r a 
3 I t i  r r t r  r  si l  efi iti  study, fr nkly, r  t r  
4 ti   l      re.   .  i , i  t -- there is very clearly a 
5 ld l    t  r r t ti     require ent in order for OSHA to even apply to the 
 by r. verson that there is no require ent that a  ct. 
7 si l  fi iti e st  ists, t  r le  it   w,        
 t t t i  t t it's  ire t fli t ith  t    t  t t r. t uldn't i t 
9 t e r  t t t   i   r lie  f r t  l   to one single definitive study, none of 
 of his argu ent, SHA.  laintiff's e erts c l  i t t  e si le 
11  t   t ard, i ting t   fi iti  st y.  t  t t t t  is t 
 ourt's tt ti    -- t        ply. 
 ce,    r. urswell's  Now, I suspect that the argu ent in 
 f i vit. e l   t t t e  t ndard's  response to that, if e had ti e for an argu ent 
15 i  t  a l  is if t ere's a sical azar  a   i  res se t  t at --
 t at's t i  like ti , t i  t t   T: I'm i  t  i  i  fi  
 can do actual physical har  to so ething, or if  i tes. 
18 t's  th r .   e      . : ay. ll ri ht. 
 ti  910. 2 0, cifi ll  t e fi itio  f  T E T: nd I'd like you to kind of rap 
20 lt  r .  it up before r. Strother jumps up and starts 
 at tion  -  tion  screa ing. 
 requires a che ical for hich there is  R. LLOYD: Sure. I expect that the 
 st tisti ll  si ifica t idence s   t  argu ent in response to that is that that 
24 least   cted n  th  definition says in totality a che ical for hich 
 established scientific principles.  ere s ti ti l y i ica    
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 on at least one study conducted in accordance ith   d, nsel. 
 established scientific principles that acute or  . : J t -     
 chronic health effects ay occur in exposed  standard, I'd just encourage the court to take a 
4 l . 4   e  ,   r . 
 So the argu ent I suspect ill be,  t's  .3d 3.      
 l , e te e ts  , , f r ,  Idaho 129. It's a 2009 upre e ourt case. 
 it falls under health standard and you have to  Then also another Idaho Supre e Court 
 arn against that particular target.  e,   .  -- t's . 
 But, again, that doesn't get to the 9 Both of them deal with the proximate cause issue 
 rt f t 're t l ing t r . I   and scientific evidence that's necessary to 
 conceive i  y ind a arning that ould go on  support their proximate cause link. And they both 
 that label that would say: arning: Acute  recognize that an expert can look at --  
 t r r  r rsi le r s ir t r  ff ts ill  overall grouping of evidence, like I've been 
 r lt fro  -  talking about, as r. ost did, and dra  valid 
 E T:  e'd   .  ti  s ro  t. 
 . :  e'd till  . t  On 145 of Dr. Yost's deposition and 146 
 esn't et t  t e eart f here e are.  1--
18 nd ith that, our onor, again,  E T:   e t.   e 
 unless  have any questions, I think our r  s re t at I have that. I've got a lot of 
 has already identified any of the other issues I  deposition aterial here. I've got ost. kay. 
  s .  145 you said? 
 THE COURT: Counsel, very brief response and  . : -hu . 
23 t e  - then hat I'm going to do is take up  THE COURT: Okay. 
 r. Strother so he can get out of here, e'll take  . S : kay. o , he's just been 
  ie  re , d I' l e a  i .  asked a few questions about -- t's . 'm 
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trying to okay Well do you think and it
says DAW but its obviously do you think people
that were trained in toxicology such as yourself
would have been able to review the medical
literature and the scientific
THE COURT Can you tellme where you are
MR OVERSON Im sorry I bumped up one
just for context 144 start at line 21
THE COURT Okay I must have the wrong
does he have two depositions that I donthave
copies of Ive got a deposition Yost
deposition 419 2011
MR OVERSON No that would be the same one
I must be looking at I just grabbed the rough
draft Your Honor I apologize But it is it
is at the end of the deposition Itsthe last of
four pages And hesasked
THE COURT Just a second Im trying to
find it because Id like to be to read along with
you What page is it
MR OVERSON On the rough it was one
excuse me 144
THE COURT And what is it hessaying it
starts off with
MR OVERSON Lets see The question is
72
should know back in 08 And he says probably
not no Its this is something for
toxicologists for scientists to look into
And under OSHA itstheir obligation to
investigate the safety of their product before
they put it out there
THE COURT I know but counsel go on
further Read his answer
MR OVERSON Right I dontsee the
evidence
THE COURT Let let me point out what Im
looking at
MR OVERSON Okay
THE COURT He said Dontsee any evidence
that normal ways for industrial hygiene officers
and personnel to evaluate such kinds of exposure
may or may not have existed at that time I
haventseen it I mean I donthave any I
donthave evidence that would say heresan MSVS
sheet that says this bad thing is going to happen
if you expose it It does say you know this is
an irritant This is an acute thing not chronic
Its going to cause this this and this and so
youd better be aware of it But Imnot aware of
anything that the normal lay person in the
GVP11003515
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1 Well do you think people that were trained in
2 toxicology such as yourself would have been able
3 to review the medical literature and the
4 scientific literature that existed on or prior to
5 March 2008 and been able to determine that there
6 would have been a life altering condition that
7 resulted from pepper spray exposure
8 Idontsee evidence of the normal
9 ways for industrial hygiene officers and personnel
10 to evaluate such kinds ofexposure
11 THE COURT I cantfind this counsel
12 MR BURKE Its actually at page 154 Your
13 Honor
14 THE COURT Oh okay Sorry Im trying to
15 follow along
16 MR OVERSON And I apologize
17 THE COURT Thatsall right
18 MR BURKE It starts it started with the
19 question on line 12
20 THE COURT Okay Well do you think people
21 that were trained Okay
22 MR BURKE Right
23 MR OVERSON And this is an example of what
24 I was talking about is because the way the
25 question was framed is do you think the lay person
73
1 industry would would say or see would
2 necessarily show that
3 The problem just okay I dont
4 want to get into this but really it is this
5 distinction between acute and chronic Thats
6 really what the issue is
7 MR OVERSON Yeah And I see him going on
8 and saying conversely maybe there is something
9 And the question that hesbeen asked is as to the
10 lay person
11 But he goes on and then he explains I
12 can say I think theres an association between
13 conditions she now has and that exposure And
14 thats based on your many years of experience as a
15 toxicologist Yes
16 And itsbased on your extrapolation
17 of a number of scientific papers and your weighing
18 your weighing of the evidence is that right
19 Yes But you cantcite me to one specific
20 paper out there that existed prior to March 2008
21 that specifically would have put lay persons
22 without your background on notice that exposure to
23 their product could have caused these longterm
24 health conditions No The question is
25 extremely specific
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1 t in  t  -- y. ll,   t i  --  it  "W ll,   t i  l  t t  t i  i  
 sa s , t it's i sl    t i  e le  t ic l  s c  as rself l  a e ee  a le 
3 t t re tr i  i  t i l  s  s rself     i  t    
4 ould have been able to revie  the edical  scientific literature that existed on or prior to 
 literat re a  t e scie tific --         t  
6  RT:   ll    r .  ould have been a life-altering condition that 
7 . N: I'm s rry, I     r lt  fr  r r  r ?" 
 just  t t. 4 , I t t t li e .  "I on't     l 
 T E C RT: kay. I ust have the rong--  ays for industrial hygiene officers and personnel 
 es   t  iti  t t  on't   to evaluate such kinds of exposure." 
11 ies f? 've   ositi ,    T:  an't  i , sel. 
12 pOSiti , /192011.  . : It's actually at page 154, our 
 . N: ,        or. 
14  st  l i  t.  j t  t    T E T: h, okay. Sorry. I'm trying to 
 ft,  r.  ol gi e.    -- it  f ll  l . 
16 i  t t   f t  siti . It's t  l t f  . S N: nd I apologize. 
  s.  e's  --   T: hat's all ri t. 
  T: J st a sec . I'm tr in  t   . KE:  t  --     
19 fi  it s  I  like t   t  r  l  ith  ti   li  . 
 . t  i  it?   T: kay. ell, do you think people 
21 . :  t e r  it as e--  that ere trained. kay. 
 s  , .  . : ight. 
  T:  at is it e's sa i  it  . :  t is is a  e a le f at 
 ts  ith? 24 I as talking about, is because the ay the 
 R. OVERSON: Let's see. The question is,  question was fra ed is do you think the lay person 
  
1 should kno  back in '08. nd he says, probably  industry ould -- ould say or see ould 
2 t, . t's -- this is so ething for  ssaril  s  t at." 
3 t i l i t ,  i tists t  l  i t .  he proble  -- just -- okay. I don't 
4 nd under  it's their obligation to 4 want to get into this, but really it is this 
5 i estigate t  s f t  f t ir r ct f r   ion    i . at's 
6 t e   it  t r .  really hat the issue is. 
7  T: I kno , but, counsel, go on  R. OVERSON: Yeah. And I see him going on 
8 f rt er. ea  is a s er.  and saying conversely aybe there is so ething. 
9 . E S : ight. "I don't see the  nd the question that he's been asked is as to the 
10 i " --  la rs . 
11  : et --l t  i t t at I'm  ut he goes on and then he explains, "I 
12 looking at.  can say I think there's an association bet een 
13 . : a .  conditions she now has and that exposure." "And 
14 T E C RT: e said, "Don't see any evidence  that's based on your any years of experience as a 
15 at r al s  i t ial iene ice s  toxicologist?" "Yes." 
16 and personnel to evaluate such kinds of exposure  "And it's based on your extrapolation 
17 ayor ay not have existed at that ti e. I  of a number of scientific papers and your weighing 
18 haven't seen it. I ean, I don't have any -- I  r -- ei i  f t e e i e ce; is t at ri t?" 
19 't ave idence t t ld s  re's  S S  "Yes." "But you can't cite e to one specific 
20 sheet that says this bad thing is going to happen  paper out there that existed prior to arch 2008 
21 if  e se it. It es sa ,  , t is is  that specifically ould have put lay persons 
22 an irritant. his is an acute thing, not chronic.  ithout your background on notice that exposure to 
23 It's i  t  ca se t is, t is a  t is a  s   their product could have caused these long-term 
24 y u'd tter e are f it. t I'm t re f  t  o s?" "No." The question is 
25 anything that the nor al lay person in the  extremely specific. 
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1 THE COURT Right And then your affidavit 1 they have
2 that youveprovided where you had the opportunity 2 THE COURT No thats not a burden In
3 to solve that in my opinion doesntHis 3 order to create a material dispute of fact youve
4 testimony in the affidavit doesn talk about 4 got to come back with facts that are actually
5 chronic conditions It talks about acute His 5 material to what theyr alleging And thats
6 affidavit where he comes up with his conclusion 6 what hessaying is you haventdone that
7 about the foreseeability is is specifically 7 MROVERSON Thank you Your Honor
8 related to a series of studies about half of 8 THE COURT Yeah Ive got to think about
9 which are beyond the time frame that were looking 9 it But what Imgoing to do is just take Im
10 at And thatsthe problem And thatsthe 10 going to take up Mr Strother because hesbeen
11 problem that your affidavit presented not the 11 very patient and then welltake a brief recess so
12 questioning by counsel during the deposition 12 I can lookup a few things
13 So letssee ifwe can wrap this up so 13 Recess
14 I can take care of MrStrother 14 THE COURT First I want to address the
15 MROVERSON Yeah and myapologies 15 implied warranty claim I know we didntget a
16 And remember we are on summary 16 lot of argument on it I think itspretty
17 motion for summary judgment And the initial 17 straight forward
18 burden to show that the plaintiff hasntcarried 18 There are two reasons to grant summary
19 the burden on one of the necessary elements is on 19 judgment on the implied warranty If I had to
20 the moving party Once theyv done that then 20 reach the second I would But its clear that
21 the burden shifts to us You show that 21 the responses to Request for Production No 21 is
22 THE COURT But to show to show a dispute 22 that it specifically says Plaintiff
23 of material fact youvegot to come back with 23 supplements her response to request forproduction
24 facts that meet their evidence 24 this is on June 24th 2010 by stating she
25 MR OVERSON But before that burdenshifts 25 will be dismissing the warranty claim And
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1 theresnothing in there to alert the defendants 1 is a question for the jury However the Supreme
2 that theyr not going to pursue just the 2 Court has made it clear that there aretimes when
3 express warranty claim 3 the evidence is so overwhelming and theres
4 And it appears to the court that the 4 nothing to show that the injuries would have been
5 supplemental response which was filed on June 5 foreseeable that summary judgment is appropriate
6 apparently June 7th of 2011 now explains that 6 Now in this particular case its
7 they want to dismiss only the express warranty 7 either that the product has been mismanufactured
8 claim but the problem is the time for filing 8 or is unaccompanied by adequate warnings This is
9 summaryjudgment is passed and clearly theres 9 why I had so many questions about the affidavit
10 prejudice to the defendant So I am going to 10 And to me the affidavit of the affidavit of
11 grant summary judgment on that 11 Mr Yost compared to his deposition is extremely
12 Ialso would note that there as 12 critical Because as we all know when summary
13 counsel for the defendants defendant noted 13 when there is summaryjudgment theburden is
14 theresno privity here and so therefore it 14 on the moving party and all reasonable inferences
15 would be unlikely shed be successful on that 15 are taken on behalf of the non moving party
16 claim anyway 16 However where an issue where a
17 The products liability issue is a 17 factual allegation has been made supported by
18 pretty interesting issue actually And Iwant to 18 affidavit or other admissible evidence then the
19 make it really clear that it is well settled Idaho 19 non moving party must come forward with admissible
20 law that a manufacturer has a duty to design its 20 evidence that shows that there is a material
21 products so to eliminate unreasonable risk of 21 dispute of that fact
22 foreseeable injuries And thatsreally the 22 The fact in this case is whether at the
23 thrust of the of the issue before me 23 time Miss Majors Miss Majorwas exposed to the
24 Normally and I would say to both 24 capsacin or pepper spray was the potential for
25 counsel normally whether something is foreseeable 25 Imsorry was the risk Imgoing to get the
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1  RT: i ht.    ff i   they have--
2 t t ou've r i  r    t  rt it    URT: o, at's   r en.  
       esn't.   r r t  r t   t ri l i t  f f ct, ou've 
4    f  esn't    got to co e back ith facts that are actually 
  diti s.  s  t . s  t ri l t  t they're ll i .  t at's 
6 affida it ere e c es  it  is c cl si   hat he's saying, is you haven't done that. 
7 t t  f r s abilit  is -- is s cifi ll   . : a  , r or. 
 a    s  ,  l   8  RT: h. I've t t  t i  t 
9 ic  are e  t e ti e fra e t at e're l i   it. t t I'm i  t   is j st ta e - I'm 
 t.  t at's t  l .  t at's t   going to take up r. Strother because he's been 
11 r le  t t r ffid it r s nted, t t  11 er  atie t a  t e  e'll ta e a rief recess s  
 ti ing  l ing t  siti .  I  l    f  t i s. 
13  t's   e  a  s    ( e ss) 
14 I can take care of r. trother.   RT: i t,      
 . : ,   l i .  i plied arranty clai . I kno  e didn't get a 
16  r r  r   s r  --  l t f r t  it. I t i  it's r tt  
 tion   j t.  t  i iti l  tr i t f r rd. 
 burden to sho  that the plaintiff hasn't carried  There are t o reasons to grant su ary 
 t e r e   e f t e ecessar  ele e ts is   j e t  t e i lie  arranty. If I a  t  
 t e ing rt .  they've  t t, t     cond,  uld.  t's  t  
21 t  r  s ifts t  s.  s  t t --  the responses to equest for Production o. 21 is 
  : ut to sho  -- t    i te   -- it specifically says, Plaintiff 
 of aterial fact, you've got to co e back ith  supplements her response to request for production 
     .  -- t i  i   e t ,  --  t ti   
 . : t    i ,  ill be dis issing the arranty clai . nd 
  
1 t ere's t i  i  t r  t  l rt t  fe ts  is a question for the jury. o ever, the Supre e 
 that ey're    rsue ust -- t   rt   it l r t t t r  r  ti e   
 press rra t  l i .  t  i e e is s  r l i   t ere's 
 nd it appears to the court that the  nothing to sho  that the injuries ould have been 
 s le e tal res se, ich as file   J e --  f reseea le t at s ar  j e t is a propriate. 
6 apparently June 7th of 2011, no  explains that  o , in this particular case it's 
 they a t to dis iss only the express arranty  either that the product has been is anufactured 
 clai , t the r le  is t e ti e f r filin   or is unacco panied by adequate warnings. This is 
 su ary judg ent is passed and clearly there's  hy I had so any questions about the affidavit. 
 rej ice t  t e efe a t. o I a  i  t    t   t  ffi it f -- t  ffi it f 
 r t r  judg e t  t t.  r. Yost co pared to his deposition is extre ely 
  ls  ld te t t t  --   critical. Because, as e all kno , hen su ary 
 l f r t e f t  -- e t ,  - when there is summary judgment, the burden is 
14 t re's  ri it  r , , s , t r f r , it  on the moving party and all reasonable inferences 
  e ikely he'd e l    are taken on behalf of the non- oving party. 
 l i  y.  r,    - ere  
 he products liability issue is a  factual allegation has been ade supported by 
 pretty i teresti  iss e act all . nd I a t t   ida t   le ,  e 
 ake t l  lea  t at t   e  da   non- oving party ust co e for ard ith ad issible 
 la  that  fa turer as  ty t  si  its  idence t t s s t t t r  is  t ri l 
 products so to eli inate unreasonable risk of  dispute of that fact. 
 foreseeable injuries. nd that's really the  e  n   s    
23 thrust f t e -- f the iss e f re .  time iss ajors - iss ajor was exposed to the 
 r ll  -- and I ould say to both  capsacin or pepper spray, as the potential for --
 counsel, nor ally hether so ething is foreseeable  I'm sorry, was the risk -- I'm going to get the 
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right wording Just a minute Was there an
unreasonable risk of the foreseeable injury that
she suffered in this case the chronic illness
that she suffered as a result And the emphasis
really is on the chronic nature of her illness
In looking at this it is clear that
Securities Equipment Corporation came forward with
an affidavit from their expert who said
essentially that there were no studies in
existence at the time that would have put Security
Equipment Corporation on notice that therewas a
foreseeable risk of excuse me a risk of the
foreseeable injury of chronic lung illness that
was suffered by the plaintiff in this case He
clearly makes that known
In response wehave first the
deposition of Mr Yost Mr Yostsdeposition
and Ido agree with Mr Lloyd you do have to
distinguish between whenMr Yost is talking about
the linkbetween the capsacin as being the cause
of her chronic illness as opposed to whether there
was information available that put Security
Equipment Corporation on notice that the risk of
of the chronic illness that she suffered was
foreseeable Thats the real issue at the time
80
as late as 2010 We cant expect the defendant to
have guessed what future research was going to
show
But in addition if you actually look
at what he says he does not really address the
real issue here which was whether they would have
known in 2008 when this this product was
marketed that there was this danger a foreseeable
risk of developing a chronic illness such as the
plaintiff developed
This is what he says Based on my
review of the abovecited articles and my
education training research and knowledge of the
scientific literature in the relevant area it is
myopinion that the risk to the respiratory track
posed by exposure to this were a known and
foreseeable risk at the SEC when at the time SEC
sold its product to the IDOC Whatsmissing
from that is he doesn talk about what is he
referring to
And the reason that becomes important
whether he is talking about acute or chronic is
that subsequent in seven he says it is known now
and it was known prior to 2008 that people with
asthma and chronic cough are more sensitive to
79
1 in 2008 would the defendant have known that there
2 was this foreseeable danger to people usingthat
3 product
4 Mr Yost in response to the questions
5 in the deposition which I have read clearly
6 indicates that he cannot point to any existing
7 studies that would have put Security Equipment
8 Corporation on notice that there was this risk of
9 this kind of that it was a foreseeable danger
10 to people using the product
11 Now its true that in his affidavit he
12 makes certain statements and I want to talk about
13 those because I think they are important
14 First in paragraph six what he says
15 and he does he doesntreally do a good job in
16 his affidavit and my suspicion is that his
17 affidavit was actually written pretty carefully
18 Because first inparagraph six he talks about
19 what body of scientific research he relied on
20 relating to the effects of this and I cantsay
21 it I have trouble with it onhuman and animal
22 tissues And heidentifies these research
23 articles Abouthalf of them were well beyond the
24 period that the defendant would have had knowledge
25 of them They were 2008 and beyond And one was
81
1 pepper spray than other people with normal
2 respiratory function Okay That doesn say
3 that it was known that you could develop a chronic
4 condition as a result
5 And then he says that people with
6 greater sensitivity to capsacin would be expected
7 to have increased the TRPV1 or T I
8 thinksV1 receptor populations Okay Again
9 hes not saying that it was known there was a risk
10 of a chronic condition developing as a result of
11 exposure to capsacin
12 He says Thus it is reasonable to
13 expect the multiple TRP channels act in concert
14 with each other to result in a higher and I
15 want to emphasize he says acute respiratory
16 responses to a multitude of respiratory irritants
17 particularly in people with increased sensitivity
18 to pepper sprays
19 Now I assume that hesbeing very
20 specific as a scientist because he doesntwant to
21 say something that he cantsupport In a prior
22 paragraph again he doesntsay chronic
23 development of chronic disease Henever says
24 that
25 In the second paragraph he does not say
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 distinguish bet een hen r. ost is talking about  hat body of scientific research he relied on 
 the li  t een t  s i  s i  t  s  20 relati  t  t e effects f t is -- a  I can't sa  
 of her chronic illness as opposed to hether there  it, I e tr le ith it --     
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 as late as . e ca 't e ect t e efe a t t   e er s ra  t a  t er e le it  r al 
 have guessed hat future research as going to  respiratory function. kay. That doesn't say 
 .  that it was known that you could develop a chronic 
 ut, in addition, if you actually look  o    sult. 
 at at e sa s, e es t reall  a ress t e  nd then he says that people ith 
 r l iss e r , ich as t er t e  l    greater sensitivity to capsacin ould be expected 
      -- this product as   e creas  -  I --   --  
 arketed that there as this danger, a foreseeable  think's I receptor populations. kay. gain, 
 risk of developing a chronic illness such as the  he's not saying that it was known there was a risk 
 plaintiff developed.  of a chronic condition developing as a result of 
 is is at  s s, "Base     exposure to capsacin. 
 revie  of the above-cited articles and y  He says, "Thus it is reasonable to 
 education, training, research and kno ledge of the  expect the ultiple T P channels act in concert 
 ti  iterature  e e a t , t   it  eac  t er t  res lt i  a i er --  I 
 y opinion that the risk to the respiratory track  ant to e phasize he says "acute respiratory 
 se   e s re t  t is ere a    responses to a ultitude of respiratory irritants 
 res         ti e   particularly in people ith increased sensitivity 
 sold its product to the IDOC." hat's missing  to pepper sprays." 
 ro   s  sn't l    s   , I ass e t at e's ei  er  
 referring to.  specific as a scientist because he doesn't want to 
 And the reason that beco es i portant,  say something that he can't support. In a prior 
 hether he is talking about acute or chronic, is  paragraph, again, he doesn't say chronic --
 that subsequent in seven he says, it is kno n no   develop ent of chronic disease. e never says 
 and it as kno n prior to 2008 that people ith  t. 
 asth a and chronic cough are ore sensitive to  In the second paragraph he does not say 
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1 chronic He says acute Thats what he says 1 thatsomehow translates into the creation of
2 And I read all of the rest of the things While 2 chronic disease is simply it doesn make
3 he generally criticizes Reilly and says he doesnt 3 sense
4 agree with him well okay thats not creating 4 So I dontfind that there is any
5 as far as I can see that there is and then 5 dispute of material fact that has been identified
6 this is the other thing that he also says This 6 for this court And Ill just note that we have
7 is paragraph nine And heres where hes 7 and these are pretty extensive files in this
8 attacking Dr Reilly and he says Certainly there 8 case SoIm going to grant summary judgment to
9 is a degree of controversy about the chronic 9 the defendant as to this issue
10 effects and whether they can be associated with 10 Now the other issue that exists is
11 acute exposures And thenhe criticizes Reilly 11 this preemption issue and I want to make it clear
12 he says But to state that all of the studies 12 that in the preemption issue the case law suggests
13 adhere to this paradigm is not true 13 that that FA Federal Hazardous Substance Act
14 In other words whatIm trying to say 14 is very broad And if it applies it preempts
15 is this affidavit does not clearly tee up the 15 Even the OSHA regulations recognize that if this
16 issue of does not create a material dispute of 16 applies it preempts And if you think about it
17 fact because there is not a direct dispute between 17 it makes sense This is Federal Hazardous
18 Dr Reilly other than for him to say I dontagree 18 Substances Act Presumably these are hazardous
19 with him But he doesntcome back and say that 19 substances So if they are regulated thats
20 its undisputed or that there are these studies or 20 going to be the totality of the regulation
21 something that says there is this risk of chronic 21 And as and if you look at the case
22 disease as a result to the exposure 22 law and not just the Canty case which was cited
23 And to the extent he suggests that 23 which is a New Jersey case but there are federal
24 that because there are people who have died as a 24 cases also which make it clear that if it applies
25 result of acute exposure to pepper spray that 25 it preempts
1 So the issue is does it apply And if
2 you look at the CRFs it says the appropriate
3 test is not whether its marketed this way but
4 whether under any customary or reasonably
5 foreseeable condition of purchase storage or use
6 may be brought into or around a house apartment
7 or other place people dwell
8 Now I think if you read this and its
9 supposed to be read pretty broadly because the
10 purpose behind it is to protect those people who
11 are going to come intocontact with the hazardous
12 substance to protect them and thatswhy the
13 federal government has stepped into this and
14 thats the purpose behind the legislation
15 Letstalk letsthink about it from
16 this standpoint This product whether this
17 company marketing it to the general public is
18 kind of a red herring And I say that with due
19 respect Probably there are other companies that
20 are marketing it fine Im not going to make my
21 decision based on that But I am going to say
22 that they are carried and everyone here agrees
23 they are carried by law enforcement Law
24 enforcement in fact I can tell that you they
25 come right here into this courtroom with it Ive
1 seen it They carry it with them pretty much at
2 all times That means its going to under any
3 customary or reasonably foreseeable condition
4 which is if this goes to law enforcement it
5 isntjust law enforcement in a prison whichIm
6 going to get to in a moment its law enforcement
7 It says foreseeable condition of purchase storage
8 or use may be brought into or around a house
9 apartment or other place where people dwell Law
10 enforcement go into houses all of the time They
11 do
12 But I dontthink you have to stop
13 there Letstalk about a prison Of all the
14 places there you would want and in particular
15 I want to talk about you gave me some
16 documents counsel which I thought were really
17 interesting which is the MKFogger and how its
18 used And Illtake notice of the Cell Buster
19 for example Where is it used Lets see the
20 picture even shows it being put into a persons
21 cell where the person dwells and they dwell by
22 force People like me put them in there Theyr
23 there It is a dwelling Okay
24 Now it also happens to be a workplace
25 Thats I mean thats the truth Its a
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 agree ith hi , ell, okay, that's not creating,   I n't fin  t t t r  is  
      e,    --  t   dispute of aterial fact that has been identified 
 this is the other thing that he also says. This  for this court. nd I'll just note that e have 
 is paragraph nine. nd here's here he's 7 -- and these are pretty extensive files in this 
 attac i  r. eill  a  e sa s, "Certai l  t ere  case. So I'm going to grant su ary judg ent to 
 is a degree of controversy about the chronic       . 
 effects and hether they can be associated ith  , t  t r i  t t i t  i  
 acute exposures. nd then he criticizes eilly,  t is ree ti  iss e a  I a t t  a e it clear 
 he says, "But to state that all of the studies  that in the pree ption issue the case la  suggests 
 ere t  t is i  i  t t ue."   --   --   e  
 In other words, what I'm trying to say  is very broad. nd if it applies, it pree pts. 
 is this affidavit does not clearly tee up the  Even the S  regulations recognize that if this 
 iss e f -- es t create a aterial is te f  a lies, it ree pts.  if  t i  a t it, 
 fact because there is not a direct dispute bet een  t  e. s    
 r. eilly other than for hi  to say I don't agree  Substances ct. Presu ably these are hazardous 
 with him. But he doesn't come back and say that  substances. So if they are regulated, that's 
20 it's undisputed or that there are these studies or  going to be the totality of the regulation. 
 so ething that says there is this risk of chronic    -- and if you look at the case 
 disease as a result to the exposure.  la , and not just the Canty case hich as cited, 
 nd to the extent he suggests that --  which is a New Jersey case, but there are federal 
 that because there are people ho have died as a 24 s s ls  i   it l r t t if it lies 
 t   s re  r r y,    t . 
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 So the issue is does it apply. nd if  seen it. They carry it ith the  pretty uch at 
 you look at the RF's, it says the appropriate  all ti es. at ea s it's i  t  er a  
 test is not hether it's arketed this ay, but  custo ary or reasonably foreseeable condition, 
 whether under any customary or reasonably  hich is if this goes to la  enforce ent -- it 
 foreseeable condition of purchase, storage or use  isn't just law enforce ent in a prison, which I'm 
 ay be brought into or around a house, apart ent  going to get to in a o ent, it's la  enforce ent. 
 or other place people dwell.  It says foreseeable condition of purchase, storage 
 Now, I think if you read this, and it's  or use ay be brought into or around a house, 
 supposed to be read pretty broadly, because the  apart ent or other place here people d ell. La  
 purpose behind it is to protect those people ho  enforcement go into houses all of the time. They 
 are i  t  c e i t  c tact it  t e azar s  . 
 substance to protect the  and that's hy the  But I don't think you have to stop 
 federal govern ent has stepped into this and  there. et's talk about a prison. f all the 
 that's the purpose behind the legislation.  places there, you would want -- and in particular 
 t's l  -- t's    ro        -- you gave e so e 
 this standpoint. This product, whether this  documents, counsel, which I thought were really 
 company's marketing it to the general public is  interesting, which is the -K Fogger and how it's 
 kind of a red herring. And I say that with due  d.  'll     l  r, 
 respect. Probably there are other co panies that  for exa ple. here is it used? Let's see, the 
 are arketing it fine. I'm not going to ake y  picture even shows it being put into a person's 
 decision based on that. But I am going to say  cell where the person dwells and they dwell by 
 that they are carried, and everyone here agrees,  force. People like e put the  in there. They're 
 they are carried by la  enforce ent. La   there. It is a d elling. kay. 
  -- in fact, I can tell that you they  Now, it also happens to be a workplace. 
 come right here into this courtroom with it. I've  at's -- I n, t at's t  tr th. It's  
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1 workplace too That doesn mean for those 1 fairly could be interpreted to at least raise the
2 things which are not preempted under the Federal 2 issue under notice pleading Im not I
3 Hazardous Substances Act that OSHA might have some 3 certainly am not in a position to determine
4 implication for how itsused for example They 4 whether the failure to warn claim whether the
5 might be able to determine where itsused 5 failure whether they appropriately labeled it
6 And the example you gave me of the 6 under the Federal HazardousSubstances Act I
7 hazardous what was it Clorox I guess Okay 7 have no clue That issue is really not
8 It clearly would be under the Federal Hazardous 8 appropriately before me
9 Substances Act if in fact they want to regulate 9 But as to whether the failure to warn
10 that But how itsused might be regulated under 10 claims are preempted and whether the Federal
11 OSHA They may say you can use it in these 11 Hazardous Substances Act preempts any action
12 certain areas 12 any OSHA action I think the lawsclear it does
13 For the purposes of determining whether 13 And so Imgoing to grant summary judgment on that
14 the warning label is sufficient or the the 14 particular issue
15 foreseeable nature of its use that would be 15 Now again Imnot addressing the
16 regulated under the Federal Hazardous Substances 16 other issue that was raised by theplaintiff in
17 Act in other words it would be under the federal 17 this case at this at this point I think now
18 law and the federal law clearly would preempt 18 Ive addressed pretty much all of the issues
19 And that would include whether the product has 19 And along those lines this iswhat Im
20 been appropriately labeled Now I know thats 20 going to do on the affidavit I recognize the
21 been raised as an issue in the crossmotion Im 21 basis for the motion to strike Werenot Im
22 not going to address that now but it may be 22 not addressing the ones dealing with the ones
23 appropriate for further motion practice 23 that were filed the 11th and 12th because I just
24 And you may look I don Iwas 24 I haven read them
25 trying to look at the complaint to see if it 25 But with respect to the motion to
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1 strike MrYosts Dr Yosts affidavit Imnot 1 started out I hope I didntcome across quite
2 going to do that Im not going to find 2 I wasntmeaning to come across grumpy My
3 because of the way that I interpret his affidavit 3 clerk suggested I may have come across grumpy
4 I dontinterpret it as directly being directly 4 Imnot I just think it is important for all
5 at odds with his deposition In fact as I 5 counsel to realize how difficult it is sometimes
6 indicated I think itswritten very carefully if 6 to get hearing dates Itsvery very hard to do
7 you read it read between the lines I think 7 that
8 itswritten carefully to avoid exactly that 8 And I think also you need to understand
9 So Im not going to find it is a sham 9 that at least in my court I really like to read
10 affidavit Imnot going to strike it And I 10 everything because I think itsimportant I also
11 think if you look at the case law I think we 11 think oral argument is extremely important And
12 should be loathe to strike something on that basis 12 even though I put you on some time constraints
13 unless itsvery very clear that one is saying 13 you can see that I kind of ignored them because I
14 one thing and the other onessaying something 14 think these issues are very interesting I dont
15 totally different And I cantsay that about 15 think theyr easy issue I really appreciate the
16 what Dr Yost said But Ido think that his 16 way both sides have really addressed the issue and
17 affidavit does not create a material dispute a 17 have been I thought the briefing was really
18 dispute of material fact And so thatswhat my 18 good very very good on both sides I really
19 ruling is And I would ask you to provide me the 19 appreciate that a lot
20 appropriate order on that 20 So I want to thank you We dont
21 And again if you want to tee up the 21 usually get terribly interesting cases Time
22 issue of whether theyv complied with the federal 22 consuming but not necessarily interesting case
23 lawImnot precluding you from doing that 23 MRBURKE Your Honor I have a question
24 MR OVERSON Thank you Your Honor 24 THE COURT And by the way Imreally
25 THE COURT Okay And I appreciate I 25 sorry I understand your father passed away
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 issue of hether they've co plied ith the federal  consu ing, but not necessarily interesting case. 
 law, I'm not precluding you from doing that.  R. B R E: our onor, I have a question. 
 R. ERS : Thank you, our onor.  THE COURT: And, by the way, I'm really 
 T E T: kay. nd I appreciate --   sorry. I understand your father passed a ay. 
8/15/201  01:36:27  .. i  , ffiCi l t rt r, Oi , I  
M 0
MAJORVS SEOUIRTY EQUIPMENT CORP CVPI 1003515
Kim Madsen Official Court Reporter Boise Idaho UtyiLU11 U1SoLrm
90 91
1 MR BURKE Oh I appreciate that 1 MR OVERSON Just I apologize I asked
2 THE COURT Okay 2 on my cross motion
3 MR BURKE We have a trial date I think 3 THE COURT Yes
4 itsset for October 17th 4 MR OVERSON I understood that my staff
5 THE COURT Yeah 5 had contacted your clerk and that
6 MRBURKE Its very likely we will try to 6 THE COURT Oh dontworry about it
7 tee this up Is that if you do that are we 7 MROVERSON So therewas a
8 going to be in jeopardy of losing that trial date 8 miscommunication in my office so I apologize for
9 THE COURT Imgoing to try real hard not 9 that
10 to have you lose the trial date But make sure 10 THE COURT Dontworry about it I
11 that you you file it and let me go ahead and 11 MR OVERSON Actually its a pet peeve of
12 set some schedule something based on my 12 mine too Ive had opposing counsel do that to
13 calendar 13 me before
14 And even though I like things to be 14 THE COURT I know and they just notice
15 heard 60 days out you know thatsmy discretion 15 things up You just want to go but no I
16 as to whether I force people and I think this 16 don because because of the nature of the
17 case is interesting enough that it will get 17 cross motion it didn really cause any problems
18 priority Not the priority that my statutory one 18 but I think youvegot to be really careful I
19 has but definitely priority 19 wasntgrumpy about that I just and you
20 MR BURKE I will commit we will try to 20 notice that I did I considered it so I read
21 file something as soon as we possibly can 21 all of it
22 THE COURT I would appreciate that and I 22 And it wasn I guess also because
23 assume youlldo the same thing 23 you filed it just about the same time that the
24 MROVERSON Yes Your Honor 24 I had given everyone the scheduling dates it
25 THE COURT Okay 25 didntcause me a lot of heartburn When I found
92
1 out about it I didntcall my clerk I didnt 93
2 have my clerk call you and say Imnot listening
1 R E P O R T E R S C E R T F C A T E
3 to your cross motion But no and it was a 2
4 real cross motion So it was fine Dontworry 3
5 about it 4 I KIM I MADSEN Official Court
6 MR OVERSON Thank you Your Honor
5 Reporter County of Ada State of Idaho hereby
7 THE COURT I guess Imjust trying to tell
6 certify
took the7 That I am the reporter who
8 everybody how bad the and were not going to 8 proceedings had in the above entitled action in
9 get any relief So anyway thank you gentlemen 9 machine shorthand and thereafter the same was
10 MR LLOYD Thank you Your Honor
10 reduced into typewriting under my direct
11 MR OVERSON Thank you Your Honor
11 supervision and
12 That the foregoing transcript contains
12 THE COURT I appreciate it 13 a full true and accurate record of the
13 14 proceedings had in the above and foregoing cause
14
15 which was heard at Boise Idaho
15
16 IN WITNESS WHEREOF have hereunto set
17 my hand thisdayof 2011
16
18
17 19
18 20
19
21
KIM I MADSEN Official Court Reporter
20
22 CSR No 428
23
21 24
22 25
23
24
25
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 R. B R E: h, I appreciate that. 
2 E : kay. 
3 . : e ave  trial . I thin  
 it's s t for t  1 . 
 E T: e . 
6 . E: It's very likely e ill try to 
7 tee this up. Is that -- if you do that, are e 
 going to be in jeopardy of losing that trial date? 
 E : I'm going to try real hard not 
0 to have you lose the trial date. But ake sure 
11 that you -- you file it -- and let e go ahead and 
1   e -- sc e le s et ing ase    
13 r. 
 And even though I like things to be 
 heard 60 days out, you kno , that's y discretion 
 as to hether I force people -- d I t i  t is 
 case is interesting enough that it will get 
 priority. Not the priority that my statutory one 
 has, but definitely priority. 
 . : I ill c it e ill tr  t  
 file so ething as soon as e possibly can. 
 THE COURT: I ould appreciate that and I 
 assu e you'll do the sa e thing? 
 . : ,  r. 
 T E C RT: kay. 
 
 out about it, I didn't call y clerk --  i n't 
 have y clerk call you and say I'm not listening 
 to your cross-motion. But -- no, a  it as a 
 r l r ss- ti .  it  fi e. n't rr  
  . 
 R. OVERSON: Thank you, Your onor. 
 T E C RT: I guess I'm just trying to tell 
 everybody ho  bad the -- and we're not going to 
 get any relief. So, anyway, thank you, gentlemen. 
 . : hank you, our onor. 
11 R. OVERSON: Thank you, Your onor. 
 THE COURT: I appreciate it. 
 
 
 
16 
 
 
 
20 
21 
 
 
 
 
CVPI1003515 
91 
 . : t -- I l i . I  
 on y cross- otion --
3 E : es. 
 . : --  stood that  f 
 ad tacted  e   that --
 E : , n't rr  t it. 
 . :  t r  as  
 is i ti  i   ffi , s  I l ize f r 
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  it sn't -- I guess, also because 
 you filed it just about the sa e ti e that the --
 I had given everyone the scheduling dates, it 
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IN THE DISTRICTCOURT OF THE FOURTH JUDICIAL DISTRICTOF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
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CORPORATION a Missouri corporation
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MEMORANDUM IN SUPPORT OF
SEC MOTION TO STRIKE
PORTIONS OF THE SECOND
AFFIDAVIT OF GAROLD S YOST
PhD
Defendant
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA pursuant toIRCP26 56e andIRE705 submits
this Memorandum in support of its Motion to Strike Portions of the Second Affidavit of Garold
S Yost PhD Dr Yost filed in Support of Plaintiffs Motion to Reconsider the Courts
Order on DefendantsMotion for Summary Judgment Motion to Reconsider
INTRODUCTION
Dr Yost has now provided testimony in this case on three different occasions First on
April 19 2011 SECs counsel deposed Dr Yost at his home in Sandy Utah Yost
Deposition second on June 10 2011 Plaintiff submitted the original Affidavit of Gerald Yost
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h.D. 
efendant Security Equip ent Corporation ("SE "),   t r  its s l f 
record, reener urke hoe aker P.A., pursuant to I.R.C.P. 26, 56(e), and I.R.E. 705, sub its 
this e orandu  in support of its otion to Strike Portions of the Second ffidavit of arold 
S. Yost, Ph.D. ("Dr. Yost"), filed in Support of Plaintiffs otion to Reconsider the Court's 
rder on efendant's otion for Su ary Judg ent ("Motion to econsider"). 
 
Dr. Yost has now provided testimony in this case on three different occasions: First, on 
April 19, 2011, SEC's counsel deposed Dr. Yost at his home in Sandy, tah ("Yost 
Deposition"); second, on June 10, 2011, Plaintiff sub itted the original ffidavit of Gerald ost, 
E ORANDU  IN SUPPORT OF SEC'S OTION TO STRIKE PORTIONS OF THE SECOND 
FFIDAVI  OF AROLD S. YOST, Ph.D. - Page I 14542-  ( 06756.doc) 
PhD in Opposition to DefendantsMotion for Summary Judgment First Yost Affidavit
finally Plaintiff has most recently submitted a second Affidavit of Dr Yost in support of her
pending Motion for Reconsideration of this Court Order granting Summary Judgment to SEC
on a number of issues presented in this case Second Yost Affidavit Through each of these
variations on issues material to the outcome of this litigation Dr Yosts testimony has
continually changed Moreover his latest affidavit testimony is in direct contradiction to his
earliest deposition testimony and should be stricken as sham affidavit testimony
As the Court is well aware the First Yost Affidavit was determined not to provide the
evidence necessary to withstand SECs Motion for Summary Judgment SECs MSJ
Plaintiff could not prove and did not prove with the First Yost Affidavit the existence of
scientific knowledge prior to 2008 that would have sufficiently put SEC on notice of known or
foreseeable risks of chronic adverse health effects resulting from exposure to its law enforcement
branded oleoresin capsicum OC spray products Largely on that basis the Court rightfully
granted summary judgment to SEC on Plaintiffsclaims for Negligence and Strict Liability
SEC previously filed a Motion to Strike the First Yost Affidavit following Plaintiffs
Opposition to SECs Motion for Summary Judgment SEC contended that the First Yost
Affidavit was vague and in all events insufficient to assist Plaintiffs resistance to summary
judgment read one way the affidavit was inadmissible as a sham affidavit because of its direct
contradiction to the Yost Deposition read another way the affidavit failed to assert the facts
necessary to withstand summary judgment as it did not establish that the alleged chronic adverse
health effects alleged in this case were known or foreseeable to SEC at the time it manufactured
the product to which Plaintiff was exposed Adopting the latter interpretation the Court denied
MEMORANDUM IN SUPPORT OF SEC MOTION TO STRIKE PORTIONS OF THE SECOND
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Ph.D., in Opposition to Defendant's otion for Summary Judgment ("First Yost Affidavit"); 
finally, Plaintiff has most recently submitted a second Affidavit of Dr. Yost in support of her 
pending Motion for Reconsideration of this Court's Order granting Summary Judgment to SEC 
on a nu ber of issues presented in this case ("Second ost ffidavit"). hrough  f t ese 
variations, on issues aterial to the outco e of this litigation, r. ost's testi ony has 
continually changed. or r, is latest ffi it t ti  is i  ire t tr i tion t  is 
earliest deposition testi ony and should be stricken as sha  affidavit testi ony. 
s the ourt is ell-a are, the First ost ffidavit as deter ined not to provide the 
evidence necessary to ithstand SEC's otion for Su ary Judg ent ("S 's SJ"). 
Plaintiff could not prove, and did not prove with the First Yost Affidavit, the existence of 
scientific knowledge prior to 2008 that would have sufficiently put SEC on notice of known or 
f res l  ris s f r i  erse lt  ffe ts r s lti  fr  s r  t  its l  f r t 
branded oleoresin capsicu  ("OC") spray products. argely on that basis, the ourt rightfully 
granted summary judgment to SEC on Plaintiffs claims for Negligence and Strict Liability. 
SEC previously filed a Motion to Strike the First Yost Affidavit following Plaintiff s 
Opposition to SEC's otion for Su ary Judg ent.    t    
Affidavit was vague, and in all events insufficient to assist Plaintiff s resistance to summary 
judgment: read one way, the affidavit was inadmissible as a sham affidavit because of its direct 
contradiction to the Yost Deposition; read another way, the affidavit failed to assert the facts 
necessary to withstand summary judgment, as it did not establish that the alleged chronic adverse 
health effects alleged in this case ere kno n or foreseeable to SE  at the ti e it anufactured 
the product to which Plaintiff was exposed. Adopting the latter interpretation, the Court denied 
RA  I  SUPP  F SEC'S TI  TO STRIK  PORTI S OF T  SECO  
AFFIDA VIT OF GAROLD S. YOST, Ph.D. - Page 2 14542- 11 ( 06756.doc) 
SECs earlier Motion to Strike because the First Yost Affidavit was too vague to directly
contradict the Yost Deposition and in all events did not definitively say that the alleged chronic
adverse health effects of exposure to OC spray were known andor foreseeable to SEC when it
manufactured the product to which Plaintiff was exposed
Now in support of PlaintiffsMotion to Reconsider Plaintiff has filed another Affidavit
of Gerald Yost PhD In contrast to the First Yost Affidavit the Second Yost Affidavit has
taken the extra step to definitively state conclusions that are in direct contradiction to the Yost
Deposition Dr Yost has belatedly identified new articles and stated new opinions that were not
previously disclosed either during discovery in Plaintiffs expert designation Dr Yosts report
Dr Yostsdeposition testimony nor in the First Yost Affidavit Notwithstanding the obvious
prejudice that this places upon SEC in being unable to confront the ever changing opinions of
Dr Yost the relevant portions of the Second Yost Affidavit should be appropriately deemed
sham testimony and stricken from this Court consideration for any purpose in this litigation
To be clear for purposes of this Motion to Strike as was the case with the earlier Motion
to Strike SEC seeks only to strike the specific opinions rendered and conclusions asserted by Dr
Yost in his affidavit that contradict his prior deposition testimony While SEC does not
specifically object to or move to strike the totality of the Second Yost Affidavit it reserves the
right to do so if necessary at a later time As with the earlier motion this Motion to Strike is
limited to the issue of whether the scientific knowledge available in March 2008 would have put
SEC on notice that exposure to OC spray could cause the long term adverse health effects of
which Plaintiff complains
MEMORANDUM IN SUPPORT OF SEC MOTION TO STRIKE PORTIONS OF THE SECOND
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C's e ier otion t  ike ecause the irst ost ffida it as t    re  
contradict the ost eposition, and in all events did not definitively say that the alleged chronic 
adverse health effects of exposure to  spray ere kno n andlor foreseeable to S  hen it 
anufactured the product to hich Plaintiff as exposed. 
o , in support f laintiffs otion to econsider, laintiff has filed another ffidavit 
of erald ost, h.D. In contrast to the irst ost ffidavit, the econd ost ffidavit has 
taken the extra step to definitively state conclusions that are in direct contradiction to the Yost 
Deposition. Dr. Yost has belatedly identified new articles and stated new opinions that were not 
previously disclosed either during discovery, in Plaintiff s expert designation, r. ost's report, 
Dr. Yost's deposition testi ony, nor in the First Yost Affidavit. Notwithstanding the obvious 
prejudice that this places upon SEC in being unable to confront the ever-changing opinions of 
r. ost, the relevant portions of the Second ost ffidavit should be appropriately dee ed 
sha  testi ony and stricken fro  this ourt's consideration for any purpose in this litigation. 
 e clear, f r r ses f t is ti  t  tri e, as as t e case it  t e earlier ti  
to Strike, SE  seeks only to strike the specific opinions rendered and conclusions asserted by r. 
st i  is affi a it t at c tra ict is ri r e siti  testi ny.     
specifically object to or ove to strike the totality of the Second Yost Affidavit, it reserves the 
right to do so if necessary at a later ti e. s ith the earlier otion, this otion to Strike is 
li ite  t  t e iss e f et er t e scientific le e a aila le i  arch,  l  a e t 
SEC on notice that exposure to OC spray could cause the long term adverse health effects of 
hich Plaintiff co plains. 
III 
 I    EC'S I   T I  I     
I A I   L  . ST, h.D. - Page 3 145 -  ( 06756.doc) 
FACTUAL BACKGROUND
Though much of the factual background on this Motion is the same as that which was
previously described in the earlier Motion to Strike the First Yost Affidavit the relevant facts are
restated and supplemented as follows for the convenience ofthe Court
Plaintiff originally disclosed Dr Yost as an expert witness on August 5 2010 just over
six 6 months in advance of the original deadline for Plaintiffs disclosure of expert witnesses
See Affidavit of Thomas J Lloyd III filed in Support of Motion to Strike Affidavit of Dr Yost
previously filed in this action on June 24 2011 Lloyd June Aff 2 and Exhibit A With
that disclosure was an expert report authored by Dr Yost dated July 28 2010 Id His report
detailed his opinions as to three specific questions
Could occupational exposure to Sabre Red be a causative factor for Billie
Majorsmedical condition
What are the toxicities of oleoresin capsicum which is the active ingredient in
Sabre Red and other similar OC Spray products
How does the toxicity and strength of Sabre Red compare to other similar OC
Spray products on the market
Id Attached to the First Yost Affidavit was a copy of this very same expert report which had
not been updated or revised Nothing in Dr Yostsreport renders an opinion or makes reference
to any fact regarding the availability of information or literature prior to March 2008 that would
have put SEC on notice of the risk of longterm adverse health effects such as Plaintiff alleges
as a result of exposure to OC spray
SEC took the deposition of Dr Yost in Sandy Utah on April 19 2011 During that
deposition Dr Yost detailed his testimony in this litigation and stated that he did not have any
additional opinions beyond what was covered in the deposition See Lloyd June Aff 6 and Ex
E at 156410 SECscounsel questioned Dr Yost extensively as to what information literature
MEMORANDUM IN SUPPORT OF SEC MOTION TO STRIKE PORTIONS OF THE SECOND
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hough uch of the factual background on this otion is the sa e as that hich as 
previously described in the earlier otion to Strike the First ost ffidavit, the relevant facts are 
restate  a  s le e ted as follo s f r t e c e ie ce f t e rt: 
Plaintiff originally disclosed r. ost as an expert itness on ugust 5, 2010, just over 
six (6) onths in advance of the original deadline for Plaintiff s disclosure of expert itnesses. 
(See ffidavit of Tho as 1. Lloyd III filed in Support of otion to Strike ffidavit of r. ost, 
previously filed in this action on June 24, 2011 ("Lloyd June Aff."), ~   t .) t  
t at is los re a   rt r rt t r   r. t, t  l  , . (I .) i  r rt 
detailed his opinions as to three specific questions: 
• ould occupational exposure to Sabre ed be a causative factor for illie 
ajor's edical condition? 
• hat are the toxicities f oleoresin capsicu , hich is the active ingredient in 
Sabre ed and other si ilar  Spray products? 
•   t  t i it   tr t  f r   r  t  t r i il r  
Spray products on the arket? 
(Id.) Attached to the First Yost Affidavit was a copy of this very same expert report, which had 
t ee  ate  r re ise . t i  i  r. st's re rt re ers a  i i  r a es refere ce 
to any fact regarding the availability of infor ation or literature prior to arch, 2008 that ould 
have put SEC on notice of the risk of long-ter  adverse health effects, such as Plaintiff alleges, 
as a result of exposure to C spray. 
 took the deposition of r. ost in andy, tah on pril 19, 2011. uring that 
deposition, r. ost detailed his testi ony in this litigation and stated that he did not have any 
additional opinions beyond hat as covered in the deposition. ( ee loyd June ff. ~   x. 
Eat 156:4-10.) SEC's counsel questioned Dr. Yost extensively as to what information, literature 
 I    EC'S   STRI  TI    SEC  
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and scientific knowledge was available to SEC at the time it manufactured and sold the OC spray
at issue and whether SEC could have known or foreseen the risk of longterm chronic injuries
akin to what Plaintiff alleges in this litigation Dr Yost responded unequivocally and on several
occasions that SEC could not have known or foreseen those alleged risks at that time Id
1536 156
On April 22 2011 SEC filed and served its Motion for Summary Judgment and
supporting Memorandum and Affidavit of Counsel SEC moved for summary judgment as to
Plaintiffs claims for strict liability and failure to provide an adequate warning based upon the
fact that the risks of the long term chronic injuries alleged by Plaintiff were not known or
foreseeable by SEC or anyone else and accordingly that Plaintiffs claims fail SEC has no
duty to warn against or design around injuries which are not known or foreseeable See
generally SECsMSJ
On June 10 2011 Plaintiff filed her opposition to SECsmotion for summary judgment
including the First Yost Affidavit Plaintiff based her argument that the injuries alleged by
Plaintiff were known and foreseeable to SEC entirely on that First Yost Affidavit However as
noted above the Court rejected the notion that the First Yost Affidavit had presented the
evidence necessary to withstand summary judgment in that it did not specifically state that there
was sufficient information or knowledge available in 2008 that would have put SEC on notice
that their OC products could cause chronic respiratory injuries On that basis the Court granted
Summary Judgment to SEC
In response to the Courts criticism of the shortfalls of the First Yost Affidavit Plaintiff
has gone back to Dr Yost yet again in an attempt to dredge testimony that will salvage her tort
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and scientific kno ledge as available to  at the ti e it anufactured and sold the  spray 
at issue, and hether  could have kno n or foreseen the risk of long-ter  chronic injuries 
akin to hat Plaintiff alleges in this litigation. r. ost responded, unequivocally and on several 
i , t t  l  t   r f res  t s  lle  ri  t t t ti . (I ., 
153:16-156:1.) 
n pril 22, 2011,  filed and served its otion for u ary Judg ent, and 
supporting e orandu  and ffidavit of ounsel. SE  oved for su ary judg ent as to 
laintiffs clai s for strict liability and failure to provide an adequate arning based upon the 
fact that the risks of the long-ter  chronic injuries alleged by Plaintiff ere not kno n or 
foreseeable by SE  (or anyone else) and, accordingly, that Plaintiffs clai s fail. SE  has no 
duty to arn against or design around injuries hich are not kno n or foreseeable. (See 
generally, SEC's SJ.) 
 J  , , l i tiff fil  r siti  t  EC's ti  f r s r  j t, 
including the First Yost Affidavit. laintiff based her argu ent that the injuries alleged by 
Plaintiff ere kno n and foreseeable to S  entirely on that First ost ffidavit. o ever, as 
noted above, the ourt rejected the notion that the First ost ffidavit had presented the 
e i e ce ecessar  t  it sta  s ar  j ent, i  t at it i  t s ecificall  state t at t ere 
as sufficient infor ation or kno ledge available in 2008 that ould have put SE  on notice 
that their OC products could cause chronic respiratory injuries. On that basis, the Court granted 
Su ary Judg ent to S . 
In response to the Court's criticis  of the shortfalls of the First ost ffidavit, Plaintiff 
has gone back to r. ost, yet again, in an atte pt to dredge testi ony that ill salvage her tort 
 I    EC'S I   STRI  I    SEC  
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claimsagainst SEC In the Second Yost Affidavit Plaintiff has still failed to identify any
source or citation that provides the information necessary to have put SEC on notice prior to
March 2008 that its OC products may cause longterm chronic adverse health effects Still Dr
Yost has now made unequivocal assertions regarding what he contends were known risks of OC
spray in 2008 which assertions directly contradict his prior deposition testimony Those
assertions SEC argues must be stricken from the record as inadmissible sham testimony
LEGAL STANDARD
IRCP56e provides that an affidavit submitted in support of or in opposition to a
motion for summary judgment shall set forth such facts as would be admissible in evidence
IRCP56eRyan v Beisner 123 Idaho 42 44 844P2d 24 26 1992 citing Petricevich
v Salmon River Canal Co 92 Idaho 865 452 P2d 362 1969 A court will consider only
that material contained in affidavits or depositions which is based upon personal knowledge and
which would be admissible at trial In ruling on a motion for summary judgment the
admissibility of the evidence presented in support of or in opposition to a motion for summary
judgment is a threshold question to be answered before applying the liberal construction and
reasonable inference standard to determine whether the evidence is sufficient to create a genuine
issue of fact for trial Hecla Mining Co v Star Morning Mining Co 122 Idaho 778 839 P 2d
1192 1992 Ryan v Beisner 123 Idaho 42 844 P2d 24 1992 Evans v Twin Falls County
118 Idaho 210 796P2d 87 1990 If the admissibility of evidence presented in support of or in
As the Plaintiffspending motion which the Second Yost Affidavit was submitted in support
of is seeking reconsideration of a motion for summary judgment the same evidentiary standards apply
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claim(s) against SEC.  t e  st id i , i t   till le   t   
rce r it ti  t at r ides t  i f r ti  r  t   t   ti , ri r t  
arc  , t at its  r ts  s  l -ter , r i , rs  lt  ff ts. till, r. 
ost as  a e e i cal asserti s re ar i  at e c te s ere  ris s f  
spray in 2008, hich assertions directly contradict his prior deposition testi ony. s  
rti ,  r s, t  tri  fr  t  r r   i i i l   t ti ny. 
  
I.R.C.P. 6(e) r ides t t  ffi it itte  i  rt f r i  iti  t   
otion for su ary judg ent shall" ...          nce . 
.. " I.R.C.P. 6(e); y  v. eis er,  I a  , ,  .2d ,  (1 2), citi  etricevic  
. l  i  l o.,   ,  .2d  (1 9) ("[A] rt ill i  l  
t at aterial c tai e  i  affi a its r e siti s ic  is ase   ers al le e a  
hich ould be ad issible at trial"). 1 In ruling on a otion for su ary judg ent, the 
i i ilit   t  i  t  i  t   i  iti  t   ti    
judg ent is a threshold question to be ans ered before applying the liberal construction and 
reasonable inference standard to deter ine hether the evidence is sufficient to create a genuine 
issue of fact for trial. ecla ining o. v. Star- orning ining o., 122 Idaho 778, 839 P. 2d 
1192 (1992); Ryan v. Beisner, 123 Idaho 42, 844 P.2d 24 (1992); Evans v. Twin Falls County, 
 I a  ,  .2d 87 (1 0). If t e a issi ilit  f e i e ce rese te  i  s rt f r i  
1 As the Plaintiff's pending otion, which the Second Yost Affidavit was sub itted in support 
of, is seeking reconsideration of a motion for summary judgment, the same evidentiary standards apply. 
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opposition to a motion for summary judgment is raised by one of the parties the Court must
address that issue first Id
A courtsdecision to admit or exclude evidence is reviewed under the abuse of discretion
standard Morris ex rel Morris v Thomson 130 Idaho 138 141 937 P2d 1212 1215 1997
Error may not be predicated upon a ruling which admits or excludes evidence unless the ruling
is a manifest abuse of the trial courtsdiscretion and a substantial right of the party is affected
Burgess v Salmon River Canal Co Ltd 127 Idaho 565 574 903P2d 730 739 1994
The problem presented by affidavit testimony that contradicts earlier deposition
testimony has been addressed in great detail by Idaho federal and state courts and is generally
known as the sham affidavit rule Essentially the sham affidavit rule precludes a party from
creating an issue of fact to prevent summary judgment by simply submitting an affidavit that
directly contradicts prior deposition testimony by the affiant Without such a rule in place the
utility of summary judgment as a procedure for screening out meritless claims would be lost
Courts have consistently held that parties cannot prevent summary judgment by filing
sham affidavits that directly contradict deposition testimony See eg Boise Tower
Associates LLC v Washington Capital Joint Master Trust 2007 WL 1035158 1213 D Idaho
2007 quoting Cleveland v Policy Mgmt Sys Corp 526 US 795 806 1999 Courts have
held with virtual unanimity that a party cannot create a genuine issue of fact sufficient to survive
summary judgment simply by contradicting his or her own previous sworn statement by say
filing a later affidavit that flatly contradicts that partys earlier sworn deposition without
explaining the contradiction or attempting to resolve the disparity Van Asdale v IntlGame
Tech 577 F3d 989 99899 9th Cir 2009 quoting Kennedy v Allied Mut Ins Co 952F2d
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opposition to a motion for summary judgment is raised by one of the parties, the Court must 
addre s that i sue first. Id. 
 c rt's de ision to a   e clude idence is reviewed under the se of discretion 
st . is e . reI is v. ,  Ida  , 1,  .2d , 5 (19 7). 
"Error ay not be predicated upon a ruling which ad its or excludes evidence unless the ruling 
is  fes  s  f t e trial urt's is retion a d  s  ig t    is cted." 
Burgess v. Salmon River Canal Co., Ltd., 127 Idaho 565, 574903 P.2d 730, 739 (1994). 
The problem presented by affidavit testimony that contradicts earlier deposition 
testimony has been addressed in great detail by Idaho federal and state courts, and is generally 
kno n as the "sha  affidavit rule." ssentially, the sha  affidavit rule precludes a party fro  
creating an issue of fact to prevent summary judgment by simply submitting an affidavit that 
directly contradicts prior deposition testimony by the affiant. Without such a rule in place, the 
utility of summary judgment as a procedure for screening out meritless claims would be lost. 
ourts have consistently held that parties cannot prevent su ary judg ent by filing 
"sha " affidavits that directly contradict deposition testi ony. ee, .g.,  er 
Associates, LLC v. Washington Capital Joint Master Trust, 2007 L 1035158, 12-13 (D. Idaho 
2007) (quoting Clevelandv. Policy Mgmt. Sys. Corp., 526 U.S. 795, 806 (1999)) ("[Courts] have 
held with virtual unani ity that a party cannot create a genuine issue of fact sufficient to survive 
summary judgment simply by contradicting his or her own previous sworn statement (by, say, 
filing a later affidavit that flatly contradicts that party's earlier sworn deposition) without 
explaining the contradiction or attempting to resolve the disparity.");  sdal  v. Int'l  
Tech., 577 F.3d 989,998-99 (9th Cir. 2009) (quoting Kennedy v. Allied ut. Ins. Co., 952 F.2d 
RA DU  I  S PP  F SEC'S I  TO STRI  PORTI S OF TH  SECOND 
AFFIDAVIT OF GAROLD S. YOST, Ph.D. - Page 7 14542- 1 ( 06756.doc) 
262 266 9th Cir1991 Ifaparty who has been examined at length on deposition could raise
an issue of fact simply by submitting an affidavit contradicting his own prior testimony this
would greatly diminish the utility of summary judgment as a procedure for screening out sham
issues of fact see also Matter ofEstate ofKeeven 126 Idaho 290 298 882 P2d 457 465 Ct
App 1994 A sham affidavit which directly contradicts prior testimony may be disregarded
on a summary judgment motion Tolmie Farms Inc v JR Simplot Co Inc 124 Idaho
607 862P2d299 1993 Weagree that the purpose of summary judgment is served by a rule
that prevents a party from creating sham issues by offering contradictory testimony
ARGUMENT
A Dr YostsContradicting Testimony Is A Sham
SEC acknowledges that not every discrepancy between deposition testimony and a
subsequent affidavit constitute an inadmissible sham Courts have found that contradicting
testimony is not a sham where it is the result of an honest discrepancy a mistake or the result
of newly discovered evidence Smythe v Safeco Ins Co ofAmerica 33 Fed Appx 303 9
Cir 2002 citing Kennedy v Allied Mut Ins Co 952F2d 262 9 Cir 1991 However where
the affidavit testimony flatly contradicts earlier testimony the affidavit is a sham and cannot
be used to create an issue of fact Radobenko v Automated Equipment Corp 520F2d 540 9th
Cir 1975 Dr Yost does not give any explanation as to why his testimony has changed so
significantly with respect to what was known in 2008 about the potential health risks of exposure
to OC spray nor does he claim that he was honestly mistaken when he provided his deposition
testimony
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262,266 (9th Cir.1991)) ("[I]f a party who has been examined at length on deposition could raise 
an issue of fact si ply by sub itting an affidavit contradicting his o n prior testi ony, this 
would greatly di inish the utility of su ary judgment as a procedure for screening out sha  
issues of fact."); see also atter f state f eeven, 126 Idaho 290, 298, 882 .2d 457,465 (Ct. 
App. 1994) ("[A] sham affidavit which directly contradicts prior testimony may be disregarded 
on a su ary judgment otion .... "); l ie , . . R.  ., c.,   
607,862 P.2d 299 (1993) ("[W]e agree that the purpose of summary judgment is served by a rule 
that prevents a party from creating sham issues by offering contradictory testimony ... "). 
 
. Dr. Yost's Contradicting Testi ony Is A Sha . 
SE  ackno ledges that not every discrepancy bet een deposition testi ony and a 
subsequent affidavit constitute an inadmissible sham.      
testimony is not a "sham" where it is "the result of an honest discrepancy, a mistake, or the result 
of newly discovered evidence." Smythe v. Safeco Ins. Co. of America, 33 Fed. Appx. 303 (9th 
Cir. 2002) citing Kennedy v. Allied ut. Ins. Co., 952 F.2d 262 (9th Cir. 1991). However, where 
the affidavit testimony flatly contradicts earlier testimony, the affidavit is a "sham" and cannot 
  t  r t   i  f f ct.  . t t  i ent. orp.,  .2d 5  (9th 
Cir. 1975). r. ost does not give any explanation as to hy his testi ony has changed so 
significantly with respect to what was known in 2008 about the potential health risks of exposure 
to OC spray, nor does he claim that he was honestly mistaken when he provided his deposition 
testimony. 
E  I  SUPPO T OF SEC'S TI  TO STRI E PORTI S OF THE SECON  
FI AVI   A OLD S. ST, Ph.D. - Page 8 14542-011 ( 06756.doc) 
Further the Second Yost Affidavit is not based upon any newly discovered information
that was previously unavailable Indeed all of the information required to support his conclusion
is necessarily old information which should have existed in 2008 or earlier To the extent that
Dr Yost has now provided additional citations allegedly in support of his opinion the new
sources cited in the Second Yost Affidavit still do not conclude that longterm chronic adverse
health effects may result from exposure to OC spray See Second Yost Affidavit and Exhibits
thereto Dr Yosts conclusion therefore is still not supported by the literature which he cites
Accordingly Plaintiff is still unable to come forward with any evidence other than Dr Yosts
unsupported assertion contradicting his earlier deposition testimony that would create a question
of fact as to whether SEC should have known or foreseen the longterm chronic adverse health
effects that she has alleged in this action
It is true that the Second Yost Affidavit does now purport to clarify an issue previously
brought before this Court but only insofar as his earlier affidavit left a confusing impression
with this Court Second Yost Aff 8 What Dr Yost still does not do is even attempt to
clarify the relevant and contradicting portions of his deposition testimony Essentially all that
Dr Yost has clarified for the Court is that he really did intend all along to make assertions that
do contradict his prior testimony ie that his affidavit testimony does fit the description of sham
testimony
Dr Yost answered the same question during his deposition several different times all
with the same result there was not any scientific or medical literature available prior to March
2008 or at the time Dr Yost was deposed in April 2011 that would have enabled SEC or others
to have known or foreseen the risks of injuries such as alleged here by Plaintiff See Lloyd June
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Further, the Second Yost Affidavit is not based upon any newly discovered information 
that was previously unavailable. Indeed, all of the information required to support his conclusion 
is necessarily "old" information, which should have existed in 2008 or earlier. To the extent that 
Dr. Yost has now provided additional citations allegedly in support of his opinion, the new 
s urces cited in t e Second ost ffida it till  not clude that lo -ter , i  erse 
health effects ay result fro  exposure to C spray. (See Second ost ffidavit and Exhibits 
thereto.) Dr. Yost's conclusion, therefore, is still not supported by the literature hich he cites. 
Accordingly, Plaintiff is still unable to come forward with any evidence, other than Dr. Yost's 
unsupported assertion contradicting his earlier deposition testimony, that would create a question 
 t  t  t   l     res  t e l -te , i   lt  
effects that she has alleged in this action. 
It is tr e t at t e ec  st ffida it es  r rt t  clarif  a  iss e re i sl  
brought before this Court, but only insofar as his "earlier affidavit left a confusing impression 
ith this ourt." (Second ost ff., ~ .) t r. t till  t  i   tt t t  
clarify the relevant and contradicting portions of his deposition testimony. Essentially, all that 
r. t  l ri i   t  t i  t t  r all  i  i t  ll l  t   sserti  t t 
do contradict his prior testimony, i.e. that his affidavit testimony does fit the description of sham 
testimony. 
r. ost ans ered the sa e question during his deposition several different ti es, all 
ith the sa e result: there as not any scientific or edical literature available prior to arch, 
2008 (or at the time Dr. Yost was deposed in April, 2011) that would have enabled SEC or others 
to have known or foreseen the risks of injuries such as alleged here by Plaintiff. (See Lloyd June 
E RANDUM I  SUPPORT OF SEC'S MOTION TO STRIK  PORTIONS OF THE SECOND 
AFFIDAVIT OF GAROLD S. YOST, Ph.D. - Page 9 14542-011 ( 067S6.doc) 
Aff 6 and Ex E at 1536156 To the extent that he has now testified to the contrary that
testimony is a sham attempt to address the deficiencies noted by this Court during the hearing on
SECsMotion for Summary Judgment and in all events is not supported by any of the evidence
that either he or the Plaintiff has presented
B The Majority Of The Second Yost Affidavit Does Not Alter The State Of The
Evidence Previously Presented Further Evidencing The Sham Nature Of Dr Yosts
Conclusions
Plaintiff is again attempting to offer conclusory testimony of Dr Yost that directly
contradicts his prior deposition testimony given in this case for the single purpose of overturning
this Court decision on summary judgment The heart of the issue remains a very simple and
straightforward question Was there anything in the scientific literature in existence prior to
March 2008 that would have put SEC on notice of alleged risks of long term or chronic adverse
health effects as a result of exposure to OC Spray According to Dr Yosts deposition
testimony again confirmed by the admissions of Plaintiffs counsel on the record in open court
during the hearing on SECsfirst Motion for Summary Judgment the answer to that question is a
resounding No See Affidavit of Thomas J Lloyd III in Support of SECsMotion to Strike
Portions of the Second Affidavit of Garold S Yost PhDfiled concurrently herewith dated
August 18 2011 Lloyd August Aff 2 and Ex A at 322 3325 and 40224116 Neither
Plaintiff nor Dr Yost ought to be permitted to now assert otherwise in order to reverse this
Courtsdecision on Summary Judgment
That said a review of the Second Yost Affidavit reveals that there is no substantive or
meaningful change in the information relied upon by Dr Yost in stating that the alleged risks of
longterm chronic adverse health effects were known andor foreseeable in or prior to 2008
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. ~ 6 a d E .  at 153: 16- 56: 1. )  the e tent that he as no  testified to the c tr r , that 
testimony is a sham attempt to address the deficiencies noted by this Court during the hearing on 
S C's otion for Su ary Judg ent, and in all events is not supported by any of the evidence 
that either he or the laintiff has presented. 
. he ajority f he Second ost ffidavit oes ot lter he State f he 
Evidence Previously Presented, Further Evidencing The Sha  ature f r. ost's 
. 
Plaintiff is again atte pting to offer conc1usory testi ony of r. ost that directly 
contradicts his prior deposition testi ony given in this case, for the single purpose of overturning 
this Court's decision on su ary judg ent. The heart of the issue re ains a very si ple and 
straightforward question: as there anything in the scientific literature in existence prior to 
arch 2008 that ould have put SE  on notice of alleged risks of long-ter  or chronic adverse 
health effects as a result of exposure to  Spray? r i  t  r. st's siti  
testi ony, again confir ed by the ad issions of Plaintiff s counsel on the record in open court 
during the hearing on SEC's first otion for Su ary Judg ent, the answer to that question is a 
resounding "No." (See Affidavit of Thomas J. Lloyd III in Support of SEC's otion to Strike 
    fida    . t, h.D.,  rr ntl  rewith,  
August 18,2011 ("Lloyd August Aff."), ~   x.  t 2: 2-33:25  0: 2- 1:16.) it  
Plaintiff nor r. ost ought to be per itted to no  assert other ise in order to reverse this 
Court's decision on Su ary Judg ent. 
 aid,     c   i  r l  t  t    ubstanti  r 
eaningful change in the infor ation relied upon by r. ost in stating that the alleged risks of 
long-term, chronic adverse health effects were known andlor foreseeable in or prior to 2008. 
A  I    SEC'S  T  STRIKE PORTI  OF  SECON  
FFIDAVI  F L  S. ST, Ph.D. - Page 10 14542-  ( 06756.doc) 
Previously as noted by the Court Dr Yost was unable to provide any source report study
article or other document that has concluded that such risks exist The Court is reminded that
counsel for Plaintiff admitted unequivocally on the record that indeed no such authority existed
at that time Id During Dr Yosts deposition he very clearly expressed that he did not believe
any authority exists even now that would support that proposition
Q In your opinion as of March of 2008 was there anything
definitively published in the peerreviewed scientific and medical
literature that would have put a manufacturer of pepper spray
products such as SEC on notice that exposure to their products by
somebody with the chronic health conditions of Ms Major would
have caused her an exacerbated response which would have
included an ongoing chronic cough for the subsequent period of
time
A I dont think its possible for me to place a nefarious intent
You know the responsibility of whether or not there was sufficient
evidence there to say you know if you do if you expose
somebody to this they are going to have life altering changes I
dontthink that existed then In the literature today I dont
think it exists except through the preponderance of evidence
and it may very well be that other people dont believe that
thatsthe case but I do And so you know blame is for the jury
to decide
I I
Q But you cantcite me to one specific paper out there that
existed prior to March of 2008 that specifically would have put
laypersons without your background on notice that exposure to
their product could have caused these long term health conditions
A No
Lloyd June Af 6 and Ex E at 15361541 and 15520 156
By the Second Yost Affidavit and exhibits thereto the evidence has not changed
Though Dr Yost has identified a handful of additional articles that he claims support his
opinions on the forseeability of alleged chronic adverse health effects from exposure to OC
spray none of those articles do anything more than did the articles previously provided which
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Previously, as noted by the ourt, r. ost as unable to provide any source, report, study, 
a ticle    t at as de  that  is s t. he t    
s l f r l i tiff itted i ll   the re r  t t, ind ,  s  t rit  isted 
at that ti e. (ld.) uring r. ost's deposition, he very clearly expressed that he did not believe 
any authority exists even no  that ould support that proposition: 
Q. In your opinion, as of arch of 2008, was there anything 
definitively published in the peer-reviewed scientific and edical 
literature that l  a e t a a fact rer f e er s ra  
products such as SEC on notice that exposure to their products by 
somebody with the chronic health conditions of s. ajor would 
have caused her an exacerbated response hich ould have 
include  a  i  c r ic c  f r t e s se e t eri  f 
? 
. I n't t i  it's ssi le f r e t  lace a efari s i tent. 
ou kno , the responsibility of hether or not there as sufficient 
evidence there to say, you kno , if you do -- if you expose 
so ebody to this, they are going to have life altering changes. I 
n't t i  t t i t  t n.  t  literat re t   on't 
think it exists except through the preponderance of evidence, 
and it ay very ell be that other people don't believe that 
t at's t  case, t I .  s ,  , la e is f r t e j r  
 i . 
[ ... ] 
. But you can't cite e to one specific paper out there that 
existed prior to arch f 2008 that specifically ould have put 
laypersons without your background on notice that exposure to 
their product could have caused these long-term health conditions? 
. . 
(Lloyd June Aff., ~   x. t 53:16-154:11  5 :20-156:1.) 
By the Second Yost Affidavit and exhibits thereto, the evidence has not changed. 
Though r. ost has identified a handful of additional articles that he clai s support his 
opinions on the forseeability of alleged chronic adverse health effects from exposure to OC 
spray, none of those articles do anything more than did the articles previously provided (which 
  S   EC'S   TRI  TI    SECO  
FFI IT F R L  S. ST, Ph.D. - Page 11 14542-  ( 06756.doc) 
this Court has already and rightly determined did not provide the notice to SEC that would be
required to render Plaintiffs claims sustainable In other words in providing the additional
seven 7 citations Dr Yost has done nothing more than shoot an additional set of arrows
towards his intended target but as with his prior citations he has again missed the bullseye
Indeed even with the three 3 articles that Dr Yost identifies as reviewing the available
scientific literature which three articles discuss a total of three hundred fortysix 346 citations
Dr Yost still cannot point to any scientifically accepted or peer reviewed article study report or
other literature that draws the conclusions that Plaintiff needs in order to overturn summary
judgment
The folly of the Second Yost Affidavit is evidenced by the tortured logic that Dr Yost
uses to arrive at his conclusions based on the available literature Specifically paragraphs 10
and 11 to the Second Yost Affidavit set forth the scheme by which Dr Yost arrives at his
conclusion that longterm chronic adverse health risks should have been foreseen by SEC at the
time it sold the law enforcement branded OC Spray to which Plaintiff was ultimately exposed
Dr Yost explains that the inflammatory properties associated with exposure to capsaicinoids
were known in 2008 to greatly enhance the sensitivity of neuronal and respiratory tissues
Second Yost Af 10 Dr Yost does not clarify whether that enhanced sensitivity causes
or was known to cause either temporary acute or lasting chronic effects Then for the
remainder of paragraphs 10 and 11 Dr Yost proceeds to articulate his theory as to how that
increased sensitization may ultimately develop into a long term condition thereby giving his
own opinion on causation without providing any additional reinforcement for his conclusions
about the state of the scientific knowledge circa 2008 Id Dr Yostspersonal causation
MEMORANDUM IN SUPPORT OF SEC MOTION TO STRIKE PORTIONS OF THE SECOND
AFFIDAVIT OF GAROLD S YOST PhD Page 12 14542 011 406756doc
001341
this Court has already and rightly deter ined did not provide the notice to S C that ould be 
required to render Plaintiffs claims sustainable). In other ords, in r iding the a itional 
seven (7) citations, Dr. Yost has done nothing ore than shoot an additional set of arrows 
to ards his intended target but, as ith his prior citations, he has again issed the bullseye. 
Indeed, even ith the three (3) articles that r. ost identifies as revie ing the available 
scie tific literat re, hich three articles iscuss a total f t ree dred f rt -six (34 ) citati s, 
Dr. Yost still cannot point to any scientifically-accepted or peer-reviewed article, study, report or 
t er literat re t at ra s the c clusions t at lai tiff ee s i  r er t  ert r  s ar  
judgment. 
The folly of the Second Yost Affidavit is evidenced by the tortured logic that Dr. Yost 
s s  e  s s   e a le ite . cifi al ,   
and 11 to the Second ost ffidavit set forth the sche e by hich r. ost arrives at his 
conclusion that long-ter , chronic adverse health risks should have been foreseen by S  at the 
ti e it s l  t e la  e f rce e t ra e   ra  t  ic  laintiff as lti atel  e sed. 
Dr. Yost explains that "the inflammatory properties associated with exposure to capsaicinoids" 
ere kno n in 2008 to "greatly enhance[] the sensitivity of neuronal and respiratory tissues ... 
. " (Second Yost Aff., ~ 10.) Dr. Yost does not clarify whether that enhanced sensitivity causes 
or was known to cause either temporary (acute) or lasting (chronic) effects. en, r  
remainder of paragraphs 10 and 11, Dr. Yost proceeds to articulate his theory as to how that 
increased sensitization may ultimately develop into a long-term condition, thereby giving his 
own opinion on causation without providing any additional reinforcement for his conclusions 
about the state of the scientific kno ledge circa 2008. (J .) r. ost's pers l causati  
E RANDUM I  SUPPORT OF SEC'S TI  T  STRI E PORTI S OF T E SECON  
AFFIDAVIT OF GAROLD S. YOST, Ph.D. - Page 12 14542-011 (406756 doc) 
opinion however fails to provide the requisite evidence that Plaintiff needs to overturn the
Courtsentry of summary judgment that his theory was accepted known or even shared by
anyone else in or prior to 2008
Moreover the progression from Dr Yosts initial sentence in paragraph 10 to the
conclusion ultimately drawn andor inferred is nothing more than a logical fallacy to wit the
fallacy of composition Simply because the inflammatory properties associated with exposure
to capsaicinoids were known prior to 2008 and that those inflammatory properties play a role in
Dr Yosts personal theory of the pathology of the alleged chronic health effects of exposure to
OC spray does not logically support the conclusion that the alleged chronic health risks were
themselves scientifically known or even foreseeable prior to 2008 Accordingly just as the First
Yost Affidavit failed to provide a logical andor supported basis for Dr Yostsclaims that long
term chronic adverse health risks were known or foreseeable in or prior to 2008 so too does the
Second Yost Affidavit Unsupported and in contradiction with the earlier deposition testimony
the conclusions drawn in the Second Yost Affidavit are undoubtedly sham conclusions
manufactured for the sole purpose of salvaging Plaintiffsclaims
At a basic level the problem with the Second Yost Affidavit is identical to that which
plagued the First Yost Affidavit As this Court previously noted regarding Dr Yosts initial
Affidavit the expert opinion of Dr Yost regarding the foreseeability of the alleged risks of
chronic injury is nothing more than an unsupported legal conclusion
2 The fallacy of composition establishes that the following is illogical 1 X is a property ofA 2
A is a part ofB 3 therefore X is a property of B Another classic example of this fallacy goes as
follows 1 Human cells are invisible to the naked eye 2 Humans are made up ofhuman cells 3
therefore Humans are invisible to the naked eye
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opinion, however, fails to provide the requisite evidence that Plaintiff needs to overturn the 
Court's entry of su mary judgment - that his theory as acce te , kno n or e en shared by 
anyone else in or prior to 2008. 
oreover, the progression from Dr. Yost's initial sentence in paragraph 10 to the 
conclusion ultimately dra n and/or inferred is nothing ore than a logical fallacy, to it: the 
fallacy of composition? Simply because "the inflammatory properties associated with exposure 
to capsaicinoids" were known prior to 2008, and that those inflammatory properties playa role in 
Dr. Yost's personal theory of the pathology of the alleged chronic health effects of exposure to 
OC spray, does not logically support the conclusion that the alleged chronic health risks were 
themselves scientifically known or even foreseeable prior to 2008. Accordingly, just as the First 
ost ffidavit failed to provide a logical and/or supported basis for r. ost's clai s that long-
term, chronic adverse health risks were known or foreseeable in or prior to 2008, so too does the 
Second ost ffidavit. nsupported and in contradiction ith the earlier deposition testi ony, 
          s   
anufactured for the sole purpose of salvaging Plaintiff s clai s. 
t a basic level, the proble  ith the Second ost ffidavit is identical to that hich 
plagued the First Yost Affidavit. s this ourt previously noted regarding r. ost's initial 
Affidavit, the "expert opinion" of Dr. Yost regarding the foreseeability of the alleged risks of 
chronic injury is nothing more than an unsupported legal conclusion: 
2 The fallacy of composition establishes that the following is illogical: 1) X is a property of A; 2) 
A is a part ofB; 3) therefore X is a property ofB. Another, classic example of this fallacy goes as 
follows: 1) Human cells are invisible to the naked eye; 2) Humans are made up of human cells; 3) 
therefore Hu ans are invisible to the naked eye. 
E RANDU  I  SUPPORT OF SEC'S MOTION TO STRIKE PORTIONS OF THE SECON  
AFFIDAVIT OF GAROLD S. YOST, Ph.D. - Page 13 14542- 11 ( 06756.doc) 
THE COURT And I guess the point is that if I take that
paragraph as true it doesn support his conclusion And thats
whats really important is does he have anything to support his
conclusion which is completely conclusory
And thats why I think what counsel is saying is right
theres you have to distinguish between his statements on
causation which really at this point is not relevant to the issues
that are before the court or whether because this is a products
liability case whether it was foreseeable to the company that they
should have foreseen these kinds of injuries as potential
And just him saying the conclusion thats a
conclusory statement just like when as far as Im concerned
their expert having a conclusory statement that it wasnt
foreseeable thats really a legal conclusion I think the more
important thing is what do you base that on Whats the basis
for the statement
Lloyd August Af 2 and Ex A at 39184019 emphasis added This was a point of
continuing emphasis in the Courtscomments during oral argument on July 14 2011
THE COURT No I understand that and I agree with you about
that The problem youve got is when asked specifically
whether there were any studies that showed exactly what the
issue is he says no Thats the problem He cant he cant
say no and then turn around but I conclude that in fact it
was foreseeable Hes got to say whats the basis for that
Lloyd August Af 2 and Ex A at 4211 emphasis added To date Dr Yost has offered
nothing to alter the conclusory nature of his statements regarding foreseeability there remains
no factual basis including in the additional literature he has provided to buttress those
conclusions
C Dr Yosts Conclusions In The Second Yost Affidavit Ought To Be Stricken As
Inadmissible Sham Testimony
Despite the fact that the majority of the Second Yost Affidavit still fails to provide the
evidence that Plaintiff needs in order to overturn summary judgment there is at least some
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THE CO : [ ... ] And I guess the point is that if I take that 
paragraph as true, it doesn't support his conclusion. And that's 
what's really important, is does he have anything to support his 
conclusion which is co pletely conclus r . 
[ ... ] 
And that's why I think hat counsel is saying is right, 
th r 's -- you have to distinguish between his statements on 
causation, hich really at this point is not relevant to the issues 
that are before the court, or hether -- because this is a products 
liability case, whether it was foreseeable to the company that they 
s ld ha e foresee  t es  inds f injuries as l. 
nd just i  saying t  l i  -- that's a 
conclusory statement, just like when --    I'm , 
their expert having a conclusory st t e t at it asn't 
foreseeable, that's really a legal conclusion. I think the ore 
important thing is what do you base that on. hat's the basis 
f r t  st t ent? 
(Lloyd August Aff., ~   x.   9:18-40:19 (emphasis ded).) s     
continuing emphasis in the Court's comments during oral argument on July 14,2011: 
 T: , I ersta  t at a  I a ree it   a t 
t at. The proble  you've got is when asked specifically 
et er t ere ere a  st ies t t s e  e actl  t t e 
issue is, he says no. That's the proble . He can't -- he can't 
say no and then turn around, ["]but I conclude that, in fact, it 
was foreseeable.["] e's got to say hat's the basis for that. 
(Lloyd August Aff., ~  a  x.  at 2:4-  (e asis added).)  date, r. st as ffere  
nothing to alter the conclusory nature of his statements regarding foreseeability - there re ains 
no factual basis, including in the additional literature he has provided, to buttress those 
conclusions. 
. r. ost's oncl i  I   Seco  st ffi vit t T  B  Stri  As 
Inad issible Sha  Testimony. 
Despite the fact that the majority of the Second Yost Affidavit still fails to provide the 
evi e ce that Plaintiff needs in order to overtur  summary judgment, there is at least some 
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language that requires additional scrutiny in light of Dr Yosts prior testimony Specifically
paragraph 9 of the Second Yost Affidavit states
First I believe it best to state unequivocally that it is my expert
opinion based on my education research and training that the
scientific literature and studies in existence prior to 2008 was such
that when viewed as a body of literature and human and animal
studies it was known that a product such as SEC MK9 Fogger
posed a risk of both acute and chronic respiratory injury such as
that described in Ms Major medical records
Second Yost Af 9 Additionally Dr Yost himself describes his conclusion saying it was
known prior to 2008 that a product like SECsMK9 Fogger posed a risk of causing acute and
chronic injury to the respiratory system Id 12
At their roots these statements attempt to say with greater clarity that which Plaintiff
needed to present in her original opposition to SECs first Motion for Summary Judgment It
was because SEC anticipated this to be the original intent of Plaintiff in submitting the First Yost
Affidavit that SEC filed its original Motion to Strike portions of the First Yost Affidavit
However because Dr Yost had not directly said what he has now said in paragraphs 9 and 12 of
the Second Yost Affidavit the Court denied that Motion Now that Dr Yost has been
unequivocal on that point SEC believes this renewed Motion to be appropriate
In his clarified conclusions Dr Yost has definitively and unquestionably contradicted his
prior position in which he affirmed his familiarity with the scientific literature available and his
own knowledge that the adverse health effects associated with exposure to OC Spray are
temporary
A Sorry Prior to this case did I do
Q Any independent research of the scientific literature of the
subject Thatswhat Imgetting at Did you yourself do that
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language that requires additional scrutiny in light of Dr. Yost's prior testimony. Specifically, 
paragraph 9 of the Second Yost Affidavit states: 
First, I believe it best to state u e i call  that it is y e pert 
opinion, based on y education, research, and training, that the 
s ie ific literature and st dies in istence prior to  as s  
that hen viewed as a body of literature and hu an and ani al 
st ies, it as  that a product s  as C's -9 ger 
posed a risk of both acute and chronic respiratory injury such as 
that escribed in s. aj r's e ical rec r s. 
(Second Yost Aff., ~ 9.) Additionally, Dr. Yost hi self describes his conclusion, saying "it was 
known prior to 2008 that a product like SEC's K-9 Fogger posed a risk of causing acute and 
chronic injury to the respiratory system." (Id., ~ 2.) 
t their roots, these state ents atte pt to say ith greater clarity that hich Plaintiff 
needed to present in her original opposition to SEC's first Motion for Summary Judgment. It 
was because SEC anticipated this to be the original intent of Plaintiff in sub itting the First Yost 
Affidavit that SEC filed its original otion to Strike portions of the First Yost Affidavit. 
However, because Dr. Yost had not directly said what he has now said in paragraphs 9 and 12 of 
the econd ost ffidavit, the ourt denied that otion.  t at r. st as ee  
unequivocal on that point, SEC believes this renewed Motion to be appropriate. 
I  is clarifie  c cl si s, r. st as efi iti el  a  esti a l  c tra icte  is 
prior position, in which he affirmed his familiarity with the scientific literature available and his 
own knowledge that the adverse health effects associated with exposure to OC Spray are 
temporary: 
. Sorry. Prior to this case did I do --
Q. Any independent research of the scientific literature of the 
subject. That's what I'm getting at. Did you yourself do that? 
MEMORANDUM IN SUPPORT OF SEC'S MOTION TO STRIKE PORTIONS OF THE SECOND 
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A Well yeah Maybe Im not understanding the question but
we have been working with capsaicinoids for 10 years 11
years and I do literature all the time especially when we go to
publish something make sure theresnothing thatIve missed
Q What do you understand either in connection with your own
experience with exposure or what youve read of what the
physiological effects of OC exposure on humans to be
A Well its tissue dependent but in general the effects center
around the inflammatory process pretty much affecting any
mucosal tissue eyes mouth ears stomach Thatsmostly it I
believe And depending upon the specific tissue different types of
responsiveness certainly tearing pain lacrimation tearing same
thing from eyes reddening of the eyes blood flow changes a
number of various things In most cases pain whether thats eyes
mouth skin lungs
Q Anything else thats associated symptomwise that youre
aware of
A Usually increase in blood flow Thats not necessarily a
symptom
Q Is it your understanding that the adverse health affects that
exposure to OC and capsaicinoids by humans are generally
deemed to be temporary reversible and not longterm
A I think thats fair yes
Lloyd June Af 6 and Ex E at 621638emphasis added
Moreover Dr Yost confirmed that studies on the potential for chronic adverse health
effects as a result of exposure to OC spray have not been conducted such that SEC could have
even possibly been on notice of such a study
Q All right Do you recall having in your review of the scientific
and medical literature seeing any peerreviewed publications that
specifically address the association between OC exposure on the
one hand and longterm chronic adverse health effects on the
other
A Well thats what I was referring to before that I dontthink
the studies have been done or published that definitively well
that provide robust data about that scenario that OC exposure
now Im talking about OC exposure in a chronic sense multiple
cases of exposure
Q Oh multiple exposures
A Yes
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A. ell, yeah. aybe I'm not understanding the question, but 
e have been orking ith capsaicinoids for 10 years, 11 
years, and I do literature all the time, especially hen e go to 
publish so ething, ake sure there's nothing that I've issed. 
. hat do you understand, either in connection ith your o n 
experience with exposure or what you've read, of what the 
physiological effects of  exposure on hu ans to be? 
. ell, it's tissue dependent, but in general the effects center 
around the inflammatory process pretty uch affecting any 
ucosal tissue, eyes, outh, ears, sto ach. at's  i ,  
elie e. nd e e i   the s ecific tiss e, iffere t t pes f 
responsiveness, certainly tearing, pain -- a ti , ri , e 
thing -- fro  eyes, reddening f the eyes, blood flo  changes, a 
nu ber of various things. In ost cases, pain, hether that's eyes, 
outh, skin, lungs. 
Q. Anything else that's associated sy pto -wise that you're 
 f? 
. sually increase in blood flo . at's  ri   
sy pto . 
. Is it your understanding that the adverse health affects that 
exposure to  and capsaicinoids by hu ans are generally 
dee ed to be te porary, reversible and not long-ter ? 
. I t i  t at's f ir, s. 
(Lloyd June Aff., ~ 6 and x. at 62:1-63:8 (emphasis added).) 
re ver, r. st c fir e  t at st ies  t e te tial f r c r ic a erse ealt  
effects as a result of exposure to OC spray have not been conducted, such that SEC could have 
even possibly been on notice of such a study: 
Q. All right. Do you recall having in your review of the scientific 
and edical literature seeing any peer-reviewed publications that 
specifically address the association between OC exposure on the 
one hand and long-ter  chronic adverse health effects on the 
ther? 
A. ell, that's what I was referring to before, that I don't think 
the studies have been done or published that definitively -- ell, 
that provide robust data about that scenario, that OC exposure --
now, I'm talking about  exposure in a chronic sense, ultiple 
cases of exposure. 
Q. Oh, multiple exposures? 
. es. 
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Q Thats fine
A And no I dontthink that I haventseen studies that make
that that come to that conclusion that there are adverse
effects because I dont think people have done the studies
Lloyd June Aff 6 and Ex E at 10022 1015 emphasis added Indeed the only known
effects of exposure to OC spray in Dr Yosts own words are transitory
Q Have you in your review of peer reviewed publications seen
any articles that focus on the duration of time after exposure to OC
that adverse health effects are customarily deemed persistent in
humans
A I would say my general opinion is that general
conclusion from literature is that they are transitory and that
would generally mean you know more than a minute and
probably less than a day or two So I think theres substantial
evidence that the pain irritation lacrimation et cetera that
we talked about before is not long it doesn persist for weeks
and months
Id At 1012 1028emphasis added
Finally Dr Yost unequivocally stated in his deposition that there was no literature prior
to March 2008 that would have put someone on notice that exposure to OC spray could cause
longterm adverse health conditions
Q But you cant cite me to one specific paper our there that
existed prior to March of 2008 that specifically would have put
laypersons without your background on notice that exposure to
their product could have caused these long term health conditions
A No
Id at 15520156 emphasis added
After the conclusion of his deposition Dr Yost was provided the opportunity to review
and correct his deposition testimony Id 4 and 5 Ex C and Ex DDr Yost however did
not make any edits or alterations to his deposition testimony within the allotted time Id
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. t's fin . 
. , n , I n't think that -- I n't s  st ies that ake 
that -- that come to that  that there re erse 
e fe t , ecause I d 't think people have ne the st i . 
(Lloyd June Aff., ~   . t 00:22- 01: 5 (emphasis ded).) In , the ly  
effects of exposure to C spray, in r. ost's o n ords, are transitory: 
. ave , in r r ie  f r-r ie ed li ti s, s  
a  articles t at focus n the ration f ti e after e s re t   
that a erse ealt  effects are c st aril  ee e  ersiste t i  
s? 
. I ould say y general opinion is that --  
c clusion fro  literature is that t e  are tra sit r  a  t at 
would generally ean, you know, ore than a inute and 
probably less than a day or two.    ere's t t  
evidence that the pain, irritation, lacri ation, et cetera, that 
e talked a t ef re is t l  -- it esn't ersist f r ee s 
 . 
(ld At 101:21-102:8 (emphasis added).) 
i all , r. st e i call  state  i  is e siti  t at t ere as  literat re ri r 
to arch 2008 that ould have put so eone on notice that exposure to  spray could cause 
long-term adverse health conditions: 
Q. t  can't cite e t  e s ecific a er r t ere t at 
existed prior to arch of 2008 that specifically would have put 
laypersons without your background on notice that exposure to 
their product could have caused these long-ter  health conditions? 
. o. 
(ld at 155:20-156:1 (e phasis added).) 
fter the conclusion of his deposition, r. ost as provided the opportunity to revie  
and correct his deposition testi ony. (ld, ~~  a  , x.  a  x. .) r. st, ever, i  
not make any edits or alterations to his deposition testimony within the allotted time. (Id) 
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During oral argument on July 14 2011 Plaintiffs counsel even admitted that there was
no scientific literature available prior to March 2008 to support the contention that SEC should
have known about the alleged risks of chronic long term health effects resulting from exposure
to OC spray
MR OVERSON Well and what he explains in his affidavit is
that no he cantpoint to a single study that would demonstrate
that definitively Okay
THE COURT So you would agree that there you have not
identified any study that this company should have been aware of
that OC spray had the had the it was foreseeable that it could
cause chronic lung problems like your client claims
MR OVERSON The okay Theresno study where theyv
taken subjects exposed them to OCspray and found that it
caused the symptoms and condition that my client has
See Lloyd August Af 2 and Ex A at 322 3325 emphasis added This admission alone
should be dispositive of SECsMotion to Strike and Plaintiff s Motion for Reconsideration
Now in his Second Affidavit Dr Yost has undeniably changed his testimony without
any explanation as to why he has reversed his position This is not a situation in which Dr Yost
has now found that which he lacked before a citation to anything available in 2008 that draws
the same conclusion that he now draws in this litigation The additional literature that he relies
upon as indicated above simply does not say that exposure to OC spray may cause long term
chronic adverse health effects Once again the only conceivable reason for the change in his
testimony then is a lastditch attempt by Plaintiff to keep her claims against SEC alive Such an
attempt should be rejected by this Court and the sham testimony excluded from evidence for all
purposes
D Plaintiffs Attempt To Subvert Discovery Rules Should Not Be Condoned
A plain reading of the additional sources of authority presented with the Second Yost
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ring ral ar e t  J l  , , lai tiff s c sel e e  a itte  t at t ere as 
no scientific literature available prior to arch, 2008 to support the contention that  should 
have kno n about the alleged risks of chronic, long ter  health effects resulting fro  exposure 
to  spray: 
. :  - and hat he explains in his affidavit is 
that no, he can't point to a single study that ould de onstrate 
that definitively. Okay. 
E :   l  ree t t t r  -    
identified any study that this co pany should have been a are of 
t at .C. s r   t  -  e - t as res  t   
cause chronic lung proble s like your client clai s. 
. :  - okay. here's no study here they've 
ta e  s jects, e se  t e  t  .c. s ra  a  f  t at it 
caused the sy pto s and condition that y client has .... 
(See Lloyd ugust ff., ~   x.  t 2: 2-33:25 (e phasis dded).) i  i i  l  
should be dispositive f EC's otion to trike and laintiffs otion for econsideration. 
, i  i   i it, r. t  i l   i  t ti ny, it t 
any explanation as to why he has reversed his position. This is not a situation in which Dr. Yost 
        -  it ti  t  t i  il l  i   t t r s 
t   l i  t t   r  i  t i  liti ti .  iti l lit r t r  t t  r li  
upon, as indicated above, si ply does not say that exposure to OC spray ay cause long-ter , 
i   lt  f ts. nce again, the only conceivable reason for the change in his 
testi ony, then, is a last-ditch atte pt by Plaintiff to keep her clai s against SE  alive. Such an 
atte pt should be rejected by this ourt and the sha  testi ony excluded fro  evidence for all 
purposes. 
. Plaintiff's Atte pt To Subvert Discovery Rules Should Not Be Condoned. 
A plain reading of the additional sources of authority presented with the Second Yost 
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Affidavit reveals that indeed none of the authority relied upon by Dr Yost actually supports his
assertion that the alleged chronic adverse health effects of exposure to OC spray were known in
or before 2008 See Second Yost Affidavit Ex 1 Nonetheless as an additional basis to reject
the Second Yost Affidavit it should be noted that none of those articles were previously
disclosed to SEC as having any bearing on this lawsuit or Dr Yosts opinions despite the
following interrogatory having been outstanding since April 2010
INTERROGATORY NO 3 Identify each person whom You
expect or intend to testify as an expert at a trial of this matter and
with respect to each such person state the following
A The substance and summary of all facts and opinions about
which each expert is expected to testify
B Identify each fact Document and all data pursuant to
Rule 705 IRE upon which each expert intends to rely in
rendering any opinions at a trial of this matter and
C Identify all information and Documents required to be
disclosed by expert witnesses pursuant to Rule 26aIdaho
Rules of Civil Procedure
See Affidavit of Counsel in Support of DefendantsMotion for Summary Judgment previously
filed in this action on April 22 2011 Counsel April Aff 9 and Ex H at p 6 Rule 705 of
the Idaho Rules of Evidence provides in relevant part
The expert may testify in terms of opinion or inference and give
the reasons therefore without prior disclosure of the underlying
facts or data provided that the court may require otherwise and
provided further that if requested pursuant to the rules of
discovery the underlying facts or data were disclosed
IRE705 emphasis added As discussed in detail above in the Second Yost Affidavit Dr
Yost has now presented and relied upon a significant amount of information that was not
previously disclosed See generally Second Yost Affidavit and Ex 1 thereto Though a party
on a Motion for Reconsideration may assert evidence not previously presented with the
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Affidavit reveals that, indeed, none of the authority relied upon by Dr. Yost actually supports his 
assertion that the alleged chronic adverse health effects of exposure to OC spray were known in 
or before 2008. (See Second ost ffidavit, Ex. 1.) onetheless, as an additional basis to reject 
the ec d ost ffida it, it s uld e noted that one of t ose articles ere re iously 
disclosed to SEC as having any bearing on this lawsuit or Dr. Yost's opinions, despite the 
following interrogatory having been outstanding since April, 20 1 0: 
INTER  . : I tif   rs  o  o  
expect or intend to testify as an expert at a trial of this matter, and 
with respect to each such person, state the following: 
. e ta ce    ll a ts  i i  t 
which each expert is expected to testify; 
. Identify each fact, Document and all data, pursuant to 
ule 705, I.R.E., upon hich each expert intends to rely in 
re eri g a y o i io s at a trial f t is atter; and 
. Identify all infor ation and ocu ents required to be 
disclosed by expert itnesses pursuant to ule 26(a)(2), Idaho 
le  f i il r r . 
(See Affidavit of Counsel in Support of Defendant's Motion for Summary Judgment, previously 
filed in this action on April 22, 2011 ("Counsel April Aff."), ~   x. at . .)    
the Idaho Rules of Evidence provides in relevant part: 
The expert ay testify in ter s of opinion or inference and give 
the reasons therefore ithout prior disclosure of the underlying 
facts or data, provided that the court ay require otherwise, and 
provided further that, if requested pursuant to the rules of 
discovery the underlying facts or data ere disclosed. 
I.R.E. 705 (emphasis added). As discussed in detail above, in the Second Yost Affidavit, Dr. 
Yost has now presented and relied upon a significant amount of information that was not 
previously disclosed. (See generally Second Yost Affidavit and Ex. 1 thereto.) Though a party 
on a otion for Reconsideration ay assert evidence not previously presented ith the 
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underlying motion Johnson v Lambros 143 Idaho 468 147 P3d 100 Ct App 2006 such
latitude should not be at the expense of all other applicable rules governing evidence and
procedure in the matter
With the deadlines for completion of discovery now long passed SEC is deprived of the
opportunity to depose Dr Yost on the contents of these newly disclosed articles which were not
identified in any timely supplemental discovery response as required underIRCP26e1
SEC contends as noted above that the additional articles do nothing to make the point that is
Plaintiffs burden to make but it is disingenuous at best for Plaintiff to have withheld the
evidence that she contends helps make that point until after SECs opportunity to conduct
additional discovery has passed The Idaho Supreme Court does not condone such tactics
In its analysis of the issue this Court quoted the language of
IRCP26e1stating that the rule unambiguously imposes a
continuing duty to supplement responses to discovery with respect
to the substance and subject matter of an experts testimony where
the initial responses have been rejected modified expanded upon
or otherwise altered in some manner
This Court also quoted one scholar for the proposition that
It is fundamental that opportunity be had for full
cross examination and this cannot be done properly
in many cases without resort to pretrial discovery
particularly when expert witnesses are involved
Before an attorney can even hope to deal on cross
examination with an unfavorable expert opinion he
or she must have some idea of the bases of that
opinion and the data relied upon If an attorney is
required to await examination at trial to get this
information he or she often will have too little
time to recognize and expose vulnerable spots in the
testimony
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underlying motion, Johnson v. Lambros, 143 Idaho 468, 147 P.3d 100 (Ct. App. 2006), such 
latitude should not be at the expense of all other applicable rules governing evidence and 
procedure in the matter. 
ith the deadlines for co pletion of discovery no  long-passed, SE  is deprived of the 
opportunity to depose Dr. Yost on the contents of these newly-disclosed articles, which were not 
identified in any ti ely supple ental discovery response as required under I.R.C.P. 26(e)(1). 
S  contends, as noted above, that the additional articles do nothing to ake the point that is 
laintiffs burden to ake, but it is disingenuous at best for laintiff to have ithheld the 
evidence that she contends helps ake that point until after SEC's opportunity to conduct 
additional discovery has passed. The Idaho Supreme Court does not condone such tactics: 
In its analysis of the issue, this Court quoted the language of 
I.R.C.P. 26(e)(1), stating that the rule "unambiguously imposes a 
continuing duty to supplement responses to discovery with respect 
to the substance and subject atter of an expert's testi ony here 
the initial responses have been rejected, odified, expanded upon, 
     nner." [ ... ] 
This Court also quoted one scholar for the proposition that: 
It i  f t l t t rt it    f r f ll 
r - xa i ation,  t i  t   r erl  
in many cases without resort to pretrial discovery, 
particularly when expert witnesses are involved .... 
efore an attorney can even hope to deal on cross-
exa ination ith an unfavorable expert opinion he 
[or she] ust have so e idea of the bases of that 
opinion and the data relied upon. If an attorney is 
required to a ait exa ination at trial to get this 
infor ation, he [or she] often ill have too little 
ti e to recognize and expose vulnerable spots in the 
testi ony. 
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Clark v Klein 137 Idaho 154 15758 45 P3d 810 813 14 2002 internal citations omitted
Based on these principals the Clark court found that the admission of previously undisclosed
expert testimony was in error and it reversed the underlying jury verdict Id at 159 See also
Hopkins v DuoFast Corp 123 Idaho 205 217218 846 P2d 207 21920 1993 noting that
IRCP26e1obligates counsel to supplement discovery responses particularly the substance
of an expertstestimony Radmer v Ford Motor Co 120 Idaho 86 813 P2d 897 1991
holding that the trial judge committed reversible error when evidence was admitted that was not
properly and timely disclosed pursuant toIRCP26
For the same reasons SEC contends that the portions of the Second Yost Affidavit which
contain andor rely upon new data or facts not previously disclosed in discovery should be
stricken as inadmissible testimony pursuant to IRE 705 andIRCP 26 SEC suffers a
substantial prejudice not having had any opportunity to have deposed Dr Yost on the newly
identified foundations for his testimony in this action not the least of which is the opportunity to
go through each of the newlydisclosed and newly produced articles to determine that they do
not in fact stand for the proposition that SEC could have known of the alleged risks of chronic
adverse health effects resulting from exposure to OC spray Plaintiff should not be able to
overturn the previous findings of this Court by simply ignoring the applicable rules and for that
reason among all others in this brief the testimony offered by Dr Yost ought to be stricken
CONCLUSION
The Second Yost Affidavit without a doubt provides the sham testimony that this Court
rightfully did not perceive to be present in the First Yost Affidavit which testimony is clearly
made for the sole purpose of salvaging Plaintiffs case As established by the case law cited
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Clark v. Klein, 137 Idaho 154, 157-58, 45 P.3d 810, 813-14 (2002) (internal citations o itted). 
ased on these principals, the lark court found that the ad ission of previously undisclosed 
expert testi ony as in error, and it reversed the underlying jury verdict. Id. at 159. See also 
Hopkins v. Duo-Fast Corp., 123 Idaho 205, 217-218, 846 P.2d 207, 219-20 (1993) (noting that 
I.R.C.P. 26(e)(l) obligates counsel to supplement discovery responses, particularly the substance 
of an expert's testi ony); Rad er v. Ford otor o., 120 Idaho 86, 813 P.2d 897 (1991) 
(holding that the trial judge committed reversible error when evidence was admitted that was not 
properly and ti ely disclosed pursuant to I.R.C.P. 26). 
 t e  ,  te s t at t  ti s  t   t id it ic  
contain andlor rely upon ne  data or facts not previously disclosed in discovery should be 
stricken as inad issible testi ony, pursuant to I.R.E. 705 and I.R.C.P. 26.  ers  
substantial prejudice not having had any opportunity to have deposed Dr. Yost on the newly-
identified foundations for his testi ony in this action, not the least of hich is the opportunity to 
go through each of the newly-disclosed (and ne ly-produced) articles to deter ine that they do 
not, in fact, stand for the proposition that SEC could have known of the alleged risks of chronic 
adverse health effects resulting fro  exposure to  spray. l intif  l      
overturn the previous findings of this ourt by si ply ignoring the applicable rules, and for that 
reason, among all others in this brief, the testimony offered by Dr. Yost ought to be stricken. 
 
he econd ost ffidavit, ithout a doubt, provides the sha  testi ony that this ourt 
rightfully did not perceive to be present in the First ost ffidavit, hich testi ony is clearly 
made for the sole purpose of salvaging Plaintiffs case. As established by the case law cited 
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herein this sham testimony cannot be the basis for reversing this Court grant of summary
judgment or for any other purpose Further the additional information relied upon by Dr Yost
to now button up his prior testimony has been offered in violation of the applicable rules
governing discovery and the rules of evidence Accordingly SEC respectfully requests that Dr
Yosts conclusions to the extent that they attempt to establish that the alleged potential for
chronic adverse health effects was known in 2008 be stricken from the record and that those
conclusions not be considered for any purpose in this litigation
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herein, this sham testimony cannot be the basis for reversing this Court's grant of su mary 
judgment or for any other purpose. Further, the additional information relied upon by Dr. Yost 
to now "button up" his prior testimony has been offered in violation of the applicable rules 
governing discovery and the rules of evidence. Accordingly, SEC respectfully requests that Dr. 
Yost's conclusions, to the extent that they atte pt to establish that the alleged potential for 
c r ic a verse he lth effects as no n in , e stricken from the rd  that t ose 
conclusions not be considered for any purpose in this litigation. 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
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CORPORATION a Missouri corporation
CaseNo CVPI1003515
REPLY MEMORANDUM IN SUPPORT
OF DEFENDANTSSECOND MOTION
FOR SUMMARY JUDGMENT AND IN
OPPOSITION TO PLAINTIFFS
MOTION FOR RECONSIDERATION
Defendant
Defendant Security Equipment Corporation SEC or Defendant by and through its
counsel of record Greener Burke Shoemaker PA pursuant to IRCP 56 submits this
memorandum both in reply to Plaintiffs Opposition to SECs Second Motion for Summary
Judgment Second MSJ and in opposition to PlaintiffsMotion for Reconsideration
INTRODUCTION
By the memorandum filed in opposition to SECs Second MSJ and in support of her
Motion for Reconsideration Plaintiff has attempted to raise a number of additional issues for this
Courtsconsideration in order to distract from the ultimate issue upon which the entire case
turns Whether in March of 2008 SEC knew or should have known that exposure to its OC
spray products created a risk of causing longterm or chronic irreversible injuries like those that
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Defendant Security Equip ent Corporation ("SEC" or "Defendant"),     
l  r ,    .A., t t  .R.C.P. , it  t i  
e orandu  both in reply to Plaintiffs pposition to SEC's Second otion for Su ary 
Judgment ("Second MSJ") and in opposition to Plaintiffs otion for Reconsideration. 
 
By the e orandu  filed in opposition to SEC's Second SJ and in support of her 
otion for econsideration, Plaintiff has atte pted to raise a nu ber of additional issues for this 
ourt's si r ti  i  r r t  istr t fr  t  lti t  iss   i  t  ntir  s  
t s: ther, i    08,   r sho l    t t  t  it   
spray products created a risk of causing long-term or chronic irreversible injuries like those that 
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JUDGMENT, AND IN OPPOSITION TO PLAINTIFF'S OTION FOR RECONSIDERATION - Page 1 
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have been alleged in Plaintiff s Complaint In her memorandum Plaintiff spends a considerable
amount of time making unsubstantiated allegations in many cases for the first time about
misuse of SECs products by IDOC employees and adverse health risks associated with
overexposure to OC spray By this memorandum SEC does not intend to address each and
every one of these surface fires that Plaintiff has ignited in an attempt to avoid the dispositive
issues in the case Instead SEC will refocus this memorandum on the three arguments that as
set forth in its Second MSJ resolve the entirety of this litigation
1 There is no private cause of action under the Federal Hazardous Substances Act
FHSA
2 The FHSA does not define the standard of conduct required of a product
manufacturer sufficiently andor clearly enough to give rise to a cause of action in
negligence per se and
3 Plaintiff has not yet come forward with any evidence to establish that the long
term or chronic health risks that she has alleged were or should have been known
by SEC in 2008 as would be necessary to maintain any common law cause of
action in negligence or strict liability
HI
1 Plaintiff has not produced any evidence by expert testimony or otherwise that anyone with the
IDOC actually misused any of SECsproducts nor that an overexposure of the products to which
Plaintiff was exposed may actually cause a chronic longterm adverse health reaction like that which
Plaintiff alleges in this litigation Plaintiffs arguments on these points are therefore nothing more than
red herrings
2 Plaintiff has conceded the fact that she has no private cause of action under the FHSA so that
issue will not be addressed any further in this memorandum
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have been alleged in Plaintiff s Complaint. In her memorandum, Plaintiff spends a considerable 
a ount of time aking unsubstantiated allegations, in any cases for the first ti e, about 
isuse of S 's products by I  e ployees and adverse health risks associated ith 
"overexposure" to OC spray. 1 By this memorandum, SEC does not intend to address each and 
everyone of these surface fires that Plaintiff has ignited in an atte pt to avoid the dispositive 
issues in the case. Instead,  ill refocus this e orandu  on the three argu ents that, as 
set forth in its Second SJ, resolve the entirety of this litigation: 
1. There is no private cause of action under the Federal Hazardous Substances Act 
("FHSA,,);2 
.   es t fi  t  t r   t r ire    r t 
anufacturer sufficiently andlor clearly enough to give rise to a cause of action in 
negligence per se; and 
. Plaintiff has not yet come forward with any evidence to establish that the long-
  i  l      l   r     
by SEC in 2008, as would be necessary to aintain any co on law cause of 
action in negligence or strict liability. 
III 
III 
1 Plaintiff has not produced any evidence, by expert testimony or otherwise, that anyone with the 
moc actually misused any of SEC's products, nor that an overexposure of the products to which 
Plaintiff was exposed may actually cause a chronic, long-term adverse health reaction like that which 
Plaintiff alleges in this litigation. Plaintiffs arguments on these points are therefore nothing more than 
red herrings. 
2 laintiff has conceded the fact that she has no private cause of action under the FHSA, so that 
issue ill not be addressed any further in this emorandum. 
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ARGUMENT
1 Plaintiff Has Failed To Meet The Burden Required To Sustain A Negligence Per Se
Claim
In SECsmemorandum in support of its Second MSJ SEC set forth the applicable
standard to sustain a cause of action in negligence per se See Memorandum in Support of
SECsSecond MSJ SECs Memo pp 1719 Plaintiff has not disputed that standard
which as stated by the Obendorfcase relied upon by SEC requires that the statute or regulation
must clearly define the required standard of conduct Obendorf v Terra Hug Spray Co Inc
145 Idaho 892 188 P3d 834 2008 Neither has Plaintiff disputed that where material terms
are vague or undefined negligence per se is not appropriate See Ahles v Tabor 136 Idaho 393
34 P3d 1076 2001 Rather than disputing the accuracy or applicability of these standards
Plaintiff simply attempts to force the ambiguous language employed by the FHSA into the rigid
construct that is negligence per se The result is not persuasive
As previously noted the standard of conduct required by the FHSA is not sufficiently
concrete to identify a clear course of action required from a manufacturer resulting in a vague
and ambiguous standard that does not accommodate a claim for negligence per se Plaintiffs
response that the requirement for a balanced perspective of the potential hazards of the
product is neither vague nor difficult to comply with is unsupported by Idaho law See
Plaintiffs Memo p 22 Idaho courts have found negligence per se only where there is an
unambiguous standard of conduct clearly defined by the statutory or regulatory scheme See
egOGuin v Bingham County 142 Idaho 49 122 P3d 308 2005 regulation requiring that
solid waste management sites be fenced or otherwise blocked to access when an attendant is not
on duty was clear where site had not built a fence around or otherwise blocked access to the
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. l i tiff as ile   e t  de  i e  o st i   lige ce   
. 
 C's e ra  in t  ts  ,   rt  e  
standard to sustain a cause of action in negligence per se. (Se  e ra  i  t  
C's  SJ ("S 's e ."), pp. 17-19.) l i tiff  t is t  t t t ard, 
hich as stated by the bendorf case relied upon by SE , requires that "the statute or regulation 
ust clearly define the required standard of conduct." bendorfv. Terra ug Spray o., Inc., 
145 Idaho 892, 188 P.3d 834 (2008). either has Plaintiff disputed that, here aterial ter s 
are vague or undefined, negligence per se is not appropriate. See Ahles v. Tabor, 136 Idaho 393, 
34 P.3d 1076 (2001). Rather than disputing the accuracy or applicability of these standards, 
Plaintiff si ply atte pts to force the a biguous language e ployed by the F S  into the rigid 
str t t t is li  r s .  r s lt is t rs siv . 
As previously noted, the standard of conduct required by the FHSA is not sufficiently 
concrete to identify a clear course of action required fro  a anufacturer, resulting in a vague 
and a biguous standard that does not acco odate a clai  for negligence per se. Plaintiff s 
response, that the require ent for a "balanced perspective of the potential hazards of the 
product" is "neither vague nor difficult to co ply ith," is unsupported by Idaho la . (S  
Plaintiffs emo., p. 22.) Idaho courts have found negligence per se only here there is an 
unambiguous standard of conduct clearly defined by the statutory or regulatory scheme. See, 
e.g., O'Guin v. Bingham County, 142 Idaho 49, 122 P.3d 308 (2005) (regulation requiring that 
solid aste anage ent sites "be fenced or other ise blocked to access hen an attendant is not 
 uty" as clear ere site a  t ilt a fe ce ar  r t er ise l c e  access t  t e 
L   I  S P   EFENDANT'S    SUM Y 
JUDGMENT, AND IN OPPOSITION TO PLAINTIFF'S OTION FOR RECONSIDERATION - Page 3 
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facility Griffith v Schmidt 110 Idaho 235 715 P2d 905 1985 violation of speed limit of
fiftyfive 55 miles per hour constitutes negligence per se Woodman v Knight 85 Idaho 453
380 P2d 222 1963 violation of statute prohibiting passing a left turning vehicle within one
hundred 100 feet of an intersection constituted negligence per se The requirement for a
balanced perspective begs the question as to what constitutes balanced and what must be
included and what may be omitted from the label according to that balance The requirement
simply does not set forth the bright line rules of conduct that are typical and necessary for
negligence per se Id see also Ahles 136 Idaho 393
In an attempt to skirt the Ahles requirement for definitions of material terms Plaintiff has
claimed that principal hazard is defined by the FHSA regulations as wording descriptive of
the principal or primary hazardsassociated with a hazardous substance See Plaintiffs
Memo p 22 This is simply not true 1d A complete reading of the regulatory provision
cited by Plaintiff illuminates her misstatement
vii Statement of principal hazards means that wording
descriptive of the principal or primary hazardsassociated with a
hazardous substance required by section2p1Eof the Act
Some examples of such statements are HARMFUL OR FATAL
IF SWALLOWED VAPOR HARMFUL FLAMMABLE
and SKIN AND EYE IRRITANT
16 CFR 150021vii emphasis added Even if this Statement of principal hazard
may be deemed a definition of principal hazard which it is not the Statement is still not clear
enough to give rise to a negligence per se claim
3 Without reviewing the regulations this point is rather evident from Plaintiffs awkward
argument removing the adjectival phrase from Plaintiff s asserted definition Plaintiff is left claiming that
principal hazard is defined as wording This argument is nonsensical SEC doubts that the drafters
of the FHSA intended to protect American consumers from wording
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facility); Griffith v. Schmidt, 110 Idaho 235,715 P.2d 905 (1985) (violation of speed limit of 
fifty-five (55) miles per hour constitutes negligence per se); Woodman v. Knight, 85 Idaho 453, 
380 P.2d 222 (1963) (violation of statute prohibiting passing a left-turning vehicle ithin one 
hundred (100) feet of an intersection constituted negligence per se). he re ire e t fo   
"balanced perspective" begs the question as to hat constitutes "balanced," and hat ust be 
included and hat ay be o itted fro  the label according to that balance. he require ent 
simply does not set forth the bright line rules of conduct that are typical and necessary for 
negligence per se. Id.; see also Ahles, 136 Idaho 393. 
In an attempt to skirt the Ahles requirement for definitions of material terms, Plaintiff has 
claimed that "principal hazard" is defined by the FHSA regulations as "wording descriptive of 
the principal or pri ary hazard(s) associated with a hazardous substance." (S  l i ti s 
emo., p. 22.) This is simply not true.3 (Id.) A complete reading of the regulatory provision 
cited by Plaintiff illuminates her misstatement: 
(vii) Statement of principal hazard(s)  t t i  
descriptive of the principal or pri ary hazard(s) associated with a 
hazardous substance required by section 2(p)(1 )(E) of the ct. 
So e exa ples of such state ents are "HAR F L  F T L 
I  ALLOWED," "VAPO  MFUL," "F ABLE," 
 "S    RITANT." 
 .F.R. § 1500.121(a)(2)(vii) (emphasis added). Even if this Statement of principal hazard 
may be deemed a definition of "principal hazard," which it is not, the Statement is still not clear 
enough to give rise to a negligence per se claim. 
3 Without reviewing the regulations, this point is rather evident from Plaintiffs awkward 
argument: removing the adjectival phrase from Plaintiffs asserted definition, Plaintiff is left claiming that 
"principal hazard" is defined as "wording". This argu ent is nonsensical. SEC doubts that the drafters 
ofthe FHSA intended to protect American consumers from wording. 
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In short Plaintiff has failed to come forward with an actual statutory or regulatory
definition of principal hazard such as would be required to provide the clarity necessary for a
cause of action in negligence per se As a result Plaintiff cannot and does not distinguish this
case from the Ahles precedent Indisputably the fact remains that the FHSA does not clearly
define a standard of conduct with which SEC ought to have complied and Plaintiffs cause of
action for negligence per se ought to be dismissed as a matter of law
2 Plaintiff Has Failed To Establish That SEC Knew Or Should Have Known Of The
Alleged Chronic Health Effects OfExposure To OC Spray
As Plaintiff is unable to support a cause of action for negligence per se her remaining
claims in this case are limited to the same issues that this Court previously decided on SECs
first Motion for Summary Judgment Thus the issues raised in SECs Second MSJ and
Plaintiff s Motion to Reconsider intersect for the remainder of this memorandum Since Plaintiff
has relied heavily on the new Affidavit of Gerald Yost PhD filed on July 26 2011 with her
Motion for Reconsideration Second Yost Aff SEC incorporates herein by reference the
arguments asserted in its Motion to Strike Dr Yostsnew Affidavit filed on August 18 2011
As the Court will recall Plaintiff previously attempted to establish that the alleged
chronic long term health risks about which she complains should have been known by SEC in
2008 when Plaintiff was last exposed to SECs OC spray products by citing to a number of
articles identified in the First Yost Affidavit However as the Court noted the problem with the
articles cited by Dr Yost in the First Yost Affidavit was that they did not in fact conclude that
OC exposure causes irreversible chronic disease or identify any report study or other
documented literature that identifies this chronic condition as a result of exposure jr at
415 Now in a dual attempt to both reverse this Courts Order on SECs first motion for
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In short, Plaintiff has failed to co e forward ith an actual statutory or regulatory 
definition of "principal hazard", s  s ould e required t  r ide t e l rit  e ess r  f r  
cause f action in negligence per se. s a result, laintiff cannot and does not distinguish this 
case fro  the Ahles precedent. Indisputably, the fact re ains that the F S  does not clearly 
efi e a sta ard f c ct ith ic   ht t  a e c lie , a  lai tiff s ca se f 
action for negligence per se ought to be dis issed as a atter of la . 
. f as led o ish   ne    a e    
llege  r ic ealth ffects f posure   ra . 
s lai tiff is a le t  s rt a ca se f acti n f r e lige ce er se, er re ai i  
s     ite       s     EC's 
first otion for Summary Judgment. , t e i  i  i  EC's    
i      t       u .  i ti  
has relied heavily on the ne  ffidavit of erald ost, Ph.D., filed on July 26, 2011 ith her 
ti   i ti  ("Seco  t ff."),  i t  i    t  
arguments asserted in its otion to Strike Dr. Yost's new Affidavit, filed on August 18, 2011. 
s t  rt ill r all, l i tiff r i sl  tt t  t  stablis  t t t  ll  
chronic, long-ter  health risks about which she co plains should have been known by SEC in 
2008, hen Plaintiff as last exposed to SEC's  spray products, by citing to a nu ber of 
articles i e tifie  i  t e irst st ffi avit. ever, as t e rt oted, t e r le  it  t e 
articles cited by r. ost in the irst ost ffidavit as that they did not, in fact, conclude that 
C exposure causes irreversible chronic disease, or identify any report, study, or other 
docu ented literature that identifies "this chronic condition as a result f exposure." (T . at 
41 :4-5.) Now, in a dual atte pt to both reverse this Court's Order on SEC's first otion for 
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summary judgment and oppose SECs second motion for summary judgment Plaintiff has
produced another affidavit ofDr Yost citing to an additional handful of articles upon which Dr
Yost claims to base his conclusion that the adverse chronic health effects that Plaintiff alleges in
this action were or should have been known in 2008 For the reasons set forth herein Dr Yost
has again failed to create a genuine issue ofmaterial fact as to whether SEC knew or should have
known in March 2008 that irreversible chronic disease such as that complained of by Plaintiff
was a risk of exposure to OC pepper spray Accordingly SEC is entitled to summary judgment
on Plaintiff s first and second causes of action
A The Second Yost Affidavit is fraught with conclusory statements and does
not present the foundation evidence that this Court has already deemed
necessary to establish the foreseeability of Plaintiffs alleged chronic health
condition
Likely the most significant element of the Courts criticism of the First Yost Affidavit
was that it contained a number of conclusory statements in fact legal conclusions without
providing an adequate basis for those conclusions
THE COURT And thatswhy I think what counsel is saying
is right theres you have to distinguish between his statements
on causation which really at this point is not relevant to the issues
that are before the court or whether because this is a products
liability case whether it was foreseeable to the company that they
should have foreseen these kinds of injuries as potential
And just him saying the conclusion thats a conclusory
statement just like when as far as Im concerned their expert
having a conclusory statement that it wasn foreseeable thats
really a legal conclusion I think the more important thing is what
do you base that on Whatsthe basis for that statement
And I dont see anything in any of his affidavits that
really definitively point to whether he whether studies existed
at the time that this product was used whether studies existed that
would have identified chronic this chronic condition as a result
ofexposure
REPLY MEMORANDUM IN SUPPORT OF DEFENDANTSSECOND MOTION FOR SUMMARY
JUDGMENT AND IN OPPOSITION TO PLAINTIFF MOTION FOR RECONSIDERATION Page 6
14542011 408838doc
001357
su ary judgment and oppose SEC's second otion for su ary judg ent, Plaintiff has 
produced another affidavit of Dr. Yost, citing to an additional handful of articles upon which Dr. 
ost claims t  ase is  t t t e , ic  fects t at  le e  i  
this a tion e  or s ld ha e e   in 2 .  t e reas s t forth i , . os  
has again failed to create a genuine issue of aterial fact as to whether SEC knew or should have 
 in arch  t at i revers le  is ,   t laine    i tiff, 
as a risk of exposure to  pepper spray. ccordingly, S  is entitled to su ary judg ent 
 f  irs    s   . 
.   t ffida it is ra t ith l  t t ts   
not present the foundation evidence that this ourt has already dee ed 
necessary to establish the foreseeability of Plaintiff's alleged chronic health 
iti . 
Likely the ost significant ele ent of the Court's criticis  of the First Yost Affidavit 
 t t it t i     l  t t nts, i  t l l l i , it t 
providing an adequate basis for those conclusions: 
 T: [ ... J nd that's hy I think hat counsel is saying 
is right, there's -- you have to distinguish bet een his state ents 
on causation, hich really at this point is not relevant to the issues 
t t   t  rt,  t  -- because this is a products 
liability case, hether it as foreseeable to the co pany that they 
s l   f r s  t s  i s f i j ri s s t ntial. 
nd just hi  saying the conclusion -- t at's a c cl s r  
state ent, just like hen --  f r  I'm rned, t ir x rt 
having a conclusory state ent that it asn't foreseeable, that's 
r ll   l l clusion. I t i  t  r  i rt t t i  is t 
do you base that on. hat's the basis for that statement? 
[ ... J nd I don't see anything in any of his affidavits that 
really definitively point to hether he -- t r st i s xist  --
at t e ti e t at t is r ct as sed et er st ies existe  t at 
l   e  r i  -- t  chr i  it    l  
of exposure. 
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And thats the problem because it is in his depositions
thatswhat he says He said there arent he cant point to any
studies that show that
The problem youve got is when asked specifically
whether there were any studies that showed exactly what the issue
is he says no Thatsthe problem He cant he cantsay no and
then turn around but I conclude that in fact it was foreseeable
Hesgot to say whatsthe basis for that
Jr at 4019 4025 41942511
The state of the record since this Court above quoted observations has not meaningfully
changed To date Plaintiff is still unable to identify even one study or report that itself has
concluded that exposure to OC spray may potentially cause longterm irreversible chronic
adverse health conditions See generally Second Yost Aff and Exhibits thereto Rather
Plaintiff has produced through the Second Yost Affidavit some new articles which may at best
lend support to Dr Yosts personal theory of causation in this case but which fail to conclude
or cite to any other report or study that concludes that OC exposure may cause irreversible
chronic disease At a very fundamental level then the Second Yost Affidavit is plagued with
the same problems that ultimately led this Court to conclude that the First Yost Affidavit was
insufficient to withstand SECsfirst motion for summary judgment The Second Yost Affidavit
like the first fails to give any basis for Dr Yostsconclusory statement that SEC should have
known prior to March 2008 that exposure to its OC products could cause longterm irreversible
chronic disease
Perhaps more importantly Plaintiffscounsel has already admitted during oral argument
on July 14 2011 that there were no studies available prior to March 2008 that would have put
SEC on notice that its OC products could cause irreversible chronic disease
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nd t at's t  r le  se it i  -- i  is itions 
that's hat he says. e said there aren't --  n't i t t   
   t. 
[ ... ]  r l  ou've t i    cifi ll  
het er t ere ere a  st ies t at s e  e actl  at t e iss e 
is, he says no. hat's the proble . e can't --  n't    
t e  t m r , t I l e t t, i  f t, it a  f r able. 
e's got to say hat's the basis for that. 
(Tr. t 0:4-1 , 0:25 -41:9, 2:5-1 .) 
e state f t e rec r  si ce t is urt's a e- te  ser ati s as t eani gf ll  
changed.  t , l i tiff i  till le t  i tif    t  r r rt t t it lf  
c clude  t at e s re t   s ra  a  te tiall  ca se l -ter , irre ersi le, c r ic 
s  l  i . (See generally, Second ost ff. and xhibits thereto.) t er, 
l i tiff s r  t r  t   st ffid it s   rti l s i  y, t st, 
l  s rt t  r. st's rs l t r  f s ti  i  t is se, t i  f il t  l , 
or cite to any other report or study that concludes that  exposure ay cause irreversible 
r i  i e. t  r  f t l l l, t , t   t ffida it i  l  it  
t e sa e r le s t at lti atel  le  t is rt t  c cl e t at t e irst st ffida it as 
insufficient to ithstand SEC's first otion for su ary judg ent. he Second ost ffidavit, 
like the first, fails to give any basis for r. ost's conclusory state ent that SEC should have 
kno n prior to arch 2008 that exposure to its C products could cause long-ter , irreversible 
i  . 
Perhaps ore i portantly, Plaintiffs counsel has already ad itted during oral argu ent 
on July 14, 2011 that there ere no studies available prior to arch, 2008 that ould have put 
  ti  t t its  r ts l  s  irr rsi l  r i  is se: 
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MR OVERSON Well and what he explains in his affidavit is
that no he cantpoint to a single study that would demonstrate
that definitively Okay
THE COURT So you would agree that there you have not
identified any study that this company should have been aware of
that OC spray had the had the it was foreseeable that it could
cause chronic lung problems like your client claims
MR OVERSON The okay Theresno study where theyv
taken subjects exposed them to OCspray and found that it
caused the symptoms and condition that my client has
See Lloyd August Af 2 and Ex A at 322 3325 emphasis added This is a judicial
admission It should by itself be dispositive of the remaining issues in this case
Finally as argued more fully in SECspending motion to strike filed on August 18
2011 the real significance of the Second Yost Affidavit is that it unequivocally contradicts Dr
Yostsdeposition testimony It is therefore a sham affidavit and should be stricken and not
considered by this Court While Dr Yost has consistently been unable to present any evidentiary
basis for his conclusion that the chronic adverse health risks about which Plaintiff complains
were known or foreseeable in 2008 he has unquestionably reversed his position as to what
should have been known by SEC at that time See SECsMotion to Strike Portions of Second
Affidavit of Gerald Yost Since the inadmissible sham and conclusory affidavit testimony of
Dr Yost is Plaintiffs only basis for asserting that chronic health risks of exposure to OC spray
should have been known by SEC in March 2008 Plaintiff cannot meet her burden of creating a
genuine issue of material fact on the foreseeability requirement necessary to support claims for
negligence and strict liability and therefore entry of summary judgment in favor of SEC was
and still remains appropriate
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. : l  -       f   
t at , e n't i t t  a si le st  t t l  e strate 
t t fi iti ely. y. 
 T:   l   t t t  -   t 
i ti ie   t  t t t i   l      
t t .C. s r   t  -   -   res     
s  r i  l  r le s li  r li t l i s. 
. :  - y. ere's  st  ere t ey've 
taken subjects, exposed the  to .c. spray and found that it 
ca se  t e s t s a  c ition t at  clie t as .... 
(See loyd ugust ff., ~ 2 and x.  at 32:22-33:25 (e phasis added).) his is a judicial 
ission. It s l   its lf  is siti  f t  r i i  iss s i  t is se. 
Finally, as argued ore fully in S C's pending otion to strike, filed on ugust 18, 
, t  r l i ificance f t   t ffida it i  t t it i ll  tr i t  r. 
ost's deposition testi ony.      f vit,      t 
c si ere   t is urt. ile r. st as c siste tl  ee  a le t  rese t a  e i e tiar  
basis for his conclusion that the chronic adverse health risks about hich Plaintiff co plains 
r   r f res le i  ,   ti l  r r  i  iti   t  t 
should have been kno n by SE  at that ti e. (See SEC's otion to Strike Portions of Second 
ffida it f eral  st.) i ce t e i a issi le s a  a  c cl s r  affi avit testi  f 
r. ost is Plaintiff s only basis for asserting that chronic health risks of exposure to  spray 
should have been kno n by SE  in arch, 2008, Plaintiff cannot eet her burden of creating a 
genuine issue of aterial fact on the foreseeability require ent necessary to support clai s for 
negligence and strict liability, and therefore entry of su ary judg ent in favor of SE  as, 
and still re ains, appropriate. 
III 
III 
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B Dr Yostsown medical theory on the cause of Plaintiffs alleged adverse
health condition is not substantiated by the available literature
In addition to the unsubstantiated conclusions that Dr Yost has drawn regarding the
foreseeability of chronic adverse health risks attendant to exposure to OC spray the Second Yost
Affidavit also expresses a seemingly new theory regarding the cause of Plaintiffs alleged
injuries In paragraphs 10 and 11 of the Second Yost Affidavit Dr Yost explains his new theory
that Plaintiffs exposure to OC spray has resulted in an increased sensitivity of Plaintiff to a
variety of respiratory irritants which in turn has resulted in a higher number of repeated acute
reactions to other respiratory irritants to the extent that Plaintiffs condition has become for all
intents and purposes chronic Second Yost Af 11 The new theory described by Dr Yost
in paragraphs 10 and 11 of the Second Yost Affidavit should be recognized as first and
foremost not a theory regarding the foreseeability of the chronic risks alleged by Plaintiff so
much as a theory or an unqualified medical diagnosis of the causal connection between
Plaintiffs exposure to OC spray and her present alleged health condition To the extent that Dr
Yost does attempt to map a route between Plaintiffs alleged injuries and the literature and
scientific studies available as of March 2008 Dr Yosts testimony is necessarily colored by an
additional three 3 years worth of research knowledge and literature on the subjects he
describes in his affidavit The fact is that none of the articles cited by Dr Yost set forth the same
theory of causation nor do they arrive at the same conclusion as that set forth in Paragraphs 10
and 11 of the Second Yost Affidavit See generally Second Yost Aff and Exhibits thereto
Accordingly Dr Yost has simply developed his own personal theory regarding the cause of
Plaintiffs alleged injuries from a very limited amount of information that he has gleaned from
the literature none of which reveals the same conclusions that Dr Yost has reached
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. r. ost's o n edical theory on the cause of Plaintiff's alleged adverse 
health condition is not substantiated by the available literature. 
I  iti  t  t e s st ti t  l si s t t r. st s r  r r i  t  
f reseeabilit  f c r ic a erse ealt  ris s atte a t t  e s re t   s ray, t e ec  st 
fida it l  ress   i l   t  i  t    l i ti  s ll  
i j ri . I  r r s    f t   t ffi it, r. t l i  i   t r  
t t l i tiff s s r  t   s r  s r s lt  i   i r s  s nsiti it  f l i tiff t   
ariet  f res irat r  irrita ts, ic  i  t m as res lte  i  a i er er f re eate  ac te 
reactions to other respiratory irritants to the extent that laintiffs condition has beco e "for all 
intents and purposes chronic." (Second ost ff., ~ 11.) The ne  theory described by r. ost 
i  ara ra s  a  11 f t e ec  st ffida it s l  e rec ize  as, first a  
fore ost, not a theory regarding the foreseeability f the chronic risks alleged by laintiff, so 
uch as a theory, or an unqualified edical diagnosis, of the causal connection bet een 
Plaintiffs exposure to C spray and her present alleged health condition. To the extent that r. 
ost does atte pt to ap a route bet een Plaintiff s alleged injuries and the literature and 
i tifi  t i  il le  f r  , r. st's t ti  i  saril  l r    
additional three (3) years orth of research, kno ledge and literature on the subjects he 
describes in his affidavit. he fact is that none f the articles cited by r. ost set forth the sa e 
theory of causation, nor do they arrive at the sa e conclusion, as that set forth in Paragraphs 10 
and 11 of the Second Yost Affidavit. (See generally, Second Yost Aff. and Exhibits thereto.) 
ccordingly, r. ost has si ply developed his o n personal theory regarding the cause of 
laintiffs alleged injuries fro  a very li ited a ount f infor ation that he has gleaned fro  
t e literat re, e f ic  re eals t e sa e c cl si s t at r. st as reac ed. 
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Again revealing the sham nature of the second Yost affidavit Dr Yost has now asserted
that a person such as Ms Major who is already sensitized to some extent would be expected to
become increasingly sensitized by repeated andor high levels of respiratory exposure to OC
spray Second Yost Af 10 The relevant question in this litigation of course is whether
one would have held that same expectation in March 2008 Dr Yost has previously answered
this question no
Q All right do you recall having in your review of the
scientific and medical literature seeing any peerreviewed
publications that specifically address the association
between OC exposure on the one hand and longterm
chronic health effects on the other
A Well thats what I was referring to before that I dont
think the studies have been done or published that
definitively well that provide robust data about that
scenario that OC exposure now Im talking about OC
exposure in a chronic sense multiple cases of exposure
Q Oh multiple exposures
A Yes
Q Thats fine
A And no I dontthink that I haventseen studies that
make that that come to that conclusion that there are
adverse effects because I dont think people have done the
studies
Yost Depo at pp 10022 1015 Thus Dr Yost previously testified that exposure to OC
Spray has not and had not in 2008 been sufficiently studied to ascertain the potential for long
term chronic health effects Id Now without citing to any supporting study Dr Yost has
conclusively asserted that a person in such a situation would be expected to develop a
condition that is for all intents and purposes chronic Second Yost Af T 1011
Irrespective of his changing diagnoses Dr Yost has still failed to identify any literature prior to
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gain revealing the sha  nature of the second ost affidavit, r. ost has no  asserted 
t t "a r    . j r  i  lr  iti  t   t t l   t  t  
ec e i creasi l  se sitize   re eate  a /or i  le els f res irat r  e s re t   
spray." (Second ost ff., ~ 10.) he relevant question in this litigation, f course, is hether 
one ould have held that sa e expectation in arch 2008. r. ost has previously ans ered 
this question "no": 
. ll ri t.   r ll i  i  r r i  f t  
ic   te  i   er-  
publications  specifically   i  
t e   r   t     l -ter  
c l  ects   t er? 
. ell, that's hat I as referring to before, that I don't 
think the studies have been done r published that 
definitively -- ell, that provide robust data about that 
scenario, that  exposure -- no , I'm talking about  
exposure in a chronic sense, ultiple cases of exposure. 
. h, ultiple exposures? 
. . 
. at's . 
. , ,  on't   -  ven't  t i  t t 
e  -         
adverse effects, because I don't think people have done the 
t i s. 
(Yost e o. at . 0 :22 - 101: 15.) Thus, Dr. Yost previously testified that exposure to OC 
Spray has not, and had not in 2008, been sufficiently studied to ascertain the potential for "long-
ter  chronic health effects." (Id.) o , ithout citing to any supporting study, r. ost has 
conclusively asserted that a person in such a situation "would be expected" to develop a 
iti  t t is "for ll i te ts  r s s ronic." (Se  st ff., ~~ -1 .) 
Irrespective of his changing diagnoses, r. ost has still failed to identify any literature prior to 
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2008 that mirrors his present theories of causation rendering the Second Yost Affidavit in all
relevant respects as conclusory as the First
3 SEC is entitled to judgment as a matter of law on both Plaintiffs claims for
Negligence and Strict Liability because the risk was not foreseeable
As has been argued at length previously the specific legal basis for amanufacturersduty
to warn is set forth in Puckett v Oakfabco Inc as follows
Failure to warn can be a basis for recovery in a products liability
action whether alleged under a theory of strict liability in tort or
negligence See Watson v Navistar IntlTrans Corp 121 Idaho
643 660 827 P2d 656 673 1992 A product is defective if the
defendant has reason to anticipate that danger may result from a
particular use of his product and fails to give adequate warnings
of such danger
Puckett v Oakfabco Inc 132 Idaho 816 979 P2d 1174 1999 quoting Rindlisbaker v Wilson
95 Idaho 752 519 P2d 421 1974 and Restatement Second of Torts 402A cmt h
emphasis added The limitation outlined in Puckett that a manufacturer has a duty to warn of a
danger only if it has reason to anticipate that danger is repeated throughout Idaho case law
The duty to warn has been held generally to apply only to a supplier who knows or has reason
to know the unsafe condition of the product when used for the purpose for which it was
supplied Robinson v Williamsen Idaho Equipment Company Inc 94 Idaho 819 826 498
P2d 1292 1299 1972 Hornbook law is consistent with this principle
One who supplies a chattel for another to use is subject to
liability to those whom the supplier should expect to use the chattel
for physical harm caused by the use of the chattel in the
manner for which and by a person for whose use it is supplied if
the supplier
a knows or has reason to know that the chattel is or is
likely to be dangerous for the use for which it is supplied and
b has no reason to believe that those for whose use the
chattel is supplied will realize its dangerous condition and
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 t at irrors is r t t ries f ti , r ri  t e  ost ffid it, i  ll 
relevant respects, as conclusory as the First. 
.  is title  t  judg e t s  tt  f l   t  l i tiff's l i s f  
egligence and Strict iability because the risk as not foreseeable. 
s has been argued at length previously, the specific legal basis for a anufacturer's duty 
to arn is set forth in uckett v. ak/abco, Inc., as follo s: 
ailure to arn can be a basis for recovery in a products liability 
action, hether alleged under a theory of strict liability in tort or 
li .  t  . i t  I t'! ns., orp.,  I  
, ,  .2d ,  (19 )  r ct is efective if "the 
fe t 'has r s  t  ti i t  t t r  r s lt fr   
rti lar s ' f is r t  f ils t  i e t  r i s 
of such danger." 
uckett v. alifabco, Inc., 132 Idaho 816, 979 P.2d 1174 (1999) (quoting indlisbaker v. ilson, 
95 Idaho 752, 519 P.2d 421 (1974), and estate ent (Second) of Torts § , t. ) 
(emphasis added). The li itation outlined in Puckett, that a anufacturer has a duty to warn of a 
danger only if it has "reason to anticipate" that danger, is repeated throughout Idaho case la : 
"The duty to arn has been held generally to apply only to a supplier ho kno s or has reason 
to k  t e safe c iti  f t e r ct e  se  f r t e r se f r ic  it as 
supplied." obinson v. illia sen Idaho quip ent o pany, Inc., 94 Idaho 819, 826,498 
P.2d 1292,1299 (1972). ornbook la  is consistent ith this principle: 
One who supplies . . . a chattel for another to use is subject to 
liability to those ho  the supplier should expect to use the chattel 
. . . for physical har  caused by the use of the chattel in the 
anner for which and by a person for whose use it is supplied, if 
the supplier 
(a)     t   t t t  tt l i   i  
likely to be dangerous for the use for hich it is supplied, and 
(b) has no reason to believe that those for whose use the 
chattel is supplied will realize its dangerous condition, and 
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c fails to exercise reasonable care to inform them of its
dangerous condition or of the facts which make it likely to be
dangerous
Restatement Second of Torts 388 emphasis added The supplier is under a duty to
exercise reasonable care to disclose its condition in so far as it is known to him to those who are
to use it or to inform them that it is fit only for these limited uses or if used with the particular
precautions Id cmt H emphasis added
Further as with a product like OC spray that carries with it certain known adverse health
effects a manufacturer will not be held liable for failure to warn of a risk of a product that is
otherwise dangerous if the specific danger or harm alleged by the plaintiff is unknown or
unforeseeable See Sidwell v William Prym Inc 112 Idaho 76 730 P2d 996 1986 In
Sidwell the Idaho Supreme Court determined that even though a manufacturer of sewing pins
could anticipate the danger of a pin pricking puncturing or piercing dressmaking or other
materials or the bodily surface of a user no reasonable juror could find that the manufacturer
could foresee the danger that the pins would be thrust into the body with sufficient force to
strike a bone and shatter Id at 7879 Notably the Court based its decision in part on the fact
thateven plaintiffs own expert witness admitted that while billions of such pins have been
sold that he had no knowledge of any other similar accident or complaint of injury caused by
such pins Id at 79 In the present case similar admissions exist by Plaintiffs expert and by
her own attorney
These same principles apply to a cause of action based on an alleged design defect
According to wellsettled Idaho law a manufacturer has a duty to design its product so as to
eliminate unreasonable risks of foreseeable injuries Puckett 132 Idaho at 821 citing
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(c) fails to e ercise reasonable care to inform the  f its 
a erous co ition r f the facts ich a e it likely t  e 
dangerous. 
Restatement (Second) of Torts § 388 (emphasis added). "[T]he ier is   t   
e ercise reas nable are to disclose its iti , in s  fa  s it is  t  i , to t ose ho re 
to se it, r to infor  t  that it is fit l  f r t ese li ite  s s, r if s  it  t  rti lar 
precautions." Id., c t. H (emphasis added). 
Further, as ith a product like  spray that carries ith it certain kno n adverse health 
effects, a a fact rer ill t e el  lia le f r fail re t  ar  f a ris  f a r ct t at is 
otherwise dangerous if the specific danger or harm alleged by the plaintiff is unknown or 
fores l . See Sid ell v. illia  Pry , Inc., 112 Idaho 76, 730 P.2d 996 (1986). In 
i ell, t  I a  r  rt t r i e  t t  t   f t r r f s i  i s 
"could anticipate the danger of a pin pricking, puncturing, or piercing dress aking or other 
materials or the bodily surface of a user," no reasonable juror could find that the manufacturer 
could "foresee the danger that the pins ould be thrust into the body ith sufficient force to 
stri e a e a  s atter." I . at -7 . tably, t e rt ase  its ecision, i  art,  t e fact 
that "[e]ven plaintiffs o n expert itness ad itted that hile billions f such pins have been 
sold, that he had no knowledge of any other [similar] accident or complaint of injury caused by 
such pins." !d. at 79. In the present case, similar admissions exist by Plaintiffs expert, and by 
her own attorney. 
These sa e principles apply to a cause of action based on an alleged design defect. 
According to well-settled Idaho law, "a anufacturer has a duty to design its product 'so as to 
eli inate unreasonable risks of foreseeable injuries. '" ckett,  I  t  (  
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Zimmerman v Volkswagen ofAm Inc 128 Idaho 851 854 920P2d 67 70 1996 emphasis
added see also Pate v Columbia Mach Inc 930 F Supp 451 460 D Idaho 1996 finding
strict liability only for design defect that was found to be foreseeable and in fact well known
Farmer v IntlHarvester Co 97 Idaho 742 751 553 P2d 1306 1315 1976 it is thus the
manufacturersduty to design and manufacture its products so as to eliminate unreasonable risks
offoreseeable injury citing Larsen v General Motors Corp 391 F2d 495 8th Cir 1968
Dyson v General Motors Corp 298FSupp 1064EDPa1969 Baumgardner v American
Motors Corp 83 Wash2d 751 522P2d 829 1974
Especially when dealing with products that provide a benefit to society as does OC spray
in providing an effective non lethal tool for law enforcement personnel strict liability will not
be found for unforeseeable dangers It follows that when the balance appears at the time of
distribution to tip toward the benefit of a product strict liability will not attach when an
unexpected and unknown risk injures a user Toner v Lederle Laboratories 112 Idaho 328
338 732 P2d 297 307 1987 Thus the balancing between benefits and risks is based on the
best available information at the time of distribution Id see also Restatement Second of
Torts 402A cmt k The seller of such products is not to be held to strict liability for
unfortunate consequences attending their use merely because he has undertaken to supply the
public with an apparently useful and desirable product attended with a known but apparently
reasonable risk Simply stated the law does not require the manufacturer to be clairvoyant
but instead guardsagainst strict liability resulting from unknown risks Toner 112 Idaho at
338
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Zimmerman v. Volks agen oj A ., Inc., 128 Idaho 851, 854,920 P.2d 67, 70 (1996» (emphasis 
added); see also Pate v. Columbia Mach., Inc., 930 F. Supp. 451, 460 (D. Idaho 1996) (finding 
strict liability only for design defect that was found to be "foreseeable, and in fact well-known"); 
arme  v. I t'l arvest  ., 97 Idaho , ,  .2d ,  (19 ) (" ... it is thus the 
anufacturer's duty to design and anufacture its products so as to eli inate unreasonable risks 
ofJoreseeable injury.") (citing arsen v. eneral otors orp., 391 .2d 495 (8th ir. 1968); 
Dyson v. General Motors Corp., 298 F.Supp. 1064 (E.D.Pa.l969); Baumgardner v. American 
Motors Corp., 83 ash.2d 751,522 P.2d 829 (1974». 
Especially when dealing with products that provide a benefit to society, as does OC spray 
in providing an effective, non-lethal tool for law enforcement personnel, strict liability will not 
be found for unforeseeable dangers: "It follo s that hen the balance appears at the ti e of 
distribution to tip toward the benefit of a product, strict liability will not attach when an 
unexpected and unknown risk injures a user." Toner v. Lederle Laboratories, 112 Idaho 328, 
338, 732 P.2d 297, 307 (1987). "Thus, the balancing bet een benefits and risks is based on the 
best available infor ation at the ti e of distribution .... " ;  l  t t t (S nd) f 
orts, § 402A, c t. k ("The seller of such products ...   t   l   tri  l ili  r 
unfortunate consequences attending their use, merely because he has undertaken to supply the 
public with an apparently useful and desirable product, attended with a known but apparently 
r l  ri k."). Simply stated, the law does not require the manufacturer to "be clairvoyant," 
but instead "guard[s] against strict liability resulting from unknown risks." Toner, 112 Idaho at 
38. 
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Even if as Dr Yost opines Plaintiff exposure to OC caused her irreversible chronic
adverse health condition which SEC disputes there is still no evidence in the record that would
support a conclusion that prior to March 2008 irreversible chronic disease was a known or
foreseeable risk of OC exposure Therefore s a matter of law Plaintiff has no legal basis for a
negligence or strict liability claim against SEC
CONCLUSION
In light of the foregoing arguments in addition to those asserted in SECs pending
motion to strike portions of the Second Yost Affidavit summary judgment is appropriate on
Plaintiffsfirst and second causes of action and PlaintiffsMotion for Reconsideration should
be denied Notwithstanding Dr Yosts sham and conclusory Second Affidavit Plaintiff has been
unable to present any admissible evidence demonstrating that SEC knew or should have known
that exposure to OC spray carries with it any risks of chronic longterm irreversible adverse
health effects To the contrary Dr Yosts deposition testimony the judicial admission of
Plaintiffs counsel Dr Reillys affidavit and the Affidavit of Plaintiff herself have all
confirmed that prior to 2008 the adverse health effects of exposure to OC were only known to be
transient reversible and recoverable Plaintiff has to date failed to provide the scientific basis for
Dr Yosts conclusory statements that the Court demanded and therefore Dr Yosts Second
Affidavit like the first simply cannot create a question of material fact regarding the
foreseeability of the risks about which Plaintiff complains Accordingly Plaintiff cannot satisfy
the required elements to prove liability in either negligence or strict liability and summary
judgment on Plaintiffs first and second causes of action ought to be sustained thereby
concluding this case
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Even if, as r. ost opines, Plaintiff s exposure to C caused her irreversible chronic 
adverse he lth iti , hich  dis t , there is still  idence in t e record that l  
support a conclusion that, prior to March 2008, irreversible, chronic disease was a known or 
foresee le ris  f C s r . r f r , s  atter f la , l i tiff s  le al asis f r  
negligence or strict liability clai  against SEC. 
 
In light of the foregoing argu ents, in addition to those asserted in SEC's pending 
otion to strike portions f the econd ost ffidavit, su ary judg ent is appropriate on 
l intif  s rs      ti ,  l intif  s tio   i t   
be denied. ot ithstanding r. ost's sha  and conclusory Second ffidavit, Plaintiff has been 
unable to present any ad issible evidence de onstrating that SEC kne  or should have kno n 
that exposure to OC spray carries with it any risks of chronic, long-term irreversible adverse 
l  ts. o the contrary, r. ost's deposition testi ony, the judicial ad ission of 
l i tiffs sel, r. eilly's ffi vit,  t  ffid it f l i tiff rself,  all 
confir ed that prior to 2008, the adverse health effects of exposure to  ere only kno n to be 
transient, reversible and recoverable. Plaintiff has to date failed to provide the scientific basis for 
r. st's c cl s r  state e ts t at t e rt e anded, a  t eref re r. ost's ec  
ffidavit, like the first, si ply cannot create a question of aterial fact regarding the 
foreseeability of the risks about hich Plaintiff co plains. ccordingly, Plaintiff cannot satisfy 
the required elements to prove liability in either negligence or strict liability, and summary 
judgment on Plaintiff s first and second causes of action ought to be sustained, thereby 
concluding this case. 
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Motion to Strike Portions of Second Affidavit of Gerold S Yost PhDwhich was filed with
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(14S42'() 1 410859) 
2011 0831 165 Gree Burke 12083192601 287 6919 P 34
DATED this 31 st day of August 2011
GREENER BURKE SHOEMAKERPA
Christopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
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14542011 410859
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing NOTICE OF HEARING ON
SEC MOTION TO STRIKE PORTIONS OF SECOND AFFIDAVIT OF GEROLD S
YOST PHDon the following named personson the date indicated below in the manner
indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Dr Suite 220
POBox 7808
Boise ID 83707
ViaUS Mail
Via Hand Delivery
X Via Facsimile 208 4898988
Via Overnight Delivery
DATED this 31st day of August 2011
Christopher C Burke
Thomas J LIoyd III
NOTICE OFHEARING ON SECMOTIONTO STRIKE PORTIONS OFSECOND AFFIDAVIT OF
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IC   E I   C'S OTION   P .TIONS  S  F I   
C  . O , PH.D. - P CE  
(14S42-011 4 S ) 
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
POBOX 7808
Boise Idaho 837077808
Telephone 208 4898989
Facsimile 208 4898988
Email eric@jonesandswartzlawom
Attorneys for Defendants
NO
AM Rm
SEP 0 8 2011
CHRISlutIERD RICH Clerk
By ELYSHIA HOLMES
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIALDISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
TEUFEL NURSERY INC an Oregon
corporation
Plaintiff
VS
W JOHN THIEL and THIEL LAW OFFICE
PLLC a professional limited liability company
Defendants
Case No CVOC1004959
NOTICE OF COMPLIANCE
TO THE CLERK OF THE ABOVEENTITLED COURT
PLEASE TAKE NOTICE that on the 6th day of September 2011 Defendants by and
through their counsel of record Jones Swartz PLLC served Defendants Second Supplemental
Answers and Responses to Plaintiffs First Request for Discovery together with a copy ofthis
Notice of Compliance upon counsel for Plaintiff as follows
NOTICE OF COMPLIANCE 1
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Eric B. S artz, ISB #6396 
J ES & S RTZ P LC 
1673 . Shoreline Drive, Suite 200 [83702] 
P.O. Box 7808 
Boise, Idaho 83707-7808 
Telephone: (208) 489-8989 
Facsimile: (208) 489-8988 
E-mail: eric@jonesandswartzlaw.com 
Attorneys for Defendants 
NO. /1.:~¥ Fll~ .M·-._ .. __ P.M. _____ ~
SEP   2011 
I -' Ul"'hER . I , l r  
By LYSHIA L  
DEPUTY 
IN E IS I   F E  I I  I I   
E TE F I ,        
 , I ., an regon 
corporation, 
Plaintiff, 
vs. 
. J  I   I   I , 
PLLC, a professional limited liability company, 
nts. 
s  . - -  
   
:     VE-  URT: 
PLE SE T E TICE that on the 6th day of September, 2011, efendants, by and 
through their counsel of record, Jones & artz LL , ser e  efe ants' ec  upple e tal 
ns ers and esponses to Plaintiff's First equest for iscovery, together ith a copy ofthis 
Notice of Compliance, upon counsel for Plaintiff as follows: 
TI E OF COMPLIA E - 1 
Allen B Ellis
ELLIS BROWN SHEILS CHARTERED
707 North 8th Street
POBox 388
Boise ID 83701 0388
DATED this 6th day of September 2011
USMail
Fax 3459564
Messenger Delivery
Email aellis@ebslawcom
JONES SWARTZ PLLC
By
ERIC B SWARTZ
NOTICE OF COMPLIANCE 2
001371
Allen B. Ellis 
ELLIS, BROWN & SHEILS, CHARTERED 
707 North 8th Str et 
P.o. Box 388 
Boise, ID 83701-0388 
DATED this 6th day of Septe ber, 2011. 
NOTICE OF COMPLIANCE - 2 
[ ] U.S. Mail [>4- Fa : 345-9564 
[ ] Me senger Delivery 
[ ] E : ae lis@ebslaw.com 
J ES & S RTZ PLLC n 
Y~ 
?/ IC . S TZ 
N0
FILED
AM PM
SEP 0 8 2011
CHRISTCP CRQ RICH Clerk
By EHIA HOLMES
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Case No CV PI 1003515
PLAINTIFFSOPPOSITION TO SEC
MOTION TO STRIKE PORTIONS OF
THE SECOND AFFIDAVIT OF
GAROLD S YOST PHDFILED IN
SUPPORT OF PLAINTIFF MOTION
FOR RECONSIDERATION
Defendant
Plaintiff respectfully opposes Defendant Motion to Strike Portions of the Second
Affidavit ofDr Yost None of the grounds claimed by the Defendant justify striking any portion
ofDr YostsAffidavit in Support ofPlaintiffsMotion for Reconsideration
I STANDARD
Before the Court can strike an affidavit as being a sham there must be a factual finding
that the affidavit atly contradicts earlier testimony in an attempt to create an issue of fact and
avoid summary judgment The district court must make a factual determination that the
PLAINTIFFSOPPOSITION TO SEC MOTION TO STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF
GAROLD S YOSTPHDFILED IN SUPPORT OF PLAINTIFF MOTION FOR RECONSIDERATION I
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
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a issouri corporation, 
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nt. 
Plaintiff respectfully opposes efendant's otion to Strike Portions of the Second 
ffidavit of r. ost. one of the grounds clai ed by the efendant justify striking any portion 
f r. ost's ffidavit in upport f laintiffs otion for econsideration. 
.  
efore the ourt can strike an affidavit as being a sham, there ust be a factual finding 
t at   ':flatly contradicts earlier testi ony in an atte pt to 'create' an issue of fact and 
avoid su ary judgment. . .. [T]he district court ust ake a factual deter ination that the 
I TIFF'S I   EC'S   I      I   
 . T, H.D., I  I    LAINTIF 'S I   I I  - 1 
contradiction was actually a sham Furthermore in construing whether there is a conflict this
Court must view the facts in a light most favorable to the Plaintiff
II SUMMARY OF PRIOR PROCEEDINGS
Defendant moved for summary judgment and in response Plaintiff filed the Affidavit of
Garold S Yost PhDin Opposition to DefendantsMotion for Summary Judgment Shortly
thereafter Defendant filed its Motion to Strike Affidavit of Dr Yost Filed in Support of
Opposition to DefendantsMotion for Summary Judgment In its motion Defendant argued that
1 the affidavit directly contradicts deposition testimony and should be stricken pursuant to the
sham affidavit doctrine and 2 the affidavit does not provide any explanation as to why
Dr Yoststestimony has changed from the testimony given during his deposition on April 19
2011
After hearing arguments on Defendantsmotion to strike this Court denied Defendants
motion on the grounds that the Doctorsaffidavit was not in conflict with his deposition
testimony Although it did not strike Dr Yostsaffidavit this Court granted SECsmotion for
summary judgment explaining that the affidavit did not provide a sufficient issue of fact to
withstand summary judgment on the issue of whether there was scientific literature available at
the time of sale to put SEC on notice that its product posed a risk of acute and chronic injury
such as that suffered by the Plaintiff
This Court explained that while Dr Yosts affidavit clearly supported the notion that
1 Kennedy v Allied Mutual Insurance Co 952 F2d 262 26667 9 Cir 1991 cited in Frazier v JR
Simplot 136 Idaho 100 103 2001 emphasis added
2
Frazier 136 Idaho at 104
3
Lloyd Aff8181 2Ex A7141 hearing trans 8725 8820
4
Lloyd Aff181 2 Ex A7141 hearing trans 7624 839
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.    S 
efendant oved for su ary judg ent and, in response, laintiff filed the ffidavit of 
r ld . st, h.D., i  siti  t  f ndant's otio  f r r  J nt. rtl  
t f r, e e t ile  ts  t   fida   r. s  le     
siti  t  efendant's ti  f r ar  J e t. I  its ti , efe a t ar e  t at 
(1) t e affi a it irectl  c tra icts e siti  testi  a  s l  e stric e  rs a t t  t e 
sha  affidavit doctrine; and (2) the affidavit does not provide any explanation as to hy 
r. ost's testi ony has changed fro  the testi ony given during his deposition on pril 19, 
. 
fter hearing argu ents on efendant's otion to strike, this ourt denied efendant's 
otion on the grounds that the octor's affidavit as not in conflict ith his deposition 
testi ony. 3 lth  it i  t stri e r. st's affi avit, t is rt ra te  EC's ti  for 
s r  j t, l i i  t t t  ffi it i  t r i   s ffi i t iss  f f t t  
ithstand su ary judg ent on the issue f hether there as scientific literature available at 
t e ti e f sale t  t   tice t at its r ct se  a ris  f ac te a  c r ic i j r  
such as that suffered by the laintiff.4 
This Court explained that while Dr. Yost's affidavit clearly supported the notion that 
1 ennedy v. llied utual Insurance o., 952 .2d 262, 266-67 (9th ir. 1991) (cited in razier v. J.R. 
i l t,  I a  0,  (2 1)) (e phasis a ded). 
2 razier, 136 Idaho at 104. 
3 Lloyd Aff. (8118111), ~ 2, Ex. A (7114/11 hearing trans., 87:25 - 88:20). 
4 Lloyd Aff. (8/18/11), ~ 2, Ex. A (7/14/11 hearing trans., 76:24 - 83:9). 
L I TIFF'S I   EC'S        I I   
 . T, H.D., I  I    LAINTIF 'S I   SI I  -  
SECs OC Spray product was known at the time of sale to cause acute injury the affidavit did
not seem to say that there was literature prior to the date of sale to support the notion that SECs
OC Spray product caused long term or chronic injury
This Court also pointed to the literature cited in Dr Yosts affidavit and identified several
articles that were published after the date ofsale The Court concluded that Dr Yost had relied
on articles published after the date of sale to reach his opinion that it was known prior to the date
of sale that SECs OC Spray product could cause both acute and chronic injury such as that
suffered by Ms Major On that ground this Court granted Defendantsmotion for summary
judgment reserving for further briefing the issue of whether the Plaintiff could support a claim
under FHSA standards
Thereafter Defendant filed its second motion for summary judgment and the Plaintiff
filed her motion for reconsideration In support of her motion for reconsideration and in
opposition to the Defendants second motion for summary judgment Plaintiff filed a second
affidavit of Dr Yost wherein he clarified some of the statements in his earlier affidavit and
identified additional literature that supported his opinion that sufficient literature existed prior to
the date of sale that should have put SEC on notice that its product posed a risk of acute and
chronic respiratory injury such as that suffered by Ms Major
In reference to the articles cited in his earlier affidavit Dr Yost explained that they were
but a few of a larger body of work that supported his opinion that the risks posed to the
5
LloydAff8181 2Ex A7141 hearing trans 8022 839
6
Lloyd Aff181 2 Ex A7141 hearing trans 7914 803
Id
8 This Court found the FHSA and not OSHA provides the warning label standards for the product
liability claim Lloyd Aff8181 2 Ex A7141 hearing trans 8310 8623
9 Aff of Yost72611 614 Ex 1
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OC Spray product caused long ter  or chronic injury. 5 
is rt als  inted t  t e literature cite  i  r. st's affida it a  i e tified se eral 
articles that ere published after the date of sale.6 The Court concluded that r. ost had relied 
on articles published after the date of sale to reach his opinion that it as kno n prior to the date 
of sale that SEC's  Spray product could cause both acute and chronic injury such as that 
suffered by s. ajor.7 n that ground, this ourt granted efendant's otion for su ary 
judg ent, reserving for further briefing the issue of whether the Plaintiff could support a clai  
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r ft r, f t file  its s  tion f r s r  j e t  t  l i tiff 
le   on  i ration. I  s rt f r ti  f r r si r ti   i  
opposition to the efendant's second otion for su ary judg ent, Plaintiff filed a second 
  r. s    ie        rl  f i   
i e tifie  a iti al literat re t at s rte  is i i  t at s fficie t literat re e iste  ri r t  
the date of sale that should have put SEC on notice that its product posed a risk of acute and 
chronic respiratory injury such as that suffered by s. ajor. 9 
I  refere ce t  t e articles cite  i  is earlier affi avit, r. st e lai e  t at t e  ere 
but a fe  f a larger body f ork that supported his opinion that the risks posed to the 
5 Lloyd Aff. (8118111), ~ 2, Ex. A (7/14/11 hearing trans., 80:22 - 83:9). 
6 Lloyd Aff. (8118/11), ~ 2, x.  (7114111 hearing trans., 79:14 - 80:3). 
7 d. 
8 is rt f  t e  a  t  r i es t e ar i  la el sta ar s f r t e r ct 
liability claim. Lloyd Aff. (8118111), ~ 2, Ex. A (7114/11 hearing trans., 83:10 - 86:23). 
9 ff. f ost (7/26/11), ~~ -1  & x. . 
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respiratory system by SECs OC Spray product were known at the time it sold its product to
IDOC He further clarified that although he had included articles published after the date of
sale those articles were not necessary to his opinion relating to the foreseeability of injury
issue
11
To clarify matters Dr Yost restated his opinion in unequivocal language
First I believe it best to state unequivocally that it is my expert
opinion based on my education research and training that the
scientific literature and studies in existence prior to 2008 was such
that when viewed as a body of literature and human and animal
studies it was known that a product such as SEC MK9 Fogger
posed a risk of both acute and chronic respiratory injury such as
that described in Ms Major medical records
12
With more detail and clarity Dr Yost explained in his second affidavit the mechanism by which
SECs product was known prior to the date of sale to cause both acute and chronic injury to the
respiratory tract by receptor mechanisms that make certain exposed persons hypersensitive to OC
and other more common irritants normally encountered in the environment
13
Dr Yost identified those articles cited to earlier that were published before the date of
sale as being sufficient ground for his conclusions regarding the known risk of acute and chronic
respiratory injury
14
In further support of his position that a wider body of literature existed prior
to the date of sale that supported his opinions relating to causation he identified four additional
articles that were published prior to the date of sale
15
Dr Yost then identified three additional articles that were published after the date of sale
10 Aff of Yost72611 68 1213
11 Id
12 Aff ofYost72611 9
13 Aff of Yost2611 1011
14 Aff of Yost72611 12
15 Id
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t i , it   t t  r t   EC's -9 r 
s   ris  f t  t   r i  r s ir t r  i j r  s  s 
t at escri e  i  s. ajor's e ical rec r s.  
ith ore detail and clarity, r. ost explained in his second affidavit the echanis  by hich 
SEC's product as kno n prior to the date of sale to cause both acute and chronic injury to the 
respiratory tract by receptor echanis s that ake certain exposed persons hypersensitive to OC 
and other ore co on irritants nor ally encountered in the environ ent. 13 
. s  ie  s  e  t   r    s      
sale as being sufficient ground for his conclusions regarding the known risk of acute and chronic 
respiratory injury. 14 In further support f his position that a ider body ofliterature existed prior 
to the date of sale that supported his opinions relating to causation, he identified four additional 
articles that were published prior to the date of sale.  
r. ost then identified three additional articles that ere published after the date f sale 
\0 ff.  st (7/26 11), ~~ -8, -1 . 
IIId. 
12 ff. f st (7/26 11), ~ . 
13 ff. f st (7/26 11), ~~ -1 . 
14 ff. f st (7/26/11), ~ 2. 
l5Id. 
I TIFF'S SI I   EC'S   I      I   
R L  S. ST, PH.D., FILE  I  S PP RT F PLAINTIFF'S TI  F R REC SI ER TI  - 4 
but which reviewed a portion of the body of literature as it existed during the period prior to the
date of sale
16
He pointed out that the first article cited 58 articles and of those only 8 were
published in or after 2008 In the second article the authors cited 59 articles of which only 3
were published in 2008 and none were published after 2008 The third article cited 226
articles and only 14 were published during or after 2008
After Plaintiff filed the second affidavit of Dr Yost SEC moved to strike his affidavit
claiming among other things that it relies on facts and data not previously disclosed in
discovery
20
The following information relating to Dr Yost and his anticipated testimony has
been disclosed
Date of Service Document Name Content Disclosed
Aug 5 2010 Pltfs Expert Witness Disclosure Dr Yostsidentity
substance oftestimony
Aug 5 2010 Pltfs Second Supplemental Answers and Copies ofarticles from
Responses to Def s First Set of Interrogatories Dr Yost
and Requests for Production of Documents
March 28 2011 Pltfs Supplemental Expert Witness Disclosure What is known ofthe
mechanisms by which an
injury such as Ms Major
may occur
23
April 18 2011 Pltf s Answers and Responses to Defs First Set Eleven articles that support
ofRequests for Admissions and Second Set of Dr Yostsopinions
Interrogatories and Request for Productions of
Documents
16 Aff of Yost72611113
17 Id
18 Id
19 Id
20 SECsMot to Strike Portions ofDr Yosts2d Aff pp 12
21 Aff of Counsel in Opp to SECs2d Motion to Strike 3 Ex A
22 Aff of Counsel in Opp to SECs2d Motion to Strike 4 Ex B
23 Aff of Counsel in Opp to SECs2d Motion to Strike 5 Ex C
24 Aff of Counsel in Opp to SECs2d Motion to Strike 6 Ex D
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16 Aff. of Yost (7/26/11), ~ 13. 
17 d. 
18Id. 
19 d. 
20 EC's t. t  tri e rti   r. st's  ff., . -2. 
21 ff. of ounsel in pp. to SEC's 2d otion to Strike, ~ 3, x. . 
22 ff. of ounsel in pp. to SEC's 2d otion to Strike, ~ , . . 
23 ff. of Counsel in pp. to SEC's 2d otion to Strike, ~ , . . 
24 ff. of ounsel in pp. to SEC's 2d otion to Strike, ~ , . . 
 s s  
r. ost's identity; 
substance oftestimony.zl 
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r. OSt.22 
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Date ofService Document Name Content Disclosed
June 10 2011 Pltf s Disclosure of Rebuttal Expert Witness Testimony regarding what
Testimony was known at the time of
sale to IDOC ofthe
mechanisms by which
injuries such as Ms
Majorsmayoccur
25
July 26 2011 Affidavit ofGarold S Yost PhDin Support More articles further
ofPltf s Motion to Reconsider CourtsOrder on explanation and
Def s Motion for Summary Judgment clarification ofDr Yosts
opinions
26
July 26 2011 Pltf s Second Supplemental Expert Witness Same
27
Disclosure
July 26 2011 Pltfs Fifth Supplemental Answers and Same
28
Responses to Defs First Set of Interrogatories
and Requests for Production of Documents
July 26 2011 Pltf s Supplemental Answers and Responses to Same
29
Def s Second Set of Interrogatories and
Requests for Production ofDocuments
Sept 7 2011 Pltf s Third Supplemental Expert Witness Further clarification of
Disclosure testimony
30
On August 22 2011 Plaintiffs attorney informed SECsattorneys that Dr Yost would
be made available at their convenience for an additional deposition if they so desired Plaintiff
offered to make Dr Yost available by live audiovideo feed to avoid the costs associated with
traveling to Utah where Dr Yost resides
32
As of this date SEC has not requested a second
25 Aff of Counsel in Opp to SECs 2d Motion to Strike 7 Ex E
26 Aff of Counsel in Opp to SECs 2d Motion to Strike 8
27 Aff of Counsel in Opp to SECs 2d Motion to Strike 9 Ex F
28 Aff of Counsel in Opp to SECs 2d Motion to Strike 10 Ex G
29 Aff of Counsel in Opp to SECs 2d Motion to Strike 11 Ex H
30 Aff of Counsel in Opp to SECs 2d Motion to Strike 12 Ex I
31 Aff of Counsel in Opp to SECs 2d Motion to Strike 13 Ex J
32 Id
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25 ff.  s l i  . t  C's  ti  t  tri , ~ , . . 
26 ff.  s l i  . t  C's  ti  t  tri , ~ . 
 f.  s l i  . t  C's  ti  t  t i , ~ , . . 
 f.  s l i  . t  C's  ti  t  t i , ~ , . . 
29 ff. of ounsel in pp. to S C's 2d otion to Strike, ~ , . . 
30 ff. of ounsel in pp. to S C's 2d otion to Strike, ~ , .!. 
31 ff. of Counsel in pp. to SEC's 2d otion to Strike, ~ , . J. 
2I . 
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deposition ofDr Yost 33
III ARGUMENT
A Dr Yosts SecondAffidavit Does Not Contradict His Deposition Testimony
Defendant argues that Dr Yosts second affidavit conflicts with his testimony given
during his deposition and asks this Court to strike Dr Yosts second affidavit as a sham
However Idaho courts only strike affidavits under the sham affidavit doctrine where there is a
true unequivocal conflict between what was testified to in the witnesssdeposition and what is
stated in the affidavit The appellate courts generally find that apparent conflicts are to be
resolved in favor of the non moving party and credibility issues left to be decided by the jury
35
Defendant argues that when Dr Yost was questioned in his deposition he responded
unequivocally and on several occasions that SEC could not have known or foreseen those
alleged risks at that time Defendant claims to have questioned Dr Yost extensively as to
what information literature and scientific knowledge was available to SEC at the time it
manufactured and sold the OC Spray at issue and whether SEC could have known or foreseen
the risk of longterm chronic injuries akin to what Plaintiff alleges in this litigation For both
propositions Defendant cites the deposition of Dr Yost at pages 153 line 16 to page 156 line
10 The testimony cited by the Defendant is as follows
33 Aff of Counsel in Opp to SECs2d Motion to Strike 13 Ex J
34 Frazier v J R Simplot 136 Idaho 100 10304 2001
35 See Moins v Cach 143 Idaho 221 225 26 2006 apparent conflict is no reason to strike It is then
just a credibility issue Frazier v JR Simplot 136 Idaho 100 1034 2001 a no answer to the question
whether deponent was verbally and physically abused was not in conflict with affidavit stating that
physical abuse had occurred it was error to strike the affidavit since the deposition was ambiguous
Estate of Keeven 126 Idaho 290 298 Ct App 1994 vague and uncertain testimony does not directly
contradict a clarifying affidavit
36 Memo in Supp of SECsMot to Strike Portions of Dr Yosts 2dAff p 5
37 Memo in Supp of SECsMot to Strike Portions ofDr Yosts2dAff pp 45
38 Id
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iti   . OSt.33 
I.  
. . st's  fida  es   s o  t  
efendant argues that r. ost's second affidavit conflicts ith his testi ony given 
during his deposition, and asks this ourt to strike r. ost's second affidavit as a sha . 
, da  ts  e t      e     
true unequivocal conflict bet een hat as testified to in the itness's deposition and hat is 
stated in the affidavit.34 he appellate courts generally find that apparent conflicts are to be 
r l  i  f r f t  - in  rt   r i ilit  i s l ft t   i   t  j ry.35 
efendant argues that hen r. ost as questioned in his deposition, he "responded, 
i ll    l i s, t t  l  t     t  
alleged risks at that ti e.,,36 f t l i s t   "questione  r. st t si l  s t  
hat infor ation, literature and scientific kno ledge as available to S  at the ti e it 
t   l  t    t i ,  t   l      
the risk of long-ter  chronic injuries akin to hat Plaintiff alleges in this litigation.,,37 r t  
propositions, efendant cites the deposition of r. ost at pages 153, line 16, to page 156, line 
10.38 The testi ony cited by the efendant is as follo s: 
33 Aff. of Counsel in Opp. to SEC's 2d otion to Strike, ~ 13, x. J. 
34 razier v. J. . Si p/ot, 136 Idaho 100, 103-04 (2001). 
35 ee i s v. each,  I a  , -2  (2 6) (appare t c flict is  reas  t  stri e. It is t e  
just a credibility issue); Frazier v. J.R. Si p/ot, 136 Idaho 100, 103-4 (2001) (a no ans er to the question 
hether deponent as verbally and physically abused as not in conflict ith affidavit stating that 
physical abuse had occurred, it as error to strike the affidavit since the deposition as a biguous); 
state f eeven, 126 Idaho 290, 298 (Ct. pp.1994) (vague and uncertain testi ony does not directly 
contradict a clarifying affidavit). 
36 e o. in Supp. of SEC's ot. to Strike Portions of r. ost's 2d ff., p. 5. 
37 o. i  pp. f EC's t. t  tri  rti s f r. st's  ff., . -5. 
38 [d. 
I TIFF'S I   EC'S   I      I   
 . T, H.D., I     LAINTIF 'S   NSI RA I  -  
Q In your opinion as of March of 2008 was there anything
definitively published in the peerreviewed scientific and medical
literature that would have put a manufacturer of pepper spray
products such as SEC on notice that exposure to their products by
somebody with the chronic health conditions of Ms Major would
have caused her an exacerbated response which would have
included an ongoing chronic cough for the subsequent period of
time
A I dont think its possible for me to place a nefarious intent
You know the responsibility ofwhether or not there was sufficient
evidence there to say you know if you do if you expose
somebody to this they are going to have life altering changes I
dont think that existed then In the literature today I dont think it
exists except through the preponderance of evidence and it may
very well be that other people dontbelieve that thats the case but
I do And so you know blame is for the jury to decide
Q Well do you think people that were trained in toxicology such
as yourself would have been able to review the medical literature
and the scientific literature that existed on or prior to March of
2008 and have been able to determine that there would have
been a life altering condition that resulted from pepper spray
exposure
A I dont see evidence that the normal ways for industrial hygiene
officers and personnel to evaluate such kinds of exposures may or
may not have existed at that time I havent seen it I mean I dont
have evidence that would say heresan MSVS sheet that says
this bad thing is going to happen if you expose it It does say
you know this is an irritant This is an acute thing It is going to
cause this this and this so you better be aware of But Im not
aware of anything that the normal layperson in the industry would
say or would see that would necessarily show that
Conversely maybe there is something in the not in the
maybe in the product information or whatever which I havent
seen just the MSVS So again I really cant place blame
necessarily on whomever All I can say is I think theres an
association between the condition she now has and that exposure
Q And thats based upon your many years of experience as a
toxicologist
39 MSDS Material Safety Data Sheet
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. In your OpInIOn, as of arch of 2008, as there anything 
efmitively lished in t e eer-re ie ed scie tific a  e ical 
literature that ould have put a a fact rer f e er s ray 
products such as SEC on notice that exposure to their products by 
so ebody ith the chronic health conditions of s. ajor ould 
a e ca se  er a  e acer ate  res se ic  l  a e 
included an ongoing chronic cough for the subsequent period of 
ti ? 
. I n't t i  it's ssi l  f r  t  la e  f ri s i t t. 
ou , t e r s sibilit  f et er r t t ere s s fficie t 
e idence there t  sa ,  , if   --   ose 
s e  t  t is, t e  are i  t  a e life-alteri  c a es. I 
n't t in  t t ist  t . I  t e liter t r  t  I n't t i  it 
ists t t r  t  r r  f i ,  it  
very ell be that other people don't believe that that's the case, but 
I .  s ,  , la  is f r t  j r  t  i . 
. ell,   t i  e le t at ere trai e  i  t ic l  s c  
as rself l  a e ee  a le t  re ie  t e e ical literat re 
a  t e scie tific literat re t at e iste   r ri r t  arc  f 
      e     
been a life-altering condition that resulted fro  pepper spray 
exposure? 
. I don't see evidence that the nor al ays for industrial hygiene 
officers and personnel to evaluate such kinds f exposures a r 
ay not have existed at that ti e. I haven't seen it. I ean, I don't 
have evidence that ould say, here's an SVS39 sheet that says 
t is  t i  is i  t  e  if  e se it. It es say, 
you kno , this is an irritant. his is an acute thing. It is going to 
cause this, this and this, so you better be a are of. ut I'm not 
aware of anything that the nor al layperson in the industry would 
say or ould see that ould necessarily sho  that. 
Conversely, aybe there is so ething in the -- t i  t  --
a e i  t e r ct i f r ati  r ate er ic  I aven't 
seen, just the SVS. o, a ain, I reall  can't lace la e, 
necessarily, on who ever. ll I can say is I think there's an 
associati  et ee  t e c diti  s e  as a  t at e sure. 
Q. And that's based upon your many years of experience as a 
toxicologist? 
39 MSDS (Material Safety Data Sheet). 
LAINTIF 'S POSITI   EC'S   I  RTI     I   
 S. ST, PH.D., FI  I  S PP  F PLAINTIFF'S I  F  SI I  -  
A Yes
Q Its based on your extrapolation of a number of scientific
papers and your weighing of the evidence is that right
A Yes
Q But you cant cite me to one specific paper out there that
existed prior to March of 2008 that specifically would have put
laypersons without your background on notice that exposure to
their product could have caused these longterm health conditions
A No
Q By Mr Burke Okay I think Im almost done Let me ask
you kind of a catchall question Do you have any other opinions
that you have not expressed in your report or in the deposition here
today as we have been talking through this subject that you can
think ofright now
A I think wev covered the gamut
The transcript clearly shows that SEC framed its questions far too narrowly asking
Dr Yost whether there was anything definitively published that would have put a
manufacturer on notice that the exposure to their products by somebody with the chronic
health conditions of Mrs Major would have caused her an exacerbated response which would
have included an ongoing chronic cough for the subsequent period of time The question
asked was whether there were any definitive articles at the time to which Dr Yost testified
that there were none he was aware of However Dr Yost explained in his first affidavit that
statements relating to the issues of causation and whether a manufacturer would have been on
ao Aff of Counsel in Supp of Pltfs Opp to SECsMSJ6101 4 Ex 2 Yost Dep 1536
1560
ai Aff of Counsel in Supp of Pltfs Opp to SECs MSJ6101 4 Ex 2 Yost Dep 153625
emphasis added
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. . 
. It's   r tr l ti  f  er f i tific 
papers and your eighing f the evidence; is that right? 
. . 
. t  can't cite e t  e s ecific a er t t ere t at 
e iste  rior t  arc  f  t at s ecificall  l  a e t 
laypersons ithout your background on notice that exposure to 
t ir r t l    t  l -ter  lt  diti ns? 
. . 
. (By r. urke) kay. I think I'm al ost done.    
you kind of a catchall question. o you have any other opinions 
that you have not expressed in your report or in the deposition here 
today as e have been talking through this subject that you can 
think of right no ? 
. I think e've covered the gamut.40 
he transcript clearly sho s that S  fra ed its questions far too narro ly-asking 
r. ost hether there as anything "definitively published ... that ould have put a 
t  ...  tice t at t e e s re t  t eir r cts  s e  it  t e c r ic 
health conditions f rs. ajor ould have caused her an exacerbated response hich ould 
have included an ongoing chronic cough for the subsequent period of ti e?,,41 The question 
asked as hether there ere any "definitive" articles at the ti e, to hich r. ost testified 
that there ere none he as a are of. o ever, r. ost explained in his first affidavit that 
state ents relating to the issues of causation and hether a anufacturer ould have been on 
40 ff. of ounsel in Supp. of Pltfs pp. to SEC's SJ (6/10/11), ~ , x.  (Yost ep., 53:16 -
156:10). 
41 ff. of ounsel in Supp. of Pltfs pp. to SEC's SJ (6/10/11), ~ 4, x. 2 (Yost ep., 153:16-25) 
(e phasis added). 
L I TIFF'S SI I   EC'S   I  I     I   
L  S. ST, PH.D., FILE  I  S PP T F PLAINTIFF'S TI  F  E SI E TI  -  
notice at the time cannot be couched in absolute certainty Rather many of the conclusions
Dr Reilly draws should be based on the sum ofscientific evidence and judgments ofthe expert
scientists Dr Yost explained in his affidavit that it is misleading to make absolute statements
from data that does not warrant conclusions with absolute certainty
The questions put to Dr Yost relating to the state of the science prior to the date of sale
were couched in terms of certainties and absolutes
45
In his deposition Dr Yost tried to explain
that there is no such thing as absolute proof in science
Q So would you accept that conclusion as being accurate
A No I would accept it as being a possibility Theres a
difference between proving something and postulating something
Itspossible
Q When you say theresa difference between proving something
and postulating something what do you mean that difference to
be What is the difference between proving and postulating
A Well there is no such thing as absolute proof in science If
yourea true scientist then nothing is ever absolute So proof to
me means a weight of evidence argument that the weight of the
evidence provided is convincing and well convincing
Q And a simple Imsorry
A Its convincing to me Im only going to talk about myself
here but its convincing to me that its true that until proven
otherwise thats a process that Ill accept as being proof where
there is no such thing as true proof
46
There is nothing inconsistent between Dr Yosts deposition and affidavit testimony Certainly
42 Dr Reilly is a retained expert witness for SEC
43 Aff of Yost6101 8
44 Id
45 Aff of Counsel in Supp of Pltfs Opp to SECsMSJ6101 4 Ex 2 Yost Dep 153625
46 Aff of Counsel in Supp of Pltfs Opp to SECsMSJ101 4 Ex 2 Yost Dep 13021
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tic  t t  ti e t   i  "absolute rt inty. t r,  f t  l si s 
r. eilly42 r s s ld  s   t  s  f s i tifi  ide ce  j e ts f t  rt 
tists.,,43 r. ost explained in his affidavit that it is isleading to ake absolute state ents 
fro  t  t t s t rr t l si s it  s l te ertainty.44 
 ti s t t  r. t r l ti  t  t  t t  f t  i  ri r t  t  t  f l  
ere e     ies  l .  In his deposition, r. ost tried to explain 
that "there is no such thing as absolute proof in science." 
. So ould you accept that conclusion as being accurate? 
. , I l  t it s i   ssibilit . ere's  
ifference et ee  r i  s et i  a  st lati  s ething. 
It's possible. 
. e   sa  t ere's a iffere ce et ee  r i  s et i  
and postulating so ething, hat do you ean that difference to 
be? hat is the difference bet een proving and postulating? 
A. ell, there is no such thing as absolute proof in science.  
you're a true scientist, then nothing is ever absolute. So proof to 
e eans a eight of evidence argu ent, that the eight of the 
evidence provided is convincing and -- ell, convincing. 
.  a si le - I'm s rry. 
. It's c i ci  t  e. I'm only going to talk about yself 
here, but it's convincing to e that it's true, that until proven 
otherwise, that's a process that I'll accept as being proof, where 
there is no such thing as true proof.  
here is nothing inconsistent bet een r. ost's deposition and affidavit testi ony. ertainly 
42 r. eilly is a retained expert itness for S . 
43 ff. of ost (6/10/11), ~ . 
44 !d. 
45 Aff. ofCounse1 in Supp. ofPltfs Opp. to SEC's SJ (6/10/11), ~ , . , (Yost ep. 53:16-2 ). 
46 ff. f sel i  . f ltfs . t  EC's J (6110/11), ~ 4, Ex. 2 (Yost Dep., 130:1-21). 
I TIFF'S I   EC'S   I      I I   
 . , H.D., I  I    LAINTIF 'S I   I I  -  
the Defendant has not identified a direct conflict which is what the law in Idaho requires
before an affidavit may be stricken as a sham
Dr Yost also cautioned in his deposition that there was a difference between questions
phrased in terms of would cause or is going to cause and questions phrased in terms of
scientific probabilities He testified in this respect as follows
Q All right Let me talk about something other than possibilities
because in the legal profession we have to deal in probabilities
Okay So what Im wondering is are you able to state based upon
reasonable scientific certainty which I will define to you as being
from a scientific standpoint that a proposition is more probably true
than not true are you able to say from that standpoint whether or
not a person who is sensitive to capsaicin and has a chronic
respiratory condition will get a longterm exacerbation of that
condition because of that exposure
A Well it depends on what verb you use If you say will get
or can get I have a different answer
Q Okay How would your answer be different
A Yes and no It is more likely than not on the basis of the
literature that Ive seen that the cough well the respiratory issues
that are in play here
Q Ms Major
A Ms Major could be exacerbated to a chronic respiratory
outcome So what Im saying is in my opinion it is more probable
than not that that hypothesis is valid in this case If Im going to
take somebody with you know who has been sprayed on the foot
with capsaicin and they get you know irritation or something then
I may not make that same conclusion because I want to see what
the association is between type of exposure you know the type of
issues that come about as a result of exposure and whether the
science bears up as a mechanism for that chronic situation
developing And I think of sic all of those things are consistent
and valid here
Q So youre saying from a reasonable scientific certainty its
more probable than not that Ms Major underlying respiratory
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the efe a t as t ide tified a "direct c nflict," ich is at t e la  i  I a  re ires 
before an affidavit ay be stricken as a sha . 
r. ost als  ca ti e  i  is e siti  t at t ere as a ifference et ee  esti s 
phrased in ter s f "would cause" or "is going to cause" and questions phrased in ter s f 
scientific probabilities. e testified in this respect as follo s: 
. ll right. et e talk about so ething other than possibilities, 
because in the legal profession e have to deal in probabilities. 
ay?  at I'm eri  is are  a le t  state ase   
reas a le scie tific certai t , ic  I ill efi e t   as ei  
fro  a scientific standpoint that a proposition is ore probably true 
than not true, are you able to say fro  that standpoint hether or 
not a person ho is sensitive to capsaicin and has a chronic 
respiratory condition ill get a long-ter  exacerbation of that 
condition because of that exposure? 
. ell, it depends on hat verb you use. If you say ill get 
or can get, I have a different answer. 
. a .  l  r a s er e ifferent? 
. e   . It is r  li l  t  t  t  sis f t  
literature that I've seen that the cough -- l ,    
that are in play here --
. s. ajor? 
. -- s. ajor could be exacerbated to a chronic respiratory 
tc e.  at I'm sa i  is i   i i  it is re r a le 
than not that that hypothesis is valid in this case. If I'm going to 
take so ebody ith -- you know, ho has been sprayed on the foot 
it  ca saici  a  t e  et,  , irritati  r s ething, t e  
I ay not ake that sa e conclusion because I want to see what 
t e ass ciati  is et ee  t e f e s re,  w, t e t e f 
iss es t at c e a t as a res lt f e s re a  et er t e 
science bears up as a echanis  for that chronic situation 
developing. nd I think of [sic] all of those things are consistent 
  r . 
.  ou're s yi  fr   r s l  s i tifi  rt inty, it's 
ore probable than not that s. ajor's underlying respiratory 
I TIF 'S I   EC'S   I      I I   
 . T, H.D., I  I    LAINTIF 'S I   I I  - 11 
illnesses were exacerbated causing her to have a chronic condition
A Yes 47
Furthermore Dr Yostsanswer made it clear that his opinions were not based on any
single definitive study or article He explained that it was based on a preponderance of the
scientific evidence I dont think it exists except through the preponderance of evidence and it
may very well be that other people dont believe that thatsthe case but I do He has now
explained in both of his affidavits that he is relying on an entire body of scientific literature and
not a single definitive study
49
The Plaintiff is not required to point to any single definitive study that concludes that
exposure to OC Spray would have caused her an exacerbated response which would have
included an ongoing chronic cough for the subsequent period of time which is how the question
was put to Dr Yost in his deposition The Plaintiff is only required to show that based on the
scientific knowledge as it existed at the time the Defendant knew or should have known that
there was a risk of injury to the respiratorypulmona system similar to that suffered by
Ms Major
B Dr Yosts Second Affidavit Explains Any Perceived Difference Between His
Deposition His First Affidavit and His Second AffidavitPrim rilyThat His
Second Affidavit is a Clarification of His First Affidavit and His Deposition
As SEC points out courts have found that testimony is not a sham where it is the result
of an honest discrepancy a mistake or the result of newly discovered evidence Here as
4 Aff of Counsel in Supp ofPltfs Opp to SECs MSJ6101 4 Ex 2 Yost Dep 1385 1405
48 Aff of Counsel in Supp ofPltfs Opp to SECs MSJ101 4 Ex 2 Yost Dep 154610
49 Aff of Yost6101 6 Aff ofYost72611 68 1213
so See Aff of Counsel in Supp of Pltfs Opp to SECs MSJ6101 4 Ex 2 Yost Dep 1532225
51 Smythe v Safeco Ins Co ofAmerica 33 Fed Appx 303 9Cir 2002
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lnesse          dition? 
. s.47 
Furthennore, r. ost's ans er ade it clear that his opinions ere not based on any 
i l  i iti e t   ti l . e explained that it as based on a preponderance of the 
scientific evidence: "I don't think it exists except through the preponderance of evidence, and it 
ay very ell be that other people don't believe that that's the case, but 1 do.,,48    
explained in both of his affidavits that he is relying on an entire body of scientific literature and 
t  si l  fi iti  st dy.49 
he Plaintiff is not required to point to any single definitive study that concludes that 
s re t    "would     t   i  l   
included an ongoing chronic cough for the subsequent period of ti e," hich is ho  the question 
as put to r. ost in his deposition. 50 he Plaintiff is only required to sho  that based on the 
scientific kno ledge as it existed at the ti e, the efendant kne  or should have kno n that 
there as a risk of injury to the respiratory/pulmonary syste  si ilar to that suffered by 
s. ajor. 
. r. ost's econd ffidavit xplains ny erceived ifference et een is 
Deposition, His First Affidavit, and His Second Affidavit-Primarily That His 
ec  ffida it is a larification f is irst ffida it a  is e siti  
s  points out, courts have found that testi ony is not a sha  here it is the "result 
of an honest discrepancy, a istake, or the result of ne ly discovered evidence.,,51 ere, as 
47 ff. f ounsel in Supp. of ltf's pp. to SEC's SJ (6110111), ~ 4, Ex. 2 (Yost Dep. 138:15 -140:5). 
48 ff. of ounsel in Supp. of ltf's pp. to SEC's SJ (6110111), ~ 4, x. 2 (Yost ep. 154:6-10). 
49 ff. of ost (6110111), ~ 6; ff. of ost (7/26111), ~~ 6-8, 12-13. 
50 See ff. f ounsel in upp. of ltf's pp. to EC's J (6/10111), ~ 4, x. 2 (Yost ep. 153:22-25). 
51 S ythe v. Safeco Ins. o. f A erica, 33 Fed. ppx. 303 (9th ir. 2002). 
I TIF 'S I   EC'S   I      I   
 . , H.D., I  I    I TIF 'S I   I I  -  
already explained there are no conflicts between Dr Yosts deposition testimony his first
affidavit and his second affidavit His second affidavit as he explains is simply clarifying his
earlier affidavit Any perceived discrepancies were created as a function of an honest mistake in
the way his opinions were stated and not as a function of any actual changes to his opinions
SEC makes much of the fact that Dr Yost has included additional article citations in his
second affidavit and argues that they are not newly discovered evidence that was not otherwise
available earlier However as Dr Yost states the articles cited in his earlier affidavit that
predated the date of sale are sufficient to support his opinions He referenced a body of literature
to which those articles were but a portion All he has done is include additional articles from the
same body of literature already referenced in his earlier testimony
C Dr YostsDeposition Testimony Regarding the Effects Generally Expected From
OC Exposure Does Not Contradict His Affidavit Testimony Regarding the Risks to
Specific Populations AlreadySensitized to OC
SEC cites to Dr Yostsaffirmative response in his deposition where he was asked Is it
your understanding that the adverse health effects that exposure to OC and capsaicinoids by
humans are generally deemed to be temporary reversible and not long term However that
testimony is not in conflict with his second affidavit because it is true that generally speaking
most individuals exposed to OC andorcapsaicinoids experience temporary reversible effects
That says nothing about the risks to certain populations that are already sensitized to an extent to
OC andorcapsaicinoids Dr Yost explains in much detail the risks such products pose to a
certain segment of society who react to OC products differently than what is expected generally
Throughout SECs arguments there is an osculation between representing Dr Yosts
12 Aff of Counsel in Supp of Pltfls Opp to SECs MSJ6101 4 Ex 2 Yost Dep 6347
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lr  l i , t r  r   fli ts t  r. st's siti  t sti ony, is first 
ffi avit,  is s  ffi avit. is s c  ffi avit, s  l i s, is si l  l rif i  is 
rli r ffi avit.  r i  is r i s r  r t  s  f ti  f  st ist  i  
t   is i i s r  st t   t s  f ti  f  t l s t  is i i s. 
       r.    diti l rt     
 ffi vit,  r  t t t  r  t l  i r  i  t t  t t r i  
il l  rli r. r,  r. st t t s, t  ti l  it  i  i  rli  f i it t t 
t  t  t   l   i i t t  t is i i s.      lit t  
t  i  t  rti l  r  t  rti . ll    i  i l  iti l rti l  fr  t  
   liter t r  lr  r f r  i  i  rli r t ti y. 
. r. ost's eposition esti ony egarding the ffects "Generally" xpected ro  
 xposure oes ot ontradict is ffidavit esti ony egarding the isks to 
i i  l io s l e  i ize    
S  cites to r. ost's affir ative response in his deposition here he as asked "Is it 
 t i  t t t  s  lt  e ts t t e t    i i i s  
hu ans are generally dee ed to be te porary, reversible and not long-ter ?"s2 r, t t 
testi ony is not in conflict ith his second affidavit because it is true that generally speaking 
t i i iduals s  t   nd/or i i i s ri  t r r  r r i l  ff ts. 
hat says nothing about the risks to certain populations that are already sensitized to an extent to 
 nd/or sai i i s. r. ost explains in uch detail the risks such products pose to a 
rt i  t f i t   r t t   r t  iffer tl  t  t i  t  erally. 
Throughout SEC's argu ents, there is an osculation bet een representing r. ost's 
52 ff. f s l i  . f ltf's . t  EC's SJ (6110/11), ~ , .  (Yost . 3:4-7). 
I TIFF'S I   EC'S          
 . , H.D., I E  IN   I TIFF'S   I  -  
testimony as being more general than specific and then when it is convenient representing his
testimony as more specific than general When Dr Yost clearly stated that he was relying on a
body of literature to support his opinions SECscounsel framed the questions in terms of the
specific ie do you have a definitive study that proves OC spray causes these particular chronic
symptoms Dr Yost was honest and answered that he did not have such a study because one
does not exist He further explained however that when the entire body of literature is
examined the information was there that a risk of acute and chronic respiratory injury exists for
certain populations
Then SEC skews Dr Yoststestimony as stating that OC andorcapsaicinoids in all cases
only cause temporary reversible effects That was not his testimony at all His testimony was
that while the effects of OC andor capsaicinoids are generally temporary and reversible there
are individuals for whom that general rule does not apply
54
There are individuals who are
already sensitized to some extent for whom further exposure poses a more serious risk of chronic
respiratory injury
D SEC is Unjustified in Arguing that Plaintiffs Counsel Conceded that There Was No
Scientific Literature Published Before 2008 to Support Dr YostsCausation
Opinion
SEC quotes to this Court the transcript of the July 14 2011 hearing on its motion for
summary judgment and leaves out pertinent portions ofPlaintiffsattorneysstatement
The Court So you would agree that there you have not
identified any study that this company should have been aware of
that OC spray had the had the it was foreseeable that it could
13 Aff of Counsel in Supp of Pltfs Opp to SECsMSJ6101 4 Ex 2 Yost Dep 10022
1015
14 Aff of Counsel in Supp of PltfsOpp to SECsMSJ6101 4 Ex 2 Yost Dep 621 638
1012 1028
ss Aff of Counsel in Supp of Pltfs Opp to SECs MSJ6101 4 Ex 2 Yost Dep 102319
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t sti  s i  re r l t  s cifi ,  t  hen it is i t, r r s ti  is 
t sti  s re s ifi  t  r l.  r. ost l rl  st t  t t  s r l i    
 f literat r  t  s rt is i i s, EC's s l fr  t  sti s i  t r s f t  
s ifi , i.e.,     fi itive st  t t r es  s r  s s t s  rti l r r i  
t . r. ost a  est  r  t t  i  t    t    
es  t.  f rt r l i , r, t t e  t  tire  f literat re i  
i , t  i f r ti  as t r  t t  ris  f t   r i  r s ir t r  i j r  ists f r 
certain populations. 
he   s s r. st's t sti  s st ti  t t  nd/or s i i i s i  ll s s 
l  ca se te rar  re ersi le effects. 53 at as t is testi  at all. is testi  as 
t at ile t  ffects f  a /or ca saici ids are e erall  te rar  a  re ersible, t ere 
are i i iduals f r  t at e eral r le es t a ply. 54   id s   
alrea  se sitize  t  s e e te t f r  f rt er e s re ses a re seri s ris  f c r ic 
respiratory injury. 55 
. SE  is njustified in rguing that Plaintiff's ounsel onceded that here as o 
Scientific Literature Published efore 2008 to Support r. ost's ausation 
pinion 
 quotes to this ourt the transcript f the July 14, 2011 hearing on its otion for 
s ar  j e t a  lea es t erti e t rti s f laintiffs attorney's state ent: 
 urt:   l  a ree t at t ere --  a e t 
i e tifie  a  st  t at t is c a  s l  a e ee  a are f 
that OC spray had the --   -- t  l     
53 ff. f ounsel in upp. f ltf's pp. to EC's J (6/10/11), ~ 4, x. 2 (Yost ep. 100:22 -
01:15). 
54 ff. f sel i  Upp. f ltf's p. t  EC's J (6/10/11), ~ , .  ( ost ep. 2:1 - 3:8, 
01:21 -102:8). 
55 Aff. of Counsel in Supp. ofPltf's Opp. to SEC's SJ (6/10/11), ~ 4, x. 2 (Yost ep. 102:13-19.) 
I TIFF'S SI I   EC'S        I I   
 . T, H.D., I  I    LAINTIF 'S I   I I  - 14 
cause chronic lung problems like your client claims
Mr Overson The okay Theresno study where theyv taken
subjects exposed them to OC spray and found that it caused the
symptoms and condition that my client has But thats not whats
required under the law Dr Yost explained in his affidavit and it
goes to his criticism ofDr Reilly who they work in the same lab
ironically is that Dr Yost is taking a view of the entire area of
study and he is combining that to draw conclusions And as he
does that hes following his scientific method based on his
education research and involvement in this area and hes saying
that given the conglomeration of studies that existed at the time
SEC and companies like SEC should have known that there was a
risk associated with their product of causing an individual with
who is susceptible to having a greater sensitivity to capsaicin
which would result in the type of injury that she has
Counsel made a point of talking about the Groneberg study and
Dr Yost talked about it and he said yeah theyr talking about
acute effects He says our findings indicate that the TrpV1
receptors may contribute to an enhanced cough reflex and cough
response and chronic persistent cough of diverse causes Those
TrpV 1 receptors according to Dr Yost as it was written in his
report as an individual is exposed to capsaicin which is really a
unique chemical for the human body because it seems to be the
primary irritant Once youre sensitized to do that youre
sensitized at a greater level to other irritants such as dust and its
kind ofa core irritant
All hessaying here though is this is one of the studies he looked
at and it explains the it explains part of the picture
56
After this exchange the Court explained that based on Dr Yostsaffidavit it concerned
the Court that he was relying to some degree on studies from 2008 and 2010 along with those
published prior to 2008 to reach his opinion
57
Dr Yosts second affidavit clarifies that the
articles cited in his first affidavit that were published prior to 2008 were sufficient for him to
reach his opinions relating to whether it was known at the time of sale whether SECs product
16
Lloyd Aff8181 2 Ex A7141 hearing trans 3315 357
57
Lloyd Aff181 2 Ex A7141 hearing trans 379 4413
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a se c r ic lu  r le s like r lie t l i s? 
. : he -- . re's  st  r  t ey've t  
s jects, e ose  t e  t   s ra  a  fo  t at it ca se  t e 
s pto s  ition t t  lient s. t t t's t at's 
r ire  er t e l . r. ost lained i  is ffi vit,  it 
goes to his criticis  of r. eilly, ho -- t  r  i  t   l  
iro i ll  -- is t t r. ost is t i   ie  f t e tire r  f 
st    is i i  t t t  r  l si s. n  s  
es t at, e's f llo i  is scie tific et  ase   is 
e cati , researc  a  in olve e t i  t is area a  e's sa i  
t at i e  t  l er tion f st ies t t ist  t t  ti , 
 a  c a ies li e  s l  a e  t at t ere as a 
ris  ss i t  it  t ir r t f si   i i i l it  --
ho is s s ti le t  i   r t r s siti it  t  ca SaICI  
hich ould result in the type of injury that she has. 
sel a e a i t f tal i  a t t e r e er  st  a  
r. ost talked about it and he said, yeah, they're talking about 
 ts. e sa s, r fi i s i icate t at t e r l 
rece t rs a  c tri te t  a  e a ce  c  refle  a  c  
response and chronic persistent cough of diverse causes.  
r l rece t rs, acc r i  t  r. st as it as ritte  i  is 
re rt, as a  i i id al is e se  t  ca saicin, ic  is reall  a 
ique c e ical f r t e a   eca se it see s t  e t e 
pri ary irritant.  ou're s siti  t   t t, ou're 
s siti  t  r t r l l t  t r irrita ts s  s st  it's 
    t. 
ll e's s i  r , t h, is t is is  f t  st i s  l  
at and it explains the -- it explains part of the picture. 56 
fter t is e c ange, t e rt e lai e  t at ase   r. st's affi avit, it c cer e  
the Court that he as relying to so e degree on studies fro  2008 and 2010 along ith those 
published prior to 2008 to reach his opinion. 57 r. st's econ  ff vit l ri  t  t  
articles cite  i  is first affi a it t at ere lis e  ri r t   ere sufficie t f r i  to 
reach his opinions relating to hether it as kno n at the ti e of sale hether SEC's product 
56 Lloyd Aff. (8/18/11), ~ 2, x.  (7/14/11 hearing trans., 33: 15 - 35 :7). 
57 Lloyd Aff. (8/18/11), ~ 2, Ex. A (7/14/11 hearing trans., 37:9 - 44:13). 
LAINTIF 'S POSITI   EC'S   T I  I    SEC  I A I   
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posed a risk of injury such as that claimed by the Plaintiff Furthermore he goes on to explain
in significant detail the mechanism by which chronic injury would take place and how that
mechanism was understood prior to 2008 That is he not only states his opinion regarding
what was known but he identifies an entire body of literature that he relies on and what that
literature says in terms of the way human respiratory tissues would respond to create a
hypersensitivity for some predisposed individuals
E There Has Been No Attempt to Subvert The Discovery Rules
SEC claims that the Plaintiff has attempted to subvert the discovery rules CitingIRE
705 SEC claims this Court should strike Dr Yostssecond affidavit because it requested the
underlying data in discovery interrogatories and the new articles were not included However
SEC neglects the holding in Puckett v Verska where the Idaho Supreme Court upheld the trial
courtsgrant of the plaintiffs motion for reconsideration based on its expert affidavit filed after
the trial court initially granted the defendantsmotion for summaryjudgment 61 The trial court
had initially granted the defendantsmotion for summary judgment because the plaintiffs expert
had not familiarized himself with the community standard of care in a medical malpractice
case62 Once the physician expert witness had contacted other physicians in the area and
familiarized himself with the community standard of care he submitted another affidavit which
the trial court accepted as creating an issue of fact precluding summary judgment The
defendant argued that because the affidavit was not submitted with the plaintiffs opposition to
58 Aff of Yost72611 68 1213
59 Aff of Yost 2611 68 1011
60 144 Idaho 161 166 2007
61 Id emphasis added
62 Id at 16465
63 Id at 165
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posed a risk f injury such as that clai ed by the laintiff. 58 urthennore, he goes on to explain 
i  si ifica t etail t e ec a is   ic  c r ic i j r  l  ta e lace a   t at 
is  as rst  ri r t  008.59 t is,  t l  st t s is i i  r r i  
t s , t  i tifies  tir   f liter t r  t t  r li s   t t t 
literat r  s s i  t nns f t    r s ir t r  tiss s l  r s  t  r t   
rs siti it  f r s  r is s  i i i ls. 
. re  e   tte t t  rt  i r  l  
 l i s t t t  l i ti   tt t  t  t t  i  l . iti  LR.E. 
,  l i s t is rt s l  stri  r. st's s  ffi it s  it r st  t  
underlying data in discovery interrogatories and the "ne " articles ere not included. o ever, 
 l ts t e l i  i  ckett v. erska,60 r  t  I  r  rt l  t  tri l 
urt's r t f t  l i tiffs ti  f r r si r ti  s   its xpert's ffida itjile  ft r 
the trial court initially granted the defendant's otion for su ary judg ent.     
had initially granted the defendant's otion for su ary judg ent because the plaintiffs expert 
 t f iliariz  i lf it  t  it  t r  f r  i   i l l r ti  
.62 nce the physician expert itness had contacted other physicians in the area and 
fa iliarized hi self ith the co unity standard of care, he sub itted another affidavit hich 
the trial court accepted as creating an issue of fact precluding su ary judg ent. 63  
defendant argued that because the affidavit as not sub itted ith the plaintiff s opposition to 
58 ff. f ost (7/26/11), ~~ -8, -1 . 
59 ff. f ost (7/26 11), ~~ -8, -1 . 
60  I  ,  (20 7). 
61 I . (emphasis a ded). 
.  -6 . 
63 I . t . 
I TIFF'S I   EC'S        I I   
 . T, H.D., I  I    L I TIFF'S I   I I  -  
the motion for summary judgment it was error for the court to consider the affidavit The
Idaho Supreme Court upheld the trial courts order granting the plaintiffs motion for
reconsideration explaining that trial courts should consider affidavits submitted with Rule
11a2Bmotions for reconsideration where the affidavit presents new facts bearing on the
correctness of the interlocutory order
65
Similarly in Edmunds v Kraner the Idaho Supreme Court held that a plaintiff may
supplement discovery responses relating to expert opinions as those opinions develop through the
course of litigation
66
There the trial court struck an expert witnesssaffidavit filed in opposition
to a motion for summary judgment in a medical malpractice case 67 The trial court struck the
affidavit as untimely under its discovery order andIRCP26 because it was filed almost a year
after the discovery deadline for the naming of expert witnesses two months before trial and
it contained opinions not contained in his first affidavit The affidavit in question was a
supplement to the expertsinitial affidavit which was filed in a timely manner and in which the
trial court had determined there lacked a proper foundation concerning the standard of care for
pharmacists in the community
69
The Idaho Supreme Court reversed finding that it was an abuse of discretion for the trial
court to strike the affidavit based on the timeliness of the disclosure of the opinions set forth in
the affidavit and based on a pretrial order that only ordered the disclosure of the names of expert
witnesses The first reason given by the Court for reversing was that the order governing
64 144 Idaho 161 166 2007
65 Id
66 142 Idaho 867 874 75 2006
67 Id
68 Id at 873
69 Id
70 Id at 874
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t  ti  f r r  j t, it  rr r f r t  rt t  i r t  ffidavit.64  
I  r  rt l  t  tri l ourt's r r r ti  t  l i tiffs ti  f r 
r si rati n, l i i  t t tri l rts s l  si r ffi its s itt  it  l  
11(a)(2)(B) otions for reconsideration here the affidavit presents ne  facts bearing on the 
rre tness f t  i t rl t r  r r.  
i ilarly, in d unds v. raner, the Idaho upre e ourt held that a plaintiff ay 
supple ent discovery responses relating to expert opinions as those opinions develop through the 
course oflitigation.  here, the trial court struck an expert itness's affidavit filed in opposition 
t   ti  f r s r  j t i   i l l r tice s .67    t   
affidavit as unti ely under its discovery order and LR.C.P. 26 because it as filed "almost a year 
after the discovery deadline for the na ing of expert itnesses, t o onths before trial, and ... 
it t i  i ions ...      ffi avit.,,68  ffi it i  sti  s  
supple ent to the expert's initial affidavit, hich as filed in a ti ely anner, and in hich the 
trial court had deter ined there lacked a proper foundation concerning the standard of care for 
phar acists in the co unity.69 
The Idaho Supre e ourt reversed, finding that it as an abuse of discretion for the trial 
court to strike the affidavit "based on the ti eliness of the disclosure of the opinions set forth in 
the affidavit and based on a pretrial order that only ordered the disclosure of the na es of expert 
t es.,,7o The first reason given by the Court for reversing was that "the order governing 
64  I a  ,  (20 7). 
65Id. 
66142 Idaho 867, 874-75 (2006). 
67 d. 
8 .  . 
9I . 
°I . t . 
I TIFF'S I   EC'S   I      I   
 . , H.D., I  I    I TIFF'S I   I I  -  
expert witness disclosures simply stated Plaintiff s experts to be disclosed by April 14 2003
and the Edmunds had timely disclosed the names of their experts
71
In the case at hand this
Courtsorder governing the proceedings states that Unless otherwise stipulated the advancing
partysexpert witnesses shall be disclosed 180 days before trial The Plaintiff disclosed
Dr Yosts identity on August 5 2010 which was over six months before the original
deadline 72 Thus the Plaintiffwas more than timely in her expert disclosure
The second reason given by the Idaho Supreme Court for reversing the trial court was that
Idaho law specifically contemplates that expert testimony can change after the initial disclosure
Idaho Rule of Civil Procedure261Brequires the litigants supplement discovery responses
as to the identity of each person expected to be called as an expert witnesses at trial the subject
matter on which the person is expected to testify and the substance of the personstestimony
73
Quoting Clark v Lein
74
the Court emphasized that it had held that Rule261B
unambiguously imposes a continuing duty to supplement
responses to discovery with respect to the substance and subject
matter of an expertstestimony where the initial responses have
been rejected modified expanded upon or otherwise altered in
some manner
The third reason given for reversing the trial court was that it was error for the trial court
to adopt the defendantsargument that the affidavit was the plaintiff s attempt to circumvent the
trial courts earlier decision excluding the plaintiffs other expert who had been untimely
disclosed The affidavit ofthe expert who was at issue included an opinion identical to that of
71 142 Idaho 867 874 2006
72 SECsMemo in Supp ofMotion to Strike Dr Yosts 2d Aff p 4
73 Edmunds 142 Idaho at 874
74 137 Idaho 154 157 2002
75
Edmunds 142 Idaho at 874
76 Id
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rt itness is l s res si l  st t d: 'Pl i tiffs rts t   is l s   ril , '" 
 t e s  ti l  is l s  t  es f t ir erts.71     d,  
ourt's r r r i  t  r ce ings st t s t t "Unless t r is  sti l t d, t  i  
party's expert itnesses shall be disclosed 180 days before trial."  l i tif   
r. st's i tit   t , , ic   r i  t  f re t  ri i l 
deadline."n Thus, the Plaintiff as ore than ti ely in her expert disclosure. 
The second reason given by the Idaho Supre e ourt for reversing the trial court as that 
"Idah  l  cifi ll  t late  t t rt t ti    ft r t  i iti l i l ure. 
I  l  f i il r re 6( e)( 1 )(B) r ir s t  litiga ts s l t is r  r s s s 
as to 'the identity of each person expected to be called as an expert itnesses at trial, the subject 
atter  hich the person is expected to testify, and the substance f the person's testi ony.",73 
uoting lark v. ein,74 the ourt e phasized that it had held that ule 26(e)(I)(B) 
"[ u ]nambiguously imposes a continuing duty to supplement 
res ses t  isc er  it  res ect t  t e s sta ce a  s ject 
atter f an expert's testi ony here the initial responses have 
been rejected, odified, expanded upon or other ise altered in 
 nner.,,75 
The third reason given for reversing the trial court was that it was error for the trial court 
to adopt the defendant's argu ent that the affidavit as the plaintiff s "atte pt to circu vent the 
trial court's earlier decision excluding" the plaintiff s other expert ho had been unti ely 
disclosed.76 he affidavit f the expert ho as at issue included an opinion identical to that f 
71 142 Idaho 867, 874 (2006). 
72 SEC's emo. in Supp. of otion to Strike Dr. Yost's 2d Aff., p. 4. 
73 ,   t . 
74  I a  ,  (2 2). 
75 s,  I  t . 
76 d. 
I TIFF'S I   EC'S          
 . T, H.D., I  I    LAINTIF 'S I   I I  -  
the expert who had been excluded for being untimely disclosed The Court found that the
similarity of the two experts affidavits was an issue of credibility for the jury and not one to be
decided on summary judgment Here many of SECscomplaints about Dr Yosts second
affidavit seem to go more toward a credibility issue than to whether the second affidavit should
be considered in ruling on the Plaintiff s motion for reconsideration
Like the defendant in Edmunds SEC seems to be arguing that the Plaintiffs response to
SECsInterrogatory No 3 and Rule 26 expert disclosures were not seasonably supplemented
Whether a party has seasonably supplemented a discovery response is left to the discretion of the
Court as the term is not very precise In Edmunds however the Court did provide the
following guidance
This Court has not yet announced a more precise definition of
seasonably However as Justice Bakes noted in Hopkins an
important inquiry in determining whether a response was given
seasonably is was the opposing party given an opportunity for
full cross examination If yes then there probably would be no
abuse of discretion in admitting the testimony St Alphonsus
was afforded a full opportunity not only to cross examine
Dr Hollander as to these newly expressed opinions because the
supplementation was eight months prior to trial but also to
undertake additional discovery at no or very little additional cost as
they had not yet deposed Dr Hollander Therefore the
supplementation ofDr Hollander opinion was seasonable
81
Here SEC seems to argue that 1 Plaintiff has not disclosed Dr Yost as an expert who will
testify as to the state of scientific knowledge prior to 2008 relating OC exposure causing chronic
77
Edmunds 142 Idaho at 874
78 Id
79 Id at 875
80
Hopkins v DuoFast Corp 123 Idaho 205 213 1993 Bakes CJ concurring citing Radmer v
Ford Motor Co 120 Idaho 86 813P2d 897 1991
81
Edmunds 142 Idaho at 875
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         i closed.77      
si ilarit  f t e t  e erts' affida its as a  iss e f cre i ilit  f r t e j r  a  t e to e 
   ment.78 ere, a  f EC's c lai ts a t r. st's sec  
affidavit see  to go ore to ard a credibility issue than to hether the second affidavit should 
e c si ere  i  r li   t e lai tiff s ti  f r rec si erati n. 
ike the defendant in d unds,  see s to be arguing that the laintiffs response to 
C's Interrogatory .  and ule 26 expert disclosures ere not seasonably supple ented. 
et er a art  as seas a l  s le e te  a isc er  res se is left t  t e iscreti  f t e 
t       ecise.79 In d unds, ho ever, the ourt did provide the 
follo ing guidance: 
his ourt has not yet announced a ore precise definition of 
"seasonably." o ever, as Justice akes noted in opkins: "an 
i portant inquiry in deter ining hether a response as given 
'seasonably' is: as the opposing party given an opportunity for 
full cross exa ination? If 'yes,' then there probably ould be no 
abuse of discretion in ad itting the testi ony."so St. lphonsus 
as afforded a full opportunity not only to cross-exa ine 
r. ollander as to these ne ly expressed opinions because the 
supple entation as eight onths prior to trial, but also to 
undertake additional discovery at no or very little additional cost as 
they had not yet deposed r. er. f , t  
supple entation of r. ollander's opinion as seasonable.sl 
Here, SEC see s to argue that (1) Plaintiff has not disclosed Dr. Yost as an expert who will 
testif  as t  t e state f scie tific le e ri r t   relati   e s re ca si  c r ic 
77 s,  I  t . 
 . 
 ! .  . 
80 opkins v. uo-Fast orp., 123 Idaho 205, 213 (1993) (Bakes, .J. concurring) (citing ad er v. 
ord otor o., 120 Idaho 86,813 .2d 897 (1991)). 
81 ,   t . 
I TIFF'S I   EC'S        I   
 . , H.D., I  I    I TIFF'S I   I I  -  
respiratory illness and 2 Plaintiff was untimely in disclosing the handful of articles cited in
Dr Yosts second affidavit that were not cited in his first affidavit For the reasons set forth
below neither argument sets forth an appropriate basis for striking Dr Yostssecond affidavit
The Plaintiff has repeatedly supplemented her discovery responses and has given SEC
every opportunity to prepare to cross examine Dr Yost at trial As far back as June 10 2011 the
Plaintiff disclosed Dr Yost as an expert witness who
may testify to those matters contained in his affidavit filed on
June 10 2011 and in his deposition He may testify regarding the
sensitizing effect some individuals have relating to OC and other
irritants as well as the research that has been done in the scientific
community on the subject He may further explain to the jury
how based on the state of understanding within the scientific
community at the time SEC sold its SABRE Red products to Idaho
Department of Corrections the Defendant either knew or should
have known of the risks associated with their product for
individuals with respiratory tract illness
82
SEC has been made fully aware of Dr Yosts anticipated trial testimony and has been given
ample opportunity to prepare to cross examine him The contents ofDr Yostssecond affidavit
were disclosed to SEC by multiple means just short of three months prior to trial Plaintiff has
invited defense counsel to take his deposition in order to answer any questions they may have
regarding anything they believe is newly disclosed information Plaintiff has appropriately and
seasonably supplemented her discovery responses relating to Dr Yosts testimony The
Defendant has not been prejudiced and has not even attempted to identify any prejudice it may
suffer by this Court consideration ofDr Yostssecond affidavit In the interest ofjustice and
fairness Dr Yosts second affidavit should not be stricken and SECs motion should therefore be
denied
82 Aff of Counsel in Opp to SECs2d Motion to Strike 7 Ex E emphasis added
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respiratory illness, and (2) Plaintiff as unti ely in disclosing the handful f articles cited in 
. t's second affidavit that ere not ited in his first it. or the reasons set forth 
below, neither argu ent sets forth an appropriate basis for striking Dr. Yost's second affidavit. 
he lai tiff as re eate l  s le e te  er isc er  res onses a  as iven  
every opportunity to prepare to cross exa ine Dr. Yost at trial. As far back as June 10,2011, the 
lai tiff disclosed r. ost as a  e ert itness ho 
ay testify to those atters contained in his affidavit filed on 
J e , ,  in is iti . e  t tif  r r i  t e 
sensitizing effect so e individuals have relating to  and other 
irrita ts, s ll s t  r s r  t t s  e i  t  s i tifi  
co unity on the subject. '"   f rt r l i  t  t e jur  
       t    
co unity at the ti e SEC sold its SABRE Red products to Idaho 
Department of Corrections, the Defendant either knew or should 
have kno n f the risks associated ith their product for 
individuals with respiratory tract illness.  
 s  a e f ll  r  f r. st's ti i at  tri l t sti   s  i  
a ple opportunity to prepare to cross exa ine hi . The contents of r. ost's second affidavit 
ere disclosed to SE  by ultiple eans just short of three onths prior to trial. Plaintiff has 
i it  f s  s l t  t  is siti  i  r r t  s r  sti s t    
regarding anything they believe is newly disclosed infor ation. Plaintiff has appropriately and 
seasonably supple ented her discovery responses relating to r. ost's testi ony.  
efendant has not been prejudiced and has not even atte pted to identify any prejudice it ay 
suffer by this Court's consideration of Dr. Yost's second affidavit. In the interest of justice and 
fairness, r. ost's second affidavit should not be stricken and SEC's otion should therefore be 
i d. 
82 Aff. of Counsel in Opp. to SEC's 2d otion to Strike, ~ 7, x.  (e phasis added). 
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F SEC Cites Cases That Do Not Support Its Position Regarding Supplementing
Discovery Responses
The cases cited by SEC in support of its claim that Dr Yosts second affidavit should be
stricken on the grounds of an alleged discovery violation do not support that claim In Clark v
Klein the trial court erred by letting the expert testify at trial even though the identity and
substance of anticipated testimony were requested but not provided until after the trial had
begun In Radmer v FordMotor Co the plaintiff similarly failed to supplement its response
to the defendants discovery request seeking the identity of experts and the substance of their
testimony until the first day of the trial after the jury had been empanelled 84 In both cases
the Idaho Supreme Court ruled that it was error to admit the experts testimony because of
prejudice to the defendants ability to prepare for cross examination
85
By comparison in Hopkins v DuoFast Corp the trial court admitted expert testimony
where the defendant did not disclose the experts new theory of how the accident happened until
just before he took the stand at trial However instead of reversing the Idaho Supreme Court
upheld the trial courts decision to allow the testimony because the defendant had not learned of
the expertsrecent testing until the night just prior to the expert taking the stand The Court
held that the trial court made its decision within the bounds ofdiscretion based on the fact that it
did not appear to be a situation where the defendant had engaged in sandbagging
Here the Plaintiff disclosed Dr Yost six months prior to the deadline set by this Court
137 Idaho 154 15658 2002 emphasis added
84 120 Idaho 86 90 1991 emphasis added
85
Clark 137 Idaho at 15658 Radmer 120 Idaho at 90
86 123 Idaho 205 206 212 1993
87 Id
88 Id
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The cases cited by SE  in support of its clai  that r. ost's second affidavit should be 
stricken  the r unds f  lle e  is r  iolation  t s rt t t l i . I  l r  v. 
lein, the trial court erred by letting the expert testify at trial even though the identity and 
substance f anticipated testi ony ere requested but not provided "until after the trial had 
begun.,,83   .  t  o., t  l i ti  i il l  aile  t  l t its  
to the defendant's discovery request seeking the identity of experts and the substance of their 
testi ony "until the first day f the trial, after the jury had been e panel/ed. ,,84 In both cases, 
the Idaho Supre e ourt ruled that it as error to ad it the experts' testi ony because of 
prejudice to the defendants' ability to prepare for cross examination.85 
By comparison, in Hopkins v. Duo-Fast Corp., the trial court admitted expert testimony 
here the defendant did not disclose the expert's ne  theory of ho  the accident happened until 
just before he took the stand at trial. 86 However, instead of reversing, the Idaho Supreme Court 
upheld the trial court's decision to allo  the testi ony because the defendant had not learned of 
the expert's recent testing until the night just prior to the expert taking the stand.87 The Court 
       i i      ti     t   
did not appear to be a situation here the defendant had engaged in "sandbagging.,,88 
r , t  l i tiff i l  r. t i  t  ri r t  t  dli  t  t i  ourt's 
83 137 Idaho 154, 156-58 (2002) (emphasis added). 
84 120 Idaho 86, 90 (1991) (emphasis added). 
85 lark,  I a  at -5 ; d er,  I a  at 0. 
86 123 Idaho 205, 206-212 (1993). 
87Id. 
88Id. 
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scheduling order Unlike the parties in Clark Radmer and Hopkins the Plaintiff served
Dr Yosts second affidavit her supplemental responses to Defendantsinterrogatories and
requests for production and her expert disclosures long before trial The Plaintiff has offered to
make Dr Yost available for additional deposition testimony and that offer remains open to the
Defendant On this record it would be an abuse of discretion to strike Dr Yosts second
affidavit on the basis of a purported discovery violation
IV CONCLUSION
For the above stated reasons Defendant motion to strike portions ofDr Yostssecond
affidavit must be denied
DATED this 8th day ofSeptember 2011
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scheduling order. nlike the parties in lark, ad er and opkins, the Plaintiff served 
r. st's s d affi it, r le e tal res nses t  f ant's interrogatories  
requests for production, and her expert disclosures long before trial. he Plaintiff has offered to 
ake r. ost available for additional deposition testi ony, and that offer re ains open to the 
t.  s , t  e      ke . st's  
affidavit on the basis of a purported discovery violation. 
.  
 t  - t t  , f ndant's ti  t  t i e ti s  . st's  
t  e . 
 this 8th day of Septe ber, 2011. 
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 8th day of September 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
Messenger Delivery
mail cburke@greenerlawcom
tllovdOereenerlawcom
DARWM OVERSON
ERIC B SWARTZ
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
STATE OF IDAHO
County of Ada
MX19
Case No CV PI 1003515
AFFIDAVIT OF COUNSEL IN
OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND
AFFIDAVIT OFGAROLD S YOST
PHDFILED IN SUPPORT OF
PLAINTIFFSMOTION FOR
RECONSIDERATION
I Darwin L Overson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
AFFIDAVIT OF COUNSEL IN OPPOSITION TO SEC MOTION TO STRIKE PORTIONS OF THE
SECOND AFFIDAVIT OF GAROLD S YOST PHD I
a
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys forPlaintiff Billie Jo Major
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I, Darwin L. Overson, being first duly sworn upon oath, depose and state upon y own 
personal knowledge as follows: 
. I a  an attorney ith the la  fir  of Jones & rt  LL ,   ut ri  t  
practice law before this and all courts of the State ofIdaho. 
I   L  OSITI   EC'S   T I  ORTI    
 I I    . ST, H.D. - 1 
2 I am counsel of record for Plaintiff Billie Jo Major in the above action and have
firsthand knowledge of the documents materials and all other discovery that has been produced
by either party in this case
3 On August 5 2010 I caused to be served on Defendantsattorneys Plaintiff
Expert Witness Disclosure a true and correct copy ofwhich is attached hereto as Exhibit A
4 On August 5 2010 I caused to be served on Defendants attorneys Plaintiff
Second Supplemental Answers and Responses to DefendantsFirst Set of Interrogatories and
Requests for Production of Documents A true and correct copy of those portions relating to
Dr Yost is attached hereto as Exhibit B
5 On March 28 2011 I caused to be served on Defendantsattorneys Plaintiff
Supplemental Expert Witness Disclosure A true and correct copy of those portions relating to
Dr Yost is attached hereto as Exhibit C
6 On April 18 2011 I caused to be served on Defendants attorneys Plaintiff
Answers and Responses to DefendantsFirst Set of Requests for Admissions and Second Set of
Interrogatories and Request for Productions of Documents A true and correct copy of those
portions relating to Dr Yost is attached hereto as Exhibit D
7 On June 10 2011 I caused to be served on Defendantsattorneys Plaintiff
Disclosure of Rebuttal Expert Witness Testimony A true and correct copy of those portions
relating to Dr Yost is attached hereto as Exhibit E
8 On July 26 2011 I caused to be served on Defendantsattorneys the Affidavit of
Garold S Yost PhD in Support of Plaintiffs Motion to Reconsider Courts Order on
DefendantsMotion for Summary Judgment
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firsthand kno ledge f the docu ents, aterials, and all other discovery that has been produced 
by either party in this case. 
.  ugust , , I se  t  e s r e   f dant's tt r s l intiff's 
Expert Witness Disclosure, a true and correct copy of which is attached hereto as Exhibit A. 
. n ugust 5, 2010, I caused to be served on efendant's attorneys Plaintiff's 
Second Supple ental Answers and Responses to efendant's First Set of Interrogatories and 
Requests for Production of ocu ents.  true and correct copy of those portions relating to 
. st      . 
.  ar  , , I s  t   r   f ndant's tt r  laintiff's 
Supple ental xpert itness isclosure.  true and correct copy of those portions relating to 
. s       c. 
. n pril 18, 2011, I caused to be served on efendant's attorneys Plaintiff's 
Answers and Responses to efendant's First Set of Requests for Ad issions, and Second Set of 
Interrogatories and Request for Productions of ocu ents.  true and correct copy of those 
portions relating to Dr. Yost is attached hereto as Exhibit D. 
. n June 10, 2011, I caused to be served on efendant's attorneys laintiff's 
Disclosure of Rebuttal Expert Witness Testimony.  tr   rr t  f t  rti  
relating to Dr. Yost is attached hereto as Exhibit E. 
. n July 26, 2011, I caused to be served on efendant's attorneys the Affidavit of 
arold S. Yost, Ph.D., in Support of Plaintiff's otion to Reconsider Court's rder on 
Defendant's Motion for Summary Judgment. 
I    I  OSITI   EC'S   TRI  PORTI    
 FI A I    . ST, H.D. -  
9 On July 26 2011 I caused to be served on Defendantsattorneys Plaintiffs
Second Supplemental Expert Witness Disclosure A true and correct copy of those portions
relating to Dr Yost is attached hereto as Exhibit F
10 On July 26 2011 I caused to be served on Defendantsattorneys Plaintiffs Fifth
Supplemental Answers and Responses to DefendantsFirst Set ofInterrogatories and Requests
for Production ofDocuments A true and correct copy of those portions relating to Dr Yost is
attached hereto as Exhibit G
11 On July 26 2011 I caused to be served on Defendantsattorneys Plaintiff
Supplemental Answers and Responses to Defendant Second Set oflnterrogatories and Requests
for Production ofDocuments A true and correct copy of those portions relating to Dr Yost is
attached hereto as Exhibit H
12 On September 7 2011 I caused to be served on Defendantsattorneys Plaintiff
Third Supplemental Expert Witness Disclosure A true and correct copy of those portions
relating to Dr Yost is attached hereto as Exhibit I
13 On August 22 2011 I sent Mr Chris Burke and Mr Tom Lloyd who are SECs
attorneys of record in this case an email informing them that I would make Dr Yost available to
them at their convenience and that it could be accomplished via live audiovideo feed to avoid
the costs associated with traveling to Utah where Dr Yost resides Attached hereto as Exhibit J
is a true and correct copy of the email to which I refer As of the date I sign this affidavit I have
not been informed that SEC would like to take the continued deposition ofDr Yost
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.  l  , 1, I  t   r   f ndant's tt r  l i tiff'  
Second Supple ental xpert itness isclosure.  true and correct copy of those portions 
relating to r. ost is attached hereto as xhibit F. 
.  J l  , 011, I ca se  t  e ser e   efendant's att r e s l i tiff's ift  
le e t l s ers  es ses t  efendant's irst et f I terr t ries  e ests 
for roduction f ocu ents.  true and correct copy f those portions relating to r. ost is 
tt  r t   i it . 
. n July 26, 2011, I caused to be served on efendant's attorneys laintiff's 
Supple ental Ans ers and Responses to efendant's Second Set of Interrogatories and Requests 
for Production of ocu ents.  true and correct copy of those portions relating to r. ost is 
    . 
. n Septe ber 7, 2011, I caused to be served on efendant's attorneys Plaintiff's 
Third Supplemental Expert itness Disclosure.  tr e a  c rrect c  f t se rti s 
relating to r. ost is attached hereto as Exhibit I. 
.  st , 11, I se t r. ris r e a  r.  l d,  are EC's 
attorneys f record in this case, an e ail infor ing the  that I ould ake r. ost available to 
the  at their convenience and that it could be acco plished via live audiolvideo feed to avoid 
t  t  i t  it  t li  t  t  ere r. t i . tta  t   i i   
is a true and correct copy of the e ail to hich I refer. s of the date I sign this affidavit, I have 
not been infor ed that SE  ould like to take the continued deposition of r. ost. 
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FURTHER YOUR AFFIANT SAYET
SUBSCRIBED AND SWORN TO before me this day of September 2011
01AJt Notary Public for Idaho
pUBLG MyCommission expires b z
of
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 8th day of September 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
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Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
Case No CV PI 1003515
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
PLAINTIFFSEXPERT
WITNESS DISCLOSURE
PRELIMINARY STATEMENT
Discovery in this matter is ongoing This disclosure is made and based upon the
Plaintiffscurrent understanding of the facts claims and defenses at issue in this litigation It is
anticipated that further discovery investigation and consultation with witnesses and experts may
supply additional facts add meaning to known facts and establish new factual conclusions and
legal contentions all of which may lead to additions to modifications of and variations from the
disclosures set forth herein This disclosure is therefore made without prejudice to Plaintiffs
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iscovery in t is atter is i . This disclosure is ade and based upon the 
l intiff s rrent rst i  f t  fa ts, l i s,  fe ses t iss  i  t is litig ti . It is 
anticipated that further discovery, investigation, and consultation ith itnesses and experts ay 
s  a tional , a  ea ing   fa , a d s    lusions  
legal c te ti s, all f hich a  lea  to a itions t , o ifications f, a d variations fro  the 
disclosures set forth herein. This disclosure is therefore ade ithout prejudice to Plaintiffs 
P I I F'S EXPERT ITNESS DISCLOSURE - 1 
right to disclose evidence of subsequently discovered facts or opinions thereon Subject to and
without waiving the right to supplement the scope of the testimony disclosed herein based upon
information learned or documents acquired through the completion of discovery in this action
Plaintiff makes the following disclosure
Garold S Yost PhD
Professor ofPharmacology and Toxicology
College ofPharmacy
University ofUtah
30North 1900 East 201
Salt Lake City Utah 84112
80158 7956
Dr Yost is a Professor of Pharmacology and Toxicology at the University of Utah and is
an expert in lung diseases druginduced toxicities and adverse drug reactions Dr Yost is also
an expert in the analysis chemistry receptor activation and biological effects including
toxicities of capsaicinoids Dr Yost is expected to testify regarding the human bodysreaction
to capsaicinoids and oleoresin capsicum OC spray which is the subject matter of this case
Dr Yost will testify that Plaintiffs repeated exposure to OC spray while performing her duties as
a correctional officer caused an acute adverse health response and greatly exacerbated Plaintiffs
underlying respiratory disease Dr Yostsopinions are based upon his review of Plaintiffs
medical records Idaho Department of Corrections records and Sabre Red product information
all of which were produced in discovery by Defendant and Plaintiff Dr Yost has not prepared
any trial exhibits or a written report at this time In the event that any of those items are
prepared they will be produced in accordance with this Court June 1 2010 Scheduling Order
and Rule 26a4ofthe Idaho Rules of Civil Procedure The letter Dr Yost has prepared to date
which summarizes his opinions in whole or in part is produced herewith as Exhibit A
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r. ost is a Professor of Phar acology and Toxicology at the niversity of tah, and is 
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a  e ert i  t e a alysis, c e istr , rece t r activation, a  i l ical effects (includin  
t i iti s) f saici i s. r. ost is t  t  t stif  r r i  t   ody's r ti  
to capsaicinoids and oleoresin capsicu  CO ) spray, hich is the subject atter of this case. 
r. st ill testif  t at lai tiff s re eate  e s re t   s ra  ile erf r i  er ties as 
a correctional officer caused an acute adverse health response and greatly exacerbated Plaintiffs 
l ing i t  is . r. ost's opinions are based upon his revie  of Plaintiffs 
edical records, Idaho epart ent f orrections records, and abre ed product infor ation, 
all of which were produced in discovery by Defendant and Plaintiff. Dr. Yost has not prepared 
 trial i its r  ritten r rt t t is ti . In the event that any of those ite s are 
prepared, they will be produced in accordance with this Court's June 1, 2010 Scheduling Order 
and ule 26(a)(4) of the Idaho ules of ivil Procedure. The letter r. ost has prepared to date 
hich su arizes his opinions in hole or in part is produced here ith as xhibit . 
I TIFF'S E PERT ITNESS IS OS E -  
Dr Yosts qualifications are outlined in his Curriculum Vitae and his profile and
biosketch on the University of Utah College of Pharmacy website and are attached hereto as
Exhibits B and C respectively Dr Yosts agreedupon compensation for analysis of the issues
in this case and to testify is 450 per hour A copy of the signed agreement is attached hereto as
Exhibit D
Plaintiff reserves the right to elicit opinion testimony from any expert non retained
treating medical provider and any other witnesses disclosed in discovery or deposition by the
Plaintiff or Defendant Further Plaintiff reserves the right to supplement or amend this
disclosure and to list rebuttal experts
DATED this 5th day of August 2010
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 5th day of August 2010 a true and correct copy of the
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950W Bannock Street Suite 900
Boise ID 83702
PLAINTIFFSEXPERTWITNESS DISCLOSURE 4
USMail
Fax 3192601
Overnight Delivery
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Eric B Swartz ISB 6396
JONES SWARTZPLLC
1673 W Shoreline Drive Suite 200 83702
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Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURTOF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Case No CV PI 1003515
PLAINTIFFSSECOND
SUPPLEMENTAL ANSWERS AND
RESPONSES TO DEFENDANT
FIRST SET OF INTERROGATORIES
AND REQUESTS FORPRODUCTION
OF DOCUMENTS
Defendant
COMES NOW the Plaintiff by and through her counsel of record Jones Swartz PLLC
and hereby supplements her answers and responses to Defendants First Set of Interrogatories
and Requests for Production ofDocuments as follows
PRELIMINARY STATEMENT
The following Supplemental Answers and Responses are based upon a reasonable inquiry
and diligent search by the Plaintiff but reflect only the current state of Plaintiffsunderstanding
and belief respecting the matters about which inquiry was made It is anticipated that further
PLAINTIFFSSECOND SUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANTSFIRST SETOF
INTERROGATORIES ANDREQUESTS FOR PRODUCTION OF DOCUMENTS I
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INTERROG TORIES  E ESTS    S - I 
Garold S Yost
Professor of Pharmacology and Toxicology
College of Pharmacy
University ofUtah
30North 1900 East 4201
Salt Lake City Utah 84112
80158 7956
has knowledge ofPlaintiffscondition after she was injured
INTERROGATORYNO 3 Identify each person whom You expect or intend to
testify as an expert at a trial of this matter and with respect to each such person state the
following
A The substance and summary of all facts and opinions about which each expert
is expected to testify
B Identify each fact Document and all data pursuant to Rule 705IRE upon
which each expert intends to rely in rendering any opinions at a trial of this matter and
C Identify all information and Documents required to be disclosed by expert
witnesses pursuant to Rule26aIdaho Rules of Civil Procedure
ANSWER TO INTERROGATORY NO 3 Plaintiff at this point have not
determined who their expert may be at trail but reserve the right to identify them at a later date
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 3 Plaintiff supplements
her answer to Interrogatory No 3 by stating as follows
Garold S Yost
Professor of Pharmacology and Toxicology
College ofPharmacy
University ofUtah
A It is Professor Yosts opinion that people with respiratory disease are up to 30
times more sensitive to capsaicininduced cough Plaintiffs exposure to Saber Red caused acute
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A. It is Professor Yost's opinion that people with respiratory disease are up to 30 
times ore sensitive to capsaicin-induced cough. Plaintiffs exposure to Saber ed caused acute 
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adverse health responses and exacerbated herunderlying respiratory diseases
B Please see accompanying documents marked as Bates Nos YOST 00001 50
C Please see accompanying documents marked as Bates Nos YOST 00001 50
INTERROGATORYNO 4 Identify each exhibit which You intend to offer into
evidence at a trial of this matter
ANSWER TO INTERROGATORY NO 4 Plaintiff answers Interrogatory No 4 by
referring Defendants to the documents produced herewith on the accompanying compact
diskette
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 4 Plaintiff supplements
her answer to Interrogatory No 4 by referring Defendant to documents marked as Bates
Nos TRPA 00001 12 and TRVP 000015 produced herewith
INTERROGATORY NO 7 With respect to each Health Care Provider who has
examined Major or provided her with any treatment diagnosis prognosis or health care for any
symptom complaint injury aggravation or adverse reaction to any injury which You allege she
suffered as a result of the Incident please state
A The name address and telephone number of each
B The dates of inclusive care treatment diagnosis or examination
C The names and addresses of each hospital the dates of admission and dates of
discharge for each hospitalization and
D The nature of any treatment or therapy received tests performed andor
surgeries performed
ANSWER TO INTERROGATORYNO 7 Plaintiff answers Interrogatory No 7 by
referring Defendant to the medical records and bills contained on the compact diskette provided
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You expect or intend to offer into evidence at a trial of this matter
RESPONSE TO REQUEST FOR PRODUCTION NO 1 Plaintiff responds to
Request for Production No 1 by referring the Defendant to the documents contained on the
accompanying compact diskette
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 1
Plaintiff supplements her response to Request for Production No 1 by producing herewith
documents marked as Bates Nos TRVP 000015 and TRPA 0000112
REQUEST FOR PRODUCTION NO 2 Please produce all Documents identified by
You in response to the Interrogatories hereinabove
RESPONSE TO REQUEST FORPRODUCTION NO 2 Plaintiff responds to
Request for Production No 2 by referring the Defendant to the documents contained on the
accompanying compact diskette
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 2
Plaintiff supplements her response to Request for Production No 2 by producing herewith
documents marked as Bates Nos TRVP 000015 TRPA 0000112 SLFH 00001 96 SWIENT
00001 61 SARMC 00001192 IEC 000015 BSG 000016 IPA 0007680 and YOST 00001
50
REQUEST FOR PRODUCTION NO 3 Please produce each and every Document
pertaining to any medical psychological or health care treatment diagnosis testing therapy or
prognosis rendered to or for Major by any Health Care Provider in connection with the injuries
for which compensation is sought in this Lawsuit
RESPONSE TO REQUEST FOR PRODUCTION NO 3 Plaintiff responds to
Request for Production No 3 by referring the Defendant to the documents contained on the
PLAINTIFFSSECOND SUPPLEMENTAL ANSWERS ANDRESPONSES TODEFENDANT FIRST SET OF
INTERROGATORIES AND REQUESTS FOR PRODUCTION OF DOCUMENTS 9
001408
ou expect or intend to offer into evidence at a trial of this atter. 
     . : i  s t  
e est f r r cti  .   referri  t e efe a t t  t e c e ts c tai e   t e 
i  t i tt . 
      .1: 
l i tiff s le e ts r r s s  t  st f r r ti  .   r i  r it  
e ts e    .  -5   -1 . 
   . : lease produce all ocu ents identified by 
 i  res se to t e Interrogat ries erei a e. 
     . : i ti    
Request for Production No. 2 by referring the Defendant to the docu ents contained on the 
i  t is tt . 
L       .2: 
laintiff supple ents her response to equest for roduction o. 2 by producing here ith 
    .  -5,  -1 ,  -9 ,  
-6 ,  -19 , I  -5,  -6, I  -8 ,   01-
. 
   . :     r   
pertaining to any edical, psychological or health care, treat ent, diagnosis, testing, therapy, or 
prognosis, rendered to or for ajor by any Health Care Provider in connection with the injuries 
for hich co pensation is sought in this La suit. 
     . : l i ti  res s  
equest for roduction o. 3 by referring the efendant to the docu ents contained on the 
L I TIFF'S  L      FENDANT'S    
I I     I    -  
DATED this 5th day of August 2010
OBJECTIONS IFANY BY
JONES SWARTZ PLLc
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WIN L OVERSON
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 5th day of August 2010 a true and correct copy of the
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
J USMail
Fax 3192601
Overnight Delivery
X Messenger Delivery
Email cburke reenerlawcom
DARWIN LOVERSON
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EXHIBIT C
TOAFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
EXHIBIT C
TO AFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post OfficeBox 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswart7lawc m
Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Case No CV 11003515
Plaintiff
V5 PLAINTIFFSSUPPLEMENTAL
EXPERT WITNESS DISCLOSURE
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
PRELIMINARY STATEMENT
Discovery in this matter is ongoing This disclosure is made and based upon the
Plaintiffs current understanding of the facts claims and defenses at issue in this litigation It is
anticipated that further discovery investigation and consultation with witnesses and experts may
supply additional facts add meaning to known facts and establish new factual conclusions and
legal contentions all ofwhich may lead to additions to modifications of and variations from the
disclosures set forth herein This disclosure is therefore made without prejudice to Plaintiffs
PLAINTIFFSSUPPLEMENTAL EXPERT WITNESS DISCLOSURE t
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Plaintiff's current understanding of the facts, clai s, and defenses at issue in this litigation. It is 
anticipated that further discovery, investigation, and consultation ith itnesses and experts ay 
s l  iti l f ts,  i  t   f ts,  st lis   f t l l si s  
legal contentions, all f hich ay lead to additions to, odifications of, and variations fro  the 
isclosures set f rt  erei . is isclos re is t eref re a e it t rej ice t  lai tiff's 
I TIFF' S  P   LOSURE - I 
right to disclose evidence of subsequently discovered facts or opinions thereon Subject to and
without waiving the right to supplement the scope of the testimony disclosed herein based upon
information learned or documents acquired through the completion of discovery in this action
Plaintiff snakes the following disclosure
Original Disclosure
Garold S Yost PhD
Professor of Pharmacology and Toxicology
College of Pharmacy
University ofUtah
30 North 1900 East 201
Salt Lake City Utah 84112
80158 7956
Dr Yost is a Professor of Pharmacology and Toxicology at the University of Utah He is
internationally recognized as an authority on toxicology in the respiratory tract with particular
expertise on the cytochrome P450mediated mechanisms of lung injury Research in the Yost
laboratory is largely focused on the elucidation of the chemical biochemical and cellular
mechanisms of toxicity to lung tissues that are caused by exposure to environmental pollutants
There are a number of chemicals that cause selective damage to lung tissues after inhalation or
from ingestion followed by systemic exposure to circulating chemicals He is also an expert in
lung diseases drug induced toxicities and adverse drug reactions His expertise extends also to
the analysis chemistry receptor activation and biological effects including toxicities of
capsaicinoids
Dr Yost is expected to testify regarding the human body s reaction to and toxicity of
capsaicinoids and oleoresin capsicum OC spray as well as similar compounds Dr Yost will
testify that within a reasonable degree of certainty it was Plaintiff exposure to DefendantsOC
spray products while performing her duties as a correctional officer with the Idaho Department of
PLAINTIFFSSUPPLEMENTAL EXPERT WITNESS DISCLOSURE 2
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Dr. Yost is a Professor of Phalmacology and Toxicology at the University of Utah. He is 
internationally recognized as an authority on toxicology in the respiratory tract, with particular 
expertise on the cytochro e P450- ediated echanis s of lung injury. esearch in the ost 
laboratory is largely focused on the elucidation f the che ical, bioche ical, and cellular 
mechanisms of toxicity to lung tissues that are caused by exposure to environmental pollutants. 
here are a nu ber of che icals that cause selective da age to lung tissues after inhalation or 
from ingestion followed by systemic exposure to circulating chemicals. He is also an expert in 
lung diseases, drug-induced toxicities, and adverse drug reactions. is expertise extends also to 
the analysis, chemistry, receptor activation, and biological effects (including toxicities) of 
ca . 
Dr. Yost is expected to testify regarding the human body's reaction to, and toxicity of, 
capsaicinoids and oleoresin capsicum (Oe) spray, as well as similar compounds. Dr. Yost will 
testify that within a reasonable degree of certainty it as Plaintiff's exposure to efendant's C 
spray products while performing her duties as a correctional officer with the Idaho Department of 
P F'S S PP E ENTAL EXPERT WITNE S DISCLOSURE ..... 2 
Corrections that caused an acute and chronic adverse health response and greatly exacerbated
Plaintiffs underlying respiratory illness He will testify to how such injury takes place by
explaining the physiological and chemical mechanisms by which the compounds found in the
DefendantsOC Spray products affect the relevant human tissues He will testify about the
research in this area explaining to the jury what is known of these mechanisms and physiological
responses
Dr Yosts opinions are based upon his review of records produced in discovery
including but not limited to Plaintiffs medical records NJHR 159 Hendrickson 1 6
Moldenhauer DC 23 St Als 14 other experts reports Idaho Department of Correction
records IDC Records 35120 Sabre Red product information Sabre Red 12 Material Safety
Sheet 14 and deposition testimony Billie Major Robert Nance Bret Kimmel Daniel J
Schaffer Joshua Overgaard Nicholas Doan and Sara AnneMarie Link His opinions are also
based on his professional experience education observations and the research of his own and
others including research articles entitled Increased Expression of Transient Receptor Potential
vanilloid1 in Airway Nerves of Chronic Cou and Breat TRChannels TRPA1 and
TRPVI in Airway Chemosens andReflexControltrai ing
Dr Yost has not prepared any trial exhibits at this time In the event that any of those
items are prepared they will be produced in accordance with this Courts June 1 2010
Scheduling Order and Rule 26a4of the Idaho Rules of Civil Procedure Dr Yosts initial
report outlines his opinions in part and is produced herewith as Exhibit A In the event further
depositions are taken in this matter Dr Yostsopinions may change based on his subsequent
review of such deposition testimony and ifso this disclosure will be supplemented accordingly
PLAINTIFFSSUPPLEMENTAL EXPERT WITNESS DISCLOSURE 3
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I TIFF'S L  ES   -  
Exhibits Dr Yost may utilize during trial may include medical records deposition
testimony deposition exhibits photographs monographs research articles material safety data
sheets package inserts and any other document or thing produced by any party or any nonparty
to this matter or which is referred to by any party in discovery or referred to in any document or
answers or response to discovery in this matter IIlustrative exhibits demonstrative exhibits and
anatomical models may also be utilized Discovery is ongoing in this matter and additional
information may yet be discovered Plaintiff reserves the right to utilize other presently
unidentified exhibits at trial which will be timely disclosed at a later date
Dr Yostsqualifications are further outlined in his Curriculum Vitae and his profile and
biosketch on the University of Utah College of Pharmacy website which includes a list of his
publications all of which are attached hereto as Exhibits B and C respectively Dr Yosts
agreedupon compensation for analysis of the issues in this case and to testify is 450 per hour
A copy of the signed agreement is attached hereto as Exhibit D
Plaintiff reserves the right to elicit opinion testimony from any expert non retained
treating medical provider and any other witnesses disclosed in discovery or deposition by the
Plaintiff or Defendant Further Plaintiff reserves the right to supplement or amend this
disclosure and to list rebuttal experts
Supplemental Disclosure
I Karin PachecoMDMSPH
National Jewish Hospital
1400 Jackson Street Room G 211
Denver CO 80206
303 3981520
Dr Pacheco is an Assistant Professor of Preventative Medicine and AllergyImmunology
at the University of Colorado Denver where she teaches courses regarding bioaerosols in
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IFF'S  P  WITNESS ISCLOSURE-  
Plaintiff reserves the right to elicit opinion testimony from any person duly qualified
who has been disclosed by Defendants in this action
Plaintiff reserves the right to elicit opinion testimony from any expert non retained
treating medical provider and any other witnesses disclosed in discovery or deposition by the
Plaintiff or Defendants Further Plaintiff reserves the right to supplement or amend this
disclosure and to list rebuttal experts In the event further depositions are taken in this matter
the testimony of non retained medical providers who provided care and treatment to Plaintiff
as a result of the incident at issue in this case may change based on subsequent review of such
deposition testimony and if so this disclosure will be supplemented accordingly
As discovery and Plaintiffs treatment remains ongoing there may be other persons not
identified herein who may fall within the scope of this disclosure that are not yet known If such
persons are identified Plaintiff reserves the right to seasonably disclose such persons and to call
them as witnesses at the time of trial
Any of the persons identified above may be called for purposes of rebuttal andor
impeachment Plaintiff also reserves the right to seasonably supplement this list with other
rebuttal andor impeachment witnesses
Plaintiff reserves the right to alter amend or supplement this disclosure as the Idaho
Rules of Civil Procedure and the Court may allow
DATED this 28nd day of March 2011
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 28nd day of March 2011 a true and correct copy of
the foregoing document was served on the following individualsby themethod indicated
Christopher C Burke
GREENER BURtu SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
UMailf 1 Fax 3192601
ERIC B SWARTZ
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post OfficeBox 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
cric@jonesandswartzlawm
Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JOMAJOR and individual
Case No CV PI 1003515
Plaintiff
vs
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
PLAINTIFFSANSWERS AND
RESPONSES TO DEFENDANT
FIRST SET OFREQUESTS FOR
ADMISSION AND SECOND SET OF
INTERROGATORIES AND REQUESTS
FOR PRODUCTION OF DOCUMENTS
Defendant
COMES NOW the Plaintiff by and through her counsel of record Jones Swartz PLLC
and answers and responds to Defendants First Set of Requests for Admission and Second Set of
Interrogatories and Requests for Production ofDocuments served by facsimile and USMail on
March 18 2011 as follows
PRELIMINARY STATEMENT
The following Answers and Responses are based upon a reasonable inquiry and diligent
search by the Plaintiff but reflect only the current state of Plaintiffs understanding and belief
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search by the laintiff, but reflect only the current state f laintiffs understanding and belief 
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respecting the matters about which inquiry was made It is anticipated that further discovery
independent investigation and consultation with experts may supply additional facts add
meaning to known facts and establish entirely new factual conclusions and legal contentions all
of which may lead to substantial additions to modifications of and variations from the Answers
and Responses herein The following Answers and Responses are therefore made without
prejudice to the Plaintiffs right to produce evidence of subsequently discovered facts which she
may then have available
CONTINUING OBJECTIONS
Nothing herein contained is intended to be nor should be construed as a waiver of any
attorneyclient privilege workproduct protection trade secrets proprietary information or the
right of privacy and to the extent the Requests for Admission Interrogatories and Requests for
Production may be construed as calling for the disclosure of information protected by such
privileges andor doctrines a continuing objection to each and every Request for Admission
Interrogatory and Request for Production is hereby imposed
REQUESTS FORADMISSION
REQUEST FORADMISSIONNO 1 Please admit that you are not aware of any
Documents articles studies or other scientific or medical literature that concludes that OC
Spray causes or is likely to cause longterm andor chronic respiratory health problems
RESPONSE TO REQUEST FOR ADMISSION NO 1 Deny
REQUEST FORADMISSIONNO 2 Please admit that you are not aware of any
reported case or study of any person who developed longterm andor chronic adverse respiratory
health affects as a result of exposure to OC Spray
RESPONSE TO REOUEST FOR ADMISSION NO 2 Deny
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roduction ay be construed as calling for the disclosure f infor ation protected by such 
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  IS  
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REQUEST FORADMISSION NO 3 Please admit that you are not aware of any
reported case or study of any person who developed longterm andorchronic adverse respiratory
health affects as a result of exposure to OC Spray as a result of exposure to oleoresin capsicum
RESPONSE TO REQUESTFOR ADMISSION NO 3 Deny
REQUEST FOR ADMISSION NO 4 Please admit that you were exposed to OC
Spray manufactured by companies other than SEC during the course of your employment with
IDOC during the period of time between July 2004 and May 2008
RESPONSE TO REQUEST FOR ADMISSIONNO 4 Admit the Plaintiff was
exposed to other OC Spray products manufactured by other companies than the Defendants
products during the course of her employment between July 2004 and the last date she worked at
IDOC
INTERROGATORIES
INTERROGATORY NO 16 Please identify any and all Occupational medicine
specialists or similar health care providers which you have consulted with seen or been treated
by in the preceding twenty 20 years
ANSWER TO INTERROGATORY NO 16 Plaintiff objects to Interrogatory No 16
on the grounds that it is vague overly broad and seeks information not reasonably likely to lead
to the discovery of admissible evidence Plaintiff further objects on the grounds ofwork product
privilege Without waiving said objections Plaintiff answers Interrogatory No 16 by referring
Defendant to her supplemental expert disclosures and medical records previously produced to the
Defendant Plaintiff has consulted with Dr Pacheco Dr Hendrickson Dr Loveland Dr
ODonnell and othermedical treatment providers
INTERROGATORY NO 17 Please identify and sic all counselors psychologists
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specialists or si ilar health care providers hich you have consulted ith, seen or been treated 
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on the grounds that it is vague, overly broad, and seeks infor ation not reasonably likely to lead 
to the discovery f ad issible evidence. laintiff further objects on the grounds f ork product 
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efendant to her supple ental expert disclosures and edical records previously produced to the 
nt. laintiff has consulted ith r. acheco, r. endrickson, r. oveland, r. 
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identify each of those persons is unduly burdensome Without waiving said objections Plaintiff
answers Interrogatory No 20 by referring the Defendant to her Answers to Interrogatory Nos 1
2 and 11 along with all documents obtained by the Defendant pursuant to subpoenas served on
the Idaho Department of Correction
INTERROGATORY NO 21 If your responses to Requests for Admission Nos 1 2 or
3 are anything other than unqualified admissions please identify with particularity each and
every fact Document statement example study report andor other evidence that you contend
forms the basis for each such response
ANSWER TO INTERROGATORY NO 21 Plaintiff answers Interrogatory No 21 by
stating the following articles have helped form the basis of her responses to Request for
Admission Nos 1 2 and 3
1 Hamyman Mark Kam Peter CAPSAICIN A REVIEW OF ITS PHARMACOLOGY
AND CLINICAL APPLICATION Vol 19 Journal Current Anesthesia and Critical Care pp 338343
2008
2 Alawi Khadija Keeble Julie THE PARADOXICAL ROLE OFTRPVI RECEPTOR IN
INFLAMMATION Vol 125 Pharmacology and Therapeutics pp 189195 2010
3 CA Reilly DJ Crouch GS Yost and A Fatah DETERMINATION OF
CAPSAICIN NONIVAMIDE AND DIHYDROCAPSAICIN IN BLOOD AND TISSUE By LIQUID
CHROMATOGRAPHY TANDEM MASS SPECTROMETRY J Anal Toxicol 26 313 319 2002
4 CA Reilly JL Taylor DL Lanza BA Carr DJ Crouch and GS Yost
CAPSAICINOIDS CAUSE INFLAMMATION AND EPITHELIAL CELL DEATH THROUGH ACTIVATION OF
VANILLOID RECEPTORS Tox Sci7317081 2003
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S E  T  I TE T  . 21: Plaintiff ans ers Interrogatory o. 21 by 
stating the follo ing articles have helped for  the basis of her responses to equest for 
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. n, r  & , ter, AI I :  I   I   
 I I  pP I I , ol. 19 Journal urrent nesthesia and ritical are, pp. 338-343 
(20 8). 
2. l i, h ija & l , li ,  I      I  
I FL TI , ol. 125, har acology and herapeutics, pp. 189-195 (2010). 
. .A. eilly, J. rouch, O.S. ost, and .A. Fatah, DETER INATION OF 
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CHRO ATOGRAPHy-TANDE  ASS SPECTRO ETRY, J Anal. Toxicol., 26, 313 -319 (2002). 
4. .A. eilly, J.L. aylor, .L. anza, .A. an, J. rouch, and .S. ost, 
P I I I S S  I TIO       I TION  
NILLOID E EPT S, Tox. Sci., 73,170-181 (2003). 
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5 CA Reilly and GS Yost STRUCTURAL AND ENZYMATIC PARAMETERS THAT
DETERMINE ALKYL DEHYDROGENATIONHYDROXYLATION OF CAPSAICINOIDS BY P450 ENZYMES
Drug Metab Dispos 33 530 536 2005
6 CA Reilly ME Johansen DL Lanza J Lee JO Lim and GS Yost
CALCIUM DEPENDENT AND INDEPENDENT MECHANISMS OF CAPSAICIN RECEPTOR TRPVI
MEDIATED CYTOKINE PRODUCTION AND CELL DEATH IN HUMAN BRONCHIAL EPITHELIAL CELLS
J Biochem Molec Toxicol 19 266275 2005
7 ME Johansen C A Reilly andGS Yost TRPVI ANTAGONISTS ELEVATE CELL
SURFACE POPULATIONS AND RECEPTOR FUNCTION TO EXACERBATE TRPVI MEDIATED
TOXICITIES IN HUMAN LUNG EPITHELIAL CELLS Toxicol Sci 89 27886 2006
8 CAReilly andGS Yost METABOLISM OF CAPSAICINOIDS BY P450 ENZYMES A
REVIEW OF RECENT FINDINGS ON REACTION MECHANISMS BIOACTIVATION AND
DETOXIFICATIONPROCESSES Drug Metab Rev 38 685706 2006
9 KCThomas AS SabnisME Johansen DLLanza PJ Moos GS Yost and
CA Reilly TRPVI AGONISTS CAUSE ENDOPLASMIC RETICULUM STRESS AND CELL DEATH IN
HUMAN LUNG CELLS J Pharmacol Exp Ther 321 830838 2007
10 BF Bessae andSEJordt BREATHTAKING TRP CHANNELS TRPAI AND TRPVI
IN AIRWAY CHEMOSENSATION AND REFLEX CONTROL Physiology 23 360370 2008
11 DA Groneberg A Niimi Q Thai Dinh B Cosio Mark Hew A Fischer and
KF Chung INCREASED EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID1 IN
AIRWAY NERVES OF CHRONIC COUGH American Journal of Respiratory and Critical Care
Medicine Vol 170 12761280 2004
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6. C.A. Reilly, .E. Johansen, D.L. Lanza, J. Lee, J.- . Lim, and O.S. Yost, 
CALCIU -DEPENDENT AND INDEPENDENT ECHANIS S OF CAPSAICIN RECEPTOR (TRPVl)-
E I TE  T I E P TI   ELL E T  I   I L EPIT ELI L ELLS, 
. i . l c. xicol. ,26 -2  (2 05). 
7. .E. nsen, . . eilly,  O.S. t, l I    
 I       PVI-MEDIAT  
T ICITIES IN  L  EPIT ELI L CELLS, Toxicol. Sci. 89,278-86 (2006). 
8. .A. i   O.S. t,   f    :  
I  OF RECENT    I , Bro-AcTIVATION,  
I I I  , rug et . ev. , -706 (2006). 
. K.C. Thomas, A.S. Sabnis, M.E. Johansen, D.L. Lanza, PJ. Moos, O.S. Yost, and 
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 UNG , . l. . r. , -838 (20 7). 
10. .F. essac  .E. r t, I  P :   l 
IN AlR A Y CI-IE OSENSATION AND REFLEX CONTROL, Physiology, 23, 360-370 (2008) 
. D.A. Oroneberg, A. Niimi, Q. Thai Dinh, B. Cosio, ark Hew, A. Fischer, and 
.F. , I CREASED EXPRESSI  F TR NSIE T  I  ANI LOID-l I  
AIRWAY NERVES OF CHRONIC COUGH, American Journal of Respiratory and Critical Care 
e ici e, ol. 170, 1276-1280 (20 ). 
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Plaintiff further answers this Interrogatory by referring Defendant to documents produced
herewith marked as Bates Nos ARTICLES 000001 100 and documents previously produced
marked as Bates Nos TRPV 000015 and TRPA 0000112
REQUESTS FORPRODUCTION OF DOCUMENTS
REQUEST FOR PRODUCTION NO 51 Please produce copies of any and all
medical records regarding your consultation treatment andor care with each of the medical
providers identified in response to Interrogatory No 16 above
RESPONSE TO REQUEST FOR PRODUCTION NO 51 Plaintiff responds to
Request for Production No 51 by incorporating herein as though fully set forth her objections
and answers to Interrogatory No 16
REQUEST FOR PRODUCTION NO 52 Please produce copies of any and all
medical records regarding your consultation treatment andor care with each of the medical
providers identified in response to Interrogatory No 17 above
RESPONSE TO REOUEST FOR PRODUCTION NO 52 Plaintiff responds to
Request for Production No 52 by incorporating herein as though fully set forth her objections
and answers to Interrogatory No 17
REQUEST FOR PRODUCTION NO 53 Please produce copies of all medical
records regarding any visit treatment consultation testing evaluation or other care you have
received from Dr Negron
RESPONSE TO REQUEST FOR PRODUCTION NO 53 Plaintiff responds to
Request for Production No 53 by stating during Dr Negrons February 2 2010 psychological
assessment of Plaintiff two pages of notes were taken and were used in the drafting of the
psychological assessment that has already been produced Following the drafting of the said
PLAINTIFFSANSWERS AND RESPONSES TO DEFENDANSFIRST SET OF REQUESTS FOR
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Plaintiff fmther ans ers this Inten'ogatory by refelTing efendant to docu ents produced 
herewith arked as Bates Nos. ARTICLES 000001-100, and docu ents previously produced 
 a   s.  0 -  and  0 - . 
 F  ROD TI    
  D TI  . 1: Please produce copies of any and all 
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 t e     t  .  bove. 
     . : l i ti  responds  
Request for Production No. 51 by incorporating herein as though fully set forth her objections 
a  a s ers t  I terr at r  . . 
   . : Please produce copies of any and all 
i l r r s r r i  r s lt ti , tr t t /or r  it   f t  i l 
ders ie   nse   .  e. 
S   Q    . : f responds  
Request for Production No. 52 by incorporating herein as though fully set forth her objections 
 s ers to nterroga  . . 
   . : Please produce copies of all edical 
records regarding any visit, treat ent, consultation, testing, evaluation or other care you have 
received fro  . e . 
ESP SE  ES   P ION . : f responds t  
Request for Production No. 53 by stating during r. egron's Febtuary 2, 2010 psychological 
assessment of Plaintiff, two pages of notes were taken and were used in the drafting of the 
psychological assess ent that has already been produce . Following the drafting of the said 
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assessment the two pages of notes were misplaced and now cannot be located Plaintiff further
responds to Request for Production No 53 by stating that she has been assured by Dr Negron
that all of the information that was contained in the two pages of notes can also be found in his
psychological assessment ofPlaintiff
REQUEST FOR PRODUCTION NO 54 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications which you contend
support the contention that SEC knew or should have known that the Sabre Red OC Spray may
cause respiratory illness such as RADS chronic cough syndrome vocal cord dysfunction
esophageal dysmotility and reflux as set forth in Paragraph 19 of your Complaint
RESPONSE TO REQUEST FOR PRODUCTION NO 54 Plaintiff responds to
Request for Production No 54 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 00001 12 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but will be made available to Defendant as soon
as we get copies
REQUEST FOR PRODUCTION NO 55 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications available andor
published prior to May 2008 which would support the contention that Sabre Red OC Spray may
cause respiratory illness such as RADS chronic cough syndrome vocal cord dysfunction
esophageal dysmotility and reflux as set forth in Paragraph 19 of your Complaint
RESPONSE TO REQUEST FOR PRODUCTION NO 55 Plaintiff responds to
Request for Production No 55 by referring Defendant to documents produced herewith marked
PLAINTIFFSANSWERS AND RESPONSES TO DEFENDANTSFIRST SET OF REQUESTS FOR
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sessment,            ted. l i ti  fUl  
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that all of the infor ation that as contained in the t o pages of notes can also be found in his 
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as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 000015 and TRPA 0000112 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but will be made available to Defendant as soon
as we get copies
REQUEST FOR PRODUCTION NO 56 If your responses to Requests for Admission
Nos 1 2 or 3 are anything other than unqualified admissions please produce andor identify
each and every Document article medical or scientific study medical or scientific literature
example or other evidence that you rely upon in formulating each such response
RESPONSE TO REOUEST FORPRODUCTION NO 56 Plaintiff responds to
Request for Production No 56 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 000015 and TRPA 00001 12 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but will be made available to Defendant as soon
as we get copies
REQUEST FOR PRODUCTION NO 57 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications which supports the
contention that OC Spray should only be used for training officers who do not have a history of
respiratory illness such as chronic asthma or bronchitis or other health problems that may make
the officer more susceptible to injury by OC Spray as set forth in Paragraph 19 of your
Complaint
RESPONSE TOREQUEST FORPRODUCTION NO 57 Plaintiff responds to
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a   os.  -1  and d c t  r i l  pr  r  as B t  
s.  -5   - . Plaintiff further responds to this Request for 
Production by stating that articles 1, 2, and 3 fro  the list of articles in Interrogatory o. 21 are 
 tT  i   l i ti  i   fOl ,  i    vail l  t  f nt   
   pies. 
  I  . 6: If r res ses t  e ests f r issi  
os. 1, 2 or 3 are anything other than unqualified ad issions, please produce and/or identify 
each and every ocu ent, aIticle, edical or scientific study, edical or scientific literature, 
exa ple, or other evidence that you rely upon in fOl ulating each such response. 
  Q    . : l i tif  responds  
equest for Production o. 56 by referring efendant to docu ents produced here ith arked 
as ates os. TI LES 000001-100 and docu ents previously produced arked as ates 
os. P  00001-5 and P  00001-12. laintiff further responds to this equest for 
Production by stating that articles 1, 2, and 3 fro  the list of articles in IntetTogatory o. 21 are 
t tl  ila le t  l i ti f i  r , t ill   ila le t  e t   
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   . : Please produce copies of any and all 
journals, articles, studies, reports, or peer reviewed or refereed publications, which supp0l1s the 
contention that "OC Spray should only be used for training officers ho do not have a history of 
respiratory illness, such as chronic asthma or bronchitis, or other health problems that may make 
the officer ore susceptible to injury by" OC Spray, as set f011h in Paragraph 19 of your 
l i t. 
S SE  ES   I  . : ff responds t  
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Request for Production No 57 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 000015 and TRPA 00001 12 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper fonn but will be made available to Defendant as soon
as we get copies
REQUEST FOR PRODUCTION NO 58 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications which supports the
contention that OC Spray may act as an aggravating factor for those who may already have one
or more of the medical conditions listed in Paragraph 19 of your Complaint
RESPONSE TO REQUEST FOR PRODUCTION NO 58 Plaintiff responds to
Request for Production No 58 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 00001 12 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but but will be made available to Defendant as
soon as we get copies
REQUEST FOR PRODUCTION NO 59 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications which you contend
identify the standard for what is reasonably safe for use within closed environments such as
within the IDC in regards to the potency of OC Spray as set forth in Paragraph 16 of your
Complaint
RESPONSE TO REQUEST FORPRODUCTION NO59 Plaintiff responds to
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Production by stating that articles 1, 2, and 3 fro  the list of articles in Interrogatory o. 21 are 
 UlTe  v il  t  l intif  i     ill   avail bl  t  f t  soon 
   i s. 
   . 8: lease produce copies f any and all 
journals, articles, studies, reports, or peer revie ed or refereed publications, hich SUppOlts the 
contention that  Spray "may act as an aggravating factor for those ho ay already have one 
r re" f t  i l iti s liste  i  r r   f r l i t. 
    I  . 58: l i ti  responds t  
Request for Production No. 58 by referring Defendant to docu ents produced herewith arked 
as ates os. TI LES 000001-100 and docu ents previously produced arked as ates 
.  01-5    01-1 . lai tiff f rt er res s t  t is e est f r 
ti   t ting t t ticles , ,   r  t  list  ti les i  t t  .   
not currently available to laintiff in paper fonn but but ill be ade available to efendant as 
 s   . 
S    . : Please produce copies of any and all 
joumals, articles, studies, reports, or peer revie ed or refereed publications, hich you contend 
i ti  the sta ar   "what is l  e fo  s  ithin lose  ir e ts   
ithin the I C," in regards to the potency of C Spray, as set forth in Parab:rraph 16 of your 
. 
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Request for Production No 59 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 0000112 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but but will be made available to Defendant as
soon as we get copies
DATED this 18th day of April 2011
OBJECTIONS IF ANY BY
JONES SWARTZ PLLc
By
ARWIN ERSON
ERIC B SWARTZ
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 18th day of April 2011 a true and correct copy of the
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
JMessenger Delivery
Email cburke@greenerlawcom
DARWIN L VERSON
ERIC B SWART7
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CERTIFICAT  OF SERVICE 
I HEREBY CERTIFY that on this 18th day of April, 2011, a true and correct copy of the 
foregoing docu ent as served on the follo ing individuates) by the method indicated: 
Chri t er C. Bur  
GREENE  B  SHOEMA  P  
950 . nnock treet, Suit  900 
oise, I  83702 
[ ] U.S. ail 
[ ] Fax: 319M 1 
H-Messenger elivery 
( ] Email: cburke greencrIaw.com 
~~~ .. Q/ ~ - -- .-INLVERSON 
I  . S A TZ 
PLAINTIFF'S ANSWERS AND RESPONSES TO DEFENDANT'S FIRST SET OF REQUESTS FOR 
ADMISSION, AND SECOND SET OF INTERROGATORIES AND REQUESTS FOR PRODUCTION 
OF DOCUMENTS -- 14 
EXHIBIT E
TOAFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
EXHIBIT E
TO AFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JOMAJOR and individual
Plaintiff
Case No CV PI 1003515
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
PLAINTIFFSDISCLOSURE OF
REBUTTAL EXPERT WITNESS
TESTIMONY
PRELIMINARY STATEMENT
Discovery in this matter is ongoing This disclosure is made and based upon the
Plaintiffscurrent understanding of the facts claims and defenses at issue in this litigation It is
anticipated that further discovery investigation and consultation with witnesses and experts may
supply additional facts add meaning to known facts and establish new factual conclusions and
legal contentions all of which may lead to additions to modifications of and variations from the
disclosures set forth herein This disclosure is therefore made without prejudice to Plaintiffs
right to disclose evidence of subsequently discovered facts or opinions thereon Subject to and
PLAINTIFFSDISCLOSURE OF REBUTTAL EXPERT WITNESS TESTIMONY 1
Darwin Overson TSB 5887
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
k Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
Attorneys for Plaintiff Billie Jo Major
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isco ery in t is atter is i . This disclosure is made and based upon the 
Plaintiff's current understanding of the facts, claims, and defenses at issue in this litigation. It is 
anticipated that further discovery, investigation, and consultation with witnesses and experts may 
s l  a itional fa ts, a d ea ing t   fa ts, and est lish  factual c nclusions a d 
legal c t ti , all of hich ay lead t  a itions t , o ifications f, a  variations fro  the 
disclosures set forth herein. This disclosure is therefore made without prejudice to Plaintiff's 
right to disclose evidence of subsequently discovered facts or opinions thereon. SUbject to and 
P I F'S DISCLOSURE OF RE TTAL EXPERT ITNE S TES I ONY - 1 
without waiving the right to supplement the scope of the testimony disclosed herein based upon
information learned or documents acquired through the completion of discovery in this action
Plaintiff makes the following disclosure of rebuttal testimony that may be presented at trial by the
Defendantsexperts
1 Garold S Yost PhD
Professor ofPharmacology and Toxicology
College ofPharmacy
University ofUtah
30 North 1900 East 201
Salt Lake City Utah 84112
801 5817956
Dr Yost may testify to those matters contained in his affidavit filed on June 10 2011 and
in his deposition He may testify regarding the sensitizing effect some individuals have relating
to OC and other irritants as well as the research that has been done in the scientific community
on the subject Hemay further discuss those articles cited in his affidavit as well as articles cited
and discussed by other researchers that support his opinions and conclusions He may testify
about any of the research articles cited by any of the Defendantsexperts and explain why that
body of articles does not undermine the expert opinions and conclusions he has expressed in this
case in his report affidavits and deposition He may further explain to thejury how based on the
state of understanding within the scientific community at the time SEC sold its SABRE Red
products to the Idaho Department of Corrections the Defendant either knew or should have
known of the risks associated with their product for individuals with respiratory tract illness He
may testify about Dr Reillysopinions and conclusions contained in Dr Reillysaffidavit expert
report and of Dr Reillystrial testimony He may testify about the opinions conclusions and
alleged basis therefor contained in the expert disclosures and reports of Drs Mark Utell and
Roger McClellan as well as any trial testimony they may offer He may also testify on the
PLAINTIFFSDISCLOSURE OF REBUTTAL EXPERT WITNESS TESTIMONY 2
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infonnation learned or docu ents acquired through the co pletion of discovery in this action, 
lai tiff a es t e f ll i  iscl s re f re ttal testi  t at a  e rese te  at trial  t e 
f ndant's rts: 
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r. st  t ti  t  t s  tt  t i  i  i  i it il    , ,  
in his deposition. e ay testify regarding the sensitizing effect so e individuals have relating 
t    t r irrit ts, s ll s t  r s r  t t s   i  t  s i tifi  it  
  j ct.      les        rt   
and discussed by other researchers that support his opinions and conclusions. e ay testify 
about any f the research articles cited by any f the efendant's experts and explain hy that 
body of articles does not under ine the expelt opinions and conclusions he has expressed in this 
 i  is r rt, ffi its  siti .   f rt r l i  t  t  j r     t  
t t  f r t i  it i  t  i tific it  t t  ti   l  it    
ucts  t   e t e t  ,        
 f t  ris s ss i t  it  t ir r t f r i i id ls it  r s ir t r  tr t ill ss.  
may testify about Dr. Reilly's opinions and conclusions contained in Dr. Reilly's affidavit, expelt 
report and of Dr. Reilly's trial testi ony. He ay testify about the opinions, conclusions and 
lle e  sis t r f r t ine  i  t e rt is los res  r rts f rs. ar  t ll  
 c lella   ll   t ial t ti  t   r. e ay also testify on the 
I IFF'S IS S     ES   -  
subject of Mr Nances opinions conclusions trial testimony deposition testimony affidavits
and the discovery responses He may testify regarding any expert opinions and conclusions
offered by the nonretained defense experts such as Sergeant Bret Kimmel Sergeant Schaffer
Sergeant Overgaard Sergeant Doan and any of the healthcare providers including Steve Asher
MD MPH Joseph J Callam MD Dan Hendrickson MD William Loveland MD Glenn
Moldenhauer DC William Robinson DC JanatODonnell MD Karin Pacheco MD MSPH
Matthew Schwartz MD and Mousoomi Sur MD insofar as their testimony relates to Dr Yosts
held of expertise
2 Karin PachecoMDMSPH
National Jewish Hospital
1400 Jackson Street Room G 211
Denver CO 80206
303 3981520
Dr Pacheco may testify to those matters contained in her reports medical records and in
her deposition She may testify regarding the sensitizing effect some individuals have relating to
OC and other irritants as well as the research that has been done in the scientific community on
the subject She may testify about research article IrritantAssociated Vocal Cord Dysfunction
and other similar articles of scientific inquiry She may testy about Irritant Associated Vocal
Cord Dysfunction as an occupational diseaseillness how it is diagnosed treated and caused
She may testify to the understanding of the causes of Irritant Associated Vocal Cord Dysfunction
during the period when the Defendant sold its SABRE Red products to the Idaho Department of
Corrections She may further discuss those articles cited in affidavits of Dr Yost and Dr Reilly
as well as articles cited and discussed by other researchers that support her opinions and
conclusions She may testify about any of the research articles cited by any of the Defendants
experts and explain why that body of articles does not undermine the expert opinions and
PLAINTIFFSDISCLOSURE OF REBUTTAL EXPERT WITNESS TESTIMONY 3
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her deposition. She ay testify regarding the sensitizing effect so e individuals have relating to 
 mId other irritants, as ell as the research that has been done in the scientific co unity on 
t  s j ct.   t stif  t r s r  rti le Init nt- ss i t  l r  sf ti , 
and other si ilar articles of scientific inquiry. She ay testy about Irritant ssociated ocal 
ord ysfunction as an occupational disease/illness, ho  it is diagnosed, treated and caused. 
he ay testify to the understanding of the causes f Irritant ssociated ocal ord ysfunction 
during the period hen the efendant sold its S BRE Red products to the Idaho epart ent of 
Con·ections. She ay further discuss those articles cited in affidavits of Dr. Yost and Dr. Reilly 
as ell as articles cited and discussed by other researchers that support her opinions and 
conclusions. She ay testify about any of the research articles cited by any of the efendant's 
experts and explain hy that body f articles does not undennine the expert opinions and 
I IFF'S ISCLOS RE F  PE T ITNESS  -  
Dr Negron may testify to those matters contained in his reports and in his deposition
including but not limited to the impairment rating he has assigned the Plaintiff and he arrived at
that impairment rating He may testify regarding any psychological explanation or lack thereof
for the Plaintiffsmedical condition
DATED this 6day ofJune 2011
PLAINTIFFSDISCLOSURE OF REBUTTAL EXPERT WITNESS TESTIMONY 5
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i l i  t t li it  t  t  i ir t r ti    assig  t  laintiff an  he rri  t 
that i pair ent rating. e ay testify regarding any psychological explanation, or lack thereof, 
f r t  laintiff's i l ndition. 
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 10 day of June 2011 a true and correct copy of the
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
JUSMail
Fax 3192601
Messenger Delivery
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EXHIBIT F
TOAFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOST PHD
EXHIBIT F
TO AFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S POST PHD
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
Case No CV PI 1003515
vs
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
PLAINTIFFSSECOND
SUPPLEMENTAL EXPERT
WITNESS DISCLOSURE
PRELIMINARY STATEMENT
Discovery in this matter is ongoing This disclosure is made and based upon the
Plaintiffscurrent understanding of the facts claims and defenses at issue in this litigation It is
anticipated that further discovery investigation and consultation with witnesses and experts may
supply additional facts add meaning to known facts and establish new factual conclusions and
legal contentions all of which may lead to additions to modifications of and variations from the
disclosures set forth herein This disclosure is therefore made without prejudice to Plaintiffs
PLAINTIFFSSECOND SUPPLEMENTAL EXPERT WITNESS DISCLOSURE 1
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iscovery in this atter is ongoing. This disclosure is made and based upon the 
Plaintiffs current understanding of the facts, clai s, and defenses at issue in this litigation. It is 
anticipated that further discovery, investigation, and consultation with witnesses and experts may 
s ply a itional fa ts, a d ea ing to kno n facts,  esta lish ne  factual c nclusions a d 
legal contentions, all of which ay lead to additions to, odifications of, and variations fro  the 
disclosures set forth herein. This disclosure is therefore made without prejudice to Plaintiffs 
P 'S SECOND S P L EXPERT WITNE S DISCLOSURE - 1 
right to disclose evidence of subsequently discovered facts or opinions thereon Subject to and
without waiving the right to supplement the scope of the testimony disclosed herein based upon
information learned or documents acquired through the completion of discovery in this action
Plaintiffmakes the following disclosure
Original Disclosure
Garold S Yost PhD
Professor of Pharmacology and Toxicology
College ofPharmacy
University ofUtah
30North 1900 East 201
Salt Lake City Utah 84112
80158 7956
Dr Yost is a Professor of Pharmacology and Toxicology at the University ofUtah He is
internationally recognized as an authority on toxicology in the respiratory tract with particular
expertise on the cytochrome P450mediated mechanisms of lung injury Research in the Yost
laboratory is largely focused on the elucidation of the chemical biochemical and cellular
mechanisms of toxicity to lung tissues that are caused by exposure to environmental pollutants
There are a number of chemicals that cause selective damage to lung tissues after inhalation or
from ingestion followed by systemic exposure to circulating chemicals He is also an expert in
lung diseases druginduced toxicities and adverse drug reactions His expertise extends also to
the analysis chemistry receptor activation and biological effects including toxicities of
capsaicinoids
Dr Yost is expected to testify regarding the human bodys reaction to and toxicity of
capsaicinoids and oleoresin capsicum OC spray as well as similar compounds Dr Yost will
testify that within a reasonable degree of certainty it was Plaintiff exposure to DefendantsOC
spray products while performing her duties as a correctional officer with the Idaho Department of
PLAINTIFFSSECOND SUPPLEMENTAL EXPERT WITNESSDISCLOSURE 2
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right to disclose evidence f subsequently discovered facts or opinions thereon. Subject to and 
it t ai i  t e ri t t  s le e t t e sc e f t e testi  discl se  herei  ase  upo  
infor ation learned or docu ents acquired through the co pletion of discovery in this action, 
laintiff s t  f ll i  is l s re: 
ri i l i l sure: 
 . t, h.D. 
  r l   i l  
 fPhann  
   
 rt   t #20  
t  it ,   
(801)581-79  
r. t i   r f r  r l   i l  t t  i r it   t h.  i  
internationally recognized as an authority on toxicology in the respiratory tract, ith particular 
is     0-     j ry.     
la rat r  is lar el  f c se   t e el ci ati  f t e c e ical, i c e ical, a  cell lar 
echanis s of toxicity to lung tissues that are caused by exposure to environ ental pollutants. 
here are a nu ber f che icals that cause selective da age to lung tissues after inhalation or 
fro  ingestion followed by syste ic exposure to circulating che icals. He is also an expert in 
lung diseases, drug-induced toxicities, and adverse drug reactions. is expertise extends also to 
the a al sis, c e istr , rece t r acti ati , a  i lo ical effects (including t icities) f 
i . 
r. ost is expected to testify regarding the hu an body's reaction to, and toxicity of, 
capsaicinoids and oleoresin capsicu  (O ) spray, as ell as si ilar co pounds. r. ost ill 
testify that ithin a reasonable degree of certainty it as Plaintiffs exposure to efendant's  
s ra  products hile perfor ing er duties as a c rrectional fficer it  t e Idaho epart ent f 
P I F'S S D S TAL EXPERT ITNESS DISCLOSURE - 2 
Corrections that caused an acute and chronic adverse health response and greatly exacerbated
Plaintiffs underlying respiratory illness He will testify to how such injury takes place by
explaining the physiological and chemical mechanisms by which the compounds found in the
Defendants OC Spray products affect the relevant human tissues He will testify about the
research in this area explaining to the jury what is known of these mechanisms and physiological
responses
Dr Yosts opinions are based upon his review of records produced in discovery
including but not limited to Plaintiffs medical records NJHR 159 Hendrickson 16
Moldenhaucr DC 23 St Als 14 other experts reports Idaho Department of Correction
records IDC Records 35120 Sabre Red product information Sabre Red 12 Material Safety
Sheet 1 4 and deposition testimony Billie Major Robert Nance Bret Kimmel Daniel J
Schaffer Joshua Ovcrgaard Nicholas Doan and Sara AnneMarie Link His opinions are also
based on his professional experience education observations and the research of his own and
others including research articles entitled Increased Expression of Transient Rector Potential
Vanilloid1 in Airway Nerves of Chronic Cough and Breathtaking TRP Channels TRPAI and
TRPV1 in Airway Chemosensation and Reflex Controltrai ing
Dr Yost has not prepared any trial exhibits at this time In the event that any of those
items are prepared they will be produced in accordance with this Court June 1 2010
Scheduling Order and Rule 26a4of the Idaho Rules of Civil Procedure Dr Yosts initial
report outlines his opinions in part and is produced herewith as Exhibit A In the event further
depositions are taken in this matter Dr Yosts opinions may change based on his subsequent
review of such deposition testimony and if so this disclosure will be supplemented accordingly
PLAINTIFFSSECOND SUPPLEMENTAL EXPERT WITNESS DISCLOSURE 3
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Exhibits Dr Yost may utilize during trial may include medical records deposition
testimony deposition exhibits photographs monographs research articles material safety data
sheets package inserts and any other document or thing produced by any party or any nonparty
to this matter or which is referred to by any party in discovery or referred to in any document or
answers or response to discovery in this matter Illustrative exhibits demonstrative exhibits and
anatomical models may also be utilized Discovery is ongoing in this platter and additional
information may yet be discovered Plaintiff reserves the right to utilize other presently
unidentified exhibits at trial which will be timely disclosed at a later date
Dr Yosts qualifications are further outlined in his Curriculum Vitae and his profile and
biosketch on the University of Utah College ofPharmacy website which includes a list of his
publications all of which are attached hereto as Exhibits B and C respectively Dr Yosts
agreedupon compensation for analysis of the issues in this case and to testify is 450 per hour
A copy ofthe signed agreement is attached hereto as Exhibit D
Plaintiff reserves the right to elicit opinion testimony from any expert non retained
treating medical provider and any other witnesses disclosed in discovery or deposition by the
Plaintiff or Defendant Further Plaintiff reserves the right to supplement or amend this
disclosure and to list rebuttal experts
Supplemental Disclosure
1 Karin PachecoMDMSPH
National Jewish Hospital
1400 Jackson Street Room G 211
Denver CO 80206
303 3981520
Dr Pacheco is an Assistant Professor of Preventative Medicine and AllergyImmunology
at the University of Colorado Denver where she teaches courses regarding bioaerosols in
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Exhibits Dr. Yost ay utilize during trial ay include edical records, deposition 
testimony, deposition exhibits, photographs, monographs, research articles, material safety data 
sheets, package inserts, and any other docu ent or thing produced by any party or any non-party 
to this atter or hich is refelTed to by any party in discovery or referred to in any docu ent or 
r   r  t  t  i  t i  at er. I  xhibits, str ti  exhi i  an  
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publications, all of hich are attached hereto as Exhibits and C, respectively. r. st's 
agreed-upon compensation for analysis of the issues in this case and to testify is $450 per hour. 
   t e   s    t . 
Plaintiff reserves the right to elicit opinion testi ony fro  any expert, non-retained 
treating medical provider, and any other witnesses disclosed in discovery or deposition by the 
laintiff or efendant. urther, laintiff reserves the right to supple ent or a end this 
disclosure and to list rebuttal experts. 
le e tal isclos re: 
1. arin , .D., S  
atio l is  os ital 
400 J son , oo   11 
e ,  0206 
(30 ) 398-1520 
Dr. Pacheco is an Assistant Professor of Preventative Medicine and Allergy/Immunology 
at the University of Colorado, Denver, where she teaches courses regarding bioaerosols in 
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6 Garold S Yost PhD
Professor of Pharmacology and Toxicology
College ofPharmacy
University ofUtah
30North 1900 East 201
Salt Lake City Utah 84112
801581 7956
Attached hereto as Exhibit CC is a list of all cases in which Dr Yost has testified going
back four years Plaintiff further supplements her disclosure of Dr Yost by stating that Dr Yost
has additionally been provided for his review the deposition transcripts of Joshua Overgaard
Bret R Kimmel Nicholas Doan Daniel J Schaffer Billie Major Vols I II with errata sheets
Sara AnnMarie Link and the rough transcript from Bob Nances deposition Dr Yosts
publication have previously been disclosed along with his Curriculum Vitae
Dr Yost has not prepared any trial exhibits at this time but it is anticipated that Dr Yost
may use any materials relied upon in the drafting of his initial report as exhibits at trial
Additional exhibits Dr Yost may utilize during trial may include any of Plaintiffsmedical
records deposition testimony deposition exhibits photographs monographs and material
safety data sheets Illustrative exhibits demonstrative exhibits and anatomical models may
also be utilized Discovery is ongoing in this matter and additional information may yet be
discovered Dr Yost reserves the right to revise his opinion as additional information becomes
available
In addition to the retained experts identified herein the Plaintiff hereby discloses as
non retained treating physicians the following medical professionals who may be called upon
to testify consistent with their medical records and deposition testimony
7 JanetODonnell
William Loveland
Danny J Hendrix
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6. ar l  . st, h.D. 
r   r c l  and xi l  
l  fPhannac  
i rsit  f  
 rt   st #20  
l   ity,   
(8 )58 -79  
i1ac e  eret  as i it  is a list f all cases i  ic  r. st as testifie  i  
back four years. Plaintiff further supple ents her disclosure of r. ost by stating that r. ost 
has additionally, been provided for his review, the deposition transcripts f Joshua vergaard, 
t . i el, i las n, i l . chaf er, illie j  ls. I & II with en-ata sheets, 
Sara nn-Marie ink, and the rough transcript fro  ob ance's deposition. r. st's 
        r  . 
r. ost has not prepared any trial exhibits at this ti e but it is anticipated that r. ost 
ay use any aterials relied upon in the drafting f his initial report as exhibits at trial. 
iti al e i its r. st a  tilize ri  trial a  i cl e a  f laintiffs e ical 
records, deposition testi ony, deposition exhibits, photographs, onographs, and aterial 
  t . Illustrative exhibits, de onstrative exhibits and anato ical odels ay 
also be utilized. Discovery is ongoing in this atter and additional infor ation ay yet be 
isc ere . r. st reser es t e rig t t  re ise is i i  as a iti al i fonnati  ec es 
il l . 
In ition t  the r t i  rts ide tified r i , t e l i tiff r  is loses s 
non-retained treating physicians the follo ing edical professionals ho ay be called upon 
to te tif  siste t ith t ir e ical re rds  iti  te ti . 
7.  'Do ne l 
i lia  oveland 
anny J. e rix 
P IFF'S S  S L PERT ITNESS ISCLOS RE - 15 
Plaintiff reserves the right to elicit opinion testimony from any person duly qualified
who has been disclosed by Defendants in this action
Plaintiff reserves the right to elicit opinion testimony from any expert non retained
treating medical provider and any other witnesses disclosed in discovery or deposition by the
Plaintiff or Defendants Further Plaintiff reserves the right to supplement or amend this
disclosure and to list rebuttal experts In the event further depositions are taken in this matter
the testimony of non retained medical providers who provided care and treatment to Plaintiff
as a result of the incident at issue in this case may change based on subsequent review of such
deposition testimony and if so this disclosure will be supplemented accordingly
As discovery and Plaintiff s treatment remains ongoing there may be other persons not
identified herein who may fall within the scope of this disclosure that are not yet known Ifsuch
persons are identified Plaintiffreserves the right to seasonably disclose such persons and to call
them as witnesses at the time oftrial
Any of the persons identified above may be called for purposes of rebuttal andor
impeachment Plaintiff also reserves the right to seasonably supplement this list with other
rebuttal andor impeachment witnesses
Plaintiff reserves the right to alter amend or supplement this disclosure as the Idaho
Rules of Civil Procedure and the Court may allow
Second Supplemental Disclosure
Plaintiff further supplements her disclosure ofDr Yost by stating that Dr Yost has relied
on the following articles and the articles cited therein in forming his expert opinion
I Hamyman Mark Kam Peter CAPSAICIN A REVIEw OF ITS PHARMACOLOGY
AND CLINICAL APPLICATION Vol 19 Journal Current Anesthesia and Critical Care pp 338343
2008
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laintiff reserves the right to elicit opinion testi ony fro  any person, duly qualified, 
  b  di cl d by f t  i  t i  action. 
laintiff reser es t e ri t to elicit pi i  testi  fr  any expert, non-retai e  
treating edical provider, and any other itnesses disclosed in discovery or deposition by the 
laintiff or efendants. urther, laintiff reserves the right to supple ent or a end this 
disclosure and to list rebuttal experts. In the event further depositions are taken in this atter, 
t e testi  f -retai e  e ical r i ers  r i e  care a  treat e t t  lai tiff 
as a result of the incident at issue in this case ay change based on subsequent revie  of such 
deposition testi ony, and if so, this disclosure ill be supple ented accordingly. 
s discovery and Plaintiffs treat ent re ains ongoing, there ay be other persons not 
i e tified erei   a  fall it i  t e sc e f t is iscl s re t at are t et n. If s c  
persons are identified, Plaintiff reserves the right to seasonably disclose such persons and to call 
t e  as itnesses at t e ti e f trial. 
ny of the persons identified above ay be called for purposes of rebuttal and/or 
i pe . laintiff also reserves the right to seasonably supple ent this list ith other 
t  /or peach ent itnes . 
Plaintiff reserves the right to alter, a end, or supple ent this disclosure as the Idaho 
ules f i il r ce re a  t e rt a  all . 
Se nd ple ental isclos : 
Plaintiff further supplements her disclosure of Dr. Yost by stating that Dr. Yost has relied 
on the following articles and the articles cited therein in for ing his expert opinion: 
1. a , ar  & a , eter, I I :  I W F ITS P COLO  
AND CLINICAL ApPLICATION, Vol. 19, Journal Current Anesthesia and Critical Care, pp. 338-343 
(20 ). 
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2 Alawi Khadija Keeble Julie THE PARADOXICAL ROLE OF TRPV 1 RECEPTOR IN
INFLAMMATION Vol 125 Pharmacology and Therapeutics pp 189195 2010
3 CAReilly DJCrouch GS Yost and AFatah Determination of Capsaicin
NONIVAMIDE AND DIHYDROCAPSAICIN IN BLOOD AND TISSUE BY LIQUID CHROMATOGRAPHY
TANDEM MASS SPECTROMETRY J Anal Toxicol 26 31319 2002
4 CA Reilly JL Taylor DL Lanza BA Carr DJ Crouch and GS Yost
CAPSAICINOIDS CAUSE INFLAMMATION AND EPITHELIAL CELL DEATH THROUGH ACTIVATION OF
VANILLOID RECEPTORS Tox Sci7317081 2003
5 CA Reilly and GS Yost STRUCTURAL AND ENZYMATIC PARAMETERS THAT
DETERMINE ALKYL DEHYDROGENATIONHYDROXYLATION OF CAPSAICINOIDS BY P450 ENZYMES
DrugMetab Dispos 33 530536 2005
6 CA Reilly ME Johansen DL Lanza J Lee JO Lim and GS Yost
CALCIUM DEPENDENT AND INDEPENDENT MECHANISMS OF CAPSAICIN RECEPTOR TRPV1
MEDIATED CYTOKINE PRODUCTION AND CELL DEATH IN HUMAN BRONCHIAL EPITHELIAL CELLS
J Biochem Molec Toxicol19266752005
7 MEJohansen CAReilly and GSYost TRPV1 ANTAGONISTS ELEVATE CELL
SURFACE POPULATI NS AND RECEPTOR FUNCTION TO EXACERBATE TRPVIMEDIATED
TOXICITIES IN HUMAN LUNG EPITHELIAL CEIIS Toxicol Sci 89 278 286 2006
8 CAReilly andGSYost METABOLISM OF CAPSAICINOIDS BY P450 ENZYMES A
REVIEW OF RECENT FINDINGS ON REACTION MECHANISMS B10ACTIVATION AND
DETOXIFICATION PROCESSES DrugMetab Rev386857062006
9 KCThomasAS Sabnis MEJohansenDL Lanza PJMoosGS Yost and
CA Reilly TRPV1 AGONISTS CAUSE ENDOPLASMIC RETICULUM STRESS AND CELL DEATH IN
HUMAN LUNG CELLS J Pharmacol Exp Ther 321 830838 2007
10 BF Bessac and SEJordt BREATHTAKING TRP CHANNELS TRPAI AND TRPVI
IN AIRWAY CHEMOSENSATION AND REFLEX CONTROL Physiology 23 360370 2008
11 DAGroneberg A Niimi Q Thai Dinh B Cosio Mark Hew A Fischer and
KF Chung INCREASED EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID1IN
AIRWAY NERVES OF CHRONIC COUGH American Journal of Respiratory and Critical Care
Medicine Vol 1702768 2004
12 JE Mitchel AP Campbell NE New LR Sadofsky JA Kastelik SA
Mulrennan SJ Compton and AH Monce EXPRESSION AND CHARACTERIZATION OF THE
INTRACELLULAR VANILLOID RECEPTOR TRPV1 IN BRONCHI FROM PATIENTS WITH CHRONIC
COUGH Experimental Lung Research 31295306 2005
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2. lawi, ij  & ble, ulie, T  PARADOXICAL ROL   l EPTOR I  
I L I , ol. 125, r c l y  herapeutics, p. 1 -1  (2 10). 
. .A eilly, J. r uch, .S. st,  A atah, ter i ti  f apsaicin, 
NIVA I E,  I AI I  I    I   I I  -
  SPECTROMETRY,  nal. oxicol., 6,313-  (2 02). 
4. .A eil y, .L. yl r, .L. nza, .A n, .l rouch, an  .S. st, 
    PITHELIAL    I   
I I  , ax. ci., 3, 170- 81 (2 3). 
5. .A il   .S. st, T U T   Z I    
I   I /HYDR I   I I I    , 
 t b. s. , -5  (2 5). 
6. .A eilly, .E. Johansen, .L. anza, J. ee, J.- . i , and .S. ost, 
I - P   I P  IS S F PS I I  P  (T Vl)-
I  I  I     I   I  I I  , 
 . c. xicol. 9,266-275 (2 5). 
. .E. , .A. ill ,  .S. t, l IS    
 OPULATIONS   I    PVI-MEDI  
T ICITIES IN  L  EPIT ELI L ELLS, Toxicol. Sci. 89,278-286 (2006). 
8. .A ill   .S. t,  AI I    :  
I       E IS S, IO- TI TI ,  
l f I  , r  t . . 8, 685-706 (2 6). 
. .C. , S. i , .E. , .L. , J. s, .S. t,  
.A. il y, l IS  S  I   S      
  , J r c l. x . er. 321, 830-838 (2007). 
10. .F. essac  .B. t, I  P : 1   
I  I  S S I   F  , hysiology, 23,360-370 (2008). 
. .A Groneberg, A Niimi, Q. Thai Dinh, B. Cosio, ark Hew, A Fischer, and 
.F. , S  P       LOID-1  
AIR AY NERVES OF CHRONIC COUGH, A erican Journal of Respiratory and ritical are 
e , . 70, 12 6-1280 (20 4). 
. J.E. itchel, .P. a pbell, .E. e , L.R. Sadofsky, J.A. astelik, S.A 
ulren , J. t , a  H. ri , PRES I  ND I TIO   E 
I T ELL L  ANILLOID E EPT R (TRP l) IN I FR  P TIE TS ITH I  
, xpe imental Lung r , 1 :295-306 (20 5). 
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13 T Higenbottam CHRONIC COUGH AND COUGH REFLEX IN COMMON LUNG
DISEASES PulmonaryPharmacology Therapeutics 15241247 2002
14 Pierangelo Geppetti Serena Materazzi Paola Nicoletti THE TRANSIENT
RECEPTOR POTENTIAL VANILLOID 1 ROLE IN AIRWAY INFLAMMATION AND DISEASE European
Journal ofPharmacology 533207214 2006
15 WJ Meggs NEUROGENIC INFLAMMATION AND SENSITIVITY TO ENVIRONMENTAL
CHEMICALS Environ Health Prospect 101234238 1993
16 John J Adcock TRPV 1 RECEPTORS IN SENSITIZATION OF COUGH AND PAIN
REFLEXES Pulmonary Pharmacology Therapeutics226570 2009
17 LuYuan Lee and Qihai Gu ROLE OFTRPV 1 IN INFLAMMATIONDUCEDAIRWAY
HYPERSENSITIVITY Current Opinion in Pharmacology9243249 2009
18 K Alawi and J Keeble THE PARADOXICAL ROLE OF THE TRANSIENT RECEPTOR
POTENTIAL VANILLOID 1 RECEPTOR IN INFLAMMATION Pharmacology and Therapeutics
12581195 2010
Plaintiff further supplements this disclosure by stating that copies of all of the above
listed articles have previously been produced in discovery
DATED this 25th day of July 2011
JOl
ERICB SWARTZ
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13. . i bottam, CH ONI  COUGH  OUGH REFLEX IN COM   
I ES, ul onary r l  & Therape,utics, 15:241-247 (2002). 
14. i r ngelo ep etti, Serena aterazzi, aola icoletti, T  T SI T 
E EPT  POTENTIAL  ILL I  1: OLE I  I  I FL TI   ISE SE, uropean 
J r l f r c l y 33 :207-2  (2 06). 
15. .1. s, I    ENSITIVI  TO I  
E I A , nviron. alt  r pect, 01 :234-2  (1 93). 
6.  1. ck, I  I  ENSITIZ     AI  
, l r  l  & herapeutics, 2:65-7  (2 09). 
17. -Yua    i i u,   IIN NFLAMMATION-INDUCED I  
SENSITIVIT , r t i i  i  r acology, :243-24  (2 09). 
8. . la i and J. eeble, T E PARADOXICAL ROLE OF THE TR SIE T RECEPTOR 
POTENTIAL V ANILLOID 1 RECEPTOR IN INFLAMMATION, Pharmacology and Therapeutics, 
25:181-19  (2 0). 
Plaintiff further supple ents this disclosure by stating that copies of all of the above 
list  rti l   r i l   r  i  i ry. 
 s    l , . 
 .  
P 'S SE D SUP E L EXPERT ITNESS DISCLOSURE .. - 19 
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this ZCR day of July 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
IMessenger Del
Email cburkef
DARWINOV
ERIC B SWARTZ
lawcom
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ERTI I   E I  
I E E  E  TJF  that on this e day of July, 2011, a hue and correct copy of 
t  f r i  d t s s r   t  f ll i  i dividual(s)  t  t  i di ated: 
li  .  
     
 . mm  tr et, i  9  
i , J   
[ ] .S. il 
[ ] x: 3 -  
,nMesseng r eliver:..<-__ 
'[ ] a~burk . greenerlaw .com 
C 
/ 
ARWI 
 .  
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EXHIBITG
TOAFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOST PHD
EXHIBIT G
TO AFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTYOF ADA
BILLIE JO MAJOR and individual
Case No CV PI 1003515
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
PLAINTIFFSFIFTH SUPPLEMENTAL
ANSWERS AND RESPONSES TO
DEFENDANT FIRST SET OF
INTERROGATORIES AND REQUESTS
FOR PRODUCTION OF DOCUMENTS
Defendant
COMES NOW the Plaintiff by and through her counsel of record Jones Swartz PLLc
and supplements her Answers and Responses to Defendants First Set of Interrogatories and
Requests for Production ofDocuments as follows
PRELIMINARY STATEMENT
The following Supplemental Answers and Responses are based upon a reasonable inquiry
and diligent search by the Plaintiff but reflect only the current state ofPlaintiffsunderstanding
and belief respecting the matters about which inquiry was made It is anticipated that further
discovery independent investigation and consultation with experts may supply additional facts
PLAINTIFFSFIFTH SUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANTSFIRST SET OF
INTERROGATORIES AND REQUESTS FOR PRODUCTION OF DOCUMENTS I
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ES  the Plaintiff, by and through her counsel of record, Jones & rt  PJ. C, 
and supple ents her ns ers and Responses to efendants' First Set of Interrogatories and 
ests f r r ti   c e ts  f ll : 
IN   
The following Supplemental Answers and Responses are based upon a reasonable inquiry 
and diligent search by the Plaintiff, but reflect only the current state of Plaintiffs understanding 
and belief respecting the atters about hich inquiry as ade. It is anticipated that further 
isc er , i de e e t in esti ati , a  c s ltati  ith e erts a  s l  a iti al facts, 
IFF'S IF   NS ERS    ENDANT'S IRST   
I TERR TORIES  E ESTS   F E TS - I 
add meaning to known facts and establish entirely new factual conclusions and legal
contentions all of which may lead to substantial additions to modifications of and variations
from the Supplemental Answers and Responses herein The following Supplemental Answers
and Responses are therefore made without prejudice to the Plaintiffsright to produce evidence
of subsequently discovered facts which the Plaintiffmay then have available
CONTINUING OBJECTIONS
Nothing herein contained is intended to be nor should be construed as a waiver of any
attorneyclient privilege work product protection trade secrets proprietary information or the
right of privacy and to the extent the Interrogatories and Requests for Production may be
construed as calling for the disclosure of information protected by such privileges andor
doctrines a continuing objection to each and every Interrogatory and Request for Production is
hereby imposed
INTERROGATORIES
INTERROGATORY NO 3 Identify each person whom You expect or intend to
testify as an expert at a trial of this matter and with respect to each such person state the
following
A The substance and summary of all facts and opinions about which each expert
is expected to testify
B Identify each fact Document and all data pursuant to Rule 705IRE upon
which each expert intends to rely in rendering any opinions at a trial of this matter and
C Identify all information and Documents required to be disclosed by expert
witnesses pursuant to Rule26aIdaho Rules ofCivil Procedure
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add eaning to kno n facts, and establish entirely ne  factual conclusions and legal 
t nti s, l   i    t  tanti l i  t , i  f,   
fro  the Supple ental ns ers and esponses herein. he follo ing Supple ental ns ers 
a  es ses are t eref re a e it t rej ice t  t e laintiffs ri t t  r ce e i e ce 
 equentl      l intiff    vailable. 
  
othing herein contained is intended to be nor should be construed as a aiver of any 
attomey/c1ient privilege, ork-product protection, trade secrets, proprietary infonnation, or the 
right of privacy, and to the extent the Interrogatories and equests for Production ay be 
construed as calling for the disclosure of infor ation protected by such privileges and/or 
doctrines, a continuing objection to each and every Interrogatory and equest for Production is 
 . 
S 
E  . : Identify each person ho  ou expect or intend to 
testif  as a  e ert at a trial f t is atter, a  it  res ect t  eac  s c  ers , state t e 
f ll i : 
A. The substance and su ary of all facts and opinions about which each expert 
s e te  t  t tif ; 
B. Identify each fact, Document and all data, pursuant to Rule 705, I.R.E., upon 
i   rt i te  t  r l  i  r ri   i ions t  trial ft i  tt r;  
c. Identify all infor ation and ocu ents required to be disclosed by expert 
itnesses rs a t to le 6(a)(2), Idaho les f i il r ce re. 
P I I F'S IF  S L NS ERS  ESP SES  NDANT'S IRST   
I TE ROGATORIES ND E UESTS  RODUCTION  E TS -  
ANSWER TO INTERROGATORY NO 3 Plaintiff at this point have not
determined who their expert may be at trail but reserve the right to identify them at a later date
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 3 Plaintiff supplements
her answer to Interrogatory No 3 by stating as follows
Garold S Yost
Professor ofPharmacology and Toxicology
College ofPharmacy
University ofUtah
A It is Professor Yosts opinion that people with respiratory disease are up to 30
times more sensitive to capsaicin induced cough Plaintiffs exposure to Saber Red caused acute
adverse health responses and exacerbated her underlying respiratory diseases
B Please see accompanying documents marked as Bates Nos YOST 00001 50
C Please see accompanying documents marked as Bates Nos YOST 00001 50
SECOND SUPPLEMENTAL ANSWER TO INTERROGATORY NO 3 Plaintiff
further supplements her answer to Interrogatory No 3 by stating as follows
Karin A PachecoMDMSPH
National Jewish Health
1400 Jackson Street
Denver CO 80206
303 3884461
A It is Dr Pachecos opinion that Ms Majors chronic medical respiratory condition
was caused by her occupational exposure to Oleoresin Capsicum spray while working as a
correctional guard for the Idaho Department of Correction Dr Pacheco is expected to testify
regarding Ms Major medical condition and her perceived cause ofthat condition
B See documents produced herewith marked as Bates Nos PACHECO 00019 25
PLAINTIFFSFIFTH SUPPLEMENrAL ANSWERS AND RESPONSES TO DEFENDANT FIRST SET OF
INTERROGAORIESANDREQUESTS FOR PRODUCTION OF DOCUMENTS 3
001449
   . : l intif , t  int,   
t r i   t ir rt   t tr il t r r  t  ri t t  i tif  t  t  l t r t . 
   I  . : laintiff supple ents 
er a s er t  I terr at r  .   stati  as f ll s: 
 . ost 
r fe r  r l   i l  
lle    
   
. It is r f ss r st's i i  t t le it  r s ir t r  iseas  r   t   
ti  r  iti  t  saicin-i  h. l i tiffs r  t  r   t  
a erse ealt  res nses a  e acer ate  er erl i  res irat r  iseases. 
. Please see acco panying docu ents arked as ates os. ST 00001-50. 
. lease see acco panying docu ents arked as ates os.  00001-50. 
     . : l i ti  
f rt r l t  r r t  I t rr t r  .   t ti   f ll s: 
i  . checo, .D.,  
   
   
,   
- -446  
. It is r. checo's i i  t t s. jor's r i  i l r spiratOlY iti  
was caused by her occupational exposure to Oleoresin Capsicum spray while working as a 
con'ectionaI guard for the Idaho epart ent f OlTection. r. acheco is expected to testify 
regarding s. ajor's edical condition and her perceived cause of that condition. 
. ee c e ts r ce  ere it  ar e  as ates s.  19- . 
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TE ROGATORIES  ESTS    S -  
further still answers Interrogatory No 3 by referring the Defendant to documents produced
herewith marked as Bates Nos Purswell 000001 7
THIRD SUPPLEMENTAL ANSWER TO INTERROGATORY NO 3 Plaintiff
further supplements her Answer to Interrogatory No 3 by stating that in addition to the articles
previously identified being relied upon by Dr Yost he will also be relying on the following
articles in the rendering of his expert opinion
1 JE Mitchel AP Campbell NE New LR Sadofsky JA Kastelik SA
Mulrennan SJ Compton and AH Morice EXPRESSION AND CHARACTERIZATION OF THE
INTRACELLULAR VANILLOID RECEPTOR TRPVI IN BRONCHI FROM PATIENTS WITH CHRONIC
COUGH Experimental Lung Research 31295306 2005
2 T Higenbottam CHRONIC COUGH AND COUGH REFLEX IN COMMON LUNG
DISEASES Pulmonary Pharmacology Therapeutics 15241247 2002
3 Pierangelo Geppetti Serena Materazzi Paola Nicoletti TIME TRANSIENT
RECEPTOR POTENTIAL VANILLOID 1 ROLE IN AIRWAY INFLAMMATION AND DISEASE European
Journal ofPharmacology 533207214 2006
4 W J Meggs NEUROGENIC INFLAMMATONAND SENSITIVITY TO ENVIRONMENTAL
CHEMICALS Environ Health Prospect 101234238 1993
5 John J Adcock TRPV 1 RECEPTORS IN SENSITIZATION OF COUGH AND PAIN
REFLEXES Pulmonary Pharmacology Therapeutics 226570 2009
6 LuYuan Lee and Qihai Gu ROLE orTRPVI IN INFLAMMATION INDUCED AIRWAY
HYPERSENSITIVITY Current Opinion in Pharmacology9243249 2009
7 K Alawi and J Keeble THE PARADOXICAL ROLE OF THE TRANSIENT RECEPTOR
POTENTIAL VANILLOID 1 RECEPTOR IN INFLAMMATION Pharmacology and Therapeutics 125
181 195 2010
Plaintiff further supplements her answer to this Interrogatory by referring Defendant to
documents produced herewith marked as Bates Nos NEGRON 000001423
INTERROGATORYNO 4 Identify each exhibit which You intend to offer into
evidence at a trial ofthis matter
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further supple ents her ns er to IntclTogatory o. 3 by stating that in addition to the articles 
previously identified being relied upon by r. ost, he ill also be relying on the follo ing 
articles in the rendering of his expert opinion: 
. J.E. it l, .P. bell, .E. , .R. fsk , J.A. stelik, .A. 
ulrennan, J. o pton, and .H. orice, E PRESSI  AND C R CTERIZ TI  OF T E 
 I LOI   (T V1) I     I   
, xperi ental ung esearch, 31 :295-306 (2005). 
. T. Higenbottam, CHRONIC COUGH AND COUGH REFLEX IN COMMON LUNG 
DISEASES, Pulmonary Pharmacology & uti s, 5:241-247 (2 2). 
. Pierangelo etti, r  t r zzi, l  i letti, H  I  
 I  I I  :  I  I  I I   I E, e  
Journal f har acology 533:207-214 (2006). 
. . J. e s, I  I FLAMMATION  S SI I I   I  
I , ir n. fl lt  r s ct, 01 :234-23  (1 3). 
.  . ck, l   I I      
, l r  r l  & r utics, 2:65-70 (2 9). 
. Lu-Yuan Lee and ihai u, LEOFT P l IN INFLA ATION-INDUCED IR  
PERSE SITIVIT , urrent pinion in Phar acology, 9:243-249 (2009). 
. . la i and J. eeble, T E P R IC L R LE OF T E TR SIE T RECEPT R 
I  I I    I  I F I , r c l y  er eutics, 5: 
181-195 (2010). 
l i tiff f rt r l t  r r t  t i  I t lT t r   r f rri  f t t  
docu ents produced here ith arked as ates os.  0000014-23. 
 . : I e tif  eac  ex i it ic   i te  t  ffer i t  
   l   tt r. 
LA NTIF 'S  L      FENDANT'S    
INTE ROGATORIE     I    -  
SECOND SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION
NO 47 sic 481 Plaintiff further supplements her Response to Request for Production No 47
sic 48 by referring Defendant to documents produced herewith marked as Bates Nos MAJOR
0000014
THIRD SUPPLEMENTAL RESPONSE TO REOUEST FOR PRODUCTION
NO 47 sic 481 Plaintiff supplements her Response to Request for Production No 47 sic 48
by referring Defendant to documents previously produced marked as Bates Nos MAJOR
000056145 Plaintiff further supplements her Response to Request for Production No 47 sic
481 by referring Defendant to documents produced herewith marked as Bates Nos MAJOR
0000146290
DATED this 25 day of July 2011
OBJECTIONS IF
JONES SWAR
DARWIN L UVEI
ERIC B SWARTZ
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. 7 [sic; J: l i tiff furth r s le ents r es nse t  t f r r ti  . 7 
[sic; ]  referrin  efe a t to c e ts r ce  ere it  ar e  as ates s. J  
00 01-40. 
IR     Q    
.  [sic; J: l i tiff s le ents r s s  t  e st f r r ti  .  [si ; ] 
by referring efendant to docu ents previously produced arked as ates os. J  
000056-145. laintiff further supple ents her esponse to equest for roduction o. 47 [sic; 
48] by referring Defendant to docu ents produced herewith arked as Bates Nos. AJOR 
-2 . 
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 26O day of July 2011 a true and correct copy of
the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Yax 3192601
rfMessenger Delivery
Email cburkiq@gm
DARWINLf
ERIC B SWARTZ
com
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      .0  f l , 1,  tr   rr t  f 
the foregoing docu ent as served on the follo ing individual(s) by the ethod indicated: 
ist  . e 
     
 .  t,   
,   
[ ] .S. il [ ] Jax: 319-2601 
vr e   
[ ] ail: kegreen~~law.com 
 . RSON 
IC .  
L I TIFF'S       FENDANT'S    
I IES    fI    -  
EXHIBITH
TOAFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
EXHIBIT H
TO AFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWART7 PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 489 8989
Facsimile 208 4898988
Email darwin@jonesandswartzlawc m
eric@jonesandswartzl wc
Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Case No CV PI 1003515
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
PLAINTIFFSSUPPLEMENTAL
ANSWERS AND RESPONSES TO
DEFENDANT SECOND SET OF
INTERROGATORIES AND REQUESTS
FOR PRODUCTION OFDOCUMENTS
Defendant
COMES NOW the Plaintiff by and through her counsel of record Jones Swartz PLLC
and supplements her Answers and Responses to Defendants Second Set of Interrogatories and
Requests for Production ofDocuments as follows
PRELIMINARY STATEMENT
The following Supplemental Answers and Responses are based upon a reasonable inquiry
and diligent search by the Plaintiff but reflect only the current state of Plaintiffsunderstanding
and belief respecting the matters about which inquiry was made It is anticipated that further
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSESTO DEFENDANTSSECOND SETOF
INTERROGAORIESAND REQUESTS FOR PRODUCTION OF DOCUMENTS 1
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r i  rson,  #588  
 . artz,  #639  
 & Z  
 . r l  ri , i   [8 2] 
ost ffice ox 7808 
i e,   
l hone: (2 ) -8  
csimile: (2 ) -898  
ail: rwin@jonesandswartzlaw.com 
ric@jonesa dsw rtzlaw.com 
  laintif , i    
       I I    
   ,        
I I   ,  i i i l, 
laintif , 
vs. 
I  I  ORATI N, 
 is  ti , 
nt. 
 .    
I ... AINTIF 'S PL  
S S    
ENDANT'S    
IES   
    
ES  the Plaintiff, by and through her counsel of record, Jones & S artz PLLC, 
and supplements her Answers and Responses to Defendants' Second Set of Interrogatories and 
ests    ,  : 
  
The following Supplemental Answers and Responses are based upon a reasonable inquiry 
and diligent search by the Plaintiff, but reflect only the current state of Plaintiffs understanding 
and belief respecting the atters about hich inquiry as ade. It is anticipated that further 
P I I F'S L NS ERS   O ENDANT'S   F 
I TE ROGATORIES ND E UESTS  I   E TS -  
discovery independent investigation and consultation with experts may supply additional facts
add meaning to known facts and establish entirely new factual conclusions and legal
contentions all of which may lead to substantial additions to modifications of and variations
from the Supplemental Answers and Responses herein The following Supplemental Answers
and Responses are therefore made without prejudice to the Plaintiffsright to produce evidence
of subsequently discovered facts which she may then have available
CONTINUING OBJECTIONS
Nothing herein contained is intended to be nor should be construed as a waiver of any
attorneyclient privilege work product protection trade secrets proprietary information or the
right of privacy and to the extent the Interrogatories and Requests for Production may be
construed as calling for the disclosure of information protected by such privileges andor
doctrines a continuing objection to each and every Interrogatory and Request for Production is
hereby imposed
INTERROGATORIES
INTERROGATORY NO 17 Please identify and sic all counselors psychologists
psychiatrists neuropsychologists or other similar health care providers which you have consulted
with seen or been treated by in the preceding twenty20 years
ANSWER TO INTERROGATORY NO 17 Plaintiff objects to Interrogatory No 17
on the grounds that it is overly broad unduly burdensome and seeks information not reasonably
likely to lead to the discovery of admissible evidence Plaintiff further objects on the grounds
that the interrogatory is duplicative of discovery requests previously served upon the Plaintiff to
which she has fully responded Defendant has also taken thePlaintiffsdeposition wherein many
questions were propounded to the Plaintiff exploring all of her medical treatment Interrogatory
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TODEFENDANT SECOND SET OF
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i ry, i t i ti ti ,  lt ti  it  rts  l  iti l f ts, 
add eaning to kno n facts, and establish entirely ne  factual conclusions and legal 
t ti , ll  i   l  t  t ti l iti  t , i ications f,  i ti  
fr  t e le e tal ns ers a  es ses erein. e f ll i  le e tal s ers 
and esponses are therefore ade ithout prejudice to the laintiffs right to produce evidence 
f subsequently discovered facts hich she ay then have available. 
 S 
othing herein contained is intended to be nor should be construed as a aiver of any 
tt m /clie t ri il , r - r t r t cti n, tr  r t , r ri t r  i f nn ti n, r t  
right f privacy, and to the extent the Inten'ogatories and equests for roduction ay be 
c str e  as calli  f r t e iscl s re f i f nnati  r tecte   s c  ri ileges a /or 
ctri es, a c ti i  jecti  t  eac  a  e er  I terr at r  a  e est f r r cti  is 
r  i . 
E IES 
I TE T  . 17: Please identify and [sic] all counselors, psychologists, 
psychiatrists, neuropsychologists or other si ilar health care providers hich you have consulted 
it ,  r  tr t   i  t  r i  t t  (2 ) r . 
S   I  . 17: laintiff objects to Inten'ogatory o. 17 
 t e r wl s t at it is erl  r ad, l  r e s e a  see s i f nnati  t reas a l  
li el  t  lea  t  t e isc er  f a issi le e i e ce. lai tiff f rt er jects  t e r s 
that the interrogatory is duplicative of discovery requests previously served upon the Plaintiff, to 
i    f ll  r d. f t  l  t  t  l intiffs iti  r i   
sti s r  r  t  t  l i tiff l ri  ll f r i l tr t t. I t rr t r  
LAINTIF 'S  S E     ENDANT'S    
I I     I   S -  
No 17 appears to be served for the purpose of harassment Without waiving said objections
Plaintiff answers Interrogatory No 17 by referring the Defendant to Plaintiffsdeposition
testimony medical records obtained directly from medical providers by the Defendant pursuant
to service of subpoenas Plaintiff answers to DefendantsInterrogatory Nos 1 7 8 and 10
Plaintiffsresponses to DefendantsRequest for Production Nos 1 through 13 and Plaintiffs
expert disclosures
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 17 Plaintiff
supplements her Answer to Interrogatory No 17 by stating that to the best of her recollection
she has not seen or treated with any counselors psychologists psychiatrists neuropsychologists
or other similar mental health care providers in the last twenty 20 years other than Dr Roberto
Negron
In July 2003 Plaintiff lost her job at SCP Global Technologies Following this event
Plaintiff remained unemployed and she spent much of the next several months at her
Grandfathers house aiding in the renovation of his house Plaintiff often referred to this time
she spent at her Grandfathershouse and the work she performed at his house as her therapy
PIaintiff further understands that during Dr Negrons deposition he testified that the
Plaintiff had mentioned the name of one or two counselors that she had seen Plaintiff believes
that Dr Ncgron was mistaken
INTERROGATORY NO 21 If your responses to Requests for Admission Nos 1 2 or
3 are anything other than unqualified admissions please identify with particularity each and
every fact Document statement example study report andor other evidence that you contend
forms the basis for each such response
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.   t     t  s   nt. it t i i  i  j ti s, 
laintiff ans ers Intenogatory o. 17 by referring the efendant to laintiffs deposition 
t sti y; i l r r s t i  ir tl  fr  i l r i ers  t  f t rs t 
to service of subpoenas; Plaintiffs ans ers to efendant's IntelTogatory os. 1, 7, 8, and 10; 
Plaintiffs responses to efendant's equest for Production os. 1 through 13; and Plaintiffs 
e ert iscl s res. 
    . : i  
supple ents her ns er to Interrogatory o. 17 by stating that, to the best of her recollection, 
  t   t t  it   l rs, l i t , i tri t , r l i t  
or other si ilar ental health care providers in the last t enty (20) years other than r. oberto 
egron. 
I  J l  , l i tiff l st r j  t  l l l i s. ll i  t is t, 
l i tiff r i  l e    t   t  t r l t  t r 
dfather's ,       . l intiff      
s e s e t at er randfather's se a  t e r  s e erf r e  at is se as er "therapy." 
l i tiff fmi r rst s t t ri  r. gron's siti n,  t stifie  t t t  
i ti    e          . l i ti  es 
that r. egron as istaken. 
I  . : If r r s s s t  sts f r issi  s. ,  r 
3 are anything other than unqualified ad issions, please identify ith particularity each and 
every fact, ocu ent, state ent, exa ple, study, report, and/or other evidence that you contend 
for s the basis for each such response. 
I TIFF'S      ENDANT'S    
I TE T IES  E ESTS F  P TI  F E TS - 3 
ANSWER TO INTERROGATORY NO 21 PIaintiff answers Interrogatory No 21 by
stating the following articles have helped form the basis of her responses to Request for
Admission Nos 1 2 and 3
1 Hamyman Mark Kam Peter CAPSAICIN A REVIEW OF ITS PHARMACOLOGY
AND CLINICAL APPLICATION Vol 19 Journal Current Anesthesia and Critical Care pp 338 343
2008
2 Alawi Khadija Keeble Julie THE PARADOXICAL ROLE OF TRPVI RECEPTOR IN
INFLAMMATION Vol 125 Pharmacology and Therapeutics pp 189195 2010
3 CA Reilly DJ Crouch GS Yost and A Fatah DETERMINATION OF
CAPSAICIN NONIVAMIDE AND IIIYDROCAPSAICIN IN BLOOD AND TISSUE BY LIQUID
CHROMATOGRAPHYTANDEM MASS SPECTROMETRY J Anal Toxicol 26 313319 2002
4 CA Reilly JL Taylor DL Lanza BA Carr DJ Crouch and GS Yost
CAPSAICINOIDS CAUSE INFLAMMATION AND EPITHELIAL CELL DEATH T14ROUGH ACTIVATION OF
VANILLOID RECEPTORS Tox Sci 73 170181 2003
5 CA Reilly and GS Yost STRUCTURAL AND ENZYMATIC PARAMETERS THAT
DETERMINE ALKYL DEHYDROGENATIONHYDROXYLATION OF CAPSAICINOIDS BY P450 ENZYMES
DrugMetab Dispos 33 530536 2005
6 CA Reilly ME Johansen DL Lanza J Lee JO Lim and GS Yost
CALCIUM DEPENDENT AND INDEPENDENT MECHANISMS OF CAPSAICIN RECEPTOR TRPVI
MEDIATED CYTOKINE PRODUCTION AND CELL DEATH IN HUMAN BRONCHIAL EPITHELIAL CELLS
J Biochem Molec Toxicol 19266752005
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S   I  . 21: Plaintiff ans ers Interrogatory o. 21 by 
stating the fol1o ing articles have helped foml the basis f her responses to equest for 
s  . ,   : 
. n,  & , ter, SAICIN:      
AND CLINICAL ApPLICATION, ol. 19 Journal urrent Anesthesia and ritical are, pp. 338-343 
(2 8). 
. la i, a ija & ee le, Julie,  I    l  I  
I I , l. , l   r eutics, . -19  (2 0). 
. .A. il , .J. , .S. t,  A t h,   
AI I ,  I  I ,  DU-IYDROCAPSAICI  I    I   I I  
r-I HY-  S  ECTROMETRY,  al. xieol., , -31  (2 02). 
4. .A Reilly, J.L. Taylor, .L. Lanza, B.A. Carr, J. rouch, and .S. ost, 
I S SE I   I LI    H    
 ANILL I  , . Ci., , -181 (20 3). 
5. .A. ill   .S. t,   I    
ETER I E L L EHYDROGE ATION/HYDR L TI  F C PS ICI I S B  P450 E Z ES, 
r  t . is s. , -53  (2 5). 
6. .A. eilly, .E. Johansen, .L. Lanza, J. Lee, J.-O. Li , and .S. ost, 
I - P   I EPE E T IS S F PS I I  P  (T Vl)-
EDIA TED CYTOKINE PRODUCTION AND CELL DEATH IN HU AN BRONCHIAL EPITHELIAL CELLS, 
J. i c e . lec. xieo!. 9,266-275 (20 5). 
LAINTIFF'S      ENDANT'S    
IES      S -  
7 MEJohansen C A Reilly and GSYostTRPV1 ANTAGONISTS ELEVATE CELL
SURFACE POPULATIONS AND RECEPTOR FUNCTION TO EXACERBATE TRPVIMEDIATED
TOXICITIES IN HUMAN LUNG EPITHELIAL CELLS Toxicol Sci 89 27886 2006
8 CAReilly and GS Yost METABOLISM OF CAPSAICINOIDS BY P450 ENZYMES A
REVIEW OF RECENT FINDINGS ON REACCION MECHANISMS BIOACTIVATION AND
DETOXIFICATION PROCESSES DrugMetab Rev 38 685706 2006
9 KC Thomas ASSabnisMEJohansenDLLanza PJ MoosGSYost and
CA Reilly TRPV1 AGONISTS CAUSE ENDOPLASMIC RETICULUM STRESS AND CELL DEATH IN
HUMAN LUNG CELLS J Pharmacol Exp Ther 321 830838 2007
10 BF Bessac andSEJordt BREATHTAKING TRP CHANNELS TRPAI AND TRPVI
IN AIRWAY CHEMOSENSATION AND REFLEX CONTROL Physiology 23 360370 2008
11 DAGroneberg A Niimi Q Thai Dinh B Cosio Mark Hew A Fischer and
KF Chung INCREASED EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 IN
AIRWAY NERVES OF CHRONIC COUGH American Journal of Respiratory and Critical Care
Medicine Vol 170 1276 1280 2004
Plaintiff further answers this Interrogatory by referring Defendant to documents produced
herewith marked as Bates Nos ARTICLES 000001 100 and documents previously produced
marked as Bates Nos TRPV 00001 5 and TRPA 00001 12
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 21 Plaintiff
supplements her answer to Interrogatory No 21 by stating that the following articles and the
articles cited therein have also helped to form the basis of her responses to Request for
Admission Nos 1 2 and 3
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANT SECOND SET OF
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. .E. J , . . ill , a  .S. o t, RPVl GO IS S   
 P TIONS  ECEPTOR I   CE TE I-ME I  
ICITIES I    I I  , i l. ci. , -86 (20 6). 
. C.A. Reilly and G.S. Yost, ETABOLIS  OF CAPSAICINOIDS BY P450 ENZY ES: A 
   I GS  rr  I , - ,  
I I I  , r  et . ev. , -706 (2 6). 
. .C. , .S. i , .E. n, .L. , J. , .S. t,  
.A. eilly, P l fSTS SE E PL S IC RETIC L  ST ESS  ELL E T  I  
  S, J. har acol. xp. her. 321,830-838 (2007). 
. .F.   .E. r t, I   : 1  l 
  i-I     L, i l y, , -37  (2 8) 
. .A. roneberg, . ii i, . hai inh, . osio, ark e , . Fischer, and 
.F. hung, INCREASED EXPRESSION OF TRANSIENT RECEPTOR POTENTIAL  NILLOID-l IN 
    ,  r l  i     
edicine, ol. 170, 1276-1280 (2004). 
l i tiff f rt r s rs t is I t lT t r   r f rri  f t t  ts r  
r it  r  s t s s. I  -1 ,  ts r i sl  r  
r   t  .  -5   -1 . 
L     . 1: l intif  
supplements her answer to Interrogatory No. 21 by stating that the following articles and the 
articles cited therein have also helped to for  the basis of her responses to Request for 
i i  . ,   : 
LAINTIF 'S PLE      EFENDANT'S SECOND  F 
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1 JE Mitchel AP Campbell NE New LR Sadofsky JA Kastelik SA
Mulrennan SJ Compton and AH Morice EXPRESSION AND CHARACTERIZATION OF THE
INTRACELLULAR VANILLOID RECEPTOR TRPV1 IN BRONC141 FROM PATIENTS WITH CHRONIC
COUGH Experimental Lung Research 31295306 2005
2 T Higenbottam CHRONIC Cough AND COUGH REFLEX IN COMMON LUNG
DISEASES Pulmonary Pharmacology Therapeutics 15241247 2002
3 Pierangelo Geppetti Serena Materazzi Paola Nieoletti THE TRANSIENT
RECEPTOR POTENTIAL VANILLOID 1 ROLE IN AIRWAY INFLAMMATION AND DISEASE European
Journal ofPharmacology 533207214 2006
4 WJ Meggs NEUROGENIC INFLAMMATION AND SENSITIVITY TO ENVIRONMENTAL
CHEMICALS Environ Health Prospect 101234238 1993
5 John J Adcock TRPV1 RECEPTORS IN SENSITIZATION OF COUGH AND PAIN
REFLEXES Pulmonary Pharmacology Therapeutics 226570 2009
6 LuYuan Lee and Qihai Gu ROLE OF TRPV 1 IN INFLAMMATION INDUCED AIRWAY
HYPERSENSITIVITYCurrent Opinion in Pharmacology9243249 2009
7 K Alawi and J Keeble THE PARADOXICAL ROLE OF TILE TRANSIENT RECEPTOR
POTENTIAL VANILLOID 1 RECEPTOR IN INFLAMMATION Pharmacology and Therapeutics
12581195 2010
REQUESTS FOR PRODUCTION OF DOCUMENTS
REQUEST FOR PRODUCTION NO 52 Please produce copies of any and all
medical records regarding your consultation treatment andor care with each of the medical
providers identified in response to Interrogatory No 17 above
RESPONSE TO REQUEST FOR PRODUCTION NO 52 Plaintiff responds to
Request for Production No 52 by incorporating herein as though fully set forth her objections
and answers to Interrogatory No 17
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 52
Plaintiff supplements her Response to Request for Production No 52 by stating that to the best
of her recollection she has not seen or treated with any counselors psychologists psychiatrists
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANT SECOND SET OF
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. lE. it l, .P. pbell, .E. , .R. dofsky, lA. teli , .A. 
lre , J. t ,  .H. i , I   I I    
I  I I   (TRPVI) I  CHI  I  I  I  
, x eri e t l  esearc , 31 :295-306 (20 5). 
. . i e tta , I     F  I    
I , l r  r l  & r utics, 5:241-247 (2 2). 
. i r l  ppetti, r  t r zzi, l  ic l tti,  I  
E EPT  P TE TI L  ANILLOl  1: LE IN I  I FL TI   IS S , uropean 
Journal o/Pharmacology 533:207-214 (2006). 
. J. s, I  I I   ITI I   I  
I , ir n. lt  r s t, 01:234-23  (1 3). 
.  . , I   I I      
, l  l  & r utics, 2 :65-70 (2 9). 
. -Yua    i i ,     I  ] I -I  I  
YPERSEN ITIVITY, e    l y, :243-249 (2 9). 
. .   . l ,     H    
r  I l    I  I I , r l   r uti s, 
25:181-195 (2 0). 
     
   . : lease r ce c ies f a  a  all 
e ical rec r s re ar i  r c sultati n, treat e t a /or care it  eac  f t e e ical 
providers identified in response to Interrogatory o. 17 above. 
     . : l i ti  responds  
Request for Production No. 52 by incorporating herein as though fully set forth her objections 
 s rs t  I t rr t r  . . 
  ·    . : 
Plaintiff supple ents her esponse to equest for Production o. 52 by stating that, to the best 
 r r ll cti n,   t  r tr t  it   l r , l i t , i tri t , 
I TIF 'S      FENDANT'S    
I IES    I    -  
neuropsychologists or other similar mental health care providers in the last twenty 20 years
other than Dr Roberto Negron
In July 2003 Plaintiff lost her job at SCP Global Technologies Following this event
Plaintiff remained unemployed and she spent much of the next several months at her
Grandfathershouse aiding in the renovation of his house Plaintiff often referred to this time
she spent at her Grandfathershouse and the work she performed at his house as her therapy
REQUEST FOR PRODUCTION NO 53 Please produce copies of all medical
records regarding any visit treatment consultation testing evaluation or other care you have
received from Dr Negron
RESPONSE TO REQUEST FOR PRODUCTION NO 53 Plaintiff responds to
Request for Production No 53 by stating during Dr NegronsFebruary 2 2011 psychological
assessment of Plaintiff two pages of notes were taken and were used in the drafting of the
psychological assessment That assessment has already been produced Dr Negron is unable to
locate the two pages of notes from his February 2 2011 assessment Plaintiff further responds to
Request for Production No 53 by stating that she has been assured by Dr Negron that all of the
information that was contained in the two pages of notes can also be found in his psychological
assessment of Plaintiff
SUPPLEMENTAL RESPONSE TO REO UFST FOR PRODUCTION NO 53
Plaintiff supplements her Response to Request for Production No 53 by referring Defendant to
documents produced in Plaintiffs Fifth Supplemental Answers and Responses to Defendants
First Set of Interrogatories and Request for Production marked as Bates Nos NEGRON 00014
16
REOUEST FOR PRODUCTION NO 54 Please produce copies of any and all
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neuropsychologists or other si ilar ental health care providers in the last t enty (20) years 
 t  r. r  gron. 
I  J l  3, l i tiff l st r j  t  l l nol gi s. ll i  t is event, 
l intif  i  l    s t   t  t sev r l t  t r 
r ndfather's , i i  i  t  ti   i  e. l intif  t   t  t i  ti  
she spent at her randfather's house and the ork she perfor ed at his house as her "therapy." 
  I  . 3: l s  r  i s f ll i l 
records regarding any visit, treat ent, consultation, testing, evaluation or other care you have 
 TO  r. . 
     . 3: l i tif  responds  
Request for Production o. 53 by stating during r. egron's February 2, 2011 psychological 
assess ent f laintiff, t o pages f notes ere taken and ere used in the drafting f the 
psychological assessment. That assess ent has already been produced. Dr. Negron is unable to 
locate the two pages of notes fro  his February 2,2011 assess ent. Plaintiff further responds to 
equest for Production o. 53 by stating that she has been assured by r. egron that all of the 
infor ation that as contained in the t o pages of notes can also be found in his psychological 
t  l i tiff. 
   Q EST   . : 
Plaintiff supple ents her Response to Request for Production No. 53 by referring Defendant to 
e ts r ce  in l intiffs ift  l e tal ns ers  s ses t  f ndant's 
First Set of IntelTogatories and equest for Production, arked as ates os. E  00014-
16. 
Q   I  . : lease roduce c ies f a  a  all 
P I F'S L NS ERS  S SES  NDANT'S   F 
INTERROG TORIES N  ESTS F   F E TS -  
journals articles studies reports or peer reviewed or refereed publications which you contend
support the contention that SEC knew or should have known that the Sabre Red OC Spray may
cause respiratory illness such as RADS chronic cough syndrome vocal cord dysfunction
esophageal dysmotility and reflux as set forth in Paragraph 19 of your Complaint
RESPONSE TO REQUEST FOR PRODUCTION NO 54 Plaintiff responds to
Request for Production No 54 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 00001 12 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but will be made available to Defendant as soon
as we get copies
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 54
Plaintiff supplements her Response to Request for Production No 54 by referring Defendant to
documents produced in PlaintiffsFifth Supplemental Answers and Responses to Defendants
First Set of Interrogatories and Request for Production marked as Bates Nos ARTICLES
000101 166
REQUEST FOR PRODUCTION NO 55 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications available andor
published prior to May 2008 which would support the contention that Sabre Red OC Spray may
cause respiratory illness such as RADS chronic cough syndrome vocal cord dysfunction
esophageal dysmotility and reflux as set forth in Paragraph 19 of your Complaint
RESPONSE TO REQUEST FOR PRODUCTION NO 55 Plaintiff responds to
Request for Production No 55 by referring Defendant to documents produced herewith marked
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANTSSECOND SET OF
INTERROGATORIES AND REQUESTS FOR PRODUCTION OF DOCUMEN 8
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joumals, articles, studies, reports, or peer revie ed or refereed publications hich you contend 
support the contention that SEC knew or shoUld have known that the "Sabre Red OC Spray ay 
cause respiratory illness such as S, chronic cough syndro e, vocal cord dysfunction, 
esophageal dys otility and reflux," as set fOl1h in Paragraph 19 of your Co plaint. 
     . : l i ti  r s  
Request for Production No. 54 by referring Defendant to docu ents produced herewith arked 
as ates os. TI LES 000001-100 and docu ents previously produced arked as ates 
.  001-5   1-1 . l i tiff f rt r r s s t  t is est f r 
roduction by stating that articles 1, 2, and 3 fro  the list f articles in Interrogatory o. 21 are 
t c rre tl  a aila le t  lai tiff i  a er f rnl, t ill e a e a aila le t  efe a t as s  
as e get copies. 
L       . : 
Plaintiff supple ents her Response to Request for Production o. 54 by referring efendant to 
docu ents produced in Plaintiffs Fifth Supple ental ns ers and esponses to efendant's 
irst t  I t rr t ries  t f r r ti , r   t  . I  
-1 . 
   . : lease r ce c ies f a  a  all 
journals, articles, studies, reports, or peer revie ed or refereed publications available and/or 
published prior to ay, 2008 which would support the contention that "Sabre Red OC Spray may 
cause respiratory illness such as , chronic cough syndro e, vocal cord dysfunction, 
esophageal dys otility and reflux," as set forth in Paragraph 19 of your Co plaint. 
     . 5: l intif  r  t  
equest for Production o. 55 by referring efendant to docu ents produced here ith arked 
LAINTIFF'S L      FENDANT'S    
I IES    I   CUMENTS --  
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 0000112 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the Iist of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but will be made available to Defendant as soon
as we get copies
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 55
Plaintiff supplements her Response to Request for Production No 55 by referring Defendant to
documents produced in Plaintiffs Fifth Supplemental Answers and Responses to Defendants
First Set of Interrogatories and Request for Production marked as Bates Nos ARTICLES
00010166
REQUEST FOR PRODUCTION NO 56 If your responses to Requests for Admission
Nos 1 2 or 3 are anything other than unqualified admissions please produce andor identify
each and every Document article medical or scientific study medical or scientific literature
example or other evidence that you rely upon in formulating each such response
RESPONSE TO REQUEST FOR PRODUCTION NO 56 Plaintiff responds to
Request for Production No 56 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 0000112 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but will be made available to Defendant as soon
as we get copies
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 56
Plaintiff supplements her Response to Request for Production No 56 by referring Defendant to
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TODEFENDANT SECOND SET OF
INTERROGATORIES AND REQUESTS FORPRODUCTION OF DOCUMENTS 9
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 tes . I  01-10   t  r i l  r  r  s tes 
.  -5   -1 . l i tif  t   t  t i  t  
roduction by stating that articles 1,2, and 3 fro  the list of articles in IntelTogatory o. 21 are 
t rr tl  il l  t  l i tiff i  r f nn, t ill   il l  t  f t   
as e et c ies. 
      . 5: 
l i ti  l t   s  t  t  ti  .   i  t t  
docu ents produced in laintiffs ifth upple ental ns ers and esponses to efendant's 
ir t t f I t rr at ries  t f r r uction, r   t  s. I  
01-166. 
S   I  . : If r r ses t  t  f r is i  
os. 1, 2 or 3 are anything other than unqualified ad issions, please produce andlor identify 
eac  a  e er  c ent, article, e ical r scie tific st y, e ical r scie tific literat re, 
l , r t r i e e t t  r l   i  f r l ti    r nse. 
     . : l i tif    
Request for Production o. 56 by referring efendant to docu ents produced here ith arked 
s t  . I  001-10   t  r i l  r  r  s t  
.  -5   -1 . Plaintiff further responds to this equest for 
Production by stating that articles 1, 2, and 3 fro  the list of articles in Interrogatory o. 21 are 
t rr tl  il l  t  l i tiff i  r f nn, t ill   il l  t  f t s  
as e et c ies. 
      . 6: 
lai tiff s le e ts er es se t  e est f r r cti  .   referri  efe a t t  
I TIFF'S      FENDANT'S    
I E TORIES  ES S  I    -  
documents produced in PlaintiffsFifth Supplemental Answers and Responses to Defendants
First Set of Interrogatories and Request for Production marked as Bates Nos ARTICLES
000101166
REQUEST FOR PRODUCTION NO 57 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications which supports the
contention that OC Spray should only be used for training officers who do not have a history of
respiratory illness such as chronic asthma or bronchitis or other health problems that may make
the officer more susceptible to injury by OC Spray as set forth in Paragraph 19 of your
Complaint
RESPONSE TO REQUEST FORPRODUCTION NO 57 Plaintiff responds to
Request for Production No 57 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 00001 12 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but will be made available to Defendant as soon
as we get copies
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 57
Plaintiff supplements her Response to Request for Production No 57 by referring Defendant to
documents produced in Plaintiffs Fifth Supplemental Answers and Responses to Defendants
First Set of Interrogatories and Request for Production marked as Bates Nos ARTICLES
000101 166
REQUEST FOR PRODUCTION NO 58 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications which supports the
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TODEFENDANT SECOND SET OF
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ents roduced i  l intiffs ift  le e tal ns ers  ses t  f ndant's 
First Set of Interrogatories and equest for Production, arked as ates os. TI LES 
01-16 . 
   . : leas  r  i  f   ll 
journals, articles, studies, reports, or peer revie ed or refereed publications, hich supports the 
t tion t t "OC r  s l  l   s  f r tr i i  fficers   t   ist r  f 
respiratory illness, such as chronic asth a or bronchitis, or other health proble s that ay ake 
the officer ore susceptible to injury by"  Spray, as set f01th in Paragraph 19 of your 
o plaint. 
S      . : l i ti  responds t  
equest for Production o. 57 by refelTing efendant to docu ents produced here ith arked 
 t  . I E  -10   t  i l     t  
.  1-5   -1 . laintiff further responds to this equest for 
r cti   stati  t at articles 1, , a   fr  t e list f articles i  I terr at r  . 21 are 
not currently available to Plaintiff in paper fonn but ill be ade available to efendant as soon 
as e get copies. 
L      I  . : 
laintiff supple ents her esponse to equest for roduction o. 57 by referring efendant to 
c e ts r ce  i  laintiff's ift  le e tal s ers a  es ses t  efendant's 
irst et f Interrogatories and equest for roduction, arked as ates os. I  
-1 . 
   . : Please produce copies of any and all 
journals, articles, studies, reports, or peer revie ed or refereed publications, hich supports the 
I TIFF'S      FENDANT'S    
I I     I    -  
contention that OC Spray may act as an aggravating factor for those who may already have one
or more of the medical conditions listed in Paragraph 19 of your Complaint
RESPONSE TO REQUEST FOR PRODUCTIONNO 58 Plaintiff responds to
Request for Production No 58 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 00001 12 Plaintiff further responds to this Request for
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but but will be made available to Defendant as
soon as we get copies
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 58
Plaintiff supplements her Response to Request for Production No 58 by referring Defendant to
documents produced in PlaintiffsFifth Supplemental Answers and Responses to Defendants
First Set of Interrogatories and Request for Production marked as Bates Nos ARTICLES
000101 166
REQUEST FOR PRODUCTION NO 59 Please produce copies of any and all
journals articles studies reports or peer reviewed or refereed publications which you contend
identify the standard for what is reasonably safe for use within closed environments such as
within the IDC in regards to the potency of OC Spray as set forth in Paragraph 16 of your
Complaint
RESPONSE TOREQUEST FOR PRODUCTION NO 59 PIaintiff responds to
Request for Production No 59 by referring Defendant to documents produced herewith marked
as Bates Nos ARTICLES 000001 100 and documents previously produced marked as Bates
Nos TRPV 00001 5 and TRPA 0000112 Plaintiff further responds to this Request for
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANT SECOND SET OF
INTERROGATORIES AND REQUESTS FOR PRODUCTION OF DOCUMENTS 11
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t ti  t t   "ma  t   ti  t r f r t    l    
r re" f t  i l iti  li t  i  r r   f r plaint. 
    TI  . 8: l i tif  responds  
equest for Production o. 58 by refen'ing efendant to docu ents produced here ith arked 
as ates s. I  -1  a  c e ts re i sl  r ce  ar e  as ates 
.  -5   -1 . l i tiff f rt r r s s t  t is st f r 
r ti   st ti  t t rti l s , ,   fr  t  list f rti l s i  I t rr t r  .  r  
   t  i ti    Ol    i    i     
    . 
      . : 
l i ti    s   t   o.      
docu ents produced in Plaintiffs Fifth Supple ental ns ers and Responses to efendant's 
i t t  t t ies  t  r uction,   tes s.  
1-1 . 
   . 9: l  r ce i  f   ll 
j l , ti l , t i , t ,   i    li ti , i   t  
i tif  t  t r  f r "what is r l  f  f r  it i  l  ir e ts   
ithin the I e," in regards to the potency of  Spray, as set forth in Paragraph 16 of your 
i t. 
     . 9: l i tif  responds  
equest for Production o. 59 by referring efendant to docu ents produced here ith arked 
as ates os. I ES 000001-100 and docu ents previously produced arked as ates 
.  01-5   1-1 . l i tiff f rt r r s s t  t is st f r 
LAINTIFF'S  S E S    ENDANT'S    
E TORIES    f    -  
Production by stating that articles 1 2 and 3 from the list of articles in Interrogatory No 21 are
not currently available to Plaintiff in paper form but but will be made available to Defendant as
soon as we get copies
SUPPLEMENTAL RESPONSE TO REQUEST FOR PRODUCTION NO 59
Plaintiff supplements her Response to Request for Production No 59 by referring Defendant to
docu vents produced in PlaintiffsFifth Supplemental Answers and Responses to Defendants
First Set of Interrogatories and Request for Production marked as Bates Nos ARTICLES
000101166
DATED this 25th day ofJuly 2011
OBJECTIONS IF ANY BY
JONES SWARTLIC
D LOV
ERIC B SWARTZ
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roduction by stating that articles 1, 2, and 3 fi'o  the list of articles in Interrogatory o. 21 are 
not currently available to laintiff in paper for  but but ill be ade available to efendant as 
soon as we get copies. 
 S      . : 
l i tiff s le ents r es onse t  t f r r tion .   r f rri  f t t  
documents produced in Plaintiffs Fifth Supple ental ns ers and esponses to efendant's 
irst t f I t lTogatories  st f r r ti , r e  as ates s. I  
1-16 . 
 this 25th day of July, 2011. 
I ,  ,  
JONES&SWT1~ -Q'I B~~~_ 
. ARWINL. OVERSON 
 .  
LAINTIF 'S PLE      FENDANT'S SECON   F 
I I S  S S F  P D TI  F S - 1  
CERTIFICATEOF SERVICE
I HEREBY CERTIFY that on this day ofJuly 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
kDelivery
Email eburke@greenerlawcom
r Q
DARW f7 RSON
ERIC B SWARTZ
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      t( /') a  f J ly, , a tr e a  c rrect c  f 
the foregoing docu ent was served on the follo~g individual(s) by the ethod indicated: 
risto er . r e 
     
 .  t,   
,   
[ ] .S.  
[ ] a]G -260  
hlViessenger elivery 
[ ] ail: cburke greenerlaw.com 
~CC~. 
n "R lNt:-eV'"E  
 .  
I TIFF'S      ENDANT'S    
I E IES  S S  I    -  
EXHIBIT I
TO AFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
EXHIBIT I
TO AFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
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 F IT  S  I  I   C's OTION  
E I S F E  F I IT F  . , H.D. 
I   
 I I    I  POSITI   EC's I   
I  I    SEC  I I   A L  S. ST, H.D. 
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post OfficeBox 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys forPlaintiff Billie Jo Major
IN THE DISTRICT COURTOF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
Case No CV PI 1003515
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
PLAINTIFFSTHIRD
SUPPLEMENTAL EXPERT
WITNESS DISCLOSURE
PRELIMINARY STATEMENT
Discovery in this matter is ongoing This disclosure is made and based upon the
Plaintiffs current understanding of the facts claims and defenses at issue in this litigation It is
anticipated that further discovery investigation and consultation with witnesses and experts may
supply additional facts add meaning to known facts and establish new factual conclusions and
legal contentions all ofwhich may lead to additions to modifications of and variations from the
disclosures set forth herein This disclosure is therefore made without prejudice to Plaintiffs
PLAINTIFFSTHIRD SUPPLEMENTAL EXPERT WITNESS DISCLOSURE 1
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 . r l  ri e,   [8 02] 
Post ffice ox 7808 
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e: (2 ) -89  
acsi ile: (2 ) -89  
ail: r jonesandswartzlaw.com 
ri jonesandswartzlaw.com 
ttorne s f r l intiff, illie  j r 
          
   ,        
IE  ,  i al, 
i tif , 
vs. 
I  I  RATI , 
 is ri r r ti , 
nt. 
 .  I  
I TIFF'S  
  
ESS  
  
isc er  i  t is atter is i . This disclosure is ade and based upon the 
l intiff's rr t erst ing f t  f ts, l i s,  f s s t iss  i  t is litig ti . It is 
anticipated that further discovery, investigation, and consultation with witnesses and experts ay 
s l  a itio al facts, a  ea i  t   facts, a  esta lis  e  fact al c cl si s a  
le l c t ti s, ll f hich  le  t  itions t , ifications f,  riations fr  t  
disclosures set forth herein. This disclosure is therefore ade ithout prejudice to Plaintiff s 
I TIFF'S IRD  P  ITNESS ISCLOSURE -  
13 T Higenbottam CHRONIC COUGH AND COUGH REFLEX IN COMMON LUNG
DISEASES Pulmonary Pharmacology Therapeutics 15241247 2002
14 Pierangelo Geppetti Serena Materazzi Paola Nicoletti THE TRANSIENT
RECEPTOR POTENTIAL VANILLOID 1 ROLE IN AIRWAY INFLAMMATION AND DISEASE European
Journal ofPharmacology 533207214 2006
15 WJ Meggs NEUROGENIC INFLAMMATION AND SENSITIVITY TO ENVIRONMENTAL
CHEMICALS Environ Health Prospect 101234238 1993
16 John J Adcock TRPV1 RECEPTORS IN SENSITIZATION OF COUGH AND PAIN
REFLEXES Pulmonary Pharmacology Therapeutics 226570 2009
17 LuYuan Lee and Qihai Gu ROLE OF TRPV 1 IN INFLAMMATION INDUCED AIRWAY
HYPERSENSITIVITY Current Opinion in Pharmacology9243249 2009
Plaintiff further supplements this disclosure by stating that copies of all of the above
listed articles have previously been produced in discovery
THIRD SUPPLEMENTAL DISCLOSURE
Plaintiff further supplements her disclosure of Dr Yost by stating that it is anticipated
that Dr Yost will testify regarding the state of knowledge as it existed prior to the date SEC sold
its SABRE Red Law Enforcement Grade 10 OC Spray MK9 Fogger and similar products
to IDOC and that that knowledge included a body of scientific literature that should have put
SEC on notice that its product as identified herein posed a risk of acute and chronic injury to the
respiratory tract such as that suffered by the Plaintiff For further details please see the Affidavit
of Dr Yost filed in opposition to DefendantsMotion for Summary Judgment the Affidavit of
Dr Yost in support of PlaintiffsMotion for Reconsideration and the deposition of Dr Yost
Dr Yost may testify to any opinions expressed in his Affidavit filed in opposition to Defendants
Motion for Summary Judgment his Affidavit in support of Plaintiffs Motion for
Reconsideration and in his deposition
PLAINTIFFSTHIRD SUPPLEMENTAL EXPERT WITNESSDISCLOSURE 19
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laintiff further supple ents this disclosure by stating that copies f all f the above 
liste  articles a e re i sl  ee  r ce  i  iscovery. 
I  L  I : 
lai tiff f rt er s le e ts r iscl s re f r. st  stati  t at it is a tici ate  
t t r. st ill t stif  r r i  t  st t  f le  s it ist  ri r t  t  t   s l  
its  , a  f rce t r , 0%  r y, -9 r,  si ilar r ts, 
to I , and that that kno ledge included a body of scientific literature that should have put 
SE  on notice that its product, as identified herein, posed a risk of acute and chronic injury to the 
r s ir t r  tr t s  s t t s ffere   t  l intiff. r f rt r tails, l s  s  t  ffida it 
f r. ost file  i  ition t  f ndant's tio  f r r  nt, t  ffida it f 
r. ost in support of Plaintiffs otion for Reconsideration, and the deposition of r. ost. 
r. st  t tif  t   i io  res  i  is ffida it file  i  ition t  f ndant's 
otion f r ary nt, s ffidavit in support  l intif  s io   
Reconsideration, and in his deposition. 
I TIFF'S I     I  -  
Dr Yost may also testify regarding the increased risk of acute and chronic respiratory
injury posed by a product such as SEC SABRE Red Law Enforcement Grade 10 OC Spray
MK9 Fogger and similar products that are designed with the purpose of targeting the respiratory
tract by deploying OC in a highly aerosolized micro particulate spray He may testify as to how
such spray would be anticipated to impact the respiratory tract differently than other spray
patterns such as a stream which does not create such an extensive respiratory exposure to OC or
at least creates a different kind of exposure than is the case with a fogtype spray pattern
Plaintiff further supplements her disclosure of Dr Karin Pacheco by stating that
Dr Pacheco was provided a copy of Dr Roberto Negronssupplemental report dated June 8
2011 A copy of Dr Negrons supplemental report was provided to Defendant at Dr Negrons
deposition on June 9 2011 Plaintiff further supplements her disclosure ofDr Karin Pacheco by
producing herewith a copy of Dr Pachecos supplemental expert report marked as Bates Nos
PACHEC000027 28
Plaintiff further supplements her disclosure of Gary Couillard CPA by stating that
Plaintiff has provided Mr Couillard with updated billing records to review These billing
records were previously produced to Defendant in Plaintiffs Fifth Supplemental Answers and
Responses to Defendants First Set of Interrogatories and Requests for Production and are
marked as Bates Nos BRG BILL 0000014 MOLDENHAUER BILL 0004956 and SLFH
BILL 0002324 Plaintiff also provided Mr Couillard with Plaintiffs prescription medication
bills marked as Bates Nos SAVON 000001102 and Norco bills marked as Bates Nos MAJOR
00004355 and MAJOR 000291294 Plaintiff also provided Mr Couillard with a copy of
Dr Pachecossupplemental report dated August 15 2011 Plaintiff additionally provided
Mr Couillard with a spreadsheet which lists all of Plaintiffsmedical expenses since the date of
PLAINTIFFSTHIRD SUPPLEMENTAL EXPERT WITNESS DISCLOSURE 20
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r. t  l  t tif  r r i  t  i r  ri  f ac t   r i  r spiratory 
i j r     r t   EC's  d,  f r t r de, 0%  pray, 
-9 r  i   t t  i   t   f t r ti  t  pir t r  
tract  epl i   i  a i l  aer s lize  icr - artic late spray. e ay testif  as t   
such spray would be anticipated to i pact the respiratory tract differently than other spray 
atter s, s c  as a stream, ic  es t create s c  a  e te si e respirat r  e s re t   r 
t l st r t s  iffer t i  f s r  t  is t  s  it   f -typ  s r  ttern. 
Plaintiff further supple ents her disclosure of r. arin Pacheco by stating that 
r. ac ec  as r i e  a c  f r. ert  egron's s le e tal re rt ate  J e , 
2011.  copy of r. egron's supple ental report as provided to efendant at r. egron's 
deposition on June 9, 2011. Plaintiff further supple ents her disclosure of r. arin Pacheco by 
producing here ith a copy of Dr. Pacheco's supple ental expert report arked as Bates os. 
0 -2 . 
Plaintiff further supple ents her disclosure of ary ouillard, PA, by stating that 
Plaintiff has provided r. ouillard ith updated billing records to revie . These billing 
r r s r  r i sl  r ce  t  fe t i  l i tiff s ift  l t l ns ers  
esponses to efendant's First Set of Interrogatories and equests for Production, and are 
r   ates .  I  1-4,  I  -5 ,   
I  -2 . l i tiff ls  r ided r. illard it  l i tiffs r ri ti  i ti  
ls e   ates .  1-102  r  ls   t  . J  
-5   J  -29 . Plaintiff also provided r. ouillard ith a copy of 
r. checo's s le ental r rt t  ug st , . Plaintiff additionally provided 
r. Couillard ith a spreadsheet hich lists all of Plaintiffs edical expenses since the date of 
IFF'S T IRD L P T ITNESS IS OS RE - 20 
injury A copy of the spreadsheet is being produced herewith and is marked as Bates Nos
MAJOR BILLS 00000113 Also produced herewith are copies of Plaintiffsprescription
medication records and Norco bills marked as Bates nos SAVON 000098102 and MAJOR
000291294 respectively
After review of the additional information provided to him it is anticipated that
Mr Couillard will amend or supplement his expert report to include the new information
DATED this 7 day of September 2011
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 t is 7th a  f e te ber, . 
I TIFF'S    ES   -  
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 7th day of September 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
X USMail
Fax 3192601
Messenger Delivery
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I TIFF'S  L   ESS  -  
EXHIBIT J
TOAFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
EXHIBIT J
TOAFFIDAVIT OF COUNSEL IN OPPOSITION TO SECMOTION TO
STRIKE PORTIONS OF THE SECOND AFFIDAVIT OF GAROLD S YOSTPHD
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Darwin Overson
From Darwin Overson
Sent Monday August 22 201161 PM
To tlloyd@GreenerLawcomChristopher Carl Burke cburke@greenerlawcomEric Swartz
Cc Mat Cundiff
Subject 22572 Majro v SEC
Tom Chris
I just received your motion to strike Dr Yostsaffidavit We will make Dr Yost available to you for a follow up deposition
if you would like I am sure we can set it up in our office through live videoaudio feed so that you dont have to travel
to Salt Lake again Let me know if that is something you would like to do
Darwin LOverson
Jones Swartz PLLC
1673 WShoreline Drive Ste 200
PO Box 7808
Boise ID 837077808
208 4898989
208 4898988 fax
darwin ionesandswartzlaw c om
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tlloyd GreenerLaw.com; hristopher arl urke (cburke greenerlaw.com); ric artz 
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawc m
Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO INAND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
N0 2
1
FILED
AM
CHRISTOPHER D RICH Clerk
By ELYSHIA HOLMES
DEPUTY
Case No CV PI 1003515
REPLY MEMORANDUM IN SUPPORT
OF PLAINTIFFSMOTION FOR
RECONSIDERATION OF THE
COURTSORDERGRANTING
DEFENDANT MOTION FOR
SUMMARY JUDGMENT
Defendant
I ARGUMENT
A Plaintiff Is Not Required To Identify ADefinitive Study Showing That Exposure
To OC SprayWill Cause Chronic Respiratory Injury Such As That Suffered By
Ms Major
The Defendant has repeatedly asserted that it is entitled to summary judgment because the
Plaintiff cannot cite to a single study definitively demonstrating that exposure to OC Spray will
cause chronic respiratory injury However the Defendant has not supported its assertion with
any law that even suggests that such a rigid requirement has ever been adopted by the courts
There is no element of a failure to warn cause of action that requires the Plaintiff to
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l intiff, 
vs. 
SEC RIT  E IP E T C RP RATI N, 
a issouri corporation, 
    
 I TIFF'S   
I    
URT'S   
ENDANT'S   
  
nt. 
.  
. l i tiff Is t ir   I tif   fi itive t  i  t s r  
To C Spray ill Cause Chronic Respiratory Injury Such s That Suffered By 
s. j r 
The efendant has repeatedly asserted that it is entitled to su ary judg ent because the 
lai tiff ca t cite t  a si le st  efi iti el  e strati  t at e s re t   ra  ill 
ca se c r ic res irat r  i j ry. e er, t e efe a t as t s rte  its asserti  it  
a  la  t at e e  s ests t at s c  a ri i  re ire e t as e er ee  a te   t e c rts. 
There is no element of a failure to warn cause of action that requires the Plaintiff to 
     I TIFF'S   I    
URT'S  I  FENDANT'S     -  
identify any one specific study that definitively establishes that it was known prior to 2008 that
exposure to OC Spray would cause chronic respiratory illness such as that suffered by Ms Major
The relevant element of a failure to warn cause of action is that the defendant knew or should
have known that danger to users or bystanders could result from a particular use ofthe product
One way the Plaintiff can meet this burden is by direct evidence that SEC knew of the safety
concerns that existed with OC Spray when used on people with respiratory illness The Plaintiff
has presented such evidence in the form of SECsVice Presidentstestimony that he knew a
danger existed for people exposed to OC Spray who suffered pulmonary issues
Q Okay Particularly there are concerns with the safety of OC
products when used on individuals with pulmonary issues
generally
Q Respiratory issues
A The effects may be greater
SECsVice President acknowledged in his deposition that at certain concentrations such as
145 20and30capsaicinoids OC Spray products are dangerous According to SECs
Vice President the risks associated with OC Spray products that are too hot are that they
cause could cause some could possibly cause longterm damage or extremely long recovery
periods
Plaintiff can also meet her burden by presenting evidence of a body of scientific literature
in existence prior to the date of sale from which it can be concluded within a reasonable degree
of scientific certainty that SECsSABRE Red Law Enforcement Grade 10 OC Spray MK9
IDJI 1006 Puckett v Oakfabco Inc 132 Idaho 816 979 P2d 1174 1999 Rindlisbaker v Wilson 95
Idaho 752 519P2d 421 1974 RESTATEMENT SECOND OF TORTS 402A comment h 1977
2 Aff of Counsel in Opp to DefsMSJ 10 Ex 8 Nance Dep441217
3 Aff of Counsel in Opp to DefsMSJ 10 Ex 8 Nance Dep 643 654
4 Aff of Counsel in Opp to DefsMSJ 10 Ex 8 Nance Dep 641021 and generally 214 4311
441217 501 5917 6322 1307 13725 1390 1402 1574 1635and Exs B LO
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   i    f  is es         
exposure to  Spray ould cause chronic respiratory illness such as that suffered by s. ajor. 
 l t l t   il  t     ti  i  t t t  "defenda t   l  
a e  t at a er t  sers r sta ers c l  res lt fr  a artic lar se f the product."] 
  t  l i tiff  t t is r  is  ir t i  t t   f t  s f t  
c cer s t at e iste  it   ra  e  se   e le it  res irat r  ill ess. e lai tiff 
has presented such evidence in the for  of S C's ice President's testi ony that he kne  a 
danger existed for people exposed to  Spray ho suffered pul onary issues: 
. kay. Particularly there are concerns ith the safety of  
products hen used on individuals ith pul onary issues, 
generally? 
*** 
. espiratory issues. 
. e ffects   r ater.2 
C's ice resi e t ac le ge  i  is e siti  t at at certai  c ce trati s, s c  as 
.45%, .0% a  .0% ca saici i s,  ra  r cts are a erous.3 cc r i  t  EC's 
ice resi ent, t e ris s ass ciate  it   ra  r cts t at are "too ot" are t at t e  
"cause --    -- could possibly cause long-ter  da age or extre ely long recovery 
, periods.,,4 
lai tiff ca  als  eet er r e   rese ti  e i e ce f a  f scie tific literat re 
in existence prior to the date of sale fro  which it can be concluded within a reasonable degree 
f scientific certainty that EC's  ed, a  nforce ent rade, 10%  pray, -9 
1 I JI 10.06; Puckett v. alifabco, Inc., 132 Idaho 816, 979 P.2d 1174 (1999); Rindlisbaker v. ilson, 95 
Idaho 752, 519 P.2d 421 (1974); RESTATE ENT (SECOND) OF TORTS, § 402A, co ent (h) (1977). 
2 ff. f sel i  . t  efs J, ~ , .  (Nance ep., 4:12-1 ). 
3 ff. f ounsel in pp. to efs J, ~ 10, x. 8 (Nance ep., 64:3 - 65:4). 
4 ff. of ounsel in pp. to efs SJ, ~ 10, x. 8 (Nance ep., 64:10-21 and generally 21:24 - 3: 1, 
44:12-17,50: 10 - 9:17, 3:6-2 , 30:7 - 37:25, 39:10 - 40:12, 57:14 - 163:5, and Exs. , L-O). 
  I    I TIFF'S I   I I    
URT'S   ENDANT'S     -  
Fogger posed a risk of respiratory injury such as that suffered by the Ms Major That is
Plaintiff can meet the relevant element of her case by showing that the risks of chronic injury
such as that complained ofby the Plaintiff should have been known by SEC in light ofavailable
scientific knowledge at the time the product was sold to the IDOC
The majority view is that information known in the scientific and expert community
regarding the dangers of a particular product will be imputed to the manufacturer when assessing
what themanufacturer should have known at the timeofsale
Moreover the courts reason the presence of the required
knowledge can be established by evidence that the dangerous
quality of the product should have been known by a manufacturer
because it was known in the scientific or expert community As
Judge John Minor Wisdom stated for the court in another case
involving a claimed injury from asbestos Borel v Fibreboard
Paper Products Corporation 493 F2d 1076 1089 5th Cir 1973
cert denied 419US 869 95 SCt 127 42LEd2 107 1974
In cases such as the instant case the manufacturer
is held to the knowledge and skill of an expert This
is relevant in determining 1 whether the
manufacturer knew or should have known the
danger The manufacturersstatus as expert
means that at a minimum he must keep abreast of
scientific knowledge discoveries and advances and
is presumed to know what is imparted thereby
The same point was made by the United States Court of Appeals
for the Fourth Circuit in Lohrmann v Pittsburgh Corning Corp
782F2d 1156 1164 4th Cir 1986
Industry standards and state of the art are not
synonymous State of the art includes all of the
available knowledge on a subject at a given time
and this includes scientific medical engineering
and any other knowledge that may be available
5 OwenIllinois Inc v Zenibia 601 A2d 633 63940 Md 1992 see 402A RESTATEMENT SECOND
OF TORTS 1965 strict product liability Potter v Chicago Pneumatic Tools Co 694 A2d 1319 1328
29 Conn 1997 strict liability relieves plaintiff of burden of proving manufacturer was negligent and
allows plaintiff to establish instead defective condition of product as principal basis of liability
REPLY MEMORANDUM IN SUPPORT OF PLAINTIFFSMOTION FORRECONSIDERATION OF THE
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Plaintiff can meet the relevant element of her case by showing that the risks of chronic injury 
such as that co plained of by the Plaintiff should have been known by SEC in light of available 
i ti    t   t    l  t   I OC.5 
The ajority view is that infor ation known in the scientific and expert co unity 
regarding the dangers of a particular product will be imputed to the manufacturer when assessing 
          le: 
oreover, the courts reason, the presence of the required 
le    t li   i  t t t   
quality of the product should have been kno n by a anufacturer 
because it was known in the scientific or expert co unity. s 
   s         
     t , r l . e  
Paper Products Corporation, 493 F.2d 1076, 1089 (5th Cir. 1973), 
cert. e ie ,  .S. ,  .Ct. ,  .Ed.2d  (1 4), 
[I]n    t  i t t , t  f t r r 
is held to the kno ledge and skill of an expert. his 
i  r l t i  t r i i  (1 )   
       
nger....  facturer's t t   rt 
eans that at a ini u  he ust keep abreast of 
s i tific l , is ri s,  a ces  
is presu ed to know what is i parted thereby. 
he sa e point as ade by the nited States ourt of ppeals 
for the Fourth ircuit in Lohr ann v. ittsburgh orning orp., 
 .2d ,  (4th ir. 6): 
Industr  st r s  st t  f the rt r  t 
s s. t     includes   t e 
available kno ledge on a subject at a given ti e, 
and this includes scientific, medical, engineering, 
  ther ledge that  e il l . 
5 Owen-Illinois, Inc. v. Zenibia, 601 A.2d 633, 639-40 (Md. 1992); see 402A RESTATEMENT (SECOND) 
OF TORTS (1965) (strict product liability); Potter v. Chicago Pneumatic Tools Co., 694 A.2d 1319, 1328-
29 (Conn. 1997) (strict liability relieves plaintiff of burden of proving manufacturer was negligent and 
allows plaintiff to establish instead defective condition of product as principal basis ofliability). 
R  E O  IN  F P I F'S OTION F  ION F THE 
C RT'S ORDER GR NTING D DANT'S OTION FOR S R  J  - 3 
State of the art includes the element of time What
is known and when was this knowledge available
See eg Hardy v Johns Manville Sales Corp 681 F2d 334 344
5thCir1982 Gordon v Niagara Mach Tool Works 574 F2d
1182 1190 5th Cir 1978 Shell Oil Co v Gutierrez 119 Ariz
426 434 581 P2d 271 279 1978 Oakes v Geigy Agricultural
Chemicals 272 CalApp2d645 651 77 CalRptr 709 713 3d
Dist 1969 Woodill v Parke Davis Co supra 79 Ill 2d at 37
37 Ill Dec at 308 402NE2d at 198 Smith v ER Squibb
Sons Inc 405 Mich 79 90 273NW2d476 480 1979 McKee
v Moore 648 P2d 21 Okla1982 Cochran v Brooke 243 Or
89 9496 409 P2d 904 906907 1966 See also C Marvel
Annotation STRICT PRODUCTS LIABILITY LIABILITY FOR FAILURE
TO WARN AS DEPENDENT ON DEFENDANT KNOWLEDGE OF
DANGER 33ALR4th 368 1984 and cases cited therein
Other courts have similarly held that the knowledge of available scientific data will be
imputed to the manufacturer for the purpose of determining whether there was sufficient notice
of the dangers involved
The conduct should be measured by knowledge at the time the
manufacturer distributed the product Given the scientific
technological and other information available when the product
was distributed did the manufacturer know or should he have
known of the danger In other words did he have actual or
constructive knowledge of the danger A product related danger
may be regarded as knowable if the available scientific data
gave rise to a reasonable inference that the danger is likely to
exist Wade On The Effect in Product Liability of Knowledge
Prior to Marketing 58 NYULREv 734 749 1983 A
manufacturer is held to the knowledge and skill of an expert and
is required to test his products and keep abreast of scientific
discoveries related to his products but he has a duty to warn only
of dangers that the employment of the reasonable foresight of an
expert could reveal See Borel v Fibreboard Prods Corp 493
F2d 1076 10891090 5th Cir 1973 Wisdom J applying
Texas law cert denied 419US 869 1974 See generally IA L
Frumer M Friedman PRODUCTS LIABILITY 120731985
6 OwenIllinois Inc 601 A2d at 639 40 emphasis added
Bernier v Raymark Industries Inc 516A2d 534 53839 Me 1986 emphasis added
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t t  f t  art i  t  l t f ti e: t 
     t   available. 
ee, .g.,  . J - vil  al  orp.,  .2d 3 ,3  
(5t  ir.1982); r  . i r  ch. & Tool orks,  F.2d 
82, 1  (5t  ir. 978); hell il o. v. utierr z, 11  riz. 
, 4,  .2d 1,  (1 78); kes v. ei y gric lt r l 
e icals,  al.App.2d 5, 1,  al.Rptr. 09, 7  (3  
i t. 969); oodill .  i  & o., supra, 79 Ill. 2d at 37, 
37 111. ec. at 308, 402 .E.2d at 198; S ith v. .R. Squibb & 
Sons, Inc., 405 ich. 79, 90, 273 .W.2d 476, 480 (1979); c ee 
. re,  .2d  ( kla. 198 ); r  . r e,  r. 
, -9 ,  .2d 4, -90  (1 6).  l  . rvel, 
tation,   I I Y:    
     FENDANT'S   
,  .L.R. t   (1 4),   it  t erein.6 
t er c rts a e si ilarl  el  t at t e le e f a aila le scie tific ata ill e 
i puted to the anufacturer for the purpose f deter ining hether there as sufficient notice 
 t   i l : 
The conduct should be easured by kno ledge at the ti e the 
t  ist ibute  t  ct. i e  t  i ntifi , 
technological and other infor ation available hen the product 
 ,         
  the r. I  t r r , i    t l r 
constructive kno ledge of the danger. A product-related danger 
ay be regarded as kno able "if the available scientific data 
gave rise to a reasonable inference that the danger is likely to 
exist." ade, n The Effect in Product Liability of Knowledge 
Prior to arketing, 58 N.Y.U.L. REv. 734, 749 (1983).  
anufacturer is held to the kno ledge and skill of an expert, and 
is required to test his products and keep abreast of scientific 
discoveries related to his products, but he has a duty to arn only 
of dangers that the e ploy ent of the reasonable foresight of an 
expert could reveal. See Borel v. Fibreboard Prods. Corp., 493 
F.2d 1076, 1089-1090 (5th Cir. 1973) (Wisdom, J.) (applying 
Texas law), cert. denied, 419 U.S. 869 (1974). See generally l  L. 
ru er & . rie , S I I I  § 12.07[3] (1985).7 
6 -Illinoi , I ., 1 .2d at 639-40 (emphasis d). 
7 Bernier v. Raymark Industries, Inc., 516 A.2d 534, 538-39 (Me. 1986) (emphasis added). 
RE  E OR  I  S P  F P I F'S OTION FOR RE IO   E 
RT'S ER TING DE ANT'S OTION F  S  J  -  
It should also be emphasized that the knowledge imputed to the manufacturer is not
merely the standard within the relevant industry
The majority of courts however have defined stateoftheart
evidence as the level ofrelevant scientific technological and safety
knowledge existing and reasonably feasible at the time of design
See eg Carter v MasseyFerguson Inc 716F2d 344 347 5th
Cir 1983 state of the art refers to the technological
environment that is what can be done emphasis in original
Gosewisch v American Honda Motor Co 153 Ariz 389 394 737
P2d 365 App 1985 state of the art refers to what feasibly could
have been done Montgomery Ward Co v Gregg 554NE2d
1145 1155 56 Ind App 1990 defining state of the art as
technological advancement not as industry custom or practice
Chown v USMCorp 297NW2d218 222 Iowa 1980 defining
state of the art as technological and practical feasibility OBrien
v Muskin Corp 94NJ 169 182 463 A2d 298 1983 defining
state of the art as existing level of technological expertise and
scientific knowledge relevant to a particular industry at the time a
product is designed Boatland of Houston Inc v Bailey 609
SW2d 743 748 Tex 1980 state of the art includes the
scientific knowledge economic feasibility and the practicalities of
implementation when the product was manufactured see also
2 AMERICAN LAw OF PRODUCTS LIABILITY 3d 1996 305
p 3077 state of the art has been defined as the safety
technical mechanical and scientific knowledge in existence and
reasonably feasible for use at the time ofmanufacture
The law places on the manufacturer an affirmative duty to investigate and test Where
investigation andor testing would have revealed a danger that arises under normal use of the
product the manufacture must warn ofthe danger For instance in a case where there were no
known reports of mini trampolines causing users to suffer stress fractures the Tenth Circuit
Potter 694 A2d at 1346 see also Mercer v Pittway Corp 616 NW2d 602 Iowa 2000
distinguishing between custom of the industry and state of the art and concluding that the relevant
question is not what others were doing at the time but whether the evidence disclosed that anything
more could reasonably and economically be done
9 Richter v Limax Intern Inc 45 11464 146869 10ffiCir 1995 see also Mercer v Pittway Corp
616NW2d 602 624 Iowa 2000 the inquiry in a negligent failure to warn case is whether a
reasonable manufacturer knew or should have known of the danger in light of the generally recognized
and prevailing best scientific knowledge yet failed to provide adequate warning to users or customers
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It sh l  als   si  t t t  k l  i t  t  t  anuf ctur r is not 
r l  t  t r  i i  t  r l  i ustry: 
 aj rit  f rts, ver,  fi  stat -o -the-a t 
evidence as the level of relevant scientific, technological and safety 
kno ledge existing and reasonably feasible at the ti e of design. 
See, e.g., arter v. assey-Ferguson, Inc., 716 F.2d 344, 347 (5th 
ir. 83) ("'state f t  rt' refers to the technological 
environ ent, that is, hat can be done" [e phasis in original]); 
i  . ri   t  o.,  riz. 9, 4,  
P.2d 365 (App. 1985) ("state of the art refers to hat feasibly could 
  "); t r  r  & o. v. regg, 554 .E.2d 
, -5  (In . p. 990) (defi i  st t  f t  rt s 
technological advance ent, not as industry custo  or practice); 
 v.  orp.,  .W.2d ,  (Io  980) (defini  
state of the art as technological and practical feasibility); 0 'Brien 
v. uskin orp., 94 .J. 169, 182, 463 .2d 298 (1983) (defining 
state of the art as "existing level of technological expertise and 
s i tifi  le  r l t t   rti l r i str  t t  ti   
  "); t/  f ston, I c. v. iley,  
.W.2d ,  (T . ) ("[state f t  rt] i l s t  
s i tifi  l , i  f sibility,  t  r ti lities f 
le e t ion     ");   
2 A ERICAN LAW OF PRODUCTS LIABILITY 3d (1996) § 0:50, 
. -77 ('''[s]tate of the art' has been defined as the safety, 
technical, echanical, and scientific kno ledge in existence and 
r l  fe i l  f r  t t  ti  f anufacture,,).8 
he la  places on the anufacturer an affir ative duty to investigate and test. here 
investigation andlor testing ould have revealed a danger that arises under nor al use of the 
r t, the facture st arn f t e ger.9 r i st , i   ase ere t r  ere  
 re rts f i i-tra lines ca si  sers t  s ffer stress fract res, t e e t  irc it 
8 Potter, 694 A.2d at 1346; see a/so, Mercer v. Pi/tway Corp., 616 N.W.2d 602, (Iowa 2000) 
(distinguishing between custo  of the industry and "state of the art" and concluding that the relevant 
question is not what others were doing at the ti e but "whether the evidence disclosed that anything 
r  c l  rea l  and e i ll  e ."). 
9 Richter v. Limax Intern., Inc., 45 F3d 1464, 1468-69 (lOth Cir. 1995); see a/so, ercer v. Pittway Corp., 
616 .W.2d 602, 624 (Iowa 2000) (the inquiry in a negligent failure to arn case "is hether a 
reasonable manufacturer knew or should have known of the danger, in light of the generally recognized 
and prevailing best scientific knowledge, yet failed to provide adequate warning to users or customers."). 
REP  E OR NDUM IN S PP  F P I I F'S OTION FOR R I TION F E 
RT'S ORDER G NTING DE ANT'S OTION F  S  J ENT - 5 
reversed the district courtsdecision dismissing the case The district court dismissed on the
grounds that the manufacturer did not know and should not have known of the danger of stress
fractures caused by the normal use ofmini trampolines
l
Plaintiffsexperts testified at trial that
observations from very simple tests interpreted in light of well
established knowledge about the structure of the foot and the
causes of stress fractures would have made it apparent that the
repetitive use of the mini trampoline for jogging could cause stress
fractures Two experts testified the danger was well within the
state of society knowledge about such matters One of Richters
experts pointed out that although there were no known reports
concerning mini trampolines as a cause of stress fractures sport
and exercise magazines as well as scientific and medical journals
have long published articles establishing that repetitive jogging can
cause stress fractures
12
Quoting an earlier district court case applying Kansas law the appellate court explained the duty
placed on themanufacturer
Ordinarily a manufacturer has a duty under Kansas law to warn
consumers and users of its products when it knows or has reason to
know that its product is or is likely to be dangerous during normal
use The duty to warn is a continuous one requiring the
manufacturer to keep abreast of the current state of knowledge of
its products as acquired through research adverse reaction
reports scientific literature and other available methods A
manufacturers failure to adequately warn of its product
reasonably foreseeable dangers renders that product defective
under the doctrine of strict liability 3
B Nothing Under IdahosCommon Law Requires Plaintiff To Prove The Existence Of
A Single Definitive Study Showing That Exposure To OC Spray Causes Chronic
Respiratory Illness Such As That Suffered By Ms Major
SEC misconstrues the law when it argues that Plaintiffmust demonstrate the existence of
10
Richter 45 F3d at 146869
Id
12 Id at 1467
13 Id at 1468 quoting Pfeiffer v Eagle Mfg Co 771 F Supp 1133 1139DKan 1991 emphasis
added
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uoting an earlier district court case applying ansas la , the appellate court explained the duty 
la   t  f t rer: 
r i ril ,  f t r r s  t  r s s l  t  r  
             
kno  that its product is or is likely to be dangerous during nor al 
. e ty t  r  is  c ti s e, re iri  t e 
manufacturer to keep abreast of the current state of knowledge of 
its products as acquired through research, adverse reaction 
reports, scientific literature, and other available ethods.  
ufacturer's   adequately arn f its product's 
reasonably foreseeable dangers renders that product defective 
under the doctrine of strict liability. 13 
. othing nder Idaho's o on a  equires Plaintiff o Prove he xistence f 
 i le fi itive t  i  t s re   r  ses r i  
espiratory Illness Such s hat Suffered y s. ajor 
 isconstrues t e la  e  it es t at l i ti  t t t  t  iste e  
10 r,  3d  -69. 
II [ . 
12 [ . t . 
13 [d. at 1468 (quoting feiffer v. agle fg. o., 771 F. Supp. 1133, 1139 (D.Kan. 1991)) (emphasis 
added). 
  I    IFF'S OTION  I   E 
RT'S ER ING NDANT'S IO    J  -  
a single definitive study showing OC Spray exposure causes chronic injuries such as those
suffered by Ms Major
Under a strict liability theory the relevant element of Plaintiffs cause of action is the
requirement that she prove the product was in a defective and unreasonably dangerous condition
when it left the hands of the defendant 14
A product may be defective because of a defect in its design or
manufacture or because of a failure to adequately warn the
consumer of a hazard involved in the foreseeable use of the
product A product has a defect when it exposes a user or
bystander to an unreasonable risk of physical injury or if it is more
dangerous than would be expected by an ordinary person who may
reasonably be expected to use it The law does not say what would
be expected by an ordinary person or who may reasonably be
expected to use the product Both of these issues are for you to
decide
1 s
Under a negligence theory the relevant element is whether the manufacturer knew or
should have known that danger to users or bystanders could result from a particular use of the
product and failed to give adequate warning of such danger
Neither the strict liability nor negligence theory requires a plaintiff to show the existence
of a definitive study that the defendantsproduct would cause the plaintiff s injuries
Where as here a significant body of scientific literature existed at the time of sale that
demonstrates within a reasonable scientific certainty that SECs product posed a risk of causing
the type of injuries complained of by the Plaintiff the Defendant may be held liable because the
14 IDJI 1004 IDJI 1002RESTATEMENT SECOND OF TORTS 402A
IDJI 1001 Puckett v Oakfabco Inc 132 Idaho 816 979 P2d 1174 1999 See also
RESTATEMENT SECOND OF TORTS 402A comments g and i RESTATEMENT THIRD OF TORTS
PRODUCTS LIABILITY 2 Tent Draft 1994 IDJI 10012duty to design and manufacture its product
to avoid the unreasonable risk of foreseeable injury to persons using the product with ordinary care
16 IDJI 1006 Puckett v Oakfabco Inc 132 Idaho 816 979 P2d 1174 1999 Rindlisbaker v Wilson
95 Idaho 752 519P2d 421 1974 RESTATEMENT SECOND TORTS 402A comment h1977
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 i  f  t  i      r i      
suffered by s. ajor. 
  t i t li ilit  t ory, t  l t l t  l i ti    ti  i  t  
     "prod     f     i  
 it l ft t    t  f dant.,,1  
 t   ti e    f t i  it  i   
anufacture or because of a failure to adequately arn the 
         f  
r ct.  r t   f t  it   r r 
t r t   r l  ri   i l i j ry, r i  it i  r  
r  t  l   t    r i r  r    
r l   t  t   it.  l   t  t l  
be expected by an ordinary person or ho ay reasonably be 
t  t  s  t  r ct. t  f t s  iss s r  f r  t  
i . ls 
  li  t ory, t  l t l t i  t  t  t  "kne   
should have kno n that danger to users or bystanders could result fro  a particular use of the 
r ct; a  ... faile  t  i e a e ate ar i  f s c  a ger.,,16 
it r t  tri t lia ility r lige ce t r  r ir   l i tiff t   t  i t  
of a definitive study that the defendant's product ould cause the plaintiffs injuries. 
ere, as ere, a si ifica t  f scie tific literat re e iste  at t e ti e f sale t at 
demonstrates within a reasonable scientific certainty that SEC's product posed a risk of causing 
the type f injuries co plained f by the laintiff, the efendant ay be held liable because the 
14 I JI 10.04; I JI 10.02.1; EST TE E T (SE ) F T TS § . 
15 I JI 10.01.1; uckett v. akfabco, Inc., 132 Idaho 816, 979 P.2d 1174 (1999). See also, 
 (S )  , § 402 , co ents (g) and (i); S  (T I ) F S, 
S  § 2 (Tent. raft 1994); I JI 10.01.2 ("duty to design and anufacture its product 
to avoid the unreasonable risk of foreseeable injury to persons using the product ith ordinary care"). 
16 I JI 0. 6; tt v. f , I c., 2 Ida  ,  .2d  (1 9); i lisbak r v. ils , 
95 Idaho 752, 519 .2d 421 (1974); S  (SE ) , § 402A, comment (h) (1977). 
     I TIFF'S I      
RT'S   ENDANT'S     -  
available scientific knowledge will be imputed to themanufacturer
17
C Nothing In The FHSA Requires Plaintiff To Prove The Existence Of A Single
Definitive Study Showing That Exposure To OC Spray Causes Chronic Respiratory
Illness Such As That Suffered By Ms Major
There is nothing in the FHSA that requires the Plaintiff to prove a single definitive study
published prior to the date of sale showing a causal link between SECsproduct and Ms Major
injuries The applicable law under the Federal Hazardous Substance Act is found at
15USCA 1261fwhich defines a hazardous substance as follows
Any substance or mixture of substances which i is toxic iiis
corrosive iii is an irritant iv is a strong sensitizer v is
flammable or combustible or vigenerates pressure through
decomposition heat or other means ifsuch substances ormixture
of substances may cause substantial personal injury or substantial
illness during or as a proximate result of any customary or
reasonably foreseeable handling or use including reasonably
foreseeable ingestion by children
19
The term toxic is defined under the statute as any substance other than a radioactive
substance which has the capacity to produce personal injury or illness to man through ingestion
inhalation or absorption through any body surface20 The term corrosive is defined under the
statute as any substance which in contact with living tissue will cause destruction of tissue by
chemical action but shall not refer to action on inanimate surfaces21 The term irritant is
defined under the statute as any substance not corrosive within the meaning of subparagraph
i ofthis section which on immediate prolonged or repeated contact with normal living tissue
17
See supra
This Court has already ruled that the applicable warning label standards are those found under the
Federal Hazardous Substance Act and not those found under OSHA While the Plaintiff maintains that
the OSHA rule is the applicable standard for the purpose of this motion and trial it will be assumed that
FHSA provides the applicable standard
19 15UC 2161fA
20 15SA 2161g
21 15USCA 2161i
22
Referencing 15USCA 1261fi
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. othing In The F S  Requires Plaintiff To Prove The Existence f  Single 
fi itive t  i  t s re   r  s s r i  s ir t r  
Illness  s t ffere   s. j r 
here is nothing in the F S  that requires the Plaintiff to prove a single definitive study 
published prior to the date f sale sho ing a causal link bet een EC's product and s. ajor's 
lllJunes.  li le l wl8  t  l s t  t i   t 
 .S.c.A. § 261(f), i  fine   "hazardo  tance"  f ll s: 
ny substance or ixture of substances hich (i) is toxic, (ii) is 
rr i , (iii) i   irrit t, (i ) i   tr  nsiti er, (v) i  
fla able or co bustible, or (vi) generates pressure through 
deco position, heat, or other eans, if such substances or ixture 
f substances ay cause substantial personal injury or substantial 
illness during or as a proxi ate result f any custo ary or 
reasonably foreseeable handling or use, induding reasonably 
foreseeable ingestion by children. 19 
e t r  "to i " i  fi  r t  t t t   "an  t  (other t   r i ti  
substance) hich has the capacity to produce personal injury or illness to an through ingestion, 
i alati , r a s r ti  t r  a   s rface.,,2o e ter  "corr si e" is efi e  er t e 
statute as "any substance hich in contact ith living tissue ill cause destruction of tissue by 
i l ti ; t ll t r f r t  ti   i i ate rf .',2l   "i rita t"  
defined under the statute as "any substance not corrosive ithin the eaning of subparagraph 
(i)22 of this section hich on i ediate, prolonged, or repeated contact ith nor al living tissue 
17 See supra. 
18 This ourt has already ruled that the applicable arning label standards are those found under the 
r l r  t e t,  t t  f  r HA. il  t  l i tiff i t i  t t 
the S  rule is the applicable standard, for the purpose of this otion and trial, it ill be assu ed that 
 r ides t e a lica le sta ard. 
 V.S.c.A. § 2161(f)(a)(A). 
20  V.S.C.A. § 2161(g). 
1  V.S.C.A. § 2161(i). 
22 Referencing 15 V.S.C.A. § 1261(f)(i). 
     I TIFF'S   I    
URT'S   FENDANT'S     -  
will induce a local inflammatory reaction
Thus under the FHSA there is no requirement that Plaintiff point to one single study
definitively demonstrating that if you expose people to OC Spray they will suffer the type of
chronic illness suffered by Ms Major All that is required under the FHSA is that the Plaintiff
show that the substance in question is a hazardous substance as defined by the FHSA and that
the product was not appropriately labeled
D Plaintiffs Counsel Did Not Admit At Oral Argument That There Were Studies
Available Prior toMarch 2008 That Would Have Put SEC On Notice That Its OC
Products Could Cause Irreversible Chronic Disease
SEC claims that there has been a judicial admission that forecloses Plaintiff cause of
action Specifically SEC points to the fact that Plaintiffscounsel acknowledged during oral
argument that there is no one single study definitively demonstrating that exposure to OC Spray
causes the type of injury suffered by Ms Major However that acknowledgement is not the
same thing as a judicial admission that there were no studies prior to the date of sale that should
have put SEC on notice that its SABRE Red Law Enforcement Grade 10 OC Spray MK9
Fogger posed a risk ofcausing chronic respiratory injuries such as those suffered by the Plaintiff
II CONCLUSION
For the reasons set forth herein Plaintiff respectfully requests that this Court grant her
Motion for Reconsideration
DATED this 8th day ofSeptember 2011
23 15USCA 21610
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ill i ce  l l i fla t r  r action.,,23 
s, er t e , t ere is  re ire e t t at lai tiff i t t  e si le st  
definitively de onstrating that if you expose people to  pray they ill suffer the type f 
ic illnes  e e   . j . ll t t i  i   t   i  t t t  l i tif  
sho  that the substance in question is a hazardous substance as defined by the F S , and that 
t e r ct as t a r riatel  la eled. 
. l i tiff's l i  t it t r l r t t r  r  "No t  
a la le   arc           ts  
ts  se rre e le  se" 
 l i  t t t     j i i l i i  t t e los  laintif s   
. Specifically, SE  points to the fact that Plaintiffs counsel ackno ledged during oral 
argu ent that there is no one single study definitively de onstrating that exposure to  Spray 
s s t e t  f i j r  s ffer   s. j r. r, t t le t is t t  
sa e thing as a judicial ad ission that there were no studies prior to the date of sale that should 
have put  on notice that its  ed, a  nforce ent rade, 10%  pray, -9 
Fogger, posed a risk f causing chronic respiratory injuries such as those suffered by the Plaintiff. 
I.  
r t e reas s set f rt  erei , lai tiff res ectfull  re ests t at t is rt ra t er 
tion  si erati n. 
 this 8th day of Septe ber, 2011. 
  .S.C.A. § 2161(j). 
SON 
 .  
     I TIFF'S   I    
URT'S   FENDANT'S     -  
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   I , I        
I   ,  i i i l, 
l intif , 
vs. 
  ORATI N, 
a issouri corporation, 
f nt. 
 .  I  
L INTIF 'S   
laintiffs trial brief is sub itted pursuant to this ourt's ay 13, 2011 rder overning 
r cee i s a  etti  rial. 
. e e ts  i ti 's  
a. Strict Liability 
i. Design Defoct: 
( a) The defendant was the "manufacturer" of the product; 
(b) e r ct as "defective"; 
fs  ie  -  
c The defect existed when the product left the defendants
control
d The defect was a proximate cause of injury to the plaintiff and
e The damages
1 The factual basis for this claim is that along
with the failure to warn ofacute and chronic
respiratory injury the product was defective
in its design The MK9 Fogger produces a
very fine mist that is easily inhaled The
mist consists of oleoresin capsicum The
constituting elements of oleoresin are
capsaicinoids which are known to be
irritants and neurotoxins At the time SEC
sold its product to IDOC it was known in
the scientific community that capsaicinoids
particularly capsaicin caused inflammation
of the respiratory tract cell death and in a
certain population sensitization
Paradoxically exposure to capsaicin was
also known to cause certain populations to
become desensitized rather than sensitized
The MK9 Fogger stands in stark
contrast to SECsstream and foam products
in that it produces a fine mist that is capable
of reaching the deep lung Streams and
foams have little effect on the respiratory
system because the particulates are larger
The MK9 Fogger like the entire
SABRE Red Law Enforcement 10
oleoresin product line sold by SEC lacks
any warnings regarding possible damage to
the respiratory tract or that it could lead to
aggravation of diseases such as RADS
NADS GERD and other conditions known
to be related to damage to the respiratory
system
Under this claim the focus is on the
product when it left the hands of SEC as
opposed to a focus on SECsconduct SEC
could have done everything possible to
eliminate the danger and still be held liable
ii Failure to Warn
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(c) he defect existed hen the product left the defendant's 
tr l; 
(d) he defect as a proxi ate cause f injury to the plaintiff; and 
( e)  s. 
i ti 's a   -  
1. he factual basis for this clai  is that along 
t          
respiratory injury, the product as defective 
in its design. he -9 ogger produces a 
very fine ist that is easily inhaled.  
ist consists f oleoresin capsicu .  
constituting     
ca saici i s      
ita t   r t xi .     
sold its product to I , it as kno n in 
t  i tifi  it  t t saici oi s, 
particularly capsaicin, caused infla ation 
of the respiratory tract, cell death, and in a 
 l ti  nsitizati n. 
Paradoxically, exposure to capsaicin as 
also kno n to cause certain populations to 
 i    nsiti d. 
he -9 Fogger stands in stark 
contrast to SEC's strea  and foa  products 
in that it produces a fine ist that is capable 
of reaching the deep lung.   
foa s have little effect on the respiratory 
t   t  rti late  r  l r er. 
The -9 Fogger, like the entire 
 ,  f r ent, 0% 
oleoresin, product line sold by SE  lacks 
any arnings regarding possible da age to 
the respiratory tract or that it could lead to 
aggravation of diseases such as S, 
,   t r iti s  
to be related to da age to the respiratory 
t . 
r t i  l i , t  f  i   t  
product hen it left the hands of S  as 
opposed to a focus on SEC's conduct. S  
could have done everything possible to 
eli inate the danger and still be held liable. 
i. e  rn: 
Same as 1aiDesign Defect except that a defect by failure to warn requires the
Plaintiff to prove that the Defendant knew or should have known of the danger
The standard for should have known imputes to the manufacturer the
knowledge of an expert in the relevant field
1 The factual basis for the failure to warn is the same as for
the defect in design claim other than the design defect
element includes considerations that are not required under
the failure to warn claim For instance it is not necessary
that there be another design that does not deploy mist sized
particles
Under this claim the focus is on the product when it
left the hands of SEC as opposed to a focus on SECs
conduct SEC could have done everything possible to
eliminate the danger and still be held liable The only
concern with SECsconduct is that involved with what
SEC should have known regarding the danger posed
b Negligence
i Design Defect
a The defendant was the manufacturer of the product and
b The defendant knew or should have known that danger to users
or bystanders could result from a particular use of the product
and
c The defendant was negligent in designing or manufacturing the
product and
Richter v Liman Intern Inc 45 F3d 1464 146869 10 Cir 1995 see also Mercer v Pittway Corp 616
NW2d 602 624 Iowa 2000 the inquiry in a negligent failure to warn case is whether a reasonable
manufacturer knew or should have known of the danger in light of the generally recognized and prevailing best
scientific knowledge yet failed to provide adequate warning to users or customers Pfeiffer v Eagle Mfg Co
771 F Supp 1133 1139DKan 1991 Bernier v Raymark Industries Inc 516 A2d 534 53839 Me
1986 Owen Illinois Inc v Zenibia 601 A2d 633 63940 Md 1992 see 402A Restatement Second of Torts
1965 strict product liability Potter v Chicago Pneumatic Tools Co 694 A2d 1319 132829 Conn 1997
strict liability relieves plaintiff of burden of proving manufacturer was negligent and allows plaintiff to establish
instead defective condition of product as principal basis of liability Lohrmann v Pittsburgh Corning Corp 782
F2d 1156 1164 4th Cir 1986
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a e as l(a)(i) esi  efect e ce t t at a efect  fail re t  ar  re ires t e 
laintiff to prove that the efendant kne  or should have kno n f the danger. 
 t   "sh   own" tes t     
e        ld. 1 
.      i        r 
t e efect i  esi  clai  t er t a  t e esi  efect 
ele e t i cl es c si erati s t at are t re ire  er 
t e fail re t  ar  clai . r i stance, it is t ecessar  
t at t ere e a t er esi  t at es t e l  ist size  
rti l s. 
er t is clai , t e f c s is  t e r ct e  it 
left t e a s f  as se  t  a f c s  EC's 
t.  c l  a e e e er t i  ssi le to 
eli inate the danger and still be held liable. he only 
 t  EC's       
 should have kno n regarding the danger posed. 
h. lige  
i. esi  efect: 
(a) e efe a t as t e a fact rer f t e r uct; a  
(b) e efe a t e  r s l  a e  t at a er t  sers 
r sta ers c l  res lt fr  a artic lar se f t e r ct; 
 
( c) e efe a t as e li e t i  esi i  r a fact ri  t e 
r ct; a  
1 Richter v. Li ax Intern., Inc., 45 F3d 1464, 1468-69 (lOth ir. 1995); see also, ercer v. itt ay orp., 616 
.W.2d ,  (Iowa ) (the         "is    
a a t rer  r      r,  ig t  t e r ll    i   
scientific kno ledge, yet failed to provide adequate arning to users or customers. "); feiffer v. agle fg. o., 
71 . . , 9 (D.Kan. 91»; ie  . k In t i , I c.,  .2d ,5 -39 (M . 
86); -Illin i , I . . i i ,  .2d , -40 (M . 92);   t t t (Se d)  rts 
(19 ) (strict r t li bility); tte  . i  ti  l  o.,  .2d , -29 (Co . ) 
(strict liability relieves plaintiff of burden of proving anufacturer as negligent and allo s plaintiff to establish 
instead defective condition of product as principal basis ofliability); Lohr ann v. Pittsburgh oming orp., 782 
.2d , 4 (4th ir. 6). 
lai tiff's rial rief -  
d The defendantsnegligence was a proximate cause of injury to
the plaintiff and
e The nature and extent of the injuries the elements of damage
and the amount thereof
1 The factual basis for the claim is similar that
for strict liability design defect The only
difference being that the focus is on SECs
conduct
ii Failure to Warn
a The defendant manufactured the product
b The defendant knew or should have known that danger to
users or bystanders could result from a particular use of the
product
c The defendant failed to give adequate warning of such danger
d The failure to give adequate warning was a proximate cause of
the injury and
e The damages
1 The factual basis for the claim is similar that
for strict liability design defect The only
difference being that the focus is on SECs
conduct
2 Contested Facts
a Whether the product that MsMajor was exposed to was that of SECs
b Whether SECsSABRE Red productscaused Ms Major injuries
c Whether the state of knowledge at the time SEC sold its SABRE Red
products to Ms Major employer was such that it should have known the
danger of injury such as that suffered by Ms Major
d Whether SECsSABRE Red products posed a risk of acute and chronic
2 The same standard as in strict liability applies to the should have known element
PlaintiffsTrial Brief 4
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(d) he defendant's negligence as a proxi ate cause of injury to 
t e laintiff; a  
( e) he nature and extent of the injuries, the ele ents of da age, 
   r of. 
.  l      i   
for strict liability design defect. he only 
difference being that the focus is on EC's 
t. 
i. e  arn: 
(a)  f t f t r  t  r ct; 
(b) e f t  r l   n2 t t r t  
s rs r st rs l  r s lt fr   rti l r s  f t  
product; 
(c) e efe a t faile  t  i e a e ate ar i  f s c  a er; 
(d) e fail re to i e a e ate ar i  as a r i ate ca se f 
the injury; and 
( e)  s. 
.  ts: 
I.      i   i i   
f r strict lia ilit  esi  efect. The only 
ifference i  t t t  f s is  EC's 
t. 
a. et er t e r ct t at s. aj r as e se  t  as t at f EC's. 
b. hether SEC's S BRE Red product(s) caused s. ajor's injuries. 
. t r t  st t  f le  t t  ti   s l  its   
products to s. ajor's e ployer as such that it should have kno n the 
danger of injury such as that suffered by s. ajor. 
d. hether EC's  ed products posed a risk of acute and chronic 
2 he sa e standard as in strict liability applies to the "should have kno n" ele ent. 
laintiff's  e  -  
injury to the respiratory capable of resulting in the illness that Ms Major
suffers from
3 Contested Issues of Law
a Whether FHSA standards were violated by the warning label on SABRE
Red products
b Whether FHSA preemption as an affirmative defense may be asserted at
trial since the Defendant has never pleaded the affirmative defense sought
to amend its answer or sought to amend this Courts deadline for
amending the pleadings If the preemption defense has been waived the
Plaintiff can prevail either by proving the standards under FHSA were
violated or that SEC breached its common law duties which might be
broader than was is required under the FHSA
c It is likely that there is a difference of opinion as to the burden shifting that
takes place when the defendant raises state of the art as defense
d It is likely that there is a difference of opinion as to the burden shifting that
takes place once the plaintiff proves that a defect caused her injury under
the strict liability theory The burden shifts to the defendant to show that
the alternative design was impossible economically infeasible or the cost
benefit analysis favors the design chosen by the manufacturer
4 Evidentiary Issues At this point it is not clear There have been a number of
motions in limine filed that will raise most of the evidentiary issues Plaintiff has
filed motions in limine on the following subjects a Whether evidence of SECs
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injury to the respiratory, capable f resulting in the illness that s. ajor 
fers . 
.  ss es   
. hether  standards ere violated by the arning label on  
e  r cts. 
b. hether  pree ption as an affir ative defense ay be asserted at 
trial since the efendant has never pleaded the affir ative defense sought 
to a end its ans er or sought to a end this ourt's deadline for 
a ending the pleadings. If the pree ption defense has been aived, the 
Plaintiff can prevail either by proving the standards under F S  ere 
iolate  r t t  r  its  l  ti s i  i t  
broader than as is required under the F S . 
. It is likely that there is a difference of opinion as to the burden shifting that 
takes place hen the defendant raises state of the art as defense. 
d. It is likely that there is a difference of opinion as to the burden shifting that 
takes place once the plaintiff proves that a defect caused her injury under 
the strict liability theory. The burden shifts to the defendant to sho  that 
the alternative design as i possible, econo ically infeasible, or the cost-
benefit analysis favors the design chosen by the anufacturer. 
4. videntiary Issues: t this point, it is not clear. here have been a nu ber of 
otions in li ine filed that ill raise ost of the evidentiary issues. Plaintiff has 
filed otions in li ine on the follo ing subjects: (a) hether evidence of SEC's 
l i ti  ia  e  -  
compliance with FHSA should be admitted for the purpose of proving
preemption since it appears to have waived that defense See Sherman v
Winco Fireworks 532 F3d 709 8 Cir 2009 reversible error where trial
court allowed a FHSA preemption defense at trial where it had not been pleaded
in the answer and there was no attempt to seek to amend scheduling order to
allow for amending the answer b Whether evidence that the Plaintiff has or
had herpes should be admitted c Whether evidence of negative action andor
discipline taken against the Plaintiff during her employment at IDOC should be
admitted d Whether evidence of an investigation by Plaintiffsemployer into
the appropriateness of Plaintiff spraying OC on an inmate who grabbed at
another correctional officer should be admitted e Whether SEC should be
permitted to present evidence that none of its health questionnaires included a
report of chronic respiratory illness resulting from OC exposure since SEC
limited the number of questionnaires it produced f Whether use of force
evidence tending to show that the use of OC Spray by law enforcement during
arrest poses low risk of incustodydeaths due to psychiatric and cardiac reasons
5 Agreed or Stipulated Facts The parties are still working toward developing a
set of stipulated facts There is actually much common factual ground in this case
and it is anticipated that the parties can reach significant agreement and narrow
the factual issues for trial
6 Memorandum on Issues of Law
a Known or ShouldHave Known Standard
The relevant element of a failure to warn cause ofaction is that the defendant knew or
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liance ith  s l   itte  f r t  r ose f r i  
r ti  i e it rs t   ai e  t t f .  r  . 
inc  ir r ,  .3d  (8th ir. 9) (reversi le rr r r  tri l 
rt ll e    r ti  fe s  t tri l r  it  t  l  
in t  r,  t r  a   tt t t   t   li  r r t  
ll  f r i  t e swer). (b) t r i e  t t t  l i tiff  r 
 r  l   itt . (c) et r i   ti  ti  /or 
s ine   e         
itt . (d) het r i e ce f  i e ti ti   laintiff's l r i t  
the appropriateness of Plaintiff spraying  on an in ate ho grabbed at 
  ice    i d. (e)     
r itte  t  r t i  t t  f it  lt  ti ires i l   
report of chronic respiratory illness resulting fro   exposure since S  
li ited the nu ber of questionnaires it produced. (f) hether "use of force" 
i  t i  t   t t t       l  t i  
arrest poses lo  risk of in-custody-deaths due to psychiatric and cardiac reasons. 
5. greed r tipulated acts: he parties are still orking to ard developing a 
set f sti late  facts. ere is act all  c  c  fact al r  i  t is case 
and it is anticipated that the parties can reach significant agree ent and narro  
    i l. 
. a     : 
.   l    t  
         f  i    "defend    
laintif '   rief -  
should have known that danger to users or bystanders could result from a particular use of the
product One way the Plaintiff can meet this burden is by direct evidence that SEC knew of the
safety concerns that existed with OC Spray when used on people with respiratory illness
Plaintiff can also meet her burden by presenting evidence of a body of scientific literature
in existence prior to the date of sale from which it can be concluded within a reasonable degree
of scientific certainty that SECs SABRE Red Law Enforcement Grade 10 OC Spray MK9
Fogger posed a risk of respiratory injury such as that suffered by the Ms Major That is
Plaintiff can meet the relevant element of her case by showing that the risks of chronic injury
such as that complained of by the Plaintiff should have been known by SEC in light of available
scientific knowledge at the time the product was sold to the IDOC
The majority view is that information known in the scientific and expert community
regarding the dangers of a particular product will be imputed to the manufacturer when assessing
what the manufacturer should have known at the time ofsale
Moreover the courts reason the presence of the required
knowledge can be established by evidence that the dangerous
quality of the product should have been known by a manufacturer
because it was known in the scientific or expert community As
Judge John Minor Wisdom stated for the court in another case
involving a claimed injury from asbestos Borel v Fibreboard
Paper Products Corporation 493F2d 1076 1089 5th Cir 1973
cert denied 419US869 95 SCt 127 42LEd2 107 1974
In cases such as the instant case the manufacturer
is held to the knowledge and skill of an expert This
is relevant in determining 1 whether the
3 IDJI 1006 Puckett v Oakfabco Inc 132 Idaho 816 979 P2d 1174 1999 Rindlisbaker v Wilson 95
Idaho 752 519P2d 421 1974 RESTATEMENT SECOND OF TORTS 402A comment h 1977
4 OwenIllinois Inc v Zenibia 601 A2d 633 63940 Md 1992 see 402A RESTATEMENT SECOND
OF TORTS 1965 strict product liability Potter v Chicago Pneumatic Tools Co 694A2d 1319 1328
29 Conn 1997 strict liability relieves plaintiff of burden of proving manufacturer was negligent and
allows plaintiff to establish instead defective condition of product as principal basis of liability
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should have kno n that danger to users or bystanders could result fro  a particular use of the 
product.,,3 ne ay the Plaintiff can eet this burden is by direct evidence that SE  kne  of the 
safety concerns that existed ith  Spray hen used on people ith respiratory illness. 
l i tiff  l  eet r r e   res ting idence     i tific literat re 
in existence prior to the date of sale fro  hich it can be concluded ithin a reasonable degree 
of scientific certainty that S C's S  ed, a  nforce ent rade, 10%  Spray, -9 
Fogger, posed a risk of respiratory injury such as that suffered by the s. ajor. at , 
l i ti   e t t  l t l t   se  i  t t t  i   i  i j  
such as that co plained of by the Plaintiff should have been kno n by SEC in light of available 
scientific kno ledge at the ti e the product as sold to the I C.4 
The ajority vie  is that infor ation kno n in the scientific and expert co unity 
regarding the dangers of a particular product ill be i puted to the anufacturer hen assessing 
          l : 
r r, t  rt  r son, t  r  f t  r ir  
kno ledge can be established by evidence that the dangerous 
quality of the product should have been kno n by a anufacturer 
because it as kno n in the scientific or expert co unity.  
Judge John inor isdo  stated for the court in another case 
involving a clai ed injury fro  asbestos, Borel v. Fibreboard 
r r ts r oration,  .2d ,  (5t  ir. 73), 
rt. i ,  .S. ,  .Ct. ,  .Ed.2d  (1 4), 
[I]n cases s c  as t e i sta t case, t e a fact rer 
is held to the kno ledge and skill of an expert. This 
   deter ining (1)   
3 IDJI 10.06; Puckett v. Oakfabco, Inc., 132 Idaho 816, 979 P.2d 1174 (1999); Rindlisbaker v. ilson, 95 
Idaho 752,519 P.2d 421 (1974); RESTATE ENT (SECOND) OF TORTS, § 02A, c e t ( ) (1 77). 
4 en-Illi is, I c. v. nibia,  .2d 33, -4  (M . 992); s  02A TA  (S ND) 
OF TORTS (1965) (strict product liability); Potter v. Chicago Pneu atic Tools Co., 694 .2d 1319, 1328-
29 (Conn. 1997) (strict liability relieves plaintiff of burden of proving anufacturer was negligent and 
allo s plaintiff to establish instead defective condition of product as principal basis of liability). 
laintiff's i l ri f -  
manufacturer knew or should have known the
danger The manufacturersstatus as expert
means that at a minimum he must keep abreast of
scientific knowledge discoveries and advances and
is presumed to know what is imparted thereby
The same point was made by the United States Court ofAppeals
for the Fourth Circuit in Lohrmann v Pittsburgh Corning Corp
782F2d 1156 1164 4th Cir 1986
Industry standards and state of the art are not
synonymous State of the art includes all of the
available knowledge on a subject at a given time
and this includes scientific medical engineering
and any other knowledge that may be available
State of the art includes the element oftime What
is known and when was this knowledge available
See eg Hardy v Johns Manville Sales Corp 681 F2d 334 344
5th Cir 1982 Gordon v Niagara Mach Tool Works 574F2d
1182 1190 5th Cir 1978 Shell Oil Co v Gutierrez 119 Ariz
426 434 581 P2d 271 279 1978 Oakes v Geigy Agricultural
Chemicals 272 CalApp2d 645 651 77 CalRptr 709 713 3d
Dist 1969 Woodill v Parke Davis Co supra 79 Ill 2d at 37
37 Ill Dec at 308 402NE2d at 198 Smith v ERSquibb
Sons Inc 405 Mich 79 90 273NW2d476 480 1979 McKee
v Moore 648 P2d 21 Okla1982 Cochran v Brooke 243 Or
89 9496 409 P2d 904 906907 1966 See also C Marvel
Annotation STRICT PRODUCTS LIABILITY LIABILITY FOR FAILURE
TO WARN As DEPENDENT ON DEFENDANTs KNOWLEDGE OF
DANGER 33ALR4th 368 1984 and cases cited therein
Other courts have similarly held that the knowledge of available scientific data will be
imputed to the manufacturer for the purpose of determining whether there was sufficient notice
of the dangers involved
The conduct should be measured by knowledge at the time the
manufacturer distributed the product Given the scientific
technological and other information available when the product
was distributed did the manufacturer know or should he have
known of the danger In other words did he have actual or
5 OwenIllinois Inc 601 A2d at 63940 emphasis added
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rer       
nger....  nufacturer's st t s s rt 
ea s t at at a i i  e st ee  a reast f 
scie tific le e, isc eries, a  a a ces a  
is presu ed to kno  hat is i parted thereby. 
e sa e i t as a e  t e ite  tates rt f eals 
for the ourth ircuit in r  v. itts r  r i  orp., 
  .2d ,  (4th ir. 86): 
I str  st r s  st t  f t  rt r  t 
. t t   t  t i ludes ll f t  
a aila le le e  a s ject at a i e  ti e, 
and this includes scientific, edical, engineering, 
and any other kno ledge that ay be available. 
e    ludes    :  
is kno n and hen as this kno ledge available. 
See, e.g., ardy v. Johns- anville Sales orp., 681 .2d 334, 344 
(5th ir.1982); ordon v. iagara ach. & l ,  .2d 
1182, 1190 (5th ir. 1978); Shell il o. v. utierrez, 119 riz. 
426, 434, 581 .2d 271, 279 (1978); akes v. eigy gricultural 
he icals, 272 al.App.2d 645, 651, 77 al. Rptr. 709, 713 (3d 
i t. 69); ill .  is & o., r ,  ll.  t , 
37 Ill. ec. at 308, 402 .E.2d at 198; S ith v. .R. Squibb & 
Sons, Inc., 405 ich. 79, 90, 273 .W.2d 476, 480 (1979); c ee 
v. oore, 648 P.2d 21 (Okla.1982); ochran v. rooke, 243 r. 
89, 94-96, 409 P.2d 904, 906-907 (1966).  l  . r l, 
t ti n, 1   I I I : I I I   I  
  S   FENDANT'S   
, 33 .L.R. 4th 368 (1984), and cases cited therein.5 
ther courts have si ilarly held that the kno ledge of available scientific data ill be 
i puted to the anufacturer for the purpose of deter ining hether there as sufficient notice 
of the dangers involved: 
he conduct should be easured by kno ledge at the ti e the 
anufacturer distributed the product. iven the scientific, 
technological and other infor ation available hen the product 
 i t i t , i  t  t    l    
kno n f the danger. In other ords, did he have actual or 
5 en-Illinois, Inc., 601 .2d at 639-40 (emphasis added). 
i ti 's  rief -  
constructive knowledge of the danger A product related danger
may be regarded as knowable if the available scientific data
gave rise to a reasonable inference that the danger is likely to
exist Wade On The Effect in Product Liability of Knowledge
Prior to Marketing 58NYUL REv 734 749 1983 A
manufacturer is held to the knowledge and skill ofan expert and
is required to test his products and keep abreast of scientific
discoveries related to his products but he has a duty to warn only
of dangers that the employment of the reasonable foresight of an
expert could reveal See Borel v Fibreboard Prods Corp 493
F2d 1076 10891090 5th Cir 1973 Wisdom J applying
Texas law cert denied 419US 869 1974 See generally IA L
Frumer M Friedman PRODUCTS LuBiury 120731985
It should also be emphasized that the knowledge imputed to the manufacturer is not
merely the standard within the relevant industry
The majority of courts however have defined stateoftheart
evidence as the level of relevant scientific technological and safety
knowledge existing and reasonably feasible at the time of design
See eg Carter v Massey Ferguson Inc 716F2d 344 347 5th
Cir 1983 state of the art refers to the technological
environment that is what can be done emphasis in original
Gosewisch v American Honda Motor Co 153 Ariz 389 394 737
P2d 365 App 1985 state of the art refers to what feasibly could
have been done Montgomery Ward Co v Gregg 554NE2d
1145 115556 Ind App 1990 defining state of the art as
technological advancement not as industry custom or practice
Chown v USM Corp 297NW2d218 222 Iowa 1980 defining
state of the art as technological and practical feasibilityOBrien
v Muskin Corp 94 NJ 169 182 463 A2d 298 1983 defining
state of the art as existing level of technological expertise and
scientific knowledge relevant to a particular industry at the time a
product is designed Boatland ofHouston Inc v Bailey 609
SW2d 743 748 Tex 1980 state of the art includes the
scientific knowledge economic feasibility and the practicalities of
implementation when the product was manufactured see also
2 AMERICAN LAw OF PRODUCTS LIABILITY 3d 1996 305
p3077state of the art has been defined as the safety
technical mechanical and scientific knowledge in existence and
reasonably feasible for use at the time ofmanufacture
6 Bernier v Raymark Industries Inc 516A2d 534 53839 Me 1986 emphasis added
7 Potter 694 A2d at 1346 see also Mercer v Pittway Corp 616 NW2d 602 Iowa 2000
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constructive kno ledge of the danger.  product-related danger 
 e re rded s le "if t e ila le s i tific t  
gave rise to a reasonable inference that the danger is likely to 
exist. " a e,  e ffect i  r ct i ility f le e 
ri r t  r ti ,  .Y.U.L. . ,  (19 3).  
f t  is l  t  t e le  d ill f  ert,  
is required to test his products and keep abreast f scientific 
is ies elate  t  is t , t e   t  t  r  l  
of dangers that the e ploy ent of the reasonable foresight of an 
expert could reveal. See orel v. ibreboard rods. orp., 493 
.2d , -1090 (5th ir. 3) (Wisd , .) (ap l in  
e as l w), t. i ,  .S.  (19 4).  r ll  l  . 
 & . ri ,  IA ILITY § 2.0 [3] (1 85).6 
It should also be e phasized that the kno ledge i puted to the anufacturer is not 
erely the standard ithin the relevant industry: 
The ajority of courts, ho ever, have defined state-of-the-art 
i e ce  t  l l f r l t i ntifi , t l i l  f t  
kno ledge existing and reasonably feasible at the ti e of design. 
See, e.g., arter v. assey- erguson, Inc., 716 F.2d 344, 347 (5th 
ir. 1983) ('''state   rt' r f rs t  t  t l i l 
environ ent, that is, hat can be done" [e phasis in original]); 
 .    o.,  i . , ,  
P.2d 365 (App. 1985) ("state of the art refers to hat feasibly could 
  "); ontgo ery ard & . . g,  .E.2d 
1145, 1155-56 (Ind. pp. 1990) (defining state of the art as 
technological advance ent, not as industry custo  or practice); 
 .  orp.,  .W.2d ,  (Io  80) (de i i  
state of the art as technological and practical feasibility); 0 'Brien 
v. uskin orp., 94 .J. 169, 182,463 .2d 298 (1983) (defining 
state of the art as "existing level of technological expertise and 
scientific kno ledge relevant to a particular industry at the ti e a 
product is designed"); oatland of ouston, Inc. v. ailey, 609 
S.W.2d 743, 748 (Tex. 1980) ("[state of the art] includes the 
scientific kno ledge, econo ic feasibility, and the practicalities of 
i ple entation hen the product as anufactured");  l  
 I  W F  I I I   (1 6) § 0:50, 
p.30-77 ('''[s]tate of the art' has been defined as the safety, 
t chnical, chanical,  sci ntifi  l  i  ist   
reasonably feasible for use at the ti e of anufacture"). 7 
6 Bernier v. Ray ark Industries, Inc., 516 .2d 534,538-39 ( e. 1986) (e phasis added). 
7 Potter, 694 .2d at 1346; see a/so, ercer v. Pittway Corp., 616 .W.2d 602, (Io a 2000) 
l i ti  i l i  -  
The law places on the manufacturer an affirmative duty to investigate and test Where
investigation andortesting would have revealed a danger that arises under normal use of the
product the manufacture must warn of the danger For instance in a case where there were no
known reports of mini trampolines causing users to suffer stress fractures the Tenth Circuit
reversed the district courtsdecision dismissing the case The district court dismissed on the
grounds that the manufacturer did not know and should not have known of the danger of stress
fractures caused by the normal use ofminitrampolines Plaintiff experts testified at trial that
observations from very simple tests interpreted in light of well
established knowledge about the structure of the foot and the
causes of stress fractures would have made it apparent that the
repetitive use of the mini trampoline for jogging could cause stress
fractures Two experts testified the danger was well within the
state of society knowledge about such matters One of Richters
experts pointed out that although there were no known reports
concerning mini trampolines as a cause of stress fractures sport
and exercise magazines as well as scientific and medical journals
have long published articles establishing that repetitive jogging can
cause stress fracturesII
Quoting an earlier district court case applying Kansas law the appellate court explained the duty
placed on the manufacturer
Ordinarily a manufacturer has a duty under Kansas law to warn
consumers and users of its products when it knows or has reason to
know that its product is or is likely to be dangerous during normal
use The duty to warn is a continuous one requiring the
distinguishing between custom of the industry and state of the art and concluding that the relevant
question is not what others were doing at the time but whether the evidence disclosed that anything
more could reasonably and economically be done
8 Richter v Limax Intern Inc 45 F3d 1464 146869 10 Cir 1995 see also Mercer v Pittway Corp
616NW2d 602 624 Iowa 2000 the inquiry in a negligent failure to warn case is whether a
reasonable manufacturer knew or should have known of the danger in light of the generally recognized
and prevailing best scientific knowledge yet failed to provide adequate warning to users or customers
9
Richter 45 F3d at 146869
to Id
11 Id at 1467
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       r      t.  
investigation and/or testing ould have revealed a danger that arises under nor al use f the 
t,   s     nger.s  ,        
kno n reports of ini-tra polines causing users to suffer stress fractures, the enth ircuit 
 t  i t i t urt's i i  i i i  t  se.9  i t i t t i i   t  
r s t at t e a fact rer i  t  a  s l  t a e  f t e a er f stress 
fract res ca se   t e r al se f ini-tra polines. 10 laintiffs e erts testifie  at trial t at 
observations fro  very si ple tests, interpreted in light f ell-
established kno ledge about the structure of the foot and the 
causes of stress fractures, ould have ade it apparent that the 
repetitive use of the ini-tra poline for jogging could cause stress 
fract res. o experts testified the danger as ell ithin the 
state of society's kno ledge about such atters. ne of ichter's 
experts pointed out that although there ere no kno n reports 
concerning ini-tra polines as a cause of stress fractures, sport 
and exercise agazines as ell as scientific and edical journals 
have long published articles establishing that repetitive jogging can 
 ess tures. I  
uoting an earlier district court case applying ansas la , the appellate court explained the duty 
placed on the anufacturer: 
rdinarily, a anufacturer has a duty under ansas la  to arn 
consu ers and users of its products hen it kno s or has reason to 
kno  that its product is or is likely to be dangerous during nor al 
. The duty to arn is a continuous one, requiring the 
(distinguishing bet een custo  of the industry and "state of the art" and concluding that the relevant 
question is not hat others ere doing at the ti e but "whether the evidence disclosed that anything 
ore could reasonably and econo ically be done."). 
 i ter v. i  I t rn., I .,   4, -69 (loth ir. 995); s  ls , r r v. itt  rp., 
616 .W.2d 602, 624 (Iowa 2000) (the inquiry in a negligent failure to arn case "is hether a 
reasonable anufacturer kne  or should have kno n of the danger, in light of the generally recognized 
and prevailing best scientific kno ledge, yet failed to provide adequate arning to users or custo ers."). 
9 t r,    -6 . 
\0 I . 
11 . t . 
s  ri f-  
manufacturer to keep abreast of the current state of knowledge of
its products as acquired through research adverse reaction
reports scientific literature and other available methods A
manufacturers failure to adequately warn of its product
reasonably foreseeable dangers renders that product defective
under the doctrine ofstrict liability
b FHSA Standards
The applicable law 13 under the Federal Hazardous Substance Act is found at 15USCA
1261fwhich defines a hazardous substance as follows
Any substance or mixture of substances which i is toxic iiis
corrosive iii is an irritant iv is a strong sensitizer v is
flammable or combustible or vigenerates pressure through
decomposition heat or other means if such substances or mixture
of substances may cause substantial personal injury or substantial
illness during or as a proximate result of any customary or
reasonably foreseeable handling or use including reasonably
foreseeable ingestion by children
14
The term toxic is defined under the statute as any substance other than a radioactive
substance which has the capacity to produce personal injury or illness to man through ingestion
inhalation or absorption through anybody surface The term corrosive is defined under the
statute as any substance which in contact with living tissue will cause destruction of tissue by
chemical action but shall not refer to action on inanimate surfaces The term irritant is
defined under the statute as any substance not corrosive within the meaning of subparagraph
12 Id at 1468 quoting Pfeiffer v Eagle Mfg Co 771 F Supp 1133 1139DKan 1991 emphasis
added
13 This Court has already ruled that the applicable warning label standards are those found under the
Federal Hazardous Substance Act and not those found under OSHA While the Plaintiff maintains that
the OSHA rule is the applicable standard for the purpose of this motion and trial it will be assumed that
FHSA provides the applicable standard
14 15UC 2161fA
15SA 2161g
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f ct rer t  kee  re st f t e c rre t st te f k le e f 
its roducts s ire  t r  r s arch, rs  r ti  
r rts, s i tifi  lit r t r ,  t r il l  t s.  
ufacturer's   a e atel  ar  f its roduct's 
reas a l  foreseea le a ers re ers t at r ct efecti e 
 t e t i e  t i t li bility.12 
.   
e a lica le la l3           V.S.C.A. 
§ 261(f), ic  fines  "hazardous s st ce" s f ll s: 
 s sta ce r i t re f s sta ces ic  (i) is t xic, (ii) is 
corrosive, (iii) is an irritant, (iv) is a strong sensitizer, (v) is 
fla able or co bustible, or (vi) generates pressure through 
deco position, heat, or other eans, if such substances or ixture 
f substances ay cause substantial personal injury or substantial 
illness during or as a proxi ate result f any custo ary or 
reasonably foreseeable handling or use, including reasonably 
foreseeable ingestion by children. 14 
he ter  "toxic" is defined under the statute as "any substance (other than a radioactive 
substance) hich has the capacity to produce personal injury or illness to an through ingestion, 
inhalation, or absorption through anybody surface.,,15   "corr ive"  f    
statute as "any substance hich in contact ith living tissue ill cause destruction f tissue by 
i l ti n; t ll t  t  ti   i i ate rf ces.,,16   "i rita t"  
defined under the statute as "any substance not corrosive ithin the eaning f subparagraph 
12Id. at 1468 (quoting feiffer v. agle fg. o., 771 F. upp. 1133, 1139 (D.Kan. 1991)) (e phasis 
a ded). 
13 This Court has already ruled that the applicable arning label standards are those found under the 
 s  t,      HA. le  l i ti    
t e  r le is t e a lica le sta dard, f r t e r se f t is ti  a  trial, it ill e ass e  t at 
F S  provides the applicable standard. 
14  V.S.C.A. § 2161(f)(a)(A). 
15  V.S.C.A. § 2161(g). 
laintiff's  rief -  
i
17
of this section which on immediate prolonged or repeated contact with normal living tissue
will induce a local inflammatory reaction
18
The FHSA requires manufacturers of products containing irritant andor toxic
substances to include conspicuous warnings and instructions on the label that among others
includes 1 an affirmative statement of the principal hazard or hazards such as Flammable
Combustible Vapor Harmful Causes Burns Absorbed Through Skin or similar
wording descriptive of the hazard 2 precautionary measures describing the action to be
followed or avoided 3 instruction when necessary or appropriate for firstaid treatment
and 4 instructions for handling and storage of packages which require special care in handling
or storage The statements must be located prominently in conspicuous and legible type
in contrast by typography layout or color with other printed matter on the label
As to what is actually required by the FHSA label standards the Mattis case is very
instructive and by comparison demonstrates that a genuine issue of material fact exists in this
case Mattis involved a young electrician who inhaled chemical vapors from piping cement that
contained respiratory irritants
21
The electrician became ill as a result and was diagnosed as
suffering from reactive airway syndrome RADS
In Mattis
the district court held that there was a question of fact for the jury
about whether these requirements were met because the label did
not statekeep out of the reach of children and because the
16 15USCA 2161i
17
Referencing 15USCA 1261fi
15USCA 21610
195 USC 1261p defining misbranded hazardous substance see 15 USC 1263
prohibiting introduction into interstate commerce ofmisbranded hazardous substance
20 15USC 1261p
2 295F3d at 85960
22 id
PlaintiffsTrial Brief 12
001496
(i)17 f t is s cti  i   i i te, r l d, r r t  t t it  r l li i  tiss  
ill induce a local infla atory reaction.,,18 
  r ire  f t r rs  r t  t i i  "irrit nt" nd/or "to ic" 
t  t  i l  i  r ings  i tr ti s  t  l l t t,  t ers, 
i l s: (1) "an f i ti  t t t  t  i i l   r s,   "Fla l ", 
"Combusti le", "Vapor r f l", "Causes m ", "Absorb  r  i ",  i  
i  ri ti   t  "; (2) "precautionary easures describing the action to be 
follo ed or avoided"; (3) "instruction, hen necessary or appropriate, for first-aid treat ent"; 
 (4) "instructions f r li   t r  f a es i  r ir  i l r  i  li  
r st r ge.,,19 The state ents ust be "located pro inently ... in conspicuous and legible type 
i  tr t  t r y, l t, r l r it  t r ri t  tt r  t  l el.,,2o 
s t  t i  t ll  i   t   l l t r , t  tti   i   
instructive and, by co parison, de onstrates that a genuine issue f aterial fact exists in this 
. is e             
t i e  i t  i it t .21 he electrician beca e ill as a result and as diagnosed as 
s fferi  fr  reacti e air a  s r e (R DS).22 
 tti , 
[t ]he district court held that there as a question of fact for the jury 
about hether these require ents ere et because the label did 
not state "[k]eep out of the reach of children" and because the 
16  V.S.C.A. § 161(i). 
17 f r i   V.S.C.A. § 261(t)(i). 
18  V.S.C.A. § 1(j). 
19 15 V.S.C. § 261(P)(1) (definin  "misbrande   t ");   V.S.C. §  
(prohibitin  tr i  t  terst t  er   "misbrande   "). 
20  V.S.C. § 1261(p)(2). 
21  .3d  -6 . 
2I . 
l intiff's rial ri f -  
aevidence about the harmful effects of Carlon cement called into
question whether the labelsstatements about principal hazards
precautionary measures or instructions for handling were
inadequate We agree Although the label stated vapor harmful
this warning was followed by the statements may irritate eyes and
skin and vapors may cause flash fires The label does not make
it clear that inhalation of the vapors is harmful The label did not
state handling instructions or specify any precautionary measures
regarding inhalation of fumes from the cement other than to say
if inhaled get fresh air
The label in Mattis was described by the court as
Danger extremely flammable harmful or fatal if swallowed
vapor harmful may irritate eyes and skin may be absorbed
through the skin Vapors may cause flash fires Read precaution
on back label With regard to vapors the back of the label stated
Vapors may ignite explosively Prevent buildup of vaporsopen
all windows and doorsuse only with cross ventilation Close
container after use Ifinhaled getfresh air If ill feelings persist
seek medical attention
Under the FHSA a product having more than one principal hazard must include on its label an
affirmative statement of each such hazard the precautionary measures describing the action to be
followed or avoided for each hazard and instructions for handling and storage necessitated by
the existence ofmore than one hazard The regulations define principal hazards aswording
descriptive of the principal or primary hazardsassociated with a hazardous substance
c Negligence Per Se
Mattis 295 F3d at 862 emphasis in original
14
Mattis 295F3d at 859 n2 emphasis added
15 16CFR 150027 15USC 1261p
26 16CFR 150021vii
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sti  t  t  l bel's t t t  t ri i l azards, 
ti  sures, r i  f  handling r  
i ate.  r e. lt  t  l l t t  "vap r annful," 
t i  i   ll   t  tate ents, "ma  i it t    
kin"  "vapor    l  ires."  l l  t  
it l  t t i l ti   t   i  r ful.  l l i  t 
t t  li  i t ti   ecif   uti r   
 l t   f      t   ay, 
"if inhaled, get fresh air. ,,23 
   s      s: 
"Dan er: e tre el  fla a le •   l  l  • 
v r r f l •  itat     • a  e a s r e  
t r  t  i . r    fla  fir s.  r ti  
  l el." it   t  r , t    t  l l t ted: 
"Vapors ay ignite explosively. Prevent build-up of vapors-open 
ll i s  s-us  l  it  s - ntilation .... l  
t i  t  se ....  i l  t f e  ir.  ill li  r i t, 
  tt ntion.,,24 
r t  ,  r t i  re t   ri i l r  t i l   it  l l "an 
affir ative state ent of each such hazard; the precautionary easures describing the action to be 
follo ed or avoided for each hazard," and instructions for handling and storage necessitated by 
the existence of ore than one hazard.25 The regulations define principal hazard( s) as "wording 
escri ti e f t e rincipal r ri ar  azard( s) ass ciate  ith a azar s s sta ce. ,,26 
. ligence   
23 Mattis,  .3d t  (emphasis in ri i al). 
24 ttis,  .3d t  .2 (emphasis ed). 
25  .F.R. § 500.127; 15 .S.C. § 1261(p). 
26  .F.R. § 500.121(a)(2)(vii). 
i ti '  ria  rief -  
An FHSA warning label violation is evidence of a failure to warn and of a defective
product in state tort product liability cases
27
Violation of a statute or regulation may be
negligence per se where the statute or regulation was intended to prevent the type of harm the
defendants act or omission caused and the plaintiff is a member of the protected persons the
statute or regulation aims to protect
28
The FHSA requires manufacturers of hazardous substance products to include on the
label certain warnings and directions A hazardous substance means
1AAny substance or mixture of substances which i is toxic
ii is corrosive iii is an irritant iv is a strong sensitizer v is
flammable or combustible or vi generates pressure through
decomposition heat or other means if such substances or
mixture of substances may cause substantial personal injury or
substantial illness during or as a proximate result of any
customary or reasonably foreseeable handling or use including
reasonably foreseeable ingestion by children
All that is required under the FHSA is a balanced perspective of the potential hazards of
the product Many products which may cause chronic health effects may also be acutely
toxic and present physical hazards such as flammability The product labeling must take into
consideration both the acute and chronic inhalation hazards 32
27 Sanchez v Galey 112 Idaho 609 61718 1987 OSHA violation may be evidence ofnegligence per
se citing Dixon v International Harvester Co 754F2d 573 581 5th Cir 1985 we reiterated that a
violation of an OSHA regulation can be evidence of negligence or even in appropriate circumstances
negligence per se see Leibstein v Lagarge North Amer 689 F Supp2d 373 38090EDNY2010
state claim using FHSA
28 Walton v Potlach Corp 116 Idaho 892 898 n1 1989
29 15USC 1261fAemphasis added
30
Busch 644NE2d at 844 quoting 57 Fed Reg 46 664 1992
31 Id
32 Id
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  r i  l l i l ti  is i  f  f il r  t  r  and f  f cti  
r t i  st t  t rt r t li ilit  ses.  i l ti  f  st t t  r r l ti    
li e  r s  r  t  st t t  r r l ti  s i t  t  r t t  t  f r  t  
defendant's act or o ission caused and the plaintiff is a e ber of the protected persons the 
st t t  r r l ti  i s t  r tect. 28 
  r ir s f t r rs f r s s st  r ts t  i l   t  
l l rt i  r i s  ir ti s.  "hazar s s stance" ns: 
(l)(A)  t  r i t r  f t  i  (i) i  t xic, 
(ii) is corrosive, (iii) is an irritant, (iv) is a strong sensitizer, (v) is 
fla able or co bustible, or (vi) generates pressure through 
o position, at,   ,     
i t re f s sta ces a  ca se s sta tial ers al i j r  r 
s sta tial illness ri  r as a r i ate res lt f a  
custo ary r reasonably foreseeable handling r use, including 
reas a l  f reseea le i esti   children.29 
ll that is required under the  is "a balanced perspective f the potential hazards f 
t  uct.,,3o "Many products hich ay cause chronic health effects ay also be acutely 
toxic and present physical hazards, such as fla ability.,,3! The product labeling ust take into 
       .32 
27 Sanchez v. Galey, 112 Idaho 609, 617-18 (1987) (OSHA violation may be evidence of negligence per 
se) (citing ixon v. Intern tion l rvester o.,  .2d ,  (5th ir. ) ("we reiterate  t at a 
violation of an OSHA regulation can be evidence of negligence or even, in appropriate circu stances, 
negligence er se")); see Leibstein v. Lagarge North Amer., 689 F. Supp.2d 373, 380-90 (E.D.N.Y. 2010) 
(state claim si  A). 
28 t  . lach ., 6 Idaho ,  & n.l (1989). 
29  .S.C. § 261(t)(I)(A) (emphasis ded). 
30 sc , 4 .E.2d at 4 (quoting  e . e . ,  (1 2)). 
31 Id. 
2I . 
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I HEREBY CERTIFY that on this 15 day of September 2011 a true and correct copy
of the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
950 W Bannock Street Suite 900
Boise ID 83702
USMail
Fax 3192601
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BILLIE JO MAJOR and individual
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICTOF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
N0
FILED
AM PM
SEP 15 2011
CHRISTOPHER D RICH Clerk
ay PATRICIA A DWONCH
DEPUTY
Case No CV PI 1003515
PLAINTIFFS
WITNESS LIST
Defendant
Billie Jo Major by and through her counsel of record hereby submits the following list of
witnesses who may be expected to testify at trial
1 Billie Jo Major
2 Bret Kimmel
3 Daniel Shaffer
4 Joshua Overgaard
5 Nicholas Doan
PLAINTIFFSWITNESS LIST 1
IQ
Darwin Overson ISB 5887
Eric BSwartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
P1 Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
001501
 ,  #5887 
 . rt ,  #639  
 &   
1673 . Shoreline rive, Suite 200 [83702] 
 ice   
i ,   
elephone: (208) 489-8989 
si il : (2 ) -898  
ail: dar in jonesandswartzlaw.com 
eric jonesandswartzlaw.com 
ttorneys  l intif , lie   
NO. I O (%It .M~ P.M.~/~I:;..----
    
CHRISTOPHER O. RICH, Clerk 
By PATRICIA A. DWONCH 
O  
        I   
   I , I        
I IE J  J ,  i i i l, 
l intiff, 
vs. 
I  I  RATI , 
a issouri corporation, 
nt. 
 .    
LAINTIF 'S 
ES   
illie J  aj r,  a  t r  er c sel f record, ere  s its t e f ll i  list f 
itnesses ho ay be expected to testify at trial: 
1. illie Jo ajor 
.  i  
.   
4. Joshua vergaard 
. c la   
I TIF 'S  IST-1 
6 Sara Link
7 Dr JanatODonnell
8 Dr Danny J Hendrickson
9 Dr William Loveland
10 Dr Rees Verner
11 Dr Matthew Schwarz
12 Dr Glenn Moldenhauer
13 Dr Phillip D Jensen
14 Dr Nic R Cordum
15 Dr Lance Coleman
16 Dr Mousoomi M Sur
17 Dr Terry G Ribbens
18 Dr Ronald M Kristensen
19 Dr Lee Parsons
20 Dr Christopher J Jennings
21 Dr Brent D Nelson
22 Dr Shane K Ball
23 Dr Spencer
24 Dr Stephen Asher
25 Dr TGibbons
26 DavidB Talford PAC
27 Dr Roberto Negron
28 Dr Karin Pacheco
PLAINTIFFSWITNESS LIST 2
001502
. araLi  
. r. Janat 'Donnell 
. r.  . ndri  
9. r. illia  oveland 
0. r.   
. r. att e  c arz 
. r.  lde  
. r. illip .  
. r. ic . r  
15. r. ance ole an 
. r. s i . r 
. r. ry . e  
. .  . ristens  
. . e   
. . st  . ngs 
. . rent . elson 
. r. a e . all 
. . e cer 
. . tephen sher 
. . . ibbons 
. a id . , -C 
2 . . oberto e ron 
2 . . arin Pacheco 
P I F'S ITNESS IS  - 2 
29 Dr Garold Yost
30 Dr Mary BarrosBailey
31 Gary Couillard
32 Dr Bob Long
33 Dr Annette Phillip
34 Becky Coles
35 Roger Barnheardt
36 DianeBrown
37 Gary Schaeffer
38 Angie Schaeffer
39 JeffChampagne
40 Andrew Remm
41 Robert Nance
Plaintiff reserves the right to call any witness disclosed by any party to this matter
Additionally Plaintiff reserves the right to call any witness listed on the Defendants Witness
List for Trial Plaintiff further reserves the right to call rebuttal witnesses and witnesses for
impeachment Finally Plaintiff reserves the right to amend or supplement this list in advance of
trial
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38. ngie Schaeffer 
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Plaintiff reserves the right to call any itness disclosed by any party to this atter. 
dditionally, Plaintiff reserves the right to call any itness listed on the efendants' itness 
ist for rial. Plaintiff further reserves the right to call rebuttal itnesses and itnesses for 
i peach ent. Finally, Plaintiff reserves the right to a end or supple ent this list in advance of 
i l. 
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CERTIFICATE OF SERVICE
r
I HEREBY CERTIFY that on this j5 day of September 2011 a true and correct
copy of the foregoing document was served on the following individualsby the method
indicated
ChristopherC Burke USMail
GREENERBURKE SHOEMAKER PA Fax 3192601
950W Bannock Street Suite 900 Messenger Deliv
Boise ID 83702 Email cburke@greenerlawcom
DARWIN L OVERSON
ERIC BSWARTZ
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FILED
SEP 15 2011
CHRISTOPHER D RICH Clerk
By PATRICIA A DWONCH
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Case No CV PI 1003515
Plaintiff
VS PLAINTIFFS EXHIBIT LIST
FOR TRIAL
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
COME NOW the Plaintiffs by and through their counsel ofrecord Jones Swartz PLLC
and submit the attached proposed Exhibit List for trial in the above referenced matter Plaintiff
reserves the right to amend her proposed Exhibit List Plaintiff further reserves the right to use as
exhibits documents that are as yet unknown to her and any and all materials produced incident to
discovery whether producedby a partyor nonparty demonstrative exhibits any and all pleadings
answers and responses to discovery and responses to subpoenas
PLAINTIFFS EXHIBIT LIST FOR TRIAL 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZPLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 208 4898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawo
Attorneys for Plaintiff Billie Jo Major
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C E  the Plaintiffs, by and through their counsel of record , Jones & artz , 
and sub it the attached proposed Exhibit List for trial in the above-referenced atter. Plaintiff 
reserves the right to a end her proposed xhibit ist. laintiff further reserves the right to use as 
exhibits docu ents that are as yet unkno n to her, and any and all aterials produced incident to 
discovery, hether produced by a party or non-party, de onstrative exhibits, any and all pleadings, 
ans ers and responses to discovery, and responses to subpoenas. 
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DATED this 15 day ofSeptember 2011
JONES SWARTZ
0
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 15 dayofSeptember 2011 a true and correct copy ofthe
foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
950W Bannock Street Suite 900
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USMail
Fax 3192601
essengerDeliver
Email cburke@greenerlawcom
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MAJORv.SEC 
PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
MEDICAL RECORDS 
St. Luke's Family 12/0812002- 51 001058-1204 
1 Health medical OS/2312011 and SLFH 
records 00095-96 
Southwest Idaho Ear 02/1012003- SWIENT 
2 Nose & Throat 1011212009 00001-61 
medical Records 
St. Alphonsus 0211 012003- 000731-1038 
3 Regional Medical 02/0412010 andSARMC 
Center medical 00001-44, 
records 00112, 
00190-191 
St. Luke's Regional 0811512003- St Lukes 
4 Medical Center 0512412011 ~MC 
medical records 000005-119 
5/512010 and 
SLRMC 
00120-153 
and 000092-
94, 102-120, 
130, 146, 
~07-209, 214-
~15,231 
Northwest Pulmonary 03/1212008- 48 000016-74 
5 Medical Records 02/0112011 and and IPA 
49 00053-86 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex.# BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Idaho Endoscopy 0611712008- 001231-1254 
6 Center medical 08/0812008 andIEC 
records 00005 
National Jewish 3/31/2009- 50 NJH 00001-
7 Hospital medical 10/06/2010 and 87 
records 72 
Boise Surgical Group 06122/2009- BSG 00001-
8 medical records 1111612009 10 
Moldenhauer 0111112005- MOULDENH 
9 Chiropractic Center 06/02/2011 AUER 
medical records 00001-279 
Moldenhauer letter 612212009 Moldenhauer 
10 D.C. 000002-
3 03/17/2010 
Moldenhauer letter to 912312010 
11 Dr. Karin Pacheco 
MEDICAL BILLS 
St. Alphonsus 05/0112008 - SARMC 
12 Regional Medical 02/04/2010 ~ILL 00001-6 
Center bills 
SW Idaho Ear Nose 10/12/2009 SWIENT 
13 and Throat bills BILL 000002 
St. Alphonsus 0511512008 SAPGBILL 
14 Pathology Group bill 00001 
St. Luke's Regional 03112/2008 - SLRMC 
15 Medical Center bill 09/10/2009 ~ILL 00001-3 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
St. Luke's Family 3/412008 - 51 SLFH 00013-
16 Health bill & 0512312011 24 
Summary 
Gem State Radiology 51112008- GSRBILL 
17 bill 1111112009 00002 
NW Pulmonary bill 03/1212008 - IPA BILL 
18 02/0112011 00001-8 . 
Idaho Endoscopy 06/1712008 - IEC BILL 
19 Center bill 08/0412008 00001-2 
Moldenhauer 12/16/2008 - IMOLDENHA 
20 Chiropractic Center 0610212011 ~ERBILL 
bill & Summary 00001-56 
National Jewish 3/30/2009 - NJH BILL 
21 Hospital bill 1010612010 00001-4 
Boise Surgical Group 0612212009 - BSG BILL 
22 bill 11/1612009 00001 
Boise Radiology 3/12/2008 - BRGBILL 
23 Group bill 05124/2011 000002-4 
St. Luke's Metabolic 92 SLMBS 
24 and Bariatric Surgery 000001-2 
price list 
Norco bill MAJOR 
25 000043 -
55 and 
000291-296 
Prescription SAVON 
26 Medication bills & 000001-106 
Summary 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex.# BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
EXPERT REpORTS 
Gerold Yost expert 07/2812010 57 YOST 00049-
27 report 50 
Mary Barros-Bailey 3124/2011 90 BARROS-
28 expert report BAILEY 
000001-36 
Gary Couillard expert 3/27/2011 82 COUILLARD 
29 report 000343-403 
Roberto Negron NEGRON 
30 expert report 000011-13 
Roberto Negron 6/812011 89 NEGRON 
31 supplemental expert 000014 - 16 
report 
Karin Pacheco expert 0111112011 50 PACHECO 
32 report 00019-26 
Karin Pacheco expert 08/1512011 PACHECO 
33 report 00027-28 
DEPOSITION 
TRANSCRIPTS 
Sara Link Deposition 02/15/2011 
34 Transcript 
Joshua Overgaard 02/1512011 
35 Deposition Transcript 
Nicolas Doan 02/1512011 
36 Deposition Transcript 
Daniel Schaffer 02/14/2011 
37 Deposition Transcript 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Bret Kimmel 02/1412011 
38 Deposition Transcript 
William D. Loveland, 0311112011 
39 MD Deposition 
Transcript 
Janat O'Donnell, MD 03/0912011 
40 Deposition Transcript 
Dan J. Hendrickson, 03/03/2011 
41 MD Deposition 
Transcript 
Karin A. Pacheco, MD 04/2112011 
42 Deposition Transcript 
- Vol I 
Karin A. Pacheco, MD 0412212011 
43 Deposition Transcript 
- Vol II 
Gerald S. Yost, MD 04119/2011 
44 Deposition Transcrij)t 
Roberto Negron, MD 0610912011 
45 Deposition Transcript 
Mary Barros-Bailey, 0612312011 
46 PhD Deposition 
Transcript 
Gary Couillard, CPA 06103/2011 
47 Deposition Transcript 
Robert Nance 03/17/2011 
48 Deposition Transcript 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Billie Jo Major 01105/2011 
49 Deposition Transcript 
- Voll 
Billie Jo Major 01106/2011 
50 Deposition Transcript 
- Vol II 
SABRE PRODUCT 
INFORMATION 
TAXES 
2003 Federal taxes 2003 Irax 2003 to 
51 and W-2's ~009 000007-
124/6110 
2004 Federal taxes 2004 iTax 2003 to 
52 and W-2's ~009 000031-
354/6110 
2005 Federal taxes 2005 iTax 2003 to 
53 and W-2's ~009 000057-
594/6/10 
2006 Federal taxes 2006 iTax 2003 to 
54 and W-2's ~009 000075-
794/6/10 i 
2007 Federal taxes 2007 iTax 2003 to I 
55 and W-2's ~009 000086- I 
I 
904/6/10 
2008 Federal taxes 2008 iTax 2003 to 
56 and W-2's ~009 000093-
954/6/10 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
2009 Federal taxes 2009 Tax 2003 to 
57 and W-2's 2009000100-
101 4/6/10 
2010 Federal taxes 2010 ~010 Taxes 
58 00001-2 
RESEARCH/STUDIES 
M.Hayman: A 
59 Review of Phann. 
And Clin. App. 
K.Alawi: Paradox. 
60 role ofTRPVl 
Receptor in 
Inflamation. 
Reilly: Determ of Cap 
61 in Blood Tissue 
Reilly: Capsaicinoids 
62 Cause Inflammation 
and Epithelial Cell 
Death Through 
Activation of 
Vanilloid Receptors 
Reilly: Structural and 
63 Enzymatic Parameters 
that Determine Alkyl 
Dehydrogenation-
Hydroxylation of 
Capsaicinoids by P450 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
EXo# DESCRIPTION DATE EXo# BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Enzymes 
Reilly: Calcium-
64 Dependent and 
Independent 
Mechanisms of 
Capsaicin Receptor 
(TRPV 1 )-Mediated 
Cytokine Production 
and Cell Death 
Johansen: TRPVl 
65 Antagonists Elevate 
Cell Surface 
Populations and 
Receptor Function to 
Exacerbate TRPVl 
Reilly: Metabolism of 
66 capsaicinoids by P450 
enzymes a review 
Thomas: TRPVl 
67 Agonists Cause 
, 
Endoplasmic I 
Reticulum Stress and 
Cell Death in Human 
Lungs 
TRPAI and TRPVl 
I 
68 lung review Jordt 
Groneberg: Increased 
69 Expression of TRPVa 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex.# DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
in Airway Nerves of 
Chronic Cough 
Mitchel: Expression 
70 and Character of 
Interacellular TRPV1 
in Bronchi 
Higenbottam: Chronic 
71 Cough and Cough 
Reflex in Common 
Lung Disease 
Geppetti: Role in 
72 Airway Inflamation 
and Disease 
Meggs: Neurogenic 
73 Inflammation and 
Sensitivity to Enviro. 
Chemicals 
Lu-Yuan: Role of 
74 TRPV1 in 
inflammation -
induced airway 
hypersensitivity 
Adcock: TRPV1 
75 Receptors in 
Sensitisation of Cough 
and Pain Reflexes 
Drazen: Animal 
76 Models of Asthma and 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Chronic Bronchitis 
Billmire: Pepperspray 
77 Induced Respiratory 
Failure Treated W. 
EMO 
Chard: Capsaicin-
78 induced neurotoxicity 
in cultured dorsal root 
ganglion neurons 
Guarino: Increased 
79 TRPV1 gene 
expression in 
Esophageal Mucosa in 
Patients w Non-
Erosive and Erosive 
Reflux 
Ramirez-Romero: 
80 Dihydrocapsaicin Txt 
Depletes peptidergic 
nerve Fibers of 
Substance P and 
Alters Mast Cells in 
Neonatal Sheep 
Franco-Penteado: 
81 Mechanisms Involved 
in the Enhancement of 
Allergic Airways 
Neutrophil Influx by 
-
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Permanent C-Fiber 
Degeneration in Rats 
Groneberg: Models of 
82 Chronic Obstructive 
Pulm. Disease 
Long: Respiratory 
83 Tract Inflammation 
during induction of 
chronic bronchitis in 
rats. a role ofC-fibres 
Olajos: Riot Control 
84 Agents Pharmacology, 
Toxicology, 
Biochemistry and 
Chemistry 
Long: Airway 
85 hyperresponsi veness 
in a rat Model of 
Chronic Bronchitis -
Role of C Fibers 
Hope-Gill: A Study of 
86 the Cough Reflex in 
Idiopathic Pulmonary 
Fibrosis 
Acs: Differential 
87 Activation and 
Desensitization of 
Sensory Neurons by 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Resiniferatoxin 
Gatti: Protease-
88 Activated Receptor-2 
Activation 
Exaggerates TRPV1-
Mediated Cough in 
Guinea Pigs 
Szallasi: Vanilloid 
89 (Capsaicin) Receptors 
in Health and Disease 
Tominaga: Gating, 
90 Sensitization, and 
Desensitizing of 
TRPV1 
Caterina: TRPV1 a 
91 polymodal sensor in 
the nocicpetor 
terminal-prime-HL 
DuBay: aerodynamic 
92 particle size analysis 
Dicpinigaitis: Safety 
93 of Capsaicin Cough 
Challenge Testing 
Reilly: Quantitative 
94 Analysis in Fresh 
Peppers, Oleoresin 
Capsicum and Pepper 
Spray 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex.# DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Szallas: Vanilloid 
95 (Capsaicin) Receptors 
and Mechanisms 
Texas Criminal Justice 
96 Coalition: Pepper 
Spray in Texas Youth 
Commission: 
Research Review and 
Policy 
Recommendations 
US Army Edgewood 
97 Chern and Biological 
Center: Human 
Effectiveness and Risk 
Characterization of 
C and P A V A Hand 
Held Devices 
Perkner: Irritant-
98 Associated Vocal 
Cord Dysfunction 
Blanc: Cough and Hot 
99 Pepper Workers 
Simon: How Irritating 
100 the role ofTRPA1 in 
sensing cigarette 
smoke 
Zhang: Altered 
101 Expression ofTRPV1 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
Ro: Activation of 
102 TRPV1 and TRPA1 
Leads to Muscle 
Nociception and 
Mechanical 
Hyperalgesia 
Reilly: Capsaicin 
103 Detected in Clothing 
Study: Impact of OC 5118/2000 Q SEC001092 -
104 Spray on Respiratory 1160 
function in Human 
Subjects 
MSDS&OTHER 
PRODUCT 
INFORMATION 
Sigma - Aldrich 
105 MSDS - Capsaicin 
Capsaicin - Natural -
106 msds - Science Lab 
Capsaicin Extract -
107 msds - Science Lab 
Dihydrocapsaicin -
108 msds - Science Lab 
SABRE Red MSDS Material 
109 Received by Billie Safety Sheet 
000001-4 
SABRE Red MK-9 SECOOO022-
_ 110 Fogger - MSDS 24 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
SABRE Red Cell SECOOOO16-
111 Buster MSDS 18 
Sabre Red Thermostat Sabre Red 
112 Comparison Ad 000001-2 
0311712010 
SABRE Red Labels 117 SECOOO126-
113 andD 128 
SABRE Red Brochure 115, SECOO0272-
114 116, ~83 
andB 
SABRE Red Instructor E SECOO0332-
115 Manual 382 
Power Point - SEC , , 
116 SABRE 
Power Point - IDOC !DOCOOO062-
117 SABRE Red Training 108 
- 01 
MK 9 Fogger Specs SECOO0784- i 
118 785 
SABRE - Decon SECOO0773-
119 Literature and Product 774 
Specs 
Press Releases - NON SECOO0777 
120 TOXIC 
Sabre Instructor SEC000600 -
121 Certification Power 768 
Point Presentation 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
ADMITIED I Ex. # DESCRIPTION DATE Ex. # BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED 
Oleoresin Capsicum K SEC001047 -
122 Material Safety Data 1048 
Sheet 
TRAINING 
MATERIALS 
REIDOC& 
PURCHASES 
Certification of Doan SECOO0913 
123 and 000937-
938 
Certification of SECOO0922 
124 Overgaard and 000939-
940 
Certification of SECOO0907 
125 Schafer and 000945-
~46 
Instructor Test SECOOO595-
126 599 
June 2007 Training SECOO0902-
127 Materials Order 903 
Invoices for IDOC IDOCOOOO03-
128 Purchases of OC 55 
including early MK-9 
Fogger 
IDOC - SEC Invoices lDocoo 1080-
129 1091 
IDOC OC Spray lDocooooO 1-
L-
130 Purchases ~ 
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex.# BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
IDOC MATERIALS 
RE BILLIE MAJOR 
Billie's Training DOCOOO056-
131 Transcript 61 
Billie's Medical Work 
132 Releases 
Major IDOC Records DOCOO0202-
! 
133 showing OC 210 and 
Deployment 000227-231 
Billie's Employment MAJOR 
134 History 000041-42 
AFFIDAVITS & 
OTHER STATEMENTS 
Affidavit of C. Reilly 
135 
Affidavit of Nicholas 
136 Roberts 
Affidavit ofR. Nance 
137 
Aff ofR. Nance-2nd 
138 
Reilly Email REILLY 
139 000001 
VIDEO 
5 5 FOG 
140 
---- --- ---
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PLAINTIFFS' EXHIBIT LIST 
DEPO CONDo 
Ex. # DESCRIPTION DATE Ex.# BATES RANGE STIPULATION MARKED OBJECT ADMIT DENIED ADMITTED 
MK9FOGPA 
141 
MK9FOG 
142 
55STREAM 
143 
STREAM 
144 
DIRECTAP 
145 
crovvdnaanagenaent 
146 
Cell Buster V ideo 
147 
MISCELLANEOUS 
SEC Conapetitor LABELS 
148 Product Labels 000001 - 51 
Medical Expense 
149 Sunanaaries 
Medical Treatnaent 
150 Sunanaary 
Tinaeline 
151 
Territorial Supply -
152 MK9 Fogger 
SABRE HPLC 
153 
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N0
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Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707
Telephone 208 4898989
Facsimile 2084898988
Email darwin@jonesandswartzlawcom
eric@jonesandswartzlawc m
SEP 15 2011
CHRISTOPHER D RICH Clerk
By PATRICIAA DWONCH
DEPUTY
Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Plaintiff
VS
SECURITY EQUIPMENT CORPORATION
a Missouri corporation
Defendant
Case No CV PI 1003515
PLAINTIFFSPROPOSED
JURY INSTRUCTIONS
COMES NOW the Plaintiff by and through her counsel of record herein and pursuant to
this CourtMay 13 2011 Order Governing Proceedings and hereby proposes the following jury
instructions
STANDARD IDIKS
IDJI 100 Introductory Instruction
IDJI 101 Deliberation Procedures
IDJI 102 Corporate Parties
PLAINTIFFSPROPOSED JURY INSTRUCTIONS 1
4
001527
ar in verson, IS  #5887 
ric . rt , S  #6396 
J ES &  LC 
1673 . Shoreline rive, Suite 200 [83702] 
ost fice   
oise,I   
Telephone: (208) 489-8989 
si il : (20 ) 9-8988 
E ail: dar in jonesandswartzlaw.com 
eric jonesandswartzlaw.com 
ttorneys for Plaintiff, illie Jo ajor 
NO. FILE~ '1zv 
.M. __ --P,. .rAI#-~---
  5  
I  O. I , lerk 
y I I .  
P  
          
   ,        
I IE J  J , and individual, 
laintiff, 
vs. 
I  I  RATI , 
a issouri corporation, 
ant. 
 .    
I TIFF'S  
 I S 
ES  the Plaintiff, by and through her counsel of record herein, and pursuant to 
this ourt's ay 13, 2011 rder overning Proceedings, and hereby proposes the follo ing jury 
t ti s: 
 JIs 
 .00 - Introductory Instruction 
 .01 -  r  
 .02 - orporate Parties 
LAINTIF 'S  J y I  -  
IDJI 103 Admonition to jury
IDJI103 Reminder Admonition to Jury
IDJI 104 Insurance Cautionary
IDJI 105 Statement ofclaims not evidence
IDJI 109 Quotient verdicts
IDJI 11 Communications with Court
IDJI 1 13 Concluding remarks alternative form
IDJI 115 Completion of verdict form general verdict
IDJI 15 Completion ofverdict form on special interrogatories
IDJI 17 Post verdict jury instruction
IDJI120 Burden of proof preponderance of evidence
IDJI 122 Deposition testimony
IDJI124 Circumstantial evidence with definition
IDJI143 Instruction on special verdict form
IDJI1412 Companion instruction defendantsburden
IDJI1413 Companion instruction Nonparty negligence defendantsburden
IDJI20 Definition of negligence
IDJI900 Cautionary instruction on damages
IDJI901 Damage instruction for injuries to plaintiff general case
IDJI902 Aggravation of preexisting condition
IDJI913 Present cash value
Plaintiff has requested a general verdict form but has submitted in the alternative a proposed special
verdict form IDJI 15 is requested only if the Court opts to use a special verdict form
PLAINTIFFSPROPOSED JURY INSTRUCTIONS 2
001528
I JI .03 - d onition to jury 
I JI .0 .1 - inder d o ition t   
I J  .04 - Insurance autionary 
I JI .05 - t  lai s t idence 
I J  .09 - uotient verdicts 
I J  . 1 - c ions ith rt 
 . 3.1 - oncluding re arks (alternative for ) 
 . 5.1 - leti  f er ict f r  - e eral er ict 
 .15 - Co pletion of verdict for  on special interrogatories l 
 .17 - Post verdict jury instruction 
 .2 .1 - Burden of proof - preponderance f evidence 
 . 2 - Deposition testimony 
 .2 .2 -   t  tion 
 .4 .1 - Instruction on special verdict for  
 .41.4.2 - Co panion instruction - f ndant's  
 .41.4.3 - Companion instruction - Non-party negligence - efendant's  
 .20 - Definition of negligence 
 .00 - Cautionary instruction on da ages 
I .01 - Damage instruction for injuries to plaintiff - general case 
 .02 - ggravation of pre-existing condition 
 .13 - r t   
1 Plaintiff has requested a general verdict for  but has sub itted in the alternative a proposed special 
verdict form. IDJI 1.15 is requested only if the Court opts to use a special verdict form. 
LAINTIF 'S    -  
